original_sentence	e1	e2	relation_type	metadata	preprocessed_sentence
Patients studied in clinical trials of TNKase were routinely treated with heparin and aspirin. 	TNKase	heparin	none	{'e1': {'word': 'TNKase', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d773.s1.e0'}, 'e2': {'word': 'heparin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d773.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d773.s1'}	Patients studied clinical trials TNKase routinely treated heparin aspirin
Patients studied in clinical trials of TNKase were routinely treated with heparin and aspirin. 	TNKase	aspirin	none	{'e1': {'word': 'TNKase', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d773.s1.e0'}, 'e2': {'word': 'aspirin', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d773.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d773.s1'}	Patients studied clinical trials TNKase routinely treated heparin aspirin
Patients studied in clinical trials of TNKase were routinely treated with heparin and aspirin. 	heparin	aspirin	none	{'e1': {'word': 'heparin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d773.s1.e1'}, 'e2': {'word': 'aspirin', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d773.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d773.s1'}	Patients studied clinical trials TNKase routinely treated heparin aspirin
Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. 	Anticoagulants	heparin	none	{'e1': {'word': 'Anticoagulants', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d773.s2.e0'}, 'e2': {'word': 'heparin', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d773.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d773.s2'}	Anticoagulants heparin vitamin K antagonists drugs alter platelet function acetylsalicylic acid dipyridamole GP IIb IIIa inhibitors may increase risk bleeding administered prior TNKase therapy
Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. 	Anticoagulants	vitamin K antagonists	none	{'e1': {'word': 'Anticoagulants', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d773.s2.e0'}, 'e2': {'word': 'vitamin K antagonists', 'word_index': [(2, 4)], 'id': 'DDI-DrugBank.d773.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d773.s2'}	Anticoagulants heparin vitamin K antagonists drugs alter platelet function acetylsalicylic acid dipyridamole GP IIb IIIa inhibitors may increase risk bleeding administered prior TNKase therapy
Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. 	Anticoagulants	acetylsalicylic acid	none	{'e1': {'word': 'Anticoagulants', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d773.s2.e0'}, 'e2': {'word': 'acetylsalicylic acid', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d773.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d773.s2'}	Anticoagulants heparin vitamin K antagonists drugs alter platelet function acetylsalicylic acid dipyridamole GP IIb IIIa inhibitors may increase risk bleeding administered prior TNKase therapy
Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. 	Anticoagulants	dipyridamole	none	{'e1': {'word': 'Anticoagulants', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d773.s2.e0'}, 'e2': {'word': 'dipyridamole', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d773.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d773.s2'}	Anticoagulants heparin vitamin K antagonists drugs alter platelet function acetylsalicylic acid dipyridamole GP IIb IIIa inhibitors may increase risk bleeding administered prior TNKase therapy
Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. 	Anticoagulants	TNKase	effect	{'e1': {'word': 'Anticoagulants', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d773.s2.e0'}, 'e2': {'word': 'TNKase', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d773.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d773.s2'}	Anticoagulants heparin vitamin K antagonists drugs alter platelet function acetylsalicylic acid dipyridamole GP IIb IIIa inhibitors may increase risk bleeding administered prior TNKase therapy
Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. 	heparin	vitamin K antagonists	none	{'e1': {'word': 'heparin', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d773.s2.e1'}, 'e2': {'word': 'vitamin K antagonists', 'word_index': [(2, 4)], 'id': 'DDI-DrugBank.d773.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d773.s2'}	Anticoagulants heparin vitamin K antagonists drugs alter platelet function acetylsalicylic acid dipyridamole GP IIb IIIa inhibitors may increase risk bleeding administered prior TNKase therapy
Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. 	heparin	acetylsalicylic acid	none	{'e1': {'word': 'heparin', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d773.s2.e1'}, 'e2': {'word': 'acetylsalicylic acid', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d773.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d773.s2'}	Anticoagulants heparin vitamin K antagonists drugs alter platelet function acetylsalicylic acid dipyridamole GP IIb IIIa inhibitors may increase risk bleeding administered prior TNKase therapy
Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. 	heparin	dipyridamole	none	{'e1': {'word': 'heparin', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d773.s2.e1'}, 'e2': {'word': 'dipyridamole', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d773.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d773.s2'}	Anticoagulants heparin vitamin K antagonists drugs alter platelet function acetylsalicylic acid dipyridamole GP IIb IIIa inhibitors may increase risk bleeding administered prior TNKase therapy
Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. 	heparin	TNKase	effect	{'e1': {'word': 'heparin', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d773.s2.e1'}, 'e2': {'word': 'TNKase', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d773.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d773.s2'}	Anticoagulants heparin vitamin K antagonists drugs alter platelet function acetylsalicylic acid dipyridamole GP IIb IIIa inhibitors may increase risk bleeding administered prior TNKase therapy
Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. 	vitamin K antagonists	acetylsalicylic acid	none	{'e1': {'word': 'vitamin K antagonists', 'word_index': [(2, 4)], 'id': 'DDI-DrugBank.d773.s2.e2'}, 'e2': {'word': 'acetylsalicylic acid', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d773.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d773.s2'}	Anticoagulants heparin vitamin K antagonists drugs alter platelet function acetylsalicylic acid dipyridamole GP IIb IIIa inhibitors may increase risk bleeding administered prior TNKase therapy
Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. 	vitamin K antagonists	dipyridamole	none	{'e1': {'word': 'vitamin K antagonists', 'word_index': [(2, 4)], 'id': 'DDI-DrugBank.d773.s2.e2'}, 'e2': {'word': 'dipyridamole', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d773.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d773.s2'}	Anticoagulants heparin vitamin K antagonists drugs alter platelet function acetylsalicylic acid dipyridamole GP IIb IIIa inhibitors may increase risk bleeding administered prior TNKase therapy
Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. 	vitamin K antagonists	TNKase	effect	{'e1': {'word': 'vitamin K antagonists', 'word_index': [(2, 4)], 'id': 'DDI-DrugBank.d773.s2.e2'}, 'e2': {'word': 'TNKase', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d773.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d773.s2'}	Anticoagulants heparin vitamin K antagonists drugs alter platelet function acetylsalicylic acid dipyridamole GP IIb IIIa inhibitors may increase risk bleeding administered prior TNKase therapy
Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. 	acetylsalicylic acid	dipyridamole	none	{'e1': {'word': 'acetylsalicylic acid', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d773.s2.e3'}, 'e2': {'word': 'dipyridamole', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d773.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d773.s2'}	Anticoagulants heparin vitamin K antagonists drugs alter platelet function acetylsalicylic acid dipyridamole GP IIb IIIa inhibitors may increase risk bleeding administered prior TNKase therapy
Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. 	acetylsalicylic acid	TNKase	effect	{'e1': {'word': 'acetylsalicylic acid', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d773.s2.e3'}, 'e2': {'word': 'TNKase', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d773.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d773.s2'}	Anticoagulants heparin vitamin K antagonists drugs alter platelet function acetylsalicylic acid dipyridamole GP IIb IIIa inhibitors may increase risk bleeding administered prior TNKase therapy
Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. 	dipyridamole	TNKase	effect	{'e1': {'word': 'dipyridamole', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d773.s2.e4'}, 'e2': {'word': 'TNKase', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d773.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d773.s2'}	Anticoagulants heparin vitamin K antagonists drugs alter platelet function acetylsalicylic acid dipyridamole GP IIb IIIa inhibitors may increase risk bleeding administered prior TNKase therapy
Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter. 	Terfenadine	astemizole	none	{'e1': {'word': 'Terfenadine', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d709.s1.e0'}, 'e2': {'word': 'astemizole', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d709.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d709.s1'}	Concomitant administrations recommended Terfenadine astemizole Certain macrolides interact terfenadine astemizole leading increased serum concentrations latter
Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter. 	Terfenadine	macrolides	none	{'e1': {'word': 'Terfenadine', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d709.s1.e0'}, 'e2': {'word': 'macrolides', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d709.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d709.s1'}	Concomitant administrations recommended Terfenadine astemizole Certain macrolides interact terfenadine astemizole leading increased serum concentrations latter
Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter. 	Terfenadine	terfenadine	none	{'e1': {'word': 'Terfenadine', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d709.s1.e0'}, 'e2': {'word': 'terfenadine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d709.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d709.s1'}	Concomitant administrations recommended Terfenadine astemizole Certain macrolides interact terfenadine astemizole leading increased serum concentrations latter
Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter. 	Terfenadine	astemizole	none	{'e1': {'word': 'Terfenadine', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d709.s1.e0'}, 'e2': {'word': 'astemizole', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d709.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d709.s1'}	Concomitant administrations recommended Terfenadine astemizole Certain macrolides interact terfenadine astemizole leading increased serum concentrations latter
Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter. 	astemizole	macrolides	none	{'e1': {'word': 'astemizole', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d709.s1.e1'}, 'e2': {'word': 'macrolides', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d709.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d709.s1'}	Concomitant administrations recommended Terfenadine astemizole Certain macrolides interact terfenadine astemizole leading increased serum concentrations latter
Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter. 	astemizole	terfenadine	none	{'e1': {'word': 'astemizole', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d709.s1.e1'}, 'e2': {'word': 'terfenadine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d709.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d709.s1'}	Concomitant administrations recommended Terfenadine astemizole Certain macrolides interact terfenadine astemizole leading increased serum concentrations latter
Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter. 	astemizole	astemizole	none	{'e1': {'word': 'astemizole', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d709.s1.e1'}, 'e2': {'word': 'astemizole', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d709.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d709.s1'}	Concomitant administrations recommended Terfenadine astemizole Certain macrolides interact terfenadine astemizole leading increased serum concentrations latter
Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter. 	macrolides	terfenadine	int	{'e1': {'word': 'macrolides', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d709.s1.e2'}, 'e2': {'word': 'terfenadine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d709.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d709.s1'}	Concomitant administrations recommended Terfenadine astemizole Certain macrolides interact terfenadine astemizole leading increased serum concentrations latter
Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter. 	macrolides	astemizole	int	{'e1': {'word': 'macrolides', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d709.s1.e2'}, 'e2': {'word': 'astemizole', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d709.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d709.s1'}	Concomitant administrations recommended Terfenadine astemizole Certain macrolides interact terfenadine astemizole leading increased serum concentrations latter
Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter. 	terfenadine	astemizole	none	{'e1': {'word': 'terfenadine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d709.s1.e3'}, 'e2': {'word': 'astemizole', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d709.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d709.s1'}	Concomitant administrations recommended Terfenadine astemizole Certain macrolides interact terfenadine astemizole leading increased serum concentrations latter
Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended. 	roxithromycin	roxithromycin	none	{'e1': {'word': 'roxithromycin', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d709.s3.e0'}, 'e2': {'word': 'roxithromycin', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d709.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d709.s3'}	Although reaction demonstrated roxithromycin concomitant administration roxithromycin terfenadine astemizole recommended
Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended. 	roxithromycin	terfenadine	none	{'e1': {'word': 'roxithromycin', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d709.s3.e0'}, 'e2': {'word': 'terfenadine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d709.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d709.s3'}	Although reaction demonstrated roxithromycin concomitant administration roxithromycin terfenadine astemizole recommended
Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended. 	roxithromycin	astemizole	none	{'e1': {'word': 'roxithromycin', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d709.s3.e0'}, 'e2': {'word': 'astemizole', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d709.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d709.s3'}	Although reaction demonstrated roxithromycin concomitant administration roxithromycin terfenadine astemizole recommended
Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended. 	roxithromycin	terfenadine	advise	{'e1': {'word': 'roxithromycin', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d709.s3.e1'}, 'e2': {'word': 'terfenadine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d709.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d709.s3'}	Although reaction demonstrated roxithromycin concomitant administration roxithromycin terfenadine astemizole recommended
Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended. 	roxithromycin	astemizole	advise	{'e1': {'word': 'roxithromycin', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d709.s3.e1'}, 'e2': {'word': 'astemizole', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d709.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d709.s3'}	Although reaction demonstrated roxithromycin concomitant administration roxithromycin terfenadine astemizole recommended
Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended. 	terfenadine	astemizole	none	{'e1': {'word': 'terfenadine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d709.s3.e2'}, 'e2': {'word': 'astemizole', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d709.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d709.s3'}	Although reaction demonstrated roxithromycin concomitant administration roxithromycin terfenadine astemizole recommended
- Cisapride, pimozide: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. 	Cisapride	pimozide	none	{'e1': {'word': 'Cisapride', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d709.s4.e0'}, 'e2': {'word': 'pimozide', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d709.s4.e1'}, 'sentence_id': 'DDI-DrugBank.d709.s4'}	Cisapride pimozide drugs cisapride pimozide metabolised hepatic CYP3A isozymes associated QT interval prolongation cardiac arrythmias typically torsades de pointe result increase serum level subsequent interaction significant inhibitors isozyme including macrolide antibacterials
- Cisapride, pimozide: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. 	Cisapride	cisapride	none	{'e1': {'word': 'Cisapride', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d709.s4.e0'}, 'e2': {'word': 'cisapride', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d709.s4.e2'}, 'sentence_id': 'DDI-DrugBank.d709.s4'}	Cisapride pimozide drugs cisapride pimozide metabolised hepatic CYP3A isozymes associated QT interval prolongation cardiac arrythmias typically torsades de pointe result increase serum level subsequent interaction significant inhibitors isozyme including macrolide antibacterials
- Cisapride, pimozide: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. 	Cisapride	pimozide	none	{'e1': {'word': 'Cisapride', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d709.s4.e0'}, 'e2': {'word': 'pimozide', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d709.s4.e3'}, 'sentence_id': 'DDI-DrugBank.d709.s4'}	Cisapride pimozide drugs cisapride pimozide metabolised hepatic CYP3A isozymes associated QT interval prolongation cardiac arrythmias typically torsades de pointe result increase serum level subsequent interaction significant inhibitors isozyme including macrolide antibacterials
- Cisapride, pimozide: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. 	Cisapride	macrolide antibacterials	none	{'e1': {'word': 'Cisapride', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d709.s4.e0'}, 'e2': {'word': 'macrolide antibacterials', 'word_index': [(29, 30)], 'id': 'DDI-DrugBank.d709.s4.e4'}, 'sentence_id': 'DDI-DrugBank.d709.s4'}	Cisapride pimozide drugs cisapride pimozide metabolised hepatic CYP3A isozymes associated QT interval prolongation cardiac arrythmias typically torsades de pointe result increase serum level subsequent interaction significant inhibitors isozyme including macrolide antibacterials
- Cisapride, pimozide: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. 	pimozide	cisapride	none	{'e1': {'word': 'pimozide', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d709.s4.e1'}, 'e2': {'word': 'cisapride', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d709.s4.e2'}, 'sentence_id': 'DDI-DrugBank.d709.s4'}	Cisapride pimozide drugs cisapride pimozide metabolised hepatic CYP3A isozymes associated QT interval prolongation cardiac arrythmias typically torsades de pointe result increase serum level subsequent interaction significant inhibitors isozyme including macrolide antibacterials
- Cisapride, pimozide: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. 	pimozide	pimozide	none	{'e1': {'word': 'pimozide', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d709.s4.e1'}, 'e2': {'word': 'pimozide', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d709.s4.e3'}, 'sentence_id': 'DDI-DrugBank.d709.s4'}	Cisapride pimozide drugs cisapride pimozide metabolised hepatic CYP3A isozymes associated QT interval prolongation cardiac arrythmias typically torsades de pointe result increase serum level subsequent interaction significant inhibitors isozyme including macrolide antibacterials
- Cisapride, pimozide: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. 	pimozide	macrolide antibacterials	mechanism	{'e1': {'word': 'pimozide', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d709.s4.e1'}, 'e2': {'word': 'macrolide antibacterials', 'word_index': [(29, 30)], 'id': 'DDI-DrugBank.d709.s4.e4'}, 'sentence_id': 'DDI-DrugBank.d709.s4'}	Cisapride pimozide drugs cisapride pimozide metabolised hepatic CYP3A isozymes associated QT interval prolongation cardiac arrythmias typically torsades de pointe result increase serum level subsequent interaction significant inhibitors isozyme including macrolide antibacterials
- Cisapride, pimozide: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. 	cisapride	pimozide	none	{'e1': {'word': 'cisapride', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d709.s4.e2'}, 'e2': {'word': 'pimozide', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d709.s4.e3'}, 'sentence_id': 'DDI-DrugBank.d709.s4'}	Cisapride pimozide drugs cisapride pimozide metabolised hepatic CYP3A isozymes associated QT interval prolongation cardiac arrythmias typically torsades de pointe result increase serum level subsequent interaction significant inhibitors isozyme including macrolide antibacterials
- Cisapride, pimozide: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. 	cisapride	macrolide antibacterials	mechanism	{'e1': {'word': 'cisapride', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d709.s4.e2'}, 'e2': {'word': 'macrolide antibacterials', 'word_index': [(29, 30)], 'id': 'DDI-DrugBank.d709.s4.e4'}, 'sentence_id': 'DDI-DrugBank.d709.s4'}	Cisapride pimozide drugs cisapride pimozide metabolised hepatic CYP3A isozymes associated QT interval prolongation cardiac arrythmias typically torsades de pointe result increase serum level subsequent interaction significant inhibitors isozyme including macrolide antibacterials
- Cisapride, pimozide: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. 	pimozide	macrolide antibacterials	none	{'e1': {'word': 'pimozide', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d709.s4.e3'}, 'e2': {'word': 'macrolide antibacterials', 'word_index': [(29, 30)], 'id': 'DDI-DrugBank.d709.s4.e4'}, 'sentence_id': 'DDI-DrugBank.d709.s4'}	Cisapride pimozide drugs cisapride pimozide metabolised hepatic CYP3A isozymes associated QT interval prolongation cardiac arrythmias typically torsades de pointe result increase serum level subsequent interaction significant inhibitors isozyme including macrolide antibacterials
Although such a risk is not verified for roxithromycin, combination of roxithromycin with such drugs is not recommended.	roxithromycin	roxithromycin	none	{'e1': {'word': 'roxithromycin', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d709.s5.e0'}, 'e2': {'word': 'roxithromycin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d709.s5.e1'}, 'sentence_id': 'DDI-DrugBank.d709.s5'}	Although risk verified roxithromycin combination roxithromycin drugs recommended
When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. 	methyldopa	antihypertensive drugs	effect	{'e1': {'word': 'methyldopa', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d779.s0.e0'}, 'e2': {'word': 'antihypertensive drugs', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d779.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d779.s0'}	methyldopa used antihypertensive drugs potentiation antihypertensive effect may occur
Patients may require reduced doses of anesthetics when on methyldopa. 	anesthetics	methyldopa	advise	{'e1': {'word': 'anesthetics', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d779.s2.e0'}, 'e2': {'word': 'methyldopa', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d779.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d779.s2'}	Patients may require reduced doses anesthetics methyldopa
When methyldopa and lithium are given concomitantly the patient should be carefully monitored for symptoms of lithium toxicity. 	methyldopa	lithium	advise	{'e1': {'word': 'methyldopa', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d779.s5.e0'}, 'e2': {'word': 'lithium', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d779.s5.e1'}, 'sentence_id': 'DDI-DrugBank.d779.s5'}	methyldopa lithium given concomitantly patient carefully monitored symptoms lithium toxicity
When methyldopa and lithium are given concomitantly the patient should be carefully monitored for symptoms of lithium toxicity. 	methyldopa	lithium	none	{'e1': {'word': 'methyldopa', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d779.s5.e0'}, 'e2': {'word': 'lithium', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d779.s5.e2'}, 'sentence_id': 'DDI-DrugBank.d779.s5'}	methyldopa lithium given concomitantly patient carefully monitored symptoms lithium toxicity
When methyldopa and lithium are given concomitantly the patient should be carefully monitored for symptoms of lithium toxicity. 	lithium	lithium	none	{'e1': {'word': 'lithium', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d779.s5.e1'}, 'e2': {'word': 'lithium', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d779.s5.e2'}, 'sentence_id': 'DDI-DrugBank.d779.s5'}	methyldopa lithium given concomitantly patient carefully monitored symptoms lithium toxicity
Several studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with ferrous sulfate or ferrous gluconate. 	methyldopa	ferrous sulfate	mechanism	{'e1': {'word': 'methyldopa', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d779.s7.e0'}, 'e2': {'word': 'ferrous sulfate', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d779.s7.e1'}, 'sentence_id': 'DDI-DrugBank.d779.s7'}	Several studies demonstrate decrease bioavailability methyldopa ingested ferrous sulfate ferrous gluconate
Several studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with ferrous sulfate or ferrous gluconate. 	methyldopa	ferrous gluconate	mechanism	{'e1': {'word': 'methyldopa', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d779.s7.e0'}, 'e2': {'word': 'ferrous gluconate', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d779.s7.e2'}, 'sentence_id': 'DDI-DrugBank.d779.s7'}	Several studies demonstrate decrease bioavailability methyldopa ingested ferrous sulfate ferrous gluconate
Several studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with ferrous sulfate or ferrous gluconate. 	ferrous sulfate	ferrous gluconate	none	{'e1': {'word': 'ferrous sulfate', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d779.s7.e1'}, 'e2': {'word': 'ferrous gluconate', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d779.s7.e2'}, 'sentence_id': 'DDI-DrugBank.d779.s7'}	Several studies demonstrate decrease bioavailability methyldopa ingested ferrous sulfate ferrous gluconate
Coadministration of methyldopa with ferrous sulfate or ferrous gluconate is not recommended. 	methyldopa	ferrous sulfate	advise	{'e1': {'word': 'methyldopa', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d779.s9.e0'}, 'e2': {'word': 'ferrous sulfate', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d779.s9.e1'}, 'sentence_id': 'DDI-DrugBank.d779.s9'}	Coadministration methyldopa ferrous sulfate ferrous gluconate recommended
Coadministration of methyldopa with ferrous sulfate or ferrous gluconate is not recommended. 	methyldopa	ferrous gluconate	advise	{'e1': {'word': 'methyldopa', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d779.s9.e0'}, 'e2': {'word': 'ferrous gluconate', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d779.s9.e2'}, 'sentence_id': 'DDI-DrugBank.d779.s9'}	Coadministration methyldopa ferrous sulfate ferrous gluconate recommended
Coadministration of methyldopa with ferrous sulfate or ferrous gluconate is not recommended. 	ferrous sulfate	ferrous gluconate	none	{'e1': {'word': 'ferrous sulfate', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d779.s9.e1'}, 'e2': {'word': 'ferrous gluconate', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d779.s9.e2'}, 'sentence_id': 'DDI-DrugBank.d779.s9'}	Coadministration methyldopa ferrous sulfate ferrous gluconate recommended
Methyldopa does not interfere with measurement of VMA (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert VMA to vanillin. 	Methyldopa	VMA	none	{'e1': {'word': 'Methyldopa', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d779.s16.e0'}, 'e2': {'word': 'VMA', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d779.s16.e1'}, 'sentence_id': 'DDI-DrugBank.d779.s16'}	Methyldopa interfere measurement VMA vanillylmandelic acid test pheochromocytoma methods convert VMA vanillin
Methyldopa does not interfere with measurement of VMA (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert VMA to vanillin. 	Methyldopa	vanillylmandelic acid	none	{'e1': {'word': 'Methyldopa', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d779.s16.e0'}, 'e2': {'word': 'vanillylmandelic acid', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d779.s16.e2'}, 'sentence_id': 'DDI-DrugBank.d779.s16'}	Methyldopa interfere measurement VMA vanillylmandelic acid test pheochromocytoma methods convert VMA vanillin
Methyldopa does not interfere with measurement of VMA (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert VMA to vanillin. 	Methyldopa	VMA	none	{'e1': {'word': 'Methyldopa', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d779.s16.e0'}, 'e2': {'word': 'VMA', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d779.s16.e3'}, 'sentence_id': 'DDI-DrugBank.d779.s16'}	Methyldopa interfere measurement VMA vanillylmandelic acid test pheochromocytoma methods convert VMA vanillin
Methyldopa does not interfere with measurement of VMA (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert VMA to vanillin. 	Methyldopa	vanillin	none	{'e1': {'word': 'Methyldopa', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d779.s16.e0'}, 'e2': {'word': 'vanillin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d779.s16.e4'}, 'sentence_id': 'DDI-DrugBank.d779.s16'}	Methyldopa interfere measurement VMA vanillylmandelic acid test pheochromocytoma methods convert VMA vanillin
Methyldopa does not interfere with measurement of VMA (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert VMA to vanillin. 	VMA	vanillylmandelic acid	none	{'e1': {'word': 'VMA', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d779.s16.e1'}, 'e2': {'word': 'vanillylmandelic acid', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d779.s16.e2'}, 'sentence_id': 'DDI-DrugBank.d779.s16'}	Methyldopa interfere measurement VMA vanillylmandelic acid test pheochromocytoma methods convert VMA vanillin
Methyldopa does not interfere with measurement of VMA (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert VMA to vanillin. 	VMA	VMA	none	{'e1': {'word': 'VMA', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d779.s16.e1'}, 'e2': {'word': 'VMA', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d779.s16.e3'}, 'sentence_id': 'DDI-DrugBank.d779.s16'}	Methyldopa interfere measurement VMA vanillylmandelic acid test pheochromocytoma methods convert VMA vanillin
Methyldopa does not interfere with measurement of VMA (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert VMA to vanillin. 	VMA	vanillin	none	{'e1': {'word': 'VMA', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d779.s16.e1'}, 'e2': {'word': 'vanillin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d779.s16.e4'}, 'sentence_id': 'DDI-DrugBank.d779.s16'}	Methyldopa interfere measurement VMA vanillylmandelic acid test pheochromocytoma methods convert VMA vanillin
Methyldopa does not interfere with measurement of VMA (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert VMA to vanillin. 	vanillylmandelic acid	VMA	none	{'e1': {'word': 'vanillylmandelic acid', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d779.s16.e2'}, 'e2': {'word': 'VMA', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d779.s16.e3'}, 'sentence_id': 'DDI-DrugBank.d779.s16'}	Methyldopa interfere measurement VMA vanillylmandelic acid test pheochromocytoma methods convert VMA vanillin
Methyldopa does not interfere with measurement of VMA (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert VMA to vanillin. 	vanillylmandelic acid	vanillin	none	{'e1': {'word': 'vanillylmandelic acid', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d779.s16.e2'}, 'e2': {'word': 'vanillin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d779.s16.e4'}, 'sentence_id': 'DDI-DrugBank.d779.s16'}	Methyldopa interfere measurement VMA vanillylmandelic acid test pheochromocytoma methods convert VMA vanillin
Methyldopa does not interfere with measurement of VMA (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert VMA to vanillin. 	VMA	vanillin	none	{'e1': {'word': 'VMA', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d779.s16.e3'}, 'e2': {'word': 'vanillin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d779.s16.e4'}, 'sentence_id': 'DDI-DrugBank.d779.s16'}	Methyldopa interfere measurement VMA vanillylmandelic acid test pheochromocytoma methods convert VMA vanillin
Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. 	tetracyclines	anticoagulant	advise	{'e1': {'word': 'tetracyclines', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d711.s0.e0'}, 'e2': {'word': 'anticoagulant', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d711.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d711.s0'}	tetracyclines shown depress plasma prothrombin activity patients anticoagulant therapy may require downward adjustment anticoagulant dosage
Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. 	tetracyclines	anticoagulant	none	{'e1': {'word': 'tetracyclines', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d711.s0.e0'}, 'e2': {'word': 'anticoagulant', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d711.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d711.s0'}	tetracyclines shown depress plasma prothrombin activity patients anticoagulant therapy may require downward adjustment anticoagulant dosage
Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. 	anticoagulant	anticoagulant	none	{'e1': {'word': 'anticoagulant', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d711.s0.e1'}, 'e2': {'word': 'anticoagulant', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d711.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d711.s0'}	tetracyclines shown depress plasma prothrombin activity patients anticoagulant therapy may require downward adjustment anticoagulant dosage
Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline class drugs in conjunction with penicillin. 	penicillin	tetracycline class drugs	none	{'e1': {'word': 'penicillin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d711.s1.e0'}, 'e2': {'word': 'tetracycline class drugs', 'word_index': [(11, 13)], 'id': 'DDI-DrugBank.d711.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d711.s1'}	Since bacteriostatic drugs may interfere bactericidal action penicillin advisable avoid giving tetracycline class drugs conjunction penicillin
Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline class drugs in conjunction with penicillin. 	penicillin	penicillin	none	{'e1': {'word': 'penicillin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d711.s1.e0'}, 'e2': {'word': 'penicillin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d711.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d711.s1'}	Since bacteriostatic drugs may interfere bactericidal action penicillin advisable avoid giving tetracycline class drugs conjunction penicillin
Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline class drugs in conjunction with penicillin. 	tetracycline class drugs	penicillin	advise	{'e1': {'word': 'tetracycline class drugs', 'word_index': [(11, 13)], 'id': 'DDI-DrugBank.d711.s1.e1'}, 'e2': {'word': 'penicillin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d711.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d711.s1'}	Since bacteriostatic drugs may interfere bactericidal action penicillin advisable avoid giving tetracycline class drugs conjunction penicillin
Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. 	tetracyclines	antacids	none	{'e1': {'word': 'tetracyclines', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d711.s2.e0'}, 'e2': {'word': 'antacids', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d711.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d711.s2'}	Absorption tetracyclines impaired antacids containing aluminum calcium magnesium iron containing preparations
Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. 	tetracyclines	aluminum	mechanism	{'e1': {'word': 'tetracyclines', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d711.s2.e0'}, 'e2': {'word': 'aluminum', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d711.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d711.s2'}	Absorption tetracyclines impaired antacids containing aluminum calcium magnesium iron containing preparations
Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. 	tetracyclines	calcium	mechanism	{'e1': {'word': 'tetracyclines', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d711.s2.e0'}, 'e2': {'word': 'calcium', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d711.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d711.s2'}	Absorption tetracyclines impaired antacids containing aluminum calcium magnesium iron containing preparations
Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. 	tetracyclines	magnesium	mechanism	{'e1': {'word': 'tetracyclines', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d711.s2.e0'}, 'e2': {'word': 'magnesium', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d711.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d711.s2'}	Absorption tetracyclines impaired antacids containing aluminum calcium magnesium iron containing preparations
Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. 	tetracyclines	iron	mechanism	{'e1': {'word': 'tetracyclines', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d711.s2.e0'}, 'e2': {'word': 'iron', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d711.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d711.s2'}	Absorption tetracyclines impaired antacids containing aluminum calcium magnesium iron containing preparations
Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. 	antacids	aluminum	none	{'e1': {'word': 'antacids', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d711.s2.e1'}, 'e2': {'word': 'aluminum', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d711.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d711.s2'}	Absorption tetracyclines impaired antacids containing aluminum calcium magnesium iron containing preparations
Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. 	antacids	calcium	none	{'e1': {'word': 'antacids', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d711.s2.e1'}, 'e2': {'word': 'calcium', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d711.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d711.s2'}	Absorption tetracyclines impaired antacids containing aluminum calcium magnesium iron containing preparations
Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. 	antacids	magnesium	none	{'e1': {'word': 'antacids', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d711.s2.e1'}, 'e2': {'word': 'magnesium', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d711.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d711.s2'}	Absorption tetracyclines impaired antacids containing aluminum calcium magnesium iron containing preparations
Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. 	antacids	iron	none	{'e1': {'word': 'antacids', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d711.s2.e1'}, 'e2': {'word': 'iron', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d711.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d711.s2'}	Absorption tetracyclines impaired antacids containing aluminum calcium magnesium iron containing preparations
Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. 	aluminum	calcium	none	{'e1': {'word': 'aluminum', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d711.s2.e2'}, 'e2': {'word': 'calcium', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d711.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d711.s2'}	Absorption tetracyclines impaired antacids containing aluminum calcium magnesium iron containing preparations
Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. 	aluminum	magnesium	none	{'e1': {'word': 'aluminum', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d711.s2.e2'}, 'e2': {'word': 'magnesium', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d711.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d711.s2'}	Absorption tetracyclines impaired antacids containing aluminum calcium magnesium iron containing preparations
Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. 	aluminum	iron	none	{'e1': {'word': 'aluminum', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d711.s2.e2'}, 'e2': {'word': 'iron', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d711.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d711.s2'}	Absorption tetracyclines impaired antacids containing aluminum calcium magnesium iron containing preparations
Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. 	calcium	magnesium	none	{'e1': {'word': 'calcium', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d711.s2.e3'}, 'e2': {'word': 'magnesium', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d711.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d711.s2'}	Absorption tetracyclines impaired antacids containing aluminum calcium magnesium iron containing preparations
Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. 	calcium	iron	none	{'e1': {'word': 'calcium', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d711.s2.e3'}, 'e2': {'word': 'iron', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d711.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d711.s2'}	Absorption tetracyclines impaired antacids containing aluminum calcium magnesium iron containing preparations
Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. 	magnesium	iron	none	{'e1': {'word': 'magnesium', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d711.s2.e4'}, 'e2': {'word': 'iron', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d711.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d711.s2'}	Absorption tetracyclines impaired antacids containing aluminum calcium magnesium iron containing preparations
The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity. 	tetracycline	methoxyflurane	effect	{'e1': {'word': 'tetracycline', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d711.s3.e0'}, 'e2': {'word': 'methoxyflurane', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d711.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d711.s3'}	concurrent use tetracycline methoxyflurane reported result fatal renal toxicity
Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.	tetracyclines	contraceptives	effect	{'e1': {'word': 'tetracyclines', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d711.s4.e0'}, 'e2': {'word': 'contraceptives', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d711.s4.e1'}, 'sentence_id': 'DDI-DrugBank.d711.s4'}	Concurrent use tetracyclines oral contraceptives may render oral contraceptives less effective
Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.	tetracyclines	contraceptives	none	{'e1': {'word': 'tetracyclines', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d711.s4.e0'}, 'e2': {'word': 'contraceptives', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d711.s4.e2'}, 'sentence_id': 'DDI-DrugBank.d711.s4'}	Concurrent use tetracyclines oral contraceptives may render oral contraceptives less effective
Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.	contraceptives	contraceptives	none	{'e1': {'word': 'contraceptives', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d711.s4.e1'}, 'e2': {'word': 'contraceptives', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d711.s4.e2'}, 'sentence_id': 'DDI-DrugBank.d711.s4'}	Concurrent use tetracyclines oral contraceptives may render oral contraceptives less effective
Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). 	mifepristone	ketoconazole	none	{'e1': {'word': 'mifepristone', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d668.s0.e0'}, 'e2': {'word': 'ketoconazole', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d668.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d668.s0'}	Although specific drug food interactions mifepristone studied basis drug metabolism CYP 3A4 possible ketoconazole itraconazole erythromycin grapefruit juice may inhibit metabolism increasing serum levels mifepristone
Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). 	mifepristone	itraconazole	none	{'e1': {'word': 'mifepristone', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d668.s0.e0'}, 'e2': {'word': 'itraconazole', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d668.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d668.s0'}	Although specific drug food interactions mifepristone studied basis drug metabolism CYP 3A4 possible ketoconazole itraconazole erythromycin grapefruit juice may inhibit metabolism increasing serum levels mifepristone
Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). 	mifepristone	erythromycin	none	{'e1': {'word': 'mifepristone', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d668.s0.e0'}, 'e2': {'word': 'erythromycin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d668.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d668.s0'}	Although specific drug food interactions mifepristone studied basis drug metabolism CYP 3A4 possible ketoconazole itraconazole erythromycin grapefruit juice may inhibit metabolism increasing serum levels mifepristone
Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). 	mifepristone	mifepristone	none	{'e1': {'word': 'mifepristone', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d668.s0.e0'}, 'e2': {'word': 'mifepristone', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d668.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d668.s0'}	Although specific drug food interactions mifepristone studied basis drug metabolism CYP 3A4 possible ketoconazole itraconazole erythromycin grapefruit juice may inhibit metabolism increasing serum levels mifepristone
Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). 	ketoconazole	itraconazole	none	{'e1': {'word': 'ketoconazole', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d668.s0.e1'}, 'e2': {'word': 'itraconazole', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d668.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d668.s0'}	Although specific drug food interactions mifepristone studied basis drug metabolism CYP 3A4 possible ketoconazole itraconazole erythromycin grapefruit juice may inhibit metabolism increasing serum levels mifepristone
Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). 	ketoconazole	erythromycin	none	{'e1': {'word': 'ketoconazole', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d668.s0.e1'}, 'e2': {'word': 'erythromycin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d668.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d668.s0'}	Although specific drug food interactions mifepristone studied basis drug metabolism CYP 3A4 possible ketoconazole itraconazole erythromycin grapefruit juice may inhibit metabolism increasing serum levels mifepristone
Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). 	ketoconazole	mifepristone	mechanism	{'e1': {'word': 'ketoconazole', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d668.s0.e1'}, 'e2': {'word': 'mifepristone', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d668.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d668.s0'}	Although specific drug food interactions mifepristone studied basis drug metabolism CYP 3A4 possible ketoconazole itraconazole erythromycin grapefruit juice may inhibit metabolism increasing serum levels mifepristone
Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). 	itraconazole	erythromycin	none	{'e1': {'word': 'itraconazole', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d668.s0.e2'}, 'e2': {'word': 'erythromycin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d668.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d668.s0'}	Although specific drug food interactions mifepristone studied basis drug metabolism CYP 3A4 possible ketoconazole itraconazole erythromycin grapefruit juice may inhibit metabolism increasing serum levels mifepristone
Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). 	itraconazole	mifepristone	mechanism	{'e1': {'word': 'itraconazole', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d668.s0.e2'}, 'e2': {'word': 'mifepristone', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d668.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d668.s0'}	Although specific drug food interactions mifepristone studied basis drug metabolism CYP 3A4 possible ketoconazole itraconazole erythromycin grapefruit juice may inhibit metabolism increasing serum levels mifepristone
Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). 	erythromycin	mifepristone	mechanism	{'e1': {'word': 'erythromycin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d668.s0.e3'}, 'e2': {'word': 'mifepristone', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d668.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d668.s0'}	Although specific drug food interactions mifepristone studied basis drug metabolism CYP 3A4 possible ketoconazole itraconazole erythromycin grapefruit juice may inhibit metabolism increasing serum levels mifepristone
Furthermore, rifampin, dexamethasone, St. 	rifampin	dexamethasone	none	{'e1': {'word': 'rifampin', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d668.s1.e0'}, 'e2': {'word': 'dexamethasone', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d668.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d668.s1'}	Furthermore rifampin dexamethasone St.
John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). 	anticonvulsants	phenytoin	none	{'e1': {'word': 'anticonvulsants', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d668.s2.e0'}, 'e2': {'word': 'phenytoin', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d668.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d668.s2'}	John Wort certain anticonvulsants phenytoin phenobarbital carbamazepine may induce mifepristone metabolism lowering serum levels mifepristone
John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). 	anticonvulsants	phenobarbital	none	{'e1': {'word': 'anticonvulsants', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d668.s2.e0'}, 'e2': {'word': 'phenobarbital', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d668.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d668.s2'}	John Wort certain anticonvulsants phenytoin phenobarbital carbamazepine may induce mifepristone metabolism lowering serum levels mifepristone
John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). 	anticonvulsants	carbamazepine	none	{'e1': {'word': 'anticonvulsants', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d668.s2.e0'}, 'e2': {'word': 'carbamazepine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d668.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d668.s2'}	John Wort certain anticonvulsants phenytoin phenobarbital carbamazepine may induce mifepristone metabolism lowering serum levels mifepristone
John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). 	anticonvulsants	mifepristone	mechanism	{'e1': {'word': 'anticonvulsants', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d668.s2.e0'}, 'e2': {'word': 'mifepristone', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d668.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d668.s2'}	John Wort certain anticonvulsants phenytoin phenobarbital carbamazepine may induce mifepristone metabolism lowering serum levels mifepristone
John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). 	anticonvulsants	mifepristone	none	{'e1': {'word': 'anticonvulsants', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d668.s2.e0'}, 'e2': {'word': 'mifepristone', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d668.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d668.s2'}	John Wort certain anticonvulsants phenytoin phenobarbital carbamazepine may induce mifepristone metabolism lowering serum levels mifepristone
John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). 	phenytoin	phenobarbital	none	{'e1': {'word': 'phenytoin', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d668.s2.e1'}, 'e2': {'word': 'phenobarbital', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d668.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d668.s2'}	John Wort certain anticonvulsants phenytoin phenobarbital carbamazepine may induce mifepristone metabolism lowering serum levels mifepristone
John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). 	phenytoin	carbamazepine	none	{'e1': {'word': 'phenytoin', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d668.s2.e1'}, 'e2': {'word': 'carbamazepine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d668.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d668.s2'}	John Wort certain anticonvulsants phenytoin phenobarbital carbamazepine may induce mifepristone metabolism lowering serum levels mifepristone
John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). 	phenytoin	mifepristone	mechanism	{'e1': {'word': 'phenytoin', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d668.s2.e1'}, 'e2': {'word': 'mifepristone', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d668.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d668.s2'}	John Wort certain anticonvulsants phenytoin phenobarbital carbamazepine may induce mifepristone metabolism lowering serum levels mifepristone
John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). 	phenytoin	mifepristone	none	{'e1': {'word': 'phenytoin', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d668.s2.e1'}, 'e2': {'word': 'mifepristone', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d668.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d668.s2'}	John Wort certain anticonvulsants phenytoin phenobarbital carbamazepine may induce mifepristone metabolism lowering serum levels mifepristone
John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). 	phenobarbital	carbamazepine	none	{'e1': {'word': 'phenobarbital', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d668.s2.e2'}, 'e2': {'word': 'carbamazepine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d668.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d668.s2'}	John Wort certain anticonvulsants phenytoin phenobarbital carbamazepine may induce mifepristone metabolism lowering serum levels mifepristone
John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). 	phenobarbital	mifepristone	mechanism	{'e1': {'word': 'phenobarbital', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d668.s2.e2'}, 'e2': {'word': 'mifepristone', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d668.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d668.s2'}	John Wort certain anticonvulsants phenytoin phenobarbital carbamazepine may induce mifepristone metabolism lowering serum levels mifepristone
John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). 	phenobarbital	mifepristone	none	{'e1': {'word': 'phenobarbital', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d668.s2.e2'}, 'e2': {'word': 'mifepristone', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d668.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d668.s2'}	John Wort certain anticonvulsants phenytoin phenobarbital carbamazepine may induce mifepristone metabolism lowering serum levels mifepristone
John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). 	carbamazepine	mifepristone	mechanism	{'e1': {'word': 'carbamazepine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d668.s2.e3'}, 'e2': {'word': 'mifepristone', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d668.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d668.s2'}	John Wort certain anticonvulsants phenytoin phenobarbital carbamazepine may induce mifepristone metabolism lowering serum levels mifepristone
John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). 	carbamazepine	mifepristone	none	{'e1': {'word': 'carbamazepine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d668.s2.e3'}, 'e2': {'word': 'mifepristone', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d668.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d668.s2'}	John Wort certain anticonvulsants phenytoin phenobarbital carbamazepine may induce mifepristone metabolism lowering serum levels mifepristone
John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). 	mifepristone	mifepristone	none	{'e1': {'word': 'mifepristone', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d668.s2.e4'}, 'e2': {'word': 'mifepristone', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d668.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d668.s2'}	John Wort certain anticonvulsants phenytoin phenobarbital carbamazepine may induce mifepristone metabolism lowering serum levels mifepristone
Although MIVACRON (a mixture of three stereoisomers) has been administered safely following succinylcholine-facilitated tracheal intubation, the interaction between MIVACRON and succinylcholine has not been systematically studied. 	MIVACRON	MIVACRON	none	{'e1': {'word': 'MIVACRON', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d775.s0.e0'}, 'e2': {'word': 'MIVACRON', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d775.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d775.s0'}	Although MIVACRON mixture NUMBER stereoisomers administered safely following succinylcholine facilitated tracheal intubation interaction MIVACRON succinylcholine systematically studied
Although MIVACRON (a mixture of three stereoisomers) has been administered safely following succinylcholine-facilitated tracheal intubation, the interaction between MIVACRON and succinylcholine has not been systematically studied. 	MIVACRON	succinylcholine	none	{'e1': {'word': 'MIVACRON', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d775.s0.e0'}, 'e2': {'word': 'succinylcholine', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d775.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d775.s0'}	Although MIVACRON mixture NUMBER stereoisomers administered safely following succinylcholine facilitated tracheal intubation interaction MIVACRON succinylcholine systematically studied
Although MIVACRON (a mixture of three stereoisomers) has been administered safely following succinylcholine-facilitated tracheal intubation, the interaction between MIVACRON and succinylcholine has not been systematically studied. 	MIVACRON	succinylcholine	none	{'e1': {'word': 'MIVACRON', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d775.s0.e1'}, 'e2': {'word': 'succinylcholine', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d775.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d775.s0'}	Although MIVACRON mixture NUMBER stereoisomers administered safely following succinylcholine facilitated tracheal intubation interaction MIVACRON succinylcholine systematically studied
Prior administration of succinylcholine can potentiate the neuromuscular blocking effects of nondepolarizing agents. 	succinylcholine	nondepolarizing agents	effect	{'e1': {'word': 'succinylcholine', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d775.s1.e0'}, 'e2': {'word': 'nondepolarizing agents', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d775.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d775.s1'}	Prior administration succinylcholine potentiate neuromuscular blocking effects nondepolarizing agents
Evidence of spontaneous recovery from succinylcholine should be observed before the administration of MIVACRON. 	succinylcholine	MIVACRON	advise	{'e1': {'word': 'succinylcholine', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d775.s2.e0'}, 'e2': {'word': 'MIVACRON', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d775.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d775.s2'}	Evidence spontaneous recovery succinylcholine observed administration MIVACRON
The use of MIVACRON before succinylcholine to attenuate some of the side effects of succinylcholine has not been studied. 	MIVACRON	succinylcholine	none	{'e1': {'word': 'MIVACRON', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d775.s3.e0'}, 'e2': {'word': 'succinylcholine', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d775.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d775.s3'}	use MIVACRON succinylcholine attenuate side effects succinylcholine studied
The use of MIVACRON before succinylcholine to attenuate some of the side effects of succinylcholine has not been studied. 	MIVACRON	succinylcholine	none	{'e1': {'word': 'MIVACRON', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d775.s3.e0'}, 'e2': {'word': 'succinylcholine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d775.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d775.s3'}	use MIVACRON succinylcholine attenuate side effects succinylcholine studied
The use of MIVACRON before succinylcholine to attenuate some of the side effects of succinylcholine has not been studied. 	succinylcholine	succinylcholine	none	{'e1': {'word': 'succinylcholine', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d775.s3.e1'}, 'e2': {'word': 'succinylcholine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d775.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d775.s3'}	use MIVACRON succinylcholine attenuate side effects succinylcholine studied
There are no clinical data on the use of MIVACRON with other nondepolarizing neuromuscular blocking agents. 	MIVACRON	nondepolarizing neuromuscular blocking agents	none	{'e1': {'word': 'MIVACRON', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d775.s4.e0'}, 'e2': {'word': 'nondepolarizing neuromuscular blocking agents', 'word_index': [(4, 7)], 'id': 'DDI-DrugBank.d775.s4.e1'}, 'sentence_id': 'DDI-DrugBank.d775.s4'}	clinical data use MIVACRON nondepolarizing neuromuscular blocking agents
Isoflurane and enflurane (administered with nitrous oxide/oxygen to achieve 1.25 M.C. 	Isoflurane	enflurane	none	{'e1': {'word': 'Isoflurane', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d775.s5.e0'}, 'e2': {'word': 'enflurane', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d775.s5.e1'}, 'sentence_id': 'DDI-DrugBank.d775.s5'}	Isoflurane enflurane administered nitrous oxide oxygen achieve NUMBER M.C.
Isoflurane and enflurane (administered with nitrous oxide/oxygen to achieve 1.25 M.C. 	Isoflurane	nitrous oxide	none	{'e1': {'word': 'Isoflurane', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d775.s5.e0'}, 'e2': {'word': 'nitrous oxide', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d775.s5.e2'}, 'sentence_id': 'DDI-DrugBank.d775.s5'}	Isoflurane enflurane administered nitrous oxide oxygen achieve NUMBER M.C.
Isoflurane and enflurane (administered with nitrous oxide/oxygen to achieve 1.25 M.C. 	Isoflurane	oxygen	none	{'e1': {'word': 'Isoflurane', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d775.s5.e0'}, 'e2': {'word': 'oxygen', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d775.s5.e3'}, 'sentence_id': 'DDI-DrugBank.d775.s5'}	Isoflurane enflurane administered nitrous oxide oxygen achieve NUMBER M.C.
Isoflurane and enflurane (administered with nitrous oxide/oxygen to achieve 1.25 M.C. 	enflurane	nitrous oxide	none	{'e1': {'word': 'enflurane', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d775.s5.e1'}, 'e2': {'word': 'nitrous oxide', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d775.s5.e2'}, 'sentence_id': 'DDI-DrugBank.d775.s5'}	Isoflurane enflurane administered nitrous oxide oxygen achieve NUMBER M.C.
Isoflurane and enflurane (administered with nitrous oxide/oxygen to achieve 1.25 M.C. 	enflurane	oxygen	none	{'e1': {'word': 'enflurane', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d775.s5.e1'}, 'e2': {'word': 'oxygen', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d775.s5.e3'}, 'sentence_id': 'DDI-DrugBank.d775.s5'}	Isoflurane enflurane administered nitrous oxide oxygen achieve NUMBER M.C.
Isoflurane and enflurane (administered with nitrous oxide/oxygen to achieve 1.25 M.C. 	nitrous oxide	oxygen	none	{'e1': {'word': 'nitrous oxide', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d775.s5.e2'}, 'e2': {'word': 'oxygen', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d775.s5.e3'}, 'sentence_id': 'DDI-DrugBank.d775.s5'}	Isoflurane enflurane administered nitrous oxide oxygen achieve NUMBER M.C.
A greater potentiation of the neuromuscular blocking effects of MIVACRON may be expected with higher concentrations of enflurane or isoflurane. 	MIVACRON	enflurane	none	{'e1': {'word': 'MIVACRON', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d775.s8.e0'}, 'e2': {'word': 'enflurane', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d775.s8.e1'}, 'sentence_id': 'DDI-DrugBank.d775.s8'}	greater potentiation neuromuscular blocking effects MIVACRON may expected higher concentrations enflurane isoflurane
A greater potentiation of the neuromuscular blocking effects of MIVACRON may be expected with higher concentrations of enflurane or isoflurane. 	MIVACRON	isoflurane	none	{'e1': {'word': 'MIVACRON', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d775.s8.e0'}, 'e2': {'word': 'isoflurane', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d775.s8.e2'}, 'sentence_id': 'DDI-DrugBank.d775.s8'}	greater potentiation neuromuscular blocking effects MIVACRON may expected higher concentrations enflurane isoflurane
A greater potentiation of the neuromuscular blocking effects of MIVACRON may be expected with higher concentrations of enflurane or isoflurane. 	enflurane	isoflurane	none	{'e1': {'word': 'enflurane', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d775.s8.e1'}, 'e2': {'word': 'isoflurane', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d775.s8.e2'}, 'sentence_id': 'DDI-DrugBank.d775.s8'}	greater potentiation neuromuscular blocking effects MIVACRON may expected higher concentrations enflurane isoflurane
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	nondepolarizing agents	MIVACRON	none	{'e1': {'word': 'nondepolarizing agents', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d775.s10.e0'}, 'e2': {'word': 'MIVACRON', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d775.s10.e1'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	nondepolarizing agents	antibiotics	int	{'e1': {'word': 'nondepolarizing agents', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d775.s10.e0'}, 'e2': {'word': 'antibiotics', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d775.s10.e2'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	nondepolarizing agents	aminoglycosides	int	{'e1': {'word': 'nondepolarizing agents', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d775.s10.e0'}, 'e2': {'word': 'aminoglycosides', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d775.s10.e3'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	nondepolarizing agents	tetracyclines	int	{'e1': {'word': 'nondepolarizing agents', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d775.s10.e0'}, 'e2': {'word': 'tetracyclines', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d775.s10.e4'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	nondepolarizing agents	bacitracin	int	{'e1': {'word': 'nondepolarizing agents', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d775.s10.e0'}, 'e2': {'word': 'bacitracin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d775.s10.e5'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	nondepolarizing agents	polymyxins	int	{'e1': {'word': 'nondepolarizing agents', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d775.s10.e0'}, 'e2': {'word': 'polymyxins', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d775.s10.e6'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	nondepolarizing agents	lincomycin	int	{'e1': {'word': 'nondepolarizing agents', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d775.s10.e0'}, 'e2': {'word': 'lincomycin', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d775.s10.e7'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	nondepolarizing agents	clindamycin	int	{'e1': {'word': 'nondepolarizing agents', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d775.s10.e0'}, 'e2': {'word': 'clindamycin', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d775.s10.e8'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	nondepolarizing agents	colistin	int	{'e1': {'word': 'nondepolarizing agents', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d775.s10.e0'}, 'e2': {'word': 'colistin', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d775.s10.e9'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	nondepolarizing agents	sodium colistimethate	int	{'e1': {'word': 'nondepolarizing agents', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d775.s10.e0'}, 'e2': {'word': 'sodium colistimethate', 'word_index': [(20, 21)], 'id': 'DDI-DrugBank.d775.s10.e10'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	nondepolarizing agents	magnesium	int	{'e1': {'word': 'nondepolarizing agents', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d775.s10.e0'}, 'e2': {'word': 'magnesium', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d775.s10.e11'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	nondepolarizing agents	lithium	int	{'e1': {'word': 'nondepolarizing agents', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d775.s10.e0'}, 'e2': {'word': 'lithium', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d775.s10.e12'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	nondepolarizing agents	anesthetics	int	{'e1': {'word': 'nondepolarizing agents', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d775.s10.e0'}, 'e2': {'word': 'anesthetics', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d775.s10.e13'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	nondepolarizing agents	procainamide	int	{'e1': {'word': 'nondepolarizing agents', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d775.s10.e0'}, 'e2': {'word': 'procainamide', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d775.s10.e14'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	nondepolarizing agents	quinidine	int	{'e1': {'word': 'nondepolarizing agents', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d775.s10.e0'}, 'e2': {'word': 'quinidine', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d775.s10.e15'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	MIVACRON	antibiotics	int	{'e1': {'word': 'MIVACRON', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d775.s10.e1'}, 'e2': {'word': 'antibiotics', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d775.s10.e2'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	MIVACRON	aminoglycosides	int	{'e1': {'word': 'MIVACRON', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d775.s10.e1'}, 'e2': {'word': 'aminoglycosides', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d775.s10.e3'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	MIVACRON	tetracyclines	int	{'e1': {'word': 'MIVACRON', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d775.s10.e1'}, 'e2': {'word': 'tetracyclines', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d775.s10.e4'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	MIVACRON	bacitracin	int	{'e1': {'word': 'MIVACRON', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d775.s10.e1'}, 'e2': {'word': 'bacitracin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d775.s10.e5'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	MIVACRON	polymyxins	int	{'e1': {'word': 'MIVACRON', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d775.s10.e1'}, 'e2': {'word': 'polymyxins', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d775.s10.e6'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	MIVACRON	lincomycin	int	{'e1': {'word': 'MIVACRON', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d775.s10.e1'}, 'e2': {'word': 'lincomycin', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d775.s10.e7'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	MIVACRON	clindamycin	int	{'e1': {'word': 'MIVACRON', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d775.s10.e1'}, 'e2': {'word': 'clindamycin', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d775.s10.e8'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	MIVACRON	colistin	int	{'e1': {'word': 'MIVACRON', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d775.s10.e1'}, 'e2': {'word': 'colistin', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d775.s10.e9'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	MIVACRON	sodium colistimethate	int	{'e1': {'word': 'MIVACRON', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d775.s10.e1'}, 'e2': {'word': 'sodium colistimethate', 'word_index': [(20, 21)], 'id': 'DDI-DrugBank.d775.s10.e10'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	MIVACRON	magnesium	int	{'e1': {'word': 'MIVACRON', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d775.s10.e1'}, 'e2': {'word': 'magnesium', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d775.s10.e11'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	MIVACRON	lithium	int	{'e1': {'word': 'MIVACRON', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d775.s10.e1'}, 'e2': {'word': 'lithium', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d775.s10.e12'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	MIVACRON	anesthetics	int	{'e1': {'word': 'MIVACRON', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d775.s10.e1'}, 'e2': {'word': 'anesthetics', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d775.s10.e13'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	MIVACRON	procainamide	int	{'e1': {'word': 'MIVACRON', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d775.s10.e1'}, 'e2': {'word': 'procainamide', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d775.s10.e14'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	MIVACRON	quinidine	int	{'e1': {'word': 'MIVACRON', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d775.s10.e1'}, 'e2': {'word': 'quinidine', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d775.s10.e15'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	antibiotics	aminoglycosides	none	{'e1': {'word': 'antibiotics', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d775.s10.e2'}, 'e2': {'word': 'aminoglycosides', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d775.s10.e3'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	antibiotics	tetracyclines	none	{'e1': {'word': 'antibiotics', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d775.s10.e2'}, 'e2': {'word': 'tetracyclines', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d775.s10.e4'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	antibiotics	bacitracin	none	{'e1': {'word': 'antibiotics', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d775.s10.e2'}, 'e2': {'word': 'bacitracin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d775.s10.e5'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	antibiotics	polymyxins	none	{'e1': {'word': 'antibiotics', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d775.s10.e2'}, 'e2': {'word': 'polymyxins', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d775.s10.e6'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	antibiotics	lincomycin	none	{'e1': {'word': 'antibiotics', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d775.s10.e2'}, 'e2': {'word': 'lincomycin', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d775.s10.e7'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	antibiotics	clindamycin	none	{'e1': {'word': 'antibiotics', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d775.s10.e2'}, 'e2': {'word': 'clindamycin', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d775.s10.e8'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	antibiotics	colistin	none	{'e1': {'word': 'antibiotics', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d775.s10.e2'}, 'e2': {'word': 'colistin', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d775.s10.e9'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	antibiotics	sodium colistimethate	none	{'e1': {'word': 'antibiotics', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d775.s10.e2'}, 'e2': {'word': 'sodium colistimethate', 'word_index': [(20, 21)], 'id': 'DDI-DrugBank.d775.s10.e10'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	antibiotics	magnesium	none	{'e1': {'word': 'antibiotics', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d775.s10.e2'}, 'e2': {'word': 'magnesium', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d775.s10.e11'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	antibiotics	lithium	none	{'e1': {'word': 'antibiotics', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d775.s10.e2'}, 'e2': {'word': 'lithium', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d775.s10.e12'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	antibiotics	anesthetics	none	{'e1': {'word': 'antibiotics', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d775.s10.e2'}, 'e2': {'word': 'anesthetics', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d775.s10.e13'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	antibiotics	procainamide	none	{'e1': {'word': 'antibiotics', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d775.s10.e2'}, 'e2': {'word': 'procainamide', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d775.s10.e14'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	antibiotics	quinidine	none	{'e1': {'word': 'antibiotics', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d775.s10.e2'}, 'e2': {'word': 'quinidine', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d775.s10.e15'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	aminoglycosides	tetracyclines	none	{'e1': {'word': 'aminoglycosides', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d775.s10.e3'}, 'e2': {'word': 'tetracyclines', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d775.s10.e4'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	aminoglycosides	bacitracin	none	{'e1': {'word': 'aminoglycosides', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d775.s10.e3'}, 'e2': {'word': 'bacitracin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d775.s10.e5'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	aminoglycosides	polymyxins	none	{'e1': {'word': 'aminoglycosides', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d775.s10.e3'}, 'e2': {'word': 'polymyxins', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d775.s10.e6'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	aminoglycosides	lincomycin	none	{'e1': {'word': 'aminoglycosides', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d775.s10.e3'}, 'e2': {'word': 'lincomycin', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d775.s10.e7'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	aminoglycosides	clindamycin	none	{'e1': {'word': 'aminoglycosides', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d775.s10.e3'}, 'e2': {'word': 'clindamycin', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d775.s10.e8'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	aminoglycosides	colistin	none	{'e1': {'word': 'aminoglycosides', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d775.s10.e3'}, 'e2': {'word': 'colistin', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d775.s10.e9'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	aminoglycosides	sodium colistimethate	none	{'e1': {'word': 'aminoglycosides', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d775.s10.e3'}, 'e2': {'word': 'sodium colistimethate', 'word_index': [(20, 21)], 'id': 'DDI-DrugBank.d775.s10.e10'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	aminoglycosides	magnesium	none	{'e1': {'word': 'aminoglycosides', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d775.s10.e3'}, 'e2': {'word': 'magnesium', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d775.s10.e11'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	aminoglycosides	lithium	none	{'e1': {'word': 'aminoglycosides', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d775.s10.e3'}, 'e2': {'word': 'lithium', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d775.s10.e12'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	aminoglycosides	anesthetics	none	{'e1': {'word': 'aminoglycosides', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d775.s10.e3'}, 'e2': {'word': 'anesthetics', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d775.s10.e13'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	aminoglycosides	procainamide	none	{'e1': {'word': 'aminoglycosides', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d775.s10.e3'}, 'e2': {'word': 'procainamide', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d775.s10.e14'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	aminoglycosides	quinidine	none	{'e1': {'word': 'aminoglycosides', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d775.s10.e3'}, 'e2': {'word': 'quinidine', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d775.s10.e15'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	tetracyclines	bacitracin	none	{'e1': {'word': 'tetracyclines', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d775.s10.e4'}, 'e2': {'word': 'bacitracin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d775.s10.e5'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	tetracyclines	polymyxins	none	{'e1': {'word': 'tetracyclines', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d775.s10.e4'}, 'e2': {'word': 'polymyxins', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d775.s10.e6'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	tetracyclines	lincomycin	none	{'e1': {'word': 'tetracyclines', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d775.s10.e4'}, 'e2': {'word': 'lincomycin', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d775.s10.e7'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	tetracyclines	clindamycin	none	{'e1': {'word': 'tetracyclines', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d775.s10.e4'}, 'e2': {'word': 'clindamycin', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d775.s10.e8'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	tetracyclines	colistin	none	{'e1': {'word': 'tetracyclines', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d775.s10.e4'}, 'e2': {'word': 'colistin', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d775.s10.e9'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	tetracyclines	sodium colistimethate	none	{'e1': {'word': 'tetracyclines', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d775.s10.e4'}, 'e2': {'word': 'sodium colistimethate', 'word_index': [(20, 21)], 'id': 'DDI-DrugBank.d775.s10.e10'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	tetracyclines	magnesium	none	{'e1': {'word': 'tetracyclines', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d775.s10.e4'}, 'e2': {'word': 'magnesium', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d775.s10.e11'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	tetracyclines	lithium	none	{'e1': {'word': 'tetracyclines', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d775.s10.e4'}, 'e2': {'word': 'lithium', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d775.s10.e12'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	tetracyclines	anesthetics	none	{'e1': {'word': 'tetracyclines', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d775.s10.e4'}, 'e2': {'word': 'anesthetics', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d775.s10.e13'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	tetracyclines	procainamide	none	{'e1': {'word': 'tetracyclines', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d775.s10.e4'}, 'e2': {'word': 'procainamide', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d775.s10.e14'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	tetracyclines	quinidine	none	{'e1': {'word': 'tetracyclines', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d775.s10.e4'}, 'e2': {'word': 'quinidine', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d775.s10.e15'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	bacitracin	polymyxins	none	{'e1': {'word': 'bacitracin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d775.s10.e5'}, 'e2': {'word': 'polymyxins', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d775.s10.e6'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	bacitracin	lincomycin	none	{'e1': {'word': 'bacitracin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d775.s10.e5'}, 'e2': {'word': 'lincomycin', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d775.s10.e7'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	bacitracin	clindamycin	none	{'e1': {'word': 'bacitracin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d775.s10.e5'}, 'e2': {'word': 'clindamycin', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d775.s10.e8'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	bacitracin	colistin	none	{'e1': {'word': 'bacitracin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d775.s10.e5'}, 'e2': {'word': 'colistin', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d775.s10.e9'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	bacitracin	sodium colistimethate	none	{'e1': {'word': 'bacitracin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d775.s10.e5'}, 'e2': {'word': 'sodium colistimethate', 'word_index': [(20, 21)], 'id': 'DDI-DrugBank.d775.s10.e10'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	bacitracin	magnesium	none	{'e1': {'word': 'bacitracin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d775.s10.e5'}, 'e2': {'word': 'magnesium', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d775.s10.e11'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	bacitracin	lithium	none	{'e1': {'word': 'bacitracin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d775.s10.e5'}, 'e2': {'word': 'lithium', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d775.s10.e12'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	bacitracin	anesthetics	none	{'e1': {'word': 'bacitracin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d775.s10.e5'}, 'e2': {'word': 'anesthetics', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d775.s10.e13'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	bacitracin	procainamide	none	{'e1': {'word': 'bacitracin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d775.s10.e5'}, 'e2': {'word': 'procainamide', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d775.s10.e14'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	bacitracin	quinidine	none	{'e1': {'word': 'bacitracin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d775.s10.e5'}, 'e2': {'word': 'quinidine', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d775.s10.e15'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	polymyxins	lincomycin	none	{'e1': {'word': 'polymyxins', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d775.s10.e6'}, 'e2': {'word': 'lincomycin', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d775.s10.e7'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	polymyxins	clindamycin	none	{'e1': {'word': 'polymyxins', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d775.s10.e6'}, 'e2': {'word': 'clindamycin', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d775.s10.e8'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	polymyxins	colistin	none	{'e1': {'word': 'polymyxins', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d775.s10.e6'}, 'e2': {'word': 'colistin', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d775.s10.e9'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	polymyxins	sodium colistimethate	none	{'e1': {'word': 'polymyxins', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d775.s10.e6'}, 'e2': {'word': 'sodium colistimethate', 'word_index': [(20, 21)], 'id': 'DDI-DrugBank.d775.s10.e10'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	polymyxins	magnesium	none	{'e1': {'word': 'polymyxins', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d775.s10.e6'}, 'e2': {'word': 'magnesium', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d775.s10.e11'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	polymyxins	lithium	none	{'e1': {'word': 'polymyxins', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d775.s10.e6'}, 'e2': {'word': 'lithium', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d775.s10.e12'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	polymyxins	anesthetics	none	{'e1': {'word': 'polymyxins', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d775.s10.e6'}, 'e2': {'word': 'anesthetics', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d775.s10.e13'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	polymyxins	procainamide	none	{'e1': {'word': 'polymyxins', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d775.s10.e6'}, 'e2': {'word': 'procainamide', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d775.s10.e14'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	polymyxins	quinidine	none	{'e1': {'word': 'polymyxins', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d775.s10.e6'}, 'e2': {'word': 'quinidine', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d775.s10.e15'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	lincomycin	clindamycin	none	{'e1': {'word': 'lincomycin', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d775.s10.e7'}, 'e2': {'word': 'clindamycin', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d775.s10.e8'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	lincomycin	colistin	none	{'e1': {'word': 'lincomycin', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d775.s10.e7'}, 'e2': {'word': 'colistin', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d775.s10.e9'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	lincomycin	sodium colistimethate	none	{'e1': {'word': 'lincomycin', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d775.s10.e7'}, 'e2': {'word': 'sodium colistimethate', 'word_index': [(20, 21)], 'id': 'DDI-DrugBank.d775.s10.e10'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	lincomycin	magnesium	none	{'e1': {'word': 'lincomycin', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d775.s10.e7'}, 'e2': {'word': 'magnesium', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d775.s10.e11'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	lincomycin	lithium	none	{'e1': {'word': 'lincomycin', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d775.s10.e7'}, 'e2': {'word': 'lithium', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d775.s10.e12'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	lincomycin	anesthetics	none	{'e1': {'word': 'lincomycin', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d775.s10.e7'}, 'e2': {'word': 'anesthetics', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d775.s10.e13'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	lincomycin	procainamide	none	{'e1': {'word': 'lincomycin', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d775.s10.e7'}, 'e2': {'word': 'procainamide', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d775.s10.e14'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	lincomycin	quinidine	none	{'e1': {'word': 'lincomycin', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d775.s10.e7'}, 'e2': {'word': 'quinidine', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d775.s10.e15'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	clindamycin	colistin	none	{'e1': {'word': 'clindamycin', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d775.s10.e8'}, 'e2': {'word': 'colistin', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d775.s10.e9'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	clindamycin	sodium colistimethate	none	{'e1': {'word': 'clindamycin', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d775.s10.e8'}, 'e2': {'word': 'sodium colistimethate', 'word_index': [(20, 21)], 'id': 'DDI-DrugBank.d775.s10.e10'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	clindamycin	magnesium	none	{'e1': {'word': 'clindamycin', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d775.s10.e8'}, 'e2': {'word': 'magnesium', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d775.s10.e11'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	clindamycin	lithium	none	{'e1': {'word': 'clindamycin', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d775.s10.e8'}, 'e2': {'word': 'lithium', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d775.s10.e12'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	clindamycin	anesthetics	none	{'e1': {'word': 'clindamycin', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d775.s10.e8'}, 'e2': {'word': 'anesthetics', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d775.s10.e13'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	clindamycin	procainamide	none	{'e1': {'word': 'clindamycin', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d775.s10.e8'}, 'e2': {'word': 'procainamide', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d775.s10.e14'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	clindamycin	quinidine	none	{'e1': {'word': 'clindamycin', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d775.s10.e8'}, 'e2': {'word': 'quinidine', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d775.s10.e15'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	colistin	sodium colistimethate	none	{'e1': {'word': 'colistin', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d775.s10.e9'}, 'e2': {'word': 'sodium colistimethate', 'word_index': [(20, 21)], 'id': 'DDI-DrugBank.d775.s10.e10'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	colistin	magnesium	none	{'e1': {'word': 'colistin', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d775.s10.e9'}, 'e2': {'word': 'magnesium', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d775.s10.e11'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	colistin	lithium	none	{'e1': {'word': 'colistin', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d775.s10.e9'}, 'e2': {'word': 'lithium', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d775.s10.e12'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	colistin	anesthetics	none	{'e1': {'word': 'colistin', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d775.s10.e9'}, 'e2': {'word': 'anesthetics', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d775.s10.e13'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	colistin	procainamide	none	{'e1': {'word': 'colistin', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d775.s10.e9'}, 'e2': {'word': 'procainamide', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d775.s10.e14'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	colistin	quinidine	none	{'e1': {'word': 'colistin', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d775.s10.e9'}, 'e2': {'word': 'quinidine', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d775.s10.e15'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	sodium colistimethate	magnesium	none	{'e1': {'word': 'sodium colistimethate', 'word_index': [(20, 21)], 'id': 'DDI-DrugBank.d775.s10.e10'}, 'e2': {'word': 'magnesium', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d775.s10.e11'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	sodium colistimethate	lithium	none	{'e1': {'word': 'sodium colistimethate', 'word_index': [(20, 21)], 'id': 'DDI-DrugBank.d775.s10.e10'}, 'e2': {'word': 'lithium', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d775.s10.e12'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	sodium colistimethate	anesthetics	none	{'e1': {'word': 'sodium colistimethate', 'word_index': [(20, 21)], 'id': 'DDI-DrugBank.d775.s10.e10'}, 'e2': {'word': 'anesthetics', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d775.s10.e13'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	sodium colistimethate	procainamide	none	{'e1': {'word': 'sodium colistimethate', 'word_index': [(20, 21)], 'id': 'DDI-DrugBank.d775.s10.e10'}, 'e2': {'word': 'procainamide', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d775.s10.e14'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	sodium colistimethate	quinidine	none	{'e1': {'word': 'sodium colistimethate', 'word_index': [(20, 21)], 'id': 'DDI-DrugBank.d775.s10.e10'}, 'e2': {'word': 'quinidine', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d775.s10.e15'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	magnesium	lithium	none	{'e1': {'word': 'magnesium', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d775.s10.e11'}, 'e2': {'word': 'lithium', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d775.s10.e12'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	magnesium	anesthetics	none	{'e1': {'word': 'magnesium', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d775.s10.e11'}, 'e2': {'word': 'anesthetics', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d775.s10.e13'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	magnesium	procainamide	none	{'e1': {'word': 'magnesium', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d775.s10.e11'}, 'e2': {'word': 'procainamide', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d775.s10.e14'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	magnesium	quinidine	none	{'e1': {'word': 'magnesium', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d775.s10.e11'}, 'e2': {'word': 'quinidine', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d775.s10.e15'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	lithium	anesthetics	none	{'e1': {'word': 'lithium', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d775.s10.e12'}, 'e2': {'word': 'anesthetics', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d775.s10.e13'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	lithium	procainamide	none	{'e1': {'word': 'lithium', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d775.s10.e12'}, 'e2': {'word': 'procainamide', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d775.s10.e14'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	lithium	quinidine	none	{'e1': {'word': 'lithium', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d775.s10.e12'}, 'e2': {'word': 'quinidine', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d775.s10.e15'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	anesthetics	procainamide	none	{'e1': {'word': 'anesthetics', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d775.s10.e13'}, 'e2': {'word': 'procainamide', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d775.s10.e14'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	anesthetics	quinidine	none	{'e1': {'word': 'anesthetics', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d775.s10.e13'}, 'e2': {'word': 'quinidine', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d775.s10.e15'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. 	procainamide	quinidine	none	{'e1': {'word': 'procainamide', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d775.s10.e14'}, 'e2': {'word': 'quinidine', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d775.s10.e15'}, 'sentence_id': 'DDI-DrugBank.d775.s10'}	drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON include certain antibiotics e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate magnesium salts lithium local anesthetics procainamide quinidine
The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. 	MIVACRON	contraceptives	effect	{'e1': {'word': 'MIVACRON', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d775.s11.e0'}, 'e2': {'word': 'contraceptives', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d775.s11.e1'}, 'sentence_id': 'DDI-DrugBank.d775.s11'}	neuromuscular blocking effect MIVACRON may enhanced drugs reduce plasma cholinesterase activity e.g. chronically administered oral contraceptives glucocorticoids certain monoamine oxidase inhibitors drugs irreversibly inhibit plasma cholinesterase Resistance neuromuscular blocking action nondepolarizing neuromuscular blocking agents demonstrated patients chronically administered phenytoin carbamazepine
The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. 	MIVACRON	glucocorticoids	effect	{'e1': {'word': 'MIVACRON', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d775.s11.e0'}, 'e2': {'word': 'glucocorticoids', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d775.s11.e2'}, 'sentence_id': 'DDI-DrugBank.d775.s11'}	neuromuscular blocking effect MIVACRON may enhanced drugs reduce plasma cholinesterase activity e.g. chronically administered oral contraceptives glucocorticoids certain monoamine oxidase inhibitors drugs irreversibly inhibit plasma cholinesterase Resistance neuromuscular blocking action nondepolarizing neuromuscular blocking agents demonstrated patients chronically administered phenytoin carbamazepine
The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. 	MIVACRON	monoamine oxidase inhibitors	effect	{'e1': {'word': 'MIVACRON', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d775.s11.e0'}, 'e2': {'word': 'monoamine oxidase inhibitors', 'word_index': [(18, 20)], 'id': 'DDI-DrugBank.d775.s11.e3'}, 'sentence_id': 'DDI-DrugBank.d775.s11'}	neuromuscular blocking effect MIVACRON may enhanced drugs reduce plasma cholinesterase activity e.g. chronically administered oral contraceptives glucocorticoids certain monoamine oxidase inhibitors drugs irreversibly inhibit plasma cholinesterase Resistance neuromuscular blocking action nondepolarizing neuromuscular blocking agents demonstrated patients chronically administered phenytoin carbamazepine
The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. 	MIVACRON	neuromuscular blocking agents	none	{'e1': {'word': 'MIVACRON', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d775.s11.e0'}, 'e2': {'word': 'neuromuscular blocking agents', 'word_index': [(31, 33)], 'id': 'DDI-DrugBank.d775.s11.e4'}, 'sentence_id': 'DDI-DrugBank.d775.s11'}	neuromuscular blocking effect MIVACRON may enhanced drugs reduce plasma cholinesterase activity e.g. chronically administered oral contraceptives glucocorticoids certain monoamine oxidase inhibitors drugs irreversibly inhibit plasma cholinesterase Resistance neuromuscular blocking action nondepolarizing neuromuscular blocking agents demonstrated patients chronically administered phenytoin carbamazepine
The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. 	MIVACRON	phenytoin	none	{'e1': {'word': 'MIVACRON', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d775.s11.e0'}, 'e2': {'word': 'phenytoin', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d775.s11.e5'}, 'sentence_id': 'DDI-DrugBank.d775.s11'}	neuromuscular blocking effect MIVACRON may enhanced drugs reduce plasma cholinesterase activity e.g. chronically administered oral contraceptives glucocorticoids certain monoamine oxidase inhibitors drugs irreversibly inhibit plasma cholinesterase Resistance neuromuscular blocking action nondepolarizing neuromuscular blocking agents demonstrated patients chronically administered phenytoin carbamazepine
The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. 	MIVACRON	carbamazepine	none	{'e1': {'word': 'MIVACRON', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d775.s11.e0'}, 'e2': {'word': 'carbamazepine', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d775.s11.e6'}, 'sentence_id': 'DDI-DrugBank.d775.s11'}	neuromuscular blocking effect MIVACRON may enhanced drugs reduce plasma cholinesterase activity e.g. chronically administered oral contraceptives glucocorticoids certain monoamine oxidase inhibitors drugs irreversibly inhibit plasma cholinesterase Resistance neuromuscular blocking action nondepolarizing neuromuscular blocking agents demonstrated patients chronically administered phenytoin carbamazepine
The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. 	contraceptives	glucocorticoids	none	{'e1': {'word': 'contraceptives', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d775.s11.e1'}, 'e2': {'word': 'glucocorticoids', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d775.s11.e2'}, 'sentence_id': 'DDI-DrugBank.d775.s11'}	neuromuscular blocking effect MIVACRON may enhanced drugs reduce plasma cholinesterase activity e.g. chronically administered oral contraceptives glucocorticoids certain monoamine oxidase inhibitors drugs irreversibly inhibit plasma cholinesterase Resistance neuromuscular blocking action nondepolarizing neuromuscular blocking agents demonstrated patients chronically administered phenytoin carbamazepine
The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. 	contraceptives	monoamine oxidase inhibitors	none	{'e1': {'word': 'contraceptives', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d775.s11.e1'}, 'e2': {'word': 'monoamine oxidase inhibitors', 'word_index': [(18, 20)], 'id': 'DDI-DrugBank.d775.s11.e3'}, 'sentence_id': 'DDI-DrugBank.d775.s11'}	neuromuscular blocking effect MIVACRON may enhanced drugs reduce plasma cholinesterase activity e.g. chronically administered oral contraceptives glucocorticoids certain monoamine oxidase inhibitors drugs irreversibly inhibit plasma cholinesterase Resistance neuromuscular blocking action nondepolarizing neuromuscular blocking agents demonstrated patients chronically administered phenytoin carbamazepine
The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. 	contraceptives	neuromuscular blocking agents	none	{'e1': {'word': 'contraceptives', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d775.s11.e1'}, 'e2': {'word': 'neuromuscular blocking agents', 'word_index': [(31, 33)], 'id': 'DDI-DrugBank.d775.s11.e4'}, 'sentence_id': 'DDI-DrugBank.d775.s11'}	neuromuscular blocking effect MIVACRON may enhanced drugs reduce plasma cholinesterase activity e.g. chronically administered oral contraceptives glucocorticoids certain monoamine oxidase inhibitors drugs irreversibly inhibit plasma cholinesterase Resistance neuromuscular blocking action nondepolarizing neuromuscular blocking agents demonstrated patients chronically administered phenytoin carbamazepine
The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. 	contraceptives	phenytoin	none	{'e1': {'word': 'contraceptives', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d775.s11.e1'}, 'e2': {'word': 'phenytoin', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d775.s11.e5'}, 'sentence_id': 'DDI-DrugBank.d775.s11'}	neuromuscular blocking effect MIVACRON may enhanced drugs reduce plasma cholinesterase activity e.g. chronically administered oral contraceptives glucocorticoids certain monoamine oxidase inhibitors drugs irreversibly inhibit plasma cholinesterase Resistance neuromuscular blocking action nondepolarizing neuromuscular blocking agents demonstrated patients chronically administered phenytoin carbamazepine
The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. 	contraceptives	carbamazepine	none	{'e1': {'word': 'contraceptives', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d775.s11.e1'}, 'e2': {'word': 'carbamazepine', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d775.s11.e6'}, 'sentence_id': 'DDI-DrugBank.d775.s11'}	neuromuscular blocking effect MIVACRON may enhanced drugs reduce plasma cholinesterase activity e.g. chronically administered oral contraceptives glucocorticoids certain monoamine oxidase inhibitors drugs irreversibly inhibit plasma cholinesterase Resistance neuromuscular blocking action nondepolarizing neuromuscular blocking agents demonstrated patients chronically administered phenytoin carbamazepine
The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. 	glucocorticoids	monoamine oxidase inhibitors	none	{'e1': {'word': 'glucocorticoids', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d775.s11.e2'}, 'e2': {'word': 'monoamine oxidase inhibitors', 'word_index': [(18, 20)], 'id': 'DDI-DrugBank.d775.s11.e3'}, 'sentence_id': 'DDI-DrugBank.d775.s11'}	neuromuscular blocking effect MIVACRON may enhanced drugs reduce plasma cholinesterase activity e.g. chronically administered oral contraceptives glucocorticoids certain monoamine oxidase inhibitors drugs irreversibly inhibit plasma cholinesterase Resistance neuromuscular blocking action nondepolarizing neuromuscular blocking agents demonstrated patients chronically administered phenytoin carbamazepine
The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. 	glucocorticoids	neuromuscular blocking agents	none	{'e1': {'word': 'glucocorticoids', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d775.s11.e2'}, 'e2': {'word': 'neuromuscular blocking agents', 'word_index': [(31, 33)], 'id': 'DDI-DrugBank.d775.s11.e4'}, 'sentence_id': 'DDI-DrugBank.d775.s11'}	neuromuscular blocking effect MIVACRON may enhanced drugs reduce plasma cholinesterase activity e.g. chronically administered oral contraceptives glucocorticoids certain monoamine oxidase inhibitors drugs irreversibly inhibit plasma cholinesterase Resistance neuromuscular blocking action nondepolarizing neuromuscular blocking agents demonstrated patients chronically administered phenytoin carbamazepine
The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. 	glucocorticoids	phenytoin	none	{'e1': {'word': 'glucocorticoids', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d775.s11.e2'}, 'e2': {'word': 'phenytoin', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d775.s11.e5'}, 'sentence_id': 'DDI-DrugBank.d775.s11'}	neuromuscular blocking effect MIVACRON may enhanced drugs reduce plasma cholinesterase activity e.g. chronically administered oral contraceptives glucocorticoids certain monoamine oxidase inhibitors drugs irreversibly inhibit plasma cholinesterase Resistance neuromuscular blocking action nondepolarizing neuromuscular blocking agents demonstrated patients chronically administered phenytoin carbamazepine
The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. 	glucocorticoids	carbamazepine	none	{'e1': {'word': 'glucocorticoids', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d775.s11.e2'}, 'e2': {'word': 'carbamazepine', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d775.s11.e6'}, 'sentence_id': 'DDI-DrugBank.d775.s11'}	neuromuscular blocking effect MIVACRON may enhanced drugs reduce plasma cholinesterase activity e.g. chronically administered oral contraceptives glucocorticoids certain monoamine oxidase inhibitors drugs irreversibly inhibit plasma cholinesterase Resistance neuromuscular blocking action nondepolarizing neuromuscular blocking agents demonstrated patients chronically administered phenytoin carbamazepine
The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. 	monoamine oxidase inhibitors	neuromuscular blocking agents	none	{'e1': {'word': 'monoamine oxidase inhibitors', 'word_index': [(18, 20)], 'id': 'DDI-DrugBank.d775.s11.e3'}, 'e2': {'word': 'neuromuscular blocking agents', 'word_index': [(31, 33)], 'id': 'DDI-DrugBank.d775.s11.e4'}, 'sentence_id': 'DDI-DrugBank.d775.s11'}	neuromuscular blocking effect MIVACRON may enhanced drugs reduce plasma cholinesterase activity e.g. chronically administered oral contraceptives glucocorticoids certain monoamine oxidase inhibitors drugs irreversibly inhibit plasma cholinesterase Resistance neuromuscular blocking action nondepolarizing neuromuscular blocking agents demonstrated patients chronically administered phenytoin carbamazepine
The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. 	monoamine oxidase inhibitors	phenytoin	none	{'e1': {'word': 'monoamine oxidase inhibitors', 'word_index': [(18, 20)], 'id': 'DDI-DrugBank.d775.s11.e3'}, 'e2': {'word': 'phenytoin', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d775.s11.e5'}, 'sentence_id': 'DDI-DrugBank.d775.s11'}	neuromuscular blocking effect MIVACRON may enhanced drugs reduce plasma cholinesterase activity e.g. chronically administered oral contraceptives glucocorticoids certain monoamine oxidase inhibitors drugs irreversibly inhibit plasma cholinesterase Resistance neuromuscular blocking action nondepolarizing neuromuscular blocking agents demonstrated patients chronically administered phenytoin carbamazepine
The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. 	monoamine oxidase inhibitors	carbamazepine	none	{'e1': {'word': 'monoamine oxidase inhibitors', 'word_index': [(18, 20)], 'id': 'DDI-DrugBank.d775.s11.e3'}, 'e2': {'word': 'carbamazepine', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d775.s11.e6'}, 'sentence_id': 'DDI-DrugBank.d775.s11'}	neuromuscular blocking effect MIVACRON may enhanced drugs reduce plasma cholinesterase activity e.g. chronically administered oral contraceptives glucocorticoids certain monoamine oxidase inhibitors drugs irreversibly inhibit plasma cholinesterase Resistance neuromuscular blocking action nondepolarizing neuromuscular blocking agents demonstrated patients chronically administered phenytoin carbamazepine
The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. 	neuromuscular blocking agents	phenytoin	effect	{'e1': {'word': 'neuromuscular blocking agents', 'word_index': [(31, 33)], 'id': 'DDI-DrugBank.d775.s11.e4'}, 'e2': {'word': 'phenytoin', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d775.s11.e5'}, 'sentence_id': 'DDI-DrugBank.d775.s11'}	neuromuscular blocking effect MIVACRON may enhanced drugs reduce plasma cholinesterase activity e.g. chronically administered oral contraceptives glucocorticoids certain monoamine oxidase inhibitors drugs irreversibly inhibit plasma cholinesterase Resistance neuromuscular blocking action nondepolarizing neuromuscular blocking agents demonstrated patients chronically administered phenytoin carbamazepine
The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. 	neuromuscular blocking agents	carbamazepine	effect	{'e1': {'word': 'neuromuscular blocking agents', 'word_index': [(31, 33)], 'id': 'DDI-DrugBank.d775.s11.e4'}, 'e2': {'word': 'carbamazepine', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d775.s11.e6'}, 'sentence_id': 'DDI-DrugBank.d775.s11'}	neuromuscular blocking effect MIVACRON may enhanced drugs reduce plasma cholinesterase activity e.g. chronically administered oral contraceptives glucocorticoids certain monoamine oxidase inhibitors drugs irreversibly inhibit plasma cholinesterase Resistance neuromuscular blocking action nondepolarizing neuromuscular blocking agents demonstrated patients chronically administered phenytoin carbamazepine
The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. 	phenytoin	carbamazepine	none	{'e1': {'word': 'phenytoin', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d775.s11.e5'}, 'e2': {'word': 'carbamazepine', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d775.s11.e6'}, 'sentence_id': 'DDI-DrugBank.d775.s11'}	neuromuscular blocking effect MIVACRON may enhanced drugs reduce plasma cholinesterase activity e.g. chronically administered oral contraceptives glucocorticoids certain monoamine oxidase inhibitors drugs irreversibly inhibit plasma cholinesterase Resistance neuromuscular blocking action nondepolarizing neuromuscular blocking agents demonstrated patients chronically administered phenytoin carbamazepine
While the effects of chronic phenytoin or carbamazepine therapy on the action of MIVACRON are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher. 	phenytoin	carbamazepine	none	{'e1': {'word': 'phenytoin', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d775.s12.e0'}, 'e2': {'word': 'carbamazepine', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d775.s12.e1'}, 'sentence_id': 'DDI-DrugBank.d775.s12'}	effects chronic phenytoin carbamazepine therapy action MIVACRON unknown slightly shorter durations neuromuscular block may anticipated infusion rate requirements may higher
While the effects of chronic phenytoin or carbamazepine therapy on the action of MIVACRON are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher. 	phenytoin	MIVACRON	effect	{'e1': {'word': 'phenytoin', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d775.s12.e0'}, 'e2': {'word': 'MIVACRON', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d775.s12.e2'}, 'sentence_id': 'DDI-DrugBank.d775.s12'}	effects chronic phenytoin carbamazepine therapy action MIVACRON unknown slightly shorter durations neuromuscular block may anticipated infusion rate requirements may higher
While the effects of chronic phenytoin or carbamazepine therapy on the action of MIVACRON are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher. 	carbamazepine	MIVACRON	effect	{'e1': {'word': 'carbamazepine', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d775.s12.e1'}, 'e2': {'word': 'MIVACRON', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d775.s12.e2'}, 'sentence_id': 'DDI-DrugBank.d775.s12'}	effects chronic phenytoin carbamazepine therapy action MIVACRON unknown slightly shorter durations neuromuscular block may anticipated infusion rate requirements may higher
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	corticosteroids	phenytoin	none	{'e1': {'word': 'corticosteroids', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d775.s13.e0'}, 'e2': {'word': 'phenytoin', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d775.s13.e1'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	corticosteroids	carbamazepine	none	{'e1': {'word': 'corticosteroids', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d775.s13.e0'}, 'e2': {'word': 'carbamazepine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d775.s13.e2'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	corticosteroids	antibiotics	none	{'e1': {'word': 'corticosteroids', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d775.s13.e0'}, 'e2': {'word': 'antibiotics', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d775.s13.e3'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	corticosteroids	cisplatin	none	{'e1': {'word': 'corticosteroids', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d775.s13.e0'}, 'e2': {'word': 'cisplatin', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d775.s13.e4'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	corticosteroids	edrophonium	none	{'e1': {'word': 'corticosteroids', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d775.s13.e0'}, 'e2': {'word': 'edrophonium', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d775.s13.e5'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	corticosteroids	neostigmine	none	{'e1': {'word': 'corticosteroids', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d775.s13.e0'}, 'e2': {'word': 'neostigmine', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d775.s13.e6'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	corticosteroids	polymyxin B	none	{'e1': {'word': 'corticosteroids', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d775.s13.e0'}, 'e2': {'word': 'polymyxin B', 'word_index': [(25, 26)], 'id': 'DDI-DrugBank.d775.s13.e7'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	corticosteroids	bacitracin	none	{'e1': {'word': 'corticosteroids', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d775.s13.e0'}, 'e2': {'word': 'bacitracin', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d775.s13.e8'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	corticosteroids	anesthetics	none	{'e1': {'word': 'corticosteroids', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d775.s13.e0'}, 'e2': {'word': 'anesthetics', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d775.s13.e9'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	corticosteroids	procaine	none	{'e1': {'word': 'corticosteroids', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d775.s13.e0'}, 'e2': {'word': 'procaine', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d775.s13.e10'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	corticosteroids	anesthetics	none	{'e1': {'word': 'corticosteroids', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d775.s13.e0'}, 'e2': {'word': 'anesthetics', 'word_index': [(32, 32)], 'id': 'DDI-DrugBank.d775.s13.e11'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	corticosteroids	succinylcholine	none	{'e1': {'word': 'corticosteroids', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d775.s13.e0'}, 'e2': {'word': 'succinylcholine', 'word_index': [(33, 33)], 'id': 'DDI-DrugBank.d775.s13.e12'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	corticosteroids	muscle relaxants	none	{'e1': {'word': 'corticosteroids', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d775.s13.e0'}, 'e2': {'word': 'muscle relaxants', 'word_index': [(34, 35)], 'id': 'DDI-DrugBank.d775.s13.e13'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	phenytoin	carbamazepine	none	{'e1': {'word': 'phenytoin', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d775.s13.e1'}, 'e2': {'word': 'carbamazepine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d775.s13.e2'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	phenytoin	antibiotics	none	{'e1': {'word': 'phenytoin', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d775.s13.e1'}, 'e2': {'word': 'antibiotics', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d775.s13.e3'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	phenytoin	cisplatin	none	{'e1': {'word': 'phenytoin', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d775.s13.e1'}, 'e2': {'word': 'cisplatin', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d775.s13.e4'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	phenytoin	edrophonium	none	{'e1': {'word': 'phenytoin', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d775.s13.e1'}, 'e2': {'word': 'edrophonium', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d775.s13.e5'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	phenytoin	neostigmine	none	{'e1': {'word': 'phenytoin', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d775.s13.e1'}, 'e2': {'word': 'neostigmine', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d775.s13.e6'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	phenytoin	polymyxin B	none	{'e1': {'word': 'phenytoin', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d775.s13.e1'}, 'e2': {'word': 'polymyxin B', 'word_index': [(25, 26)], 'id': 'DDI-DrugBank.d775.s13.e7'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	phenytoin	bacitracin	none	{'e1': {'word': 'phenytoin', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d775.s13.e1'}, 'e2': {'word': 'bacitracin', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d775.s13.e8'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	phenytoin	anesthetics	none	{'e1': {'word': 'phenytoin', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d775.s13.e1'}, 'e2': {'word': 'anesthetics', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d775.s13.e9'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	phenytoin	procaine	none	{'e1': {'word': 'phenytoin', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d775.s13.e1'}, 'e2': {'word': 'procaine', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d775.s13.e10'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	phenytoin	anesthetics	none	{'e1': {'word': 'phenytoin', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d775.s13.e1'}, 'e2': {'word': 'anesthetics', 'word_index': [(32, 32)], 'id': 'DDI-DrugBank.d775.s13.e11'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	phenytoin	succinylcholine	none	{'e1': {'word': 'phenytoin', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d775.s13.e1'}, 'e2': {'word': 'succinylcholine', 'word_index': [(33, 33)], 'id': 'DDI-DrugBank.d775.s13.e12'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	phenytoin	muscle relaxants	none	{'e1': {'word': 'phenytoin', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d775.s13.e1'}, 'e2': {'word': 'muscle relaxants', 'word_index': [(34, 35)], 'id': 'DDI-DrugBank.d775.s13.e13'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	carbamazepine	antibiotics	none	{'e1': {'word': 'carbamazepine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d775.s13.e2'}, 'e2': {'word': 'antibiotics', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d775.s13.e3'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	carbamazepine	cisplatin	none	{'e1': {'word': 'carbamazepine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d775.s13.e2'}, 'e2': {'word': 'cisplatin', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d775.s13.e4'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	carbamazepine	edrophonium	none	{'e1': {'word': 'carbamazepine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d775.s13.e2'}, 'e2': {'word': 'edrophonium', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d775.s13.e5'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	carbamazepine	neostigmine	none	{'e1': {'word': 'carbamazepine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d775.s13.e2'}, 'e2': {'word': 'neostigmine', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d775.s13.e6'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	carbamazepine	polymyxin B	none	{'e1': {'word': 'carbamazepine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d775.s13.e2'}, 'e2': {'word': 'polymyxin B', 'word_index': [(25, 26)], 'id': 'DDI-DrugBank.d775.s13.e7'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	carbamazepine	bacitracin	none	{'e1': {'word': 'carbamazepine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d775.s13.e2'}, 'e2': {'word': 'bacitracin', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d775.s13.e8'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	carbamazepine	anesthetics	none	{'e1': {'word': 'carbamazepine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d775.s13.e2'}, 'e2': {'word': 'anesthetics', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d775.s13.e9'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	carbamazepine	procaine	none	{'e1': {'word': 'carbamazepine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d775.s13.e2'}, 'e2': {'word': 'procaine', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d775.s13.e10'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	carbamazepine	anesthetics	none	{'e1': {'word': 'carbamazepine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d775.s13.e2'}, 'e2': {'word': 'anesthetics', 'word_index': [(32, 32)], 'id': 'DDI-DrugBank.d775.s13.e11'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	carbamazepine	succinylcholine	none	{'e1': {'word': 'carbamazepine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d775.s13.e2'}, 'e2': {'word': 'succinylcholine', 'word_index': [(33, 33)], 'id': 'DDI-DrugBank.d775.s13.e12'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	carbamazepine	muscle relaxants	none	{'e1': {'word': 'carbamazepine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d775.s13.e2'}, 'e2': {'word': 'muscle relaxants', 'word_index': [(34, 35)], 'id': 'DDI-DrugBank.d775.s13.e13'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	antibiotics	cisplatin	none	{'e1': {'word': 'antibiotics', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d775.s13.e3'}, 'e2': {'word': 'cisplatin', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d775.s13.e4'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	antibiotics	edrophonium	none	{'e1': {'word': 'antibiotics', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d775.s13.e3'}, 'e2': {'word': 'edrophonium', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d775.s13.e5'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	antibiotics	neostigmine	none	{'e1': {'word': 'antibiotics', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d775.s13.e3'}, 'e2': {'word': 'neostigmine', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d775.s13.e6'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	antibiotics	polymyxin B	none	{'e1': {'word': 'antibiotics', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d775.s13.e3'}, 'e2': {'word': 'polymyxin B', 'word_index': [(25, 26)], 'id': 'DDI-DrugBank.d775.s13.e7'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	antibiotics	bacitracin	none	{'e1': {'word': 'antibiotics', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d775.s13.e3'}, 'e2': {'word': 'bacitracin', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d775.s13.e8'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	antibiotics	anesthetics	none	{'e1': {'word': 'antibiotics', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d775.s13.e3'}, 'e2': {'word': 'anesthetics', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d775.s13.e9'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	antibiotics	procaine	none	{'e1': {'word': 'antibiotics', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d775.s13.e3'}, 'e2': {'word': 'procaine', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d775.s13.e10'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	antibiotics	anesthetics	none	{'e1': {'word': 'antibiotics', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d775.s13.e3'}, 'e2': {'word': 'anesthetics', 'word_index': [(32, 32)], 'id': 'DDI-DrugBank.d775.s13.e11'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	antibiotics	succinylcholine	none	{'e1': {'word': 'antibiotics', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d775.s13.e3'}, 'e2': {'word': 'succinylcholine', 'word_index': [(33, 33)], 'id': 'DDI-DrugBank.d775.s13.e12'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	antibiotics	muscle relaxants	none	{'e1': {'word': 'antibiotics', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d775.s13.e3'}, 'e2': {'word': 'muscle relaxants', 'word_index': [(34, 35)], 'id': 'DDI-DrugBank.d775.s13.e13'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	cisplatin	edrophonium	none	{'e1': {'word': 'cisplatin', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d775.s13.e4'}, 'e2': {'word': 'edrophonium', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d775.s13.e5'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	cisplatin	neostigmine	none	{'e1': {'word': 'cisplatin', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d775.s13.e4'}, 'e2': {'word': 'neostigmine', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d775.s13.e6'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	cisplatin	polymyxin B	none	{'e1': {'word': 'cisplatin', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d775.s13.e4'}, 'e2': {'word': 'polymyxin B', 'word_index': [(25, 26)], 'id': 'DDI-DrugBank.d775.s13.e7'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	cisplatin	bacitracin	none	{'e1': {'word': 'cisplatin', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d775.s13.e4'}, 'e2': {'word': 'bacitracin', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d775.s13.e8'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	cisplatin	anesthetics	none	{'e1': {'word': 'cisplatin', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d775.s13.e4'}, 'e2': {'word': 'anesthetics', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d775.s13.e9'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	cisplatin	procaine	none	{'e1': {'word': 'cisplatin', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d775.s13.e4'}, 'e2': {'word': 'procaine', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d775.s13.e10'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	cisplatin	anesthetics	none	{'e1': {'word': 'cisplatin', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d775.s13.e4'}, 'e2': {'word': 'anesthetics', 'word_index': [(32, 32)], 'id': 'DDI-DrugBank.d775.s13.e11'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	cisplatin	succinylcholine	none	{'e1': {'word': 'cisplatin', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d775.s13.e4'}, 'e2': {'word': 'succinylcholine', 'word_index': [(33, 33)], 'id': 'DDI-DrugBank.d775.s13.e12'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	cisplatin	muscle relaxants	none	{'e1': {'word': 'cisplatin', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d775.s13.e4'}, 'e2': {'word': 'muscle relaxants', 'word_index': [(34, 35)], 'id': 'DDI-DrugBank.d775.s13.e13'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	edrophonium	neostigmine	none	{'e1': {'word': 'edrophonium', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d775.s13.e5'}, 'e2': {'word': 'neostigmine', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d775.s13.e6'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	edrophonium	polymyxin B	none	{'e1': {'word': 'edrophonium', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d775.s13.e5'}, 'e2': {'word': 'polymyxin B', 'word_index': [(25, 26)], 'id': 'DDI-DrugBank.d775.s13.e7'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	edrophonium	bacitracin	none	{'e1': {'word': 'edrophonium', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d775.s13.e5'}, 'e2': {'word': 'bacitracin', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d775.s13.e8'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	edrophonium	anesthetics	none	{'e1': {'word': 'edrophonium', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d775.s13.e5'}, 'e2': {'word': 'anesthetics', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d775.s13.e9'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	edrophonium	procaine	none	{'e1': {'word': 'edrophonium', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d775.s13.e5'}, 'e2': {'word': 'procaine', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d775.s13.e10'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	edrophonium	anesthetics	none	{'e1': {'word': 'edrophonium', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d775.s13.e5'}, 'e2': {'word': 'anesthetics', 'word_index': [(32, 32)], 'id': 'DDI-DrugBank.d775.s13.e11'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	edrophonium	succinylcholine	none	{'e1': {'word': 'edrophonium', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d775.s13.e5'}, 'e2': {'word': 'succinylcholine', 'word_index': [(33, 33)], 'id': 'DDI-DrugBank.d775.s13.e12'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	edrophonium	muscle relaxants	none	{'e1': {'word': 'edrophonium', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d775.s13.e5'}, 'e2': {'word': 'muscle relaxants', 'word_index': [(34, 35)], 'id': 'DDI-DrugBank.d775.s13.e13'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	neostigmine	polymyxin B	none	{'e1': {'word': 'neostigmine', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d775.s13.e6'}, 'e2': {'word': 'polymyxin B', 'word_index': [(25, 26)], 'id': 'DDI-DrugBank.d775.s13.e7'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	neostigmine	bacitracin	none	{'e1': {'word': 'neostigmine', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d775.s13.e6'}, 'e2': {'word': 'bacitracin', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d775.s13.e8'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	neostigmine	anesthetics	none	{'e1': {'word': 'neostigmine', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d775.s13.e6'}, 'e2': {'word': 'anesthetics', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d775.s13.e9'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	neostigmine	procaine	none	{'e1': {'word': 'neostigmine', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d775.s13.e6'}, 'e2': {'word': 'procaine', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d775.s13.e10'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	neostigmine	anesthetics	none	{'e1': {'word': 'neostigmine', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d775.s13.e6'}, 'e2': {'word': 'anesthetics', 'word_index': [(32, 32)], 'id': 'DDI-DrugBank.d775.s13.e11'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	neostigmine	succinylcholine	none	{'e1': {'word': 'neostigmine', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d775.s13.e6'}, 'e2': {'word': 'succinylcholine', 'word_index': [(33, 33)], 'id': 'DDI-DrugBank.d775.s13.e12'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	neostigmine	muscle relaxants	none	{'e1': {'word': 'neostigmine', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d775.s13.e6'}, 'e2': {'word': 'muscle relaxants', 'word_index': [(34, 35)], 'id': 'DDI-DrugBank.d775.s13.e13'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	polymyxin B	bacitracin	none	{'e1': {'word': 'polymyxin B', 'word_index': [(25, 26)], 'id': 'DDI-DrugBank.d775.s13.e7'}, 'e2': {'word': 'bacitracin', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d775.s13.e8'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	polymyxin B	anesthetics	none	{'e1': {'word': 'polymyxin B', 'word_index': [(25, 26)], 'id': 'DDI-DrugBank.d775.s13.e7'}, 'e2': {'word': 'anesthetics', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d775.s13.e9'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	polymyxin B	procaine	none	{'e1': {'word': 'polymyxin B', 'word_index': [(25, 26)], 'id': 'DDI-DrugBank.d775.s13.e7'}, 'e2': {'word': 'procaine', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d775.s13.e10'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	polymyxin B	anesthetics	none	{'e1': {'word': 'polymyxin B', 'word_index': [(25, 26)], 'id': 'DDI-DrugBank.d775.s13.e7'}, 'e2': {'word': 'anesthetics', 'word_index': [(32, 32)], 'id': 'DDI-DrugBank.d775.s13.e11'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	polymyxin B	succinylcholine	none	{'e1': {'word': 'polymyxin B', 'word_index': [(25, 26)], 'id': 'DDI-DrugBank.d775.s13.e7'}, 'e2': {'word': 'succinylcholine', 'word_index': [(33, 33)], 'id': 'DDI-DrugBank.d775.s13.e12'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	polymyxin B	muscle relaxants	none	{'e1': {'word': 'polymyxin B', 'word_index': [(25, 26)], 'id': 'DDI-DrugBank.d775.s13.e7'}, 'e2': {'word': 'muscle relaxants', 'word_index': [(34, 35)], 'id': 'DDI-DrugBank.d775.s13.e13'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	bacitracin	anesthetics	none	{'e1': {'word': 'bacitracin', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d775.s13.e8'}, 'e2': {'word': 'anesthetics', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d775.s13.e9'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	bacitracin	procaine	none	{'e1': {'word': 'bacitracin', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d775.s13.e8'}, 'e2': {'word': 'procaine', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d775.s13.e10'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	bacitracin	anesthetics	none	{'e1': {'word': 'bacitracin', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d775.s13.e8'}, 'e2': {'word': 'anesthetics', 'word_index': [(32, 32)], 'id': 'DDI-DrugBank.d775.s13.e11'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	bacitracin	succinylcholine	none	{'e1': {'word': 'bacitracin', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d775.s13.e8'}, 'e2': {'word': 'succinylcholine', 'word_index': [(33, 33)], 'id': 'DDI-DrugBank.d775.s13.e12'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	bacitracin	muscle relaxants	none	{'e1': {'word': 'bacitracin', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d775.s13.e8'}, 'e2': {'word': 'muscle relaxants', 'word_index': [(34, 35)], 'id': 'DDI-DrugBank.d775.s13.e13'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	anesthetics	procaine	none	{'e1': {'word': 'anesthetics', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d775.s13.e9'}, 'e2': {'word': 'procaine', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d775.s13.e10'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	anesthetics	anesthetics	none	{'e1': {'word': 'anesthetics', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d775.s13.e9'}, 'e2': {'word': 'anesthetics', 'word_index': [(32, 32)], 'id': 'DDI-DrugBank.d775.s13.e11'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	anesthetics	succinylcholine	none	{'e1': {'word': 'anesthetics', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d775.s13.e9'}, 'e2': {'word': 'succinylcholine', 'word_index': [(33, 33)], 'id': 'DDI-DrugBank.d775.s13.e12'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	anesthetics	muscle relaxants	none	{'e1': {'word': 'anesthetics', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d775.s13.e9'}, 'e2': {'word': 'muscle relaxants', 'word_index': [(34, 35)], 'id': 'DDI-DrugBank.d775.s13.e13'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	procaine	anesthetics	none	{'e1': {'word': 'procaine', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d775.s13.e10'}, 'e2': {'word': 'anesthetics', 'word_index': [(32, 32)], 'id': 'DDI-DrugBank.d775.s13.e11'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	procaine	succinylcholine	none	{'e1': {'word': 'procaine', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d775.s13.e10'}, 'e2': {'word': 'succinylcholine', 'word_index': [(33, 33)], 'id': 'DDI-DrugBank.d775.s13.e12'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	procaine	muscle relaxants	none	{'e1': {'word': 'procaine', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d775.s13.e10'}, 'e2': {'word': 'muscle relaxants', 'word_index': [(34, 35)], 'id': 'DDI-DrugBank.d775.s13.e13'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	anesthetics	succinylcholine	none	{'e1': {'word': 'anesthetics', 'word_index': [(32, 32)], 'id': 'DDI-DrugBank.d775.s13.e11'}, 'e2': {'word': 'succinylcholine', 'word_index': [(33, 33)], 'id': 'DDI-DrugBank.d775.s13.e12'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	anesthetics	muscle relaxants	none	{'e1': {'word': 'anesthetics', 'word_index': [(32, 32)], 'id': 'DDI-DrugBank.d775.s13.e11'}, 'e2': {'word': 'muscle relaxants', 'word_index': [(34, 35)], 'id': 'DDI-DrugBank.d775.s13.e13'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	succinylcholine	muscle relaxants	none	{'e1': {'word': 'succinylcholine', 'word_index': [(33, 33)], 'id': 'DDI-DrugBank.d775.s13.e12'}, 'e2': {'word': 'muscle relaxants', 'word_index': [(34, 35)], 'id': 'DDI-DrugBank.d775.s13.e13'}, 'sentence_id': 'DDI-DrugBank.d775.s13'}	drug interactions birth control pills corticosteroids medicines angina high blood pressure medicines pain medicines control seizures phenytoin carbamazepine certain antibiotics given injection cisplatin edrophonium neostigmine polymyxin B bacitracin local anesthetics procaine general anesthetics succinylcholine muscle relaxants
These include sympathomimetic bronchodilators, methylxanthines, and oral and inhaled steroids. 	sympathomimetic bronchodilators	methylxanthines	none	{'e1': {'word': 'sympathomimetic bronchodilators', 'word_index': [(1, 2)], 'id': 'DDI-DrugBank.d702.s1.e0'}, 'e2': {'word': 'methylxanthines', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d702.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d702.s1'}	include sympathomimetic bronchodilators methylxanthines oral inhaled steroids
These include sympathomimetic bronchodilators, methylxanthines, and oral and inhaled steroids. 	sympathomimetic bronchodilators	steroids	none	{'e1': {'word': 'sympathomimetic bronchodilators', 'word_index': [(1, 2)], 'id': 'DDI-DrugBank.d702.s1.e0'}, 'e2': {'word': 'steroids', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d702.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d702.s1'}	include sympathomimetic bronchodilators methylxanthines oral inhaled steroids
These include sympathomimetic bronchodilators, methylxanthines, and oral and inhaled steroids. 	methylxanthines	steroids	none	{'e1': {'word': 'methylxanthines', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d702.s1.e1'}, 'e2': {'word': 'steroids', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d702.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d702.s1'}	include sympathomimetic bronchodilators methylxanthines oral inhaled steroids
However, the co   administration of SPIRIVA with other anticholinergic   containing drugs (e.g., ipratropium) has not been studied and is therefore not recommended.	SPIRIVA	anticholinergic	advise	{'e1': {'word': 'SPIRIVA', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d702.s2.e0'}, 'e2': {'word': 'anticholinergic', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d702.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d702.s2'}	However co administration SPIRIVA anticholinergic containing drugs e.g. ipratropium studied therefore recommended
However, the co   administration of SPIRIVA with other anticholinergic   containing drugs (e.g., ipratropium) has not been studied and is therefore not recommended.	SPIRIVA	ipratropium	advise	{'e1': {'word': 'SPIRIVA', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d702.s2.e0'}, 'e2': {'word': 'ipratropium', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d702.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d702.s2'}	However co administration SPIRIVA anticholinergic containing drugs e.g. ipratropium studied therefore recommended
However, the co   administration of SPIRIVA with other anticholinergic   containing drugs (e.g., ipratropium) has not been studied and is therefore not recommended.	anticholinergic	ipratropium	none	{'e1': {'word': 'anticholinergic', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d702.s2.e1'}, 'e2': {'word': 'ipratropium', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d702.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d702.s2'}	However co administration SPIRIVA anticholinergic containing drugs e.g. ipratropium studied therefore recommended
The metabolism of Metopirone is accelerated by phenytoin; 	Metopirone	phenytoin	mechanism	{'e1': {'word': 'Metopirone', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d678.s1.e0'}, 'e2': {'word': 'phenytoin', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d678.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d678.s1'}	metabolism Metopirone accelerated phenytoin
Metopirone inhibits the glucuronidation of acetaminophen and could possibly potentiate acetaminophen toxicity.	Metopirone	acetaminophen	mechanism	{'e1': {'word': 'Metopirone', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d678.s4.e0'}, 'e2': {'word': 'acetaminophen', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d678.s4.e1'}, 'sentence_id': 'DDI-DrugBank.d678.s4'}	Metopirone inhibits glucuronidation acetaminophen could possibly potentiate acetaminophen toxicity
Metopirone inhibits the glucuronidation of acetaminophen and could possibly potentiate acetaminophen toxicity.	Metopirone	acetaminophen	effect	{'e1': {'word': 'Metopirone', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d678.s4.e0'}, 'e2': {'word': 'acetaminophen', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d678.s4.e2'}, 'sentence_id': 'DDI-DrugBank.d678.s4'}	Metopirone inhibits glucuronidation acetaminophen could possibly potentiate acetaminophen toxicity
Metopirone inhibits the glucuronidation of acetaminophen and could possibly potentiate acetaminophen toxicity.	acetaminophen	acetaminophen	none	{'e1': {'word': 'acetaminophen', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d678.s4.e1'}, 'e2': {'word': 'acetaminophen', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d678.s4.e2'}, 'sentence_id': 'DDI-DrugBank.d678.s4'}	Metopirone inhibits glucuronidation acetaminophen could possibly potentiate acetaminophen toxicity
Aminoglutethimide administered concomitantly with depo-subQ provera 104 may significantly decrease the serum concentrations of MPA. 	Aminoglutethimide	depo-subQ provera 104	mechanism	{'e1': {'word': 'Aminoglutethimide', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d623.s1.e0'}, 'e2': {'word': 'depo-subQ provera 104', 'word_index': [(3, 5)], 'id': 'DDI-DrugBank.d623.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d623.s1'}	Aminoglutethimide administered concomitantly depo-subQ provera NUMBER may significantly decrease serum concentrations MPA
Aminoglutethimide administered concomitantly with depo-subQ provera 104 may significantly decrease the serum concentrations of MPA. 	Aminoglutethimide	MPA	none	{'e1': {'word': 'Aminoglutethimide', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d623.s1.e0'}, 'e2': {'word': 'MPA', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d623.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d623.s1'}	Aminoglutethimide administered concomitantly depo-subQ provera NUMBER may significantly decrease serum concentrations MPA
Aminoglutethimide administered concomitantly with depo-subQ provera 104 may significantly decrease the serum concentrations of MPA. 	depo-subQ provera 104	MPA	none	{'e1': {'word': 'depo-subQ provera 104', 'word_index': [(3, 5)], 'id': 'DDI-DrugBank.d623.s1.e1'}, 'e2': {'word': 'MPA', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d623.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d623.s1'}	Aminoglutethimide administered concomitantly depo-subQ provera NUMBER may significantly decrease serum concentrations MPA
The interaction of CYLERT (pemoline) with other drugs has not been studied in humans. 	CYLERT	pemoline	none	{'e1': {'word': 'CYLERT', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d671.s0.e0'}, 'e2': {'word': 'pemoline', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d671.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d671.s0'}	interaction CYLERT pemoline drugs studied humans
Decreased seizure threshold has been reported in patients receiving CYLERT concomitantly with antiepileptic medications.	CYLERT	antiepileptic medications	effect	{'e1': {'word': 'CYLERT', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d671.s2.e0'}, 'e2': {'word': 'antiepileptic medications', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d671.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d671.s2'}	Decreased seizure threshold reported patients receiving CYLERT concomitantly antiepileptic medications
Diuretics: Patients on diuretics, and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of ACEON    Tablets therapy. 	Diuretics	diuretics	none	{'e1': {'word': 'Diuretics', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d781.s0.e0'}, 'e2': {'word': 'diuretics', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d781.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d781.s0'}	Diuretics Patients diuretics especially started recently may occasionally experience excessive reduction blood pressure initiation ACEON Tablets therapy
Diuretics: Patients on diuretics, and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of ACEON    Tablets therapy. 	Diuretics	ACEON	none	{'e1': {'word': 'Diuretics', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d781.s0.e0'}, 'e2': {'word': 'ACEON', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d781.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d781.s0'}	Diuretics Patients diuretics especially started recently may occasionally experience excessive reduction blood pressure initiation ACEON Tablets therapy
Diuretics: Patients on diuretics, and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of ACEON    Tablets therapy. 	diuretics	ACEON	effect	{'e1': {'word': 'diuretics', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d781.s0.e1'}, 'e2': {'word': 'ACEON', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d781.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d781.s0'}	Diuretics Patients diuretics especially started recently may occasionally experience excessive reduction blood pressure initiation ACEON Tablets therapy
The possibility of hypotensive effects can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with perindopril. 	diuretic	perindopril	effect	{'e1': {'word': 'diuretic', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d781.s1.e0'}, 'e2': {'word': 'perindopril', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d781.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d781.s1'}	possibility hypotensive effects minimized either discontinuing diuretic increasing salt intake prior initiation treatment perindopril
If diuretics cannot be interrupted, close medical supervision should be provided with the first dose of ACEON    Tablets, for at least two hours and until blood pressure has stabilized for another hour. 	diuretics	ACEON	advise	{'e1': {'word': 'diuretics', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d781.s2.e0'}, 'e2': {'word': 'ACEON', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d781.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d781.s2'}	diuretics interrupted close medical supervision provided first dose ACEON Tablets least NUMBER hours blood pressure stabilized another hour
The rate and extent of perindopril absorption and elimination are not affected by concomitant diuretics. 	perindopril	diuretics	none	{'e1': {'word': 'perindopril', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d781.s3.e0'}, 'e2': {'word': 'diuretics', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d781.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d781.s3'}	rate extent perindopril absorption elimination affected concomitant diuretics
The bioavailability of perindoprilat was reduced by diuretics, however, and this was associated with a decrease in plasma ACE inhibition. 	perindoprilat	diuretics	none	{'e1': {'word': 'perindoprilat', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d781.s4.e0'}, 'e2': {'word': 'diuretics', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d781.s4.e1'}, 'sentence_id': 'DDI-DrugBank.d781.s4'}	bioavailability perindoprilat reduced diuretics however associated decrease plasma ACE inhibition
Potassium Supplements and Potassium-Sparing Diuretics: ACEON    Tablets may increase serum potassium because of its potential to decrease aldosterone production. 	Potassium	Potassium-Sparing Diuretics	none	{'e1': {'word': 'Potassium', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d781.s5.e0'}, 'e2': {'word': 'Potassium-Sparing Diuretics', 'word_index': [(2, 4)], 'id': 'DDI-DrugBank.d781.s5.e1'}, 'sentence_id': 'DDI-DrugBank.d781.s5'}	Potassium Supplements Potassium Sparing Diuretics ACEON Tablets may increase serum potassium potential decrease aldosterone production
Potassium Supplements and Potassium-Sparing Diuretics: ACEON    Tablets may increase serum potassium because of its potential to decrease aldosterone production. 	Potassium	ACEON	none	{'e1': {'word': 'Potassium', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d781.s5.e0'}, 'e2': {'word': 'ACEON', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d781.s5.e2'}, 'sentence_id': 'DDI-DrugBank.d781.s5'}	Potassium Supplements Potassium Sparing Diuretics ACEON Tablets may increase serum potassium potential decrease aldosterone production
Potassium Supplements and Potassium-Sparing Diuretics: ACEON    Tablets may increase serum potassium because of its potential to decrease aldosterone production. 	Potassium-Sparing Diuretics	ACEON	none	{'e1': {'word': 'Potassium-Sparing Diuretics', 'word_index': [(2, 4)], 'id': 'DDI-DrugBank.d781.s5.e1'}, 'e2': {'word': 'ACEON', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d781.s5.e2'}, 'sentence_id': 'DDI-DrugBank.d781.s5'}	Potassium Supplements Potassium Sparing Diuretics ACEON Tablets may increase serum potassium potential decrease aldosterone production
Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. 	potassium-sparing diuretics	spironolactone	none	{'e1': {'word': 'potassium-sparing diuretics', 'word_index': [(1, 3)], 'id': 'DDI-DrugBank.d781.s6.e0'}, 'e2': {'word': 'spironolactone', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d781.s6.e1'}, 'sentence_id': 'DDI-DrugBank.d781.s6'}	Use potassium sparing diuretics spironolactone amiloride triamterene others potassium supplements drugs capable increasing serum potassium indomethacin heparin cyclosporine others increase risk hyperkalemia
Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. 	potassium-sparing diuretics	amiloride	none	{'e1': {'word': 'potassium-sparing diuretics', 'word_index': [(1, 3)], 'id': 'DDI-DrugBank.d781.s6.e0'}, 'e2': {'word': 'amiloride', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d781.s6.e2'}, 'sentence_id': 'DDI-DrugBank.d781.s6'}	Use potassium sparing diuretics spironolactone amiloride triamterene others potassium supplements drugs capable increasing serum potassium indomethacin heparin cyclosporine others increase risk hyperkalemia
Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. 	potassium-sparing diuretics	triamterene	none	{'e1': {'word': 'potassium-sparing diuretics', 'word_index': [(1, 3)], 'id': 'DDI-DrugBank.d781.s6.e0'}, 'e2': {'word': 'triamterene', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d781.s6.e3'}, 'sentence_id': 'DDI-DrugBank.d781.s6'}	Use potassium sparing diuretics spironolactone amiloride triamterene others potassium supplements drugs capable increasing serum potassium indomethacin heparin cyclosporine others increase risk hyperkalemia
Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. 	potassium-sparing diuretics	potassium	none	{'e1': {'word': 'potassium-sparing diuretics', 'word_index': [(1, 3)], 'id': 'DDI-DrugBank.d781.s6.e0'}, 'e2': {'word': 'potassium', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d781.s6.e4'}, 'sentence_id': 'DDI-DrugBank.d781.s6'}	Use potassium sparing diuretics spironolactone amiloride triamterene others potassium supplements drugs capable increasing serum potassium indomethacin heparin cyclosporine others increase risk hyperkalemia
Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. 	potassium-sparing diuretics	indomethacin	none	{'e1': {'word': 'potassium-sparing diuretics', 'word_index': [(1, 3)], 'id': 'DDI-DrugBank.d781.s6.e0'}, 'e2': {'word': 'indomethacin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d781.s6.e5'}, 'sentence_id': 'DDI-DrugBank.d781.s6'}	Use potassium sparing diuretics spironolactone amiloride triamterene others potassium supplements drugs capable increasing serum potassium indomethacin heparin cyclosporine others increase risk hyperkalemia
Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. 	potassium-sparing diuretics	heparin	none	{'e1': {'word': 'potassium-sparing diuretics', 'word_index': [(1, 3)], 'id': 'DDI-DrugBank.d781.s6.e0'}, 'e2': {'word': 'heparin', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d781.s6.e6'}, 'sentence_id': 'DDI-DrugBank.d781.s6'}	Use potassium sparing diuretics spironolactone amiloride triamterene others potassium supplements drugs capable increasing serum potassium indomethacin heparin cyclosporine others increase risk hyperkalemia
Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. 	potassium-sparing diuretics	cyclosporine	none	{'e1': {'word': 'potassium-sparing diuretics', 'word_index': [(1, 3)], 'id': 'DDI-DrugBank.d781.s6.e0'}, 'e2': {'word': 'cyclosporine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d781.s6.e7'}, 'sentence_id': 'DDI-DrugBank.d781.s6'}	Use potassium sparing diuretics spironolactone amiloride triamterene others potassium supplements drugs capable increasing serum potassium indomethacin heparin cyclosporine others increase risk hyperkalemia
Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. 	spironolactone	amiloride	none	{'e1': {'word': 'spironolactone', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d781.s6.e1'}, 'e2': {'word': 'amiloride', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d781.s6.e2'}, 'sentence_id': 'DDI-DrugBank.d781.s6'}	Use potassium sparing diuretics spironolactone amiloride triamterene others potassium supplements drugs capable increasing serum potassium indomethacin heparin cyclosporine others increase risk hyperkalemia
Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. 	spironolactone	triamterene	none	{'e1': {'word': 'spironolactone', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d781.s6.e1'}, 'e2': {'word': 'triamterene', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d781.s6.e3'}, 'sentence_id': 'DDI-DrugBank.d781.s6'}	Use potassium sparing diuretics spironolactone amiloride triamterene others potassium supplements drugs capable increasing serum potassium indomethacin heparin cyclosporine others increase risk hyperkalemia
Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. 	spironolactone	potassium	none	{'e1': {'word': 'spironolactone', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d781.s6.e1'}, 'e2': {'word': 'potassium', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d781.s6.e4'}, 'sentence_id': 'DDI-DrugBank.d781.s6'}	Use potassium sparing diuretics spironolactone amiloride triamterene others potassium supplements drugs capable increasing serum potassium indomethacin heparin cyclosporine others increase risk hyperkalemia
Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. 	spironolactone	indomethacin	none	{'e1': {'word': 'spironolactone', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d781.s6.e1'}, 'e2': {'word': 'indomethacin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d781.s6.e5'}, 'sentence_id': 'DDI-DrugBank.d781.s6'}	Use potassium sparing diuretics spironolactone amiloride triamterene others potassium supplements drugs capable increasing serum potassium indomethacin heparin cyclosporine others increase risk hyperkalemia
Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. 	spironolactone	heparin	none	{'e1': {'word': 'spironolactone', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d781.s6.e1'}, 'e2': {'word': 'heparin', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d781.s6.e6'}, 'sentence_id': 'DDI-DrugBank.d781.s6'}	Use potassium sparing diuretics spironolactone amiloride triamterene others potassium supplements drugs capable increasing serum potassium indomethacin heparin cyclosporine others increase risk hyperkalemia
Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. 	spironolactone	cyclosporine	none	{'e1': {'word': 'spironolactone', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d781.s6.e1'}, 'e2': {'word': 'cyclosporine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d781.s6.e7'}, 'sentence_id': 'DDI-DrugBank.d781.s6'}	Use potassium sparing diuretics spironolactone amiloride triamterene others potassium supplements drugs capable increasing serum potassium indomethacin heparin cyclosporine others increase risk hyperkalemia
Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. 	amiloride	triamterene	none	{'e1': {'word': 'amiloride', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d781.s6.e2'}, 'e2': {'word': 'triamterene', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d781.s6.e3'}, 'sentence_id': 'DDI-DrugBank.d781.s6'}	Use potassium sparing diuretics spironolactone amiloride triamterene others potassium supplements drugs capable increasing serum potassium indomethacin heparin cyclosporine others increase risk hyperkalemia
Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. 	amiloride	potassium	none	{'e1': {'word': 'amiloride', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d781.s6.e2'}, 'e2': {'word': 'potassium', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d781.s6.e4'}, 'sentence_id': 'DDI-DrugBank.d781.s6'}	Use potassium sparing diuretics spironolactone amiloride triamterene others potassium supplements drugs capable increasing serum potassium indomethacin heparin cyclosporine others increase risk hyperkalemia
Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. 	amiloride	indomethacin	none	{'e1': {'word': 'amiloride', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d781.s6.e2'}, 'e2': {'word': 'indomethacin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d781.s6.e5'}, 'sentence_id': 'DDI-DrugBank.d781.s6'}	Use potassium sparing diuretics spironolactone amiloride triamterene others potassium supplements drugs capable increasing serum potassium indomethacin heparin cyclosporine others increase risk hyperkalemia
Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. 	amiloride	heparin	none	{'e1': {'word': 'amiloride', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d781.s6.e2'}, 'e2': {'word': 'heparin', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d781.s6.e6'}, 'sentence_id': 'DDI-DrugBank.d781.s6'}	Use potassium sparing diuretics spironolactone amiloride triamterene others potassium supplements drugs capable increasing serum potassium indomethacin heparin cyclosporine others increase risk hyperkalemia
Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. 	amiloride	cyclosporine	none	{'e1': {'word': 'amiloride', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d781.s6.e2'}, 'e2': {'word': 'cyclosporine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d781.s6.e7'}, 'sentence_id': 'DDI-DrugBank.d781.s6'}	Use potassium sparing diuretics spironolactone amiloride triamterene others potassium supplements drugs capable increasing serum potassium indomethacin heparin cyclosporine others increase risk hyperkalemia
Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. 	triamterene	potassium	none	{'e1': {'word': 'triamterene', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d781.s6.e3'}, 'e2': {'word': 'potassium', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d781.s6.e4'}, 'sentence_id': 'DDI-DrugBank.d781.s6'}	Use potassium sparing diuretics spironolactone amiloride triamterene others potassium supplements drugs capable increasing serum potassium indomethacin heparin cyclosporine others increase risk hyperkalemia
Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. 	triamterene	indomethacin	none	{'e1': {'word': 'triamterene', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d781.s6.e3'}, 'e2': {'word': 'indomethacin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d781.s6.e5'}, 'sentence_id': 'DDI-DrugBank.d781.s6'}	Use potassium sparing diuretics spironolactone amiloride triamterene others potassium supplements drugs capable increasing serum potassium indomethacin heparin cyclosporine others increase risk hyperkalemia
Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. 	triamterene	heparin	none	{'e1': {'word': 'triamterene', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d781.s6.e3'}, 'e2': {'word': 'heparin', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d781.s6.e6'}, 'sentence_id': 'DDI-DrugBank.d781.s6'}	Use potassium sparing diuretics spironolactone amiloride triamterene others potassium supplements drugs capable increasing serum potassium indomethacin heparin cyclosporine others increase risk hyperkalemia
Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. 	triamterene	cyclosporine	none	{'e1': {'word': 'triamterene', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d781.s6.e3'}, 'e2': {'word': 'cyclosporine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d781.s6.e7'}, 'sentence_id': 'DDI-DrugBank.d781.s6'}	Use potassium sparing diuretics spironolactone amiloride triamterene others potassium supplements drugs capable increasing serum potassium indomethacin heparin cyclosporine others increase risk hyperkalemia
Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. 	potassium	indomethacin	none	{'e1': {'word': 'potassium', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d781.s6.e4'}, 'e2': {'word': 'indomethacin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d781.s6.e5'}, 'sentence_id': 'DDI-DrugBank.d781.s6'}	Use potassium sparing diuretics spironolactone amiloride triamterene others potassium supplements drugs capable increasing serum potassium indomethacin heparin cyclosporine others increase risk hyperkalemia
Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. 	potassium	heparin	none	{'e1': {'word': 'potassium', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d781.s6.e4'}, 'e2': {'word': 'heparin', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d781.s6.e6'}, 'sentence_id': 'DDI-DrugBank.d781.s6'}	Use potassium sparing diuretics spironolactone amiloride triamterene others potassium supplements drugs capable increasing serum potassium indomethacin heparin cyclosporine others increase risk hyperkalemia
Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. 	potassium	cyclosporine	none	{'e1': {'word': 'potassium', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d781.s6.e4'}, 'e2': {'word': 'cyclosporine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d781.s6.e7'}, 'sentence_id': 'DDI-DrugBank.d781.s6'}	Use potassium sparing diuretics spironolactone amiloride triamterene others potassium supplements drugs capable increasing serum potassium indomethacin heparin cyclosporine others increase risk hyperkalemia
Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. 	indomethacin	heparin	none	{'e1': {'word': 'indomethacin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d781.s6.e5'}, 'e2': {'word': 'heparin', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d781.s6.e6'}, 'sentence_id': 'DDI-DrugBank.d781.s6'}	Use potassium sparing diuretics spironolactone amiloride triamterene others potassium supplements drugs capable increasing serum potassium indomethacin heparin cyclosporine others increase risk hyperkalemia
Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. 	indomethacin	cyclosporine	none	{'e1': {'word': 'indomethacin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d781.s6.e5'}, 'e2': {'word': 'cyclosporine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d781.s6.e7'}, 'sentence_id': 'DDI-DrugBank.d781.s6'}	Use potassium sparing diuretics spironolactone amiloride triamterene others potassium supplements drugs capable increasing serum potassium indomethacin heparin cyclosporine others increase risk hyperkalemia
Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. 	heparin	cyclosporine	none	{'e1': {'word': 'heparin', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d781.s6.e6'}, 'e2': {'word': 'cyclosporine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d781.s6.e7'}, 'sentence_id': 'DDI-DrugBank.d781.s6'}	Use potassium sparing diuretics spironolactone amiloride triamterene others potassium supplements drugs capable increasing serum potassium indomethacin heparin cyclosporine others increase risk hyperkalemia
Lithium: Increased serum lithium and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy. 	Lithium	lithium	none	{'e1': {'word': 'Lithium', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d781.s8.e0'}, 'e2': {'word': 'lithium', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d781.s8.e1'}, 'sentence_id': 'DDI-DrugBank.d781.s8'}	Lithium Increased serum lithium symptoms lithium toxicity reported patients receiving concomitant lithium ACE inhibitor therapy
Lithium: Increased serum lithium and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy. 	Lithium	lithium	none	{'e1': {'word': 'Lithium', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d781.s8.e0'}, 'e2': {'word': 'lithium', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d781.s8.e2'}, 'sentence_id': 'DDI-DrugBank.d781.s8'}	Lithium Increased serum lithium symptoms lithium toxicity reported patients receiving concomitant lithium ACE inhibitor therapy
Lithium: Increased serum lithium and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy. 	Lithium	lithium	none	{'e1': {'word': 'Lithium', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d781.s8.e0'}, 'e2': {'word': 'lithium', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d781.s8.e3'}, 'sentence_id': 'DDI-DrugBank.d781.s8'}	Lithium Increased serum lithium symptoms lithium toxicity reported patients receiving concomitant lithium ACE inhibitor therapy
Lithium: Increased serum lithium and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy. 	lithium	lithium	none	{'e1': {'word': 'lithium', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d781.s8.e1'}, 'e2': {'word': 'lithium', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d781.s8.e2'}, 'sentence_id': 'DDI-DrugBank.d781.s8'}	Lithium Increased serum lithium symptoms lithium toxicity reported patients receiving concomitant lithium ACE inhibitor therapy
Lithium: Increased serum lithium and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy. 	lithium	lithium	none	{'e1': {'word': 'lithium', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d781.s8.e1'}, 'e2': {'word': 'lithium', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d781.s8.e3'}, 'sentence_id': 'DDI-DrugBank.d781.s8'}	Lithium Increased serum lithium symptoms lithium toxicity reported patients receiving concomitant lithium ACE inhibitor therapy
Lithium: Increased serum lithium and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy. 	lithium	lithium	none	{'e1': {'word': 'lithium', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d781.s8.e2'}, 'e2': {'word': 'lithium', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d781.s8.e3'}, 'sentence_id': 'DDI-DrugBank.d781.s8'}	Lithium Increased serum lithium symptoms lithium toxicity reported patients receiving concomitant lithium ACE inhibitor therapy
Use of a diuretic may further increase the risk of lithium toxicity. 	diuretic	lithium	none	{'e1': {'word': 'diuretic', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d781.s10.e0'}, 'e2': {'word': 'lithium', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d781.s10.e1'}, 'sentence_id': 'DDI-DrugBank.d781.s10'}	Use diuretic may increase risk lithium toxicity
Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. 	Digoxin	digoxin	none	{'e1': {'word': 'Digoxin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d781.s11.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d781.s11.e1'}, 'sentence_id': 'DDI-DrugBank.d781.s11'}	Digoxin controlled pharmacokinetic study shown effect plasma digoxin concentrations coadministered ACEON Tablets effect digoxin plasma concentration perindopril perindoprilat excluded
Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. 	Digoxin	ACEON	none	{'e1': {'word': 'Digoxin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d781.s11.e0'}, 'e2': {'word': 'ACEON', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d781.s11.e2'}, 'sentence_id': 'DDI-DrugBank.d781.s11'}	Digoxin controlled pharmacokinetic study shown effect plasma digoxin concentrations coadministered ACEON Tablets effect digoxin plasma concentration perindopril perindoprilat excluded
Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. 	Digoxin	digoxin	none	{'e1': {'word': 'Digoxin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d781.s11.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d781.s11.e3'}, 'sentence_id': 'DDI-DrugBank.d781.s11'}	Digoxin controlled pharmacokinetic study shown effect plasma digoxin concentrations coadministered ACEON Tablets effect digoxin plasma concentration perindopril perindoprilat excluded
Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. 	Digoxin	perindopril	none	{'e1': {'word': 'Digoxin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d781.s11.e0'}, 'e2': {'word': 'perindopril', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d781.s11.e4'}, 'sentence_id': 'DDI-DrugBank.d781.s11'}	Digoxin controlled pharmacokinetic study shown effect plasma digoxin concentrations coadministered ACEON Tablets effect digoxin plasma concentration perindopril perindoprilat excluded
Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. 	Digoxin	perindoprilat	none	{'e1': {'word': 'Digoxin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d781.s11.e0'}, 'e2': {'word': 'perindoprilat', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d781.s11.e5'}, 'sentence_id': 'DDI-DrugBank.d781.s11'}	Digoxin controlled pharmacokinetic study shown effect plasma digoxin concentrations coadministered ACEON Tablets effect digoxin plasma concentration perindopril perindoprilat excluded
Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. 	digoxin	ACEON	none	{'e1': {'word': 'digoxin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d781.s11.e1'}, 'e2': {'word': 'ACEON', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d781.s11.e2'}, 'sentence_id': 'DDI-DrugBank.d781.s11'}	Digoxin controlled pharmacokinetic study shown effect plasma digoxin concentrations coadministered ACEON Tablets effect digoxin plasma concentration perindopril perindoprilat excluded
Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. 	digoxin	digoxin	none	{'e1': {'word': 'digoxin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d781.s11.e1'}, 'e2': {'word': 'digoxin', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d781.s11.e3'}, 'sentence_id': 'DDI-DrugBank.d781.s11'}	Digoxin controlled pharmacokinetic study shown effect plasma digoxin concentrations coadministered ACEON Tablets effect digoxin plasma concentration perindopril perindoprilat excluded
Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. 	digoxin	perindopril	none	{'e1': {'word': 'digoxin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d781.s11.e1'}, 'e2': {'word': 'perindopril', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d781.s11.e4'}, 'sentence_id': 'DDI-DrugBank.d781.s11'}	Digoxin controlled pharmacokinetic study shown effect plasma digoxin concentrations coadministered ACEON Tablets effect digoxin plasma concentration perindopril perindoprilat excluded
Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. 	digoxin	perindoprilat	none	{'e1': {'word': 'digoxin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d781.s11.e1'}, 'e2': {'word': 'perindoprilat', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d781.s11.e5'}, 'sentence_id': 'DDI-DrugBank.d781.s11'}	Digoxin controlled pharmacokinetic study shown effect plasma digoxin concentrations coadministered ACEON Tablets effect digoxin plasma concentration perindopril perindoprilat excluded
Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. 	ACEON	digoxin	none	{'e1': {'word': 'ACEON', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d781.s11.e2'}, 'e2': {'word': 'digoxin', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d781.s11.e3'}, 'sentence_id': 'DDI-DrugBank.d781.s11'}	Digoxin controlled pharmacokinetic study shown effect plasma digoxin concentrations coadministered ACEON Tablets effect digoxin plasma concentration perindopril perindoprilat excluded
Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. 	ACEON	perindopril	none	{'e1': {'word': 'ACEON', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d781.s11.e2'}, 'e2': {'word': 'perindopril', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d781.s11.e4'}, 'sentence_id': 'DDI-DrugBank.d781.s11'}	Digoxin controlled pharmacokinetic study shown effect plasma digoxin concentrations coadministered ACEON Tablets effect digoxin plasma concentration perindopril perindoprilat excluded
Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. 	ACEON	perindoprilat	none	{'e1': {'word': 'ACEON', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d781.s11.e2'}, 'e2': {'word': 'perindoprilat', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d781.s11.e5'}, 'sentence_id': 'DDI-DrugBank.d781.s11'}	Digoxin controlled pharmacokinetic study shown effect plasma digoxin concentrations coadministered ACEON Tablets effect digoxin plasma concentration perindopril perindoprilat excluded
Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. 	digoxin	perindopril	mechanism	{'e1': {'word': 'digoxin', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d781.s11.e3'}, 'e2': {'word': 'perindopril', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d781.s11.e4'}, 'sentence_id': 'DDI-DrugBank.d781.s11'}	Digoxin controlled pharmacokinetic study shown effect plasma digoxin concentrations coadministered ACEON Tablets effect digoxin plasma concentration perindopril perindoprilat excluded
Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. 	digoxin	perindoprilat	mechanism	{'e1': {'word': 'digoxin', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d781.s11.e3'}, 'e2': {'word': 'perindoprilat', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d781.s11.e5'}, 'sentence_id': 'DDI-DrugBank.d781.s11'}	Digoxin controlled pharmacokinetic study shown effect plasma digoxin concentrations coadministered ACEON Tablets effect digoxin plasma concentration perindopril perindoprilat excluded
Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. 	perindopril	perindoprilat	none	{'e1': {'word': 'perindopril', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d781.s11.e4'}, 'e2': {'word': 'perindoprilat', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d781.s11.e5'}, 'sentence_id': 'DDI-DrugBank.d781.s11'}	Digoxin controlled pharmacokinetic study shown effect plasma digoxin concentrations coadministered ACEON Tablets effect digoxin plasma concentration perindopril perindoprilat excluded
Gentamicin: Animal data have suggested the possibility of interaction between perindopril and gentamicin. 	Gentamicin	perindopril	none	{'e1': {'word': 'Gentamicin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d781.s12.e0'}, 'e2': {'word': 'perindopril', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d781.s12.e1'}, 'sentence_id': 'DDI-DrugBank.d781.s12'}	Gentamicin Animal data suggested possibility interaction perindopril gentamicin
Gentamicin: Animal data have suggested the possibility of interaction between perindopril and gentamicin. 	Gentamicin	gentamicin	none	{'e1': {'word': 'Gentamicin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d781.s12.e0'}, 'e2': {'word': 'gentamicin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d781.s12.e2'}, 'sentence_id': 'DDI-DrugBank.d781.s12'}	Gentamicin Animal data suggested possibility interaction perindopril gentamicin
Gentamicin: Animal data have suggested the possibility of interaction between perindopril and gentamicin. 	perindopril	gentamicin	int	{'e1': {'word': 'perindopril', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d781.s12.e1'}, 'e2': {'word': 'gentamicin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d781.s12.e2'}, 'sentence_id': 'DDI-DrugBank.d781.s12'}	Gentamicin Animal data suggested possibility interaction perindopril gentamicin
Food Interaction: Oral administration of ACEON    Tablets with food does not significantly lower the rate or extent of perindopril absorption relative to the fasted state. 	ACEON	perindopril	none	{'e1': {'word': 'ACEON', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d781.s15.e0'}, 'e2': {'word': 'perindopril', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d781.s15.e1'}, 'sentence_id': 'DDI-DrugBank.d781.s15'}	Food Interaction Oral administration ACEON Tablets food significantly lower rate extent perindopril absorption relative fasted state
However, the extent of biotransformation of perindopril to the active metabolite, perindoprilat, is reduced approximately 43%, resulting in a reduction in the plasma ACE inhibition curve of approximately 20%, probably clinically insignificant. 	perindopril	perindoprilat	none	{'e1': {'word': 'perindopril', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d781.s16.e0'}, 'e2': {'word': 'perindoprilat', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d781.s16.e1'}, 'sentence_id': 'DDI-DrugBank.d781.s16'}	However extent biotransformation perindopril active metabolite perindoprilat reduced approximately NUMBER % resulting reduction plasma ACE inhibition curve approximately NUMBER % probably clinically insignificant
Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); 	Dopamine antagonists	neuroleptics	none	{'e1': {'word': 'Dopamine antagonists', 'word_index': [(0, 1)], 'id': 'DDI-DrugBank.d650.s0.e0'}, 'e2': {'word': 'neuroleptics', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d650.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d650.s0'}	Dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthines metoclopramide ordinarily administered concurrently Permax dopamine agonist
Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); 	Dopamine antagonists	phenothiazines	none	{'e1': {'word': 'Dopamine antagonists', 'word_index': [(0, 1)], 'id': 'DDI-DrugBank.d650.s0.e0'}, 'e2': {'word': 'phenothiazines', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d650.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d650.s0'}	Dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthines metoclopramide ordinarily administered concurrently Permax dopamine agonist
Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); 	Dopamine antagonists	butyrophenones	none	{'e1': {'word': 'Dopamine antagonists', 'word_index': [(0, 1)], 'id': 'DDI-DrugBank.d650.s0.e0'}, 'e2': {'word': 'butyrophenones', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d650.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d650.s0'}	Dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthines metoclopramide ordinarily administered concurrently Permax dopamine agonist
Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); 	Dopamine antagonists	thioxanthines	none	{'e1': {'word': 'Dopamine antagonists', 'word_index': [(0, 1)], 'id': 'DDI-DrugBank.d650.s0.e0'}, 'e2': {'word': 'thioxanthines', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d650.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d650.s0'}	Dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthines metoclopramide ordinarily administered concurrently Permax dopamine agonist
Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); 	Dopamine antagonists	metoclopramide	none	{'e1': {'word': 'Dopamine antagonists', 'word_index': [(0, 1)], 'id': 'DDI-DrugBank.d650.s0.e0'}, 'e2': {'word': 'metoclopramide', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d650.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d650.s0'}	Dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthines metoclopramide ordinarily administered concurrently Permax dopamine agonist
Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); 	Dopamine antagonists	Permax	advise	{'e1': {'word': 'Dopamine antagonists', 'word_index': [(0, 1)], 'id': 'DDI-DrugBank.d650.s0.e0'}, 'e2': {'word': 'Permax', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d650.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d650.s0'}	Dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthines metoclopramide ordinarily administered concurrently Permax dopamine agonist
Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); 	Dopamine antagonists	dopamine agonist	none	{'e1': {'word': 'Dopamine antagonists', 'word_index': [(0, 1)], 'id': 'DDI-DrugBank.d650.s0.e0'}, 'e2': {'word': 'dopamine agonist', 'word_index': [(11, 12)], 'id': 'DDI-DrugBank.d650.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d650.s0'}	Dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthines metoclopramide ordinarily administered concurrently Permax dopamine agonist
Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); 	neuroleptics	phenothiazines	none	{'e1': {'word': 'neuroleptics', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d650.s0.e1'}, 'e2': {'word': 'phenothiazines', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d650.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d650.s0'}	Dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthines metoclopramide ordinarily administered concurrently Permax dopamine agonist
Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); 	neuroleptics	butyrophenones	none	{'e1': {'word': 'neuroleptics', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d650.s0.e1'}, 'e2': {'word': 'butyrophenones', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d650.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d650.s0'}	Dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthines metoclopramide ordinarily administered concurrently Permax dopamine agonist
Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); 	neuroleptics	thioxanthines	none	{'e1': {'word': 'neuroleptics', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d650.s0.e1'}, 'e2': {'word': 'thioxanthines', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d650.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d650.s0'}	Dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthines metoclopramide ordinarily administered concurrently Permax dopamine agonist
Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); 	neuroleptics	metoclopramide	none	{'e1': {'word': 'neuroleptics', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d650.s0.e1'}, 'e2': {'word': 'metoclopramide', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d650.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d650.s0'}	Dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthines metoclopramide ordinarily administered concurrently Permax dopamine agonist
Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); 	neuroleptics	Permax	advise	{'e1': {'word': 'neuroleptics', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d650.s0.e1'}, 'e2': {'word': 'Permax', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d650.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d650.s0'}	Dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthines metoclopramide ordinarily administered concurrently Permax dopamine agonist
Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); 	neuroleptics	dopamine agonist	none	{'e1': {'word': 'neuroleptics', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d650.s0.e1'}, 'e2': {'word': 'dopamine agonist', 'word_index': [(11, 12)], 'id': 'DDI-DrugBank.d650.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d650.s0'}	Dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthines metoclopramide ordinarily administered concurrently Permax dopamine agonist
Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); 	phenothiazines	butyrophenones	none	{'e1': {'word': 'phenothiazines', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d650.s0.e2'}, 'e2': {'word': 'butyrophenones', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d650.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d650.s0'}	Dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthines metoclopramide ordinarily administered concurrently Permax dopamine agonist
Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); 	phenothiazines	thioxanthines	none	{'e1': {'word': 'phenothiazines', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d650.s0.e2'}, 'e2': {'word': 'thioxanthines', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d650.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d650.s0'}	Dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthines metoclopramide ordinarily administered concurrently Permax dopamine agonist
Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); 	phenothiazines	metoclopramide	none	{'e1': {'word': 'phenothiazines', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d650.s0.e2'}, 'e2': {'word': 'metoclopramide', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d650.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d650.s0'}	Dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthines metoclopramide ordinarily administered concurrently Permax dopamine agonist
Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); 	phenothiazines	Permax	advise	{'e1': {'word': 'phenothiazines', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d650.s0.e2'}, 'e2': {'word': 'Permax', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d650.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d650.s0'}	Dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthines metoclopramide ordinarily administered concurrently Permax dopamine agonist
Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); 	phenothiazines	dopamine agonist	none	{'e1': {'word': 'phenothiazines', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d650.s0.e2'}, 'e2': {'word': 'dopamine agonist', 'word_index': [(11, 12)], 'id': 'DDI-DrugBank.d650.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d650.s0'}	Dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthines metoclopramide ordinarily administered concurrently Permax dopamine agonist
Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); 	butyrophenones	thioxanthines	none	{'e1': {'word': 'butyrophenones', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d650.s0.e3'}, 'e2': {'word': 'thioxanthines', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d650.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d650.s0'}	Dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthines metoclopramide ordinarily administered concurrently Permax dopamine agonist
Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); 	butyrophenones	metoclopramide	none	{'e1': {'word': 'butyrophenones', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d650.s0.e3'}, 'e2': {'word': 'metoclopramide', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d650.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d650.s0'}	Dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthines metoclopramide ordinarily administered concurrently Permax dopamine agonist
Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); 	butyrophenones	Permax	advise	{'e1': {'word': 'butyrophenones', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d650.s0.e3'}, 'e2': {'word': 'Permax', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d650.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d650.s0'}	Dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthines metoclopramide ordinarily administered concurrently Permax dopamine agonist
Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); 	butyrophenones	dopamine agonist	none	{'e1': {'word': 'butyrophenones', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d650.s0.e3'}, 'e2': {'word': 'dopamine agonist', 'word_index': [(11, 12)], 'id': 'DDI-DrugBank.d650.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d650.s0'}	Dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthines metoclopramide ordinarily administered concurrently Permax dopamine agonist
Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); 	thioxanthines	metoclopramide	none	{'e1': {'word': 'thioxanthines', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d650.s0.e4'}, 'e2': {'word': 'metoclopramide', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d650.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d650.s0'}	Dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthines metoclopramide ordinarily administered concurrently Permax dopamine agonist
Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); 	thioxanthines	Permax	advise	{'e1': {'word': 'thioxanthines', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d650.s0.e4'}, 'e2': {'word': 'Permax', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d650.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d650.s0'}	Dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthines metoclopramide ordinarily administered concurrently Permax dopamine agonist
Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); 	thioxanthines	dopamine agonist	none	{'e1': {'word': 'thioxanthines', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d650.s0.e4'}, 'e2': {'word': 'dopamine agonist', 'word_index': [(11, 12)], 'id': 'DDI-DrugBank.d650.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d650.s0'}	Dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthines metoclopramide ordinarily administered concurrently Permax dopamine agonist
Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); 	metoclopramide	Permax	advise	{'e1': {'word': 'metoclopramide', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d650.s0.e5'}, 'e2': {'word': 'Permax', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d650.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d650.s0'}	Dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthines metoclopramide ordinarily administered concurrently Permax dopamine agonist
Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); 	metoclopramide	dopamine agonist	none	{'e1': {'word': 'metoclopramide', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d650.s0.e5'}, 'e2': {'word': 'dopamine agonist', 'word_index': [(11, 12)], 'id': 'DDI-DrugBank.d650.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d650.s0'}	Dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthines metoclopramide ordinarily administered concurrently Permax dopamine agonist
Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); 	Permax	dopamine agonist	none	{'e1': {'word': 'Permax', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d650.s0.e6'}, 'e2': {'word': 'dopamine agonist', 'word_index': [(11, 12)], 'id': 'DDI-DrugBank.d650.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d650.s0'}	Dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthines metoclopramide ordinarily administered concurrently Permax dopamine agonist
Because pergolide mesylate is approximately 90% bound to plasma proteins, caution should be exercised if pergolide mesylate is coadministered with other drugs known to affect protein binding.	pergolide mesylate	pergolide mesylate	none	{'e1': {'word': 'pergolide mesylate', 'word_index': [(0, 1)], 'id': 'DDI-DrugBank.d650.s2.e0'}, 'e2': {'word': 'pergolide mesylate', 'word_index': [(10, 11)], 'id': 'DDI-DrugBank.d650.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d650.s2'}	pergolide mesylate approximately NUMBER % bound plasma proteins caution exercised pergolide mesylate coadministered drugs known affect protein binding
MAO inhibitors and beta adrenergic blockers increase the effects of pseudoephedrine. 	MAO inhibitors	beta adrenergic blockers	none	{'e1': {'word': 'MAO inhibitors', 'word_index': [(0, 1)], 'id': 'DDI-DrugBank.d606.s0.e0'}, 'e2': {'word': 'beta adrenergic blockers', 'word_index': [(2, 4)], 'id': 'DDI-DrugBank.d606.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d606.s0'}	MAO inhibitors beta adrenergic blockers increase effects pseudoephedrine
MAO inhibitors and beta adrenergic blockers increase the effects of pseudoephedrine. 	MAO inhibitors	pseudoephedrine	effect	{'e1': {'word': 'MAO inhibitors', 'word_index': [(0, 1)], 'id': 'DDI-DrugBank.d606.s0.e0'}, 'e2': {'word': 'pseudoephedrine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d606.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d606.s0'}	MAO inhibitors beta adrenergic blockers increase effects pseudoephedrine
MAO inhibitors and beta adrenergic blockers increase the effects of pseudoephedrine. 	beta adrenergic blockers	pseudoephedrine	effect	{'e1': {'word': 'beta adrenergic blockers', 'word_index': [(2, 4)], 'id': 'DDI-DrugBank.d606.s0.e1'}, 'e2': {'word': 'pseudoephedrine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d606.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d606.s0'}	MAO inhibitors beta adrenergic blockers increase effects pseudoephedrine
Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.	Sympathomimetics	methyldopa	effect	{'e1': {'word': 'Sympathomimetics', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d606.s1.e0'}, 'e2': {'word': 'methyldopa', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d606.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d606.s1'}	Sympathomimetics may reduce antihypertensive effects methyldopa mecamylamine reserpine veratrum alkaloids
Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.	Sympathomimetics	mecamylamine	effect	{'e1': {'word': 'Sympathomimetics', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d606.s1.e0'}, 'e2': {'word': 'mecamylamine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d606.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d606.s1'}	Sympathomimetics may reduce antihypertensive effects methyldopa mecamylamine reserpine veratrum alkaloids
Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.	Sympathomimetics	reserpine	effect	{'e1': {'word': 'Sympathomimetics', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d606.s1.e0'}, 'e2': {'word': 'reserpine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d606.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d606.s1'}	Sympathomimetics may reduce antihypertensive effects methyldopa mecamylamine reserpine veratrum alkaloids
Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.	Sympathomimetics	veratrum alkaloids	effect	{'e1': {'word': 'Sympathomimetics', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d606.s1.e0'}, 'e2': {'word': 'veratrum alkaloids', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d606.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d606.s1'}	Sympathomimetics may reduce antihypertensive effects methyldopa mecamylamine reserpine veratrum alkaloids
Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.	methyldopa	mecamylamine	none	{'e1': {'word': 'methyldopa', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d606.s1.e1'}, 'e2': {'word': 'mecamylamine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d606.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d606.s1'}	Sympathomimetics may reduce antihypertensive effects methyldopa mecamylamine reserpine veratrum alkaloids
Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.	methyldopa	reserpine	none	{'e1': {'word': 'methyldopa', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d606.s1.e1'}, 'e2': {'word': 'reserpine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d606.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d606.s1'}	Sympathomimetics may reduce antihypertensive effects methyldopa mecamylamine reserpine veratrum alkaloids
Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.	methyldopa	veratrum alkaloids	none	{'e1': {'word': 'methyldopa', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d606.s1.e1'}, 'e2': {'word': 'veratrum alkaloids', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d606.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d606.s1'}	Sympathomimetics may reduce antihypertensive effects methyldopa mecamylamine reserpine veratrum alkaloids
Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.	mecamylamine	reserpine	none	{'e1': {'word': 'mecamylamine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d606.s1.e2'}, 'e2': {'word': 'reserpine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d606.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d606.s1'}	Sympathomimetics may reduce antihypertensive effects methyldopa mecamylamine reserpine veratrum alkaloids
Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.	mecamylamine	veratrum alkaloids	none	{'e1': {'word': 'mecamylamine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d606.s1.e2'}, 'e2': {'word': 'veratrum alkaloids', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d606.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d606.s1'}	Sympathomimetics may reduce antihypertensive effects methyldopa mecamylamine reserpine veratrum alkaloids
Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.	reserpine	veratrum alkaloids	none	{'e1': {'word': 'reserpine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d606.s1.e3'}, 'e2': {'word': 'veratrum alkaloids', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d606.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d606.s1'}	Sympathomimetics may reduce antihypertensive effects methyldopa mecamylamine reserpine veratrum alkaloids
Concomitant administration of vancomycin and anesthetic agents has been associated with erythema and histamine-like flushing and anaphylactoid reactions. 	vancomycin	anesthetic agents	effect	{'e1': {'word': 'vancomycin', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d669.s0.e0'}, 'e2': {'word': 'anesthetic agents', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d669.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d669.s0'}	Concomitant administration vancomycin anesthetic agents associated erythema histamine like flushing anaphylactoid reactions
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.	amphotericin B	aminoglycosides	none	{'e1': {'word': 'amphotericin B', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d669.s1.e0'}, 'e2': {'word': 'aminoglycosides', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d669.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d669.s1'}	Concurrent sequential systemic topical use potentially neurotoxic nephrotoxic drugs amphotericin B aminoglycosides bacitracin polymyxin B colistin viomycin cisplatin indicated requires careful monitoring
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.	amphotericin B	bacitracin	none	{'e1': {'word': 'amphotericin B', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d669.s1.e0'}, 'e2': {'word': 'bacitracin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d669.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d669.s1'}	Concurrent sequential systemic topical use potentially neurotoxic nephrotoxic drugs amphotericin B aminoglycosides bacitracin polymyxin B colistin viomycin cisplatin indicated requires careful monitoring
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.	amphotericin B	polymyxin B	none	{'e1': {'word': 'amphotericin B', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d669.s1.e0'}, 'e2': {'word': 'polymyxin B', 'word_index': [(13, 14)], 'id': 'DDI-DrugBank.d669.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d669.s1'}	Concurrent sequential systemic topical use potentially neurotoxic nephrotoxic drugs amphotericin B aminoglycosides bacitracin polymyxin B colistin viomycin cisplatin indicated requires careful monitoring
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.	amphotericin B	colistin	none	{'e1': {'word': 'amphotericin B', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d669.s1.e0'}, 'e2': {'word': 'colistin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d669.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d669.s1'}	Concurrent sequential systemic topical use potentially neurotoxic nephrotoxic drugs amphotericin B aminoglycosides bacitracin polymyxin B colistin viomycin cisplatin indicated requires careful monitoring
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.	amphotericin B	viomycin	none	{'e1': {'word': 'amphotericin B', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d669.s1.e0'}, 'e2': {'word': 'viomycin', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d669.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d669.s1'}	Concurrent sequential systemic topical use potentially neurotoxic nephrotoxic drugs amphotericin B aminoglycosides bacitracin polymyxin B colistin viomycin cisplatin indicated requires careful monitoring
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.	amphotericin B	cisplatin	none	{'e1': {'word': 'amphotericin B', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d669.s1.e0'}, 'e2': {'word': 'cisplatin', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d669.s1.e6'}, 'sentence_id': 'DDI-DrugBank.d669.s1'}	Concurrent sequential systemic topical use potentially neurotoxic nephrotoxic drugs amphotericin B aminoglycosides bacitracin polymyxin B colistin viomycin cisplatin indicated requires careful monitoring
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.	aminoglycosides	bacitracin	none	{'e1': {'word': 'aminoglycosides', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d669.s1.e1'}, 'e2': {'word': 'bacitracin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d669.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d669.s1'}	Concurrent sequential systemic topical use potentially neurotoxic nephrotoxic drugs amphotericin B aminoglycosides bacitracin polymyxin B colistin viomycin cisplatin indicated requires careful monitoring
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.	aminoglycosides	polymyxin B	none	{'e1': {'word': 'aminoglycosides', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d669.s1.e1'}, 'e2': {'word': 'polymyxin B', 'word_index': [(13, 14)], 'id': 'DDI-DrugBank.d669.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d669.s1'}	Concurrent sequential systemic topical use potentially neurotoxic nephrotoxic drugs amphotericin B aminoglycosides bacitracin polymyxin B colistin viomycin cisplatin indicated requires careful monitoring
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.	aminoglycosides	colistin	none	{'e1': {'word': 'aminoglycosides', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d669.s1.e1'}, 'e2': {'word': 'colistin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d669.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d669.s1'}	Concurrent sequential systemic topical use potentially neurotoxic nephrotoxic drugs amphotericin B aminoglycosides bacitracin polymyxin B colistin viomycin cisplatin indicated requires careful monitoring
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.	aminoglycosides	viomycin	none	{'e1': {'word': 'aminoglycosides', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d669.s1.e1'}, 'e2': {'word': 'viomycin', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d669.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d669.s1'}	Concurrent sequential systemic topical use potentially neurotoxic nephrotoxic drugs amphotericin B aminoglycosides bacitracin polymyxin B colistin viomycin cisplatin indicated requires careful monitoring
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.	aminoglycosides	cisplatin	none	{'e1': {'word': 'aminoglycosides', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d669.s1.e1'}, 'e2': {'word': 'cisplatin', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d669.s1.e6'}, 'sentence_id': 'DDI-DrugBank.d669.s1'}	Concurrent sequential systemic topical use potentially neurotoxic nephrotoxic drugs amphotericin B aminoglycosides bacitracin polymyxin B colistin viomycin cisplatin indicated requires careful monitoring
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.	bacitracin	polymyxin B	none	{'e1': {'word': 'bacitracin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d669.s1.e2'}, 'e2': {'word': 'polymyxin B', 'word_index': [(13, 14)], 'id': 'DDI-DrugBank.d669.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d669.s1'}	Concurrent sequential systemic topical use potentially neurotoxic nephrotoxic drugs amphotericin B aminoglycosides bacitracin polymyxin B colistin viomycin cisplatin indicated requires careful monitoring
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.	bacitracin	colistin	none	{'e1': {'word': 'bacitracin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d669.s1.e2'}, 'e2': {'word': 'colistin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d669.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d669.s1'}	Concurrent sequential systemic topical use potentially neurotoxic nephrotoxic drugs amphotericin B aminoglycosides bacitracin polymyxin B colistin viomycin cisplatin indicated requires careful monitoring
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.	bacitracin	viomycin	none	{'e1': {'word': 'bacitracin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d669.s1.e2'}, 'e2': {'word': 'viomycin', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d669.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d669.s1'}	Concurrent sequential systemic topical use potentially neurotoxic nephrotoxic drugs amphotericin B aminoglycosides bacitracin polymyxin B colistin viomycin cisplatin indicated requires careful monitoring
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.	bacitracin	cisplatin	none	{'e1': {'word': 'bacitracin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d669.s1.e2'}, 'e2': {'word': 'cisplatin', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d669.s1.e6'}, 'sentence_id': 'DDI-DrugBank.d669.s1'}	Concurrent sequential systemic topical use potentially neurotoxic nephrotoxic drugs amphotericin B aminoglycosides bacitracin polymyxin B colistin viomycin cisplatin indicated requires careful monitoring
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.	polymyxin B	colistin	none	{'e1': {'word': 'polymyxin B', 'word_index': [(13, 14)], 'id': 'DDI-DrugBank.d669.s1.e3'}, 'e2': {'word': 'colistin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d669.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d669.s1'}	Concurrent sequential systemic topical use potentially neurotoxic nephrotoxic drugs amphotericin B aminoglycosides bacitracin polymyxin B colistin viomycin cisplatin indicated requires careful monitoring
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.	polymyxin B	viomycin	none	{'e1': {'word': 'polymyxin B', 'word_index': [(13, 14)], 'id': 'DDI-DrugBank.d669.s1.e3'}, 'e2': {'word': 'viomycin', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d669.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d669.s1'}	Concurrent sequential systemic topical use potentially neurotoxic nephrotoxic drugs amphotericin B aminoglycosides bacitracin polymyxin B colistin viomycin cisplatin indicated requires careful monitoring
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.	polymyxin B	cisplatin	none	{'e1': {'word': 'polymyxin B', 'word_index': [(13, 14)], 'id': 'DDI-DrugBank.d669.s1.e3'}, 'e2': {'word': 'cisplatin', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d669.s1.e6'}, 'sentence_id': 'DDI-DrugBank.d669.s1'}	Concurrent sequential systemic topical use potentially neurotoxic nephrotoxic drugs amphotericin B aminoglycosides bacitracin polymyxin B colistin viomycin cisplatin indicated requires careful monitoring
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.	colistin	viomycin	none	{'e1': {'word': 'colistin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d669.s1.e4'}, 'e2': {'word': 'viomycin', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d669.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d669.s1'}	Concurrent sequential systemic topical use potentially neurotoxic nephrotoxic drugs amphotericin B aminoglycosides bacitracin polymyxin B colistin viomycin cisplatin indicated requires careful monitoring
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.	colistin	cisplatin	none	{'e1': {'word': 'colistin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d669.s1.e4'}, 'e2': {'word': 'cisplatin', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d669.s1.e6'}, 'sentence_id': 'DDI-DrugBank.d669.s1'}	Concurrent sequential systemic topical use potentially neurotoxic nephrotoxic drugs amphotericin B aminoglycosides bacitracin polymyxin B colistin viomycin cisplatin indicated requires careful monitoring
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.	viomycin	cisplatin	none	{'e1': {'word': 'viomycin', 'word_index': [(16, 15)], 'id': 'DDI-DrugBank.d669.s1.e5'}, 'e2': {'word': 'cisplatin', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d669.s1.e6'}, 'sentence_id': 'DDI-DrugBank.d669.s1'}	Concurrent sequential systemic topical use potentially neurotoxic nephrotoxic drugs amphotericin B aminoglycosides bacitracin polymyxin B colistin cisplatin indicated requires careful monitoring
Anticoagulants Anabolic steroids may increase sensitivity to oral anticoagulants. 	Anticoagulants	Anabolic steroids	none	{'e1': {'word': 'Anticoagulants', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d584.s0.e0'}, 'e2': {'word': 'Anabolic steroids', 'word_index': [(1, 2)], 'id': 'DDI-DrugBank.d584.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d584.s0'}	Anticoagulants Anabolic steroids may increase sensitivity oral anticoagulants
Anticoagulants Anabolic steroids may increase sensitivity to oral anticoagulants. 	Anticoagulants	anticoagulants	none	{'e1': {'word': 'Anticoagulants', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d584.s0.e0'}, 'e2': {'word': 'anticoagulants', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d584.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d584.s0'}	Anticoagulants Anabolic steroids may increase sensitivity oral anticoagulants
Anticoagulants Anabolic steroids may increase sensitivity to oral anticoagulants. 	Anabolic steroids	anticoagulants	effect	{'e1': {'word': 'Anabolic steroids', 'word_index': [(1, 2)], 'id': 'DDI-DrugBank.d584.s0.e1'}, 'e2': {'word': 'anticoagulants', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d584.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d584.s0'}	Anticoagulants Anabolic steroids may increase sensitivity oral anticoagulants
Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. 	Warfarin	oxandrolone	none	{'e1': {'word': 'Warfarin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d584.s3.e0'}, 'e2': {'word': 'oxandrolone', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d584.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d584.s3'}	Warfarin multidose study oxandrolone given NUMBER NUMBER mg BID NUMBER healthy subjects concurrently treated warfarin resulted mean increase warfarin half life NUMBER NUMBER hours AUC NUMBER NUMBER ng * hr / mL similar increases R warfarin half life AUC also detected
Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. 	Warfarin	warfarin	none	{'e1': {'word': 'Warfarin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d584.s3.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d584.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d584.s3'}	Warfarin multidose study oxandrolone given NUMBER NUMBER mg BID NUMBER healthy subjects concurrently treated warfarin resulted mean increase warfarin half life NUMBER NUMBER hours AUC NUMBER NUMBER ng * hr / mL similar increases R warfarin half life AUC also detected
Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. 	Warfarin	S-warfarin	none	{'e1': {'word': 'Warfarin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d584.s3.e0'}, 'e2': {'word': 'S-warfarin', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d584.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d584.s3'}	Warfarin multidose study oxandrolone given NUMBER NUMBER mg BID NUMBER healthy subjects concurrently treated warfarin resulted mean increase warfarin half life NUMBER NUMBER hours AUC NUMBER NUMBER ng * hr / mL similar increases R warfarin half life AUC also detected
Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. 	Warfarin	R-warfarin	none	{'e1': {'word': 'Warfarin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d584.s3.e0'}, 'e2': {'word': 'R-warfarin', 'word_index': [(34, 35)], 'id': 'DDI-DrugBank.d584.s3.e4'}, 'sentence_id': 'DDI-DrugBank.d584.s3'}	Warfarin multidose study oxandrolone given NUMBER NUMBER mg BID NUMBER healthy subjects concurrently treated warfarin resulted mean increase warfarin half life NUMBER NUMBER hours AUC NUMBER NUMBER ng * hr / mL similar increases R warfarin half life AUC also detected
Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. 	oxandrolone	warfarin	mechanism	{'e1': {'word': 'oxandrolone', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d584.s3.e1'}, 'e2': {'word': 'warfarin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d584.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d584.s3'}	Warfarin multidose study oxandrolone given NUMBER NUMBER mg BID NUMBER healthy subjects concurrently treated warfarin resulted mean increase warfarin half life NUMBER NUMBER hours AUC NUMBER NUMBER ng * hr / mL similar increases R warfarin half life AUC also detected
Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. 	oxandrolone	S-warfarin	none	{'e1': {'word': 'oxandrolone', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d584.s3.e1'}, 'e2': {'word': 'S-warfarin', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d584.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d584.s3'}	Warfarin multidose study oxandrolone given NUMBER NUMBER mg BID NUMBER healthy subjects concurrently treated warfarin resulted mean increase warfarin half life NUMBER NUMBER hours AUC NUMBER NUMBER ng * hr / mL similar increases R warfarin half life AUC also detected
Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. 	oxandrolone	R-warfarin	none	{'e1': {'word': 'oxandrolone', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d584.s3.e1'}, 'e2': {'word': 'R-warfarin', 'word_index': [(34, 35)], 'id': 'DDI-DrugBank.d584.s3.e4'}, 'sentence_id': 'DDI-DrugBank.d584.s3'}	Warfarin multidose study oxandrolone given NUMBER NUMBER mg BID NUMBER healthy subjects concurrently treated warfarin resulted mean increase warfarin half life NUMBER NUMBER hours AUC NUMBER NUMBER ng * hr / mL similar increases R warfarin half life AUC also detected
Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. 	warfarin	S-warfarin	none	{'e1': {'word': 'warfarin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d584.s3.e2'}, 'e2': {'word': 'S-warfarin', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d584.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d584.s3'}	Warfarin multidose study oxandrolone given NUMBER NUMBER mg BID NUMBER healthy subjects concurrently treated warfarin resulted mean increase warfarin half life NUMBER NUMBER hours AUC NUMBER NUMBER ng * hr / mL similar increases R warfarin half life AUC also detected
Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. 	warfarin	R-warfarin	none	{'e1': {'word': 'warfarin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d584.s3.e2'}, 'e2': {'word': 'R-warfarin', 'word_index': [(34, 35)], 'id': 'DDI-DrugBank.d584.s3.e4'}, 'sentence_id': 'DDI-DrugBank.d584.s3'}	Warfarin multidose study oxandrolone given NUMBER NUMBER mg BID NUMBER healthy subjects concurrently treated warfarin resulted mean increase warfarin half life NUMBER NUMBER hours AUC NUMBER NUMBER ng * hr / mL similar increases R warfarin half life AUC also detected
Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. 	S-warfarin	R-warfarin	none	{'e1': {'word': 'S-warfarin', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d584.s3.e3'}, 'e2': {'word': 'R-warfarin', 'word_index': [(34, 35)], 'id': 'DDI-DrugBank.d584.s3.e4'}, 'sentence_id': 'DDI-DrugBank.d584.s3'}	Warfarin multidose study oxandrolone given NUMBER NUMBER mg BID NUMBER healthy subjects concurrently treated warfarin resulted mean increase warfarin half life NUMBER NUMBER hours AUC NUMBER NUMBER ng * hr / mL similar increases R warfarin half life AUC also detected
A 5.5-fold decrease in the mean warfarin dose from 6.13 mg/day to 1.13 mg/day (approximately 80-85% reduction of warfarin dose), was necessary to maintain a target INR of 1.5. 	warfarin	warfarin	none	{'e1': {'word': 'warfarin', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d584.s5.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d584.s5.e1'}, 'sentence_id': 'DDI-DrugBank.d584.s5'}	5.5-fold decrease mean warfarin dose NUMBER mg / day NUMBER mg / day approximately NUMBER - NUMBER % reduction warfarin dose necessary maintain target INR NUMBER
When oxandrolone therapy is initiated in a patient already receiving treatment with warfarin, the INR or prothrombin time (PT) should be monitored closely and the dose of warfarin adjusted as necessary until a stable target INR or PT has been achieved. 	oxandrolone	warfarin	advise	{'e1': {'word': 'oxandrolone', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d584.s6.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d584.s6.e1'}, 'sentence_id': 'DDI-DrugBank.d584.s6'}	oxandrolone therapy initiated patient already receiving treatment warfarin INR prothrombin time PT monitored closely dose warfarin adjusted necessary stable target INR PT achieved
When oxandrolone therapy is initiated in a patient already receiving treatment with warfarin, the INR or prothrombin time (PT) should be monitored closely and the dose of warfarin adjusted as necessary until a stable target INR or PT has been achieved. 	oxandrolone	warfarin	none	{'e1': {'word': 'oxandrolone', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d584.s6.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d584.s6.e2'}, 'sentence_id': 'DDI-DrugBank.d584.s6'}	oxandrolone therapy initiated patient already receiving treatment warfarin INR prothrombin time PT monitored closely dose warfarin adjusted necessary stable target INR PT achieved
When oxandrolone therapy is initiated in a patient already receiving treatment with warfarin, the INR or prothrombin time (PT) should be monitored closely and the dose of warfarin adjusted as necessary until a stable target INR or PT has been achieved. 	warfarin	warfarin	none	{'e1': {'word': 'warfarin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d584.s6.e1'}, 'e2': {'word': 'warfarin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d584.s6.e2'}, 'sentence_id': 'DDI-DrugBank.d584.s6'}	oxandrolone therapy initiated patient already receiving treatment warfarin INR prothrombin time PT monitored closely dose warfarin adjusted necessary stable target INR PT achieved
Furthermore, in patients receiving both drugs, careful monitoring of the INR or PT, and adjustment of the warfarin dosage if indicated are recommended when the oxandrolone dose is changed or discontinued. 	warfarin	oxandrolone	advise	{'e1': {'word': 'warfarin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d584.s7.e0'}, 'e2': {'word': 'oxandrolone', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d584.s7.e1'}, 'sentence_id': 'DDI-DrugBank.d584.s7'}	Furthermore patients receiving drugs careful monitoring INR PT adjustment warfarin dosage indicated recommended oxandrolone dose changed discontinued
Oral hypoglycemic agents Oxandrolone may inhibit the metabolism of oral hypoglycemic agents. 	hypoglycemic agents	Oxandrolone	none	{'e1': {'word': 'hypoglycemic agents', 'word_index': [(1, 2)], 'id': 'DDI-DrugBank.d584.s9.e0'}, 'e2': {'word': 'Oxandrolone', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d584.s9.e1'}, 'sentence_id': 'DDI-DrugBank.d584.s9'}	Oral hypoglycemic agents Oxandrolone may inhibit metabolism oral hypoglycemic agents
Oral hypoglycemic agents Oxandrolone may inhibit the metabolism of oral hypoglycemic agents. 	hypoglycemic agents	hypoglycemic agents	none	{'e1': {'word': 'hypoglycemic agents', 'word_index': [(1, 2)], 'id': 'DDI-DrugBank.d584.s9.e0'}, 'e2': {'word': 'hypoglycemic agents', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d584.s9.e2'}, 'sentence_id': 'DDI-DrugBank.d584.s9'}	Oral hypoglycemic agents Oxandrolone may inhibit metabolism oral hypoglycemic agents
Oral hypoglycemic agents Oxandrolone may inhibit the metabolism of oral hypoglycemic agents. 	Oxandrolone	hypoglycemic agents	mechanism	{'e1': {'word': 'Oxandrolone', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d584.s9.e1'}, 'e2': {'word': 'hypoglycemic agents', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d584.s9.e2'}, 'sentence_id': 'DDI-DrugBank.d584.s9'}	Oral hypoglycemic agents Oxandrolone may inhibit metabolism oral hypoglycemic agents
Adrenal steroids or ACTH In patients with edema, concomitant administration with adrenal cortical steroids or ACTH may increase the edema. 	Adrenal steroids	ACTH	none	{'e1': {'word': 'Adrenal steroids', 'word_index': [(0, 1)], 'id': 'DDI-DrugBank.d584.s10.e0'}, 'e2': {'word': 'ACTH', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d584.s10.e1'}, 'sentence_id': 'DDI-DrugBank.d584.s10'}	Adrenal steroids ACTH patients edema concomitant administration adrenal cortical steroids ACTH may increase edema
Adrenal steroids or ACTH In patients with edema, concomitant administration with adrenal cortical steroids or ACTH may increase the edema. 	Adrenal steroids	adrenal cortical steroids	none	{'e1': {'word': 'Adrenal steroids', 'word_index': [(0, 1)], 'id': 'DDI-DrugBank.d584.s10.e0'}, 'e2': {'word': 'adrenal cortical steroids', 'word_index': [(7, 9)], 'id': 'DDI-DrugBank.d584.s10.e2'}, 'sentence_id': 'DDI-DrugBank.d584.s10'}	Adrenal steroids ACTH patients edema concomitant administration adrenal cortical steroids ACTH may increase edema
Adrenal steroids or ACTH In patients with edema, concomitant administration with adrenal cortical steroids or ACTH may increase the edema. 	Adrenal steroids	ACTH	none	{'e1': {'word': 'Adrenal steroids', 'word_index': [(0, 1)], 'id': 'DDI-DrugBank.d584.s10.e0'}, 'e2': {'word': 'ACTH', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d584.s10.e3'}, 'sentence_id': 'DDI-DrugBank.d584.s10'}	Adrenal steroids ACTH patients edema concomitant administration adrenal cortical steroids ACTH may increase edema
Adrenal steroids or ACTH In patients with edema, concomitant administration with adrenal cortical steroids or ACTH may increase the edema. 	ACTH	adrenal cortical steroids	none	{'e1': {'word': 'ACTH', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d584.s10.e1'}, 'e2': {'word': 'adrenal cortical steroids', 'word_index': [(7, 9)], 'id': 'DDI-DrugBank.d584.s10.e2'}, 'sentence_id': 'DDI-DrugBank.d584.s10'}	Adrenal steroids ACTH patients edema concomitant administration adrenal cortical steroids ACTH may increase edema
Adrenal steroids or ACTH In patients with edema, concomitant administration with adrenal cortical steroids or ACTH may increase the edema. 	ACTH	ACTH	none	{'e1': {'word': 'ACTH', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d584.s10.e1'}, 'e2': {'word': 'ACTH', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d584.s10.e3'}, 'sentence_id': 'DDI-DrugBank.d584.s10'}	Adrenal steroids ACTH patients edema concomitant administration adrenal cortical steroids ACTH may increase edema
Adrenal steroids or ACTH In patients with edema, concomitant administration with adrenal cortical steroids or ACTH may increase the edema. 	adrenal cortical steroids	ACTH	none	{'e1': {'word': 'adrenal cortical steroids', 'word_index': [(7, 9)], 'id': 'DDI-DrugBank.d584.s10.e2'}, 'e2': {'word': 'ACTH', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d584.s10.e3'}, 'sentence_id': 'DDI-DrugBank.d584.s10'}	Adrenal steroids ACTH patients edema concomitant administration adrenal cortical steroids ACTH may increase edema
The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. 	SKELID	calcium	mechanism	{'e1': {'word': 'SKELID', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d721.s0.e0'}, 'e2': {'word': 'calcium', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d721.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d721.s0'}	bioavailability SKELID decreased NUMBER % calcium calcium SKELID administered time NUMBER % aluminum magnesium containing antacids administered NUMBER hour SKELID
The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. 	SKELID	calcium	none	{'e1': {'word': 'SKELID', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d721.s0.e0'}, 'e2': {'word': 'calcium', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d721.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d721.s0'}	bioavailability SKELID decreased NUMBER % calcium calcium SKELID administered time NUMBER % aluminum magnesium containing antacids administered NUMBER hour SKELID
The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. 	SKELID	SKELID	none	{'e1': {'word': 'SKELID', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d721.s0.e0'}, 'e2': {'word': 'SKELID', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d721.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d721.s0'}	bioavailability SKELID decreased NUMBER % calcium calcium SKELID administered time NUMBER % aluminum magnesium containing antacids administered NUMBER hour SKELID
The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. 	SKELID	aluminum	none	{'e1': {'word': 'SKELID', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d721.s0.e0'}, 'e2': {'word': 'aluminum', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d721.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d721.s0'}	bioavailability SKELID decreased NUMBER % calcium calcium SKELID administered time NUMBER % aluminum magnesium containing antacids administered NUMBER hour SKELID
The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. 	SKELID	magnesium	none	{'e1': {'word': 'SKELID', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d721.s0.e0'}, 'e2': {'word': 'magnesium', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d721.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d721.s0'}	bioavailability SKELID decreased NUMBER % calcium calcium SKELID administered time NUMBER % aluminum magnesium containing antacids administered NUMBER hour SKELID
The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. 	SKELID	antacids	none	{'e1': {'word': 'SKELID', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d721.s0.e0'}, 'e2': {'word': 'antacids', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d721.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d721.s0'}	bioavailability SKELID decreased NUMBER % calcium calcium SKELID administered time NUMBER % aluminum magnesium containing antacids administered NUMBER hour SKELID
The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. 	SKELID	SKELID	none	{'e1': {'word': 'SKELID', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d721.s0.e0'}, 'e2': {'word': 'SKELID', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d721.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d721.s0'}	bioavailability SKELID decreased NUMBER % calcium calcium SKELID administered time NUMBER % aluminum magnesium containing antacids administered NUMBER hour SKELID
The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. 	calcium	calcium	none	{'e1': {'word': 'calcium', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d721.s0.e1'}, 'e2': {'word': 'calcium', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d721.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d721.s0'}	bioavailability SKELID decreased NUMBER % calcium calcium SKELID administered time NUMBER % aluminum magnesium containing antacids administered NUMBER hour SKELID
The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. 	calcium	SKELID	none	{'e1': {'word': 'calcium', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d721.s0.e1'}, 'e2': {'word': 'SKELID', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d721.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d721.s0'}	bioavailability SKELID decreased NUMBER % calcium calcium SKELID administered time NUMBER % aluminum magnesium containing antacids administered NUMBER hour SKELID
The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. 	calcium	aluminum	none	{'e1': {'word': 'calcium', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d721.s0.e1'}, 'e2': {'word': 'aluminum', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d721.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d721.s0'}	bioavailability SKELID decreased NUMBER % calcium calcium SKELID administered time NUMBER % aluminum magnesium containing antacids administered NUMBER hour SKELID
The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. 	calcium	magnesium	none	{'e1': {'word': 'calcium', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d721.s0.e1'}, 'e2': {'word': 'magnesium', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d721.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d721.s0'}	bioavailability SKELID decreased NUMBER % calcium calcium SKELID administered time NUMBER % aluminum magnesium containing antacids administered NUMBER hour SKELID
The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. 	calcium	antacids	none	{'e1': {'word': 'calcium', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d721.s0.e1'}, 'e2': {'word': 'antacids', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d721.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d721.s0'}	bioavailability SKELID decreased NUMBER % calcium calcium SKELID administered time NUMBER % aluminum magnesium containing antacids administered NUMBER hour SKELID
The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. 	calcium	SKELID	none	{'e1': {'word': 'calcium', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d721.s0.e1'}, 'e2': {'word': 'SKELID', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d721.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d721.s0'}	bioavailability SKELID decreased NUMBER % calcium calcium SKELID administered time NUMBER % aluminum magnesium containing antacids administered NUMBER hour SKELID
The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. 	calcium	SKELID	none	{'e1': {'word': 'calcium', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d721.s0.e2'}, 'e2': {'word': 'SKELID', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d721.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d721.s0'}	bioavailability SKELID decreased NUMBER % calcium calcium SKELID administered time NUMBER % aluminum magnesium containing antacids administered NUMBER hour SKELID
The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. 	calcium	aluminum	none	{'e1': {'word': 'calcium', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d721.s0.e2'}, 'e2': {'word': 'aluminum', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d721.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d721.s0'}	bioavailability SKELID decreased NUMBER % calcium calcium SKELID administered time NUMBER % aluminum magnesium containing antacids administered NUMBER hour SKELID
The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. 	calcium	magnesium	none	{'e1': {'word': 'calcium', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d721.s0.e2'}, 'e2': {'word': 'magnesium', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d721.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d721.s0'}	bioavailability SKELID decreased NUMBER % calcium calcium SKELID administered time NUMBER % aluminum magnesium containing antacids administered NUMBER hour SKELID
The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. 	calcium	antacids	none	{'e1': {'word': 'calcium', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d721.s0.e2'}, 'e2': {'word': 'antacids', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d721.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d721.s0'}	bioavailability SKELID decreased NUMBER % calcium calcium SKELID administered time NUMBER % aluminum magnesium containing antacids administered NUMBER hour SKELID
The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. 	calcium	SKELID	none	{'e1': {'word': 'calcium', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d721.s0.e2'}, 'e2': {'word': 'SKELID', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d721.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d721.s0'}	bioavailability SKELID decreased NUMBER % calcium calcium SKELID administered time NUMBER % aluminum magnesium containing antacids administered NUMBER hour SKELID
The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. 	SKELID	aluminum	none	{'e1': {'word': 'SKELID', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d721.s0.e3'}, 'e2': {'word': 'aluminum', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d721.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d721.s0'}	bioavailability SKELID decreased NUMBER % calcium calcium SKELID administered time NUMBER % aluminum magnesium containing antacids administered NUMBER hour SKELID
The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. 	SKELID	magnesium	none	{'e1': {'word': 'SKELID', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d721.s0.e3'}, 'e2': {'word': 'magnesium', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d721.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d721.s0'}	bioavailability SKELID decreased NUMBER % calcium calcium SKELID administered time NUMBER % aluminum magnesium containing antacids administered NUMBER hour SKELID
The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. 	SKELID	antacids	none	{'e1': {'word': 'SKELID', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d721.s0.e3'}, 'e2': {'word': 'antacids', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d721.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d721.s0'}	bioavailability SKELID decreased NUMBER % calcium calcium SKELID administered time NUMBER % aluminum magnesium containing antacids administered NUMBER hour SKELID
The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. 	SKELID	SKELID	none	{'e1': {'word': 'SKELID', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d721.s0.e3'}, 'e2': {'word': 'SKELID', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d721.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d721.s0'}	bioavailability SKELID decreased NUMBER % calcium calcium SKELID administered time NUMBER % aluminum magnesium containing antacids administered NUMBER hour SKELID
The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. 	aluminum	magnesium	none	{'e1': {'word': 'aluminum', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d721.s0.e4'}, 'e2': {'word': 'magnesium', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d721.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d721.s0'}	bioavailability SKELID decreased NUMBER % calcium calcium SKELID administered time NUMBER % aluminum magnesium containing antacids administered NUMBER hour SKELID
The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. 	aluminum	antacids	none	{'e1': {'word': 'aluminum', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d721.s0.e4'}, 'e2': {'word': 'antacids', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d721.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d721.s0'}	bioavailability SKELID decreased NUMBER % calcium calcium SKELID administered time NUMBER % aluminum magnesium containing antacids administered NUMBER hour SKELID
The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. 	aluminum	SKELID	mechanism	{'e1': {'word': 'aluminum', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d721.s0.e4'}, 'e2': {'word': 'SKELID', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d721.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d721.s0'}	bioavailability SKELID decreased NUMBER % calcium calcium SKELID administered time NUMBER % aluminum magnesium containing antacids administered NUMBER hour SKELID
The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. 	magnesium	antacids	none	{'e1': {'word': 'magnesium', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d721.s0.e5'}, 'e2': {'word': 'antacids', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d721.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d721.s0'}	bioavailability SKELID decreased NUMBER % calcium calcium SKELID administered time NUMBER % aluminum magnesium containing antacids administered NUMBER hour SKELID
The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. 	magnesium	SKELID	mechanism	{'e1': {'word': 'magnesium', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d721.s0.e5'}, 'e2': {'word': 'SKELID', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d721.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d721.s0'}	bioavailability SKELID decreased NUMBER % calcium calcium SKELID administered time NUMBER % aluminum magnesium containing antacids administered NUMBER hour SKELID
The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. 	antacids	SKELID	none	{'e1': {'word': 'antacids', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d721.s0.e6'}, 'e2': {'word': 'SKELID', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d721.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d721.s0'}	bioavailability SKELID decreased NUMBER % calcium calcium SKELID administered time NUMBER % aluminum magnesium containing antacids administered NUMBER hour SKELID
Aspirin may decrease bioavailability of SKELID by up to 50% when taken 2 hours after SKELID. 	Aspirin	SKELID	mechanism	{'e1': {'word': 'Aspirin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d721.s1.e0'}, 'e2': {'word': 'SKELID', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d721.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d721.s1'}	Aspirin may decrease bioavailability SKELID NUMBER % taken NUMBER hours SKELID
Aspirin may decrease bioavailability of SKELID by up to 50% when taken 2 hours after SKELID. 	Aspirin	SKELID	none	{'e1': {'word': 'Aspirin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d721.s1.e0'}, 'e2': {'word': 'SKELID', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d721.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d721.s1'}	Aspirin may decrease bioavailability SKELID NUMBER % taken NUMBER hours SKELID
Aspirin may decrease bioavailability of SKELID by up to 50% when taken 2 hours after SKELID. 	SKELID	SKELID	none	{'e1': {'word': 'SKELID', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d721.s1.e1'}, 'e2': {'word': 'SKELID', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d721.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d721.s1'}	Aspirin may decrease bioavailability SKELID NUMBER % taken NUMBER hours SKELID
The bioavailability of SKELID is increased 2-4 fold by indomethacin but is not significantly altered by coadministration of diclofenac. 	SKELID	indomethacin	mechanism	{'e1': {'word': 'SKELID', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d721.s2.e0'}, 'e2': {'word': 'indomethacin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d721.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d721.s2'}	bioavailability SKELID increased NUMBER - NUMBER fold indomethacin significantly altered coadministration diclofenac
The bioavailability of SKELID is increased 2-4 fold by indomethacin but is not significantly altered by coadministration of diclofenac. 	SKELID	diclofenac	none	{'e1': {'word': 'SKELID', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d721.s2.e0'}, 'e2': {'word': 'diclofenac', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d721.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d721.s2'}	bioavailability SKELID increased NUMBER - NUMBER fold indomethacin significantly altered coadministration diclofenac
The bioavailability of SKELID is increased 2-4 fold by indomethacin but is not significantly altered by coadministration of diclofenac. 	indomethacin	diclofenac	none	{'e1': {'word': 'indomethacin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d721.s2.e1'}, 'e2': {'word': 'diclofenac', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d721.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d721.s2'}	bioavailability SKELID increased NUMBER - NUMBER fold indomethacin significantly altered coadministration diclofenac
The pharmacokinetic parameters of digoxin are not significantly modified by SKELID coadministration. 	digoxin	SKELID	none	{'e1': {'word': 'digoxin', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d721.s3.e0'}, 'e2': {'word': 'SKELID', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d721.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d721.s3'}	pharmacokinetic parameters digoxin significantly modified SKELID coadministration
In vitro studies show that tiludronate does not displace warfarin from its binding site on protein.	tiludronate	warfarin	none	{'e1': {'word': 'tiludronate', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d721.s4.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d721.s4.e1'}, 'sentence_id': 'DDI-DrugBank.d721.s4'}	vitro studies show tiludronate displace warfarin binding site protein
Because ondansetron is metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes (CYP3A4, CYP2D6, CYP1A2), inducers or inhibitors of these enzymes may change the clearance and, hence, the half-life of ondansetron. 	ondansetron	ondansetron	none	{'e1': {'word': 'ondansetron', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d763.s1.e0'}, 'e2': {'word': 'ondansetron', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d763.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d763.s1'}	ondansetron metabolized hepatic cytochrome P NUMBER drug metabolizing enzymes CYP3A4 CYP2D6 CYP1A2 inducers inhibitors enzymes may change clearance hence half life ondansetron
Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. 	Phenytoin	Carbamazepine	none	{'e1': {'word': 'Phenytoin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d763.s3.e0'}, 'e2': {'word': 'Carbamazepine', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d763.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d763.s3'}	Phenytoin Carbamazepine Rifampicin patients treated potent inducers CYP3A4 i.e. phenytoin carbamazepine rifampicin clearance ondansetron significantly increased ondansetron blood concentrations decreased
Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. 	Phenytoin	Rifampicin	none	{'e1': {'word': 'Phenytoin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d763.s3.e0'}, 'e2': {'word': 'Rifampicin', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d763.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d763.s3'}	Phenytoin Carbamazepine Rifampicin patients treated potent inducers CYP3A4 i.e. phenytoin carbamazepine rifampicin clearance ondansetron significantly increased ondansetron blood concentrations decreased
Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. 	Phenytoin	phenytoin	none	{'e1': {'word': 'Phenytoin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d763.s3.e0'}, 'e2': {'word': 'phenytoin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d763.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d763.s3'}	Phenytoin Carbamazepine Rifampicin patients treated potent inducers CYP3A4 i.e. phenytoin carbamazepine rifampicin clearance ondansetron significantly increased ondansetron blood concentrations decreased
Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. 	Phenytoin	carbamazepine	none	{'e1': {'word': 'Phenytoin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d763.s3.e0'}, 'e2': {'word': 'carbamazepine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d763.s3.e4'}, 'sentence_id': 'DDI-DrugBank.d763.s3'}	Phenytoin Carbamazepine Rifampicin patients treated potent inducers CYP3A4 i.e. phenytoin carbamazepine rifampicin clearance ondansetron significantly increased ondansetron blood concentrations decreased
Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. 	Phenytoin	rifampicin	none	{'e1': {'word': 'Phenytoin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d763.s3.e0'}, 'e2': {'word': 'rifampicin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d763.s3.e5'}, 'sentence_id': 'DDI-DrugBank.d763.s3'}	Phenytoin Carbamazepine Rifampicin patients treated potent inducers CYP3A4 i.e. phenytoin carbamazepine rifampicin clearance ondansetron significantly increased ondansetron blood concentrations decreased
Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. 	Phenytoin	ondansetron	none	{'e1': {'word': 'Phenytoin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d763.s3.e0'}, 'e2': {'word': 'ondansetron', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d763.s3.e6'}, 'sentence_id': 'DDI-DrugBank.d763.s3'}	Phenytoin Carbamazepine Rifampicin patients treated potent inducers CYP3A4 i.e. phenytoin carbamazepine rifampicin clearance ondansetron significantly increased ondansetron blood concentrations decreased
Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. 	Phenytoin	ondansetron	none	{'e1': {'word': 'Phenytoin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d763.s3.e0'}, 'e2': {'word': 'ondansetron', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d763.s3.e7'}, 'sentence_id': 'DDI-DrugBank.d763.s3'}	Phenytoin Carbamazepine Rifampicin patients treated potent inducers CYP3A4 i.e. phenytoin carbamazepine rifampicin clearance ondansetron significantly increased ondansetron blood concentrations decreased
Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. 	Carbamazepine	Rifampicin	none	{'e1': {'word': 'Carbamazepine', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d763.s3.e1'}, 'e2': {'word': 'Rifampicin', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d763.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d763.s3'}	Phenytoin Carbamazepine Rifampicin patients treated potent inducers CYP3A4 i.e. phenytoin carbamazepine rifampicin clearance ondansetron significantly increased ondansetron blood concentrations decreased
Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. 	Carbamazepine	phenytoin	none	{'e1': {'word': 'Carbamazepine', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d763.s3.e1'}, 'e2': {'word': 'phenytoin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d763.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d763.s3'}	Phenytoin Carbamazepine Rifampicin patients treated potent inducers CYP3A4 i.e. phenytoin carbamazepine rifampicin clearance ondansetron significantly increased ondansetron blood concentrations decreased
Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. 	Carbamazepine	carbamazepine	none	{'e1': {'word': 'Carbamazepine', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d763.s3.e1'}, 'e2': {'word': 'carbamazepine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d763.s3.e4'}, 'sentence_id': 'DDI-DrugBank.d763.s3'}	Phenytoin Carbamazepine Rifampicin patients treated potent inducers CYP3A4 i.e. phenytoin carbamazepine rifampicin clearance ondansetron significantly increased ondansetron blood concentrations decreased
Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. 	Carbamazepine	rifampicin	none	{'e1': {'word': 'Carbamazepine', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d763.s3.e1'}, 'e2': {'word': 'rifampicin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d763.s3.e5'}, 'sentence_id': 'DDI-DrugBank.d763.s3'}	Phenytoin Carbamazepine Rifampicin patients treated potent inducers CYP3A4 i.e. phenytoin carbamazepine rifampicin clearance ondansetron significantly increased ondansetron blood concentrations decreased
Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. 	Carbamazepine	ondansetron	none	{'e1': {'word': 'Carbamazepine', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d763.s3.e1'}, 'e2': {'word': 'ondansetron', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d763.s3.e6'}, 'sentence_id': 'DDI-DrugBank.d763.s3'}	Phenytoin Carbamazepine Rifampicin patients treated potent inducers CYP3A4 i.e. phenytoin carbamazepine rifampicin clearance ondansetron significantly increased ondansetron blood concentrations decreased
Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. 	Carbamazepine	ondansetron	none	{'e1': {'word': 'Carbamazepine', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d763.s3.e1'}, 'e2': {'word': 'ondansetron', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d763.s3.e7'}, 'sentence_id': 'DDI-DrugBank.d763.s3'}	Phenytoin Carbamazepine Rifampicin patients treated potent inducers CYP3A4 i.e. phenytoin carbamazepine rifampicin clearance ondansetron significantly increased ondansetron blood concentrations decreased
Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. 	Rifampicin	phenytoin	none	{'e1': {'word': 'Rifampicin', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d763.s3.e2'}, 'e2': {'word': 'phenytoin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d763.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d763.s3'}	Phenytoin Carbamazepine Rifampicin patients treated potent inducers CYP3A4 i.e. phenytoin carbamazepine rifampicin clearance ondansetron significantly increased ondansetron blood concentrations decreased
Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. 	Rifampicin	carbamazepine	none	{'e1': {'word': 'Rifampicin', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d763.s3.e2'}, 'e2': {'word': 'carbamazepine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d763.s3.e4'}, 'sentence_id': 'DDI-DrugBank.d763.s3'}	Phenytoin Carbamazepine Rifampicin patients treated potent inducers CYP3A4 i.e. phenytoin carbamazepine rifampicin clearance ondansetron significantly increased ondansetron blood concentrations decreased
Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. 	Rifampicin	rifampicin	none	{'e1': {'word': 'Rifampicin', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d763.s3.e2'}, 'e2': {'word': 'rifampicin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d763.s3.e5'}, 'sentence_id': 'DDI-DrugBank.d763.s3'}	Phenytoin Carbamazepine Rifampicin patients treated potent inducers CYP3A4 i.e. phenytoin carbamazepine rifampicin clearance ondansetron significantly increased ondansetron blood concentrations decreased
Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. 	Rifampicin	ondansetron	none	{'e1': {'word': 'Rifampicin', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d763.s3.e2'}, 'e2': {'word': 'ondansetron', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d763.s3.e6'}, 'sentence_id': 'DDI-DrugBank.d763.s3'}	Phenytoin Carbamazepine Rifampicin patients treated potent inducers CYP3A4 i.e. phenytoin carbamazepine rifampicin clearance ondansetron significantly increased ondansetron blood concentrations decreased
Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. 	Rifampicin	ondansetron	none	{'e1': {'word': 'Rifampicin', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d763.s3.e2'}, 'e2': {'word': 'ondansetron', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d763.s3.e7'}, 'sentence_id': 'DDI-DrugBank.d763.s3'}	Phenytoin Carbamazepine Rifampicin patients treated potent inducers CYP3A4 i.e. phenytoin carbamazepine rifampicin clearance ondansetron significantly increased ondansetron blood concentrations decreased
Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. 	phenytoin	carbamazepine	none	{'e1': {'word': 'phenytoin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d763.s3.e3'}, 'e2': {'word': 'carbamazepine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d763.s3.e4'}, 'sentence_id': 'DDI-DrugBank.d763.s3'}	Phenytoin Carbamazepine Rifampicin patients treated potent inducers CYP3A4 i.e. phenytoin carbamazepine rifampicin clearance ondansetron significantly increased ondansetron blood concentrations decreased
Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. 	phenytoin	rifampicin	none	{'e1': {'word': 'phenytoin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d763.s3.e3'}, 'e2': {'word': 'rifampicin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d763.s3.e5'}, 'sentence_id': 'DDI-DrugBank.d763.s3'}	Phenytoin Carbamazepine Rifampicin patients treated potent inducers CYP3A4 i.e. phenytoin carbamazepine rifampicin clearance ondansetron significantly increased ondansetron blood concentrations decreased
Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. 	phenytoin	ondansetron	mechanism	{'e1': {'word': 'phenytoin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d763.s3.e3'}, 'e2': {'word': 'ondansetron', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d763.s3.e6'}, 'sentence_id': 'DDI-DrugBank.d763.s3'}	Phenytoin Carbamazepine Rifampicin patients treated potent inducers CYP3A4 i.e. phenytoin carbamazepine rifampicin clearance ondansetron significantly increased ondansetron blood concentrations decreased
Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. 	phenytoin	ondansetron	mechanism	{'e1': {'word': 'phenytoin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d763.s3.e3'}, 'e2': {'word': 'ondansetron', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d763.s3.e7'}, 'sentence_id': 'DDI-DrugBank.d763.s3'}	Phenytoin Carbamazepine Rifampicin patients treated potent inducers CYP3A4 i.e. phenytoin carbamazepine rifampicin clearance ondansetron significantly increased ondansetron blood concentrations decreased
Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. 	carbamazepine	rifampicin	none	{'e1': {'word': 'carbamazepine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d763.s3.e4'}, 'e2': {'word': 'rifampicin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d763.s3.e5'}, 'sentence_id': 'DDI-DrugBank.d763.s3'}	Phenytoin Carbamazepine Rifampicin patients treated potent inducers CYP3A4 i.e. phenytoin carbamazepine rifampicin clearance ondansetron significantly increased ondansetron blood concentrations decreased
Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. 	carbamazepine	ondansetron	mechanism	{'e1': {'word': 'carbamazepine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d763.s3.e4'}, 'e2': {'word': 'ondansetron', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d763.s3.e6'}, 'sentence_id': 'DDI-DrugBank.d763.s3'}	Phenytoin Carbamazepine Rifampicin patients treated potent inducers CYP3A4 i.e. phenytoin carbamazepine rifampicin clearance ondansetron significantly increased ondansetron blood concentrations decreased
Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. 	carbamazepine	ondansetron	mechanism	{'e1': {'word': 'carbamazepine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d763.s3.e4'}, 'e2': {'word': 'ondansetron', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d763.s3.e7'}, 'sentence_id': 'DDI-DrugBank.d763.s3'}	Phenytoin Carbamazepine Rifampicin patients treated potent inducers CYP3A4 i.e. phenytoin carbamazepine rifampicin clearance ondansetron significantly increased ondansetron blood concentrations decreased
Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. 	rifampicin	ondansetron	mechanism	{'e1': {'word': 'rifampicin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d763.s3.e5'}, 'e2': {'word': 'ondansetron', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d763.s3.e6'}, 'sentence_id': 'DDI-DrugBank.d763.s3'}	Phenytoin Carbamazepine Rifampicin patients treated potent inducers CYP3A4 i.e. phenytoin carbamazepine rifampicin clearance ondansetron significantly increased ondansetron blood concentrations decreased
Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. 	rifampicin	ondansetron	mechanism	{'e1': {'word': 'rifampicin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d763.s3.e5'}, 'e2': {'word': 'ondansetron', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d763.s3.e7'}, 'sentence_id': 'DDI-DrugBank.d763.s3'}	Phenytoin Carbamazepine Rifampicin patients treated potent inducers CYP3A4 i.e. phenytoin carbamazepine rifampicin clearance ondansetron significantly increased ondansetron blood concentrations decreased
Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. 	ondansetron	ondansetron	none	{'e1': {'word': 'ondansetron', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d763.s3.e6'}, 'e2': {'word': 'ondansetron', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d763.s3.e7'}, 'sentence_id': 'DDI-DrugBank.d763.s3'}	Phenytoin Carbamazepine Rifampicin patients treated potent inducers CYP3A4 i.e. phenytoin carbamazepine rifampicin clearance ondansetron significantly increased ondansetron blood concentrations decreased
However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. 	ondansetron	Tramadol	none	{'e1': {'word': 'ondansetron', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d763.s4.e0'}, 'e2': {'word': 'Tramadol', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d763.s4.e1'}, 'sentence_id': 'DDI-DrugBank.d763.s4'}	However basis available data dosage adjustment ondansetron recommended patients drugs NUMBER NUMBER Tramadol Although pharmacokinetic drug interaction ondansetron tramadol observed data NUMBER small studies indicate ondansetron may associated increase patient controlled administration tramadol NUMBER NUMBER Chemotherapy Tumor response chemotherapy P NUMBER mouse leukemia model affected ondansetron
However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. 	ondansetron	ondansetron	none	{'e1': {'word': 'ondansetron', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d763.s4.e0'}, 'e2': {'word': 'ondansetron', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d763.s4.e2'}, 'sentence_id': 'DDI-DrugBank.d763.s4'}	However basis available data dosage adjustment ondansetron recommended patients drugs NUMBER NUMBER Tramadol Although pharmacokinetic drug interaction ondansetron tramadol observed data NUMBER small studies indicate ondansetron may associated increase patient controlled administration tramadol NUMBER NUMBER Chemotherapy Tumor response chemotherapy P NUMBER mouse leukemia model affected ondansetron
However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. 	ondansetron	tramadol	none	{'e1': {'word': 'ondansetron', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d763.s4.e0'}, 'e2': {'word': 'tramadol', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d763.s4.e3'}, 'sentence_id': 'DDI-DrugBank.d763.s4'}	However basis available data dosage adjustment ondansetron recommended patients drugs NUMBER NUMBER Tramadol Although pharmacokinetic drug interaction ondansetron tramadol observed data NUMBER small studies indicate ondansetron may associated increase patient controlled administration tramadol NUMBER NUMBER Chemotherapy Tumor response chemotherapy P NUMBER mouse leukemia model affected ondansetron
However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. 	ondansetron	ondansetron	none	{'e1': {'word': 'ondansetron', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d763.s4.e0'}, 'e2': {'word': 'ondansetron', 'word_index': [(25, 25)], 'id': 'DDI-DrugBank.d763.s4.e4'}, 'sentence_id': 'DDI-DrugBank.d763.s4'}	However basis available data dosage adjustment ondansetron recommended patients drugs NUMBER NUMBER Tramadol Although pharmacokinetic drug interaction ondansetron tramadol observed data NUMBER small studies indicate ondansetron may associated increase patient controlled administration tramadol NUMBER NUMBER Chemotherapy Tumor response chemotherapy P NUMBER mouse leukemia model affected ondansetron
However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. 	ondansetron	tramadol	none	{'e1': {'word': 'ondansetron', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d763.s4.e0'}, 'e2': {'word': 'tramadol', 'word_index': [(32, 32)], 'id': 'DDI-DrugBank.d763.s4.e5'}, 'sentence_id': 'DDI-DrugBank.d763.s4'}	However basis available data dosage adjustment ondansetron recommended patients drugs NUMBER NUMBER Tramadol Although pharmacokinetic drug interaction ondansetron tramadol observed data NUMBER small studies indicate ondansetron may associated increase patient controlled administration tramadol NUMBER NUMBER Chemotherapy Tumor response chemotherapy P NUMBER mouse leukemia model affected ondansetron
However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. 	ondansetron	ondansetron	none	{'e1': {'word': 'ondansetron', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d763.s4.e0'}, 'e2': {'word': 'ondansetron', 'word_index': [(45, 45)], 'id': 'DDI-DrugBank.d763.s4.e6'}, 'sentence_id': 'DDI-DrugBank.d763.s4'}	However basis available data dosage adjustment ondansetron recommended patients drugs NUMBER NUMBER Tramadol Although pharmacokinetic drug interaction ondansetron tramadol observed data NUMBER small studies indicate ondansetron may associated increase patient controlled administration tramadol NUMBER NUMBER Chemotherapy Tumor response chemotherapy P NUMBER mouse leukemia model affected ondansetron
However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. 	Tramadol	ondansetron	none	{'e1': {'word': 'Tramadol', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d763.s4.e1'}, 'e2': {'word': 'ondansetron', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d763.s4.e2'}, 'sentence_id': 'DDI-DrugBank.d763.s4'}	However basis available data dosage adjustment ondansetron recommended patients drugs NUMBER NUMBER Tramadol Although pharmacokinetic drug interaction ondansetron tramadol observed data NUMBER small studies indicate ondansetron may associated increase patient controlled administration tramadol NUMBER NUMBER Chemotherapy Tumor response chemotherapy P NUMBER mouse leukemia model affected ondansetron
However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. 	Tramadol	tramadol	none	{'e1': {'word': 'Tramadol', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d763.s4.e1'}, 'e2': {'word': 'tramadol', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d763.s4.e3'}, 'sentence_id': 'DDI-DrugBank.d763.s4'}	However basis available data dosage adjustment ondansetron recommended patients drugs NUMBER NUMBER Tramadol Although pharmacokinetic drug interaction ondansetron tramadol observed data NUMBER small studies indicate ondansetron may associated increase patient controlled administration tramadol NUMBER NUMBER Chemotherapy Tumor response chemotherapy P NUMBER mouse leukemia model affected ondansetron
However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. 	Tramadol	ondansetron	none	{'e1': {'word': 'Tramadol', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d763.s4.e1'}, 'e2': {'word': 'ondansetron', 'word_index': [(25, 25)], 'id': 'DDI-DrugBank.d763.s4.e4'}, 'sentence_id': 'DDI-DrugBank.d763.s4'}	However basis available data dosage adjustment ondansetron recommended patients drugs NUMBER NUMBER Tramadol Although pharmacokinetic drug interaction ondansetron tramadol observed data NUMBER small studies indicate ondansetron may associated increase patient controlled administration tramadol NUMBER NUMBER Chemotherapy Tumor response chemotherapy P NUMBER mouse leukemia model affected ondansetron
However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. 	Tramadol	tramadol	none	{'e1': {'word': 'Tramadol', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d763.s4.e1'}, 'e2': {'word': 'tramadol', 'word_index': [(32, 32)], 'id': 'DDI-DrugBank.d763.s4.e5'}, 'sentence_id': 'DDI-DrugBank.d763.s4'}	However basis available data dosage adjustment ondansetron recommended patients drugs NUMBER NUMBER Tramadol Although pharmacokinetic drug interaction ondansetron tramadol observed data NUMBER small studies indicate ondansetron may associated increase patient controlled administration tramadol NUMBER NUMBER Chemotherapy Tumor response chemotherapy P NUMBER mouse leukemia model affected ondansetron
However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. 	Tramadol	ondansetron	none	{'e1': {'word': 'Tramadol', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d763.s4.e1'}, 'e2': {'word': 'ondansetron', 'word_index': [(45, 45)], 'id': 'DDI-DrugBank.d763.s4.e6'}, 'sentence_id': 'DDI-DrugBank.d763.s4'}	However basis available data dosage adjustment ondansetron recommended patients drugs NUMBER NUMBER Tramadol Although pharmacokinetic drug interaction ondansetron tramadol observed data NUMBER small studies indicate ondansetron may associated increase patient controlled administration tramadol NUMBER NUMBER Chemotherapy Tumor response chemotherapy P NUMBER mouse leukemia model affected ondansetron
However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. 	ondansetron	tramadol	none	{'e1': {'word': 'ondansetron', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d763.s4.e2'}, 'e2': {'word': 'tramadol', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d763.s4.e3'}, 'sentence_id': 'DDI-DrugBank.d763.s4'}	However basis available data dosage adjustment ondansetron recommended patients drugs NUMBER NUMBER Tramadol Although pharmacokinetic drug interaction ondansetron tramadol observed data NUMBER small studies indicate ondansetron may associated increase patient controlled administration tramadol NUMBER NUMBER Chemotherapy Tumor response chemotherapy P NUMBER mouse leukemia model affected ondansetron
However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. 	ondansetron	ondansetron	none	{'e1': {'word': 'ondansetron', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d763.s4.e2'}, 'e2': {'word': 'ondansetron', 'word_index': [(25, 25)], 'id': 'DDI-DrugBank.d763.s4.e4'}, 'sentence_id': 'DDI-DrugBank.d763.s4'}	However basis available data dosage adjustment ondansetron recommended patients drugs NUMBER NUMBER Tramadol Although pharmacokinetic drug interaction ondansetron tramadol observed data NUMBER small studies indicate ondansetron may associated increase patient controlled administration tramadol NUMBER NUMBER Chemotherapy Tumor response chemotherapy P NUMBER mouse leukemia model affected ondansetron
However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. 	ondansetron	tramadol	none	{'e1': {'word': 'ondansetron', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d763.s4.e2'}, 'e2': {'word': 'tramadol', 'word_index': [(32, 32)], 'id': 'DDI-DrugBank.d763.s4.e5'}, 'sentence_id': 'DDI-DrugBank.d763.s4'}	However basis available data dosage adjustment ondansetron recommended patients drugs NUMBER NUMBER Tramadol Although pharmacokinetic drug interaction ondansetron tramadol observed data NUMBER small studies indicate ondansetron may associated increase patient controlled administration tramadol NUMBER NUMBER Chemotherapy Tumor response chemotherapy P NUMBER mouse leukemia model affected ondansetron
However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. 	ondansetron	ondansetron	none	{'e1': {'word': 'ondansetron', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d763.s4.e2'}, 'e2': {'word': 'ondansetron', 'word_index': [(45, 45)], 'id': 'DDI-DrugBank.d763.s4.e6'}, 'sentence_id': 'DDI-DrugBank.d763.s4'}	However basis available data dosage adjustment ondansetron recommended patients drugs NUMBER NUMBER Tramadol Although pharmacokinetic drug interaction ondansetron tramadol observed data NUMBER small studies indicate ondansetron may associated increase patient controlled administration tramadol NUMBER NUMBER Chemotherapy Tumor response chemotherapy P NUMBER mouse leukemia model affected ondansetron
However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. 	tramadol	ondansetron	none	{'e1': {'word': 'tramadol', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d763.s4.e3'}, 'e2': {'word': 'ondansetron', 'word_index': [(25, 25)], 'id': 'DDI-DrugBank.d763.s4.e4'}, 'sentence_id': 'DDI-DrugBank.d763.s4'}	However basis available data dosage adjustment ondansetron recommended patients drugs NUMBER NUMBER Tramadol Although pharmacokinetic drug interaction ondansetron tramadol observed data NUMBER small studies indicate ondansetron may associated increase patient controlled administration tramadol NUMBER NUMBER Chemotherapy Tumor response chemotherapy P NUMBER mouse leukemia model affected ondansetron
However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. 	tramadol	tramadol	none	{'e1': {'word': 'tramadol', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d763.s4.e3'}, 'e2': {'word': 'tramadol', 'word_index': [(32, 32)], 'id': 'DDI-DrugBank.d763.s4.e5'}, 'sentence_id': 'DDI-DrugBank.d763.s4'}	However basis available data dosage adjustment ondansetron recommended patients drugs NUMBER NUMBER Tramadol Although pharmacokinetic drug interaction ondansetron tramadol observed data NUMBER small studies indicate ondansetron may associated increase patient controlled administration tramadol NUMBER NUMBER Chemotherapy Tumor response chemotherapy P NUMBER mouse leukemia model affected ondansetron
However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. 	tramadol	ondansetron	none	{'e1': {'word': 'tramadol', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d763.s4.e3'}, 'e2': {'word': 'ondansetron', 'word_index': [(45, 45)], 'id': 'DDI-DrugBank.d763.s4.e6'}, 'sentence_id': 'DDI-DrugBank.d763.s4'}	However basis available data dosage adjustment ondansetron recommended patients drugs NUMBER NUMBER Tramadol Although pharmacokinetic drug interaction ondansetron tramadol observed data NUMBER small studies indicate ondansetron may associated increase patient controlled administration tramadol NUMBER NUMBER Chemotherapy Tumor response chemotherapy P NUMBER mouse leukemia model affected ondansetron
However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. 	ondansetron	tramadol	effect	{'e1': {'word': 'ondansetron', 'word_index': [(25, 25)], 'id': 'DDI-DrugBank.d763.s4.e4'}, 'e2': {'word': 'tramadol', 'word_index': [(32, 32)], 'id': 'DDI-DrugBank.d763.s4.e5'}, 'sentence_id': 'DDI-DrugBank.d763.s4'}	However basis available data dosage adjustment ondansetron recommended patients drugs NUMBER NUMBER Tramadol Although pharmacokinetic drug interaction ondansetron tramadol observed data NUMBER small studies indicate ondansetron may associated increase patient controlled administration tramadol NUMBER NUMBER Chemotherapy Tumor response chemotherapy P NUMBER mouse leukemia model affected ondansetron
However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. 	ondansetron	ondansetron	none	{'e1': {'word': 'ondansetron', 'word_index': [(25, 25)], 'id': 'DDI-DrugBank.d763.s4.e4'}, 'e2': {'word': 'ondansetron', 'word_index': [(45, 45)], 'id': 'DDI-DrugBank.d763.s4.e6'}, 'sentence_id': 'DDI-DrugBank.d763.s4'}	However basis available data dosage adjustment ondansetron recommended patients drugs NUMBER NUMBER Tramadol Although pharmacokinetic drug interaction ondansetron tramadol observed data NUMBER small studies indicate ondansetron may associated increase patient controlled administration tramadol NUMBER NUMBER Chemotherapy Tumor response chemotherapy P NUMBER mouse leukemia model affected ondansetron
However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. 	tramadol	ondansetron	none	{'e1': {'word': 'tramadol', 'word_index': [(32, 32)], 'id': 'DDI-DrugBank.d763.s4.e5'}, 'e2': {'word': 'ondansetron', 'word_index': [(45, 45)], 'id': 'DDI-DrugBank.d763.s4.e6'}, 'sentence_id': 'DDI-DrugBank.d763.s4'}	However basis available data dosage adjustment ondansetron recommended patients drugs NUMBER NUMBER Tramadol Although pharmacokinetic drug interaction ondansetron tramadol observed data NUMBER small studies indicate ondansetron may associated increase patient controlled administration tramadol NUMBER NUMBER Chemotherapy Tumor response chemotherapy P NUMBER mouse leukemia model affected ondansetron
In humans, carmustine, etoposide, and cisplatin do not affect the pharmacokinetics of ondansetron.  	carmustine	etoposide	none	{'e1': {'word': 'carmustine', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d763.s5.e0'}, 'e2': {'word': 'etoposide', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d763.s5.e1'}, 'sentence_id': 'DDI-DrugBank.d763.s5'}	humans carmustine etoposide cisplatin affect pharmacokinetics ondansetron
In humans, carmustine, etoposide, and cisplatin do not affect the pharmacokinetics of ondansetron.  	carmustine	cisplatin	none	{'e1': {'word': 'carmustine', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d763.s5.e0'}, 'e2': {'word': 'cisplatin', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d763.s5.e2'}, 'sentence_id': 'DDI-DrugBank.d763.s5'}	humans carmustine etoposide cisplatin affect pharmacokinetics ondansetron
In humans, carmustine, etoposide, and cisplatin do not affect the pharmacokinetics of ondansetron.  	carmustine	ondansetron	none	{'e1': {'word': 'carmustine', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d763.s5.e0'}, 'e2': {'word': 'ondansetron', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d763.s5.e3'}, 'sentence_id': 'DDI-DrugBank.d763.s5'}	humans carmustine etoposide cisplatin affect pharmacokinetics ondansetron
In humans, carmustine, etoposide, and cisplatin do not affect the pharmacokinetics of ondansetron.  	etoposide	cisplatin	none	{'e1': {'word': 'etoposide', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d763.s5.e1'}, 'e2': {'word': 'cisplatin', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d763.s5.e2'}, 'sentence_id': 'DDI-DrugBank.d763.s5'}	humans carmustine etoposide cisplatin affect pharmacokinetics ondansetron
In humans, carmustine, etoposide, and cisplatin do not affect the pharmacokinetics of ondansetron.  	etoposide	ondansetron	none	{'e1': {'word': 'etoposide', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d763.s5.e1'}, 'e2': {'word': 'ondansetron', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d763.s5.e3'}, 'sentence_id': 'DDI-DrugBank.d763.s5'}	humans carmustine etoposide cisplatin affect pharmacokinetics ondansetron
In humans, carmustine, etoposide, and cisplatin do not affect the pharmacokinetics of ondansetron.  	cisplatin	ondansetron	none	{'e1': {'word': 'cisplatin', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d763.s5.e2'}, 'e2': {'word': 'ondansetron', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d763.s5.e3'}, 'sentence_id': 'DDI-DrugBank.d763.s5'}	humans carmustine etoposide cisplatin affect pharmacokinetics ondansetron
ondansetron did not increase blood levels of high-dose methotrexate.	ondansetron	methotrexate	none	{'e1': {'word': 'ondansetron', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d763.s7.e0'}, 'e2': {'word': 'methotrexate', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d763.s7.e1'}, 'sentence_id': 'DDI-DrugBank.d763.s7'}	ondansetron increase blood levels high dose methotrexate
Diuretics: Furosemide and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes. 	Diuretics	Furosemide	none	{'e1': {'word': 'Diuretics', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d588.s0.e0'}, 'e2': {'word': 'Furosemide', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d588.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d588.s0'}	Diuretics Furosemide probably loop diuretics given concomitantly metolazone cause unusually large prolonged losses fluid electrolytes
Diuretics: Furosemide and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes. 	Diuretics	loop diuretics	none	{'e1': {'word': 'Diuretics', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d588.s0.e0'}, 'e2': {'word': 'loop diuretics', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d588.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d588.s0'}	Diuretics Furosemide probably loop diuretics given concomitantly metolazone cause unusually large prolonged losses fluid electrolytes
Diuretics: Furosemide and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes. 	Diuretics	metolazone	none	{'e1': {'word': 'Diuretics', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d588.s0.e0'}, 'e2': {'word': 'metolazone', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d588.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d588.s0'}	Diuretics Furosemide probably loop diuretics given concomitantly metolazone cause unusually large prolonged losses fluid electrolytes
Diuretics: Furosemide and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes. 	Furosemide	loop diuretics	none	{'e1': {'word': 'Furosemide', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d588.s0.e1'}, 'e2': {'word': 'loop diuretics', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d588.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d588.s0'}	Diuretics Furosemide probably loop diuretics given concomitantly metolazone cause unusually large prolonged losses fluid electrolytes
Diuretics: Furosemide and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes. 	Furosemide	metolazone	effect	{'e1': {'word': 'Furosemide', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d588.s0.e1'}, 'e2': {'word': 'metolazone', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d588.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d588.s0'}	Diuretics Furosemide probably loop diuretics given concomitantly metolazone cause unusually large prolonged losses fluid electrolytes
Diuretics: Furosemide and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes. 	loop diuretics	metolazone	effect	{'e1': {'word': 'loop diuretics', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d588.s0.e2'}, 'e2': {'word': 'metolazone', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d588.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d588.s0'}	Diuretics Furosemide probably loop diuretics given concomitantly metolazone cause unusually large prolonged losses fluid electrolytes
Other Antihypertensives: When MYKROX Tablets are used with other antihypertensive drugs, care must be taken, especially during initial therapy. 	Antihypertensives	MYKROX	none	{'e1': {'word': 'Antihypertensives', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d588.s1.e0'}, 'e2': {'word': 'MYKROX', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d588.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d588.s1'}	Antihypertensives MYKROX Tablets used antihypertensive drugs care must taken especially initial therapy
Other Antihypertensives: When MYKROX Tablets are used with other antihypertensive drugs, care must be taken, especially during initial therapy. 	Antihypertensives	antihypertensive drugs	none	{'e1': {'word': 'Antihypertensives', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d588.s1.e0'}, 'e2': {'word': 'antihypertensive drugs', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d588.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d588.s1'}	Antihypertensives MYKROX Tablets used antihypertensive drugs care must taken especially initial therapy
Other Antihypertensives: When MYKROX Tablets are used with other antihypertensive drugs, care must be taken, especially during initial therapy. 	MYKROX	antihypertensive drugs	advise	{'e1': {'word': 'MYKROX', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d588.s1.e1'}, 'e2': {'word': 'antihypertensive drugs', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d588.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d588.s1'}	Antihypertensives MYKROX Tablets used antihypertensive drugs care must taken especially initial therapy
Alcohol, Barbiturates, and Narcotics: The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy. 	Alcohol	Barbiturates	none	{'e1': {'word': 'Alcohol', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d588.s3.e0'}, 'e2': {'word': 'Barbiturates', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d588.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d588.s3'}	Alcohol Barbiturates Narcotics hypotensive effects drugs may potentiated volume contraction may associated metolazone therapy
Alcohol, Barbiturates, and Narcotics: The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy. 	Alcohol	Narcotics	none	{'e1': {'word': 'Alcohol', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d588.s3.e0'}, 'e2': {'word': 'Narcotics', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d588.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d588.s3'}	Alcohol Barbiturates Narcotics hypotensive effects drugs may potentiated volume contraction may associated metolazone therapy
Alcohol, Barbiturates, and Narcotics: The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy. 	Alcohol	metolazone	none	{'e1': {'word': 'Alcohol', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d588.s3.e0'}, 'e2': {'word': 'metolazone', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d588.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d588.s3'}	Alcohol Barbiturates Narcotics hypotensive effects drugs may potentiated volume contraction may associated metolazone therapy
Alcohol, Barbiturates, and Narcotics: The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy. 	Barbiturates	Narcotics	none	{'e1': {'word': 'Barbiturates', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d588.s3.e1'}, 'e2': {'word': 'Narcotics', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d588.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d588.s3'}	Alcohol Barbiturates Narcotics hypotensive effects drugs may potentiated volume contraction may associated metolazone therapy
Alcohol, Barbiturates, and Narcotics: The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy. 	Barbiturates	metolazone	none	{'e1': {'word': 'Barbiturates', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d588.s3.e1'}, 'e2': {'word': 'metolazone', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d588.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d588.s3'}	Alcohol Barbiturates Narcotics hypotensive effects drugs may potentiated volume contraction may associated metolazone therapy
Alcohol, Barbiturates, and Narcotics: The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy. 	Narcotics	metolazone	none	{'e1': {'word': 'Narcotics', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d588.s3.e2'}, 'e2': {'word': 'metolazone', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d588.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d588.s3'}	Alcohol Barbiturates Narcotics hypotensive effects drugs may potentiated volume contraction may associated metolazone therapy
Digitalis Glycosides: Diuretic-induced hypokalemia can increase the sensitivity of the myocardium to digitalis. 	Digitalis Glycosides	Diuretic	none	{'e1': {'word': 'Digitalis Glycosides', 'word_index': [(0, 1)], 'id': 'DDI-DrugBank.d588.s4.e0'}, 'e2': {'word': 'Diuretic', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d588.s4.e1'}, 'sentence_id': 'DDI-DrugBank.d588.s4'}	Digitalis Glycosides Diuretic induced hypokalemia increase sensitivity myocardium digitalis
Digitalis Glycosides: Diuretic-induced hypokalemia can increase the sensitivity of the myocardium to digitalis. 	Digitalis Glycosides	digitalis	none	{'e1': {'word': 'Digitalis Glycosides', 'word_index': [(0, 1)], 'id': 'DDI-DrugBank.d588.s4.e0'}, 'e2': {'word': 'digitalis', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d588.s4.e2'}, 'sentence_id': 'DDI-DrugBank.d588.s4'}	Digitalis Glycosides Diuretic induced hypokalemia increase sensitivity myocardium digitalis
Digitalis Glycosides: Diuretic-induced hypokalemia can increase the sensitivity of the myocardium to digitalis. 	Diuretic	digitalis	effect	{'e1': {'word': 'Diuretic', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d588.s4.e1'}, 'e2': {'word': 'digitalis', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d588.s4.e2'}, 'sentence_id': 'DDI-DrugBank.d588.s4'}	Digitalis Glycosides Diuretic induced hypokalemia increase sensitivity myocardium digitalis
Corticosteroids or ACTH: May increase the risk of hypokalemia and increase salt and water retention. 	Corticosteroids	ACTH	none	{'e1': {'word': 'Corticosteroids', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d588.s6.e0'}, 'e2': {'word': 'ACTH', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d588.s6.e1'}, 'sentence_id': 'DDI-DrugBank.d588.s6'}	Corticosteroids ACTH May increase risk hypokalemia increase salt water retention
Lithium: Serum lithium levels may increase. 	Lithium	lithium	none	{'e1': {'word': 'Lithium', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d588.s7.e0'}, 'e2': {'word': 'lithium', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d588.s7.e1'}, 'sentence_id': 'DDI-DrugBank.d588.s7'}	Lithium Serum lithium levels may increase
Curariform Drugs: Diuretic-induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs (such as tubocurarine) the most serious effect would be respiratory depression which could proceed to apnea. 	Curariform Drugs	Diuretic	none	{'e1': {'word': 'Curariform Drugs', 'word_index': [(0, 1)], 'id': 'DDI-DrugBank.d588.s8.e0'}, 'e2': {'word': 'Diuretic', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d588.s8.e1'}, 'sentence_id': 'DDI-DrugBank.d588.s8'}	Curariform Drugs Diuretic induced hypokalemia may enhance neuromuscular blocking effects curariform drugs tubocurarine serious effect would respiratory depression could proceed apnea
Curariform Drugs: Diuretic-induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs (such as tubocurarine) the most serious effect would be respiratory depression which could proceed to apnea. 	Curariform Drugs	curariform drugs	none	{'e1': {'word': 'Curariform Drugs', 'word_index': [(0, 1)], 'id': 'DDI-DrugBank.d588.s8.e0'}, 'e2': {'word': 'curariform drugs', 'word_index': [(10, 11)], 'id': 'DDI-DrugBank.d588.s8.e2'}, 'sentence_id': 'DDI-DrugBank.d588.s8'}	Curariform Drugs Diuretic induced hypokalemia may enhance neuromuscular blocking effects curariform drugs tubocurarine serious effect would respiratory depression could proceed apnea
Curariform Drugs: Diuretic-induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs (such as tubocurarine) the most serious effect would be respiratory depression which could proceed to apnea. 	Curariform Drugs	tubocurarine	none	{'e1': {'word': 'Curariform Drugs', 'word_index': [(0, 1)], 'id': 'DDI-DrugBank.d588.s8.e0'}, 'e2': {'word': 'tubocurarine', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d588.s8.e3'}, 'sentence_id': 'DDI-DrugBank.d588.s8'}	Curariform Drugs Diuretic induced hypokalemia may enhance neuromuscular blocking effects curariform drugs tubocurarine serious effect would respiratory depression could proceed apnea
Curariform Drugs: Diuretic-induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs (such as tubocurarine) the most serious effect would be respiratory depression which could proceed to apnea. 	Diuretic	curariform drugs	effect	{'e1': {'word': 'Diuretic', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d588.s8.e1'}, 'e2': {'word': 'curariform drugs', 'word_index': [(10, 11)], 'id': 'DDI-DrugBank.d588.s8.e2'}, 'sentence_id': 'DDI-DrugBank.d588.s8'}	Curariform Drugs Diuretic induced hypokalemia may enhance neuromuscular blocking effects curariform drugs tubocurarine serious effect would respiratory depression could proceed apnea
Curariform Drugs: Diuretic-induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs (such as tubocurarine) the most serious effect would be respiratory depression which could proceed to apnea. 	Diuretic	tubocurarine	effect	{'e1': {'word': 'Diuretic', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d588.s8.e1'}, 'e2': {'word': 'tubocurarine', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d588.s8.e3'}, 'sentence_id': 'DDI-DrugBank.d588.s8'}	Curariform Drugs Diuretic induced hypokalemia may enhance neuromuscular blocking effects curariform drugs tubocurarine serious effect would respiratory depression could proceed apnea
Curariform Drugs: Diuretic-induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs (such as tubocurarine) the most serious effect would be respiratory depression which could proceed to apnea. 	curariform drugs	tubocurarine	none	{'e1': {'word': 'curariform drugs', 'word_index': [(10, 11)], 'id': 'DDI-DrugBank.d588.s8.e2'}, 'e2': {'word': 'tubocurarine', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d588.s8.e3'}, 'sentence_id': 'DDI-DrugBank.d588.s8'}	Curariform Drugs Diuretic induced hypokalemia may enhance neuromuscular blocking effects curariform drugs tubocurarine serious effect would respiratory depression could proceed apnea
Salicylates and Other Non-Steroidal Anti-Inflammatory Drugs: May decrease the antihypertensive effects of MYKROX Tablets. 	Salicylates	Non-Steroidal Anti-Inflammatory Drugs	none	{'e1': {'word': 'Salicylates', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d588.s10.e0'}, 'e2': {'word': 'Non-Steroidal Anti-Inflammatory Drugs', 'word_index': [(1, 3)], 'id': 'DDI-DrugBank.d588.s10.e1'}, 'sentence_id': 'DDI-DrugBank.d588.s10'}	Salicylates Non-Steroidal Anti-Inflammatory Drugs May decrease antihypertensive effects MYKROX Tablets
Salicylates and Other Non-Steroidal Anti-Inflammatory Drugs: May decrease the antihypertensive effects of MYKROX Tablets. 	Salicylates	MYKROX	effect	{'e1': {'word': 'Salicylates', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d588.s10.e0'}, 'e2': {'word': 'MYKROX', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d588.s10.e2'}, 'sentence_id': 'DDI-DrugBank.d588.s10'}	Salicylates Non-Steroidal Anti-Inflammatory Drugs May decrease antihypertensive effects MYKROX Tablets
Salicylates and Other Non-Steroidal Anti-Inflammatory Drugs: May decrease the antihypertensive effects of MYKROX Tablets. 	Non-Steroidal Anti-Inflammatory Drugs	MYKROX	effect	{'e1': {'word': 'Non-Steroidal Anti-Inflammatory Drugs', 'word_index': [(1, 3)], 'id': 'DDI-DrugBank.d588.s10.e1'}, 'e2': {'word': 'MYKROX', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d588.s10.e2'}, 'sentence_id': 'DDI-DrugBank.d588.s10'}	Salicylates Non-Steroidal Anti-Inflammatory Drugs May decrease antihypertensive effects MYKROX Tablets
Sympathomimetics: Metolazone may decrease arterial responsiveness to norepinephrine, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use. 	Sympathomimetics	Metolazone	none	{'e1': {'word': 'Sympathomimetics', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d588.s11.e0'}, 'e2': {'word': 'Metolazone', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d588.s11.e1'}, 'sentence_id': 'DDI-DrugBank.d588.s11'}	Sympathomimetics Metolazone may decrease arterial responsiveness norepinephrine diminution sufficient preclude effectiveness pressor agent therapeutic use
Sympathomimetics: Metolazone may decrease arterial responsiveness to norepinephrine, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use. 	Sympathomimetics	norepinephrine	none	{'e1': {'word': 'Sympathomimetics', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d588.s11.e0'}, 'e2': {'word': 'norepinephrine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d588.s11.e2'}, 'sentence_id': 'DDI-DrugBank.d588.s11'}	Sympathomimetics Metolazone may decrease arterial responsiveness norepinephrine diminution sufficient preclude effectiveness pressor agent therapeutic use
Sympathomimetics: Metolazone may decrease arterial responsiveness to norepinephrine, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use. 	Metolazone	norepinephrine	effect	{'e1': {'word': 'Metolazone', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d588.s11.e1'}, 'e2': {'word': 'norepinephrine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d588.s11.e2'}, 'sentence_id': 'DDI-DrugBank.d588.s11'}	Sympathomimetics Metolazone may decrease arterial responsiveness norepinephrine diminution sufficient preclude effectiveness pressor agent therapeutic use
Methenamine: Efficacy may be decreased due to urinary alkalizing effect of metolazone. 	Methenamine	metolazone	effect	{'e1': {'word': 'Methenamine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d588.s12.e0'}, 'e2': {'word': 'metolazone', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d588.s12.e1'}, 'sentence_id': 'DDI-DrugBank.d588.s12'}	Methenamine Efficacy may decreased due urinary alkalizing effect metolazone
Anticoagulants: Metolazone, as well as other thiazide-like diuretics, may affect the hypoprothrombinemic response to anticoagulants; 	Anticoagulants	Metolazone	none	{'e1': {'word': 'Anticoagulants', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d588.s13.e0'}, 'e2': {'word': 'Metolazone', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d588.s13.e1'}, 'sentence_id': 'DDI-DrugBank.d588.s13'}	Anticoagulants Metolazone well thiazide like diuretics may affect hypoprothrombinemic response anticoagulants
Anticoagulants: Metolazone, as well as other thiazide-like diuretics, may affect the hypoprothrombinemic response to anticoagulants; 	Anticoagulants	thiazide-like diuretics	none	{'e1': {'word': 'Anticoagulants', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d588.s13.e0'}, 'e2': {'word': 'thiazide-like diuretics', 'word_index': [(3, 5)], 'id': 'DDI-DrugBank.d588.s13.e2'}, 'sentence_id': 'DDI-DrugBank.d588.s13'}	Anticoagulants Metolazone well thiazide like diuretics may affect hypoprothrombinemic response anticoagulants
Anticoagulants: Metolazone, as well as other thiazide-like diuretics, may affect the hypoprothrombinemic response to anticoagulants; 	Anticoagulants	anticoagulants	none	{'e1': {'word': 'Anticoagulants', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d588.s13.e0'}, 'e2': {'word': 'anticoagulants', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d588.s13.e3'}, 'sentence_id': 'DDI-DrugBank.d588.s13'}	Anticoagulants Metolazone well thiazide like diuretics may affect hypoprothrombinemic response anticoagulants
Anticoagulants: Metolazone, as well as other thiazide-like diuretics, may affect the hypoprothrombinemic response to anticoagulants; 	Metolazone	thiazide-like diuretics	none	{'e1': {'word': 'Metolazone', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d588.s13.e1'}, 'e2': {'word': 'thiazide-like diuretics', 'word_index': [(3, 5)], 'id': 'DDI-DrugBank.d588.s13.e2'}, 'sentence_id': 'DDI-DrugBank.d588.s13'}	Anticoagulants Metolazone well thiazide like diuretics may affect hypoprothrombinemic response anticoagulants
Anticoagulants: Metolazone, as well as other thiazide-like diuretics, may affect the hypoprothrombinemic response to anticoagulants; 	Metolazone	anticoagulants	effect	{'e1': {'word': 'Metolazone', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d588.s13.e1'}, 'e2': {'word': 'anticoagulants', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d588.s13.e3'}, 'sentence_id': 'DDI-DrugBank.d588.s13'}	Anticoagulants Metolazone well thiazide like diuretics may affect hypoprothrombinemic response anticoagulants
Anticoagulants: Metolazone, as well as other thiazide-like diuretics, may affect the hypoprothrombinemic response to anticoagulants; 	thiazide-like diuretics	anticoagulants	none	{'e1': {'word': 'thiazide-like diuretics', 'word_index': [(3, 5)], 'id': 'DDI-DrugBank.d588.s13.e2'}, 'e2': {'word': 'anticoagulants', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d588.s13.e3'}, 'sentence_id': 'DDI-DrugBank.d588.s13'}	Anticoagulants Metolazone well thiazide like diuretics may affect hypoprothrombinemic response anticoagulants
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	ketoconazole	paricalcitol	mechanism	{'e1': {'word': 'ketoconazole', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d726.s1.e0'}, 'e2': {'word': 'paricalcitol', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d726.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	ketoconazole	paricalcitol	none	{'e1': {'word': 'ketoconazole', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d726.s1.e0'}, 'e2': {'word': 'paricalcitol', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d726.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	ketoconazole	ketoconazole	none	{'e1': {'word': 'ketoconazole', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d726.s1.e0'}, 'e2': {'word': 'ketoconazole', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d726.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	ketoconazole	paricalcitol	none	{'e1': {'word': 'ketoconazole', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d726.s1.e0'}, 'e2': {'word': 'paricalcitol', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d726.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	ketoconazole	ketoconazole	none	{'e1': {'word': 'ketoconazole', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d726.s1.e0'}, 'e2': {'word': 'ketoconazole', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d726.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	ketoconazole	atazanavir	none	{'e1': {'word': 'ketoconazole', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d726.s1.e0'}, 'e2': {'word': 'atazanavir', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d726.s1.e6'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	ketoconazole	clarithromycin	none	{'e1': {'word': 'ketoconazole', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d726.s1.e0'}, 'e2': {'word': 'clarithromycin', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d726.s1.e7'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	ketoconazole	indinavir	none	{'e1': {'word': 'ketoconazole', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d726.s1.e0'}, 'e2': {'word': 'indinavir', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d726.s1.e8'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	ketoconazole	itraconazole	none	{'e1': {'word': 'ketoconazole', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d726.s1.e0'}, 'e2': {'word': 'itraconazole', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d726.s1.e9'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	ketoconazole	nefazodone	none	{'e1': {'word': 'ketoconazole', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d726.s1.e0'}, 'e2': {'word': 'nefazodone', 'word_index': [(40, 40)], 'id': 'DDI-DrugBank.d726.s1.e10'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	ketoconazole	nelfinavir	none	{'e1': {'word': 'ketoconazole', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d726.s1.e0'}, 'e2': {'word': 'nelfinavir', 'word_index': [(41, 41)], 'id': 'DDI-DrugBank.d726.s1.e11'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	ketoconazole	ritonavir	none	{'e1': {'word': 'ketoconazole', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d726.s1.e0'}, 'e2': {'word': 'ritonavir', 'word_index': [(42, 42)], 'id': 'DDI-DrugBank.d726.s1.e12'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	ketoconazole	saquinavir	none	{'e1': {'word': 'ketoconazole', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d726.s1.e0'}, 'e2': {'word': 'saquinavir', 'word_index': [(43, 43)], 'id': 'DDI-DrugBank.d726.s1.e13'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	ketoconazole	telithromycin	none	{'e1': {'word': 'ketoconazole', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d726.s1.e0'}, 'e2': {'word': 'telithromycin', 'word_index': [(44, 44)], 'id': 'DDI-DrugBank.d726.s1.e14'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	ketoconazole	voriconazole	none	{'e1': {'word': 'ketoconazole', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d726.s1.e0'}, 'e2': {'word': 'voriconazole', 'word_index': [(45, 45)], 'id': 'DDI-DrugBank.d726.s1.e15'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	paricalcitol	paricalcitol	none	{'e1': {'word': 'paricalcitol', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d726.s1.e1'}, 'e2': {'word': 'paricalcitol', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d726.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	paricalcitol	ketoconazole	none	{'e1': {'word': 'paricalcitol', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d726.s1.e1'}, 'e2': {'word': 'ketoconazole', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d726.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	paricalcitol	paricalcitol	none	{'e1': {'word': 'paricalcitol', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d726.s1.e1'}, 'e2': {'word': 'paricalcitol', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d726.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	paricalcitol	ketoconazole	none	{'e1': {'word': 'paricalcitol', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d726.s1.e1'}, 'e2': {'word': 'ketoconazole', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d726.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	paricalcitol	atazanavir	none	{'e1': {'word': 'paricalcitol', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d726.s1.e1'}, 'e2': {'word': 'atazanavir', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d726.s1.e6'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	paricalcitol	clarithromycin	none	{'e1': {'word': 'paricalcitol', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d726.s1.e1'}, 'e2': {'word': 'clarithromycin', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d726.s1.e7'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	paricalcitol	indinavir	none	{'e1': {'word': 'paricalcitol', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d726.s1.e1'}, 'e2': {'word': 'indinavir', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d726.s1.e8'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	paricalcitol	itraconazole	none	{'e1': {'word': 'paricalcitol', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d726.s1.e1'}, 'e2': {'word': 'itraconazole', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d726.s1.e9'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	paricalcitol	nefazodone	none	{'e1': {'word': 'paricalcitol', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d726.s1.e1'}, 'e2': {'word': 'nefazodone', 'word_index': [(40, 40)], 'id': 'DDI-DrugBank.d726.s1.e10'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	paricalcitol	nelfinavir	none	{'e1': {'word': 'paricalcitol', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d726.s1.e1'}, 'e2': {'word': 'nelfinavir', 'word_index': [(41, 41)], 'id': 'DDI-DrugBank.d726.s1.e11'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	paricalcitol	ritonavir	none	{'e1': {'word': 'paricalcitol', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d726.s1.e1'}, 'e2': {'word': 'ritonavir', 'word_index': [(42, 42)], 'id': 'DDI-DrugBank.d726.s1.e12'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	paricalcitol	saquinavir	none	{'e1': {'word': 'paricalcitol', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d726.s1.e1'}, 'e2': {'word': 'saquinavir', 'word_index': [(43, 43)], 'id': 'DDI-DrugBank.d726.s1.e13'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	paricalcitol	telithromycin	none	{'e1': {'word': 'paricalcitol', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d726.s1.e1'}, 'e2': {'word': 'telithromycin', 'word_index': [(44, 44)], 'id': 'DDI-DrugBank.d726.s1.e14'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	paricalcitol	voriconazole	none	{'e1': {'word': 'paricalcitol', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d726.s1.e1'}, 'e2': {'word': 'voriconazole', 'word_index': [(45, 45)], 'id': 'DDI-DrugBank.d726.s1.e15'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	paricalcitol	ketoconazole	none	{'e1': {'word': 'paricalcitol', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d726.s1.e2'}, 'e2': {'word': 'ketoconazole', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d726.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	paricalcitol	paricalcitol	none	{'e1': {'word': 'paricalcitol', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d726.s1.e2'}, 'e2': {'word': 'paricalcitol', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d726.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	paricalcitol	ketoconazole	none	{'e1': {'word': 'paricalcitol', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d726.s1.e2'}, 'e2': {'word': 'ketoconazole', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d726.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	paricalcitol	atazanavir	none	{'e1': {'word': 'paricalcitol', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d726.s1.e2'}, 'e2': {'word': 'atazanavir', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d726.s1.e6'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	paricalcitol	clarithromycin	none	{'e1': {'word': 'paricalcitol', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d726.s1.e2'}, 'e2': {'word': 'clarithromycin', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d726.s1.e7'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	paricalcitol	indinavir	none	{'e1': {'word': 'paricalcitol', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d726.s1.e2'}, 'e2': {'word': 'indinavir', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d726.s1.e8'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	paricalcitol	itraconazole	none	{'e1': {'word': 'paricalcitol', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d726.s1.e2'}, 'e2': {'word': 'itraconazole', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d726.s1.e9'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	paricalcitol	nefazodone	none	{'e1': {'word': 'paricalcitol', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d726.s1.e2'}, 'e2': {'word': 'nefazodone', 'word_index': [(40, 40)], 'id': 'DDI-DrugBank.d726.s1.e10'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	paricalcitol	nelfinavir	none	{'e1': {'word': 'paricalcitol', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d726.s1.e2'}, 'e2': {'word': 'nelfinavir', 'word_index': [(41, 41)], 'id': 'DDI-DrugBank.d726.s1.e11'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	paricalcitol	ritonavir	none	{'e1': {'word': 'paricalcitol', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d726.s1.e2'}, 'e2': {'word': 'ritonavir', 'word_index': [(42, 42)], 'id': 'DDI-DrugBank.d726.s1.e12'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	paricalcitol	saquinavir	none	{'e1': {'word': 'paricalcitol', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d726.s1.e2'}, 'e2': {'word': 'saquinavir', 'word_index': [(43, 43)], 'id': 'DDI-DrugBank.d726.s1.e13'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	paricalcitol	telithromycin	none	{'e1': {'word': 'paricalcitol', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d726.s1.e2'}, 'e2': {'word': 'telithromycin', 'word_index': [(44, 44)], 'id': 'DDI-DrugBank.d726.s1.e14'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	paricalcitol	voriconazole	none	{'e1': {'word': 'paricalcitol', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d726.s1.e2'}, 'e2': {'word': 'voriconazole', 'word_index': [(45, 45)], 'id': 'DDI-DrugBank.d726.s1.e15'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	ketoconazole	paricalcitol	none	{'e1': {'word': 'ketoconazole', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d726.s1.e3'}, 'e2': {'word': 'paricalcitol', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d726.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	ketoconazole	ketoconazole	none	{'e1': {'word': 'ketoconazole', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d726.s1.e3'}, 'e2': {'word': 'ketoconazole', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d726.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	ketoconazole	atazanavir	none	{'e1': {'word': 'ketoconazole', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d726.s1.e3'}, 'e2': {'word': 'atazanavir', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d726.s1.e6'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	ketoconazole	clarithromycin	none	{'e1': {'word': 'ketoconazole', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d726.s1.e3'}, 'e2': {'word': 'clarithromycin', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d726.s1.e7'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	ketoconazole	indinavir	none	{'e1': {'word': 'ketoconazole', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d726.s1.e3'}, 'e2': {'word': 'indinavir', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d726.s1.e8'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	ketoconazole	itraconazole	none	{'e1': {'word': 'ketoconazole', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d726.s1.e3'}, 'e2': {'word': 'itraconazole', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d726.s1.e9'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	ketoconazole	nefazodone	none	{'e1': {'word': 'ketoconazole', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d726.s1.e3'}, 'e2': {'word': 'nefazodone', 'word_index': [(40, 40)], 'id': 'DDI-DrugBank.d726.s1.e10'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	ketoconazole	nelfinavir	none	{'e1': {'word': 'ketoconazole', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d726.s1.e3'}, 'e2': {'word': 'nelfinavir', 'word_index': [(41, 41)], 'id': 'DDI-DrugBank.d726.s1.e11'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	ketoconazole	ritonavir	none	{'e1': {'word': 'ketoconazole', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d726.s1.e3'}, 'e2': {'word': 'ritonavir', 'word_index': [(42, 42)], 'id': 'DDI-DrugBank.d726.s1.e12'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	ketoconazole	saquinavir	none	{'e1': {'word': 'ketoconazole', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d726.s1.e3'}, 'e2': {'word': 'saquinavir', 'word_index': [(43, 43)], 'id': 'DDI-DrugBank.d726.s1.e13'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	ketoconazole	telithromycin	none	{'e1': {'word': 'ketoconazole', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d726.s1.e3'}, 'e2': {'word': 'telithromycin', 'word_index': [(44, 44)], 'id': 'DDI-DrugBank.d726.s1.e14'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	ketoconazole	voriconazole	none	{'e1': {'word': 'ketoconazole', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d726.s1.e3'}, 'e2': {'word': 'voriconazole', 'word_index': [(45, 45)], 'id': 'DDI-DrugBank.d726.s1.e15'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	paricalcitol	ketoconazole	advise	{'e1': {'word': 'paricalcitol', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d726.s1.e4'}, 'e2': {'word': 'ketoconazole', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d726.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	paricalcitol	atazanavir	advise	{'e1': {'word': 'paricalcitol', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d726.s1.e4'}, 'e2': {'word': 'atazanavir', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d726.s1.e6'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	paricalcitol	clarithromycin	advise	{'e1': {'word': 'paricalcitol', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d726.s1.e4'}, 'e2': {'word': 'clarithromycin', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d726.s1.e7'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	paricalcitol	indinavir	advise	{'e1': {'word': 'paricalcitol', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d726.s1.e4'}, 'e2': {'word': 'indinavir', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d726.s1.e8'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	paricalcitol	itraconazole	advise	{'e1': {'word': 'paricalcitol', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d726.s1.e4'}, 'e2': {'word': 'itraconazole', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d726.s1.e9'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	paricalcitol	nefazodone	advise	{'e1': {'word': 'paricalcitol', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d726.s1.e4'}, 'e2': {'word': 'nefazodone', 'word_index': [(40, 40)], 'id': 'DDI-DrugBank.d726.s1.e10'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	paricalcitol	nelfinavir	advise	{'e1': {'word': 'paricalcitol', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d726.s1.e4'}, 'e2': {'word': 'nelfinavir', 'word_index': [(41, 41)], 'id': 'DDI-DrugBank.d726.s1.e11'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	paricalcitol	ritonavir	advise	{'e1': {'word': 'paricalcitol', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d726.s1.e4'}, 'e2': {'word': 'ritonavir', 'word_index': [(42, 42)], 'id': 'DDI-DrugBank.d726.s1.e12'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	paricalcitol	saquinavir	advise	{'e1': {'word': 'paricalcitol', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d726.s1.e4'}, 'e2': {'word': 'saquinavir', 'word_index': [(43, 43)], 'id': 'DDI-DrugBank.d726.s1.e13'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	paricalcitol	telithromycin	advise	{'e1': {'word': 'paricalcitol', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d726.s1.e4'}, 'e2': {'word': 'telithromycin', 'word_index': [(44, 44)], 'id': 'DDI-DrugBank.d726.s1.e14'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	paricalcitol	voriconazole	advise	{'e1': {'word': 'paricalcitol', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d726.s1.e4'}, 'e2': {'word': 'voriconazole', 'word_index': [(45, 45)], 'id': 'DDI-DrugBank.d726.s1.e15'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	ketoconazole	atazanavir	none	{'e1': {'word': 'ketoconazole', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d726.s1.e5'}, 'e2': {'word': 'atazanavir', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d726.s1.e6'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	ketoconazole	clarithromycin	none	{'e1': {'word': 'ketoconazole', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d726.s1.e5'}, 'e2': {'word': 'clarithromycin', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d726.s1.e7'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	ketoconazole	indinavir	none	{'e1': {'word': 'ketoconazole', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d726.s1.e5'}, 'e2': {'word': 'indinavir', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d726.s1.e8'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	ketoconazole	itraconazole	none	{'e1': {'word': 'ketoconazole', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d726.s1.e5'}, 'e2': {'word': 'itraconazole', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d726.s1.e9'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	ketoconazole	nefazodone	none	{'e1': {'word': 'ketoconazole', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d726.s1.e5'}, 'e2': {'word': 'nefazodone', 'word_index': [(40, 40)], 'id': 'DDI-DrugBank.d726.s1.e10'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	ketoconazole	nelfinavir	none	{'e1': {'word': 'ketoconazole', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d726.s1.e5'}, 'e2': {'word': 'nelfinavir', 'word_index': [(41, 41)], 'id': 'DDI-DrugBank.d726.s1.e11'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	ketoconazole	ritonavir	none	{'e1': {'word': 'ketoconazole', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d726.s1.e5'}, 'e2': {'word': 'ritonavir', 'word_index': [(42, 42)], 'id': 'DDI-DrugBank.d726.s1.e12'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	ketoconazole	saquinavir	none	{'e1': {'word': 'ketoconazole', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d726.s1.e5'}, 'e2': {'word': 'saquinavir', 'word_index': [(43, 43)], 'id': 'DDI-DrugBank.d726.s1.e13'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	ketoconazole	telithromycin	none	{'e1': {'word': 'ketoconazole', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d726.s1.e5'}, 'e2': {'word': 'telithromycin', 'word_index': [(44, 44)], 'id': 'DDI-DrugBank.d726.s1.e14'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	ketoconazole	voriconazole	none	{'e1': {'word': 'ketoconazole', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d726.s1.e5'}, 'e2': {'word': 'voriconazole', 'word_index': [(45, 45)], 'id': 'DDI-DrugBank.d726.s1.e15'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	atazanavir	clarithromycin	none	{'e1': {'word': 'atazanavir', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d726.s1.e6'}, 'e2': {'word': 'clarithromycin', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d726.s1.e7'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	atazanavir	indinavir	none	{'e1': {'word': 'atazanavir', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d726.s1.e6'}, 'e2': {'word': 'indinavir', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d726.s1.e8'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	atazanavir	itraconazole	none	{'e1': {'word': 'atazanavir', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d726.s1.e6'}, 'e2': {'word': 'itraconazole', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d726.s1.e9'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	atazanavir	nefazodone	none	{'e1': {'word': 'atazanavir', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d726.s1.e6'}, 'e2': {'word': 'nefazodone', 'word_index': [(40, 40)], 'id': 'DDI-DrugBank.d726.s1.e10'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	atazanavir	nelfinavir	none	{'e1': {'word': 'atazanavir', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d726.s1.e6'}, 'e2': {'word': 'nelfinavir', 'word_index': [(41, 41)], 'id': 'DDI-DrugBank.d726.s1.e11'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	atazanavir	ritonavir	none	{'e1': {'word': 'atazanavir', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d726.s1.e6'}, 'e2': {'word': 'ritonavir', 'word_index': [(42, 42)], 'id': 'DDI-DrugBank.d726.s1.e12'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	atazanavir	saquinavir	none	{'e1': {'word': 'atazanavir', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d726.s1.e6'}, 'e2': {'word': 'saquinavir', 'word_index': [(43, 43)], 'id': 'DDI-DrugBank.d726.s1.e13'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	atazanavir	telithromycin	none	{'e1': {'word': 'atazanavir', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d726.s1.e6'}, 'e2': {'word': 'telithromycin', 'word_index': [(44, 44)], 'id': 'DDI-DrugBank.d726.s1.e14'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	atazanavir	voriconazole	none	{'e1': {'word': 'atazanavir', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d726.s1.e6'}, 'e2': {'word': 'voriconazole', 'word_index': [(45, 45)], 'id': 'DDI-DrugBank.d726.s1.e15'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	clarithromycin	indinavir	none	{'e1': {'word': 'clarithromycin', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d726.s1.e7'}, 'e2': {'word': 'indinavir', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d726.s1.e8'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	clarithromycin	itraconazole	none	{'e1': {'word': 'clarithromycin', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d726.s1.e7'}, 'e2': {'word': 'itraconazole', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d726.s1.e9'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	clarithromycin	nefazodone	none	{'e1': {'word': 'clarithromycin', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d726.s1.e7'}, 'e2': {'word': 'nefazodone', 'word_index': [(40, 40)], 'id': 'DDI-DrugBank.d726.s1.e10'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	clarithromycin	nelfinavir	none	{'e1': {'word': 'clarithromycin', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d726.s1.e7'}, 'e2': {'word': 'nelfinavir', 'word_index': [(41, 41)], 'id': 'DDI-DrugBank.d726.s1.e11'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	clarithromycin	ritonavir	none	{'e1': {'word': 'clarithromycin', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d726.s1.e7'}, 'e2': {'word': 'ritonavir', 'word_index': [(42, 42)], 'id': 'DDI-DrugBank.d726.s1.e12'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	clarithromycin	saquinavir	none	{'e1': {'word': 'clarithromycin', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d726.s1.e7'}, 'e2': {'word': 'saquinavir', 'word_index': [(43, 43)], 'id': 'DDI-DrugBank.d726.s1.e13'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	clarithromycin	telithromycin	none	{'e1': {'word': 'clarithromycin', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d726.s1.e7'}, 'e2': {'word': 'telithromycin', 'word_index': [(44, 44)], 'id': 'DDI-DrugBank.d726.s1.e14'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	clarithromycin	voriconazole	none	{'e1': {'word': 'clarithromycin', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d726.s1.e7'}, 'e2': {'word': 'voriconazole', 'word_index': [(45, 45)], 'id': 'DDI-DrugBank.d726.s1.e15'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	indinavir	itraconazole	none	{'e1': {'word': 'indinavir', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d726.s1.e8'}, 'e2': {'word': 'itraconazole', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d726.s1.e9'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	indinavir	nefazodone	none	{'e1': {'word': 'indinavir', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d726.s1.e8'}, 'e2': {'word': 'nefazodone', 'word_index': [(40, 40)], 'id': 'DDI-DrugBank.d726.s1.e10'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	indinavir	nelfinavir	none	{'e1': {'word': 'indinavir', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d726.s1.e8'}, 'e2': {'word': 'nelfinavir', 'word_index': [(41, 41)], 'id': 'DDI-DrugBank.d726.s1.e11'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	indinavir	ritonavir	none	{'e1': {'word': 'indinavir', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d726.s1.e8'}, 'e2': {'word': 'ritonavir', 'word_index': [(42, 42)], 'id': 'DDI-DrugBank.d726.s1.e12'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	indinavir	saquinavir	none	{'e1': {'word': 'indinavir', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d726.s1.e8'}, 'e2': {'word': 'saquinavir', 'word_index': [(43, 43)], 'id': 'DDI-DrugBank.d726.s1.e13'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	indinavir	telithromycin	none	{'e1': {'word': 'indinavir', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d726.s1.e8'}, 'e2': {'word': 'telithromycin', 'word_index': [(44, 44)], 'id': 'DDI-DrugBank.d726.s1.e14'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	indinavir	voriconazole	none	{'e1': {'word': 'indinavir', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d726.s1.e8'}, 'e2': {'word': 'voriconazole', 'word_index': [(45, 45)], 'id': 'DDI-DrugBank.d726.s1.e15'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	itraconazole	nefazodone	none	{'e1': {'word': 'itraconazole', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d726.s1.e9'}, 'e2': {'word': 'nefazodone', 'word_index': [(40, 40)], 'id': 'DDI-DrugBank.d726.s1.e10'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	itraconazole	nelfinavir	none	{'e1': {'word': 'itraconazole', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d726.s1.e9'}, 'e2': {'word': 'nelfinavir', 'word_index': [(41, 41)], 'id': 'DDI-DrugBank.d726.s1.e11'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	itraconazole	ritonavir	none	{'e1': {'word': 'itraconazole', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d726.s1.e9'}, 'e2': {'word': 'ritonavir', 'word_index': [(42, 42)], 'id': 'DDI-DrugBank.d726.s1.e12'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	itraconazole	saquinavir	none	{'e1': {'word': 'itraconazole', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d726.s1.e9'}, 'e2': {'word': 'saquinavir', 'word_index': [(43, 43)], 'id': 'DDI-DrugBank.d726.s1.e13'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	itraconazole	telithromycin	none	{'e1': {'word': 'itraconazole', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d726.s1.e9'}, 'e2': {'word': 'telithromycin', 'word_index': [(44, 44)], 'id': 'DDI-DrugBank.d726.s1.e14'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	itraconazole	voriconazole	none	{'e1': {'word': 'itraconazole', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d726.s1.e9'}, 'e2': {'word': 'voriconazole', 'word_index': [(45, 45)], 'id': 'DDI-DrugBank.d726.s1.e15'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	nefazodone	nelfinavir	none	{'e1': {'word': 'nefazodone', 'word_index': [(40, 40)], 'id': 'DDI-DrugBank.d726.s1.e10'}, 'e2': {'word': 'nelfinavir', 'word_index': [(41, 41)], 'id': 'DDI-DrugBank.d726.s1.e11'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	nefazodone	ritonavir	none	{'e1': {'word': 'nefazodone', 'word_index': [(40, 40)], 'id': 'DDI-DrugBank.d726.s1.e10'}, 'e2': {'word': 'ritonavir', 'word_index': [(42, 42)], 'id': 'DDI-DrugBank.d726.s1.e12'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	nefazodone	saquinavir	none	{'e1': {'word': 'nefazodone', 'word_index': [(40, 40)], 'id': 'DDI-DrugBank.d726.s1.e10'}, 'e2': {'word': 'saquinavir', 'word_index': [(43, 43)], 'id': 'DDI-DrugBank.d726.s1.e13'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	nefazodone	telithromycin	none	{'e1': {'word': 'nefazodone', 'word_index': [(40, 40)], 'id': 'DDI-DrugBank.d726.s1.e10'}, 'e2': {'word': 'telithromycin', 'word_index': [(44, 44)], 'id': 'DDI-DrugBank.d726.s1.e14'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	nefazodone	voriconazole	none	{'e1': {'word': 'nefazodone', 'word_index': [(40, 40)], 'id': 'DDI-DrugBank.d726.s1.e10'}, 'e2': {'word': 'voriconazole', 'word_index': [(45, 45)], 'id': 'DDI-DrugBank.d726.s1.e15'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	nelfinavir	ritonavir	none	{'e1': {'word': 'nelfinavir', 'word_index': [(41, 41)], 'id': 'DDI-DrugBank.d726.s1.e11'}, 'e2': {'word': 'ritonavir', 'word_index': [(42, 42)], 'id': 'DDI-DrugBank.d726.s1.e12'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	nelfinavir	saquinavir	none	{'e1': {'word': 'nelfinavir', 'word_index': [(41, 41)], 'id': 'DDI-DrugBank.d726.s1.e11'}, 'e2': {'word': 'saquinavir', 'word_index': [(43, 43)], 'id': 'DDI-DrugBank.d726.s1.e13'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	nelfinavir	telithromycin	none	{'e1': {'word': 'nelfinavir', 'word_index': [(41, 41)], 'id': 'DDI-DrugBank.d726.s1.e11'}, 'e2': {'word': 'telithromycin', 'word_index': [(44, 44)], 'id': 'DDI-DrugBank.d726.s1.e14'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	nelfinavir	voriconazole	none	{'e1': {'word': 'nelfinavir', 'word_index': [(41, 41)], 'id': 'DDI-DrugBank.d726.s1.e11'}, 'e2': {'word': 'voriconazole', 'word_index': [(45, 45)], 'id': 'DDI-DrugBank.d726.s1.e15'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	ritonavir	saquinavir	none	{'e1': {'word': 'ritonavir', 'word_index': [(42, 42)], 'id': 'DDI-DrugBank.d726.s1.e12'}, 'e2': {'word': 'saquinavir', 'word_index': [(43, 43)], 'id': 'DDI-DrugBank.d726.s1.e13'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	ritonavir	telithromycin	none	{'e1': {'word': 'ritonavir', 'word_index': [(42, 42)], 'id': 'DDI-DrugBank.d726.s1.e12'}, 'e2': {'word': 'telithromycin', 'word_index': [(44, 44)], 'id': 'DDI-DrugBank.d726.s1.e14'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	ritonavir	voriconazole	none	{'e1': {'word': 'ritonavir', 'word_index': [(42, 42)], 'id': 'DDI-DrugBank.d726.s1.e12'}, 'e2': {'word': 'voriconazole', 'word_index': [(45, 45)], 'id': 'DDI-DrugBank.d726.s1.e15'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	saquinavir	telithromycin	none	{'e1': {'word': 'saquinavir', 'word_index': [(43, 43)], 'id': 'DDI-DrugBank.d726.s1.e13'}, 'e2': {'word': 'telithromycin', 'word_index': [(44, 44)], 'id': 'DDI-DrugBank.d726.s1.e14'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	saquinavir	voriconazole	none	{'e1': {'word': 'saquinavir', 'word_index': [(43, 43)], 'id': 'DDI-DrugBank.d726.s1.e13'}, 'e2': {'word': 'voriconazole', 'word_index': [(45, 45)], 'id': 'DDI-DrugBank.d726.s1.e15'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. 	telithromycin	voriconazole	none	{'e1': {'word': 'telithromycin', 'word_index': [(44, 44)], 'id': 'DDI-DrugBank.d726.s1.e14'}, 'e2': {'word': 'voriconazole', 'word_index': [(45, 45)], 'id': 'DDI-DrugBank.d726.s1.e15'}, 'sentence_id': 'DDI-DrugBank.d726.s1'}	multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole
Dose adjustment of Zemplar Capsules may be required, and iPTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor such as ketoconazole. 	Zemplar	ketoconazole	advise	{'e1': {'word': 'Zemplar', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d726.s2.e0'}, 'e2': {'word': 'ketoconazole', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d726.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d726.s2'}	Dose adjustment Zemplar Capsules may required iPTH serum calcium concentrations closely monitored patient initiates discontinues therapy strong CYP3A4 inhibitor ketoconazole
Drugs that impair intestinal absorption of fat-soluble vitamins, such as cholestyramine, may interfere with the absorption of Zemplar Capsules.	fat-soluble vitamins	cholestyramine	mechanism	{'e1': {'word': 'fat-soluble vitamins', 'word_index': [(4, 6)], 'id': 'DDI-DrugBank.d726.s3.e0'}, 'e2': {'word': 'cholestyramine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d726.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d726.s3'}	Drugs impair intestinal absorption fat soluble vitamins cholestyramine may interfere absorption Zemplar Capsules
Drugs that impair intestinal absorption of fat-soluble vitamins, such as cholestyramine, may interfere with the absorption of Zemplar Capsules.	fat-soluble vitamins	Zemplar	none	{'e1': {'word': 'fat-soluble vitamins', 'word_index': [(4, 6)], 'id': 'DDI-DrugBank.d726.s3.e0'}, 'e2': {'word': 'Zemplar', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d726.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d726.s3'}	Drugs impair intestinal absorption fat soluble vitamins cholestyramine may interfere absorption Zemplar Capsules
Drugs that impair intestinal absorption of fat-soluble vitamins, such as cholestyramine, may interfere with the absorption of Zemplar Capsules.	cholestyramine	Zemplar	mechanism	{'e1': {'word': 'cholestyramine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d726.s3.e1'}, 'e2': {'word': 'Zemplar', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d726.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d726.s3'}	Drugs impair intestinal absorption fat soluble vitamins cholestyramine may interfere absorption Zemplar Capsules
Drugs Affecting Hepatic Metabolism The metabolism and pharmacokinetics of REMERON SolTab    (mirtazapine) Orally Disintegrating Tablets may be affected by the induction or inhibition of drug-metab-olizing enzymes. 	REMERON SolTab	mirtazapine	none	{'e1': {'word': 'REMERON SolTab', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d742.s2.e0'}, 'e2': {'word': 'mirtazapine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d742.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d742.s2'}	Drugs Affecting Hepatic Metabolism metabolism pharmacokinetics REMERON SolTab mirtazapine Orally Disintegrating Tablets may affected induction inhibition drug metab olizing enzymes
While in vitro studies have shown that mirtazapine is not a potent inhibitor of any of these enzymes, an indication that mirtazapine is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome P450 enzymes, the concomitant use of REMERON SolTab with most other drugs metabolized by these enzymes has not been formally studied. 	mirtazapine	mirtazapine	none	{'e1': {'word': 'mirtazapine', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d742.s5.e0'}, 'e2': {'word': 'mirtazapine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d742.s5.e1'}, 'sentence_id': 'DDI-DrugBank.d742.s5'}	vitro studies shown mirtazapine potent inhibitor enzymes indication mirtazapine likely clinically significant inhibitory effect metabolism drugs substrates cytochrome P450 enzymes concomitant use REMERON SolTab drugs metabolized enzymes formally studied
While in vitro studies have shown that mirtazapine is not a potent inhibitor of any of these enzymes, an indication that mirtazapine is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome P450 enzymes, the concomitant use of REMERON SolTab with most other drugs metabolized by these enzymes has not been formally studied. 	mirtazapine	REMERON SolTab	none	{'e1': {'word': 'mirtazapine', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d742.s5.e0'}, 'e2': {'word': 'REMERON SolTab', 'word_index': [(22, 23)], 'id': 'DDI-DrugBank.d742.s5.e2'}, 'sentence_id': 'DDI-DrugBank.d742.s5'}	vitro studies shown mirtazapine potent inhibitor enzymes indication mirtazapine likely clinically significant inhibitory effect metabolism drugs substrates cytochrome P450 enzymes concomitant use REMERON SolTab drugs metabolized enzymes formally studied
While in vitro studies have shown that mirtazapine is not a potent inhibitor of any of these enzymes, an indication that mirtazapine is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome P450 enzymes, the concomitant use of REMERON SolTab with most other drugs metabolized by these enzymes has not been formally studied. 	mirtazapine	REMERON SolTab	none	{'e1': {'word': 'mirtazapine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d742.s5.e1'}, 'e2': {'word': 'REMERON SolTab', 'word_index': [(22, 23)], 'id': 'DDI-DrugBank.d742.s5.e2'}, 'sentence_id': 'DDI-DrugBank.d742.s5'}	vitro studies shown mirtazapine potent inhibitor enzymes indication mirtazapine likely clinically significant inhibitory effect metabolism drugs substrates cytochrome P450 enzymes concomitant use REMERON SolTab drugs metabolized enzymes formally studied
Alcohol: Concomitant administration of alcohol (equivalent to 60 g) had a minimal effect on plasma levels of mirtazapine (15 mg) in 6 healthy male subjects. 	Alcohol	alcohol	none	{'e1': {'word': 'Alcohol', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d742.s7.e0'}, 'e2': {'word': 'alcohol', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d742.s7.e1'}, 'sentence_id': 'DDI-DrugBank.d742.s7'}	Alcohol Concomitant administration alcohol equivalent NUMBER g minimal effect plasma levels mirtazapine NUMBER mg NUMBER healthy male subjects
Alcohol: Concomitant administration of alcohol (equivalent to 60 g) had a minimal effect on plasma levels of mirtazapine (15 mg) in 6 healthy male subjects. 	Alcohol	mirtazapine	none	{'e1': {'word': 'Alcohol', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d742.s7.e0'}, 'e2': {'word': 'mirtazapine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d742.s7.e2'}, 'sentence_id': 'DDI-DrugBank.d742.s7'}	Alcohol Concomitant administration alcohol equivalent NUMBER g minimal effect plasma levels mirtazapine NUMBER mg NUMBER healthy male subjects
Alcohol: Concomitant administration of alcohol (equivalent to 60 g) had a minimal effect on plasma levels of mirtazapine (15 mg) in 6 healthy male subjects. 	alcohol	mirtazapine	mechanism	{'e1': {'word': 'alcohol', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d742.s7.e1'}, 'e2': {'word': 'mirtazapine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d742.s7.e2'}, 'sentence_id': 'DDI-DrugBank.d742.s7'}	Alcohol Concomitant administration alcohol equivalent NUMBER g minimal effect plasma levels mirtazapine NUMBER mg NUMBER healthy male subjects
However, the impairment of cognitive and motor skills produced by REMERON    were shown to be additive with those produced by alcohol. 	REMERON	alcohol	effect	{'e1': {'word': 'REMERON', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d742.s8.e0'}, 'e2': {'word': 'alcohol', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d742.s8.e1'}, 'sentence_id': 'DDI-DrugBank.d742.s8'}	However impairment cognitive motor skills produced REMERON shown additive produced alcohol
Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. 	alcohol	REMERON SolTab	advise	{'e1': {'word': 'alcohol', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d742.s9.e0'}, 'e2': {'word': 'REMERON SolTab', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d742.s9.e1'}, 'sentence_id': 'DDI-DrugBank.d742.s9'}	Accordingly patients advised avoid alcohol taking REMERON SolTab Diazepam Concomitant administration diazepam NUMBER mg minimal effect plasma levels mirtazapine NUMBER mg NUMBER healthy subjects
Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. 	alcohol	Diazepam	none	{'e1': {'word': 'alcohol', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d742.s9.e0'}, 'e2': {'word': 'Diazepam', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d742.s9.e2'}, 'sentence_id': 'DDI-DrugBank.d742.s9'}	Accordingly patients advised avoid alcohol taking REMERON SolTab Diazepam Concomitant administration diazepam NUMBER mg minimal effect plasma levels mirtazapine NUMBER mg NUMBER healthy subjects
Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. 	alcohol	diazepam	none	{'e1': {'word': 'alcohol', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d742.s9.e0'}, 'e2': {'word': 'diazepam', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d742.s9.e3'}, 'sentence_id': 'DDI-DrugBank.d742.s9'}	Accordingly patients advised avoid alcohol taking REMERON SolTab Diazepam Concomitant administration diazepam NUMBER mg minimal effect plasma levels mirtazapine NUMBER mg NUMBER healthy subjects
Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. 	alcohol	mirtazapine	none	{'e1': {'word': 'alcohol', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d742.s9.e0'}, 'e2': {'word': 'mirtazapine', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d742.s9.e4'}, 'sentence_id': 'DDI-DrugBank.d742.s9'}	Accordingly patients advised avoid alcohol taking REMERON SolTab Diazepam Concomitant administration diazepam NUMBER mg minimal effect plasma levels mirtazapine NUMBER mg NUMBER healthy subjects
Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. 	REMERON SolTab	Diazepam	none	{'e1': {'word': 'REMERON SolTab', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d742.s9.e1'}, 'e2': {'word': 'Diazepam', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d742.s9.e2'}, 'sentence_id': 'DDI-DrugBank.d742.s9'}	Accordingly patients advised avoid alcohol taking REMERON SolTab Diazepam Concomitant administration diazepam NUMBER mg minimal effect plasma levels mirtazapine NUMBER mg NUMBER healthy subjects
Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. 	REMERON SolTab	diazepam	none	{'e1': {'word': 'REMERON SolTab', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d742.s9.e1'}, 'e2': {'word': 'diazepam', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d742.s9.e3'}, 'sentence_id': 'DDI-DrugBank.d742.s9'}	Accordingly patients advised avoid alcohol taking REMERON SolTab Diazepam Concomitant administration diazepam NUMBER mg minimal effect plasma levels mirtazapine NUMBER mg NUMBER healthy subjects
Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. 	REMERON SolTab	mirtazapine	none	{'e1': {'word': 'REMERON SolTab', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d742.s9.e1'}, 'e2': {'word': 'mirtazapine', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d742.s9.e4'}, 'sentence_id': 'DDI-DrugBank.d742.s9'}	Accordingly patients advised avoid alcohol taking REMERON SolTab Diazepam Concomitant administration diazepam NUMBER mg minimal effect plasma levels mirtazapine NUMBER mg NUMBER healthy subjects
Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. 	Diazepam	diazepam	none	{'e1': {'word': 'Diazepam', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d742.s9.e2'}, 'e2': {'word': 'diazepam', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d742.s9.e3'}, 'sentence_id': 'DDI-DrugBank.d742.s9'}	Accordingly patients advised avoid alcohol taking REMERON SolTab Diazepam Concomitant administration diazepam NUMBER mg minimal effect plasma levels mirtazapine NUMBER mg NUMBER healthy subjects
Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. 	Diazepam	mirtazapine	none	{'e1': {'word': 'Diazepam', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d742.s9.e2'}, 'e2': {'word': 'mirtazapine', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d742.s9.e4'}, 'sentence_id': 'DDI-DrugBank.d742.s9'}	Accordingly patients advised avoid alcohol taking REMERON SolTab Diazepam Concomitant administration diazepam NUMBER mg minimal effect plasma levels mirtazapine NUMBER mg NUMBER healthy subjects
Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. 	diazepam	mirtazapine	mechanism	{'e1': {'word': 'diazepam', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d742.s9.e3'}, 'e2': {'word': 'mirtazapine', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d742.s9.e4'}, 'sentence_id': 'DDI-DrugBank.d742.s9'}	Accordingly patients advised avoid alcohol taking REMERON SolTab Diazepam Concomitant administration diazepam NUMBER mg minimal effect plasma levels mirtazapine NUMBER mg NUMBER healthy subjects
However, the impairment of motor skills produced by REMERON has been shown to be additive with those caused by diazepam. 	REMERON	diazepam	effect	{'e1': {'word': 'REMERON', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d742.s10.e0'}, 'e2': {'word': 'diazepam', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d742.s10.e1'}, 'sentence_id': 'DDI-DrugBank.d742.s10'}	However impairment motor skills produced REMERON shown additive caused diazepam
Accordingly, patients should be advised to avoid diazepam and other similar drugs while taking REMERON SolTab.	diazepam	REMERON SolTab	advise	{'e1': {'word': 'diazepam', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d742.s11.e0'}, 'e2': {'word': 'REMERON SolTab', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d742.s11.e1'}, 'sentence_id': 'DDI-DrugBank.d742.s11'}	Accordingly patients advised avoid diazepam similar drugs taking REMERON SolTab
Montelukast at a Dose of 10 mg Once Daily Dosed to Pharmacokinetic Steady State  - did not cause clinically significant changes in the kinetics of a single intravenous dose of theophylline (predominantly a cytochrome P450 1A2 substrate). 	Montelukast	theophylline	none	{'e1': {'word': 'Montelukast', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d739.s0.e0'}, 'e2': {'word': 'theophylline', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d739.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d739.s0'}	Montelukast Dose NUMBER mg Daily Dosed Pharmacokinetic Steady State cause clinically significant changes kinetics single intravenous dose theophylline predominantly cytochrome P450 1A2 substrate
- did not change the pharmacokinetic profile of warfarin (a substrate of cytochromes P450 2A6 and 2C9) or influence the effect of a single 30-mg oral dose of warfarin on prothrombin time or the INR (International Normalized Ratio). 	warfarin	warfarin	none	{'e1': {'word': 'warfarin', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d739.s1.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d739.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d739.s1'}	change pharmacokinetic profile warfarin substrate cytochromes P450 2A6 2C9 influence effect single NUMBER mg oral dose warfarin prothrombin time INR International Normalized Ratio
- did not change the plasma concentration profile of terfenadine (a substrate of cytochrome P450 3A4) or fexofenadine, its carboxylated metabolite, and did not prolong the QTc interval following co-administration with terfenadine 60 mg twice daily. 	terfenadine	fexofenadine	none	{'e1': {'word': 'terfenadine', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d739.s3.e0'}, 'e2': {'word': 'fexofenadine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d739.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d739.s3'}	change plasma concentration profile terfenadine substrate cytochrome P450 3A4 fexofenadine carboxylated metabolite prolong QTc interval following co-administration terfenadine NUMBER mg twice daily
- did not change the plasma concentration profile of terfenadine (a substrate of cytochrome P450 3A4) or fexofenadine, its carboxylated metabolite, and did not prolong the QTc interval following co-administration with terfenadine 60 mg twice daily. 	terfenadine	terfenadine	none	{'e1': {'word': 'terfenadine', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d739.s3.e0'}, 'e2': {'word': 'terfenadine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d739.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d739.s3'}	change plasma concentration profile terfenadine substrate cytochrome P450 3A4 fexofenadine carboxylated metabolite prolong QTc interval following co-administration terfenadine NUMBER mg twice daily
- did not change the plasma concentration profile of terfenadine (a substrate of cytochrome P450 3A4) or fexofenadine, its carboxylated metabolite, and did not prolong the QTc interval following co-administration with terfenadine 60 mg twice daily. 	fexofenadine	terfenadine	none	{'e1': {'word': 'fexofenadine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d739.s3.e1'}, 'e2': {'word': 'terfenadine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d739.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d739.s3'}	change plasma concentration profile terfenadine substrate cytochrome P450 3A4 fexofenadine carboxylated metabolite prolong QTc interval following co-administration terfenadine NUMBER mg twice daily
Montelukast at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl estradiol 35 mcg. 	Montelukast	contraceptive	none	{'e1': {'word': 'Montelukast', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d739.s4.e0'}, 'e2': {'word': 'contraceptive', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d739.s4.e1'}, 'sentence_id': 'DDI-DrugBank.d739.s4'}	Montelukast Doses NUMBER mg Daily Dosed Pharmacokinetic Steady State significantly alter plasma concentrations either component oral contraceptive containing norethindrone NUMBER mg / ethinyl estradiol NUMBER mcg
Montelukast at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl estradiol 35 mcg. 	Montelukast	norethindrone	none	{'e1': {'word': 'Montelukast', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d739.s4.e0'}, 'e2': {'word': 'norethindrone', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d739.s4.e2'}, 'sentence_id': 'DDI-DrugBank.d739.s4'}	Montelukast Doses NUMBER mg Daily Dosed Pharmacokinetic Steady State significantly alter plasma concentrations either component oral contraceptive containing norethindrone NUMBER mg / ethinyl estradiol NUMBER mcg
Montelukast at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl estradiol 35 mcg. 	Montelukast	estradiol	none	{'e1': {'word': 'Montelukast', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d739.s4.e0'}, 'e2': {'word': 'estradiol', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d739.s4.e3'}, 'sentence_id': 'DDI-DrugBank.d739.s4'}	Montelukast Doses NUMBER mg Daily Dosed Pharmacokinetic Steady State significantly alter plasma concentrations either component oral contraceptive containing norethindrone NUMBER mg / ethinyl estradiol NUMBER mcg
Montelukast at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl estradiol 35 mcg. 	contraceptive	norethindrone	none	{'e1': {'word': 'contraceptive', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d739.s4.e1'}, 'e2': {'word': 'norethindrone', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d739.s4.e2'}, 'sentence_id': 'DDI-DrugBank.d739.s4'}	Montelukast Doses NUMBER mg Daily Dosed Pharmacokinetic Steady State significantly alter plasma concentrations either component oral contraceptive containing norethindrone NUMBER mg / ethinyl estradiol NUMBER mcg
Montelukast at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl estradiol 35 mcg. 	contraceptive	estradiol	none	{'e1': {'word': 'contraceptive', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d739.s4.e1'}, 'e2': {'word': 'estradiol', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d739.s4.e3'}, 'sentence_id': 'DDI-DrugBank.d739.s4'}	Montelukast Doses NUMBER mg Daily Dosed Pharmacokinetic Steady State significantly alter plasma concentrations either component oral contraceptive containing norethindrone NUMBER mg / ethinyl estradiol NUMBER mcg
Montelukast at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl estradiol 35 mcg. 	norethindrone	estradiol	none	{'e1': {'word': 'norethindrone', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d739.s4.e2'}, 'e2': {'word': 'estradiol', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d739.s4.e3'}, 'sentence_id': 'DDI-DrugBank.d739.s4'}	Montelukast Doses NUMBER mg Daily Dosed Pharmacokinetic Steady State significantly alter plasma concentrations either component oral contraceptive containing norethindrone NUMBER mg / ethinyl estradiol NUMBER mcg
- did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral prednisone or intravenous prednisolone.  	prednisone	prednisolone	none	{'e1': {'word': 'prednisone', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d739.s5.e0'}, 'e2': {'word': 'prednisolone', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d739.s5.e1'}, 'sentence_id': 'DDI-DrugBank.d739.s5'}	cause clinically significant change plasma profiles prednisone prednisolone following administration either oral prednisone intravenous prednisolone
- did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral prednisone or intravenous prednisolone.  	prednisone	prednisone	none	{'e1': {'word': 'prednisone', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d739.s5.e0'}, 'e2': {'word': 'prednisone', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d739.s5.e2'}, 'sentence_id': 'DDI-DrugBank.d739.s5'}	cause clinically significant change plasma profiles prednisone prednisolone following administration either oral prednisone intravenous prednisolone
- did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral prednisone or intravenous prednisolone.  	prednisone	prednisolone	none	{'e1': {'word': 'prednisone', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d739.s5.e0'}, 'e2': {'word': 'prednisolone', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d739.s5.e3'}, 'sentence_id': 'DDI-DrugBank.d739.s5'}	cause clinically significant change plasma profiles prednisone prednisolone following administration either oral prednisone intravenous prednisolone
- did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral prednisone or intravenous prednisolone.  	prednisolone	prednisone	none	{'e1': {'word': 'prednisolone', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d739.s5.e1'}, 'e2': {'word': 'prednisone', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d739.s5.e2'}, 'sentence_id': 'DDI-DrugBank.d739.s5'}	cause clinically significant change plasma profiles prednisone prednisolone following administration either oral prednisone intravenous prednisolone
- did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral prednisone or intravenous prednisolone.  	prednisolone	prednisolone	none	{'e1': {'word': 'prednisolone', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d739.s5.e1'}, 'e2': {'word': 'prednisolone', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d739.s5.e3'}, 'sentence_id': 'DDI-DrugBank.d739.s5'}	cause clinically significant change plasma profiles prednisone prednisolone following administration either oral prednisone intravenous prednisolone
- did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral prednisone or intravenous prednisolone.  	prednisone	prednisolone	none	{'e1': {'word': 'prednisone', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d739.s5.e2'}, 'e2': {'word': 'prednisolone', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d739.s5.e3'}, 'sentence_id': 'DDI-DrugBank.d739.s5'}	cause clinically significant change plasma profiles prednisone prednisolone following administration either oral prednisone intravenous prednisolone
Phenobarbital, which induces hepatic metabolism, decreased the AUC of montelukast approximately 40% following a single 10-mg dose of montelukast. 	Phenobarbital	montelukast	none	{'e1': {'word': 'Phenobarbital', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d739.s6.e0'}, 'e2': {'word': 'montelukast', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d739.s6.e1'}, 'sentence_id': 'DDI-DrugBank.d739.s6'}	Phenobarbital induces hepatic metabolism decreased AUC montelukast approximately NUMBER % following single NUMBER mg dose montelukast
Phenobarbital, which induces hepatic metabolism, decreased the AUC of montelukast approximately 40% following a single 10-mg dose of montelukast. 	Phenobarbital	montelukast	none	{'e1': {'word': 'Phenobarbital', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d739.s6.e0'}, 'e2': {'word': 'montelukast', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d739.s6.e2'}, 'sentence_id': 'DDI-DrugBank.d739.s6'}	Phenobarbital induces hepatic metabolism decreased AUC montelukast approximately NUMBER % following single NUMBER mg dose montelukast
Phenobarbital, which induces hepatic metabolism, decreased the AUC of montelukast approximately 40% following a single 10-mg dose of montelukast. 	montelukast	montelukast	none	{'e1': {'word': 'montelukast', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d739.s6.e1'}, 'e2': {'word': 'montelukast', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d739.s6.e2'}, 'sentence_id': 'DDI-DrugBank.d739.s6'}	Phenobarbital induces hepatic metabolism decreased AUC montelukast approximately NUMBER % following single NUMBER mg dose montelukast
It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast. 	phenobarbital	rifampin	none	{'e1': {'word': 'phenobarbital', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d739.s8.e0'}, 'e2': {'word': 'rifampin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d739.s8.e1'}, 'sentence_id': 'DDI-DrugBank.d739.s8'}	reasonable employ appropriate clinical monitoring potent cytochrome P450 enzyme inducers phenobarbital rifampin co-administered montelukast
It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast. 	phenobarbital	montelukast	advise	{'e1': {'word': 'phenobarbital', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d739.s8.e0'}, 'e2': {'word': 'montelukast', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d739.s8.e2'}, 'sentence_id': 'DDI-DrugBank.d739.s8'}	reasonable employ appropriate clinical monitoring potent cytochrome P450 enzyme inducers phenobarbital rifampin co-administered montelukast
It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast. 	rifampin	montelukast	advise	{'e1': {'word': 'rifampin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d739.s8.e1'}, 'e2': {'word': 'montelukast', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d739.s8.e2'}, 'sentence_id': 'DDI-DrugBank.d739.s8'}	reasonable employ appropriate clinical monitoring potent cytochrome P450 enzyme inducers phenobarbital rifampin co-administered montelukast
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. 	montelukast	theophylline	none	{'e1': {'word': 'montelukast', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d739.s10.e0'}, 'e2': {'word': 'theophylline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d739.s10.e1'}, 'sentence_id': 'DDI-DrugBank.d739.s10'}	drug interaction studies recommended clinical dose montelukast clinically important effects pharmacokinetics following drugs theophylline prednisone prednisolone oral contraceptives norethindrone NUMBER mg / ethinyl estradiol NUMBER mcg terfenadine digoxin warfarin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. 	montelukast	prednisone	none	{'e1': {'word': 'montelukast', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d739.s10.e0'}, 'e2': {'word': 'prednisone', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d739.s10.e2'}, 'sentence_id': 'DDI-DrugBank.d739.s10'}	drug interaction studies recommended clinical dose montelukast clinically important effects pharmacokinetics following drugs theophylline prednisone prednisolone oral contraceptives norethindrone NUMBER mg / ethinyl estradiol NUMBER mcg terfenadine digoxin warfarin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. 	montelukast	prednisolone	none	{'e1': {'word': 'montelukast', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d739.s10.e0'}, 'e2': {'word': 'prednisolone', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d739.s10.e3'}, 'sentence_id': 'DDI-DrugBank.d739.s10'}	drug interaction studies recommended clinical dose montelukast clinically important effects pharmacokinetics following drugs theophylline prednisone prednisolone oral contraceptives norethindrone NUMBER mg / ethinyl estradiol NUMBER mcg terfenadine digoxin warfarin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. 	montelukast	contraceptives	none	{'e1': {'word': 'montelukast', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d739.s10.e0'}, 'e2': {'word': 'contraceptives', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d739.s10.e4'}, 'sentence_id': 'DDI-DrugBank.d739.s10'}	drug interaction studies recommended clinical dose montelukast clinically important effects pharmacokinetics following drugs theophylline prednisone prednisolone oral contraceptives norethindrone NUMBER mg / ethinyl estradiol NUMBER mcg terfenadine digoxin warfarin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. 	montelukast	norethindrone	none	{'e1': {'word': 'montelukast', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d739.s10.e0'}, 'e2': {'word': 'norethindrone', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d739.s10.e5'}, 'sentence_id': 'DDI-DrugBank.d739.s10'}	drug interaction studies recommended clinical dose montelukast clinically important effects pharmacokinetics following drugs theophylline prednisone prednisolone oral contraceptives norethindrone NUMBER mg / ethinyl estradiol NUMBER mcg terfenadine digoxin warfarin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. 	montelukast	ethinyl estradiol	none	{'e1': {'word': 'montelukast', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d739.s10.e0'}, 'e2': {'word': 'ethinyl estradiol', 'word_index': [(22, 23)], 'id': 'DDI-DrugBank.d739.s10.e6'}, 'sentence_id': 'DDI-DrugBank.d739.s10'}	drug interaction studies recommended clinical dose montelukast clinically important effects pharmacokinetics following drugs theophylline prednisone prednisolone oral contraceptives norethindrone NUMBER mg / ethinyl estradiol NUMBER mcg terfenadine digoxin warfarin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. 	montelukast	terfenadine	none	{'e1': {'word': 'montelukast', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d739.s10.e0'}, 'e2': {'word': 'terfenadine', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d739.s10.e7'}, 'sentence_id': 'DDI-DrugBank.d739.s10'}	drug interaction studies recommended clinical dose montelukast clinically important effects pharmacokinetics following drugs theophylline prednisone prednisolone oral contraceptives norethindrone NUMBER mg / ethinyl estradiol NUMBER mcg terfenadine digoxin warfarin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. 	montelukast	digoxin	none	{'e1': {'word': 'montelukast', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d739.s10.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d739.s10.e8'}, 'sentence_id': 'DDI-DrugBank.d739.s10'}	drug interaction studies recommended clinical dose montelukast clinically important effects pharmacokinetics following drugs theophylline prednisone prednisolone oral contraceptives norethindrone NUMBER mg / ethinyl estradiol NUMBER mcg terfenadine digoxin warfarin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. 	montelukast	warfarin	none	{'e1': {'word': 'montelukast', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d739.s10.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d739.s10.e9'}, 'sentence_id': 'DDI-DrugBank.d739.s10'}	drug interaction studies recommended clinical dose montelukast clinically important effects pharmacokinetics following drugs theophylline prednisone prednisolone oral contraceptives norethindrone NUMBER mg / ethinyl estradiol NUMBER mcg terfenadine digoxin warfarin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. 	theophylline	prednisone	none	{'e1': {'word': 'theophylline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d739.s10.e1'}, 'e2': {'word': 'prednisone', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d739.s10.e2'}, 'sentence_id': 'DDI-DrugBank.d739.s10'}	drug interaction studies recommended clinical dose montelukast clinically important effects pharmacokinetics following drugs theophylline prednisone prednisolone oral contraceptives norethindrone NUMBER mg / ethinyl estradiol NUMBER mcg terfenadine digoxin warfarin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. 	theophylline	prednisolone	none	{'e1': {'word': 'theophylline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d739.s10.e1'}, 'e2': {'word': 'prednisolone', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d739.s10.e3'}, 'sentence_id': 'DDI-DrugBank.d739.s10'}	drug interaction studies recommended clinical dose montelukast clinically important effects pharmacokinetics following drugs theophylline prednisone prednisolone oral contraceptives norethindrone NUMBER mg / ethinyl estradiol NUMBER mcg terfenadine digoxin warfarin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. 	theophylline	contraceptives	none	{'e1': {'word': 'theophylline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d739.s10.e1'}, 'e2': {'word': 'contraceptives', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d739.s10.e4'}, 'sentence_id': 'DDI-DrugBank.d739.s10'}	drug interaction studies recommended clinical dose montelukast clinically important effects pharmacokinetics following drugs theophylline prednisone prednisolone oral contraceptives norethindrone NUMBER mg / ethinyl estradiol NUMBER mcg terfenadine digoxin warfarin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. 	theophylline	norethindrone	none	{'e1': {'word': 'theophylline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d739.s10.e1'}, 'e2': {'word': 'norethindrone', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d739.s10.e5'}, 'sentence_id': 'DDI-DrugBank.d739.s10'}	drug interaction studies recommended clinical dose montelukast clinically important effects pharmacokinetics following drugs theophylline prednisone prednisolone oral contraceptives norethindrone NUMBER mg / ethinyl estradiol NUMBER mcg terfenadine digoxin warfarin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. 	theophylline	ethinyl estradiol	none	{'e1': {'word': 'theophylline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d739.s10.e1'}, 'e2': {'word': 'ethinyl estradiol', 'word_index': [(22, 23)], 'id': 'DDI-DrugBank.d739.s10.e6'}, 'sentence_id': 'DDI-DrugBank.d739.s10'}	drug interaction studies recommended clinical dose montelukast clinically important effects pharmacokinetics following drugs theophylline prednisone prednisolone oral contraceptives norethindrone NUMBER mg / ethinyl estradiol NUMBER mcg terfenadine digoxin warfarin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. 	theophylline	terfenadine	none	{'e1': {'word': 'theophylline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d739.s10.e1'}, 'e2': {'word': 'terfenadine', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d739.s10.e7'}, 'sentence_id': 'DDI-DrugBank.d739.s10'}	drug interaction studies recommended clinical dose montelukast clinically important effects pharmacokinetics following drugs theophylline prednisone prednisolone oral contraceptives norethindrone NUMBER mg / ethinyl estradiol NUMBER mcg terfenadine digoxin warfarin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. 	theophylline	digoxin	none	{'e1': {'word': 'theophylline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d739.s10.e1'}, 'e2': {'word': 'digoxin', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d739.s10.e8'}, 'sentence_id': 'DDI-DrugBank.d739.s10'}	drug interaction studies recommended clinical dose montelukast clinically important effects pharmacokinetics following drugs theophylline prednisone prednisolone oral contraceptives norethindrone NUMBER mg / ethinyl estradiol NUMBER mcg terfenadine digoxin warfarin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. 	theophylline	warfarin	none	{'e1': {'word': 'theophylline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d739.s10.e1'}, 'e2': {'word': 'warfarin', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d739.s10.e9'}, 'sentence_id': 'DDI-DrugBank.d739.s10'}	drug interaction studies recommended clinical dose montelukast clinically important effects pharmacokinetics following drugs theophylline prednisone prednisolone oral contraceptives norethindrone NUMBER mg / ethinyl estradiol NUMBER mcg terfenadine digoxin warfarin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. 	prednisone	prednisolone	none	{'e1': {'word': 'prednisone', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d739.s10.e2'}, 'e2': {'word': 'prednisolone', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d739.s10.e3'}, 'sentence_id': 'DDI-DrugBank.d739.s10'}	drug interaction studies recommended clinical dose montelukast clinically important effects pharmacokinetics following drugs theophylline prednisone prednisolone oral contraceptives norethindrone NUMBER mg / ethinyl estradiol NUMBER mcg terfenadine digoxin warfarin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. 	prednisone	contraceptives	none	{'e1': {'word': 'prednisone', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d739.s10.e2'}, 'e2': {'word': 'contraceptives', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d739.s10.e4'}, 'sentence_id': 'DDI-DrugBank.d739.s10'}	drug interaction studies recommended clinical dose montelukast clinically important effects pharmacokinetics following drugs theophylline prednisone prednisolone oral contraceptives norethindrone NUMBER mg / ethinyl estradiol NUMBER mcg terfenadine digoxin warfarin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. 	prednisone	norethindrone	none	{'e1': {'word': 'prednisone', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d739.s10.e2'}, 'e2': {'word': 'norethindrone', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d739.s10.e5'}, 'sentence_id': 'DDI-DrugBank.d739.s10'}	drug interaction studies recommended clinical dose montelukast clinically important effects pharmacokinetics following drugs theophylline prednisone prednisolone oral contraceptives norethindrone NUMBER mg / ethinyl estradiol NUMBER mcg terfenadine digoxin warfarin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. 	prednisone	ethinyl estradiol	none	{'e1': {'word': 'prednisone', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d739.s10.e2'}, 'e2': {'word': 'ethinyl estradiol', 'word_index': [(22, 23)], 'id': 'DDI-DrugBank.d739.s10.e6'}, 'sentence_id': 'DDI-DrugBank.d739.s10'}	drug interaction studies recommended clinical dose montelukast clinically important effects pharmacokinetics following drugs theophylline prednisone prednisolone oral contraceptives norethindrone NUMBER mg / ethinyl estradiol NUMBER mcg terfenadine digoxin warfarin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. 	prednisone	terfenadine	none	{'e1': {'word': 'prednisone', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d739.s10.e2'}, 'e2': {'word': 'terfenadine', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d739.s10.e7'}, 'sentence_id': 'DDI-DrugBank.d739.s10'}	drug interaction studies recommended clinical dose montelukast clinically important effects pharmacokinetics following drugs theophylline prednisone prednisolone oral contraceptives norethindrone NUMBER mg / ethinyl estradiol NUMBER mcg terfenadine digoxin warfarin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. 	prednisone	digoxin	none	{'e1': {'word': 'prednisone', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d739.s10.e2'}, 'e2': {'word': 'digoxin', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d739.s10.e8'}, 'sentence_id': 'DDI-DrugBank.d739.s10'}	drug interaction studies recommended clinical dose montelukast clinically important effects pharmacokinetics following drugs theophylline prednisone prednisolone oral contraceptives norethindrone NUMBER mg / ethinyl estradiol NUMBER mcg terfenadine digoxin warfarin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. 	prednisone	warfarin	none	{'e1': {'word': 'prednisone', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d739.s10.e2'}, 'e2': {'word': 'warfarin', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d739.s10.e9'}, 'sentence_id': 'DDI-DrugBank.d739.s10'}	drug interaction studies recommended clinical dose montelukast clinically important effects pharmacokinetics following drugs theophylline prednisone prednisolone oral contraceptives norethindrone NUMBER mg / ethinyl estradiol NUMBER mcg terfenadine digoxin warfarin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. 	prednisolone	contraceptives	none	{'e1': {'word': 'prednisolone', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d739.s10.e3'}, 'e2': {'word': 'contraceptives', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d739.s10.e4'}, 'sentence_id': 'DDI-DrugBank.d739.s10'}	drug interaction studies recommended clinical dose montelukast clinically important effects pharmacokinetics following drugs theophylline prednisone prednisolone oral contraceptives norethindrone NUMBER mg / ethinyl estradiol NUMBER mcg terfenadine digoxin warfarin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. 	prednisolone	norethindrone	none	{'e1': {'word': 'prednisolone', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d739.s10.e3'}, 'e2': {'word': 'norethindrone', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d739.s10.e5'}, 'sentence_id': 'DDI-DrugBank.d739.s10'}	drug interaction studies recommended clinical dose montelukast clinically important effects pharmacokinetics following drugs theophylline prednisone prednisolone oral contraceptives norethindrone NUMBER mg / ethinyl estradiol NUMBER mcg terfenadine digoxin warfarin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. 	prednisolone	ethinyl estradiol	none	{'e1': {'word': 'prednisolone', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d739.s10.e3'}, 'e2': {'word': 'ethinyl estradiol', 'word_index': [(22, 23)], 'id': 'DDI-DrugBank.d739.s10.e6'}, 'sentence_id': 'DDI-DrugBank.d739.s10'}	drug interaction studies recommended clinical dose montelukast clinically important effects pharmacokinetics following drugs theophylline prednisone prednisolone oral contraceptives norethindrone NUMBER mg / ethinyl estradiol NUMBER mcg terfenadine digoxin warfarin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. 	prednisolone	terfenadine	none	{'e1': {'word': 'prednisolone', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d739.s10.e3'}, 'e2': {'word': 'terfenadine', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d739.s10.e7'}, 'sentence_id': 'DDI-DrugBank.d739.s10'}	drug interaction studies recommended clinical dose montelukast clinically important effects pharmacokinetics following drugs theophylline prednisone prednisolone oral contraceptives norethindrone NUMBER mg / ethinyl estradiol NUMBER mcg terfenadine digoxin warfarin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. 	prednisolone	digoxin	none	{'e1': {'word': 'prednisolone', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d739.s10.e3'}, 'e2': {'word': 'digoxin', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d739.s10.e8'}, 'sentence_id': 'DDI-DrugBank.d739.s10'}	drug interaction studies recommended clinical dose montelukast clinically important effects pharmacokinetics following drugs theophylline prednisone prednisolone oral contraceptives norethindrone NUMBER mg / ethinyl estradiol NUMBER mcg terfenadine digoxin warfarin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. 	prednisolone	warfarin	none	{'e1': {'word': 'prednisolone', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d739.s10.e3'}, 'e2': {'word': 'warfarin', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d739.s10.e9'}, 'sentence_id': 'DDI-DrugBank.d739.s10'}	drug interaction studies recommended clinical dose montelukast clinically important effects pharmacokinetics following drugs theophylline prednisone prednisolone oral contraceptives norethindrone NUMBER mg / ethinyl estradiol NUMBER mcg terfenadine digoxin warfarin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. 	contraceptives	norethindrone	none	{'e1': {'word': 'contraceptives', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d739.s10.e4'}, 'e2': {'word': 'norethindrone', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d739.s10.e5'}, 'sentence_id': 'DDI-DrugBank.d739.s10'}	drug interaction studies recommended clinical dose montelukast clinically important effects pharmacokinetics following drugs theophylline prednisone prednisolone oral contraceptives norethindrone NUMBER mg / ethinyl estradiol NUMBER mcg terfenadine digoxin warfarin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. 	contraceptives	ethinyl estradiol	none	{'e1': {'word': 'contraceptives', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d739.s10.e4'}, 'e2': {'word': 'ethinyl estradiol', 'word_index': [(22, 23)], 'id': 'DDI-DrugBank.d739.s10.e6'}, 'sentence_id': 'DDI-DrugBank.d739.s10'}	drug interaction studies recommended clinical dose montelukast clinically important effects pharmacokinetics following drugs theophylline prednisone prednisolone oral contraceptives norethindrone NUMBER mg / ethinyl estradiol NUMBER mcg terfenadine digoxin warfarin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. 	contraceptives	terfenadine	none	{'e1': {'word': 'contraceptives', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d739.s10.e4'}, 'e2': {'word': 'terfenadine', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d739.s10.e7'}, 'sentence_id': 'DDI-DrugBank.d739.s10'}	drug interaction studies recommended clinical dose montelukast clinically important effects pharmacokinetics following drugs theophylline prednisone prednisolone oral contraceptives norethindrone NUMBER mg / ethinyl estradiol NUMBER mcg terfenadine digoxin warfarin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. 	contraceptives	digoxin	none	{'e1': {'word': 'contraceptives', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d739.s10.e4'}, 'e2': {'word': 'digoxin', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d739.s10.e8'}, 'sentence_id': 'DDI-DrugBank.d739.s10'}	drug interaction studies recommended clinical dose montelukast clinically important effects pharmacokinetics following drugs theophylline prednisone prednisolone oral contraceptives norethindrone NUMBER mg / ethinyl estradiol NUMBER mcg terfenadine digoxin warfarin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. 	contraceptives	warfarin	none	{'e1': {'word': 'contraceptives', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d739.s10.e4'}, 'e2': {'word': 'warfarin', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d739.s10.e9'}, 'sentence_id': 'DDI-DrugBank.d739.s10'}	drug interaction studies recommended clinical dose montelukast clinically important effects pharmacokinetics following drugs theophylline prednisone prednisolone oral contraceptives norethindrone NUMBER mg / ethinyl estradiol NUMBER mcg terfenadine digoxin warfarin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. 	norethindrone	ethinyl estradiol	none	{'e1': {'word': 'norethindrone', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d739.s10.e5'}, 'e2': {'word': 'ethinyl estradiol', 'word_index': [(22, 23)], 'id': 'DDI-DrugBank.d739.s10.e6'}, 'sentence_id': 'DDI-DrugBank.d739.s10'}	drug interaction studies recommended clinical dose montelukast clinically important effects pharmacokinetics following drugs theophylline prednisone prednisolone oral contraceptives norethindrone NUMBER mg / ethinyl estradiol NUMBER mcg terfenadine digoxin warfarin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. 	norethindrone	terfenadine	none	{'e1': {'word': 'norethindrone', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d739.s10.e5'}, 'e2': {'word': 'terfenadine', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d739.s10.e7'}, 'sentence_id': 'DDI-DrugBank.d739.s10'}	drug interaction studies recommended clinical dose montelukast clinically important effects pharmacokinetics following drugs theophylline prednisone prednisolone oral contraceptives norethindrone NUMBER mg / ethinyl estradiol NUMBER mcg terfenadine digoxin warfarin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. 	norethindrone	digoxin	none	{'e1': {'word': 'norethindrone', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d739.s10.e5'}, 'e2': {'word': 'digoxin', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d739.s10.e8'}, 'sentence_id': 'DDI-DrugBank.d739.s10'}	drug interaction studies recommended clinical dose montelukast clinically important effects pharmacokinetics following drugs theophylline prednisone prednisolone oral contraceptives norethindrone NUMBER mg / ethinyl estradiol NUMBER mcg terfenadine digoxin warfarin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. 	norethindrone	warfarin	none	{'e1': {'word': 'norethindrone', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d739.s10.e5'}, 'e2': {'word': 'warfarin', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d739.s10.e9'}, 'sentence_id': 'DDI-DrugBank.d739.s10'}	drug interaction studies recommended clinical dose montelukast clinically important effects pharmacokinetics following drugs theophylline prednisone prednisolone oral contraceptives norethindrone NUMBER mg / ethinyl estradiol NUMBER mcg terfenadine digoxin warfarin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. 	ethinyl estradiol	terfenadine	none	{'e1': {'word': 'ethinyl estradiol', 'word_index': [(22, 23)], 'id': 'DDI-DrugBank.d739.s10.e6'}, 'e2': {'word': 'terfenadine', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d739.s10.e7'}, 'sentence_id': 'DDI-DrugBank.d739.s10'}	drug interaction studies recommended clinical dose montelukast clinically important effects pharmacokinetics following drugs theophylline prednisone prednisolone oral contraceptives norethindrone NUMBER mg / ethinyl estradiol NUMBER mcg terfenadine digoxin warfarin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. 	ethinyl estradiol	digoxin	none	{'e1': {'word': 'ethinyl estradiol', 'word_index': [(22, 23)], 'id': 'DDI-DrugBank.d739.s10.e6'}, 'e2': {'word': 'digoxin', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d739.s10.e8'}, 'sentence_id': 'DDI-DrugBank.d739.s10'}	drug interaction studies recommended clinical dose montelukast clinically important effects pharmacokinetics following drugs theophylline prednisone prednisolone oral contraceptives norethindrone NUMBER mg / ethinyl estradiol NUMBER mcg terfenadine digoxin warfarin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. 	ethinyl estradiol	warfarin	none	{'e1': {'word': 'ethinyl estradiol', 'word_index': [(22, 23)], 'id': 'DDI-DrugBank.d739.s10.e6'}, 'e2': {'word': 'warfarin', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d739.s10.e9'}, 'sentence_id': 'DDI-DrugBank.d739.s10'}	drug interaction studies recommended clinical dose montelukast clinically important effects pharmacokinetics following drugs theophylline prednisone prednisolone oral contraceptives norethindrone NUMBER mg / ethinyl estradiol NUMBER mcg terfenadine digoxin warfarin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. 	terfenadine	digoxin	none	{'e1': {'word': 'terfenadine', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d739.s10.e7'}, 'e2': {'word': 'digoxin', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d739.s10.e8'}, 'sentence_id': 'DDI-DrugBank.d739.s10'}	drug interaction studies recommended clinical dose montelukast clinically important effects pharmacokinetics following drugs theophylline prednisone prednisolone oral contraceptives norethindrone NUMBER mg / ethinyl estradiol NUMBER mcg terfenadine digoxin warfarin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. 	terfenadine	warfarin	none	{'e1': {'word': 'terfenadine', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d739.s10.e7'}, 'e2': {'word': 'warfarin', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d739.s10.e9'}, 'sentence_id': 'DDI-DrugBank.d739.s10'}	drug interaction studies recommended clinical dose montelukast clinically important effects pharmacokinetics following drugs theophylline prednisone prednisolone oral contraceptives norethindrone NUMBER mg / ethinyl estradiol NUMBER mcg terfenadine digoxin warfarin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. 	digoxin	warfarin	none	{'e1': {'word': 'digoxin', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d739.s10.e8'}, 'e2': {'word': 'warfarin', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d739.s10.e9'}, 'sentence_id': 'DDI-DrugBank.d739.s10'}	drug interaction studies recommended clinical dose montelukast clinically important effects pharmacokinetics following drugs theophylline prednisone prednisolone oral contraceptives norethindrone NUMBER mg / ethinyl estradiol NUMBER mcg terfenadine digoxin warfarin
These medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants. 	thyroid hormones	sedative hypnotics	none	{'e1': {'word': 'thyroid hormones', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d739.s12.e0'}, 'e2': {'word': 'sedative hypnotics', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d739.s12.e1'}, 'sentence_id': 'DDI-DrugBank.d739.s12'}	medications included thyroid hormones sedative hypnotics non-steroidal anti-inflammatory agents benzodiazepines decongestants
These medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants. 	thyroid hormones	non-steroidal anti-inflammatory agents	none	{'e1': {'word': 'thyroid hormones', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d739.s12.e0'}, 'e2': {'word': 'non-steroidal anti-inflammatory agents', 'word_index': [(6, 8)], 'id': 'DDI-DrugBank.d739.s12.e2'}, 'sentence_id': 'DDI-DrugBank.d739.s12'}	medications included thyroid hormones sedative hypnotics non-steroidal anti-inflammatory agents benzodiazepines decongestants
These medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants. 	thyroid hormones	benzodiazepines	none	{'e1': {'word': 'thyroid hormones', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d739.s12.e0'}, 'e2': {'word': 'benzodiazepines', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d739.s12.e3'}, 'sentence_id': 'DDI-DrugBank.d739.s12'}	medications included thyroid hormones sedative hypnotics non-steroidal anti-inflammatory agents benzodiazepines decongestants
These medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants. 	thyroid hormones	decongestants	none	{'e1': {'word': 'thyroid hormones', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d739.s12.e0'}, 'e2': {'word': 'decongestants', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d739.s12.e4'}, 'sentence_id': 'DDI-DrugBank.d739.s12'}	medications included thyroid hormones sedative hypnotics non-steroidal anti-inflammatory agents benzodiazepines decongestants
These medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants. 	sedative hypnotics	non-steroidal anti-inflammatory agents	none	{'e1': {'word': 'sedative hypnotics', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d739.s12.e1'}, 'e2': {'word': 'non-steroidal anti-inflammatory agents', 'word_index': [(6, 8)], 'id': 'DDI-DrugBank.d739.s12.e2'}, 'sentence_id': 'DDI-DrugBank.d739.s12'}	medications included thyroid hormones sedative hypnotics non-steroidal anti-inflammatory agents benzodiazepines decongestants
These medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants. 	sedative hypnotics	benzodiazepines	none	{'e1': {'word': 'sedative hypnotics', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d739.s12.e1'}, 'e2': {'word': 'benzodiazepines', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d739.s12.e3'}, 'sentence_id': 'DDI-DrugBank.d739.s12'}	medications included thyroid hormones sedative hypnotics non-steroidal anti-inflammatory agents benzodiazepines decongestants
These medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants. 	sedative hypnotics	decongestants	none	{'e1': {'word': 'sedative hypnotics', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d739.s12.e1'}, 'e2': {'word': 'decongestants', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d739.s12.e4'}, 'sentence_id': 'DDI-DrugBank.d739.s12'}	medications included thyroid hormones sedative hypnotics non-steroidal anti-inflammatory agents benzodiazepines decongestants
These medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants. 	non-steroidal anti-inflammatory agents	benzodiazepines	none	{'e1': {'word': 'non-steroidal anti-inflammatory agents', 'word_index': [(6, 8)], 'id': 'DDI-DrugBank.d739.s12.e2'}, 'e2': {'word': 'benzodiazepines', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d739.s12.e3'}, 'sentence_id': 'DDI-DrugBank.d739.s12'}	medications included thyroid hormones sedative hypnotics non-steroidal anti-inflammatory agents benzodiazepines decongestants
These medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants. 	non-steroidal anti-inflammatory agents	decongestants	none	{'e1': {'word': 'non-steroidal anti-inflammatory agents', 'word_index': [(6, 8)], 'id': 'DDI-DrugBank.d739.s12.e2'}, 'e2': {'word': 'decongestants', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d739.s12.e4'}, 'sentence_id': 'DDI-DrugBank.d739.s12'}	medications included thyroid hormones sedative hypnotics non-steroidal anti-inflammatory agents benzodiazepines decongestants
These medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants. 	benzodiazepines	decongestants	none	{'e1': {'word': 'benzodiazepines', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d739.s12.e3'}, 'e2': {'word': 'decongestants', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d739.s12.e4'}, 'sentence_id': 'DDI-DrugBank.d739.s12'}	medications included thyroid hormones sedative hypnotics non-steroidal anti-inflammatory agents benzodiazepines decongestants
Phenobarbital, which induces hepatic metabolism, decreased the AUC of montelukast approximately 40% following a single 10-mg dose of montelukast. 	Phenobarbital	montelukast	none	{'e1': {'word': 'Phenobarbital', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d739.s13.e0'}, 'e2': {'word': 'montelukast', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d739.s13.e1'}, 'sentence_id': 'DDI-DrugBank.d739.s13'}	Phenobarbital induces hepatic metabolism decreased AUC montelukast approximately NUMBER % following single NUMBER mg dose montelukast
Phenobarbital, which induces hepatic metabolism, decreased the AUC of montelukast approximately 40% following a single 10-mg dose of montelukast. 	Phenobarbital	montelukast	none	{'e1': {'word': 'Phenobarbital', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d739.s13.e0'}, 'e2': {'word': 'montelukast', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d739.s13.e2'}, 'sentence_id': 'DDI-DrugBank.d739.s13'}	Phenobarbital induces hepatic metabolism decreased AUC montelukast approximately NUMBER % following single NUMBER mg dose montelukast
Phenobarbital, which induces hepatic metabolism, decreased the AUC of montelukast approximately 40% following a single 10-mg dose of montelukast. 	montelukast	montelukast	none	{'e1': {'word': 'montelukast', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d739.s13.e1'}, 'e2': {'word': 'montelukast', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d739.s13.e2'}, 'sentence_id': 'DDI-DrugBank.d739.s13'}	Phenobarbital induces hepatic metabolism decreased AUC montelukast approximately NUMBER % following single NUMBER mg dose montelukast
It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast.	phenobarbital	rifampin	none	{'e1': {'word': 'phenobarbital', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d739.s15.e0'}, 'e2': {'word': 'rifampin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d739.s15.e1'}, 'sentence_id': 'DDI-DrugBank.d739.s15'}	reasonable employ appropriate clinical monitoring potent cytochrome P450 enzyme inducers phenobarbital rifampin co-administered montelukast
It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast.	phenobarbital	montelukast	advise	{'e1': {'word': 'phenobarbital', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d739.s15.e0'}, 'e2': {'word': 'montelukast', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d739.s15.e2'}, 'sentence_id': 'DDI-DrugBank.d739.s15'}	reasonable employ appropriate clinical monitoring potent cytochrome P450 enzyme inducers phenobarbital rifampin co-administered montelukast
It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast.	rifampin	montelukast	advise	{'e1': {'word': 'rifampin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d739.s15.e1'}, 'e2': {'word': 'montelukast', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d739.s15.e2'}, 'sentence_id': 'DDI-DrugBank.d739.s15'}	reasonable employ appropriate clinical monitoring potent cytochrome P450 enzyme inducers phenobarbital rifampin co-administered montelukast
Vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all. 	Vasopressors	metaraminol	none	{'e1': {'word': 'Vasopressors', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d689.s0.e0'}, 'e2': {'word': 'metaraminol', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d689.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d689.s0'}	Vasopressors particularly metaraminol may cause serious cardiac arrhythmias halothane anesthesia therefore used great caution
Vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all. 	Vasopressors	halothane	effect	{'e1': {'word': 'Vasopressors', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d689.s0.e0'}, 'e2': {'word': 'halothane', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d689.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d689.s0'}	Vasopressors particularly metaraminol may cause serious cardiac arrhythmias halothane anesthesia therefore used great caution
Vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all. 	metaraminol	halothane	effect	{'e1': {'word': 'metaraminol', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d689.s0.e1'}, 'e2': {'word': 'halothane', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d689.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d689.s0'}	Vasopressors particularly metaraminol may cause serious cardiac arrhythmias halothane anesthesia therefore used great caution
MAO Inhibitors - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). 	MAO Inhibitors	sympathomimetic pressor amines	none	{'e1': {'word': 'MAO Inhibitors', 'word_index': [(0, 1)], 'id': 'DDI-DrugBank.d689.s1.e0'}, 'e2': {'word': 'sympathomimetic pressor amines', 'word_index': [(4, 6)], 'id': 'DDI-DrugBank.d689.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d689.s1'}	MAO Inhibitors pressor effect sympathomimetic pressor amines markedly potentiated patients receiving monoamine oxidase inhibitors MAOI
MAO Inhibitors - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). 	MAO Inhibitors	monoamine oxidase inhibitors	none	{'e1': {'word': 'MAO Inhibitors', 'word_index': [(0, 1)], 'id': 'DDI-DrugBank.d689.s1.e0'}, 'e2': {'word': 'monoamine oxidase inhibitors', 'word_index': [(11, 13)], 'id': 'DDI-DrugBank.d689.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d689.s1'}	MAO Inhibitors pressor effect sympathomimetic pressor amines markedly potentiated patients receiving monoamine oxidase inhibitors MAOI
MAO Inhibitors - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). 	MAO Inhibitors	MAOI	none	{'e1': {'word': 'MAO Inhibitors', 'word_index': [(0, 1)], 'id': 'DDI-DrugBank.d689.s1.e0'}, 'e2': {'word': 'MAOI', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d689.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d689.s1'}	MAO Inhibitors pressor effect sympathomimetic pressor amines markedly potentiated patients receiving monoamine oxidase inhibitors MAOI
MAO Inhibitors - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). 	sympathomimetic pressor amines	monoamine oxidase inhibitors	effect	{'e1': {'word': 'sympathomimetic pressor amines', 'word_index': [(4, 6)], 'id': 'DDI-DrugBank.d689.s1.e1'}, 'e2': {'word': 'monoamine oxidase inhibitors', 'word_index': [(11, 13)], 'id': 'DDI-DrugBank.d689.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d689.s1'}	MAO Inhibitors pressor effect sympathomimetic pressor amines markedly potentiated patients receiving monoamine oxidase inhibitors MAOI
MAO Inhibitors - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). 	sympathomimetic pressor amines	MAOI	effect	{'e1': {'word': 'sympathomimetic pressor amines', 'word_index': [(4, 6)], 'id': 'DDI-DrugBank.d689.s1.e1'}, 'e2': {'word': 'MAOI', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d689.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d689.s1'}	MAO Inhibitors pressor effect sympathomimetic pressor amines markedly potentiated patients receiving monoamine oxidase inhibitors MAOI
MAO Inhibitors - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). 	monoamine oxidase inhibitors	MAOI	none	{'e1': {'word': 'monoamine oxidase inhibitors', 'word_index': [(11, 13)], 'id': 'DDI-DrugBank.d689.s1.e2'}, 'e2': {'word': 'MAOI', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d689.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d689.s1'}	MAO Inhibitors pressor effect sympathomimetic pressor amines markedly potentiated patients receiving monoamine oxidase inhibitors MAOI
The pressor response of adrenergic agents may also be potentiated by tricyclic antidepressants.	adrenergic agents	tricyclic antidepressants	effect	{'e1': {'word': 'adrenergic agents', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d689.s3.e0'}, 'e2': {'word': 'tricyclic antidepressants', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d689.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d689.s3'}	pressor response adrenergic agents may also potentiated tricyclic antidepressants
Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) 	Phenothiazines	CNS depressants	effect	{'e1': {'word': 'Phenothiazines', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d677.s0.e0'}, 'e2': {'word': 'CNS depressants', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d677.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d677.s0'}	Phenothiazines capable potentiating CNS depressants e.g. barbiturates anesthetics opiates alcohol etc.
Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) 	Phenothiazines	barbiturates	effect	{'e1': {'word': 'Phenothiazines', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d677.s0.e0'}, 'e2': {'word': 'barbiturates', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d677.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d677.s0'}	Phenothiazines capable potentiating CNS depressants e.g. barbiturates anesthetics opiates alcohol etc.
Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) 	Phenothiazines	anesthetics	effect	{'e1': {'word': 'Phenothiazines', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d677.s0.e0'}, 'e2': {'word': 'anesthetics', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d677.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d677.s0'}	Phenothiazines capable potentiating CNS depressants e.g. barbiturates anesthetics opiates alcohol etc.
Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) 	Phenothiazines	opiates	effect	{'e1': {'word': 'Phenothiazines', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d677.s0.e0'}, 'e2': {'word': 'opiates', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d677.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d677.s0'}	Phenothiazines capable potentiating CNS depressants e.g. barbiturates anesthetics opiates alcohol etc.
Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) 	Phenothiazines	alcohol	effect	{'e1': {'word': 'Phenothiazines', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d677.s0.e0'}, 'e2': {'word': 'alcohol', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d677.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d677.s0'}	Phenothiazines capable potentiating CNS depressants e.g. barbiturates anesthetics opiates alcohol etc.
Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) 	CNS depressants	barbiturates	none	{'e1': {'word': 'CNS depressants', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d677.s0.e1'}, 'e2': {'word': 'barbiturates', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d677.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d677.s0'}	Phenothiazines capable potentiating CNS depressants e.g. barbiturates anesthetics opiates alcohol etc.
Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) 	CNS depressants	anesthetics	none	{'e1': {'word': 'CNS depressants', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d677.s0.e1'}, 'e2': {'word': 'anesthetics', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d677.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d677.s0'}	Phenothiazines capable potentiating CNS depressants e.g. barbiturates anesthetics opiates alcohol etc.
Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) 	CNS depressants	opiates	none	{'e1': {'word': 'CNS depressants', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d677.s0.e1'}, 'e2': {'word': 'opiates', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d677.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d677.s0'}	Phenothiazines capable potentiating CNS depressants e.g. barbiturates anesthetics opiates alcohol etc.
Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) 	CNS depressants	alcohol	none	{'e1': {'word': 'CNS depressants', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d677.s0.e1'}, 'e2': {'word': 'alcohol', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d677.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d677.s0'}	Phenothiazines capable potentiating CNS depressants e.g. barbiturates anesthetics opiates alcohol etc.
Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) 	barbiturates	anesthetics	none	{'e1': {'word': 'barbiturates', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d677.s0.e2'}, 'e2': {'word': 'anesthetics', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d677.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d677.s0'}	Phenothiazines capable potentiating CNS depressants e.g. barbiturates anesthetics opiates alcohol etc.
Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) 	barbiturates	opiates	none	{'e1': {'word': 'barbiturates', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d677.s0.e2'}, 'e2': {'word': 'opiates', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d677.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d677.s0'}	Phenothiazines capable potentiating CNS depressants e.g. barbiturates anesthetics opiates alcohol etc.
Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) 	barbiturates	alcohol	none	{'e1': {'word': 'barbiturates', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d677.s0.e2'}, 'e2': {'word': 'alcohol', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d677.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d677.s0'}	Phenothiazines capable potentiating CNS depressants e.g. barbiturates anesthetics opiates alcohol etc.
Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) 	anesthetics	opiates	none	{'e1': {'word': 'anesthetics', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d677.s0.e3'}, 'e2': {'word': 'opiates', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d677.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d677.s0'}	Phenothiazines capable potentiating CNS depressants e.g. barbiturates anesthetics opiates alcohol etc.
Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) 	anesthetics	alcohol	none	{'e1': {'word': 'anesthetics', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d677.s0.e3'}, 'e2': {'word': 'alcohol', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d677.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d677.s0'}	Phenothiazines capable potentiating CNS depressants e.g. barbiturates anesthetics opiates alcohol etc.
Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) 	opiates	alcohol	none	{'e1': {'word': 'opiates', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d677.s0.e4'}, 'e2': {'word': 'alcohol', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d677.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d677.s0'}	Phenothiazines capable potentiating CNS depressants e.g. barbiturates anesthetics opiates alcohol etc.
as well as atropine and phosphorous insecticides.	atropine	phosphorous insecticides	none	{'e1': {'word': 'atropine', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d677.s1.e0'}, 'e2': {'word': 'phosphorous insecticides', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d677.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d677.s1'}	well atropine phosphorous insecticides
Ropivacaine should be used with caution in patients receiving other local anesthetics or agents structurally related to amide-type local anesthetics, since the toxic effects of these drugs are additive. 	Ropivacaine	anesthetics	advise	{'e1': {'word': 'Ropivacaine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d591.s0.e0'}, 'e2': {'word': 'anesthetics', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d591.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d591.s0'}	Ropivacaine used caution patients receiving local anesthetics agents structurally related amide type local anesthetics since toxic effects drugs additive
Ropivacaine should be used with caution in patients receiving other local anesthetics or agents structurally related to amide-type local anesthetics, since the toxic effects of these drugs are additive. 	Ropivacaine	amide-type local anesthetics	none	{'e1': {'word': 'Ropivacaine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d591.s0.e0'}, 'e2': {'word': 'amide-type local anesthetics', 'word_index': [(10, 13)], 'id': 'DDI-DrugBank.d591.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d591.s0'}	Ropivacaine used caution patients receiving local anesthetics agents structurally related amide type local anesthetics since toxic effects drugs additive
Ropivacaine should be used with caution in patients receiving other local anesthetics or agents structurally related to amide-type local anesthetics, since the toxic effects of these drugs are additive. 	anesthetics	amide-type local anesthetics	none	{'e1': {'word': 'anesthetics', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d591.s0.e1'}, 'e2': {'word': 'amide-type local anesthetics', 'word_index': [(10, 13)], 'id': 'DDI-DrugBank.d591.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d591.s0'}	Ropivacaine used caution patients receiving local anesthetics agents structurally related amide type local anesthetics since toxic effects drugs additive
In vivo, the plasma clearance of ropivacaine was reduced by 70% during coadministration of fluvoxamine (25 mg bid for 2 days), a selective and potent CYP1A2 inhibitor. 	ropivacaine	fluvoxamine	mechanism	{'e1': {'word': 'ropivacaine', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d591.s2.e0'}, 'e2': {'word': 'fluvoxamine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d591.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d591.s2'}	vivo plasma clearance ropivacaine reduced NUMBER % coadministration fluvoxamine NUMBER mg bid NUMBER days selective potent CYP1A2 inhibitor
Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of Ropivacaine, can interact with Ropivacaine leading to increased ropivacaine plasma levels. 	fluvoxamine	Ropivacaine	int	{'e1': {'word': 'fluvoxamine', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d591.s3.e0'}, 'e2': {'word': 'Ropivacaine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d591.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d591.s3'}	Thus strong inhibitors cytochrome P4501A2 fluvoxamine given concomitantly administration Ropivacaine interact Ropivacaine leading increased ropivacaine plasma levels
Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of Ropivacaine, can interact with Ropivacaine leading to increased ropivacaine plasma levels. 	fluvoxamine	Ropivacaine	none	{'e1': {'word': 'fluvoxamine', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d591.s3.e0'}, 'e2': {'word': 'Ropivacaine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d591.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d591.s3'}	Thus strong inhibitors cytochrome P4501A2 fluvoxamine given concomitantly administration Ropivacaine interact Ropivacaine leading increased ropivacaine plasma levels
Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of Ropivacaine, can interact with Ropivacaine leading to increased ropivacaine plasma levels. 	fluvoxamine	ropivacaine	none	{'e1': {'word': 'fluvoxamine', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d591.s3.e0'}, 'e2': {'word': 'ropivacaine', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d591.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d591.s3'}	Thus strong inhibitors cytochrome P4501A2 fluvoxamine given concomitantly administration Ropivacaine interact Ropivacaine leading increased ropivacaine plasma levels
Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of Ropivacaine, can interact with Ropivacaine leading to increased ropivacaine plasma levels. 	Ropivacaine	Ropivacaine	none	{'e1': {'word': 'Ropivacaine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d591.s3.e1'}, 'e2': {'word': 'Ropivacaine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d591.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d591.s3'}	Thus strong inhibitors cytochrome P4501A2 fluvoxamine given concomitantly administration Ropivacaine interact Ropivacaine leading increased ropivacaine plasma levels
Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of Ropivacaine, can interact with Ropivacaine leading to increased ropivacaine plasma levels. 	Ropivacaine	ropivacaine	none	{'e1': {'word': 'Ropivacaine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d591.s3.e1'}, 'e2': {'word': 'ropivacaine', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d591.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d591.s3'}	Thus strong inhibitors cytochrome P4501A2 fluvoxamine given concomitantly administration Ropivacaine interact Ropivacaine leading increased ropivacaine plasma levels
Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of Ropivacaine, can interact with Ropivacaine leading to increased ropivacaine plasma levels. 	Ropivacaine	ropivacaine	none	{'e1': {'word': 'Ropivacaine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d591.s3.e2'}, 'e2': {'word': 'ropivacaine', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d591.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d591.s3'}	Thus strong inhibitors cytochrome P4501A2 fluvoxamine given concomitantly administration Ropivacaine interact Ropivacaine leading increased ropivacaine plasma levels
Possible interactions with drugs known to be metabolized by CYP1A2 via competitive inhibition such as theophylline and imipramine may also occur. 	theophylline	imipramine	none	{'e1': {'word': 'theophylline', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d591.s5.e0'}, 'e2': {'word': 'imipramine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d591.s5.e1'}, 'sentence_id': 'DDI-DrugBank.d591.s5'}	Possible interactions drugs known metabolized CYP1A2 via competitive inhibition theophylline imipramine may also occur
Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.	ketoconazole	ropivacaine	none	{'e1': {'word': 'ketoconazole', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d591.s6.e0'}, 'e2': {'word': 'ropivacaine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d591.s6.e1'}, 'sentence_id': 'DDI-DrugBank.d591.s6'}	Coadministration selective potent inhibitor CYP3A4 ketoconazole NUMBER mg bid NUMBER days ropivacaine infusion administered NUMBER hour ketoconazole caused NUMBER % reduction vivo plasma clearance ropivacaine
Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.	ketoconazole	ketoconazole	none	{'e1': {'word': 'ketoconazole', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d591.s6.e0'}, 'e2': {'word': 'ketoconazole', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d591.s6.e2'}, 'sentence_id': 'DDI-DrugBank.d591.s6'}	Coadministration selective potent inhibitor CYP3A4 ketoconazole NUMBER mg bid NUMBER days ropivacaine infusion administered NUMBER hour ketoconazole caused NUMBER % reduction vivo plasma clearance ropivacaine
Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.	ketoconazole	ropivacaine	mechanism	{'e1': {'word': 'ketoconazole', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d591.s6.e0'}, 'e2': {'word': 'ropivacaine', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d591.s6.e3'}, 'sentence_id': 'DDI-DrugBank.d591.s6'}	Coadministration selective potent inhibitor CYP3A4 ketoconazole NUMBER mg bid NUMBER days ropivacaine infusion administered NUMBER hour ketoconazole caused NUMBER % reduction vivo plasma clearance ropivacaine
Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.	ropivacaine	ketoconazole	none	{'e1': {'word': 'ropivacaine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d591.s6.e1'}, 'e2': {'word': 'ketoconazole', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d591.s6.e2'}, 'sentence_id': 'DDI-DrugBank.d591.s6'}	Coadministration selective potent inhibitor CYP3A4 ketoconazole NUMBER mg bid NUMBER days ropivacaine infusion administered NUMBER hour ketoconazole caused NUMBER % reduction vivo plasma clearance ropivacaine
Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.	ropivacaine	ropivacaine	none	{'e1': {'word': 'ropivacaine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d591.s6.e1'}, 'e2': {'word': 'ropivacaine', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d591.s6.e3'}, 'sentence_id': 'DDI-DrugBank.d591.s6'}	Coadministration selective potent inhibitor CYP3A4 ketoconazole NUMBER mg bid NUMBER days ropivacaine infusion administered NUMBER hour ketoconazole caused NUMBER % reduction vivo plasma clearance ropivacaine
Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.	ketoconazole	ropivacaine	none	{'e1': {'word': 'ketoconazole', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d591.s6.e2'}, 'e2': {'word': 'ropivacaine', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d591.s6.e3'}, 'sentence_id': 'DDI-DrugBank.d591.s6'}	Coadministration selective potent inhibitor CYP3A4 ketoconazole NUMBER mg bid NUMBER days ropivacaine infusion administered NUMBER hour ketoconazole caused NUMBER % reduction vivo plasma clearance ropivacaine
Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin, resulting in a prolongation of prothrombin time. 	metronidazole	coumarin	effect	{'e1': {'word': 'metronidazole', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d629.s0.e0'}, 'e2': {'word': 'coumarin', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d629.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d629.s0'}	Oral metronidazole reported potentiate anticoagulant effect coumarin warfarin resulting prolongation prothrombin time
Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin, resulting in a prolongation of prothrombin time. 	metronidazole	warfarin	effect	{'e1': {'word': 'metronidazole', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d629.s0.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d629.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d629.s0'}	Oral metronidazole reported potentiate anticoagulant effect coumarin warfarin resulting prolongation prothrombin time
Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin, resulting in a prolongation of prothrombin time. 	coumarin	warfarin	none	{'e1': {'word': 'coumarin', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d629.s0.e1'}, 'e2': {'word': 'warfarin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d629.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d629.s0'}	Oral metronidazole reported potentiate anticoagulant effect coumarin warfarin resulting prolongation prothrombin time
Drug interactions should be kept in mind when METROGEL (metronidazole gel), 1% is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical metronidazole administration because of low absorption.    	METROGEL	metronidazole	none	{'e1': {'word': 'METROGEL', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d629.s1.e0'}, 'e2': {'word': 'metronidazole', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d629.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d629.s1'}	Drug interactions kept mind METROGEL metronidazole gel NUMBER % prescribed patients receiving anticoagulant treatment although less likely occur topical metronidazole administration low absorption
Drug interactions should be kept in mind when METROGEL (metronidazole gel), 1% is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical metronidazole administration because of low absorption.    	METROGEL	metronidazole	none	{'e1': {'word': 'METROGEL', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d629.s1.e0'}, 'e2': {'word': 'metronidazole', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d629.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d629.s1'}	Drug interactions kept mind METROGEL metronidazole gel NUMBER % prescribed patients receiving anticoagulant treatment although less likely occur topical metronidazole administration low absorption
Drug interactions should be kept in mind when METROGEL (metronidazole gel), 1% is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical metronidazole administration because of low absorption.    	metronidazole	metronidazole	none	{'e1': {'word': 'metronidazole', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d629.s1.e1'}, 'e2': {'word': 'metronidazole', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d629.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d629.s1'}	Drug interactions kept mind METROGEL metronidazole gel NUMBER % prescribed patients receiving anticoagulant treatment although less likely occur topical metronidazole administration low absorption
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	Melatonin	aspirin	int	{'e1': {'word': 'Melatonin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d643.s0.e0'}, 'e2': {'word': 'aspirin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d643.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	Melatonin	NSAIDs	int	{'e1': {'word': 'Melatonin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d643.s0.e0'}, 'e2': {'word': 'NSAIDs', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d643.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	Melatonin	melatonin	none	{'e1': {'word': 'Melatonin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d643.s0.e0'}, 'e2': {'word': 'melatonin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d643.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	Melatonin	fluvoxamine	int	{'e1': {'word': 'Melatonin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d643.s0.e0'}, 'e2': {'word': 'fluvoxamine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d643.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	Melatonin	melatonin	none	{'e1': {'word': 'Melatonin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d643.s0.e0'}, 'e2': {'word': 'melatonin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d643.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	Melatonin	beta blockers	int	{'e1': {'word': 'Melatonin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d643.s0.e0'}, 'e2': {'word': 'beta blockers', 'word_index': [(17, 18)], 'id': 'DDI-DrugBank.d643.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	Melatonin	melatonin	none	{'e1': {'word': 'Melatonin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d643.s0.e0'}, 'e2': {'word': 'melatonin', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d643.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	Melatonin	fluoxetine	int	{'e1': {'word': 'Melatonin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d643.s0.e0'}, 'e2': {'word': 'fluoxetine', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d643.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	Melatonin	progestin	int	{'e1': {'word': 'Melatonin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d643.s0.e0'}, 'e2': {'word': 'progestin', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d643.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	Melatonin	melatonin	none	{'e1': {'word': 'Melatonin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d643.s0.e0'}, 'e2': {'word': 'melatonin', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d643.s0.e10'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	Melatonin	progestin	none	{'e1': {'word': 'Melatonin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d643.s0.e0'}, 'e2': {'word': 'progestin', 'word_index': [(31, 31)], 'id': 'DDI-DrugBank.d643.s0.e11'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	Melatonin	benzodiazepenes	int	{'e1': {'word': 'Melatonin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d643.s0.e0'}, 'e2': {'word': 'benzodiazepenes', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d643.s0.e12'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	Melatonin	corticosteroids	int	{'e1': {'word': 'Melatonin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d643.s0.e0'}, 'e2': {'word': 'corticosteroids', 'word_index': [(47, 47)], 'id': 'DDI-DrugBank.d643.s0.e13'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	Melatonin	melatonin	none	{'e1': {'word': 'Melatonin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d643.s0.e0'}, 'e2': {'word': 'melatonin', 'word_index': [(49, 49)], 'id': 'DDI-DrugBank.d643.s0.e14'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	Melatonin	corticosteroids	none	{'e1': {'word': 'Melatonin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d643.s0.e0'}, 'e2': {'word': 'corticosteroids', 'word_index': [(50, 50)], 'id': 'DDI-DrugBank.d643.s0.e15'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	Melatonin	corticosteroids	none	{'e1': {'word': 'Melatonin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d643.s0.e0'}, 'e2': {'word': 'corticosteroids', 'word_index': [(54, 54)], 'id': 'DDI-DrugBank.d643.s0.e16'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	aspirin	NSAIDs	none	{'e1': {'word': 'aspirin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d643.s0.e1'}, 'e2': {'word': 'NSAIDs', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d643.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	aspirin	melatonin	none	{'e1': {'word': 'aspirin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d643.s0.e1'}, 'e2': {'word': 'melatonin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d643.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	aspirin	fluvoxamine	none	{'e1': {'word': 'aspirin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d643.s0.e1'}, 'e2': {'word': 'fluvoxamine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d643.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	aspirin	melatonin	none	{'e1': {'word': 'aspirin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d643.s0.e1'}, 'e2': {'word': 'melatonin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d643.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	aspirin	beta blockers	none	{'e1': {'word': 'aspirin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d643.s0.e1'}, 'e2': {'word': 'beta blockers', 'word_index': [(17, 18)], 'id': 'DDI-DrugBank.d643.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	aspirin	melatonin	none	{'e1': {'word': 'aspirin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d643.s0.e1'}, 'e2': {'word': 'melatonin', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d643.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	aspirin	fluoxetine	none	{'e1': {'word': 'aspirin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d643.s0.e1'}, 'e2': {'word': 'fluoxetine', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d643.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	aspirin	progestin	none	{'e1': {'word': 'aspirin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d643.s0.e1'}, 'e2': {'word': 'progestin', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d643.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	aspirin	melatonin	none	{'e1': {'word': 'aspirin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d643.s0.e1'}, 'e2': {'word': 'melatonin', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d643.s0.e10'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	aspirin	progestin	none	{'e1': {'word': 'aspirin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d643.s0.e1'}, 'e2': {'word': 'progestin', 'word_index': [(31, 31)], 'id': 'DDI-DrugBank.d643.s0.e11'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	aspirin	benzodiazepenes	none	{'e1': {'word': 'aspirin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d643.s0.e1'}, 'e2': {'word': 'benzodiazepenes', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d643.s0.e12'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	aspirin	corticosteroids	none	{'e1': {'word': 'aspirin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d643.s0.e1'}, 'e2': {'word': 'corticosteroids', 'word_index': [(47, 47)], 'id': 'DDI-DrugBank.d643.s0.e13'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	aspirin	melatonin	none	{'e1': {'word': 'aspirin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d643.s0.e1'}, 'e2': {'word': 'melatonin', 'word_index': [(49, 49)], 'id': 'DDI-DrugBank.d643.s0.e14'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	aspirin	corticosteroids	none	{'e1': {'word': 'aspirin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d643.s0.e1'}, 'e2': {'word': 'corticosteroids', 'word_index': [(50, 50)], 'id': 'DDI-DrugBank.d643.s0.e15'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	aspirin	corticosteroids	none	{'e1': {'word': 'aspirin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d643.s0.e1'}, 'e2': {'word': 'corticosteroids', 'word_index': [(54, 54)], 'id': 'DDI-DrugBank.d643.s0.e16'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	NSAIDs	melatonin	none	{'e1': {'word': 'NSAIDs', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d643.s0.e2'}, 'e2': {'word': 'melatonin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d643.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	NSAIDs	fluvoxamine	none	{'e1': {'word': 'NSAIDs', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d643.s0.e2'}, 'e2': {'word': 'fluvoxamine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d643.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	NSAIDs	melatonin	none	{'e1': {'word': 'NSAIDs', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d643.s0.e2'}, 'e2': {'word': 'melatonin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d643.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	NSAIDs	beta blockers	none	{'e1': {'word': 'NSAIDs', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d643.s0.e2'}, 'e2': {'word': 'beta blockers', 'word_index': [(17, 18)], 'id': 'DDI-DrugBank.d643.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	NSAIDs	melatonin	none	{'e1': {'word': 'NSAIDs', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d643.s0.e2'}, 'e2': {'word': 'melatonin', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d643.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	NSAIDs	fluoxetine	none	{'e1': {'word': 'NSAIDs', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d643.s0.e2'}, 'e2': {'word': 'fluoxetine', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d643.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	NSAIDs	progestin	none	{'e1': {'word': 'NSAIDs', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d643.s0.e2'}, 'e2': {'word': 'progestin', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d643.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	NSAIDs	melatonin	none	{'e1': {'word': 'NSAIDs', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d643.s0.e2'}, 'e2': {'word': 'melatonin', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d643.s0.e10'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	NSAIDs	progestin	none	{'e1': {'word': 'NSAIDs', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d643.s0.e2'}, 'e2': {'word': 'progestin', 'word_index': [(31, 31)], 'id': 'DDI-DrugBank.d643.s0.e11'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	NSAIDs	benzodiazepenes	none	{'e1': {'word': 'NSAIDs', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d643.s0.e2'}, 'e2': {'word': 'benzodiazepenes', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d643.s0.e12'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	NSAIDs	corticosteroids	none	{'e1': {'word': 'NSAIDs', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d643.s0.e2'}, 'e2': {'word': 'corticosteroids', 'word_index': [(47, 47)], 'id': 'DDI-DrugBank.d643.s0.e13'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	NSAIDs	melatonin	none	{'e1': {'word': 'NSAIDs', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d643.s0.e2'}, 'e2': {'word': 'melatonin', 'word_index': [(49, 49)], 'id': 'DDI-DrugBank.d643.s0.e14'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	NSAIDs	corticosteroids	none	{'e1': {'word': 'NSAIDs', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d643.s0.e2'}, 'e2': {'word': 'corticosteroids', 'word_index': [(50, 50)], 'id': 'DDI-DrugBank.d643.s0.e15'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	NSAIDs	corticosteroids	none	{'e1': {'word': 'NSAIDs', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d643.s0.e2'}, 'e2': {'word': 'corticosteroids', 'word_index': [(54, 54)], 'id': 'DDI-DrugBank.d643.s0.e16'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	fluvoxamine	none	{'e1': {'word': 'melatonin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d643.s0.e3'}, 'e2': {'word': 'fluvoxamine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d643.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	melatonin	none	{'e1': {'word': 'melatonin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d643.s0.e3'}, 'e2': {'word': 'melatonin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d643.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	beta blockers	none	{'e1': {'word': 'melatonin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d643.s0.e3'}, 'e2': {'word': 'beta blockers', 'word_index': [(17, 18)], 'id': 'DDI-DrugBank.d643.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	melatonin	none	{'e1': {'word': 'melatonin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d643.s0.e3'}, 'e2': {'word': 'melatonin', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d643.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	fluoxetine	none	{'e1': {'word': 'melatonin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d643.s0.e3'}, 'e2': {'word': 'fluoxetine', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d643.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	progestin	none	{'e1': {'word': 'melatonin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d643.s0.e3'}, 'e2': {'word': 'progestin', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d643.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	melatonin	none	{'e1': {'word': 'melatonin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d643.s0.e3'}, 'e2': {'word': 'melatonin', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d643.s0.e10'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	progestin	none	{'e1': {'word': 'melatonin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d643.s0.e3'}, 'e2': {'word': 'progestin', 'word_index': [(31, 31)], 'id': 'DDI-DrugBank.d643.s0.e11'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	benzodiazepenes	none	{'e1': {'word': 'melatonin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d643.s0.e3'}, 'e2': {'word': 'benzodiazepenes', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d643.s0.e12'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	corticosteroids	none	{'e1': {'word': 'melatonin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d643.s0.e3'}, 'e2': {'word': 'corticosteroids', 'word_index': [(47, 47)], 'id': 'DDI-DrugBank.d643.s0.e13'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	melatonin	none	{'e1': {'word': 'melatonin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d643.s0.e3'}, 'e2': {'word': 'melatonin', 'word_index': [(49, 49)], 'id': 'DDI-DrugBank.d643.s0.e14'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	corticosteroids	none	{'e1': {'word': 'melatonin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d643.s0.e3'}, 'e2': {'word': 'corticosteroids', 'word_index': [(50, 50)], 'id': 'DDI-DrugBank.d643.s0.e15'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	corticosteroids	none	{'e1': {'word': 'melatonin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d643.s0.e3'}, 'e2': {'word': 'corticosteroids', 'word_index': [(54, 54)], 'id': 'DDI-DrugBank.d643.s0.e16'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	fluvoxamine	melatonin	none	{'e1': {'word': 'fluvoxamine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d643.s0.e4'}, 'e2': {'word': 'melatonin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d643.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	fluvoxamine	beta blockers	none	{'e1': {'word': 'fluvoxamine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d643.s0.e4'}, 'e2': {'word': 'beta blockers', 'word_index': [(17, 18)], 'id': 'DDI-DrugBank.d643.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	fluvoxamine	melatonin	none	{'e1': {'word': 'fluvoxamine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d643.s0.e4'}, 'e2': {'word': 'melatonin', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d643.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	fluvoxamine	fluoxetine	none	{'e1': {'word': 'fluvoxamine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d643.s0.e4'}, 'e2': {'word': 'fluoxetine', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d643.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	fluvoxamine	progestin	none	{'e1': {'word': 'fluvoxamine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d643.s0.e4'}, 'e2': {'word': 'progestin', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d643.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	fluvoxamine	melatonin	none	{'e1': {'word': 'fluvoxamine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d643.s0.e4'}, 'e2': {'word': 'melatonin', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d643.s0.e10'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	fluvoxamine	progestin	none	{'e1': {'word': 'fluvoxamine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d643.s0.e4'}, 'e2': {'word': 'progestin', 'word_index': [(31, 31)], 'id': 'DDI-DrugBank.d643.s0.e11'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	fluvoxamine	benzodiazepenes	none	{'e1': {'word': 'fluvoxamine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d643.s0.e4'}, 'e2': {'word': 'benzodiazepenes', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d643.s0.e12'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	fluvoxamine	corticosteroids	none	{'e1': {'word': 'fluvoxamine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d643.s0.e4'}, 'e2': {'word': 'corticosteroids', 'word_index': [(47, 47)], 'id': 'DDI-DrugBank.d643.s0.e13'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	fluvoxamine	melatonin	none	{'e1': {'word': 'fluvoxamine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d643.s0.e4'}, 'e2': {'word': 'melatonin', 'word_index': [(49, 49)], 'id': 'DDI-DrugBank.d643.s0.e14'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	fluvoxamine	corticosteroids	none	{'e1': {'word': 'fluvoxamine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d643.s0.e4'}, 'e2': {'word': 'corticosteroids', 'word_index': [(50, 50)], 'id': 'DDI-DrugBank.d643.s0.e15'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	fluvoxamine	corticosteroids	none	{'e1': {'word': 'fluvoxamine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d643.s0.e4'}, 'e2': {'word': 'corticosteroids', 'word_index': [(54, 54)], 'id': 'DDI-DrugBank.d643.s0.e16'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	beta blockers	none	{'e1': {'word': 'melatonin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d643.s0.e5'}, 'e2': {'word': 'beta blockers', 'word_index': [(17, 18)], 'id': 'DDI-DrugBank.d643.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	melatonin	none	{'e1': {'word': 'melatonin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d643.s0.e5'}, 'e2': {'word': 'melatonin', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d643.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	fluoxetine	none	{'e1': {'word': 'melatonin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d643.s0.e5'}, 'e2': {'word': 'fluoxetine', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d643.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	progestin	none	{'e1': {'word': 'melatonin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d643.s0.e5'}, 'e2': {'word': 'progestin', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d643.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	melatonin	none	{'e1': {'word': 'melatonin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d643.s0.e5'}, 'e2': {'word': 'melatonin', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d643.s0.e10'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	progestin	none	{'e1': {'word': 'melatonin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d643.s0.e5'}, 'e2': {'word': 'progestin', 'word_index': [(31, 31)], 'id': 'DDI-DrugBank.d643.s0.e11'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	benzodiazepenes	none	{'e1': {'word': 'melatonin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d643.s0.e5'}, 'e2': {'word': 'benzodiazepenes', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d643.s0.e12'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	corticosteroids	none	{'e1': {'word': 'melatonin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d643.s0.e5'}, 'e2': {'word': 'corticosteroids', 'word_index': [(47, 47)], 'id': 'DDI-DrugBank.d643.s0.e13'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	melatonin	none	{'e1': {'word': 'melatonin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d643.s0.e5'}, 'e2': {'word': 'melatonin', 'word_index': [(49, 49)], 'id': 'DDI-DrugBank.d643.s0.e14'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	corticosteroids	none	{'e1': {'word': 'melatonin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d643.s0.e5'}, 'e2': {'word': 'corticosteroids', 'word_index': [(50, 50)], 'id': 'DDI-DrugBank.d643.s0.e15'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	corticosteroids	none	{'e1': {'word': 'melatonin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d643.s0.e5'}, 'e2': {'word': 'corticosteroids', 'word_index': [(54, 54)], 'id': 'DDI-DrugBank.d643.s0.e16'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	beta blockers	melatonin	none	{'e1': {'word': 'beta blockers', 'word_index': [(17, 18)], 'id': 'DDI-DrugBank.d643.s0.e6'}, 'e2': {'word': 'melatonin', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d643.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	beta blockers	fluoxetine	none	{'e1': {'word': 'beta blockers', 'word_index': [(17, 18)], 'id': 'DDI-DrugBank.d643.s0.e6'}, 'e2': {'word': 'fluoxetine', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d643.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	beta blockers	progestin	none	{'e1': {'word': 'beta blockers', 'word_index': [(17, 18)], 'id': 'DDI-DrugBank.d643.s0.e6'}, 'e2': {'word': 'progestin', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d643.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	beta blockers	melatonin	none	{'e1': {'word': 'beta blockers', 'word_index': [(17, 18)], 'id': 'DDI-DrugBank.d643.s0.e6'}, 'e2': {'word': 'melatonin', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d643.s0.e10'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	beta blockers	progestin	none	{'e1': {'word': 'beta blockers', 'word_index': [(17, 18)], 'id': 'DDI-DrugBank.d643.s0.e6'}, 'e2': {'word': 'progestin', 'word_index': [(31, 31)], 'id': 'DDI-DrugBank.d643.s0.e11'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	beta blockers	benzodiazepenes	none	{'e1': {'word': 'beta blockers', 'word_index': [(17, 18)], 'id': 'DDI-DrugBank.d643.s0.e6'}, 'e2': {'word': 'benzodiazepenes', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d643.s0.e12'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	beta blockers	corticosteroids	none	{'e1': {'word': 'beta blockers', 'word_index': [(17, 18)], 'id': 'DDI-DrugBank.d643.s0.e6'}, 'e2': {'word': 'corticosteroids', 'word_index': [(47, 47)], 'id': 'DDI-DrugBank.d643.s0.e13'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	beta blockers	melatonin	none	{'e1': {'word': 'beta blockers', 'word_index': [(17, 18)], 'id': 'DDI-DrugBank.d643.s0.e6'}, 'e2': {'word': 'melatonin', 'word_index': [(49, 49)], 'id': 'DDI-DrugBank.d643.s0.e14'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	beta blockers	corticosteroids	none	{'e1': {'word': 'beta blockers', 'word_index': [(17, 18)], 'id': 'DDI-DrugBank.d643.s0.e6'}, 'e2': {'word': 'corticosteroids', 'word_index': [(50, 50)], 'id': 'DDI-DrugBank.d643.s0.e15'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	beta blockers	corticosteroids	none	{'e1': {'word': 'beta blockers', 'word_index': [(17, 18)], 'id': 'DDI-DrugBank.d643.s0.e6'}, 'e2': {'word': 'corticosteroids', 'word_index': [(54, 54)], 'id': 'DDI-DrugBank.d643.s0.e16'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	fluoxetine	none	{'e1': {'word': 'melatonin', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d643.s0.e7'}, 'e2': {'word': 'fluoxetine', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d643.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	progestin	none	{'e1': {'word': 'melatonin', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d643.s0.e7'}, 'e2': {'word': 'progestin', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d643.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	melatonin	none	{'e1': {'word': 'melatonin', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d643.s0.e7'}, 'e2': {'word': 'melatonin', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d643.s0.e10'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	progestin	none	{'e1': {'word': 'melatonin', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d643.s0.e7'}, 'e2': {'word': 'progestin', 'word_index': [(31, 31)], 'id': 'DDI-DrugBank.d643.s0.e11'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	benzodiazepenes	none	{'e1': {'word': 'melatonin', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d643.s0.e7'}, 'e2': {'word': 'benzodiazepenes', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d643.s0.e12'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	corticosteroids	none	{'e1': {'word': 'melatonin', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d643.s0.e7'}, 'e2': {'word': 'corticosteroids', 'word_index': [(47, 47)], 'id': 'DDI-DrugBank.d643.s0.e13'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	melatonin	none	{'e1': {'word': 'melatonin', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d643.s0.e7'}, 'e2': {'word': 'melatonin', 'word_index': [(49, 49)], 'id': 'DDI-DrugBank.d643.s0.e14'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	corticosteroids	none	{'e1': {'word': 'melatonin', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d643.s0.e7'}, 'e2': {'word': 'corticosteroids', 'word_index': [(50, 50)], 'id': 'DDI-DrugBank.d643.s0.e15'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	corticosteroids	none	{'e1': {'word': 'melatonin', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d643.s0.e7'}, 'e2': {'word': 'corticosteroids', 'word_index': [(54, 54)], 'id': 'DDI-DrugBank.d643.s0.e16'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	fluoxetine	progestin	none	{'e1': {'word': 'fluoxetine', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d643.s0.e8'}, 'e2': {'word': 'progestin', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d643.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	fluoxetine	melatonin	none	{'e1': {'word': 'fluoxetine', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d643.s0.e8'}, 'e2': {'word': 'melatonin', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d643.s0.e10'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	fluoxetine	progestin	none	{'e1': {'word': 'fluoxetine', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d643.s0.e8'}, 'e2': {'word': 'progestin', 'word_index': [(31, 31)], 'id': 'DDI-DrugBank.d643.s0.e11'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	fluoxetine	benzodiazepenes	none	{'e1': {'word': 'fluoxetine', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d643.s0.e8'}, 'e2': {'word': 'benzodiazepenes', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d643.s0.e12'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	fluoxetine	corticosteroids	none	{'e1': {'word': 'fluoxetine', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d643.s0.e8'}, 'e2': {'word': 'corticosteroids', 'word_index': [(47, 47)], 'id': 'DDI-DrugBank.d643.s0.e13'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	fluoxetine	melatonin	none	{'e1': {'word': 'fluoxetine', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d643.s0.e8'}, 'e2': {'word': 'melatonin', 'word_index': [(49, 49)], 'id': 'DDI-DrugBank.d643.s0.e14'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	fluoxetine	corticosteroids	none	{'e1': {'word': 'fluoxetine', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d643.s0.e8'}, 'e2': {'word': 'corticosteroids', 'word_index': [(50, 50)], 'id': 'DDI-DrugBank.d643.s0.e15'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	fluoxetine	corticosteroids	none	{'e1': {'word': 'fluoxetine', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d643.s0.e8'}, 'e2': {'word': 'corticosteroids', 'word_index': [(54, 54)], 'id': 'DDI-DrugBank.d643.s0.e16'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	progestin	melatonin	none	{'e1': {'word': 'progestin', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d643.s0.e9'}, 'e2': {'word': 'melatonin', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d643.s0.e10'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	progestin	progestin	none	{'e1': {'word': 'progestin', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d643.s0.e9'}, 'e2': {'word': 'progestin', 'word_index': [(31, 31)], 'id': 'DDI-DrugBank.d643.s0.e11'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	progestin	benzodiazepenes	none	{'e1': {'word': 'progestin', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d643.s0.e9'}, 'e2': {'word': 'benzodiazepenes', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d643.s0.e12'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	progestin	corticosteroids	none	{'e1': {'word': 'progestin', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d643.s0.e9'}, 'e2': {'word': 'corticosteroids', 'word_index': [(47, 47)], 'id': 'DDI-DrugBank.d643.s0.e13'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	progestin	melatonin	none	{'e1': {'word': 'progestin', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d643.s0.e9'}, 'e2': {'word': 'melatonin', 'word_index': [(49, 49)], 'id': 'DDI-DrugBank.d643.s0.e14'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	progestin	corticosteroids	none	{'e1': {'word': 'progestin', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d643.s0.e9'}, 'e2': {'word': 'corticosteroids', 'word_index': [(50, 50)], 'id': 'DDI-DrugBank.d643.s0.e15'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	progestin	corticosteroids	none	{'e1': {'word': 'progestin', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d643.s0.e9'}, 'e2': {'word': 'corticosteroids', 'word_index': [(54, 54)], 'id': 'DDI-DrugBank.d643.s0.e16'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	progestin	effect	{'e1': {'word': 'melatonin', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d643.s0.e10'}, 'e2': {'word': 'progestin', 'word_index': [(31, 31)], 'id': 'DDI-DrugBank.d643.s0.e11'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	benzodiazepenes	none	{'e1': {'word': 'melatonin', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d643.s0.e10'}, 'e2': {'word': 'benzodiazepenes', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d643.s0.e12'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	corticosteroids	none	{'e1': {'word': 'melatonin', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d643.s0.e10'}, 'e2': {'word': 'corticosteroids', 'word_index': [(47, 47)], 'id': 'DDI-DrugBank.d643.s0.e13'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	melatonin	none	{'e1': {'word': 'melatonin', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d643.s0.e10'}, 'e2': {'word': 'melatonin', 'word_index': [(49, 49)], 'id': 'DDI-DrugBank.d643.s0.e14'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	corticosteroids	none	{'e1': {'word': 'melatonin', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d643.s0.e10'}, 'e2': {'word': 'corticosteroids', 'word_index': [(50, 50)], 'id': 'DDI-DrugBank.d643.s0.e15'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	corticosteroids	none	{'e1': {'word': 'melatonin', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d643.s0.e10'}, 'e2': {'word': 'corticosteroids', 'word_index': [(54, 54)], 'id': 'DDI-DrugBank.d643.s0.e16'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	progestin	benzodiazepenes	none	{'e1': {'word': 'progestin', 'word_index': [(31, 31)], 'id': 'DDI-DrugBank.d643.s0.e11'}, 'e2': {'word': 'benzodiazepenes', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d643.s0.e12'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	progestin	corticosteroids	none	{'e1': {'word': 'progestin', 'word_index': [(31, 31)], 'id': 'DDI-DrugBank.d643.s0.e11'}, 'e2': {'word': 'corticosteroids', 'word_index': [(47, 47)], 'id': 'DDI-DrugBank.d643.s0.e13'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	progestin	melatonin	none	{'e1': {'word': 'progestin', 'word_index': [(31, 31)], 'id': 'DDI-DrugBank.d643.s0.e11'}, 'e2': {'word': 'melatonin', 'word_index': [(49, 49)], 'id': 'DDI-DrugBank.d643.s0.e14'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	progestin	corticosteroids	none	{'e1': {'word': 'progestin', 'word_index': [(31, 31)], 'id': 'DDI-DrugBank.d643.s0.e11'}, 'e2': {'word': 'corticosteroids', 'word_index': [(50, 50)], 'id': 'DDI-DrugBank.d643.s0.e15'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	progestin	corticosteroids	none	{'e1': {'word': 'progestin', 'word_index': [(31, 31)], 'id': 'DDI-DrugBank.d643.s0.e11'}, 'e2': {'word': 'corticosteroids', 'word_index': [(54, 54)], 'id': 'DDI-DrugBank.d643.s0.e16'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	benzodiazepenes	corticosteroids	none	{'e1': {'word': 'benzodiazepenes', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d643.s0.e12'}, 'e2': {'word': 'corticosteroids', 'word_index': [(47, 47)], 'id': 'DDI-DrugBank.d643.s0.e13'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	benzodiazepenes	melatonin	none	{'e1': {'word': 'benzodiazepenes', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d643.s0.e12'}, 'e2': {'word': 'melatonin', 'word_index': [(49, 49)], 'id': 'DDI-DrugBank.d643.s0.e14'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	benzodiazepenes	corticosteroids	none	{'e1': {'word': 'benzodiazepenes', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d643.s0.e12'}, 'e2': {'word': 'corticosteroids', 'word_index': [(50, 50)], 'id': 'DDI-DrugBank.d643.s0.e15'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	benzodiazepenes	corticosteroids	none	{'e1': {'word': 'benzodiazepenes', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d643.s0.e12'}, 'e2': {'word': 'corticosteroids', 'word_index': [(54, 54)], 'id': 'DDI-DrugBank.d643.s0.e16'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	corticosteroids	melatonin	none	{'e1': {'word': 'corticosteroids', 'word_index': [(47, 47)], 'id': 'DDI-DrugBank.d643.s0.e13'}, 'e2': {'word': 'melatonin', 'word_index': [(49, 49)], 'id': 'DDI-DrugBank.d643.s0.e14'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	corticosteroids	corticosteroids	none	{'e1': {'word': 'corticosteroids', 'word_index': [(47, 47)], 'id': 'DDI-DrugBank.d643.s0.e13'}, 'e2': {'word': 'corticosteroids', 'word_index': [(50, 50)], 'id': 'DDI-DrugBank.d643.s0.e15'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	corticosteroids	corticosteroids	none	{'e1': {'word': 'corticosteroids', 'word_index': [(47, 47)], 'id': 'DDI-DrugBank.d643.s0.e13'}, 'e2': {'word': 'corticosteroids', 'word_index': [(54, 54)], 'id': 'DDI-DrugBank.d643.s0.e16'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	corticosteroids	effect	{'e1': {'word': 'melatonin', 'word_index': [(49, 49)], 'id': 'DDI-DrugBank.d643.s0.e14'}, 'e2': {'word': 'corticosteroids', 'word_index': [(50, 50)], 'id': 'DDI-DrugBank.d643.s0.e15'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	corticosteroids	none	{'e1': {'word': 'melatonin', 'word_index': [(49, 49)], 'id': 'DDI-DrugBank.d643.s0.e14'}, 'e2': {'word': 'corticosteroids', 'word_index': [(54, 54)], 'id': 'DDI-DrugBank.d643.s0.e16'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	corticosteroids	corticosteroids	none	{'e1': {'word': 'corticosteroids', 'word_index': [(50, 50)], 'id': 'DDI-DrugBank.d643.s0.e15'}, 'e2': {'word': 'corticosteroids', 'word_index': [(54, 54)], 'id': 'DDI-DrugBank.d643.s0.e16'}, 'sentence_id': 'DDI-DrugBank.d643.s0'}	Melatonin may interact following drugs aspirin NSAIDs may lower melatonin levels fluvoxamine bioavailability oral melatonin increased coadministration beta blockers may decrease melatonin levels fluoxetine reports psychotic episodes coadministered progestin coadministration melatonin progestin inhibit ovarian function women benzodiazepenes sedating drugs may result additive sedation increased incidence adverse effects corticosteroids coadministration melatonin corticosteroids may interfere efficacy corticosteroids
Trimethoprim may inhibit the hepatic metabolism of phenytoin. 	Trimethoprim	phenytoin	mechanism	{'e1': {'word': 'Trimethoprim', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d598.s0.e0'}, 'e2': {'word': 'phenytoin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d598.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d598.s0'}	Trimethoprim may inhibit hepatic metabolism phenytoin
Trimethoprim, given at a common clinical dosage, increased the phenytoin half-life by 51% and decreased the phenytoin metabolic clearance rate by 30%. 	Trimethoprim	phenytoin	mechanism	{'e1': {'word': 'Trimethoprim', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d598.s1.e0'}, 'e2': {'word': 'phenytoin', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d598.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d598.s1'}	Trimethoprim given common clinical dosage increased phenytoin half life NUMBER % decreased phenytoin metabolic clearance rate NUMBER %
Trimethoprim, given at a common clinical dosage, increased the phenytoin half-life by 51% and decreased the phenytoin metabolic clearance rate by 30%. 	Trimethoprim	phenytoin	mechanism	{'e1': {'word': 'Trimethoprim', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d598.s1.e0'}, 'e2': {'word': 'phenytoin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d598.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d598.s1'}	Trimethoprim given common clinical dosage increased phenytoin half life NUMBER % decreased phenytoin metabolic clearance rate NUMBER %
Trimethoprim, given at a common clinical dosage, increased the phenytoin half-life by 51% and decreased the phenytoin metabolic clearance rate by 30%. 	phenytoin	phenytoin	none	{'e1': {'word': 'phenytoin', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d598.s1.e1'}, 'e2': {'word': 'phenytoin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d598.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d598.s1'}	Trimethoprim given common clinical dosage increased phenytoin half life NUMBER % decreased phenytoin metabolic clearance rate NUMBER %
Usage with Alcohol: Due to the potential for increased CNS depressants effects, alcohol should be used with caution in patients who are currently receiving pentazocine.	Alcohol	alcohol	none	{'e1': {'word': 'Alcohol', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d757.s0.e0'}, 'e2': {'word': 'alcohol', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d757.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d757.s0'}	Usage Alcohol Due potential increased CNS depressants effects alcohol used caution patients currently receiving pentazocine
Usage with Alcohol: Due to the potential for increased CNS depressants effects, alcohol should be used with caution in patients who are currently receiving pentazocine.	Alcohol	pentazocine	none	{'e1': {'word': 'Alcohol', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d757.s0.e0'}, 'e2': {'word': 'pentazocine', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d757.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d757.s0'}	Usage Alcohol Due potential increased CNS depressants effects alcohol used caution patients currently receiving pentazocine
Usage with Alcohol: Due to the potential for increased CNS depressants effects, alcohol should be used with caution in patients who are currently receiving pentazocine.	alcohol	pentazocine	advise	{'e1': {'word': 'alcohol', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d757.s0.e1'}, 'e2': {'word': 'pentazocine', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d757.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d757.s0'}	Usage Alcohol Due potential increased CNS depressants effects alcohol used caution patients currently receiving pentazocine
CYP3A4 Inhibitors: Ketoconazole, an inhibitor of the drug metabolizing enzyme CYP3A4, significantly increased plasma concentrations of tolterodine when coadministered to subjects who were poor metabolizers (see CLINICAL PHARMACOLOGY, Variability in Metabolism and Drug-Drug Interactions). 	Ketoconazole	tolterodine	mechanism	{'e1': {'word': 'Ketoconazole', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d765.s0.e0'}, 'e2': {'word': 'tolterodine', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d765.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d765.s0'}	CYP3A4 Inhibitors Ketoconazole inhibitor drug metabolizing enzyme CYP3A4 significantly increased plasma concentrations tolterodine coadministered subjects poor metabolizers see CLINICAL PHARMACOLOGY Variability Metabolism Drug Drug Interactions
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 	ketoconazole	azole antifungals	none	{'e1': {'word': 'ketoconazole', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d765.s1.e0'}, 'e2': {'word': 'azole antifungals', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d765.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d765.s1'}	patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals eg itraconazole miconazole macrolide antibiotics eg erythromycin clarithromycin cyclosporine vinblastine recommended dose DETROL LA NUMBER mg daily
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 	ketoconazole	itraconazole	none	{'e1': {'word': 'ketoconazole', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d765.s1.e0'}, 'e2': {'word': 'itraconazole', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d765.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d765.s1'}	patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals eg itraconazole miconazole macrolide antibiotics eg erythromycin clarithromycin cyclosporine vinblastine recommended dose DETROL LA NUMBER mg daily
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 	ketoconazole	miconazole	none	{'e1': {'word': 'ketoconazole', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d765.s1.e0'}, 'e2': {'word': 'miconazole', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d765.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d765.s1'}	patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals eg itraconazole miconazole macrolide antibiotics eg erythromycin clarithromycin cyclosporine vinblastine recommended dose DETROL LA NUMBER mg daily
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 	ketoconazole	macrolide antibiotics	none	{'e1': {'word': 'ketoconazole', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d765.s1.e0'}, 'e2': {'word': 'macrolide antibiotics', 'word_index': [(11, 12)], 'id': 'DDI-DrugBank.d765.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d765.s1'}	patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals eg itraconazole miconazole macrolide antibiotics eg erythromycin clarithromycin cyclosporine vinblastine recommended dose DETROL LA NUMBER mg daily
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 	ketoconazole	erythromycin	none	{'e1': {'word': 'ketoconazole', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d765.s1.e0'}, 'e2': {'word': 'erythromycin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d765.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d765.s1'}	patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals eg itraconazole miconazole macrolide antibiotics eg erythromycin clarithromycin cyclosporine vinblastine recommended dose DETROL LA NUMBER mg daily
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 	ketoconazole	clarithromycin	none	{'e1': {'word': 'ketoconazole', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d765.s1.e0'}, 'e2': {'word': 'clarithromycin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d765.s1.e6'}, 'sentence_id': 'DDI-DrugBank.d765.s1'}	patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals eg itraconazole miconazole macrolide antibiotics eg erythromycin clarithromycin cyclosporine vinblastine recommended dose DETROL LA NUMBER mg daily
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 	ketoconazole	cyclosporine	none	{'e1': {'word': 'ketoconazole', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d765.s1.e0'}, 'e2': {'word': 'cyclosporine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d765.s1.e7'}, 'sentence_id': 'DDI-DrugBank.d765.s1'}	patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals eg itraconazole miconazole macrolide antibiotics eg erythromycin clarithromycin cyclosporine vinblastine recommended dose DETROL LA NUMBER mg daily
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 	ketoconazole	vinblastine	none	{'e1': {'word': 'ketoconazole', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d765.s1.e0'}, 'e2': {'word': 'vinblastine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d765.s1.e8'}, 'sentence_id': 'DDI-DrugBank.d765.s1'}	patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals eg itraconazole miconazole macrolide antibiotics eg erythromycin clarithromycin cyclosporine vinblastine recommended dose DETROL LA NUMBER mg daily
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 	ketoconazole	DETROL LA	advise	{'e1': {'word': 'ketoconazole', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d765.s1.e0'}, 'e2': {'word': 'DETROL LA', 'word_index': [(20, 21)], 'id': 'DDI-DrugBank.d765.s1.e9'}, 'sentence_id': 'DDI-DrugBank.d765.s1'}	patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals eg itraconazole miconazole macrolide antibiotics eg erythromycin clarithromycin cyclosporine vinblastine recommended dose DETROL LA NUMBER mg daily
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 	azole antifungals	itraconazole	none	{'e1': {'word': 'azole antifungals', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d765.s1.e1'}, 'e2': {'word': 'itraconazole', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d765.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d765.s1'}	patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals eg itraconazole miconazole macrolide antibiotics eg erythromycin clarithromycin cyclosporine vinblastine recommended dose DETROL LA NUMBER mg daily
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 	azole antifungals	miconazole	none	{'e1': {'word': 'azole antifungals', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d765.s1.e1'}, 'e2': {'word': 'miconazole', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d765.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d765.s1'}	patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals eg itraconazole miconazole macrolide antibiotics eg erythromycin clarithromycin cyclosporine vinblastine recommended dose DETROL LA NUMBER mg daily
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 	azole antifungals	macrolide antibiotics	none	{'e1': {'word': 'azole antifungals', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d765.s1.e1'}, 'e2': {'word': 'macrolide antibiotics', 'word_index': [(11, 12)], 'id': 'DDI-DrugBank.d765.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d765.s1'}	patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals eg itraconazole miconazole macrolide antibiotics eg erythromycin clarithromycin cyclosporine vinblastine recommended dose DETROL LA NUMBER mg daily
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 	azole antifungals	erythromycin	none	{'e1': {'word': 'azole antifungals', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d765.s1.e1'}, 'e2': {'word': 'erythromycin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d765.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d765.s1'}	patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals eg itraconazole miconazole macrolide antibiotics eg erythromycin clarithromycin cyclosporine vinblastine recommended dose DETROL LA NUMBER mg daily
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 	azole antifungals	clarithromycin	none	{'e1': {'word': 'azole antifungals', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d765.s1.e1'}, 'e2': {'word': 'clarithromycin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d765.s1.e6'}, 'sentence_id': 'DDI-DrugBank.d765.s1'}	patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals eg itraconazole miconazole macrolide antibiotics eg erythromycin clarithromycin cyclosporine vinblastine recommended dose DETROL LA NUMBER mg daily
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 	azole antifungals	cyclosporine	none	{'e1': {'word': 'azole antifungals', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d765.s1.e1'}, 'e2': {'word': 'cyclosporine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d765.s1.e7'}, 'sentence_id': 'DDI-DrugBank.d765.s1'}	patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals eg itraconazole miconazole macrolide antibiotics eg erythromycin clarithromycin cyclosporine vinblastine recommended dose DETROL LA NUMBER mg daily
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 	azole antifungals	vinblastine	none	{'e1': {'word': 'azole antifungals', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d765.s1.e1'}, 'e2': {'word': 'vinblastine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d765.s1.e8'}, 'sentence_id': 'DDI-DrugBank.d765.s1'}	patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals eg itraconazole miconazole macrolide antibiotics eg erythromycin clarithromycin cyclosporine vinblastine recommended dose DETROL LA NUMBER mg daily
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 	azole antifungals	DETROL LA	advise	{'e1': {'word': 'azole antifungals', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d765.s1.e1'}, 'e2': {'word': 'DETROL LA', 'word_index': [(20, 21)], 'id': 'DDI-DrugBank.d765.s1.e9'}, 'sentence_id': 'DDI-DrugBank.d765.s1'}	patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals eg itraconazole miconazole macrolide antibiotics eg erythromycin clarithromycin cyclosporine vinblastine recommended dose DETROL LA NUMBER mg daily
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 	itraconazole	miconazole	none	{'e1': {'word': 'itraconazole', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d765.s1.e2'}, 'e2': {'word': 'miconazole', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d765.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d765.s1'}	patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals eg itraconazole miconazole macrolide antibiotics eg erythromycin clarithromycin cyclosporine vinblastine recommended dose DETROL LA NUMBER mg daily
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 	itraconazole	macrolide antibiotics	none	{'e1': {'word': 'itraconazole', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d765.s1.e2'}, 'e2': {'word': 'macrolide antibiotics', 'word_index': [(11, 12)], 'id': 'DDI-DrugBank.d765.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d765.s1'}	patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals eg itraconazole miconazole macrolide antibiotics eg erythromycin clarithromycin cyclosporine vinblastine recommended dose DETROL LA NUMBER mg daily
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 	itraconazole	erythromycin	none	{'e1': {'word': 'itraconazole', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d765.s1.e2'}, 'e2': {'word': 'erythromycin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d765.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d765.s1'}	patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals eg itraconazole miconazole macrolide antibiotics eg erythromycin clarithromycin cyclosporine vinblastine recommended dose DETROL LA NUMBER mg daily
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 	itraconazole	clarithromycin	none	{'e1': {'word': 'itraconazole', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d765.s1.e2'}, 'e2': {'word': 'clarithromycin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d765.s1.e6'}, 'sentence_id': 'DDI-DrugBank.d765.s1'}	patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals eg itraconazole miconazole macrolide antibiotics eg erythromycin clarithromycin cyclosporine vinblastine recommended dose DETROL LA NUMBER mg daily
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 	itraconazole	cyclosporine	none	{'e1': {'word': 'itraconazole', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d765.s1.e2'}, 'e2': {'word': 'cyclosporine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d765.s1.e7'}, 'sentence_id': 'DDI-DrugBank.d765.s1'}	patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals eg itraconazole miconazole macrolide antibiotics eg erythromycin clarithromycin cyclosporine vinblastine recommended dose DETROL LA NUMBER mg daily
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 	itraconazole	vinblastine	none	{'e1': {'word': 'itraconazole', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d765.s1.e2'}, 'e2': {'word': 'vinblastine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d765.s1.e8'}, 'sentence_id': 'DDI-DrugBank.d765.s1'}	patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals eg itraconazole miconazole macrolide antibiotics eg erythromycin clarithromycin cyclosporine vinblastine recommended dose DETROL LA NUMBER mg daily
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 	itraconazole	DETROL LA	advise	{'e1': {'word': 'itraconazole', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d765.s1.e2'}, 'e2': {'word': 'DETROL LA', 'word_index': [(20, 21)], 'id': 'DDI-DrugBank.d765.s1.e9'}, 'sentence_id': 'DDI-DrugBank.d765.s1'}	patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals eg itraconazole miconazole macrolide antibiotics eg erythromycin clarithromycin cyclosporine vinblastine recommended dose DETROL LA NUMBER mg daily
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 	miconazole	macrolide antibiotics	none	{'e1': {'word': 'miconazole', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d765.s1.e3'}, 'e2': {'word': 'macrolide antibiotics', 'word_index': [(11, 12)], 'id': 'DDI-DrugBank.d765.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d765.s1'}	patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals eg itraconazole miconazole macrolide antibiotics eg erythromycin clarithromycin cyclosporine vinblastine recommended dose DETROL LA NUMBER mg daily
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 	miconazole	erythromycin	none	{'e1': {'word': 'miconazole', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d765.s1.e3'}, 'e2': {'word': 'erythromycin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d765.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d765.s1'}	patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals eg itraconazole miconazole macrolide antibiotics eg erythromycin clarithromycin cyclosporine vinblastine recommended dose DETROL LA NUMBER mg daily
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 	miconazole	clarithromycin	none	{'e1': {'word': 'miconazole', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d765.s1.e3'}, 'e2': {'word': 'clarithromycin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d765.s1.e6'}, 'sentence_id': 'DDI-DrugBank.d765.s1'}	patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals eg itraconazole miconazole macrolide antibiotics eg erythromycin clarithromycin cyclosporine vinblastine recommended dose DETROL LA NUMBER mg daily
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 	miconazole	cyclosporine	none	{'e1': {'word': 'miconazole', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d765.s1.e3'}, 'e2': {'word': 'cyclosporine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d765.s1.e7'}, 'sentence_id': 'DDI-DrugBank.d765.s1'}	patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals eg itraconazole miconazole macrolide antibiotics eg erythromycin clarithromycin cyclosporine vinblastine recommended dose DETROL LA NUMBER mg daily
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 	miconazole	vinblastine	none	{'e1': {'word': 'miconazole', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d765.s1.e3'}, 'e2': {'word': 'vinblastine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d765.s1.e8'}, 'sentence_id': 'DDI-DrugBank.d765.s1'}	patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals eg itraconazole miconazole macrolide antibiotics eg erythromycin clarithromycin cyclosporine vinblastine recommended dose DETROL LA NUMBER mg daily
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 	miconazole	DETROL LA	advise	{'e1': {'word': 'miconazole', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d765.s1.e3'}, 'e2': {'word': 'DETROL LA', 'word_index': [(20, 21)], 'id': 'DDI-DrugBank.d765.s1.e9'}, 'sentence_id': 'DDI-DrugBank.d765.s1'}	patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals eg itraconazole miconazole macrolide antibiotics eg erythromycin clarithromycin cyclosporine vinblastine recommended dose DETROL LA NUMBER mg daily
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 	macrolide antibiotics	erythromycin	none	{'e1': {'word': 'macrolide antibiotics', 'word_index': [(11, 12)], 'id': 'DDI-DrugBank.d765.s1.e4'}, 'e2': {'word': 'erythromycin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d765.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d765.s1'}	patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals eg itraconazole miconazole macrolide antibiotics eg erythromycin clarithromycin cyclosporine vinblastine recommended dose DETROL LA NUMBER mg daily
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 	macrolide antibiotics	clarithromycin	none	{'e1': {'word': 'macrolide antibiotics', 'word_index': [(11, 12)], 'id': 'DDI-DrugBank.d765.s1.e4'}, 'e2': {'word': 'clarithromycin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d765.s1.e6'}, 'sentence_id': 'DDI-DrugBank.d765.s1'}	patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals eg itraconazole miconazole macrolide antibiotics eg erythromycin clarithromycin cyclosporine vinblastine recommended dose DETROL LA NUMBER mg daily
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 	macrolide antibiotics	cyclosporine	none	{'e1': {'word': 'macrolide antibiotics', 'word_index': [(11, 12)], 'id': 'DDI-DrugBank.d765.s1.e4'}, 'e2': {'word': 'cyclosporine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d765.s1.e7'}, 'sentence_id': 'DDI-DrugBank.d765.s1'}	patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals eg itraconazole miconazole macrolide antibiotics eg erythromycin clarithromycin cyclosporine vinblastine recommended dose DETROL LA NUMBER mg daily
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 	macrolide antibiotics	vinblastine	none	{'e1': {'word': 'macrolide antibiotics', 'word_index': [(11, 12)], 'id': 'DDI-DrugBank.d765.s1.e4'}, 'e2': {'word': 'vinblastine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d765.s1.e8'}, 'sentence_id': 'DDI-DrugBank.d765.s1'}	patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals eg itraconazole miconazole macrolide antibiotics eg erythromycin clarithromycin cyclosporine vinblastine recommended dose DETROL LA NUMBER mg daily
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 	macrolide antibiotics	DETROL LA	advise	{'e1': {'word': 'macrolide antibiotics', 'word_index': [(11, 12)], 'id': 'DDI-DrugBank.d765.s1.e4'}, 'e2': {'word': 'DETROL LA', 'word_index': [(20, 21)], 'id': 'DDI-DrugBank.d765.s1.e9'}, 'sentence_id': 'DDI-DrugBank.d765.s1'}	patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals eg itraconazole miconazole macrolide antibiotics eg erythromycin clarithromycin cyclosporine vinblastine recommended dose DETROL LA NUMBER mg daily
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 	erythromycin	clarithromycin	none	{'e1': {'word': 'erythromycin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d765.s1.e5'}, 'e2': {'word': 'clarithromycin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d765.s1.e6'}, 'sentence_id': 'DDI-DrugBank.d765.s1'}	patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals eg itraconazole miconazole macrolide antibiotics eg erythromycin clarithromycin cyclosporine vinblastine recommended dose DETROL LA NUMBER mg daily
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 	erythromycin	cyclosporine	none	{'e1': {'word': 'erythromycin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d765.s1.e5'}, 'e2': {'word': 'cyclosporine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d765.s1.e7'}, 'sentence_id': 'DDI-DrugBank.d765.s1'}	patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals eg itraconazole miconazole macrolide antibiotics eg erythromycin clarithromycin cyclosporine vinblastine recommended dose DETROL LA NUMBER mg daily
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 	erythromycin	vinblastine	none	{'e1': {'word': 'erythromycin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d765.s1.e5'}, 'e2': {'word': 'vinblastine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d765.s1.e8'}, 'sentence_id': 'DDI-DrugBank.d765.s1'}	patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals eg itraconazole miconazole macrolide antibiotics eg erythromycin clarithromycin cyclosporine vinblastine recommended dose DETROL LA NUMBER mg daily
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 	erythromycin	DETROL LA	advise	{'e1': {'word': 'erythromycin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d765.s1.e5'}, 'e2': {'word': 'DETROL LA', 'word_index': [(20, 21)], 'id': 'DDI-DrugBank.d765.s1.e9'}, 'sentence_id': 'DDI-DrugBank.d765.s1'}	patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals eg itraconazole miconazole macrolide antibiotics eg erythromycin clarithromycin cyclosporine vinblastine recommended dose DETROL LA NUMBER mg daily
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 	clarithromycin	cyclosporine	none	{'e1': {'word': 'clarithromycin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d765.s1.e6'}, 'e2': {'word': 'cyclosporine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d765.s1.e7'}, 'sentence_id': 'DDI-DrugBank.d765.s1'}	patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals eg itraconazole miconazole macrolide antibiotics eg erythromycin clarithromycin cyclosporine vinblastine recommended dose DETROL LA NUMBER mg daily
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 	clarithromycin	vinblastine	none	{'e1': {'word': 'clarithromycin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d765.s1.e6'}, 'e2': {'word': 'vinblastine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d765.s1.e8'}, 'sentence_id': 'DDI-DrugBank.d765.s1'}	patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals eg itraconazole miconazole macrolide antibiotics eg erythromycin clarithromycin cyclosporine vinblastine recommended dose DETROL LA NUMBER mg daily
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 	clarithromycin	DETROL LA	advise	{'e1': {'word': 'clarithromycin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d765.s1.e6'}, 'e2': {'word': 'DETROL LA', 'word_index': [(20, 21)], 'id': 'DDI-DrugBank.d765.s1.e9'}, 'sentence_id': 'DDI-DrugBank.d765.s1'}	patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals eg itraconazole miconazole macrolide antibiotics eg erythromycin clarithromycin cyclosporine vinblastine recommended dose DETROL LA NUMBER mg daily
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 	cyclosporine	vinblastine	none	{'e1': {'word': 'cyclosporine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d765.s1.e7'}, 'e2': {'word': 'vinblastine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d765.s1.e8'}, 'sentence_id': 'DDI-DrugBank.d765.s1'}	patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals eg itraconazole miconazole macrolide antibiotics eg erythromycin clarithromycin cyclosporine vinblastine recommended dose DETROL LA NUMBER mg daily
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 	cyclosporine	DETROL LA	advise	{'e1': {'word': 'cyclosporine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d765.s1.e7'}, 'e2': {'word': 'DETROL LA', 'word_index': [(20, 21)], 'id': 'DDI-DrugBank.d765.s1.e9'}, 'sentence_id': 'DDI-DrugBank.d765.s1'}	patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals eg itraconazole miconazole macrolide antibiotics eg erythromycin clarithromycin cyclosporine vinblastine recommended dose DETROL LA NUMBER mg daily
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. 	vinblastine	DETROL LA	advise	{'e1': {'word': 'vinblastine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d765.s1.e8'}, 'e2': {'word': 'DETROL LA', 'word_index': [(20, 21)], 'id': 'DDI-DrugBank.d765.s1.e9'}, 'sentence_id': 'DDI-DrugBank.d765.s1'}	patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals eg itraconazole miconazole macrolide antibiotics eg erythromycin clarithromycin cyclosporine vinblastine recommended dose DETROL LA NUMBER mg daily
Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives, tranquilizers, or alcohol. 	Scopolamine	sedatives	advise	{'e1': {'word': 'Scopolamine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d771.s1.e0'}, 'e2': {'word': 'sedatives', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d771.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d771.s1'}	Scopolamine used care patients taking drugs capable causing CNS effects sedatives tranquilizers alcohol
Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives, tranquilizers, or alcohol. 	Scopolamine	tranquilizers	advise	{'e1': {'word': 'Scopolamine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d771.s1.e0'}, 'e2': {'word': 'tranquilizers', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d771.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d771.s1'}	Scopolamine used care patients taking drugs capable causing CNS effects sedatives tranquilizers alcohol
Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives, tranquilizers, or alcohol. 	Scopolamine	alcohol	advise	{'e1': {'word': 'Scopolamine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d771.s1.e0'}, 'e2': {'word': 'alcohol', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d771.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d771.s1'}	Scopolamine used care patients taking drugs capable causing CNS effects sedatives tranquilizers alcohol
Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives, tranquilizers, or alcohol. 	sedatives	tranquilizers	none	{'e1': {'word': 'sedatives', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d771.s1.e1'}, 'e2': {'word': 'tranquilizers', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d771.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d771.s1'}	Scopolamine used care patients taking drugs capable causing CNS effects sedatives tranquilizers alcohol
Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives, tranquilizers, or alcohol. 	sedatives	alcohol	none	{'e1': {'word': 'sedatives', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d771.s1.e1'}, 'e2': {'word': 'alcohol', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d771.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d771.s1'}	Scopolamine used care patients taking drugs capable causing CNS effects sedatives tranquilizers alcohol
Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives, tranquilizers, or alcohol. 	tranquilizers	alcohol	none	{'e1': {'word': 'tranquilizers', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d771.s1.e2'}, 'e2': {'word': 'alcohol', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d771.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d771.s1'}	Scopolamine used care patients taking drugs capable causing CNS effects sedatives tranquilizers alcohol
e.g., other belladonna alkaloids, antihistamines (including meclizine), tricyclic antidepressants, and muscle relaxants. 	belladonna alkaloids	antihistamines	none	{'e1': {'word': 'belladonna alkaloids', 'word_index': [(1, 2)], 'id': 'DDI-DrugBank.d771.s3.e0'}, 'e2': {'word': 'antihistamines', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d771.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d771.s3'}	e.g. belladonna alkaloids antihistamines including meclizine tricyclic antidepressants muscle relaxants
e.g., other belladonna alkaloids, antihistamines (including meclizine), tricyclic antidepressants, and muscle relaxants. 	belladonna alkaloids	meclizine	none	{'e1': {'word': 'belladonna alkaloids', 'word_index': [(1, 2)], 'id': 'DDI-DrugBank.d771.s3.e0'}, 'e2': {'word': 'meclizine', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d771.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d771.s3'}	e.g. belladonna alkaloids antihistamines including meclizine tricyclic antidepressants muscle relaxants
e.g., other belladonna alkaloids, antihistamines (including meclizine), tricyclic antidepressants, and muscle relaxants. 	belladonna alkaloids	tricyclic antidepressants	none	{'e1': {'word': 'belladonna alkaloids', 'word_index': [(1, 2)], 'id': 'DDI-DrugBank.d771.s3.e0'}, 'e2': {'word': 'tricyclic antidepressants', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d771.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d771.s3'}	e.g. belladonna alkaloids antihistamines including meclizine tricyclic antidepressants muscle relaxants
e.g., other belladonna alkaloids, antihistamines (including meclizine), tricyclic antidepressants, and muscle relaxants. 	belladonna alkaloids	muscle relaxants	none	{'e1': {'word': 'belladonna alkaloids', 'word_index': [(1, 2)], 'id': 'DDI-DrugBank.d771.s3.e0'}, 'e2': {'word': 'muscle relaxants', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d771.s3.e4'}, 'sentence_id': 'DDI-DrugBank.d771.s3'}	e.g. belladonna alkaloids antihistamines including meclizine tricyclic antidepressants muscle relaxants
e.g., other belladonna alkaloids, antihistamines (including meclizine), tricyclic antidepressants, and muscle relaxants. 	antihistamines	meclizine	none	{'e1': {'word': 'antihistamines', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d771.s3.e1'}, 'e2': {'word': 'meclizine', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d771.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d771.s3'}	e.g. belladonna alkaloids antihistamines including meclizine tricyclic antidepressants muscle relaxants
e.g., other belladonna alkaloids, antihistamines (including meclizine), tricyclic antidepressants, and muscle relaxants. 	antihistamines	tricyclic antidepressants	none	{'e1': {'word': 'antihistamines', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d771.s3.e1'}, 'e2': {'word': 'tricyclic antidepressants', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d771.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d771.s3'}	e.g. belladonna alkaloids antihistamines including meclizine tricyclic antidepressants muscle relaxants
e.g., other belladonna alkaloids, antihistamines (including meclizine), tricyclic antidepressants, and muscle relaxants. 	antihistamines	muscle relaxants	none	{'e1': {'word': 'antihistamines', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d771.s3.e1'}, 'e2': {'word': 'muscle relaxants', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d771.s3.e4'}, 'sentence_id': 'DDI-DrugBank.d771.s3'}	e.g. belladonna alkaloids antihistamines including meclizine tricyclic antidepressants muscle relaxants
e.g., other belladonna alkaloids, antihistamines (including meclizine), tricyclic antidepressants, and muscle relaxants. 	meclizine	tricyclic antidepressants	none	{'e1': {'word': 'meclizine', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d771.s3.e2'}, 'e2': {'word': 'tricyclic antidepressants', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d771.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d771.s3'}	e.g. belladonna alkaloids antihistamines including meclizine tricyclic antidepressants muscle relaxants
e.g., other belladonna alkaloids, antihistamines (including meclizine), tricyclic antidepressants, and muscle relaxants. 	meclizine	muscle relaxants	none	{'e1': {'word': 'meclizine', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d771.s3.e2'}, 'e2': {'word': 'muscle relaxants', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d771.s3.e4'}, 'sentence_id': 'DDI-DrugBank.d771.s3'}	e.g. belladonna alkaloids antihistamines including meclizine tricyclic antidepressants muscle relaxants
e.g., other belladonna alkaloids, antihistamines (including meclizine), tricyclic antidepressants, and muscle relaxants. 	tricyclic antidepressants	muscle relaxants	none	{'e1': {'word': 'tricyclic antidepressants', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d771.s3.e3'}, 'e2': {'word': 'muscle relaxants', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d771.s3.e4'}, 'sentence_id': 'DDI-DrugBank.d771.s3'}	e.g. belladonna alkaloids antihistamines including meclizine tricyclic antidepressants muscle relaxants
Coumarin-Derivative Anticoagulants: Prolongation of prothrombin time (PT) and International Normalized Ratio (INR) were observed in patients receiving ZOLINZA concomitantly with coumarin-derivative anticoagulants. 	Coumarin-Derivative Anticoagulants	ZOLINZA	none	{'e1': {'word': 'Coumarin-Derivative Anticoagulants', 'word_index': [(0, 2)], 'id': 'DDI-DrugBank.d769.s0.e0'}, 'e2': {'word': 'ZOLINZA', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d769.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d769.s0'}	Coumarin Derivative Anticoagulants Prolongation prothrombin time PT International Normalized Ratio INR observed patients receiving ZOLINZA concomitantly coumarin derivative anticoagulants
Coumarin-Derivative Anticoagulants: Prolongation of prothrombin time (PT) and International Normalized Ratio (INR) were observed in patients receiving ZOLINZA concomitantly with coumarin-derivative anticoagulants. 	Coumarin-Derivative Anticoagulants	coumarin-derivative anticoagulants	none	{'e1': {'word': 'Coumarin-Derivative Anticoagulants', 'word_index': [(0, 2)], 'id': 'DDI-DrugBank.d769.s0.e0'}, 'e2': {'word': 'coumarin-derivative anticoagulants', 'word_index': [(16, 18)], 'id': 'DDI-DrugBank.d769.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d769.s0'}	Coumarin Derivative Anticoagulants Prolongation prothrombin time PT International Normalized Ratio INR observed patients receiving ZOLINZA concomitantly coumarin derivative anticoagulants
Coumarin-Derivative Anticoagulants: Prolongation of prothrombin time (PT) and International Normalized Ratio (INR) were observed in patients receiving ZOLINZA concomitantly with coumarin-derivative anticoagulants. 	ZOLINZA	coumarin-derivative anticoagulants	effect	{'e1': {'word': 'ZOLINZA', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d769.s0.e1'}, 'e2': {'word': 'coumarin-derivative anticoagulants', 'word_index': [(16, 18)], 'id': 'DDI-DrugBank.d769.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d769.s0'}	Coumarin Derivative Anticoagulants Prolongation prothrombin time PT International Normalized Ratio INR observed patients receiving ZOLINZA concomitantly coumarin derivative anticoagulants
Physicians should carefully monitor PT and INR in patients concurrently administered ZOLINZA and coumarin derivatives. 	ZOLINZA	coumarin derivatives	advise	{'e1': {'word': 'ZOLINZA', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d769.s1.e0'}, 'e2': {'word': 'coumarin derivatives', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d769.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d769.s1'}	Physicians carefully monitor PT INR patients concurrently administered ZOLINZA coumarin derivatives
Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other HDAC inhibitors (e.g., valproic acid). 	HDAC Inhibitors	ZOLINZA	none	{'e1': {'word': 'HDAC Inhibitors', 'word_index': [(0, 1)], 'id': 'DDI-DrugBank.d769.s2.e0'}, 'e2': {'word': 'ZOLINZA', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d769.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d769.s2'}	HDAC Inhibitors Severe thrombocytopenia gastrointestinal bleeding reported concomitant use ZOLINZA HDAC inhibitors e.g. valproic acid
Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other HDAC inhibitors (e.g., valproic acid). 	HDAC Inhibitors	HDAC inhibitors	none	{'e1': {'word': 'HDAC Inhibitors', 'word_index': [(0, 1)], 'id': 'DDI-DrugBank.d769.s2.e0'}, 'e2': {'word': 'HDAC inhibitors', 'word_index': [(10, 11)], 'id': 'DDI-DrugBank.d769.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d769.s2'}	HDAC Inhibitors Severe thrombocytopenia gastrointestinal bleeding reported concomitant use ZOLINZA HDAC inhibitors e.g. valproic acid
Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other HDAC inhibitors (e.g., valproic acid). 	HDAC Inhibitors	valproic acid	none	{'e1': {'word': 'HDAC Inhibitors', 'word_index': [(0, 1)], 'id': 'DDI-DrugBank.d769.s2.e0'}, 'e2': {'word': 'valproic acid', 'word_index': [(13, 14)], 'id': 'DDI-DrugBank.d769.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d769.s2'}	HDAC Inhibitors Severe thrombocytopenia gastrointestinal bleeding reported concomitant use ZOLINZA HDAC inhibitors e.g. valproic acid
Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other HDAC inhibitors (e.g., valproic acid). 	ZOLINZA	HDAC inhibitors	effect	{'e1': {'word': 'ZOLINZA', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d769.s2.e1'}, 'e2': {'word': 'HDAC inhibitors', 'word_index': [(10, 11)], 'id': 'DDI-DrugBank.d769.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d769.s2'}	HDAC Inhibitors Severe thrombocytopenia gastrointestinal bleeding reported concomitant use ZOLINZA HDAC inhibitors e.g. valproic acid
Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other HDAC inhibitors (e.g., valproic acid). 	ZOLINZA	valproic acid	effect	{'e1': {'word': 'ZOLINZA', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d769.s2.e1'}, 'e2': {'word': 'valproic acid', 'word_index': [(13, 14)], 'id': 'DDI-DrugBank.d769.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d769.s2'}	HDAC Inhibitors Severe thrombocytopenia gastrointestinal bleeding reported concomitant use ZOLINZA HDAC inhibitors e.g. valproic acid
Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other HDAC inhibitors (e.g., valproic acid). 	HDAC inhibitors	valproic acid	none	{'e1': {'word': 'HDAC inhibitors', 'word_index': [(10, 11)], 'id': 'DDI-DrugBank.d769.s2.e2'}, 'e2': {'word': 'valproic acid', 'word_index': [(13, 14)], 'id': 'DDI-DrugBank.d769.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d769.s2'}	HDAC Inhibitors Severe thrombocytopenia gastrointestinal bleeding reported concomitant use ZOLINZA HDAC inhibitors e.g. valproic acid
Cimetidine: The effects of chronic cimetidine use on the metabolism of rimantadine are not known. 	Cimetidine	cimetidine	none	{'e1': {'word': 'Cimetidine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d710.s0.e0'}, 'e2': {'word': 'cimetidine', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d710.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d710.s0'}	Cimetidine effects chronic cimetidine use metabolism rimantadine known
Cimetidine: The effects of chronic cimetidine use on the metabolism of rimantadine are not known. 	Cimetidine	rimantadine	none	{'e1': {'word': 'Cimetidine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d710.s0.e0'}, 'e2': {'word': 'rimantadine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d710.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d710.s0'}	Cimetidine effects chronic cimetidine use metabolism rimantadine known
Cimetidine: The effects of chronic cimetidine use on the metabolism of rimantadine are not known. 	cimetidine	rimantadine	none	{'e1': {'word': 'cimetidine', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d710.s0.e1'}, 'e2': {'word': 'rimantadine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d710.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d710.s0'}	Cimetidine effects chronic cimetidine use metabolism rimantadine known
When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine). 	rimantadine HCl	Cimetidine	mechanism	{'e1': {'word': 'rimantadine HCl', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d710.s1.e0'}, 'e2': {'word': 'Cimetidine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d710.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d710.s1'}	single NUMBER mg dose rimantadine HCl administered NUMBER hour initiation Cimetidine NUMBER mg NUMBER times day apparent total rimantadine clearance single dose normal healthy adults reduced NUMBER % compared apparent total rimantadine clearance subjects absence cimetidine
When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine). 	rimantadine HCl	rimantadine	none	{'e1': {'word': 'rimantadine HCl', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d710.s1.e0'}, 'e2': {'word': 'rimantadine', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d710.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d710.s1'}	single NUMBER mg dose rimantadine HCl administered NUMBER hour initiation Cimetidine NUMBER mg NUMBER times day apparent total rimantadine clearance single dose normal healthy adults reduced NUMBER % compared apparent total rimantadine clearance subjects absence cimetidine
When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine). 	rimantadine HCl	rimantadine	none	{'e1': {'word': 'rimantadine HCl', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d710.s1.e0'}, 'e2': {'word': 'rimantadine', 'word_index': [(31, 31)], 'id': 'DDI-DrugBank.d710.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d710.s1'}	single NUMBER mg dose rimantadine HCl administered NUMBER hour initiation Cimetidine NUMBER mg NUMBER times day apparent total rimantadine clearance single dose normal healthy adults reduced NUMBER % compared apparent total rimantadine clearance subjects absence cimetidine
When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine). 	rimantadine HCl	cimetidine	none	{'e1': {'word': 'rimantadine HCl', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d710.s1.e0'}, 'e2': {'word': 'cimetidine', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d710.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d710.s1'}	single NUMBER mg dose rimantadine HCl administered NUMBER hour initiation Cimetidine NUMBER mg NUMBER times day apparent total rimantadine clearance single dose normal healthy adults reduced NUMBER % compared apparent total rimantadine clearance subjects absence cimetidine
When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine). 	Cimetidine	rimantadine	none	{'e1': {'word': 'Cimetidine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d710.s1.e1'}, 'e2': {'word': 'rimantadine', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d710.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d710.s1'}	single NUMBER mg dose rimantadine HCl administered NUMBER hour initiation Cimetidine NUMBER mg NUMBER times day apparent total rimantadine clearance single dose normal healthy adults reduced NUMBER % compared apparent total rimantadine clearance subjects absence cimetidine
When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine). 	Cimetidine	rimantadine	none	{'e1': {'word': 'Cimetidine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d710.s1.e1'}, 'e2': {'word': 'rimantadine', 'word_index': [(31, 31)], 'id': 'DDI-DrugBank.d710.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d710.s1'}	single NUMBER mg dose rimantadine HCl administered NUMBER hour initiation Cimetidine NUMBER mg NUMBER times day apparent total rimantadine clearance single dose normal healthy adults reduced NUMBER % compared apparent total rimantadine clearance subjects absence cimetidine
When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine). 	Cimetidine	cimetidine	none	{'e1': {'word': 'Cimetidine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d710.s1.e1'}, 'e2': {'word': 'cimetidine', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d710.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d710.s1'}	single NUMBER mg dose rimantadine HCl administered NUMBER hour initiation Cimetidine NUMBER mg NUMBER times day apparent total rimantadine clearance single dose normal healthy adults reduced NUMBER % compared apparent total rimantadine clearance subjects absence cimetidine
When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine). 	rimantadine	rimantadine	none	{'e1': {'word': 'rimantadine', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d710.s1.e2'}, 'e2': {'word': 'rimantadine', 'word_index': [(31, 31)], 'id': 'DDI-DrugBank.d710.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d710.s1'}	single NUMBER mg dose rimantadine HCl administered NUMBER hour initiation Cimetidine NUMBER mg NUMBER times day apparent total rimantadine clearance single dose normal healthy adults reduced NUMBER % compared apparent total rimantadine clearance subjects absence cimetidine
When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine). 	rimantadine	cimetidine	none	{'e1': {'word': 'rimantadine', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d710.s1.e2'}, 'e2': {'word': 'cimetidine', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d710.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d710.s1'}	single NUMBER mg dose rimantadine HCl administered NUMBER hour initiation Cimetidine NUMBER mg NUMBER times day apparent total rimantadine clearance single dose normal healthy adults reduced NUMBER % compared apparent total rimantadine clearance subjects absence cimetidine
When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine). 	rimantadine	cimetidine	none	{'e1': {'word': 'rimantadine', 'word_index': [(31, 31)], 'id': 'DDI-DrugBank.d710.s1.e3'}, 'e2': {'word': 'cimetidine', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d710.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d710.s1'}	single NUMBER mg dose rimantadine HCl administered NUMBER hour initiation Cimetidine NUMBER mg NUMBER times day apparent total rimantadine clearance single dose normal healthy adults reduced NUMBER % compared apparent total rimantadine clearance subjects absence cimetidine
Acetaminophen: Rimantadine HCl, 100 mg, was given twice daily for 13 days to 12 healthy volunteers. 	Acetaminophen	Rimantadine HCl	none	{'e1': {'word': 'Acetaminophen', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d710.s2.e0'}, 'e2': {'word': 'Rimantadine HCl', 'word_index': [(1, 2)], 'id': 'DDI-DrugBank.d710.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d710.s2'}	Acetaminophen Rimantadine HCl NUMBER mg given twice daily NUMBER days NUMBER healthy volunteers
Coadministration with acetaminophen reduced the peak concentration and AUC values for rimantadine by approximately 11%. 	acetaminophen	rimantadine	mechanism	{'e1': {'word': 'acetaminophen', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d710.s5.e0'}, 'e2': {'word': 'rimantadine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d710.s5.e1'}, 'sentence_id': 'DDI-DrugBank.d710.s5'}	Coadministration acetaminophen reduced peak concentration AUC values rimantadine approximately NUMBER %
Aspirin: Rimantadine HCl, 100 mg, was given twice daily fro 13 days to 12 healthy volunteers. 	Aspirin	Rimantadine HCl	none	{'e1': {'word': 'Aspirin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d710.s6.e0'}, 'e2': {'word': 'Rimantadine HCl', 'word_index': [(1, 2)], 'id': 'DDI-DrugBank.d710.s6.e1'}, 'sentence_id': 'DDI-DrugBank.d710.s6'}	Aspirin Rimantadine HCl NUMBER mg given twice daily fro NUMBER days NUMBER healthy volunteers
Peak plasma concentrations and AUC of rimantadine were reduced approximately 10% in the presence of aspirin.	rimantadine	aspirin	mechanism	{'e1': {'word': 'rimantadine', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d710.s9.e0'}, 'e2': {'word': 'aspirin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d710.s9.e1'}, 'sentence_id': 'DDI-DrugBank.d710.s9'}	Peak plasma concentrations AUC rimantadine reduced approximately NUMBER % presence aspirin
The effects of metoclopramide on gastrointestinal motility are antagonized by anticholinergic drugs and narcotic analgesics. 	metoclopramide	anticholinergic drugs	effect	{'e1': {'word': 'metoclopramide', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d652.s0.e0'}, 'e2': {'word': 'anticholinergic drugs', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d652.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d652.s0'}	effects metoclopramide gastrointestinal motility antagonized anticholinergic drugs narcotic analgesics
The effects of metoclopramide on gastrointestinal motility are antagonized by anticholinergic drugs and narcotic analgesics. 	metoclopramide	narcotic analgesics	effect	{'e1': {'word': 'metoclopramide', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d652.s0.e0'}, 'e2': {'word': 'narcotic analgesics', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d652.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d652.s0'}	effects metoclopramide gastrointestinal motility antagonized anticholinergic drugs narcotic analgesics
The effects of metoclopramide on gastrointestinal motility are antagonized by anticholinergic drugs and narcotic analgesics. 	anticholinergic drugs	narcotic analgesics	none	{'e1': {'word': 'anticholinergic drugs', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d652.s0.e1'}, 'e2': {'word': 'narcotic analgesics', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d652.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d652.s0'}	effects metoclopramide gastrointestinal motility antagonized anticholinergic drugs narcotic analgesics
Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. 	metoclopramide	alcohol	effect	{'e1': {'word': 'metoclopramide', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d652.s1.e0'}, 'e2': {'word': 'alcohol', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d652.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d652.s1'}	Additive sedative effects occur metoclopramide given alcohol sedatives hypnotics narcotics tranquilizers
Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. 	metoclopramide	sedatives	effect	{'e1': {'word': 'metoclopramide', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d652.s1.e0'}, 'e2': {'word': 'sedatives', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d652.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d652.s1'}	Additive sedative effects occur metoclopramide given alcohol sedatives hypnotics narcotics tranquilizers
Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. 	metoclopramide	hypnotics	effect	{'e1': {'word': 'metoclopramide', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d652.s1.e0'}, 'e2': {'word': 'hypnotics', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d652.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d652.s1'}	Additive sedative effects occur metoclopramide given alcohol sedatives hypnotics narcotics tranquilizers
Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. 	metoclopramide	narcotics	effect	{'e1': {'word': 'metoclopramide', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d652.s1.e0'}, 'e2': {'word': 'narcotics', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d652.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d652.s1'}	Additive sedative effects occur metoclopramide given alcohol sedatives hypnotics narcotics tranquilizers
Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. 	metoclopramide	tranquilizers	effect	{'e1': {'word': 'metoclopramide', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d652.s1.e0'}, 'e2': {'word': 'tranquilizers', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d652.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d652.s1'}	Additive sedative effects occur metoclopramide given alcohol sedatives hypnotics narcotics tranquilizers
Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. 	alcohol	sedatives	none	{'e1': {'word': 'alcohol', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d652.s1.e1'}, 'e2': {'word': 'sedatives', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d652.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d652.s1'}	Additive sedative effects occur metoclopramide given alcohol sedatives hypnotics narcotics tranquilizers
Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. 	alcohol	hypnotics	none	{'e1': {'word': 'alcohol', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d652.s1.e1'}, 'e2': {'word': 'hypnotics', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d652.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d652.s1'}	Additive sedative effects occur metoclopramide given alcohol sedatives hypnotics narcotics tranquilizers
Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. 	alcohol	narcotics	none	{'e1': {'word': 'alcohol', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d652.s1.e1'}, 'e2': {'word': 'narcotics', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d652.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d652.s1'}	Additive sedative effects occur metoclopramide given alcohol sedatives hypnotics narcotics tranquilizers
Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. 	alcohol	tranquilizers	none	{'e1': {'word': 'alcohol', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d652.s1.e1'}, 'e2': {'word': 'tranquilizers', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d652.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d652.s1'}	Additive sedative effects occur metoclopramide given alcohol sedatives hypnotics narcotics tranquilizers
Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. 	sedatives	hypnotics	none	{'e1': {'word': 'sedatives', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d652.s1.e2'}, 'e2': {'word': 'hypnotics', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d652.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d652.s1'}	Additive sedative effects occur metoclopramide given alcohol sedatives hypnotics narcotics tranquilizers
Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. 	sedatives	narcotics	none	{'e1': {'word': 'sedatives', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d652.s1.e2'}, 'e2': {'word': 'narcotics', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d652.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d652.s1'}	Additive sedative effects occur metoclopramide given alcohol sedatives hypnotics narcotics tranquilizers
Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. 	sedatives	tranquilizers	none	{'e1': {'word': 'sedatives', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d652.s1.e2'}, 'e2': {'word': 'tranquilizers', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d652.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d652.s1'}	Additive sedative effects occur metoclopramide given alcohol sedatives hypnotics narcotics tranquilizers
Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. 	hypnotics	narcotics	none	{'e1': {'word': 'hypnotics', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d652.s1.e3'}, 'e2': {'word': 'narcotics', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d652.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d652.s1'}	Additive sedative effects occur metoclopramide given alcohol sedatives hypnotics narcotics tranquilizers
Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. 	hypnotics	tranquilizers	none	{'e1': {'word': 'hypnotics', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d652.s1.e3'}, 'e2': {'word': 'tranquilizers', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d652.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d652.s1'}	Additive sedative effects occur metoclopramide given alcohol sedatives hypnotics narcotics tranquilizers
Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. 	narcotics	tranquilizers	none	{'e1': {'word': 'narcotics', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d652.s1.e4'}, 'e2': {'word': 'tranquilizers', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d652.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d652.s1'}	Additive sedative effects occur metoclopramide given alcohol sedatives hypnotics narcotics tranquilizers
The finding that metoclopramide releases catecholamines in patients with essential hypertension suggests that it should be used cautiously, if at all, in patients receiving monoamine oxi-dase inhibitors. 	metoclopramide	monoamine oxi-dase inhibitors	advise	{'e1': {'word': 'metoclopramide', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d652.s2.e0'}, 'e2': {'word': 'monoamine oxi-dase inhibitors', 'word_index': [(12, 14)], 'id': 'DDI-DrugBank.d652.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d652.s2'}	finding metoclopramide releases catecholamines patients essential hypertension suggests used cautiously patients receiving monoamine oxi-dase inhibitors
Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). 	digoxin	metoclopramide	mechanism	{'e1': {'word': 'digoxin', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d652.s3.e0'}, 'e2': {'word': 'metoclopramide', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d652.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d652.s3'}	Absorption drugs stomach may diminished e.g. digoxin metoclopramide whereas rate extent absorption drugs small bowel may increased e.g. acetaminophen tetracycline levodopa ethanol cyclosporine
Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). 	digoxin	acetaminophen	none	{'e1': {'word': 'digoxin', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d652.s3.e0'}, 'e2': {'word': 'acetaminophen', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d652.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d652.s3'}	Absorption drugs stomach may diminished e.g. digoxin metoclopramide whereas rate extent absorption drugs small bowel may increased e.g. acetaminophen tetracycline levodopa ethanol cyclosporine
Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). 	digoxin	tetracycline	none	{'e1': {'word': 'digoxin', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d652.s3.e0'}, 'e2': {'word': 'tetracycline', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d652.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d652.s3'}	Absorption drugs stomach may diminished e.g. digoxin metoclopramide whereas rate extent absorption drugs small bowel may increased e.g. acetaminophen tetracycline levodopa ethanol cyclosporine
Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). 	digoxin	levodopa	none	{'e1': {'word': 'digoxin', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d652.s3.e0'}, 'e2': {'word': 'levodopa', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d652.s3.e4'}, 'sentence_id': 'DDI-DrugBank.d652.s3'}	Absorption drugs stomach may diminished e.g. digoxin metoclopramide whereas rate extent absorption drugs small bowel may increased e.g. acetaminophen tetracycline levodopa ethanol cyclosporine
Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). 	digoxin	ethanol	none	{'e1': {'word': 'digoxin', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d652.s3.e0'}, 'e2': {'word': 'ethanol', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d652.s3.e5'}, 'sentence_id': 'DDI-DrugBank.d652.s3'}	Absorption drugs stomach may diminished e.g. digoxin metoclopramide whereas rate extent absorption drugs small bowel may increased e.g. acetaminophen tetracycline levodopa ethanol cyclosporine
Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). 	digoxin	cyclosporine	none	{'e1': {'word': 'digoxin', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d652.s3.e0'}, 'e2': {'word': 'cyclosporine', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d652.s3.e6'}, 'sentence_id': 'DDI-DrugBank.d652.s3'}	Absorption drugs stomach may diminished e.g. digoxin metoclopramide whereas rate extent absorption drugs small bowel may increased e.g. acetaminophen tetracycline levodopa ethanol cyclosporine
Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). 	metoclopramide	acetaminophen	mechanism	{'e1': {'word': 'metoclopramide', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d652.s3.e1'}, 'e2': {'word': 'acetaminophen', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d652.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d652.s3'}	Absorption drugs stomach may diminished e.g. digoxin metoclopramide whereas rate extent absorption drugs small bowel may increased e.g. acetaminophen tetracycline levodopa ethanol cyclosporine
Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). 	metoclopramide	tetracycline	none	{'e1': {'word': 'metoclopramide', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d652.s3.e1'}, 'e2': {'word': 'tetracycline', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d652.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d652.s3'}	Absorption drugs stomach may diminished e.g. digoxin metoclopramide whereas rate extent absorption drugs small bowel may increased e.g. acetaminophen tetracycline levodopa ethanol cyclosporine
Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). 	metoclopramide	levodopa	none	{'e1': {'word': 'metoclopramide', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d652.s3.e1'}, 'e2': {'word': 'levodopa', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d652.s3.e4'}, 'sentence_id': 'DDI-DrugBank.d652.s3'}	Absorption drugs stomach may diminished e.g. digoxin metoclopramide whereas rate extent absorption drugs small bowel may increased e.g. acetaminophen tetracycline levodopa ethanol cyclosporine
Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). 	metoclopramide	ethanol	none	{'e1': {'word': 'metoclopramide', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d652.s3.e1'}, 'e2': {'word': 'ethanol', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d652.s3.e5'}, 'sentence_id': 'DDI-DrugBank.d652.s3'}	Absorption drugs stomach may diminished e.g. digoxin metoclopramide whereas rate extent absorption drugs small bowel may increased e.g. acetaminophen tetracycline levodopa ethanol cyclosporine
Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). 	metoclopramide	cyclosporine	none	{'e1': {'word': 'metoclopramide', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d652.s3.e1'}, 'e2': {'word': 'cyclosporine', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d652.s3.e6'}, 'sentence_id': 'DDI-DrugBank.d652.s3'}	Absorption drugs stomach may diminished e.g. digoxin metoclopramide whereas rate extent absorption drugs small bowel may increased e.g. acetaminophen tetracycline levodopa ethanol cyclosporine
Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). 	acetaminophen	tetracycline	none	{'e1': {'word': 'acetaminophen', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d652.s3.e2'}, 'e2': {'word': 'tetracycline', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d652.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d652.s3'}	Absorption drugs stomach may diminished e.g. digoxin metoclopramide whereas rate extent absorption drugs small bowel may increased e.g. acetaminophen tetracycline levodopa ethanol cyclosporine
Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). 	acetaminophen	levodopa	none	{'e1': {'word': 'acetaminophen', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d652.s3.e2'}, 'e2': {'word': 'levodopa', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d652.s3.e4'}, 'sentence_id': 'DDI-DrugBank.d652.s3'}	Absorption drugs stomach may diminished e.g. digoxin metoclopramide whereas rate extent absorption drugs small bowel may increased e.g. acetaminophen tetracycline levodopa ethanol cyclosporine
Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). 	acetaminophen	ethanol	none	{'e1': {'word': 'acetaminophen', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d652.s3.e2'}, 'e2': {'word': 'ethanol', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d652.s3.e5'}, 'sentence_id': 'DDI-DrugBank.d652.s3'}	Absorption drugs stomach may diminished e.g. digoxin metoclopramide whereas rate extent absorption drugs small bowel may increased e.g. acetaminophen tetracycline levodopa ethanol cyclosporine
Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). 	acetaminophen	cyclosporine	none	{'e1': {'word': 'acetaminophen', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d652.s3.e2'}, 'e2': {'word': 'cyclosporine', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d652.s3.e6'}, 'sentence_id': 'DDI-DrugBank.d652.s3'}	Absorption drugs stomach may diminished e.g. digoxin metoclopramide whereas rate extent absorption drugs small bowel may increased e.g. acetaminophen tetracycline levodopa ethanol cyclosporine
Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). 	tetracycline	levodopa	none	{'e1': {'word': 'tetracycline', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d652.s3.e3'}, 'e2': {'word': 'levodopa', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d652.s3.e4'}, 'sentence_id': 'DDI-DrugBank.d652.s3'}	Absorption drugs stomach may diminished e.g. digoxin metoclopramide whereas rate extent absorption drugs small bowel may increased e.g. acetaminophen tetracycline levodopa ethanol cyclosporine
Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). 	tetracycline	ethanol	none	{'e1': {'word': 'tetracycline', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d652.s3.e3'}, 'e2': {'word': 'ethanol', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d652.s3.e5'}, 'sentence_id': 'DDI-DrugBank.d652.s3'}	Absorption drugs stomach may diminished e.g. digoxin metoclopramide whereas rate extent absorption drugs small bowel may increased e.g. acetaminophen tetracycline levodopa ethanol cyclosporine
Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). 	tetracycline	cyclosporine	none	{'e1': {'word': 'tetracycline', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d652.s3.e3'}, 'e2': {'word': 'cyclosporine', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d652.s3.e6'}, 'sentence_id': 'DDI-DrugBank.d652.s3'}	Absorption drugs stomach may diminished e.g. digoxin metoclopramide whereas rate extent absorption drugs small bowel may increased e.g. acetaminophen tetracycline levodopa ethanol cyclosporine
Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). 	levodopa	ethanol	none	{'e1': {'word': 'levodopa', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d652.s3.e4'}, 'e2': {'word': 'ethanol', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d652.s3.e5'}, 'sentence_id': 'DDI-DrugBank.d652.s3'}	Absorption drugs stomach may diminished e.g. digoxin metoclopramide whereas rate extent absorption drugs small bowel may increased e.g. acetaminophen tetracycline levodopa ethanol cyclosporine
Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). 	levodopa	cyclosporine	none	{'e1': {'word': 'levodopa', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d652.s3.e4'}, 'e2': {'word': 'cyclosporine', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d652.s3.e6'}, 'sentence_id': 'DDI-DrugBank.d652.s3'}	Absorption drugs stomach may diminished e.g. digoxin metoclopramide whereas rate extent absorption drugs small bowel may increased e.g. acetaminophen tetracycline levodopa ethanol cyclosporine
Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). 	ethanol	cyclosporine	none	{'e1': {'word': 'ethanol', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d652.s3.e5'}, 'e2': {'word': 'cyclosporine', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d652.s3.e6'}, 'sentence_id': 'DDI-DrugBank.d652.s3'}	Absorption drugs stomach may diminished e.g. digoxin metoclopramide whereas rate extent absorption drugs small bowel may increased e.g. acetaminophen tetracycline levodopa ethanol cyclosporine
Because the action of metoclopramide will influence the delivery of food to the intestines and thus the rate of absorption, insulin dosage or timing of dosage may require adjustment.	metoclopramide	insulin	advise	{'e1': {'word': 'metoclopramide', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d652.s6.e0'}, 'e2': {'word': 'insulin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d652.s6.e1'}, 'sentence_id': 'DDI-DrugBank.d652.s6'}	action metoclopramide influence delivery food intestines thus rate absorption insulin dosage timing dosage may require adjustment
Interactions for Vitamin B2 (Riboflavin):  Alcohol - impairs the intestinal absorption of riboflavin	Vitamin B2	Riboflavin	none	{'e1': {'word': 'Vitamin B2', 'word_index': [(1, 2)], 'id': 'DDI-DrugBank.d698.s0.e0'}, 'e2': {'word': 'Riboflavin', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d698.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d698.s0'}	Interactions Vitamin B2 Riboflavin Alcohol impairs intestinal absorption riboflavin
Interactions for Vitamin B2 (Riboflavin):  Alcohol - impairs the intestinal absorption of riboflavin	Vitamin B2	Alcohol	none	{'e1': {'word': 'Vitamin B2', 'word_index': [(1, 2)], 'id': 'DDI-DrugBank.d698.s0.e0'}, 'e2': {'word': 'Alcohol', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d698.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d698.s0'}	Interactions Vitamin B2 Riboflavin Alcohol impairs intestinal absorption riboflavin
Interactions for Vitamin B2 (Riboflavin):  Alcohol - impairs the intestinal absorption of riboflavin	Vitamin B2	riboflavin	none	{'e1': {'word': 'Vitamin B2', 'word_index': [(1, 2)], 'id': 'DDI-DrugBank.d698.s0.e0'}, 'e2': {'word': 'riboflavin', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d698.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d698.s0'}	Interactions Vitamin B2 Riboflavin Alcohol impairs intestinal absorption riboflavin
Interactions for Vitamin B2 (Riboflavin):  Alcohol - impairs the intestinal absorption of riboflavin	Riboflavin	Alcohol	none	{'e1': {'word': 'Riboflavin', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d698.s0.e1'}, 'e2': {'word': 'Alcohol', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d698.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d698.s0'}	Interactions Vitamin B2 Riboflavin Alcohol impairs intestinal absorption riboflavin
Interactions for Vitamin B2 (Riboflavin):  Alcohol - impairs the intestinal absorption of riboflavin	Riboflavin	riboflavin	none	{'e1': {'word': 'Riboflavin', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d698.s0.e1'}, 'e2': {'word': 'riboflavin', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d698.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d698.s0'}	Interactions Vitamin B2 Riboflavin Alcohol impairs intestinal absorption riboflavin
Interactions for Vitamin B2 (Riboflavin):  Alcohol - impairs the intestinal absorption of riboflavin	Alcohol	riboflavin	mechanism	{'e1': {'word': 'Alcohol', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d698.s0.e2'}, 'e2': {'word': 'riboflavin', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d698.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d698.s0'}	Interactions Vitamin B2 Riboflavin Alcohol impairs intestinal absorption riboflavin
Probenecid - concurrent use decreases gastrointestinal absorption of riboflavin; 	Probenecid	riboflavin	mechanism	{'e1': {'word': 'Probenecid', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d698.s1.e0'}, 'e2': {'word': 'riboflavin', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d698.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d698.s1'}	Probenecid concurrent use decreases gastrointestinal absorption riboflavin
requirements for riboflavin may be increased in patients receiving probenecid.	riboflavin	probenecid	effect	{'e1': {'word': 'riboflavin', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d698.s2.e0'}, 'e2': {'word': 'probenecid', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d698.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d698.s2'}	requirements riboflavin may increased patients receiving probenecid
Anticoagulants (oral): The activity of oral anticoagulants may be potentiated by anti-vitamin-K activity attributed to methimazole.    	Anticoagulants	anticoagulants	none	{'e1': {'word': 'Anticoagulants', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d634.s0.e0'}, 'e2': {'word': 'anticoagulants', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d634.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d634.s0'}	Anticoagulants oral activity oral anticoagulants may potentiated anti-vitamin K activity attributed methimazole
Anticoagulants (oral): The activity of oral anticoagulants may be potentiated by anti-vitamin-K activity attributed to methimazole.    	Anticoagulants	methimazole	none	{'e1': {'word': 'Anticoagulants', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d634.s0.e0'}, 'e2': {'word': 'methimazole', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d634.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d634.s0'}	Anticoagulants oral activity oral anticoagulants may potentiated anti-vitamin K activity attributed methimazole
Anticoagulants (oral): The activity of oral anticoagulants may be potentiated by anti-vitamin-K activity attributed to methimazole.    	anticoagulants	methimazole	effect	{'e1': {'word': 'anticoagulants', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d634.s0.e1'}, 'e2': {'word': 'methimazole', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d634.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d634.s0'}	Anticoagulants oral activity oral anticoagulants may potentiated anti-vitamin K activity attributed methimazole
Digitalis glycosides: Serum digitalis levels may be increased when hyperthyroid patients on a stable digitalis glycoside regimen become euthyroid; 	Digitalis glycosides	digitalis glycoside	none	{'e1': {'word': 'Digitalis glycosides', 'word_index': [(0, 1)], 'id': 'DDI-DrugBank.d634.s3.e0'}, 'e2': {'word': 'digitalis glycoside', 'word_index': [(10, 11)], 'id': 'DDI-DrugBank.d634.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d634.s3'}	Digitalis glycosides Serum digitalis levels may increased hyperthyroid patients stable digitalis glycoside regimen become euthyroid
Theophylline: Theophylline clearance may decrease when hyperthyroid patients on a stable theophylline regimen become euthyroid; 	Theophylline	Theophylline	none	{'e1': {'word': 'Theophylline', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d634.s5.e0'}, 'e2': {'word': 'Theophylline', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d634.s5.e1'}, 'sentence_id': 'DDI-DrugBank.d634.s5'}	Theophylline Theophylline clearance may decrease hyperthyroid patients stable theophylline regimen become euthyroid
Theophylline: Theophylline clearance may decrease when hyperthyroid patients on a stable theophylline regimen become euthyroid; 	Theophylline	theophylline	none	{'e1': {'word': 'Theophylline', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d634.s5.e0'}, 'e2': {'word': 'theophylline', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d634.s5.e2'}, 'sentence_id': 'DDI-DrugBank.d634.s5'}	Theophylline Theophylline clearance may decrease hyperthyroid patients stable theophylline regimen become euthyroid
Theophylline: Theophylline clearance may decrease when hyperthyroid patients on a stable theophylline regimen become euthyroid; 	Theophylline	theophylline	none	{'e1': {'word': 'Theophylline', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d634.s5.e1'}, 'e2': {'word': 'theophylline', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d634.s5.e2'}, 'sentence_id': 'DDI-DrugBank.d634.s5'}	Theophylline Theophylline clearance may decrease hyperthyroid patients stable theophylline regimen become euthyroid
Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	Barbiturates	contraceptives	int	{'e1': {'word': 'Barbiturates', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d601.s0.e0'}, 'e2': {'word': 'contraceptives', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d601.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d601.s0'}	Barbiturates may decrease effectiveness oral contraceptives certain antibiotics quinidine theophylline corticosteroids anticoagulants beta blockers
Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	Barbiturates	antibiotics	int	{'e1': {'word': 'Barbiturates', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d601.s0.e0'}, 'e2': {'word': 'antibiotics', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d601.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d601.s0'}	Barbiturates may decrease effectiveness oral contraceptives certain antibiotics quinidine theophylline corticosteroids anticoagulants beta blockers
Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	Barbiturates	quinidine	int	{'e1': {'word': 'Barbiturates', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d601.s0.e0'}, 'e2': {'word': 'quinidine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d601.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d601.s0'}	Barbiturates may decrease effectiveness oral contraceptives certain antibiotics quinidine theophylline corticosteroids anticoagulants beta blockers
Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	Barbiturates	theophylline	int	{'e1': {'word': 'Barbiturates', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d601.s0.e0'}, 'e2': {'word': 'theophylline', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d601.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d601.s0'}	Barbiturates may decrease effectiveness oral contraceptives certain antibiotics quinidine theophylline corticosteroids anticoagulants beta blockers
Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	Barbiturates	corticosteroids	int	{'e1': {'word': 'Barbiturates', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d601.s0.e0'}, 'e2': {'word': 'corticosteroids', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d601.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d601.s0'}	Barbiturates may decrease effectiveness oral contraceptives certain antibiotics quinidine theophylline corticosteroids anticoagulants beta blockers
Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	Barbiturates	anticoagulants	int	{'e1': {'word': 'Barbiturates', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d601.s0.e0'}, 'e2': {'word': 'anticoagulants', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d601.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d601.s0'}	Barbiturates may decrease effectiveness oral contraceptives certain antibiotics quinidine theophylline corticosteroids anticoagulants beta blockers
Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	Barbiturates	beta blockers	int	{'e1': {'word': 'Barbiturates', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d601.s0.e0'}, 'e2': {'word': 'beta blockers', 'word_index': [(12, 13)], 'id': 'DDI-DrugBank.d601.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d601.s0'}	Barbiturates may decrease effectiveness oral contraceptives certain antibiotics quinidine theophylline corticosteroids anticoagulants beta blockers
Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	contraceptives	antibiotics	none	{'e1': {'word': 'contraceptives', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d601.s0.e1'}, 'e2': {'word': 'antibiotics', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d601.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d601.s0'}	Barbiturates may decrease effectiveness oral contraceptives certain antibiotics quinidine theophylline corticosteroids anticoagulants beta blockers
Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	contraceptives	quinidine	none	{'e1': {'word': 'contraceptives', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d601.s0.e1'}, 'e2': {'word': 'quinidine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d601.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d601.s0'}	Barbiturates may decrease effectiveness oral contraceptives certain antibiotics quinidine theophylline corticosteroids anticoagulants beta blockers
Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	contraceptives	theophylline	none	{'e1': {'word': 'contraceptives', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d601.s0.e1'}, 'e2': {'word': 'theophylline', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d601.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d601.s0'}	Barbiturates may decrease effectiveness oral contraceptives certain antibiotics quinidine theophylline corticosteroids anticoagulants beta blockers
Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	contraceptives	corticosteroids	none	{'e1': {'word': 'contraceptives', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d601.s0.e1'}, 'e2': {'word': 'corticosteroids', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d601.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d601.s0'}	Barbiturates may decrease effectiveness oral contraceptives certain antibiotics quinidine theophylline corticosteroids anticoagulants beta blockers
Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	contraceptives	anticoagulants	none	{'e1': {'word': 'contraceptives', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d601.s0.e1'}, 'e2': {'word': 'anticoagulants', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d601.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d601.s0'}	Barbiturates may decrease effectiveness oral contraceptives certain antibiotics quinidine theophylline corticosteroids anticoagulants beta blockers
Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	contraceptives	beta blockers	none	{'e1': {'word': 'contraceptives', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d601.s0.e1'}, 'e2': {'word': 'beta blockers', 'word_index': [(12, 13)], 'id': 'DDI-DrugBank.d601.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d601.s0'}	Barbiturates may decrease effectiveness oral contraceptives certain antibiotics quinidine theophylline corticosteroids anticoagulants beta blockers
Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	antibiotics	quinidine	none	{'e1': {'word': 'antibiotics', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d601.s0.e2'}, 'e2': {'word': 'quinidine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d601.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d601.s0'}	Barbiturates may decrease effectiveness oral contraceptives certain antibiotics quinidine theophylline corticosteroids anticoagulants beta blockers
Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	antibiotics	theophylline	none	{'e1': {'word': 'antibiotics', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d601.s0.e2'}, 'e2': {'word': 'theophylline', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d601.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d601.s0'}	Barbiturates may decrease effectiveness oral contraceptives certain antibiotics quinidine theophylline corticosteroids anticoagulants beta blockers
Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	antibiotics	corticosteroids	none	{'e1': {'word': 'antibiotics', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d601.s0.e2'}, 'e2': {'word': 'corticosteroids', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d601.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d601.s0'}	Barbiturates may decrease effectiveness oral contraceptives certain antibiotics quinidine theophylline corticosteroids anticoagulants beta blockers
Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	antibiotics	anticoagulants	none	{'e1': {'word': 'antibiotics', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d601.s0.e2'}, 'e2': {'word': 'anticoagulants', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d601.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d601.s0'}	Barbiturates may decrease effectiveness oral contraceptives certain antibiotics quinidine theophylline corticosteroids anticoagulants beta blockers
Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	antibiotics	beta blockers	none	{'e1': {'word': 'antibiotics', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d601.s0.e2'}, 'e2': {'word': 'beta blockers', 'word_index': [(12, 13)], 'id': 'DDI-DrugBank.d601.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d601.s0'}	Barbiturates may decrease effectiveness oral contraceptives certain antibiotics quinidine theophylline corticosteroids anticoagulants beta blockers
Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	quinidine	theophylline	none	{'e1': {'word': 'quinidine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d601.s0.e3'}, 'e2': {'word': 'theophylline', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d601.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d601.s0'}	Barbiturates may decrease effectiveness oral contraceptives certain antibiotics quinidine theophylline corticosteroids anticoagulants beta blockers
Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	quinidine	corticosteroids	none	{'e1': {'word': 'quinidine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d601.s0.e3'}, 'e2': {'word': 'corticosteroids', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d601.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d601.s0'}	Barbiturates may decrease effectiveness oral contraceptives certain antibiotics quinidine theophylline corticosteroids anticoagulants beta blockers
Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	quinidine	anticoagulants	none	{'e1': {'word': 'quinidine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d601.s0.e3'}, 'e2': {'word': 'anticoagulants', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d601.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d601.s0'}	Barbiturates may decrease effectiveness oral contraceptives certain antibiotics quinidine theophylline corticosteroids anticoagulants beta blockers
Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	quinidine	beta blockers	none	{'e1': {'word': 'quinidine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d601.s0.e3'}, 'e2': {'word': 'beta blockers', 'word_index': [(12, 13)], 'id': 'DDI-DrugBank.d601.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d601.s0'}	Barbiturates may decrease effectiveness oral contraceptives certain antibiotics quinidine theophylline corticosteroids anticoagulants beta blockers
Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	theophylline	corticosteroids	none	{'e1': {'word': 'theophylline', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d601.s0.e4'}, 'e2': {'word': 'corticosteroids', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d601.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d601.s0'}	Barbiturates may decrease effectiveness oral contraceptives certain antibiotics quinidine theophylline corticosteroids anticoagulants beta blockers
Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	theophylline	anticoagulants	none	{'e1': {'word': 'theophylline', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d601.s0.e4'}, 'e2': {'word': 'anticoagulants', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d601.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d601.s0'}	Barbiturates may decrease effectiveness oral contraceptives certain antibiotics quinidine theophylline corticosteroids anticoagulants beta blockers
Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	theophylline	beta blockers	none	{'e1': {'word': 'theophylline', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d601.s0.e4'}, 'e2': {'word': 'beta blockers', 'word_index': [(12, 13)], 'id': 'DDI-DrugBank.d601.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d601.s0'}	Barbiturates may decrease effectiveness oral contraceptives certain antibiotics quinidine theophylline corticosteroids anticoagulants beta blockers
Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	corticosteroids	anticoagulants	none	{'e1': {'word': 'corticosteroids', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d601.s0.e5'}, 'e2': {'word': 'anticoagulants', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d601.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d601.s0'}	Barbiturates may decrease effectiveness oral contraceptives certain antibiotics quinidine theophylline corticosteroids anticoagulants beta blockers
Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	corticosteroids	beta blockers	none	{'e1': {'word': 'corticosteroids', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d601.s0.e5'}, 'e2': {'word': 'beta blockers', 'word_index': [(12, 13)], 'id': 'DDI-DrugBank.d601.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d601.s0'}	Barbiturates may decrease effectiveness oral contraceptives certain antibiotics quinidine theophylline corticosteroids anticoagulants beta blockers
Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	anticoagulants	beta blockers	none	{'e1': {'word': 'anticoagulants', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d601.s0.e6'}, 'e2': {'word': 'beta blockers', 'word_index': [(12, 13)], 'id': 'DDI-DrugBank.d601.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d601.s0'}	Barbiturates may decrease effectiveness oral contraceptives certain antibiotics quinidine theophylline corticosteroids anticoagulants beta blockers
Vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all. 	Vasopressors	metaraminol	none	{'e1': {'word': 'Vasopressors', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d725.s0.e0'}, 'e2': {'word': 'metaraminol', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d725.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d725.s0'}	Vasopressors particularly metaraminol may cause serious cardiac arrhythmias halothane anesthesia therefore used great caution
Vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all. 	Vasopressors	halothane	effect	{'e1': {'word': 'Vasopressors', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d725.s0.e0'}, 'e2': {'word': 'halothane', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d725.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d725.s0'}	Vasopressors particularly metaraminol may cause serious cardiac arrhythmias halothane anesthesia therefore used great caution
Vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all. 	metaraminol	halothane	effect	{'e1': {'word': 'metaraminol', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d725.s0.e1'}, 'e2': {'word': 'halothane', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d725.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d725.s0'}	Vasopressors particularly metaraminol may cause serious cardiac arrhythmias halothane anesthesia therefore used great caution
MAO Inhibitors: The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). 	MAO Inhibitors	sympathomimetic pressor amines	none	{'e1': {'word': 'MAO Inhibitors', 'word_index': [(0, 1)], 'id': 'DDI-DrugBank.d725.s1.e0'}, 'e2': {'word': 'sympathomimetic pressor amines', 'word_index': [(4, 6)], 'id': 'DDI-DrugBank.d725.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d725.s1'}	MAO Inhibitors pressor effect sympathomimetic pressor amines markedly potentiated patients receiving monoamine oxidase inhibitors MAOI
MAO Inhibitors: The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). 	MAO Inhibitors	monoamine oxidase inhibitors	none	{'e1': {'word': 'MAO Inhibitors', 'word_index': [(0, 1)], 'id': 'DDI-DrugBank.d725.s1.e0'}, 'e2': {'word': 'monoamine oxidase inhibitors', 'word_index': [(11, 13)], 'id': 'DDI-DrugBank.d725.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d725.s1'}	MAO Inhibitors pressor effect sympathomimetic pressor amines markedly potentiated patients receiving monoamine oxidase inhibitors MAOI
MAO Inhibitors: The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). 	MAO Inhibitors	MAOI	none	{'e1': {'word': 'MAO Inhibitors', 'word_index': [(0, 1)], 'id': 'DDI-DrugBank.d725.s1.e0'}, 'e2': {'word': 'MAOI', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d725.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d725.s1'}	MAO Inhibitors pressor effect sympathomimetic pressor amines markedly potentiated patients receiving monoamine oxidase inhibitors MAOI
MAO Inhibitors: The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). 	sympathomimetic pressor amines	monoamine oxidase inhibitors	effect	{'e1': {'word': 'sympathomimetic pressor amines', 'word_index': [(4, 6)], 'id': 'DDI-DrugBank.d725.s1.e1'}, 'e2': {'word': 'monoamine oxidase inhibitors', 'word_index': [(11, 13)], 'id': 'DDI-DrugBank.d725.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d725.s1'}	MAO Inhibitors pressor effect sympathomimetic pressor amines markedly potentiated patients receiving monoamine oxidase inhibitors MAOI
MAO Inhibitors: The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). 	sympathomimetic pressor amines	MAOI	effect	{'e1': {'word': 'sympathomimetic pressor amines', 'word_index': [(4, 6)], 'id': 'DDI-DrugBank.d725.s1.e1'}, 'e2': {'word': 'MAOI', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d725.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d725.s1'}	MAO Inhibitors pressor effect sympathomimetic pressor amines markedly potentiated patients receiving monoamine oxidase inhibitors MAOI
MAO Inhibitors: The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). 	monoamine oxidase inhibitors	MAOI	none	{'e1': {'word': 'monoamine oxidase inhibitors', 'word_index': [(11, 13)], 'id': 'DDI-DrugBank.d725.s1.e2'}, 'e2': {'word': 'MAOI', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d725.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d725.s1'}	MAO Inhibitors pressor effect sympathomimetic pressor amines markedly potentiated patients receiving monoamine oxidase inhibitors MAOI
The pressor response of adrenergic agents may also be potentiated by tricyclic antidepressants.	adrenergic agents	tricyclic antidepressants	effect	{'e1': {'word': 'adrenergic agents', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d725.s3.e0'}, 'e2': {'word': 'tricyclic antidepressants', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d725.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d725.s3'}	pressor response adrenergic agents may also potentiated tricyclic antidepressants
However, ketoconazole, a potent inhibitor of cytochrome P450 3A4, may increase plasma levels of mometasone furoate during concomitant dosing.	ketoconazole	mometasone furoate	mechanism	{'e1': {'word': 'ketoconazole', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d580.s1.e0'}, 'e2': {'word': 'mometasone furoate', 'word_index': [(11, 12)], 'id': 'DDI-DrugBank.d580.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d580.s1'}	However ketoconazole potent inhibitor cytochrome P450 3A4 may increase plasma levels mometasone furoate concomitant dosing
Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. 	Thiazide diuretics	phenothiazines	effect	{'e1': {'word': 'Thiazide diuretics', 'word_index': [(0, 1)], 'id': 'DDI-DrugBank.d734.s0.e0'}, 'e2': {'word': 'phenothiazines', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d734.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d734.s0'}	Thiazide diuretics may accentuate orthostatic hypotension may occur phenothiazines
Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concomitantly. 	guanethidine	phenothiazines	effect	{'e1': {'word': 'guanethidine', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d734.s1.e0'}, 'e2': {'word': 'phenothiazines', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d734.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d734.s1'}	Antihypertensive effects guanethidine related compounds may counteracted phenothiazines used concomitantly
Concomitant administration of propranolol with phenothiazines results in increased plasma levels of both drugs.	propranolol	phenothiazines	mechanism	{'e1': {'word': 'propranolol', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d734.s2.e0'}, 'e2': {'word': 'phenothiazines', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d734.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d734.s2'}	Concomitant administration propranolol phenothiazines results increased plasma levels drugs
Interaction with Guanethidine: Although minoxidil does not itself cause orthostatic hypotension, its administration to patients already receiving guanethidine can result in profound orthostatic effects. 	Guanethidine	minoxidil	none	{'e1': {'word': 'Guanethidine', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d573.s0.e0'}, 'e2': {'word': 'minoxidil', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d573.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d573.s0'}	Interaction Guanethidine Although minoxidil cause orthostatic hypotension administration patients already receiving guanethidine result profound orthostatic effects
Interaction with Guanethidine: Although minoxidil does not itself cause orthostatic hypotension, its administration to patients already receiving guanethidine can result in profound orthostatic effects. 	Guanethidine	guanethidine	none	{'e1': {'word': 'Guanethidine', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d573.s0.e0'}, 'e2': {'word': 'guanethidine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d573.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d573.s0'}	Interaction Guanethidine Although minoxidil cause orthostatic hypotension administration patients already receiving guanethidine result profound orthostatic effects
Interaction with Guanethidine: Although minoxidil does not itself cause orthostatic hypotension, its administration to patients already receiving guanethidine can result in profound orthostatic effects. 	minoxidil	guanethidine	effect	{'e1': {'word': 'minoxidil', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d573.s0.e1'}, 'e2': {'word': 'guanethidine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d573.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d573.s0'}	Interaction Guanethidine Although minoxidil cause orthostatic hypotension administration patients already receiving guanethidine result profound orthostatic effects
If at all possible guanethidine should be discontinued well before minoxidil is begun. 	guanethidine	minoxidil	advise	{'e1': {'word': 'guanethidine', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d573.s1.e0'}, 'e2': {'word': 'minoxidil', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d573.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d573.s1'}	possible guanethidine discontinued well minoxidil begun
Methysergide may reverse the analgesic activity of narcotic analgesics. 	Methysergide	narcotic analgesics	effect	{'e1': {'word': 'Methysergide', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d696.s0.e0'}, 'e2': {'word': 'narcotic analgesics', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d696.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d696.s0'}	Methysergide may reverse analgesic activity narcotic analgesics
Concurrent use with vasoconstrictor agents including ergot alkaloids, sumatriptan, and nicotine (e.g. smoking) may result in enhanced vasoconstriction.	vasoconstrictor agents	ergot alkaloids	none	{'e1': {'word': 'vasoconstrictor agents', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d696.s1.e0'}, 'e2': {'word': 'ergot alkaloids', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d696.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d696.s1'}	Concurrent use vasoconstrictor agents including ergot alkaloids sumatriptan nicotine e.g. smoking may result enhanced vasoconstriction
Concurrent use with vasoconstrictor agents including ergot alkaloids, sumatriptan, and nicotine (e.g. smoking) may result in enhanced vasoconstriction.	vasoconstrictor agents	sumatriptan	none	{'e1': {'word': 'vasoconstrictor agents', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d696.s1.e0'}, 'e2': {'word': 'sumatriptan', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d696.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d696.s1'}	Concurrent use vasoconstrictor agents including ergot alkaloids sumatriptan nicotine e.g. smoking may result enhanced vasoconstriction
Concurrent use with vasoconstrictor agents including ergot alkaloids, sumatriptan, and nicotine (e.g. smoking) may result in enhanced vasoconstriction.	vasoconstrictor agents	nicotine	none	{'e1': {'word': 'vasoconstrictor agents', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d696.s1.e0'}, 'e2': {'word': 'nicotine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d696.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d696.s1'}	Concurrent use vasoconstrictor agents including ergot alkaloids sumatriptan nicotine e.g. smoking may result enhanced vasoconstriction
Concurrent use with vasoconstrictor agents including ergot alkaloids, sumatriptan, and nicotine (e.g. smoking) may result in enhanced vasoconstriction.	ergot alkaloids	sumatriptan	none	{'e1': {'word': 'ergot alkaloids', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d696.s1.e1'}, 'e2': {'word': 'sumatriptan', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d696.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d696.s1'}	Concurrent use vasoconstrictor agents including ergot alkaloids sumatriptan nicotine e.g. smoking may result enhanced vasoconstriction
Concurrent use with vasoconstrictor agents including ergot alkaloids, sumatriptan, and nicotine (e.g. smoking) may result in enhanced vasoconstriction.	ergot alkaloids	nicotine	none	{'e1': {'word': 'ergot alkaloids', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d696.s1.e1'}, 'e2': {'word': 'nicotine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d696.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d696.s1'}	Concurrent use vasoconstrictor agents including ergot alkaloids sumatriptan nicotine e.g. smoking may result enhanced vasoconstriction
Concurrent use with vasoconstrictor agents including ergot alkaloids, sumatriptan, and nicotine (e.g. smoking) may result in enhanced vasoconstriction.	sumatriptan	nicotine	none	{'e1': {'word': 'sumatriptan', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d696.s1.e2'}, 'e2': {'word': 'nicotine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d696.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d696.s1'}	Concurrent use vasoconstrictor agents including ergot alkaloids sumatriptan nicotine e.g. smoking may result enhanced vasoconstriction
however, in patients with Paget's Disease prior diphosphonate use appears to reduce the anti-resorptive response to Calcitonin (salmon) nasal spray.	diphosphonate	Calcitonin (salmon)	effect	{'e1': {'word': 'diphosphonate', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d770.s4.e0'}, 'e2': {'word': 'Calcitonin (salmon)', 'word_index': [(12, 13)], 'id': 'DDI-DrugBank.d770.s4.e1'}, 'sentence_id': 'DDI-DrugBank.d770.s4'}	however patients Paget 's Disease prior diphosphonate use appears reduce anti-resorptive response Calcitonin salmon nasal spray
Streptozocin has been reported to prolong the elimination half-life of doxorubicin and may lead to severe bone marrow suppression; 	Streptozocin	doxorubicin	mechanism	{'e1': {'word': 'Streptozocin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d647.s1.e0'}, 'e2': {'word': 'doxorubicin', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d647.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d647.s1'}	Streptozocin reported prolong elimination half life doxorubicin may lead severe bone marrow suppression
a reduction of the doxorubicin dosage should be considered in patients receiving ZANOSAR concurrently. 	doxorubicin	ZANOSAR	advise	{'e1': {'word': 'doxorubicin', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d647.s2.e0'}, 'e2': {'word': 'ZANOSAR', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d647.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d647.s2'}	reduction doxorubicin dosage considered patients receiving ZANOSAR concurrently
The concurrent use of streptozocin and phenytoin has been reported in one case to result in reduced streptozocin cytotoxicity.    	streptozocin	phenytoin	effect	{'e1': {'word': 'streptozocin', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d647.s3.e0'}, 'e2': {'word': 'phenytoin', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d647.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d647.s3'}	concurrent use streptozocin phenytoin reported NUMBER case result reduced streptozocin cytotoxicity
The concurrent use of streptozocin and phenytoin has been reported in one case to result in reduced streptozocin cytotoxicity.    	streptozocin	streptozocin	none	{'e1': {'word': 'streptozocin', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d647.s3.e0'}, 'e2': {'word': 'streptozocin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d647.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d647.s3'}	concurrent use streptozocin phenytoin reported NUMBER case result reduced streptozocin cytotoxicity
The concurrent use of streptozocin and phenytoin has been reported in one case to result in reduced streptozocin cytotoxicity.    	phenytoin	streptozocin	none	{'e1': {'word': 'phenytoin', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d647.s3.e1'}, 'e2': {'word': 'streptozocin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d647.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d647.s3'}	concurrent use streptozocin phenytoin reported NUMBER case result reduced streptozocin cytotoxicity
Preliminary evidence suggests that cimetidine inhibits mebendazole metabolism and may result in an increase in plasma concentrations of mebendazole.	cimetidine	mebendazole	mechanism	{'e1': {'word': 'cimetidine', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d679.s0.e0'}, 'e2': {'word': 'mebendazole', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d679.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d679.s0'}	Preliminary evidence suggests cimetidine inhibits mebendazole metabolism may result increase plasma concentrations mebendazole
Preliminary evidence suggests that cimetidine inhibits mebendazole metabolism and may result in an increase in plasma concentrations of mebendazole.	cimetidine	mebendazole	none	{'e1': {'word': 'cimetidine', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d679.s0.e0'}, 'e2': {'word': 'mebendazole', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d679.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d679.s0'}	Preliminary evidence suggests cimetidine inhibits mebendazole metabolism may result increase plasma concentrations mebendazole
Preliminary evidence suggests that cimetidine inhibits mebendazole metabolism and may result in an increase in plasma concentrations of mebendazole.	mebendazole	mebendazole	none	{'e1': {'word': 'mebendazole', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d679.s0.e1'}, 'e2': {'word': 'mebendazole', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d679.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d679.s0'}	Preliminary evidence suggests cimetidine inhibits mebendazole metabolism may result increase plasma concentrations mebendazole
Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. 	Alcohol	XENICAL	none	{'e1': {'word': 'Alcohol', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d761.s0.e0'}, 'e2': {'word': 'XENICAL', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d761.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d761.s0'}	Alcohol multiple dose study NUMBER normal weight subjects coadministration XENICAL NUMBER grams alcohol e.g. approximately NUMBER glasses wine result alteration alcohol pharmacokinetics orlistat pharmacodynamics fecal fat excretion systemic exposure orlistat
Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. 	Alcohol	alcohol	none	{'e1': {'word': 'Alcohol', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d761.s0.e0'}, 'e2': {'word': 'alcohol', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d761.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d761.s0'}	Alcohol multiple dose study NUMBER normal weight subjects coadministration XENICAL NUMBER grams alcohol e.g. approximately NUMBER glasses wine result alteration alcohol pharmacokinetics orlistat pharmacodynamics fecal fat excretion systemic exposure orlistat
Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. 	Alcohol	alcohol	none	{'e1': {'word': 'Alcohol', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d761.s0.e0'}, 'e2': {'word': 'alcohol', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d761.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d761.s0'}	Alcohol multiple dose study NUMBER normal weight subjects coadministration XENICAL NUMBER grams alcohol e.g. approximately NUMBER glasses wine result alteration alcohol pharmacokinetics orlistat pharmacodynamics fecal fat excretion systemic exposure orlistat
Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. 	Alcohol	orlistat	none	{'e1': {'word': 'Alcohol', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d761.s0.e0'}, 'e2': {'word': 'orlistat', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d761.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d761.s0'}	Alcohol multiple dose study NUMBER normal weight subjects coadministration XENICAL NUMBER grams alcohol e.g. approximately NUMBER glasses wine result alteration alcohol pharmacokinetics orlistat pharmacodynamics fecal fat excretion systemic exposure orlistat
Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. 	Alcohol	orlistat	none	{'e1': {'word': 'Alcohol', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d761.s0.e0'}, 'e2': {'word': 'orlistat', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d761.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d761.s0'}	Alcohol multiple dose study NUMBER normal weight subjects coadministration XENICAL NUMBER grams alcohol e.g. approximately NUMBER glasses wine result alteration alcohol pharmacokinetics orlistat pharmacodynamics fecal fat excretion systemic exposure orlistat
Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. 	XENICAL	alcohol	none	{'e1': {'word': 'XENICAL', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d761.s0.e1'}, 'e2': {'word': 'alcohol', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d761.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d761.s0'}	Alcohol multiple dose study NUMBER normal weight subjects coadministration XENICAL NUMBER grams alcohol e.g. approximately NUMBER glasses wine result alteration alcohol pharmacokinetics orlistat pharmacodynamics fecal fat excretion systemic exposure orlistat
Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. 	XENICAL	alcohol	none	{'e1': {'word': 'XENICAL', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d761.s0.e1'}, 'e2': {'word': 'alcohol', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d761.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d761.s0'}	Alcohol multiple dose study NUMBER normal weight subjects coadministration XENICAL NUMBER grams alcohol e.g. approximately NUMBER glasses wine result alteration alcohol pharmacokinetics orlistat pharmacodynamics fecal fat excretion systemic exposure orlistat
Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. 	XENICAL	orlistat	none	{'e1': {'word': 'XENICAL', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d761.s0.e1'}, 'e2': {'word': 'orlistat', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d761.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d761.s0'}	Alcohol multiple dose study NUMBER normal weight subjects coadministration XENICAL NUMBER grams alcohol e.g. approximately NUMBER glasses wine result alteration alcohol pharmacokinetics orlistat pharmacodynamics fecal fat excretion systemic exposure orlistat
Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. 	XENICAL	orlistat	none	{'e1': {'word': 'XENICAL', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d761.s0.e1'}, 'e2': {'word': 'orlistat', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d761.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d761.s0'}	Alcohol multiple dose study NUMBER normal weight subjects coadministration XENICAL NUMBER grams alcohol e.g. approximately NUMBER glasses wine result alteration alcohol pharmacokinetics orlistat pharmacodynamics fecal fat excretion systemic exposure orlistat
Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. 	alcohol	alcohol	none	{'e1': {'word': 'alcohol', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d761.s0.e2'}, 'e2': {'word': 'alcohol', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d761.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d761.s0'}	Alcohol multiple dose study NUMBER normal weight subjects coadministration XENICAL NUMBER grams alcohol e.g. approximately NUMBER glasses wine result alteration alcohol pharmacokinetics orlistat pharmacodynamics fecal fat excretion systemic exposure orlistat
Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. 	alcohol	orlistat	none	{'e1': {'word': 'alcohol', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d761.s0.e2'}, 'e2': {'word': 'orlistat', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d761.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d761.s0'}	Alcohol multiple dose study NUMBER normal weight subjects coadministration XENICAL NUMBER grams alcohol e.g. approximately NUMBER glasses wine result alteration alcohol pharmacokinetics orlistat pharmacodynamics fecal fat excretion systemic exposure orlistat
Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. 	alcohol	orlistat	none	{'e1': {'word': 'alcohol', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d761.s0.e2'}, 'e2': {'word': 'orlistat', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d761.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d761.s0'}	Alcohol multiple dose study NUMBER normal weight subjects coadministration XENICAL NUMBER grams alcohol e.g. approximately NUMBER glasses wine result alteration alcohol pharmacokinetics orlistat pharmacodynamics fecal fat excretion systemic exposure orlistat
Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. 	alcohol	orlistat	none	{'e1': {'word': 'alcohol', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d761.s0.e3'}, 'e2': {'word': 'orlistat', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d761.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d761.s0'}	Alcohol multiple dose study NUMBER normal weight subjects coadministration XENICAL NUMBER grams alcohol e.g. approximately NUMBER glasses wine result alteration alcohol pharmacokinetics orlistat pharmacodynamics fecal fat excretion systemic exposure orlistat
Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. 	alcohol	orlistat	none	{'e1': {'word': 'alcohol', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d761.s0.e3'}, 'e2': {'word': 'orlistat', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d761.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d761.s0'}	Alcohol multiple dose study NUMBER normal weight subjects coadministration XENICAL NUMBER grams alcohol e.g. approximately NUMBER glasses wine result alteration alcohol pharmacokinetics orlistat pharmacodynamics fecal fat excretion systemic exposure orlistat
Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. 	orlistat	orlistat	none	{'e1': {'word': 'orlistat', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d761.s0.e4'}, 'e2': {'word': 'orlistat', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d761.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d761.s0'}	Alcohol multiple dose study NUMBER normal weight subjects coadministration XENICAL NUMBER grams alcohol e.g. approximately NUMBER glasses wine result alteration alcohol pharmacokinetics orlistat pharmacodynamics fecal fat excretion systemic exposure orlistat
Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. 	Cyclosporine	XENICAL	none	{'e1': {'word': 'Cyclosporine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d761.s1.e0'}, 'e2': {'word': 'XENICAL', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d761.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d761.s1'}	Cyclosporine Preliminary data XENICAL cyclosporine drug interaction study indicate reduction cyclosporine plasma levels XENICAL coadministered cyclosporine
Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. 	Cyclosporine	cyclosporine	none	{'e1': {'word': 'Cyclosporine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d761.s1.e0'}, 'e2': {'word': 'cyclosporine', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d761.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d761.s1'}	Cyclosporine Preliminary data XENICAL cyclosporine drug interaction study indicate reduction cyclosporine plasma levels XENICAL coadministered cyclosporine
Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. 	Cyclosporine	cyclosporine	none	{'e1': {'word': 'Cyclosporine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d761.s1.e0'}, 'e2': {'word': 'cyclosporine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d761.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d761.s1'}	Cyclosporine Preliminary data XENICAL cyclosporine drug interaction study indicate reduction cyclosporine plasma levels XENICAL coadministered cyclosporine
Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. 	Cyclosporine	XENICAL	none	{'e1': {'word': 'Cyclosporine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d761.s1.e0'}, 'e2': {'word': 'XENICAL', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d761.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d761.s1'}	Cyclosporine Preliminary data XENICAL cyclosporine drug interaction study indicate reduction cyclosporine plasma levels XENICAL coadministered cyclosporine
Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. 	Cyclosporine	cyclosporine	none	{'e1': {'word': 'Cyclosporine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d761.s1.e0'}, 'e2': {'word': 'cyclosporine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d761.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d761.s1'}	Cyclosporine Preliminary data XENICAL cyclosporine drug interaction study indicate reduction cyclosporine plasma levels XENICAL coadministered cyclosporine
Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. 	XENICAL	cyclosporine	none	{'e1': {'word': 'XENICAL', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d761.s1.e1'}, 'e2': {'word': 'cyclosporine', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d761.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d761.s1'}	Cyclosporine Preliminary data XENICAL cyclosporine drug interaction study indicate reduction cyclosporine plasma levels XENICAL coadministered cyclosporine
Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. 	XENICAL	cyclosporine	none	{'e1': {'word': 'XENICAL', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d761.s1.e1'}, 'e2': {'word': 'cyclosporine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d761.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d761.s1'}	Cyclosporine Preliminary data XENICAL cyclosporine drug interaction study indicate reduction cyclosporine plasma levels XENICAL coadministered cyclosporine
Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. 	XENICAL	XENICAL	none	{'e1': {'word': 'XENICAL', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d761.s1.e1'}, 'e2': {'word': 'XENICAL', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d761.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d761.s1'}	Cyclosporine Preliminary data XENICAL cyclosporine drug interaction study indicate reduction cyclosporine plasma levels XENICAL coadministered cyclosporine
Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. 	XENICAL	cyclosporine	none	{'e1': {'word': 'XENICAL', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d761.s1.e1'}, 'e2': {'word': 'cyclosporine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d761.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d761.s1'}	Cyclosporine Preliminary data XENICAL cyclosporine drug interaction study indicate reduction cyclosporine plasma levels XENICAL coadministered cyclosporine
Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. 	cyclosporine	cyclosporine	none	{'e1': {'word': 'cyclosporine', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d761.s1.e2'}, 'e2': {'word': 'cyclosporine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d761.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d761.s1'}	Cyclosporine Preliminary data XENICAL cyclosporine drug interaction study indicate reduction cyclosporine plasma levels XENICAL coadministered cyclosporine
Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. 	cyclosporine	XENICAL	none	{'e1': {'word': 'cyclosporine', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d761.s1.e2'}, 'e2': {'word': 'XENICAL', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d761.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d761.s1'}	Cyclosporine Preliminary data XENICAL cyclosporine drug interaction study indicate reduction cyclosporine plasma levels XENICAL coadministered cyclosporine
Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. 	cyclosporine	cyclosporine	none	{'e1': {'word': 'cyclosporine', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d761.s1.e2'}, 'e2': {'word': 'cyclosporine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d761.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d761.s1'}	Cyclosporine Preliminary data XENICAL cyclosporine drug interaction study indicate reduction cyclosporine plasma levels XENICAL coadministered cyclosporine
Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. 	cyclosporine	XENICAL	none	{'e1': {'word': 'cyclosporine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d761.s1.e3'}, 'e2': {'word': 'XENICAL', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d761.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d761.s1'}	Cyclosporine Preliminary data XENICAL cyclosporine drug interaction study indicate reduction cyclosporine plasma levels XENICAL coadministered cyclosporine
Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. 	cyclosporine	cyclosporine	none	{'e1': {'word': 'cyclosporine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d761.s1.e3'}, 'e2': {'word': 'cyclosporine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d761.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d761.s1'}	Cyclosporine Preliminary data XENICAL cyclosporine drug interaction study indicate reduction cyclosporine plasma levels XENICAL coadministered cyclosporine
Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. 	XENICAL	cyclosporine	mechanism	{'e1': {'word': 'XENICAL', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d761.s1.e4'}, 'e2': {'word': 'cyclosporine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d761.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d761.s1'}	Cyclosporine Preliminary data XENICAL cyclosporine drug interaction study indicate reduction cyclosporine plasma levels XENICAL coadministered cyclosporine
Digoxin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the pharmacokinetics of a single dose of digoxin. 	Digoxin	XENICAL	none	{'e1': {'word': 'Digoxin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d761.s2.e0'}, 'e2': {'word': 'XENICAL', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d761.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d761.s2'}	Digoxin NUMBER normal weight subjects receiving XENICAL NUMBER mg NUMBER times day NUMBER days XENICAL alter pharmacokinetics single dose digoxin
Digoxin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the pharmacokinetics of a single dose of digoxin. 	Digoxin	XENICAL	none	{'e1': {'word': 'Digoxin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d761.s2.e0'}, 'e2': {'word': 'XENICAL', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d761.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d761.s2'}	Digoxin NUMBER normal weight subjects receiving XENICAL NUMBER mg NUMBER times day NUMBER days XENICAL alter pharmacokinetics single dose digoxin
Digoxin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the pharmacokinetics of a single dose of digoxin. 	Digoxin	digoxin	none	{'e1': {'word': 'Digoxin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d761.s2.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d761.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d761.s2'}	Digoxin NUMBER normal weight subjects receiving XENICAL NUMBER mg NUMBER times day NUMBER days XENICAL alter pharmacokinetics single dose digoxin
Digoxin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the pharmacokinetics of a single dose of digoxin. 	XENICAL	XENICAL	none	{'e1': {'word': 'XENICAL', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d761.s2.e1'}, 'e2': {'word': 'XENICAL', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d761.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d761.s2'}	Digoxin NUMBER normal weight subjects receiving XENICAL NUMBER mg NUMBER times day NUMBER days XENICAL alter pharmacokinetics single dose digoxin
Digoxin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the pharmacokinetics of a single dose of digoxin. 	XENICAL	digoxin	none	{'e1': {'word': 'XENICAL', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d761.s2.e1'}, 'e2': {'word': 'digoxin', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d761.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d761.s2'}	Digoxin NUMBER normal weight subjects receiving XENICAL NUMBER mg NUMBER times day NUMBER days XENICAL alter pharmacokinetics single dose digoxin
Digoxin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the pharmacokinetics of a single dose of digoxin. 	XENICAL	digoxin	none	{'e1': {'word': 'XENICAL', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d761.s2.e2'}, 'e2': {'word': 'digoxin', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d761.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d761.s2'}	Digoxin NUMBER normal weight subjects receiving XENICAL NUMBER mg NUMBER times day NUMBER days XENICAL alter pharmacokinetics single dose digoxin
Fat-soluble Vitamin Supplements and Analogues: A pharmacokinetic interaction study showed a 30% reduction in beta-carotene supplement absorption when concomitantly administered with XENICAL. 	Fat-soluble Vitamin Supplements	beta-carotene	none	{'e1': {'word': 'Fat-soluble Vitamin Supplements', 'word_index': [(0, 2)], 'id': 'DDI-DrugBank.d761.s3.e0'}, 'e2': {'word': 'beta-carotene', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d761.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d761.s3'}	Fat Vitamin Supplements and : interaction study showed a NUMBER reduction in beta-carotene supplement absorption when administered with .
Fat-soluble Vitamin Supplements and Analogues: A pharmacokinetic interaction study showed a 30% reduction in beta-carotene supplement absorption when concomitantly administered with XENICAL. 	Fat-soluble Vitamin Supplements	XENICAL	none	{'e1': {'word': 'Fat-soluble Vitamin Supplements', 'word_index': [(0, 2)], 'id': 'DDI-DrugBank.d761.s3.e0'}, 'e2': {'word': 'XENICAL', 'word_index': [(17, 16)], 'id': 'DDI-DrugBank.d761.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d761.s3'}	Fat Vitamin Supplements and : interaction study showed a NUMBER reduction in supplement absorption when concomitantly with .
Fat-soluble Vitamin Supplements and Analogues: A pharmacokinetic interaction study showed a 30% reduction in beta-carotene supplement absorption when concomitantly administered with XENICAL. 	beta-carotene	XENICAL	mechanism	{'e1': {'word': 'beta-carotene', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d761.s3.e1'}, 'e2': {'word': 'XENICAL', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d761.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d761.s3'}	Fat-soluble Vitamin Supplements and : interaction study showed a NUMBER reduction in beta-carotene supplement absorption when administered with XENICAL .
XENICAL inhibited absorption of a vitamin E acetate supplement by approximately 60%. 	XENICAL	vitamin E acetate	mechanism	{'e1': {'word': 'XENICAL', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d761.s4.e0'}, 'e2': {'word': 'vitamin E acetate', 'word_index': [(3, 5)], 'id': 'DDI-DrugBank.d761.s4.e1'}, 'sentence_id': 'DDI-DrugBank.d761.s4'}	XENICAL inhibited absorption vitamin E acetate supplement approximately NUMBER %
The effect of orlistat on the absorption of supplemental vitamin D, vitamin A, and nutritionally-derived vitamin K is not known at this time. 	orlistat	vitamin D	none	{'e1': {'word': 'orlistat', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d761.s5.e0'}, 'e2': {'word': 'vitamin D', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d761.s5.e1'}, 'sentence_id': 'DDI-DrugBank.d761.s5'}	effect orlistat absorption supplemental vitamin vitamin nutritionally derived vitamin K known time
The effect of orlistat on the absorption of supplemental vitamin D, vitamin A, and nutritionally-derived vitamin K is not known at this time. 	orlistat	vitamin A	none	{'e1': {'word': 'orlistat', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d761.s5.e0'}, 'e2': {'word': 'vitamin A', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d761.s5.e2'}, 'sentence_id': 'DDI-DrugBank.d761.s5'}	effect orlistat absorption supplemental vitamin vitamin nutritionally derived vitamin K known time
The effect of orlistat on the absorption of supplemental vitamin D, vitamin A, and nutritionally-derived vitamin K is not known at this time. 	orlistat	vitamin K	none	{'e1': {'word': 'orlistat', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d761.s5.e0'}, 'e2': {'word': 'vitamin K', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d761.s5.e3'}, 'sentence_id': 'DDI-DrugBank.d761.s5'}	effect orlistat absorption supplemental vitamin vitamin nutritionally derived vitamin K known time
The effect of orlistat on the absorption of supplemental vitamin D, vitamin A, and nutritionally-derived vitamin K is not known at this time. 	vitamin D	vitamin A	none	{'e1': {'word': 'vitamin D', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d761.s5.e1'}, 'e2': {'word': 'vitamin A', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d761.s5.e2'}, 'sentence_id': 'DDI-DrugBank.d761.s5'}	effect orlistat absorption supplemental vitamin vitamin nutritionally derived vitamin K known time
The effect of orlistat on the absorption of supplemental vitamin D, vitamin A, and nutritionally-derived vitamin K is not known at this time. 	vitamin D	vitamin K	none	{'e1': {'word': 'vitamin D', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d761.s5.e1'}, 'e2': {'word': 'vitamin K', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d761.s5.e3'}, 'sentence_id': 'DDI-DrugBank.d761.s5'}	effect orlistat absorption supplemental vitamin vitamin nutritionally derived vitamin K known time
The effect of orlistat on the absorption of supplemental vitamin D, vitamin A, and nutritionally-derived vitamin K is not known at this time. 	vitamin A	vitamin K	none	{'e1': {'word': 'vitamin A', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d761.s5.e2'}, 'e2': {'word': 'vitamin K', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d761.s5.e3'}, 'sentence_id': 'DDI-DrugBank.d761.s5'}	effect orlistat absorption supplemental vitamin vitamin nutritionally derived vitamin K known time
Glyburide: In 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days, orlistat did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of glyburide. 	Glyburide	orlistat	none	{'e1': {'word': 'Glyburide', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d761.s6.e0'}, 'e2': {'word': 'orlistat', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d761.s6.e1'}, 'sentence_id': 'DDI-DrugBank.d761.s6'}	Glyburide NUMBER normal weight subjects receiving orlistat NUMBER mg NUMBER times day NUMBER days orlistat alter pharmacokinetics pharmacodynamics blood glucose lowering glyburide
Glyburide: In 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days, orlistat did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of glyburide. 	Glyburide	orlistat	none	{'e1': {'word': 'Glyburide', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d761.s6.e0'}, 'e2': {'word': 'orlistat', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d761.s6.e2'}, 'sentence_id': 'DDI-DrugBank.d761.s6'}	Glyburide NUMBER normal weight subjects receiving orlistat NUMBER mg NUMBER times day NUMBER days orlistat alter pharmacokinetics pharmacodynamics blood glucose lowering glyburide
Glyburide: In 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days, orlistat did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of glyburide. 	Glyburide	glyburide	none	{'e1': {'word': 'Glyburide', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d761.s6.e0'}, 'e2': {'word': 'glyburide', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d761.s6.e3'}, 'sentence_id': 'DDI-DrugBank.d761.s6'}	Glyburide NUMBER normal weight subjects receiving orlistat NUMBER mg NUMBER times day NUMBER days orlistat alter pharmacokinetics pharmacodynamics blood glucose lowering glyburide
Glyburide: In 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days, orlistat did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of glyburide. 	orlistat	orlistat	none	{'e1': {'word': 'orlistat', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d761.s6.e1'}, 'e2': {'word': 'orlistat', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d761.s6.e2'}, 'sentence_id': 'DDI-DrugBank.d761.s6'}	Glyburide NUMBER normal weight subjects receiving orlistat NUMBER mg NUMBER times day NUMBER days orlistat alter pharmacokinetics pharmacodynamics blood glucose lowering glyburide
Glyburide: In 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days, orlistat did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of glyburide. 	orlistat	glyburide	none	{'e1': {'word': 'orlistat', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d761.s6.e1'}, 'e2': {'word': 'glyburide', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d761.s6.e3'}, 'sentence_id': 'DDI-DrugBank.d761.s6'}	Glyburide NUMBER normal weight subjects receiving orlistat NUMBER mg NUMBER times day NUMBER days orlistat alter pharmacokinetics pharmacodynamics blood glucose lowering glyburide
Glyburide: In 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days, orlistat did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of glyburide. 	orlistat	glyburide	none	{'e1': {'word': 'orlistat', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d761.s6.e2'}, 'e2': {'word': 'glyburide', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d761.s6.e3'}, 'sentence_id': 'DDI-DrugBank.d761.s6'}	Glyburide NUMBER normal weight subjects receiving orlistat NUMBER mg NUMBER times day NUMBER days orlistat alter pharmacokinetics pharmacodynamics blood glucose lowering glyburide
Nifedipine (extended-release tablets): In 17 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the bioavailability of nifedipine (extended-release tablets). 	Nifedipine	XENICAL	none	{'e1': {'word': 'Nifedipine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d761.s7.e0'}, 'e2': {'word': 'XENICAL', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d761.s7.e1'}, 'sentence_id': 'DDI-DrugBank.d761.s7'}	Nifedipine extended release tablets NUMBER normal weight subjects receiving XENICAL NUMBER mg NUMBER times day NUMBER days XENICAL alter bioavailability nifedipine extended release tablets
Nifedipine (extended-release tablets): In 17 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the bioavailability of nifedipine (extended-release tablets). 	Nifedipine	XENICAL	none	{'e1': {'word': 'Nifedipine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d761.s7.e0'}, 'e2': {'word': 'XENICAL', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d761.s7.e2'}, 'sentence_id': 'DDI-DrugBank.d761.s7'}	Nifedipine extended release tablets NUMBER normal weight subjects receiving XENICAL NUMBER mg NUMBER times day NUMBER days XENICAL alter bioavailability nifedipine extended release tablets
Nifedipine (extended-release tablets): In 17 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the bioavailability of nifedipine (extended-release tablets). 	Nifedipine	nifedipine	none	{'e1': {'word': 'Nifedipine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d761.s7.e0'}, 'e2': {'word': 'nifedipine', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d761.s7.e3'}, 'sentence_id': 'DDI-DrugBank.d761.s7'}	Nifedipine extended release tablets NUMBER normal weight subjects receiving XENICAL NUMBER mg NUMBER times day NUMBER days XENICAL alter bioavailability nifedipine extended release tablets
Nifedipine (extended-release tablets): In 17 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the bioavailability of nifedipine (extended-release tablets). 	XENICAL	XENICAL	none	{'e1': {'word': 'XENICAL', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d761.s7.e1'}, 'e2': {'word': 'XENICAL', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d761.s7.e2'}, 'sentence_id': 'DDI-DrugBank.d761.s7'}	Nifedipine extended release tablets NUMBER normal weight subjects receiving XENICAL NUMBER mg NUMBER times day NUMBER days XENICAL alter bioavailability nifedipine extended release tablets
Nifedipine (extended-release tablets): In 17 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the bioavailability of nifedipine (extended-release tablets). 	XENICAL	nifedipine	none	{'e1': {'word': 'XENICAL', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d761.s7.e1'}, 'e2': {'word': 'nifedipine', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d761.s7.e3'}, 'sentence_id': 'DDI-DrugBank.d761.s7'}	Nifedipine extended release tablets NUMBER normal weight subjects receiving XENICAL NUMBER mg NUMBER times day NUMBER days XENICAL alter bioavailability nifedipine extended release tablets
Nifedipine (extended-release tablets): In 17 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the bioavailability of nifedipine (extended-release tablets). 	XENICAL	nifedipine	none	{'e1': {'word': 'XENICAL', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d761.s7.e2'}, 'e2': {'word': 'nifedipine', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d761.s7.e3'}, 'sentence_id': 'DDI-DrugBank.d761.s7'}	Nifedipine extended release tablets NUMBER normal weight subjects receiving XENICAL NUMBER mg NUMBER times day NUMBER days XENICAL alter bioavailability nifedipine extended release tablets
Oral Contraceptives: In 20 normal-weight female subjects, the treatment of XENICAL 120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral contraceptives. 	Contraceptives	XENICAL	none	{'e1': {'word': 'Contraceptives', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d761.s8.e0'}, 'e2': {'word': 'XENICAL', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d761.s8.e1'}, 'sentence_id': 'DDI-DrugBank.d761.s8'}	Oral Contraceptives NUMBER normal weight female subjects treatment XENICAL NUMBER mg NUMBER times day NUMBER days resulted changes ovulation suppressing action oral contraceptives
Oral Contraceptives: In 20 normal-weight female subjects, the treatment of XENICAL 120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral contraceptives. 	Contraceptives	contraceptives	none	{'e1': {'word': 'Contraceptives', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d761.s8.e0'}, 'e2': {'word': 'contraceptives', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d761.s8.e2'}, 'sentence_id': 'DDI-DrugBank.d761.s8'}	Oral Contraceptives NUMBER normal weight female subjects treatment XENICAL NUMBER mg NUMBER times day NUMBER days resulted changes ovulation suppressing action oral contraceptives
Oral Contraceptives: In 20 normal-weight female subjects, the treatment of XENICAL 120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral contraceptives. 	XENICAL	contraceptives	none	{'e1': {'word': 'XENICAL', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d761.s8.e1'}, 'e2': {'word': 'contraceptives', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d761.s8.e2'}, 'sentence_id': 'DDI-DrugBank.d761.s8'}	Oral Contraceptives NUMBER normal weight female subjects treatment XENICAL NUMBER mg NUMBER times day NUMBER days resulted changes ovulation suppressing action oral contraceptives
Phenytoin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 7 days, XENICAL did not alter the pharmacokinetics of a single 300-mg dose of phenytoin. 	Phenytoin	XENICAL	none	{'e1': {'word': 'Phenytoin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d761.s9.e0'}, 'e2': {'word': 'XENICAL', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d761.s9.e1'}, 'sentence_id': 'DDI-DrugBank.d761.s9'}	Phenytoin NUMBER normal weight subjects receiving XENICAL NUMBER mg NUMBER times day NUMBER days XENICAL alter pharmacokinetics single NUMBER mg dose phenytoin
Phenytoin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 7 days, XENICAL did not alter the pharmacokinetics of a single 300-mg dose of phenytoin. 	Phenytoin	XENICAL	none	{'e1': {'word': 'Phenytoin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d761.s9.e0'}, 'e2': {'word': 'XENICAL', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d761.s9.e2'}, 'sentence_id': 'DDI-DrugBank.d761.s9'}	Phenytoin NUMBER normal weight subjects receiving XENICAL NUMBER mg NUMBER times day NUMBER days XENICAL alter pharmacokinetics single NUMBER mg dose phenytoin
Phenytoin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 7 days, XENICAL did not alter the pharmacokinetics of a single 300-mg dose of phenytoin. 	Phenytoin	phenytoin	none	{'e1': {'word': 'Phenytoin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d761.s9.e0'}, 'e2': {'word': 'phenytoin', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d761.s9.e3'}, 'sentence_id': 'DDI-DrugBank.d761.s9'}	Phenytoin NUMBER normal weight subjects receiving XENICAL NUMBER mg NUMBER times day NUMBER days XENICAL alter pharmacokinetics single NUMBER mg dose phenytoin
Phenytoin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 7 days, XENICAL did not alter the pharmacokinetics of a single 300-mg dose of phenytoin. 	XENICAL	XENICAL	none	{'e1': {'word': 'XENICAL', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d761.s9.e1'}, 'e2': {'word': 'XENICAL', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d761.s9.e2'}, 'sentence_id': 'DDI-DrugBank.d761.s9'}	Phenytoin NUMBER normal weight subjects receiving XENICAL NUMBER mg NUMBER times day NUMBER days XENICAL alter pharmacokinetics single NUMBER mg dose phenytoin
Phenytoin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 7 days, XENICAL did not alter the pharmacokinetics of a single 300-mg dose of phenytoin. 	XENICAL	phenytoin	none	{'e1': {'word': 'XENICAL', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d761.s9.e1'}, 'e2': {'word': 'phenytoin', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d761.s9.e3'}, 'sentence_id': 'DDI-DrugBank.d761.s9'}	Phenytoin NUMBER normal weight subjects receiving XENICAL NUMBER mg NUMBER times day NUMBER days XENICAL alter pharmacokinetics single NUMBER mg dose phenytoin
Phenytoin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 7 days, XENICAL did not alter the pharmacokinetics of a single 300-mg dose of phenytoin. 	XENICAL	phenytoin	none	{'e1': {'word': 'XENICAL', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d761.s9.e2'}, 'e2': {'word': 'phenytoin', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d761.s9.e3'}, 'sentence_id': 'DDI-DrugBank.d761.s9'}	Phenytoin NUMBER normal weight subjects receiving XENICAL NUMBER mg NUMBER times day NUMBER days XENICAL alter pharmacokinetics single NUMBER mg dose phenytoin
Pravastatin: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not affect the pharmacokinetics of pravastatin. 	Pravastatin	XENICAL	none	{'e1': {'word': 'Pravastatin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d761.s10.e0'}, 'e2': {'word': 'XENICAL', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d761.s10.e1'}, 'sentence_id': 'DDI-DrugBank.d761.s10'}	Pravastatin NUMBER way crossover study NUMBER normal weight mildly hypercholesterolemic patients receiving XENICAL NUMBER mg NUMBER times day NUMBER days XENICAL affect pharmacokinetics pravastatin
Pravastatin: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not affect the pharmacokinetics of pravastatin. 	Pravastatin	XENICAL	none	{'e1': {'word': 'Pravastatin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d761.s10.e0'}, 'e2': {'word': 'XENICAL', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d761.s10.e2'}, 'sentence_id': 'DDI-DrugBank.d761.s10'}	Pravastatin NUMBER way crossover study NUMBER normal weight mildly hypercholesterolemic patients receiving XENICAL NUMBER mg NUMBER times day NUMBER days XENICAL affect pharmacokinetics pravastatin
Pravastatin: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not affect the pharmacokinetics of pravastatin. 	Pravastatin	pravastatin	none	{'e1': {'word': 'Pravastatin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d761.s10.e0'}, 'e2': {'word': 'pravastatin', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d761.s10.e3'}, 'sentence_id': 'DDI-DrugBank.d761.s10'}	Pravastatin NUMBER way crossover study NUMBER normal weight mildly hypercholesterolemic patients receiving XENICAL NUMBER mg NUMBER times day NUMBER days XENICAL affect pharmacokinetics pravastatin
Pravastatin: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not affect the pharmacokinetics of pravastatin. 	XENICAL	XENICAL	none	{'e1': {'word': 'XENICAL', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d761.s10.e1'}, 'e2': {'word': 'XENICAL', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d761.s10.e2'}, 'sentence_id': 'DDI-DrugBank.d761.s10'}	Pravastatin NUMBER way crossover study NUMBER normal weight mildly hypercholesterolemic patients receiving XENICAL NUMBER mg NUMBER times day NUMBER days XENICAL affect pharmacokinetics pravastatin
Pravastatin: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not affect the pharmacokinetics of pravastatin. 	XENICAL	pravastatin	none	{'e1': {'word': 'XENICAL', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d761.s10.e1'}, 'e2': {'word': 'pravastatin', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d761.s10.e3'}, 'sentence_id': 'DDI-DrugBank.d761.s10'}	Pravastatin NUMBER way crossover study NUMBER normal weight mildly hypercholesterolemic patients receiving XENICAL NUMBER mg NUMBER times day NUMBER days XENICAL affect pharmacokinetics pravastatin
Pravastatin: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not affect the pharmacokinetics of pravastatin. 	XENICAL	pravastatin	none	{'e1': {'word': 'XENICAL', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d761.s10.e2'}, 'e2': {'word': 'pravastatin', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d761.s10.e3'}, 'sentence_id': 'DDI-DrugBank.d761.s10'}	Pravastatin NUMBER way crossover study NUMBER normal weight mildly hypercholesterolemic patients receiving XENICAL NUMBER mg NUMBER times day NUMBER days XENICAL affect pharmacokinetics pravastatin
Warfarin: In 12 normal-weight subjects, administration of XENICAL 120 mg three times a day for 16 days did not result in any change in either warfarin pharmacokinetics (both R- and S-enantiomers) or pharmacodynamics (prothrombin time and serum Factor VII). 	Warfarin	XENICAL	none	{'e1': {'word': 'Warfarin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d761.s11.e0'}, 'e2': {'word': 'XENICAL', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d761.s11.e1'}, 'sentence_id': 'DDI-DrugBank.d761.s11'}	Warfarin NUMBER normal weight subjects administration XENICAL NUMBER mg NUMBER times day NUMBER days result change either warfarin pharmacokinetics R enantiomers pharmacodynamics prothrombin time serum Factor NUMBER
Warfarin: In 12 normal-weight subjects, administration of XENICAL 120 mg three times a day for 16 days did not result in any change in either warfarin pharmacokinetics (both R- and S-enantiomers) or pharmacodynamics (prothrombin time and serum Factor VII). 	Warfarin	warfarin	none	{'e1': {'word': 'Warfarin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d761.s11.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d761.s11.e2'}, 'sentence_id': 'DDI-DrugBank.d761.s11'}	Warfarin NUMBER normal weight subjects administration XENICAL NUMBER mg NUMBER times day NUMBER days result change either warfarin pharmacokinetics R enantiomers pharmacodynamics prothrombin time serum Factor NUMBER
Warfarin: In 12 normal-weight subjects, administration of XENICAL 120 mg three times a day for 16 days did not result in any change in either warfarin pharmacokinetics (both R- and S-enantiomers) or pharmacodynamics (prothrombin time and serum Factor VII). 	XENICAL	warfarin	none	{'e1': {'word': 'XENICAL', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d761.s11.e1'}, 'e2': {'word': 'warfarin', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d761.s11.e2'}, 'sentence_id': 'DDI-DrugBank.d761.s11'}	Warfarin NUMBER normal weight subjects administration XENICAL NUMBER mg NUMBER times day NUMBER days result change either warfarin pharmacokinetics R enantiomers pharmacodynamics prothrombin time serum Factor NUMBER
Although undercarboxylated osteocalcin, a marker of vitamin K nutritional status, was unaltered with XENICAL administration, vitamin K levels tended to decline in subjects taking XENICAL. 	XENICAL	XENICAL	none	{'e1': {'word': 'XENICAL', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d761.s12.e0'}, 'e2': {'word': 'XENICAL', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d761.s12.e1'}, 'sentence_id': 'DDI-DrugBank.d761.s12'}	Although undercarboxylated osteocalcin marker vitamin K nutritional status unaltered XENICAL administration vitamin K levels tended decline subjects taking XENICAL
Therefore, as vitamin K absorption may be decreased with XENICAL, patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.	vitamin K	XENICAL	mechanism	{'e1': {'word': 'vitamin K', 'word_index': [(1, 2)], 'id': 'DDI-DrugBank.d761.s13.e0'}, 'e2': {'word': 'XENICAL', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d761.s13.e1'}, 'sentence_id': 'DDI-DrugBank.d761.s13'}	Therefore vitamin K absorption may decreased XENICAL patients chronic stable doses warfarin prescribed XENICAL monitored closely changes coagulation parameters
Therefore, as vitamin K absorption may be decreased with XENICAL, patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.	vitamin K	warfarin	none	{'e1': {'word': 'vitamin K', 'word_index': [(1, 2)], 'id': 'DDI-DrugBank.d761.s13.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d761.s13.e2'}, 'sentence_id': 'DDI-DrugBank.d761.s13'}	Therefore vitamin K absorption may decreased XENICAL patients chronic stable doses warfarin prescribed XENICAL monitored closely changes coagulation parameters
Therefore, as vitamin K absorption may be decreased with XENICAL, patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.	vitamin K	XENICAL	none	{'e1': {'word': 'vitamin K', 'word_index': [(1, 2)], 'id': 'DDI-DrugBank.d761.s13.e0'}, 'e2': {'word': 'XENICAL', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d761.s13.e3'}, 'sentence_id': 'DDI-DrugBank.d761.s13'}	Therefore vitamin K absorption may decreased XENICAL patients chronic stable doses warfarin prescribed XENICAL monitored closely changes coagulation parameters
Therefore, as vitamin K absorption may be decreased with XENICAL, patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.	XENICAL	warfarin	none	{'e1': {'word': 'XENICAL', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d761.s13.e1'}, 'e2': {'word': 'warfarin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d761.s13.e2'}, 'sentence_id': 'DDI-DrugBank.d761.s13'}	Therefore vitamin K absorption may decreased XENICAL patients chronic stable doses warfarin prescribed XENICAL monitored closely changes coagulation parameters
Therefore, as vitamin K absorption may be decreased with XENICAL, patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.	XENICAL	XENICAL	none	{'e1': {'word': 'XENICAL', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d761.s13.e1'}, 'e2': {'word': 'XENICAL', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d761.s13.e3'}, 'sentence_id': 'DDI-DrugBank.d761.s13'}	Therefore vitamin K absorption may decreased XENICAL patients chronic stable doses warfarin prescribed XENICAL monitored closely changes coagulation parameters
Therefore, as vitamin K absorption may be decreased with XENICAL, patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.	warfarin	XENICAL	advise	{'e1': {'word': 'warfarin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d761.s13.e2'}, 'e2': {'word': 'XENICAL', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d761.s13.e3'}, 'sentence_id': 'DDI-DrugBank.d761.s13'}	Therefore vitamin K absorption may decreased XENICAL patients chronic stable doses warfarin prescribed XENICAL monitored closely changes coagulation parameters
The concomitant use of Sanctura with other anticholinergic agents that produce dry mouth, constipation, and other anticholinergic pharmacological effects may increase the frequency and/or severity of such effects. 	Sanctura	anticholinergic agents	effect	{'e1': {'word': 'Sanctura', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d713.s0.e0'}, 'e2': {'word': 'anticholinergic agents', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d713.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d713.s0'}	concomitant use Sanctura anticholinergic agents produce dry mouth constipation anticholinergic pharmacological effects may increase frequency severity effects
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). 	Sanctura	Sanctura	none	{'e1': {'word': 'Sanctura', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d713.s2.e0'}, 'e2': {'word': 'Sanctura', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d713.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d713.s2'}	Drugs Eliminated Active Tubular Secretion Although studies assess drug drug interactions Sanctura conducted Sanctura potential pharmacokinetic interactions drugs eliminated active tubular secretion e.g. digoxin procainamide pancuronium morphine vancomycin metformin tenofovir
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). 	Sanctura	digoxin	none	{'e1': {'word': 'Sanctura', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d713.s2.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d713.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d713.s2'}	Drugs Eliminated Active Tubular Secretion Although studies assess drug drug interactions Sanctura conducted Sanctura potential pharmacokinetic interactions drugs eliminated active tubular secretion e.g. digoxin procainamide pancuronium morphine vancomycin metformin tenofovir
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). 	Sanctura	procainamide	none	{'e1': {'word': 'Sanctura', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d713.s2.e0'}, 'e2': {'word': 'procainamide', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d713.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d713.s2'}	Drugs Eliminated Active Tubular Secretion Although studies assess drug drug interactions Sanctura conducted Sanctura potential pharmacokinetic interactions drugs eliminated active tubular secretion e.g. digoxin procainamide pancuronium morphine vancomycin metformin tenofovir
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). 	Sanctura	pancuronium	none	{'e1': {'word': 'Sanctura', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d713.s2.e0'}, 'e2': {'word': 'pancuronium', 'word_index': [(25, 25)], 'id': 'DDI-DrugBank.d713.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d713.s2'}	Drugs Eliminated Active Tubular Secretion Although studies assess drug drug interactions Sanctura conducted Sanctura potential pharmacokinetic interactions drugs eliminated active tubular secretion e.g. digoxin procainamide pancuronium morphine vancomycin metformin tenofovir
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). 	Sanctura	morphine	none	{'e1': {'word': 'Sanctura', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d713.s2.e0'}, 'e2': {'word': 'morphine', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d713.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d713.s2'}	Drugs Eliminated Active Tubular Secretion Although studies assess drug drug interactions Sanctura conducted Sanctura potential pharmacokinetic interactions drugs eliminated active tubular secretion e.g. digoxin procainamide pancuronium morphine vancomycin metformin tenofovir
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). 	Sanctura	vancomycin	none	{'e1': {'word': 'Sanctura', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d713.s2.e0'}, 'e2': {'word': 'vancomycin', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d713.s2.e6'}, 'sentence_id': 'DDI-DrugBank.d713.s2'}	Drugs Eliminated Active Tubular Secretion Although studies assess drug drug interactions Sanctura conducted Sanctura potential pharmacokinetic interactions drugs eliminated active tubular secretion e.g. digoxin procainamide pancuronium morphine vancomycin metformin tenofovir
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). 	Sanctura	metformin	none	{'e1': {'word': 'Sanctura', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d713.s2.e0'}, 'e2': {'word': 'metformin', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d713.s2.e7'}, 'sentence_id': 'DDI-DrugBank.d713.s2'}	Drugs Eliminated Active Tubular Secretion Although studies assess drug drug interactions Sanctura conducted Sanctura potential pharmacokinetic interactions drugs eliminated active tubular secretion e.g. digoxin procainamide pancuronium morphine vancomycin metformin tenofovir
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). 	Sanctura	tenofovir	none	{'e1': {'word': 'Sanctura', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d713.s2.e0'}, 'e2': {'word': 'tenofovir', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d713.s2.e8'}, 'sentence_id': 'DDI-DrugBank.d713.s2'}	Drugs Eliminated Active Tubular Secretion Although studies assess drug drug interactions Sanctura conducted Sanctura potential pharmacokinetic interactions drugs eliminated active tubular secretion e.g. digoxin procainamide pancuronium morphine vancomycin metformin tenofovir
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). 	Sanctura	digoxin	mechanism	{'e1': {'word': 'Sanctura', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d713.s2.e1'}, 'e2': {'word': 'digoxin', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d713.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d713.s2'}	Drugs Eliminated Active Tubular Secretion Although studies assess drug drug interactions Sanctura conducted Sanctura potential pharmacokinetic interactions drugs eliminated active tubular secretion e.g. digoxin procainamide pancuronium morphine vancomycin metformin tenofovir
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). 	Sanctura	procainamide	mechanism	{'e1': {'word': 'Sanctura', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d713.s2.e1'}, 'e2': {'word': 'procainamide', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d713.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d713.s2'}	Drugs Eliminated Active Tubular Secretion Although studies assess drug drug interactions Sanctura conducted Sanctura potential pharmacokinetic interactions drugs eliminated active tubular secretion e.g. digoxin procainamide pancuronium morphine vancomycin metformin tenofovir
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). 	Sanctura	pancuronium	mechanism	{'e1': {'word': 'Sanctura', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d713.s2.e1'}, 'e2': {'word': 'pancuronium', 'word_index': [(25, 25)], 'id': 'DDI-DrugBank.d713.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d713.s2'}	Drugs Eliminated Active Tubular Secretion Although studies assess drug drug interactions Sanctura conducted Sanctura potential pharmacokinetic interactions drugs eliminated active tubular secretion e.g. digoxin procainamide pancuronium morphine vancomycin metformin tenofovir
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). 	Sanctura	morphine	mechanism	{'e1': {'word': 'Sanctura', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d713.s2.e1'}, 'e2': {'word': 'morphine', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d713.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d713.s2'}	Drugs Eliminated Active Tubular Secretion Although studies assess drug drug interactions Sanctura conducted Sanctura potential pharmacokinetic interactions drugs eliminated active tubular secretion e.g. digoxin procainamide pancuronium morphine vancomycin metformin tenofovir
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). 	Sanctura	vancomycin	mechanism	{'e1': {'word': 'Sanctura', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d713.s2.e1'}, 'e2': {'word': 'vancomycin', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d713.s2.e6'}, 'sentence_id': 'DDI-DrugBank.d713.s2'}	Drugs Eliminated Active Tubular Secretion Although studies assess drug drug interactions Sanctura conducted Sanctura potential pharmacokinetic interactions drugs eliminated active tubular secretion e.g. digoxin procainamide pancuronium morphine vancomycin metformin tenofovir
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). 	Sanctura	metformin	mechanism	{'e1': {'word': 'Sanctura', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d713.s2.e1'}, 'e2': {'word': 'metformin', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d713.s2.e7'}, 'sentence_id': 'DDI-DrugBank.d713.s2'}	Drugs Eliminated Active Tubular Secretion Although studies assess drug drug interactions Sanctura conducted Sanctura potential pharmacokinetic interactions drugs eliminated active tubular secretion e.g. digoxin procainamide pancuronium morphine vancomycin metformin tenofovir
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). 	Sanctura	tenofovir	mechanism	{'e1': {'word': 'Sanctura', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d713.s2.e1'}, 'e2': {'word': 'tenofovir', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d713.s2.e8'}, 'sentence_id': 'DDI-DrugBank.d713.s2'}	Drugs Eliminated Active Tubular Secretion Although studies assess drug drug interactions Sanctura conducted Sanctura potential pharmacokinetic interactions drugs eliminated active tubular secretion e.g. digoxin procainamide pancuronium morphine vancomycin metformin tenofovir
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). 	digoxin	procainamide	none	{'e1': {'word': 'digoxin', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d713.s2.e2'}, 'e2': {'word': 'procainamide', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d713.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d713.s2'}	Drugs Eliminated Active Tubular Secretion Although studies assess drug drug interactions Sanctura conducted Sanctura potential pharmacokinetic interactions drugs eliminated active tubular secretion e.g. digoxin procainamide pancuronium morphine vancomycin metformin tenofovir
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). 	digoxin	pancuronium	none	{'e1': {'word': 'digoxin', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d713.s2.e2'}, 'e2': {'word': 'pancuronium', 'word_index': [(25, 25)], 'id': 'DDI-DrugBank.d713.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d713.s2'}	Drugs Eliminated Active Tubular Secretion Although studies assess drug drug interactions Sanctura conducted Sanctura potential pharmacokinetic interactions drugs eliminated active tubular secretion e.g. digoxin procainamide pancuronium morphine vancomycin metformin tenofovir
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). 	digoxin	morphine	none	{'e1': {'word': 'digoxin', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d713.s2.e2'}, 'e2': {'word': 'morphine', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d713.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d713.s2'}	Drugs Eliminated Active Tubular Secretion Although studies assess drug drug interactions Sanctura conducted Sanctura potential pharmacokinetic interactions drugs eliminated active tubular secretion e.g. digoxin procainamide pancuronium morphine vancomycin metformin tenofovir
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). 	digoxin	vancomycin	none	{'e1': {'word': 'digoxin', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d713.s2.e2'}, 'e2': {'word': 'vancomycin', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d713.s2.e6'}, 'sentence_id': 'DDI-DrugBank.d713.s2'}	Drugs Eliminated Active Tubular Secretion Although studies assess drug drug interactions Sanctura conducted Sanctura potential pharmacokinetic interactions drugs eliminated active tubular secretion e.g. digoxin procainamide pancuronium morphine vancomycin metformin tenofovir
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). 	digoxin	metformin	none	{'e1': {'word': 'digoxin', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d713.s2.e2'}, 'e2': {'word': 'metformin', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d713.s2.e7'}, 'sentence_id': 'DDI-DrugBank.d713.s2'}	Drugs Eliminated Active Tubular Secretion Although studies assess drug drug interactions Sanctura conducted Sanctura potential pharmacokinetic interactions drugs eliminated active tubular secretion e.g. digoxin procainamide pancuronium morphine vancomycin metformin tenofovir
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). 	digoxin	tenofovir	none	{'e1': {'word': 'digoxin', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d713.s2.e2'}, 'e2': {'word': 'tenofovir', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d713.s2.e8'}, 'sentence_id': 'DDI-DrugBank.d713.s2'}	Drugs Eliminated Active Tubular Secretion Although studies assess drug drug interactions Sanctura conducted Sanctura potential pharmacokinetic interactions drugs eliminated active tubular secretion e.g. digoxin procainamide pancuronium morphine vancomycin metformin tenofovir
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). 	procainamide	pancuronium	none	{'e1': {'word': 'procainamide', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d713.s2.e3'}, 'e2': {'word': 'pancuronium', 'word_index': [(25, 25)], 'id': 'DDI-DrugBank.d713.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d713.s2'}	Drugs Eliminated Active Tubular Secretion Although studies assess drug drug interactions Sanctura conducted Sanctura potential pharmacokinetic interactions drugs eliminated active tubular secretion e.g. digoxin procainamide pancuronium morphine vancomycin metformin tenofovir
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). 	procainamide	morphine	none	{'e1': {'word': 'procainamide', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d713.s2.e3'}, 'e2': {'word': 'morphine', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d713.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d713.s2'}	Drugs Eliminated Active Tubular Secretion Although studies assess drug drug interactions Sanctura conducted Sanctura potential pharmacokinetic interactions drugs eliminated active tubular secretion e.g. digoxin procainamide pancuronium morphine vancomycin metformin tenofovir
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). 	procainamide	vancomycin	none	{'e1': {'word': 'procainamide', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d713.s2.e3'}, 'e2': {'word': 'vancomycin', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d713.s2.e6'}, 'sentence_id': 'DDI-DrugBank.d713.s2'}	Drugs Eliminated Active Tubular Secretion Although studies assess drug drug interactions Sanctura conducted Sanctura potential pharmacokinetic interactions drugs eliminated active tubular secretion e.g. digoxin procainamide pancuronium morphine vancomycin metformin tenofovir
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). 	procainamide	metformin	none	{'e1': {'word': 'procainamide', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d713.s2.e3'}, 'e2': {'word': 'metformin', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d713.s2.e7'}, 'sentence_id': 'DDI-DrugBank.d713.s2'}	Drugs Eliminated Active Tubular Secretion Although studies assess drug drug interactions Sanctura conducted Sanctura potential pharmacokinetic interactions drugs eliminated active tubular secretion e.g. digoxin procainamide pancuronium morphine vancomycin metformin tenofovir
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). 	procainamide	tenofovir	none	{'e1': {'word': 'procainamide', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d713.s2.e3'}, 'e2': {'word': 'tenofovir', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d713.s2.e8'}, 'sentence_id': 'DDI-DrugBank.d713.s2'}	Drugs Eliminated Active Tubular Secretion Although studies assess drug drug interactions Sanctura conducted Sanctura potential pharmacokinetic interactions drugs eliminated active tubular secretion e.g. digoxin procainamide pancuronium morphine vancomycin metformin tenofovir
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). 	pancuronium	morphine	none	{'e1': {'word': 'pancuronium', 'word_index': [(25, 25)], 'id': 'DDI-DrugBank.d713.s2.e4'}, 'e2': {'word': 'morphine', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d713.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d713.s2'}	Drugs Eliminated Active Tubular Secretion Although studies assess drug drug interactions Sanctura conducted Sanctura potential pharmacokinetic interactions drugs eliminated active tubular secretion e.g. digoxin procainamide pancuronium morphine vancomycin metformin tenofovir
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). 	pancuronium	vancomycin	none	{'e1': {'word': 'pancuronium', 'word_index': [(25, 25)], 'id': 'DDI-DrugBank.d713.s2.e4'}, 'e2': {'word': 'vancomycin', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d713.s2.e6'}, 'sentence_id': 'DDI-DrugBank.d713.s2'}	Drugs Eliminated Active Tubular Secretion Although studies assess drug drug interactions Sanctura conducted Sanctura potential pharmacokinetic interactions drugs eliminated active tubular secretion e.g. digoxin procainamide pancuronium morphine vancomycin metformin tenofovir
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). 	pancuronium	metformin	none	{'e1': {'word': 'pancuronium', 'word_index': [(25, 25)], 'id': 'DDI-DrugBank.d713.s2.e4'}, 'e2': {'word': 'metformin', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d713.s2.e7'}, 'sentence_id': 'DDI-DrugBank.d713.s2'}	Drugs Eliminated Active Tubular Secretion Although studies assess drug drug interactions Sanctura conducted Sanctura potential pharmacokinetic interactions drugs eliminated active tubular secretion e.g. digoxin procainamide pancuronium morphine vancomycin metformin tenofovir
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). 	pancuronium	tenofovir	none	{'e1': {'word': 'pancuronium', 'word_index': [(25, 25)], 'id': 'DDI-DrugBank.d713.s2.e4'}, 'e2': {'word': 'tenofovir', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d713.s2.e8'}, 'sentence_id': 'DDI-DrugBank.d713.s2'}	Drugs Eliminated Active Tubular Secretion Although studies assess drug drug interactions Sanctura conducted Sanctura potential pharmacokinetic interactions drugs eliminated active tubular secretion e.g. digoxin procainamide pancuronium morphine vancomycin metformin tenofovir
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). 	morphine	vancomycin	none	{'e1': {'word': 'morphine', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d713.s2.e5'}, 'e2': {'word': 'vancomycin', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d713.s2.e6'}, 'sentence_id': 'DDI-DrugBank.d713.s2'}	Drugs Eliminated Active Tubular Secretion Although studies assess drug drug interactions Sanctura conducted Sanctura potential pharmacokinetic interactions drugs eliminated active tubular secretion e.g. digoxin procainamide pancuronium morphine vancomycin metformin tenofovir
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). 	morphine	metformin	none	{'e1': {'word': 'morphine', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d713.s2.e5'}, 'e2': {'word': 'metformin', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d713.s2.e7'}, 'sentence_id': 'DDI-DrugBank.d713.s2'}	Drugs Eliminated Active Tubular Secretion Although studies assess drug drug interactions Sanctura conducted Sanctura potential pharmacokinetic interactions drugs eliminated active tubular secretion e.g. digoxin procainamide pancuronium morphine vancomycin metformin tenofovir
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). 	morphine	tenofovir	none	{'e1': {'word': 'morphine', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d713.s2.e5'}, 'e2': {'word': 'tenofovir', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d713.s2.e8'}, 'sentence_id': 'DDI-DrugBank.d713.s2'}	Drugs Eliminated Active Tubular Secretion Although studies assess drug drug interactions Sanctura conducted Sanctura potential pharmacokinetic interactions drugs eliminated active tubular secretion e.g. digoxin procainamide pancuronium morphine vancomycin metformin tenofovir
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). 	vancomycin	metformin	none	{'e1': {'word': 'vancomycin', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d713.s2.e6'}, 'e2': {'word': 'metformin', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d713.s2.e7'}, 'sentence_id': 'DDI-DrugBank.d713.s2'}	Drugs Eliminated Active Tubular Secretion Although studies assess drug drug interactions Sanctura conducted Sanctura potential pharmacokinetic interactions drugs eliminated active tubular secretion e.g. digoxin procainamide pancuronium morphine vancomycin metformin tenofovir
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). 	vancomycin	tenofovir	none	{'e1': {'word': 'vancomycin', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d713.s2.e6'}, 'e2': {'word': 'tenofovir', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d713.s2.e8'}, 'sentence_id': 'DDI-DrugBank.d713.s2'}	Drugs Eliminated Active Tubular Secretion Although studies assess drug drug interactions Sanctura conducted Sanctura potential pharmacokinetic interactions drugs eliminated active tubular secretion e.g. digoxin procainamide pancuronium morphine vancomycin metformin tenofovir
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). 	metformin	tenofovir	none	{'e1': {'word': 'metformin', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d713.s2.e7'}, 'e2': {'word': 'tenofovir', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d713.s2.e8'}, 'sentence_id': 'DDI-DrugBank.d713.s2'}	Drugs Eliminated Active Tubular Secretion Although studies assess drug drug interactions Sanctura conducted Sanctura potential pharmacokinetic interactions drugs eliminated active tubular secretion e.g. digoxin procainamide pancuronium morphine vancomycin metformin tenofovir
Coadministration of Sanctura with drugs that are eliminated by active renal tubular secretion may increase the serum concentration of Sanctura and/or the coadministered drug due to competition for this elimination pathway. 	Sanctura	Sanctura	none	{'e1': {'word': 'Sanctura', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d713.s3.e0'}, 'e2': {'word': 'Sanctura', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d713.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d713.s3'}	Coadministration Sanctura drugs eliminated active renal tubular secretion may increase serum concentration Sanctura coadministered drug due competition elimination pathway
The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) 	DIPRIVAN	narcotics	effect	{'e1': {'word': 'DIPRIVAN', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d628.s0.e0'}, 'e2': {'word': 'narcotics', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d628.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d628.s0'}	induction dose requirements DIPRIVAN Injectable Emulsion may reduced patients intramuscular intravenous premedication particularly narcotics eg morphine meperidine fentanyl etc.
The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) 	DIPRIVAN	morphine	effect	{'e1': {'word': 'DIPRIVAN', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d628.s0.e0'}, 'e2': {'word': 'morphine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d628.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d628.s0'}	induction dose requirements DIPRIVAN Injectable Emulsion may reduced patients intramuscular intravenous premedication particularly narcotics eg morphine meperidine fentanyl etc.
The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) 	DIPRIVAN	meperidine	effect	{'e1': {'word': 'DIPRIVAN', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d628.s0.e0'}, 'e2': {'word': 'meperidine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d628.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d628.s0'}	induction dose requirements DIPRIVAN Injectable Emulsion may reduced patients intramuscular intravenous premedication particularly narcotics eg morphine meperidine fentanyl etc.
The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) 	DIPRIVAN	fentanyl	effect	{'e1': {'word': 'DIPRIVAN', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d628.s0.e0'}, 'e2': {'word': 'fentanyl', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d628.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d628.s0'}	induction dose requirements DIPRIVAN Injectable Emulsion may reduced patients intramuscular intravenous premedication particularly narcotics eg morphine meperidine fentanyl etc.
The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) 	narcotics	morphine	none	{'e1': {'word': 'narcotics', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d628.s0.e1'}, 'e2': {'word': 'morphine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d628.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d628.s0'}	induction dose requirements DIPRIVAN Injectable Emulsion may reduced patients intramuscular intravenous premedication particularly narcotics eg morphine meperidine fentanyl etc.
The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) 	narcotics	meperidine	none	{'e1': {'word': 'narcotics', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d628.s0.e1'}, 'e2': {'word': 'meperidine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d628.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d628.s0'}	induction dose requirements DIPRIVAN Injectable Emulsion may reduced patients intramuscular intravenous premedication particularly narcotics eg morphine meperidine fentanyl etc.
The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) 	narcotics	fentanyl	none	{'e1': {'word': 'narcotics', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d628.s0.e1'}, 'e2': {'word': 'fentanyl', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d628.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d628.s0'}	induction dose requirements DIPRIVAN Injectable Emulsion may reduced patients intramuscular intravenous premedication particularly narcotics eg morphine meperidine fentanyl etc.
The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) 	morphine	meperidine	none	{'e1': {'word': 'morphine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d628.s0.e2'}, 'e2': {'word': 'meperidine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d628.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d628.s0'}	induction dose requirements DIPRIVAN Injectable Emulsion may reduced patients intramuscular intravenous premedication particularly narcotics eg morphine meperidine fentanyl etc.
The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) 	morphine	fentanyl	none	{'e1': {'word': 'morphine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d628.s0.e2'}, 'e2': {'word': 'fentanyl', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d628.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d628.s0'}	induction dose requirements DIPRIVAN Injectable Emulsion may reduced patients intramuscular intravenous premedication particularly narcotics eg morphine meperidine fentanyl etc.
The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) 	meperidine	fentanyl	none	{'e1': {'word': 'meperidine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d628.s0.e3'}, 'e2': {'word': 'fentanyl', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d628.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d628.s0'}	induction dose requirements DIPRIVAN Injectable Emulsion may reduced patients intramuscular intravenous premedication particularly narcotics eg morphine meperidine fentanyl etc.
and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). 	opioids	sedatives	none	{'e1': {'word': 'opioids', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d628.s1.e0'}, 'e2': {'word': 'sedatives', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d628.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d628.s1'}	combinations opioids sedatives eg benzodiazepines barbiturates chloral hydrate droperidol etc.
and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). 	opioids	benzodiazepines	none	{'e1': {'word': 'opioids', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d628.s1.e0'}, 'e2': {'word': 'benzodiazepines', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d628.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d628.s1'}	combinations opioids sedatives eg benzodiazepines barbiturates chloral hydrate droperidol etc.
and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). 	opioids	barbiturates	none	{'e1': {'word': 'opioids', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d628.s1.e0'}, 'e2': {'word': 'barbiturates', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d628.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d628.s1'}	combinations opioids sedatives eg benzodiazepines barbiturates chloral hydrate droperidol etc.
and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). 	opioids	chloral hydrate	none	{'e1': {'word': 'opioids', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d628.s1.e0'}, 'e2': {'word': 'chloral hydrate', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d628.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d628.s1'}	combinations opioids sedatives eg benzodiazepines barbiturates chloral hydrate droperidol etc.
and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). 	opioids	droperidol	none	{'e1': {'word': 'opioids', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d628.s1.e0'}, 'e2': {'word': 'droperidol', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d628.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d628.s1'}	combinations opioids sedatives eg benzodiazepines barbiturates chloral hydrate droperidol etc.
and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). 	sedatives	benzodiazepines	none	{'e1': {'word': 'sedatives', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d628.s1.e1'}, 'e2': {'word': 'benzodiazepines', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d628.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d628.s1'}	combinations opioids sedatives eg benzodiazepines barbiturates chloral hydrate droperidol etc.
and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). 	sedatives	barbiturates	none	{'e1': {'word': 'sedatives', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d628.s1.e1'}, 'e2': {'word': 'barbiturates', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d628.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d628.s1'}	combinations opioids sedatives eg benzodiazepines barbiturates chloral hydrate droperidol etc.
and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). 	sedatives	chloral hydrate	none	{'e1': {'word': 'sedatives', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d628.s1.e1'}, 'e2': {'word': 'chloral hydrate', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d628.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d628.s1'}	combinations opioids sedatives eg benzodiazepines barbiturates chloral hydrate droperidol etc.
and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). 	sedatives	droperidol	none	{'e1': {'word': 'sedatives', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d628.s1.e1'}, 'e2': {'word': 'droperidol', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d628.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d628.s1'}	combinations opioids sedatives eg benzodiazepines barbiturates chloral hydrate droperidol etc.
and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). 	benzodiazepines	barbiturates	none	{'e1': {'word': 'benzodiazepines', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d628.s1.e2'}, 'e2': {'word': 'barbiturates', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d628.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d628.s1'}	combinations opioids sedatives eg benzodiazepines barbiturates chloral hydrate droperidol etc.
and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). 	benzodiazepines	chloral hydrate	none	{'e1': {'word': 'benzodiazepines', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d628.s1.e2'}, 'e2': {'word': 'chloral hydrate', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d628.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d628.s1'}	combinations opioids sedatives eg benzodiazepines barbiturates chloral hydrate droperidol etc.
and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). 	benzodiazepines	droperidol	none	{'e1': {'word': 'benzodiazepines', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d628.s1.e2'}, 'e2': {'word': 'droperidol', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d628.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d628.s1'}	combinations opioids sedatives eg benzodiazepines barbiturates chloral hydrate droperidol etc.
and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). 	barbiturates	chloral hydrate	none	{'e1': {'word': 'barbiturates', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d628.s1.e3'}, 'e2': {'word': 'chloral hydrate', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d628.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d628.s1'}	combinations opioids sedatives eg benzodiazepines barbiturates chloral hydrate droperidol etc.
and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). 	barbiturates	droperidol	none	{'e1': {'word': 'barbiturates', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d628.s1.e3'}, 'e2': {'word': 'droperidol', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d628.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d628.s1'}	combinations opioids sedatives eg benzodiazepines barbiturates chloral hydrate droperidol etc.
and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). 	chloral hydrate	droperidol	none	{'e1': {'word': 'chloral hydrate', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d628.s1.e4'}, 'e2': {'word': 'droperidol', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d628.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d628.s1'}	combinations opioids sedatives eg benzodiazepines barbiturates chloral hydrate droperidol etc.
During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or opioids). 	DIPRIVAN	analgesic agents	advise	{'e1': {'word': 'DIPRIVAN', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d628.s3.e0'}, 'e2': {'word': 'analgesic agents', 'word_index': [(18, 19)], 'id': 'DDI-DrugBank.d628.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d628.s3'}	maintenance anesthesia sedation rate DIPRIVAN Injectable Emulsion administration adjusted according desired level anesthesia sedation may reduced presence supplemental analgesic agents eg nitrous oxide opioids
During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or opioids). 	DIPRIVAN	nitrous oxide	advise	{'e1': {'word': 'DIPRIVAN', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d628.s3.e0'}, 'e2': {'word': 'nitrous oxide', 'word_index': [(21, 22)], 'id': 'DDI-DrugBank.d628.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d628.s3'}	maintenance anesthesia sedation rate DIPRIVAN Injectable Emulsion administration adjusted according desired level anesthesia sedation may reduced presence supplemental analgesic agents eg nitrous oxide opioids
During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or opioids). 	DIPRIVAN	opioids	advise	{'e1': {'word': 'DIPRIVAN', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d628.s3.e0'}, 'e2': {'word': 'opioids', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d628.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d628.s3'}	maintenance anesthesia sedation rate DIPRIVAN Injectable Emulsion administration adjusted according desired level anesthesia sedation may reduced presence supplemental analgesic agents eg nitrous oxide opioids
During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or opioids). 	analgesic agents	nitrous oxide	none	{'e1': {'word': 'analgesic agents', 'word_index': [(18, 19)], 'id': 'DDI-DrugBank.d628.s3.e1'}, 'e2': {'word': 'nitrous oxide', 'word_index': [(21, 22)], 'id': 'DDI-DrugBank.d628.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d628.s3'}	maintenance anesthesia sedation rate DIPRIVAN Injectable Emulsion administration adjusted according desired level anesthesia sedation may reduced presence supplemental analgesic agents eg nitrous oxide opioids
During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or opioids). 	analgesic agents	opioids	none	{'e1': {'word': 'analgesic agents', 'word_index': [(18, 19)], 'id': 'DDI-DrugBank.d628.s3.e1'}, 'e2': {'word': 'opioids', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d628.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d628.s3'}	maintenance anesthesia sedation rate DIPRIVAN Injectable Emulsion administration adjusted according desired level anesthesia sedation may reduced presence supplemental analgesic agents eg nitrous oxide opioids
During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or opioids). 	nitrous oxide	opioids	none	{'e1': {'word': 'nitrous oxide', 'word_index': [(21, 22)], 'id': 'DDI-DrugBank.d628.s3.e2'}, 'e2': {'word': 'opioids', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d628.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d628.s3'}	maintenance anesthesia sedation rate DIPRIVAN Injectable Emulsion administration adjusted according desired level anesthesia sedation may reduced presence supplemental analgesic agents eg nitrous oxide opioids
The concurrent administration of potent inhalational agents (eg, isoflurane, enflurane, and halothane) during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated. 	isoflurane	enflurane	none	{'e1': {'word': 'isoflurane', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d628.s4.e0'}, 'e2': {'word': 'enflurane', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d628.s4.e1'}, 'sentence_id': 'DDI-DrugBank.d628.s4'}	concurrent administration potent inhalational agents eg isoflurane enflurane halothane maintenance DIPRIVAN Injectable Emulsion extensively evaluated
The concurrent administration of potent inhalational agents (eg, isoflurane, enflurane, and halothane) during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated. 	isoflurane	halothane	none	{'e1': {'word': 'isoflurane', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d628.s4.e0'}, 'e2': {'word': 'halothane', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d628.s4.e2'}, 'sentence_id': 'DDI-DrugBank.d628.s4'}	concurrent administration potent inhalational agents eg isoflurane enflurane halothane maintenance DIPRIVAN Injectable Emulsion extensively evaluated
The concurrent administration of potent inhalational agents (eg, isoflurane, enflurane, and halothane) during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated. 	isoflurane	DIPRIVAN	none	{'e1': {'word': 'isoflurane', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d628.s4.e0'}, 'e2': {'word': 'DIPRIVAN', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d628.s4.e3'}, 'sentence_id': 'DDI-DrugBank.d628.s4'}	concurrent administration potent inhalational agents eg isoflurane enflurane halothane maintenance DIPRIVAN Injectable Emulsion extensively evaluated
The concurrent administration of potent inhalational agents (eg, isoflurane, enflurane, and halothane) during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated. 	enflurane	halothane	none	{'e1': {'word': 'enflurane', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d628.s4.e1'}, 'e2': {'word': 'halothane', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d628.s4.e2'}, 'sentence_id': 'DDI-DrugBank.d628.s4'}	concurrent administration potent inhalational agents eg isoflurane enflurane halothane maintenance DIPRIVAN Injectable Emulsion extensively evaluated
The concurrent administration of potent inhalational agents (eg, isoflurane, enflurane, and halothane) during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated. 	enflurane	DIPRIVAN	none	{'e1': {'word': 'enflurane', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d628.s4.e1'}, 'e2': {'word': 'DIPRIVAN', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d628.s4.e3'}, 'sentence_id': 'DDI-DrugBank.d628.s4'}	concurrent administration potent inhalational agents eg isoflurane enflurane halothane maintenance DIPRIVAN Injectable Emulsion extensively evaluated
The concurrent administration of potent inhalational agents (eg, isoflurane, enflurane, and halothane) during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated. 	halothane	DIPRIVAN	none	{'e1': {'word': 'halothane', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d628.s4.e2'}, 'e2': {'word': 'DIPRIVAN', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d628.s4.e3'}, 'sentence_id': 'DDI-DrugBank.d628.s4'}	concurrent administration potent inhalational agents eg isoflurane enflurane halothane maintenance DIPRIVAN Injectable Emulsion extensively evaluated
DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used neuromuscular blocking agents (eg, succinylcholine and nondepolarizing muscle relaxants). 	DIPRIVAN	neuromuscular blocking agents	none	{'e1': {'word': 'DIPRIVAN', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d628.s6.e0'}, 'e2': {'word': 'neuromuscular blocking agents', 'word_index': [(13, 15)], 'id': 'DDI-DrugBank.d628.s6.e1'}, 'sentence_id': 'DDI-DrugBank.d628.s6'}	DIPRIVAN Injectable Emulsion cause clinically significant change onset intensity duration action commonly used neuromuscular blocking agents eg succinylcholine nondepolarizing muscle relaxants
DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used neuromuscular blocking agents (eg, succinylcholine and nondepolarizing muscle relaxants). 	DIPRIVAN	succinylcholine	none	{'e1': {'word': 'DIPRIVAN', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d628.s6.e0'}, 'e2': {'word': 'succinylcholine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d628.s6.e2'}, 'sentence_id': 'DDI-DrugBank.d628.s6'}	DIPRIVAN Injectable Emulsion cause clinically significant change onset intensity duration action commonly used neuromuscular blocking agents eg succinylcholine nondepolarizing muscle relaxants
DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used neuromuscular blocking agents (eg, succinylcholine and nondepolarizing muscle relaxants). 	DIPRIVAN	nondepolarizing muscle relaxants	none	{'e1': {'word': 'DIPRIVAN', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d628.s6.e0'}, 'e2': {'word': 'nondepolarizing muscle relaxants', 'word_index': [(18, 20)], 'id': 'DDI-DrugBank.d628.s6.e3'}, 'sentence_id': 'DDI-DrugBank.d628.s6'}	DIPRIVAN Injectable Emulsion cause clinically significant change onset intensity duration action commonly used neuromuscular blocking agents eg succinylcholine nondepolarizing muscle relaxants
DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used neuromuscular blocking agents (eg, succinylcholine and nondepolarizing muscle relaxants). 	neuromuscular blocking agents	succinylcholine	none	{'e1': {'word': 'neuromuscular blocking agents', 'word_index': [(13, 15)], 'id': 'DDI-DrugBank.d628.s6.e1'}, 'e2': {'word': 'succinylcholine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d628.s6.e2'}, 'sentence_id': 'DDI-DrugBank.d628.s6'}	DIPRIVAN Injectable Emulsion cause clinically significant change onset intensity duration action commonly used neuromuscular blocking agents eg succinylcholine nondepolarizing muscle relaxants
DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used neuromuscular blocking agents (eg, succinylcholine and nondepolarizing muscle relaxants). 	neuromuscular blocking agents	nondepolarizing muscle relaxants	none	{'e1': {'word': 'neuromuscular blocking agents', 'word_index': [(13, 15)], 'id': 'DDI-DrugBank.d628.s6.e1'}, 'e2': {'word': 'nondepolarizing muscle relaxants', 'word_index': [(18, 20)], 'id': 'DDI-DrugBank.d628.s6.e3'}, 'sentence_id': 'DDI-DrugBank.d628.s6'}	DIPRIVAN Injectable Emulsion cause clinically significant change onset intensity duration action commonly used neuromuscular blocking agents eg succinylcholine nondepolarizing muscle relaxants
DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used neuromuscular blocking agents (eg, succinylcholine and nondepolarizing muscle relaxants). 	succinylcholine	nondepolarizing muscle relaxants	none	{'e1': {'word': 'succinylcholine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d628.s6.e2'}, 'e2': {'word': 'nondepolarizing muscle relaxants', 'word_index': [(18, 20)], 'id': 'DDI-DrugBank.d628.s6.e3'}, 'sentence_id': 'DDI-DrugBank.d628.s6'}	DIPRIVAN Injectable Emulsion cause clinically significant change onset intensity duration action commonly used neuromuscular blocking agents eg succinylcholine nondepolarizing muscle relaxants
No significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation (including a range of muscle relaxants, inhalational agents, analgesic agents, and local anesthetic agents) have been observed.	muscle relaxants	analgesic agents	none	{'e1': {'word': 'muscle relaxants', 'word_index': [(12, 13)], 'id': 'DDI-DrugBank.d628.s7.e0'}, 'e2': {'word': 'analgesic agents', 'word_index': [(16, 17)], 'id': 'DDI-DrugBank.d628.s7.e1'}, 'sentence_id': 'DDI-DrugBank.d628.s7'}	significant adverse interactions commonly used premedications drugs used anesthesia sedation including range muscle relaxants inhalational agents analgesic agents local anesthetic agents observed
No significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation (including a range of muscle relaxants, inhalational agents, analgesic agents, and local anesthetic agents) have been observed.	muscle relaxants	anesthetic agents	none	{'e1': {'word': 'muscle relaxants', 'word_index': [(12, 13)], 'id': 'DDI-DrugBank.d628.s7.e0'}, 'e2': {'word': 'anesthetic agents', 'word_index': [(19, 20)], 'id': 'DDI-DrugBank.d628.s7.e2'}, 'sentence_id': 'DDI-DrugBank.d628.s7'}	significant adverse interactions commonly used premedications drugs used anesthesia sedation including range muscle relaxants inhalational agents analgesic agents local anesthetic agents observed
No significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation (including a range of muscle relaxants, inhalational agents, analgesic agents, and local anesthetic agents) have been observed.	analgesic agents	anesthetic agents	none	{'e1': {'word': 'analgesic agents', 'word_index': [(16, 17)], 'id': 'DDI-DrugBank.d628.s7.e1'}, 'e2': {'word': 'anesthetic agents', 'word_index': [(19, 20)], 'id': 'DDI-DrugBank.d628.s7.e2'}, 'sentence_id': 'DDI-DrugBank.d628.s7'}	significant adverse interactions commonly used premedications drugs used anesthesia sedation including range muscle relaxants inhalational agents analgesic agents local anesthetic agents observed
Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.	Tetracycline	antibiotic	none	{'e1': {'word': 'Tetracycline', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d747.s0.e0'}, 'e2': {'word': 'antibiotic', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d747.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d747.s0'}	Tetracycline bacteriostatic antibiotic may antagonize bactericidal effect penicillin concurrent use drugs avoided
Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.	Tetracycline	penicillin	effect	{'e1': {'word': 'Tetracycline', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d747.s0.e0'}, 'e2': {'word': 'penicillin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d747.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d747.s0'}	Tetracycline bacteriostatic antibiotic may antagonize bactericidal effect penicillin concurrent use drugs avoided
Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.	antibiotic	penicillin	none	{'e1': {'word': 'antibiotic', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d747.s0.e1'}, 'e2': {'word': 'penicillin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d747.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d747.s0'}	Tetracycline bacteriostatic antibiotic may antagonize bactericidal effect penicillin concurrent use drugs avoided
Anticholinesterases: Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride. 	Anticholinesterases	procaine hydrochloride	none	{'e1': {'word': 'Anticholinesterases', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d780.s0.e0'}, 'e2': {'word': 'procaine hydrochloride', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d780.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d780.s0'}	Anticholinesterases Concurrent use procaine hydrochloride anticholinesterase agents may result increased systemic toxicity since anticholinesterases inhibit breakdown procaine hydrochloride
Anticholinesterases: Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride. 	Anticholinesterases	anticholinesterase agents	none	{'e1': {'word': 'Anticholinesterases', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d780.s0.e0'}, 'e2': {'word': 'anticholinesterase agents', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d780.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d780.s0'}	Anticholinesterases Concurrent use procaine hydrochloride anticholinesterase agents may result increased systemic toxicity since anticholinesterases inhibit breakdown procaine hydrochloride
Anticholinesterases: Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride. 	Anticholinesterases	anticholinesterases	none	{'e1': {'word': 'Anticholinesterases', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d780.s0.e0'}, 'e2': {'word': 'anticholinesterases', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d780.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d780.s0'}	Anticholinesterases Concurrent use procaine hydrochloride anticholinesterase agents may result increased systemic toxicity since anticholinesterases inhibit breakdown procaine hydrochloride
Anticholinesterases: Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride. 	Anticholinesterases	procaine hydrochloride	none	{'e1': {'word': 'Anticholinesterases', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d780.s0.e0'}, 'e2': {'word': 'procaine hydrochloride', 'word_index': [(16, 17)], 'id': 'DDI-DrugBank.d780.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d780.s0'}	Anticholinesterases Concurrent use procaine hydrochloride anticholinesterase agents may result increased systemic toxicity since anticholinesterases inhibit breakdown procaine hydrochloride
Anticholinesterases: Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride. 	procaine hydrochloride	anticholinesterase agents	effect	{'e1': {'word': 'procaine hydrochloride', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d780.s0.e1'}, 'e2': {'word': 'anticholinesterase agents', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d780.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d780.s0'}	Anticholinesterases Concurrent use procaine hydrochloride anticholinesterase agents may result increased systemic toxicity since anticholinesterases inhibit breakdown procaine hydrochloride
Anticholinesterases: Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride. 	procaine hydrochloride	anticholinesterases	none	{'e1': {'word': 'procaine hydrochloride', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d780.s0.e1'}, 'e2': {'word': 'anticholinesterases', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d780.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d780.s0'}	Anticholinesterases Concurrent use procaine hydrochloride anticholinesterase agents may result increased systemic toxicity since anticholinesterases inhibit breakdown procaine hydrochloride
Anticholinesterases: Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride. 	procaine hydrochloride	procaine hydrochloride	none	{'e1': {'word': 'procaine hydrochloride', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d780.s0.e1'}, 'e2': {'word': 'procaine hydrochloride', 'word_index': [(16, 17)], 'id': 'DDI-DrugBank.d780.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d780.s0'}	Anticholinesterases Concurrent use procaine hydrochloride anticholinesterase agents may result increased systemic toxicity since anticholinesterases inhibit breakdown procaine hydrochloride
Anticholinesterases: Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride. 	anticholinesterase agents	anticholinesterases	none	{'e1': {'word': 'anticholinesterase agents', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d780.s0.e2'}, 'e2': {'word': 'anticholinesterases', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d780.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d780.s0'}	Anticholinesterases Concurrent use procaine hydrochloride anticholinesterase agents may result increased systemic toxicity since anticholinesterases inhibit breakdown procaine hydrochloride
Anticholinesterases: Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride. 	anticholinesterase agents	procaine hydrochloride	none	{'e1': {'word': 'anticholinesterase agents', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d780.s0.e2'}, 'e2': {'word': 'procaine hydrochloride', 'word_index': [(16, 17)], 'id': 'DDI-DrugBank.d780.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d780.s0'}	Anticholinesterases Concurrent use procaine hydrochloride anticholinesterase agents may result increased systemic toxicity since anticholinesterases inhibit breakdown procaine hydrochloride
Anticholinesterases: Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride. 	anticholinesterases	procaine hydrochloride	mechanism	{'e1': {'word': 'anticholinesterases', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d780.s0.e3'}, 'e2': {'word': 'procaine hydrochloride', 'word_index': [(16, 17)], 'id': 'DDI-DrugBank.d780.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d780.s0'}	Anticholinesterases Concurrent use procaine hydrochloride anticholinesterase agents may result increased systemic toxicity since anticholinesterases inhibit breakdown procaine hydrochloride
CNS depressant medications: Concurrent use of procaine hydrochloride and CNS depressant medications may result in additive depressant effects. 	CNS depressant	procaine hydrochloride	none	{'e1': {'word': 'CNS depressant', 'word_index': [(0, 1)], 'id': 'DDI-DrugBank.d780.s4.e0'}, 'e2': {'word': 'procaine hydrochloride', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d780.s4.e1'}, 'sentence_id': 'DDI-DrugBank.d780.s4'}	CNS depressant medications Concurrent use procaine hydrochloride CNS depressant medications may result additive depressant effects
CNS depressant medications: Concurrent use of procaine hydrochloride and CNS depressant medications may result in additive depressant effects. 	CNS depressant	CNS depressant medications	none	{'e1': {'word': 'CNS depressant', 'word_index': [(0, 1)], 'id': 'DDI-DrugBank.d780.s4.e0'}, 'e2': {'word': 'CNS depressant medications', 'word_index': [(7, 9)], 'id': 'DDI-DrugBank.d780.s4.e2'}, 'sentence_id': 'DDI-DrugBank.d780.s4'}	CNS depressant medications Concurrent use procaine hydrochloride CNS depressant medications may result additive depressant effects
CNS depressant medications: Concurrent use of procaine hydrochloride and CNS depressant medications may result in additive depressant effects. 	procaine hydrochloride	CNS depressant medications	effect	{'e1': {'word': 'procaine hydrochloride', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d780.s4.e1'}, 'e2': {'word': 'CNS depressant medications', 'word_index': [(7, 9)], 'id': 'DDI-DrugBank.d780.s4.e2'}, 'sentence_id': 'DDI-DrugBank.d780.s4'}	CNS depressant medications Concurrent use procaine hydrochloride CNS depressant medications may result additive depressant effects
Hyaluronidase: Hyaluronidase may increase the diffusion rate of procaine hydrochloride, resulting in a decreased time of onset, but an increase in systemic toxicity. 	Hyaluronidase	Hyaluronidase	none	{'e1': {'word': 'Hyaluronidase', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d780.s5.e0'}, 'e2': {'word': 'Hyaluronidase', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d780.s5.e1'}, 'sentence_id': 'DDI-DrugBank.d780.s5'}	Hyaluronidase Hyaluronidase may increase diffusion rate procaine hydrochloride resulting decreased time onset increase systemic toxicity
Hyaluronidase: Hyaluronidase may increase the diffusion rate of procaine hydrochloride, resulting in a decreased time of onset, but an increase in systemic toxicity. 	Hyaluronidase	procaine hydrochloride	none	{'e1': {'word': 'Hyaluronidase', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d780.s5.e0'}, 'e2': {'word': 'procaine hydrochloride', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d780.s5.e2'}, 'sentence_id': 'DDI-DrugBank.d780.s5'}	Hyaluronidase Hyaluronidase may increase diffusion rate procaine hydrochloride resulting decreased time onset increase systemic toxicity
Hyaluronidase: Hyaluronidase may increase the diffusion rate of procaine hydrochloride, resulting in a decreased time of onset, but an increase in systemic toxicity. 	Hyaluronidase	procaine hydrochloride	mechanism	{'e1': {'word': 'Hyaluronidase', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d780.s5.e1'}, 'e2': {'word': 'procaine hydrochloride', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d780.s5.e2'}, 'sentence_id': 'DDI-DrugBank.d780.s5'}	Hyaluronidase Hyaluronidase may increase diffusion rate procaine hydrochloride resulting decreased time onset increase systemic toxicity
Neuromuscular blocking agents (such as suxamethonium chloride): Concurrent use of procaine hydrochloride and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade. 	Neuromuscular blocking agents	suxamethonium chloride	none	{'e1': {'word': 'Neuromuscular blocking agents', 'word_index': [(0, 2)], 'id': 'DDI-DrugBank.d780.s6.e0'}, 'e2': {'word': 'suxamethonium chloride', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d780.s6.e1'}, 'sentence_id': 'DDI-DrugBank.d780.s6'}	Neuromuscular blocking agents suxamethonium chloride Concurrent use procaine hydrochloride neuromuscular blocking agents may result prolongation enhancement neuromuscular blockade
Neuromuscular blocking agents (such as suxamethonium chloride): Concurrent use of procaine hydrochloride and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade. 	Neuromuscular blocking agents	procaine hydrochloride	none	{'e1': {'word': 'Neuromuscular blocking agents', 'word_index': [(0, 2)], 'id': 'DDI-DrugBank.d780.s6.e0'}, 'e2': {'word': 'procaine hydrochloride', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d780.s6.e2'}, 'sentence_id': 'DDI-DrugBank.d780.s6'}	Neuromuscular blocking agents suxamethonium chloride Concurrent use procaine hydrochloride neuromuscular blocking agents may result prolongation enhancement neuromuscular blockade
Neuromuscular blocking agents (such as suxamethonium chloride): Concurrent use of procaine hydrochloride and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade. 	Neuromuscular blocking agents	neuromuscular blocking agents	none	{'e1': {'word': 'Neuromuscular blocking agents', 'word_index': [(0, 2)], 'id': 'DDI-DrugBank.d780.s6.e0'}, 'e2': {'word': 'neuromuscular blocking agents', 'word_index': [(9, 11)], 'id': 'DDI-DrugBank.d780.s6.e3'}, 'sentence_id': 'DDI-DrugBank.d780.s6'}	Neuromuscular blocking agents suxamethonium chloride Concurrent use procaine hydrochloride neuromuscular blocking agents may result prolongation enhancement neuromuscular blockade
Neuromuscular blocking agents (such as suxamethonium chloride): Concurrent use of procaine hydrochloride and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade. 	suxamethonium chloride	procaine hydrochloride	none	{'e1': {'word': 'suxamethonium chloride', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d780.s6.e1'}, 'e2': {'word': 'procaine hydrochloride', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d780.s6.e2'}, 'sentence_id': 'DDI-DrugBank.d780.s6'}	Neuromuscular blocking agents suxamethonium chloride Concurrent use procaine hydrochloride neuromuscular blocking agents may result prolongation enhancement neuromuscular blockade
Neuromuscular blocking agents (such as suxamethonium chloride): Concurrent use of procaine hydrochloride and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade. 	suxamethonium chloride	neuromuscular blocking agents	none	{'e1': {'word': 'suxamethonium chloride', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d780.s6.e1'}, 'e2': {'word': 'neuromuscular blocking agents', 'word_index': [(9, 11)], 'id': 'DDI-DrugBank.d780.s6.e3'}, 'sentence_id': 'DDI-DrugBank.d780.s6'}	Neuromuscular blocking agents suxamethonium chloride Concurrent use procaine hydrochloride neuromuscular blocking agents may result prolongation enhancement neuromuscular blockade
Neuromuscular blocking agents (such as suxamethonium chloride): Concurrent use of procaine hydrochloride and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade. 	procaine hydrochloride	neuromuscular blocking agents	effect	{'e1': {'word': 'procaine hydrochloride', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d780.s6.e2'}, 'e2': {'word': 'neuromuscular blocking agents', 'word_index': [(9, 11)], 'id': 'DDI-DrugBank.d780.s6.e3'}, 'sentence_id': 'DDI-DrugBank.d780.s6'}	Neuromuscular blocking agents suxamethonium chloride Concurrent use procaine hydrochloride neuromuscular blocking agents may result prolongation enhancement neuromuscular blockade
Sulfonamides: Concurrent use of procaine hydrochloride and sulfonamides may result in a reduction of the antibacterial action of the sulfonamide. 	Sulfonamides	procaine hydrochloride	none	{'e1': {'word': 'Sulfonamides', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d780.s7.e0'}, 'e2': {'word': 'procaine hydrochloride', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d780.s7.e1'}, 'sentence_id': 'DDI-DrugBank.d780.s7'}	Sulfonamides Concurrent use procaine hydrochloride sulfonamides may result reduction antibacterial action sulfonamide
Sulfonamides: Concurrent use of procaine hydrochloride and sulfonamides may result in a reduction of the antibacterial action of the sulfonamide. 	Sulfonamides	sulfonamides	none	{'e1': {'word': 'Sulfonamides', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d780.s7.e0'}, 'e2': {'word': 'sulfonamides', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d780.s7.e2'}, 'sentence_id': 'DDI-DrugBank.d780.s7'}	Sulfonamides Concurrent use procaine hydrochloride sulfonamides may result reduction antibacterial action sulfonamide
Sulfonamides: Concurrent use of procaine hydrochloride and sulfonamides may result in a reduction of the antibacterial action of the sulfonamide. 	Sulfonamides	sulfonamide	none	{'e1': {'word': 'Sulfonamides', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d780.s7.e0'}, 'e2': {'word': 'sulfonamide', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d780.s7.e3'}, 'sentence_id': 'DDI-DrugBank.d780.s7'}	Sulfonamides Concurrent use procaine hydrochloride sulfonamides may result reduction antibacterial action sulfonamide
Sulfonamides: Concurrent use of procaine hydrochloride and sulfonamides may result in a reduction of the antibacterial action of the sulfonamide. 	procaine hydrochloride	sulfonamides	effect	{'e1': {'word': 'procaine hydrochloride', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d780.s7.e1'}, 'e2': {'word': 'sulfonamides', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d780.s7.e2'}, 'sentence_id': 'DDI-DrugBank.d780.s7'}	Sulfonamides Concurrent use procaine hydrochloride sulfonamides may result reduction antibacterial action sulfonamide
Sulfonamides: Concurrent use of procaine hydrochloride and sulfonamides may result in a reduction of the antibacterial action of the sulfonamide. 	procaine hydrochloride	sulfonamide	none	{'e1': {'word': 'procaine hydrochloride', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d780.s7.e1'}, 'e2': {'word': 'sulfonamide', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d780.s7.e3'}, 'sentence_id': 'DDI-DrugBank.d780.s7'}	Sulfonamides Concurrent use procaine hydrochloride sulfonamides may result reduction antibacterial action sulfonamide
Sulfonamides: Concurrent use of procaine hydrochloride and sulfonamides may result in a reduction of the antibacterial action of the sulfonamide. 	sulfonamides	sulfonamide	none	{'e1': {'word': 'sulfonamides', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d780.s7.e2'}, 'e2': {'word': 'sulfonamide', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d780.s7.e3'}, 'sentence_id': 'DDI-DrugBank.d780.s7'}	Sulfonamides Concurrent use procaine hydrochloride sulfonamides may result reduction antibacterial action sulfonamide
Acetazolamide: Concurrent use of acetazolamide and procaine hydrochloride may extend the plasma half-life of procaine.	Acetazolamide	acetazolamide	none	{'e1': {'word': 'Acetazolamide', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d780.s8.e0'}, 'e2': {'word': 'acetazolamide', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d780.s8.e1'}, 'sentence_id': 'DDI-DrugBank.d780.s8'}	Acetazolamide Concurrent use acetazolamide procaine hydrochloride may extend plasma half life procaine
Acetazolamide: Concurrent use of acetazolamide and procaine hydrochloride may extend the plasma half-life of procaine.	Acetazolamide	procaine hydrochloride	none	{'e1': {'word': 'Acetazolamide', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d780.s8.e0'}, 'e2': {'word': 'procaine hydrochloride', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d780.s8.e2'}, 'sentence_id': 'DDI-DrugBank.d780.s8'}	Acetazolamide Concurrent use acetazolamide procaine hydrochloride may extend plasma half life procaine
Acetazolamide: Concurrent use of acetazolamide and procaine hydrochloride may extend the plasma half-life of procaine.	Acetazolamide	procaine	none	{'e1': {'word': 'Acetazolamide', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d780.s8.e0'}, 'e2': {'word': 'procaine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d780.s8.e3'}, 'sentence_id': 'DDI-DrugBank.d780.s8'}	Acetazolamide Concurrent use acetazolamide procaine hydrochloride may extend plasma half life procaine
Acetazolamide: Concurrent use of acetazolamide and procaine hydrochloride may extend the plasma half-life of procaine.	acetazolamide	procaine hydrochloride	mechanism	{'e1': {'word': 'acetazolamide', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d780.s8.e1'}, 'e2': {'word': 'procaine hydrochloride', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d780.s8.e2'}, 'sentence_id': 'DDI-DrugBank.d780.s8'}	Acetazolamide Concurrent use acetazolamide procaine hydrochloride may extend plasma half life procaine
Acetazolamide: Concurrent use of acetazolamide and procaine hydrochloride may extend the plasma half-life of procaine.	acetazolamide	procaine	none	{'e1': {'word': 'acetazolamide', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d780.s8.e1'}, 'e2': {'word': 'procaine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d780.s8.e3'}, 'sentence_id': 'DDI-DrugBank.d780.s8'}	Acetazolamide Concurrent use acetazolamide procaine hydrochloride may extend plasma half life procaine
Acetazolamide: Concurrent use of acetazolamide and procaine hydrochloride may extend the plasma half-life of procaine.	procaine hydrochloride	procaine	none	{'e1': {'word': 'procaine hydrochloride', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d780.s8.e2'}, 'e2': {'word': 'procaine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d780.s8.e3'}, 'sentence_id': 'DDI-DrugBank.d780.s8'}	Acetazolamide Concurrent use acetazolamide procaine hydrochloride may extend plasma half life procaine
Thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and reserpine. 	Thalidomide	barbiturates	effect	{'e1': {'word': 'Thalidomide', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d604.s0.e0'}, 'e2': {'word': 'barbiturates', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d604.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d604.s0'}	Thalidomide reported enhance sedative activity barbiturates alcohol chlorpromazine reserpine
Thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and reserpine. 	Thalidomide	alcohol	none	{'e1': {'word': 'Thalidomide', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d604.s0.e0'}, 'e2': {'word': 'alcohol', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d604.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d604.s0'}	Thalidomide reported enhance sedative activity barbiturates alcohol chlorpromazine reserpine
Thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and reserpine. 	Thalidomide	chlorpromazine	none	{'e1': {'word': 'Thalidomide', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d604.s0.e0'}, 'e2': {'word': 'chlorpromazine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d604.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d604.s0'}	Thalidomide reported enhance sedative activity barbiturates alcohol chlorpromazine reserpine
Thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and reserpine. 	Thalidomide	reserpine	none	{'e1': {'word': 'Thalidomide', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d604.s0.e0'}, 'e2': {'word': 'reserpine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d604.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d604.s0'}	Thalidomide reported enhance sedative activity barbiturates alcohol chlorpromazine reserpine
Thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and reserpine. 	barbiturates	alcohol	none	{'e1': {'word': 'barbiturates', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d604.s0.e1'}, 'e2': {'word': 'alcohol', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d604.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d604.s0'}	Thalidomide reported enhance sedative activity barbiturates alcohol chlorpromazine reserpine
Thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and reserpine. 	barbiturates	chlorpromazine	none	{'e1': {'word': 'barbiturates', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d604.s0.e1'}, 'e2': {'word': 'chlorpromazine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d604.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d604.s0'}	Thalidomide reported enhance sedative activity barbiturates alcohol chlorpromazine reserpine
Thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and reserpine. 	barbiturates	reserpine	none	{'e1': {'word': 'barbiturates', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d604.s0.e1'}, 'e2': {'word': 'reserpine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d604.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d604.s0'}	Thalidomide reported enhance sedative activity barbiturates alcohol chlorpromazine reserpine
Thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and reserpine. 	alcohol	chlorpromazine	none	{'e1': {'word': 'alcohol', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d604.s0.e2'}, 'e2': {'word': 'chlorpromazine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d604.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d604.s0'}	Thalidomide reported enhance sedative activity barbiturates alcohol chlorpromazine reserpine
Thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and reserpine. 	alcohol	reserpine	none	{'e1': {'word': 'alcohol', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d604.s0.e2'}, 'e2': {'word': 'reserpine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d604.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d604.s0'}	Thalidomide reported enhance sedative activity barbiturates alcohol chlorpromazine reserpine
Thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and reserpine. 	chlorpromazine	reserpine	none	{'e1': {'word': 'chlorpromazine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d604.s0.e3'}, 'e2': {'word': 'reserpine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d604.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d604.s0'}	Thalidomide reported enhance sedative activity barbiturates alcohol chlorpromazine reserpine
Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied. 	Contraceptives	norethindrone	none	{'e1': {'word': 'Contraceptives', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d604.s2.e0'}, 'e2': {'word': 'norethindrone', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d604.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d604.s2'}	Oral Contraceptives NUMBER healthy women pharmacokinetic profiles norethindrone ethinyl estradiol following administration single dose containing NUMBER mg norethindrone acetate NUMBER g ethinyl estradiol studied
Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied. 	Contraceptives	ethinyl estradiol	none	{'e1': {'word': 'Contraceptives', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d604.s2.e0'}, 'e2': {'word': 'ethinyl estradiol', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d604.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d604.s2'}	Oral Contraceptives NUMBER healthy women pharmacokinetic profiles norethindrone ethinyl estradiol following administration single dose containing NUMBER mg norethindrone acetate NUMBER g ethinyl estradiol studied
Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied. 	Contraceptives	norethindrone acetate	none	{'e1': {'word': 'Contraceptives', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d604.s2.e0'}, 'e2': {'word': 'norethindrone acetate', 'word_index': [(17, 18)], 'id': 'DDI-DrugBank.d604.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d604.s2'}	Oral Contraceptives NUMBER healthy women pharmacokinetic profiles norethindrone ethinyl estradiol following administration single dose containing NUMBER mg norethindrone acetate NUMBER g ethinyl estradiol studied
Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied. 	Contraceptives	ethinyl estradiol	none	{'e1': {'word': 'Contraceptives', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d604.s2.e0'}, 'e2': {'word': 'ethinyl estradiol', 'word_index': [(21, 22)], 'id': 'DDI-DrugBank.d604.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d604.s2'}	Oral Contraceptives NUMBER healthy women pharmacokinetic profiles norethindrone ethinyl estradiol following administration single dose containing NUMBER mg norethindrone acetate NUMBER g ethinyl estradiol studied
Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied. 	norethindrone	ethinyl estradiol	none	{'e1': {'word': 'norethindrone', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d604.s2.e1'}, 'e2': {'word': 'ethinyl estradiol', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d604.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d604.s2'}	Oral Contraceptives NUMBER healthy women pharmacokinetic profiles norethindrone ethinyl estradiol following administration single dose containing NUMBER mg norethindrone acetate NUMBER g ethinyl estradiol studied
Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied. 	norethindrone	norethindrone acetate	none	{'e1': {'word': 'norethindrone', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d604.s2.e1'}, 'e2': {'word': 'norethindrone acetate', 'word_index': [(17, 18)], 'id': 'DDI-DrugBank.d604.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d604.s2'}	Oral Contraceptives NUMBER healthy women pharmacokinetic profiles norethindrone ethinyl estradiol following administration single dose containing NUMBER mg norethindrone acetate NUMBER g ethinyl estradiol studied
Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied. 	norethindrone	ethinyl estradiol	none	{'e1': {'word': 'norethindrone', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d604.s2.e1'}, 'e2': {'word': 'ethinyl estradiol', 'word_index': [(21, 22)], 'id': 'DDI-DrugBank.d604.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d604.s2'}	Oral Contraceptives NUMBER healthy women pharmacokinetic profiles norethindrone ethinyl estradiol following administration single dose containing NUMBER mg norethindrone acetate NUMBER g ethinyl estradiol studied
Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied. 	ethinyl estradiol	norethindrone acetate	none	{'e1': {'word': 'ethinyl estradiol', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d604.s2.e2'}, 'e2': {'word': 'norethindrone acetate', 'word_index': [(17, 18)], 'id': 'DDI-DrugBank.d604.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d604.s2'}	Oral Contraceptives NUMBER healthy women pharmacokinetic profiles norethindrone ethinyl estradiol following administration single dose containing NUMBER mg norethindrone acetate NUMBER g ethinyl estradiol studied
Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied. 	ethinyl estradiol	ethinyl estradiol	none	{'e1': {'word': 'ethinyl estradiol', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d604.s2.e2'}, 'e2': {'word': 'ethinyl estradiol', 'word_index': [(21, 22)], 'id': 'DDI-DrugBank.d604.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d604.s2'}	Oral Contraceptives NUMBER healthy women pharmacokinetic profiles norethindrone ethinyl estradiol following administration single dose containing NUMBER mg norethindrone acetate NUMBER g ethinyl estradiol studied
Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied. 	norethindrone acetate	ethinyl estradiol	none	{'e1': {'word': 'norethindrone acetate', 'word_index': [(17, 18)], 'id': 'DDI-DrugBank.d604.s2.e3'}, 'e2': {'word': 'ethinyl estradiol', 'word_index': [(21, 22)], 'id': 'DDI-DrugBank.d604.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d604.s2'}	Oral Contraceptives NUMBER healthy women pharmacokinetic profiles norethindrone ethinyl estradiol following administration single dose containing NUMBER mg norethindrone acetate NUMBER g ethinyl estradiol studied
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 	Thalidomide	Hormonal Contraceptives	none	{'e1': {'word': 'Thalidomide', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d604.s4.e0'}, 'e2': {'word': 'Hormonal Contraceptives', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d604.s4.e1'}, 'sentence_id': 'DDI-DrugBank.d604.s4'}	Important Non Thalidomide Drug Interactions Drugs Interfere Hormonal Contraceptives Concomitant use HIV protease inhibitors griseofulvin modafinil penicillins rifampin rifabutin phenytoin carbamazepine certain herbal supplements St.
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 	Thalidomide	HIV-protease inhibitors	none	{'e1': {'word': 'Thalidomide', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d604.s4.e0'}, 'e2': {'word': 'HIV-protease inhibitors', 'word_index': [(11, 13)], 'id': 'DDI-DrugBank.d604.s4.e2'}, 'sentence_id': 'DDI-DrugBank.d604.s4'}	Important Non Thalidomide Drug Interactions Drugs Interfere Hormonal Contraceptives Concomitant use HIV protease inhibitors griseofulvin modafinil penicillins rifampin rifabutin phenytoin carbamazepine certain herbal supplements St.
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 	Thalidomide	griseofulvin	none	{'e1': {'word': 'Thalidomide', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d604.s4.e0'}, 'e2': {'word': 'griseofulvin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d604.s4.e3'}, 'sentence_id': 'DDI-DrugBank.d604.s4'}	Important Non Thalidomide Drug Interactions Drugs Interfere Hormonal Contraceptives Concomitant use HIV protease inhibitors griseofulvin modafinil penicillins rifampin rifabutin phenytoin carbamazepine certain herbal supplements St.
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 	Thalidomide	modafinil	none	{'e1': {'word': 'Thalidomide', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d604.s4.e0'}, 'e2': {'word': 'modafinil', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d604.s4.e4'}, 'sentence_id': 'DDI-DrugBank.d604.s4'}	Important Non Thalidomide Drug Interactions Drugs Interfere Hormonal Contraceptives Concomitant use HIV protease inhibitors griseofulvin modafinil penicillins rifampin rifabutin phenytoin carbamazepine certain herbal supplements St.
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 	Thalidomide	penicillins	none	{'e1': {'word': 'Thalidomide', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d604.s4.e0'}, 'e2': {'word': 'penicillins', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d604.s4.e5'}, 'sentence_id': 'DDI-DrugBank.d604.s4'}	Important Non Thalidomide Drug Interactions Drugs Interfere Hormonal Contraceptives Concomitant use HIV protease inhibitors griseofulvin modafinil penicillins rifampin rifabutin phenytoin carbamazepine certain herbal supplements St.
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 	Thalidomide	rifampin	none	{'e1': {'word': 'Thalidomide', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d604.s4.e0'}, 'e2': {'word': 'rifampin', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d604.s4.e6'}, 'sentence_id': 'DDI-DrugBank.d604.s4'}	Important Non Thalidomide Drug Interactions Drugs Interfere Hormonal Contraceptives Concomitant use HIV protease inhibitors griseofulvin modafinil penicillins rifampin rifabutin phenytoin carbamazepine certain herbal supplements St.
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 	Thalidomide	rifabutin	none	{'e1': {'word': 'Thalidomide', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d604.s4.e0'}, 'e2': {'word': 'rifabutin', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d604.s4.e7'}, 'sentence_id': 'DDI-DrugBank.d604.s4'}	Important Non Thalidomide Drug Interactions Drugs Interfere Hormonal Contraceptives Concomitant use HIV protease inhibitors griseofulvin modafinil penicillins rifampin rifabutin phenytoin carbamazepine certain herbal supplements St.
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 	Thalidomide	phenytoin	none	{'e1': {'word': 'Thalidomide', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d604.s4.e0'}, 'e2': {'word': 'phenytoin', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d604.s4.e8'}, 'sentence_id': 'DDI-DrugBank.d604.s4'}	Important Non Thalidomide Drug Interactions Drugs Interfere Hormonal Contraceptives Concomitant use HIV protease inhibitors griseofulvin modafinil penicillins rifampin rifabutin phenytoin carbamazepine certain herbal supplements St.
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 	Thalidomide	carbamazepine	none	{'e1': {'word': 'Thalidomide', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d604.s4.e0'}, 'e2': {'word': 'carbamazepine', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d604.s4.e9'}, 'sentence_id': 'DDI-DrugBank.d604.s4'}	Important Non Thalidomide Drug Interactions Drugs Interfere Hormonal Contraceptives Concomitant use HIV protease inhibitors griseofulvin modafinil penicillins rifampin rifabutin phenytoin carbamazepine certain herbal supplements St.
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 	Hormonal Contraceptives	HIV-protease inhibitors	none	{'e1': {'word': 'Hormonal Contraceptives', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d604.s4.e1'}, 'e2': {'word': 'HIV-protease inhibitors', 'word_index': [(11, 13)], 'id': 'DDI-DrugBank.d604.s4.e2'}, 'sentence_id': 'DDI-DrugBank.d604.s4'}	Important Non Thalidomide Drug Interactions Drugs Interfere Hormonal Contraceptives Concomitant use HIV protease inhibitors griseofulvin modafinil penicillins rifampin rifabutin phenytoin carbamazepine certain herbal supplements St.
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 	Hormonal Contraceptives	griseofulvin	none	{'e1': {'word': 'Hormonal Contraceptives', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d604.s4.e1'}, 'e2': {'word': 'griseofulvin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d604.s4.e3'}, 'sentence_id': 'DDI-DrugBank.d604.s4'}	Important Non Thalidomide Drug Interactions Drugs Interfere Hormonal Contraceptives Concomitant use HIV protease inhibitors griseofulvin modafinil penicillins rifampin rifabutin phenytoin carbamazepine certain herbal supplements St.
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 	Hormonal Contraceptives	modafinil	none	{'e1': {'word': 'Hormonal Contraceptives', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d604.s4.e1'}, 'e2': {'word': 'modafinil', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d604.s4.e4'}, 'sentence_id': 'DDI-DrugBank.d604.s4'}	Important Non Thalidomide Drug Interactions Drugs Interfere Hormonal Contraceptives Concomitant use HIV protease inhibitors griseofulvin modafinil penicillins rifampin rifabutin phenytoin carbamazepine certain herbal supplements St.
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 	Hormonal Contraceptives	penicillins	none	{'e1': {'word': 'Hormonal Contraceptives', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d604.s4.e1'}, 'e2': {'word': 'penicillins', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d604.s4.e5'}, 'sentence_id': 'DDI-DrugBank.d604.s4'}	Important Non Thalidomide Drug Interactions Drugs Interfere Hormonal Contraceptives Concomitant use HIV protease inhibitors griseofulvin modafinil penicillins rifampin rifabutin phenytoin carbamazepine certain herbal supplements St.
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 	Hormonal Contraceptives	rifampin	none	{'e1': {'word': 'Hormonal Contraceptives', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d604.s4.e1'}, 'e2': {'word': 'rifampin', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d604.s4.e6'}, 'sentence_id': 'DDI-DrugBank.d604.s4'}	Important Non Thalidomide Drug Interactions Drugs Interfere Hormonal Contraceptives Concomitant use HIV protease inhibitors griseofulvin modafinil penicillins rifampin rifabutin phenytoin carbamazepine certain herbal supplements St.
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 	Hormonal Contraceptives	rifabutin	none	{'e1': {'word': 'Hormonal Contraceptives', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d604.s4.e1'}, 'e2': {'word': 'rifabutin', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d604.s4.e7'}, 'sentence_id': 'DDI-DrugBank.d604.s4'}	Important Non Thalidomide Drug Interactions Drugs Interfere Hormonal Contraceptives Concomitant use HIV protease inhibitors griseofulvin modafinil penicillins rifampin rifabutin phenytoin carbamazepine certain herbal supplements St.
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 	Hormonal Contraceptives	phenytoin	none	{'e1': {'word': 'Hormonal Contraceptives', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d604.s4.e1'}, 'e2': {'word': 'phenytoin', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d604.s4.e8'}, 'sentence_id': 'DDI-DrugBank.d604.s4'}	Important Non Thalidomide Drug Interactions Drugs Interfere Hormonal Contraceptives Concomitant use HIV protease inhibitors griseofulvin modafinil penicillins rifampin rifabutin phenytoin carbamazepine certain herbal supplements St.
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 	Hormonal Contraceptives	carbamazepine	none	{'e1': {'word': 'Hormonal Contraceptives', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d604.s4.e1'}, 'e2': {'word': 'carbamazepine', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d604.s4.e9'}, 'sentence_id': 'DDI-DrugBank.d604.s4'}	Important Non Thalidomide Drug Interactions Drugs Interfere Hormonal Contraceptives Concomitant use HIV protease inhibitors griseofulvin modafinil penicillins rifampin rifabutin phenytoin carbamazepine certain herbal supplements St.
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 	HIV-protease inhibitors	griseofulvin	none	{'e1': {'word': 'HIV-protease inhibitors', 'word_index': [(11, 13)], 'id': 'DDI-DrugBank.d604.s4.e2'}, 'e2': {'word': 'griseofulvin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d604.s4.e3'}, 'sentence_id': 'DDI-DrugBank.d604.s4'}	Important Non Thalidomide Drug Interactions Drugs Interfere Hormonal Contraceptives Concomitant use HIV protease inhibitors griseofulvin modafinil penicillins rifampin rifabutin phenytoin carbamazepine certain herbal supplements St.
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 	HIV-protease inhibitors	modafinil	none	{'e1': {'word': 'HIV-protease inhibitors', 'word_index': [(11, 13)], 'id': 'DDI-DrugBank.d604.s4.e2'}, 'e2': {'word': 'modafinil', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d604.s4.e4'}, 'sentence_id': 'DDI-DrugBank.d604.s4'}	Important Non Thalidomide Drug Interactions Drugs Interfere Hormonal Contraceptives Concomitant use HIV protease inhibitors griseofulvin modafinil penicillins rifampin rifabutin phenytoin carbamazepine certain herbal supplements St.
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 	HIV-protease inhibitors	penicillins	none	{'e1': {'word': 'HIV-protease inhibitors', 'word_index': [(11, 13)], 'id': 'DDI-DrugBank.d604.s4.e2'}, 'e2': {'word': 'penicillins', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d604.s4.e5'}, 'sentence_id': 'DDI-DrugBank.d604.s4'}	Important Non Thalidomide Drug Interactions Drugs Interfere Hormonal Contraceptives Concomitant use HIV protease inhibitors griseofulvin modafinil penicillins rifampin rifabutin phenytoin carbamazepine certain herbal supplements St.
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 	HIV-protease inhibitors	rifampin	none	{'e1': {'word': 'HIV-protease inhibitors', 'word_index': [(11, 13)], 'id': 'DDI-DrugBank.d604.s4.e2'}, 'e2': {'word': 'rifampin', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d604.s4.e6'}, 'sentence_id': 'DDI-DrugBank.d604.s4'}	Important Non Thalidomide Drug Interactions Drugs Interfere Hormonal Contraceptives Concomitant use HIV protease inhibitors griseofulvin modafinil penicillins rifampin rifabutin phenytoin carbamazepine certain herbal supplements St.
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 	HIV-protease inhibitors	rifabutin	none	{'e1': {'word': 'HIV-protease inhibitors', 'word_index': [(11, 13)], 'id': 'DDI-DrugBank.d604.s4.e2'}, 'e2': {'word': 'rifabutin', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d604.s4.e7'}, 'sentence_id': 'DDI-DrugBank.d604.s4'}	Important Non Thalidomide Drug Interactions Drugs Interfere Hormonal Contraceptives Concomitant use HIV protease inhibitors griseofulvin modafinil penicillins rifampin rifabutin phenytoin carbamazepine certain herbal supplements St.
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 	HIV-protease inhibitors	phenytoin	none	{'e1': {'word': 'HIV-protease inhibitors', 'word_index': [(11, 13)], 'id': 'DDI-DrugBank.d604.s4.e2'}, 'e2': {'word': 'phenytoin', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d604.s4.e8'}, 'sentence_id': 'DDI-DrugBank.d604.s4'}	Important Non Thalidomide Drug Interactions Drugs Interfere Hormonal Contraceptives Concomitant use HIV protease inhibitors griseofulvin modafinil penicillins rifampin rifabutin phenytoin carbamazepine certain herbal supplements St.
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 	HIV-protease inhibitors	carbamazepine	none	{'e1': {'word': 'HIV-protease inhibitors', 'word_index': [(11, 13)], 'id': 'DDI-DrugBank.d604.s4.e2'}, 'e2': {'word': 'carbamazepine', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d604.s4.e9'}, 'sentence_id': 'DDI-DrugBank.d604.s4'}	Important Non Thalidomide Drug Interactions Drugs Interfere Hormonal Contraceptives Concomitant use HIV protease inhibitors griseofulvin modafinil penicillins rifampin rifabutin phenytoin carbamazepine certain herbal supplements St.
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 	griseofulvin	modafinil	none	{'e1': {'word': 'griseofulvin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d604.s4.e3'}, 'e2': {'word': 'modafinil', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d604.s4.e4'}, 'sentence_id': 'DDI-DrugBank.d604.s4'}	Important Non Thalidomide Drug Interactions Drugs Interfere Hormonal Contraceptives Concomitant use HIV protease inhibitors griseofulvin modafinil penicillins rifampin rifabutin phenytoin carbamazepine certain herbal supplements St.
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 	griseofulvin	penicillins	none	{'e1': {'word': 'griseofulvin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d604.s4.e3'}, 'e2': {'word': 'penicillins', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d604.s4.e5'}, 'sentence_id': 'DDI-DrugBank.d604.s4'}	Important Non Thalidomide Drug Interactions Drugs Interfere Hormonal Contraceptives Concomitant use HIV protease inhibitors griseofulvin modafinil penicillins rifampin rifabutin phenytoin carbamazepine certain herbal supplements St.
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 	griseofulvin	rifampin	none	{'e1': {'word': 'griseofulvin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d604.s4.e3'}, 'e2': {'word': 'rifampin', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d604.s4.e6'}, 'sentence_id': 'DDI-DrugBank.d604.s4'}	Important Non Thalidomide Drug Interactions Drugs Interfere Hormonal Contraceptives Concomitant use HIV protease inhibitors griseofulvin modafinil penicillins rifampin rifabutin phenytoin carbamazepine certain herbal supplements St.
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 	griseofulvin	rifabutin	none	{'e1': {'word': 'griseofulvin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d604.s4.e3'}, 'e2': {'word': 'rifabutin', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d604.s4.e7'}, 'sentence_id': 'DDI-DrugBank.d604.s4'}	Important Non Thalidomide Drug Interactions Drugs Interfere Hormonal Contraceptives Concomitant use HIV protease inhibitors griseofulvin modafinil penicillins rifampin rifabutin phenytoin carbamazepine certain herbal supplements St.
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 	griseofulvin	phenytoin	none	{'e1': {'word': 'griseofulvin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d604.s4.e3'}, 'e2': {'word': 'phenytoin', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d604.s4.e8'}, 'sentence_id': 'DDI-DrugBank.d604.s4'}	Important Non Thalidomide Drug Interactions Drugs Interfere Hormonal Contraceptives Concomitant use HIV protease inhibitors griseofulvin modafinil penicillins rifampin rifabutin phenytoin carbamazepine certain herbal supplements St.
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 	griseofulvin	carbamazepine	none	{'e1': {'word': 'griseofulvin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d604.s4.e3'}, 'e2': {'word': 'carbamazepine', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d604.s4.e9'}, 'sentence_id': 'DDI-DrugBank.d604.s4'}	Important Non Thalidomide Drug Interactions Drugs Interfere Hormonal Contraceptives Concomitant use HIV protease inhibitors griseofulvin modafinil penicillins rifampin rifabutin phenytoin carbamazepine certain herbal supplements St.
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 	modafinil	penicillins	none	{'e1': {'word': 'modafinil', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d604.s4.e4'}, 'e2': {'word': 'penicillins', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d604.s4.e5'}, 'sentence_id': 'DDI-DrugBank.d604.s4'}	Important Non Thalidomide Drug Interactions Drugs Interfere Hormonal Contraceptives Concomitant use HIV protease inhibitors griseofulvin modafinil penicillins rifampin rifabutin phenytoin carbamazepine certain herbal supplements St.
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 	modafinil	rifampin	none	{'e1': {'word': 'modafinil', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d604.s4.e4'}, 'e2': {'word': 'rifampin', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d604.s4.e6'}, 'sentence_id': 'DDI-DrugBank.d604.s4'}	Important Non Thalidomide Drug Interactions Drugs Interfere Hormonal Contraceptives Concomitant use HIV protease inhibitors griseofulvin modafinil penicillins rifampin rifabutin phenytoin carbamazepine certain herbal supplements St.
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 	modafinil	rifabutin	none	{'e1': {'word': 'modafinil', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d604.s4.e4'}, 'e2': {'word': 'rifabutin', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d604.s4.e7'}, 'sentence_id': 'DDI-DrugBank.d604.s4'}	Important Non Thalidomide Drug Interactions Drugs Interfere Hormonal Contraceptives Concomitant use HIV protease inhibitors griseofulvin modafinil penicillins rifampin rifabutin phenytoin carbamazepine certain herbal supplements St.
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 	modafinil	phenytoin	none	{'e1': {'word': 'modafinil', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d604.s4.e4'}, 'e2': {'word': 'phenytoin', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d604.s4.e8'}, 'sentence_id': 'DDI-DrugBank.d604.s4'}	Important Non Thalidomide Drug Interactions Drugs Interfere Hormonal Contraceptives Concomitant use HIV protease inhibitors griseofulvin modafinil penicillins rifampin rifabutin phenytoin carbamazepine certain herbal supplements St.
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 	modafinil	carbamazepine	none	{'e1': {'word': 'modafinil', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d604.s4.e4'}, 'e2': {'word': 'carbamazepine', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d604.s4.e9'}, 'sentence_id': 'DDI-DrugBank.d604.s4'}	Important Non Thalidomide Drug Interactions Drugs Interfere Hormonal Contraceptives Concomitant use HIV protease inhibitors griseofulvin modafinil penicillins rifampin rifabutin phenytoin carbamazepine certain herbal supplements St.
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 	penicillins	rifampin	none	{'e1': {'word': 'penicillins', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d604.s4.e5'}, 'e2': {'word': 'rifampin', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d604.s4.e6'}, 'sentence_id': 'DDI-DrugBank.d604.s4'}	Important Non Thalidomide Drug Interactions Drugs Interfere Hormonal Contraceptives Concomitant use HIV protease inhibitors griseofulvin modafinil penicillins rifampin rifabutin phenytoin carbamazepine certain herbal supplements St.
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 	penicillins	rifabutin	none	{'e1': {'word': 'penicillins', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d604.s4.e5'}, 'e2': {'word': 'rifabutin', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d604.s4.e7'}, 'sentence_id': 'DDI-DrugBank.d604.s4'}	Important Non Thalidomide Drug Interactions Drugs Interfere Hormonal Contraceptives Concomitant use HIV protease inhibitors griseofulvin modafinil penicillins rifampin rifabutin phenytoin carbamazepine certain herbal supplements St.
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 	penicillins	phenytoin	none	{'e1': {'word': 'penicillins', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d604.s4.e5'}, 'e2': {'word': 'phenytoin', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d604.s4.e8'}, 'sentence_id': 'DDI-DrugBank.d604.s4'}	Important Non Thalidomide Drug Interactions Drugs Interfere Hormonal Contraceptives Concomitant use HIV protease inhibitors griseofulvin modafinil penicillins rifampin rifabutin phenytoin carbamazepine certain herbal supplements St.
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 	penicillins	carbamazepine	none	{'e1': {'word': 'penicillins', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d604.s4.e5'}, 'e2': {'word': 'carbamazepine', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d604.s4.e9'}, 'sentence_id': 'DDI-DrugBank.d604.s4'}	Important Non Thalidomide Drug Interactions Drugs Interfere Hormonal Contraceptives Concomitant use HIV protease inhibitors griseofulvin modafinil penicillins rifampin rifabutin phenytoin carbamazepine certain herbal supplements St.
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 	rifampin	rifabutin	none	{'e1': {'word': 'rifampin', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d604.s4.e6'}, 'e2': {'word': 'rifabutin', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d604.s4.e7'}, 'sentence_id': 'DDI-DrugBank.d604.s4'}	Important Non Thalidomide Drug Interactions Drugs Interfere Hormonal Contraceptives Concomitant use HIV protease inhibitors griseofulvin modafinil penicillins rifampin rifabutin phenytoin carbamazepine certain herbal supplements St.
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 	rifampin	phenytoin	none	{'e1': {'word': 'rifampin', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d604.s4.e6'}, 'e2': {'word': 'phenytoin', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d604.s4.e8'}, 'sentence_id': 'DDI-DrugBank.d604.s4'}	Important Non Thalidomide Drug Interactions Drugs Interfere Hormonal Contraceptives Concomitant use HIV protease inhibitors griseofulvin modafinil penicillins rifampin rifabutin phenytoin carbamazepine certain herbal supplements St.
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 	rifampin	carbamazepine	none	{'e1': {'word': 'rifampin', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d604.s4.e6'}, 'e2': {'word': 'carbamazepine', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d604.s4.e9'}, 'sentence_id': 'DDI-DrugBank.d604.s4'}	Important Non Thalidomide Drug Interactions Drugs Interfere Hormonal Contraceptives Concomitant use HIV protease inhibitors griseofulvin modafinil penicillins rifampin rifabutin phenytoin carbamazepine certain herbal supplements St.
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 	rifabutin	phenytoin	none	{'e1': {'word': 'rifabutin', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d604.s4.e7'}, 'e2': {'word': 'phenytoin', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d604.s4.e8'}, 'sentence_id': 'DDI-DrugBank.d604.s4'}	Important Non Thalidomide Drug Interactions Drugs Interfere Hormonal Contraceptives Concomitant use HIV protease inhibitors griseofulvin modafinil penicillins rifampin rifabutin phenytoin carbamazepine certain herbal supplements St.
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 	rifabutin	carbamazepine	none	{'e1': {'word': 'rifabutin', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d604.s4.e7'}, 'e2': {'word': 'carbamazepine', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d604.s4.e9'}, 'sentence_id': 'DDI-DrugBank.d604.s4'}	Important Non Thalidomide Drug Interactions Drugs Interfere Hormonal Contraceptives Concomitant use HIV protease inhibitors griseofulvin modafinil penicillins rifampin rifabutin phenytoin carbamazepine certain herbal supplements St.
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. 	phenytoin	carbamazepine	none	{'e1': {'word': 'phenytoin', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d604.s4.e8'}, 'e2': {'word': 'carbamazepine', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d604.s4.e9'}, 'sentence_id': 'DDI-DrugBank.d604.s4'}	Important Non Thalidomide Drug Interactions Drugs Interfere Hormonal Contraceptives Concomitant use HIV protease inhibitors griseofulvin modafinil penicillins rifampin rifabutin phenytoin carbamazepine certain herbal supplements St.
John's Wort with hormonal contraceptive agents may reduce the effectiveness of the contraception and up to one month after discontinuation of these concomitant therapies. 	John's Wort	hormonal contraceptive agents	effect	"{'e1': {'word': ""John's Wort"", 'word_index': [(0, 2)], 'id': 'DDI-DrugBank.d604.s5.e0'}, 'e2': {'word': 'hormonal contraceptive agents', 'word_index': [(3, 5)], 'id': 'DDI-DrugBank.d604.s5.e1'}, 'sentence_id': 'DDI-DrugBank.d604.s5'}"	John 's Wort hormonal contraceptive agents may reduce effectiveness contraception NUMBER month discontinuation concomitant therapies
Digoxin: There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days. 	Digoxin	digoxin	none	{'e1': {'word': 'Digoxin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d694.s0.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d694.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d694.s0'}	Digoxin slight increase area curve AUC NUMBER % mean peak drug concentration Cmax NUMBER % digoxin co-administration NUMBER mg sitagliptin NUMBER days
Digoxin: There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days. 	Digoxin	sitagliptin	none	{'e1': {'word': 'Digoxin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d694.s0.e0'}, 'e2': {'word': 'sitagliptin', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d694.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d694.s0'}	Digoxin slight increase area curve AUC NUMBER % mean peak drug concentration Cmax NUMBER % digoxin co-administration NUMBER mg sitagliptin NUMBER days
Digoxin: There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days. 	digoxin	sitagliptin	mechanism	{'e1': {'word': 'digoxin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d694.s0.e1'}, 'e2': {'word': 'sitagliptin', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d694.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d694.s0'}	Digoxin slight increase area curve AUC NUMBER % mean peak drug concentration Cmax NUMBER % digoxin co-administration NUMBER mg sitagliptin NUMBER days
No dosage adjustment of digoxin or JANUVIA is recommended.	digoxin	JANUVIA	none	{'e1': {'word': 'digoxin', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d694.s2.e0'}, 'e2': {'word': 'JANUVIA', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d694.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d694.s2'}	dosage adjustment digoxin JANUVIA recommended
ARAMINE should be used with caution in digitalized patients, since the combination of digitalis and sympathomimetic amines may cause ectopic arrhythmias. 	ARAMINE	digitalis	none	{'e1': {'word': 'ARAMINE', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d746.s0.e0'}, 'e2': {'word': 'digitalis', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d746.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d746.s0'}	ARAMINE used caution digitalized patients since combination digitalis sympathomimetic amines may cause ectopic arrhythmias
ARAMINE should be used with caution in digitalized patients, since the combination of digitalis and sympathomimetic amines may cause ectopic arrhythmias. 	ARAMINE	sympathomimetic amines	none	{'e1': {'word': 'ARAMINE', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d746.s0.e0'}, 'e2': {'word': 'sympathomimetic amines', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d746.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d746.s0'}	ARAMINE used caution digitalized patients since combination digitalis sympathomimetic amines may cause ectopic arrhythmias
ARAMINE should be used with caution in digitalized patients, since the combination of digitalis and sympathomimetic amines may cause ectopic arrhythmias. 	digitalis	sympathomimetic amines	effect	{'e1': {'word': 'digitalis', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d746.s0.e1'}, 'e2': {'word': 'sympathomimetic amines', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d746.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d746.s0'}	ARAMINE used caution digitalized patients since combination digitalis sympathomimetic amines may cause ectopic arrhythmias
Monoamine oxidase inhibitors or tricyclic antidepressants may potentiate the action of sympathomimetic amines. 	Monoamine oxidase inhibitors	tricyclic antidepressants	none	{'e1': {'word': 'Monoamine oxidase inhibitors', 'word_index': [(0, 2)], 'id': 'DDI-DrugBank.d746.s1.e0'}, 'e2': {'word': 'tricyclic antidepressants', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d746.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d746.s1'}	Monoamine oxidase inhibitors tricyclic antidepressants may potentiate action sympathomimetic amines
Monoamine oxidase inhibitors or tricyclic antidepressants may potentiate the action of sympathomimetic amines. 	Monoamine oxidase inhibitors	sympathomimetic amines	effect	{'e1': {'word': 'Monoamine oxidase inhibitors', 'word_index': [(0, 2)], 'id': 'DDI-DrugBank.d746.s1.e0'}, 'e2': {'word': 'sympathomimetic amines', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d746.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d746.s1'}	Monoamine oxidase inhibitors tricyclic antidepressants may potentiate action sympathomimetic amines
Monoamine oxidase inhibitors or tricyclic antidepressants may potentiate the action of sympathomimetic amines. 	tricyclic antidepressants	sympathomimetic amines	effect	{'e1': {'word': 'tricyclic antidepressants', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d746.s1.e1'}, 'e2': {'word': 'sympathomimetic amines', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d746.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d746.s1'}	Monoamine oxidase inhibitors tricyclic antidepressants may potentiate action sympathomimetic amines
In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, and cyclosporine. 	terbinafine	tolbutamide	none	{'e1': {'word': 'terbinafine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d645.s0.e0'}, 'e2': {'word': 'tolbutamide', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d645.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d645.s0'}	vitro studies human liver microsomes showed terbinafine inhibit metabolism tolbutamide ethinylestradiol ethoxycoumarin cyclosporine
In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, and cyclosporine. 	terbinafine	ethinylestradiol	none	{'e1': {'word': 'terbinafine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d645.s0.e0'}, 'e2': {'word': 'ethinylestradiol', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d645.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d645.s0'}	vitro studies human liver microsomes showed terbinafine inhibit metabolism tolbutamide ethinylestradiol ethoxycoumarin cyclosporine
In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, and cyclosporine. 	terbinafine	ethoxycoumarin	none	{'e1': {'word': 'terbinafine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d645.s0.e0'}, 'e2': {'word': 'ethoxycoumarin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d645.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d645.s0'}	vitro studies human liver microsomes showed terbinafine inhibit metabolism tolbutamide ethinylestradiol ethoxycoumarin cyclosporine
In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, and cyclosporine. 	terbinafine	cyclosporine	none	{'e1': {'word': 'terbinafine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d645.s0.e0'}, 'e2': {'word': 'cyclosporine', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d645.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d645.s0'}	vitro studies human liver microsomes showed terbinafine inhibit metabolism tolbutamide ethinylestradiol ethoxycoumarin cyclosporine
In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, and cyclosporine. 	tolbutamide	ethinylestradiol	none	{'e1': {'word': 'tolbutamide', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d645.s0.e1'}, 'e2': {'word': 'ethinylestradiol', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d645.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d645.s0'}	vitro studies human liver microsomes showed terbinafine inhibit metabolism tolbutamide ethinylestradiol ethoxycoumarin cyclosporine
In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, and cyclosporine. 	tolbutamide	ethoxycoumarin	none	{'e1': {'word': 'tolbutamide', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d645.s0.e1'}, 'e2': {'word': 'ethoxycoumarin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d645.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d645.s0'}	vitro studies human liver microsomes showed terbinafine inhibit metabolism tolbutamide ethinylestradiol ethoxycoumarin cyclosporine
In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, and cyclosporine. 	tolbutamide	cyclosporine	none	{'e1': {'word': 'tolbutamide', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d645.s0.e1'}, 'e2': {'word': 'cyclosporine', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d645.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d645.s0'}	vitro studies human liver microsomes showed terbinafine inhibit metabolism tolbutamide ethinylestradiol ethoxycoumarin cyclosporine
In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, and cyclosporine. 	ethinylestradiol	ethoxycoumarin	none	{'e1': {'word': 'ethinylestradiol', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d645.s0.e2'}, 'e2': {'word': 'ethoxycoumarin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d645.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d645.s0'}	vitro studies human liver microsomes showed terbinafine inhibit metabolism tolbutamide ethinylestradiol ethoxycoumarin cyclosporine
In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, and cyclosporine. 	ethinylestradiol	cyclosporine	none	{'e1': {'word': 'ethinylestradiol', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d645.s0.e2'}, 'e2': {'word': 'cyclosporine', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d645.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d645.s0'}	vitro studies human liver microsomes showed terbinafine inhibit metabolism tolbutamide ethinylestradiol ethoxycoumarin cyclosporine
In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, and cyclosporine. 	ethoxycoumarin	cyclosporine	none	{'e1': {'word': 'ethoxycoumarin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d645.s0.e3'}, 'e2': {'word': 'cyclosporine', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d645.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d645.s0'}	vitro studies human liver microsomes showed terbinafine inhibit metabolism tolbutamide ethinylestradiol ethoxycoumarin cyclosporine
This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as tricyclic antidepressants,    -blockers, selective serotonin reuptake inhibitors (SSRIs), and monoamine oxidase inhibitors (MAO-Is) Type B, if they have a narrow therapeutic window. 	tricyclic antidepressants	selective serotonin reuptake inhibitors	none	{'e1': {'word': 'tricyclic antidepressants', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d645.s2.e0'}, 'e2': {'word': 'selective serotonin reuptake inhibitors', 'word_index': [(10, 13)], 'id': 'DDI-DrugBank.d645.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d645.s2'}	may clinical relevance compounds predominantly metabolized enzyme tricyclic antidepressants blockers selective serotonin reuptake inhibitors SSRIs monoamine oxidase inhibitors MAO Type B narrow therapeutic window
This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as tricyclic antidepressants,    -blockers, selective serotonin reuptake inhibitors (SSRIs), and monoamine oxidase inhibitors (MAO-Is) Type B, if they have a narrow therapeutic window. 	tricyclic antidepressants	SSRIs	none	{'e1': {'word': 'tricyclic antidepressants', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d645.s2.e0'}, 'e2': {'word': 'SSRIs', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d645.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d645.s2'}	may clinical relevance compounds predominantly metabolized enzyme tricyclic antidepressants blockers selective serotonin reuptake inhibitors SSRIs monoamine oxidase inhibitors MAO Type B narrow therapeutic window
This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as tricyclic antidepressants,    -blockers, selective serotonin reuptake inhibitors (SSRIs), and monoamine oxidase inhibitors (MAO-Is) Type B, if they have a narrow therapeutic window. 	tricyclic antidepressants	monoamine oxidase inhibitors (MAO-Is) Type B	none	{'e1': {'word': 'tricyclic antidepressants', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d645.s2.e0'}, 'e2': {'word': 'monoamine oxidase inhibitors (MAO-Is) Type B', 'word_index': [(15, 20)], 'id': 'DDI-DrugBank.d645.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d645.s2'}	may clinical relevance compounds predominantly metabolized enzyme tricyclic antidepressants blockers selective serotonin reuptake inhibitors SSRIs monoamine oxidase inhibitors MAO Type B narrow therapeutic window
This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as tricyclic antidepressants,    -blockers, selective serotonin reuptake inhibitors (SSRIs), and monoamine oxidase inhibitors (MAO-Is) Type B, if they have a narrow therapeutic window. 	selective serotonin reuptake inhibitors	SSRIs	none	{'e1': {'word': 'selective serotonin reuptake inhibitors', 'word_index': [(10, 13)], 'id': 'DDI-DrugBank.d645.s2.e1'}, 'e2': {'word': 'SSRIs', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d645.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d645.s2'}	may clinical relevance compounds predominantly metabolized enzyme tricyclic antidepressants blockers selective serotonin reuptake inhibitors SSRIs monoamine oxidase inhibitors MAO Type B narrow therapeutic window
This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as tricyclic antidepressants,    -blockers, selective serotonin reuptake inhibitors (SSRIs), and monoamine oxidase inhibitors (MAO-Is) Type B, if they have a narrow therapeutic window. 	selective serotonin reuptake inhibitors	monoamine oxidase inhibitors (MAO-Is) Type B	none	{'e1': {'word': 'selective serotonin reuptake inhibitors', 'word_index': [(10, 13)], 'id': 'DDI-DrugBank.d645.s2.e1'}, 'e2': {'word': 'monoamine oxidase inhibitors (MAO-Is) Type B', 'word_index': [(15, 20)], 'id': 'DDI-DrugBank.d645.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d645.s2'}	may clinical relevance compounds predominantly metabolized enzyme tricyclic antidepressants blockers selective serotonin reuptake inhibitors SSRIs monoamine oxidase inhibitors MAO Type B narrow therapeutic window
This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as tricyclic antidepressants,    -blockers, selective serotonin reuptake inhibitors (SSRIs), and monoamine oxidase inhibitors (MAO-Is) Type B, if they have a narrow therapeutic window. 	SSRIs	monoamine oxidase inhibitors (MAO-Is) Type B	none	{'e1': {'word': 'SSRIs', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d645.s2.e2'}, 'e2': {'word': 'monoamine oxidase inhibitors (MAO-Is) Type B', 'word_index': [(15, 20)], 'id': 'DDI-DrugBank.d645.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d645.s2'}	may clinical relevance compounds predominantly metabolized enzyme tricyclic antidepressants blockers selective serotonin reuptake inhibitors SSRIs monoamine oxidase inhibitors MAO Type B narrow therapeutic window
In vivo drug-drug interaction studies conducted in normal volunteer subjects showed that terbinafine does not affect the clearance of antipyrine or digoxin. 	terbinafine	antipyrine	none	{'e1': {'word': 'terbinafine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d645.s3.e0'}, 'e2': {'word': 'antipyrine', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d645.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d645.s3'}	vivo drug drug interaction studies conducted normal volunteer subjects showed terbinafine affect clearance antipyrine digoxin
In vivo drug-drug interaction studies conducted in normal volunteer subjects showed that terbinafine does not affect the clearance of antipyrine or digoxin. 	terbinafine	digoxin	none	{'e1': {'word': 'terbinafine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d645.s3.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d645.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d645.s3'}	vivo drug drug interaction studies conducted normal volunteer subjects showed terbinafine affect clearance antipyrine digoxin
In vivo drug-drug interaction studies conducted in normal volunteer subjects showed that terbinafine does not affect the clearance of antipyrine or digoxin. 	antipyrine	digoxin	none	{'e1': {'word': 'antipyrine', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d645.s3.e1'}, 'e2': {'word': 'digoxin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d645.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d645.s3'}	vivo drug drug interaction studies conducted normal volunteer subjects showed terbinafine affect clearance antipyrine digoxin
Terbinafine decreases the clearance of caffeine by 19%. 	Terbinafine	caffeine	mechanism	{'e1': {'word': 'Terbinafine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d645.s4.e0'}, 'e2': {'word': 'caffeine', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d645.s4.e1'}, 'sentence_id': 'DDI-DrugBank.d645.s4'}	Terbinafine decreases clearance caffeine NUMBER %
Terbinafine increases the clearance of cyclosporine by 15%. 	Terbinafine	cyclosporine	mechanism	{'e1': {'word': 'Terbinafine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d645.s5.e0'}, 'e2': {'word': 'cyclosporine', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d645.s5.e1'}, 'sentence_id': 'DDI-DrugBank.d645.s5'}	Terbinafine increases clearance cyclosporine NUMBER %
There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral terbinafine and warfarin, however, a causal relationship between LAMISIL    Tablets and these changes has not been established. 	terbinafine	warfarin	effect	{'e1': {'word': 'terbinafine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d645.s6.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d645.s6.e1'}, 'sentence_id': 'DDI-DrugBank.d645.s6'}	spontaneous reports increase decrease prothrombin times patients concomitantly taking oral terbinafine warfarin however causal relationship LAMISIL Tablets changes established
There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral terbinafine and warfarin, however, a causal relationship between LAMISIL    Tablets and these changes has not been established. 	terbinafine	LAMISIL	none	{'e1': {'word': 'terbinafine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d645.s6.e0'}, 'e2': {'word': 'LAMISIL', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d645.s6.e2'}, 'sentence_id': 'DDI-DrugBank.d645.s6'}	spontaneous reports increase decrease prothrombin times patients concomitantly taking oral terbinafine warfarin however causal relationship LAMISIL Tablets changes established
There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral terbinafine and warfarin, however, a causal relationship between LAMISIL    Tablets and these changes has not been established. 	warfarin	LAMISIL	none	{'e1': {'word': 'warfarin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d645.s6.e1'}, 'e2': {'word': 'LAMISIL', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d645.s6.e2'}, 'sentence_id': 'DDI-DrugBank.d645.s6'}	spontaneous reports increase decrease prothrombin times patients concomitantly taking oral terbinafine warfarin however causal relationship LAMISIL Tablets changes established
Terbinafine clearance is increased 100% by rifampin, a CyP450 enzyme inducer, and decreased 33% by cimetidine, a CyP450 enzyme inhibitor. 	Terbinafine	rifampin	mechanism	{'e1': {'word': 'Terbinafine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d645.s7.e0'}, 'e2': {'word': 'rifampin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d645.s7.e1'}, 'sentence_id': 'DDI-DrugBank.d645.s7'}	Terbinafine clearance increased NUMBER % rifampin CyP450 enzyme inducer decreased NUMBER % cimetidine CyP450 enzyme inhibitor
Terbinafine clearance is increased 100% by rifampin, a CyP450 enzyme inducer, and decreased 33% by cimetidine, a CyP450 enzyme inhibitor. 	Terbinafine	cimetidine	mechanism	{'e1': {'word': 'Terbinafine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d645.s7.e0'}, 'e2': {'word': 'cimetidine', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d645.s7.e2'}, 'sentence_id': 'DDI-DrugBank.d645.s7'}	Terbinafine clearance increased NUMBER % rifampin CyP450 enzyme inducer decreased NUMBER % cimetidine CyP450 enzyme inhibitor
Terbinafine clearance is increased 100% by rifampin, a CyP450 enzyme inducer, and decreased 33% by cimetidine, a CyP450 enzyme inhibitor. 	rifampin	cimetidine	none	{'e1': {'word': 'rifampin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d645.s7.e1'}, 'e2': {'word': 'cimetidine', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d645.s7.e2'}, 'sentence_id': 'DDI-DrugBank.d645.s7'}	Terbinafine clearance increased NUMBER % rifampin CyP450 enzyme inducer decreased NUMBER % cimetidine CyP450 enzyme inhibitor
Terbinafine clearance is unaffected by cyclosporine. 	Terbinafine	cyclosporine	none	{'e1': {'word': 'Terbinafine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d645.s8.e0'}, 'e2': {'word': 'cyclosporine', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d645.s8.e1'}, 'sentence_id': 'DDI-DrugBank.d645.s8'}	Terbinafine clearance unaffected cyclosporine
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.	contraceptives	hypoglycemics	none	{'e1': {'word': 'contraceptives', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d645.s9.e0'}, 'e2': {'word': 'hypoglycemics', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d645.s9.e1'}, 'sentence_id': 'DDI-DrugBank.d645.s9'}	information available adequate drug drug interaction studies following classes drugs oral contraceptives hormone replacement therapies hypoglycemics theophyllines phenytoins thiazide diuretics beta blockers calcium channel blockers
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.	contraceptives	theophyllines	none	{'e1': {'word': 'contraceptives', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d645.s9.e0'}, 'e2': {'word': 'theophyllines', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d645.s9.e2'}, 'sentence_id': 'DDI-DrugBank.d645.s9'}	information available adequate drug drug interaction studies following classes drugs oral contraceptives hormone replacement therapies hypoglycemics theophyllines phenytoins thiazide diuretics beta blockers calcium channel blockers
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.	contraceptives	phenytoins	none	{'e1': {'word': 'contraceptives', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d645.s9.e0'}, 'e2': {'word': 'phenytoins', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d645.s9.e3'}, 'sentence_id': 'DDI-DrugBank.d645.s9'}	information available adequate drug drug interaction studies following classes drugs oral contraceptives hormone replacement therapies hypoglycemics theophyllines phenytoins thiazide diuretics beta blockers calcium channel blockers
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.	contraceptives	thiazide diuretics	none	{'e1': {'word': 'contraceptives', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d645.s9.e0'}, 'e2': {'word': 'thiazide diuretics', 'word_index': [(18, 19)], 'id': 'DDI-DrugBank.d645.s9.e4'}, 'sentence_id': 'DDI-DrugBank.d645.s9'}	information available adequate drug drug interaction studies following classes drugs oral contraceptives hormone replacement therapies hypoglycemics theophyllines phenytoins thiazide diuretics beta blockers calcium channel blockers
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.	contraceptives	beta blockers	none	{'e1': {'word': 'contraceptives', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d645.s9.e0'}, 'e2': {'word': 'beta blockers', 'word_index': [(20, 21)], 'id': 'DDI-DrugBank.d645.s9.e5'}, 'sentence_id': 'DDI-DrugBank.d645.s9'}	information available adequate drug drug interaction studies following classes drugs oral contraceptives hormone replacement therapies hypoglycemics theophyllines phenytoins thiazide diuretics beta blockers calcium channel blockers
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.	contraceptives	calcium channel blockers	none	{'e1': {'word': 'contraceptives', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d645.s9.e0'}, 'e2': {'word': 'calcium channel blockers', 'word_index': [(22, 24)], 'id': 'DDI-DrugBank.d645.s9.e6'}, 'sentence_id': 'DDI-DrugBank.d645.s9'}	information available adequate drug drug interaction studies following classes drugs oral contraceptives hormone replacement therapies hypoglycemics theophyllines phenytoins thiazide diuretics beta blockers calcium channel blockers
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.	hypoglycemics	theophyllines	none	{'e1': {'word': 'hypoglycemics', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d645.s9.e1'}, 'e2': {'word': 'theophyllines', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d645.s9.e2'}, 'sentence_id': 'DDI-DrugBank.d645.s9'}	information available adequate drug drug interaction studies following classes drugs oral contraceptives hormone replacement therapies hypoglycemics theophyllines phenytoins thiazide diuretics beta blockers calcium channel blockers
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.	hypoglycemics	phenytoins	none	{'e1': {'word': 'hypoglycemics', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d645.s9.e1'}, 'e2': {'word': 'phenytoins', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d645.s9.e3'}, 'sentence_id': 'DDI-DrugBank.d645.s9'}	information available adequate drug drug interaction studies following classes drugs oral contraceptives hormone replacement therapies hypoglycemics theophyllines phenytoins thiazide diuretics beta blockers calcium channel blockers
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.	hypoglycemics	thiazide diuretics	none	{'e1': {'word': 'hypoglycemics', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d645.s9.e1'}, 'e2': {'word': 'thiazide diuretics', 'word_index': [(18, 19)], 'id': 'DDI-DrugBank.d645.s9.e4'}, 'sentence_id': 'DDI-DrugBank.d645.s9'}	information available adequate drug drug interaction studies following classes drugs oral contraceptives hormone replacement therapies hypoglycemics theophyllines phenytoins thiazide diuretics beta blockers calcium channel blockers
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.	hypoglycemics	beta blockers	none	{'e1': {'word': 'hypoglycemics', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d645.s9.e1'}, 'e2': {'word': 'beta blockers', 'word_index': [(20, 21)], 'id': 'DDI-DrugBank.d645.s9.e5'}, 'sentence_id': 'DDI-DrugBank.d645.s9'}	information available adequate drug drug interaction studies following classes drugs oral contraceptives hormone replacement therapies hypoglycemics theophyllines phenytoins thiazide diuretics beta blockers calcium channel blockers
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.	hypoglycemics	calcium channel blockers	none	{'e1': {'word': 'hypoglycemics', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d645.s9.e1'}, 'e2': {'word': 'calcium channel blockers', 'word_index': [(22, 24)], 'id': 'DDI-DrugBank.d645.s9.e6'}, 'sentence_id': 'DDI-DrugBank.d645.s9'}	information available adequate drug drug interaction studies following classes drugs oral contraceptives hormone replacement therapies hypoglycemics theophyllines phenytoins thiazide diuretics beta blockers calcium channel blockers
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.	theophyllines	phenytoins	none	{'e1': {'word': 'theophyllines', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d645.s9.e2'}, 'e2': {'word': 'phenytoins', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d645.s9.e3'}, 'sentence_id': 'DDI-DrugBank.d645.s9'}	information available adequate drug drug interaction studies following classes drugs oral contraceptives hormone replacement therapies hypoglycemics theophyllines phenytoins thiazide diuretics beta blockers calcium channel blockers
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.	theophyllines	thiazide diuretics	none	{'e1': {'word': 'theophyllines', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d645.s9.e2'}, 'e2': {'word': 'thiazide diuretics', 'word_index': [(18, 19)], 'id': 'DDI-DrugBank.d645.s9.e4'}, 'sentence_id': 'DDI-DrugBank.d645.s9'}	information available adequate drug drug interaction studies following classes drugs oral contraceptives hormone replacement therapies hypoglycemics theophyllines phenytoins thiazide diuretics beta blockers calcium channel blockers
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.	theophyllines	beta blockers	none	{'e1': {'word': 'theophyllines', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d645.s9.e2'}, 'e2': {'word': 'beta blockers', 'word_index': [(20, 21)], 'id': 'DDI-DrugBank.d645.s9.e5'}, 'sentence_id': 'DDI-DrugBank.d645.s9'}	information available adequate drug drug interaction studies following classes drugs oral contraceptives hormone replacement therapies hypoglycemics theophyllines phenytoins thiazide diuretics beta blockers calcium channel blockers
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.	theophyllines	calcium channel blockers	none	{'e1': {'word': 'theophyllines', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d645.s9.e2'}, 'e2': {'word': 'calcium channel blockers', 'word_index': [(22, 24)], 'id': 'DDI-DrugBank.d645.s9.e6'}, 'sentence_id': 'DDI-DrugBank.d645.s9'}	information available adequate drug drug interaction studies following classes drugs oral contraceptives hormone replacement therapies hypoglycemics theophyllines phenytoins thiazide diuretics beta blockers calcium channel blockers
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.	phenytoins	thiazide diuretics	none	{'e1': {'word': 'phenytoins', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d645.s9.e3'}, 'e2': {'word': 'thiazide diuretics', 'word_index': [(18, 19)], 'id': 'DDI-DrugBank.d645.s9.e4'}, 'sentence_id': 'DDI-DrugBank.d645.s9'}	information available adequate drug drug interaction studies following classes drugs oral contraceptives hormone replacement therapies hypoglycemics theophyllines phenytoins thiazide diuretics beta blockers calcium channel blockers
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.	phenytoins	beta blockers	none	{'e1': {'word': 'phenytoins', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d645.s9.e3'}, 'e2': {'word': 'beta blockers', 'word_index': [(20, 21)], 'id': 'DDI-DrugBank.d645.s9.e5'}, 'sentence_id': 'DDI-DrugBank.d645.s9'}	information available adequate drug drug interaction studies following classes drugs oral contraceptives hormone replacement therapies hypoglycemics theophyllines phenytoins thiazide diuretics beta blockers calcium channel blockers
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.	phenytoins	calcium channel blockers	none	{'e1': {'word': 'phenytoins', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d645.s9.e3'}, 'e2': {'word': 'calcium channel blockers', 'word_index': [(22, 24)], 'id': 'DDI-DrugBank.d645.s9.e6'}, 'sentence_id': 'DDI-DrugBank.d645.s9'}	information available adequate drug drug interaction studies following classes drugs oral contraceptives hormone replacement therapies hypoglycemics theophyllines phenytoins thiazide diuretics beta blockers calcium channel blockers
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.	thiazide diuretics	beta blockers	none	{'e1': {'word': 'thiazide diuretics', 'word_index': [(18, 19)], 'id': 'DDI-DrugBank.d645.s9.e4'}, 'e2': {'word': 'beta blockers', 'word_index': [(20, 21)], 'id': 'DDI-DrugBank.d645.s9.e5'}, 'sentence_id': 'DDI-DrugBank.d645.s9'}	information available adequate drug drug interaction studies following classes drugs oral contraceptives hormone replacement therapies hypoglycemics theophyllines phenytoins thiazide diuretics beta blockers calcium channel blockers
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.	thiazide diuretics	calcium channel blockers	none	{'e1': {'word': 'thiazide diuretics', 'word_index': [(18, 19)], 'id': 'DDI-DrugBank.d645.s9.e4'}, 'e2': {'word': 'calcium channel blockers', 'word_index': [(22, 24)], 'id': 'DDI-DrugBank.d645.s9.e6'}, 'sentence_id': 'DDI-DrugBank.d645.s9'}	information available adequate drug drug interaction studies following classes drugs oral contraceptives hormone replacement therapies hypoglycemics theophyllines phenytoins thiazide diuretics beta blockers calcium channel blockers
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.	beta blockers	calcium channel blockers	none	{'e1': {'word': 'beta blockers', 'word_index': [(20, 21)], 'id': 'DDI-DrugBank.d645.s9.e5'}, 'e2': {'word': 'calcium channel blockers', 'word_index': [(22, 24)], 'id': 'DDI-DrugBank.d645.s9.e6'}, 'sentence_id': 'DDI-DrugBank.d645.s9'}	information available adequate drug drug interaction studies following classes drugs oral contraceptives hormone replacement therapies hypoglycemics theophyllines phenytoins thiazide diuretics beta blockers calcium channel blockers
If glucocorticoid replacement is required, the glucocorticoid dose should be carefully adjusted. 	glucocorticoid	glucocorticoid	none	{'e1': {'word': 'glucocorticoid', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d599.s4.e0'}, 'e2': {'word': 'glucocorticoid', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d599.s4.e1'}, 'sentence_id': 'DDI-DrugBank.d599.s4'}	glucocorticoid replacement required glucocorticoid dose carefully adjusted
Limited published data indicate that GH treatment increases cytochrome P450 (CP450) mediated antipyrine clearance in man. 	GH	antipyrine	mechanism	{'e1': {'word': 'GH', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d599.s6.e0'}, 'e2': {'word': 'antipyrine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d599.s6.e1'}, 'sentence_id': 'DDI-DrugBank.d599.s6'}	Limited published data indicate GH treatment increases cytochrome P450 CP450 mediated antipyrine clearance man
These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin). 	GH	corticosteroids	mechanism	{'e1': {'word': 'GH', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d599.s7.e0'}, 'e2': {'word': 'corticosteroids', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d599.s7.e1'}, 'sentence_id': 'DDI-DrugBank.d599.s7'}	data suggest GH administration may alter clearance compounds known metabolized CP450 liver enzymes e.g. corticosteroids sex steroids anticonvulsants cyclosporin
These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin). 	GH	sex steroids	mechanism	{'e1': {'word': 'GH', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d599.s7.e0'}, 'e2': {'word': 'sex steroids', 'word_index': [(15, 16)], 'id': 'DDI-DrugBank.d599.s7.e2'}, 'sentence_id': 'DDI-DrugBank.d599.s7'}	data suggest GH administration may alter clearance compounds known metabolized CP450 liver enzymes e.g. corticosteroids sex steroids anticonvulsants cyclosporin
These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin). 	GH	anticonvulsants	mechanism	{'e1': {'word': 'GH', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d599.s7.e0'}, 'e2': {'word': 'anticonvulsants', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d599.s7.e3'}, 'sentence_id': 'DDI-DrugBank.d599.s7'}	data suggest GH administration may alter clearance compounds known metabolized CP450 liver enzymes e.g. corticosteroids sex steroids anticonvulsants cyclosporin
These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin). 	GH	cyclosporin	mechanism	{'e1': {'word': 'GH', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d599.s7.e0'}, 'e2': {'word': 'cyclosporin', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d599.s7.e4'}, 'sentence_id': 'DDI-DrugBank.d599.s7'}	data suggest GH administration may alter clearance compounds known metabolized CP450 liver enzymes e.g. corticosteroids sex steroids anticonvulsants cyclosporin
These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin). 	corticosteroids	sex steroids	none	{'e1': {'word': 'corticosteroids', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d599.s7.e1'}, 'e2': {'word': 'sex steroids', 'word_index': [(15, 16)], 'id': 'DDI-DrugBank.d599.s7.e2'}, 'sentence_id': 'DDI-DrugBank.d599.s7'}	data suggest GH administration may alter clearance compounds known metabolized CP450 liver enzymes e.g. corticosteroids sex steroids anticonvulsants cyclosporin
These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin). 	corticosteroids	anticonvulsants	none	{'e1': {'word': 'corticosteroids', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d599.s7.e1'}, 'e2': {'word': 'anticonvulsants', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d599.s7.e3'}, 'sentence_id': 'DDI-DrugBank.d599.s7'}	data suggest GH administration may alter clearance compounds known metabolized CP450 liver enzymes e.g. corticosteroids sex steroids anticonvulsants cyclosporin
These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin). 	corticosteroids	cyclosporin	none	{'e1': {'word': 'corticosteroids', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d599.s7.e1'}, 'e2': {'word': 'cyclosporin', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d599.s7.e4'}, 'sentence_id': 'DDI-DrugBank.d599.s7'}	data suggest GH administration may alter clearance compounds known metabolized CP450 liver enzymes e.g. corticosteroids sex steroids anticonvulsants cyclosporin
These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin). 	sex steroids	anticonvulsants	none	{'e1': {'word': 'sex steroids', 'word_index': [(15, 16)], 'id': 'DDI-DrugBank.d599.s7.e2'}, 'e2': {'word': 'anticonvulsants', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d599.s7.e3'}, 'sentence_id': 'DDI-DrugBank.d599.s7'}	data suggest GH administration may alter clearance compounds known metabolized CP450 liver enzymes e.g. corticosteroids sex steroids anticonvulsants cyclosporin
These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin). 	sex steroids	cyclosporin	none	{'e1': {'word': 'sex steroids', 'word_index': [(15, 16)], 'id': 'DDI-DrugBank.d599.s7.e2'}, 'e2': {'word': 'cyclosporin', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d599.s7.e4'}, 'sentence_id': 'DDI-DrugBank.d599.s7'}	data suggest GH administration may alter clearance compounds known metabolized CP450 liver enzymes e.g. corticosteroids sex steroids anticonvulsants cyclosporin
These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin). 	anticonvulsants	cyclosporin	none	{'e1': {'word': 'anticonvulsants', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d599.s7.e3'}, 'e2': {'word': 'cyclosporin', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d599.s7.e4'}, 'sentence_id': 'DDI-DrugBank.d599.s7'}	data suggest GH administration may alter clearance compounds known metabolized CP450 liver enzymes e.g. corticosteroids sex steroids anticonvulsants cyclosporin
Drug-Drug Interactions: The pharmacokinetic and pharmacodynamic interactions between FLOMAX capsules and other alpha-adrenergic blocking agents have not been determined. 	FLOMAX	alpha-adrenergic blocking agents	none	{'e1': {'word': 'FLOMAX', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d704.s0.e0'}, 'e2': {'word': 'alpha-adrenergic blocking agents', 'word_index': [(8, 11)], 'id': 'DDI-DrugBank.d704.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d704.s0'}	Drug Drug Interactions pharmacokinetic pharmacodynamic interactions FLOMAX capsules alpha adrenergic blocking agents determined
However, interactions may be expected and FLOMAX capsules should NOT be used in combination with other alpha-adrenergic blocking agents. 	FLOMAX	alpha-adrenergic blocking agents	advise	{'e1': {'word': 'FLOMAX', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d704.s1.e0'}, 'e2': {'word': 'alpha-adrenergic blocking agents', 'word_index': [(8, 11)], 'id': 'DDI-DrugBank.d704.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d704.s1'}	However interactions may expected FLOMAX capsules used combination alpha adrenergic blocking agents
The pharmacokinetic interaction between cimetidine and FLOMAX capsules was investigated. 	cimetidine	FLOMAX	none	{'e1': {'word': 'cimetidine', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d704.s2.e0'}, 'e2': {'word': 'FLOMAX', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d704.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d704.s2'}	pharmacokinetic interaction cimetidine FLOMAX capsules investigated
Therefore, FLOMAX capsules should be used with caution in combination with cimetidine, particularly at doses higher than 0.4 mg. 	FLOMAX	cimetidine	advise	{'e1': {'word': 'FLOMAX', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d704.s4.e0'}, 'e2': {'word': 'cimetidine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d704.s4.e1'}, 'sentence_id': 'DDI-DrugBank.d704.s4'}	Therefore FLOMAX capsules used caution combination cimetidine particularly doses higher NUMBER mg
Results from limited in vitro and in vivo drug-drug interaction studies between tamsulosin HCI and warfarin are inconclusive. 	tamsulosin HCI	warfarin	none	{'e1': {'word': 'tamsulosin HCI', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d704.s5.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d704.s5.e1'}, 'sentence_id': 'DDI-DrugBank.d704.s5'}	Results limited vitro vivo drug drug interaction studies tamsulosin HCI warfarin inconclusive
Therefore, caution should be exercised with concomitant administration of warfarin and FLOMAX capsules.        	warfarin	FLOMAX	advise	{'e1': {'word': 'warfarin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d704.s6.e0'}, 'e2': {'word': 'FLOMAX', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d704.s6.e1'}, 'sentence_id': 'DDI-DrugBank.d704.s6'}	Therefore caution exercised concomitant administration warfarin FLOMAX capsules
Ketoconazole: Spontaneous adverse reaction reports of patients taking concomitant ketoconazole with recommended doses of terfenadine demonstrate QT interval prolongation and rare serious cardiac events, e.g. 	Ketoconazole	ketoconazole	none	{'e1': {'word': 'Ketoconazole', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d743.s0.e0'}, 'e2': {'word': 'ketoconazole', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d743.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d743.s0'}	Ketoconazole Spontaneous adverse reaction reports patients taking concomitant ketoconazole recommended doses terfenadine demonstrate QT interval prolongation rare serious cardiac events e.g.
Ketoconazole: Spontaneous adverse reaction reports of patients taking concomitant ketoconazole with recommended doses of terfenadine demonstrate QT interval prolongation and rare serious cardiac events, e.g. 	Ketoconazole	terfenadine	none	{'e1': {'word': 'Ketoconazole', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d743.s0.e0'}, 'e2': {'word': 'terfenadine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d743.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d743.s0'}	Ketoconazole Spontaneous adverse reaction reports patients taking concomitant ketoconazole recommended doses terfenadine demonstrate QT interval prolongation rare serious cardiac events e.g.
Ketoconazole: Spontaneous adverse reaction reports of patients taking concomitant ketoconazole with recommended doses of terfenadine demonstrate QT interval prolongation and rare serious cardiac events, e.g. 	ketoconazole	terfenadine	effect	{'e1': {'word': 'ketoconazole', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d743.s0.e1'}, 'e2': {'word': 'terfenadine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d743.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d743.s0'}	Ketoconazole Spontaneous adverse reaction reports patients taking concomitant ketoconazole recommended doses terfenadine demonstrate QT interval prolongation rare serious cardiac events e.g.
Pharmacokinetic data indicate that ketoconazole markedly inhibits the metabolism of terfenadine, resulting in elevated plasma terfenadine levels. 	ketoconazole	terfenadine	mechanism	{'e1': {'word': 'ketoconazole', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d743.s2.e0'}, 'e2': {'word': 'terfenadine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d743.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d743.s2'}	Pharmacokinetic data indicate ketoconazole markedly inhibits metabolism terfenadine resulting elevated plasma terfenadine levels
Pharmacokinetic data indicate that ketoconazole markedly inhibits the metabolism of terfenadine, resulting in elevated plasma terfenadine levels. 	ketoconazole	terfenadine	none	{'e1': {'word': 'ketoconazole', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d743.s2.e0'}, 'e2': {'word': 'terfenadine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d743.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d743.s2'}	Pharmacokinetic data indicate ketoconazole markedly inhibits metabolism terfenadine resulting elevated plasma terfenadine levels
Pharmacokinetic data indicate that ketoconazole markedly inhibits the metabolism of terfenadine, resulting in elevated plasma terfenadine levels. 	terfenadine	terfenadine	none	{'e1': {'word': 'terfenadine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d743.s2.e1'}, 'e2': {'word': 'terfenadine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d743.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d743.s2'}	Pharmacokinetic data indicate ketoconazole markedly inhibits metabolism terfenadine resulting elevated plasma terfenadine levels
Concomitant administration of ketoconazole and terfenadine is contraindicated. 	ketoconazole	terfenadine	advise	{'e1': {'word': 'ketoconazole', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d743.s4.e0'}, 'e2': {'word': 'terfenadine', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d743.s4.e1'}, 'sentence_id': 'DDI-DrugBank.d743.s4'}	Concomitant administration ketoconazole terfenadine contraindicated
Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources. 	Itraconazole	terfenadine	none	{'e1': {'word': 'Itraconazole', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d743.s5.e0'}, 'e2': {'word': 'terfenadine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d743.s5.e1'}, 'sentence_id': 'DDI-DrugBank.d743.s5'}	Itraconazole Torsades de pointes elevated parent terfenadine levels reported concomitant use terfenadine itraconazole clinical trials itraconazole foreign post-marketing sources
Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources. 	Itraconazole	terfenadine	none	{'e1': {'word': 'Itraconazole', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d743.s5.e0'}, 'e2': {'word': 'terfenadine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d743.s5.e2'}, 'sentence_id': 'DDI-DrugBank.d743.s5'}	Itraconazole Torsades de pointes elevated parent terfenadine levels reported concomitant use terfenadine itraconazole clinical trials itraconazole foreign post-marketing sources
Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources. 	Itraconazole	itraconazole	none	{'e1': {'word': 'Itraconazole', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d743.s5.e0'}, 'e2': {'word': 'itraconazole', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d743.s5.e3'}, 'sentence_id': 'DDI-DrugBank.d743.s5'}	Itraconazole Torsades de pointes elevated parent terfenadine levels reported concomitant use terfenadine itraconazole clinical trials itraconazole foreign post-marketing sources
Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources. 	Itraconazole	itraconazole	none	{'e1': {'word': 'Itraconazole', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d743.s5.e0'}, 'e2': {'word': 'itraconazole', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d743.s5.e4'}, 'sentence_id': 'DDI-DrugBank.d743.s5'}	Itraconazole Torsades de pointes elevated parent terfenadine levels reported concomitant use terfenadine itraconazole clinical trials itraconazole foreign post-marketing sources
Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources. 	terfenadine	terfenadine	none	{'e1': {'word': 'terfenadine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d743.s5.e1'}, 'e2': {'word': 'terfenadine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d743.s5.e2'}, 'sentence_id': 'DDI-DrugBank.d743.s5'}	Itraconazole Torsades de pointes elevated parent terfenadine levels reported concomitant use terfenadine itraconazole clinical trials itraconazole foreign post-marketing sources
Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources. 	terfenadine	itraconazole	none	{'e1': {'word': 'terfenadine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d743.s5.e1'}, 'e2': {'word': 'itraconazole', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d743.s5.e3'}, 'sentence_id': 'DDI-DrugBank.d743.s5'}	Itraconazole Torsades de pointes elevated parent terfenadine levels reported concomitant use terfenadine itraconazole clinical trials itraconazole foreign post-marketing sources
Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources. 	terfenadine	itraconazole	none	{'e1': {'word': 'terfenadine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d743.s5.e1'}, 'e2': {'word': 'itraconazole', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d743.s5.e4'}, 'sentence_id': 'DDI-DrugBank.d743.s5'}	Itraconazole Torsades de pointes elevated parent terfenadine levels reported concomitant use terfenadine itraconazole clinical trials itraconazole foreign post-marketing sources
Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources. 	terfenadine	itraconazole	mechanism	{'e1': {'word': 'terfenadine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d743.s5.e2'}, 'e2': {'word': 'itraconazole', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d743.s5.e3'}, 'sentence_id': 'DDI-DrugBank.d743.s5'}	Itraconazole Torsades de pointes elevated parent terfenadine levels reported concomitant use terfenadine itraconazole clinical trials itraconazole foreign post-marketing sources
Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources. 	terfenadine	itraconazole	none	{'e1': {'word': 'terfenadine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d743.s5.e2'}, 'e2': {'word': 'itraconazole', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d743.s5.e4'}, 'sentence_id': 'DDI-DrugBank.d743.s5'}	Itraconazole Torsades de pointes elevated parent terfenadine levels reported concomitant use terfenadine itraconazole clinical trials itraconazole foreign post-marketing sources
Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources. 	itraconazole	itraconazole	none	{'e1': {'word': 'itraconazole', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d743.s5.e3'}, 'e2': {'word': 'itraconazole', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d743.s5.e4'}, 'sentence_id': 'DDI-DrugBank.d743.s5'}	Itraconazole Torsades de pointes elevated parent terfenadine levels reported concomitant use terfenadine itraconazole clinical trials itraconazole foreign post-marketing sources
Concomitant administration of itraconazole and terfenadine is contraindicated. 	itraconazole	terfenadine	advise	{'e1': {'word': 'itraconazole', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d743.s7.e0'}, 'e2': {'word': 'terfenadine', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d743.s7.e1'}, 'sentence_id': 'DDI-DrugBank.d743.s7'}	Concomitant administration itraconazole terfenadine contraindicated
Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. 	azole-type antifungal agents	fluconazole	none	{'e1': {'word': 'azole-type antifungal agents', 'word_index': [(3, 6)], 'id': 'DDI-DrugBank.d743.s8.e0'}, 'e2': {'word': 'fluconazole', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d743.s8.e1'}, 'sentence_id': 'DDI-DrugBank.d743.s8'}	Due chemical similarity azole type antifungal agents including fluconazole metronidazole miconazole ketoconazole itraconazole concomitant use products terfenadine recommended pending full examination potential interactions
Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. 	azole-type antifungal agents	metronidazole	none	{'e1': {'word': 'azole-type antifungal agents', 'word_index': [(3, 6)], 'id': 'DDI-DrugBank.d743.s8.e0'}, 'e2': {'word': 'metronidazole', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d743.s8.e2'}, 'sentence_id': 'DDI-DrugBank.d743.s8'}	Due chemical similarity azole type antifungal agents including fluconazole metronidazole miconazole ketoconazole itraconazole concomitant use products terfenadine recommended pending full examination potential interactions
Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. 	azole-type antifungal agents	miconazole	none	{'e1': {'word': 'azole-type antifungal agents', 'word_index': [(3, 6)], 'id': 'DDI-DrugBank.d743.s8.e0'}, 'e2': {'word': 'miconazole', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d743.s8.e3'}, 'sentence_id': 'DDI-DrugBank.d743.s8'}	Due chemical similarity azole type antifungal agents including fluconazole metronidazole miconazole ketoconazole itraconazole concomitant use products terfenadine recommended pending full examination potential interactions
Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. 	azole-type antifungal agents	ketoconazole	none	{'e1': {'word': 'azole-type antifungal agents', 'word_index': [(3, 6)], 'id': 'DDI-DrugBank.d743.s8.e0'}, 'e2': {'word': 'ketoconazole', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d743.s8.e4'}, 'sentence_id': 'DDI-DrugBank.d743.s8'}	Due chemical similarity azole type antifungal agents including fluconazole metronidazole miconazole ketoconazole itraconazole concomitant use products terfenadine recommended pending full examination potential interactions
Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. 	azole-type antifungal agents	itraconazole	none	{'e1': {'word': 'azole-type antifungal agents', 'word_index': [(3, 6)], 'id': 'DDI-DrugBank.d743.s8.e0'}, 'e2': {'word': 'itraconazole', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d743.s8.e5'}, 'sentence_id': 'DDI-DrugBank.d743.s8'}	Due chemical similarity azole type antifungal agents including fluconazole metronidazole miconazole ketoconazole itraconazole concomitant use products terfenadine recommended pending full examination potential interactions
Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. 	azole-type antifungal agents	terfenadine	advise	{'e1': {'word': 'azole-type antifungal agents', 'word_index': [(3, 6)], 'id': 'DDI-DrugBank.d743.s8.e0'}, 'e2': {'word': 'terfenadine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d743.s8.e6'}, 'sentence_id': 'DDI-DrugBank.d743.s8'}	Due chemical similarity azole type antifungal agents including fluconazole metronidazole miconazole ketoconazole itraconazole concomitant use products terfenadine recommended pending full examination potential interactions
Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. 	fluconazole	metronidazole	none	{'e1': {'word': 'fluconazole', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d743.s8.e1'}, 'e2': {'word': 'metronidazole', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d743.s8.e2'}, 'sentence_id': 'DDI-DrugBank.d743.s8'}	Due chemical similarity azole type antifungal agents including fluconazole metronidazole miconazole ketoconazole itraconazole concomitant use products terfenadine recommended pending full examination potential interactions
Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. 	fluconazole	miconazole	none	{'e1': {'word': 'fluconazole', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d743.s8.e1'}, 'e2': {'word': 'miconazole', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d743.s8.e3'}, 'sentence_id': 'DDI-DrugBank.d743.s8'}	Due chemical similarity azole type antifungal agents including fluconazole metronidazole miconazole ketoconazole itraconazole concomitant use products terfenadine recommended pending full examination potential interactions
Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. 	fluconazole	ketoconazole	none	{'e1': {'word': 'fluconazole', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d743.s8.e1'}, 'e2': {'word': 'ketoconazole', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d743.s8.e4'}, 'sentence_id': 'DDI-DrugBank.d743.s8'}	Due chemical similarity azole type antifungal agents including fluconazole metronidazole miconazole ketoconazole itraconazole concomitant use products terfenadine recommended pending full examination potential interactions
Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. 	fluconazole	itraconazole	none	{'e1': {'word': 'fluconazole', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d743.s8.e1'}, 'e2': {'word': 'itraconazole', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d743.s8.e5'}, 'sentence_id': 'DDI-DrugBank.d743.s8'}	Due chemical similarity azole type antifungal agents including fluconazole metronidazole miconazole ketoconazole itraconazole concomitant use products terfenadine recommended pending full examination potential interactions
Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. 	fluconazole	terfenadine	advise	{'e1': {'word': 'fluconazole', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d743.s8.e1'}, 'e2': {'word': 'terfenadine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d743.s8.e6'}, 'sentence_id': 'DDI-DrugBank.d743.s8'}	Due chemical similarity azole type antifungal agents including fluconazole metronidazole miconazole ketoconazole itraconazole concomitant use products terfenadine recommended pending full examination potential interactions
Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. 	metronidazole	miconazole	none	{'e1': {'word': 'metronidazole', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d743.s8.e2'}, 'e2': {'word': 'miconazole', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d743.s8.e3'}, 'sentence_id': 'DDI-DrugBank.d743.s8'}	Due chemical similarity azole type antifungal agents including fluconazole metronidazole miconazole ketoconazole itraconazole concomitant use products terfenadine recommended pending full examination potential interactions
Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. 	metronidazole	ketoconazole	none	{'e1': {'word': 'metronidazole', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d743.s8.e2'}, 'e2': {'word': 'ketoconazole', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d743.s8.e4'}, 'sentence_id': 'DDI-DrugBank.d743.s8'}	Due chemical similarity azole type antifungal agents including fluconazole metronidazole miconazole ketoconazole itraconazole concomitant use products terfenadine recommended pending full examination potential interactions
Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. 	metronidazole	itraconazole	none	{'e1': {'word': 'metronidazole', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d743.s8.e2'}, 'e2': {'word': 'itraconazole', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d743.s8.e5'}, 'sentence_id': 'DDI-DrugBank.d743.s8'}	Due chemical similarity azole type antifungal agents including fluconazole metronidazole miconazole ketoconazole itraconazole concomitant use products terfenadine recommended pending full examination potential interactions
Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. 	metronidazole	terfenadine	advise	{'e1': {'word': 'metronidazole', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d743.s8.e2'}, 'e2': {'word': 'terfenadine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d743.s8.e6'}, 'sentence_id': 'DDI-DrugBank.d743.s8'}	Due chemical similarity azole type antifungal agents including fluconazole metronidazole miconazole ketoconazole itraconazole concomitant use products terfenadine recommended pending full examination potential interactions
Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. 	miconazole	ketoconazole	none	{'e1': {'word': 'miconazole', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d743.s8.e3'}, 'e2': {'word': 'ketoconazole', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d743.s8.e4'}, 'sentence_id': 'DDI-DrugBank.d743.s8'}	Due chemical similarity azole type antifungal agents including fluconazole metronidazole miconazole ketoconazole itraconazole concomitant use products terfenadine recommended pending full examination potential interactions
Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. 	miconazole	itraconazole	none	{'e1': {'word': 'miconazole', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d743.s8.e3'}, 'e2': {'word': 'itraconazole', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d743.s8.e5'}, 'sentence_id': 'DDI-DrugBank.d743.s8'}	Due chemical similarity azole type antifungal agents including fluconazole metronidazole miconazole ketoconazole itraconazole concomitant use products terfenadine recommended pending full examination potential interactions
Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. 	miconazole	terfenadine	advise	{'e1': {'word': 'miconazole', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d743.s8.e3'}, 'e2': {'word': 'terfenadine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d743.s8.e6'}, 'sentence_id': 'DDI-DrugBank.d743.s8'}	Due chemical similarity azole type antifungal agents including fluconazole metronidazole miconazole ketoconazole itraconazole concomitant use products terfenadine recommended pending full examination potential interactions
Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. 	ketoconazole	itraconazole	none	{'e1': {'word': 'ketoconazole', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d743.s8.e4'}, 'e2': {'word': 'itraconazole', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d743.s8.e5'}, 'sentence_id': 'DDI-DrugBank.d743.s8'}	Due chemical similarity azole type antifungal agents including fluconazole metronidazole miconazole ketoconazole itraconazole concomitant use products terfenadine recommended pending full examination potential interactions
Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. 	ketoconazole	terfenadine	none	{'e1': {'word': 'ketoconazole', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d743.s8.e4'}, 'e2': {'word': 'terfenadine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d743.s8.e6'}, 'sentence_id': 'DDI-DrugBank.d743.s8'}	Due chemical similarity azole type antifungal agents including fluconazole metronidazole miconazole ketoconazole itraconazole concomitant use products terfenadine recommended pending full examination potential interactions
Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. 	itraconazole	terfenadine	none	{'e1': {'word': 'itraconazole', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d743.s8.e5'}, 'e2': {'word': 'terfenadine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d743.s8.e6'}, 'sentence_id': 'DDI-DrugBank.d743.s8'}	Due chemical similarity azole type antifungal agents including fluconazole metronidazole miconazole ketoconazole itraconazole concomitant use products terfenadine recommended pending full examination potential interactions
Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. 	Macrolides	erythromycin	none	{'e1': {'word': 'Macrolides', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d743.s9.e0'}, 'e2': {'word': 'erythromycin', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d743.s9.e1'}, 'sentence_id': 'DDI-DrugBank.d743.s9'}	Macrolides Clinical drug interaction studies indicate erythromycin clarithromycin exert effect terfenadine metabolism mechanism may similar ketoconazole lesser extent
Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. 	Macrolides	clarithromycin	none	{'e1': {'word': 'Macrolides', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d743.s9.e0'}, 'e2': {'word': 'clarithromycin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d743.s9.e2'}, 'sentence_id': 'DDI-DrugBank.d743.s9'}	Macrolides Clinical drug interaction studies indicate erythromycin clarithromycin exert effect terfenadine metabolism mechanism may similar ketoconazole lesser extent
Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. 	Macrolides	terfenadine	none	{'e1': {'word': 'Macrolides', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d743.s9.e0'}, 'e2': {'word': 'terfenadine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d743.s9.e3'}, 'sentence_id': 'DDI-DrugBank.d743.s9'}	Macrolides Clinical drug interaction studies indicate erythromycin clarithromycin exert effect terfenadine metabolism mechanism may similar ketoconazole lesser extent
Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. 	Macrolides	ketoconazole	none	{'e1': {'word': 'Macrolides', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d743.s9.e0'}, 'e2': {'word': 'ketoconazole', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d743.s9.e4'}, 'sentence_id': 'DDI-DrugBank.d743.s9'}	Macrolides Clinical drug interaction studies indicate erythromycin clarithromycin exert effect terfenadine metabolism mechanism may similar ketoconazole lesser extent
Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. 	erythromycin	clarithromycin	none	{'e1': {'word': 'erythromycin', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d743.s9.e1'}, 'e2': {'word': 'clarithromycin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d743.s9.e2'}, 'sentence_id': 'DDI-DrugBank.d743.s9'}	Macrolides Clinical drug interaction studies indicate erythromycin clarithromycin exert effect terfenadine metabolism mechanism may similar ketoconazole lesser extent
Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. 	erythromycin	terfenadine	mechanism	{'e1': {'word': 'erythromycin', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d743.s9.e1'}, 'e2': {'word': 'terfenadine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d743.s9.e3'}, 'sentence_id': 'DDI-DrugBank.d743.s9'}	Macrolides Clinical drug interaction studies indicate erythromycin clarithromycin exert effect terfenadine metabolism mechanism may similar ketoconazole lesser extent
Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. 	erythromycin	ketoconazole	none	{'e1': {'word': 'erythromycin', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d743.s9.e1'}, 'e2': {'word': 'ketoconazole', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d743.s9.e4'}, 'sentence_id': 'DDI-DrugBank.d743.s9'}	Macrolides Clinical drug interaction studies indicate erythromycin clarithromycin exert effect terfenadine metabolism mechanism may similar ketoconazole lesser extent
Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. 	clarithromycin	terfenadine	mechanism	{'e1': {'word': 'clarithromycin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d743.s9.e2'}, 'e2': {'word': 'terfenadine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d743.s9.e3'}, 'sentence_id': 'DDI-DrugBank.d743.s9'}	Macrolides Clinical drug interaction studies indicate erythromycin clarithromycin exert effect terfenadine metabolism mechanism may similar ketoconazole lesser extent
Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. 	clarithromycin	ketoconazole	none	{'e1': {'word': 'clarithromycin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d743.s9.e2'}, 'e2': {'word': 'ketoconazole', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d743.s9.e4'}, 'sentence_id': 'DDI-DrugBank.d743.s9'}	Macrolides Clinical drug interaction studies indicate erythromycin clarithromycin exert effect terfenadine metabolism mechanism may similar ketoconazole lesser extent
Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. 	terfenadine	ketoconazole	none	{'e1': {'word': 'terfenadine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d743.s9.e3'}, 'e2': {'word': 'ketoconazole', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d743.s9.e4'}, 'sentence_id': 'DDI-DrugBank.d743.s9'}	Macrolides Clinical drug interaction studies indicate erythromycin clarithromycin exert effect terfenadine metabolism mechanism may similar ketoconazole lesser extent
A few spontaneous accounts of QT interval prolongation with ventricular arrhythmia including torsades de pointes, have been reported in patients receiving erythromycin or troleandomycin. 	erythromycin	troleandomycin	none	{'e1': {'word': 'erythromycin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d743.s11.e0'}, 'e2': {'word': 'troleandomycin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d743.s11.e1'}, 'sentence_id': 'DDI-DrugBank.d743.s11'}	spontaneous accounts QT interval prolongation ventricular arrhythmia including torsades de pointes reported patients receiving erythromycin troleandomycin
Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. 	terfenadine	clarithromycin	advise	{'e1': {'word': 'terfenadine', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d743.s12.e0'}, 'e2': {'word': 'clarithromycin', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d743.s12.e1'}, 'sentence_id': 'DDI-DrugBank.d743.s12'}	Concomitant administration terfenadine clarithromycin erythromycin troleandomycin contraindicated Pending full characterization potential interactions concomitant administration terfenadine macrolide antibiotics including azithromycin recommended
Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. 	terfenadine	erythromycin	advise	{'e1': {'word': 'terfenadine', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d743.s12.e0'}, 'e2': {'word': 'erythromycin', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d743.s12.e2'}, 'sentence_id': 'DDI-DrugBank.d743.s12'}	Concomitant administration terfenadine clarithromycin erythromycin troleandomycin contraindicated Pending full characterization potential interactions concomitant administration terfenadine macrolide antibiotics including azithromycin recommended
Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. 	terfenadine	troleandomycin	advise	{'e1': {'word': 'terfenadine', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d743.s12.e0'}, 'e2': {'word': 'troleandomycin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d743.s12.e3'}, 'sentence_id': 'DDI-DrugBank.d743.s12'}	Concomitant administration terfenadine clarithromycin erythromycin troleandomycin contraindicated Pending full characterization potential interactions concomitant administration terfenadine macrolide antibiotics including azithromycin recommended
Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. 	terfenadine	terfenadine	none	{'e1': {'word': 'terfenadine', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d743.s12.e0'}, 'e2': {'word': 'terfenadine', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d743.s12.e4'}, 'sentence_id': 'DDI-DrugBank.d743.s12'}	Concomitant administration terfenadine clarithromycin erythromycin troleandomycin contraindicated Pending full characterization potential interactions concomitant administration terfenadine macrolide antibiotics including azithromycin recommended
Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. 	terfenadine	macrolide antibiotics	none	{'e1': {'word': 'terfenadine', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d743.s12.e0'}, 'e2': {'word': 'macrolide antibiotics', 'word_index': [(15, 16)], 'id': 'DDI-DrugBank.d743.s12.e5'}, 'sentence_id': 'DDI-DrugBank.d743.s12'}	Concomitant administration terfenadine clarithromycin erythromycin troleandomycin contraindicated Pending full characterization potential interactions concomitant administration terfenadine macrolide antibiotics including azithromycin recommended
Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. 	terfenadine	azithromycin	none	{'e1': {'word': 'terfenadine', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d743.s12.e0'}, 'e2': {'word': 'azithromycin', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d743.s12.e6'}, 'sentence_id': 'DDI-DrugBank.d743.s12'}	Concomitant administration terfenadine clarithromycin erythromycin troleandomycin contraindicated Pending full characterization potential interactions concomitant administration terfenadine macrolide antibiotics including azithromycin recommended
Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. 	clarithromycin	erythromycin	none	{'e1': {'word': 'clarithromycin', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d743.s12.e1'}, 'e2': {'word': 'erythromycin', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d743.s12.e2'}, 'sentence_id': 'DDI-DrugBank.d743.s12'}	Concomitant administration terfenadine clarithromycin erythromycin troleandomycin contraindicated Pending full characterization potential interactions concomitant administration terfenadine macrolide antibiotics including azithromycin recommended
Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. 	clarithromycin	troleandomycin	none	{'e1': {'word': 'clarithromycin', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d743.s12.e1'}, 'e2': {'word': 'troleandomycin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d743.s12.e3'}, 'sentence_id': 'DDI-DrugBank.d743.s12'}	Concomitant administration terfenadine clarithromycin erythromycin troleandomycin contraindicated Pending full characterization potential interactions concomitant administration terfenadine macrolide antibiotics including azithromycin recommended
Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. 	clarithromycin	terfenadine	none	{'e1': {'word': 'clarithromycin', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d743.s12.e1'}, 'e2': {'word': 'terfenadine', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d743.s12.e4'}, 'sentence_id': 'DDI-DrugBank.d743.s12'}	Concomitant administration terfenadine clarithromycin erythromycin troleandomycin contraindicated Pending full characterization potential interactions concomitant administration terfenadine macrolide antibiotics including azithromycin recommended
Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. 	clarithromycin	macrolide antibiotics	none	{'e1': {'word': 'clarithromycin', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d743.s12.e1'}, 'e2': {'word': 'macrolide antibiotics', 'word_index': [(15, 16)], 'id': 'DDI-DrugBank.d743.s12.e5'}, 'sentence_id': 'DDI-DrugBank.d743.s12'}	Concomitant administration terfenadine clarithromycin erythromycin troleandomycin contraindicated Pending full characterization potential interactions concomitant administration terfenadine macrolide antibiotics including azithromycin recommended
Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. 	clarithromycin	azithromycin	none	{'e1': {'word': 'clarithromycin', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d743.s12.e1'}, 'e2': {'word': 'azithromycin', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d743.s12.e6'}, 'sentence_id': 'DDI-DrugBank.d743.s12'}	Concomitant administration terfenadine clarithromycin erythromycin troleandomycin contraindicated Pending full characterization potential interactions concomitant administration terfenadine macrolide antibiotics including azithromycin recommended
Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. 	erythromycin	troleandomycin	none	{'e1': {'word': 'erythromycin', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d743.s12.e2'}, 'e2': {'word': 'troleandomycin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d743.s12.e3'}, 'sentence_id': 'DDI-DrugBank.d743.s12'}	Concomitant administration terfenadine clarithromycin erythromycin troleandomycin contraindicated Pending full characterization potential interactions concomitant administration terfenadine macrolide antibiotics including azithromycin recommended
Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. 	erythromycin	terfenadine	none	{'e1': {'word': 'erythromycin', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d743.s12.e2'}, 'e2': {'word': 'terfenadine', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d743.s12.e4'}, 'sentence_id': 'DDI-DrugBank.d743.s12'}	Concomitant administration terfenadine clarithromycin erythromycin troleandomycin contraindicated Pending full characterization potential interactions concomitant administration terfenadine macrolide antibiotics including azithromycin recommended
Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. 	erythromycin	macrolide antibiotics	none	{'e1': {'word': 'erythromycin', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d743.s12.e2'}, 'e2': {'word': 'macrolide antibiotics', 'word_index': [(15, 16)], 'id': 'DDI-DrugBank.d743.s12.e5'}, 'sentence_id': 'DDI-DrugBank.d743.s12'}	Concomitant administration terfenadine clarithromycin erythromycin troleandomycin contraindicated Pending full characterization potential interactions concomitant administration terfenadine macrolide antibiotics including azithromycin recommended
Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. 	erythromycin	azithromycin	none	{'e1': {'word': 'erythromycin', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d743.s12.e2'}, 'e2': {'word': 'azithromycin', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d743.s12.e6'}, 'sentence_id': 'DDI-DrugBank.d743.s12'}	Concomitant administration terfenadine clarithromycin erythromycin troleandomycin contraindicated Pending full characterization potential interactions concomitant administration terfenadine macrolide antibiotics including azithromycin recommended
Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. 	troleandomycin	terfenadine	none	{'e1': {'word': 'troleandomycin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d743.s12.e3'}, 'e2': {'word': 'terfenadine', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d743.s12.e4'}, 'sentence_id': 'DDI-DrugBank.d743.s12'}	Concomitant administration terfenadine clarithromycin erythromycin troleandomycin contraindicated Pending full characterization potential interactions concomitant administration terfenadine macrolide antibiotics including azithromycin recommended
Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. 	troleandomycin	macrolide antibiotics	none	{'e1': {'word': 'troleandomycin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d743.s12.e3'}, 'e2': {'word': 'macrolide antibiotics', 'word_index': [(15, 16)], 'id': 'DDI-DrugBank.d743.s12.e5'}, 'sentence_id': 'DDI-DrugBank.d743.s12'}	Concomitant administration terfenadine clarithromycin erythromycin troleandomycin contraindicated Pending full characterization potential interactions concomitant administration terfenadine macrolide antibiotics including azithromycin recommended
Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. 	troleandomycin	azithromycin	none	{'e1': {'word': 'troleandomycin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d743.s12.e3'}, 'e2': {'word': 'azithromycin', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d743.s12.e6'}, 'sentence_id': 'DDI-DrugBank.d743.s12'}	Concomitant administration terfenadine clarithromycin erythromycin troleandomycin contraindicated Pending full characterization potential interactions concomitant administration terfenadine macrolide antibiotics including azithromycin recommended
Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. 	terfenadine	macrolide antibiotics	advise	{'e1': {'word': 'terfenadine', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d743.s12.e4'}, 'e2': {'word': 'macrolide antibiotics', 'word_index': [(15, 16)], 'id': 'DDI-DrugBank.d743.s12.e5'}, 'sentence_id': 'DDI-DrugBank.d743.s12'}	Concomitant administration terfenadine clarithromycin erythromycin troleandomycin contraindicated Pending full characterization potential interactions concomitant administration terfenadine macrolide antibiotics including azithromycin recommended
Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. 	terfenadine	azithromycin	advise	{'e1': {'word': 'terfenadine', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d743.s12.e4'}, 'e2': {'word': 'azithromycin', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d743.s12.e6'}, 'sentence_id': 'DDI-DrugBank.d743.s12'}	Concomitant administration terfenadine clarithromycin erythromycin troleandomycin contraindicated Pending full characterization potential interactions concomitant administration terfenadine macrolide antibiotics including azithromycin recommended
Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. 	macrolide antibiotics	azithromycin	none	{'e1': {'word': 'macrolide antibiotics', 'word_index': [(15, 16)], 'id': 'DDI-DrugBank.d743.s12.e5'}, 'e2': {'word': 'azithromycin', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d743.s12.e6'}, 'sentence_id': 'DDI-DrugBank.d743.s12'}	Concomitant administration terfenadine clarithromycin erythromycin troleandomycin contraindicated Pending full characterization potential interactions concomitant administration terfenadine macrolide antibiotics including azithromycin recommended
Studies to evaluate potential interactions of terfenadine with azithromycin are in progress.	terfenadine	azithromycin	none	{'e1': {'word': 'terfenadine', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d743.s13.e0'}, 'e2': {'word': 'azithromycin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d743.s13.e1'}, 'sentence_id': 'DDI-DrugBank.d743.s13'}	Studies evaluate potential interactions terfenadine azithromycin progress
Drugs which may potentiate the myeloproliferative effects of Leukine, such as lithium and corticosteroids, should be used with caution.	Leukine	lithium	effect	{'e1': {'word': 'Leukine', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d607.s1.e0'}, 'e2': {'word': 'lithium', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d607.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d607.s1'}	Drugs may potentiate myeloproliferative effects Leukine lithium corticosteroids used caution
Drugs which may potentiate the myeloproliferative effects of Leukine, such as lithium and corticosteroids, should be used with caution.	Leukine	corticosteroids	effect	{'e1': {'word': 'Leukine', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d607.s1.e0'}, 'e2': {'word': 'corticosteroids', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d607.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d607.s1'}	Drugs may potentiate myeloproliferative effects Leukine lithium corticosteroids used caution
Drugs which may potentiate the myeloproliferative effects of Leukine, such as lithium and corticosteroids, should be used with caution.	lithium	corticosteroids	none	{'e1': {'word': 'lithium', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d607.s1.e1'}, 'e2': {'word': 'corticosteroids', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d607.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d607.s1'}	Drugs may potentiate myeloproliferative effects Leukine lithium corticosteroids used caution
Administration of valproic acid decreases oral clearance of temozolomide by about 5%. 	valproic acid	temozolomide	mechanism	{'e1': {'word': 'valproic acid', 'word_index': [(1, 2)], 'id': 'DDI-DrugBank.d687.s0.e0'}, 'e2': {'word': 'temozolomide', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d687.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d687.s0'}	Administration valproic acid decreases oral clearance temozolomide NUMBER %
ACE inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of angiotensin-converting enzyme (ACE) inhibitors. 	ACE inhibitors	NSAIDs	none	{'e1': {'word': 'ACE inhibitors', 'word_index': [(0, 1)], 'id': 'DDI-DrugBank.d597.s0.e0'}, 'e2': {'word': 'NSAIDs', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d597.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d597.s0'}	ACE inhibitors Reports suggest NSAIDs may diminish antihypertensive effect angiotensin converting enzyme ACE inhibitors
ACE inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of angiotensin-converting enzyme (ACE) inhibitors. 	ACE inhibitors	angiotensin-converting enzyme (ACE) inhibitors	none	{'e1': {'word': 'ACE inhibitors', 'word_index': [(0, 1)], 'id': 'DDI-DrugBank.d597.s0.e0'}, 'e2': {'word': 'angiotensin-converting enzyme (ACE) inhibitors', 'word_index': [(9, 13)], 'id': 'DDI-DrugBank.d597.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d597.s0'}	ACE inhibitors Reports suggest NSAIDs may diminish antihypertensive effect angiotensin converting enzyme ACE inhibitors
ACE inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of angiotensin-converting enzyme (ACE) inhibitors. 	NSAIDs	angiotensin-converting enzyme (ACE) inhibitors	effect	{'e1': {'word': 'NSAIDs', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d597.s0.e1'}, 'e2': {'word': 'angiotensin-converting enzyme (ACE) inhibitors', 'word_index': [(9, 13)], 'id': 'DDI-DrugBank.d597.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d597.s0'}	ACE inhibitors Reports suggest NSAIDs may diminish antihypertensive effect angiotensin converting enzyme ACE inhibitors
This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors. 	NSAIDs	ACE inhibitors	advise	{'e1': {'word': 'NSAIDs', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d597.s1.e0'}, 'e2': {'word': 'ACE inhibitors', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d597.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d597.s1'}	interaction given consideration patients taking NSAIDs concomitantly ACE inhibitors
Aspirin: Concomitant administration of aspirin (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of meloxicam. 	Aspirin	aspirin	none	{'e1': {'word': 'Aspirin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d597.s2.e0'}, 'e2': {'word': 'aspirin', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d597.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d597.s2'}	Aspirin Concomitant administration aspirin NUMBER mg TID healthy volunteers tended increase AUC NUMBER % Cmax NUMBER % meloxicam
Aspirin: Concomitant administration of aspirin (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of meloxicam. 	Aspirin	meloxicam	none	{'e1': {'word': 'Aspirin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d597.s2.e0'}, 'e2': {'word': 'meloxicam', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d597.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d597.s2'}	Aspirin Concomitant administration aspirin NUMBER mg TID healthy volunteers tended increase AUC NUMBER % Cmax NUMBER % meloxicam
Aspirin: Concomitant administration of aspirin (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of meloxicam. 	aspirin	meloxicam	mechanism	{'e1': {'word': 'aspirin', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d597.s2.e1'}, 'e2': {'word': 'meloxicam', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d597.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d597.s2'}	Aspirin Concomitant administration aspirin NUMBER mg TID healthy volunteers tended increase AUC NUMBER % Cmax NUMBER % meloxicam
however, as with other NSAIDs, concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects. 	NSAIDs	meloxicam	none	{'e1': {'word': 'NSAIDs', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d597.s4.e0'}, 'e2': {'word': 'meloxicam', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d597.s4.e1'}, 'sentence_id': 'DDI-DrugBank.d597.s4'}	however NSAIDs concomitant administration meloxicam aspirin generally recommended potential increased adverse effects
however, as with other NSAIDs, concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects. 	NSAIDs	aspirin	advise	{'e1': {'word': 'NSAIDs', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d597.s4.e0'}, 'e2': {'word': 'aspirin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d597.s4.e2'}, 'sentence_id': 'DDI-DrugBank.d597.s4'}	however NSAIDs concomitant administration meloxicam aspirin generally recommended potential increased adverse effects
however, as with other NSAIDs, concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects. 	meloxicam	aspirin	advise	{'e1': {'word': 'meloxicam', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d597.s4.e1'}, 'e2': {'word': 'aspirin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d597.s4.e2'}, 'sentence_id': 'DDI-DrugBank.d597.s4'}	however NSAIDs concomitant administration meloxicam aspirin generally recommended potential increased adverse effects
Concomitant administration of low-dose aspirin with MOBIC may result in an increased rate of GI ulceration or other complications, compared to use of MOBIC alone. 	aspirin	MOBIC	effect	{'e1': {'word': 'aspirin', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d597.s5.e0'}, 'e2': {'word': 'MOBIC', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d597.s5.e1'}, 'sentence_id': 'DDI-DrugBank.d597.s5'}	Concomitant administration low dose aspirin MOBIC may result increased rate GI ulceration complications compared use MOBIC alone
Concomitant administration of low-dose aspirin with MOBIC may result in an increased rate of GI ulceration or other complications, compared to use of MOBIC alone. 	aspirin	MOBIC	none	{'e1': {'word': 'aspirin', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d597.s5.e0'}, 'e2': {'word': 'MOBIC', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d597.s5.e2'}, 'sentence_id': 'DDI-DrugBank.d597.s5'}	Concomitant administration low dose aspirin MOBIC may result increased rate GI ulceration complications compared use MOBIC alone
Concomitant administration of low-dose aspirin with MOBIC may result in an increased rate of GI ulceration or other complications, compared to use of MOBIC alone. 	MOBIC	MOBIC	none	{'e1': {'word': 'MOBIC', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d597.s5.e1'}, 'e2': {'word': 'MOBIC', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d597.s5.e2'}, 'sentence_id': 'DDI-DrugBank.d597.s5'}	Concomitant administration low dose aspirin MOBIC may result increased rate GI ulceration complications compared use MOBIC alone
MOBIC is not a substitute for aspirin for cardiovascular prophylaxis. 	MOBIC	aspirin	none	{'e1': {'word': 'MOBIC', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d597.s6.e0'}, 'e2': {'word': 'aspirin', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d597.s6.e1'}, 'sentence_id': 'DDI-DrugBank.d597.s6'}	MOBIC substitute aspirin cardiovascular prophylaxis
Cholestyramine: Pretreatment for four days with cholestyramine significantly increased the clearance of meloxicam by 50%. 	Cholestyramine	cholestyramine	none	{'e1': {'word': 'Cholestyramine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d597.s7.e0'}, 'e2': {'word': 'cholestyramine', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d597.s7.e1'}, 'sentence_id': 'DDI-DrugBank.d597.s7'}	Cholestyramine Pretreatment NUMBER days cholestyramine significantly increased clearance meloxicam NUMBER %
Cholestyramine: Pretreatment for four days with cholestyramine significantly increased the clearance of meloxicam by 50%. 	Cholestyramine	meloxicam	none	{'e1': {'word': 'Cholestyramine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d597.s7.e0'}, 'e2': {'word': 'meloxicam', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d597.s7.e2'}, 'sentence_id': 'DDI-DrugBank.d597.s7'}	Cholestyramine Pretreatment NUMBER days cholestyramine significantly increased clearance meloxicam NUMBER %
Cholestyramine: Pretreatment for four days with cholestyramine significantly increased the clearance of meloxicam by 50%. 	cholestyramine	meloxicam	mechanism	{'e1': {'word': 'cholestyramine', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d597.s7.e1'}, 'e2': {'word': 'meloxicam', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d597.s7.e2'}, 'sentence_id': 'DDI-DrugBank.d597.s7'}	Cholestyramine Pretreatment NUMBER days cholestyramine significantly increased clearance meloxicam NUMBER %
Cimetidine: Concomitant administration of 200 mg cimetidine QID did not alter the single-dose pharmacokinetics of 30 mg meloxicam. 	Cimetidine	cimetidine	none	{'e1': {'word': 'Cimetidine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d597.s11.e0'}, 'e2': {'word': 'cimetidine', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d597.s11.e1'}, 'sentence_id': 'DDI-DrugBank.d597.s11'}	Cimetidine Concomitant administration NUMBER mg cimetidine QID alter single dose pharmacokinetics NUMBER mg meloxicam
Cimetidine: Concomitant administration of 200 mg cimetidine QID did not alter the single-dose pharmacokinetics of 30 mg meloxicam. 	Cimetidine	meloxicam	none	{'e1': {'word': 'Cimetidine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d597.s11.e0'}, 'e2': {'word': 'meloxicam', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d597.s11.e2'}, 'sentence_id': 'DDI-DrugBank.d597.s11'}	Cimetidine Concomitant administration NUMBER mg cimetidine QID alter single dose pharmacokinetics NUMBER mg meloxicam
Cimetidine: Concomitant administration of 200 mg cimetidine QID did not alter the single-dose pharmacokinetics of 30 mg meloxicam. 	cimetidine	meloxicam	none	{'e1': {'word': 'cimetidine', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d597.s11.e1'}, 'e2': {'word': 'meloxicam', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d597.s11.e2'}, 'sentence_id': 'DDI-DrugBank.d597.s11'}	Cimetidine Concomitant administration NUMBER mg cimetidine QID alter single dose pharmacokinetics NUMBER mg meloxicam
Digoxin: Meloxicam 15 mg once daily for 7 days did not alter the plasma concentration profile of digoxin after b-acetyldigoxin administration for 7 days at clinical doses. 	Digoxin	Meloxicam	none	{'e1': {'word': 'Digoxin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d597.s12.e0'}, 'e2': {'word': 'Meloxicam', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d597.s12.e1'}, 'sentence_id': 'DDI-DrugBank.d597.s12'}	Digoxin Meloxicam NUMBER mg daily NUMBER days alter plasma concentration profile digoxin b-acetyldigoxin administration NUMBER days clinical doses
Digoxin: Meloxicam 15 mg once daily for 7 days did not alter the plasma concentration profile of digoxin after b-acetyldigoxin administration for 7 days at clinical doses. 	Digoxin	digoxin	none	{'e1': {'word': 'Digoxin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d597.s12.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d597.s12.e2'}, 'sentence_id': 'DDI-DrugBank.d597.s12'}	Digoxin Meloxicam NUMBER mg daily NUMBER days alter plasma concentration profile digoxin b-acetyldigoxin administration NUMBER days clinical doses
Digoxin: Meloxicam 15 mg once daily for 7 days did not alter the plasma concentration profile of digoxin after b-acetyldigoxin administration for 7 days at clinical doses. 	Meloxicam	digoxin	none	{'e1': {'word': 'Meloxicam', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d597.s12.e1'}, 'e2': {'word': 'digoxin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d597.s12.e2'}, 'sentence_id': 'DDI-DrugBank.d597.s12'}	Digoxin Meloxicam NUMBER mg daily NUMBER days alter plasma concentration profile digoxin b-acetyldigoxin administration NUMBER days clinical doses
In vitro testing found no protein binding drug interaction between digoxin and meloxicam. 	digoxin	meloxicam	none	{'e1': {'word': 'digoxin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d597.s13.e0'}, 'e2': {'word': 'meloxicam', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d597.s13.e1'}, 'sentence_id': 'DDI-DrugBank.d597.s13'}	vitro testing found protein binding drug interaction digoxin meloxicam
Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients. 	Furosemide	NSAIDs	none	{'e1': {'word': 'Furosemide', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d597.s14.e0'}, 'e2': {'word': 'NSAIDs', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d597.s14.e1'}, 'sentence_id': 'DDI-DrugBank.d597.s14'}	Furosemide Clinical studies well post-marketing observations shown NSAIDs reduce natriuretic effect furosemide thiazide diuretics patients
Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients. 	Furosemide	furosemide	none	{'e1': {'word': 'Furosemide', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d597.s14.e0'}, 'e2': {'word': 'furosemide', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d597.s14.e2'}, 'sentence_id': 'DDI-DrugBank.d597.s14'}	Furosemide Clinical studies well post-marketing observations shown NSAIDs reduce natriuretic effect furosemide thiazide diuretics patients
Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients. 	Furosemide	thiazide diuretics	none	{'e1': {'word': 'Furosemide', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d597.s14.e0'}, 'e2': {'word': 'thiazide diuretics', 'word_index': [(12, 13)], 'id': 'DDI-DrugBank.d597.s14.e3'}, 'sentence_id': 'DDI-DrugBank.d597.s14'}	Furosemide Clinical studies well post-marketing observations shown NSAIDs reduce natriuretic effect furosemide thiazide diuretics patients
Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients. 	NSAIDs	furosemide	effect	{'e1': {'word': 'NSAIDs', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d597.s14.e1'}, 'e2': {'word': 'furosemide', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d597.s14.e2'}, 'sentence_id': 'DDI-DrugBank.d597.s14'}	Furosemide Clinical studies well post-marketing observations shown NSAIDs reduce natriuretic effect furosemide thiazide diuretics patients
Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients. 	NSAIDs	thiazide diuretics	effect	{'e1': {'word': 'NSAIDs', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d597.s14.e1'}, 'e2': {'word': 'thiazide diuretics', 'word_index': [(12, 13)], 'id': 'DDI-DrugBank.d597.s14.e3'}, 'sentence_id': 'DDI-DrugBank.d597.s14'}	Furosemide Clinical studies well post-marketing observations shown NSAIDs reduce natriuretic effect furosemide thiazide diuretics patients
Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients. 	furosemide	thiazide diuretics	none	{'e1': {'word': 'furosemide', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d597.s14.e2'}, 'e2': {'word': 'thiazide diuretics', 'word_index': [(12, 13)], 'id': 'DDI-DrugBank.d597.s14.e3'}, 'sentence_id': 'DDI-DrugBank.d597.s14'}	Furosemide Clinical studies well post-marketing observations shown NSAIDs reduce natriuretic effect furosemide thiazide diuretics patients
Studies with furosemide agents and meloxicam have not demonstrated a reduction in natriuretic effect. 	furosemide	meloxicam	none	{'e1': {'word': 'furosemide', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d597.s16.e0'}, 'e2': {'word': 'meloxicam', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d597.s16.e1'}, 'sentence_id': 'DDI-DrugBank.d597.s16'}	Studies furosemide agents meloxicam demonstrated reduction natriuretic effect
Furosemide: single and multiple dose pharmacodynamics and pharmacokinetics are not affected by multiple doses of meloxicam. 	Furosemide	meloxicam	none	{'e1': {'word': 'Furosemide', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d597.s17.e0'}, 'e2': {'word': 'meloxicam', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d597.s17.e1'}, 'sentence_id': 'DDI-DrugBank.d597.s17'}	Furosemide single multiple dose pharmacodynamics pharmacokinetics affected multiple doses meloxicam
Nevertheless, during concomitant therapy with furosemide and MOBIC, patients should be observed closely for signs of declining renal function, as well as to assure diuretic efficacy. 	furosemide	MOBIC	advise	{'e1': {'word': 'furosemide', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d597.s18.e0'}, 'e2': {'word': 'MOBIC', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d597.s18.e1'}, 'sentence_id': 'DDI-DrugBank.d597.s18'}	Nevertheless concomitant therapy furosemide MOBIC patients observed closely signs declining renal function well assure diuretic efficacy
Lithium: In clinical trials, NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. 	Lithium	NSAIDs	none	{'e1': {'word': 'Lithium', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d597.s19.e0'}, 'e2': {'word': 'NSAIDs', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d597.s19.e1'}, 'sentence_id': 'DDI-DrugBank.d597.s19'}	Lithium clinical trials NSAIDs produced elevation plasma lithium levels reduction renal lithium clearance
Lithium: In clinical trials, NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. 	Lithium	lithium	none	{'e1': {'word': 'Lithium', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d597.s19.e0'}, 'e2': {'word': 'lithium', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d597.s19.e2'}, 'sentence_id': 'DDI-DrugBank.d597.s19'}	Lithium clinical trials NSAIDs produced elevation plasma lithium levels reduction renal lithium clearance
Lithium: In clinical trials, NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. 	Lithium	lithium	none	{'e1': {'word': 'Lithium', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d597.s19.e0'}, 'e2': {'word': 'lithium', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d597.s19.e3'}, 'sentence_id': 'DDI-DrugBank.d597.s19'}	Lithium clinical trials NSAIDs produced elevation plasma lithium levels reduction renal lithium clearance
Lithium: In clinical trials, NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. 	NSAIDs	lithium	mechanism	{'e1': {'word': 'NSAIDs', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d597.s19.e1'}, 'e2': {'word': 'lithium', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d597.s19.e2'}, 'sentence_id': 'DDI-DrugBank.d597.s19'}	Lithium clinical trials NSAIDs produced elevation plasma lithium levels reduction renal lithium clearance
Lithium: In clinical trials, NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. 	NSAIDs	lithium	none	{'e1': {'word': 'NSAIDs', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d597.s19.e1'}, 'e2': {'word': 'lithium', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d597.s19.e3'}, 'sentence_id': 'DDI-DrugBank.d597.s19'}	Lithium clinical trials NSAIDs produced elevation plasma lithium levels reduction renal lithium clearance
Lithium: In clinical trials, NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. 	lithium	lithium	none	{'e1': {'word': 'lithium', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d597.s19.e2'}, 'e2': {'word': 'lithium', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d597.s19.e3'}, 'sentence_id': 'DDI-DrugBank.d597.s19'}	Lithium clinical trials NSAIDs produced elevation plasma lithium levels reduction renal lithium clearance
In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving lithium alone. 	lithium	lithium	none	{'e1': {'word': 'lithium', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d597.s20.e0'}, 'e2': {'word': 'lithium', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d597.s20.e1'}, 'sentence_id': 'DDI-DrugBank.d597.s20'}	study conducted healthy subjects mean pre-dose lithium concentration AUC increased NUMBER % subjects receiving lithium doses ranging NUMBER NUMBER mg BID meloxicam NUMBER mg QD compared subjects receiving lithium alone
In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving lithium alone. 	lithium	meloxicam	none	{'e1': {'word': 'lithium', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d597.s20.e0'}, 'e2': {'word': 'meloxicam', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d597.s20.e2'}, 'sentence_id': 'DDI-DrugBank.d597.s20'}	study conducted healthy subjects mean pre-dose lithium concentration AUC increased NUMBER % subjects receiving lithium doses ranging NUMBER NUMBER mg BID meloxicam NUMBER mg QD compared subjects receiving lithium alone
In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving lithium alone. 	lithium	lithium	none	{'e1': {'word': 'lithium', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d597.s20.e0'}, 'e2': {'word': 'lithium', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d597.s20.e3'}, 'sentence_id': 'DDI-DrugBank.d597.s20'}	study conducted healthy subjects mean pre-dose lithium concentration AUC increased NUMBER % subjects receiving lithium doses ranging NUMBER NUMBER mg BID meloxicam NUMBER mg QD compared subjects receiving lithium alone
In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving lithium alone. 	lithium	meloxicam	mechanism	{'e1': {'word': 'lithium', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d597.s20.e1'}, 'e2': {'word': 'meloxicam', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d597.s20.e2'}, 'sentence_id': 'DDI-DrugBank.d597.s20'}	study conducted healthy subjects mean pre-dose lithium concentration AUC increased NUMBER % subjects receiving lithium doses ranging NUMBER NUMBER mg BID meloxicam NUMBER mg QD compared subjects receiving lithium alone
In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving lithium alone. 	lithium	lithium	none	{'e1': {'word': 'lithium', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d597.s20.e1'}, 'e2': {'word': 'lithium', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d597.s20.e3'}, 'sentence_id': 'DDI-DrugBank.d597.s20'}	study conducted healthy subjects mean pre-dose lithium concentration AUC increased NUMBER % subjects receiving lithium doses ranging NUMBER NUMBER mg BID meloxicam NUMBER mg QD compared subjects receiving lithium alone
In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving lithium alone. 	meloxicam	lithium	none	{'e1': {'word': 'meloxicam', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d597.s20.e2'}, 'e2': {'word': 'lithium', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d597.s20.e3'}, 'sentence_id': 'DDI-DrugBank.d597.s20'}	study conducted healthy subjects mean pre-dose lithium concentration AUC increased NUMBER % subjects receiving lithium doses ranging NUMBER NUMBER mg BID meloxicam NUMBER mg QD compared subjects receiving lithium alone
Patients on lithium treatment should be closely monitored when MOBIC is introduced or withdrawn. 	lithium	MOBIC	advise	{'e1': {'word': 'lithium', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d597.s22.e0'}, 'e2': {'word': 'MOBIC', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d597.s22.e1'}, 'sentence_id': 'DDI-DrugBank.d597.s22'}	Patients lithium treatment closely monitored MOBIC introduced withdrawn
Methotrexate: A study in 13 rheumatoid arthritis (RA) patients evaluated the effects of multiple doses of meloxicam on the pharmacokinetics of methotrexate taken once weekly. 	Methotrexate	meloxicam	none	{'e1': {'word': 'Methotrexate', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d597.s23.e0'}, 'e2': {'word': 'meloxicam', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d597.s23.e1'}, 'sentence_id': 'DDI-DrugBank.d597.s23'}	Methotrexate study NUMBER rheumatoid arthritis RA patients evaluated effects multiple doses meloxicam pharmacokinetics methotrexate taken weekly
Methotrexate: A study in 13 rheumatoid arthritis (RA) patients evaluated the effects of multiple doses of meloxicam on the pharmacokinetics of methotrexate taken once weekly. 	Methotrexate	methotrexate	none	{'e1': {'word': 'Methotrexate', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d597.s23.e0'}, 'e2': {'word': 'methotrexate', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d597.s23.e2'}, 'sentence_id': 'DDI-DrugBank.d597.s23'}	Methotrexate study NUMBER rheumatoid arthritis RA patients evaluated effects multiple doses meloxicam pharmacokinetics methotrexate taken weekly
Methotrexate: A study in 13 rheumatoid arthritis (RA) patients evaluated the effects of multiple doses of meloxicam on the pharmacokinetics of methotrexate taken once weekly. 	meloxicam	methotrexate	none	{'e1': {'word': 'meloxicam', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d597.s23.e1'}, 'e2': {'word': 'methotrexate', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d597.s23.e2'}, 'sentence_id': 'DDI-DrugBank.d597.s23'}	Methotrexate study NUMBER rheumatoid arthritis RA patients evaluated effects multiple doses meloxicam pharmacokinetics methotrexate taken weekly
Meloxicam did not have a significant effect on the pharmacokinetics of single doses of methotrexate. 	Meloxicam	methotrexate	none	{'e1': {'word': 'Meloxicam', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d597.s24.e0'}, 'e2': {'word': 'methotrexate', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d597.s24.e1'}, 'sentence_id': 'DDI-DrugBank.d597.s24'}	Meloxicam significant effect pharmacokinetics single doses methotrexate
In vitro, methotrexate did not displace meloxicam from its human serum binding sites. 	methotrexate	meloxicam	none	{'e1': {'word': 'methotrexate', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d597.s25.e0'}, 'e2': {'word': 'meloxicam', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d597.s25.e1'}, 'sentence_id': 'DDI-DrugBank.d597.s25'}	vitro methotrexate displace meloxicam human serum binding sites
Warfarin: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing MOBIC therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding. 	Warfarin	MOBIC	none	{'e1': {'word': 'Warfarin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d597.s26.e0'}, 'e2': {'word': 'MOBIC', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d597.s26.e1'}, 'sentence_id': 'DDI-DrugBank.d597.s26'}	Warfarin Anticoagulant activity monitored particularly first days initiating changing MOBIC therapy patients receiving warfarin similar agents since patients increased risk bleeding
Warfarin: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing MOBIC therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding. 	Warfarin	warfarin	none	{'e1': {'word': 'Warfarin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d597.s26.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d597.s26.e2'}, 'sentence_id': 'DDI-DrugBank.d597.s26'}	Warfarin Anticoagulant activity monitored particularly first days initiating changing MOBIC therapy patients receiving warfarin similar agents since patients increased risk bleeding
Warfarin: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing MOBIC therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding. 	MOBIC	warfarin	advise	{'e1': {'word': 'MOBIC', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d597.s26.e1'}, 'e2': {'word': 'warfarin', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d597.s26.e2'}, 'sentence_id': 'DDI-DrugBank.d597.s26'}	Warfarin Anticoagulant activity monitored particularly first days initiating changing MOBIC therapy patients receiving warfarin similar agents since patients increased risk bleeding
The effect of meloxicam on the anticoagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of warfarin that produced an INR (International Normalized Ratio) between 1.2 and 1.8. 	meloxicam	warfarin	none	{'e1': {'word': 'meloxicam', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d597.s27.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d597.s27.e1'}, 'sentence_id': 'DDI-DrugBank.d597.s27'}	effect meloxicam anticoagulant effect warfarin studied group healthy subjects receiving daily doses warfarin produced INR International Normalized Ratio NUMBER NUMBER
The effect of meloxicam on the anticoagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of warfarin that produced an INR (International Normalized Ratio) between 1.2 and 1.8. 	meloxicam	warfarin	none	{'e1': {'word': 'meloxicam', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d597.s27.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d597.s27.e2'}, 'sentence_id': 'DDI-DrugBank.d597.s27'}	effect meloxicam anticoagulant effect warfarin studied group healthy subjects receiving daily doses warfarin produced INR International Normalized Ratio NUMBER NUMBER
The effect of meloxicam on the anticoagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of warfarin that produced an INR (International Normalized Ratio) between 1.2 and 1.8. 	warfarin	warfarin	none	{'e1': {'word': 'warfarin', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d597.s27.e1'}, 'e2': {'word': 'warfarin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d597.s27.e2'}, 'sentence_id': 'DDI-DrugBank.d597.s27'}	effect meloxicam anticoagulant effect warfarin studied group healthy subjects receiving daily doses warfarin produced INR International Normalized Ratio NUMBER NUMBER
In these subjects, meloxicam did not alter warfarin pharmacokinetics and the average anticoagulant effect of warfarin as determined by prothrombin time. 	meloxicam	warfarin	none	{'e1': {'word': 'meloxicam', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d597.s28.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d597.s28.e1'}, 'sentence_id': 'DDI-DrugBank.d597.s28'}	subjects meloxicam alter warfarin pharmacokinetics average anticoagulant effect warfarin determined prothrombin time
In these subjects, meloxicam did not alter warfarin pharmacokinetics and the average anticoagulant effect of warfarin as determined by prothrombin time. 	meloxicam	warfarin	none	{'e1': {'word': 'meloxicam', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d597.s28.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d597.s28.e2'}, 'sentence_id': 'DDI-DrugBank.d597.s28'}	subjects meloxicam alter warfarin pharmacokinetics average anticoagulant effect warfarin determined prothrombin time
In these subjects, meloxicam did not alter warfarin pharmacokinetics and the average anticoagulant effect of warfarin as determined by prothrombin time. 	warfarin	warfarin	none	{'e1': {'word': 'warfarin', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d597.s28.e1'}, 'e2': {'word': 'warfarin', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d597.s28.e2'}, 'sentence_id': 'DDI-DrugBank.d597.s28'}	subjects meloxicam alter warfarin pharmacokinetics average anticoagulant effect warfarin determined prothrombin time
Caution should be used when administering MOBIC with warfarin since patients on warfarin may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced.	MOBIC	warfarin	advise	{'e1': {'word': 'MOBIC', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d597.s30.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d597.s30.e1'}, 'sentence_id': 'DDI-DrugBank.d597.s30'}	Caution used administering MOBIC warfarin since patients warfarin may experience changes INR increased risk bleeding complications new medication introduced
Caution should be used when administering MOBIC with warfarin since patients on warfarin may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced.	MOBIC	warfarin	none	{'e1': {'word': 'MOBIC', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d597.s30.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d597.s30.e2'}, 'sentence_id': 'DDI-DrugBank.d597.s30'}	Caution used administering MOBIC warfarin since patients warfarin may experience changes INR increased risk bleeding complications new medication introduced
Caution should be used when administering MOBIC with warfarin since patients on warfarin may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced.	warfarin	warfarin	none	{'e1': {'word': 'warfarin', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d597.s30.e1'}, 'e2': {'word': 'warfarin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d597.s30.e2'}, 'sentence_id': 'DDI-DrugBank.d597.s30'}	Caution used administering MOBIC warfarin since patients warfarin may experience changes INR increased risk bleeding complications new medication introduced
Concurrent administration of bacteriostatic antibiotics (e.g., erythromycin, tetracycline) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth. 	bacteriostatic antibiotics	erythromycin	none	{'e1': {'word': 'bacteriostatic antibiotics', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d665.s0.e0'}, 'e2': {'word': 'erythromycin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d665.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d665.s0'}	Concurrent administration bacteriostatic antibiotics e.g. erythromycin tetracycline may diminish bactericidal effects penicillins slowing rate bacterial growth
Concurrent administration of bacteriostatic antibiotics (e.g., erythromycin, tetracycline) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth. 	bacteriostatic antibiotics	tetracycline	none	{'e1': {'word': 'bacteriostatic antibiotics', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d665.s0.e0'}, 'e2': {'word': 'tetracycline', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d665.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d665.s0'}	Concurrent administration bacteriostatic antibiotics e.g. erythromycin tetracycline may diminish bactericidal effects penicillins slowing rate bacterial growth
Concurrent administration of bacteriostatic antibiotics (e.g., erythromycin, tetracycline) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth. 	bacteriostatic antibiotics	penicillins	effect	{'e1': {'word': 'bacteriostatic antibiotics', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d665.s0.e0'}, 'e2': {'word': 'penicillins', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d665.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d665.s0'}	Concurrent administration bacteriostatic antibiotics e.g. erythromycin tetracycline may diminish bactericidal effects penicillins slowing rate bacterial growth
Concurrent administration of bacteriostatic antibiotics (e.g., erythromycin, tetracycline) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth. 	erythromycin	tetracycline	none	{'e1': {'word': 'erythromycin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d665.s0.e1'}, 'e2': {'word': 'tetracycline', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d665.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d665.s0'}	Concurrent administration bacteriostatic antibiotics e.g. erythromycin tetracycline may diminish bactericidal effects penicillins slowing rate bacterial growth
Concurrent administration of bacteriostatic antibiotics (e.g., erythromycin, tetracycline) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth. 	erythromycin	penicillins	effect	{'e1': {'word': 'erythromycin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d665.s0.e1'}, 'e2': {'word': 'penicillins', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d665.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d665.s0'}	Concurrent administration bacteriostatic antibiotics e.g. erythromycin tetracycline may diminish bactericidal effects penicillins slowing rate bacterial growth
Concurrent administration of bacteriostatic antibiotics (e.g., erythromycin, tetracycline) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth. 	tetracycline	penicillins	effect	{'e1': {'word': 'tetracycline', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d665.s0.e2'}, 'e2': {'word': 'penicillins', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d665.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d665.s0'}	Concurrent administration bacteriostatic antibiotics e.g. erythromycin tetracycline may diminish bactericidal effects penicillins slowing rate bacterial growth
Penicillin blood levels may be prolonged by concurrent administration of probenecid which blocks the renal tubular secretion of penicillins. 	Penicillin	probenecid	mechanism	{'e1': {'word': 'Penicillin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d665.s6.e0'}, 'e2': {'word': 'probenecid', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d665.s6.e1'}, 'sentence_id': 'DDI-DrugBank.d665.s6'}	Penicillin blood levels may prolonged concurrent administration probenecid blocks renal tubular secretion penicillins
Penicillin blood levels may be prolonged by concurrent administration of probenecid which blocks the renal tubular secretion of penicillins. 	Penicillin	penicillins	none	{'e1': {'word': 'Penicillin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d665.s6.e0'}, 'e2': {'word': 'penicillins', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d665.s6.e2'}, 'sentence_id': 'DDI-DrugBank.d665.s6'}	Penicillin blood levels may prolonged concurrent administration probenecid blocks renal tubular secretion penicillins
Penicillin blood levels may be prolonged by concurrent administration of probenecid which blocks the renal tubular secretion of penicillins. 	probenecid	penicillins	none	{'e1': {'word': 'probenecid', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d665.s6.e1'}, 'e2': {'word': 'penicillins', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d665.s6.e2'}, 'sentence_id': 'DDI-DrugBank.d665.s6'}	Penicillin blood levels may prolonged concurrent administration probenecid blocks renal tubular secretion penicillins
Displacement of penicillin from plasma protein binding sites will elevate the level of free penicillin in the serum.	penicillin	penicillin	none	{'e1': {'word': 'penicillin', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d665.s7.e0'}, 'e2': {'word': 'penicillin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d665.s7.e1'}, 'sentence_id': 'DDI-DrugBank.d665.s7'}	Displacement penicillin plasma protein binding sites elevate level free penicillin serum
Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. 	ergotamine	ergot-type medications	none	{'e1': {'word': 'ergotamine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d720.s1.e0'}, 'e2': {'word': 'ergot-type medications', 'word_index': [(8, 10)], 'id': 'DDI-DrugBank.d720.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d720.s1'}	theoretical basis effects may additive use ergotamine containing ergot type medications like dihydroergotamine methysergide sumatriptan within NUMBER hours avoided
Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. 	ergotamine	dihydroergotamine	none	{'e1': {'word': 'ergotamine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d720.s1.e0'}, 'e2': {'word': 'dihydroergotamine', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d720.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d720.s1'}	theoretical basis effects may additive use ergotamine containing ergot type medications like dihydroergotamine methysergide sumatriptan within NUMBER hours avoided
Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. 	ergotamine	methysergide	none	{'e1': {'word': 'ergotamine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d720.s1.e0'}, 'e2': {'word': 'methysergide', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d720.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d720.s1'}	theoretical basis effects may additive use ergotamine containing ergot type medications like dihydroergotamine methysergide sumatriptan within NUMBER hours avoided
Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. 	ergotamine	sumatriptan	advise	{'e1': {'word': 'ergotamine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d720.s1.e0'}, 'e2': {'word': 'sumatriptan', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d720.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d720.s1'}	theoretical basis effects may additive use ergotamine containing ergot type medications like dihydroergotamine methysergide sumatriptan within NUMBER hours avoided
Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. 	ergot-type medications	dihydroergotamine	none	{'e1': {'word': 'ergot-type medications', 'word_index': [(8, 10)], 'id': 'DDI-DrugBank.d720.s1.e1'}, 'e2': {'word': 'dihydroergotamine', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d720.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d720.s1'}	theoretical basis effects may additive use ergotamine containing ergot type medications like dihydroergotamine methysergide sumatriptan within NUMBER hours avoided
Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. 	ergot-type medications	methysergide	none	{'e1': {'word': 'ergot-type medications', 'word_index': [(8, 10)], 'id': 'DDI-DrugBank.d720.s1.e1'}, 'e2': {'word': 'methysergide', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d720.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d720.s1'}	theoretical basis effects may additive use ergotamine containing ergot type medications like dihydroergotamine methysergide sumatriptan within NUMBER hours avoided
Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. 	ergot-type medications	sumatriptan	advise	{'e1': {'word': 'ergot-type medications', 'word_index': [(8, 10)], 'id': 'DDI-DrugBank.d720.s1.e1'}, 'e2': {'word': 'sumatriptan', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d720.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d720.s1'}	theoretical basis effects may additive use ergotamine containing ergot type medications like dihydroergotamine methysergide sumatriptan within NUMBER hours avoided
Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. 	dihydroergotamine	methysergide	none	{'e1': {'word': 'dihydroergotamine', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d720.s1.e2'}, 'e2': {'word': 'methysergide', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d720.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d720.s1'}	theoretical basis effects may additive use ergotamine containing ergot type medications like dihydroergotamine methysergide sumatriptan within NUMBER hours avoided
Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. 	dihydroergotamine	sumatriptan	advise	{'e1': {'word': 'dihydroergotamine', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d720.s1.e2'}, 'e2': {'word': 'sumatriptan', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d720.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d720.s1'}	theoretical basis effects may additive use ergotamine containing ergot type medications like dihydroergotamine methysergide sumatriptan within NUMBER hours avoided
Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. 	methysergide	sumatriptan	advise	{'e1': {'word': 'methysergide', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d720.s1.e3'}, 'e2': {'word': 'sumatriptan', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d720.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d720.s1'}	theoretical basis effects may additive use ergotamine containing ergot type medications like dihydroergotamine methysergide sumatriptan within NUMBER hours avoided
MAO-A inhibitors reduce sumatriptan clearance, significantly increasing systemic exposure. 	MAO-A inhibitors	sumatriptan	mechanism	{'e1': {'word': 'MAO-A inhibitors', 'word_index': [(0, 1)], 'id': 'DDI-DrugBank.d720.s2.e0'}, 'e2': {'word': 'sumatriptan', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d720.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d720.s2'}	MAO inhibitors reduce sumatriptan clearance significantly increasing systemic exposure
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. 	sumatriptan succinate	MAO-A inhibitors	advise	{'e1': {'word': 'sumatriptan succinate', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d720.s3.e0'}, 'e2': {'word': 'MAO-A inhibitors', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d720.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d720.s3'}	Therefore use sumatriptan succinate tablets patients receiving MAO inhibitors contraindicated Selective serotonin reuptake inhibitors SSRIs e.g. fluoxetine fluvoxamine paroxetine sertraline reported rarely cause weakness hyperreflexia incoordination coadministered sumatriptan
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. 	sumatriptan succinate	Selective serotonin reuptake inhibitors	none	{'e1': {'word': 'sumatriptan succinate', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d720.s3.e0'}, 'e2': {'word': 'Selective serotonin reuptake inhibitors', 'word_index': [(10, 13)], 'id': 'DDI-DrugBank.d720.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d720.s3'}	Therefore use sumatriptan succinate tablets patients receiving MAO inhibitors contraindicated Selective serotonin reuptake inhibitors SSRIs e.g. fluoxetine fluvoxamine paroxetine sertraline reported rarely cause weakness hyperreflexia incoordination coadministered sumatriptan
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. 	sumatriptan succinate	SSRIs	none	{'e1': {'word': 'sumatriptan succinate', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d720.s3.e0'}, 'e2': {'word': 'SSRIs', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d720.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d720.s3'}	Therefore use sumatriptan succinate tablets patients receiving MAO inhibitors contraindicated Selective serotonin reuptake inhibitors SSRIs e.g. fluoxetine fluvoxamine paroxetine sertraline reported rarely cause weakness hyperreflexia incoordination coadministered sumatriptan
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. 	sumatriptan succinate	fluoxetine	none	{'e1': {'word': 'sumatriptan succinate', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d720.s3.e0'}, 'e2': {'word': 'fluoxetine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d720.s3.e4'}, 'sentence_id': 'DDI-DrugBank.d720.s3'}	Therefore use sumatriptan succinate tablets patients receiving MAO inhibitors contraindicated Selective serotonin reuptake inhibitors SSRIs e.g. fluoxetine fluvoxamine paroxetine sertraline reported rarely cause weakness hyperreflexia incoordination coadministered sumatriptan
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. 	sumatriptan succinate	fluvoxamine	none	{'e1': {'word': 'sumatriptan succinate', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d720.s3.e0'}, 'e2': {'word': 'fluvoxamine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d720.s3.e5'}, 'sentence_id': 'DDI-DrugBank.d720.s3'}	Therefore use sumatriptan succinate tablets patients receiving MAO inhibitors contraindicated Selective serotonin reuptake inhibitors SSRIs e.g. fluoxetine fluvoxamine paroxetine sertraline reported rarely cause weakness hyperreflexia incoordination coadministered sumatriptan
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. 	sumatriptan succinate	paroxetine	none	{'e1': {'word': 'sumatriptan succinate', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d720.s3.e0'}, 'e2': {'word': 'paroxetine', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d720.s3.e6'}, 'sentence_id': 'DDI-DrugBank.d720.s3'}	Therefore use sumatriptan succinate tablets patients receiving MAO inhibitors contraindicated Selective serotonin reuptake inhibitors SSRIs e.g. fluoxetine fluvoxamine paroxetine sertraline reported rarely cause weakness hyperreflexia incoordination coadministered sumatriptan
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. 	sumatriptan succinate	sertraline	none	{'e1': {'word': 'sumatriptan succinate', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d720.s3.e0'}, 'e2': {'word': 'sertraline', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d720.s3.e7'}, 'sentence_id': 'DDI-DrugBank.d720.s3'}	Therefore use sumatriptan succinate tablets patients receiving MAO inhibitors contraindicated Selective serotonin reuptake inhibitors SSRIs e.g. fluoxetine fluvoxamine paroxetine sertraline reported rarely cause weakness hyperreflexia incoordination coadministered sumatriptan
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. 	sumatriptan succinate	sumatriptan	none	{'e1': {'word': 'sumatriptan succinate', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d720.s3.e0'}, 'e2': {'word': 'sumatriptan', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d720.s3.e8'}, 'sentence_id': 'DDI-DrugBank.d720.s3'}	Therefore use sumatriptan succinate tablets patients receiving MAO inhibitors contraindicated Selective serotonin reuptake inhibitors SSRIs e.g. fluoxetine fluvoxamine paroxetine sertraline reported rarely cause weakness hyperreflexia incoordination coadministered sumatriptan
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. 	MAO-A inhibitors	Selective serotonin reuptake inhibitors	none	{'e1': {'word': 'MAO-A inhibitors', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d720.s3.e1'}, 'e2': {'word': 'Selective serotonin reuptake inhibitors', 'word_index': [(10, 13)], 'id': 'DDI-DrugBank.d720.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d720.s3'}	Therefore use sumatriptan succinate tablets patients receiving MAO inhibitors contraindicated Selective serotonin reuptake inhibitors SSRIs e.g. fluoxetine fluvoxamine paroxetine sertraline reported rarely cause weakness hyperreflexia incoordination coadministered sumatriptan
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. 	MAO-A inhibitors	SSRIs	none	{'e1': {'word': 'MAO-A inhibitors', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d720.s3.e1'}, 'e2': {'word': 'SSRIs', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d720.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d720.s3'}	Therefore use sumatriptan succinate tablets patients receiving MAO inhibitors contraindicated Selective serotonin reuptake inhibitors SSRIs e.g. fluoxetine fluvoxamine paroxetine sertraline reported rarely cause weakness hyperreflexia incoordination coadministered sumatriptan
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. 	MAO-A inhibitors	fluoxetine	none	{'e1': {'word': 'MAO-A inhibitors', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d720.s3.e1'}, 'e2': {'word': 'fluoxetine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d720.s3.e4'}, 'sentence_id': 'DDI-DrugBank.d720.s3'}	Therefore use sumatriptan succinate tablets patients receiving MAO inhibitors contraindicated Selective serotonin reuptake inhibitors SSRIs e.g. fluoxetine fluvoxamine paroxetine sertraline reported rarely cause weakness hyperreflexia incoordination coadministered sumatriptan
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. 	MAO-A inhibitors	fluvoxamine	none	{'e1': {'word': 'MAO-A inhibitors', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d720.s3.e1'}, 'e2': {'word': 'fluvoxamine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d720.s3.e5'}, 'sentence_id': 'DDI-DrugBank.d720.s3'}	Therefore use sumatriptan succinate tablets patients receiving MAO inhibitors contraindicated Selective serotonin reuptake inhibitors SSRIs e.g. fluoxetine fluvoxamine paroxetine sertraline reported rarely cause weakness hyperreflexia incoordination coadministered sumatriptan
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. 	MAO-A inhibitors	paroxetine	none	{'e1': {'word': 'MAO-A inhibitors', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d720.s3.e1'}, 'e2': {'word': 'paroxetine', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d720.s3.e6'}, 'sentence_id': 'DDI-DrugBank.d720.s3'}	Therefore use sumatriptan succinate tablets patients receiving MAO inhibitors contraindicated Selective serotonin reuptake inhibitors SSRIs e.g. fluoxetine fluvoxamine paroxetine sertraline reported rarely cause weakness hyperreflexia incoordination coadministered sumatriptan
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. 	MAO-A inhibitors	sertraline	none	{'e1': {'word': 'MAO-A inhibitors', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d720.s3.e1'}, 'e2': {'word': 'sertraline', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d720.s3.e7'}, 'sentence_id': 'DDI-DrugBank.d720.s3'}	Therefore use sumatriptan succinate tablets patients receiving MAO inhibitors contraindicated Selective serotonin reuptake inhibitors SSRIs e.g. fluoxetine fluvoxamine paroxetine sertraline reported rarely cause weakness hyperreflexia incoordination coadministered sumatriptan
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. 	MAO-A inhibitors	sumatriptan	none	{'e1': {'word': 'MAO-A inhibitors', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d720.s3.e1'}, 'e2': {'word': 'sumatriptan', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d720.s3.e8'}, 'sentence_id': 'DDI-DrugBank.d720.s3'}	Therefore use sumatriptan succinate tablets patients receiving MAO inhibitors contraindicated Selective serotonin reuptake inhibitors SSRIs e.g. fluoxetine fluvoxamine paroxetine sertraline reported rarely cause weakness hyperreflexia incoordination coadministered sumatriptan
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. 	Selective serotonin reuptake inhibitors	SSRIs	none	{'e1': {'word': 'Selective serotonin reuptake inhibitors', 'word_index': [(10, 13)], 'id': 'DDI-DrugBank.d720.s3.e2'}, 'e2': {'word': 'SSRIs', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d720.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d720.s3'}	Therefore use sumatriptan succinate tablets patients receiving MAO inhibitors contraindicated Selective serotonin reuptake inhibitors SSRIs e.g. fluoxetine fluvoxamine paroxetine sertraline reported rarely cause weakness hyperreflexia incoordination coadministered sumatriptan
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. 	Selective serotonin reuptake inhibitors	fluoxetine	none	{'e1': {'word': 'Selective serotonin reuptake inhibitors', 'word_index': [(10, 13)], 'id': 'DDI-DrugBank.d720.s3.e2'}, 'e2': {'word': 'fluoxetine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d720.s3.e4'}, 'sentence_id': 'DDI-DrugBank.d720.s3'}	Therefore use sumatriptan succinate tablets patients receiving MAO inhibitors contraindicated Selective serotonin reuptake inhibitors SSRIs e.g. fluoxetine fluvoxamine paroxetine sertraline reported rarely cause weakness hyperreflexia incoordination coadministered sumatriptan
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. 	Selective serotonin reuptake inhibitors	fluvoxamine	none	{'e1': {'word': 'Selective serotonin reuptake inhibitors', 'word_index': [(10, 13)], 'id': 'DDI-DrugBank.d720.s3.e2'}, 'e2': {'word': 'fluvoxamine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d720.s3.e5'}, 'sentence_id': 'DDI-DrugBank.d720.s3'}	Therefore use sumatriptan succinate tablets patients receiving MAO inhibitors contraindicated Selective serotonin reuptake inhibitors SSRIs e.g. fluoxetine fluvoxamine paroxetine sertraline reported rarely cause weakness hyperreflexia incoordination coadministered sumatriptan
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. 	Selective serotonin reuptake inhibitors	paroxetine	none	{'e1': {'word': 'Selective serotonin reuptake inhibitors', 'word_index': [(10, 13)], 'id': 'DDI-DrugBank.d720.s3.e2'}, 'e2': {'word': 'paroxetine', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d720.s3.e6'}, 'sentence_id': 'DDI-DrugBank.d720.s3'}	Therefore use sumatriptan succinate tablets patients receiving MAO inhibitors contraindicated Selective serotonin reuptake inhibitors SSRIs e.g. fluoxetine fluvoxamine paroxetine sertraline reported rarely cause weakness hyperreflexia incoordination coadministered sumatriptan
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. 	Selective serotonin reuptake inhibitors	sertraline	none	{'e1': {'word': 'Selective serotonin reuptake inhibitors', 'word_index': [(10, 13)], 'id': 'DDI-DrugBank.d720.s3.e2'}, 'e2': {'word': 'sertraline', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d720.s3.e7'}, 'sentence_id': 'DDI-DrugBank.d720.s3'}	Therefore use sumatriptan succinate tablets patients receiving MAO inhibitors contraindicated Selective serotonin reuptake inhibitors SSRIs e.g. fluoxetine fluvoxamine paroxetine sertraline reported rarely cause weakness hyperreflexia incoordination coadministered sumatriptan
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. 	Selective serotonin reuptake inhibitors	sumatriptan	effect	{'e1': {'word': 'Selective serotonin reuptake inhibitors', 'word_index': [(10, 13)], 'id': 'DDI-DrugBank.d720.s3.e2'}, 'e2': {'word': 'sumatriptan', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d720.s3.e8'}, 'sentence_id': 'DDI-DrugBank.d720.s3'}	Therefore use sumatriptan succinate tablets patients receiving MAO inhibitors contraindicated Selective serotonin reuptake inhibitors SSRIs e.g. fluoxetine fluvoxamine paroxetine sertraline reported rarely cause weakness hyperreflexia incoordination coadministered sumatriptan
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. 	SSRIs	fluoxetine	none	{'e1': {'word': 'SSRIs', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d720.s3.e3'}, 'e2': {'word': 'fluoxetine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d720.s3.e4'}, 'sentence_id': 'DDI-DrugBank.d720.s3'}	Therefore use sumatriptan succinate tablets patients receiving MAO inhibitors contraindicated Selective serotonin reuptake inhibitors SSRIs e.g. fluoxetine fluvoxamine paroxetine sertraline reported rarely cause weakness hyperreflexia incoordination coadministered sumatriptan
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. 	SSRIs	fluvoxamine	none	{'e1': {'word': 'SSRIs', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d720.s3.e3'}, 'e2': {'word': 'fluvoxamine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d720.s3.e5'}, 'sentence_id': 'DDI-DrugBank.d720.s3'}	Therefore use sumatriptan succinate tablets patients receiving MAO inhibitors contraindicated Selective serotonin reuptake inhibitors SSRIs e.g. fluoxetine fluvoxamine paroxetine sertraline reported rarely cause weakness hyperreflexia incoordination coadministered sumatriptan
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. 	SSRIs	paroxetine	none	{'e1': {'word': 'SSRIs', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d720.s3.e3'}, 'e2': {'word': 'paroxetine', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d720.s3.e6'}, 'sentence_id': 'DDI-DrugBank.d720.s3'}	Therefore use sumatriptan succinate tablets patients receiving MAO inhibitors contraindicated Selective serotonin reuptake inhibitors SSRIs e.g. fluoxetine fluvoxamine paroxetine sertraline reported rarely cause weakness hyperreflexia incoordination coadministered sumatriptan
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. 	SSRIs	sertraline	none	{'e1': {'word': 'SSRIs', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d720.s3.e3'}, 'e2': {'word': 'sertraline', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d720.s3.e7'}, 'sentence_id': 'DDI-DrugBank.d720.s3'}	Therefore use sumatriptan succinate tablets patients receiving MAO inhibitors contraindicated Selective serotonin reuptake inhibitors SSRIs e.g. fluoxetine fluvoxamine paroxetine sertraline reported rarely cause weakness hyperreflexia incoordination coadministered sumatriptan
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. 	SSRIs	sumatriptan	effect	{'e1': {'word': 'SSRIs', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d720.s3.e3'}, 'e2': {'word': 'sumatriptan', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d720.s3.e8'}, 'sentence_id': 'DDI-DrugBank.d720.s3'}	Therefore use sumatriptan succinate tablets patients receiving MAO inhibitors contraindicated Selective serotonin reuptake inhibitors SSRIs e.g. fluoxetine fluvoxamine paroxetine sertraline reported rarely cause weakness hyperreflexia incoordination coadministered sumatriptan
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. 	fluoxetine	fluvoxamine	none	{'e1': {'word': 'fluoxetine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d720.s3.e4'}, 'e2': {'word': 'fluvoxamine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d720.s3.e5'}, 'sentence_id': 'DDI-DrugBank.d720.s3'}	Therefore use sumatriptan succinate tablets patients receiving MAO inhibitors contraindicated Selective serotonin reuptake inhibitors SSRIs e.g. fluoxetine fluvoxamine paroxetine sertraline reported rarely cause weakness hyperreflexia incoordination coadministered sumatriptan
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. 	fluoxetine	paroxetine	none	{'e1': {'word': 'fluoxetine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d720.s3.e4'}, 'e2': {'word': 'paroxetine', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d720.s3.e6'}, 'sentence_id': 'DDI-DrugBank.d720.s3'}	Therefore use sumatriptan succinate tablets patients receiving MAO inhibitors contraindicated Selective serotonin reuptake inhibitors SSRIs e.g. fluoxetine fluvoxamine paroxetine sertraline reported rarely cause weakness hyperreflexia incoordination coadministered sumatriptan
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. 	fluoxetine	sertraline	none	{'e1': {'word': 'fluoxetine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d720.s3.e4'}, 'e2': {'word': 'sertraline', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d720.s3.e7'}, 'sentence_id': 'DDI-DrugBank.d720.s3'}	Therefore use sumatriptan succinate tablets patients receiving MAO inhibitors contraindicated Selective serotonin reuptake inhibitors SSRIs e.g. fluoxetine fluvoxamine paroxetine sertraline reported rarely cause weakness hyperreflexia incoordination coadministered sumatriptan
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. 	fluoxetine	sumatriptan	effect	{'e1': {'word': 'fluoxetine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d720.s3.e4'}, 'e2': {'word': 'sumatriptan', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d720.s3.e8'}, 'sentence_id': 'DDI-DrugBank.d720.s3'}	Therefore use sumatriptan succinate tablets patients receiving MAO inhibitors contraindicated Selective serotonin reuptake inhibitors SSRIs e.g. fluoxetine fluvoxamine paroxetine sertraline reported rarely cause weakness hyperreflexia incoordination coadministered sumatriptan
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. 	fluvoxamine	paroxetine	none	{'e1': {'word': 'fluvoxamine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d720.s3.e5'}, 'e2': {'word': 'paroxetine', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d720.s3.e6'}, 'sentence_id': 'DDI-DrugBank.d720.s3'}	Therefore use sumatriptan succinate tablets patients receiving MAO inhibitors contraindicated Selective serotonin reuptake inhibitors SSRIs e.g. fluoxetine fluvoxamine paroxetine sertraline reported rarely cause weakness hyperreflexia incoordination coadministered sumatriptan
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. 	fluvoxamine	sertraline	none	{'e1': {'word': 'fluvoxamine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d720.s3.e5'}, 'e2': {'word': 'sertraline', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d720.s3.e7'}, 'sentence_id': 'DDI-DrugBank.d720.s3'}	Therefore use sumatriptan succinate tablets patients receiving MAO inhibitors contraindicated Selective serotonin reuptake inhibitors SSRIs e.g. fluoxetine fluvoxamine paroxetine sertraline reported rarely cause weakness hyperreflexia incoordination coadministered sumatriptan
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. 	fluvoxamine	sumatriptan	effect	{'e1': {'word': 'fluvoxamine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d720.s3.e5'}, 'e2': {'word': 'sumatriptan', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d720.s3.e8'}, 'sentence_id': 'DDI-DrugBank.d720.s3'}	Therefore use sumatriptan succinate tablets patients receiving MAO inhibitors contraindicated Selective serotonin reuptake inhibitors SSRIs e.g. fluoxetine fluvoxamine paroxetine sertraline reported rarely cause weakness hyperreflexia incoordination coadministered sumatriptan
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. 	paroxetine	sertraline	none	{'e1': {'word': 'paroxetine', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d720.s3.e6'}, 'e2': {'word': 'sertraline', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d720.s3.e7'}, 'sentence_id': 'DDI-DrugBank.d720.s3'}	Therefore use sumatriptan succinate tablets patients receiving MAO inhibitors contraindicated Selective serotonin reuptake inhibitors SSRIs e.g. fluoxetine fluvoxamine paroxetine sertraline reported rarely cause weakness hyperreflexia incoordination coadministered sumatriptan
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. 	paroxetine	sumatriptan	effect	{'e1': {'word': 'paroxetine', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d720.s3.e6'}, 'e2': {'word': 'sumatriptan', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d720.s3.e8'}, 'sentence_id': 'DDI-DrugBank.d720.s3'}	Therefore use sumatriptan succinate tablets patients receiving MAO inhibitors contraindicated Selective serotonin reuptake inhibitors SSRIs e.g. fluoxetine fluvoxamine paroxetine sertraline reported rarely cause weakness hyperreflexia incoordination coadministered sumatriptan
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. 	sertraline	sumatriptan	effect	{'e1': {'word': 'sertraline', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d720.s3.e7'}, 'e2': {'word': 'sumatriptan', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d720.s3.e8'}, 'sentence_id': 'DDI-DrugBank.d720.s3'}	Therefore use sumatriptan succinate tablets patients receiving MAO inhibitors contraindicated Selective serotonin reuptake inhibitors SSRIs e.g. fluoxetine fluvoxamine paroxetine sertraline reported rarely cause weakness hyperreflexia incoordination coadministered sumatriptan
If concomitant treatment with sumatriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised.	sumatriptan	SSRI	advise	{'e1': {'word': 'sumatriptan', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d720.s4.e0'}, 'e2': {'word': 'SSRI', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d720.s4.e1'}, 'sentence_id': 'DDI-DrugBank.d720.s4'}	concomitant treatment sumatriptan SSRI clinically warranted appropriate observation patient advised
Concomitant administration of substances that are also tubularly secreted (e.g., probenecid) could potentially result in delayed clearance of ALIMTA. 	probenecid	ALIMTA	mechanism	{'e1': {'word': 'probenecid', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d641.s2.e0'}, 'e2': {'word': 'ALIMTA', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d641.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d641.s2'}	Concomitant administration substances also tubularly secreted e.g. probenecid could potentially result delayed clearance ALIMTA
Although ibuprofen (400 mg qid) can be administered with ALIMTA in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering ibuprofen concurrently with ALIMTA to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min). 	ibuprofen	ALIMTA	none	{'e1': {'word': 'ibuprofen', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d641.s3.e0'}, 'e2': {'word': 'ALIMTA', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d641.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d641.s3'}	Although ibuprofen NUMBER mg qid administered ALIMTA patients normal renal function creatinine clearance NUMBER mL / min caution used administering ibuprofen concurrently ALIMTA patients mild moderate renal insufficiency creatinine clearance NUMBER NUMBER mL / min
Although ibuprofen (400 mg qid) can be administered with ALIMTA in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering ibuprofen concurrently with ALIMTA to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min). 	ibuprofen	ibuprofen	none	{'e1': {'word': 'ibuprofen', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d641.s3.e0'}, 'e2': {'word': 'ibuprofen', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d641.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d641.s3'}	Although ibuprofen NUMBER mg qid administered ALIMTA patients normal renal function creatinine clearance NUMBER mL / min caution used administering ibuprofen concurrently ALIMTA patients mild moderate renal insufficiency creatinine clearance NUMBER NUMBER mL / min
Although ibuprofen (400 mg qid) can be administered with ALIMTA in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering ibuprofen concurrently with ALIMTA to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min). 	ibuprofen	ALIMTA	none	{'e1': {'word': 'ibuprofen', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d641.s3.e0'}, 'e2': {'word': 'ALIMTA', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d641.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d641.s3'}	Although ibuprofen NUMBER mg qid administered ALIMTA patients normal renal function creatinine clearance NUMBER mL / min caution used administering ibuprofen concurrently ALIMTA patients mild moderate renal insufficiency creatinine clearance NUMBER NUMBER mL / min
Although ibuprofen (400 mg qid) can be administered with ALIMTA in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering ibuprofen concurrently with ALIMTA to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min). 	ALIMTA	ibuprofen	none	{'e1': {'word': 'ALIMTA', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d641.s3.e1'}, 'e2': {'word': 'ibuprofen', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d641.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d641.s3'}	Although ibuprofen NUMBER mg qid administered ALIMTA patients normal renal function creatinine clearance NUMBER mL / min caution used administering ibuprofen concurrently ALIMTA patients mild moderate renal insufficiency creatinine clearance NUMBER NUMBER mL / min
Although ibuprofen (400 mg qid) can be administered with ALIMTA in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering ibuprofen concurrently with ALIMTA to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min). 	ALIMTA	ALIMTA	none	{'e1': {'word': 'ALIMTA', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d641.s3.e1'}, 'e2': {'word': 'ALIMTA', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d641.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d641.s3'}	Although ibuprofen NUMBER mg qid administered ALIMTA patients normal renal function creatinine clearance NUMBER mL / min caution used administering ibuprofen concurrently ALIMTA patients mild moderate renal insufficiency creatinine clearance NUMBER NUMBER mL / min
Although ibuprofen (400 mg qid) can be administered with ALIMTA in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering ibuprofen concurrently with ALIMTA to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min). 	ibuprofen	ALIMTA	advise	{'e1': {'word': 'ibuprofen', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d641.s3.e2'}, 'e2': {'word': 'ALIMTA', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d641.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d641.s3'}	Although ibuprofen NUMBER mg qid administered ALIMTA patients normal renal function creatinine clearance NUMBER mL / min caution used administering ibuprofen concurrently ALIMTA patients mild moderate renal insufficiency creatinine clearance NUMBER NUMBER mL / min
Patients with mild to moderate renal insufficiency should avoid taking NSAIDs with short elimination half-lives for a period of 2 days before, the day of, and 2 days following administration of ALIMTA. 	NSAIDs	ALIMTA	advise	{'e1': {'word': 'NSAIDs', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d641.s4.e0'}, 'e2': {'word': 'ALIMTA', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d641.s4.e1'}, 'sentence_id': 'DDI-DrugBank.d641.s4'}	Patients mild moderate renal insufficiency avoid taking NSAIDs short elimination half lives period NUMBER days day NUMBER days following administration ALIMTA
In the absence of data regarding potential interaction between ALIMTA and NSAIDs with longer half-lives, all patients taking these NSAIDs should interrupt dosing for at least 5 days before, the day of, and 2 days following ALIMTA administration. 	ALIMTA	NSAIDs	none	{'e1': {'word': 'ALIMTA', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d641.s5.e0'}, 'e2': {'word': 'NSAIDs', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d641.s5.e1'}, 'sentence_id': 'DDI-DrugBank.d641.s5'}	absence data regarding potential interaction ALIMTA NSAIDs longer half lives patients taking NSAIDs interrupt dosing least NUMBER days day NUMBER days following ALIMTA administration
In the absence of data regarding potential interaction between ALIMTA and NSAIDs with longer half-lives, all patients taking these NSAIDs should interrupt dosing for at least 5 days before, the day of, and 2 days following ALIMTA administration. 	ALIMTA	NSAIDs	none	{'e1': {'word': 'ALIMTA', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d641.s5.e0'}, 'e2': {'word': 'NSAIDs', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d641.s5.e2'}, 'sentence_id': 'DDI-DrugBank.d641.s5'}	absence data regarding potential interaction ALIMTA NSAIDs longer half lives patients taking NSAIDs interrupt dosing least NUMBER days day NUMBER days following ALIMTA administration
In the absence of data regarding potential interaction between ALIMTA and NSAIDs with longer half-lives, all patients taking these NSAIDs should interrupt dosing for at least 5 days before, the day of, and 2 days following ALIMTA administration. 	ALIMTA	ALIMTA	none	{'e1': {'word': 'ALIMTA', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d641.s5.e0'}, 'e2': {'word': 'ALIMTA', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d641.s5.e3'}, 'sentence_id': 'DDI-DrugBank.d641.s5'}	absence data regarding potential interaction ALIMTA NSAIDs longer half lives patients taking NSAIDs interrupt dosing least NUMBER days day NUMBER days following ALIMTA administration
In the absence of data regarding potential interaction between ALIMTA and NSAIDs with longer half-lives, all patients taking these NSAIDs should interrupt dosing for at least 5 days before, the day of, and 2 days following ALIMTA administration. 	NSAIDs	NSAIDs	none	{'e1': {'word': 'NSAIDs', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d641.s5.e1'}, 'e2': {'word': 'NSAIDs', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d641.s5.e2'}, 'sentence_id': 'DDI-DrugBank.d641.s5'}	absence data regarding potential interaction ALIMTA NSAIDs longer half lives patients taking NSAIDs interrupt dosing least NUMBER days day NUMBER days following ALIMTA administration
In the absence of data regarding potential interaction between ALIMTA and NSAIDs with longer half-lives, all patients taking these NSAIDs should interrupt dosing for at least 5 days before, the day of, and 2 days following ALIMTA administration. 	NSAIDs	ALIMTA	none	{'e1': {'word': 'NSAIDs', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d641.s5.e1'}, 'e2': {'word': 'ALIMTA', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d641.s5.e3'}, 'sentence_id': 'DDI-DrugBank.d641.s5'}	absence data regarding potential interaction ALIMTA NSAIDs longer half lives patients taking NSAIDs interrupt dosing least NUMBER days day NUMBER days following ALIMTA administration
In the absence of data regarding potential interaction between ALIMTA and NSAIDs with longer half-lives, all patients taking these NSAIDs should interrupt dosing for at least 5 days before, the day of, and 2 days following ALIMTA administration. 	NSAIDs	ALIMTA	advise	{'e1': {'word': 'NSAIDs', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d641.s5.e2'}, 'e2': {'word': 'ALIMTA', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d641.s5.e3'}, 'sentence_id': 'DDI-DrugBank.d641.s5'}	absence data regarding potential interaction ALIMTA NSAIDs longer half lives patients taking NSAIDs interrupt dosing least NUMBER days day NUMBER days following ALIMTA administration
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 	CNS depressants	sedatives	none	{'e1': {'word': 'CNS depressants', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d753.s0.e0'}, 'e2': {'word': 'sedatives', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d753.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d753.s0'}	concomitant use CNS depressants including sedatives hypnotics tranquilizers general anesthetics phenothiazines opioids tricyclic antidepressants monoamine oxidase MAO inhibitors alcohol may produce additive CNS depressant effects
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 	CNS depressants	hypnotics	none	{'e1': {'word': 'CNS depressants', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d753.s0.e0'}, 'e2': {'word': 'hypnotics', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d753.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d753.s0'}	concomitant use CNS depressants including sedatives hypnotics tranquilizers general anesthetics phenothiazines opioids tricyclic antidepressants monoamine oxidase MAO inhibitors alcohol may produce additive CNS depressant effects
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 	CNS depressants	tranquilizers	none	{'e1': {'word': 'CNS depressants', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d753.s0.e0'}, 'e2': {'word': 'tranquilizers', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d753.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d753.s0'}	concomitant use CNS depressants including sedatives hypnotics tranquilizers general anesthetics phenothiazines opioids tricyclic antidepressants monoamine oxidase MAO inhibitors alcohol may produce additive CNS depressant effects
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 	CNS depressants	anesthetics	none	{'e1': {'word': 'CNS depressants', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d753.s0.e0'}, 'e2': {'word': 'anesthetics', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d753.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d753.s0'}	concomitant use CNS depressants including sedatives hypnotics tranquilizers general anesthetics phenothiazines opioids tricyclic antidepressants monoamine oxidase MAO inhibitors alcohol may produce additive CNS depressant effects
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 	CNS depressants	phenothiazines	none	{'e1': {'word': 'CNS depressants', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d753.s0.e0'}, 'e2': {'word': 'phenothiazines', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d753.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d753.s0'}	concomitant use CNS depressants including sedatives hypnotics tranquilizers general anesthetics phenothiazines opioids tricyclic antidepressants monoamine oxidase MAO inhibitors alcohol may produce additive CNS depressant effects
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 	CNS depressants	opioids	none	{'e1': {'word': 'CNS depressants', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d753.s0.e0'}, 'e2': {'word': 'opioids', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d753.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d753.s0'}	concomitant use CNS depressants including sedatives hypnotics tranquilizers general anesthetics phenothiazines opioids tricyclic antidepressants monoamine oxidase MAO inhibitors alcohol may produce additive CNS depressant effects
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 	CNS depressants	tricyclic antidepressants	none	{'e1': {'word': 'CNS depressants', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d753.s0.e0'}, 'e2': {'word': 'tricyclic antidepressants', 'word_index': [(12, 13)], 'id': 'DDI-DrugBank.d753.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d753.s0'}	concomitant use CNS depressants including sedatives hypnotics tranquilizers general anesthetics phenothiazines opioids tricyclic antidepressants monoamine oxidase MAO inhibitors alcohol may produce additive CNS depressant effects
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 	CNS depressants	monoamine oxidase (MAO) inhibitors	none	{'e1': {'word': 'CNS depressants', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d753.s0.e0'}, 'e2': {'word': 'monoamine oxidase (MAO) inhibitors', 'word_index': [(14, 17)], 'id': 'DDI-DrugBank.d753.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d753.s0'}	concomitant use CNS depressants including sedatives hypnotics tranquilizers general anesthetics phenothiazines opioids tricyclic antidepressants monoamine oxidase MAO inhibitors alcohol may produce additive CNS depressant effects
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 	CNS depressants	alcohol	none	{'e1': {'word': 'CNS depressants', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d753.s0.e0'}, 'e2': {'word': 'alcohol', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d753.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d753.s0'}	concomitant use CNS depressants including sedatives hypnotics tranquilizers general anesthetics phenothiazines opioids tricyclic antidepressants monoamine oxidase MAO inhibitors alcohol may produce additive CNS depressant effects
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 	sedatives	hypnotics	none	{'e1': {'word': 'sedatives', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d753.s0.e1'}, 'e2': {'word': 'hypnotics', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d753.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d753.s0'}	concomitant use CNS depressants including sedatives hypnotics tranquilizers general anesthetics phenothiazines opioids tricyclic antidepressants monoamine oxidase MAO inhibitors alcohol may produce additive CNS depressant effects
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 	sedatives	tranquilizers	none	{'e1': {'word': 'sedatives', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d753.s0.e1'}, 'e2': {'word': 'tranquilizers', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d753.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d753.s0'}	concomitant use CNS depressants including sedatives hypnotics tranquilizers general anesthetics phenothiazines opioids tricyclic antidepressants monoamine oxidase MAO inhibitors alcohol may produce additive CNS depressant effects
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 	sedatives	anesthetics	none	{'e1': {'word': 'sedatives', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d753.s0.e1'}, 'e2': {'word': 'anesthetics', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d753.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d753.s0'}	concomitant use CNS depressants including sedatives hypnotics tranquilizers general anesthetics phenothiazines opioids tricyclic antidepressants monoamine oxidase MAO inhibitors alcohol may produce additive CNS depressant effects
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 	sedatives	phenothiazines	none	{'e1': {'word': 'sedatives', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d753.s0.e1'}, 'e2': {'word': 'phenothiazines', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d753.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d753.s0'}	concomitant use CNS depressants including sedatives hypnotics tranquilizers general anesthetics phenothiazines opioids tricyclic antidepressants monoamine oxidase MAO inhibitors alcohol may produce additive CNS depressant effects
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 	sedatives	opioids	none	{'e1': {'word': 'sedatives', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d753.s0.e1'}, 'e2': {'word': 'opioids', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d753.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d753.s0'}	concomitant use CNS depressants including sedatives hypnotics tranquilizers general anesthetics phenothiazines opioids tricyclic antidepressants monoamine oxidase MAO inhibitors alcohol may produce additive CNS depressant effects
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 	sedatives	tricyclic antidepressants	none	{'e1': {'word': 'sedatives', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d753.s0.e1'}, 'e2': {'word': 'tricyclic antidepressants', 'word_index': [(12, 13)], 'id': 'DDI-DrugBank.d753.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d753.s0'}	concomitant use CNS depressants including sedatives hypnotics tranquilizers general anesthetics phenothiazines opioids tricyclic antidepressants monoamine oxidase MAO inhibitors alcohol may produce additive CNS depressant effects
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 	sedatives	monoamine oxidase (MAO) inhibitors	none	{'e1': {'word': 'sedatives', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d753.s0.e1'}, 'e2': {'word': 'monoamine oxidase (MAO) inhibitors', 'word_index': [(14, 17)], 'id': 'DDI-DrugBank.d753.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d753.s0'}	concomitant use CNS depressants including sedatives hypnotics tranquilizers general anesthetics phenothiazines opioids tricyclic antidepressants monoamine oxidase MAO inhibitors alcohol may produce additive CNS depressant effects
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 	sedatives	alcohol	none	{'e1': {'word': 'sedatives', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d753.s0.e1'}, 'e2': {'word': 'alcohol', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d753.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d753.s0'}	concomitant use CNS depressants including sedatives hypnotics tranquilizers general anesthetics phenothiazines opioids tricyclic antidepressants monoamine oxidase MAO inhibitors alcohol may produce additive CNS depressant effects
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 	hypnotics	tranquilizers	none	{'e1': {'word': 'hypnotics', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d753.s0.e2'}, 'e2': {'word': 'tranquilizers', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d753.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d753.s0'}	concomitant use CNS depressants including sedatives hypnotics tranquilizers general anesthetics phenothiazines opioids tricyclic antidepressants monoamine oxidase MAO inhibitors alcohol may produce additive CNS depressant effects
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 	hypnotics	anesthetics	none	{'e1': {'word': 'hypnotics', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d753.s0.e2'}, 'e2': {'word': 'anesthetics', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d753.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d753.s0'}	concomitant use CNS depressants including sedatives hypnotics tranquilizers general anesthetics phenothiazines opioids tricyclic antidepressants monoamine oxidase MAO inhibitors alcohol may produce additive CNS depressant effects
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 	hypnotics	phenothiazines	none	{'e1': {'word': 'hypnotics', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d753.s0.e2'}, 'e2': {'word': 'phenothiazines', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d753.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d753.s0'}	concomitant use CNS depressants including sedatives hypnotics tranquilizers general anesthetics phenothiazines opioids tricyclic antidepressants monoamine oxidase MAO inhibitors alcohol may produce additive CNS depressant effects
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 	hypnotics	opioids	none	{'e1': {'word': 'hypnotics', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d753.s0.e2'}, 'e2': {'word': 'opioids', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d753.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d753.s0'}	concomitant use CNS depressants including sedatives hypnotics tranquilizers general anesthetics phenothiazines opioids tricyclic antidepressants monoamine oxidase MAO inhibitors alcohol may produce additive CNS depressant effects
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 	hypnotics	tricyclic antidepressants	none	{'e1': {'word': 'hypnotics', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d753.s0.e2'}, 'e2': {'word': 'tricyclic antidepressants', 'word_index': [(12, 13)], 'id': 'DDI-DrugBank.d753.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d753.s0'}	concomitant use CNS depressants including sedatives hypnotics tranquilizers general anesthetics phenothiazines opioids tricyclic antidepressants monoamine oxidase MAO inhibitors alcohol may produce additive CNS depressant effects
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 	hypnotics	monoamine oxidase (MAO) inhibitors	none	{'e1': {'word': 'hypnotics', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d753.s0.e2'}, 'e2': {'word': 'monoamine oxidase (MAO) inhibitors', 'word_index': [(14, 17)], 'id': 'DDI-DrugBank.d753.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d753.s0'}	concomitant use CNS depressants including sedatives hypnotics tranquilizers general anesthetics phenothiazines opioids tricyclic antidepressants monoamine oxidase MAO inhibitors alcohol may produce additive CNS depressant effects
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 	hypnotics	alcohol	none	{'e1': {'word': 'hypnotics', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d753.s0.e2'}, 'e2': {'word': 'alcohol', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d753.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d753.s0'}	concomitant use CNS depressants including sedatives hypnotics tranquilizers general anesthetics phenothiazines opioids tricyclic antidepressants monoamine oxidase MAO inhibitors alcohol may produce additive CNS depressant effects
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 	tranquilizers	anesthetics	none	{'e1': {'word': 'tranquilizers', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d753.s0.e3'}, 'e2': {'word': 'anesthetics', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d753.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d753.s0'}	concomitant use CNS depressants including sedatives hypnotics tranquilizers general anesthetics phenothiazines opioids tricyclic antidepressants monoamine oxidase MAO inhibitors alcohol may produce additive CNS depressant effects
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 	tranquilizers	phenothiazines	none	{'e1': {'word': 'tranquilizers', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d753.s0.e3'}, 'e2': {'word': 'phenothiazines', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d753.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d753.s0'}	concomitant use CNS depressants including sedatives hypnotics tranquilizers general anesthetics phenothiazines opioids tricyclic antidepressants monoamine oxidase MAO inhibitors alcohol may produce additive CNS depressant effects
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 	tranquilizers	opioids	none	{'e1': {'word': 'tranquilizers', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d753.s0.e3'}, 'e2': {'word': 'opioids', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d753.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d753.s0'}	concomitant use CNS depressants including sedatives hypnotics tranquilizers general anesthetics phenothiazines opioids tricyclic antidepressants monoamine oxidase MAO inhibitors alcohol may produce additive CNS depressant effects
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 	tranquilizers	tricyclic antidepressants	none	{'e1': {'word': 'tranquilizers', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d753.s0.e3'}, 'e2': {'word': 'tricyclic antidepressants', 'word_index': [(12, 13)], 'id': 'DDI-DrugBank.d753.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d753.s0'}	concomitant use CNS depressants including sedatives hypnotics tranquilizers general anesthetics phenothiazines opioids tricyclic antidepressants monoamine oxidase MAO inhibitors alcohol may produce additive CNS depressant effects
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 	tranquilizers	monoamine oxidase (MAO) inhibitors	none	{'e1': {'word': 'tranquilizers', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d753.s0.e3'}, 'e2': {'word': 'monoamine oxidase (MAO) inhibitors', 'word_index': [(14, 17)], 'id': 'DDI-DrugBank.d753.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d753.s0'}	concomitant use CNS depressants including sedatives hypnotics tranquilizers general anesthetics phenothiazines opioids tricyclic antidepressants monoamine oxidase MAO inhibitors alcohol may produce additive CNS depressant effects
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 	tranquilizers	alcohol	none	{'e1': {'word': 'tranquilizers', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d753.s0.e3'}, 'e2': {'word': 'alcohol', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d753.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d753.s0'}	concomitant use CNS depressants including sedatives hypnotics tranquilizers general anesthetics phenothiazines opioids tricyclic antidepressants monoamine oxidase MAO inhibitors alcohol may produce additive CNS depressant effects
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 	anesthetics	phenothiazines	none	{'e1': {'word': 'anesthetics', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d753.s0.e4'}, 'e2': {'word': 'phenothiazines', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d753.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d753.s0'}	concomitant use CNS depressants including sedatives hypnotics tranquilizers general anesthetics phenothiazines opioids tricyclic antidepressants monoamine oxidase MAO inhibitors alcohol may produce additive CNS depressant effects
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 	anesthetics	opioids	none	{'e1': {'word': 'anesthetics', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d753.s0.e4'}, 'e2': {'word': 'opioids', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d753.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d753.s0'}	concomitant use CNS depressants including sedatives hypnotics tranquilizers general anesthetics phenothiazines opioids tricyclic antidepressants monoamine oxidase MAO inhibitors alcohol may produce additive CNS depressant effects
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 	anesthetics	tricyclic antidepressants	none	{'e1': {'word': 'anesthetics', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d753.s0.e4'}, 'e2': {'word': 'tricyclic antidepressants', 'word_index': [(12, 13)], 'id': 'DDI-DrugBank.d753.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d753.s0'}	concomitant use CNS depressants including sedatives hypnotics tranquilizers general anesthetics phenothiazines opioids tricyclic antidepressants monoamine oxidase MAO inhibitors alcohol may produce additive CNS depressant effects
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 	anesthetics	monoamine oxidase (MAO) inhibitors	none	{'e1': {'word': 'anesthetics', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d753.s0.e4'}, 'e2': {'word': 'monoamine oxidase (MAO) inhibitors', 'word_index': [(14, 17)], 'id': 'DDI-DrugBank.d753.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d753.s0'}	concomitant use CNS depressants including sedatives hypnotics tranquilizers general anesthetics phenothiazines opioids tricyclic antidepressants monoamine oxidase MAO inhibitors alcohol may produce additive CNS depressant effects
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 	anesthetics	alcohol	none	{'e1': {'word': 'anesthetics', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d753.s0.e4'}, 'e2': {'word': 'alcohol', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d753.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d753.s0'}	concomitant use CNS depressants including sedatives hypnotics tranquilizers general anesthetics phenothiazines opioids tricyclic antidepressants monoamine oxidase MAO inhibitors alcohol may produce additive CNS depressant effects
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 	phenothiazines	opioids	none	{'e1': {'word': 'phenothiazines', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d753.s0.e5'}, 'e2': {'word': 'opioids', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d753.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d753.s0'}	concomitant use CNS depressants including sedatives hypnotics tranquilizers general anesthetics phenothiazines opioids tricyclic antidepressants monoamine oxidase MAO inhibitors alcohol may produce additive CNS depressant effects
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 	phenothiazines	tricyclic antidepressants	none	{'e1': {'word': 'phenothiazines', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d753.s0.e5'}, 'e2': {'word': 'tricyclic antidepressants', 'word_index': [(12, 13)], 'id': 'DDI-DrugBank.d753.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d753.s0'}	concomitant use CNS depressants including sedatives hypnotics tranquilizers general anesthetics phenothiazines opioids tricyclic antidepressants monoamine oxidase MAO inhibitors alcohol may produce additive CNS depressant effects
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 	phenothiazines	monoamine oxidase (MAO) inhibitors	none	{'e1': {'word': 'phenothiazines', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d753.s0.e5'}, 'e2': {'word': 'monoamine oxidase (MAO) inhibitors', 'word_index': [(14, 17)], 'id': 'DDI-DrugBank.d753.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d753.s0'}	concomitant use CNS depressants including sedatives hypnotics tranquilizers general anesthetics phenothiazines opioids tricyclic antidepressants monoamine oxidase MAO inhibitors alcohol may produce additive CNS depressant effects
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 	phenothiazines	alcohol	none	{'e1': {'word': 'phenothiazines', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d753.s0.e5'}, 'e2': {'word': 'alcohol', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d753.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d753.s0'}	concomitant use CNS depressants including sedatives hypnotics tranquilizers general anesthetics phenothiazines opioids tricyclic antidepressants monoamine oxidase MAO inhibitors alcohol may produce additive CNS depressant effects
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 	opioids	tricyclic antidepressants	none	{'e1': {'word': 'opioids', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d753.s0.e6'}, 'e2': {'word': 'tricyclic antidepressants', 'word_index': [(12, 13)], 'id': 'DDI-DrugBank.d753.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d753.s0'}	concomitant use CNS depressants including sedatives hypnotics tranquilizers general anesthetics phenothiazines opioids tricyclic antidepressants monoamine oxidase MAO inhibitors alcohol may produce additive CNS depressant effects
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 	opioids	monoamine oxidase (MAO) inhibitors	none	{'e1': {'word': 'opioids', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d753.s0.e6'}, 'e2': {'word': 'monoamine oxidase (MAO) inhibitors', 'word_index': [(14, 17)], 'id': 'DDI-DrugBank.d753.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d753.s0'}	concomitant use CNS depressants including sedatives hypnotics tranquilizers general anesthetics phenothiazines opioids tricyclic antidepressants monoamine oxidase MAO inhibitors alcohol may produce additive CNS depressant effects
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 	opioids	alcohol	none	{'e1': {'word': 'opioids', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d753.s0.e6'}, 'e2': {'word': 'alcohol', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d753.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d753.s0'}	concomitant use CNS depressants including sedatives hypnotics tranquilizers general anesthetics phenothiazines opioids tricyclic antidepressants monoamine oxidase MAO inhibitors alcohol may produce additive CNS depressant effects
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 	tricyclic antidepressants	monoamine oxidase (MAO) inhibitors	none	{'e1': {'word': 'tricyclic antidepressants', 'word_index': [(12, 13)], 'id': 'DDI-DrugBank.d753.s0.e7'}, 'e2': {'word': 'monoamine oxidase (MAO) inhibitors', 'word_index': [(14, 17)], 'id': 'DDI-DrugBank.d753.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d753.s0'}	concomitant use CNS depressants including sedatives hypnotics tranquilizers general anesthetics phenothiazines opioids tricyclic antidepressants monoamine oxidase MAO inhibitors alcohol may produce additive CNS depressant effects
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 	tricyclic antidepressants	alcohol	none	{'e1': {'word': 'tricyclic antidepressants', 'word_index': [(12, 13)], 'id': 'DDI-DrugBank.d753.s0.e7'}, 'e2': {'word': 'alcohol', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d753.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d753.s0'}	concomitant use CNS depressants including sedatives hypnotics tranquilizers general anesthetics phenothiazines opioids tricyclic antidepressants monoamine oxidase MAO inhibitors alcohol may produce additive CNS depressant effects
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. 	monoamine oxidase (MAO) inhibitors	alcohol	none	{'e1': {'word': 'monoamine oxidase (MAO) inhibitors', 'word_index': [(14, 17)], 'id': 'DDI-DrugBank.d753.s0.e8'}, 'e2': {'word': 'alcohol', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d753.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d753.s0'}	concomitant use CNS depressants including sedatives hypnotics tranquilizers general anesthetics phenothiazines opioids tricyclic antidepressants monoamine oxidase MAO inhibitors alcohol may produce additive CNS depressant effects
Anticholinergics or other medications with anticholinergic activity when used concurrently with opioid analgesics may result in increased risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. 	Anticholinergics	opioid analgesics	effect	{'e1': {'word': 'Anticholinergics', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d753.s2.e0'}, 'e2': {'word': 'opioid analgesics', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d753.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d753.s2'}	Anticholinergics medications anticholinergic activity used concurrently opioid analgesics may result increased risk urinary retention severe constipation may lead paralytic ileus
It has been reported that the incidence of bradycardia was increased when oxymorphone was combined with propofol for induction of anesthesia. 	oxymorphone	propofol	effect	{'e1': {'word': 'oxymorphone', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d753.s3.e0'}, 'e2': {'word': 'propofol', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d753.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d753.s3'}	reported incidence bradycardia increased oxymorphone combined propofol induction anesthesia
In addition, CNS toxicity has been reported (confusion, disorientation, respiratory depression, apnea, seizures) following coadministration of cimetidine with opioid analgesics; 	cimetidine	opioid analgesics	effect	{'e1': {'word': 'cimetidine', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d753.s4.e0'}, 'e2': {'word': 'opioid analgesics', 'word_index': [(13, 14)], 'id': 'DDI-DrugBank.d753.s4.e1'}, 'sentence_id': 'DDI-DrugBank.d753.s4'}	addition CNS toxicity reported confusion disorientation respiratory depression apnea seizures following coadministration cimetidine opioid analgesics
Administration of paclitaxel in combination with HERCEPTIN resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies.	paclitaxel	HERCEPTIN	mechanism	{'e1': {'word': 'paclitaxel', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d712.s1.e0'}, 'e2': {'word': 'HERCEPTIN', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d712.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d712.s1'}	Administration paclitaxel combination HERCEPTIN resulted NUMBER fold decrease HERCEPTIN clearance non-human primate study 1.5-fold increase HERCEPTIN serum levels clinical studies
Administration of paclitaxel in combination with HERCEPTIN resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies.	paclitaxel	HERCEPTIN	none	{'e1': {'word': 'paclitaxel', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d712.s1.e0'}, 'e2': {'word': 'HERCEPTIN', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d712.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d712.s1'}	Administration paclitaxel combination HERCEPTIN resulted NUMBER fold decrease HERCEPTIN clearance non-human primate study 1.5-fold increase HERCEPTIN serum levels clinical studies
Administration of paclitaxel in combination with HERCEPTIN resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies.	paclitaxel	HERCEPTIN	none	{'e1': {'word': 'paclitaxel', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d712.s1.e0'}, 'e2': {'word': 'HERCEPTIN', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d712.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d712.s1'}	Administration paclitaxel combination HERCEPTIN resulted NUMBER fold decrease HERCEPTIN clearance non-human primate study 1.5-fold increase HERCEPTIN serum levels clinical studies
Administration of paclitaxel in combination with HERCEPTIN resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies.	HERCEPTIN	HERCEPTIN	none	{'e1': {'word': 'HERCEPTIN', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d712.s1.e1'}, 'e2': {'word': 'HERCEPTIN', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d712.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d712.s1'}	Administration paclitaxel combination HERCEPTIN resulted NUMBER fold decrease HERCEPTIN clearance non-human primate study 1.5-fold increase HERCEPTIN serum levels clinical studies
Administration of paclitaxel in combination with HERCEPTIN resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies.	HERCEPTIN	HERCEPTIN	none	{'e1': {'word': 'HERCEPTIN', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d712.s1.e1'}, 'e2': {'word': 'HERCEPTIN', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d712.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d712.s1'}	Administration paclitaxel combination HERCEPTIN resulted NUMBER fold decrease HERCEPTIN clearance non-human primate study 1.5-fold increase HERCEPTIN serum levels clinical studies
Administration of paclitaxel in combination with HERCEPTIN resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies.	HERCEPTIN	HERCEPTIN	none	{'e1': {'word': 'HERCEPTIN', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d712.s1.e2'}, 'e2': {'word': 'HERCEPTIN', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d712.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d712.s1'}	Administration paclitaxel combination HERCEPTIN resulted NUMBER fold decrease HERCEPTIN clearance non-human primate study 1.5-fold increase HERCEPTIN serum levels clinical studies
Pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other antibiotics. 	Pyrimethamine	sulfonamides	none	{'e1': {'word': 'Pyrimethamine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d631.s0.e0'}, 'e2': {'word': 'sulfonamides', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d631.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d631.s0'}	Pyrimethamine may used sulfonamides quinine antimalarials antibiotics
Pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other antibiotics. 	Pyrimethamine	quinine	none	{'e1': {'word': 'Pyrimethamine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d631.s0.e0'}, 'e2': {'word': 'quinine', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d631.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d631.s0'}	Pyrimethamine may used sulfonamides quinine antimalarials antibiotics
Pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other antibiotics. 	Pyrimethamine	antimalarials	none	{'e1': {'word': 'Pyrimethamine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d631.s0.e0'}, 'e2': {'word': 'antimalarials', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d631.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d631.s0'}	Pyrimethamine may used sulfonamides quinine antimalarials antibiotics
Pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other antibiotics. 	Pyrimethamine	antibiotics	none	{'e1': {'word': 'Pyrimethamine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d631.s0.e0'}, 'e2': {'word': 'antibiotics', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d631.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d631.s0'}	Pyrimethamine may used sulfonamides quinine antimalarials antibiotics
Pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other antibiotics. 	sulfonamides	quinine	none	{'e1': {'word': 'sulfonamides', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d631.s0.e1'}, 'e2': {'word': 'quinine', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d631.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d631.s0'}	Pyrimethamine may used sulfonamides quinine antimalarials antibiotics
Pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other antibiotics. 	sulfonamides	antimalarials	none	{'e1': {'word': 'sulfonamides', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d631.s0.e1'}, 'e2': {'word': 'antimalarials', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d631.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d631.s0'}	Pyrimethamine may used sulfonamides quinine antimalarials antibiotics
Pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other antibiotics. 	sulfonamides	antibiotics	none	{'e1': {'word': 'sulfonamides', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d631.s0.e1'}, 'e2': {'word': 'antibiotics', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d631.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d631.s0'}	Pyrimethamine may used sulfonamides quinine antimalarials antibiotics
Pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other antibiotics. 	quinine	antimalarials	none	{'e1': {'word': 'quinine', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d631.s0.e2'}, 'e2': {'word': 'antimalarials', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d631.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d631.s0'}	Pyrimethamine may used sulfonamides quinine antimalarials antibiotics
Pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other antibiotics. 	quinine	antibiotics	none	{'e1': {'word': 'quinine', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d631.s0.e2'}, 'e2': {'word': 'antibiotics', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d631.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d631.s0'}	Pyrimethamine may used sulfonamides quinine antimalarials antibiotics
Pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other antibiotics. 	antimalarials	antibiotics	none	{'e1': {'word': 'antimalarials', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d631.s0.e3'}, 'e2': {'word': 'antibiotics', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d631.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d631.s0'}	Pyrimethamine may used sulfonamides quinine antimalarials antibiotics
Folinic acid (leucovorin) should be administered until normal hematopoiesis is restored. 	Folinic acid	leucovorin	none	{'e1': {'word': 'Folinic acid', 'word_index': [(0, 1)], 'id': 'DDI-DrugBank.d631.s2.e0'}, 'e2': {'word': 'leucovorin', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d631.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d631.s2'}	Folinic acid leucovorin administered normal hematopoiesis restored
Mild hepatotoxicity has been reported in some patients when lorazepam and pyrimethamine were administered concomitantly.	lorazepam	pyrimethamine	effect	{'e1': {'word': 'lorazepam', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d631.s3.e0'}, 'e2': {'word': 'pyrimethamine', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d631.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d631.s3'}	Mild hepatotoxicity reported patients lorazepam pyrimethamine administered concomitantly
AGGRASTAT has been studied on a background of aspirin and heparin. 	AGGRASTAT	aspirin	none	{'e1': {'word': 'AGGRASTAT', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d751.s0.e0'}, 'e2': {'word': 'aspirin', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d751.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d751.s0'}	AGGRASTAT studied background aspirin heparin
AGGRASTAT has been studied on a background of aspirin and heparin. 	AGGRASTAT	heparin	none	{'e1': {'word': 'AGGRASTAT', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d751.s0.e0'}, 'e2': {'word': 'heparin', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d751.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d751.s0'}	AGGRASTAT studied background aspirin heparin
AGGRASTAT has been studied on a background of aspirin and heparin. 	aspirin	heparin	none	{'e1': {'word': 'aspirin', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d751.s0.e1'}, 'e2': {'word': 'heparin', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d751.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d751.s0'}	AGGRASTAT studied background aspirin heparin
The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see	AGGRASTAT	heparin	effect	{'e1': {'word': 'AGGRASTAT', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d751.s1.e0'}, 'e2': {'word': 'heparin', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d751.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d751.s1'}	use AGGRASTAT combination heparin aspirin associated increase bleeding compared heparin aspirin alone see
The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see	AGGRASTAT	aspirin	effect	{'e1': {'word': 'AGGRASTAT', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d751.s1.e0'}, 'e2': {'word': 'aspirin', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d751.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d751.s1'}	use AGGRASTAT combination heparin aspirin associated increase bleeding compared heparin aspirin alone see
The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see	AGGRASTAT	heparin	none	{'e1': {'word': 'AGGRASTAT', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d751.s1.e0'}, 'e2': {'word': 'heparin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d751.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d751.s1'}	use AGGRASTAT combination heparin aspirin associated increase bleeding compared heparin aspirin alone see
The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see	AGGRASTAT	aspirin	none	{'e1': {'word': 'AGGRASTAT', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d751.s1.e0'}, 'e2': {'word': 'aspirin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d751.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d751.s1'}	use AGGRASTAT combination heparin aspirin associated increase bleeding compared heparin aspirin alone see
The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see	heparin	aspirin	none	{'e1': {'word': 'heparin', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d751.s1.e1'}, 'e2': {'word': 'aspirin', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d751.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d751.s1'}	use AGGRASTAT combination heparin aspirin associated increase bleeding compared heparin aspirin alone see
The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see	heparin	heparin	none	{'e1': {'word': 'heparin', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d751.s1.e1'}, 'e2': {'word': 'heparin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d751.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d751.s1'}	use AGGRASTAT combination heparin aspirin associated increase bleeding compared heparin aspirin alone see
The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see	heparin	aspirin	none	{'e1': {'word': 'heparin', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d751.s1.e1'}, 'e2': {'word': 'aspirin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d751.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d751.s1'}	use AGGRASTAT combination heparin aspirin associated increase bleeding compared heparin aspirin alone see
The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see	aspirin	heparin	none	{'e1': {'word': 'aspirin', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d751.s1.e2'}, 'e2': {'word': 'heparin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d751.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d751.s1'}	use AGGRASTAT combination heparin aspirin associated increase bleeding compared heparin aspirin alone see
The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see	aspirin	aspirin	none	{'e1': {'word': 'aspirin', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d751.s1.e2'}, 'e2': {'word': 'aspirin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d751.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d751.s1'}	use AGGRASTAT combination heparin aspirin associated increase bleeding compared heparin aspirin alone see
The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see	heparin	aspirin	none	{'e1': {'word': 'heparin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d751.s1.e3'}, 'e2': {'word': 'aspirin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d751.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d751.s1'}	use AGGRASTAT combination heparin aspirin associated increase bleeding compared heparin aspirin alone see
Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.	acetylcholine chloride	Miochol	none	{'e1': {'word': 'acetylcholine chloride', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d723.s0.e0'}, 'e2': {'word': 'Miochol', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d723.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d723.s0'}	eye drops medications acetylcholine chloride Miochol carbachol Carboptic Isopto Carbachol may decrease effects suprofen ophthalmic
Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.	acetylcholine chloride	carbachol	none	{'e1': {'word': 'acetylcholine chloride', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d723.s0.e0'}, 'e2': {'word': 'carbachol', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d723.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d723.s0'}	eye drops medications acetylcholine chloride Miochol carbachol Carboptic Isopto Carbachol may decrease effects suprofen ophthalmic
Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.	acetylcholine chloride	Carboptic	none	{'e1': {'word': 'acetylcholine chloride', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d723.s0.e0'}, 'e2': {'word': 'Carboptic', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d723.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d723.s0'}	eye drops medications acetylcholine chloride Miochol carbachol Carboptic Isopto Carbachol may decrease effects suprofen ophthalmic
Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.	acetylcholine chloride	Isopto Carbachol	none	{'e1': {'word': 'acetylcholine chloride', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d723.s0.e0'}, 'e2': {'word': 'Isopto Carbachol', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d723.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d723.s0'}	eye drops medications acetylcholine chloride Miochol carbachol Carboptic Isopto Carbachol may decrease effects suprofen ophthalmic
Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.	acetylcholine chloride	suprofen	effect	{'e1': {'word': 'acetylcholine chloride', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d723.s0.e0'}, 'e2': {'word': 'suprofen', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d723.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d723.s0'}	eye drops medications acetylcholine chloride Miochol carbachol Carboptic Isopto Carbachol may decrease effects suprofen ophthalmic
Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.	Miochol	carbachol	none	{'e1': {'word': 'Miochol', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d723.s0.e1'}, 'e2': {'word': 'carbachol', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d723.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d723.s0'}	eye drops medications acetylcholine chloride Miochol carbachol Carboptic Isopto Carbachol may decrease effects suprofen ophthalmic
Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.	Miochol	Carboptic	none	{'e1': {'word': 'Miochol', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d723.s0.e1'}, 'e2': {'word': 'Carboptic', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d723.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d723.s0'}	eye drops medications acetylcholine chloride Miochol carbachol Carboptic Isopto Carbachol may decrease effects suprofen ophthalmic
Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.	Miochol	Isopto Carbachol	none	{'e1': {'word': 'Miochol', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d723.s0.e1'}, 'e2': {'word': 'Isopto Carbachol', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d723.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d723.s0'}	eye drops medications acetylcholine chloride Miochol carbachol Carboptic Isopto Carbachol may decrease effects suprofen ophthalmic
Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.	Miochol	suprofen	effect	{'e1': {'word': 'Miochol', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d723.s0.e1'}, 'e2': {'word': 'suprofen', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d723.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d723.s0'}	eye drops medications acetylcholine chloride Miochol carbachol Carboptic Isopto Carbachol may decrease effects suprofen ophthalmic
Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.	carbachol	Carboptic	none	{'e1': {'word': 'carbachol', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d723.s0.e2'}, 'e2': {'word': 'Carboptic', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d723.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d723.s0'}	eye drops medications acetylcholine chloride Miochol carbachol Carboptic Isopto Carbachol may decrease effects suprofen ophthalmic
Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.	carbachol	Isopto Carbachol	none	{'e1': {'word': 'carbachol', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d723.s0.e2'}, 'e2': {'word': 'Isopto Carbachol', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d723.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d723.s0'}	eye drops medications acetylcholine chloride Miochol carbachol Carboptic Isopto Carbachol may decrease effects suprofen ophthalmic
Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.	carbachol	suprofen	effect	{'e1': {'word': 'carbachol', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d723.s0.e2'}, 'e2': {'word': 'suprofen', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d723.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d723.s0'}	eye drops medications acetylcholine chloride Miochol carbachol Carboptic Isopto Carbachol may decrease effects suprofen ophthalmic
Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.	Carboptic	Isopto Carbachol	none	{'e1': {'word': 'Carboptic', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d723.s0.e3'}, 'e2': {'word': 'Isopto Carbachol', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d723.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d723.s0'}	eye drops medications acetylcholine chloride Miochol carbachol Carboptic Isopto Carbachol may decrease effects suprofen ophthalmic
Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.	Carboptic	suprofen	effect	{'e1': {'word': 'Carboptic', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d723.s0.e3'}, 'e2': {'word': 'suprofen', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d723.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d723.s0'}	eye drops medications acetylcholine chloride Miochol carbachol Carboptic Isopto Carbachol may decrease effects suprofen ophthalmic
Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.	Isopto Carbachol	suprofen	effect	{'e1': {'word': 'Isopto Carbachol', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d723.s0.e4'}, 'e2': {'word': 'suprofen', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d723.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d723.s0'}	eye drops medications acetylcholine chloride Miochol carbachol Carboptic Isopto Carbachol may decrease effects suprofen ophthalmic
Prothrombin time or other suitable anticoagulation test should be monitored if tigecycline is administered with warfarin.   	tigecycline	warfarin	advise	{'e1': {'word': 'tigecycline', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d642.s0.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d642.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d642.s0'}	Prothrombin time suitable anticoagulation test monitored tigecycline administered warfarin
Concurrent use of antibacterial drugs with oral contraceptives may render oral contraceptives less effective.  	antibacterial drugs	contraceptives	effect	{'e1': {'word': 'antibacterial drugs', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d642.s1.e0'}, 'e2': {'word': 'contraceptives', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d642.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d642.s1'}	Concurrent use antibacterial drugs oral contraceptives may render oral contraceptives less effective
Concurrent use of antibacterial drugs with oral contraceptives may render oral contraceptives less effective.  	antibacterial drugs	contraceptives	none	{'e1': {'word': 'antibacterial drugs', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d642.s1.e0'}, 'e2': {'word': 'contraceptives', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d642.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d642.s1'}	Concurrent use antibacterial drugs oral contraceptives may render oral contraceptives less effective
Concurrent use of antibacterial drugs with oral contraceptives may render oral contraceptives less effective.  	contraceptives	contraceptives	none	{'e1': {'word': 'contraceptives', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d642.s1.e1'}, 'e2': {'word': 'contraceptives', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d642.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d642.s1'}	Concurrent use antibacterial drugs oral contraceptives may render oral contraceptives less effective
In elderly patients concurrently receiving certain diuretics, primarily thiazides, an increased incidence of thrombopenia with purpura has been reported. 	diuretics	thiazides	none	{'e1': {'word': 'diuretics', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d577.s0.e0'}, 'e2': {'word': 'thiazides', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d577.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d577.s0'}	elderly patients concurrently receiving certain diuretics primarily thiazides increased incidence thrombopenia purpura reported
It has been reported that sulfamethoxazole may prolong the prothrombin time in patients who are receiving the anticoagulant warfarin. 	sulfamethoxazole	anticoagulant	none	{'e1': {'word': 'sulfamethoxazole', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d577.s1.e0'}, 'e2': {'word': 'anticoagulant', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d577.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d577.s1'}	reported sulfamethoxazole may prolong prothrombin time patients receiving anticoagulant warfarin
It has been reported that sulfamethoxazole may prolong the prothrombin time in patients who are receiving the anticoagulant warfarin. 	sulfamethoxazole	warfarin	effect	{'e1': {'word': 'sulfamethoxazole', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d577.s1.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d577.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d577.s1'}	reported sulfamethoxazole may prolong prothrombin time patients receiving anticoagulant warfarin
It has been reported that sulfamethoxazole may prolong the prothrombin time in patients who are receiving the anticoagulant warfarin. 	anticoagulant	warfarin	none	{'e1': {'word': 'anticoagulant', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d577.s1.e1'}, 'e2': {'word': 'warfarin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d577.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d577.s1'}	reported sulfamethoxazole may prolong prothrombin time patients receiving anticoagulant warfarin
Sulfamethoxazole may inhibit the hepatic metabolism of phenytoin. 	Sulfamethoxazole	phenytoin	mechanism	{'e1': {'word': 'Sulfamethoxazole', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d577.s3.e0'}, 'e2': {'word': 'phenytoin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d577.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d577.s3'}	Sulfamethoxazole may inhibit hepatic metabolism phenytoin
At a 1.6-g dose, sulfamethoxazole produced a slight but significant increase in the half-life of phenytoin but did not produce a corresponding decrease in the metabolic clearance rate. 	sulfamethoxazole	phenytoin	mechanism	{'e1': {'word': 'sulfamethoxazole', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d577.s4.e0'}, 'e2': {'word': 'phenytoin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d577.s4.e1'}, 'sentence_id': 'DDI-DrugBank.d577.s4'}	NUMBER g dose sulfamethoxazole produced slight significant increase half life phenytoin produce corresponding decrease metabolic clearance rate
Sulfonamides can also displace methotrexate from plasma protein-binding sites, thus increasing free methotrexate concentrations. 	Sulfonamides	methotrexate	mechanism	{'e1': {'word': 'Sulfonamides', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d577.s6.e0'}, 'e2': {'word': 'methotrexate', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d577.s6.e1'}, 'sentence_id': 'DDI-DrugBank.d577.s6'}	Sulfonamides also displace methotrexate plasma protein binding sites thus increasing free methotrexate concentrations
Sulfonamides can also displace methotrexate from plasma protein-binding sites, thus increasing free methotrexate concentrations. 	Sulfonamides	methotrexate	none	{'e1': {'word': 'Sulfonamides', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d577.s6.e0'}, 'e2': {'word': 'methotrexate', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d577.s6.e2'}, 'sentence_id': 'DDI-DrugBank.d577.s6'}	Sulfonamides also displace methotrexate plasma protein binding sites thus increasing free methotrexate concentrations
Sulfonamides can also displace methotrexate from plasma protein-binding sites, thus increasing free methotrexate concentrations. 	methotrexate	methotrexate	none	{'e1': {'word': 'methotrexate', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d577.s6.e1'}, 'e2': {'word': 'methotrexate', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d577.s6.e2'}, 'sentence_id': 'DDI-DrugBank.d577.s6'}	Sulfonamides also displace methotrexate plasma protein binding sites thus increasing free methotrexate concentrations
Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with TRENTAL with and without anticoagulants or platelet aggregation inhibitors. 	TRENTAL	anticoagulants	effect	{'e1': {'word': 'TRENTAL', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d659.s0.e0'}, 'e2': {'word': 'anticoagulants', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d659.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d659.s0'}	Although causal relationship established reports bleeding prolonged prothrombin time patients treated TRENTAL without anticoagulants platelet aggregation inhibitors
Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with TRENTAL with and without anticoagulants or platelet aggregation inhibitors. 	TRENTAL	platelet aggregation inhibitors	effect	{'e1': {'word': 'TRENTAL', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d659.s0.e0'}, 'e2': {'word': 'platelet aggregation inhibitors', 'word_index': [(14, 16)], 'id': 'DDI-DrugBank.d659.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d659.s0'}	Although causal relationship established reports bleeding prolonged prothrombin time patients treated TRENTAL without anticoagulants platelet aggregation inhibitors
Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with TRENTAL with and without anticoagulants or platelet aggregation inhibitors. 	anticoagulants	platelet aggregation inhibitors	none	{'e1': {'word': 'anticoagulants', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d659.s0.e1'}, 'e2': {'word': 'platelet aggregation inhibitors', 'word_index': [(14, 16)], 'id': 'DDI-DrugBank.d659.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d659.s0'}	Although causal relationship established reports bleeding prolonged prothrombin time patients treated TRENTAL without anticoagulants platelet aggregation inhibitors
Concomitant administration of TRENTAL and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals. 	TRENTAL	theophylline	mechanism	{'e1': {'word': 'TRENTAL', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d659.s2.e0'}, 'e2': {'word': 'theophylline', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d659.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d659.s2'}	Concomitant administration TRENTAL theophylline containing drugs leads increased theophylline levels theophylline toxicity individuals
Concomitant administration of TRENTAL and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals. 	TRENTAL	theophylline	none	{'e1': {'word': 'TRENTAL', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d659.s2.e0'}, 'e2': {'word': 'theophylline', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d659.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d659.s2'}	Concomitant administration TRENTAL theophylline containing drugs leads increased theophylline levels theophylline toxicity individuals
Concomitant administration of TRENTAL and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals. 	TRENTAL	theophylline	none	{'e1': {'word': 'TRENTAL', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d659.s2.e0'}, 'e2': {'word': 'theophylline', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d659.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d659.s2'}	Concomitant administration TRENTAL theophylline containing drugs leads increased theophylline levels theophylline toxicity individuals
Concomitant administration of TRENTAL and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals. 	theophylline	theophylline	none	{'e1': {'word': 'theophylline', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d659.s2.e1'}, 'e2': {'word': 'theophylline', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d659.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d659.s2'}	Concomitant administration TRENTAL theophylline containing drugs leads increased theophylline levels theophylline toxicity individuals
Concomitant administration of TRENTAL and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals. 	theophylline	theophylline	none	{'e1': {'word': 'theophylline', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d659.s2.e1'}, 'e2': {'word': 'theophylline', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d659.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d659.s2'}	Concomitant administration TRENTAL theophylline containing drugs leads increased theophylline levels theophylline toxicity individuals
Concomitant administration of TRENTAL and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals. 	theophylline	theophylline	none	{'e1': {'word': 'theophylline', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d659.s2.e2'}, 'e2': {'word': 'theophylline', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d659.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d659.s2'}	Concomitant administration TRENTAL theophylline containing drugs leads increased theophylline levels theophylline toxicity individuals
TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. 	TRENTAL	antihypertensive drugs	none	{'e1': {'word': 'TRENTAL', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d659.s4.e0'}, 'e2': {'word': 'antihypertensive drugs', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d659.s4.e1'}, 'sentence_id': 'DDI-DrugBank.d659.s4'}	TRENTAL used concurrently antihypertensive drugs beta blockers digitalis diuretics antidiabetic agents antiarrhythmics without observed problems
TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. 	TRENTAL	beta blockers	none	{'e1': {'word': 'TRENTAL', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d659.s4.e0'}, 'e2': {'word': 'beta blockers', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d659.s4.e2'}, 'sentence_id': 'DDI-DrugBank.d659.s4'}	TRENTAL used concurrently antihypertensive drugs beta blockers digitalis diuretics antidiabetic agents antiarrhythmics without observed problems
TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. 	TRENTAL	digitalis	none	{'e1': {'word': 'TRENTAL', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d659.s4.e0'}, 'e2': {'word': 'digitalis', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d659.s4.e3'}, 'sentence_id': 'DDI-DrugBank.d659.s4'}	TRENTAL used concurrently antihypertensive drugs beta blockers digitalis diuretics antidiabetic agents antiarrhythmics without observed problems
TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. 	TRENTAL	diuretics	none	{'e1': {'word': 'TRENTAL', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d659.s4.e0'}, 'e2': {'word': 'diuretics', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d659.s4.e4'}, 'sentence_id': 'DDI-DrugBank.d659.s4'}	TRENTAL used concurrently antihypertensive drugs beta blockers digitalis diuretics antidiabetic agents antiarrhythmics without observed problems
TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. 	TRENTAL	antidiabetic agents	none	{'e1': {'word': 'TRENTAL', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d659.s4.e0'}, 'e2': {'word': 'antidiabetic agents', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d659.s4.e5'}, 'sentence_id': 'DDI-DrugBank.d659.s4'}	TRENTAL used concurrently antihypertensive drugs beta blockers digitalis diuretics antidiabetic agents antiarrhythmics without observed problems
TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. 	TRENTAL	antiarrhythmics	none	{'e1': {'word': 'TRENTAL', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d659.s4.e0'}, 'e2': {'word': 'antiarrhythmics', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d659.s4.e6'}, 'sentence_id': 'DDI-DrugBank.d659.s4'}	TRENTAL used concurrently antihypertensive drugs beta blockers digitalis diuretics antidiabetic agents antiarrhythmics without observed problems
TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. 	antihypertensive drugs	beta blockers	none	{'e1': {'word': 'antihypertensive drugs', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d659.s4.e1'}, 'e2': {'word': 'beta blockers', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d659.s4.e2'}, 'sentence_id': 'DDI-DrugBank.d659.s4'}	TRENTAL used concurrently antihypertensive drugs beta blockers digitalis diuretics antidiabetic agents antiarrhythmics without observed problems
TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. 	antihypertensive drugs	digitalis	none	{'e1': {'word': 'antihypertensive drugs', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d659.s4.e1'}, 'e2': {'word': 'digitalis', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d659.s4.e3'}, 'sentence_id': 'DDI-DrugBank.d659.s4'}	TRENTAL used concurrently antihypertensive drugs beta blockers digitalis diuretics antidiabetic agents antiarrhythmics without observed problems
TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. 	antihypertensive drugs	diuretics	none	{'e1': {'word': 'antihypertensive drugs', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d659.s4.e1'}, 'e2': {'word': 'diuretics', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d659.s4.e4'}, 'sentence_id': 'DDI-DrugBank.d659.s4'}	TRENTAL used concurrently antihypertensive drugs beta blockers digitalis diuretics antidiabetic agents antiarrhythmics without observed problems
TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. 	antihypertensive drugs	antidiabetic agents	none	{'e1': {'word': 'antihypertensive drugs', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d659.s4.e1'}, 'e2': {'word': 'antidiabetic agents', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d659.s4.e5'}, 'sentence_id': 'DDI-DrugBank.d659.s4'}	TRENTAL used concurrently antihypertensive drugs beta blockers digitalis diuretics antidiabetic agents antiarrhythmics without observed problems
TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. 	antihypertensive drugs	antiarrhythmics	none	{'e1': {'word': 'antihypertensive drugs', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d659.s4.e1'}, 'e2': {'word': 'antiarrhythmics', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d659.s4.e6'}, 'sentence_id': 'DDI-DrugBank.d659.s4'}	TRENTAL used concurrently antihypertensive drugs beta blockers digitalis diuretics antidiabetic agents antiarrhythmics without observed problems
TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. 	beta blockers	digitalis	none	{'e1': {'word': 'beta blockers', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d659.s4.e2'}, 'e2': {'word': 'digitalis', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d659.s4.e3'}, 'sentence_id': 'DDI-DrugBank.d659.s4'}	TRENTAL used concurrently antihypertensive drugs beta blockers digitalis diuretics antidiabetic agents antiarrhythmics without observed problems
TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. 	beta blockers	diuretics	none	{'e1': {'word': 'beta blockers', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d659.s4.e2'}, 'e2': {'word': 'diuretics', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d659.s4.e4'}, 'sentence_id': 'DDI-DrugBank.d659.s4'}	TRENTAL used concurrently antihypertensive drugs beta blockers digitalis diuretics antidiabetic agents antiarrhythmics without observed problems
TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. 	beta blockers	antidiabetic agents	none	{'e1': {'word': 'beta blockers', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d659.s4.e2'}, 'e2': {'word': 'antidiabetic agents', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d659.s4.e5'}, 'sentence_id': 'DDI-DrugBank.d659.s4'}	TRENTAL used concurrently antihypertensive drugs beta blockers digitalis diuretics antidiabetic agents antiarrhythmics without observed problems
TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. 	beta blockers	antiarrhythmics	none	{'e1': {'word': 'beta blockers', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d659.s4.e2'}, 'e2': {'word': 'antiarrhythmics', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d659.s4.e6'}, 'sentence_id': 'DDI-DrugBank.d659.s4'}	TRENTAL used concurrently antihypertensive drugs beta blockers digitalis diuretics antidiabetic agents antiarrhythmics without observed problems
TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. 	digitalis	diuretics	none	{'e1': {'word': 'digitalis', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d659.s4.e3'}, 'e2': {'word': 'diuretics', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d659.s4.e4'}, 'sentence_id': 'DDI-DrugBank.d659.s4'}	TRENTAL used concurrently antihypertensive drugs beta blockers digitalis diuretics antidiabetic agents antiarrhythmics without observed problems
TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. 	digitalis	antidiabetic agents	none	{'e1': {'word': 'digitalis', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d659.s4.e3'}, 'e2': {'word': 'antidiabetic agents', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d659.s4.e5'}, 'sentence_id': 'DDI-DrugBank.d659.s4'}	TRENTAL used concurrently antihypertensive drugs beta blockers digitalis diuretics antidiabetic agents antiarrhythmics without observed problems
TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. 	digitalis	antiarrhythmics	none	{'e1': {'word': 'digitalis', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d659.s4.e3'}, 'e2': {'word': 'antiarrhythmics', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d659.s4.e6'}, 'sentence_id': 'DDI-DrugBank.d659.s4'}	TRENTAL used concurrently antihypertensive drugs beta blockers digitalis diuretics antidiabetic agents antiarrhythmics without observed problems
TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. 	diuretics	antidiabetic agents	none	{'e1': {'word': 'diuretics', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d659.s4.e4'}, 'e2': {'word': 'antidiabetic agents', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d659.s4.e5'}, 'sentence_id': 'DDI-DrugBank.d659.s4'}	TRENTAL used concurrently antihypertensive drugs beta blockers digitalis diuretics antidiabetic agents antiarrhythmics without observed problems
TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. 	diuretics	antiarrhythmics	none	{'e1': {'word': 'diuretics', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d659.s4.e4'}, 'e2': {'word': 'antiarrhythmics', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d659.s4.e6'}, 'sentence_id': 'DDI-DrugBank.d659.s4'}	TRENTAL used concurrently antihypertensive drugs beta blockers digitalis diuretics antidiabetic agents antiarrhythmics without observed problems
TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. 	antidiabetic agents	antiarrhythmics	none	{'e1': {'word': 'antidiabetic agents', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d659.s4.e5'}, 'e2': {'word': 'antiarrhythmics', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d659.s4.e6'}, 'sentence_id': 'DDI-DrugBank.d659.s4'}	TRENTAL used concurrently antihypertensive drugs beta blockers digitalis diuretics antidiabetic agents antiarrhythmics without observed problems
Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. 	coumarin-type anticoagulants	coumarin-type anticoagulants	none	{'e1': {'word': 'coumarin-type anticoagulants', 'word_index': [(4, 6)], 'id': 'DDI-DrugBank.d656.s1.e0'}, 'e2': {'word': 'coumarin-type anticoagulants', 'word_index': [(8, 10)], 'id': 'DDI-DrugBank.d656.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d656.s1'}	Although occurred vitro studies coumarin type anticoagulants interactions coumarin type anticoagulants reported FELDENE since marketing therefore physicians closely monitor patients change dosage requirements administering FELDENE patients coumarin type anticoagulants highly protein bound drugs
Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. 	coumarin-type anticoagulants	FELDENE	none	{'e1': {'word': 'coumarin-type anticoagulants', 'word_index': [(4, 6)], 'id': 'DDI-DrugBank.d656.s1.e0'}, 'e2': {'word': 'FELDENE', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d656.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d656.s1'}	Although occurred vitro studies coumarin type anticoagulants interactions coumarin type anticoagulants reported FELDENE since marketing therefore physicians closely monitor patients change dosage requirements administering FELDENE patients coumarin type anticoagulants highly protein bound drugs
Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. 	coumarin-type anticoagulants	FELDENE	none	{'e1': {'word': 'coumarin-type anticoagulants', 'word_index': [(4, 6)], 'id': 'DDI-DrugBank.d656.s1.e0'}, 'e2': {'word': 'FELDENE', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d656.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d656.s1'}	Although occurred vitro studies coumarin type anticoagulants interactions coumarin type anticoagulants reported FELDENE since marketing therefore physicians closely monitor patients change dosage requirements administering FELDENE patients coumarin type anticoagulants highly protein bound drugs
Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. 	coumarin-type anticoagulants	coumarin-type anticoagulants	none	{'e1': {'word': 'coumarin-type anticoagulants', 'word_index': [(4, 6)], 'id': 'DDI-DrugBank.d656.s1.e0'}, 'e2': {'word': 'coumarin-type anticoagulants', 'word_index': [(26, 28)], 'id': 'DDI-DrugBank.d656.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d656.s1'}	Although occurred vitro studies coumarin type anticoagulants interactions coumarin type anticoagulants reported FELDENE since marketing therefore physicians closely monitor patients change dosage requirements administering FELDENE patients coumarin type anticoagulants highly protein bound drugs
Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. 	coumarin-type anticoagulants	FELDENE	int	{'e1': {'word': 'coumarin-type anticoagulants', 'word_index': [(8, 10)], 'id': 'DDI-DrugBank.d656.s1.e1'}, 'e2': {'word': 'FELDENE', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d656.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d656.s1'}	Although occurred vitro studies coumarin type anticoagulants interactions coumarin type anticoagulants reported FELDENE since marketing therefore physicians closely monitor patients change dosage requirements administering FELDENE patients coumarin type anticoagulants highly protein bound drugs
Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. 	coumarin-type anticoagulants	FELDENE	none	{'e1': {'word': 'coumarin-type anticoagulants', 'word_index': [(8, 10)], 'id': 'DDI-DrugBank.d656.s1.e1'}, 'e2': {'word': 'FELDENE', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d656.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d656.s1'}	Although occurred vitro studies coumarin type anticoagulants interactions coumarin type anticoagulants reported FELDENE since marketing therefore physicians closely monitor patients change dosage requirements administering FELDENE patients coumarin type anticoagulants highly protein bound drugs
Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. 	coumarin-type anticoagulants	coumarin-type anticoagulants	none	{'e1': {'word': 'coumarin-type anticoagulants', 'word_index': [(8, 10)], 'id': 'DDI-DrugBank.d656.s1.e1'}, 'e2': {'word': 'coumarin-type anticoagulants', 'word_index': [(26, 28)], 'id': 'DDI-DrugBank.d656.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d656.s1'}	Although occurred vitro studies coumarin type anticoagulants interactions coumarin type anticoagulants reported FELDENE since marketing therefore physicians closely monitor patients change dosage requirements administering FELDENE patients coumarin type anticoagulants highly protein bound drugs
Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. 	FELDENE	FELDENE	none	{'e1': {'word': 'FELDENE', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d656.s1.e2'}, 'e2': {'word': 'FELDENE', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d656.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d656.s1'}	Although occurred vitro studies coumarin type anticoagulants interactions coumarin type anticoagulants reported FELDENE since marketing therefore physicians closely monitor patients change dosage requirements administering FELDENE patients coumarin type anticoagulants highly protein bound drugs
Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. 	FELDENE	coumarin-type anticoagulants	none	{'e1': {'word': 'FELDENE', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d656.s1.e2'}, 'e2': {'word': 'coumarin-type anticoagulants', 'word_index': [(26, 28)], 'id': 'DDI-DrugBank.d656.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d656.s1'}	Although occurred vitro studies coumarin type anticoagulants interactions coumarin type anticoagulants reported FELDENE since marketing therefore physicians closely monitor patients change dosage requirements administering FELDENE patients coumarin type anticoagulants highly protein bound drugs
Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. 	FELDENE	coumarin-type anticoagulants	advise	{'e1': {'word': 'FELDENE', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d656.s1.e3'}, 'e2': {'word': 'coumarin-type anticoagulants', 'word_index': [(26, 28)], 'id': 'DDI-DrugBank.d656.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d656.s1'}	Although occurred vitro studies coumarin type anticoagulants interactions coumarin type anticoagulants reported FELDENE since marketing therefore physicians closely monitor patients change dosage requirements administering FELDENE patients coumarin type anticoagulants highly protein bound drugs
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. 	piroxicam	FELDENE	none	{'e1': {'word': 'piroxicam', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d656.s2.e0'}, 'e2': {'word': 'FELDENE', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d656.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d656.s2'}	Plasma levels piroxicam depressed approximately NUMBER % normal values FELDENE administered conjunction aspirin NUMBER mg / day concomitant administration antacids effect piroxicam plasma levels Nonsteroidal anti-inflammatory agents including FELDENE reported increase steady state plasma lithium levels
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. 	piroxicam	aspirin	none	{'e1': {'word': 'piroxicam', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d656.s2.e0'}, 'e2': {'word': 'aspirin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d656.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d656.s2'}	Plasma levels piroxicam depressed approximately NUMBER % normal values FELDENE administered conjunction aspirin NUMBER mg / day concomitant administration antacids effect piroxicam plasma levels Nonsteroidal anti-inflammatory agents including FELDENE reported increase steady state plasma lithium levels
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. 	piroxicam	antacids	none	{'e1': {'word': 'piroxicam', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d656.s2.e0'}, 'e2': {'word': 'antacids', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d656.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d656.s2'}	Plasma levels piroxicam depressed approximately NUMBER % normal values FELDENE administered conjunction aspirin NUMBER mg / day concomitant administration antacids effect piroxicam plasma levels Nonsteroidal anti-inflammatory agents including FELDENE reported increase steady state plasma lithium levels
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. 	piroxicam	piroxicam	none	{'e1': {'word': 'piroxicam', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d656.s2.e0'}, 'e2': {'word': 'piroxicam', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d656.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d656.s2'}	Plasma levels piroxicam depressed approximately NUMBER % normal values FELDENE administered conjunction aspirin NUMBER mg / day concomitant administration antacids effect piroxicam plasma levels Nonsteroidal anti-inflammatory agents including FELDENE reported increase steady state plasma lithium levels
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. 	piroxicam	Nonsteroidal anti-inflammatory agents	none	{'e1': {'word': 'piroxicam', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d656.s2.e0'}, 'e2': {'word': 'Nonsteroidal anti-inflammatory agents', 'word_index': [(24, 26)], 'id': 'DDI-DrugBank.d656.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d656.s2'}	Plasma levels piroxicam depressed approximately NUMBER % normal values FELDENE administered conjunction aspirin NUMBER mg / day concomitant administration antacids effect piroxicam plasma levels Nonsteroidal anti-inflammatory agents including FELDENE reported increase steady state plasma lithium levels
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. 	piroxicam	FELDENE	none	{'e1': {'word': 'piroxicam', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d656.s2.e0'}, 'e2': {'word': 'FELDENE', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d656.s2.e6'}, 'sentence_id': 'DDI-DrugBank.d656.s2'}	Plasma levels piroxicam depressed approximately NUMBER % normal values FELDENE administered conjunction aspirin NUMBER mg / day concomitant administration antacids effect piroxicam plasma levels Nonsteroidal anti-inflammatory agents including FELDENE reported increase steady state plasma lithium levels
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. 	piroxicam	lithium	none	{'e1': {'word': 'piroxicam', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d656.s2.e0'}, 'e2': {'word': 'lithium', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d656.s2.e7'}, 'sentence_id': 'DDI-DrugBank.d656.s2'}	Plasma levels piroxicam depressed approximately NUMBER % normal values FELDENE administered conjunction aspirin NUMBER mg / day concomitant administration antacids effect piroxicam plasma levels Nonsteroidal anti-inflammatory agents including FELDENE reported increase steady state plasma lithium levels
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. 	FELDENE	aspirin	mechanism	{'e1': {'word': 'FELDENE', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d656.s2.e1'}, 'e2': {'word': 'aspirin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d656.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d656.s2'}	Plasma levels piroxicam depressed approximately NUMBER % normal values FELDENE administered conjunction aspirin NUMBER mg / day concomitant administration antacids effect piroxicam plasma levels Nonsteroidal anti-inflammatory agents including FELDENE reported increase steady state plasma lithium levels
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. 	FELDENE	antacids	none	{'e1': {'word': 'FELDENE', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d656.s2.e1'}, 'e2': {'word': 'antacids', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d656.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d656.s2'}	Plasma levels piroxicam depressed approximately NUMBER % normal values FELDENE administered conjunction aspirin NUMBER mg / day concomitant administration antacids effect piroxicam plasma levels Nonsteroidal anti-inflammatory agents including FELDENE reported increase steady state plasma lithium levels
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. 	FELDENE	piroxicam	none	{'e1': {'word': 'FELDENE', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d656.s2.e1'}, 'e2': {'word': 'piroxicam', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d656.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d656.s2'}	Plasma levels piroxicam depressed approximately NUMBER % normal values FELDENE administered conjunction aspirin NUMBER mg / day concomitant administration antacids effect piroxicam plasma levels Nonsteroidal anti-inflammatory agents including FELDENE reported increase steady state plasma lithium levels
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. 	FELDENE	Nonsteroidal anti-inflammatory agents	none	{'e1': {'word': 'FELDENE', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d656.s2.e1'}, 'e2': {'word': 'Nonsteroidal anti-inflammatory agents', 'word_index': [(24, 26)], 'id': 'DDI-DrugBank.d656.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d656.s2'}	Plasma levels piroxicam depressed approximately NUMBER % normal values FELDENE administered conjunction aspirin NUMBER mg / day concomitant administration antacids effect piroxicam plasma levels Nonsteroidal anti-inflammatory agents including FELDENE reported increase steady state plasma lithium levels
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. 	FELDENE	FELDENE	none	{'e1': {'word': 'FELDENE', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d656.s2.e1'}, 'e2': {'word': 'FELDENE', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d656.s2.e6'}, 'sentence_id': 'DDI-DrugBank.d656.s2'}	Plasma levels piroxicam depressed approximately NUMBER % normal values FELDENE administered conjunction aspirin NUMBER mg / day concomitant administration antacids effect piroxicam plasma levels Nonsteroidal anti-inflammatory agents including FELDENE reported increase steady state plasma lithium levels
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. 	FELDENE	lithium	none	{'e1': {'word': 'FELDENE', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d656.s2.e1'}, 'e2': {'word': 'lithium', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d656.s2.e7'}, 'sentence_id': 'DDI-DrugBank.d656.s2'}	Plasma levels piroxicam depressed approximately NUMBER % normal values FELDENE administered conjunction aspirin NUMBER mg / day concomitant administration antacids effect piroxicam plasma levels Nonsteroidal anti-inflammatory agents including FELDENE reported increase steady state plasma lithium levels
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. 	aspirin	antacids	none	{'e1': {'word': 'aspirin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d656.s2.e2'}, 'e2': {'word': 'antacids', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d656.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d656.s2'}	Plasma levels piroxicam depressed approximately NUMBER % normal values FELDENE administered conjunction aspirin NUMBER mg / day concomitant administration antacids effect piroxicam plasma levels Nonsteroidal anti-inflammatory agents including FELDENE reported increase steady state plasma lithium levels
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. 	aspirin	piroxicam	none	{'e1': {'word': 'aspirin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d656.s2.e2'}, 'e2': {'word': 'piroxicam', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d656.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d656.s2'}	Plasma levels piroxicam depressed approximately NUMBER % normal values FELDENE administered conjunction aspirin NUMBER mg / day concomitant administration antacids effect piroxicam plasma levels Nonsteroidal anti-inflammatory agents including FELDENE reported increase steady state plasma lithium levels
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. 	aspirin	Nonsteroidal anti-inflammatory agents	none	{'e1': {'word': 'aspirin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d656.s2.e2'}, 'e2': {'word': 'Nonsteroidal anti-inflammatory agents', 'word_index': [(24, 26)], 'id': 'DDI-DrugBank.d656.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d656.s2'}	Plasma levels piroxicam depressed approximately NUMBER % normal values FELDENE administered conjunction aspirin NUMBER mg / day concomitant administration antacids effect piroxicam plasma levels Nonsteroidal anti-inflammatory agents including FELDENE reported increase steady state plasma lithium levels
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. 	aspirin	FELDENE	none	{'e1': {'word': 'aspirin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d656.s2.e2'}, 'e2': {'word': 'FELDENE', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d656.s2.e6'}, 'sentence_id': 'DDI-DrugBank.d656.s2'}	Plasma levels piroxicam depressed approximately NUMBER % normal values FELDENE administered conjunction aspirin NUMBER mg / day concomitant administration antacids effect piroxicam plasma levels Nonsteroidal anti-inflammatory agents including FELDENE reported increase steady state plasma lithium levels
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. 	aspirin	lithium	none	{'e1': {'word': 'aspirin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d656.s2.e2'}, 'e2': {'word': 'lithium', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d656.s2.e7'}, 'sentence_id': 'DDI-DrugBank.d656.s2'}	Plasma levels piroxicam depressed approximately NUMBER % normal values FELDENE administered conjunction aspirin NUMBER mg / day concomitant administration antacids effect piroxicam plasma levels Nonsteroidal anti-inflammatory agents including FELDENE reported increase steady state plasma lithium levels
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. 	antacids	piroxicam	none	{'e1': {'word': 'antacids', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d656.s2.e3'}, 'e2': {'word': 'piroxicam', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d656.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d656.s2'}	Plasma levels piroxicam depressed approximately NUMBER % normal values FELDENE administered conjunction aspirin NUMBER mg / day concomitant administration antacids effect piroxicam plasma levels Nonsteroidal anti-inflammatory agents including FELDENE reported increase steady state plasma lithium levels
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. 	antacids	Nonsteroidal anti-inflammatory agents	none	{'e1': {'word': 'antacids', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d656.s2.e3'}, 'e2': {'word': 'Nonsteroidal anti-inflammatory agents', 'word_index': [(24, 26)], 'id': 'DDI-DrugBank.d656.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d656.s2'}	Plasma levels piroxicam depressed approximately NUMBER % normal values FELDENE administered conjunction aspirin NUMBER mg / day concomitant administration antacids effect piroxicam plasma levels Nonsteroidal anti-inflammatory agents including FELDENE reported increase steady state plasma lithium levels
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. 	antacids	FELDENE	none	{'e1': {'word': 'antacids', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d656.s2.e3'}, 'e2': {'word': 'FELDENE', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d656.s2.e6'}, 'sentence_id': 'DDI-DrugBank.d656.s2'}	Plasma levels piroxicam depressed approximately NUMBER % normal values FELDENE administered conjunction aspirin NUMBER mg / day concomitant administration antacids effect piroxicam plasma levels Nonsteroidal anti-inflammatory agents including FELDENE reported increase steady state plasma lithium levels
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. 	antacids	lithium	none	{'e1': {'word': 'antacids', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d656.s2.e3'}, 'e2': {'word': 'lithium', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d656.s2.e7'}, 'sentence_id': 'DDI-DrugBank.d656.s2'}	Plasma levels piroxicam depressed approximately NUMBER % normal values FELDENE administered conjunction aspirin NUMBER mg / day concomitant administration antacids effect piroxicam plasma levels Nonsteroidal anti-inflammatory agents including FELDENE reported increase steady state plasma lithium levels
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. 	piroxicam	Nonsteroidal anti-inflammatory agents	none	{'e1': {'word': 'piroxicam', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d656.s2.e4'}, 'e2': {'word': 'Nonsteroidal anti-inflammatory agents', 'word_index': [(24, 26)], 'id': 'DDI-DrugBank.d656.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d656.s2'}	Plasma levels piroxicam depressed approximately NUMBER % normal values FELDENE administered conjunction aspirin NUMBER mg / day concomitant administration antacids effect piroxicam plasma levels Nonsteroidal anti-inflammatory agents including FELDENE reported increase steady state plasma lithium levels
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. 	piroxicam	FELDENE	none	{'e1': {'word': 'piroxicam', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d656.s2.e4'}, 'e2': {'word': 'FELDENE', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d656.s2.e6'}, 'sentence_id': 'DDI-DrugBank.d656.s2'}	Plasma levels piroxicam depressed approximately NUMBER % normal values FELDENE administered conjunction aspirin NUMBER mg / day concomitant administration antacids effect piroxicam plasma levels Nonsteroidal anti-inflammatory agents including FELDENE reported increase steady state plasma lithium levels
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. 	piroxicam	lithium	none	{'e1': {'word': 'piroxicam', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d656.s2.e4'}, 'e2': {'word': 'lithium', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d656.s2.e7'}, 'sentence_id': 'DDI-DrugBank.d656.s2'}	Plasma levels piroxicam depressed approximately NUMBER % normal values FELDENE administered conjunction aspirin NUMBER mg / day concomitant administration antacids effect piroxicam plasma levels Nonsteroidal anti-inflammatory agents including FELDENE reported increase steady state plasma lithium levels
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. 	Nonsteroidal anti-inflammatory agents	FELDENE	none	{'e1': {'word': 'Nonsteroidal anti-inflammatory agents', 'word_index': [(24, 26)], 'id': 'DDI-DrugBank.d656.s2.e5'}, 'e2': {'word': 'FELDENE', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d656.s2.e6'}, 'sentence_id': 'DDI-DrugBank.d656.s2'}	Plasma levels piroxicam depressed approximately NUMBER % normal values FELDENE administered conjunction aspirin NUMBER mg / day concomitant administration antacids effect piroxicam plasma levels Nonsteroidal anti-inflammatory agents including FELDENE reported increase steady state plasma lithium levels
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. 	Nonsteroidal anti-inflammatory agents	lithium	mechanism	{'e1': {'word': 'Nonsteroidal anti-inflammatory agents', 'word_index': [(24, 26)], 'id': 'DDI-DrugBank.d656.s2.e5'}, 'e2': {'word': 'lithium', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d656.s2.e7'}, 'sentence_id': 'DDI-DrugBank.d656.s2'}	Plasma levels piroxicam depressed approximately NUMBER % normal values FELDENE administered conjunction aspirin NUMBER mg / day concomitant administration antacids effect piroxicam plasma levels Nonsteroidal anti-inflammatory agents including FELDENE reported increase steady state plasma lithium levels
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. 	FELDENE	lithium	mechanism	{'e1': {'word': 'FELDENE', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d656.s2.e6'}, 'e2': {'word': 'lithium', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d656.s2.e7'}, 'sentence_id': 'DDI-DrugBank.d656.s2'}	Plasma levels piroxicam depressed approximately NUMBER % normal values FELDENE administered conjunction aspirin NUMBER mg / day concomitant administration antacids effect piroxicam plasma levels Nonsteroidal anti-inflammatory agents including FELDENE reported increase steady state plasma lithium levels
It is recommended that plasma lithium levels be monitored when initiating, adjusting and discontinuing FELDENE.	lithium	FELDENE	advise	{'e1': {'word': 'lithium', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d656.s3.e0'}, 'e2': {'word': 'FELDENE', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d656.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d656.s3'}	recommended plasma lithium levels monitored initiating adjusting discontinuing FELDENE
There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine. 	PURINETHOL	mercaptopurine	none	{'e1': {'word': 'PURINETHOL', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d722.s0.e0'}, 'e2': {'word': 'mercaptopurine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d722.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d722.s0'}	usually complete cross between PURINETHOL ( mercaptopurine ) brand Thioguanine .
There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine. 	PURINETHOL	TABLOID	effect	{'e1': {'word': 'PURINETHOL', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d722.s0.e0'}, 'e2': {'word': 'TABLOID', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d722.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d722.s0'}	usually complete cross between PURINETHOL ( ) TABLOID brand Thioguanine .
There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine. 	PURINETHOL	Thioguanine	effect	{'e1': {'word': 'PURINETHOL', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d722.s0.e0'}, 'e2': {'word': 'Thioguanine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d722.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d722.s0'}	usually complete cross between PURINETHOL ( ) brand Thioguanine .
There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine. 	mercaptopurine	TABLOID	effect	{'e1': {'word': 'mercaptopurine', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d722.s0.e1'}, 'e2': {'word': 'TABLOID', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d722.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d722.s0'}	usually complete cross between ( mercaptopurine ) TABLOID brand Thioguanine .
There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine. 	mercaptopurine	Thioguanine	effect	{'e1': {'word': 'mercaptopurine', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d722.s0.e1'}, 'e2': {'word': 'Thioguanine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d722.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d722.s0'}	usually complete cross between ( mercaptopurine ) brand Thioguanine .
There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine. 	TABLOID	Thioguanine	none	{'e1': {'word': 'TABLOID', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d722.s0.e2'}, 'e2': {'word': 'Thioguanine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d722.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d722.s0'}	usually complete cross between ( ) TABLOID brand Thioguanine .
As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    	aminosalicylate derivatives	olsalazine	none	{'e1': {'word': 'aminosalicylate derivatives', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d722.s1.e0'}, 'e2': {'word': 'olsalazine', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d722.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d722.s1'}	vitro evidence aminosalicylate derivatives e.g. olsalazine mesalazine sulphasalazine inhibit TPMT enzyme administered caution patients receiving concurrent thioguanine therapy
As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    	aminosalicylate derivatives	mesalazine	none	{'e1': {'word': 'aminosalicylate derivatives', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d722.s1.e0'}, 'e2': {'word': 'mesalazine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d722.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d722.s1'}	vitro evidence aminosalicylate derivatives e.g. olsalazine mesalazine sulphasalazine inhibit TPMT enzyme administered caution patients receiving concurrent thioguanine therapy
As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    	aminosalicylate derivatives	sulphasalazine	none	{'e1': {'word': 'aminosalicylate derivatives', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d722.s1.e0'}, 'e2': {'word': 'sulphasalazine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d722.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d722.s1'}	vitro evidence aminosalicylate derivatives e.g. olsalazine mesalazine sulphasalazine inhibit TPMT enzyme administered caution patients receiving concurrent thioguanine therapy
As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    	aminosalicylate derivatives	thioguanine	mechanism	{'e1': {'word': 'aminosalicylate derivatives', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d722.s1.e0'}, 'e2': {'word': 'thioguanine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d722.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d722.s1'}	vitro evidence aminosalicylate derivatives e.g. olsalazine mesalazine sulphasalazine inhibit TPMT enzyme administered caution patients receiving concurrent thioguanine therapy
As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    	olsalazine	mesalazine	none	{'e1': {'word': 'olsalazine', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d722.s1.e1'}, 'e2': {'word': 'mesalazine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d722.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d722.s1'}	vitro evidence aminosalicylate derivatives e.g. olsalazine mesalazine sulphasalazine inhibit TPMT enzyme administered caution patients receiving concurrent thioguanine therapy
As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    	olsalazine	sulphasalazine	none	{'e1': {'word': 'olsalazine', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d722.s1.e1'}, 'e2': {'word': 'sulphasalazine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d722.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d722.s1'}	vitro evidence aminosalicylate derivatives e.g. olsalazine mesalazine sulphasalazine inhibit TPMT enzyme administered caution patients receiving concurrent thioguanine therapy
As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    	olsalazine	thioguanine	mechanism	{'e1': {'word': 'olsalazine', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d722.s1.e1'}, 'e2': {'word': 'thioguanine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d722.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d722.s1'}	vitro evidence aminosalicylate derivatives e.g. olsalazine mesalazine sulphasalazine inhibit TPMT enzyme administered caution patients receiving concurrent thioguanine therapy
As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    	mesalazine	sulphasalazine	none	{'e1': {'word': 'mesalazine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d722.s1.e2'}, 'e2': {'word': 'sulphasalazine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d722.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d722.s1'}	vitro evidence aminosalicylate derivatives e.g. olsalazine mesalazine sulphasalazine inhibit TPMT enzyme administered caution patients receiving concurrent thioguanine therapy
As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    	mesalazine	thioguanine	mechanism	{'e1': {'word': 'mesalazine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d722.s1.e2'}, 'e2': {'word': 'thioguanine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d722.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d722.s1'}	vitro evidence aminosalicylate derivatives e.g. olsalazine mesalazine sulphasalazine inhibit TPMT enzyme administered caution patients receiving concurrent thioguanine therapy
As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    	sulphasalazine	thioguanine	mechanism	{'e1': {'word': 'sulphasalazine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d722.s1.e3'}, 'e2': {'word': 'thioguanine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d722.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d722.s1'}	vitro evidence aminosalicylate derivatives e.g. olsalazine mesalazine sulphasalazine inhibit TPMT enzyme administered caution patients receiving concurrent thioguanine therapy
patients receiving lithium and Neulasta should have more frequent monitoring of neutrophil counts.	lithium	Neulasta	advise	{'e1': {'word': 'lithium', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d581.s2.e0'}, 'e2': {'word': 'Neulasta', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d581.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d581.s2'}	patients receiving lithium Neulasta frequent monitoring neutrophil counts
To minimize CNS depression and possible potentiation, barbiturates, antihistamines, narcotics, hypotensive agents or phenothiazines should be used with caution. 	barbiturates	antihistamines	none	{'e1': {'word': 'barbiturates', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d676.s0.e0'}, 'e2': {'word': 'antihistamines', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d676.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d676.s0'}	minimize CNS depression possible potentiation barbiturates antihistamines narcotics hypotensive agents phenothiazines used caution
To minimize CNS depression and possible potentiation, barbiturates, antihistamines, narcotics, hypotensive agents or phenothiazines should be used with caution. 	barbiturates	narcotics	none	{'e1': {'word': 'barbiturates', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d676.s0.e0'}, 'e2': {'word': 'narcotics', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d676.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d676.s0'}	minimize CNS depression possible potentiation barbiturates antihistamines narcotics hypotensive agents phenothiazines used caution
To minimize CNS depression and possible potentiation, barbiturates, antihistamines, narcotics, hypotensive agents or phenothiazines should be used with caution. 	barbiturates	hypotensive agents	none	{'e1': {'word': 'barbiturates', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d676.s0.e0'}, 'e2': {'word': 'hypotensive agents', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d676.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d676.s0'}	minimize CNS depression possible potentiation barbiturates antihistamines narcotics hypotensive agents phenothiazines used caution
To minimize CNS depression and possible potentiation, barbiturates, antihistamines, narcotics, hypotensive agents or phenothiazines should be used with caution. 	barbiturates	phenothiazines	none	{'e1': {'word': 'barbiturates', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d676.s0.e0'}, 'e2': {'word': 'phenothiazines', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d676.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d676.s0'}	minimize CNS depression possible potentiation barbiturates antihistamines narcotics hypotensive agents phenothiazines used caution
To minimize CNS depression and possible potentiation, barbiturates, antihistamines, narcotics, hypotensive agents or phenothiazines should be used with caution. 	antihistamines	narcotics	none	{'e1': {'word': 'antihistamines', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d676.s0.e1'}, 'e2': {'word': 'narcotics', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d676.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d676.s0'}	minimize CNS depression possible potentiation barbiturates antihistamines narcotics hypotensive agents phenothiazines used caution
To minimize CNS depression and possible potentiation, barbiturates, antihistamines, narcotics, hypotensive agents or phenothiazines should be used with caution. 	antihistamines	hypotensive agents	none	{'e1': {'word': 'antihistamines', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d676.s0.e1'}, 'e2': {'word': 'hypotensive agents', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d676.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d676.s0'}	minimize CNS depression possible potentiation barbiturates antihistamines narcotics hypotensive agents phenothiazines used caution
To minimize CNS depression and possible potentiation, barbiturates, antihistamines, narcotics, hypotensive agents or phenothiazines should be used with caution. 	antihistamines	phenothiazines	none	{'e1': {'word': 'antihistamines', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d676.s0.e1'}, 'e2': {'word': 'phenothiazines', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d676.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d676.s0'}	minimize CNS depression possible potentiation barbiturates antihistamines narcotics hypotensive agents phenothiazines used caution
To minimize CNS depression and possible potentiation, barbiturates, antihistamines, narcotics, hypotensive agents or phenothiazines should be used with caution. 	narcotics	hypotensive agents	none	{'e1': {'word': 'narcotics', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d676.s0.e2'}, 'e2': {'word': 'hypotensive agents', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d676.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d676.s0'}	minimize CNS depression possible potentiation barbiturates antihistamines narcotics hypotensive agents phenothiazines used caution
To minimize CNS depression and possible potentiation, barbiturates, antihistamines, narcotics, hypotensive agents or phenothiazines should be used with caution. 	narcotics	phenothiazines	none	{'e1': {'word': 'narcotics', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d676.s0.e2'}, 'e2': {'word': 'phenothiazines', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d676.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d676.s0'}	minimize CNS depression possible potentiation barbiturates antihistamines narcotics hypotensive agents phenothiazines used caution
To minimize CNS depression and possible potentiation, barbiturates, antihistamines, narcotics, hypotensive agents or phenothiazines should be used with caution. 	hypotensive agents	phenothiazines	none	{'e1': {'word': 'hypotensive agents', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d676.s0.e3'}, 'e2': {'word': 'phenothiazines', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d676.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d676.s0'}	minimize CNS depression possible potentiation barbiturates antihistamines narcotics hypotensive agents phenothiazines used caution
Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. 	Matulane	sympathomimetic drugs	advise	{'e1': {'word': 'Matulane', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d676.s2.e0'}, 'e2': {'word': 'sympathomimetic drugs', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d676.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d676.s2'}	Matulane exhibits monoamine oxidase inhibitory activity sympathomimetic drugs tricyclic antidepressant drugs e.g. amitriptyline HCl imipramine HCl drugs foods known high tyramine content wine yogurt ripe cheese bananas avoided
Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. 	Matulane	tricyclic antidepressant	advise	{'e1': {'word': 'Matulane', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d676.s2.e0'}, 'e2': {'word': 'tricyclic antidepressant', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d676.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d676.s2'}	Matulane exhibits monoamine oxidase inhibitory activity sympathomimetic drugs tricyclic antidepressant drugs e.g. amitriptyline HCl imipramine HCl drugs foods known high tyramine content wine yogurt ripe cheese bananas avoided
Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. 	Matulane	amitriptyline HCl	advise	{'e1': {'word': 'Matulane', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d676.s2.e0'}, 'e2': {'word': 'amitriptyline HCl', 'word_index': [(12, 13)], 'id': 'DDI-DrugBank.d676.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d676.s2'}	Matulane exhibits monoamine oxidase inhibitory activity sympathomimetic drugs tricyclic antidepressant drugs e.g. amitriptyline HCl imipramine HCl drugs foods known high tyramine content wine yogurt ripe cheese bananas avoided
Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. 	Matulane	imipramine HCl	advise	{'e1': {'word': 'Matulane', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d676.s2.e0'}, 'e2': {'word': 'imipramine HCl', 'word_index': [(14, 15)], 'id': 'DDI-DrugBank.d676.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d676.s2'}	Matulane exhibits monoamine oxidase inhibitory activity sympathomimetic drugs tricyclic antidepressant drugs e.g. amitriptyline HCl imipramine HCl drugs foods known high tyramine content wine yogurt ripe cheese bananas avoided
Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. 	Matulane	tyramine	advise	{'e1': {'word': 'Matulane', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d676.s2.e0'}, 'e2': {'word': 'tyramine', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d676.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d676.s2'}	Matulane exhibits monoamine oxidase inhibitory activity sympathomimetic drugs tricyclic antidepressant drugs e.g. amitriptyline HCl imipramine HCl drugs foods known high tyramine content wine yogurt ripe cheese bananas avoided
Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. 	sympathomimetic drugs	tricyclic antidepressant	none	{'e1': {'word': 'sympathomimetic drugs', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d676.s2.e1'}, 'e2': {'word': 'tricyclic antidepressant', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d676.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d676.s2'}	Matulane exhibits monoamine oxidase inhibitory activity sympathomimetic drugs tricyclic antidepressant drugs e.g. amitriptyline HCl imipramine HCl drugs foods known high tyramine content wine yogurt ripe cheese bananas avoided
Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. 	sympathomimetic drugs	amitriptyline HCl	none	{'e1': {'word': 'sympathomimetic drugs', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d676.s2.e1'}, 'e2': {'word': 'amitriptyline HCl', 'word_index': [(12, 13)], 'id': 'DDI-DrugBank.d676.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d676.s2'}	Matulane exhibits monoamine oxidase inhibitory activity sympathomimetic drugs tricyclic antidepressant drugs e.g. amitriptyline HCl imipramine HCl drugs foods known high tyramine content wine yogurt ripe cheese bananas avoided
Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. 	sympathomimetic drugs	imipramine HCl	none	{'e1': {'word': 'sympathomimetic drugs', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d676.s2.e1'}, 'e2': {'word': 'imipramine HCl', 'word_index': [(14, 15)], 'id': 'DDI-DrugBank.d676.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d676.s2'}	Matulane exhibits monoamine oxidase inhibitory activity sympathomimetic drugs tricyclic antidepressant drugs e.g. amitriptyline HCl imipramine HCl drugs foods known high tyramine content wine yogurt ripe cheese bananas avoided
Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. 	sympathomimetic drugs	tyramine	none	{'e1': {'word': 'sympathomimetic drugs', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d676.s2.e1'}, 'e2': {'word': 'tyramine', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d676.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d676.s2'}	Matulane exhibits monoamine oxidase inhibitory activity sympathomimetic drugs tricyclic antidepressant drugs e.g. amitriptyline HCl imipramine HCl drugs foods known high tyramine content wine yogurt ripe cheese bananas avoided
Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. 	tricyclic antidepressant	amitriptyline HCl	none	{'e1': {'word': 'tricyclic antidepressant', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d676.s2.e2'}, 'e2': {'word': 'amitriptyline HCl', 'word_index': [(12, 13)], 'id': 'DDI-DrugBank.d676.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d676.s2'}	Matulane exhibits monoamine oxidase inhibitory activity sympathomimetic drugs tricyclic antidepressant drugs e.g. amitriptyline HCl imipramine HCl drugs foods known high tyramine content wine yogurt ripe cheese bananas avoided
Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. 	tricyclic antidepressant	imipramine HCl	none	{'e1': {'word': 'tricyclic antidepressant', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d676.s2.e2'}, 'e2': {'word': 'imipramine HCl', 'word_index': [(14, 15)], 'id': 'DDI-DrugBank.d676.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d676.s2'}	Matulane exhibits monoamine oxidase inhibitory activity sympathomimetic drugs tricyclic antidepressant drugs e.g. amitriptyline HCl imipramine HCl drugs foods known high tyramine content wine yogurt ripe cheese bananas avoided
Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. 	tricyclic antidepressant	tyramine	none	{'e1': {'word': 'tricyclic antidepressant', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d676.s2.e2'}, 'e2': {'word': 'tyramine', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d676.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d676.s2'}	Matulane exhibits monoamine oxidase inhibitory activity sympathomimetic drugs tricyclic antidepressant drugs e.g. amitriptyline HCl imipramine HCl drugs foods known high tyramine content wine yogurt ripe cheese bananas avoided
Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. 	amitriptyline HCl	imipramine HCl	none	{'e1': {'word': 'amitriptyline HCl', 'word_index': [(12, 13)], 'id': 'DDI-DrugBank.d676.s2.e3'}, 'e2': {'word': 'imipramine HCl', 'word_index': [(14, 15)], 'id': 'DDI-DrugBank.d676.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d676.s2'}	Matulane exhibits monoamine oxidase inhibitory activity sympathomimetic drugs tricyclic antidepressant drugs e.g. amitriptyline HCl imipramine HCl drugs foods known high tyramine content wine yogurt ripe cheese bananas avoided
Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. 	amitriptyline HCl	tyramine	none	{'e1': {'word': 'amitriptyline HCl', 'word_index': [(12, 13)], 'id': 'DDI-DrugBank.d676.s2.e3'}, 'e2': {'word': 'tyramine', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d676.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d676.s2'}	Matulane exhibits monoamine oxidase inhibitory activity sympathomimetic drugs tricyclic antidepressant drugs e.g. amitriptyline HCl imipramine HCl drugs foods known high tyramine content wine yogurt ripe cheese bananas avoided
Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided. 	imipramine HCl	tyramine	none	{'e1': {'word': 'imipramine HCl', 'word_index': [(14, 15)], 'id': 'DDI-DrugBank.d676.s2.e4'}, 'e2': {'word': 'tyramine', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d676.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d676.s2'}	Matulane exhibits monoamine oxidase inhibitory activity sympathomimetic drugs tricyclic antidepressant drugs e.g. amitriptyline HCl imipramine HCl drugs foods known high tyramine content wine yogurt ripe cheese bananas avoided
No cross-resistance with other chemotherapeutic agents, radiotherapy or steroids has been demonstrated.	chemotherapeutic agents	steroids	none	{'e1': {'word': 'chemotherapeutic agents', 'word_index': [(1, 2)], 'id': 'DDI-DrugBank.d676.s4.e0'}, 'e2': {'word': 'steroids', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d676.s4.e1'}, 'sentence_id': 'DDI-DrugBank.d676.s4'}	cross-resistance chemotherapeutic agents radiotherapy steroids demonstrated
The occurrence of stupor, muscular rigidity, severe agitation, and elevated temperature has been reported in some patients receiving the combination of selegiline and meperidine. 	selegiline	meperidine	effect	{'e1': {'word': 'selegiline', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d619.s0.e0'}, 'e2': {'word': 'meperidine', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d619.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d619.s0'}	occurrence stupor muscular rigidity severe agitation elevated temperature reported patients receiving combination selegiline meperidine
This is typical of the interaction of meperidine and MAOIs. 	meperidine	MAOIs	int	{'e1': {'word': 'meperidine', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d619.s2.e0'}, 'e2': {'word': 'MAOIs', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d619.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d619.s2'}	typical interaction meperidine MAOIs
Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and ELDEPRYL and selective serotonin reuptake inhibitors and ELDEPRYL. 	tricyclic antidepressants	ELDEPRYL	effect	{'e1': {'word': 'tricyclic antidepressants', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d619.s4.e0'}, 'e2': {'word': 'ELDEPRYL', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d619.s4.e1'}, 'sentence_id': 'DDI-DrugBank.d619.s4'}	Severe toxicity also reported patients receiving combination tricyclic antidepressants ELDEPRYL selective serotonin reuptake inhibitors ELDEPRYL
Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and ELDEPRYL and selective serotonin reuptake inhibitors and ELDEPRYL. 	tricyclic antidepressants	selective serotonin reuptake inhibitors	none	{'e1': {'word': 'tricyclic antidepressants', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d619.s4.e0'}, 'e2': {'word': 'selective serotonin reuptake inhibitors', 'word_index': [(10, 13)], 'id': 'DDI-DrugBank.d619.s4.e2'}, 'sentence_id': 'DDI-DrugBank.d619.s4'}	Severe toxicity also reported patients receiving combination tricyclic antidepressants ELDEPRYL selective serotonin reuptake inhibitors ELDEPRYL
Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and ELDEPRYL and selective serotonin reuptake inhibitors and ELDEPRYL. 	tricyclic antidepressants	ELDEPRYL	none	{'e1': {'word': 'tricyclic antidepressants', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d619.s4.e0'}, 'e2': {'word': 'ELDEPRYL', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d619.s4.e3'}, 'sentence_id': 'DDI-DrugBank.d619.s4'}	Severe toxicity also reported patients receiving combination tricyclic antidepressants ELDEPRYL selective serotonin reuptake inhibitors ELDEPRYL
Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and ELDEPRYL and selective serotonin reuptake inhibitors and ELDEPRYL. 	ELDEPRYL	selective serotonin reuptake inhibitors	none	{'e1': {'word': 'ELDEPRYL', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d619.s4.e1'}, 'e2': {'word': 'selective serotonin reuptake inhibitors', 'word_index': [(10, 13)], 'id': 'DDI-DrugBank.d619.s4.e2'}, 'sentence_id': 'DDI-DrugBank.d619.s4'}	Severe toxicity also reported patients receiving combination tricyclic antidepressants ELDEPRYL selective serotonin reuptake inhibitors ELDEPRYL
Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and ELDEPRYL and selective serotonin reuptake inhibitors and ELDEPRYL. 	ELDEPRYL	ELDEPRYL	none	{'e1': {'word': 'ELDEPRYL', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d619.s4.e1'}, 'e2': {'word': 'ELDEPRYL', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d619.s4.e3'}, 'sentence_id': 'DDI-DrugBank.d619.s4'}	Severe toxicity also reported patients receiving combination tricyclic antidepressants ELDEPRYL selective serotonin reuptake inhibitors ELDEPRYL
Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and ELDEPRYL and selective serotonin reuptake inhibitors and ELDEPRYL. 	selective serotonin reuptake inhibitors	ELDEPRYL	effect	{'e1': {'word': 'selective serotonin reuptake inhibitors', 'word_index': [(10, 13)], 'id': 'DDI-DrugBank.d619.s4.e2'}, 'e2': {'word': 'ELDEPRYL', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d619.s4.e3'}, 'sentence_id': 'DDI-DrugBank.d619.s4'}	Severe toxicity also reported patients receiving combination tricyclic antidepressants ELDEPRYL selective serotonin reuptake inhibitors ELDEPRYL
One case of hypertensive crisis has been reported in a patient taking the recommended doses of selegiline and a sympathomimetic medication (ephedrine).	selegiline	sympathomimetic medication	effect	{'e1': {'word': 'selegiline', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d619.s5.e0'}, 'e2': {'word': 'sympathomimetic medication', 'word_index': [(10, 11)], 'id': 'DDI-DrugBank.d619.s5.e1'}, 'sentence_id': 'DDI-DrugBank.d619.s5'}	NUMBER case hypertensive crisis reported patient taking recommended doses selegiline sympathomimetic medication ephedrine
One case of hypertensive crisis has been reported in a patient taking the recommended doses of selegiline and a sympathomimetic medication (ephedrine).	selegiline	ephedrine	effect	{'e1': {'word': 'selegiline', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d619.s5.e0'}, 'e2': {'word': 'ephedrine', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d619.s5.e2'}, 'sentence_id': 'DDI-DrugBank.d619.s5'}	NUMBER case hypertensive crisis reported patient taking recommended doses selegiline sympathomimetic medication ephedrine
One case of hypertensive crisis has been reported in a patient taking the recommended doses of selegiline and a sympathomimetic medication (ephedrine).	sympathomimetic medication	ephedrine	none	{'e1': {'word': 'sympathomimetic medication', 'word_index': [(10, 11)], 'id': 'DDI-DrugBank.d619.s5.e1'}, 'e2': {'word': 'ephedrine', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d619.s5.e2'}, 'sentence_id': 'DDI-DrugBank.d619.s5'}	NUMBER case hypertensive crisis reported patient taking recommended doses selegiline sympathomimetic medication ephedrine
Carbidopa/Levodopa: Carbidopa/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10). 	Carbidopa	Levodopa	none	{'e1': {'word': 'Carbidopa', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d737.s0.e0'}, 'e2': {'word': 'Levodopa', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d737.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d737.s0'}	Carbidopa Levodopa Carbidopa Levodopa influence pharmacokinetics pramipexole healthy volunteers N = NUMBER
Carbidopa/Levodopa: Carbidopa/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10). 	Carbidopa	Carbidopa	none	{'e1': {'word': 'Carbidopa', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d737.s0.e0'}, 'e2': {'word': 'Carbidopa', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d737.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d737.s0'}	Carbidopa Levodopa Carbidopa Levodopa influence pharmacokinetics pramipexole healthy volunteers N = NUMBER
Carbidopa/Levodopa: Carbidopa/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10). 	Carbidopa	Levodopa	none	{'e1': {'word': 'Carbidopa', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d737.s0.e0'}, 'e2': {'word': 'Levodopa', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d737.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d737.s0'}	Carbidopa Levodopa Carbidopa Levodopa influence pharmacokinetics pramipexole healthy volunteers N = NUMBER
Carbidopa/Levodopa: Carbidopa/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10). 	Carbidopa	pramipexole	none	{'e1': {'word': 'Carbidopa', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d737.s0.e0'}, 'e2': {'word': 'pramipexole', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d737.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d737.s0'}	Carbidopa Levodopa Carbidopa Levodopa influence pharmacokinetics pramipexole healthy volunteers N= NUMBER
Carbidopa/Levodopa: Carbidopa/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10). 	Levodopa	Carbidopa	none	{'e1': {'word': 'Levodopa', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d737.s0.e1'}, 'e2': {'word': 'Carbidopa', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d737.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d737.s0'}	Carbidopa Levodopa Carbidopa Levodopa influence pharmacokinetics pramipexole healthy volunteers N = NUMBER
Carbidopa/Levodopa: Carbidopa/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10). 	Levodopa	Levodopa	none	{'e1': {'word': 'Levodopa', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d737.s0.e1'}, 'e2': {'word': 'Levodopa', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d737.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d737.s0'}	Carbidopa Levodopa Carbidopa Levodopa influence pharmacokinetics pramipexole healthy volunteers N = NUMBER
Carbidopa/Levodopa: Carbidopa/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10). 	Levodopa	pramipexole	none	{'e1': {'word': 'Levodopa', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d737.s0.e1'}, 'e2': {'word': 'pramipexole', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d737.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d737.s0'}	Carbidopa Levodopa Carbidopa Levodopa influence pharmacokinetics pramipexole healthy volunteers N= NUMBER
Carbidopa/Levodopa: Carbidopa/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10). 	Carbidopa	Levodopa	none	{'e1': {'word': 'Carbidopa', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d737.s0.e2'}, 'e2': {'word': 'Levodopa', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d737.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d737.s0'}	Carbidopa Levodopa Carbidopa Levodopa influence pharmacokinetics pramipexole healthy volunteers N = NUMBER
Carbidopa/Levodopa: Carbidopa/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10). 	Carbidopa	pramipexole	none	{'e1': {'word': 'Carbidopa', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d737.s0.e2'}, 'e2': {'word': 'pramipexole', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d737.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d737.s0'}	Carbidopa Levodopa Carbidopa Levodopa influence pharmacokinetics pramipexole healthy volunteers N= NUMBER
Carbidopa/Levodopa: Carbidopa/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10). 	Levodopa	pramipexole	none	{'e1': {'word': 'Levodopa', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d737.s0.e3'}, 'e2': {'word': 'pramipexole', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d737.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d737.s0'}	Carbidopa Levodopa Carbidopa Levodopa influence pharmacokinetics pramipexole healthy volunteers N= NUMBER
Selegiline: In healthy volunteers (N= 11), selegiline did not influence the pharmacokinetics of pramipexole. 	Selegiline	selegiline	none	{'e1': {'word': 'Selegiline', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d737.s2.e0'}, 'e2': {'word': 'selegiline', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d737.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d737.s2'}	Selegiline healthy volunteers N= NUMBER selegiline influence pharmacokinetics pramipexole
Selegiline: In healthy volunteers (N= 11), selegiline did not influence the pharmacokinetics of pramipexole. 	Selegiline	pramipexole	none	{'e1': {'word': 'Selegiline', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d737.s2.e0'}, 'e2': {'word': 'pramipexole', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d737.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d737.s2'}	Selegiline healthy volunteers N= NUMBER selegiline influence pharmacokinetics pramipexole
Selegiline: In healthy volunteers (N= 11), selegiline did not influence the pharmacokinetics of pramipexole. 	selegiline	pramipexole	none	{'e1': {'word': 'selegiline', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d737.s2.e1'}, 'e2': {'word': 'pramipexole', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d737.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d737.s2'}	Selegiline healthy volunteers N= NUMBER selegiline influence pharmacokinetics pramipexole
Amantadine: Population pharmacokinetic analysis suggests that amantadine is unlikely to alter the oral clearance of pramipexole (N= 54). 	Amantadine	amantadine	none	{'e1': {'word': 'Amantadine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d737.s3.e0'}, 'e2': {'word': 'amantadine', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d737.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d737.s3'}	Amantadine Population pharmacokinetic analysis suggests amantadine unlikely alter oral clearance pramipexole N= NUMBER
Amantadine: Population pharmacokinetic analysis suggests that amantadine is unlikely to alter the oral clearance of pramipexole (N= 54). 	Amantadine	pramipexole	none	{'e1': {'word': 'Amantadine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d737.s3.e0'}, 'e2': {'word': 'pramipexole', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d737.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d737.s3'}	Amantadine Population pharmacokinetic analysis suggests amantadine unlikely alter oral clearance pramipexole N= NUMBER
Amantadine: Population pharmacokinetic analysis suggests that amantadine is unlikely to alter the oral clearance of pramipexole (N= 54). 	amantadine	pramipexole	none	{'e1': {'word': 'amantadine', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d737.s3.e1'}, 'e2': {'word': 'pramipexole', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d737.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d737.s3'}	Amantadine Population pharmacokinetic analysis suggests amantadine unlikely alter oral clearance pramipexole N= 54 NUMBER
Cimetidine: Cimetidine, a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in pramipexole AUC and a 40% increase in half-life (N= 12). 	Cimetidine	Cimetidine	none	{'e1': {'word': 'Cimetidine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d737.s4.e0'}, 'e2': {'word': 'Cimetidine', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d737.s4.e1'}, 'sentence_id': 'DDI-DrugBank.d737.s4'}	Cimetidine Cimetidine known inhibitor renal tubular secretion organic bases via cationic transport system caused NUMBER % increase pramipexole AUC NUMBER % increase half life N= NUMBER
Cimetidine: Cimetidine, a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in pramipexole AUC and a 40% increase in half-life (N= 12). 	Cimetidine	pramipexole	none	{'e1': {'word': 'Cimetidine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d737.s4.e0'}, 'e2': {'word': 'pramipexole', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d737.s4.e2'}, 'sentence_id': 'DDI-DrugBank.d737.s4'}	Cimetidine Cimetidine known inhibitor renal tubular secretion organic bases via cationic transport system caused NUMBER % increase pramipexole AUC NUMBER % increase half life N= NUMBER
Cimetidine: Cimetidine, a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in pramipexole AUC and a 40% increase in half-life (N= 12). 	Cimetidine	pramipexole	mechanism	{'e1': {'word': 'Cimetidine', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d737.s4.e1'}, 'e2': {'word': 'pramipexole', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d737.s4.e2'}, 'sentence_id': 'DDI-DrugBank.d737.s4'}	Cimetidine Cimetidine known inhibitor renal tubular secretion organic bases via cationic transport system caused NUMBER % increase pramipexole AUC NUMBER % increase half life N= NUMBER
Probenecid: Probenecid, a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter, did not noticeably influence pramipexole pharmacokinetics (N= 12). 	Probenecid	Probenecid	none	{'e1': {'word': 'Probenecid', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d737.s5.e0'}, 'e2': {'word': 'Probenecid', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d737.s5.e1'}, 'sentence_id': 'DDI-DrugBank.d737.s5'}	Probenecid Probenecid known inhibitor renal tubular secretion organic acids via aruonic transporter noticeably influence pramipexole pharmacokinetics N= NUMBER
Probenecid: Probenecid, a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter, did not noticeably influence pramipexole pharmacokinetics (N= 12). 	Probenecid	pramipexole	none	{'e1': {'word': 'Probenecid', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d737.s5.e0'}, 'e2': {'word': 'pramipexole', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d737.s5.e2'}, 'sentence_id': 'DDI-DrugBank.d737.s5'}	Probenecid Probenecid known inhibitor renal tubular secretion organic acids via aruonic transporter noticeably influence pramipexole pharmacokinetics N = NUMBER
Probenecid: Probenecid, a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter, did not noticeably influence pramipexole pharmacokinetics (N= 12). 	Probenecid	pramipexole	none	{'e1': {'word': 'Probenecid', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d737.s5.e1'}, 'e2': {'word': 'pramipexole', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d737.s5.e2'}, 'sentence_id': 'DDI-DrugBank.d737.s5'}	Probenecid Probenecid known inhibitor renal tubular secretion organic acids via aruonic transporter noticeably influence pramipexole pharmacokinetics N= NUMBER
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	cimetidine	ranitidine	none	{'e1': {'word': 'cimetidine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d737.s6.e0'}, 'e2': {'word': 'ranitidine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d737.s6.e1'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	cimetidine	diltiazem	none	{'e1': {'word': 'cimetidine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d737.s6.e0'}, 'e2': {'word': 'diltiazem', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d737.s6.e2'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	cimetidine	triamterene	none	{'e1': {'word': 'cimetidine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d737.s6.e0'}, 'e2': {'word': 'triamterene', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d737.s6.e3'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	cimetidine	verapamil	none	{'e1': {'word': 'cimetidine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d737.s6.e0'}, 'e2': {'word': 'verapamil', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d737.s6.e4'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	cimetidine	quinidine	none	{'e1': {'word': 'cimetidine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d737.s6.e0'}, 'e2': {'word': 'quinidine', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d737.s6.e5'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	cimetidine	quinine	none	{'e1': {'word': 'cimetidine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d737.s6.e0'}, 'e2': {'word': 'quinine', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d737.s6.e6'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	cimetidine	pramipexole	mechanism	{'e1': {'word': 'cimetidine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d737.s6.e0'}, 'e2': {'word': 'pramipexole', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d737.s6.e7'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	cimetidine	cephalosporins	none	{'e1': {'word': 'cimetidine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d737.s6.e0'}, 'e2': {'word': 'cephalosporins', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d737.s6.e8'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	cimetidine	penicillins	none	{'e1': {'word': 'cimetidine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d737.s6.e0'}, 'e2': {'word': 'penicillins', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d737.s6.e9'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	cimetidine	indomethacin	none	{'e1': {'word': 'cimetidine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d737.s6.e0'}, 'e2': {'word': 'indomethacin', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d737.s6.e10'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	cimetidine	hydrochlorothiazide	none	{'e1': {'word': 'cimetidine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d737.s6.e0'}, 'e2': {'word': 'hydrochlorothiazide', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d737.s6.e11'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	cimetidine	chlorpropamide	none	{'e1': {'word': 'cimetidine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d737.s6.e0'}, 'e2': {'word': 'chlorpropamide', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d737.s6.e12'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	cimetidine	pramipexole	none	{'e1': {'word': 'cimetidine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d737.s6.e0'}, 'e2': {'word': 'pramipexole', 'word_index': [(44, 44)], 'id': 'DDI-DrugBank.d737.s6.e13'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	ranitidine	diltiazem	none	{'e1': {'word': 'ranitidine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d737.s6.e1'}, 'e2': {'word': 'diltiazem', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d737.s6.e2'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	ranitidine	triamterene	none	{'e1': {'word': 'ranitidine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d737.s6.e1'}, 'e2': {'word': 'triamterene', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d737.s6.e3'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	ranitidine	verapamil	none	{'e1': {'word': 'ranitidine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d737.s6.e1'}, 'e2': {'word': 'verapamil', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d737.s6.e4'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	ranitidine	quinidine	none	{'e1': {'word': 'ranitidine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d737.s6.e1'}, 'e2': {'word': 'quinidine', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d737.s6.e5'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	ranitidine	quinine	none	{'e1': {'word': 'ranitidine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d737.s6.e1'}, 'e2': {'word': 'quinine', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d737.s6.e6'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	ranitidine	pramipexole	mechanism	{'e1': {'word': 'ranitidine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d737.s6.e1'}, 'e2': {'word': 'pramipexole', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d737.s6.e7'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	ranitidine	cephalosporins	none	{'e1': {'word': 'ranitidine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d737.s6.e1'}, 'e2': {'word': 'cephalosporins', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d737.s6.e8'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	ranitidine	penicillins	none	{'e1': {'word': 'ranitidine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d737.s6.e1'}, 'e2': {'word': 'penicillins', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d737.s6.e9'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	ranitidine	indomethacin	none	{'e1': {'word': 'ranitidine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d737.s6.e1'}, 'e2': {'word': 'indomethacin', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d737.s6.e10'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	ranitidine	hydrochlorothiazide	none	{'e1': {'word': 'ranitidine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d737.s6.e1'}, 'e2': {'word': 'hydrochlorothiazide', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d737.s6.e11'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	ranitidine	chlorpropamide	none	{'e1': {'word': 'ranitidine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d737.s6.e1'}, 'e2': {'word': 'chlorpropamide', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d737.s6.e12'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	ranitidine	pramipexole	none	{'e1': {'word': 'ranitidine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d737.s6.e1'}, 'e2': {'word': 'pramipexole', 'word_index': [(44, 44)], 'id': 'DDI-DrugBank.d737.s6.e13'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	diltiazem	triamterene	none	{'e1': {'word': 'diltiazem', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d737.s6.e2'}, 'e2': {'word': 'triamterene', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d737.s6.e3'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	diltiazem	verapamil	none	{'e1': {'word': 'diltiazem', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d737.s6.e2'}, 'e2': {'word': 'verapamil', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d737.s6.e4'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	diltiazem	quinidine	none	{'e1': {'word': 'diltiazem', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d737.s6.e2'}, 'e2': {'word': 'quinidine', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d737.s6.e5'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	diltiazem	quinine	none	{'e1': {'word': 'diltiazem', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d737.s6.e2'}, 'e2': {'word': 'quinine', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d737.s6.e6'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	diltiazem	pramipexole	mechanism	{'e1': {'word': 'diltiazem', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d737.s6.e2'}, 'e2': {'word': 'pramipexole', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d737.s6.e7'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	diltiazem	cephalosporins	none	{'e1': {'word': 'diltiazem', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d737.s6.e2'}, 'e2': {'word': 'cephalosporins', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d737.s6.e8'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	diltiazem	penicillins	none	{'e1': {'word': 'diltiazem', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d737.s6.e2'}, 'e2': {'word': 'penicillins', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d737.s6.e9'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	diltiazem	indomethacin	none	{'e1': {'word': 'diltiazem', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d737.s6.e2'}, 'e2': {'word': 'indomethacin', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d737.s6.e10'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	diltiazem	hydrochlorothiazide	none	{'e1': {'word': 'diltiazem', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d737.s6.e2'}, 'e2': {'word': 'hydrochlorothiazide', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d737.s6.e11'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	diltiazem	chlorpropamide	none	{'e1': {'word': 'diltiazem', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d737.s6.e2'}, 'e2': {'word': 'chlorpropamide', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d737.s6.e12'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	diltiazem	pramipexole	none	{'e1': {'word': 'diltiazem', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d737.s6.e2'}, 'e2': {'word': 'pramipexole', 'word_index': [(44, 44)], 'id': 'DDI-DrugBank.d737.s6.e13'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	triamterene	verapamil	none	{'e1': {'word': 'triamterene', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d737.s6.e3'}, 'e2': {'word': 'verapamil', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d737.s6.e4'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	triamterene	quinidine	none	{'e1': {'word': 'triamterene', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d737.s6.e3'}, 'e2': {'word': 'quinidine', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d737.s6.e5'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	triamterene	quinine	none	{'e1': {'word': 'triamterene', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d737.s6.e3'}, 'e2': {'word': 'quinine', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d737.s6.e6'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	triamterene	pramipexole	mechanism	{'e1': {'word': 'triamterene', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d737.s6.e3'}, 'e2': {'word': 'pramipexole', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d737.s6.e7'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	triamterene	cephalosporins	none	{'e1': {'word': 'triamterene', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d737.s6.e3'}, 'e2': {'word': 'cephalosporins', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d737.s6.e8'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	triamterene	penicillins	none	{'e1': {'word': 'triamterene', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d737.s6.e3'}, 'e2': {'word': 'penicillins', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d737.s6.e9'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	triamterene	indomethacin	none	{'e1': {'word': 'triamterene', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d737.s6.e3'}, 'e2': {'word': 'indomethacin', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d737.s6.e10'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	triamterene	hydrochlorothiazide	none	{'e1': {'word': 'triamterene', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d737.s6.e3'}, 'e2': {'word': 'hydrochlorothiazide', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d737.s6.e11'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	triamterene	chlorpropamide	none	{'e1': {'word': 'triamterene', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d737.s6.e3'}, 'e2': {'word': 'chlorpropamide', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d737.s6.e12'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	triamterene	pramipexole	none	{'e1': {'word': 'triamterene', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d737.s6.e3'}, 'e2': {'word': 'pramipexole', 'word_index': [(44, 44)], 'id': 'DDI-DrugBank.d737.s6.e13'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	verapamil	quinidine	none	{'e1': {'word': 'verapamil', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d737.s6.e4'}, 'e2': {'word': 'quinidine', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d737.s6.e5'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	verapamil	quinine	none	{'e1': {'word': 'verapamil', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d737.s6.e4'}, 'e2': {'word': 'quinine', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d737.s6.e6'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	verapamil	pramipexole	mechanism	{'e1': {'word': 'verapamil', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d737.s6.e4'}, 'e2': {'word': 'pramipexole', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d737.s6.e7'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	verapamil	cephalosporins	none	{'e1': {'word': 'verapamil', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d737.s6.e4'}, 'e2': {'word': 'cephalosporins', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d737.s6.e8'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	verapamil	penicillins	none	{'e1': {'word': 'verapamil', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d737.s6.e4'}, 'e2': {'word': 'penicillins', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d737.s6.e9'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	verapamil	indomethacin	none	{'e1': {'word': 'verapamil', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d737.s6.e4'}, 'e2': {'word': 'indomethacin', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d737.s6.e10'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	verapamil	hydrochlorothiazide	none	{'e1': {'word': 'verapamil', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d737.s6.e4'}, 'e2': {'word': 'hydrochlorothiazide', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d737.s6.e11'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	verapamil	chlorpropamide	none	{'e1': {'word': 'verapamil', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d737.s6.e4'}, 'e2': {'word': 'chlorpropamide', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d737.s6.e12'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	verapamil	pramipexole	none	{'e1': {'word': 'verapamil', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d737.s6.e4'}, 'e2': {'word': 'pramipexole', 'word_index': [(44, 44)], 'id': 'DDI-DrugBank.d737.s6.e13'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	quinidine	quinine	none	{'e1': {'word': 'quinidine', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d737.s6.e5'}, 'e2': {'word': 'quinine', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d737.s6.e6'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	quinidine	pramipexole	mechanism	{'e1': {'word': 'quinidine', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d737.s6.e5'}, 'e2': {'word': 'pramipexole', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d737.s6.e7'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	quinidine	cephalosporins	none	{'e1': {'word': 'quinidine', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d737.s6.e5'}, 'e2': {'word': 'cephalosporins', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d737.s6.e8'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	quinidine	penicillins	none	{'e1': {'word': 'quinidine', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d737.s6.e5'}, 'e2': {'word': 'penicillins', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d737.s6.e9'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	quinidine	indomethacin	none	{'e1': {'word': 'quinidine', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d737.s6.e5'}, 'e2': {'word': 'indomethacin', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d737.s6.e10'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	quinidine	hydrochlorothiazide	none	{'e1': {'word': 'quinidine', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d737.s6.e5'}, 'e2': {'word': 'hydrochlorothiazide', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d737.s6.e11'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	quinidine	chlorpropamide	none	{'e1': {'word': 'quinidine', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d737.s6.e5'}, 'e2': {'word': 'chlorpropamide', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d737.s6.e12'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	quinidine	pramipexole	none	{'e1': {'word': 'quinidine', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d737.s6.e5'}, 'e2': {'word': 'pramipexole', 'word_index': [(44, 44)], 'id': 'DDI-DrugBank.d737.s6.e13'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	quinine	pramipexole	mechanism	{'e1': {'word': 'quinine', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d737.s6.e6'}, 'e2': {'word': 'pramipexole', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d737.s6.e7'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	quinine	cephalosporins	none	{'e1': {'word': 'quinine', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d737.s6.e6'}, 'e2': {'word': 'cephalosporins', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d737.s6.e8'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	quinine	penicillins	none	{'e1': {'word': 'quinine', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d737.s6.e6'}, 'e2': {'word': 'penicillins', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d737.s6.e9'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	quinine	indomethacin	none	{'e1': {'word': 'quinine', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d737.s6.e6'}, 'e2': {'word': 'indomethacin', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d737.s6.e10'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	quinine	hydrochlorothiazide	none	{'e1': {'word': 'quinine', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d737.s6.e6'}, 'e2': {'word': 'hydrochlorothiazide', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d737.s6.e11'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	quinine	chlorpropamide	none	{'e1': {'word': 'quinine', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d737.s6.e6'}, 'e2': {'word': 'chlorpropamide', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d737.s6.e12'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	quinine	pramipexole	none	{'e1': {'word': 'quinine', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d737.s6.e6'}, 'e2': {'word': 'pramipexole', 'word_index': [(44, 44)], 'id': 'DDI-DrugBank.d737.s6.e13'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	pramipexole	cephalosporins	none	{'e1': {'word': 'pramipexole', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d737.s6.e7'}, 'e2': {'word': 'cephalosporins', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d737.s6.e8'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	pramipexole	penicillins	none	{'e1': {'word': 'pramipexole', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d737.s6.e7'}, 'e2': {'word': 'penicillins', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d737.s6.e9'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	pramipexole	indomethacin	none	{'e1': {'word': 'pramipexole', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d737.s6.e7'}, 'e2': {'word': 'indomethacin', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d737.s6.e10'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	pramipexole	hydrochlorothiazide	none	{'e1': {'word': 'pramipexole', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d737.s6.e7'}, 'e2': {'word': 'hydrochlorothiazide', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d737.s6.e11'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	pramipexole	chlorpropamide	none	{'e1': {'word': 'pramipexole', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d737.s6.e7'}, 'e2': {'word': 'chlorpropamide', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d737.s6.e12'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	pramipexole	pramipexole	none	{'e1': {'word': 'pramipexole', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d737.s6.e7'}, 'e2': {'word': 'pramipexole', 'word_index': [(44, 44)], 'id': 'DDI-DrugBank.d737.s6.e13'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	cephalosporins	penicillins	none	{'e1': {'word': 'cephalosporins', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d737.s6.e8'}, 'e2': {'word': 'penicillins', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d737.s6.e9'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	cephalosporins	indomethacin	none	{'e1': {'word': 'cephalosporins', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d737.s6.e8'}, 'e2': {'word': 'indomethacin', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d737.s6.e10'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	cephalosporins	hydrochlorothiazide	none	{'e1': {'word': 'cephalosporins', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d737.s6.e8'}, 'e2': {'word': 'hydrochlorothiazide', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d737.s6.e11'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	cephalosporins	chlorpropamide	none	{'e1': {'word': 'cephalosporins', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d737.s6.e8'}, 'e2': {'word': 'chlorpropamide', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d737.s6.e12'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	cephalosporins	pramipexole	mechanism	{'e1': {'word': 'cephalosporins', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d737.s6.e8'}, 'e2': {'word': 'pramipexole', 'word_index': [(44, 44)], 'id': 'DDI-DrugBank.d737.s6.e13'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	penicillins	indomethacin	none	{'e1': {'word': 'penicillins', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d737.s6.e9'}, 'e2': {'word': 'indomethacin', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d737.s6.e10'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	penicillins	hydrochlorothiazide	none	{'e1': {'word': 'penicillins', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d737.s6.e9'}, 'e2': {'word': 'hydrochlorothiazide', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d737.s6.e11'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	penicillins	chlorpropamide	none	{'e1': {'word': 'penicillins', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d737.s6.e9'}, 'e2': {'word': 'chlorpropamide', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d737.s6.e12'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	penicillins	pramipexole	mechanism	{'e1': {'word': 'penicillins', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d737.s6.e9'}, 'e2': {'word': 'pramipexole', 'word_index': [(44, 44)], 'id': 'DDI-DrugBank.d737.s6.e13'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	indomethacin	hydrochlorothiazide	none	{'e1': {'word': 'indomethacin', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d737.s6.e10'}, 'e2': {'word': 'hydrochlorothiazide', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d737.s6.e11'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	indomethacin	chlorpropamide	none	{'e1': {'word': 'indomethacin', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d737.s6.e10'}, 'e2': {'word': 'chlorpropamide', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d737.s6.e12'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	indomethacin	pramipexole	mechanism	{'e1': {'word': 'indomethacin', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d737.s6.e10'}, 'e2': {'word': 'pramipexole', 'word_index': [(44, 44)], 'id': 'DDI-DrugBank.d737.s6.e13'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	hydrochlorothiazide	chlorpropamide	none	{'e1': {'word': 'hydrochlorothiazide', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d737.s6.e11'}, 'e2': {'word': 'chlorpropamide', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d737.s6.e12'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	hydrochlorothiazide	pramipexole	mechanism	{'e1': {'word': 'hydrochlorothiazide', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d737.s6.e11'}, 'e2': {'word': 'pramipexole', 'word_index': [(44, 44)], 'id': 'DDI-DrugBank.d737.s6.e13'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. 	chlorpropamide	pramipexole	mechanism	{'e1': {'word': 'chlorpropamide', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d737.s6.e12'}, 'e2': {'word': 'pramipexole', 'word_index': [(44, 44)], 'id': 'DDI-DrugBank.d737.s6.e13'}, 'sentence_id': 'DDI-DrugBank.d737.s6'}	drugs eliminated via renal secretion Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine decreases oral clearance pramipexole NUMBER % secreted anionic transport system e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide likely little effect oral clearance pramipexole
CYP interactions: Inhibitors of cytochrome P450 enzymes would not be expected to affect pramipexole elimination because pramipexole is not appreciably metabolized by these enzymes in vivo or in vitro. 	pramipexole	pramipexole	none	{'e1': {'word': 'pramipexole', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d737.s7.e0'}, 'e2': {'word': 'pramipexole', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d737.s7.e1'}, 'sentence_id': 'DDI-DrugBank.d737.s7'}	CYP interactions Inhibitors cytochrome P450 enzymes would expected affect pramipexole elimination pramipexole appreciably metabolized enzymes vivo vitro
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 	Dopamine antagonists	pramipexole	none	{'e1': {'word': 'Dopamine antagonists', 'word_index': [(0, 1)], 'id': 'DDI-DrugBank.d737.s10.e0'}, 'e2': {'word': 'pramipexole', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d737.s10.e1'}, 'sentence_id': 'DDI-DrugBank.d737.s10'}	Dopamine antagonists Since pramipexole dopamine agonist possible dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthenes metoclopramide may diminish effectiveness MIRAPEX
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 	Dopamine antagonists	dopamine agonist	none	{'e1': {'word': 'Dopamine antagonists', 'word_index': [(0, 1)], 'id': 'DDI-DrugBank.d737.s10.e0'}, 'e2': {'word': 'dopamine agonist', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d737.s10.e2'}, 'sentence_id': 'DDI-DrugBank.d737.s10'}	Dopamine antagonists Since pramipexole dopamine agonist possible dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthenes metoclopramide may diminish effectiveness MIRAPEX
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 	Dopamine antagonists	dopamine antagonists	none	{'e1': {'word': 'Dopamine antagonists', 'word_index': [(0, 1)], 'id': 'DDI-DrugBank.d737.s10.e0'}, 'e2': {'word': 'dopamine antagonists', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d737.s10.e3'}, 'sentence_id': 'DDI-DrugBank.d737.s10'}	Dopamine antagonists Since pramipexole dopamine agonist possible dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthenes metoclopramide may diminish effectiveness MIRAPEX
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 	Dopamine antagonists	neuroleptics	none	{'e1': {'word': 'Dopamine antagonists', 'word_index': [(0, 1)], 'id': 'DDI-DrugBank.d737.s10.e0'}, 'e2': {'word': 'neuroleptics', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d737.s10.e4'}, 'sentence_id': 'DDI-DrugBank.d737.s10'}	Dopamine antagonists Since pramipexole dopamine agonist possible dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthenes metoclopramide may diminish effectiveness MIRAPEX
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 	Dopamine antagonists	phenothiazines	none	{'e1': {'word': 'Dopamine antagonists', 'word_index': [(0, 1)], 'id': 'DDI-DrugBank.d737.s10.e0'}, 'e2': {'word': 'phenothiazines', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d737.s10.e5'}, 'sentence_id': 'DDI-DrugBank.d737.s10'}	Dopamine antagonists Since pramipexole dopamine agonist possible dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthenes metoclopramide may diminish effectiveness MIRAPEX
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 	Dopamine antagonists	butyrophenones	none	{'e1': {'word': 'Dopamine antagonists', 'word_index': [(0, 1)], 'id': 'DDI-DrugBank.d737.s10.e0'}, 'e2': {'word': 'butyrophenones', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d737.s10.e6'}, 'sentence_id': 'DDI-DrugBank.d737.s10'}	Dopamine antagonists Since pramipexole dopamine agonist possible dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthenes metoclopramide may diminish effectiveness MIRAPEX
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 	Dopamine antagonists	thioxanthenes	none	{'e1': {'word': 'Dopamine antagonists', 'word_index': [(0, 1)], 'id': 'DDI-DrugBank.d737.s10.e0'}, 'e2': {'word': 'thioxanthenes', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d737.s10.e7'}, 'sentence_id': 'DDI-DrugBank.d737.s10'}	Dopamine antagonists Since pramipexole dopamine agonist possible dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthenes metoclopramide may diminish effectiveness MIRAPEX
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 	Dopamine antagonists	metoclopramide	none	{'e1': {'word': 'Dopamine antagonists', 'word_index': [(0, 1)], 'id': 'DDI-DrugBank.d737.s10.e0'}, 'e2': {'word': 'metoclopramide', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d737.s10.e8'}, 'sentence_id': 'DDI-DrugBank.d737.s10'}	Dopamine antagonists Since pramipexole dopamine agonist possible dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthenes metoclopramide may diminish effectiveness MIRAPEX
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 	Dopamine antagonists	MIRAPEX	none	{'e1': {'word': 'Dopamine antagonists', 'word_index': [(0, 1)], 'id': 'DDI-DrugBank.d737.s10.e0'}, 'e2': {'word': 'MIRAPEX', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d737.s10.e9'}, 'sentence_id': 'DDI-DrugBank.d737.s10'}	Dopamine antagonists Since pramipexole dopamine agonist possible dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthenes metoclopramide may diminish effectiveness MIRAPEX
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 	pramipexole	dopamine agonist	none	{'e1': {'word': 'pramipexole', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d737.s10.e1'}, 'e2': {'word': 'dopamine agonist', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d737.s10.e2'}, 'sentence_id': 'DDI-DrugBank.d737.s10'}	Dopamine antagonists Since pramipexole dopamine agonist possible dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthenes metoclopramide may diminish effectiveness MIRAPEX
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 	pramipexole	dopamine antagonists	none	{'e1': {'word': 'pramipexole', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d737.s10.e1'}, 'e2': {'word': 'dopamine antagonists', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d737.s10.e3'}, 'sentence_id': 'DDI-DrugBank.d737.s10'}	Dopamine antagonists Since pramipexole dopamine agonist possible dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthenes metoclopramide may diminish effectiveness MIRAPEX
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 	pramipexole	neuroleptics	none	{'e1': {'word': 'pramipexole', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d737.s10.e1'}, 'e2': {'word': 'neuroleptics', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d737.s10.e4'}, 'sentence_id': 'DDI-DrugBank.d737.s10'}	Dopamine antagonists Since pramipexole dopamine agonist possible dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthenes metoclopramide may diminish effectiveness MIRAPEX
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 	pramipexole	phenothiazines	none	{'e1': {'word': 'pramipexole', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d737.s10.e1'}, 'e2': {'word': 'phenothiazines', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d737.s10.e5'}, 'sentence_id': 'DDI-DrugBank.d737.s10'}	Dopamine antagonists Since pramipexole dopamine agonist possible dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthenes metoclopramide may diminish effectiveness MIRAPEX
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 	pramipexole	butyrophenones	none	{'e1': {'word': 'pramipexole', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d737.s10.e1'}, 'e2': {'word': 'butyrophenones', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d737.s10.e6'}, 'sentence_id': 'DDI-DrugBank.d737.s10'}	Dopamine antagonists Since pramipexole dopamine agonist possible dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthenes metoclopramide may diminish effectiveness MIRAPEX
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 	pramipexole	thioxanthenes	none	{'e1': {'word': 'pramipexole', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d737.s10.e1'}, 'e2': {'word': 'thioxanthenes', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d737.s10.e7'}, 'sentence_id': 'DDI-DrugBank.d737.s10'}	Dopamine antagonists Since pramipexole dopamine agonist possible dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthenes metoclopramide may diminish effectiveness MIRAPEX
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 	pramipexole	metoclopramide	none	{'e1': {'word': 'pramipexole', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d737.s10.e1'}, 'e2': {'word': 'metoclopramide', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d737.s10.e8'}, 'sentence_id': 'DDI-DrugBank.d737.s10'}	Dopamine antagonists Since pramipexole dopamine agonist possible dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthenes metoclopramide may diminish effectiveness MIRAPEX
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 	pramipexole	MIRAPEX	none	{'e1': {'word': 'pramipexole', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d737.s10.e1'}, 'e2': {'word': 'MIRAPEX', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d737.s10.e9'}, 'sentence_id': 'DDI-DrugBank.d737.s10'}	Dopamine antagonists Since pramipexole dopamine agonist possible dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthenes metoclopramide may diminish effectiveness MIRAPEX
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 	dopamine agonist	dopamine antagonists	none	{'e1': {'word': 'dopamine agonist', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d737.s10.e2'}, 'e2': {'word': 'dopamine antagonists', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d737.s10.e3'}, 'sentence_id': 'DDI-DrugBank.d737.s10'}	Dopamine antagonists Since pramipexole dopamine agonist possible dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthenes metoclopramide may diminish effectiveness MIRAPEX
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 	dopamine agonist	neuroleptics	none	{'e1': {'word': 'dopamine agonist', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d737.s10.e2'}, 'e2': {'word': 'neuroleptics', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d737.s10.e4'}, 'sentence_id': 'DDI-DrugBank.d737.s10'}	Dopamine antagonists Since pramipexole dopamine agonist possible dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthenes metoclopramide may diminish effectiveness MIRAPEX
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 	dopamine agonist	phenothiazines	none	{'e1': {'word': 'dopamine agonist', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d737.s10.e2'}, 'e2': {'word': 'phenothiazines', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d737.s10.e5'}, 'sentence_id': 'DDI-DrugBank.d737.s10'}	Dopamine antagonists Since pramipexole dopamine agonist possible dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthenes metoclopramide may diminish effectiveness MIRAPEX
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 	dopamine agonist	butyrophenones	none	{'e1': {'word': 'dopamine agonist', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d737.s10.e2'}, 'e2': {'word': 'butyrophenones', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d737.s10.e6'}, 'sentence_id': 'DDI-DrugBank.d737.s10'}	Dopamine antagonists Since pramipexole dopamine agonist possible dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthenes metoclopramide may diminish effectiveness MIRAPEX
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 	dopamine agonist	thioxanthenes	none	{'e1': {'word': 'dopamine agonist', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d737.s10.e2'}, 'e2': {'word': 'thioxanthenes', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d737.s10.e7'}, 'sentence_id': 'DDI-DrugBank.d737.s10'}	Dopamine antagonists Since pramipexole dopamine agonist possible dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthenes metoclopramide may diminish effectiveness MIRAPEX
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 	dopamine agonist	metoclopramide	none	{'e1': {'word': 'dopamine agonist', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d737.s10.e2'}, 'e2': {'word': 'metoclopramide', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d737.s10.e8'}, 'sentence_id': 'DDI-DrugBank.d737.s10'}	Dopamine antagonists Since pramipexole dopamine agonist possible dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthenes metoclopramide may diminish effectiveness MIRAPEX
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 	dopamine agonist	MIRAPEX	none	{'e1': {'word': 'dopamine agonist', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d737.s10.e2'}, 'e2': {'word': 'MIRAPEX', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d737.s10.e9'}, 'sentence_id': 'DDI-DrugBank.d737.s10'}	Dopamine antagonists Since pramipexole dopamine agonist possible dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthenes metoclopramide may diminish effectiveness MIRAPEX
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 	dopamine antagonists	neuroleptics	none	{'e1': {'word': 'dopamine antagonists', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d737.s10.e3'}, 'e2': {'word': 'neuroleptics', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d737.s10.e4'}, 'sentence_id': 'DDI-DrugBank.d737.s10'}	Dopamine antagonists Since pramipexole dopamine agonist possible dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthenes metoclopramide may diminish effectiveness MIRAPEX
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 	dopamine antagonists	phenothiazines	none	{'e1': {'word': 'dopamine antagonists', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d737.s10.e3'}, 'e2': {'word': 'phenothiazines', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d737.s10.e5'}, 'sentence_id': 'DDI-DrugBank.d737.s10'}	Dopamine antagonists Since pramipexole dopamine agonist possible dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthenes metoclopramide may diminish effectiveness MIRAPEX
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 	dopamine antagonists	butyrophenones	none	{'e1': {'word': 'dopamine antagonists', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d737.s10.e3'}, 'e2': {'word': 'butyrophenones', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d737.s10.e6'}, 'sentence_id': 'DDI-DrugBank.d737.s10'}	Dopamine antagonists Since pramipexole dopamine agonist possible dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthenes metoclopramide may diminish effectiveness MIRAPEX
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 	dopamine antagonists	thioxanthenes	none	{'e1': {'word': 'dopamine antagonists', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d737.s10.e3'}, 'e2': {'word': 'thioxanthenes', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d737.s10.e7'}, 'sentence_id': 'DDI-DrugBank.d737.s10'}	Dopamine antagonists Since pramipexole dopamine agonist possible dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthenes metoclopramide may diminish effectiveness MIRAPEX
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 	dopamine antagonists	metoclopramide	none	{'e1': {'word': 'dopamine antagonists', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d737.s10.e3'}, 'e2': {'word': 'metoclopramide', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d737.s10.e8'}, 'sentence_id': 'DDI-DrugBank.d737.s10'}	Dopamine antagonists Since pramipexole dopamine agonist possible dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthenes metoclopramide may diminish effectiveness MIRAPEX
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 	dopamine antagonists	MIRAPEX	effect	{'e1': {'word': 'dopamine antagonists', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d737.s10.e3'}, 'e2': {'word': 'MIRAPEX', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d737.s10.e9'}, 'sentence_id': 'DDI-DrugBank.d737.s10'}	Dopamine antagonists Since pramipexole dopamine agonist possible dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthenes metoclopramide may diminish effectiveness MIRAPEX
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 	neuroleptics	phenothiazines	none	{'e1': {'word': 'neuroleptics', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d737.s10.e4'}, 'e2': {'word': 'phenothiazines', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d737.s10.e5'}, 'sentence_id': 'DDI-DrugBank.d737.s10'}	Dopamine antagonists Since pramipexole dopamine agonist possible dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthenes metoclopramide may diminish effectiveness MIRAPEX
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 	neuroleptics	butyrophenones	none	{'e1': {'word': 'neuroleptics', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d737.s10.e4'}, 'e2': {'word': 'butyrophenones', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d737.s10.e6'}, 'sentence_id': 'DDI-DrugBank.d737.s10'}	Dopamine antagonists Since pramipexole dopamine agonist possible dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthenes metoclopramide may diminish effectiveness MIRAPEX
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 	neuroleptics	thioxanthenes	none	{'e1': {'word': 'neuroleptics', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d737.s10.e4'}, 'e2': {'word': 'thioxanthenes', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d737.s10.e7'}, 'sentence_id': 'DDI-DrugBank.d737.s10'}	Dopamine antagonists Since pramipexole dopamine agonist possible dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthenes metoclopramide may diminish effectiveness MIRAPEX
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 	neuroleptics	metoclopramide	none	{'e1': {'word': 'neuroleptics', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d737.s10.e4'}, 'e2': {'word': 'metoclopramide', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d737.s10.e8'}, 'sentence_id': 'DDI-DrugBank.d737.s10'}	Dopamine antagonists Since pramipexole dopamine agonist possible dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthenes metoclopramide may diminish effectiveness MIRAPEX
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 	neuroleptics	MIRAPEX	effect	{'e1': {'word': 'neuroleptics', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d737.s10.e4'}, 'e2': {'word': 'MIRAPEX', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d737.s10.e9'}, 'sentence_id': 'DDI-DrugBank.d737.s10'}	Dopamine antagonists Since pramipexole dopamine agonist possible dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthenes metoclopramide may diminish effectiveness MIRAPEX
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 	phenothiazines	butyrophenones	none	{'e1': {'word': 'phenothiazines', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d737.s10.e5'}, 'e2': {'word': 'butyrophenones', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d737.s10.e6'}, 'sentence_id': 'DDI-DrugBank.d737.s10'}	Dopamine antagonists Since pramipexole dopamine agonist possible dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthenes metoclopramide may diminish effectiveness MIRAPEX
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 	phenothiazines	thioxanthenes	none	{'e1': {'word': 'phenothiazines', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d737.s10.e5'}, 'e2': {'word': 'thioxanthenes', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d737.s10.e7'}, 'sentence_id': 'DDI-DrugBank.d737.s10'}	Dopamine antagonists Since pramipexole dopamine agonist possible dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthenes metoclopramide may diminish effectiveness MIRAPEX
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 	phenothiazines	metoclopramide	none	{'e1': {'word': 'phenothiazines', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d737.s10.e5'}, 'e2': {'word': 'metoclopramide', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d737.s10.e8'}, 'sentence_id': 'DDI-DrugBank.d737.s10'}	Dopamine antagonists Since pramipexole dopamine agonist possible dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthenes metoclopramide may diminish effectiveness MIRAPEX
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 	phenothiazines	MIRAPEX	effect	{'e1': {'word': 'phenothiazines', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d737.s10.e5'}, 'e2': {'word': 'MIRAPEX', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d737.s10.e9'}, 'sentence_id': 'DDI-DrugBank.d737.s10'}	Dopamine antagonists Since pramipexole dopamine agonist possible dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthenes metoclopramide may diminish effectiveness MIRAPEX
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 	butyrophenones	thioxanthenes	none	{'e1': {'word': 'butyrophenones', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d737.s10.e6'}, 'e2': {'word': 'thioxanthenes', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d737.s10.e7'}, 'sentence_id': 'DDI-DrugBank.d737.s10'}	Dopamine antagonists Since pramipexole dopamine agonist possible dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthenes metoclopramide may diminish effectiveness MIRAPEX
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 	butyrophenones	metoclopramide	none	{'e1': {'word': 'butyrophenones', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d737.s10.e6'}, 'e2': {'word': 'metoclopramide', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d737.s10.e8'}, 'sentence_id': 'DDI-DrugBank.d737.s10'}	Dopamine antagonists Since pramipexole dopamine agonist possible dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthenes metoclopramide may diminish effectiveness MIRAPEX
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 	butyrophenones	MIRAPEX	effect	{'e1': {'word': 'butyrophenones', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d737.s10.e6'}, 'e2': {'word': 'MIRAPEX', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d737.s10.e9'}, 'sentence_id': 'DDI-DrugBank.d737.s10'}	Dopamine antagonists Since pramipexole dopamine agonist possible dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthenes metoclopramide may diminish effectiveness MIRAPEX
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 	thioxanthenes	metoclopramide	none	{'e1': {'word': 'thioxanthenes', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d737.s10.e7'}, 'e2': {'word': 'metoclopramide', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d737.s10.e8'}, 'sentence_id': 'DDI-DrugBank.d737.s10'}	Dopamine antagonists Since pramipexole dopamine agonist possible dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthenes metoclopramide may diminish effectiveness MIRAPEX
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 	thioxanthenes	MIRAPEX	effect	{'e1': {'word': 'thioxanthenes', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d737.s10.e7'}, 'e2': {'word': 'MIRAPEX', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d737.s10.e9'}, 'sentence_id': 'DDI-DrugBank.d737.s10'}	Dopamine antagonists Since pramipexole dopamine agonist possible dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthenes metoclopramide may diminish effectiveness MIRAPEX
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. 	metoclopramide	MIRAPEX	effect	{'e1': {'word': 'metoclopramide', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d737.s10.e8'}, 'e2': {'word': 'MIRAPEX', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d737.s10.e9'}, 'sentence_id': 'DDI-DrugBank.d737.s10'}	Dopamine antagonists Since pramipexole dopamine agonist possible dopamine antagonists neuroleptics phenothiazines butyrophenones thioxanthenes metoclopramide may diminish effectiveness MIRAPEX
Caution is recommended when administering NEXAVAR with compounds that are metabolized/eliminated predominantly by the UGT1A1 pathway (e.g. irinotecan). 	NEXAVAR	irinotecan	advise	{'e1': {'word': 'NEXAVAR', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d602.s0.e0'}, 'e2': {'word': 'irinotecan', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d602.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d602.s0'}	Caution recommended administering NEXAVAR compounds metabolized eliminated predominantly UGT1A1 pathway e.g. irinotecan
Concomitant treatment with NEXAVAR resulted in a 21% increase in the AUC of doxorubicin. 	NEXAVAR	doxorubicin	mechanism	{'e1': {'word': 'NEXAVAR', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d602.s1.e0'}, 'e2': {'word': 'doxorubicin', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d602.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d602.s1'}	Concomitant treatment NEXAVAR resulted NUMBER % increase AUC doxorubicin
Caution is recommended when administering doxorubicin with NEXAVAR. 	doxorubicin	NEXAVAR	advise	{'e1': {'word': 'doxorubicin', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d602.s2.e0'}, 'e2': {'word': 'NEXAVAR', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d602.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d602.s2'}	Caution recommended administering doxorubicin NEXAVAR
norepinephrine and dobutamine are incompatible with sodium bicarbonate solution. 	norepinephrine	dobutamine	none	{'e1': {'word': 'norepinephrine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d595.s1.e0'}, 'e2': {'word': 'dobutamine', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d595.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d595.s1'}	norepinephrine dobutamine incompatible sodium bicarbonate solution
norepinephrine and dobutamine are incompatible with sodium bicarbonate solution. 	norepinephrine	sodium bicarbonate	int	{'e1': {'word': 'norepinephrine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d595.s1.e0'}, 'e2': {'word': 'sodium bicarbonate', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d595.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d595.s1'}	norepinephrine dobutamine incompatible sodium bicarbonate solution
norepinephrine and dobutamine are incompatible with sodium bicarbonate solution. 	dobutamine	sodium bicarbonate	int	{'e1': {'word': 'dobutamine', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d595.s1.e1'}, 'e2': {'word': 'sodium bicarbonate', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d595.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d595.s1'}	norepinephrine dobutamine incompatible sodium bicarbonate solution
The addition of sodium bicarbonate to parenteral solutions containing calcium should be avoided, except where compatibility has been previously established. 	sodium bicarbonate	calcium	none	{'e1': {'word': 'sodium bicarbonate', 'word_index': [(1, 2)], 'id': 'DDI-DrugBank.d595.s2.e0'}, 'e2': {'word': 'calcium', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d595.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d595.s2'}	addition sodium bicarbonate parenteral solutions containing calcium avoided except compatibility previously established
Thiabendazole may compete with other drugs, such as theophylline, for sites of metabolism in the liver, thus elevating the serum levels of such compounds to potentially toxic levels. 	Thiabendazole	theophylline	mechanism	{'e1': {'word': 'Thiabendazole', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d686.s0.e0'}, 'e2': {'word': 'theophylline', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d686.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d686.s0'}	Thiabendazole may compete drugs theophylline sites metabolism liver thus elevating serum levels compounds potentially toxic levels
Therefore, when concomitant use of thiabendazole and xanthine derivatives is anticipated, it may be necessary to monitor blood levels and/or reduce the dosage of such compounds. 	thiabendazole	xanthine derivatives	advise	{'e1': {'word': 'thiabendazole', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d686.s1.e0'}, 'e2': {'word': 'xanthine derivatives', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d686.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d686.s1'}	Therefore concomitant use thiabendazole xanthine derivatives anticipated may necessary monitor blood levels reduce dosage compounds
When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when atropine is used alone. 	atropine	pralidoxime	effect	{'e1': {'word': 'atropine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d622.s0.e0'}, 'e2': {'word': 'pralidoxime', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d622.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d622.s0'}	atropine pralidoxime used together signs atropinization flushing mydriasis tachycardia dryness mouth nose may occur earlier might expected atropine used alone
When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when atropine is used alone. 	atropine	atropine	none	{'e1': {'word': 'atropine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d622.s0.e0'}, 'e2': {'word': 'atropine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d622.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d622.s0'}	atropine pralidoxime used together signs atropinization flushing mydriasis tachycardia dryness mouth nose may occur earlier might expected atropine used alone
When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when atropine is used alone. 	pralidoxime	atropine	none	{'e1': {'word': 'pralidoxime', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d622.s0.e1'}, 'e2': {'word': 'atropine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d622.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d622.s0'}	atropine pralidoxime used together signs atropinization flushing mydriasis tachycardia dryness mouth nose may occur earlier might expected atropine used alone
This is especially true if the total dose of atropine has been large and the administration of pralidoxime has been delayed. 	atropine	pralidoxime	none	{'e1': {'word': 'atropine', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d622.s1.e0'}, 'e2': {'word': 'pralidoxime', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d622.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d622.s1'}	especially true total dose atropine large administration pralidoxime delayed
2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of pralidoxime: since barbiturates are potentiated by the anticholinesterases, they should be used cautiously in the treatment of convulsions; 	pralidoxime	barbiturates	none	{'e1': {'word': 'pralidoxime', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d622.s2.e0'}, 'e2': {'word': 'barbiturates', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d622.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d622.s2'}	NUMBER - NUMBER following precautions kept mind treatment anticholinesterase poisoning although bear directly use pralidoxime since barbiturates potentiated anticholinesterases used cautiously treatment convulsions
2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of pralidoxime: since barbiturates are potentiated by the anticholinesterases, they should be used cautiously in the treatment of convulsions; 	pralidoxime	anticholinesterases	none	{'e1': {'word': 'pralidoxime', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d622.s2.e0'}, 'e2': {'word': 'anticholinesterases', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d622.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d622.s2'}	NUMBER - NUMBER following precautions kept mind treatment anticholinesterase poisoning although bear directly use pralidoxime since barbiturates potentiated anticholinesterases used cautiously treatment convulsions
2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of pralidoxime: since barbiturates are potentiated by the anticholinesterases, they should be used cautiously in the treatment of convulsions; 	barbiturates	anticholinesterases	effect	{'e1': {'word': 'barbiturates', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d622.s2.e1'}, 'e2': {'word': 'anticholinesterases', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d622.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d622.s2'}	NUMBER - NUMBER following precautions kept mind treatment anticholinesterase poisoning although bear directly use pralidoxime since barbiturates potentiated anticholinesterases used cautiously treatment convulsions
morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.	morphine	theophylline	none	{'e1': {'word': 'morphine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d622.s3.e0'}, 'e2': {'word': 'theophylline', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d622.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d622.s3'}	morphine theophylline aminophylline succinylcholine reserpine phenothiazine type tranquilizers avoided patients organophosphate poisoning
morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.	morphine	aminophylline	none	{'e1': {'word': 'morphine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d622.s3.e0'}, 'e2': {'word': 'aminophylline', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d622.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d622.s3'}	morphine theophylline aminophylline succinylcholine reserpine phenothiazine type tranquilizers avoided patients organophosphate poisoning
morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.	morphine	succinylcholine	none	{'e1': {'word': 'morphine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d622.s3.e0'}, 'e2': {'word': 'succinylcholine', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d622.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d622.s3'}	morphine theophylline aminophylline succinylcholine reserpine phenothiazine type tranquilizers avoided patients organophosphate poisoning
morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.	morphine	reserpine	none	{'e1': {'word': 'morphine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d622.s3.e0'}, 'e2': {'word': 'reserpine', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d622.s3.e4'}, 'sentence_id': 'DDI-DrugBank.d622.s3'}	morphine theophylline aminophylline succinylcholine reserpine phenothiazine type tranquilizers avoided patients organophosphate poisoning
morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.	morphine	phenothiazine-type tranquilizers	none	{'e1': {'word': 'morphine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d622.s3.e0'}, 'e2': {'word': 'phenothiazine-type tranquilizers', 'word_index': [(5, 7)], 'id': 'DDI-DrugBank.d622.s3.e5'}, 'sentence_id': 'DDI-DrugBank.d622.s3'}	morphine theophylline aminophylline succinylcholine reserpine phenothiazine type tranquilizers avoided patients organophosphate poisoning
morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.	theophylline	aminophylline	none	{'e1': {'word': 'theophylline', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d622.s3.e1'}, 'e2': {'word': 'aminophylline', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d622.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d622.s3'}	morphine theophylline aminophylline succinylcholine reserpine phenothiazine type tranquilizers avoided patients organophosphate poisoning
morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.	theophylline	succinylcholine	none	{'e1': {'word': 'theophylline', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d622.s3.e1'}, 'e2': {'word': 'succinylcholine', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d622.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d622.s3'}	morphine theophylline aminophylline succinylcholine reserpine phenothiazine type tranquilizers avoided patients organophosphate poisoning
morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.	theophylline	reserpine	none	{'e1': {'word': 'theophylline', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d622.s3.e1'}, 'e2': {'word': 'reserpine', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d622.s3.e4'}, 'sentence_id': 'DDI-DrugBank.d622.s3'}	morphine theophylline aminophylline succinylcholine reserpine phenothiazine type tranquilizers avoided patients organophosphate poisoning
morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.	theophylline	phenothiazine-type tranquilizers	none	{'e1': {'word': 'theophylline', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d622.s3.e1'}, 'e2': {'word': 'phenothiazine-type tranquilizers', 'word_index': [(5, 7)], 'id': 'DDI-DrugBank.d622.s3.e5'}, 'sentence_id': 'DDI-DrugBank.d622.s3'}	morphine theophylline aminophylline succinylcholine reserpine phenothiazine type tranquilizers avoided patients organophosphate poisoning
morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.	aminophylline	succinylcholine	none	{'e1': {'word': 'aminophylline', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d622.s3.e2'}, 'e2': {'word': 'succinylcholine', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d622.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d622.s3'}	morphine theophylline aminophylline succinylcholine reserpine phenothiazine type tranquilizers avoided patients organophosphate poisoning
morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.	aminophylline	reserpine	none	{'e1': {'word': 'aminophylline', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d622.s3.e2'}, 'e2': {'word': 'reserpine', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d622.s3.e4'}, 'sentence_id': 'DDI-DrugBank.d622.s3'}	morphine theophylline aminophylline succinylcholine reserpine phenothiazine type tranquilizers avoided patients organophosphate poisoning
morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.	aminophylline	phenothiazine-type tranquilizers	none	{'e1': {'word': 'aminophylline', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d622.s3.e2'}, 'e2': {'word': 'phenothiazine-type tranquilizers', 'word_index': [(5, 7)], 'id': 'DDI-DrugBank.d622.s3.e5'}, 'sentence_id': 'DDI-DrugBank.d622.s3'}	morphine theophylline aminophylline succinylcholine reserpine phenothiazine type tranquilizers avoided patients organophosphate poisoning
morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.	succinylcholine	reserpine	none	{'e1': {'word': 'succinylcholine', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d622.s3.e3'}, 'e2': {'word': 'reserpine', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d622.s3.e4'}, 'sentence_id': 'DDI-DrugBank.d622.s3'}	morphine theophylline aminophylline succinylcholine reserpine phenothiazine type tranquilizers avoided patients organophosphate poisoning
morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.	succinylcholine	phenothiazine-type tranquilizers	none	{'e1': {'word': 'succinylcholine', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d622.s3.e3'}, 'e2': {'word': 'phenothiazine-type tranquilizers', 'word_index': [(5, 7)], 'id': 'DDI-DrugBank.d622.s3.e5'}, 'sentence_id': 'DDI-DrugBank.d622.s3'}	morphine theophylline aminophylline succinylcholine reserpine phenothiazine type tranquilizers avoided patients organophosphate poisoning
morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.	reserpine	phenothiazine-type tranquilizers	none	{'e1': {'word': 'reserpine', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d622.s3.e4'}, 'e2': {'word': 'phenothiazine-type tranquilizers', 'word_index': [(5, 7)], 'id': 'DDI-DrugBank.d622.s3.e5'}, 'sentence_id': 'DDI-DrugBank.d622.s3'}	morphine theophylline aminophylline succinylcholine reserpine phenothiazine type tranquilizers avoided patients organophosphate poisoning
Cholestyramine: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA. 	Cholestyramine	Cholestyramine	none	{'e1': {'word': 'Cholestyramine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d648.s0.e0'}, 'e2': {'word': 'Cholestyramine', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d648.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d648.s0'}	Cholestyramine Cholestyramine causes NUMBER % reduction absorption enterohepatic cycling raloxifene coadministered EVISTA
Cholestyramine: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA. 	Cholestyramine	raloxifene	none	{'e1': {'word': 'Cholestyramine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d648.s0.e0'}, 'e2': {'word': 'raloxifene', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d648.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d648.s0'}	Cholestyramine Cholestyramine causes NUMBER % reduction absorption enterohepatic cycling raloxifene coadministered EVISTA
Cholestyramine: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA. 	Cholestyramine	EVISTA	none	{'e1': {'word': 'Cholestyramine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d648.s0.e0'}, 'e2': {'word': 'EVISTA', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d648.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d648.s0'}	Cholestyramine Cholestyramine causes NUMBER % reduction absorption enterohepatic cycling raloxifene coadministered EVISTA
Cholestyramine: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA. 	Cholestyramine	raloxifene	mechanism	{'e1': {'word': 'Cholestyramine', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d648.s0.e1'}, 'e2': {'word': 'raloxifene', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d648.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d648.s0'}	Cholestyramine Cholestyramine causes NUMBER % reduction absorption enterohepatic cycling raloxifene coadministered EVISTA
Cholestyramine: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA. 	Cholestyramine	EVISTA	advise	{'e1': {'word': 'Cholestyramine', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d648.s0.e1'}, 'e2': {'word': 'EVISTA', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d648.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d648.s0'}	Cholestyramine Cholestyramine causes NUMBER % reduction absorption enterohepatic cycling raloxifene coadministered EVISTA
Cholestyramine: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA. 	raloxifene	EVISTA	none	{'e1': {'word': 'raloxifene', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d648.s0.e2'}, 'e2': {'word': 'EVISTA', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d648.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d648.s0'}	Cholestyramine Cholestyramine causes NUMBER % reduction absorption enterohepatic cycling raloxifene coadministered EVISTA
Warfarin: The coadministration of EVISTA and warfarin has not been assessed under chronic conditions. 	Warfarin	EVISTA	none	{'e1': {'word': 'Warfarin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d648.s1.e0'}, 'e2': {'word': 'EVISTA', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d648.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d648.s1'}	Warfarin coadministration EVISTA warfarin assessed chronic conditions
Warfarin: The coadministration of EVISTA and warfarin has not been assessed under chronic conditions. 	Warfarin	warfarin	none	{'e1': {'word': 'Warfarin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d648.s1.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d648.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d648.s1'}	Warfarin coadministration EVISTA warfarin assessed chronic conditions
Warfarin: The coadministration of EVISTA and warfarin has not been assessed under chronic conditions. 	EVISTA	warfarin	none	{'e1': {'word': 'EVISTA', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d648.s1.e1'}, 'e2': {'word': 'warfarin', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d648.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d648.s1'}	Warfarin coadministration EVISTA warfarin assessed chronic conditions
If EVISTA is given concurrently with warfarin, prothrombin time should be monitored. 	EVISTA	warfarin	advise	{'e1': {'word': 'EVISTA', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d648.s3.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d648.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d648.s3'}	EVISTA given concurrently warfarin prothrombin time monitored
In vitro, raloxifene did not affect the binding of warfarin, phenytoin, or tamoxifen. 	raloxifene	warfarin	none	{'e1': {'word': 'raloxifene', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d648.s5.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d648.s5.e1'}, 'sentence_id': 'DDI-DrugBank.d648.s5'}	vitro raloxifene affect binding warfarin phenytoin tamoxifen
In vitro, raloxifene did not affect the binding of warfarin, phenytoin, or tamoxifen. 	raloxifene	phenytoin	none	{'e1': {'word': 'raloxifene', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d648.s5.e0'}, 'e2': {'word': 'phenytoin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d648.s5.e2'}, 'sentence_id': 'DDI-DrugBank.d648.s5'}	vitro raloxifene affect binding warfarin phenytoin tamoxifen
In vitro, raloxifene did not affect the binding of warfarin, phenytoin, or tamoxifen. 	raloxifene	tamoxifen	none	{'e1': {'word': 'raloxifene', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d648.s5.e0'}, 'e2': {'word': 'tamoxifen', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d648.s5.e3'}, 'sentence_id': 'DDI-DrugBank.d648.s5'}	vitro raloxifene affect binding warfarin phenytoin tamoxifen
In vitro, raloxifene did not affect the binding of warfarin, phenytoin, or tamoxifen. 	warfarin	phenytoin	none	{'e1': {'word': 'warfarin', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d648.s5.e1'}, 'e2': {'word': 'phenytoin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d648.s5.e2'}, 'sentence_id': 'DDI-DrugBank.d648.s5'}	vitro raloxifene affect binding warfarin phenytoin tamoxifen
In vitro, raloxifene did not affect the binding of warfarin, phenytoin, or tamoxifen. 	warfarin	tamoxifen	none	{'e1': {'word': 'warfarin', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d648.s5.e1'}, 'e2': {'word': 'tamoxifen', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d648.s5.e3'}, 'sentence_id': 'DDI-DrugBank.d648.s5'}	vitro raloxifene affect binding warfarin phenytoin tamoxifen
In vitro, raloxifene did not affect the binding of warfarin, phenytoin, or tamoxifen. 	phenytoin	tamoxifen	none	{'e1': {'word': 'phenytoin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d648.s5.e2'}, 'e2': {'word': 'tamoxifen', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d648.s5.e3'}, 'sentence_id': 'DDI-DrugBank.d648.s5'}	vitro raloxifene affect binding warfarin phenytoin tamoxifen
Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. 	EVISTA	clofibrate	advise	{'e1': {'word': 'EVISTA', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d648.s6.e0'}, 'e2': {'word': 'clofibrate', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d648.s6.e1'}, 'sentence_id': 'DDI-DrugBank.d648.s6'}	Caution used EVISTA coadministered highly protein bound drugs clofibrate indomethacin naproxen ibuprofen diazepam diazoxide
Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. 	EVISTA	indomethacin	advise	{'e1': {'word': 'EVISTA', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d648.s6.e0'}, 'e2': {'word': 'indomethacin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d648.s6.e2'}, 'sentence_id': 'DDI-DrugBank.d648.s6'}	Caution used EVISTA coadministered highly protein bound drugs clofibrate indomethacin naproxen ibuprofen diazepam diazoxide
Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. 	EVISTA	naproxen	advise	{'e1': {'word': 'EVISTA', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d648.s6.e0'}, 'e2': {'word': 'naproxen', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d648.s6.e3'}, 'sentence_id': 'DDI-DrugBank.d648.s6'}	Caution used EVISTA coadministered highly protein bound drugs clofibrate indomethacin naproxen ibuprofen diazepam diazoxide
Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. 	EVISTA	ibuprofen	advise	{'e1': {'word': 'EVISTA', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d648.s6.e0'}, 'e2': {'word': 'ibuprofen', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d648.s6.e4'}, 'sentence_id': 'DDI-DrugBank.d648.s6'}	Caution used EVISTA coadministered highly protein bound drugs clofibrate indomethacin naproxen ibuprofen diazepam diazoxide
Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. 	EVISTA	diazepam	advise	{'e1': {'word': 'EVISTA', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d648.s6.e0'}, 'e2': {'word': 'diazepam', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d648.s6.e5'}, 'sentence_id': 'DDI-DrugBank.d648.s6'}	Caution used EVISTA coadministered highly protein bound drugs clofibrate indomethacin naproxen ibuprofen diazepam diazoxide
Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. 	EVISTA	diazoxide	advise	{'e1': {'word': 'EVISTA', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d648.s6.e0'}, 'e2': {'word': 'diazoxide', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d648.s6.e6'}, 'sentence_id': 'DDI-DrugBank.d648.s6'}	Caution used EVISTA coadministered highly protein bound drugs clofibrate indomethacin naproxen ibuprofen diazepam diazoxide
Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. 	clofibrate	indomethacin	none	{'e1': {'word': 'clofibrate', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d648.s6.e1'}, 'e2': {'word': 'indomethacin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d648.s6.e2'}, 'sentence_id': 'DDI-DrugBank.d648.s6'}	Caution used EVISTA coadministered highly protein bound drugs clofibrate indomethacin naproxen ibuprofen diazepam diazoxide
Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. 	clofibrate	naproxen	none	{'e1': {'word': 'clofibrate', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d648.s6.e1'}, 'e2': {'word': 'naproxen', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d648.s6.e3'}, 'sentence_id': 'DDI-DrugBank.d648.s6'}	Caution used EVISTA coadministered highly protein bound drugs clofibrate indomethacin naproxen ibuprofen diazepam diazoxide
Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. 	clofibrate	ibuprofen	none	{'e1': {'word': 'clofibrate', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d648.s6.e1'}, 'e2': {'word': 'ibuprofen', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d648.s6.e4'}, 'sentence_id': 'DDI-DrugBank.d648.s6'}	Caution used EVISTA coadministered highly protein bound drugs clofibrate indomethacin naproxen ibuprofen diazepam diazoxide
Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. 	clofibrate	diazepam	none	{'e1': {'word': 'clofibrate', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d648.s6.e1'}, 'e2': {'word': 'diazepam', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d648.s6.e5'}, 'sentence_id': 'DDI-DrugBank.d648.s6'}	Caution used EVISTA coadministered highly protein bound drugs clofibrate indomethacin naproxen ibuprofen diazepam diazoxide
Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. 	clofibrate	diazoxide	none	{'e1': {'word': 'clofibrate', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d648.s6.e1'}, 'e2': {'word': 'diazoxide', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d648.s6.e6'}, 'sentence_id': 'DDI-DrugBank.d648.s6'}	Caution used EVISTA coadministered highly protein bound drugs clofibrate indomethacin naproxen ibuprofen diazepam diazoxide
Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. 	indomethacin	naproxen	none	{'e1': {'word': 'indomethacin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d648.s6.e2'}, 'e2': {'word': 'naproxen', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d648.s6.e3'}, 'sentence_id': 'DDI-DrugBank.d648.s6'}	Caution used EVISTA coadministered highly protein bound drugs clofibrate indomethacin naproxen ibuprofen diazepam diazoxide
Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. 	indomethacin	ibuprofen	none	{'e1': {'word': 'indomethacin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d648.s6.e2'}, 'e2': {'word': 'ibuprofen', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d648.s6.e4'}, 'sentence_id': 'DDI-DrugBank.d648.s6'}	Caution used EVISTA coadministered highly protein bound drugs clofibrate indomethacin naproxen ibuprofen diazepam diazoxide
Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. 	indomethacin	diazepam	none	{'e1': {'word': 'indomethacin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d648.s6.e2'}, 'e2': {'word': 'diazepam', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d648.s6.e5'}, 'sentence_id': 'DDI-DrugBank.d648.s6'}	Caution used EVISTA coadministered highly protein bound drugs clofibrate indomethacin naproxen ibuprofen diazepam diazoxide
Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. 	indomethacin	diazoxide	none	{'e1': {'word': 'indomethacin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d648.s6.e2'}, 'e2': {'word': 'diazoxide', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d648.s6.e6'}, 'sentence_id': 'DDI-DrugBank.d648.s6'}	Caution used EVISTA coadministered highly protein bound drugs clofibrate indomethacin naproxen ibuprofen diazepam diazoxide
Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. 	naproxen	ibuprofen	none	{'e1': {'word': 'naproxen', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d648.s6.e3'}, 'e2': {'word': 'ibuprofen', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d648.s6.e4'}, 'sentence_id': 'DDI-DrugBank.d648.s6'}	Caution used EVISTA coadministered highly protein bound drugs clofibrate indomethacin naproxen ibuprofen diazepam diazoxide
Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. 	naproxen	diazepam	none	{'e1': {'word': 'naproxen', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d648.s6.e3'}, 'e2': {'word': 'diazepam', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d648.s6.e5'}, 'sentence_id': 'DDI-DrugBank.d648.s6'}	Caution used EVISTA coadministered highly protein bound drugs clofibrate indomethacin naproxen ibuprofen diazepam diazoxide
Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. 	naproxen	diazoxide	none	{'e1': {'word': 'naproxen', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d648.s6.e3'}, 'e2': {'word': 'diazoxide', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d648.s6.e6'}, 'sentence_id': 'DDI-DrugBank.d648.s6'}	Caution used EVISTA coadministered highly protein bound drugs clofibrate indomethacin naproxen ibuprofen diazepam diazoxide
Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. 	ibuprofen	diazepam	none	{'e1': {'word': 'ibuprofen', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d648.s6.e4'}, 'e2': {'word': 'diazepam', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d648.s6.e5'}, 'sentence_id': 'DDI-DrugBank.d648.s6'}	Caution used EVISTA coadministered highly protein bound drugs clofibrate indomethacin naproxen ibuprofen diazepam diazoxide
Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. 	ibuprofen	diazoxide	none	{'e1': {'word': 'ibuprofen', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d648.s6.e4'}, 'e2': {'word': 'diazoxide', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d648.s6.e6'}, 'sentence_id': 'DDI-DrugBank.d648.s6'}	Caution used EVISTA coadministered highly protein bound drugs clofibrate indomethacin naproxen ibuprofen diazepam diazoxide
Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. 	diazepam	diazoxide	none	{'e1': {'word': 'diazepam', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d648.s6.e5'}, 'e2': {'word': 'diazoxide', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d648.s6.e6'}, 'sentence_id': 'DDI-DrugBank.d648.s6'}	Caution used EVISTA coadministered highly protein bound drugs clofibrate indomethacin naproxen ibuprofen diazepam diazoxide
Sulfamethizole may increase the effects of barbiturates, tolbutamide, and uricosurics. 	Sulfamethizole	barbiturates	effect	{'e1': {'word': 'Sulfamethizole', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d649.s0.e0'}, 'e2': {'word': 'barbiturates', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d649.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d649.s0'}	Sulfamethizole may increase effects barbiturates tolbutamide uricosurics
Sulfamethizole may increase the effects of barbiturates, tolbutamide, and uricosurics. 	Sulfamethizole	tolbutamide	effect	{'e1': {'word': 'Sulfamethizole', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d649.s0.e0'}, 'e2': {'word': 'tolbutamide', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d649.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d649.s0'}	Sulfamethizole may increase effects barbiturates tolbutamide uricosurics
Sulfamethizole may increase the effects of barbiturates, tolbutamide, and uricosurics. 	Sulfamethizole	uricosurics	effect	{'e1': {'word': 'Sulfamethizole', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d649.s0.e0'}, 'e2': {'word': 'uricosurics', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d649.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d649.s0'}	Sulfamethizole may increase effects barbiturates tolbutamide uricosurics
Sulfamethizole may increase the effects of barbiturates, tolbutamide, and uricosurics. 	barbiturates	tolbutamide	none	{'e1': {'word': 'barbiturates', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d649.s0.e1'}, 'e2': {'word': 'tolbutamide', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d649.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d649.s0'}	Sulfamethizole may increase effects barbiturates tolbutamide uricosurics
Sulfamethizole may increase the effects of barbiturates, tolbutamide, and uricosurics. 	barbiturates	uricosurics	none	{'e1': {'word': 'barbiturates', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d649.s0.e1'}, 'e2': {'word': 'uricosurics', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d649.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d649.s0'}	Sulfamethizole may increase effects barbiturates tolbutamide uricosurics
Sulfamethizole may increase the effects of barbiturates, tolbutamide, and uricosurics. 	tolbutamide	uricosurics	none	{'e1': {'word': 'tolbutamide', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d649.s0.e2'}, 'e2': {'word': 'uricosurics', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d649.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d649.s0'}	Sulfamethizole may increase effects barbiturates tolbutamide uricosurics
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	thiazides	cyclosporine	none	{'e1': {'word': 'thiazides', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d649.s1.e0'}, 'e2': {'word': 'cyclosporine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d649.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d649.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	thiazides	sulfonylurea agents	none	{'e1': {'word': 'thiazides', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d649.s1.e0'}, 'e2': {'word': 'sulfonylurea agents', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d649.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d649.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	thiazides	warfarin	none	{'e1': {'word': 'thiazides', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d649.s1.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d649.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d649.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	thiazides	methotrexate	none	{'e1': {'word': 'thiazides', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d649.s1.e0'}, 'e2': {'word': 'methotrexate', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d649.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d649.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	thiazides	methotrexate	none	{'e1': {'word': 'thiazides', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d649.s1.e0'}, 'e2': {'word': 'methotrexate', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d649.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d649.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	thiazides	phenytoin	none	{'e1': {'word': 'thiazides', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d649.s1.e0'}, 'e2': {'word': 'phenytoin', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d649.s1.e6'}, 'sentence_id': 'DDI-DrugBank.d649.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	thiazides	phenytoin	none	{'e1': {'word': 'thiazides', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d649.s1.e0'}, 'e2': {'word': 'phenytoin', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d649.s1.e7'}, 'sentence_id': 'DDI-DrugBank.d649.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	cyclosporine	sulfonylurea agents	none	{'e1': {'word': 'cyclosporine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d649.s1.e1'}, 'e2': {'word': 'sulfonylurea agents', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d649.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d649.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	cyclosporine	warfarin	none	{'e1': {'word': 'cyclosporine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d649.s1.e1'}, 'e2': {'word': 'warfarin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d649.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d649.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	cyclosporine	methotrexate	none	{'e1': {'word': 'cyclosporine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d649.s1.e1'}, 'e2': {'word': 'methotrexate', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d649.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d649.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	cyclosporine	methotrexate	none	{'e1': {'word': 'cyclosporine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d649.s1.e1'}, 'e2': {'word': 'methotrexate', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d649.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d649.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	cyclosporine	phenytoin	none	{'e1': {'word': 'cyclosporine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d649.s1.e1'}, 'e2': {'word': 'phenytoin', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d649.s1.e6'}, 'sentence_id': 'DDI-DrugBank.d649.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	cyclosporine	phenytoin	none	{'e1': {'word': 'cyclosporine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d649.s1.e1'}, 'e2': {'word': 'phenytoin', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d649.s1.e7'}, 'sentence_id': 'DDI-DrugBank.d649.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	sulfonylurea agents	warfarin	none	{'e1': {'word': 'sulfonylurea agents', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d649.s1.e2'}, 'e2': {'word': 'warfarin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d649.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d649.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	sulfonylurea agents	methotrexate	none	{'e1': {'word': 'sulfonylurea agents', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d649.s1.e2'}, 'e2': {'word': 'methotrexate', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d649.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d649.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	sulfonylurea agents	methotrexate	none	{'e1': {'word': 'sulfonylurea agents', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d649.s1.e2'}, 'e2': {'word': 'methotrexate', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d649.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d649.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	sulfonylurea agents	phenytoin	none	{'e1': {'word': 'sulfonylurea agents', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d649.s1.e2'}, 'e2': {'word': 'phenytoin', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d649.s1.e6'}, 'sentence_id': 'DDI-DrugBank.d649.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	sulfonylurea agents	phenytoin	none	{'e1': {'word': 'sulfonylurea agents', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d649.s1.e2'}, 'e2': {'word': 'phenytoin', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d649.s1.e7'}, 'sentence_id': 'DDI-DrugBank.d649.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	warfarin	methotrexate	none	{'e1': {'word': 'warfarin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d649.s1.e3'}, 'e2': {'word': 'methotrexate', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d649.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d649.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	warfarin	methotrexate	none	{'e1': {'word': 'warfarin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d649.s1.e3'}, 'e2': {'word': 'methotrexate', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d649.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d649.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	warfarin	phenytoin	none	{'e1': {'word': 'warfarin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d649.s1.e3'}, 'e2': {'word': 'phenytoin', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d649.s1.e6'}, 'sentence_id': 'DDI-DrugBank.d649.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	warfarin	phenytoin	none	{'e1': {'word': 'warfarin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d649.s1.e3'}, 'e2': {'word': 'phenytoin', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d649.s1.e7'}, 'sentence_id': 'DDI-DrugBank.d649.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	methotrexate	methotrexate	none	{'e1': {'word': 'methotrexate', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d649.s1.e4'}, 'e2': {'word': 'methotrexate', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d649.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d649.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	methotrexate	phenytoin	none	{'e1': {'word': 'methotrexate', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d649.s1.e4'}, 'e2': {'word': 'phenytoin', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d649.s1.e6'}, 'sentence_id': 'DDI-DrugBank.d649.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	methotrexate	phenytoin	none	{'e1': {'word': 'methotrexate', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d649.s1.e4'}, 'e2': {'word': 'phenytoin', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d649.s1.e7'}, 'sentence_id': 'DDI-DrugBank.d649.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	methotrexate	phenytoin	none	{'e1': {'word': 'methotrexate', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d649.s1.e5'}, 'e2': {'word': 'phenytoin', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d649.s1.e6'}, 'sentence_id': 'DDI-DrugBank.d649.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	methotrexate	phenytoin	none	{'e1': {'word': 'methotrexate', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d649.s1.e5'}, 'e2': {'word': 'phenytoin', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d649.s1.e7'}, 'sentence_id': 'DDI-DrugBank.d649.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	phenytoin	phenytoin	none	{'e1': {'word': 'phenytoin', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d649.s1.e6'}, 'e2': {'word': 'phenytoin', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d649.s1.e7'}, 'sentence_id': 'DDI-DrugBank.d649.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). 	midazolam	azole antimycotics	advise	{'e1': {'word': 'midazolam', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d752.s0.e0'}, 'e2': {'word': 'azole antimycotics', 'word_index': [(22, 23)], 'id': 'DDI-DrugBank.d752.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d752.s0'}	Drug Interactions Inhibitors CYP3A4 Isozymes Caution advised midazolam administered concomitantly drugs known inhibit cytochrome P450 3A4 enzyme system ie drugs drug classes azole antimycotics protease inhibitors calcium channel antagonists macrolide antibiotics
Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). 	midazolam	protease inhibitors	advise	{'e1': {'word': 'midazolam', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d752.s0.e0'}, 'e2': {'word': 'protease inhibitors', 'word_index': [(24, 25)], 'id': 'DDI-DrugBank.d752.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d752.s0'}	Drug Interactions Inhibitors CYP3A4 Isozymes Caution advised midazolam administered concomitantly drugs known inhibit cytochrome P450 3A4 enzyme system ie drugs drug classes azole antimycotics protease inhibitors calcium channel antagonists macrolide antibiotics
Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). 	midazolam	calcium channel antagonists	advise	{'e1': {'word': 'midazolam', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d752.s0.e0'}, 'e2': {'word': 'calcium channel antagonists', 'word_index': [(26, 28)], 'id': 'DDI-DrugBank.d752.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d752.s0'}	Drug Interactions Inhibitors CYP3A4 Isozymes Caution advised midazolam administered concomitantly drugs known inhibit cytochrome P450 3A4 enzyme system ie drugs drug classes azole antimycotics protease inhibitors calcium channel antagonists macrolide antibiotics
Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). 	midazolam	macrolide antibiotics	advise	{'e1': {'word': 'midazolam', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d752.s0.e0'}, 'e2': {'word': 'macrolide antibiotics', 'word_index': [(29, 30)], 'id': 'DDI-DrugBank.d752.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d752.s0'}	Drug Interactions Inhibitors CYP3A4 Isozymes Caution advised midazolam administered concomitantly drugs known inhibit cytochrome P450 3A4 enzyme system ie drugs drug classes azole antimycotics protease inhibitors calcium channel antagonists macrolide antibiotics
Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). 	azole antimycotics	protease inhibitors	none	{'e1': {'word': 'azole antimycotics', 'word_index': [(22, 23)], 'id': 'DDI-DrugBank.d752.s0.e1'}, 'e2': {'word': 'protease inhibitors', 'word_index': [(24, 25)], 'id': 'DDI-DrugBank.d752.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d752.s0'}	Drug Interactions Inhibitors CYP3A4 Isozymes Caution advised midazolam administered concomitantly drugs known inhibit cytochrome P450 3A4 enzyme system ie drugs drug classes azole antimycotics protease inhibitors calcium channel antagonists macrolide antibiotics
Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). 	azole antimycotics	calcium channel antagonists	none	{'e1': {'word': 'azole antimycotics', 'word_index': [(22, 23)], 'id': 'DDI-DrugBank.d752.s0.e1'}, 'e2': {'word': 'calcium channel antagonists', 'word_index': [(26, 28)], 'id': 'DDI-DrugBank.d752.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d752.s0'}	Drug Interactions Inhibitors CYP3A4 Isozymes Caution advised midazolam administered concomitantly drugs known inhibit cytochrome P450 3A4 enzyme system ie drugs drug classes azole antimycotics protease inhibitors calcium channel antagonists macrolide antibiotics
Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). 	azole antimycotics	macrolide antibiotics	none	{'e1': {'word': 'azole antimycotics', 'word_index': [(22, 23)], 'id': 'DDI-DrugBank.d752.s0.e1'}, 'e2': {'word': 'macrolide antibiotics', 'word_index': [(29, 30)], 'id': 'DDI-DrugBank.d752.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d752.s0'}	Drug Interactions Inhibitors CYP3A4 Isozymes Caution advised midazolam administered concomitantly drugs known inhibit cytochrome P450 3A4 enzyme system ie drugs drug classes azole antimycotics protease inhibitors calcium channel antagonists macrolide antibiotics
Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). 	protease inhibitors	calcium channel antagonists	none	{'e1': {'word': 'protease inhibitors', 'word_index': [(24, 25)], 'id': 'DDI-DrugBank.d752.s0.e2'}, 'e2': {'word': 'calcium channel antagonists', 'word_index': [(26, 28)], 'id': 'DDI-DrugBank.d752.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d752.s0'}	Drug Interactions Inhibitors CYP3A4 Isozymes Caution advised midazolam administered concomitantly drugs known inhibit cytochrome P450 3A4 enzyme system ie drugs drug classes azole antimycotics protease inhibitors calcium channel antagonists macrolide antibiotics
Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). 	protease inhibitors	macrolide antibiotics	none	{'e1': {'word': 'protease inhibitors', 'word_index': [(24, 25)], 'id': 'DDI-DrugBank.d752.s0.e2'}, 'e2': {'word': 'macrolide antibiotics', 'word_index': [(29, 30)], 'id': 'DDI-DrugBank.d752.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d752.s0'}	Drug Interactions Inhibitors CYP3A4 Isozymes Caution advised midazolam administered concomitantly drugs known inhibit cytochrome P450 3A4 enzyme system ie drugs drug classes azole antimycotics protease inhibitors calcium channel antagonists macrolide antibiotics
Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). 	calcium channel antagonists	macrolide antibiotics	none	{'e1': {'word': 'calcium channel antagonists', 'word_index': [(26, 28)], 'id': 'DDI-DrugBank.d752.s0.e3'}, 'e2': {'word': 'macrolide antibiotics', 'word_index': [(29, 30)], 'id': 'DDI-DrugBank.d752.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d752.s0'}	Drug Interactions Inhibitors CYP3A4 Isozymes Caution advised midazolam administered concomitantly drugs known inhibit cytochrome P450 3A4 enzyme system ie drugs drug classes azole antimycotics protease inhibitors calcium channel antagonists macrolide antibiotics
Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. 	erythromycin	diltiazem	none	{'e1': {'word': 'erythromycin', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d752.s1.e0'}, 'e2': {'word': 'diltiazem', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d752.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d752.s1'}	Drugs erythromycin diltiazem verapamil ketoconazole fluconazole itraconazole shown significantly increase C max AUC orally administered midazolam
Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. 	erythromycin	verapamil	none	{'e1': {'word': 'erythromycin', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d752.s1.e0'}, 'e2': {'word': 'verapamil', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d752.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d752.s1'}	Drugs erythromycin diltiazem verapamil ketoconazole fluconazole itraconazole shown significantly increase C max AUC orally administered midazolam
Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. 	erythromycin	ketoconazole	none	{'e1': {'word': 'erythromycin', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d752.s1.e0'}, 'e2': {'word': 'ketoconazole', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d752.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d752.s1'}	Drugs erythromycin diltiazem verapamil ketoconazole fluconazole itraconazole shown significantly increase C max AUC orally administered midazolam
Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. 	erythromycin	fluconazole	none	{'e1': {'word': 'erythromycin', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d752.s1.e0'}, 'e2': {'word': 'fluconazole', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d752.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d752.s1'}	Drugs erythromycin diltiazem verapamil ketoconazole fluconazole itraconazole shown significantly increase C max AUC orally administered midazolam
Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. 	erythromycin	itraconazole	none	{'e1': {'word': 'erythromycin', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d752.s1.e0'}, 'e2': {'word': 'itraconazole', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d752.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d752.s1'}	Drugs erythromycin diltiazem verapamil ketoconazole fluconazole itraconazole shown significantly increase C max AUC orally administered midazolam
Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. 	erythromycin	midazolam	mechanism	{'e1': {'word': 'erythromycin', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d752.s1.e0'}, 'e2': {'word': 'midazolam', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d752.s1.e6'}, 'sentence_id': 'DDI-DrugBank.d752.s1'}	Drugs erythromycin diltiazem verapamil ketoconazole fluconazole itraconazole shown significantly increase C max AUC orally administered midazolam
Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. 	diltiazem	verapamil	none	{'e1': {'word': 'diltiazem', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d752.s1.e1'}, 'e2': {'word': 'verapamil', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d752.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d752.s1'}	Drugs erythromycin diltiazem verapamil ketoconazole fluconazole itraconazole shown significantly increase C max AUC orally administered midazolam
Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. 	diltiazem	ketoconazole	none	{'e1': {'word': 'diltiazem', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d752.s1.e1'}, 'e2': {'word': 'ketoconazole', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d752.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d752.s1'}	Drugs erythromycin diltiazem verapamil ketoconazole fluconazole itraconazole shown significantly increase C max AUC orally administered midazolam
Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. 	diltiazem	fluconazole	none	{'e1': {'word': 'diltiazem', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d752.s1.e1'}, 'e2': {'word': 'fluconazole', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d752.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d752.s1'}	Drugs erythromycin diltiazem verapamil ketoconazole fluconazole itraconazole shown significantly increase C max AUC orally administered midazolam
Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. 	diltiazem	itraconazole	none	{'e1': {'word': 'diltiazem', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d752.s1.e1'}, 'e2': {'word': 'itraconazole', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d752.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d752.s1'}	Drugs erythromycin diltiazem verapamil ketoconazole fluconazole itraconazole shown significantly increase C max AUC orally administered midazolam
Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. 	diltiazem	midazolam	mechanism	{'e1': {'word': 'diltiazem', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d752.s1.e1'}, 'e2': {'word': 'midazolam', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d752.s1.e6'}, 'sentence_id': 'DDI-DrugBank.d752.s1'}	Drugs erythromycin diltiazem verapamil ketoconazole fluconazole itraconazole shown significantly increase C max AUC orally administered midazolam
Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. 	verapamil	ketoconazole	none	{'e1': {'word': 'verapamil', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d752.s1.e2'}, 'e2': {'word': 'ketoconazole', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d752.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d752.s1'}	Drugs erythromycin diltiazem verapamil ketoconazole fluconazole itraconazole shown significantly increase C max AUC orally administered midazolam
Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. 	verapamil	fluconazole	none	{'e1': {'word': 'verapamil', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d752.s1.e2'}, 'e2': {'word': 'fluconazole', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d752.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d752.s1'}	Drugs erythromycin diltiazem verapamil ketoconazole fluconazole itraconazole shown significantly increase C max AUC orally administered midazolam
Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. 	verapamil	itraconazole	none	{'e1': {'word': 'verapamil', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d752.s1.e2'}, 'e2': {'word': 'itraconazole', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d752.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d752.s1'}	Drugs erythromycin diltiazem verapamil ketoconazole fluconazole itraconazole shown significantly increase C max AUC orally administered midazolam
Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. 	verapamil	midazolam	mechanism	{'e1': {'word': 'verapamil', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d752.s1.e2'}, 'e2': {'word': 'midazolam', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d752.s1.e6'}, 'sentence_id': 'DDI-DrugBank.d752.s1'}	Drugs erythromycin diltiazem verapamil ketoconazole fluconazole itraconazole shown significantly increase C max AUC orally administered midazolam
Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. 	ketoconazole	fluconazole	none	{'e1': {'word': 'ketoconazole', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d752.s1.e3'}, 'e2': {'word': 'fluconazole', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d752.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d752.s1'}	Drugs erythromycin diltiazem verapamil ketoconazole fluconazole itraconazole shown significantly increase C max AUC orally administered midazolam
Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. 	ketoconazole	itraconazole	none	{'e1': {'word': 'ketoconazole', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d752.s1.e3'}, 'e2': {'word': 'itraconazole', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d752.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d752.s1'}	Drugs erythromycin diltiazem verapamil ketoconazole fluconazole itraconazole shown significantly increase C max AUC orally administered midazolam
Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. 	ketoconazole	midazolam	mechanism	{'e1': {'word': 'ketoconazole', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d752.s1.e3'}, 'e2': {'word': 'midazolam', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d752.s1.e6'}, 'sentence_id': 'DDI-DrugBank.d752.s1'}	Drugs erythromycin diltiazem verapamil ketoconazole fluconazole itraconazole shown significantly increase C max AUC orally administered midazolam
Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. 	fluconazole	itraconazole	none	{'e1': {'word': 'fluconazole', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d752.s1.e4'}, 'e2': {'word': 'itraconazole', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d752.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d752.s1'}	Drugs erythromycin diltiazem verapamil ketoconazole fluconazole itraconazole shown significantly increase C max AUC orally administered midazolam
Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. 	fluconazole	midazolam	mechanism	{'e1': {'word': 'fluconazole', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d752.s1.e4'}, 'e2': {'word': 'midazolam', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d752.s1.e6'}, 'sentence_id': 'DDI-DrugBank.d752.s1'}	Drugs erythromycin diltiazem verapamil ketoconazole fluconazole itraconazole shown significantly increase C max AUC orally administered midazolam
Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. 	itraconazole	midazolam	mechanism	{'e1': {'word': 'itraconazole', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d752.s1.e5'}, 'e2': {'word': 'midazolam', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d752.s1.e6'}, 'sentence_id': 'DDI-DrugBank.d752.s1'}	Drugs erythromycin diltiazem verapamil ketoconazole fluconazole itraconazole shown significantly increase C max AUC orally administered midazolam
Although not studied, the potent cytochrome P450 3A4 inhibitors ritonavir and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam. 	ritonavir	nelfinavir	none	{'e1': {'word': 'ritonavir', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d752.s3.e0'}, 'e2': {'word': 'nelfinavir', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d752.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d752.s3'}	Although studied potent cytochrome P450 3A4 inhibitors ritonavir nelfinavir may cause intense prolonged sedation respiratory depression due decrease plasma clearance midazolam
Although not studied, the potent cytochrome P450 3A4 inhibitors ritonavir and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam. 	ritonavir	midazolam	mechanism	{'e1': {'word': 'ritonavir', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d752.s3.e0'}, 'e2': {'word': 'midazolam', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d752.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d752.s3'}	Although studied potent cytochrome P450 3A4 inhibitors ritonavir nelfinavir may cause intense prolonged sedation respiratory depression due decrease plasma clearance midazolam
Although not studied, the potent cytochrome P450 3A4 inhibitors ritonavir and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam. 	nelfinavir	midazolam	mechanism	{'e1': {'word': 'nelfinavir', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d752.s3.e1'}, 'e2': {'word': 'midazolam', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d752.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d752.s3'}	Although studied potent cytochrome P450 3A4 inhibitors ritonavir nelfinavir may cause intense prolonged sedation respiratory depression due decrease plasma clearance midazolam
Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. 	rifampin	carbamazepine	none	{'e1': {'word': 'rifampin', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d752.s6.e0'}, 'e2': {'word': 'carbamazepine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d752.s6.e1'}, 'sentence_id': 'DDI-DrugBank.d752.s6'}	Inducers CYP3A4 Isozymes Cytochrome P450 inducers rifampin carbamazepine phenytoin induce metabolism caused markedly decreased C max AUC oral midazolam adult studies
Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. 	rifampin	phenytoin	none	{'e1': {'word': 'rifampin', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d752.s6.e0'}, 'e2': {'word': 'phenytoin', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d752.s6.e2'}, 'sentence_id': 'DDI-DrugBank.d752.s6'}	Inducers CYP3A4 Isozymes Cytochrome P450 inducers rifampin carbamazepine phenytoin induce metabolism caused markedly decreased C max AUC oral midazolam adult studies
Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. 	rifampin	midazolam	mechanism	{'e1': {'word': 'rifampin', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d752.s6.e0'}, 'e2': {'word': 'midazolam', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d752.s6.e3'}, 'sentence_id': 'DDI-DrugBank.d752.s6'}	Inducers CYP3A4 Isozymes Cytochrome P450 inducers rifampin carbamazepine phenytoin induce metabolism caused markedly decreased C max AUC oral midazolam adult studies
Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. 	carbamazepine	phenytoin	none	{'e1': {'word': 'carbamazepine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d752.s6.e1'}, 'e2': {'word': 'phenytoin', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d752.s6.e2'}, 'sentence_id': 'DDI-DrugBank.d752.s6'}	Inducers CYP3A4 Isozymes Cytochrome P450 inducers rifampin carbamazepine phenytoin induce metabolism caused markedly decreased C max AUC oral midazolam adult studies
Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. 	carbamazepine	midazolam	mechanism	{'e1': {'word': 'carbamazepine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d752.s6.e1'}, 'e2': {'word': 'midazolam', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d752.s6.e3'}, 'sentence_id': 'DDI-DrugBank.d752.s6'}	Inducers CYP3A4 Isozymes Cytochrome P450 inducers rifampin carbamazepine phenytoin induce metabolism caused markedly decreased C max AUC oral midazolam adult studies
Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. 	phenytoin	midazolam	mechanism	{'e1': {'word': 'phenytoin', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d752.s6.e2'}, 'e2': {'word': 'midazolam', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d752.s6.e3'}, 'sentence_id': 'DDI-DrugBank.d752.s6'}	Inducers CYP3A4 Isozymes Cytochrome P450 inducers rifampin carbamazepine phenytoin induce metabolism caused markedly decreased C max AUC oral midazolam adult studies
The difficulty in achieving adequate sedation may have been the result of decreased absorption of the sedatives due to both the gastrointestinal effects and stimulant effects of methylphenidate. 	sedatives	methylphenidate	none	{'e1': {'word': 'sedatives', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d752.s9.e0'}, 'e2': {'word': 'methylphenidate', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d752.s9.e1'}, 'sentence_id': 'DDI-DrugBank.d752.s9'}	difficulty achieving adequate sedation may result decreased absorption sedatives due gastrointestinal effects stimulant effects methylphenidate
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. 	VERSED Syrup	narcotics	effect	{'e1': {'word': 'VERSED Syrup', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d752.s10.e0'}, 'e2': {'word': 'narcotics', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d752.s10.e1'}, 'sentence_id': 'DDI-DrugBank.d752.s10'}	sedative effect VERSED Syrup accentuated concomitantly administered medication depresses central nervous system particularly narcotics eg morphine meperidine fentanyl propofol ketamine nitrous oxide secobarbital droperidol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. 	VERSED Syrup	morphine	effect	{'e1': {'word': 'VERSED Syrup', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d752.s10.e0'}, 'e2': {'word': 'morphine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d752.s10.e2'}, 'sentence_id': 'DDI-DrugBank.d752.s10'}	sedative effect VERSED Syrup accentuated concomitantly administered medication depresses central nervous system particularly narcotics eg morphine meperidine fentanyl propofol ketamine nitrous oxide secobarbital droperidol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. 	VERSED Syrup	meperidine	effect	{'e1': {'word': 'VERSED Syrup', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d752.s10.e0'}, 'e2': {'word': 'meperidine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d752.s10.e3'}, 'sentence_id': 'DDI-DrugBank.d752.s10'}	sedative effect VERSED Syrup accentuated concomitantly administered medication depresses central nervous system particularly narcotics eg morphine meperidine fentanyl propofol ketamine nitrous oxide secobarbital droperidol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. 	VERSED Syrup	fentanyl	effect	{'e1': {'word': 'VERSED Syrup', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d752.s10.e0'}, 'e2': {'word': 'fentanyl', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d752.s10.e4'}, 'sentence_id': 'DDI-DrugBank.d752.s10'}	sedative effect VERSED Syrup accentuated concomitantly administered medication depresses central nervous system particularly narcotics eg morphine meperidine fentanyl propofol ketamine nitrous oxide secobarbital droperidol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. 	VERSED Syrup	propofol	effect	{'e1': {'word': 'VERSED Syrup', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d752.s10.e0'}, 'e2': {'word': 'propofol', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d752.s10.e5'}, 'sentence_id': 'DDI-DrugBank.d752.s10'}	sedative effect VERSED Syrup accentuated concomitantly administered medication depresses central nervous system particularly narcotics eg morphine meperidine fentanyl propofol ketamine nitrous oxide secobarbital droperidol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. 	VERSED Syrup	ketamine	effect	{'e1': {'word': 'VERSED Syrup', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d752.s10.e0'}, 'e2': {'word': 'ketamine', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d752.s10.e6'}, 'sentence_id': 'DDI-DrugBank.d752.s10'}	sedative effect VERSED Syrup accentuated concomitantly administered medication depresses central nervous system particularly narcotics eg morphine meperidine fentanyl propofol ketamine nitrous oxide secobarbital droperidol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. 	VERSED Syrup	nitrous oxide	effect	{'e1': {'word': 'VERSED Syrup', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d752.s10.e0'}, 'e2': {'word': 'nitrous oxide', 'word_index': [(20, 21)], 'id': 'DDI-DrugBank.d752.s10.e7'}, 'sentence_id': 'DDI-DrugBank.d752.s10'}	sedative effect VERSED Syrup accentuated concomitantly administered medication depresses central nervous system particularly narcotics eg morphine meperidine fentanyl propofol ketamine nitrous oxide secobarbital droperidol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. 	VERSED Syrup	secobarbital	effect	{'e1': {'word': 'VERSED Syrup', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d752.s10.e0'}, 'e2': {'word': 'secobarbital', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d752.s10.e8'}, 'sentence_id': 'DDI-DrugBank.d752.s10'}	sedative effect VERSED Syrup accentuated concomitantly administered medication depresses central nervous system particularly narcotics eg morphine meperidine fentanyl propofol ketamine nitrous oxide secobarbital droperidol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. 	VERSED Syrup	droperidol	effect	{'e1': {'word': 'VERSED Syrup', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d752.s10.e0'}, 'e2': {'word': 'droperidol', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d752.s10.e9'}, 'sentence_id': 'DDI-DrugBank.d752.s10'}	sedative effect VERSED Syrup accentuated concomitantly administered medication depresses central nervous system particularly narcotics eg morphine meperidine fentanyl propofol ketamine nitrous oxide secobarbital droperidol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. 	narcotics	morphine	none	{'e1': {'word': 'narcotics', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d752.s10.e1'}, 'e2': {'word': 'morphine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d752.s10.e2'}, 'sentence_id': 'DDI-DrugBank.d752.s10'}	sedative effect VERSED Syrup accentuated concomitantly administered medication depresses central nervous system particularly narcotics eg morphine meperidine fentanyl propofol ketamine nitrous oxide secobarbital droperidol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. 	narcotics	meperidine	none	{'e1': {'word': 'narcotics', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d752.s10.e1'}, 'e2': {'word': 'meperidine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d752.s10.e3'}, 'sentence_id': 'DDI-DrugBank.d752.s10'}	sedative effect VERSED Syrup accentuated concomitantly administered medication depresses central nervous system particularly narcotics eg morphine meperidine fentanyl propofol ketamine nitrous oxide secobarbital droperidol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. 	narcotics	fentanyl	none	{'e1': {'word': 'narcotics', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d752.s10.e1'}, 'e2': {'word': 'fentanyl', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d752.s10.e4'}, 'sentence_id': 'DDI-DrugBank.d752.s10'}	sedative effect VERSED Syrup accentuated concomitantly administered medication depresses central nervous system particularly narcotics eg morphine meperidine fentanyl propofol ketamine nitrous oxide secobarbital droperidol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. 	narcotics	propofol	none	{'e1': {'word': 'narcotics', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d752.s10.e1'}, 'e2': {'word': 'propofol', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d752.s10.e5'}, 'sentence_id': 'DDI-DrugBank.d752.s10'}	sedative effect VERSED Syrup accentuated concomitantly administered medication depresses central nervous system particularly narcotics eg morphine meperidine fentanyl propofol ketamine nitrous oxide secobarbital droperidol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. 	narcotics	ketamine	none	{'e1': {'word': 'narcotics', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d752.s10.e1'}, 'e2': {'word': 'ketamine', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d752.s10.e6'}, 'sentence_id': 'DDI-DrugBank.d752.s10'}	sedative effect VERSED Syrup accentuated concomitantly administered medication depresses central nervous system particularly narcotics eg morphine meperidine fentanyl propofol ketamine nitrous oxide secobarbital droperidol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. 	narcotics	nitrous oxide	none	{'e1': {'word': 'narcotics', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d752.s10.e1'}, 'e2': {'word': 'nitrous oxide', 'word_index': [(20, 21)], 'id': 'DDI-DrugBank.d752.s10.e7'}, 'sentence_id': 'DDI-DrugBank.d752.s10'}	sedative effect VERSED Syrup accentuated concomitantly administered medication depresses central nervous system particularly narcotics eg morphine meperidine fentanyl propofol ketamine nitrous oxide secobarbital droperidol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. 	narcotics	secobarbital	none	{'e1': {'word': 'narcotics', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d752.s10.e1'}, 'e2': {'word': 'secobarbital', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d752.s10.e8'}, 'sentence_id': 'DDI-DrugBank.d752.s10'}	sedative effect VERSED Syrup accentuated concomitantly administered medication depresses central nervous system particularly narcotics eg morphine meperidine fentanyl propofol ketamine nitrous oxide secobarbital droperidol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. 	narcotics	droperidol	none	{'e1': {'word': 'narcotics', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d752.s10.e1'}, 'e2': {'word': 'droperidol', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d752.s10.e9'}, 'sentence_id': 'DDI-DrugBank.d752.s10'}	sedative effect VERSED Syrup accentuated concomitantly administered medication depresses central nervous system particularly narcotics eg morphine meperidine fentanyl propofol ketamine nitrous oxide secobarbital droperidol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. 	morphine	meperidine	none	{'e1': {'word': 'morphine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d752.s10.e2'}, 'e2': {'word': 'meperidine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d752.s10.e3'}, 'sentence_id': 'DDI-DrugBank.d752.s10'}	sedative effect VERSED Syrup accentuated concomitantly administered medication depresses central nervous system particularly narcotics eg morphine meperidine fentanyl propofol ketamine nitrous oxide secobarbital droperidol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. 	morphine	fentanyl	none	{'e1': {'word': 'morphine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d752.s10.e2'}, 'e2': {'word': 'fentanyl', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d752.s10.e4'}, 'sentence_id': 'DDI-DrugBank.d752.s10'}	sedative effect VERSED Syrup accentuated concomitantly administered medication depresses central nervous system particularly narcotics eg morphine meperidine fentanyl propofol ketamine nitrous oxide secobarbital droperidol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. 	morphine	propofol	none	{'e1': {'word': 'morphine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d752.s10.e2'}, 'e2': {'word': 'propofol', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d752.s10.e5'}, 'sentence_id': 'DDI-DrugBank.d752.s10'}	sedative effect VERSED Syrup accentuated concomitantly administered medication depresses central nervous system particularly narcotics eg morphine meperidine fentanyl propofol ketamine nitrous oxide secobarbital droperidol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. 	morphine	ketamine	none	{'e1': {'word': 'morphine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d752.s10.e2'}, 'e2': {'word': 'ketamine', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d752.s10.e6'}, 'sentence_id': 'DDI-DrugBank.d752.s10'}	sedative effect VERSED Syrup accentuated concomitantly administered medication depresses central nervous system particularly narcotics eg morphine meperidine fentanyl propofol ketamine nitrous oxide secobarbital droperidol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. 	morphine	nitrous oxide	none	{'e1': {'word': 'morphine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d752.s10.e2'}, 'e2': {'word': 'nitrous oxide', 'word_index': [(20, 21)], 'id': 'DDI-DrugBank.d752.s10.e7'}, 'sentence_id': 'DDI-DrugBank.d752.s10'}	sedative effect VERSED Syrup accentuated concomitantly administered medication depresses central nervous system particularly narcotics eg morphine meperidine fentanyl propofol ketamine nitrous oxide secobarbital droperidol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. 	morphine	secobarbital	none	{'e1': {'word': 'morphine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d752.s10.e2'}, 'e2': {'word': 'secobarbital', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d752.s10.e8'}, 'sentence_id': 'DDI-DrugBank.d752.s10'}	sedative effect VERSED Syrup accentuated concomitantly administered medication depresses central nervous system particularly narcotics eg morphine meperidine fentanyl propofol ketamine nitrous oxide secobarbital droperidol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. 	morphine	droperidol	none	{'e1': {'word': 'morphine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d752.s10.e2'}, 'e2': {'word': 'droperidol', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d752.s10.e9'}, 'sentence_id': 'DDI-DrugBank.d752.s10'}	sedative effect VERSED Syrup accentuated concomitantly administered medication depresses central nervous system particularly narcotics eg morphine meperidine fentanyl propofol ketamine nitrous oxide secobarbital droperidol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. 	meperidine	fentanyl	none	{'e1': {'word': 'meperidine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d752.s10.e3'}, 'e2': {'word': 'fentanyl', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d752.s10.e4'}, 'sentence_id': 'DDI-DrugBank.d752.s10'}	sedative effect VERSED Syrup accentuated concomitantly administered medication depresses central nervous system particularly narcotics eg morphine meperidine fentanyl propofol ketamine nitrous oxide secobarbital droperidol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. 	meperidine	propofol	none	{'e1': {'word': 'meperidine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d752.s10.e3'}, 'e2': {'word': 'propofol', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d752.s10.e5'}, 'sentence_id': 'DDI-DrugBank.d752.s10'}	sedative effect VERSED Syrup accentuated concomitantly administered medication depresses central nervous system particularly narcotics eg morphine meperidine fentanyl propofol ketamine nitrous oxide secobarbital droperidol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. 	meperidine	ketamine	none	{'e1': {'word': 'meperidine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d752.s10.e3'}, 'e2': {'word': 'ketamine', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d752.s10.e6'}, 'sentence_id': 'DDI-DrugBank.d752.s10'}	sedative effect VERSED Syrup accentuated concomitantly administered medication depresses central nervous system particularly narcotics eg morphine meperidine fentanyl propofol ketamine nitrous oxide secobarbital droperidol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. 	meperidine	nitrous oxide	none	{'e1': {'word': 'meperidine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d752.s10.e3'}, 'e2': {'word': 'nitrous oxide', 'word_index': [(20, 21)], 'id': 'DDI-DrugBank.d752.s10.e7'}, 'sentence_id': 'DDI-DrugBank.d752.s10'}	sedative effect VERSED Syrup accentuated concomitantly administered medication depresses central nervous system particularly narcotics eg morphine meperidine fentanyl propofol ketamine nitrous oxide secobarbital droperidol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. 	meperidine	secobarbital	none	{'e1': {'word': 'meperidine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d752.s10.e3'}, 'e2': {'word': 'secobarbital', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d752.s10.e8'}, 'sentence_id': 'DDI-DrugBank.d752.s10'}	sedative effect VERSED Syrup accentuated concomitantly administered medication depresses central nervous system particularly narcotics eg morphine meperidine fentanyl propofol ketamine nitrous oxide secobarbital droperidol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. 	meperidine	droperidol	none	{'e1': {'word': 'meperidine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d752.s10.e3'}, 'e2': {'word': 'droperidol', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d752.s10.e9'}, 'sentence_id': 'DDI-DrugBank.d752.s10'}	sedative effect VERSED Syrup accentuated concomitantly administered medication depresses central nervous system particularly narcotics eg morphine meperidine fentanyl propofol ketamine nitrous oxide secobarbital droperidol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. 	fentanyl	propofol	none	{'e1': {'word': 'fentanyl', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d752.s10.e4'}, 'e2': {'word': 'propofol', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d752.s10.e5'}, 'sentence_id': 'DDI-DrugBank.d752.s10'}	sedative effect VERSED Syrup accentuated concomitantly administered medication depresses central nervous system particularly narcotics eg morphine meperidine fentanyl propofol ketamine nitrous oxide secobarbital droperidol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. 	fentanyl	ketamine	none	{'e1': {'word': 'fentanyl', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d752.s10.e4'}, 'e2': {'word': 'ketamine', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d752.s10.e6'}, 'sentence_id': 'DDI-DrugBank.d752.s10'}	sedative effect VERSED Syrup accentuated concomitantly administered medication depresses central nervous system particularly narcotics eg morphine meperidine fentanyl propofol ketamine nitrous oxide secobarbital droperidol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. 	fentanyl	nitrous oxide	none	{'e1': {'word': 'fentanyl', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d752.s10.e4'}, 'e2': {'word': 'nitrous oxide', 'word_index': [(20, 21)], 'id': 'DDI-DrugBank.d752.s10.e7'}, 'sentence_id': 'DDI-DrugBank.d752.s10'}	sedative effect VERSED Syrup accentuated concomitantly administered medication depresses central nervous system particularly narcotics eg morphine meperidine fentanyl propofol ketamine nitrous oxide secobarbital droperidol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. 	fentanyl	secobarbital	none	{'e1': {'word': 'fentanyl', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d752.s10.e4'}, 'e2': {'word': 'secobarbital', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d752.s10.e8'}, 'sentence_id': 'DDI-DrugBank.d752.s10'}	sedative effect VERSED Syrup accentuated concomitantly administered medication depresses central nervous system particularly narcotics eg morphine meperidine fentanyl propofol ketamine nitrous oxide secobarbital droperidol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. 	fentanyl	droperidol	none	{'e1': {'word': 'fentanyl', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d752.s10.e4'}, 'e2': {'word': 'droperidol', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d752.s10.e9'}, 'sentence_id': 'DDI-DrugBank.d752.s10'}	sedative effect VERSED Syrup accentuated concomitantly administered medication depresses central nervous system particularly narcotics eg morphine meperidine fentanyl propofol ketamine nitrous oxide secobarbital droperidol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. 	propofol	ketamine	none	{'e1': {'word': 'propofol', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d752.s10.e5'}, 'e2': {'word': 'ketamine', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d752.s10.e6'}, 'sentence_id': 'DDI-DrugBank.d752.s10'}	sedative effect VERSED Syrup accentuated concomitantly administered medication depresses central nervous system particularly narcotics eg morphine meperidine fentanyl propofol ketamine nitrous oxide secobarbital droperidol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. 	propofol	nitrous oxide	none	{'e1': {'word': 'propofol', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d752.s10.e5'}, 'e2': {'word': 'nitrous oxide', 'word_index': [(20, 21)], 'id': 'DDI-DrugBank.d752.s10.e7'}, 'sentence_id': 'DDI-DrugBank.d752.s10'}	sedative effect VERSED Syrup accentuated concomitantly administered medication depresses central nervous system particularly narcotics eg morphine meperidine fentanyl propofol ketamine nitrous oxide secobarbital droperidol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. 	propofol	secobarbital	none	{'e1': {'word': 'propofol', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d752.s10.e5'}, 'e2': {'word': 'secobarbital', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d752.s10.e8'}, 'sentence_id': 'DDI-DrugBank.d752.s10'}	sedative effect VERSED Syrup accentuated concomitantly administered medication depresses central nervous system particularly narcotics eg morphine meperidine fentanyl propofol ketamine nitrous oxide secobarbital droperidol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. 	propofol	droperidol	none	{'e1': {'word': 'propofol', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d752.s10.e5'}, 'e2': {'word': 'droperidol', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d752.s10.e9'}, 'sentence_id': 'DDI-DrugBank.d752.s10'}	sedative effect VERSED Syrup accentuated concomitantly administered medication depresses central nervous system particularly narcotics eg morphine meperidine fentanyl propofol ketamine nitrous oxide secobarbital droperidol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. 	ketamine	nitrous oxide	none	{'e1': {'word': 'ketamine', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d752.s10.e6'}, 'e2': {'word': 'nitrous oxide', 'word_index': [(20, 21)], 'id': 'DDI-DrugBank.d752.s10.e7'}, 'sentence_id': 'DDI-DrugBank.d752.s10'}	sedative effect VERSED Syrup accentuated concomitantly administered medication depresses central nervous system particularly narcotics eg morphine meperidine fentanyl propofol ketamine nitrous oxide secobarbital droperidol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. 	ketamine	secobarbital	none	{'e1': {'word': 'ketamine', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d752.s10.e6'}, 'e2': {'word': 'secobarbital', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d752.s10.e8'}, 'sentence_id': 'DDI-DrugBank.d752.s10'}	sedative effect VERSED Syrup accentuated concomitantly administered medication depresses central nervous system particularly narcotics eg morphine meperidine fentanyl propofol ketamine nitrous oxide secobarbital droperidol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. 	ketamine	droperidol	none	{'e1': {'word': 'ketamine', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d752.s10.e6'}, 'e2': {'word': 'droperidol', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d752.s10.e9'}, 'sentence_id': 'DDI-DrugBank.d752.s10'}	sedative effect VERSED Syrup accentuated concomitantly administered medication depresses central nervous system particularly narcotics eg morphine meperidine fentanyl propofol ketamine nitrous oxide secobarbital droperidol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. 	nitrous oxide	secobarbital	none	{'e1': {'word': 'nitrous oxide', 'word_index': [(20, 21)], 'id': 'DDI-DrugBank.d752.s10.e7'}, 'e2': {'word': 'secobarbital', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d752.s10.e8'}, 'sentence_id': 'DDI-DrugBank.d752.s10'}	sedative effect VERSED Syrup accentuated concomitantly administered medication depresses central nervous system particularly narcotics eg morphine meperidine fentanyl propofol ketamine nitrous oxide secobarbital droperidol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. 	nitrous oxide	droperidol	none	{'e1': {'word': 'nitrous oxide', 'word_index': [(20, 21)], 'id': 'DDI-DrugBank.d752.s10.e7'}, 'e2': {'word': 'droperidol', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d752.s10.e9'}, 'sentence_id': 'DDI-DrugBank.d752.s10'}	sedative effect VERSED Syrup accentuated concomitantly administered medication depresses central nervous system particularly narcotics eg morphine meperidine fentanyl propofol ketamine nitrous oxide secobarbital droperidol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. 	secobarbital	droperidol	none	{'e1': {'word': 'secobarbital', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d752.s10.e8'}, 'e2': {'word': 'droperidol', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d752.s10.e9'}, 'sentence_id': 'DDI-DrugBank.d752.s10'}	sedative effect VERSED Syrup accentuated concomitantly administered medication depresses central nervous system particularly narcotics eg morphine meperidine fentanyl propofol ketamine nitrous oxide secobarbital droperidol
No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.	atropine	scopolamine	none	{'e1': {'word': 'atropine', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d752.s12.e0'}, 'e2': {'word': 'scopolamine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d752.s12.e1'}, 'sentence_id': 'DDI-DrugBank.d752.s12'}	significant adverse interactions common premedications atropine scopolamine glycopyrrolate diazepam hydroxyzine muscle relaxants local anesthetics observed
No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.	atropine	glycopyrrolate	none	{'e1': {'word': 'atropine', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d752.s12.e0'}, 'e2': {'word': 'glycopyrrolate', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d752.s12.e2'}, 'sentence_id': 'DDI-DrugBank.d752.s12'}	significant adverse interactions common premedications atropine scopolamine glycopyrrolate diazepam hydroxyzine muscle relaxants local anesthetics observed
No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.	atropine	diazepam	none	{'e1': {'word': 'atropine', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d752.s12.e0'}, 'e2': {'word': 'diazepam', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d752.s12.e3'}, 'sentence_id': 'DDI-DrugBank.d752.s12'}	significant adverse interactions common premedications atropine scopolamine glycopyrrolate diazepam hydroxyzine muscle relaxants local anesthetics observed
No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.	atropine	hydroxyzine	none	{'e1': {'word': 'atropine', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d752.s12.e0'}, 'e2': {'word': 'hydroxyzine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d752.s12.e4'}, 'sentence_id': 'DDI-DrugBank.d752.s12'}	significant adverse interactions common premedications atropine scopolamine glycopyrrolate diazepam hydroxyzine muscle relaxants local anesthetics observed
No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.	atropine	muscle relaxants	none	{'e1': {'word': 'atropine', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d752.s12.e0'}, 'e2': {'word': 'muscle relaxants', 'word_index': [(10, 11)], 'id': 'DDI-DrugBank.d752.s12.e5'}, 'sentence_id': 'DDI-DrugBank.d752.s12'}	significant adverse interactions common premedications atropine scopolamine glycopyrrolate diazepam hydroxyzine muscle relaxants local anesthetics observed
No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.	atropine	anesthetics	none	{'e1': {'word': 'atropine', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d752.s12.e0'}, 'e2': {'word': 'anesthetics', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d752.s12.e6'}, 'sentence_id': 'DDI-DrugBank.d752.s12'}	significant adverse interactions common premedications atropine scopolamine glycopyrrolate diazepam hydroxyzine muscle relaxants local anesthetics observed
No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.	scopolamine	glycopyrrolate	none	{'e1': {'word': 'scopolamine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d752.s12.e1'}, 'e2': {'word': 'glycopyrrolate', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d752.s12.e2'}, 'sentence_id': 'DDI-DrugBank.d752.s12'}	significant adverse interactions common premedications atropine scopolamine glycopyrrolate diazepam hydroxyzine muscle relaxants local anesthetics observed
No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.	scopolamine	diazepam	none	{'e1': {'word': 'scopolamine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d752.s12.e1'}, 'e2': {'word': 'diazepam', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d752.s12.e3'}, 'sentence_id': 'DDI-DrugBank.d752.s12'}	significant adverse interactions common premedications atropine scopolamine glycopyrrolate diazepam hydroxyzine muscle relaxants local anesthetics observed
No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.	scopolamine	hydroxyzine	none	{'e1': {'word': 'scopolamine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d752.s12.e1'}, 'e2': {'word': 'hydroxyzine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d752.s12.e4'}, 'sentence_id': 'DDI-DrugBank.d752.s12'}	significant adverse interactions common premedications atropine scopolamine glycopyrrolate diazepam hydroxyzine muscle relaxants local anesthetics observed
No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.	scopolamine	muscle relaxants	none	{'e1': {'word': 'scopolamine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d752.s12.e1'}, 'e2': {'word': 'muscle relaxants', 'word_index': [(10, 11)], 'id': 'DDI-DrugBank.d752.s12.e5'}, 'sentence_id': 'DDI-DrugBank.d752.s12'}	significant adverse interactions common premedications atropine scopolamine glycopyrrolate diazepam hydroxyzine muscle relaxants local anesthetics observed
No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.	scopolamine	anesthetics	none	{'e1': {'word': 'scopolamine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d752.s12.e1'}, 'e2': {'word': 'anesthetics', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d752.s12.e6'}, 'sentence_id': 'DDI-DrugBank.d752.s12'}	significant adverse interactions common premedications atropine scopolamine glycopyrrolate diazepam hydroxyzine muscle relaxants local anesthetics observed
No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.	glycopyrrolate	diazepam	none	{'e1': {'word': 'glycopyrrolate', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d752.s12.e2'}, 'e2': {'word': 'diazepam', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d752.s12.e3'}, 'sentence_id': 'DDI-DrugBank.d752.s12'}	significant adverse interactions common premedications atropine scopolamine glycopyrrolate diazepam hydroxyzine muscle relaxants local anesthetics observed
No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.	glycopyrrolate	hydroxyzine	none	{'e1': {'word': 'glycopyrrolate', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d752.s12.e2'}, 'e2': {'word': 'hydroxyzine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d752.s12.e4'}, 'sentence_id': 'DDI-DrugBank.d752.s12'}	significant adverse interactions common premedications atropine scopolamine glycopyrrolate diazepam hydroxyzine muscle relaxants local anesthetics observed
No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.	glycopyrrolate	muscle relaxants	none	{'e1': {'word': 'glycopyrrolate', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d752.s12.e2'}, 'e2': {'word': 'muscle relaxants', 'word_index': [(10, 11)], 'id': 'DDI-DrugBank.d752.s12.e5'}, 'sentence_id': 'DDI-DrugBank.d752.s12'}	significant adverse interactions common premedications atropine scopolamine glycopyrrolate diazepam hydroxyzine muscle relaxants local anesthetics observed
No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.	glycopyrrolate	anesthetics	none	{'e1': {'word': 'glycopyrrolate', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d752.s12.e2'}, 'e2': {'word': 'anesthetics', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d752.s12.e6'}, 'sentence_id': 'DDI-DrugBank.d752.s12'}	significant adverse interactions common premedications atropine scopolamine glycopyrrolate diazepam hydroxyzine muscle relaxants local anesthetics observed
No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.	diazepam	hydroxyzine	none	{'e1': {'word': 'diazepam', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d752.s12.e3'}, 'e2': {'word': 'hydroxyzine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d752.s12.e4'}, 'sentence_id': 'DDI-DrugBank.d752.s12'}	significant adverse interactions common premedications atropine scopolamine glycopyrrolate diazepam hydroxyzine muscle relaxants local anesthetics observed
No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.	diazepam	muscle relaxants	none	{'e1': {'word': 'diazepam', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d752.s12.e3'}, 'e2': {'word': 'muscle relaxants', 'word_index': [(10, 11)], 'id': 'DDI-DrugBank.d752.s12.e5'}, 'sentence_id': 'DDI-DrugBank.d752.s12'}	significant adverse interactions common premedications atropine scopolamine glycopyrrolate diazepam hydroxyzine muscle relaxants local anesthetics observed
No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.	diazepam	anesthetics	none	{'e1': {'word': 'diazepam', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d752.s12.e3'}, 'e2': {'word': 'anesthetics', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d752.s12.e6'}, 'sentence_id': 'DDI-DrugBank.d752.s12'}	significant adverse interactions common premedications atropine scopolamine glycopyrrolate diazepam hydroxyzine muscle relaxants local anesthetics observed
No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.	hydroxyzine	muscle relaxants	none	{'e1': {'word': 'hydroxyzine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d752.s12.e4'}, 'e2': {'word': 'muscle relaxants', 'word_index': [(10, 11)], 'id': 'DDI-DrugBank.d752.s12.e5'}, 'sentence_id': 'DDI-DrugBank.d752.s12'}	significant adverse interactions common premedications atropine scopolamine glycopyrrolate diazepam hydroxyzine muscle relaxants local anesthetics observed
No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.	hydroxyzine	anesthetics	none	{'e1': {'word': 'hydroxyzine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d752.s12.e4'}, 'e2': {'word': 'anesthetics', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d752.s12.e6'}, 'sentence_id': 'DDI-DrugBank.d752.s12'}	significant adverse interactions common premedications atropine scopolamine glycopyrrolate diazepam hydroxyzine muscle relaxants local anesthetics observed
No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.	muscle relaxants	anesthetics	none	{'e1': {'word': 'muscle relaxants', 'word_index': [(10, 11)], 'id': 'DDI-DrugBank.d752.s12.e5'}, 'e2': {'word': 'anesthetics', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d752.s12.e6'}, 'sentence_id': 'DDI-DrugBank.d752.s12'}	significant adverse interactions common premedications atropine scopolamine glycopyrrolate diazepam hydroxyzine muscle relaxants local anesthetics observed
While co-administration of ZAVESCA    appeared to increase the clearance of Cerezyme by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of Cerezyme. 	ZAVESCA	Cerezyme	mechanism	{'e1': {'word': 'ZAVESCA', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d695.s0.e0'}, 'e2': {'word': 'Cerezyme', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d695.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d695.s0'}	co-administration ZAVESCA appeared increase clearance Cerezyme NUMBER % results conclusive small number subjects studied patients took variable doses Cerezyme
While co-administration of ZAVESCA    appeared to increase the clearance of Cerezyme by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of Cerezyme. 	ZAVESCA	Cerezyme	none	{'e1': {'word': 'ZAVESCA', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d695.s0.e0'}, 'e2': {'word': 'Cerezyme', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d695.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d695.s0'}	co-administration ZAVESCA appeared increase clearance Cerezyme NUMBER % results conclusive small number subjects studied patients took variable doses Cerezyme
While co-administration of ZAVESCA    appeared to increase the clearance of Cerezyme by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of Cerezyme. 	Cerezyme	Cerezyme	none	{'e1': {'word': 'Cerezyme', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d695.s0.e1'}, 'e2': {'word': 'Cerezyme', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d695.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d695.s0'}	co-administration ZAVESCA appeared increase clearance Cerezyme NUMBER % results conclusive small number subjects studied patients took variable doses Cerezyme
Combination therapy with Cerezyme    (imiglucerase) and ZAVESCA    is not indicated.	Cerezyme	imiglucerase	none	{'e1': {'word': 'Cerezyme', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d695.s1.e0'}, 'e2': {'word': 'imiglucerase', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d695.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d695.s1'}	Combination therapy Cerezyme imiglucerase ZAVESCA indicated
Combination therapy with Cerezyme    (imiglucerase) and ZAVESCA    is not indicated.	Cerezyme	ZAVESCA	advise	{'e1': {'word': 'Cerezyme', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d695.s1.e0'}, 'e2': {'word': 'ZAVESCA', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d695.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d695.s1'}	Combination therapy Cerezyme imiglucerase ZAVESCA indicated
Combination therapy with Cerezyme    (imiglucerase) and ZAVESCA    is not indicated.	imiglucerase	ZAVESCA	advise	{'e1': {'word': 'imiglucerase', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d695.s1.e1'}, 'e2': {'word': 'ZAVESCA', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d695.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d695.s1'}	Combination therapy Cerezyme imiglucerase ZAVESCA indicated
An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of rosiglitazone. 	gemfibrozil	rosiglitazone	mechanism	{'e1': {'word': 'gemfibrozil', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d609.s0.e0'}, 'e2': {'word': 'rosiglitazone', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d609.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d609.s0'}	inhibitor CYP2C8 gemfibrozil may increase AUC rosiglitazone inducer CYP2C8 rifampin may decrease AUC rosiglitazone
An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of rosiglitazone. 	gemfibrozil	rifampin	none	{'e1': {'word': 'gemfibrozil', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d609.s0.e0'}, 'e2': {'word': 'rifampin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d609.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d609.s0'}	inhibitor CYP2C8 gemfibrozil may increase AUC rosiglitazone inducer CYP2C8 rifampin may decrease AUC rosiglitazone
An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of rosiglitazone. 	gemfibrozil	rosiglitazone	none	{'e1': {'word': 'gemfibrozil', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d609.s0.e0'}, 'e2': {'word': 'rosiglitazone', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d609.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d609.s0'}	inhibitor CYP2C8 gemfibrozil may increase AUC rosiglitazone inducer CYP2C8 rifampin may decrease AUC rosiglitazone
An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of rosiglitazone. 	rosiglitazone	rifampin	none	{'e1': {'word': 'rosiglitazone', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d609.s0.e1'}, 'e2': {'word': 'rifampin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d609.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d609.s0'}	inhibitor CYP2C8 gemfibrozil may increase AUC rosiglitazone inducer CYP2C8 rifampin may decrease AUC rosiglitazone
An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of rosiglitazone. 	rosiglitazone	rosiglitazone	none	{'e1': {'word': 'rosiglitazone', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d609.s0.e1'}, 'e2': {'word': 'rosiglitazone', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d609.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d609.s0'}	inhibitor CYP2C8 gemfibrozil may increase AUC rosiglitazone inducer CYP2C8 rifampin may decrease AUC rosiglitazone
An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of rosiglitazone. 	rifampin	rosiglitazone	mechanism	{'e1': {'word': 'rifampin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d609.s0.e2'}, 'e2': {'word': 'rosiglitazone', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d609.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d609.s0'}	inhibitor CYP2C8 gemfibrozil may increase AUC rosiglitazone inducer CYP2C8 rifampin may decrease AUC rosiglitazone
Coadministration of TRITEC with clarithromycin resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- clarithromycin plasma concentrations (31%). 	TRITEC	clarithromycin	mechanism	{'e1': {'word': 'TRITEC', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d590.s0.e0'}, 'e2': {'word': 'clarithromycin', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d590.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d590.s0'}	Coadministration TRITEC clarithromycin resulted increased plasma ranitidine concentrations NUMBER % increased plasma bismuth trough concentrations NUMBER % increased NUMBER hydroxy clarithromycin plasma concentrations NUMBER %
Coadministration of TRITEC with clarithromycin resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- clarithromycin plasma concentrations (31%). 	TRITEC	ranitidine	none	{'e1': {'word': 'TRITEC', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d590.s0.e0'}, 'e2': {'word': 'ranitidine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d590.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d590.s0'}	Coadministration TRITEC clarithromycin resulted increased plasma ranitidine concentrations NUMBER % increased plasma bismuth trough concentrations NUMBER % increased NUMBER hydroxy clarithromycin plasma concentrations NUMBER %
Coadministration of TRITEC with clarithromycin resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- clarithromycin plasma concentrations (31%). 	TRITEC	14- hydroxy- clarithromycin	none	{'e1': {'word': 'TRITEC', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d590.s0.e0'}, 'e2': {'word': '14- hydroxy- clarithromycin', 'word_index': [(18, 20)], 'id': 'DDI-DrugBank.d590.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d590.s0'}	Coadministration TRITEC clarithromycin resulted increased plasma ranitidine concentrations NUMBER % increased plasma bismuth trough concentrations NUMBER % increased NUMBER hydroxy clarithromycin plasma concentrations NUMBER %
Coadministration of TRITEC with clarithromycin resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- clarithromycin plasma concentrations (31%). 	clarithromycin	ranitidine	none	{'e1': {'word': 'clarithromycin', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d590.s0.e1'}, 'e2': {'word': 'ranitidine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d590.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d590.s0'}	Coadministration TRITEC clarithromycin resulted increased plasma ranitidine concentrations NUMBER % increased plasma bismuth trough concentrations NUMBER % increased NUMBER hydroxy clarithromycin plasma concentrations NUMBER %
Coadministration of TRITEC with clarithromycin resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- clarithromycin plasma concentrations (31%). 	clarithromycin	14- hydroxy- clarithromycin	none	{'e1': {'word': 'clarithromycin', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d590.s0.e1'}, 'e2': {'word': '14- hydroxy- clarithromycin', 'word_index': [(18, 20)], 'id': 'DDI-DrugBank.d590.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d590.s0'}	Coadministration TRITEC clarithromycin resulted increased plasma ranitidine concentrations NUMBER % increased plasma bismuth trough concentrations NUMBER % increased NUMBER hydroxy clarithromycin plasma concentrations NUMBER %
Coadministration of TRITEC with clarithromycin resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- clarithromycin plasma concentrations (31%). 	ranitidine	14- hydroxy- clarithromycin	none	{'e1': {'word': 'ranitidine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d590.s0.e2'}, 'e2': {'word': '14- hydroxy- clarithromycin', 'word_index': [(18, 20)], 'id': 'DDI-DrugBank.d590.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d590.s0'}	Coadministration TRITEC clarithromycin resulted increased plasma ranitidine concentrations NUMBER % increased plasma bismuth trough concentrations NUMBER % increased NUMBER hydroxy clarithromycin plasma concentrations NUMBER %
Coadministration with aspirin results in a slight decrease in the rate of salicylate absorption that is clinically unimportant. 	aspirin	salicylate	none	{'e1': {'word': 'aspirin', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d590.s1.e0'}, 'e2': {'word': 'salicylate', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d590.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d590.s1'}	Coadministration aspirin results slight decrease rate salicylate absorption clinically unimportant
Coadministration with a high dose of antacid (170 mEq) results in a 28% decrease in plasma concentrations of ranitidine and may decrease plasma concentrations of bismuth from TRITEC. 	antacid	ranitidine	mechanism	{'e1': {'word': 'antacid', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d590.s2.e0'}, 'e2': {'word': 'ranitidine', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d590.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d590.s2'}	Coadministration high dose antacid NUMBER mEq results NUMBER % decrease plasma concentrations ranitidine may decrease plasma concentrations bismuth TRITEC
Coadministration with a high dose of antacid (170 mEq) results in a 28% decrease in plasma concentrations of ranitidine and may decrease plasma concentrations of bismuth from TRITEC. 	antacid	TRITEC	mechanism	{'e1': {'word': 'antacid', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d590.s2.e0'}, 'e2': {'word': 'TRITEC', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d590.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d590.s2'}	Coadministration high dose antacid NUMBER mEq results NUMBER % decrease plasma concentrations ranitidine may decrease plasma concentrations bismuth TRITEC
Coadministration with a high dose of antacid (170 mEq) results in a 28% decrease in plasma concentrations of ranitidine and may decrease plasma concentrations of bismuth from TRITEC. 	ranitidine	TRITEC	none	{'e1': {'word': 'ranitidine', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d590.s2.e1'}, 'e2': {'word': 'TRITEC', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d590.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d590.s2'}	Coadministration high dose antacid NUMBER mEq results NUMBER % decrease plasma concentrations ranitidine may decrease plasma concentrations bismuth TRITEC
For information on drug interactions associated with ranitidine, refer to the ZANTAC     package insert.	ranitidine	ZANTAC	none	{'e1': {'word': 'ranitidine', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d590.s4.e0'}, 'e2': {'word': 'ZANTAC', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d590.s4.e1'}, 'sentence_id': 'DDI-DrugBank.d590.s4'}	information drug interactions associated ranitidine refer ZANTAC package insert
Drug-Drug Interactions Effect of Exelon    (rivastigmine tartrate) on the Metabolism of Other Drugs: Rivastigmine is primarily metabolized through hydrolysis by esterases. 	Exelon	rivastigmine tartrate	none	{'e1': {'word': 'Exelon', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d596.s0.e0'}, 'e2': {'word': 'rivastigmine tartrate', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d596.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d596.s0'}	Drug Drug Interactions Effect Exelon rivastigmine tartrate Metabolism Drugs Rivastigmine primarily metabolized hydrolysis esterases
Drug-Drug Interactions Effect of Exelon    (rivastigmine tartrate) on the Metabolism of Other Drugs: Rivastigmine is primarily metabolized through hydrolysis by esterases. 	Exelon	Rivastigmine	none	{'e1': {'word': 'Exelon', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d596.s0.e0'}, 'e2': {'word': 'Rivastigmine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d596.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d596.s0'}	Drug Drug Interactions Effect Exelon rivastigmine tartrate Metabolism Drugs Rivastigmine primarily metabolized hydrolysis esterases
Drug-Drug Interactions Effect of Exelon    (rivastigmine tartrate) on the Metabolism of Other Drugs: Rivastigmine is primarily metabolized through hydrolysis by esterases. 	rivastigmine tartrate	Rivastigmine	none	{'e1': {'word': 'rivastigmine tartrate', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d596.s0.e1'}, 'e2': {'word': 'Rivastigmine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d596.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d596.s0'}	Drug Drug Interactions Effect Exelon rivastigmine tartrate Metabolism Drugs Rivastigmine primarily metabolized hydrolysis esterases
No pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, diazepam, or fluoxetine in studies in healthy volunteers. 	rivastigmine	digoxin	none	{'e1': {'word': 'rivastigmine', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d596.s3.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d596.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d596.s3'}	pharmacokinetic interaction observed rivastigmine digoxin warfarin diazepam fluoxetine studies healthy volunteers
No pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, diazepam, or fluoxetine in studies in healthy volunteers. 	rivastigmine	warfarin	none	{'e1': {'word': 'rivastigmine', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d596.s3.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d596.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d596.s3'}	pharmacokinetic interaction observed rivastigmine digoxin warfarin diazepam fluoxetine studies healthy volunteers
No pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, diazepam, or fluoxetine in studies in healthy volunteers. 	rivastigmine	diazepam	none	{'e1': {'word': 'rivastigmine', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d596.s3.e0'}, 'e2': {'word': 'diazepam', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d596.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d596.s3'}	pharmacokinetic interaction observed rivastigmine digoxin warfarin diazepam fluoxetine studies healthy volunteers
No pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, diazepam, or fluoxetine in studies in healthy volunteers. 	rivastigmine	fluoxetine	none	{'e1': {'word': 'rivastigmine', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d596.s3.e0'}, 'e2': {'word': 'fluoxetine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d596.s3.e4'}, 'sentence_id': 'DDI-DrugBank.d596.s3'}	pharmacokinetic interaction observed rivastigmine digoxin warfarin diazepam fluoxetine studies healthy volunteers
No pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, diazepam, or fluoxetine in studies in healthy volunteers. 	digoxin	warfarin	none	{'e1': {'word': 'digoxin', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d596.s3.e1'}, 'e2': {'word': 'warfarin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d596.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d596.s3'}	pharmacokinetic interaction observed rivastigmine digoxin warfarin diazepam fluoxetine studies healthy volunteers
No pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, diazepam, or fluoxetine in studies in healthy volunteers. 	digoxin	diazepam	none	{'e1': {'word': 'digoxin', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d596.s3.e1'}, 'e2': {'word': 'diazepam', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d596.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d596.s3'}	pharmacokinetic interaction observed rivastigmine digoxin warfarin diazepam fluoxetine studies healthy volunteers
No pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, diazepam, or fluoxetine in studies in healthy volunteers. 	digoxin	fluoxetine	none	{'e1': {'word': 'digoxin', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d596.s3.e1'}, 'e2': {'word': 'fluoxetine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d596.s3.e4'}, 'sentence_id': 'DDI-DrugBank.d596.s3'}	pharmacokinetic interaction observed rivastigmine digoxin warfarin diazepam fluoxetine studies healthy volunteers
No pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, diazepam, or fluoxetine in studies in healthy volunteers. 	warfarin	diazepam	none	{'e1': {'word': 'warfarin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d596.s3.e2'}, 'e2': {'word': 'diazepam', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d596.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d596.s3'}	pharmacokinetic interaction observed rivastigmine digoxin warfarin diazepam fluoxetine studies healthy volunteers
No pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, diazepam, or fluoxetine in studies in healthy volunteers. 	warfarin	fluoxetine	none	{'e1': {'word': 'warfarin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d596.s3.e2'}, 'e2': {'word': 'fluoxetine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d596.s3.e4'}, 'sentence_id': 'DDI-DrugBank.d596.s3'}	pharmacokinetic interaction observed rivastigmine digoxin warfarin diazepam fluoxetine studies healthy volunteers
No pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, diazepam, or fluoxetine in studies in healthy volunteers. 	diazepam	fluoxetine	none	{'e1': {'word': 'diazepam', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d596.s3.e3'}, 'e2': {'word': 'fluoxetine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d596.s3.e4'}, 'sentence_id': 'DDI-DrugBank.d596.s3'}	pharmacokinetic interaction observed rivastigmine digoxin warfarin diazepam fluoxetine studies healthy volunteers
The elevation of prothrombin time induced by warfarin is not affected by administration of Exelon. 	warfarin	Exelon	none	{'e1': {'word': 'warfarin', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d596.s4.e0'}, 'e2': {'word': 'Exelon', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d596.s4.e1'}, 'sentence_id': 'DDI-DrugBank.d596.s4'}	elevation prothrombin time induced warfarin affected administration Exelon
Effect of Other Drugs on the Metabolism of Exelon: Drugs that induce or inhibit CYP450 metabolism are not expected to alter the metabolism of rivastigmine. 	Exelon	rivastigmine	none	{'e1': {'word': 'Exelon', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d596.s5.e0'}, 'e2': {'word': 'rivastigmine', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d596.s5.e1'}, 'sentence_id': 'DDI-DrugBank.d596.s5'}	Effect Drugs Metabolism Exelon Drugs induce inhibit CYP450 metabolism expected alter metabolism rivastigmine
Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or fluoxetine. 	rivastigmine	digoxin	none	{'e1': {'word': 'rivastigmine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d596.s6.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d596.s6.e1'}, 'sentence_id': 'DDI-DrugBank.d596.s6'}	Single dose pharmacokinetic studies demonstrated metabolism rivastigmine significantly affected concurrent administration digoxin warfarin diazepam fluoxetine
Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or fluoxetine. 	rivastigmine	warfarin	none	{'e1': {'word': 'rivastigmine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d596.s6.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d596.s6.e2'}, 'sentence_id': 'DDI-DrugBank.d596.s6'}	Single dose pharmacokinetic studies demonstrated metabolism rivastigmine significantly affected concurrent administration digoxin warfarin diazepam fluoxetine
Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or fluoxetine. 	rivastigmine	diazepam	none	{'e1': {'word': 'rivastigmine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d596.s6.e0'}, 'e2': {'word': 'diazepam', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d596.s6.e3'}, 'sentence_id': 'DDI-DrugBank.d596.s6'}	Single dose pharmacokinetic studies demonstrated metabolism rivastigmine significantly affected concurrent administration digoxin warfarin diazepam fluoxetine
Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or fluoxetine. 	rivastigmine	fluoxetine	none	{'e1': {'word': 'rivastigmine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d596.s6.e0'}, 'e2': {'word': 'fluoxetine', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d596.s6.e4'}, 'sentence_id': 'DDI-DrugBank.d596.s6'}	Single dose pharmacokinetic studies demonstrated metabolism rivastigmine significantly affected concurrent administration digoxin warfarin diazepam fluoxetine
Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or fluoxetine. 	digoxin	warfarin	none	{'e1': {'word': 'digoxin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d596.s6.e1'}, 'e2': {'word': 'warfarin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d596.s6.e2'}, 'sentence_id': 'DDI-DrugBank.d596.s6'}	Single dose pharmacokinetic studies demonstrated metabolism rivastigmine significantly affected concurrent administration digoxin warfarin diazepam fluoxetine
Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or fluoxetine. 	digoxin	diazepam	none	{'e1': {'word': 'digoxin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d596.s6.e1'}, 'e2': {'word': 'diazepam', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d596.s6.e3'}, 'sentence_id': 'DDI-DrugBank.d596.s6'}	Single dose pharmacokinetic studies demonstrated metabolism rivastigmine significantly affected concurrent administration digoxin warfarin diazepam fluoxetine
Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or fluoxetine. 	digoxin	fluoxetine	none	{'e1': {'word': 'digoxin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d596.s6.e1'}, 'e2': {'word': 'fluoxetine', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d596.s6.e4'}, 'sentence_id': 'DDI-DrugBank.d596.s6'}	Single dose pharmacokinetic studies demonstrated metabolism rivastigmine significantly affected concurrent administration digoxin warfarin diazepam fluoxetine
Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or fluoxetine. 	warfarin	diazepam	none	{'e1': {'word': 'warfarin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d596.s6.e2'}, 'e2': {'word': 'diazepam', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d596.s6.e3'}, 'sentence_id': 'DDI-DrugBank.d596.s6'}	Single dose pharmacokinetic studies demonstrated metabolism rivastigmine significantly affected concurrent administration digoxin warfarin diazepam fluoxetine
Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or fluoxetine. 	warfarin	fluoxetine	none	{'e1': {'word': 'warfarin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d596.s6.e2'}, 'e2': {'word': 'fluoxetine', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d596.s6.e4'}, 'sentence_id': 'DDI-DrugBank.d596.s6'}	Single dose pharmacokinetic studies demonstrated metabolism rivastigmine significantly affected concurrent administration digoxin warfarin diazepam fluoxetine
Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or fluoxetine. 	diazepam	fluoxetine	none	{'e1': {'word': 'diazepam', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d596.s6.e3'}, 'e2': {'word': 'fluoxetine', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d596.s6.e4'}, 'sentence_id': 'DDI-DrugBank.d596.s6'}	Single dose pharmacokinetic studies demonstrated metabolism rivastigmine significantly affected concurrent administration digoxin warfarin diazepam fluoxetine
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 	rivastigmine	antacids	none	{'e1': {'word': 'rivastigmine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d596.s7.e0'}, 'e2': {'word': 'antacids', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d596.s7.e1'}, 'sentence_id': 'DDI-DrugBank.d596.s7'}	Population PK analysis database NUMBER patients showed pharmacokinetics rivastigmine influenced commonly prescribed medications antacids n = NUMBER antihypertensives n = NUMBER calcium channel blockers n = NUMBER antidiabetics n = NUMBER nonsteroidal anti-inflammatory drugs n = NUMBER estrogens n = NUMBER salicylate analgesics n = NUMBER antianginals n = NUMBER antihistamines n = NUMBER
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 	rivastigmine	antihypertensives	none	{'e1': {'word': 'rivastigmine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d596.s7.e0'}, 'e2': {'word': 'antihypertensives', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d596.s7.e2'}, 'sentence_id': 'DDI-DrugBank.d596.s7'}	Population PK analysis database NUMBER patients showed pharmacokinetics rivastigmine influenced commonly prescribed medications antacids n= NUMBER antihypertensives n = NUMBER calcium channel blockers n = NUMBER antidiabetics n = NUMBER nonsteroidal anti-inflammatory drugs n = NUMBER estrogens n = NUMBER salicylate analgesics n = NUMBER antianginals n = NUMBER antihistamines n = NUMBER
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 	rivastigmine	calcium channel blockers	none	{'e1': {'word': 'rivastigmine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d596.s7.e0'}, 'e2': {'word': 'calcium channel blockers', 'word_index': [(20, 22)], 'id': 'DDI-DrugBank.d596.s7.e3'}, 'sentence_id': 'DDI-DrugBank.d596.s7'}	Population PK analysis database NUMBER patients showed pharmacokinetics rivastigmine influenced commonly prescribed medications antacids n= NUMBER antihypertensives n = NUMBER calcium channel blockers n = NUMBER antidiabetics n = NUMBER nonsteroidal anti-inflammatory drugs n = NUMBER estrogens n = NUMBER salicylate analgesics n = NUMBER antianginals n = NUMBER antihistamines n = NUMBER
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 	rivastigmine	antidiabetics	none	{'e1': {'word': 'rivastigmine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d596.s7.e0'}, 'e2': {'word': 'antidiabetics', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d596.s7.e4'}, 'sentence_id': 'DDI-DrugBank.d596.s7'}	Population PK analysis database NUMBER patients showed pharmacokinetics rivastigmine influenced commonly prescribed medications antacids n= NUMBER antihypertensives n = NUMBER calcium channel blockers n = NUMBER antidiabetics n = NUMBER nonsteroidal anti-inflammatory drugs n = NUMBER estrogens n = NUMBER salicylate analgesics n = NUMBER antianginals n = NUMBER antihistamines n = NUMBER
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 	rivastigmine	nonsteroidal anti-inflammatory drugs	none	{'e1': {'word': 'rivastigmine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d596.s7.e0'}, 'e2': {'word': 'nonsteroidal anti-inflammatory drugs', 'word_index': [(30, 32)], 'id': 'DDI-DrugBank.d596.s7.e5'}, 'sentence_id': 'DDI-DrugBank.d596.s7'}	Population PK analysis database NUMBER patients showed pharmacokinetics rivastigmine influenced commonly prescribed medications antacids n= NUMBER antihypertensives n = NUMBER calcium channel blockers n = NUMBER antidiabetics n = NUMBER nonsteroidal anti-inflammatory drugs n = NUMBER estrogens n = NUMBER salicylate analgesics n = NUMBER antianginals n = NUMBER antihistamines n = NUMBER
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 	rivastigmine	estrogens	none	{'e1': {'word': 'rivastigmine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d596.s7.e0'}, 'e2': {'word': 'estrogens', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d596.s7.e6'}, 'sentence_id': 'DDI-DrugBank.d596.s7'}	Population PK analysis database NUMBER patients showed pharmacokinetics rivastigmine influenced commonly prescribed medications antacids n= NUMBER antihypertensives n = NUMBER calcium channel blockers n = NUMBER antidiabetics n = NUMBER nonsteroidal anti-inflammatory drugs n = NUMBER estrogens n = NUMBER salicylate analgesics n = NUMBER antianginals n = NUMBER antihistamines n = NUMBER
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 	rivastigmine	salicylate analgesics	none	{'e1': {'word': 'rivastigmine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d596.s7.e0'}, 'e2': {'word': 'salicylate analgesics', 'word_index': [(40, 41)], 'id': 'DDI-DrugBank.d596.s7.e7'}, 'sentence_id': 'DDI-DrugBank.d596.s7'}	Population PK analysis database NUMBER patients showed pharmacokinetics rivastigmine influenced commonly prescribed medications antacids n= NUMBER antihypertensives n = NUMBER calcium channel blockers n = NUMBER antidiabetics n = NUMBER nonsteroidal anti-inflammatory drugs n = NUMBER estrogens n = NUMBER salicylate analgesics n = NUMBER antianginals n = NUMBER antihistamines n = NUMBER
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 	rivastigmine	antianginals	none	{'e1': {'word': 'rivastigmine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d596.s7.e0'}, 'e2': {'word': 'antianginals', 'word_index': [(45, 45)], 'id': 'DDI-DrugBank.d596.s7.e8'}, 'sentence_id': 'DDI-DrugBank.d596.s7'}	Population PK analysis database NUMBER patients showed pharmacokinetics rivastigmine influenced commonly prescribed medications antacids n= NUMBER antihypertensives n = NUMBER calcium channel blockers n = NUMBER antidiabetics n = NUMBER nonsteroidal anti-inflammatory drugs n = NUMBER estrogens n = NUMBER salicylate analgesics n = NUMBER antianginals n = NUMBER antihistamines n = NUMBER
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 	rivastigmine	antihistamines	none	{'e1': {'word': 'rivastigmine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d596.s7.e0'}, 'e2': {'word': 'antihistamines', 'word_index': [(49, 49)], 'id': 'DDI-DrugBank.d596.s7.e9'}, 'sentence_id': 'DDI-DrugBank.d596.s7'}	Population PK analysis database NUMBER patients showed pharmacokinetics rivastigmine influenced commonly prescribed medications antacids n= NUMBER antihypertensives n = NUMBER calcium channel blockers n = NUMBER antidiabetics n = NUMBER nonsteroidal anti-inflammatory drugs n = NUMBER estrogens n = NUMBER salicylate analgesics n = NUMBER antianginals n = NUMBER antihistamines n = NUMBER
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 	antacids	antihypertensives	none	{'e1': {'word': 'antacids', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d596.s7.e1'}, 'e2': {'word': 'antihypertensives', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d596.s7.e2'}, 'sentence_id': 'DDI-DrugBank.d596.s7'}	Population PK analysis database NUMBER patients showed pharmacokinetics rivastigmine influenced commonly prescribed medications antacids n = NUMBER antihypertensives n = NUMBER calcium channel blockers n = NUMBER antidiabetics n = NUMBER nonsteroidal anti-inflammatory drugs n = NUMBER estrogens n = NUMBER salicylate analgesics n = NUMBER antianginals n = NUMBER antihistamines n = NUMBER
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 	antacids	calcium channel blockers	none	{'e1': {'word': 'antacids', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d596.s7.e1'}, 'e2': {'word': 'calcium channel blockers', 'word_index': [(21, 23)], 'id': 'DDI-DrugBank.d596.s7.e3'}, 'sentence_id': 'DDI-DrugBank.d596.s7'}	Population PK analysis database NUMBER patients showed pharmacokinetics rivastigmine influenced commonly prescribed medications antacids n = NUMBER antihypertensives n = NUMBER calcium channel blockers n = NUMBER antidiabetics n = NUMBER nonsteroidal anti-inflammatory drugs n = NUMBER estrogens n = NUMBER salicylate analgesics n = NUMBER antianginals n = NUMBER antihistamines n = NUMBER
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 	antacids	antidiabetics	none	{'e1': {'word': 'antacids', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d596.s7.e1'}, 'e2': {'word': 'antidiabetics', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d596.s7.e4'}, 'sentence_id': 'DDI-DrugBank.d596.s7'}	Population PK analysis database NUMBER patients showed pharmacokinetics rivastigmine influenced commonly prescribed medications antacids n = NUMBER antihypertensives n = NUMBER calcium channel blockers n = NUMBER antidiabetics n = NUMBER nonsteroidal anti-inflammatory drugs n = NUMBER estrogens n = NUMBER salicylate analgesics n = NUMBER antianginals n = NUMBER antihistamines n = NUMBER
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 	antacids	nonsteroidal anti-inflammatory drugs	none	{'e1': {'word': 'antacids', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d596.s7.e1'}, 'e2': {'word': 'nonsteroidal anti-inflammatory drugs', 'word_index': [(31, 33)], 'id': 'DDI-DrugBank.d596.s7.e5'}, 'sentence_id': 'DDI-DrugBank.d596.s7'}	Population PK analysis database NUMBER patients showed pharmacokinetics rivastigmine influenced commonly prescribed medications antacids n = NUMBER antihypertensives n = NUMBER calcium channel blockers n = NUMBER antidiabetics n = NUMBER nonsteroidal anti-inflammatory drugs n = NUMBER estrogens n = NUMBER salicylate analgesics n = NUMBER antianginals n = NUMBER antihistamines n = NUMBER
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 	antacids	estrogens	none	{'e1': {'word': 'antacids', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d596.s7.e1'}, 'e2': {'word': 'estrogens', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d596.s7.e6'}, 'sentence_id': 'DDI-DrugBank.d596.s7'}	Population PK analysis database NUMBER patients showed pharmacokinetics rivastigmine influenced commonly prescribed medications antacids n = NUMBER antihypertensives n = NUMBER calcium channel blockers n = NUMBER antidiabetics n = NUMBER nonsteroidal anti-inflammatory drugs n = NUMBER estrogens n = NUMBER salicylate analgesics n = NUMBER antianginals n = NUMBER antihistamines n = NUMBER
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 	antacids	salicylate analgesics	none	{'e1': {'word': 'antacids', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d596.s7.e1'}, 'e2': {'word': 'salicylate analgesics', 'word_index': [(41, 42)], 'id': 'DDI-DrugBank.d596.s7.e7'}, 'sentence_id': 'DDI-DrugBank.d596.s7'}	Population PK analysis database NUMBER patients showed pharmacokinetics rivastigmine influenced commonly prescribed medications antacids n = NUMBER antihypertensives n = NUMBER calcium channel blockers n = NUMBER antidiabetics n = NUMBER nonsteroidal anti-inflammatory drugs n = NUMBER estrogens n = NUMBER salicylate analgesics n = NUMBER antianginals n = NUMBER antihistamines n = NUMBER
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 	antacids	antianginals	none	{'e1': {'word': 'antacids', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d596.s7.e1'}, 'e2': {'word': 'antianginals', 'word_index': [(46, 46)], 'id': 'DDI-DrugBank.d596.s7.e8'}, 'sentence_id': 'DDI-DrugBank.d596.s7'}	Population PK analysis database NUMBER patients showed pharmacokinetics rivastigmine influenced commonly prescribed medications antacids n = NUMBER antihypertensives n = NUMBER calcium channel blockers n = NUMBER antidiabetics n = NUMBER nonsteroidal anti-inflammatory drugs n = NUMBER estrogens n = NUMBER salicylate analgesics n = NUMBER antianginals n = NUMBER antihistamines n = NUMBER
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 	antacids	antihistamines	none	{'e1': {'word': 'antacids', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d596.s7.e1'}, 'e2': {'word': 'antihistamines', 'word_index': [(50, 50)], 'id': 'DDI-DrugBank.d596.s7.e9'}, 'sentence_id': 'DDI-DrugBank.d596.s7'}	Population PK analysis database NUMBER patients showed pharmacokinetics rivastigmine influenced commonly prescribed medications antacids n = NUMBER antihypertensives n = NUMBER calcium channel blockers n = NUMBER antidiabetics n = NUMBER nonsteroidal anti-inflammatory drugs n = NUMBER estrogens n = NUMBER salicylate analgesics n = NUMBER antianginals n = NUMBER antihistamines n = NUMBER
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 	antihypertensives	calcium channel blockers	none	{'e1': {'word': 'antihypertensives', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d596.s7.e2'}, 'e2': {'word': 'calcium channel blockers', 'word_index': [(20, 22)], 'id': 'DDI-DrugBank.d596.s7.e3'}, 'sentence_id': 'DDI-DrugBank.d596.s7'}	Population PK analysis database NUMBER patients showed pharmacokinetics rivastigmine influenced commonly prescribed medications antacids n= NUMBER antihypertensives n = NUMBER calcium channel blockers n = NUMBER antidiabetics n = NUMBER nonsteroidal anti-inflammatory drugs n = NUMBER estrogens n = NUMBER salicylate analgesics n = NUMBER antianginals n = NUMBER antihistamines n = NUMBER
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 	antihypertensives	antidiabetics	none	{'e1': {'word': 'antihypertensives', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d596.s7.e2'}, 'e2': {'word': 'antidiabetics', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d596.s7.e4'}, 'sentence_id': 'DDI-DrugBank.d596.s7'}	Population PK analysis database NUMBER patients showed pharmacokinetics rivastigmine influenced commonly prescribed medications antacids n= NUMBER antihypertensives n = NUMBER calcium channel blockers n = NUMBER antidiabetics n = NUMBER nonsteroidal anti-inflammatory drugs n = NUMBER estrogens n = NUMBER salicylate analgesics n = NUMBER antianginals n = NUMBER antihistamines n = NUMBER
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 	antihypertensives	nonsteroidal anti-inflammatory drugs	none	{'e1': {'word': 'antihypertensives', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d596.s7.e2'}, 'e2': {'word': 'nonsteroidal anti-inflammatory drugs', 'word_index': [(30, 32)], 'id': 'DDI-DrugBank.d596.s7.e5'}, 'sentence_id': 'DDI-DrugBank.d596.s7'}	Population PK analysis database NUMBER patients showed pharmacokinetics rivastigmine influenced commonly prescribed medications antacids n= NUMBER antihypertensives n = NUMBER calcium channel blockers n = NUMBER antidiabetics n = NUMBER nonsteroidal anti-inflammatory drugs n = NUMBER estrogens n = NUMBER salicylate analgesics n = NUMBER antianginals n = NUMBER antihistamines n = NUMBER
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 	antihypertensives	estrogens	none	{'e1': {'word': 'antihypertensives', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d596.s7.e2'}, 'e2': {'word': 'estrogens', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d596.s7.e6'}, 'sentence_id': 'DDI-DrugBank.d596.s7'}	Population PK analysis database NUMBER patients showed pharmacokinetics rivastigmine influenced commonly prescribed medications antacids n= NUMBER antihypertensives n = NUMBER calcium channel blockers n = NUMBER antidiabetics n = NUMBER nonsteroidal anti-inflammatory drugs n = NUMBER estrogens n = NUMBER salicylate analgesics n = NUMBER antianginals n = NUMBER antihistamines n = NUMBER
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 	antihypertensives	salicylate analgesics	none	{'e1': {'word': 'antihypertensives', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d596.s7.e2'}, 'e2': {'word': 'salicylate analgesics', 'word_index': [(40, 41)], 'id': 'DDI-DrugBank.d596.s7.e7'}, 'sentence_id': 'DDI-DrugBank.d596.s7'}	Population PK analysis database NUMBER patients showed pharmacokinetics rivastigmine influenced commonly prescribed medications antacids n= NUMBER antihypertensives n = NUMBER calcium channel blockers n = NUMBER antidiabetics n = NUMBER nonsteroidal anti-inflammatory drugs n = NUMBER estrogens n = NUMBER salicylate analgesics n = NUMBER antianginals n = NUMBER antihistamines n = NUMBER
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 	antihypertensives	antianginals	none	{'e1': {'word': 'antihypertensives', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d596.s7.e2'}, 'e2': {'word': 'antianginals', 'word_index': [(45, 45)], 'id': 'DDI-DrugBank.d596.s7.e8'}, 'sentence_id': 'DDI-DrugBank.d596.s7'}	Population PK analysis database NUMBER patients showed pharmacokinetics rivastigmine influenced commonly prescribed medications antacids n= NUMBER antihypertensives n = NUMBER calcium channel blockers n = NUMBER antidiabetics n = NUMBER nonsteroidal anti-inflammatory drugs n = NUMBER estrogens n = NUMBER salicylate analgesics n = NUMBER antianginals n = NUMBER antihistamines n = NUMBER
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 	antihypertensives	antihistamines	none	{'e1': {'word': 'antihypertensives', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d596.s7.e2'}, 'e2': {'word': 'antihistamines', 'word_index': [(49, 49)], 'id': 'DDI-DrugBank.d596.s7.e9'}, 'sentence_id': 'DDI-DrugBank.d596.s7'}	Population PK analysis database NUMBER patients showed pharmacokinetics rivastigmine influenced commonly prescribed medications antacids n= NUMBER antihypertensives n = NUMBER calcium channel blockers n = NUMBER antidiabetics n = NUMBER nonsteroidal anti-inflammatory drugs n = NUMBER estrogens n = NUMBER salicylate analgesics n = NUMBER antianginals n = NUMBER antihistamines n = NUMBER
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 	calcium channel blockers	antidiabetics	none	{'e1': {'word': 'calcium channel blockers', 'word_index': [(20, 22)], 'id': 'DDI-DrugBank.d596.s7.e3'}, 'e2': {'word': 'antidiabetics', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d596.s7.e4'}, 'sentence_id': 'DDI-DrugBank.d596.s7'}	Population PK analysis database NUMBER patients showed pharmacokinetics rivastigmine influenced commonly prescribed medications antacids n= NUMBER antihypertensives n = NUMBER calcium channel blockers n = NUMBER antidiabetics n = NUMBER nonsteroidal anti-inflammatory drugs n = NUMBER estrogens n = NUMBER salicylate analgesics n = NUMBER antianginals n = NUMBER antihistamines n = NUMBER
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 	calcium channel blockers	nonsteroidal anti-inflammatory drugs	none	{'e1': {'word': 'calcium channel blockers', 'word_index': [(20, 22)], 'id': 'DDI-DrugBank.d596.s7.e3'}, 'e2': {'word': 'nonsteroidal anti-inflammatory drugs', 'word_index': [(30, 32)], 'id': 'DDI-DrugBank.d596.s7.e5'}, 'sentence_id': 'DDI-DrugBank.d596.s7'}	Population PK analysis database NUMBER patients showed pharmacokinetics rivastigmine influenced commonly prescribed medications antacids n= NUMBER antihypertensives n = NUMBER calcium channel blockers n = NUMBER antidiabetics n = NUMBER nonsteroidal anti-inflammatory drugs n = NUMBER estrogens n = NUMBER salicylate analgesics n = NUMBER antianginals n = NUMBER antihistamines n = NUMBER
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 	calcium channel blockers	estrogens	none	{'e1': {'word': 'calcium channel blockers', 'word_index': [(20, 22)], 'id': 'DDI-DrugBank.d596.s7.e3'}, 'e2': {'word': 'estrogens', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d596.s7.e6'}, 'sentence_id': 'DDI-DrugBank.d596.s7'}	Population PK analysis database NUMBER patients showed pharmacokinetics rivastigmine influenced commonly prescribed medications antacids n= NUMBER antihypertensives n = NUMBER calcium channel blockers n = NUMBER antidiabetics n = NUMBER nonsteroidal anti-inflammatory drugs n = NUMBER estrogens n = NUMBER salicylate analgesics n = NUMBER antianginals n = NUMBER antihistamines n = NUMBER
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 	calcium channel blockers	salicylate analgesics	none	{'e1': {'word': 'calcium channel blockers', 'word_index': [(20, 22)], 'id': 'DDI-DrugBank.d596.s7.e3'}, 'e2': {'word': 'salicylate analgesics', 'word_index': [(40, 41)], 'id': 'DDI-DrugBank.d596.s7.e7'}, 'sentence_id': 'DDI-DrugBank.d596.s7'}	Population PK analysis database NUMBER patients showed pharmacokinetics rivastigmine influenced commonly prescribed medications antacids n= NUMBER antihypertensives n = NUMBER calcium channel blockers n = NUMBER antidiabetics n = NUMBER nonsteroidal anti-inflammatory drugs n = NUMBER estrogens n = NUMBER salicylate analgesics n = NUMBER antianginals n = NUMBER antihistamines n = NUMBER
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 	calcium channel blockers	antianginals	none	{'e1': {'word': 'calcium channel blockers', 'word_index': [(20, 22)], 'id': 'DDI-DrugBank.d596.s7.e3'}, 'e2': {'word': 'antianginals', 'word_index': [(45, 45)], 'id': 'DDI-DrugBank.d596.s7.e8'}, 'sentence_id': 'DDI-DrugBank.d596.s7'}	Population PK analysis database NUMBER patients showed pharmacokinetics rivastigmine influenced commonly prescribed medications antacids n= NUMBER antihypertensives n = NUMBER calcium channel blockers n = NUMBER antidiabetics n = NUMBER nonsteroidal anti-inflammatory drugs n = NUMBER estrogens n = NUMBER salicylate analgesics n = NUMBER antianginals n = NUMBER antihistamines n = NUMBER
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 	calcium channel blockers	antihistamines	none	{'e1': {'word': 'calcium channel blockers', 'word_index': [(20, 22)], 'id': 'DDI-DrugBank.d596.s7.e3'}, 'e2': {'word': 'antihistamines', 'word_index': [(49, 49)], 'id': 'DDI-DrugBank.d596.s7.e9'}, 'sentence_id': 'DDI-DrugBank.d596.s7'}	Population PK analysis database NUMBER patients showed pharmacokinetics rivastigmine influenced commonly prescribed medications antacids n= NUMBER antihypertensives n = NUMBER calcium channel blockers n = NUMBER antidiabetics n = NUMBER nonsteroidal anti-inflammatory drugs n = NUMBER estrogens n = NUMBER salicylate analgesics n = NUMBER antianginals n = NUMBER antihistamines n = NUMBER
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 	antidiabetics	nonsteroidal anti-inflammatory drugs	none	{'e1': {'word': 'antidiabetics', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d596.s7.e4'}, 'e2': {'word': 'nonsteroidal anti-inflammatory drugs', 'word_index': [(30, 32)], 'id': 'DDI-DrugBank.d596.s7.e5'}, 'sentence_id': 'DDI-DrugBank.d596.s7'}	Population PK analysis database NUMBER patients showed pharmacokinetics rivastigmine influenced commonly prescribed medications antacids n= NUMBER antihypertensives n = NUMBER calcium channel blockers n = NUMBER antidiabetics n = NUMBER nonsteroidal anti-inflammatory drugs n = NUMBER estrogens n = NUMBER salicylate analgesics n = NUMBER antianginals n = NUMBER antihistamines n = NUMBER
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 	antidiabetics	estrogens	none	{'e1': {'word': 'antidiabetics', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d596.s7.e4'}, 'e2': {'word': 'estrogens', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d596.s7.e6'}, 'sentence_id': 'DDI-DrugBank.d596.s7'}	Population PK analysis database NUMBER patients showed pharmacokinetics rivastigmine influenced commonly prescribed medications antacids n= NUMBER antihypertensives n = NUMBER calcium channel blockers n = NUMBER antidiabetics n = NUMBER nonsteroidal anti-inflammatory drugs n = NUMBER estrogens n = NUMBER salicylate analgesics n = NUMBER antianginals n = NUMBER antihistamines n = NUMBER
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 	antidiabetics	salicylate analgesics	none	{'e1': {'word': 'antidiabetics', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d596.s7.e4'}, 'e2': {'word': 'salicylate analgesics', 'word_index': [(40, 41)], 'id': 'DDI-DrugBank.d596.s7.e7'}, 'sentence_id': 'DDI-DrugBank.d596.s7'}	Population PK analysis database NUMBER patients showed pharmacokinetics rivastigmine influenced commonly prescribed medications antacids n= NUMBER antihypertensives n = NUMBER calcium channel blockers n = NUMBER antidiabetics n = NUMBER nonsteroidal anti-inflammatory drugs n = NUMBER estrogens n = NUMBER salicylate analgesics n = NUMBER antianginals n = NUMBER antihistamines n = NUMBER
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 	antidiabetics	antianginals	none	{'e1': {'word': 'antidiabetics', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d596.s7.e4'}, 'e2': {'word': 'antianginals', 'word_index': [(45, 45)], 'id': 'DDI-DrugBank.d596.s7.e8'}, 'sentence_id': 'DDI-DrugBank.d596.s7'}	Population PK analysis database NUMBER patients showed pharmacokinetics rivastigmine influenced commonly prescribed medications antacids n= NUMBER antihypertensives n = NUMBER calcium channel blockers n = NUMBER antidiabetics n = NUMBER nonsteroidal anti-inflammatory drugs n = NUMBER estrogens n = NUMBER salicylate analgesics n = NUMBER antianginals n = NUMBER antihistamines n = NUMBER
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 	antidiabetics	antihistamines	none	{'e1': {'word': 'antidiabetics', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d596.s7.e4'}, 'e2': {'word': 'antihistamines', 'word_index': [(49, 49)], 'id': 'DDI-DrugBank.d596.s7.e9'}, 'sentence_id': 'DDI-DrugBank.d596.s7'}	Population PK analysis database NUMBER patients showed pharmacokinetics rivastigmine influenced commonly prescribed medications antacids n= NUMBER antihypertensives n = NUMBER calcium channel blockers n = NUMBER antidiabetics n = NUMBER nonsteroidal anti-inflammatory drugs n = NUMBER estrogens n = NUMBER salicylate analgesics n = NUMBER antianginals n = NUMBER antihistamines n = NUMBER
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 	nonsteroidal anti-inflammatory drugs	estrogens	none	{'e1': {'word': 'nonsteroidal anti-inflammatory drugs', 'word_index': [(30, 32)], 'id': 'DDI-DrugBank.d596.s7.e5'}, 'e2': {'word': 'estrogens', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d596.s7.e6'}, 'sentence_id': 'DDI-DrugBank.d596.s7'}	Population PK analysis database NUMBER patients showed pharmacokinetics rivastigmine influenced commonly prescribed medications antacids n= NUMBER antihypertensives n = NUMBER calcium channel blockers n = NUMBER antidiabetics n = NUMBER nonsteroidal anti-inflammatory drugs n = NUMBER estrogens n = NUMBER salicylate analgesics n = NUMBER antianginals n = NUMBER antihistamines n = NUMBER
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 	nonsteroidal anti-inflammatory drugs	salicylate analgesics	none	{'e1': {'word': 'nonsteroidal anti-inflammatory drugs', 'word_index': [(30, 32)], 'id': 'DDI-DrugBank.d596.s7.e5'}, 'e2': {'word': 'salicylate analgesics', 'word_index': [(40, 41)], 'id': 'DDI-DrugBank.d596.s7.e7'}, 'sentence_id': 'DDI-DrugBank.d596.s7'}	Population PK analysis database NUMBER patients showed pharmacokinetics rivastigmine influenced commonly prescribed medications antacids n= NUMBER antihypertensives n = NUMBER calcium channel blockers n = NUMBER antidiabetics n = NUMBER nonsteroidal anti-inflammatory drugs n = NUMBER estrogens n = NUMBER salicylate analgesics n = NUMBER antianginals n = NUMBER antihistamines n = NUMBER
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 	nonsteroidal anti-inflammatory drugs	antianginals	none	{'e1': {'word': 'nonsteroidal anti-inflammatory drugs', 'word_index': [(30, 32)], 'id': 'DDI-DrugBank.d596.s7.e5'}, 'e2': {'word': 'antianginals', 'word_index': [(45, 45)], 'id': 'DDI-DrugBank.d596.s7.e8'}, 'sentence_id': 'DDI-DrugBank.d596.s7'}	Population PK analysis database NUMBER patients showed pharmacokinetics rivastigmine influenced commonly prescribed medications antacids n= NUMBER antihypertensives n = NUMBER calcium channel blockers n = NUMBER antidiabetics n = NUMBER nonsteroidal anti-inflammatory drugs n = NUMBER estrogens n = NUMBER salicylate analgesics n = NUMBER antianginals n = NUMBER antihistamines n = NUMBER
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 	nonsteroidal anti-inflammatory drugs	antihistamines	none	{'e1': {'word': 'nonsteroidal anti-inflammatory drugs', 'word_index': [(30, 32)], 'id': 'DDI-DrugBank.d596.s7.e5'}, 'e2': {'word': 'antihistamines', 'word_index': [(49, 49)], 'id': 'DDI-DrugBank.d596.s7.e9'}, 'sentence_id': 'DDI-DrugBank.d596.s7'}	Population PK analysis database NUMBER patients showed pharmacokinetics rivastigmine influenced commonly prescribed medications antacids n= NUMBER antihypertensives n = NUMBER calcium channel blockers n = NUMBER antidiabetics n = NUMBER nonsteroidal anti-inflammatory drugs n = NUMBER estrogens n = NUMBER salicylate analgesics n = NUMBER antianginals n = NUMBER antihistamines n = NUMBER
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 	estrogens	salicylate analgesics	none	{'e1': {'word': 'estrogens', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d596.s7.e6'}, 'e2': {'word': 'salicylate analgesics', 'word_index': [(40, 41)], 'id': 'DDI-DrugBank.d596.s7.e7'}, 'sentence_id': 'DDI-DrugBank.d596.s7'}	Population PK analysis database NUMBER patients showed pharmacokinetics rivastigmine influenced commonly prescribed medications antacids n= NUMBER antihypertensives n = NUMBER calcium channel blockers n = NUMBER antidiabetics n = NUMBER nonsteroidal anti-inflammatory drugs n = NUMBER estrogens n = NUMBER salicylate analgesics n = NUMBER antianginals n = NUMBER antihistamines n = NUMBER
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 	estrogens	antianginals	none	{'e1': {'word': 'estrogens', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d596.s7.e6'}, 'e2': {'word': 'antianginals', 'word_index': [(45, 45)], 'id': 'DDI-DrugBank.d596.s7.e8'}, 'sentence_id': 'DDI-DrugBank.d596.s7'}	Population PK analysis database NUMBER patients showed pharmacokinetics rivastigmine influenced commonly prescribed medications antacids n= NUMBER antihypertensives n = NUMBER calcium channel blockers n = NUMBER antidiabetics n = NUMBER nonsteroidal anti-inflammatory drugs n = NUMBER estrogens n = NUMBER salicylate analgesics n = NUMBER antianginals n = NUMBER antihistamines n = NUMBER
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 	estrogens	antihistamines	none	{'e1': {'word': 'estrogens', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d596.s7.e6'}, 'e2': {'word': 'antihistamines', 'word_index': [(49, 49)], 'id': 'DDI-DrugBank.d596.s7.e9'}, 'sentence_id': 'DDI-DrugBank.d596.s7'}	Population PK analysis database NUMBER patients showed pharmacokinetics rivastigmine influenced commonly prescribed medications antacids n= NUMBER antihypertensives n = NUMBER calcium channel blockers n = NUMBER antidiabetics n = NUMBER nonsteroidal anti-inflammatory drugs n = NUMBER estrogens n = NUMBER salicylate analgesics n = NUMBER antianginals n = NUMBER antihistamines n = NUMBER
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 	salicylate analgesics	antianginals	none	{'e1': {'word': 'salicylate analgesics', 'word_index': [(40, 41)], 'id': 'DDI-DrugBank.d596.s7.e7'}, 'e2': {'word': 'antianginals', 'word_index': [(45, 45)], 'id': 'DDI-DrugBank.d596.s7.e8'}, 'sentence_id': 'DDI-DrugBank.d596.s7'}	Population PK analysis database NUMBER patients showed pharmacokinetics rivastigmine influenced commonly prescribed medications antacids n= NUMBER antihypertensives n = NUMBER calcium channel blockers n = NUMBER antidiabetics n = NUMBER nonsteroidal anti-inflammatory drugs n = NUMBER estrogens n = NUMBER salicylate analgesics n = NUMBER antianginals n = NUMBER antihistamines n = NUMBER
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 	salicylate analgesics	antihistamines	none	{'e1': {'word': 'salicylate analgesics', 'word_index': [(40, 41)], 'id': 'DDI-DrugBank.d596.s7.e7'}, 'e2': {'word': 'antihistamines', 'word_index': [(49, 49)], 'id': 'DDI-DrugBank.d596.s7.e9'}, 'sentence_id': 'DDI-DrugBank.d596.s7'}	Population PK analysis database NUMBER patients showed pharmacokinetics rivastigmine influenced commonly prescribed medications antacids n= NUMBER antihypertensives n = NUMBER calcium channel blockers n = NUMBER antidiabetics n = NUMBER nonsteroidal anti-inflammatory drugs n = NUMBER estrogens n = NUMBER salicylate analgesics n = NUMBER antianginals n = NUMBER antihistamines n = NUMBER
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). 	antianginals	antihistamines	none	{'e1': {'word': 'antianginals', 'word_index': [(45, 45)], 'id': 'DDI-DrugBank.d596.s7.e8'}, 'e2': {'word': 'antihistamines', 'word_index': [(49, 49)], 'id': 'DDI-DrugBank.d596.s7.e9'}, 'sentence_id': 'DDI-DrugBank.d596.s7'}	Population PK analysis database NUMBER patients showed pharmacokinetics rivastigmine influenced commonly prescribed medications antacids n= NUMBER antihypertensives n = NUMBER calcium channel blockers n = NUMBER antidiabetics n = NUMBER nonsteroidal anti-inflammatory drugs n = NUMBER estrogens n = NUMBER salicylate analgesics n = NUMBER antianginals n = NUMBER antihistamines n = NUMBER
Use with Anticholinergics: Because of their mechanism of action, cholinesterase inhibitors have the potential to interfere with the activity of anticholinergic medications. 	Anticholinergics	cholinesterase inhibitors	none	{'e1': {'word': 'Anticholinergics', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d596.s8.e0'}, 'e2': {'word': 'cholinesterase inhibitors', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d596.s8.e1'}, 'sentence_id': 'DDI-DrugBank.d596.s8'}	Use Anticholinergics mechanism action cholinesterase inhibitors potential interfere activity anticholinergic medications
Use with Anticholinergics: Because of their mechanism of action, cholinesterase inhibitors have the potential to interfere with the activity of anticholinergic medications. 	Anticholinergics	anticholinergic medications	none	{'e1': {'word': 'Anticholinergics', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d596.s8.e0'}, 'e2': {'word': 'anticholinergic medications', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d596.s8.e2'}, 'sentence_id': 'DDI-DrugBank.d596.s8'}	Use Anticholinergics mechanism action cholinesterase inhibitors potential interfere activity anticholinergic medications
Use with Anticholinergics: Because of their mechanism of action, cholinesterase inhibitors have the potential to interfere with the activity of anticholinergic medications. 	cholinesterase inhibitors	anticholinergic medications	int	{'e1': {'word': 'cholinesterase inhibitors', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d596.s8.e1'}, 'e2': {'word': 'anticholinergic medications', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d596.s8.e2'}, 'sentence_id': 'DDI-DrugBank.d596.s8'}	Use Anticholinergics mechanism action cholinesterase inhibitors potential interfere activity anticholinergic medications
Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.	Cholinomimetics	Cholinesterase Inhibitors	none	{'e1': {'word': 'Cholinomimetics', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d596.s9.e0'}, 'e2': {'word': 'Cholinesterase Inhibitors', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d596.s9.e1'}, 'sentence_id': 'DDI-DrugBank.d596.s9'}	Use Cholinomimetics Cholinesterase Inhibitors synergistic effect may expected cholinesterase inhibitors given concurrently succinylcholine similar neuromuscular blocking agents cholinergic agonists bethanechol
Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.	Cholinomimetics	cholinesterase inhibitors	none	{'e1': {'word': 'Cholinomimetics', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d596.s9.e0'}, 'e2': {'word': 'cholinesterase inhibitors', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d596.s9.e2'}, 'sentence_id': 'DDI-DrugBank.d596.s9'}	Use Cholinomimetics Cholinesterase Inhibitors synergistic effect may expected cholinesterase inhibitors given concurrently succinylcholine similar neuromuscular blocking agents cholinergic agonists bethanechol
Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.	Cholinomimetics	succinylcholine	none	{'e1': {'word': 'Cholinomimetics', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d596.s9.e0'}, 'e2': {'word': 'succinylcholine', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d596.s9.e3'}, 'sentence_id': 'DDI-DrugBank.d596.s9'}	Use Cholinomimetics Cholinesterase Inhibitors synergistic effect may expected cholinesterase inhibitors given concurrently succinylcholine similar neuromuscular blocking agents cholinergic agonists bethanechol
Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.	Cholinomimetics	neuromuscular blocking agents	none	{'e1': {'word': 'Cholinomimetics', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d596.s9.e0'}, 'e2': {'word': 'neuromuscular blocking agents', 'word_index': [(14, 16)], 'id': 'DDI-DrugBank.d596.s9.e4'}, 'sentence_id': 'DDI-DrugBank.d596.s9'}	Use Cholinomimetics Cholinesterase Inhibitors synergistic effect may expected cholinesterase inhibitors given concurrently succinylcholine similar neuromuscular blocking agents cholinergic agonists bethanechol
Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.	Cholinomimetics	cholinergic agonists	none	{'e1': {'word': 'Cholinomimetics', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d596.s9.e0'}, 'e2': {'word': 'cholinergic agonists', 'word_index': [(17, 18)], 'id': 'DDI-DrugBank.d596.s9.e5'}, 'sentence_id': 'DDI-DrugBank.d596.s9'}	Use Cholinomimetics Cholinesterase Inhibitors synergistic effect may expected cholinesterase inhibitors given concurrently succinylcholine similar neuromuscular blocking agents cholinergic agonists bethanechol
Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.	Cholinomimetics	bethanechol	none	{'e1': {'word': 'Cholinomimetics', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d596.s9.e0'}, 'e2': {'word': 'bethanechol', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d596.s9.e6'}, 'sentence_id': 'DDI-DrugBank.d596.s9'}	Use Cholinomimetics Cholinesterase Inhibitors synergistic effect may expected cholinesterase inhibitors given concurrently succinylcholine similar neuromuscular blocking agents cholinergic agonists bethanechol
Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.	Cholinesterase Inhibitors	cholinesterase inhibitors	none	{'e1': {'word': 'Cholinesterase Inhibitors', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d596.s9.e1'}, 'e2': {'word': 'cholinesterase inhibitors', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d596.s9.e2'}, 'sentence_id': 'DDI-DrugBank.d596.s9'}	Use Cholinomimetics Cholinesterase Inhibitors synergistic effect may expected cholinesterase inhibitors given concurrently succinylcholine similar neuromuscular blocking agents cholinergic agonists bethanechol
Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.	Cholinesterase Inhibitors	succinylcholine	none	{'e1': {'word': 'Cholinesterase Inhibitors', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d596.s9.e1'}, 'e2': {'word': 'succinylcholine', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d596.s9.e3'}, 'sentence_id': 'DDI-DrugBank.d596.s9'}	Use Cholinomimetics Cholinesterase Inhibitors synergistic effect may expected cholinesterase inhibitors given concurrently succinylcholine similar neuromuscular blocking agents cholinergic agonists bethanechol
Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.	Cholinesterase Inhibitors	neuromuscular blocking agents	none	{'e1': {'word': 'Cholinesterase Inhibitors', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d596.s9.e1'}, 'e2': {'word': 'neuromuscular blocking agents', 'word_index': [(14, 16)], 'id': 'DDI-DrugBank.d596.s9.e4'}, 'sentence_id': 'DDI-DrugBank.d596.s9'}	Use Cholinomimetics Cholinesterase Inhibitors synergistic effect may expected cholinesterase inhibitors given concurrently succinylcholine similar neuromuscular blocking agents cholinergic agonists bethanechol
Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.	Cholinesterase Inhibitors	cholinergic agonists	none	{'e1': {'word': 'Cholinesterase Inhibitors', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d596.s9.e1'}, 'e2': {'word': 'cholinergic agonists', 'word_index': [(17, 18)], 'id': 'DDI-DrugBank.d596.s9.e5'}, 'sentence_id': 'DDI-DrugBank.d596.s9'}	Use Cholinomimetics Cholinesterase Inhibitors synergistic effect may expected cholinesterase inhibitors given concurrently succinylcholine similar neuromuscular blocking agents cholinergic agonists bethanechol
Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.	Cholinesterase Inhibitors	bethanechol	none	{'e1': {'word': 'Cholinesterase Inhibitors', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d596.s9.e1'}, 'e2': {'word': 'bethanechol', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d596.s9.e6'}, 'sentence_id': 'DDI-DrugBank.d596.s9'}	Use Cholinomimetics Cholinesterase Inhibitors synergistic effect may expected cholinesterase inhibitors given concurrently succinylcholine similar neuromuscular blocking agents cholinergic agonists bethanechol
Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.	cholinesterase inhibitors	succinylcholine	effect	{'e1': {'word': 'cholinesterase inhibitors', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d596.s9.e2'}, 'e2': {'word': 'succinylcholine', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d596.s9.e3'}, 'sentence_id': 'DDI-DrugBank.d596.s9'}	Use Cholinomimetics Cholinesterase Inhibitors synergistic effect may expected cholinesterase inhibitors given concurrently succinylcholine similar neuromuscular blocking agents cholinergic agonists bethanechol
Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.	cholinesterase inhibitors	neuromuscular blocking agents	effect	{'e1': {'word': 'cholinesterase inhibitors', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d596.s9.e2'}, 'e2': {'word': 'neuromuscular blocking agents', 'word_index': [(14, 16)], 'id': 'DDI-DrugBank.d596.s9.e4'}, 'sentence_id': 'DDI-DrugBank.d596.s9'}	Use Cholinomimetics Cholinesterase Inhibitors synergistic effect may expected cholinesterase inhibitors given concurrently succinylcholine similar neuromuscular blocking agents cholinergic agonists bethanechol
Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.	cholinesterase inhibitors	cholinergic agonists	effect	{'e1': {'word': 'cholinesterase inhibitors', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d596.s9.e2'}, 'e2': {'word': 'cholinergic agonists', 'word_index': [(17, 18)], 'id': 'DDI-DrugBank.d596.s9.e5'}, 'sentence_id': 'DDI-DrugBank.d596.s9'}	Use Cholinomimetics Cholinesterase Inhibitors synergistic effect may expected cholinesterase inhibitors given concurrently succinylcholine similar neuromuscular blocking agents cholinergic agonists bethanechol
Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.	cholinesterase inhibitors	bethanechol	effect	{'e1': {'word': 'cholinesterase inhibitors', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d596.s9.e2'}, 'e2': {'word': 'bethanechol', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d596.s9.e6'}, 'sentence_id': 'DDI-DrugBank.d596.s9'}	Use Cholinomimetics Cholinesterase Inhibitors synergistic effect may expected cholinesterase inhibitors given concurrently succinylcholine similar neuromuscular blocking agents cholinergic agonists bethanechol
Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.	succinylcholine	neuromuscular blocking agents	none	{'e1': {'word': 'succinylcholine', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d596.s9.e3'}, 'e2': {'word': 'neuromuscular blocking agents', 'word_index': [(14, 16)], 'id': 'DDI-DrugBank.d596.s9.e4'}, 'sentence_id': 'DDI-DrugBank.d596.s9'}	Use Cholinomimetics Cholinesterase Inhibitors synergistic effect may expected cholinesterase inhibitors given concurrently succinylcholine similar neuromuscular blocking agents cholinergic agonists bethanechol
Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.	succinylcholine	cholinergic agonists	none	{'e1': {'word': 'succinylcholine', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d596.s9.e3'}, 'e2': {'word': 'cholinergic agonists', 'word_index': [(17, 18)], 'id': 'DDI-DrugBank.d596.s9.e5'}, 'sentence_id': 'DDI-DrugBank.d596.s9'}	Use Cholinomimetics Cholinesterase Inhibitors synergistic effect may expected cholinesterase inhibitors given concurrently succinylcholine similar neuromuscular blocking agents cholinergic agonists bethanechol
Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.	succinylcholine	bethanechol	none	{'e1': {'word': 'succinylcholine', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d596.s9.e3'}, 'e2': {'word': 'bethanechol', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d596.s9.e6'}, 'sentence_id': 'DDI-DrugBank.d596.s9'}	Use Cholinomimetics Cholinesterase Inhibitors synergistic effect may expected cholinesterase inhibitors given concurrently succinylcholine similar neuromuscular blocking agents cholinergic agonists bethanechol
Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.	neuromuscular blocking agents	cholinergic agonists	none	{'e1': {'word': 'neuromuscular blocking agents', 'word_index': [(14, 16)], 'id': 'DDI-DrugBank.d596.s9.e4'}, 'e2': {'word': 'cholinergic agonists', 'word_index': [(17, 18)], 'id': 'DDI-DrugBank.d596.s9.e5'}, 'sentence_id': 'DDI-DrugBank.d596.s9'}	Use Cholinomimetics Cholinesterase Inhibitors synergistic effect may expected cholinesterase inhibitors given concurrently succinylcholine similar neuromuscular blocking agents cholinergic agonists bethanechol
Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.	neuromuscular blocking agents	bethanechol	none	{'e1': {'word': 'neuromuscular blocking agents', 'word_index': [(14, 16)], 'id': 'DDI-DrugBank.d596.s9.e4'}, 'e2': {'word': 'bethanechol', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d596.s9.e6'}, 'sentence_id': 'DDI-DrugBank.d596.s9'}	Use Cholinomimetics Cholinesterase Inhibitors synergistic effect may expected cholinesterase inhibitors given concurrently succinylcholine similar neuromuscular blocking agents cholinergic agonists bethanechol
Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.	cholinergic agonists	bethanechol	none	{'e1': {'word': 'cholinergic agonists', 'word_index': [(17, 18)], 'id': 'DDI-DrugBank.d596.s9.e5'}, 'e2': {'word': 'bethanechol', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d596.s9.e6'}, 'sentence_id': 'DDI-DrugBank.d596.s9'}	Use Cholinomimetics Cholinesterase Inhibitors synergistic effect may expected cholinesterase inhibitors given concurrently succinylcholine similar neuromuscular blocking agents cholinergic agonists bethanechol
CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. 	Macrolide Antibiotics	Protease Inhibitors	none	{'e1': {'word': 'Macrolide Antibiotics', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d675.s0.e0'}, 'e2': {'word': 'Protease Inhibitors', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d675.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d675.s0'}	CYP 3A4 Inhibitors e.g. Macrolide Antibiotics Protease Inhibitors rare reports serious adverse events connection coadministration certain ergot alkaloid drugs e.g. dihydroergotamine ergotamine potent CYP 3A4 inhibitors resulting vasospasm leading cerebral ischemia ischemia extremities
CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. 	Macrolide Antibiotics	ergot alkaloid drugs	none	{'e1': {'word': 'Macrolide Antibiotics', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d675.s0.e0'}, 'e2': {'word': 'ergot alkaloid drugs', 'word_index': [(16, 18)], 'id': 'DDI-DrugBank.d675.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d675.s0'}	CYP 3A4 Inhibitors e.g. Macrolide Antibiotics Protease Inhibitors rare reports serious adverse events connection coadministration certain ergot alkaloid drugs e.g. dihydroergotamine ergotamine potent CYP 3A4 inhibitors resulting vasospasm leading cerebral ischemia ischemia extremities
CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. 	Macrolide Antibiotics	dihydroergotamine	none	{'e1': {'word': 'Macrolide Antibiotics', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d675.s0.e0'}, 'e2': {'word': 'dihydroergotamine', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d675.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d675.s0'}	CYP 3A4 Inhibitors e.g. Macrolide Antibiotics Protease Inhibitors rare reports serious adverse events connection coadministration certain ergot alkaloid drugs e.g. dihydroergotamine ergotamine potent CYP 3A4 inhibitors resulting vasospasm leading cerebral ischemia ischemia extremities
CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. 	Macrolide Antibiotics	ergotamine	none	{'e1': {'word': 'Macrolide Antibiotics', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d675.s0.e0'}, 'e2': {'word': 'ergotamine', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d675.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d675.s0'}	CYP 3A4 Inhibitors e.g. Macrolide Antibiotics Protease Inhibitors rare reports serious adverse events connection coadministration certain ergot alkaloid drugs e.g. dihydroergotamine ergotamine potent CYP 3A4 inhibitors resulting vasospasm leading cerebral ischemia ischemia extremities
CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. 	Protease Inhibitors	ergot alkaloid drugs	none	{'e1': {'word': 'Protease Inhibitors', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d675.s0.e1'}, 'e2': {'word': 'ergot alkaloid drugs', 'word_index': [(16, 18)], 'id': 'DDI-DrugBank.d675.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d675.s0'}	CYP 3A4 Inhibitors e.g. Macrolide Antibiotics Protease Inhibitors rare reports serious adverse events connection coadministration certain ergot alkaloid drugs e.g. dihydroergotamine ergotamine potent CYP 3A4 inhibitors resulting vasospasm leading cerebral ischemia ischemia extremities
CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. 	Protease Inhibitors	dihydroergotamine	none	{'e1': {'word': 'Protease Inhibitors', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d675.s0.e1'}, 'e2': {'word': 'dihydroergotamine', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d675.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d675.s0'}	CYP 3A4 Inhibitors e.g. Macrolide Antibiotics Protease Inhibitors rare reports serious adverse events connection coadministration certain ergot alkaloid drugs e.g. dihydroergotamine ergotamine potent CYP 3A4 inhibitors resulting vasospasm leading cerebral ischemia ischemia extremities
CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. 	Protease Inhibitors	ergotamine	none	{'e1': {'word': 'Protease Inhibitors', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d675.s0.e1'}, 'e2': {'word': 'ergotamine', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d675.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d675.s0'}	CYP 3A4 Inhibitors e.g. Macrolide Antibiotics Protease Inhibitors rare reports serious adverse events connection coadministration certain ergot alkaloid drugs e.g. dihydroergotamine ergotamine potent CYP 3A4 inhibitors resulting vasospasm leading cerebral ischemia ischemia extremities
CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. 	ergot alkaloid drugs	dihydroergotamine	none	{'e1': {'word': 'ergot alkaloid drugs', 'word_index': [(16, 18)], 'id': 'DDI-DrugBank.d675.s0.e2'}, 'e2': {'word': 'dihydroergotamine', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d675.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d675.s0'}	CYP 3A4 Inhibitors e.g. Macrolide Antibiotics Protease Inhibitors rare reports serious adverse events connection coadministration certain ergot alkaloid drugs e.g. dihydroergotamine ergotamine potent CYP 3A4 inhibitors resulting vasospasm leading cerebral ischemia ischemia extremities
CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. 	ergot alkaloid drugs	ergotamine	none	{'e1': {'word': 'ergot alkaloid drugs', 'word_index': [(16, 18)], 'id': 'DDI-DrugBank.d675.s0.e2'}, 'e2': {'word': 'ergotamine', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d675.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d675.s0'}	CYP 3A4 Inhibitors e.g. Macrolide Antibiotics Protease Inhibitors rare reports serious adverse events connection coadministration certain ergot alkaloid drugs e.g. dihydroergotamine ergotamine potent CYP 3A4 inhibitors resulting vasospasm leading cerebral ischemia ischemia extremities
CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. 	dihydroergotamine	ergotamine	none	{'e1': {'word': 'dihydroergotamine', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d675.s0.e3'}, 'e2': {'word': 'ergotamine', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d675.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d675.s0'}	CYP 3A4 Inhibitors e.g. Macrolide Antibiotics Protease Inhibitors rare reports serious adverse events connection coadministration certain ergot alkaloid drugs e.g. dihydroergotamine ergotamine potent CYP 3A4 inhibitors resulting vasospasm leading cerebral ischemia ischemia extremities
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	macrolide antibiotics	erythromycin	none	{'e1': {'word': 'macrolide antibiotics', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d675.s2.e0'}, 'e2': {'word': 'erythromycin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d675.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	macrolide antibiotics	troleandomycin	none	{'e1': {'word': 'macrolide antibiotics', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d675.s2.e0'}, 'e2': {'word': 'troleandomycin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d675.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	macrolide antibiotics	clarithromycin	none	{'e1': {'word': 'macrolide antibiotics', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d675.s2.e0'}, 'e2': {'word': 'clarithromycin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d675.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	macrolide antibiotics	HIV protease inhibitors	none	{'e1': {'word': 'macrolide antibiotics', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d675.s2.e0'}, 'e2': {'word': 'HIV protease inhibitors', 'word_index': [(12, 13), (17, 17)], 'id': 'DDI-DrugBank.d675.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	macrolide antibiotics	reverse transcriptase inhibitors	none	{'e1': {'word': 'macrolide antibiotics', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d675.s2.e0'}, 'e2': {'word': 'reverse transcriptase inhibitors', 'word_index': [(14, 16)], 'id': 'DDI-DrugBank.d675.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	macrolide antibiotics	ritonavir	none	{'e1': {'word': 'macrolide antibiotics', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d675.s2.e0'}, 'e2': {'word': 'ritonavir', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d675.s2.e6'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	macrolide antibiotics	indinavir	none	{'e1': {'word': 'macrolide antibiotics', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d675.s2.e0'}, 'e2': {'word': 'indinavir', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d675.s2.e7'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	macrolide antibiotics	nelfinavir	none	{'e1': {'word': 'macrolide antibiotics', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d675.s2.e0'}, 'e2': {'word': 'nelfinavir', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d675.s2.e8'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	macrolide antibiotics	delavirdine	none	{'e1': {'word': 'macrolide antibiotics', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d675.s2.e0'}, 'e2': {'word': 'delavirdine', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d675.s2.e9'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	macrolide antibiotics	azole antifungals	none	{'e1': {'word': 'macrolide antibiotics', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d675.s2.e0'}, 'e2': {'word': 'azole antifungals', 'word_index': [(23, 24)], 'id': 'DDI-DrugBank.d675.s2.e10'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	macrolide antibiotics	ketoconazole	none	{'e1': {'word': 'macrolide antibiotics', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d675.s2.e0'}, 'e2': {'word': 'ketoconazole', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d675.s2.e11'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	macrolide antibiotics	itraconazole	none	{'e1': {'word': 'macrolide antibiotics', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d675.s2.e0'}, 'e2': {'word': 'itraconazole', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d675.s2.e12'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	macrolide antibiotics	voriconazole	none	{'e1': {'word': 'macrolide antibiotics', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d675.s2.e0'}, 'e2': {'word': 'voriconazole', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d675.s2.e13'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	erythromycin	troleandomycin	none	{'e1': {'word': 'erythromycin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d675.s2.e1'}, 'e2': {'word': 'troleandomycin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d675.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	erythromycin	clarithromycin	none	{'e1': {'word': 'erythromycin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d675.s2.e1'}, 'e2': {'word': 'clarithromycin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d675.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	erythromycin	HIV protease inhibitors	none	{'e1': {'word': 'erythromycin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d675.s2.e1'}, 'e2': {'word': 'HIV protease inhibitors', 'word_index': [(12, 13), (17, 17)], 'id': 'DDI-DrugBank.d675.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	erythromycin	reverse transcriptase inhibitors	none	{'e1': {'word': 'erythromycin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d675.s2.e1'}, 'e2': {'word': 'reverse transcriptase inhibitors', 'word_index': [(14, 16)], 'id': 'DDI-DrugBank.d675.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	erythromycin	ritonavir	none	{'e1': {'word': 'erythromycin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d675.s2.e1'}, 'e2': {'word': 'ritonavir', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d675.s2.e6'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	erythromycin	indinavir	none	{'e1': {'word': 'erythromycin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d675.s2.e1'}, 'e2': {'word': 'indinavir', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d675.s2.e7'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	erythromycin	nelfinavir	none	{'e1': {'word': 'erythromycin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d675.s2.e1'}, 'e2': {'word': 'nelfinavir', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d675.s2.e8'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	erythromycin	delavirdine	none	{'e1': {'word': 'erythromycin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d675.s2.e1'}, 'e2': {'word': 'delavirdine', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d675.s2.e9'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	erythromycin	azole antifungals	none	{'e1': {'word': 'erythromycin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d675.s2.e1'}, 'e2': {'word': 'azole antifungals', 'word_index': [(23, 24)], 'id': 'DDI-DrugBank.d675.s2.e10'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	erythromycin	ketoconazole	none	{'e1': {'word': 'erythromycin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d675.s2.e1'}, 'e2': {'word': 'ketoconazole', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d675.s2.e11'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	erythromycin	itraconazole	none	{'e1': {'word': 'erythromycin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d675.s2.e1'}, 'e2': {'word': 'itraconazole', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d675.s2.e12'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	erythromycin	voriconazole	none	{'e1': {'word': 'erythromycin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d675.s2.e1'}, 'e2': {'word': 'voriconazole', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d675.s2.e13'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	troleandomycin	clarithromycin	none	{'e1': {'word': 'troleandomycin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d675.s2.e2'}, 'e2': {'word': 'clarithromycin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d675.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	troleandomycin	HIV protease inhibitors	none	{'e1': {'word': 'troleandomycin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d675.s2.e2'}, 'e2': {'word': 'HIV protease inhibitors', 'word_index': [(12, 13), (17, 17)], 'id': 'DDI-DrugBank.d675.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	troleandomycin	reverse transcriptase inhibitors	none	{'e1': {'word': 'troleandomycin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d675.s2.e2'}, 'e2': {'word': 'reverse transcriptase inhibitors', 'word_index': [(14, 16)], 'id': 'DDI-DrugBank.d675.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	troleandomycin	ritonavir	none	{'e1': {'word': 'troleandomycin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d675.s2.e2'}, 'e2': {'word': 'ritonavir', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d675.s2.e6'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	troleandomycin	indinavir	none	{'e1': {'word': 'troleandomycin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d675.s2.e2'}, 'e2': {'word': 'indinavir', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d675.s2.e7'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	troleandomycin	nelfinavir	none	{'e1': {'word': 'troleandomycin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d675.s2.e2'}, 'e2': {'word': 'nelfinavir', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d675.s2.e8'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	troleandomycin	delavirdine	none	{'e1': {'word': 'troleandomycin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d675.s2.e2'}, 'e2': {'word': 'delavirdine', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d675.s2.e9'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	troleandomycin	azole antifungals	none	{'e1': {'word': 'troleandomycin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d675.s2.e2'}, 'e2': {'word': 'azole antifungals', 'word_index': [(23, 24)], 'id': 'DDI-DrugBank.d675.s2.e10'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	troleandomycin	ketoconazole	none	{'e1': {'word': 'troleandomycin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d675.s2.e2'}, 'e2': {'word': 'ketoconazole', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d675.s2.e11'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	troleandomycin	itraconazole	none	{'e1': {'word': 'troleandomycin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d675.s2.e2'}, 'e2': {'word': 'itraconazole', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d675.s2.e12'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	troleandomycin	voriconazole	none	{'e1': {'word': 'troleandomycin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d675.s2.e2'}, 'e2': {'word': 'voriconazole', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d675.s2.e13'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	clarithromycin	HIV protease inhibitors	none	{'e1': {'word': 'clarithromycin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d675.s2.e3'}, 'e2': {'word': 'HIV protease inhibitors', 'word_index': [(12, 13), (17, 17)], 'id': 'DDI-DrugBank.d675.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	clarithromycin	reverse transcriptase inhibitors	none	{'e1': {'word': 'clarithromycin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d675.s2.e3'}, 'e2': {'word': 'reverse transcriptase inhibitors', 'word_index': [(14, 16)], 'id': 'DDI-DrugBank.d675.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	clarithromycin	ritonavir	none	{'e1': {'word': 'clarithromycin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d675.s2.e3'}, 'e2': {'word': 'ritonavir', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d675.s2.e6'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	clarithromycin	indinavir	none	{'e1': {'word': 'clarithromycin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d675.s2.e3'}, 'e2': {'word': 'indinavir', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d675.s2.e7'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	clarithromycin	nelfinavir	none	{'e1': {'word': 'clarithromycin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d675.s2.e3'}, 'e2': {'word': 'nelfinavir', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d675.s2.e8'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	clarithromycin	delavirdine	none	{'e1': {'word': 'clarithromycin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d675.s2.e3'}, 'e2': {'word': 'delavirdine', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d675.s2.e9'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	clarithromycin	azole antifungals	none	{'e1': {'word': 'clarithromycin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d675.s2.e3'}, 'e2': {'word': 'azole antifungals', 'word_index': [(23, 24)], 'id': 'DDI-DrugBank.d675.s2.e10'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	clarithromycin	ketoconazole	none	{'e1': {'word': 'clarithromycin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d675.s2.e3'}, 'e2': {'word': 'ketoconazole', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d675.s2.e11'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	clarithromycin	itraconazole	none	{'e1': {'word': 'clarithromycin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d675.s2.e3'}, 'e2': {'word': 'itraconazole', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d675.s2.e12'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	clarithromycin	voriconazole	none	{'e1': {'word': 'clarithromycin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d675.s2.e3'}, 'e2': {'word': 'voriconazole', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d675.s2.e13'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	HIV protease inhibitors	reverse transcriptase inhibitors	none	{'e1': {'word': 'HIV protease inhibitors', 'word_index': [(12, 13), (17, 17)], 'id': 'DDI-DrugBank.d675.s2.e4'}, 'e2': {'word': 'reverse transcriptase inhibitors', 'word_index': [(14, 16)], 'id': 'DDI-DrugBank.d675.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	HIV protease inhibitors	ritonavir	none	{'e1': {'word': 'HIV protease inhibitors', 'word_index': [(12, 13), (17, 17)], 'id': 'DDI-DrugBank.d675.s2.e4'}, 'e2': {'word': 'ritonavir', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d675.s2.e6'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	HIV protease inhibitors	indinavir	none	{'e1': {'word': 'HIV protease inhibitors', 'word_index': [(12, 13), (17, 17)], 'id': 'DDI-DrugBank.d675.s2.e4'}, 'e2': {'word': 'indinavir', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d675.s2.e7'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	HIV protease inhibitors	nelfinavir	none	{'e1': {'word': 'HIV protease inhibitors', 'word_index': [(12, 13), (17, 17)], 'id': 'DDI-DrugBank.d675.s2.e4'}, 'e2': {'word': 'nelfinavir', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d675.s2.e8'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	HIV protease inhibitors	delavirdine	none	{'e1': {'word': 'HIV protease inhibitors', 'word_index': [(12, 13), (17, 17)], 'id': 'DDI-DrugBank.d675.s2.e4'}, 'e2': {'word': 'delavirdine', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d675.s2.e9'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	HIV protease inhibitors	azole antifungals	none	{'e1': {'word': 'HIV protease inhibitors', 'word_index': [(12, 13), (17, 17)], 'id': 'DDI-DrugBank.d675.s2.e4'}, 'e2': {'word': 'azole antifungals', 'word_index': [(23, 24)], 'id': 'DDI-DrugBank.d675.s2.e10'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	HIV protease inhibitors	ketoconazole	none	{'e1': {'word': 'HIV protease inhibitors', 'word_index': [(12, 13), (17, 17)], 'id': 'DDI-DrugBank.d675.s2.e4'}, 'e2': {'word': 'ketoconazole', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d675.s2.e11'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	HIV protease inhibitors	itraconazole	none	{'e1': {'word': 'HIV protease inhibitors', 'word_index': [(12, 13), (17, 17)], 'id': 'DDI-DrugBank.d675.s2.e4'}, 'e2': {'word': 'itraconazole', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d675.s2.e12'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	HIV protease inhibitors	voriconazole	none	{'e1': {'word': 'HIV protease inhibitors', 'word_index': [(12, 13), (17, 17)], 'id': 'DDI-DrugBank.d675.s2.e4'}, 'e2': {'word': 'voriconazole', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d675.s2.e13'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	reverse transcriptase inhibitors	ritonavir	none	{'e1': {'word': 'reverse transcriptase inhibitors', 'word_index': [(14, 16)], 'id': 'DDI-DrugBank.d675.s2.e5'}, 'e2': {'word': 'ritonavir', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d675.s2.e6'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	reverse transcriptase inhibitors	indinavir	none	{'e1': {'word': 'reverse transcriptase inhibitors', 'word_index': [(14, 16)], 'id': 'DDI-DrugBank.d675.s2.e5'}, 'e2': {'word': 'indinavir', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d675.s2.e7'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	reverse transcriptase inhibitors	nelfinavir	none	{'e1': {'word': 'reverse transcriptase inhibitors', 'word_index': [(14, 16)], 'id': 'DDI-DrugBank.d675.s2.e5'}, 'e2': {'word': 'nelfinavir', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d675.s2.e8'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	reverse transcriptase inhibitors	delavirdine	none	{'e1': {'word': 'reverse transcriptase inhibitors', 'word_index': [(14, 16)], 'id': 'DDI-DrugBank.d675.s2.e5'}, 'e2': {'word': 'delavirdine', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d675.s2.e9'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	reverse transcriptase inhibitors	azole antifungals	none	{'e1': {'word': 'reverse transcriptase inhibitors', 'word_index': [(14, 16)], 'id': 'DDI-DrugBank.d675.s2.e5'}, 'e2': {'word': 'azole antifungals', 'word_index': [(23, 24)], 'id': 'DDI-DrugBank.d675.s2.e10'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	reverse transcriptase inhibitors	ketoconazole	none	{'e1': {'word': 'reverse transcriptase inhibitors', 'word_index': [(14, 16)], 'id': 'DDI-DrugBank.d675.s2.e5'}, 'e2': {'word': 'ketoconazole', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d675.s2.e11'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	reverse transcriptase inhibitors	itraconazole	none	{'e1': {'word': 'reverse transcriptase inhibitors', 'word_index': [(14, 16)], 'id': 'DDI-DrugBank.d675.s2.e5'}, 'e2': {'word': 'itraconazole', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d675.s2.e12'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	reverse transcriptase inhibitors	voriconazole	none	{'e1': {'word': 'reverse transcriptase inhibitors', 'word_index': [(14, 16)], 'id': 'DDI-DrugBank.d675.s2.e5'}, 'e2': {'word': 'voriconazole', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d675.s2.e13'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	ritonavir	indinavir	none	{'e1': {'word': 'ritonavir', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d675.s2.e6'}, 'e2': {'word': 'indinavir', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d675.s2.e7'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	ritonavir	nelfinavir	none	{'e1': {'word': 'ritonavir', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d675.s2.e6'}, 'e2': {'word': 'nelfinavir', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d675.s2.e8'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	ritonavir	delavirdine	none	{'e1': {'word': 'ritonavir', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d675.s2.e6'}, 'e2': {'word': 'delavirdine', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d675.s2.e9'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	ritonavir	azole antifungals	none	{'e1': {'word': 'ritonavir', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d675.s2.e6'}, 'e2': {'word': 'azole antifungals', 'word_index': [(23, 24)], 'id': 'DDI-DrugBank.d675.s2.e10'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	ritonavir	ketoconazole	none	{'e1': {'word': 'ritonavir', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d675.s2.e6'}, 'e2': {'word': 'ketoconazole', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d675.s2.e11'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	ritonavir	itraconazole	none	{'e1': {'word': 'ritonavir', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d675.s2.e6'}, 'e2': {'word': 'itraconazole', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d675.s2.e12'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	ritonavir	voriconazole	none	{'e1': {'word': 'ritonavir', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d675.s2.e6'}, 'e2': {'word': 'voriconazole', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d675.s2.e13'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	indinavir	nelfinavir	none	{'e1': {'word': 'indinavir', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d675.s2.e7'}, 'e2': {'word': 'nelfinavir', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d675.s2.e8'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	indinavir	delavirdine	none	{'e1': {'word': 'indinavir', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d675.s2.e7'}, 'e2': {'word': 'delavirdine', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d675.s2.e9'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	indinavir	azole antifungals	none	{'e1': {'word': 'indinavir', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d675.s2.e7'}, 'e2': {'word': 'azole antifungals', 'word_index': [(23, 24)], 'id': 'DDI-DrugBank.d675.s2.e10'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	indinavir	ketoconazole	none	{'e1': {'word': 'indinavir', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d675.s2.e7'}, 'e2': {'word': 'ketoconazole', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d675.s2.e11'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	indinavir	itraconazole	none	{'e1': {'word': 'indinavir', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d675.s2.e7'}, 'e2': {'word': 'itraconazole', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d675.s2.e12'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	indinavir	voriconazole	none	{'e1': {'word': 'indinavir', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d675.s2.e7'}, 'e2': {'word': 'voriconazole', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d675.s2.e13'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	nelfinavir	delavirdine	none	{'e1': {'word': 'nelfinavir', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d675.s2.e8'}, 'e2': {'word': 'delavirdine', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d675.s2.e9'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	nelfinavir	azole antifungals	none	{'e1': {'word': 'nelfinavir', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d675.s2.e8'}, 'e2': {'word': 'azole antifungals', 'word_index': [(23, 24)], 'id': 'DDI-DrugBank.d675.s2.e10'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	nelfinavir	ketoconazole	none	{'e1': {'word': 'nelfinavir', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d675.s2.e8'}, 'e2': {'word': 'ketoconazole', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d675.s2.e11'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	nelfinavir	itraconazole	none	{'e1': {'word': 'nelfinavir', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d675.s2.e8'}, 'e2': {'word': 'itraconazole', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d675.s2.e12'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	nelfinavir	voriconazole	none	{'e1': {'word': 'nelfinavir', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d675.s2.e8'}, 'e2': {'word': 'voriconazole', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d675.s2.e13'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	delavirdine	azole antifungals	none	{'e1': {'word': 'delavirdine', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d675.s2.e9'}, 'e2': {'word': 'azole antifungals', 'word_index': [(23, 24)], 'id': 'DDI-DrugBank.d675.s2.e10'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	delavirdine	ketoconazole	none	{'e1': {'word': 'delavirdine', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d675.s2.e9'}, 'e2': {'word': 'ketoconazole', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d675.s2.e11'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	delavirdine	itraconazole	none	{'e1': {'word': 'delavirdine', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d675.s2.e9'}, 'e2': {'word': 'itraconazole', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d675.s2.e12'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	delavirdine	voriconazole	none	{'e1': {'word': 'delavirdine', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d675.s2.e9'}, 'e2': {'word': 'voriconazole', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d675.s2.e13'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	azole antifungals	ketoconazole	none	{'e1': {'word': 'azole antifungals', 'word_index': [(23, 24)], 'id': 'DDI-DrugBank.d675.s2.e10'}, 'e2': {'word': 'ketoconazole', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d675.s2.e11'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	azole antifungals	itraconazole	none	{'e1': {'word': 'azole antifungals', 'word_index': [(23, 24)], 'id': 'DDI-DrugBank.d675.s2.e10'}, 'e2': {'word': 'itraconazole', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d675.s2.e12'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	azole antifungals	voriconazole	none	{'e1': {'word': 'azole antifungals', 'word_index': [(23, 24)], 'id': 'DDI-DrugBank.d675.s2.e10'}, 'e2': {'word': 'voriconazole', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d675.s2.e13'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	ketoconazole	itraconazole	none	{'e1': {'word': 'ketoconazole', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d675.s2.e11'}, 'e2': {'word': 'itraconazole', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d675.s2.e12'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	ketoconazole	voriconazole	none	{'e1': {'word': 'ketoconazole', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d675.s2.e11'}, 'e2': {'word': 'voriconazole', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d675.s2.e13'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). 	itraconazole	voriconazole	none	{'e1': {'word': 'itraconazole', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d675.s2.e12'}, 'e2': {'word': 'voriconazole', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d675.s2.e13'}, 'sentence_id': 'DDI-DrugBank.d675.s2'}	Examples potent CYP 3A4 inhibitors include macrolide antibiotics e.g. erythromycin troleandomycin clarithromycin HIV protease reverse transcriptase inhibitors inhibitors e.g. ritonavir indinavir nelfinavir delavirdine azole antifungals e.g. ketoconazole itraconazole voriconazole
Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. 	saquinavir	nefazodone	none	{'e1': {'word': 'saquinavir', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d675.s4.e0'}, 'e2': {'word': 'nefazodone', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d675.s4.e1'}, 'sentence_id': 'DDI-DrugBank.d675.s4'}	Less potent inhibitors include saquinavir nefazodone fluconazole grapefruit juice fluoxetine fluvoxamine zileuton clotrimazole
Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. 	saquinavir	fluconazole	none	{'e1': {'word': 'saquinavir', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d675.s4.e0'}, 'e2': {'word': 'fluconazole', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d675.s4.e2'}, 'sentence_id': 'DDI-DrugBank.d675.s4'}	Less potent inhibitors include saquinavir nefazodone fluconazole grapefruit juice fluoxetine fluvoxamine zileuton clotrimazole
Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. 	saquinavir	fluoxetine	none	{'e1': {'word': 'saquinavir', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d675.s4.e0'}, 'e2': {'word': 'fluoxetine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d675.s4.e3'}, 'sentence_id': 'DDI-DrugBank.d675.s4'}	Less potent inhibitors include saquinavir nefazodone fluconazole grapefruit juice fluoxetine fluvoxamine zileuton clotrimazole
Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. 	saquinavir	fluvoxamine	none	{'e1': {'word': 'saquinavir', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d675.s4.e0'}, 'e2': {'word': 'fluvoxamine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d675.s4.e4'}, 'sentence_id': 'DDI-DrugBank.d675.s4'}	Less potent inhibitors include saquinavir nefazodone fluconazole grapefruit juice fluoxetine fluvoxamine zileuton clotrimazole
Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. 	saquinavir	zileuton	none	{'e1': {'word': 'saquinavir', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d675.s4.e0'}, 'e2': {'word': 'zileuton', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d675.s4.e5'}, 'sentence_id': 'DDI-DrugBank.d675.s4'}	Less potent inhibitors include saquinavir nefazodone fluconazole grapefruit juice fluoxetine fluvoxamine zileuton clotrimazole
Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. 	saquinavir	clotrimazole	none	{'e1': {'word': 'saquinavir', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d675.s4.e0'}, 'e2': {'word': 'clotrimazole', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d675.s4.e6'}, 'sentence_id': 'DDI-DrugBank.d675.s4'}	Less potent inhibitors include saquinavir nefazodone fluconazole grapefruit juice fluoxetine fluvoxamine zileuton clotrimazole
Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. 	nefazodone	fluconazole	none	{'e1': {'word': 'nefazodone', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d675.s4.e1'}, 'e2': {'word': 'fluconazole', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d675.s4.e2'}, 'sentence_id': 'DDI-DrugBank.d675.s4'}	Less potent inhibitors include saquinavir nefazodone fluconazole grapefruit juice fluoxetine fluvoxamine zileuton clotrimazole
Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. 	nefazodone	fluoxetine	none	{'e1': {'word': 'nefazodone', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d675.s4.e1'}, 'e2': {'word': 'fluoxetine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d675.s4.e3'}, 'sentence_id': 'DDI-DrugBank.d675.s4'}	Less potent inhibitors include saquinavir nefazodone fluconazole grapefruit juice fluoxetine fluvoxamine zileuton clotrimazole
Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. 	nefazodone	fluvoxamine	none	{'e1': {'word': 'nefazodone', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d675.s4.e1'}, 'e2': {'word': 'fluvoxamine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d675.s4.e4'}, 'sentence_id': 'DDI-DrugBank.d675.s4'}	Less potent inhibitors include saquinavir nefazodone fluconazole grapefruit juice fluoxetine fluvoxamine zileuton clotrimazole
Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. 	nefazodone	zileuton	none	{'e1': {'word': 'nefazodone', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d675.s4.e1'}, 'e2': {'word': 'zileuton', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d675.s4.e5'}, 'sentence_id': 'DDI-DrugBank.d675.s4'}	Less potent inhibitors include saquinavir nefazodone fluconazole grapefruit juice fluoxetine fluvoxamine zileuton clotrimazole
Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. 	nefazodone	clotrimazole	none	{'e1': {'word': 'nefazodone', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d675.s4.e1'}, 'e2': {'word': 'clotrimazole', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d675.s4.e6'}, 'sentence_id': 'DDI-DrugBank.d675.s4'}	Less potent inhibitors include saquinavir nefazodone fluconazole grapefruit juice fluoxetine fluvoxamine zileuton clotrimazole
Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. 	fluconazole	fluoxetine	none	{'e1': {'word': 'fluconazole', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d675.s4.e2'}, 'e2': {'word': 'fluoxetine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d675.s4.e3'}, 'sentence_id': 'DDI-DrugBank.d675.s4'}	Less potent inhibitors include saquinavir nefazodone fluconazole grapefruit juice fluoxetine fluvoxamine zileuton clotrimazole
Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. 	fluconazole	fluvoxamine	none	{'e1': {'word': 'fluconazole', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d675.s4.e2'}, 'e2': {'word': 'fluvoxamine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d675.s4.e4'}, 'sentence_id': 'DDI-DrugBank.d675.s4'}	Less potent inhibitors include saquinavir nefazodone fluconazole grapefruit juice fluoxetine fluvoxamine zileuton clotrimazole
Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. 	fluconazole	zileuton	none	{'e1': {'word': 'fluconazole', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d675.s4.e2'}, 'e2': {'word': 'zileuton', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d675.s4.e5'}, 'sentence_id': 'DDI-DrugBank.d675.s4'}	Less potent inhibitors include saquinavir nefazodone fluconazole grapefruit juice fluoxetine fluvoxamine zileuton clotrimazole
Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. 	fluconazole	clotrimazole	none	{'e1': {'word': 'fluconazole', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d675.s4.e2'}, 'e2': {'word': 'clotrimazole', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d675.s4.e6'}, 'sentence_id': 'DDI-DrugBank.d675.s4'}	Less potent inhibitors include saquinavir nefazodone fluconazole grapefruit juice fluoxetine fluvoxamine zileuton clotrimazole
Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. 	fluoxetine	fluvoxamine	none	{'e1': {'word': 'fluoxetine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d675.s4.e3'}, 'e2': {'word': 'fluvoxamine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d675.s4.e4'}, 'sentence_id': 'DDI-DrugBank.d675.s4'}	Less potent inhibitors include saquinavir nefazodone fluconazole grapefruit juice fluoxetine fluvoxamine zileuton clotrimazole
Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. 	fluoxetine	zileuton	none	{'e1': {'word': 'fluoxetine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d675.s4.e3'}, 'e2': {'word': 'zileuton', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d675.s4.e5'}, 'sentence_id': 'DDI-DrugBank.d675.s4'}	Less potent inhibitors include saquinavir nefazodone fluconazole grapefruit juice fluoxetine fluvoxamine zileuton clotrimazole
Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. 	fluoxetine	clotrimazole	none	{'e1': {'word': 'fluoxetine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d675.s4.e3'}, 'e2': {'word': 'clotrimazole', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d675.s4.e6'}, 'sentence_id': 'DDI-DrugBank.d675.s4'}	Less potent inhibitors include saquinavir nefazodone fluconazole grapefruit juice fluoxetine fluvoxamine zileuton clotrimazole
Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. 	fluvoxamine	zileuton	none	{'e1': {'word': 'fluvoxamine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d675.s4.e4'}, 'e2': {'word': 'zileuton', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d675.s4.e5'}, 'sentence_id': 'DDI-DrugBank.d675.s4'}	Less potent inhibitors include saquinavir nefazodone fluconazole grapefruit juice fluoxetine fluvoxamine zileuton clotrimazole
Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. 	fluvoxamine	clotrimazole	none	{'e1': {'word': 'fluvoxamine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d675.s4.e4'}, 'e2': {'word': 'clotrimazole', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d675.s4.e6'}, 'sentence_id': 'DDI-DrugBank.d675.s4'}	Less potent inhibitors include saquinavir nefazodone fluconazole grapefruit juice fluoxetine fluvoxamine zileuton clotrimazole
Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. 	zileuton	clotrimazole	none	{'e1': {'word': 'zileuton', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d675.s4.e5'}, 'e2': {'word': 'clotrimazole', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d675.s4.e6'}, 'sentence_id': 'DDI-DrugBank.d675.s4'}	Less potent inhibitors include saquinavir nefazodone fluconazole grapefruit juice fluoxetine fluvoxamine zileuton clotrimazole
Caution should be exercised when Methergine    (methylergonovine maleate) is used concurrently with other vasoconstrictors or ergot alkaloids.	Methergine	methylergonovine maleate	none	{'e1': {'word': 'Methergine', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d675.s7.e0'}, 'e2': {'word': 'methylergonovine maleate', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d675.s7.e1'}, 'sentence_id': 'DDI-DrugBank.d675.s7'}	Caution exercised Methergine methylergonovine maleate used concurrently vasoconstrictors ergot alkaloids
Caution should be exercised when Methergine    (methylergonovine maleate) is used concurrently with other vasoconstrictors or ergot alkaloids.	Methergine	vasoconstrictors	advise	{'e1': {'word': 'Methergine', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d675.s7.e0'}, 'e2': {'word': 'vasoconstrictors', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d675.s7.e2'}, 'sentence_id': 'DDI-DrugBank.d675.s7'}	Caution exercised Methergine methylergonovine maleate used concurrently vasoconstrictors ergot alkaloids
Caution should be exercised when Methergine    (methylergonovine maleate) is used concurrently with other vasoconstrictors or ergot alkaloids.	Methergine	ergot alkaloids	advise	{'e1': {'word': 'Methergine', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d675.s7.e0'}, 'e2': {'word': 'ergot alkaloids', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d675.s7.e3'}, 'sentence_id': 'DDI-DrugBank.d675.s7'}	Caution exercised Methergine methylergonovine maleate used concurrently vasoconstrictors ergot alkaloids
Caution should be exercised when Methergine    (methylergonovine maleate) is used concurrently with other vasoconstrictors or ergot alkaloids.	methylergonovine maleate	vasoconstrictors	advise	{'e1': {'word': 'methylergonovine maleate', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d675.s7.e1'}, 'e2': {'word': 'vasoconstrictors', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d675.s7.e2'}, 'sentence_id': 'DDI-DrugBank.d675.s7'}	Caution exercised Methergine methylergonovine maleate used concurrently vasoconstrictors ergot alkaloids
Caution should be exercised when Methergine    (methylergonovine maleate) is used concurrently with other vasoconstrictors or ergot alkaloids.	methylergonovine maleate	ergot alkaloids	none	{'e1': {'word': 'methylergonovine maleate', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d675.s7.e1'}, 'e2': {'word': 'ergot alkaloids', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d675.s7.e3'}, 'sentence_id': 'DDI-DrugBank.d675.s7'}	Caution exercised Methergine methylergonovine maleate used concurrently vasoconstrictors ergot alkaloids
Caution should be exercised when Methergine    (methylergonovine maleate) is used concurrently with other vasoconstrictors or ergot alkaloids.	vasoconstrictors	ergot alkaloids	none	{'e1': {'word': 'vasoconstrictors', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d675.s7.e2'}, 'e2': {'word': 'ergot alkaloids', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d675.s7.e3'}, 'sentence_id': 'DDI-DrugBank.d675.s7'}	Caution exercised Methergine methylergonovine maleate used concurrently vasoconstrictors ergot alkaloids
Diuretics: Excessive reductions in blood pressure may occur in patients on diuretic therapy when ACE inhibitors are started. 	Diuretics	ACE inhibitors	none	{'e1': {'word': 'Diuretics', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d640.s0.e0'}, 'e2': {'word': 'ACE inhibitors', 'word_index': [(10, 11)], 'id': 'DDI-DrugBank.d640.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d640.s0'}	Diuretics Excessive reductions blood pressure may occur patients diuretic therapy ACE inhibitors started
The possibility of hypotensive effects with UNIVASC    can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with UNIVASC   . If this is not possible, the starting dose of moexpril should be reduced.. 	UNIVASC	UNIVASC	none	{'e1': {'word': 'UNIVASC', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d640.s1.e0'}, 'e2': {'word': 'UNIVASC', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d640.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d640.s1'}	possibility hypotensive effects UNIVASC minimized discontinuing diuretic therapy several days cautiously increasing salt intake initiation treatment UNIVASC possible starting dose moexpril reduced
The possibility of hypotensive effects with UNIVASC    can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with UNIVASC   . If this is not possible, the starting dose of moexpril should be reduced.. 	UNIVASC	moexpril	none	{'e1': {'word': 'UNIVASC', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d640.s1.e0'}, 'e2': {'word': 'moexpril', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d640.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d640.s1'}	possibility hypotensive effects UNIVASC minimized discontinuing diuretic therapy several days cautiously increasing salt intake initiation treatment UNIVASC possible starting dose moexpril reduced
The possibility of hypotensive effects with UNIVASC    can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with UNIVASC   . If this is not possible, the starting dose of moexpril should be reduced.. 	UNIVASC	moexpril	none	{'e1': {'word': 'UNIVASC', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d640.s1.e1'}, 'e2': {'word': 'moexpril', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d640.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d640.s1'}	possibility hypotensive effects UNIVASC minimized discontinuing diuretic therapy several days cautiously increasing salt intake initiation treatment UNIVASC possible starting dose moexpril reduced
Potassium Supplements and Potassium-Sparing Diuretics: UNIVASC    can increase serum potassium because it decreases aldosterone secretion. 	Potassium	Potassium-Sparing Diuretics	none	{'e1': {'word': 'Potassium', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d640.s2.e0'}, 'e2': {'word': 'Potassium-Sparing Diuretics', 'word_index': [(2, 4)], 'id': 'DDI-DrugBank.d640.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d640.s2'}	Potassium Supplements Potassium Sparing Diuretics UNIVASC increase serum potassium decreases aldosterone secretion
Potassium Supplements and Potassium-Sparing Diuretics: UNIVASC    can increase serum potassium because it decreases aldosterone secretion. 	Potassium	UNIVASC	none	{'e1': {'word': 'Potassium', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d640.s2.e0'}, 'e2': {'word': 'UNIVASC', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d640.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d640.s2'}	Potassium Supplements Potassium Sparing Diuretics UNIVASC increase serum potassium decreases aldosterone secretion
Potassium Supplements and Potassium-Sparing Diuretics: UNIVASC    can increase serum potassium because it decreases aldosterone secretion. 	Potassium-Sparing Diuretics	UNIVASC	none	{'e1': {'word': 'Potassium-Sparing Diuretics', 'word_index': [(2, 4)], 'id': 'DDI-DrugBank.d640.s2.e1'}, 'e2': {'word': 'UNIVASC', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d640.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d640.s2'}	Potassium Supplements Potassium Sparing Diuretics UNIVASC increase serum potassium decreases aldosterone secretion
Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. 	potassium-sparing diuretics	spironolactone	none	{'e1': {'word': 'potassium-sparing diuretics', 'word_index': [(1, 3)], 'id': 'DDI-DrugBank.d640.s3.e0'}, 'e2': {'word': 'spironolactone', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d640.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d640.s3'}	Use potassium sparing diuretics spironolactone triamterene amiloride potassium supplements concomitantly ACE inhibitors increase risk hyperkalemia
Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. 	potassium-sparing diuretics	triamterene	none	{'e1': {'word': 'potassium-sparing diuretics', 'word_index': [(1, 3)], 'id': 'DDI-DrugBank.d640.s3.e0'}, 'e2': {'word': 'triamterene', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d640.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d640.s3'}	Use potassium sparing diuretics spironolactone triamterene amiloride potassium supplements concomitantly ACE inhibitors increase risk hyperkalemia
Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. 	potassium-sparing diuretics	amiloride	none	{'e1': {'word': 'potassium-sparing diuretics', 'word_index': [(1, 3)], 'id': 'DDI-DrugBank.d640.s3.e0'}, 'e2': {'word': 'amiloride', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d640.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d640.s3'}	Use potassium sparing diuretics spironolactone triamterene amiloride potassium supplements concomitantly ACE inhibitors increase risk hyperkalemia
Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. 	potassium-sparing diuretics	potassium	none	{'e1': {'word': 'potassium-sparing diuretics', 'word_index': [(1, 3)], 'id': 'DDI-DrugBank.d640.s3.e0'}, 'e2': {'word': 'potassium', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d640.s3.e4'}, 'sentence_id': 'DDI-DrugBank.d640.s3'}	Use potassium sparing diuretics spironolactone triamterene amiloride potassium supplements concomitantly ACE inhibitors increase risk hyperkalemia
Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. 	potassium-sparing diuretics	ACE inhibitors	effect	{'e1': {'word': 'potassium-sparing diuretics', 'word_index': [(1, 3)], 'id': 'DDI-DrugBank.d640.s3.e0'}, 'e2': {'word': 'ACE inhibitors', 'word_index': [(10, 11)], 'id': 'DDI-DrugBank.d640.s3.e5'}, 'sentence_id': 'DDI-DrugBank.d640.s3'}	Use potassium sparing diuretics spironolactone triamterene amiloride potassium supplements concomitantly ACE inhibitors increase risk hyperkalemia
Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. 	spironolactone	triamterene	none	{'e1': {'word': 'spironolactone', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d640.s3.e1'}, 'e2': {'word': 'triamterene', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d640.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d640.s3'}	Use potassium sparing diuretics spironolactone triamterene amiloride potassium supplements concomitantly ACE inhibitors increase risk hyperkalemia
Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. 	spironolactone	amiloride	none	{'e1': {'word': 'spironolactone', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d640.s3.e1'}, 'e2': {'word': 'amiloride', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d640.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d640.s3'}	Use potassium sparing diuretics spironolactone triamterene amiloride potassium supplements concomitantly ACE inhibitors increase risk hyperkalemia
Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. 	spironolactone	potassium	none	{'e1': {'word': 'spironolactone', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d640.s3.e1'}, 'e2': {'word': 'potassium', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d640.s3.e4'}, 'sentence_id': 'DDI-DrugBank.d640.s3'}	Use potassium sparing diuretics spironolactone triamterene amiloride potassium supplements concomitantly ACE inhibitors increase risk hyperkalemia
Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. 	spironolactone	ACE inhibitors	effect	{'e1': {'word': 'spironolactone', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d640.s3.e1'}, 'e2': {'word': 'ACE inhibitors', 'word_index': [(10, 11)], 'id': 'DDI-DrugBank.d640.s3.e5'}, 'sentence_id': 'DDI-DrugBank.d640.s3'}	Use potassium sparing diuretics spironolactone triamterene amiloride potassium supplements concomitantly ACE inhibitors increase risk hyperkalemia
Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. 	triamterene	amiloride	none	{'e1': {'word': 'triamterene', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d640.s3.e2'}, 'e2': {'word': 'amiloride', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d640.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d640.s3'}	Use potassium sparing diuretics spironolactone triamterene amiloride potassium supplements concomitantly ACE inhibitors increase risk hyperkalemia
Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. 	triamterene	potassium	none	{'e1': {'word': 'triamterene', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d640.s3.e2'}, 'e2': {'word': 'potassium', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d640.s3.e4'}, 'sentence_id': 'DDI-DrugBank.d640.s3'}	Use potassium sparing diuretics spironolactone triamterene amiloride potassium supplements concomitantly ACE inhibitors increase risk hyperkalemia
Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. 	triamterene	ACE inhibitors	effect	{'e1': {'word': 'triamterene', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d640.s3.e2'}, 'e2': {'word': 'ACE inhibitors', 'word_index': [(10, 11)], 'id': 'DDI-DrugBank.d640.s3.e5'}, 'sentence_id': 'DDI-DrugBank.d640.s3'}	Use potassium sparing diuretics spironolactone triamterene amiloride potassium supplements concomitantly ACE inhibitors increase risk hyperkalemia
Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. 	amiloride	potassium	none	{'e1': {'word': 'amiloride', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d640.s3.e3'}, 'e2': {'word': 'potassium', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d640.s3.e4'}, 'sentence_id': 'DDI-DrugBank.d640.s3'}	Use potassium sparing diuretics spironolactone triamterene amiloride potassium supplements concomitantly ACE inhibitors increase risk hyperkalemia
Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. 	amiloride	ACE inhibitors	effect	{'e1': {'word': 'amiloride', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d640.s3.e3'}, 'e2': {'word': 'ACE inhibitors', 'word_index': [(10, 11)], 'id': 'DDI-DrugBank.d640.s3.e5'}, 'sentence_id': 'DDI-DrugBank.d640.s3'}	Use potassium sparing diuretics spironolactone triamterene amiloride potassium supplements concomitantly ACE inhibitors increase risk hyperkalemia
Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. 	potassium	ACE inhibitors	effect	{'e1': {'word': 'potassium', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d640.s3.e4'}, 'e2': {'word': 'ACE inhibitors', 'word_index': [(10, 11)], 'id': 'DDI-DrugBank.d640.s3.e5'}, 'sentence_id': 'DDI-DrugBank.d640.s3'}	Use potassium sparing diuretics spironolactone triamterene amiloride potassium supplements concomitantly ACE inhibitors increase risk hyperkalemia
Oral Anticoagulants: Interaction studies with warfarin failed to identify any clinically important effect on the serum concentrations of the anticoagulant or on its anticoagulant effect. 	Anticoagulants	warfarin	none	{'e1': {'word': 'Anticoagulants', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d640.s5.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d640.s5.e1'}, 'sentence_id': 'DDI-DrugBank.d640.s5'}	Oral Anticoagulants Interaction studies warfarin failed identify clinically important effect serum concentrations anticoagulant anticoagulant effect
Oral Anticoagulants: Interaction studies with warfarin failed to identify any clinically important effect on the serum concentrations of the anticoagulant or on its anticoagulant effect. 	Anticoagulants	anticoagulant	none	{'e1': {'word': 'Anticoagulants', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d640.s5.e0'}, 'e2': {'word': 'anticoagulant', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d640.s5.e2'}, 'sentence_id': 'DDI-DrugBank.d640.s5'}	Oral Anticoagulants Interaction studies warfarin failed identify clinically important effect serum concentrations anticoagulant anticoagulant effect
Oral Anticoagulants: Interaction studies with warfarin failed to identify any clinically important effect on the serum concentrations of the anticoagulant or on its anticoagulant effect. 	warfarin	anticoagulant	none	{'e1': {'word': 'warfarin', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d640.s5.e1'}, 'e2': {'word': 'anticoagulant', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d640.s5.e2'}, 'sentence_id': 'DDI-DrugBank.d640.s5'}	Oral Anticoagulants Interaction studies warfarin failed identify clinically important effect serum concentrations anticoagulant anticoagulant effect
Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. 	Lithium	lithium	none	{'e1': {'word': 'Lithium', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d640.s6.e0'}, 'e2': {'word': 'lithium', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d640.s6.e1'}, 'sentence_id': 'DDI-DrugBank.d640.s6'}	Lithium Increased serum lithium levels symptoms lithium toxicity reported patients receiving ACE inhibitors therapy lithium
Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. 	Lithium	lithium	none	{'e1': {'word': 'Lithium', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d640.s6.e0'}, 'e2': {'word': 'lithium', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d640.s6.e2'}, 'sentence_id': 'DDI-DrugBank.d640.s6'}	Lithium Increased serum lithium levels symptoms lithium toxicity reported patients receiving ACE inhibitors therapy lithium
Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. 	Lithium	ACE inhibitors	none	{'e1': {'word': 'Lithium', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d640.s6.e0'}, 'e2': {'word': 'ACE inhibitors', 'word_index': [(11, 12)], 'id': 'DDI-DrugBank.d640.s6.e3'}, 'sentence_id': 'DDI-DrugBank.d640.s6'}	Lithium Increased serum lithium levels symptoms lithium toxicity reported patients receiving ACE inhibitors therapy lithium
Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. 	Lithium	lithium	none	{'e1': {'word': 'Lithium', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d640.s6.e0'}, 'e2': {'word': 'lithium', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d640.s6.e4'}, 'sentence_id': 'DDI-DrugBank.d640.s6'}	Lithium Increased serum lithium levels symptoms lithium toxicity reported patients receiving ACE inhibitors therapy lithium
Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. 	lithium	lithium	none	{'e1': {'word': 'lithium', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d640.s6.e1'}, 'e2': {'word': 'lithium', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d640.s6.e2'}, 'sentence_id': 'DDI-DrugBank.d640.s6'}	Lithium Increased serum lithium levels symptoms lithium toxicity reported patients receiving ACE inhibitors therapy lithium
Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. 	lithium	ACE inhibitors	none	{'e1': {'word': 'lithium', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d640.s6.e1'}, 'e2': {'word': 'ACE inhibitors', 'word_index': [(11, 12)], 'id': 'DDI-DrugBank.d640.s6.e3'}, 'sentence_id': 'DDI-DrugBank.d640.s6'}	Lithium Increased serum lithium levels symptoms lithium toxicity reported patients receiving ACE inhibitors therapy lithium
Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. 	lithium	lithium	none	{'e1': {'word': 'lithium', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d640.s6.e1'}, 'e2': {'word': 'lithium', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d640.s6.e4'}, 'sentence_id': 'DDI-DrugBank.d640.s6'}	Lithium Increased serum lithium levels symptoms lithium toxicity reported patients receiving ACE inhibitors therapy lithium
Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. 	lithium	ACE inhibitors	none	{'e1': {'word': 'lithium', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d640.s6.e2'}, 'e2': {'word': 'ACE inhibitors', 'word_index': [(11, 12)], 'id': 'DDI-DrugBank.d640.s6.e3'}, 'sentence_id': 'DDI-DrugBank.d640.s6'}	Lithium Increased serum lithium levels symptoms lithium toxicity reported patients receiving ACE inhibitors therapy lithium
Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. 	lithium	lithium	none	{'e1': {'word': 'lithium', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d640.s6.e2'}, 'e2': {'word': 'lithium', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d640.s6.e4'}, 'sentence_id': 'DDI-DrugBank.d640.s6'}	Lithium Increased serum lithium levels symptoms lithium toxicity reported patients receiving ACE inhibitors therapy lithium
Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. 	ACE inhibitors	lithium	effect	{'e1': {'word': 'ACE inhibitors', 'word_index': [(11, 12)], 'id': 'DDI-DrugBank.d640.s6.e3'}, 'e2': {'word': 'lithium', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d640.s6.e4'}, 'sentence_id': 'DDI-DrugBank.d640.s6'}	Lithium Increased serum lithium levels symptoms lithium toxicity reported patients receiving ACE inhibitors therapy lithium
If a diuretic is also used, the risk of lithium toxicity may be increased. 	diuretic	lithium	effect	{'e1': {'word': 'diuretic', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d640.s8.e0'}, 'e2': {'word': 'lithium', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d640.s8.e1'}, 'sentence_id': 'DDI-DrugBank.d640.s8'}	diuretic also used risk lithium toxicity may increased
Other Agents: No clinically important pharmacokinetic interactions occurred when UNIVASC    was administered concomitantly with hydrochlorothiazide, digoxin, or cimetidine. 	UNIVASC	hydrochlorothiazide	none	{'e1': {'word': 'UNIVASC', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d640.s9.e0'}, 'e2': {'word': 'hydrochlorothiazide', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d640.s9.e1'}, 'sentence_id': 'DDI-DrugBank.d640.s9'}	Agents clinically important pharmacokinetic interactions occurred UNIVASC administered concomitantly hydrochlorothiazide digoxin cimetidine
Other Agents: No clinically important pharmacokinetic interactions occurred when UNIVASC    was administered concomitantly with hydrochlorothiazide, digoxin, or cimetidine. 	UNIVASC	digoxin	none	{'e1': {'word': 'UNIVASC', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d640.s9.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d640.s9.e2'}, 'sentence_id': 'DDI-DrugBank.d640.s9'}	Agents clinically important pharmacokinetic interactions occurred UNIVASC administered concomitantly hydrochlorothiazide digoxin cimetidine
Other Agents: No clinically important pharmacokinetic interactions occurred when UNIVASC    was administered concomitantly with hydrochlorothiazide, digoxin, or cimetidine. 	UNIVASC	cimetidine	none	{'e1': {'word': 'UNIVASC', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d640.s9.e0'}, 'e2': {'word': 'cimetidine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d640.s9.e3'}, 'sentence_id': 'DDI-DrugBank.d640.s9'}	Agents clinically important pharmacokinetic interactions occurred UNIVASC administered concomitantly hydrochlorothiazide digoxin cimetidine
Other Agents: No clinically important pharmacokinetic interactions occurred when UNIVASC    was administered concomitantly with hydrochlorothiazide, digoxin, or cimetidine. 	hydrochlorothiazide	digoxin	none	{'e1': {'word': 'hydrochlorothiazide', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d640.s9.e1'}, 'e2': {'word': 'digoxin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d640.s9.e2'}, 'sentence_id': 'DDI-DrugBank.d640.s9'}	Agents clinically important pharmacokinetic interactions occurred UNIVASC administered concomitantly hydrochlorothiazide digoxin cimetidine
Other Agents: No clinically important pharmacokinetic interactions occurred when UNIVASC    was administered concomitantly with hydrochlorothiazide, digoxin, or cimetidine. 	hydrochlorothiazide	cimetidine	none	{'e1': {'word': 'hydrochlorothiazide', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d640.s9.e1'}, 'e2': {'word': 'cimetidine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d640.s9.e3'}, 'sentence_id': 'DDI-DrugBank.d640.s9'}	Agents clinically important pharmacokinetic interactions occurred UNIVASC administered concomitantly hydrochlorothiazide digoxin cimetidine
Other Agents: No clinically important pharmacokinetic interactions occurred when UNIVASC    was administered concomitantly with hydrochlorothiazide, digoxin, or cimetidine. 	digoxin	cimetidine	none	{'e1': {'word': 'digoxin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d640.s9.e2'}, 'e2': {'word': 'cimetidine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d640.s9.e3'}, 'sentence_id': 'DDI-DrugBank.d640.s9'}	Agents clinically important pharmacokinetic interactions occurred UNIVASC administered concomitantly hydrochlorothiazide digoxin cimetidine
UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. 	UNIVASC	calcium-channel-blocking agents	none	{'e1': {'word': 'UNIVASC', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d640.s10.e0'}, 'e2': {'word': 'calcium-channel-blocking agents', 'word_index': [(5, 8)], 'id': 'DDI-DrugBank.d640.s10.e1'}, 'sentence_id': 'DDI-DrugBank.d640.s10'}	UNIVASC used clinical trials concomitantly calcium channel blocking agents diuretics H2 blockers digoxin oral hypoglycemic agents cholesterol lowering agents
UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. 	UNIVASC	diuretics	none	{'e1': {'word': 'UNIVASC', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d640.s10.e0'}, 'e2': {'word': 'diuretics', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d640.s10.e2'}, 'sentence_id': 'DDI-DrugBank.d640.s10'}	UNIVASC used clinical trials concomitantly calcium channel blocking agents diuretics H2 blockers digoxin oral hypoglycemic agents cholesterol lowering agents
UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. 	UNIVASC	H2 blockers	none	{'e1': {'word': 'UNIVASC', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d640.s10.e0'}, 'e2': {'word': 'H2 blockers', 'word_index': [(10, 11)], 'id': 'DDI-DrugBank.d640.s10.e3'}, 'sentence_id': 'DDI-DrugBank.d640.s10'}	UNIVASC used clinical trials concomitantly calcium channel blocking agents diuretics H2 blockers digoxin oral hypoglycemic agents cholesterol lowering agents
UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. 	UNIVASC	digoxin	none	{'e1': {'word': 'UNIVASC', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d640.s10.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d640.s10.e4'}, 'sentence_id': 'DDI-DrugBank.d640.s10'}	UNIVASC used clinical trials concomitantly calcium channel blocking agents diuretics H2 blockers digoxin oral hypoglycemic agents cholesterol lowering agents
UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. 	UNIVASC	hypoglycemic agents	none	{'e1': {'word': 'UNIVASC', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d640.s10.e0'}, 'e2': {'word': 'hypoglycemic agents', 'word_index': [(14, 15)], 'id': 'DDI-DrugBank.d640.s10.e5'}, 'sentence_id': 'DDI-DrugBank.d640.s10'}	UNIVASC used clinical trials concomitantly calcium channel blocking agents diuretics H2 blockers digoxin oral hypoglycemic agents cholesterol lowering agents
UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. 	calcium-channel-blocking agents	diuretics	none	{'e1': {'word': 'calcium-channel-blocking agents', 'word_index': [(5, 8)], 'id': 'DDI-DrugBank.d640.s10.e1'}, 'e2': {'word': 'diuretics', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d640.s10.e2'}, 'sentence_id': 'DDI-DrugBank.d640.s10'}	UNIVASC used clinical trials concomitantly calcium channel blocking agents diuretics H2 blockers digoxin oral hypoglycemic agents cholesterol lowering agents
UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. 	calcium-channel-blocking agents	H2 blockers	none	{'e1': {'word': 'calcium-channel-blocking agents', 'word_index': [(5, 8)], 'id': 'DDI-DrugBank.d640.s10.e1'}, 'e2': {'word': 'H2 blockers', 'word_index': [(10, 11)], 'id': 'DDI-DrugBank.d640.s10.e3'}, 'sentence_id': 'DDI-DrugBank.d640.s10'}	UNIVASC used clinical trials concomitantly calcium channel blocking agents diuretics H2 blockers digoxin oral hypoglycemic agents cholesterol lowering agents
UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. 	calcium-channel-blocking agents	digoxin	none	{'e1': {'word': 'calcium-channel-blocking agents', 'word_index': [(5, 8)], 'id': 'DDI-DrugBank.d640.s10.e1'}, 'e2': {'word': 'digoxin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d640.s10.e4'}, 'sentence_id': 'DDI-DrugBank.d640.s10'}	UNIVASC used clinical trials concomitantly calcium channel blocking agents diuretics H2 blockers digoxin oral hypoglycemic agents cholesterol lowering agents
UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. 	calcium-channel-blocking agents	hypoglycemic agents	none	{'e1': {'word': 'calcium-channel-blocking agents', 'word_index': [(5, 8)], 'id': 'DDI-DrugBank.d640.s10.e1'}, 'e2': {'word': 'hypoglycemic agents', 'word_index': [(14, 15)], 'id': 'DDI-DrugBank.d640.s10.e5'}, 'sentence_id': 'DDI-DrugBank.d640.s10'}	UNIVASC used clinical trials concomitantly calcium channel blocking agents diuretics H2 blockers digoxin oral hypoglycemic agents cholesterol lowering agents
UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. 	diuretics	H2 blockers	none	{'e1': {'word': 'diuretics', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d640.s10.e2'}, 'e2': {'word': 'H2 blockers', 'word_index': [(10, 11)], 'id': 'DDI-DrugBank.d640.s10.e3'}, 'sentence_id': 'DDI-DrugBank.d640.s10'}	UNIVASC used clinical trials concomitantly calcium channel blocking agents diuretics H2 blockers digoxin oral hypoglycemic agents cholesterol lowering agents
UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. 	diuretics	digoxin	none	{'e1': {'word': 'diuretics', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d640.s10.e2'}, 'e2': {'word': 'digoxin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d640.s10.e4'}, 'sentence_id': 'DDI-DrugBank.d640.s10'}	UNIVASC used clinical trials concomitantly calcium channel blocking agents diuretics H2 blockers digoxin oral hypoglycemic agents cholesterol lowering agents
UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. 	diuretics	hypoglycemic agents	none	{'e1': {'word': 'diuretics', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d640.s10.e2'}, 'e2': {'word': 'hypoglycemic agents', 'word_index': [(14, 15)], 'id': 'DDI-DrugBank.d640.s10.e5'}, 'sentence_id': 'DDI-DrugBank.d640.s10'}	UNIVASC used clinical trials concomitantly calcium channel blocking agents diuretics H2 blockers digoxin oral hypoglycemic agents cholesterol lowering agents
UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. 	H2 blockers	digoxin	none	{'e1': {'word': 'H2 blockers', 'word_index': [(10, 11)], 'id': 'DDI-DrugBank.d640.s10.e3'}, 'e2': {'word': 'digoxin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d640.s10.e4'}, 'sentence_id': 'DDI-DrugBank.d640.s10'}	UNIVASC used clinical trials concomitantly calcium channel blocking agents diuretics H2 blockers digoxin oral hypoglycemic agents cholesterol lowering agents
UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. 	H2 blockers	hypoglycemic agents	none	{'e1': {'word': 'H2 blockers', 'word_index': [(10, 11)], 'id': 'DDI-DrugBank.d640.s10.e3'}, 'e2': {'word': 'hypoglycemic agents', 'word_index': [(14, 15)], 'id': 'DDI-DrugBank.d640.s10.e5'}, 'sentence_id': 'DDI-DrugBank.d640.s10'}	UNIVASC used clinical trials concomitantly calcium channel blocking agents diuretics H2 blockers digoxin oral hypoglycemic agents cholesterol lowering agents
UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. 	digoxin	hypoglycemic agents	none	{'e1': {'word': 'digoxin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d640.s10.e4'}, 'e2': {'word': 'hypoglycemic agents', 'word_index': [(14, 15)], 'id': 'DDI-DrugBank.d640.s10.e5'}, 'sentence_id': 'DDI-DrugBank.d640.s10'}	UNIVASC used clinical trials concomitantly calcium channel blocking agents diuretics H2 blockers digoxin oral hypoglycemic agents cholesterol lowering agents
In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent. 	tolbutamide	sodium salicylate	none	{'e1': {'word': 'tolbutamide', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d575.s0.e0'}, 'e2': {'word': 'sodium salicylate', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d575.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d575.s0'}	study NUMBER different drugs tested therapeutically relevant concentrations tolbutamide sodium salicylate sulfamethizole displaced protein bound teniposide fresh human serum small significant extent
In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent. 	tolbutamide	sulfamethizole	none	{'e1': {'word': 'tolbutamide', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d575.s0.e0'}, 'e2': {'word': 'sulfamethizole', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d575.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d575.s0'}	study NUMBER different drugs tested therapeutically relevant concentrations tolbutamide sodium salicylate sulfamethizole displaced protein bound teniposide fresh human serum small significant extent
In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent. 	tolbutamide	teniposide	mechanism	{'e1': {'word': 'tolbutamide', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d575.s0.e0'}, 'e2': {'word': 'teniposide', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d575.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d575.s0'}	study NUMBER different drugs tested therapeutically relevant concentrations tolbutamide sodium salicylate sulfamethizole displaced protein bound teniposide fresh human serum small significant extent
In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent. 	sodium salicylate	sulfamethizole	none	{'e1': {'word': 'sodium salicylate', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d575.s0.e1'}, 'e2': {'word': 'sulfamethizole', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d575.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d575.s0'}	study NUMBER different drugs tested therapeutically relevant concentrations tolbutamide sodium salicylate sulfamethizole displaced protein bound teniposide fresh human serum small significant extent
In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent. 	sodium salicylate	teniposide	mechanism	{'e1': {'word': 'sodium salicylate', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d575.s0.e1'}, 'e2': {'word': 'teniposide', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d575.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d575.s0'}	study NUMBER different drugs tested therapeutically relevant concentrations tolbutamide sodium salicylate sulfamethizole displaced protein bound teniposide fresh human serum small significant extent
In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent. 	sulfamethizole	teniposide	mechanism	{'e1': {'word': 'sulfamethizole', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d575.s0.e2'}, 'e2': {'word': 'teniposide', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d575.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d575.s0'}	study NUMBER different drugs tested therapeutically relevant concentrations tolbutamide sodium salicylate sulfamethizole displaced protein bound teniposide fresh human serum small significant extent
Therefore, caution should be used in administering VUMON (teniposide injection) to patients receiving these other agents. 	VUMON	teniposide	none	{'e1': {'word': 'VUMON', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d575.s2.e0'}, 'e2': {'word': 'teniposide', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d575.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d575.s2'}	Therefore caution used administering VUMON teniposide injection patients receiving agents
There was no change in the plasma kinetics of teniposide when coadministered with methotrexate. 	teniposide	methotrexate	none	{'e1': {'word': 'teniposide', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d575.s3.e0'}, 'e2': {'word': 'methotrexate', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d575.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d575.s3'}	change plasma kinetics teniposide coadministered methotrexate
An increase in intracellular levels of methotrexate was observed in vitro in the presence of teniposide.	methotrexate	teniposide	mechanism	{'e1': {'word': 'methotrexate', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d575.s5.e0'}, 'e2': {'word': 'teniposide', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d575.s5.e1'}, 'sentence_id': 'DDI-DrugBank.d575.s5'}	increase intracellular levels methotrexate observed vitro presence teniposide
Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents. 	reserpine	beta-blocking agents	effect	{'e1': {'word': 'reserpine', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d706.s0.e0'}, 'e2': {'word': 'beta-blocking agents', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d706.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d706.s0'}	Catecholamine depleting drugs e.g. reserpine may additive effect given beta-blocking agents
When administered concomitantly with ProAmatine   , cardiac glycosides may enhance or precipitate bradycardia, A.V. 	ProAmatine	cardiac glycosides	effect	{'e1': {'word': 'ProAmatine', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d603.s0.e0'}, 'e2': {'word': 'cardiac glycosides', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d603.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d603.s0'}	administered concomitantly ProAmatine cardiac glycosides may enhance precipitate bradycardia A.V.
The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. 	phenylephrine	pseudoephedrine	none	{'e1': {'word': 'phenylephrine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d603.s2.e0'}, 'e2': {'word': 'pseudoephedrine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d603.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d603.s2'}	use drugs stimulate alpha adrenergic receptors e.g. phenylephrine pseudoephedrine ephedrine phenylpropanolamine dihydroergotamine may enhance potentiate pressor effects ProAmatine Therefore caution used ProAmatine administered concomitantly agents cause vasoconstriction
The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. 	phenylephrine	ephedrine	none	{'e1': {'word': 'phenylephrine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d603.s2.e0'}, 'e2': {'word': 'ephedrine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d603.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d603.s2'}	use drugs stimulate alpha adrenergic receptors e.g. phenylephrine pseudoephedrine ephedrine phenylpropanolamine dihydroergotamine may enhance potentiate pressor effects ProAmatine Therefore caution used ProAmatine administered concomitantly agents cause vasoconstriction
The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. 	phenylephrine	phenylpropanolamine	none	{'e1': {'word': 'phenylephrine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d603.s2.e0'}, 'e2': {'word': 'phenylpropanolamine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d603.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d603.s2'}	use drugs stimulate alpha adrenergic receptors e.g. phenylephrine pseudoephedrine ephedrine phenylpropanolamine dihydroergotamine may enhance potentiate pressor effects ProAmatine Therefore caution used ProAmatine administered concomitantly agents cause vasoconstriction
The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. 	phenylephrine	dihydroergotamine	none	{'e1': {'word': 'phenylephrine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d603.s2.e0'}, 'e2': {'word': 'dihydroergotamine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d603.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d603.s2'}	use drugs stimulate alpha adrenergic receptors e.g. phenylephrine pseudoephedrine ephedrine phenylpropanolamine dihydroergotamine may enhance potentiate pressor effects ProAmatine Therefore caution used ProAmatine administered concomitantly agents cause vasoconstriction
The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. 	phenylephrine	ProAmatine	effect	{'e1': {'word': 'phenylephrine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d603.s2.e0'}, 'e2': {'word': 'ProAmatine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d603.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d603.s2'}	use drugs stimulate alpha adrenergic receptors e.g. phenylephrine pseudoephedrine ephedrine phenylpropanolamine dihydroergotamine may enhance potentiate pressor effects ProAmatine Therefore caution used ProAmatine administered concomitantly agents cause vasoconstriction
The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. 	phenylephrine	ProAmatine	none	{'e1': {'word': 'phenylephrine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d603.s2.e0'}, 'e2': {'word': 'ProAmatine', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d603.s2.e6'}, 'sentence_id': 'DDI-DrugBank.d603.s2'}	use drugs stimulate alpha adrenergic receptors e.g. phenylephrine pseudoephedrine ephedrine phenylpropanolamine dihydroergotamine may enhance potentiate pressor effects ProAmatine Therefore caution used ProAmatine administered concomitantly agents cause vasoconstriction
The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. 	pseudoephedrine	ephedrine	none	{'e1': {'word': 'pseudoephedrine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d603.s2.e1'}, 'e2': {'word': 'ephedrine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d603.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d603.s2'}	use drugs stimulate alpha adrenergic receptors e.g. phenylephrine pseudoephedrine ephedrine phenylpropanolamine dihydroergotamine may enhance potentiate pressor effects ProAmatine Therefore caution used ProAmatine administered concomitantly agents cause vasoconstriction
The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. 	pseudoephedrine	phenylpropanolamine	none	{'e1': {'word': 'pseudoephedrine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d603.s2.e1'}, 'e2': {'word': 'phenylpropanolamine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d603.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d603.s2'}	use drugs stimulate alpha adrenergic receptors e.g. phenylephrine pseudoephedrine ephedrine phenylpropanolamine dihydroergotamine may enhance potentiate pressor effects ProAmatine Therefore caution used ProAmatine administered concomitantly agents cause vasoconstriction
The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. 	pseudoephedrine	dihydroergotamine	none	{'e1': {'word': 'pseudoephedrine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d603.s2.e1'}, 'e2': {'word': 'dihydroergotamine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d603.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d603.s2'}	use drugs stimulate alpha adrenergic receptors e.g. phenylephrine pseudoephedrine ephedrine phenylpropanolamine dihydroergotamine may enhance potentiate pressor effects ProAmatine Therefore caution used ProAmatine administered concomitantly agents cause vasoconstriction
The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. 	pseudoephedrine	ProAmatine	effect	{'e1': {'word': 'pseudoephedrine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d603.s2.e1'}, 'e2': {'word': 'ProAmatine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d603.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d603.s2'}	use drugs stimulate alpha adrenergic receptors e.g. phenylephrine pseudoephedrine ephedrine phenylpropanolamine dihydroergotamine may enhance potentiate pressor effects ProAmatine Therefore caution used ProAmatine administered concomitantly agents cause vasoconstriction
The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. 	pseudoephedrine	ProAmatine	none	{'e1': {'word': 'pseudoephedrine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d603.s2.e1'}, 'e2': {'word': 'ProAmatine', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d603.s2.e6'}, 'sentence_id': 'DDI-DrugBank.d603.s2'}	use drugs stimulate alpha adrenergic receptors e.g. phenylephrine pseudoephedrine ephedrine phenylpropanolamine dihydroergotamine may enhance potentiate pressor effects ProAmatine Therefore caution used ProAmatine administered concomitantly agents cause vasoconstriction
The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. 	ephedrine	phenylpropanolamine	none	{'e1': {'word': 'ephedrine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d603.s2.e2'}, 'e2': {'word': 'phenylpropanolamine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d603.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d603.s2'}	use drugs stimulate alpha adrenergic receptors e.g. phenylephrine pseudoephedrine ephedrine phenylpropanolamine dihydroergotamine may enhance potentiate pressor effects ProAmatine Therefore caution used ProAmatine administered concomitantly agents cause vasoconstriction
The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. 	ephedrine	dihydroergotamine	none	{'e1': {'word': 'ephedrine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d603.s2.e2'}, 'e2': {'word': 'dihydroergotamine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d603.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d603.s2'}	use drugs stimulate alpha adrenergic receptors e.g. phenylephrine pseudoephedrine ephedrine phenylpropanolamine dihydroergotamine may enhance potentiate pressor effects ProAmatine Therefore caution used ProAmatine administered concomitantly agents cause vasoconstriction
The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. 	ephedrine	ProAmatine	effect	{'e1': {'word': 'ephedrine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d603.s2.e2'}, 'e2': {'word': 'ProAmatine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d603.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d603.s2'}	use drugs stimulate alpha adrenergic receptors e.g. phenylephrine pseudoephedrine ephedrine phenylpropanolamine dihydroergotamine may enhance potentiate pressor effects ProAmatine Therefore caution used ProAmatine administered concomitantly agents cause vasoconstriction
The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. 	ephedrine	ProAmatine	none	{'e1': {'word': 'ephedrine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d603.s2.e2'}, 'e2': {'word': 'ProAmatine', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d603.s2.e6'}, 'sentence_id': 'DDI-DrugBank.d603.s2'}	use drugs stimulate alpha adrenergic receptors e.g. phenylephrine pseudoephedrine ephedrine phenylpropanolamine dihydroergotamine may enhance potentiate pressor effects ProAmatine Therefore caution used ProAmatine administered concomitantly agents cause vasoconstriction
The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. 	phenylpropanolamine	dihydroergotamine	none	{'e1': {'word': 'phenylpropanolamine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d603.s2.e3'}, 'e2': {'word': 'dihydroergotamine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d603.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d603.s2'}	use drugs stimulate alpha adrenergic receptors e.g. phenylephrine pseudoephedrine ephedrine phenylpropanolamine dihydroergotamine may enhance potentiate pressor effects ProAmatine Therefore caution used ProAmatine administered concomitantly agents cause vasoconstriction
The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. 	phenylpropanolamine	ProAmatine	effect	{'e1': {'word': 'phenylpropanolamine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d603.s2.e3'}, 'e2': {'word': 'ProAmatine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d603.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d603.s2'}	use drugs stimulate alpha adrenergic receptors e.g. phenylephrine pseudoephedrine ephedrine phenylpropanolamine dihydroergotamine may enhance potentiate pressor effects ProAmatine Therefore caution used ProAmatine administered concomitantly agents cause vasoconstriction
The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. 	phenylpropanolamine	ProAmatine	none	{'e1': {'word': 'phenylpropanolamine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d603.s2.e3'}, 'e2': {'word': 'ProAmatine', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d603.s2.e6'}, 'sentence_id': 'DDI-DrugBank.d603.s2'}	use drugs stimulate alpha adrenergic receptors e.g. phenylephrine pseudoephedrine ephedrine phenylpropanolamine dihydroergotamine may enhance potentiate pressor effects ProAmatine Therefore caution used ProAmatine administered concomitantly agents cause vasoconstriction
The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. 	dihydroergotamine	ProAmatine	effect	{'e1': {'word': 'dihydroergotamine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d603.s2.e4'}, 'e2': {'word': 'ProAmatine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d603.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d603.s2'}	use drugs stimulate alpha adrenergic receptors e.g. phenylephrine pseudoephedrine ephedrine phenylpropanolamine dihydroergotamine may enhance potentiate pressor effects ProAmatine Therefore caution used ProAmatine administered concomitantly agents cause vasoconstriction
The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. 	dihydroergotamine	ProAmatine	none	{'e1': {'word': 'dihydroergotamine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d603.s2.e4'}, 'e2': {'word': 'ProAmatine', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d603.s2.e6'}, 'sentence_id': 'DDI-DrugBank.d603.s2'}	use drugs stimulate alpha adrenergic receptors e.g. phenylephrine pseudoephedrine ephedrine phenylpropanolamine dihydroergotamine may enhance potentiate pressor effects ProAmatine Therefore caution used ProAmatine administered concomitantly agents cause vasoconstriction
The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. 	ProAmatine	ProAmatine	none	{'e1': {'word': 'ProAmatine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d603.s2.e5'}, 'e2': {'word': 'ProAmatine', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d603.s2.e6'}, 'sentence_id': 'DDI-DrugBank.d603.s2'}	use drugs stimulate alpha adrenergic receptors e.g. phenylephrine pseudoephedrine ephedrine phenylpropanolamine dihydroergotamine may enhance potentiate pressor effects ProAmatine Therefore caution used ProAmatine administered concomitantly agents cause vasoconstriction
ProAmatine    has been used in patients concomitantly treated with salt-retaining steroid therapy (i.e., fludrocortisone acetate), with or without salt supplementation. 	ProAmatine	fludrocortisone acetate	none	{'e1': {'word': 'ProAmatine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d603.s3.e0'}, 'e2': {'word': 'fludrocortisone acetate', 'word_index': [(10, 11)], 'id': 'DDI-DrugBank.d603.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d603.s3'}	ProAmatine used patients concomitantly treated salt retaining steroid therapy i.e. fludrocortisone acetate without salt supplementation
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	ProAmatine	Alpha-adrenergic blocking agents	none	{'e1': {'word': 'ProAmatine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d603.s5.e0'}, 'e2': {'word': 'Alpha-adrenergic blocking agents', 'word_index': [(1, 4)], 'id': 'DDI-DrugBank.d603.s5.e1'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha adrenergic blocking agents prazosin terazosin doxazosin antagonize effects ProAmatine Potential Drug Interactions appears possible although supporting experimental evidence high renal clearance desglymidodrine base due active tubular secretion base secreting system also responsible secretion drugs metformin cimetidine ranitidine procainamide triamterene flecainide quinidine
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	ProAmatine	prazosin	none	{'e1': {'word': 'ProAmatine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d603.s5.e0'}, 'e2': {'word': 'prazosin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d603.s5.e2'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha- blocking agents , prazosin , , , the of . for Interactions : possible , there experimental evidence , renal clearance of ( ) to tubular secretion by - system also responsible for of as , , , , , , .
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	ProAmatine	terazosin	none	{'e1': {'word': 'ProAmatine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d603.s5.e0'}, 'e2': {'word': 'terazosin', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d603.s5.e3'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha- blocking agents , , terazosin , , the of . for Interactions : possible , there experimental evidence , renal clearance of ( ) to tubular secretion by - system also responsible for of as , , , , , , .
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	ProAmatine	doxazosin	none	{'e1': {'word': 'ProAmatine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d603.s5.e0'}, 'e2': {'word': 'doxazosin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d603.s5.e4'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha- blocking agents , , , doxazosin , the of . for Interactions : possible , there experimental evidence , renal clearance of ( ) to tubular secretion by - system also responsible for of as , , , , , , .
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	ProAmatine	ProAmatine	none	{'e1': {'word': 'ProAmatine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d603.s5.e0'}, 'e2': {'word': 'ProAmatine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d603.s5.e5'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha- blocking agents , , , , the of ProAmatine . for Interactions : possible , there experimental evidence , renal clearance of ( ) to tubular secretion by - system also responsible for of as , , , , , , .
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	ProAmatine	desglymidodrine	none	{'e1': {'word': 'ProAmatine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d603.s5.e0'}, 'e2': {'word': 'desglymidodrine', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d603.s5.e6'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha- blocking agents , , , , the of . for Interactions : possible , there experimental evidence , renal clearance of desglymidodrine ( ) to tubular secretion by - system also responsible for of as , , , , , , .
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	ProAmatine	metformin	none	{'e1': {'word': 'ProAmatine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d603.s5.e0'}, 'e2': {'word': 'metformin', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d603.s5.e7'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha- blocking agents , , , , the of . for Interactions : possible , there experimental evidence , renal clearance of ( ) to tubular secretion by - system also responsible for of as metformin , , , , , , .
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	ProAmatine	cimetidine	none	{'e1': {'word': 'ProAmatine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d603.s5.e0'}, 'e2': {'word': 'cimetidine', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d603.s5.e8'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha- blocking agents , , , , the of . for Interactions : possible , there experimental evidence , renal clearance of ( ) to tubular secretion by - system also responsible for of as , cimetidine , , , , , .
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	ProAmatine	ranitidine	none	{'e1': {'word': 'ProAmatine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d603.s5.e0'}, 'e2': {'word': 'ranitidine', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d603.s5.e9'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha- blocking agents , , , , the of . for Interactions : possible , there experimental evidence , renal clearance of ( ) to tubular secretion by - system also responsible for of as , , ranitidine , , , , .
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	ProAmatine	procainamide	none	{'e1': {'word': 'ProAmatine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d603.s5.e0'}, 'e2': {'word': 'procainamide', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d603.s5.e10'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha- blocking agents , , , , the of . for Interactions : possible , there experimental evidence , renal clearance of ( ) to tubular secretion by - system also responsible for of as , , , procainamide , , , .
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	ProAmatine	triamterene	none	{'e1': {'word': 'ProAmatine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d603.s5.e0'}, 'e2': {'word': 'triamterene', 'word_index': [(40, 40)], 'id': 'DDI-DrugBank.d603.s5.e11'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha- blocking agents , , , , the of . for Interactions : possible , there experimental evidence , renal clearance of ( ) to tubular secretion by - system also responsible for of as , , , , triamterene , , .
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	ProAmatine	flecainide	none	{'e1': {'word': 'ProAmatine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d603.s5.e0'}, 'e2': {'word': 'flecainide', 'word_index': [(41, 41)], 'id': 'DDI-DrugBank.d603.s5.e12'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha- blocking agents , , , , the of . for Interactions : possible , there experimental evidence , renal clearance of ( ) to tubular secretion by - system also responsible for of as , , , , , flecainide , .
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	ProAmatine	quinidine	none	{'e1': {'word': 'ProAmatine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d603.s5.e0'}, 'e2': {'word': 'quinidine', 'word_index': [(42, 42)], 'id': 'DDI-DrugBank.d603.s5.e13'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha- blocking agents , , , , the of . for Interactions : possible , there experimental evidence , renal clearance of ( ) to tubular secretion by - system also responsible for of as , , , , , , quinidine .
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	Alpha-adrenergic blocking agents	prazosin	none	{'e1': {'word': 'Alpha-adrenergic blocking agents', 'word_index': [(1, 4)], 'id': 'DDI-DrugBank.d603.s5.e1'}, 'e2': {'word': 'prazosin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d603.s5.e2'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha adrenergic blocking agents prazosin terazosin doxazosin antagonize effects ProAmatine Potential Drug Interactions appears possible although supporting experimental evidence high renal clearance desglymidodrine base due active tubular secretion base secreting system also responsible secretion drugs metformin cimetidine ranitidine procainamide triamterene flecainide quinidine
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	Alpha-adrenergic blocking agents	terazosin	none	{'e1': {'word': 'Alpha-adrenergic blocking agents', 'word_index': [(1, 4)], 'id': 'DDI-DrugBank.d603.s5.e1'}, 'e2': {'word': 'terazosin', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d603.s5.e3'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha adrenergic blocking agents prazosin terazosin doxazosin antagonize effects ProAmatine Potential Drug Interactions appears possible although supporting experimental evidence high renal clearance desglymidodrine base due active tubular secretion base secreting system also responsible secretion drugs metformin cimetidine ranitidine procainamide triamterene flecainide quinidine
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	Alpha-adrenergic blocking agents	doxazosin	none	{'e1': {'word': 'Alpha-adrenergic blocking agents', 'word_index': [(1, 4)], 'id': 'DDI-DrugBank.d603.s5.e1'}, 'e2': {'word': 'doxazosin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d603.s5.e4'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha adrenergic blocking agents prazosin terazosin doxazosin antagonize effects ProAmatine Potential Drug Interactions appears possible although supporting experimental evidence high renal clearance desglymidodrine base due active tubular secretion base secreting system also responsible secretion drugs metformin cimetidine ranitidine procainamide triamterene flecainide quinidine
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	Alpha-adrenergic blocking agents	ProAmatine	effect	{'e1': {'word': 'Alpha-adrenergic blocking agents', 'word_index': [(1, 4)], 'id': 'DDI-DrugBank.d603.s5.e1'}, 'e2': {'word': 'ProAmatine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d603.s5.e5'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha adrenergic blocking agents prazosin terazosin doxazosin antagonize effects ProAmatine Potential Drug Interactions appears possible although supporting experimental evidence high renal clearance desglymidodrine base due active tubular secretion base secreting system also responsible secretion drugs metformin cimetidine ranitidine procainamide triamterene flecainide quinidine
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	Alpha-adrenergic blocking agents	desglymidodrine	none	{'e1': {'word': 'Alpha-adrenergic blocking agents', 'word_index': [(1, 4)], 'id': 'DDI-DrugBank.d603.s5.e1'}, 'e2': {'word': 'desglymidodrine', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d603.s5.e6'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha adrenergic blocking agents prazosin terazosin doxazosin antagonize effects ProAmatine Potential Drug Interactions appears possible although supporting experimental evidence high renal clearance desglymidodrine base due active tubular secretion base secreting system also responsible secretion drugs metformin cimetidine ranitidine procainamide triamterene flecainide quinidine
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	Alpha-adrenergic blocking agents	metformin	none	{'e1': {'word': 'Alpha-adrenergic blocking agents', 'word_index': [(1, 4)], 'id': 'DDI-DrugBank.d603.s5.e1'}, 'e2': {'word': 'metformin', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d603.s5.e7'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha adrenergic blocking agents prazosin terazosin doxazosin antagonize effects ProAmatine Potential Drug Interactions appears possible although supporting experimental evidence high renal clearance desglymidodrine base due active tubular secretion base secreting system also responsible secretion drugs metformin cimetidine ranitidine procainamide triamterene flecainide quinidine
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	Alpha-adrenergic blocking agents	cimetidine	none	{'e1': {'word': 'Alpha-adrenergic blocking agents', 'word_index': [(1, 4)], 'id': 'DDI-DrugBank.d603.s5.e1'}, 'e2': {'word': 'cimetidine', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d603.s5.e8'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha adrenergic blocking agents prazosin terazosin doxazosin antagonize effects ProAmatine Potential Drug Interactions appears possible although supporting experimental evidence high renal clearance desglymidodrine base due active tubular secretion base secreting system also responsible secretion drugs metformin cimetidine ranitidine procainamide triamterene flecainide quinidine
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	Alpha-adrenergic blocking agents	ranitidine	none	{'e1': {'word': 'Alpha-adrenergic blocking agents', 'word_index': [(1, 4)], 'id': 'DDI-DrugBank.d603.s5.e1'}, 'e2': {'word': 'ranitidine', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d603.s5.e9'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha adrenergic blocking agents prazosin terazosin doxazosin antagonize effects ProAmatine Potential Drug Interactions appears possible although supporting experimental evidence high renal clearance desglymidodrine base due active tubular secretion base secreting system also responsible secretion drugs metformin cimetidine ranitidine procainamide triamterene flecainide quinidine
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	Alpha-adrenergic blocking agents	procainamide	none	{'e1': {'word': 'Alpha-adrenergic blocking agents', 'word_index': [(1, 4)], 'id': 'DDI-DrugBank.d603.s5.e1'}, 'e2': {'word': 'procainamide', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d603.s5.e10'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha adrenergic blocking agents prazosin terazosin doxazosin antagonize effects ProAmatine Potential Drug Interactions appears possible although supporting experimental evidence high renal clearance desglymidodrine base due active tubular secretion base secreting system also responsible secretion drugs metformin cimetidine ranitidine procainamide triamterene flecainide quinidine
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	Alpha-adrenergic blocking agents	triamterene	none	{'e1': {'word': 'Alpha-adrenergic blocking agents', 'word_index': [(1, 4)], 'id': 'DDI-DrugBank.d603.s5.e1'}, 'e2': {'word': 'triamterene', 'word_index': [(40, 40)], 'id': 'DDI-DrugBank.d603.s5.e11'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha adrenergic blocking agents prazosin terazosin doxazosin antagonize effects ProAmatine Potential Drug Interactions appears possible although supporting experimental evidence high renal clearance desglymidodrine base due active tubular secretion base secreting system also responsible secretion drugs metformin cimetidine ranitidine procainamide triamterene flecainide quinidine
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	Alpha-adrenergic blocking agents	flecainide	none	{'e1': {'word': 'Alpha-adrenergic blocking agents', 'word_index': [(1, 4)], 'id': 'DDI-DrugBank.d603.s5.e1'}, 'e2': {'word': 'flecainide', 'word_index': [(41, 41)], 'id': 'DDI-DrugBank.d603.s5.e12'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha adrenergic blocking agents prazosin terazosin doxazosin antagonize effects ProAmatine Potential Drug Interactions appears possible although supporting experimental evidence high renal clearance desglymidodrine base due active tubular secretion base secreting system also responsible secretion drugs metformin cimetidine ranitidine procainamide triamterene flecainide quinidine
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	Alpha-adrenergic blocking agents	quinidine	none	{'e1': {'word': 'Alpha-adrenergic blocking agents', 'word_index': [(1, 4)], 'id': 'DDI-DrugBank.d603.s5.e1'}, 'e2': {'word': 'quinidine', 'word_index': [(42, 42)], 'id': 'DDI-DrugBank.d603.s5.e13'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha adrenergic blocking agents prazosin terazosin doxazosin antagonize effects ProAmatine Potential Drug Interactions appears possible although supporting experimental evidence high renal clearance desglymidodrine base due active tubular secretion base secreting system also responsible secretion drugs metformin cimetidine ranitidine procainamide triamterene flecainide quinidine
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	prazosin	terazosin	none	{'e1': {'word': 'prazosin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d603.s5.e2'}, 'e2': {'word': 'terazosin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d603.s5.e3'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha- blocking agents , prazosin , terazosin , , the of . for Interactions : possible , there experimental evidence , renal clearance of ( ) to tubular secretion by - system also responsible for of as , , , , , , .
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	prazosin	doxazosin	none	{'e1': {'word': 'prazosin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d603.s5.e2'}, 'e2': {'word': 'doxazosin', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d603.s5.e4'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha- blocking agents , prazosin , , doxazosin , the of . for Interactions : possible , there experimental evidence , renal clearance of ( ) to tubular secretion by - system also responsible for of as , , , , , , .
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	prazosin	ProAmatine	effect	{'e1': {'word': 'prazosin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d603.s5.e2'}, 'e2': {'word': 'ProAmatine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d603.s5.e5'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha- blocking agents , prazosin , , , the of ProAmatine . for Interactions : possible , there experimental evidence , renal clearance of ( ) to tubular secretion by - system also responsible for of as , , , , , , .
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	prazosin	desglymidodrine	none	{'e1': {'word': 'prazosin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d603.s5.e2'}, 'e2': {'word': 'desglymidodrine', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d603.s5.e6'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha- blocking agents , prazosin , , , the of . for Interactions : possible , there experimental evidence , renal clearance of desglymidodrine ( ) to tubular secretion by - system also responsible for of as , , , , , , .
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	prazosin	metformin	none	{'e1': {'word': 'prazosin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d603.s5.e2'}, 'e2': {'word': 'metformin', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d603.s5.e7'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha- blocking agents , prazosin , , , the of . for Interactions : possible , there experimental evidence , renal clearance of ( ) to tubular secretion by - system also responsible for of as metformin , , , , , , .
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	prazosin	cimetidine	none	{'e1': {'word': 'prazosin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d603.s5.e2'}, 'e2': {'word': 'cimetidine', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d603.s5.e8'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha- blocking agents , prazosin , , , the of . for Interactions : possible , there experimental evidence , renal clearance of ( ) to tubular secretion by - system also responsible for of as , cimetidine , , , , , .
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	prazosin	ranitidine	none	{'e1': {'word': 'prazosin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d603.s5.e2'}, 'e2': {'word': 'ranitidine', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d603.s5.e9'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha- blocking agents , prazosin , , , the of . for Interactions : possible , there experimental evidence , renal clearance of ( ) to tubular secretion by - system also responsible for of as , , ranitidine , , , , .
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	prazosin	procainamide	none	{'e1': {'word': 'prazosin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d603.s5.e2'}, 'e2': {'word': 'procainamide', 'word_index': [(40, 40)], 'id': 'DDI-DrugBank.d603.s5.e10'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha- blocking agents , prazosin , , , the of . for Interactions : possible , there experimental evidence , renal clearance of ( ) to tubular secretion by - system also responsible for of as , , , procainamide , , , .
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	prazosin	triamterene	none	{'e1': {'word': 'prazosin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d603.s5.e2'}, 'e2': {'word': 'triamterene', 'word_index': [(41, 41)], 'id': 'DDI-DrugBank.d603.s5.e11'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha- blocking agents , prazosin , , , the of . for Interactions : possible , there experimental evidence , renal clearance of ( ) to tubular secretion by - system also responsible for of as , , , , triamterene , , .
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	prazosin	flecainide	none	{'e1': {'word': 'prazosin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d603.s5.e2'}, 'e2': {'word': 'flecainide', 'word_index': [(42, 42)], 'id': 'DDI-DrugBank.d603.s5.e12'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha- blocking agents , prazosin , , , the of . for Interactions : possible , there experimental evidence , renal clearance of ( ) to tubular secretion by - system also responsible for of as , , , , , flecainide , .
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	prazosin	quinidine	none	{'e1': {'word': 'prazosin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d603.s5.e2'}, 'e2': {'word': 'quinidine', 'word_index': [(43, 43)], 'id': 'DDI-DrugBank.d603.s5.e13'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha- blocking agents , prazosin , , , the of . for Interactions : possible , there experimental evidence , renal clearance of ( ) to tubular secretion by - system also responsible for of as , , , , , , quinidine .
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	terazosin	doxazosin	none	{'e1': {'word': 'terazosin', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d603.s5.e3'}, 'e2': {'word': 'doxazosin', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d603.s5.e4'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha- blocking agents , , terazosin , doxazosin , the of . for Interactions : possible , there experimental evidence , renal clearance of ( ) to tubular secretion by - system also responsible for of as , , , , , , .
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	terazosin	ProAmatine	effect	{'e1': {'word': 'terazosin', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d603.s5.e3'}, 'e2': {'word': 'ProAmatine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d603.s5.e5'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha- blocking agents , , terazosin , , the of ProAmatine . for Interactions : possible , there experimental evidence , renal clearance of ( ) to tubular secretion by - system also responsible for of as , , , , , , .
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	terazosin	desglymidodrine	none	{'e1': {'word': 'terazosin', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d603.s5.e3'}, 'e2': {'word': 'desglymidodrine', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d603.s5.e6'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha- blocking agents , , terazosin , , the of . for Interactions : possible , there experimental evidence , renal clearance of desglymidodrine ( ) to tubular secretion by - system also responsible for of as , , , , , , .
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	terazosin	metformin	none	{'e1': {'word': 'terazosin', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d603.s5.e3'}, 'e2': {'word': 'metformin', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d603.s5.e7'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha- blocking agents , , terazosin , , the of . for Interactions : possible , there experimental evidence , renal clearance of ( ) to tubular secretion by - system also responsible for of as metformin , , , , , , .
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	terazosin	cimetidine	none	{'e1': {'word': 'terazosin', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d603.s5.e3'}, 'e2': {'word': 'cimetidine', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d603.s5.e8'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha- blocking agents , , terazosin , , the of . for Interactions : possible , there experimental evidence , renal clearance of ( ) to tubular secretion by - system also responsible for of as , cimetidine , , , , , .
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	terazosin	ranitidine	none	{'e1': {'word': 'terazosin', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d603.s5.e3'}, 'e2': {'word': 'ranitidine', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d603.s5.e9'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha- blocking agents , , terazosin , , the of . for Interactions : possible , there experimental evidence , renal clearance of ( ) to tubular secretion by - system also responsible for of as , , ranitidine , , , , .
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	terazosin	procainamide	none	{'e1': {'word': 'terazosin', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d603.s5.e3'}, 'e2': {'word': 'procainamide', 'word_index': [(40, 40)], 'id': 'DDI-DrugBank.d603.s5.e10'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha- blocking agents , , terazosin , , the of . for Interactions : possible , there experimental evidence , renal clearance of ( ) to tubular secretion by - system also responsible for of as , , , procainamide , , , .
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	terazosin	triamterene	none	{'e1': {'word': 'terazosin', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d603.s5.e3'}, 'e2': {'word': 'triamterene', 'word_index': [(41, 41)], 'id': 'DDI-DrugBank.d603.s5.e11'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha- blocking agents , , terazosin , , the of . for Interactions : possible , there experimental evidence , renal clearance of ( ) to tubular secretion by - system also responsible for of as , , , , triamterene , , .
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	terazosin	flecainide	none	{'e1': {'word': 'terazosin', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d603.s5.e3'}, 'e2': {'word': 'flecainide', 'word_index': [(42, 42)], 'id': 'DDI-DrugBank.d603.s5.e12'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha- blocking agents , , terazosin , , the of . for Interactions : possible , there experimental evidence , renal clearance of ( ) to tubular secretion by - system also responsible for of as , , , , , flecainide , .
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	terazosin	quinidine	none	{'e1': {'word': 'terazosin', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d603.s5.e3'}, 'e2': {'word': 'quinidine', 'word_index': [(43, 43)], 'id': 'DDI-DrugBank.d603.s5.e13'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha- blocking agents , , terazosin , , the of . for Interactions : possible , there experimental evidence , renal clearance of ( ) to tubular secretion by - system also responsible for of as , , , , , , quinidine .
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	doxazosin	ProAmatine	effect	{'e1': {'word': 'doxazosin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d603.s5.e4'}, 'e2': {'word': 'ProAmatine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d603.s5.e5'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha- blocking agents , , , doxazosin , the of ProAmatine . for Interactions : possible , there experimental evidence , renal clearance of ( ) to tubular secretion by - system also responsible for of as , , , , , , .
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	doxazosin	desglymidodrine	none	{'e1': {'word': 'doxazosin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d603.s5.e4'}, 'e2': {'word': 'desglymidodrine', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d603.s5.e6'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha- blocking agents , , , doxazosin , the of . for Interactions : possible , there experimental evidence , renal clearance of desglymidodrine ( ) to tubular secretion by - system also responsible for of as , , , , , , .
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	doxazosin	metformin	none	{'e1': {'word': 'doxazosin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d603.s5.e4'}, 'e2': {'word': 'metformin', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d603.s5.e7'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha- blocking agents , , , doxazosin , the of . for Interactions : possible , there experimental evidence , renal clearance of ( ) to tubular secretion by - system also responsible for of as metformin , , , , , , .
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	doxazosin	cimetidine	none	{'e1': {'word': 'doxazosin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d603.s5.e4'}, 'e2': {'word': 'cimetidine', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d603.s5.e8'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha- blocking agents , , , doxazosin , the of . for Interactions : possible , there experimental evidence , renal clearance of ( ) to tubular secretion by - system also responsible for of as , cimetidine , , , , , .
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	doxazosin	ranitidine	none	{'e1': {'word': 'doxazosin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d603.s5.e4'}, 'e2': {'word': 'ranitidine', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d603.s5.e9'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha- blocking agents , , , doxazosin , the of . for Interactions : possible , there experimental evidence , renal clearance of ( ) to tubular secretion by - system also responsible for of as , , ranitidine , , , , .
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	doxazosin	procainamide	none	{'e1': {'word': 'doxazosin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d603.s5.e4'}, 'e2': {'word': 'procainamide', 'word_index': [(40, 40)], 'id': 'DDI-DrugBank.d603.s5.e10'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha- blocking agents , , , doxazosin , the of . for Interactions : possible , there experimental evidence , renal clearance of ( ) to tubular secretion by - system also responsible for of as , , , procainamide , , , .
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	doxazosin	triamterene	none	{'e1': {'word': 'doxazosin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d603.s5.e4'}, 'e2': {'word': 'triamterene', 'word_index': [(41, 41)], 'id': 'DDI-DrugBank.d603.s5.e11'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha- blocking agents , , , doxazosin , the of . for Interactions : possible , there experimental evidence , renal clearance of ( ) to tubular secretion by - system also responsible for of as , , , , triamterene , , .
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	doxazosin	flecainide	none	{'e1': {'word': 'doxazosin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d603.s5.e4'}, 'e2': {'word': 'flecainide', 'word_index': [(42, 42)], 'id': 'DDI-DrugBank.d603.s5.e12'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha- blocking agents , , , doxazosin , the of . for Interactions : possible , there experimental evidence , renal clearance of ( ) to tubular secretion by - system also responsible for of as , , , , , flecainide , .
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	doxazosin	quinidine	none	{'e1': {'word': 'doxazosin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d603.s5.e4'}, 'e2': {'word': 'quinidine', 'word_index': [(43, 43)], 'id': 'DDI-DrugBank.d603.s5.e13'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha- blocking agents , , , doxazosin , the of . for Interactions : possible , there experimental evidence , renal clearance of ( ) to tubular secretion by - system also responsible for of as , , , , , , quinidine .
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	ProAmatine	desglymidodrine	none	{'e1': {'word': 'ProAmatine', 'word_index': [(9, 8)], 'id': 'DDI-DrugBank.d603.s5.e5'}, 'e2': {'word': 'desglymidodrine', 'word_index': [(22, 21)], 'id': 'DDI-DrugBank.d603.s5.e6'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha-adrenergic agents , such terazosin and can effects . Potential Drug : It , although is evidence , that clearance of ( a is active secretion by the secreting also responsible for the such metformin cimetidine ranitidine procainamide triamterene flecainide and
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	ProAmatine	metformin	none	{'e1': {'word': 'ProAmatine', 'word_index': [(9, 8)], 'id': 'DDI-DrugBank.d603.s5.e5'}, 'e2': {'word': 'metformin', 'word_index': [(35, 34)], 'id': 'DDI-DrugBank.d603.s5.e7'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha-adrenergic agents , such terazosin and can effects . Potential Drug : It , although is evidence , that clearance of desglymidodrine a is active secretion by the secreting also responsible for the such , cimetidine ranitidine procainamide triamterene flecainide and
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	ProAmatine	cimetidine	none	{'e1': {'word': 'ProAmatine', 'word_index': [(9, 8)], 'id': 'DDI-DrugBank.d603.s5.e5'}, 'e2': {'word': 'cimetidine', 'word_index': [(36, 35)], 'id': 'DDI-DrugBank.d603.s5.e8'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha-adrenergic agents , such terazosin and can effects . Potential Drug : It , although is evidence , that clearance of desglymidodrine a is active secretion by the secreting also responsible for the such metformin , ranitidine procainamide triamterene flecainide and
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	ProAmatine	ranitidine	none	{'e1': {'word': 'ProAmatine', 'word_index': [(9, 8)], 'id': 'DDI-DrugBank.d603.s5.e5'}, 'e2': {'word': 'ranitidine', 'word_index': [(37, 36)], 'id': 'DDI-DrugBank.d603.s5.e9'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha-adrenergic agents , such terazosin and can effects . Potential Drug : It , although is evidence , that clearance of desglymidodrine a is active secretion by the secreting also responsible for the such metformin cimetidine , procainamide triamterene flecainide and
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	ProAmatine	procainamide	none	{'e1': {'word': 'ProAmatine', 'word_index': [(9, 8)], 'id': 'DDI-DrugBank.d603.s5.e5'}, 'e2': {'word': 'procainamide', 'word_index': [(38, 37)], 'id': 'DDI-DrugBank.d603.s5.e10'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha-adrenergic agents , such terazosin and can effects . Potential Drug : It , although is evidence , that clearance of desglymidodrine a is active secretion by the secreting also responsible for the such metformin cimetidine ranitidine , triamterene flecainide and
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	ProAmatine	triamterene	none	{'e1': {'word': 'ProAmatine', 'word_index': [(9, 8)], 'id': 'DDI-DrugBank.d603.s5.e5'}, 'e2': {'word': 'triamterene', 'word_index': [(39, 38)], 'id': 'DDI-DrugBank.d603.s5.e11'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha-adrenergic agents , such terazosin and can effects . Potential Drug : It , although is evidence , that clearance of desglymidodrine a is active secretion by the secreting also responsible for the such metformin cimetidine ranitidine procainamide , flecainide and
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	ProAmatine	flecainide	none	{'e1': {'word': 'ProAmatine', 'word_index': [(9, 8)], 'id': 'DDI-DrugBank.d603.s5.e5'}, 'e2': {'word': 'flecainide', 'word_index': [(40, 39)], 'id': 'DDI-DrugBank.d603.s5.e12'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha-adrenergic agents , such terazosin and can effects . Potential Drug : It , although is evidence , that clearance of desglymidodrine a is active secretion by the secreting also responsible for the such metformin cimetidine ranitidine procainamide triamterene , and
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	ProAmatine	quinidine	none	{'e1': {'word': 'ProAmatine', 'word_index': [(9, 8)], 'id': 'DDI-DrugBank.d603.s5.e5'}, 'e2': {'word': 'quinidine', 'word_index': [(42, 41)], 'id': 'DDI-DrugBank.d603.s5.e13'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha-adrenergic agents , such terazosin and can effects . Potential Drug : It , although is evidence , that clearance of desglymidodrine a is active secretion by the secreting also responsible for the such metformin cimetidine ranitidine procainamide triamterene flecainide and .
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	desglymidodrine	metformin	mechanism	{'e1': {'word': 'desglymidodrine', 'word_index': [(22, 21)], 'id': 'DDI-DrugBank.d603.s5.e6'}, 'e2': {'word': 'metformin', 'word_index': [(35, 34)], 'id': 'DDI-DrugBank.d603.s5.e7'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha-adrenergic agents , such terazosin and can effects ProAmatine Potential Drug : It , although is evidence , that clearance of ( a is active secretion by the secreting also responsible for the such , cimetidine ranitidine procainamide triamterene flecainide and
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	desglymidodrine	cimetidine	mechanism	{'e1': {'word': 'desglymidodrine', 'word_index': [(22, 21)], 'id': 'DDI-DrugBank.d603.s5.e6'}, 'e2': {'word': 'cimetidine', 'word_index': [(36, 35)], 'id': 'DDI-DrugBank.d603.s5.e8'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha-adrenergic agents , such terazosin and can effects ProAmatine Potential Drug : It , although is evidence , that clearance of ( a is active secretion by the secreting also responsible for the such metformin , ranitidine procainamide triamterene flecainide and
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	desglymidodrine	ranitidine	mechanism	{'e1': {'word': 'desglymidodrine', 'word_index': [(22, 21)], 'id': 'DDI-DrugBank.d603.s5.e6'}, 'e2': {'word': 'ranitidine', 'word_index': [(37, 36)], 'id': 'DDI-DrugBank.d603.s5.e9'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha-adrenergic agents , such terazosin and can effects ProAmatine Potential Drug : It , although is evidence , that clearance of ( a is active secretion by the secreting also responsible for the such metformin cimetidine , procainamide triamterene flecainide and
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	desglymidodrine	procainamide	mechanism	{'e1': {'word': 'desglymidodrine', 'word_index': [(22, 21)], 'id': 'DDI-DrugBank.d603.s5.e6'}, 'e2': {'word': 'procainamide', 'word_index': [(38, 37)], 'id': 'DDI-DrugBank.d603.s5.e10'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha-adrenergic agents , such terazosin and can effects ProAmatine Potential Drug : It , although is evidence , that clearance of ( a is active secretion by the secreting also responsible for the such metformin cimetidine ranitidine , triamterene flecainide and
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	desglymidodrine	triamterene	mechanism	{'e1': {'word': 'desglymidodrine', 'word_index': [(22, 21)], 'id': 'DDI-DrugBank.d603.s5.e6'}, 'e2': {'word': 'triamterene', 'word_index': [(39, 38)], 'id': 'DDI-DrugBank.d603.s5.e11'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha-adrenergic agents , such terazosin and can effects ProAmatine Potential Drug : It , although is evidence , that clearance of ( a is active secretion by the secreting also responsible for the such metformin cimetidine ranitidine procainamide , flecainide and
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	desglymidodrine	flecainide	mechanism	{'e1': {'word': 'desglymidodrine', 'word_index': [(22, 21)], 'id': 'DDI-DrugBank.d603.s5.e6'}, 'e2': {'word': 'flecainide', 'word_index': [(40, 39)], 'id': 'DDI-DrugBank.d603.s5.e12'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha-adrenergic agents , such terazosin and can effects ProAmatine Potential Drug : It , although is evidence , that clearance of ( a is active secretion by the secreting also responsible for the such metformin cimetidine ranitidine procainamide triamterene , and
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	desglymidodrine	quinidine	mechanism	{'e1': {'word': 'desglymidodrine', 'word_index': [(22, 21)], 'id': 'DDI-DrugBank.d603.s5.e6'}, 'e2': {'word': 'quinidine', 'word_index': [(42, 41)], 'id': 'DDI-DrugBank.d603.s5.e13'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha-adrenergic agents , such terazosin and can effects ProAmatine Potential Drug : It , although is evidence , that clearance of ( a is active secretion by the secreting also responsible for the such metformin cimetidine ranitidine procainamide triamterene flecainide and .
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	metformin	cimetidine	none	{'e1': {'word': 'metformin', 'word_index': [(35, 34)], 'id': 'DDI-DrugBank.d603.s5.e7'}, 'e2': {'word': 'cimetidine', 'word_index': [(36, 35)], 'id': 'DDI-DrugBank.d603.s5.e8'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha-adrenergic agents , such terazosin and can effects ProAmatine Potential Drug : It , although is evidence , that clearance of desglymidodrine a is active secretion by the secreting also responsible for the such , , ranitidine procainamide triamterene flecainide and
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	metformin	ranitidine	none	{'e1': {'word': 'metformin', 'word_index': [(35, 34)], 'id': 'DDI-DrugBank.d603.s5.e7'}, 'e2': {'word': 'ranitidine', 'word_index': [(37, 36)], 'id': 'DDI-DrugBank.d603.s5.e9'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha-adrenergic agents , such terazosin and can effects ProAmatine Potential Drug : It , although is evidence , that clearance of desglymidodrine a is active secretion by the secreting also responsible for the such , cimetidine , procainamide triamterene flecainide and
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	metformin	procainamide	none	{'e1': {'word': 'metformin', 'word_index': [(35, 34)], 'id': 'DDI-DrugBank.d603.s5.e7'}, 'e2': {'word': 'procainamide', 'word_index': [(38, 37)], 'id': 'DDI-DrugBank.d603.s5.e10'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha-adrenergic agents , such terazosin and can effects ProAmatine Potential Drug : It , although is evidence , that clearance of desglymidodrine a is active secretion by the secreting also responsible for the such , cimetidine ranitidine , triamterene flecainide and
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	metformin	triamterene	none	{'e1': {'word': 'metformin', 'word_index': [(35, 34)], 'id': 'DDI-DrugBank.d603.s5.e7'}, 'e2': {'word': 'triamterene', 'word_index': [(39, 38)], 'id': 'DDI-DrugBank.d603.s5.e11'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha-adrenergic agents , such terazosin and can effects ProAmatine Potential Drug : It , although is evidence , that clearance of desglymidodrine a is active secretion by the secreting also responsible for the such , cimetidine ranitidine procainamide , flecainide and
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	metformin	flecainide	none	{'e1': {'word': 'metformin', 'word_index': [(35, 34)], 'id': 'DDI-DrugBank.d603.s5.e7'}, 'e2': {'word': 'flecainide', 'word_index': [(40, 39)], 'id': 'DDI-DrugBank.d603.s5.e12'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha-adrenergic agents , such terazosin and can effects ProAmatine Potential Drug : It , although is evidence , that clearance of desglymidodrine a is active secretion by the secreting also responsible for the such , cimetidine ranitidine procainamide triamterene , and
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	metformin	quinidine	none	{'e1': {'word': 'metformin', 'word_index': [(35, 34)], 'id': 'DDI-DrugBank.d603.s5.e7'}, 'e2': {'word': 'quinidine', 'word_index': [(42, 41)], 'id': 'DDI-DrugBank.d603.s5.e13'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha-adrenergic agents , such terazosin and can effects ProAmatine Potential Drug : It , although is evidence , that clearance of desglymidodrine a is active secretion by the secreting also responsible for the such , cimetidine ranitidine procainamide triamterene flecainide and .
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	cimetidine	ranitidine	none	{'e1': {'word': 'cimetidine', 'word_index': [(36, 35)], 'id': 'DDI-DrugBank.d603.s5.e8'}, 'e2': {'word': 'ranitidine', 'word_index': [(37, 36)], 'id': 'DDI-DrugBank.d603.s5.e9'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha-adrenergic agents , such terazosin and can effects ProAmatine Potential Drug : It , although is evidence , that clearance of desglymidodrine a is active secretion by the secreting also responsible for the such metformin , , procainamide triamterene flecainide and
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	cimetidine	procainamide	none	{'e1': {'word': 'cimetidine', 'word_index': [(36, 35)], 'id': 'DDI-DrugBank.d603.s5.e8'}, 'e2': {'word': 'procainamide', 'word_index': [(38, 37)], 'id': 'DDI-DrugBank.d603.s5.e10'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha-adrenergic agents , such terazosin and can effects ProAmatine Potential Drug : It , although is evidence , that clearance of desglymidodrine a is active secretion by the secreting also responsible for the such metformin , ranitidine , triamterene flecainide and
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	cimetidine	triamterene	none	{'e1': {'word': 'cimetidine', 'word_index': [(36, 35)], 'id': 'DDI-DrugBank.d603.s5.e8'}, 'e2': {'word': 'triamterene', 'word_index': [(39, 38)], 'id': 'DDI-DrugBank.d603.s5.e11'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha-adrenergic agents , such terazosin and can effects ProAmatine Potential Drug : It , although is evidence , that clearance of desglymidodrine a is active secretion by the secreting also responsible for the such metformin , ranitidine procainamide , flecainide and
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	cimetidine	flecainide	none	{'e1': {'word': 'cimetidine', 'word_index': [(36, 35)], 'id': 'DDI-DrugBank.d603.s5.e8'}, 'e2': {'word': 'flecainide', 'word_index': [(40, 39)], 'id': 'DDI-DrugBank.d603.s5.e12'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha-adrenergic agents , such terazosin and can effects ProAmatine Potential Drug : It , although is evidence , that clearance of desglymidodrine a is active secretion by the secreting also responsible for the such metformin , ranitidine procainamide triamterene , and
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	cimetidine	quinidine	none	{'e1': {'word': 'cimetidine', 'word_index': [(36, 35)], 'id': 'DDI-DrugBank.d603.s5.e8'}, 'e2': {'word': 'quinidine', 'word_index': [(42, 41)], 'id': 'DDI-DrugBank.d603.s5.e13'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha-adrenergic agents , such terazosin and can effects ProAmatine Potential Drug : It , although is evidence , that clearance of desglymidodrine a is active secretion by the secreting also responsible for the such metformin , ranitidine procainamide triamterene flecainide and .
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	ranitidine	procainamide	none	{'e1': {'word': 'ranitidine', 'word_index': [(37, 36)], 'id': 'DDI-DrugBank.d603.s5.e9'}, 'e2': {'word': 'procainamide', 'word_index': [(38, 37)], 'id': 'DDI-DrugBank.d603.s5.e10'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha-adrenergic agents , such terazosin and can effects ProAmatine Potential Drug : It , although is evidence , that clearance of desglymidodrine a is active secretion by the secreting also responsible for the such metformin cimetidine , , triamterene flecainide and
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	ranitidine	triamterene	none	{'e1': {'word': 'ranitidine', 'word_index': [(37, 36)], 'id': 'DDI-DrugBank.d603.s5.e9'}, 'e2': {'word': 'triamterene', 'word_index': [(39, 38)], 'id': 'DDI-DrugBank.d603.s5.e11'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha-adrenergic agents , such terazosin and can effects ProAmatine Potential Drug : It , although is evidence , that clearance of desglymidodrine a is active secretion by the secreting also responsible for the such metformin cimetidine , procainamide , flecainide and
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	ranitidine	flecainide	none	{'e1': {'word': 'ranitidine', 'word_index': [(37, 36)], 'id': 'DDI-DrugBank.d603.s5.e9'}, 'e2': {'word': 'flecainide', 'word_index': [(40, 39)], 'id': 'DDI-DrugBank.d603.s5.e12'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha-adrenergic agents , such terazosin and can effects ProAmatine Potential Drug : It , although is evidence , that clearance of desglymidodrine a is active secretion by the secreting also responsible for the such metformin cimetidine , procainamide triamterene , and
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	ranitidine	quinidine	none	{'e1': {'word': 'ranitidine', 'word_index': [(37, 36)], 'id': 'DDI-DrugBank.d603.s5.e9'}, 'e2': {'word': 'quinidine', 'word_index': [(42, 41)], 'id': 'DDI-DrugBank.d603.s5.e13'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha-adrenergic agents , such terazosin and can effects ProAmatine Potential Drug : It , although is evidence , that clearance of desglymidodrine a is active secretion by the secreting also responsible for the such metformin cimetidine , procainamide triamterene flecainide and .
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	procainamide	triamterene	none	{'e1': {'word': 'procainamide', 'word_index': [(38, 37)], 'id': 'DDI-DrugBank.d603.s5.e10'}, 'e2': {'word': 'triamterene', 'word_index': [(39, 38)], 'id': 'DDI-DrugBank.d603.s5.e11'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha-adrenergic agents , such terazosin and can effects ProAmatine Potential Drug : It , although is evidence , that clearance of desglymidodrine a is active secretion by the secreting also responsible for the such metformin cimetidine ranitidine , , flecainide and
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	procainamide	flecainide	none	{'e1': {'word': 'procainamide', 'word_index': [(38, 37)], 'id': 'DDI-DrugBank.d603.s5.e10'}, 'e2': {'word': 'flecainide', 'word_index': [(40, 39)], 'id': 'DDI-DrugBank.d603.s5.e12'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha-adrenergic agents , such terazosin and can effects ProAmatine Potential Drug : It , although is evidence , that clearance of desglymidodrine a is active secretion by the secreting also responsible for the such metformin cimetidine ranitidine , triamterene , and
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	procainamide	quinidine	none	{'e1': {'word': 'procainamide', 'word_index': [(38, 37)], 'id': 'DDI-DrugBank.d603.s5.e10'}, 'e2': {'word': 'quinidine', 'word_index': [(42, 41)], 'id': 'DDI-DrugBank.d603.s5.e13'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha-adrenergic agents , such terazosin and can effects ProAmatine Potential Drug : It , although is evidence , that clearance of desglymidodrine a is active secretion by the secreting also responsible for the such metformin cimetidine ranitidine , triamterene flecainide and .
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	triamterene	flecainide	none	{'e1': {'word': 'triamterene', 'word_index': [(39, 38)], 'id': 'DDI-DrugBank.d603.s5.e11'}, 'e2': {'word': 'flecainide', 'word_index': [(40, 39)], 'id': 'DDI-DrugBank.d603.s5.e12'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha-adrenergic agents , such terazosin and can effects ProAmatine Potential Drug : It , although is evidence , that clearance of desglymidodrine a is active secretion by the secreting also responsible for the such metformin cimetidine ranitidine procainamide , , and
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	triamterene	quinidine	none	{'e1': {'word': 'triamterene', 'word_index': [(39, 38)], 'id': 'DDI-DrugBank.d603.s5.e11'}, 'e2': {'word': 'quinidine', 'word_index': [(42, 41)], 'id': 'DDI-DrugBank.d603.s5.e13'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha-adrenergic agents , such terazosin and can effects ProAmatine Potential Drug : It , although is evidence , that clearance of desglymidodrine a is active secretion by the secreting also responsible for the such metformin cimetidine ranitidine procainamide , flecainide and .
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. 	flecainide	quinidine	none	{'e1': {'word': 'flecainide', 'word_index': [(40, 39)], 'id': 'DDI-DrugBank.d603.s5.e12'}, 'e2': {'word': 'quinidine', 'word_index': [(42, 41)], 'id': 'DDI-DrugBank.d603.s5.e13'}, 'sentence_id': 'DDI-DrugBank.d603.s5'}	ProAmatine Alpha-adrenergic agents , such terazosin and can effects ProAmatine Potential Drug : It , although is evidence , that clearance of desglymidodrine a is active secretion by the secreting also responsible for the such metformin cimetidine ranitidine procainamide triamterene , and .
Concurrent use of alcohol and other CNS depression-producing drugs may increase the CNS depressant effects of methyprylon or these other medications.	alcohol	CNS depression-producing drugs	none	{'e1': {'word': 'alcohol', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d600.s1.e0'}, 'e2': {'word': 'CNS depression-producing drugs', 'word_index': [(3, 6)], 'id': 'DDI-DrugBank.d600.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d600.s1'}	Concurrent use alcohol CNS depression producing drugs may increase CNS depressant effects methyprylon medications
Concurrent use of alcohol and other CNS depression-producing drugs may increase the CNS depressant effects of methyprylon or these other medications.	alcohol	methyprylon	effect	{'e1': {'word': 'alcohol', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d600.s1.e0'}, 'e2': {'word': 'methyprylon', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d600.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d600.s1'}	Concurrent use alcohol CNS depression producing drugs may increase CNS depressant effects methyprylon medications
Concurrent use of alcohol and other CNS depression-producing drugs may increase the CNS depressant effects of methyprylon or these other medications.	CNS depression-producing drugs	methyprylon	effect	{'e1': {'word': 'CNS depression-producing drugs', 'word_index': [(3, 6)], 'id': 'DDI-DrugBank.d600.s1.e1'}, 'e2': {'word': 'methyprylon', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d600.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d600.s1'}	Concurrent use alcohol CNS depression producing drugs may increase CNS depressant effects methyprylon medications
Other short-acting beta adrenergic aerosol bronchodilators should not be used concomitantly with MAXAIR AUTOHALER because they may have additive effects.	short-acting beta adrenergic aerosol bronchodilators	MAXAIR AUTOHALER	advise	{'e1': {'word': 'short-acting beta adrenergic aerosol bronchodilators', 'word_index': [(0, 5)], 'id': 'DDI-DrugBank.d635.s0.e0'}, 'e2': {'word': 'MAXAIR AUTOHALER', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d635.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d635.s0'}	short acting beta adrenergic aerosol bronchodilators used concomitantly MAXAIR AUTOHALER may additive effects
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 	MYCAMINE	mycophenolate mofetil	none	{'e1': {'word': 'MYCAMINE', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d735.s0.e0'}, 'e2': {'word': 'mycophenolate mofetil', 'word_index': [(14, 15)], 'id': 'DDI-DrugBank.d735.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d735.s0'}	total NUMBER clinical drug drug interaction studies conducted healthy volunteers evaluate potential interaction MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone sirolimus nifedipine fluconazole ritonavir rifampin
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 	MYCAMINE	cyclosporine	none	{'e1': {'word': 'MYCAMINE', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d735.s0.e0'}, 'e2': {'word': 'cyclosporine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d735.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d735.s0'}	total NUMBER clinical drug drug interaction studies conducted healthy volunteers evaluate potential interaction MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone sirolimus nifedipine fluconazole ritonavir rifampin
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 	MYCAMINE	tacrolimus	none	{'e1': {'word': 'MYCAMINE', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d735.s0.e0'}, 'e2': {'word': 'tacrolimus', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d735.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d735.s0'}	total NUMBER clinical drug drug interaction studies conducted healthy volunteers evaluate potential interaction MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone sirolimus nifedipine fluconazole ritonavir rifampin
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 	MYCAMINE	prednisolone	none	{'e1': {'word': 'MYCAMINE', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d735.s0.e0'}, 'e2': {'word': 'prednisolone', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d735.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d735.s0'}	total NUMBER clinical drug drug interaction studies conducted healthy volunteers evaluate potential interaction MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone sirolimus nifedipine fluconazole ritonavir rifampin
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 	MYCAMINE	sirolimus	none	{'e1': {'word': 'MYCAMINE', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d735.s0.e0'}, 'e2': {'word': 'sirolimus', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d735.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d735.s0'}	total NUMBER clinical drug drug interaction studies conducted healthy volunteers evaluate potential interaction MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone sirolimus nifedipine fluconazole ritonavir rifampin
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 	MYCAMINE	nifedipine	none	{'e1': {'word': 'MYCAMINE', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d735.s0.e0'}, 'e2': {'word': 'nifedipine', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d735.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d735.s0'}	total NUMBER clinical drug drug interaction studies conducted healthy volunteers evaluate potential interaction MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone sirolimus nifedipine fluconazole ritonavir rifampin
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 	MYCAMINE	fluconazole	none	{'e1': {'word': 'MYCAMINE', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d735.s0.e0'}, 'e2': {'word': 'fluconazole', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d735.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d735.s0'}	total NUMBER clinical drug drug interaction studies conducted healthy volunteers evaluate potential interaction MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone sirolimus nifedipine fluconazole ritonavir rifampin
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 	MYCAMINE	ritonavir	none	{'e1': {'word': 'MYCAMINE', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d735.s0.e0'}, 'e2': {'word': 'ritonavir', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d735.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d735.s0'}	total NUMBER clinical drug drug interaction studies conducted healthy volunteers evaluate potential interaction MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone sirolimus nifedipine fluconazole ritonavir rifampin
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 	MYCAMINE	rifampin	none	{'e1': {'word': 'MYCAMINE', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d735.s0.e0'}, 'e2': {'word': 'rifampin', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d735.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d735.s0'}	total NUMBER clinical drug drug interaction studies conducted healthy volunteers evaluate potential interaction MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone sirolimus nifedipine fluconazole ritonavir rifampin
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 	mycophenolate mofetil	cyclosporine	none	{'e1': {'word': 'mycophenolate mofetil', 'word_index': [(14, 15)], 'id': 'DDI-DrugBank.d735.s0.e1'}, 'e2': {'word': 'cyclosporine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d735.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d735.s0'}	total NUMBER clinical drug drug interaction studies conducted healthy volunteers evaluate potential interaction MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone sirolimus nifedipine fluconazole ritonavir rifampin
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 	mycophenolate mofetil	tacrolimus	none	{'e1': {'word': 'mycophenolate mofetil', 'word_index': [(14, 15)], 'id': 'DDI-DrugBank.d735.s0.e1'}, 'e2': {'word': 'tacrolimus', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d735.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d735.s0'}	total NUMBER clinical drug drug interaction studies conducted healthy volunteers evaluate potential interaction MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone sirolimus nifedipine fluconazole ritonavir rifampin
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 	mycophenolate mofetil	prednisolone	none	{'e1': {'word': 'mycophenolate mofetil', 'word_index': [(14, 15)], 'id': 'DDI-DrugBank.d735.s0.e1'}, 'e2': {'word': 'prednisolone', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d735.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d735.s0'}	total NUMBER clinical drug drug interaction studies conducted healthy volunteers evaluate potential interaction MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone sirolimus nifedipine fluconazole ritonavir rifampin
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 	mycophenolate mofetil	sirolimus	none	{'e1': {'word': 'mycophenolate mofetil', 'word_index': [(14, 15)], 'id': 'DDI-DrugBank.d735.s0.e1'}, 'e2': {'word': 'sirolimus', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d735.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d735.s0'}	total NUMBER clinical drug drug interaction studies conducted healthy volunteers evaluate potential interaction MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone sirolimus nifedipine fluconazole ritonavir rifampin
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 	mycophenolate mofetil	nifedipine	none	{'e1': {'word': 'mycophenolate mofetil', 'word_index': [(14, 15)], 'id': 'DDI-DrugBank.d735.s0.e1'}, 'e2': {'word': 'nifedipine', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d735.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d735.s0'}	total NUMBER clinical drug drug interaction studies conducted healthy volunteers evaluate potential interaction MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone sirolimus nifedipine fluconazole ritonavir rifampin
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 	mycophenolate mofetil	fluconazole	none	{'e1': {'word': 'mycophenolate mofetil', 'word_index': [(14, 15)], 'id': 'DDI-DrugBank.d735.s0.e1'}, 'e2': {'word': 'fluconazole', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d735.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d735.s0'}	total NUMBER clinical drug drug interaction studies conducted healthy volunteers evaluate potential interaction MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone sirolimus nifedipine fluconazole ritonavir rifampin
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 	mycophenolate mofetil	ritonavir	none	{'e1': {'word': 'mycophenolate mofetil', 'word_index': [(14, 15)], 'id': 'DDI-DrugBank.d735.s0.e1'}, 'e2': {'word': 'ritonavir', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d735.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d735.s0'}	total NUMBER clinical drug drug interaction studies conducted healthy volunteers evaluate potential interaction MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone sirolimus nifedipine fluconazole ritonavir rifampin
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 	mycophenolate mofetil	rifampin	none	{'e1': {'word': 'mycophenolate mofetil', 'word_index': [(14, 15)], 'id': 'DDI-DrugBank.d735.s0.e1'}, 'e2': {'word': 'rifampin', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d735.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d735.s0'}	total NUMBER clinical drug drug interaction studies conducted healthy volunteers evaluate potential interaction MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone sirolimus nifedipine fluconazole ritonavir rifampin
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 	cyclosporine	tacrolimus	none	{'e1': {'word': 'cyclosporine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d735.s0.e2'}, 'e2': {'word': 'tacrolimus', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d735.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d735.s0'}	total NUMBER clinical drug drug interaction studies conducted healthy volunteers evaluate potential interaction MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone sirolimus nifedipine fluconazole ritonavir rifampin
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 	cyclosporine	prednisolone	none	{'e1': {'word': 'cyclosporine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d735.s0.e2'}, 'e2': {'word': 'prednisolone', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d735.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d735.s0'}	total NUMBER clinical drug drug interaction studies conducted healthy volunteers evaluate potential interaction MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone sirolimus nifedipine fluconazole ritonavir rifampin
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 	cyclosporine	sirolimus	none	{'e1': {'word': 'cyclosporine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d735.s0.e2'}, 'e2': {'word': 'sirolimus', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d735.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d735.s0'}	total NUMBER clinical drug drug interaction studies conducted healthy volunteers evaluate potential interaction MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone sirolimus nifedipine fluconazole ritonavir rifampin
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 	cyclosporine	nifedipine	none	{'e1': {'word': 'cyclosporine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d735.s0.e2'}, 'e2': {'word': 'nifedipine', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d735.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d735.s0'}	total NUMBER clinical drug drug interaction studies conducted healthy volunteers evaluate potential interaction MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone sirolimus nifedipine fluconazole ritonavir rifampin
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 	cyclosporine	fluconazole	none	{'e1': {'word': 'cyclosporine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d735.s0.e2'}, 'e2': {'word': 'fluconazole', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d735.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d735.s0'}	total NUMBER clinical drug drug interaction studies conducted healthy volunteers evaluate potential interaction MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone sirolimus nifedipine fluconazole ritonavir rifampin
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 	cyclosporine	ritonavir	none	{'e1': {'word': 'cyclosporine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d735.s0.e2'}, 'e2': {'word': 'ritonavir', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d735.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d735.s0'}	total NUMBER clinical drug drug interaction studies conducted healthy volunteers evaluate potential interaction MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone sirolimus nifedipine fluconazole ritonavir rifampin
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 	cyclosporine	rifampin	none	{'e1': {'word': 'cyclosporine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d735.s0.e2'}, 'e2': {'word': 'rifampin', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d735.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d735.s0'}	total NUMBER clinical drug drug interaction studies conducted healthy volunteers evaluate potential interaction MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone sirolimus nifedipine fluconazole ritonavir rifampin
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 	tacrolimus	prednisolone	none	{'e1': {'word': 'tacrolimus', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d735.s0.e3'}, 'e2': {'word': 'prednisolone', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d735.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d735.s0'}	total NUMBER clinical drug drug interaction studies conducted healthy volunteers evaluate potential interaction MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone sirolimus nifedipine fluconazole ritonavir rifampin
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 	tacrolimus	sirolimus	none	{'e1': {'word': 'tacrolimus', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d735.s0.e3'}, 'e2': {'word': 'sirolimus', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d735.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d735.s0'}	total NUMBER clinical drug drug interaction studies conducted healthy volunteers evaluate potential interaction MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone sirolimus nifedipine fluconazole ritonavir rifampin
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 	tacrolimus	nifedipine	none	{'e1': {'word': 'tacrolimus', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d735.s0.e3'}, 'e2': {'word': 'nifedipine', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d735.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d735.s0'}	total NUMBER clinical drug drug interaction studies conducted healthy volunteers evaluate potential interaction MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone sirolimus nifedipine fluconazole ritonavir rifampin
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 	tacrolimus	fluconazole	none	{'e1': {'word': 'tacrolimus', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d735.s0.e3'}, 'e2': {'word': 'fluconazole', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d735.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d735.s0'}	total NUMBER clinical drug drug interaction studies conducted healthy volunteers evaluate potential interaction MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone sirolimus nifedipine fluconazole ritonavir rifampin
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 	tacrolimus	ritonavir	none	{'e1': {'word': 'tacrolimus', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d735.s0.e3'}, 'e2': {'word': 'ritonavir', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d735.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d735.s0'}	total NUMBER clinical drug drug interaction studies conducted healthy volunteers evaluate potential interaction MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone sirolimus nifedipine fluconazole ritonavir rifampin
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 	tacrolimus	rifampin	none	{'e1': {'word': 'tacrolimus', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d735.s0.e3'}, 'e2': {'word': 'rifampin', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d735.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d735.s0'}	total NUMBER clinical drug drug interaction studies conducted healthy volunteers evaluate potential interaction MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone sirolimus nifedipine fluconazole ritonavir rifampin
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 	prednisolone	sirolimus	none	{'e1': {'word': 'prednisolone', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d735.s0.e4'}, 'e2': {'word': 'sirolimus', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d735.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d735.s0'}	total NUMBER clinical drug drug interaction studies conducted healthy volunteers evaluate potential interaction MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone sirolimus nifedipine fluconazole ritonavir rifampin
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 	prednisolone	nifedipine	none	{'e1': {'word': 'prednisolone', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d735.s0.e4'}, 'e2': {'word': 'nifedipine', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d735.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d735.s0'}	total NUMBER clinical drug drug interaction studies conducted healthy volunteers evaluate potential interaction MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone sirolimus nifedipine fluconazole ritonavir rifampin
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 	prednisolone	fluconazole	none	{'e1': {'word': 'prednisolone', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d735.s0.e4'}, 'e2': {'word': 'fluconazole', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d735.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d735.s0'}	total NUMBER clinical drug drug interaction studies conducted healthy volunteers evaluate potential interaction MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone sirolimus nifedipine fluconazole ritonavir rifampin
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 	prednisolone	ritonavir	none	{'e1': {'word': 'prednisolone', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d735.s0.e4'}, 'e2': {'word': 'ritonavir', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d735.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d735.s0'}	total NUMBER clinical drug drug interaction studies conducted healthy volunteers evaluate potential interaction MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone sirolimus nifedipine fluconazole ritonavir rifampin
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 	prednisolone	rifampin	none	{'e1': {'word': 'prednisolone', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d735.s0.e4'}, 'e2': {'word': 'rifampin', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d735.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d735.s0'}	total NUMBER clinical drug drug interaction studies conducted healthy volunteers evaluate potential interaction MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone sirolimus nifedipine fluconazole ritonavir rifampin
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 	sirolimus	nifedipine	none	{'e1': {'word': 'sirolimus', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d735.s0.e5'}, 'e2': {'word': 'nifedipine', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d735.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d735.s0'}	total NUMBER clinical drug drug interaction studies conducted healthy volunteers evaluate potential interaction MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone sirolimus nifedipine fluconazole ritonavir rifampin
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 	sirolimus	fluconazole	none	{'e1': {'word': 'sirolimus', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d735.s0.e5'}, 'e2': {'word': 'fluconazole', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d735.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d735.s0'}	total NUMBER clinical drug drug interaction studies conducted healthy volunteers evaluate potential interaction MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone sirolimus nifedipine fluconazole ritonavir rifampin
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 	sirolimus	ritonavir	none	{'e1': {'word': 'sirolimus', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d735.s0.e5'}, 'e2': {'word': 'ritonavir', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d735.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d735.s0'}	total NUMBER clinical drug drug interaction studies conducted healthy volunteers evaluate potential interaction MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone sirolimus nifedipine fluconazole ritonavir rifampin
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 	sirolimus	rifampin	none	{'e1': {'word': 'sirolimus', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d735.s0.e5'}, 'e2': {'word': 'rifampin', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d735.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d735.s0'}	total NUMBER clinical drug drug interaction studies conducted healthy volunteers evaluate potential interaction MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone sirolimus nifedipine fluconazole ritonavir rifampin
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 	nifedipine	fluconazole	none	{'e1': {'word': 'nifedipine', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d735.s0.e6'}, 'e2': {'word': 'fluconazole', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d735.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d735.s0'}	total NUMBER clinical drug drug interaction studies conducted healthy volunteers evaluate potential interaction MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone sirolimus nifedipine fluconazole ritonavir rifampin
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 	nifedipine	ritonavir	none	{'e1': {'word': 'nifedipine', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d735.s0.e6'}, 'e2': {'word': 'ritonavir', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d735.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d735.s0'}	total NUMBER clinical drug drug interaction studies conducted healthy volunteers evaluate potential interaction MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone sirolimus nifedipine fluconazole ritonavir rifampin
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 	nifedipine	rifampin	none	{'e1': {'word': 'nifedipine', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d735.s0.e6'}, 'e2': {'word': 'rifampin', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d735.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d735.s0'}	total NUMBER clinical drug drug interaction studies conducted healthy volunteers evaluate potential interaction MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone sirolimus nifedipine fluconazole ritonavir rifampin
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 	fluconazole	ritonavir	none	{'e1': {'word': 'fluconazole', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d735.s0.e7'}, 'e2': {'word': 'ritonavir', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d735.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d735.s0'}	total NUMBER clinical drug drug interaction studies conducted healthy volunteers evaluate potential interaction MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone sirolimus nifedipine fluconazole ritonavir rifampin
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 	fluconazole	rifampin	none	{'e1': {'word': 'fluconazole', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d735.s0.e7'}, 'e2': {'word': 'rifampin', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d735.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d735.s0'}	total NUMBER clinical drug drug interaction studies conducted healthy volunteers evaluate potential interaction MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone sirolimus nifedipine fluconazole ritonavir rifampin
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. 	ritonavir	rifampin	none	{'e1': {'word': 'ritonavir', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d735.s0.e8'}, 'e2': {'word': 'rifampin', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d735.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d735.s0'}	total NUMBER clinical drug drug interaction studies conducted healthy volunteers evaluate potential interaction MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone sirolimus nifedipine fluconazole ritonavir rifampin
There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics. 	MYCAMINE	mycophenolate mofetil	none	{'e1': {'word': 'MYCAMINE', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d735.s2.e0'}, 'e2': {'word': 'mycophenolate mofetil', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d735.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d735.s2'}	effect single dose multiple doses MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone fluconazole pharmacokinetics
There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics. 	MYCAMINE	cyclosporine	none	{'e1': {'word': 'MYCAMINE', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d735.s2.e0'}, 'e2': {'word': 'cyclosporine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d735.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d735.s2'}	effect single dose multiple doses MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone fluconazole pharmacokinetics
There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics. 	MYCAMINE	tacrolimus	none	{'e1': {'word': 'MYCAMINE', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d735.s2.e0'}, 'e2': {'word': 'tacrolimus', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d735.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d735.s2'}	effect single dose multiple doses MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone fluconazole pharmacokinetics
There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics. 	MYCAMINE	prednisolone	none	{'e1': {'word': 'MYCAMINE', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d735.s2.e0'}, 'e2': {'word': 'prednisolone', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d735.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d735.s2'}	effect single dose multiple doses MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone fluconazole pharmacokinetics
There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics. 	MYCAMINE	fluconazole	none	{'e1': {'word': 'MYCAMINE', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d735.s2.e0'}, 'e2': {'word': 'fluconazole', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d735.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d735.s2'}	effect single dose multiple doses MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone fluconazole pharmacokinetics
There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics. 	mycophenolate mofetil	cyclosporine	none	{'e1': {'word': 'mycophenolate mofetil', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d735.s2.e1'}, 'e2': {'word': 'cyclosporine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d735.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d735.s2'}	effect single dose multiple doses MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone fluconazole pharmacokinetics
There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics. 	mycophenolate mofetil	tacrolimus	none	{'e1': {'word': 'mycophenolate mofetil', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d735.s2.e1'}, 'e2': {'word': 'tacrolimus', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d735.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d735.s2'}	effect single dose multiple doses MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone fluconazole pharmacokinetics
There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics. 	mycophenolate mofetil	prednisolone	none	{'e1': {'word': 'mycophenolate mofetil', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d735.s2.e1'}, 'e2': {'word': 'prednisolone', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d735.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d735.s2'}	effect single dose multiple doses MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone fluconazole pharmacokinetics
There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics. 	mycophenolate mofetil	fluconazole	none	{'e1': {'word': 'mycophenolate mofetil', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d735.s2.e1'}, 'e2': {'word': 'fluconazole', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d735.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d735.s2'}	effect single dose multiple doses MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone fluconazole pharmacokinetics
There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics. 	cyclosporine	tacrolimus	none	{'e1': {'word': 'cyclosporine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d735.s2.e2'}, 'e2': {'word': 'tacrolimus', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d735.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d735.s2'}	effect single dose multiple doses MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone fluconazole pharmacokinetics
There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics. 	cyclosporine	prednisolone	none	{'e1': {'word': 'cyclosporine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d735.s2.e2'}, 'e2': {'word': 'prednisolone', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d735.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d735.s2'}	effect single dose multiple doses MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone fluconazole pharmacokinetics
There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics. 	cyclosporine	fluconazole	none	{'e1': {'word': 'cyclosporine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d735.s2.e2'}, 'e2': {'word': 'fluconazole', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d735.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d735.s2'}	effect single dose multiple doses MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone fluconazole pharmacokinetics
There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics. 	tacrolimus	prednisolone	none	{'e1': {'word': 'tacrolimus', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d735.s2.e3'}, 'e2': {'word': 'prednisolone', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d735.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d735.s2'}	effect single dose multiple doses MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone fluconazole pharmacokinetics
There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics. 	tacrolimus	fluconazole	none	{'e1': {'word': 'tacrolimus', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d735.s2.e3'}, 'e2': {'word': 'fluconazole', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d735.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d735.s2'}	effect single dose multiple doses MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone fluconazole pharmacokinetics
There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics. 	prednisolone	fluconazole	none	{'e1': {'word': 'prednisolone', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d735.s2.e4'}, 'e2': {'word': 'fluconazole', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d735.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d735.s2'}	effect single dose multiple doses MYCAMINE mycophenolate mofetil cyclosporine tacrolimus prednisolone fluconazole pharmacokinetics
Sirolimus AUC was increased by 21% with no effect on Cmax in the presence of steady-state MYCAMINE compared with sirolimus alone. 	Sirolimus	MYCAMINE	mechanism	{'e1': {'word': 'Sirolimus', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d735.s3.e0'}, 'e2': {'word': 'MYCAMINE', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d735.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d735.s3'}	Sirolimus AUC increased NUMBER % effect Cmax presence steady state MYCAMINE compared sirolimus alone
Sirolimus AUC was increased by 21% with no effect on Cmax in the presence of steady-state MYCAMINE compared with sirolimus alone. 	Sirolimus	sirolimus	none	{'e1': {'word': 'Sirolimus', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d735.s3.e0'}, 'e2': {'word': 'sirolimus', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d735.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d735.s3'}	Sirolimus AUC increased NUMBER % effect Cmax presence steady state MYCAMINE compared sirolimus alone
Sirolimus AUC was increased by 21% with no effect on Cmax in the presence of steady-state MYCAMINE compared with sirolimus alone. 	MYCAMINE	sirolimus	none	{'e1': {'word': 'MYCAMINE', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d735.s3.e1'}, 'e2': {'word': 'sirolimus', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d735.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d735.s3'}	Sirolimus AUC increased NUMBER % effect Cmax presence steady state MYCAMINE compared sirolimus alone
Nifedipine AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state MYCAMINE compared with nifedipine alone. 	Nifedipine	MYCAMINE	mechanism	{'e1': {'word': 'Nifedipine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d735.s4.e0'}, 'e2': {'word': 'MYCAMINE', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d735.s4.e1'}, 'sentence_id': 'DDI-DrugBank.d735.s4'}	Nifedipine AUC Cmax increased NUMBER % NUMBER % respectively presence steady state MYCAMINE compared nifedipine alone
Nifedipine AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state MYCAMINE compared with nifedipine alone. 	Nifedipine	nifedipine	none	{'e1': {'word': 'Nifedipine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d735.s4.e0'}, 'e2': {'word': 'nifedipine', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d735.s4.e2'}, 'sentence_id': 'DDI-DrugBank.d735.s4'}	Nifedipine AUC Cmax increased NUMBER % NUMBER % respectively presence steady state MYCAMINE compared nifedipine alone
Nifedipine AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state MYCAMINE compared with nifedipine alone. 	MYCAMINE	nifedipine	none	{'e1': {'word': 'MYCAMINE', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d735.s4.e1'}, 'e2': {'word': 'nifedipine', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d735.s4.e2'}, 'sentence_id': 'DDI-DrugBank.d735.s4'}	Nifedipine AUC Cmax increased NUMBER % NUMBER % respectively presence steady state MYCAMINE compared nifedipine alone
Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. 	sirolimus	nifedipine	none	{'e1': {'word': 'sirolimus', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d735.s5.e0'}, 'e2': {'word': 'nifedipine', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d735.s5.e1'}, 'sentence_id': 'DDI-DrugBank.d735.s5'}	Patients receiving sirolimus nifedipine combination MYCAMINE monitored sirolimus nifedipine toxicity sirolimus nifedipine dosage reduced necessary
Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. 	sirolimus	MYCAMINE	advise	{'e1': {'word': 'sirolimus', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d735.s5.e0'}, 'e2': {'word': 'MYCAMINE', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d735.s5.e2'}, 'sentence_id': 'DDI-DrugBank.d735.s5'}	Patients receiving sirolimus nifedipine combination MYCAMINE monitored sirolimus nifedipine toxicity sirolimus nifedipine dosage reduced necessary
Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. 	sirolimus	sirolimus	none	{'e1': {'word': 'sirolimus', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d735.s5.e0'}, 'e2': {'word': 'sirolimus', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d735.s5.e3'}, 'sentence_id': 'DDI-DrugBank.d735.s5'}	Patients receiving sirolimus nifedipine combination MYCAMINE monitored sirolimus nifedipine toxicity sirolimus nifedipine dosage reduced necessary
Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. 	sirolimus	nifedipine	none	{'e1': {'word': 'sirolimus', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d735.s5.e0'}, 'e2': {'word': 'nifedipine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d735.s5.e4'}, 'sentence_id': 'DDI-DrugBank.d735.s5'}	Patients receiving sirolimus nifedipine combination MYCAMINE monitored sirolimus nifedipine toxicity sirolimus nifedipine dosage reduced necessary
Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. 	sirolimus	sirolimus	none	{'e1': {'word': 'sirolimus', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d735.s5.e0'}, 'e2': {'word': 'sirolimus', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d735.s5.e5'}, 'sentence_id': 'DDI-DrugBank.d735.s5'}	Patients receiving sirolimus nifedipine combination MYCAMINE monitored sirolimus nifedipine toxicity sirolimus nifedipine dosage reduced necessary
Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. 	sirolimus	nifedipine	none	{'e1': {'word': 'sirolimus', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d735.s5.e0'}, 'e2': {'word': 'nifedipine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d735.s5.e6'}, 'sentence_id': 'DDI-DrugBank.d735.s5'}	Patients receiving sirolimus nifedipine combination MYCAMINE monitored sirolimus nifedipine toxicity sirolimus nifedipine dosage reduced necessary
Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. 	nifedipine	MYCAMINE	advise	{'e1': {'word': 'nifedipine', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d735.s5.e1'}, 'e2': {'word': 'MYCAMINE', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d735.s5.e2'}, 'sentence_id': 'DDI-DrugBank.d735.s5'}	Patients receiving sirolimus nifedipine combination MYCAMINE monitored sirolimus nifedipine toxicity sirolimus nifedipine dosage reduced necessary
Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. 	nifedipine	sirolimus	none	{'e1': {'word': 'nifedipine', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d735.s5.e1'}, 'e2': {'word': 'sirolimus', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d735.s5.e3'}, 'sentence_id': 'DDI-DrugBank.d735.s5'}	Patients receiving sirolimus nifedipine combination MYCAMINE monitored sirolimus nifedipine toxicity sirolimus nifedipine dosage reduced necessary
Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. 	nifedipine	nifedipine	none	{'e1': {'word': 'nifedipine', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d735.s5.e1'}, 'e2': {'word': 'nifedipine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d735.s5.e4'}, 'sentence_id': 'DDI-DrugBank.d735.s5'}	Patients receiving sirolimus nifedipine combination MYCAMINE monitored sirolimus nifedipine toxicity sirolimus nifedipine dosage reduced necessary
Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. 	nifedipine	sirolimus	none	{'e1': {'word': 'nifedipine', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d735.s5.e1'}, 'e2': {'word': 'sirolimus', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d735.s5.e5'}, 'sentence_id': 'DDI-DrugBank.d735.s5'}	Patients receiving sirolimus nifedipine combination MYCAMINE monitored sirolimus nifedipine toxicity sirolimus nifedipine dosage reduced necessary
Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. 	nifedipine	nifedipine	none	{'e1': {'word': 'nifedipine', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d735.s5.e1'}, 'e2': {'word': 'nifedipine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d735.s5.e6'}, 'sentence_id': 'DDI-DrugBank.d735.s5'}	Patients receiving sirolimus nifedipine combination MYCAMINE monitored sirolimus nifedipine toxicity sirolimus nifedipine dosage reduced necessary
Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. 	MYCAMINE	sirolimus	none	{'e1': {'word': 'MYCAMINE', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d735.s5.e2'}, 'e2': {'word': 'sirolimus', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d735.s5.e3'}, 'sentence_id': 'DDI-DrugBank.d735.s5'}	Patients receiving sirolimus nifedipine combination MYCAMINE monitored sirolimus nifedipine toxicity sirolimus nifedipine dosage reduced necessary
Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. 	MYCAMINE	nifedipine	none	{'e1': {'word': 'MYCAMINE', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d735.s5.e2'}, 'e2': {'word': 'nifedipine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d735.s5.e4'}, 'sentence_id': 'DDI-DrugBank.d735.s5'}	Patients receiving sirolimus nifedipine combination MYCAMINE monitored sirolimus nifedipine toxicity sirolimus nifedipine dosage reduced necessary
Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. 	MYCAMINE	sirolimus	none	{'e1': {'word': 'MYCAMINE', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d735.s5.e2'}, 'e2': {'word': 'sirolimus', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d735.s5.e5'}, 'sentence_id': 'DDI-DrugBank.d735.s5'}	Patients receiving sirolimus nifedipine combination MYCAMINE monitored sirolimus nifedipine toxicity sirolimus nifedipine dosage reduced necessary
Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. 	MYCAMINE	nifedipine	none	{'e1': {'word': 'MYCAMINE', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d735.s5.e2'}, 'e2': {'word': 'nifedipine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d735.s5.e6'}, 'sentence_id': 'DDI-DrugBank.d735.s5'}	Patients receiving sirolimus nifedipine combination MYCAMINE monitored sirolimus nifedipine toxicity sirolimus nifedipine dosage reduced necessary
Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. 	sirolimus	nifedipine	none	{'e1': {'word': 'sirolimus', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d735.s5.e3'}, 'e2': {'word': 'nifedipine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d735.s5.e4'}, 'sentence_id': 'DDI-DrugBank.d735.s5'}	Patients receiving sirolimus nifedipine combination MYCAMINE monitored sirolimus nifedipine toxicity sirolimus nifedipine dosage reduced necessary
Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. 	sirolimus	sirolimus	none	{'e1': {'word': 'sirolimus', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d735.s5.e3'}, 'e2': {'word': 'sirolimus', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d735.s5.e5'}, 'sentence_id': 'DDI-DrugBank.d735.s5'}	Patients receiving sirolimus nifedipine combination MYCAMINE monitored sirolimus nifedipine toxicity sirolimus nifedipine dosage reduced necessary
Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. 	sirolimus	nifedipine	none	{'e1': {'word': 'sirolimus', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d735.s5.e3'}, 'e2': {'word': 'nifedipine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d735.s5.e6'}, 'sentence_id': 'DDI-DrugBank.d735.s5'}	Patients receiving sirolimus nifedipine combination MYCAMINE monitored sirolimus nifedipine toxicity sirolimus nifedipine dosage reduced necessary
Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. 	nifedipine	sirolimus	none	{'e1': {'word': 'nifedipine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d735.s5.e4'}, 'e2': {'word': 'sirolimus', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d735.s5.e5'}, 'sentence_id': 'DDI-DrugBank.d735.s5'}	Patients receiving sirolimus nifedipine combination MYCAMINE monitored sirolimus nifedipine toxicity sirolimus nifedipine dosage reduced necessary
Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. 	nifedipine	nifedipine	none	{'e1': {'word': 'nifedipine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d735.s5.e4'}, 'e2': {'word': 'nifedipine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d735.s5.e6'}, 'sentence_id': 'DDI-DrugBank.d735.s5'}	Patients receiving sirolimus nifedipine combination MYCAMINE monitored sirolimus nifedipine toxicity sirolimus nifedipine dosage reduced necessary
Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. 	sirolimus	nifedipine	none	{'e1': {'word': 'sirolimus', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d735.s5.e5'}, 'e2': {'word': 'nifedipine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d735.s5.e6'}, 'sentence_id': 'DDI-DrugBank.d735.s5'}	Patients receiving sirolimus nifedipine combination MYCAMINE monitored sirolimus nifedipine toxicity sirolimus nifedipine dosage reduced necessary
The concomitant use of oxybutynin with other anticholinergic drugs or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects. 	oxybutynin	anticholinergic drugs	effect	{'e1': {'word': 'oxybutynin', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d784.s0.e0'}, 'e2': {'word': 'anticholinergic drugs', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d784.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d784.s0'}	concomitant use oxybutynin anticholinergic drugs agents produce dry mouth constipation somnolence drowsiness anticholinergic like effects may increase frequency severity effects
Mean oxybutynin chloride plasma concentrations were approximately 2 fold higher when DITROPAN XL was administered with ketoconazole, a potent CYP3A4 inhibitor. 	oxybutynin chloride	DITROPAN XL	none	{'e1': {'word': 'oxybutynin chloride', 'word_index': [(1, 2)], 'id': 'DDI-DrugBank.d784.s3.e0'}, 'e2': {'word': 'DITROPAN XL', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d784.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d784.s3'}	Mean oxybutynin chloride plasma concentrations approximately NUMBER fold higher DITROPAN XL administered ketoconazole potent CYP3A4 inhibitor
Mean oxybutynin chloride plasma concentrations were approximately 2 fold higher when DITROPAN XL was administered with ketoconazole, a potent CYP3A4 inhibitor. 	oxybutynin chloride	ketoconazole	none	{'e1': {'word': 'oxybutynin chloride', 'word_index': [(1, 2)], 'id': 'DDI-DrugBank.d784.s3.e0'}, 'e2': {'word': 'ketoconazole', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d784.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d784.s3'}	Mean oxybutynin chloride plasma concentrations approximately NUMBER fold higher DITROPAN XL administered ketoconazole potent CYP3A4 inhibitor
Mean oxybutynin chloride plasma concentrations were approximately 2 fold higher when DITROPAN XL was administered with ketoconazole, a potent CYP3A4 inhibitor. 	DITROPAN XL	ketoconazole	mechanism	{'e1': {'word': 'DITROPAN XL', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d784.s3.e1'}, 'e2': {'word': 'ketoconazole', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d784.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d784.s3'}	Mean oxybutynin chloride plasma concentrations approximately NUMBER fold higher DITROPAN XL administered ketoconazole potent CYP3A4 inhibitor
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). 	antimycotic agents	itraconazole	none	{'e1': {'word': 'antimycotic agents', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d784.s4.e0'}, 'e2': {'word': 'itraconazole', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d784.s4.e1'}, 'sentence_id': 'DDI-DrugBank.d784.s4'}	inhibitors cytochrome P450 3A4 enzyme system antimycotic agents e.g. itraconazole miconazole macrolide antibiotics e.g. erythromycin clarithromycin may alter oxybutynin mean pharmacokinetic parameters i.e. Cmax AUC
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). 	antimycotic agents	miconazole	none	{'e1': {'word': 'antimycotic agents', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d784.s4.e0'}, 'e2': {'word': 'miconazole', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d784.s4.e2'}, 'sentence_id': 'DDI-DrugBank.d784.s4'}	inhibitors cytochrome P450 3A4 enzyme system antimycotic agents e.g. itraconazole miconazole macrolide antibiotics e.g. erythromycin clarithromycin may alter oxybutynin mean pharmacokinetic parameters i.e. Cmax AUC
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). 	antimycotic agents	macrolide antibiotics	none	{'e1': {'word': 'antimycotic agents', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d784.s4.e0'}, 'e2': {'word': 'macrolide antibiotics', 'word_index': [(11, 12)], 'id': 'DDI-DrugBank.d784.s4.e3'}, 'sentence_id': 'DDI-DrugBank.d784.s4'}	inhibitors cytochrome P450 3A4 enzyme system antimycotic agents e.g. itraconazole miconazole macrolide antibiotics e.g. erythromycin clarithromycin may alter oxybutynin mean pharmacokinetic parameters i.e. Cmax AUC
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). 	antimycotic agents	erythromycin	none	{'e1': {'word': 'antimycotic agents', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d784.s4.e0'}, 'e2': {'word': 'erythromycin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d784.s4.e4'}, 'sentence_id': 'DDI-DrugBank.d784.s4'}	inhibitors cytochrome P450 3A4 enzyme system antimycotic agents e.g. itraconazole miconazole macrolide antibiotics e.g. erythromycin clarithromycin may alter oxybutynin mean pharmacokinetic parameters i.e. Cmax AUC
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). 	antimycotic agents	clarithromycin	none	{'e1': {'word': 'antimycotic agents', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d784.s4.e0'}, 'e2': {'word': 'clarithromycin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d784.s4.e5'}, 'sentence_id': 'DDI-DrugBank.d784.s4'}	inhibitors cytochrome P450 3A4 enzyme system antimycotic agents e.g. itraconazole miconazole macrolide antibiotics e.g. erythromycin clarithromycin may alter oxybutynin mean pharmacokinetic parameters i.e. Cmax AUC
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). 	antimycotic agents	oxybutynin	mechanism	{'e1': {'word': 'antimycotic agents', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d784.s4.e0'}, 'e2': {'word': 'oxybutynin', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d784.s4.e6'}, 'sentence_id': 'DDI-DrugBank.d784.s4'}	inhibitors cytochrome P450 3A4 enzyme system antimycotic agents e.g. itraconazole miconazole macrolide antibiotics e.g. erythromycin clarithromycin may alter oxybutynin mean pharmacokinetic parameters i.e. Cmax AUC
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). 	itraconazole	miconazole	none	{'e1': {'word': 'itraconazole', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d784.s4.e1'}, 'e2': {'word': 'miconazole', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d784.s4.e2'}, 'sentence_id': 'DDI-DrugBank.d784.s4'}	inhibitors cytochrome P450 3A4 enzyme system antimycotic agents e.g. itraconazole miconazole macrolide antibiotics e.g. erythromycin clarithromycin may alter oxybutynin mean pharmacokinetic parameters i.e. Cmax AUC
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). 	itraconazole	macrolide antibiotics	none	{'e1': {'word': 'itraconazole', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d784.s4.e1'}, 'e2': {'word': 'macrolide antibiotics', 'word_index': [(11, 12)], 'id': 'DDI-DrugBank.d784.s4.e3'}, 'sentence_id': 'DDI-DrugBank.d784.s4'}	inhibitors cytochrome P450 3A4 enzyme system antimycotic agents e.g. itraconazole miconazole macrolide antibiotics e.g. erythromycin clarithromycin may alter oxybutynin mean pharmacokinetic parameters i.e. Cmax AUC
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). 	itraconazole	erythromycin	none	{'e1': {'word': 'itraconazole', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d784.s4.e1'}, 'e2': {'word': 'erythromycin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d784.s4.e4'}, 'sentence_id': 'DDI-DrugBank.d784.s4'}	inhibitors cytochrome P450 3A4 enzyme system antimycotic agents e.g. itraconazole miconazole macrolide antibiotics e.g. erythromycin clarithromycin may alter oxybutynin mean pharmacokinetic parameters i.e. Cmax AUC
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). 	itraconazole	clarithromycin	none	{'e1': {'word': 'itraconazole', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d784.s4.e1'}, 'e2': {'word': 'clarithromycin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d784.s4.e5'}, 'sentence_id': 'DDI-DrugBank.d784.s4'}	inhibitors cytochrome P450 3A4 enzyme system antimycotic agents e.g. itraconazole miconazole macrolide antibiotics e.g. erythromycin clarithromycin may alter oxybutynin mean pharmacokinetic parameters i.e. Cmax AUC
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). 	itraconazole	oxybutynin	mechanism	{'e1': {'word': 'itraconazole', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d784.s4.e1'}, 'e2': {'word': 'oxybutynin', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d784.s4.e6'}, 'sentence_id': 'DDI-DrugBank.d784.s4'}	inhibitors cytochrome P450 3A4 enzyme system antimycotic agents e.g. itraconazole miconazole macrolide antibiotics e.g. erythromycin clarithromycin may alter oxybutynin mean pharmacokinetic parameters i.e. Cmax AUC
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). 	miconazole	macrolide antibiotics	none	{'e1': {'word': 'miconazole', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d784.s4.e2'}, 'e2': {'word': 'macrolide antibiotics', 'word_index': [(11, 12)], 'id': 'DDI-DrugBank.d784.s4.e3'}, 'sentence_id': 'DDI-DrugBank.d784.s4'}	inhibitors cytochrome P450 3A4 enzyme system antimycotic agents e.g. itraconazole miconazole macrolide antibiotics e.g. erythromycin clarithromycin may alter oxybutynin mean pharmacokinetic parameters i.e. Cmax AUC
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). 	miconazole	erythromycin	none	{'e1': {'word': 'miconazole', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d784.s4.e2'}, 'e2': {'word': 'erythromycin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d784.s4.e4'}, 'sentence_id': 'DDI-DrugBank.d784.s4'}	inhibitors cytochrome P450 3A4 enzyme system antimycotic agents e.g. itraconazole miconazole macrolide antibiotics e.g. erythromycin clarithromycin may alter oxybutynin mean pharmacokinetic parameters i.e. Cmax AUC
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). 	miconazole	clarithromycin	none	{'e1': {'word': 'miconazole', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d784.s4.e2'}, 'e2': {'word': 'clarithromycin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d784.s4.e5'}, 'sentence_id': 'DDI-DrugBank.d784.s4'}	inhibitors cytochrome P450 3A4 enzyme system antimycotic agents e.g. itraconazole miconazole macrolide antibiotics e.g. erythromycin clarithromycin may alter oxybutynin mean pharmacokinetic parameters i.e. Cmax AUC
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). 	miconazole	oxybutynin	mechanism	{'e1': {'word': 'miconazole', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d784.s4.e2'}, 'e2': {'word': 'oxybutynin', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d784.s4.e6'}, 'sentence_id': 'DDI-DrugBank.d784.s4'}	inhibitors cytochrome P450 3A4 enzyme system antimycotic agents e.g. itraconazole miconazole macrolide antibiotics e.g. erythromycin clarithromycin may alter oxybutynin mean pharmacokinetic parameters i.e. Cmax AUC
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). 	macrolide antibiotics	erythromycin	none	{'e1': {'word': 'macrolide antibiotics', 'word_index': [(11, 12)], 'id': 'DDI-DrugBank.d784.s4.e3'}, 'e2': {'word': 'erythromycin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d784.s4.e4'}, 'sentence_id': 'DDI-DrugBank.d784.s4'}	inhibitors cytochrome P450 3A4 enzyme system antimycotic agents e.g. itraconazole miconazole macrolide antibiotics e.g. erythromycin clarithromycin may alter oxybutynin mean pharmacokinetic parameters i.e. Cmax AUC
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). 	macrolide antibiotics	clarithromycin	none	{'e1': {'word': 'macrolide antibiotics', 'word_index': [(11, 12)], 'id': 'DDI-DrugBank.d784.s4.e3'}, 'e2': {'word': 'clarithromycin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d784.s4.e5'}, 'sentence_id': 'DDI-DrugBank.d784.s4'}	inhibitors cytochrome P450 3A4 enzyme system antimycotic agents e.g. itraconazole miconazole macrolide antibiotics e.g. erythromycin clarithromycin may alter oxybutynin mean pharmacokinetic parameters i.e. Cmax AUC
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). 	macrolide antibiotics	oxybutynin	mechanism	{'e1': {'word': 'macrolide antibiotics', 'word_index': [(11, 12)], 'id': 'DDI-DrugBank.d784.s4.e3'}, 'e2': {'word': 'oxybutynin', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d784.s4.e6'}, 'sentence_id': 'DDI-DrugBank.d784.s4'}	inhibitors cytochrome P450 3A4 enzyme system antimycotic agents e.g. itraconazole miconazole macrolide antibiotics e.g. erythromycin clarithromycin may alter oxybutynin mean pharmacokinetic parameters i.e. Cmax AUC
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). 	erythromycin	clarithromycin	none	{'e1': {'word': 'erythromycin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d784.s4.e4'}, 'e2': {'word': 'clarithromycin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d784.s4.e5'}, 'sentence_id': 'DDI-DrugBank.d784.s4'}	inhibitors cytochrome P450 3A4 enzyme system antimycotic agents e.g. itraconazole miconazole macrolide antibiotics e.g. erythromycin clarithromycin may alter oxybutynin mean pharmacokinetic parameters i.e. Cmax AUC
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). 	erythromycin	oxybutynin	mechanism	{'e1': {'word': 'erythromycin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d784.s4.e4'}, 'e2': {'word': 'oxybutynin', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d784.s4.e6'}, 'sentence_id': 'DDI-DrugBank.d784.s4'}	inhibitors cytochrome P450 3A4 enzyme system antimycotic agents e.g. itraconazole miconazole macrolide antibiotics e.g. erythromycin clarithromycin may alter oxybutynin mean pharmacokinetic parameters i.e. Cmax AUC
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). 	clarithromycin	oxybutynin	mechanism	{'e1': {'word': 'clarithromycin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d784.s4.e5'}, 'e2': {'word': 'oxybutynin', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d784.s4.e6'}, 'sentence_id': 'DDI-DrugBank.d784.s4'}	inhibitors cytochrome P450 3A4 enzyme system antimycotic agents e.g. itraconazole miconazole macrolide antibiotics e.g. erythromycin clarithromycin may alter oxybutynin mean pharmacokinetic parameters i.e. Cmax AUC
Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    	antacid	antacid	none	{'e1': {'word': 'antacid', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d784.s7.e0'}, 'e2': {'word': 'antacid', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d784.s7.e1'}, 'sentence_id': 'DDI-DrugBank.d784.s7'}	Concurrent ingestion antacid NUMBER mL antacid containing aluminum hydroxide magnesium hydroxide simethicone significantly affect exposure oxybutynin desethyloxybutynin
Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    	antacid	aluminum hydroxide	none	{'e1': {'word': 'antacid', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d784.s7.e0'}, 'e2': {'word': 'aluminum hydroxide', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d784.s7.e2'}, 'sentence_id': 'DDI-DrugBank.d784.s7'}	Concurrent ingestion antacid NUMBER mL antacid containing aluminum hydroxide magnesium hydroxide simethicone significantly affect exposure oxybutynin desethyloxybutynin
Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    	antacid	magnesium hydroxide	none	{'e1': {'word': 'antacid', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d784.s7.e0'}, 'e2': {'word': 'magnesium hydroxide', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d784.s7.e3'}, 'sentence_id': 'DDI-DrugBank.d784.s7'}	Concurrent ingestion antacid NUMBER mL antacid containing aluminum hydroxide magnesium hydroxide simethicone significantly affect exposure oxybutynin desethyloxybutynin
Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    	antacid	simethicone	none	{'e1': {'word': 'antacid', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d784.s7.e0'}, 'e2': {'word': 'simethicone', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d784.s7.e4'}, 'sentence_id': 'DDI-DrugBank.d784.s7'}	Concurrent ingestion antacid NUMBER mL antacid containing aluminum hydroxide magnesium hydroxide simethicone significantly affect exposure oxybutynin desethyloxybutynin
Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    	antacid	oxybutynin	none	{'e1': {'word': 'antacid', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d784.s7.e0'}, 'e2': {'word': 'oxybutynin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d784.s7.e5'}, 'sentence_id': 'DDI-DrugBank.d784.s7'}	Concurrent ingestion antacid NUMBER mL antacid containing aluminum hydroxide magnesium hydroxide simethicone significantly affect exposure oxybutynin desethyloxybutynin
Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    	antacid	desethyloxybutynin	none	{'e1': {'word': 'antacid', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d784.s7.e0'}, 'e2': {'word': 'desethyloxybutynin', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d784.s7.e6'}, 'sentence_id': 'DDI-DrugBank.d784.s7'}	Concurrent ingestion antacid NUMBER mL antacid containing aluminum hydroxide magnesium hydroxide simethicone significantly affect exposure oxybutynin desethyloxybutynin
Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    	antacid	aluminum hydroxide	none	{'e1': {'word': 'antacid', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d784.s7.e1'}, 'e2': {'word': 'aluminum hydroxide', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d784.s7.e2'}, 'sentence_id': 'DDI-DrugBank.d784.s7'}	Concurrent ingestion antacid NUMBER mL antacid containing aluminum hydroxide magnesium hydroxide simethicone significantly affect exposure oxybutynin desethyloxybutynin
Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    	antacid	magnesium hydroxide	none	{'e1': {'word': 'antacid', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d784.s7.e1'}, 'e2': {'word': 'magnesium hydroxide', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d784.s7.e3'}, 'sentence_id': 'DDI-DrugBank.d784.s7'}	Concurrent ingestion antacid NUMBER mL antacid containing aluminum hydroxide magnesium hydroxide simethicone significantly affect exposure oxybutynin desethyloxybutynin
Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    	antacid	simethicone	none	{'e1': {'word': 'antacid', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d784.s7.e1'}, 'e2': {'word': 'simethicone', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d784.s7.e4'}, 'sentence_id': 'DDI-DrugBank.d784.s7'}	Concurrent ingestion antacid NUMBER mL antacid containing aluminum hydroxide magnesium hydroxide simethicone significantly affect exposure oxybutynin desethyloxybutynin
Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    	antacid	oxybutynin	none	{'e1': {'word': 'antacid', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d784.s7.e1'}, 'e2': {'word': 'oxybutynin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d784.s7.e5'}, 'sentence_id': 'DDI-DrugBank.d784.s7'}	Concurrent ingestion antacid NUMBER mL antacid containing aluminum hydroxide magnesium hydroxide simethicone significantly affect exposure oxybutynin desethyloxybutynin
Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    	antacid	desethyloxybutynin	none	{'e1': {'word': 'antacid', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d784.s7.e1'}, 'e2': {'word': 'desethyloxybutynin', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d784.s7.e6'}, 'sentence_id': 'DDI-DrugBank.d784.s7'}	Concurrent ingestion antacid NUMBER mL antacid containing aluminum hydroxide magnesium hydroxide simethicone significantly affect exposure oxybutynin desethyloxybutynin
Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    	aluminum hydroxide	magnesium hydroxide	none	{'e1': {'word': 'aluminum hydroxide', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d784.s7.e2'}, 'e2': {'word': 'magnesium hydroxide', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d784.s7.e3'}, 'sentence_id': 'DDI-DrugBank.d784.s7'}	Concurrent ingestion antacid NUMBER mL antacid containing aluminum hydroxide magnesium hydroxide simethicone significantly affect exposure oxybutynin desethyloxybutynin
Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    	aluminum hydroxide	simethicone	none	{'e1': {'word': 'aluminum hydroxide', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d784.s7.e2'}, 'e2': {'word': 'simethicone', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d784.s7.e4'}, 'sentence_id': 'DDI-DrugBank.d784.s7'}	Concurrent ingestion antacid NUMBER mL antacid containing aluminum hydroxide magnesium hydroxide simethicone significantly affect exposure oxybutynin desethyloxybutynin
Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    	aluminum hydroxide	oxybutynin	none	{'e1': {'word': 'aluminum hydroxide', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d784.s7.e2'}, 'e2': {'word': 'oxybutynin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d784.s7.e5'}, 'sentence_id': 'DDI-DrugBank.d784.s7'}	Concurrent ingestion antacid NUMBER mL antacid containing aluminum hydroxide magnesium hydroxide simethicone significantly affect exposure oxybutynin desethyloxybutynin
Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    	aluminum hydroxide	desethyloxybutynin	none	{'e1': {'word': 'aluminum hydroxide', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d784.s7.e2'}, 'e2': {'word': 'desethyloxybutynin', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d784.s7.e6'}, 'sentence_id': 'DDI-DrugBank.d784.s7'}	Concurrent ingestion antacid NUMBER mL antacid containing aluminum hydroxide magnesium hydroxide simethicone significantly affect exposure oxybutynin desethyloxybutynin
Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    	magnesium hydroxide	simethicone	none	{'e1': {'word': 'magnesium hydroxide', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d784.s7.e3'}, 'e2': {'word': 'simethicone', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d784.s7.e4'}, 'sentence_id': 'DDI-DrugBank.d784.s7'}	Concurrent ingestion antacid NUMBER mL antacid containing aluminum hydroxide magnesium hydroxide simethicone significantly affect exposure oxybutynin desethyloxybutynin
Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    	magnesium hydroxide	oxybutynin	none	{'e1': {'word': 'magnesium hydroxide', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d784.s7.e3'}, 'e2': {'word': 'oxybutynin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d784.s7.e5'}, 'sentence_id': 'DDI-DrugBank.d784.s7'}	Concurrent ingestion antacid NUMBER mL antacid containing aluminum hydroxide magnesium hydroxide simethicone significantly affect exposure oxybutynin desethyloxybutynin
Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    	magnesium hydroxide	desethyloxybutynin	none	{'e1': {'word': 'magnesium hydroxide', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d784.s7.e3'}, 'e2': {'word': 'desethyloxybutynin', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d784.s7.e6'}, 'sentence_id': 'DDI-DrugBank.d784.s7'}	Concurrent ingestion antacid NUMBER mL antacid containing aluminum hydroxide magnesium hydroxide simethicone significantly affect exposure oxybutynin desethyloxybutynin
Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    	simethicone	oxybutynin	none	{'e1': {'word': 'simethicone', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d784.s7.e4'}, 'e2': {'word': 'oxybutynin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d784.s7.e5'}, 'sentence_id': 'DDI-DrugBank.d784.s7'}	Concurrent ingestion antacid NUMBER mL antacid containing aluminum hydroxide magnesium hydroxide simethicone significantly affect exposure oxybutynin desethyloxybutynin
Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    	simethicone	desethyloxybutynin	none	{'e1': {'word': 'simethicone', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d784.s7.e4'}, 'e2': {'word': 'desethyloxybutynin', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d784.s7.e6'}, 'sentence_id': 'DDI-DrugBank.d784.s7'}	Concurrent ingestion antacid NUMBER mL antacid containing aluminum hydroxide magnesium hydroxide simethicone significantly affect exposure oxybutynin desethyloxybutynin
Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    	oxybutynin	desethyloxybutynin	none	{'e1': {'word': 'oxybutynin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d784.s7.e5'}, 'e2': {'word': 'desethyloxybutynin', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d784.s7.e6'}, 'sentence_id': 'DDI-DrugBank.d784.s7'}	Concurrent ingestion antacid NUMBER mL antacid containing aluminum hydroxide magnesium hydroxide simethicone significantly affect exposure oxybutynin desethyloxybutynin
Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants	Vitamin B1	Thiamine	none	{'e1': {'word': 'Vitamin B1', 'word_index': [(1, 2)], 'id': 'DDI-DrugBank.d697.s0.e0'}, 'e2': {'word': 'Thiamine', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d697.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d697.s0'}	Interactions Vitamin B1 Thiamine Loop Diuretics Oral Contraceptives Stavudine Tricyclic Antidepressants
Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants	Vitamin B1	Loop Diuretics	int	{'e1': {'word': 'Vitamin B1', 'word_index': [(1, 2)], 'id': 'DDI-DrugBank.d697.s0.e0'}, 'e2': {'word': 'Loop Diuretics', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d697.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d697.s0'}	Interactions Vitamin B1 Thiamine Loop Diuretics Oral Contraceptives Stavudine Tricyclic Antidepressants
Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants	Vitamin B1	Contraceptives	int	{'e1': {'word': 'Vitamin B1', 'word_index': [(1, 2)], 'id': 'DDI-DrugBank.d697.s0.e0'}, 'e2': {'word': 'Contraceptives', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d697.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d697.s0'}	Interactions Vitamin B1 Thiamine Loop Diuretics Oral Contraceptives Stavudine Tricyclic Antidepressants
Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants	Vitamin B1	Stavudine	int	{'e1': {'word': 'Vitamin B1', 'word_index': [(1, 2)], 'id': 'DDI-DrugBank.d697.s0.e0'}, 'e2': {'word': 'Stavudine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d697.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d697.s0'}	Interactions Vitamin B1 Thiamine Loop Diuretics Oral Contraceptives Stavudine Tricyclic Antidepressants
Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants	Vitamin B1	Tricyclic Antidepressants	int	{'e1': {'word': 'Vitamin B1', 'word_index': [(1, 2)], 'id': 'DDI-DrugBank.d697.s0.e0'}, 'e2': {'word': 'Tricyclic Antidepressants', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d697.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d697.s0'}	Interactions Vitamin B1 Thiamine Loop Diuretics Oral Contraceptives Stavudine Tricyclic Antidepressants
Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants	Thiamine	Loop Diuretics	int	{'e1': {'word': 'Thiamine', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d697.s0.e1'}, 'e2': {'word': 'Loop Diuretics', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d697.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d697.s0'}	Interactions Vitamin B1 Thiamine Loop Diuretics Oral Contraceptives Stavudine Tricyclic Antidepressants
Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants	Thiamine	Contraceptives	int	{'e1': {'word': 'Thiamine', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d697.s0.e1'}, 'e2': {'word': 'Contraceptives', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d697.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d697.s0'}	Interactions Vitamin B1 Thiamine Loop Diuretics Oral Contraceptives Stavudine Tricyclic Antidepressants
Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants	Thiamine	Stavudine	int	{'e1': {'word': 'Thiamine', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d697.s0.e1'}, 'e2': {'word': 'Stavudine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d697.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d697.s0'}	Interactions Vitamin B1 Thiamine Loop Diuretics Oral Contraceptives Stavudine Tricyclic Antidepressants
Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants	Thiamine	Tricyclic Antidepressants	int	{'e1': {'word': 'Thiamine', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d697.s0.e1'}, 'e2': {'word': 'Tricyclic Antidepressants', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d697.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d697.s0'}	Interactions Vitamin B1 Thiamine Loop Diuretics Oral Contraceptives Stavudine Tricyclic Antidepressants
Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants	Loop Diuretics	Contraceptives	none	{'e1': {'word': 'Loop Diuretics', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d697.s0.e2'}, 'e2': {'word': 'Contraceptives', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d697.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d697.s0'}	Interactions Vitamin B1 Thiamine Loop Diuretics Oral Contraceptives Stavudine Tricyclic Antidepressants
Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants	Loop Diuretics	Stavudine	none	{'e1': {'word': 'Loop Diuretics', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d697.s0.e2'}, 'e2': {'word': 'Stavudine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d697.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d697.s0'}	Interactions Vitamin B1 Thiamine Loop Diuretics Oral Contraceptives Stavudine Tricyclic Antidepressants
Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants	Loop Diuretics	Tricyclic Antidepressants	none	{'e1': {'word': 'Loop Diuretics', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d697.s0.e2'}, 'e2': {'word': 'Tricyclic Antidepressants', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d697.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d697.s0'}	Interactions Vitamin B1 Thiamine Loop Diuretics Oral Contraceptives Stavudine Tricyclic Antidepressants
Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants	Contraceptives	Stavudine	none	{'e1': {'word': 'Contraceptives', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d697.s0.e3'}, 'e2': {'word': 'Stavudine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d697.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d697.s0'}	Interactions Vitamin B1 Thiamine Loop Diuretics Oral Contraceptives Stavudine Tricyclic Antidepressants
Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants	Contraceptives	Tricyclic Antidepressants	none	{'e1': {'word': 'Contraceptives', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d697.s0.e3'}, 'e2': {'word': 'Tricyclic Antidepressants', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d697.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d697.s0'}	Interactions Vitamin B1 Thiamine Loop Diuretics Oral Contraceptives Stavudine Tricyclic Antidepressants
Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants	Stavudine	Tricyclic Antidepressants	none	{'e1': {'word': 'Stavudine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d697.s0.e4'}, 'e2': {'word': 'Tricyclic Antidepressants', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d697.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d697.s0'}	Interactions Vitamin B1 Thiamine Loop Diuretics Oral Contraceptives Stavudine Tricyclic Antidepressants
Mutual inhibition of metabolism occurs with concurrent use of cyclosporin and methylprednisolone; 	cyclosporin	methylprednisolone	mechanism	{'e1': {'word': 'cyclosporin', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d578.s1.e0'}, 'e2': {'word': 'methylprednisolone', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d578.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d578.s1'}	Mutual inhibition metabolism occurs concurrent use cyclosporin methylprednisolone
convulsions have been reported with concurrent use of methylprednisolone and cyclosporin. 	methylprednisolone	cyclosporin	effect	{'e1': {'word': 'methylprednisolone', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d578.s3.e0'}, 'e2': {'word': 'cyclosporin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d578.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d578.s3'}	convulsions reported concurrent use methylprednisolone cyclosporin
Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. 	phenobarbital	phenytoin	none	{'e1': {'word': 'phenobarbital', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d578.s4.e0'}, 'e2': {'word': 'phenytoin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d578.s4.e1'}, 'sentence_id': 'DDI-DrugBank.d578.s4'}	Drugs induce hepatic enzymes phenobarbital phenytoin rifampin may increase clearance methylprednisolone may require increased methylprednisolone dose achieve desired response
Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. 	phenobarbital	rifampin	none	{'e1': {'word': 'phenobarbital', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d578.s4.e0'}, 'e2': {'word': 'rifampin', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d578.s4.e2'}, 'sentence_id': 'DDI-DrugBank.d578.s4'}	Drugs induce hepatic enzymes phenobarbital phenytoin rifampin may increase clearance methylprednisolone may require increased methylprednisolone dose achieve desired response
Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. 	phenobarbital	methylprednisolone	mechanism	{'e1': {'word': 'phenobarbital', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d578.s4.e0'}, 'e2': {'word': 'methylprednisolone', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d578.s4.e3'}, 'sentence_id': 'DDI-DrugBank.d578.s4'}	Drugs induce hepatic enzymes phenobarbital phenytoin rifampin may increase clearance methylprednisolone may require increased methylprednisolone dose achieve desired response
Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. 	phenobarbital	methylprednisolone	advise	{'e1': {'word': 'phenobarbital', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d578.s4.e0'}, 'e2': {'word': 'methylprednisolone', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d578.s4.e4'}, 'sentence_id': 'DDI-DrugBank.d578.s4'}	Drugs induce hepatic enzymes phenobarbital phenytoin rifampin may increase clearance methylprednisolone may require increased methylprednisolone dose achieve desired response
Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. 	phenytoin	rifampin	none	{'e1': {'word': 'phenytoin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d578.s4.e1'}, 'e2': {'word': 'rifampin', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d578.s4.e2'}, 'sentence_id': 'DDI-DrugBank.d578.s4'}	Drugs induce hepatic enzymes phenobarbital phenytoin rifampin may increase clearance methylprednisolone may require increased methylprednisolone dose achieve desired response
Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. 	phenytoin	methylprednisolone	mechanism	{'e1': {'word': 'phenytoin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d578.s4.e1'}, 'e2': {'word': 'methylprednisolone', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d578.s4.e3'}, 'sentence_id': 'DDI-DrugBank.d578.s4'}	Drugs induce hepatic enzymes phenobarbital phenytoin rifampin may increase clearance methylprednisolone may require increased methylprednisolone dose achieve desired response
Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. 	phenytoin	methylprednisolone	advise	{'e1': {'word': 'phenytoin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d578.s4.e1'}, 'e2': {'word': 'methylprednisolone', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d578.s4.e4'}, 'sentence_id': 'DDI-DrugBank.d578.s4'}	Drugs induce hepatic enzymes phenobarbital phenytoin rifampin may increase clearance methylprednisolone may require increased methylprednisolone dose achieve desired response
Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. 	rifampin	methylprednisolone	mechanism	{'e1': {'word': 'rifampin', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d578.s4.e2'}, 'e2': {'word': 'methylprednisolone', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d578.s4.e3'}, 'sentence_id': 'DDI-DrugBank.d578.s4'}	Drugs induce hepatic enzymes phenobarbital phenytoin rifampin may increase clearance methylprednisolone may require increased methylprednisolone dose achieve desired response
Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. 	rifampin	methylprednisolone	advise	{'e1': {'word': 'rifampin', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d578.s4.e2'}, 'e2': {'word': 'methylprednisolone', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d578.s4.e4'}, 'sentence_id': 'DDI-DrugBank.d578.s4'}	Drugs induce hepatic enzymes phenobarbital phenytoin rifampin may increase clearance methylprednisolone may require increased methylprednisolone dose achieve desired response
Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. 	methylprednisolone	methylprednisolone	none	{'e1': {'word': 'methylprednisolone', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d578.s4.e3'}, 'e2': {'word': 'methylprednisolone', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d578.s4.e4'}, 'sentence_id': 'DDI-DrugBank.d578.s4'}	Drugs induce hepatic enzymes phenobarbital phenytoin rifampin may increase clearance methylprednisolone may require increased methylprednisolone dose achieve desired response
Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance. 	troleandomycin	ketoconazole	none	{'e1': {'word': 'troleandomycin', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d578.s5.e0'}, 'e2': {'word': 'ketoconazole', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d578.s5.e1'}, 'sentence_id': 'DDI-DrugBank.d578.s5'}	Drugs troleandomycin ketoconazole may inhibit metabolism methylprednisolone thus decrease clearance
Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance. 	troleandomycin	methylprednisolone	mechanism	{'e1': {'word': 'troleandomycin', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d578.s5.e0'}, 'e2': {'word': 'methylprednisolone', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d578.s5.e2'}, 'sentence_id': 'DDI-DrugBank.d578.s5'}	Drugs troleandomycin ketoconazole may inhibit metabolism methylprednisolone thus decrease clearance
Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance. 	ketoconazole	methylprednisolone	mechanism	{'e1': {'word': 'ketoconazole', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d578.s5.e1'}, 'e2': {'word': 'methylprednisolone', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d578.s5.e2'}, 'sentence_id': 'DDI-DrugBank.d578.s5'}	Drugs troleandomycin ketoconazole may inhibit metabolism methylprednisolone thus decrease clearance
Methylprednisolone may increase the clearance of chronic high dose aspirin. 	Methylprednisolone	aspirin	mechanism	{'e1': {'word': 'Methylprednisolone', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d578.s7.e0'}, 'e2': {'word': 'aspirin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d578.s7.e1'}, 'sentence_id': 'DDI-DrugBank.d578.s7'}	Methylprednisolone may increase clearance chronic high dose aspirin
This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when methylprednisolone is withdrawn. 	salicylate	salicylate	none	{'e1': {'word': 'salicylate', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d578.s8.e0'}, 'e2': {'word': 'salicylate', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d578.s8.e1'}, 'sentence_id': 'DDI-DrugBank.d578.s8'}	could lead decreased salicylate serum levels increase risk salicylate toxicity methylprednisolone withdrawn
This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when methylprednisolone is withdrawn. 	salicylate	methylprednisolone	none	{'e1': {'word': 'salicylate', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d578.s8.e0'}, 'e2': {'word': 'methylprednisolone', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d578.s8.e2'}, 'sentence_id': 'DDI-DrugBank.d578.s8'}	could lead decreased salicylate serum levels increase risk salicylate toxicity methylprednisolone withdrawn
This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when methylprednisolone is withdrawn. 	salicylate	methylprednisolone	effect	{'e1': {'word': 'salicylate', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d578.s8.e1'}, 'e2': {'word': 'methylprednisolone', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d578.s8.e2'}, 'sentence_id': 'DDI-DrugBank.d578.s8'}	could lead decreased salicylate serum levels increase risk salicylate toxicity methylprednisolone withdrawn
Aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia. 	Aspirin	corticosteroids	advise	{'e1': {'word': 'Aspirin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d578.s9.e0'}, 'e2': {'word': 'corticosteroids', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d578.s9.e1'}, 'sentence_id': 'DDI-DrugBank.d578.s9'}	Aspirin used cautiously conjunction corticosteroids patients suffering hypoprothrombinemia
The effect of methylprednisolone on oral anticoagulants is variable. 	methylprednisolone	anticoagulants	none	{'e1': {'word': 'methylprednisolone', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d578.s10.e0'}, 'e2': {'word': 'anticoagulants', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d578.s10.e1'}, 'sentence_id': 'DDI-DrugBank.d578.s10'}	effect methylprednisolone oral anticoagulants variable
There are reports of enhanced as well as diminished effects of anticoagulant when given concurrently with corticosteroids. 	anticoagulant	corticosteroids	effect	{'e1': {'word': 'anticoagulant', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d578.s11.e0'}, 'e2': {'word': 'corticosteroids', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d578.s11.e1'}, 'sentence_id': 'DDI-DrugBank.d578.s11'}	reports enhanced well diminished effects anticoagulant given concurrently corticosteroids
Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem. 	Probenecid	meropenem	mechanism	{'e1': {'word': 'Probenecid', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d762.s0.e0'}, 'e2': {'word': 'meropenem', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d762.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d762.s0'}	Probenecid competes meropenem active tubular secretion thus inhibits renal excretion meropenem
Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem. 	Probenecid	meropenem	none	{'e1': {'word': 'Probenecid', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d762.s0.e0'}, 'e2': {'word': 'meropenem', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d762.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d762.s0'}	Probenecid competes meropenem active tubular secretion thus inhibits renal excretion meropenem
Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem. 	meropenem	meropenem	none	{'e1': {'word': 'meropenem', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d762.s0.e1'}, 'e2': {'word': 'meropenem', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d762.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d762.s0'}	Probenecid competes meropenem active tubular secretion thus inhibits renal excretion meropenem
Therefore, the coadministration of probenecid with meropenem is not recommended. 	probenecid	meropenem	advise	{'e1': {'word': 'probenecid', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d762.s2.e0'}, 'e2': {'word': 'meropenem', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d762.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d762.s2'}	Therefore coadministration probenecid meropenem recommended
There is evidence that meropenem may reduce serum levels of valproic acid to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total valproate).	meropenem	valproic acid	mechanism	{'e1': {'word': 'meropenem', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d762.s3.e0'}, 'e2': {'word': 'valproic acid', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d762.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d762.s3'}	evidence meropenem may reduce serum levels valproic acid subtherapeutic levels therapeutic range considered NUMBER NUMBER g / mL total valproate
There is evidence that meropenem may reduce serum levels of valproic acid to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total valproate).	meropenem	valproate	none	{'e1': {'word': 'meropenem', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d762.s3.e0'}, 'e2': {'word': 'valproate', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d762.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d762.s3'}	evidence meropenem may reduce serum levels valproic acid subtherapeutic levels therapeutic range considered NUMBER NUMBER g / mL total valproate
There is evidence that meropenem may reduce serum levels of valproic acid to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total valproate).	valproic acid	valproate	none	{'e1': {'word': 'valproic acid', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d762.s3.e1'}, 'e2': {'word': 'valproate', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d762.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d762.s3'}	evidence meropenem may reduce serum levels valproic acid subtherapeutic levels therapeutic range considered NUMBER NUMBER g / mL total valproate
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. 	mazindol	monoamine oxidase inhibitor	advise	{'e1': {'word': 'mazindol', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d716.s0.e0'}, 'e2': {'word': 'monoamine oxidase inhibitor', 'word_index': [(3, 5)], 'id': 'DDI-DrugBank.d716.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d716.s0'}	take mazindol taken monoamine oxidase inhibitor MAOI isocarboxazid Marplan tranylcypromine Parnate phenelzine Nardil last NUMBER days
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. 	mazindol	MAOI	advise	{'e1': {'word': 'mazindol', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d716.s0.e0'}, 'e2': {'word': 'MAOI', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d716.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d716.s0'}	take mazindol taken monoamine oxidase inhibitor MAOI isocarboxazid Marplan tranylcypromine Parnate phenelzine Nardil last NUMBER days
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. 	mazindol	isocarboxazid	advise	{'e1': {'word': 'mazindol', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d716.s0.e0'}, 'e2': {'word': 'isocarboxazid', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d716.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d716.s0'}	take mazindol taken monoamine oxidase inhibitor MAOI isocarboxazid Marplan tranylcypromine Parnate phenelzine Nardil last NUMBER days
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. 	mazindol	Marplan	advise	{'e1': {'word': 'mazindol', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d716.s0.e0'}, 'e2': {'word': 'Marplan', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d716.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d716.s0'}	take mazindol taken monoamine oxidase inhibitor MAOI isocarboxazid Marplan tranylcypromine Parnate phenelzine Nardil last NUMBER days
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. 	mazindol	tranylcypromine	advise	{'e1': {'word': 'mazindol', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d716.s0.e0'}, 'e2': {'word': 'tranylcypromine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d716.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d716.s0'}	take mazindol taken monoamine oxidase inhibitor MAOI isocarboxazid Marplan tranylcypromine Parnate phenelzine Nardil last NUMBER days
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. 	mazindol	Parnate	advise	{'e1': {'word': 'mazindol', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d716.s0.e0'}, 'e2': {'word': 'Parnate', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d716.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d716.s0'}	take mazindol taken monoamine oxidase inhibitor MAOI isocarboxazid Marplan tranylcypromine Parnate phenelzine Nardil last NUMBER days
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. 	mazindol	phenelzine	advise	{'e1': {'word': 'mazindol', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d716.s0.e0'}, 'e2': {'word': 'phenelzine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d716.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d716.s0'}	take mazindol taken monoamine oxidase inhibitor MAOI isocarboxazid Marplan tranylcypromine Parnate phenelzine Nardil last NUMBER days
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. 	mazindol	Nardil	advise	{'e1': {'word': 'mazindol', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d716.s0.e0'}, 'e2': {'word': 'Nardil', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d716.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d716.s0'}	take mazindol taken monoamine oxidase inhibitor MAOI isocarboxazid Marplan tranylcypromine Parnate phenelzine Nardil last NUMBER days
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. 	monoamine oxidase inhibitor	MAOI	none	{'e1': {'word': 'monoamine oxidase inhibitor', 'word_index': [(3, 5)], 'id': 'DDI-DrugBank.d716.s0.e1'}, 'e2': {'word': 'MAOI', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d716.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d716.s0'}	take mazindol taken monoamine oxidase inhibitor MAOI isocarboxazid Marplan tranylcypromine Parnate phenelzine Nardil last NUMBER days
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. 	monoamine oxidase inhibitor	isocarboxazid	none	{'e1': {'word': 'monoamine oxidase inhibitor', 'word_index': [(3, 5)], 'id': 'DDI-DrugBank.d716.s0.e1'}, 'e2': {'word': 'isocarboxazid', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d716.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d716.s0'}	take mazindol taken monoamine oxidase inhibitor MAOI isocarboxazid Marplan tranylcypromine Parnate phenelzine Nardil last NUMBER days
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. 	monoamine oxidase inhibitor	Marplan	none	{'e1': {'word': 'monoamine oxidase inhibitor', 'word_index': [(3, 5)], 'id': 'DDI-DrugBank.d716.s0.e1'}, 'e2': {'word': 'Marplan', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d716.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d716.s0'}	take mazindol taken monoamine oxidase inhibitor MAOI isocarboxazid Marplan tranylcypromine Parnate phenelzine Nardil last NUMBER days
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. 	monoamine oxidase inhibitor	tranylcypromine	none	{'e1': {'word': 'monoamine oxidase inhibitor', 'word_index': [(3, 5)], 'id': 'DDI-DrugBank.d716.s0.e1'}, 'e2': {'word': 'tranylcypromine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d716.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d716.s0'}	take mazindol taken monoamine oxidase inhibitor MAOI isocarboxazid Marplan tranylcypromine Parnate phenelzine Nardil last NUMBER days
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. 	monoamine oxidase inhibitor	Parnate	none	{'e1': {'word': 'monoamine oxidase inhibitor', 'word_index': [(3, 5)], 'id': 'DDI-DrugBank.d716.s0.e1'}, 'e2': {'word': 'Parnate', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d716.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d716.s0'}	take mazindol taken monoamine oxidase inhibitor MAOI isocarboxazid Marplan tranylcypromine Parnate phenelzine Nardil last NUMBER days
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. 	monoamine oxidase inhibitor	phenelzine	none	{'e1': {'word': 'monoamine oxidase inhibitor', 'word_index': [(3, 5)], 'id': 'DDI-DrugBank.d716.s0.e1'}, 'e2': {'word': 'phenelzine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d716.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d716.s0'}	take mazindol taken monoamine oxidase inhibitor MAOI isocarboxazid Marplan tranylcypromine Parnate phenelzine Nardil last NUMBER days
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. 	monoamine oxidase inhibitor	Nardil	none	{'e1': {'word': 'monoamine oxidase inhibitor', 'word_index': [(3, 5)], 'id': 'DDI-DrugBank.d716.s0.e1'}, 'e2': {'word': 'Nardil', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d716.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d716.s0'}	take mazindol taken monoamine oxidase inhibitor MAOI isocarboxazid Marplan tranylcypromine Parnate phenelzine Nardil last NUMBER days
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. 	MAOI	isocarboxazid	none	{'e1': {'word': 'MAOI', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d716.s0.e2'}, 'e2': {'word': 'isocarboxazid', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d716.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d716.s0'}	take mazindol taken monoamine oxidase inhibitor MAOI isocarboxazid Marplan tranylcypromine Parnate phenelzine Nardil last NUMBER days
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. 	MAOI	Marplan	none	{'e1': {'word': 'MAOI', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d716.s0.e2'}, 'e2': {'word': 'Marplan', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d716.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d716.s0'}	take mazindol taken monoamine oxidase inhibitor MAOI isocarboxazid Marplan tranylcypromine Parnate phenelzine Nardil last NUMBER days
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. 	MAOI	tranylcypromine	none	{'e1': {'word': 'MAOI', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d716.s0.e2'}, 'e2': {'word': 'tranylcypromine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d716.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d716.s0'}	take mazindol taken monoamine oxidase inhibitor MAOI isocarboxazid Marplan tranylcypromine Parnate phenelzine Nardil last NUMBER days
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. 	MAOI	Parnate	none	{'e1': {'word': 'MAOI', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d716.s0.e2'}, 'e2': {'word': 'Parnate', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d716.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d716.s0'}	take mazindol taken monoamine oxidase inhibitor MAOI isocarboxazid Marplan tranylcypromine Parnate phenelzine Nardil last NUMBER days
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. 	MAOI	phenelzine	none	{'e1': {'word': 'MAOI', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d716.s0.e2'}, 'e2': {'word': 'phenelzine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d716.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d716.s0'}	take mazindol taken monoamine oxidase inhibitor MAOI isocarboxazid Marplan tranylcypromine Parnate phenelzine Nardil last NUMBER days
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. 	MAOI	Nardil	none	{'e1': {'word': 'MAOI', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d716.s0.e2'}, 'e2': {'word': 'Nardil', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d716.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d716.s0'}	take mazindol taken monoamine oxidase inhibitor MAOI isocarboxazid Marplan tranylcypromine Parnate phenelzine Nardil last NUMBER days
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. 	isocarboxazid	Marplan	none	{'e1': {'word': 'isocarboxazid', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d716.s0.e3'}, 'e2': {'word': 'Marplan', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d716.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d716.s0'}	take mazindol taken monoamine oxidase inhibitor MAOI isocarboxazid Marplan tranylcypromine Parnate phenelzine Nardil last NUMBER days
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. 	isocarboxazid	tranylcypromine	none	{'e1': {'word': 'isocarboxazid', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d716.s0.e3'}, 'e2': {'word': 'tranylcypromine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d716.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d716.s0'}	take mazindol taken monoamine oxidase inhibitor MAOI isocarboxazid Marplan tranylcypromine Parnate phenelzine Nardil last NUMBER days
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. 	isocarboxazid	Parnate	none	{'e1': {'word': 'isocarboxazid', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d716.s0.e3'}, 'e2': {'word': 'Parnate', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d716.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d716.s0'}	take mazindol taken monoamine oxidase inhibitor MAOI isocarboxazid Marplan tranylcypromine Parnate phenelzine Nardil last NUMBER days
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. 	isocarboxazid	phenelzine	none	{'e1': {'word': 'isocarboxazid', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d716.s0.e3'}, 'e2': {'word': 'phenelzine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d716.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d716.s0'}	take mazindol taken monoamine oxidase inhibitor MAOI isocarboxazid Marplan tranylcypromine Parnate phenelzine Nardil last NUMBER days
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. 	isocarboxazid	Nardil	none	{'e1': {'word': 'isocarboxazid', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d716.s0.e3'}, 'e2': {'word': 'Nardil', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d716.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d716.s0'}	take mazindol taken monoamine oxidase inhibitor MAOI isocarboxazid Marplan tranylcypromine Parnate phenelzine Nardil last NUMBER days
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. 	Marplan	tranylcypromine	none	{'e1': {'word': 'Marplan', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d716.s0.e4'}, 'e2': {'word': 'tranylcypromine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d716.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d716.s0'}	take mazindol taken monoamine oxidase inhibitor MAOI isocarboxazid Marplan tranylcypromine Parnate phenelzine Nardil last NUMBER days
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. 	Marplan	Parnate	none	{'e1': {'word': 'Marplan', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d716.s0.e4'}, 'e2': {'word': 'Parnate', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d716.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d716.s0'}	take mazindol taken monoamine oxidase inhibitor MAOI isocarboxazid Marplan tranylcypromine Parnate phenelzine Nardil last NUMBER days
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. 	Marplan	phenelzine	none	{'e1': {'word': 'Marplan', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d716.s0.e4'}, 'e2': {'word': 'phenelzine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d716.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d716.s0'}	take mazindol taken monoamine oxidase inhibitor MAOI isocarboxazid Marplan tranylcypromine Parnate phenelzine Nardil last NUMBER days
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. 	Marplan	Nardil	none	{'e1': {'word': 'Marplan', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d716.s0.e4'}, 'e2': {'word': 'Nardil', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d716.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d716.s0'}	take mazindol taken monoamine oxidase inhibitor MAOI isocarboxazid Marplan tranylcypromine Parnate phenelzine Nardil last NUMBER days
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. 	tranylcypromine	Parnate	none	{'e1': {'word': 'tranylcypromine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d716.s0.e5'}, 'e2': {'word': 'Parnate', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d716.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d716.s0'}	take mazindol taken monoamine oxidase inhibitor MAOI isocarboxazid Marplan tranylcypromine Parnate phenelzine Nardil last NUMBER days
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. 	tranylcypromine	phenelzine	none	{'e1': {'word': 'tranylcypromine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d716.s0.e5'}, 'e2': {'word': 'phenelzine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d716.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d716.s0'}	take mazindol taken monoamine oxidase inhibitor MAOI isocarboxazid Marplan tranylcypromine Parnate phenelzine Nardil last NUMBER days
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. 	tranylcypromine	Nardil	none	{'e1': {'word': 'tranylcypromine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d716.s0.e5'}, 'e2': {'word': 'Nardil', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d716.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d716.s0'}	take mazindol taken monoamine oxidase inhibitor MAOI isocarboxazid Marplan tranylcypromine Parnate phenelzine Nardil last NUMBER days
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. 	Parnate	phenelzine	none	{'e1': {'word': 'Parnate', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d716.s0.e6'}, 'e2': {'word': 'phenelzine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d716.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d716.s0'}	take mazindol taken monoamine oxidase inhibitor MAOI isocarboxazid Marplan tranylcypromine Parnate phenelzine Nardil last NUMBER days
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. 	Parnate	Nardil	none	{'e1': {'word': 'Parnate', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d716.s0.e6'}, 'e2': {'word': 'Nardil', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d716.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d716.s0'}	take mazindol taken monoamine oxidase inhibitor MAOI isocarboxazid Marplan tranylcypromine Parnate phenelzine Nardil last NUMBER days
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days. 	phenelzine	Nardil	none	{'e1': {'word': 'phenelzine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d716.s0.e7'}, 'e2': {'word': 'Nardil', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d716.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d716.s0'}	take mazindol taken monoamine oxidase inhibitor MAOI isocarboxazid Marplan tranylcypromine Parnate phenelzine Nardil last NUMBER days
Changes in insulin and other diabetes drug therapies may be necessary during treatment with mazindol.	insulin	mazindol	advise	{'e1': {'word': 'insulin', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d716.s1.e0'}, 'e2': {'word': 'mazindol', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d716.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d716.s1'}	Changes insulin diabetes drug therapies may necessary treatment mazindol
Mazindol may reduce the effects of guanethidine (Ismelin). 	Mazindol	guanethidine	effect	{'e1': {'word': 'Mazindol', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d716.s2.e0'}, 'e2': {'word': 'guanethidine', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d716.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d716.s2'}	Mazindol may reduce effects guanethidine Ismelin
Mazindol may reduce the effects of guanethidine (Ismelin). 	Mazindol	Ismelin	effect	{'e1': {'word': 'Mazindol', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d716.s2.e0'}, 'e2': {'word': 'Ismelin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d716.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d716.s2'}	Mazindol may reduce effects guanethidine Ismelin
Mazindol may reduce the effects of guanethidine (Ismelin). 	guanethidine	Ismelin	none	{'e1': {'word': 'guanethidine', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d716.s2.e1'}, 'e2': {'word': 'Ismelin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d716.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d716.s2'}	Mazindol may reduce effects guanethidine Ismelin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	tricyclic antidepressant	amitriptyline	none	{'e1': {'word': 'tricyclic antidepressant', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d716.s5.e0'}, 'e2': {'word': 'amitriptyline', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d716.s5.e1'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	tricyclic antidepressant	Elavil	none	{'e1': {'word': 'tricyclic antidepressant', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d716.s5.e0'}, 'e2': {'word': 'Elavil', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d716.s5.e2'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	tricyclic antidepressant	amoxapine	none	{'e1': {'word': 'tricyclic antidepressant', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d716.s5.e0'}, 'e2': {'word': 'amoxapine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d716.s5.e3'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	tricyclic antidepressant	Asendin	none	{'e1': {'word': 'tricyclic antidepressant', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d716.s5.e0'}, 'e2': {'word': 'Asendin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d716.s5.e4'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	tricyclic antidepressant	doxepin	none	{'e1': {'word': 'tricyclic antidepressant', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d716.s5.e0'}, 'e2': {'word': 'doxepin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d716.s5.e5'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	tricyclic antidepressant	Sinequan	none	{'e1': {'word': 'tricyclic antidepressant', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d716.s5.e0'}, 'e2': {'word': 'Sinequan', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d716.s5.e6'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	tricyclic antidepressant	nortriptyline	none	{'e1': {'word': 'tricyclic antidepressant', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d716.s5.e0'}, 'e2': {'word': 'nortriptyline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d716.s5.e7'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	tricyclic antidepressant	Pamelor	none	{'e1': {'word': 'tricyclic antidepressant', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d716.s5.e0'}, 'e2': {'word': 'Pamelor', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d716.s5.e8'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	tricyclic antidepressant	imipramine	none	{'e1': {'word': 'tricyclic antidepressant', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d716.s5.e0'}, 'e2': {'word': 'imipramine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d716.s5.e9'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	tricyclic antidepressant	Tofranil	none	{'e1': {'word': 'tricyclic antidepressant', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d716.s5.e0'}, 'e2': {'word': 'Tofranil', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d716.s5.e10'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	tricyclic antidepressant	clomipramine	none	{'e1': {'word': 'tricyclic antidepressant', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d716.s5.e0'}, 'e2': {'word': 'clomipramine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d716.s5.e11'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	tricyclic antidepressant	Anafranil	none	{'e1': {'word': 'tricyclic antidepressant', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d716.s5.e0'}, 'e2': {'word': 'Anafranil', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d716.s5.e12'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	tricyclic antidepressant	protriptyline	none	{'e1': {'word': 'tricyclic antidepressant', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d716.s5.e0'}, 'e2': {'word': 'protriptyline', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d716.s5.e13'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	tricyclic antidepressant	Vivactil	none	{'e1': {'word': 'tricyclic antidepressant', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d716.s5.e0'}, 'e2': {'word': 'Vivactil', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d716.s5.e14'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	tricyclic antidepressant	desipramine	none	{'e1': {'word': 'tricyclic antidepressant', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d716.s5.e0'}, 'e2': {'word': 'desipramine', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d716.s5.e15'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	tricyclic antidepressant	Norpramin	none	{'e1': {'word': 'tricyclic antidepressant', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d716.s5.e0'}, 'e2': {'word': 'Norpramin', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d716.s5.e16'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	amitriptyline	Elavil	none	{'e1': {'word': 'amitriptyline', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d716.s5.e1'}, 'e2': {'word': 'Elavil', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d716.s5.e2'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	amitriptyline	amoxapine	none	{'e1': {'word': 'amitriptyline', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d716.s5.e1'}, 'e2': {'word': 'amoxapine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d716.s5.e3'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	amitriptyline	Asendin	none	{'e1': {'word': 'amitriptyline', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d716.s5.e1'}, 'e2': {'word': 'Asendin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d716.s5.e4'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	amitriptyline	doxepin	none	{'e1': {'word': 'amitriptyline', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d716.s5.e1'}, 'e2': {'word': 'doxepin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d716.s5.e5'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	amitriptyline	Sinequan	none	{'e1': {'word': 'amitriptyline', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d716.s5.e1'}, 'e2': {'word': 'Sinequan', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d716.s5.e6'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	amitriptyline	nortriptyline	none	{'e1': {'word': 'amitriptyline', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d716.s5.e1'}, 'e2': {'word': 'nortriptyline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d716.s5.e7'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	amitriptyline	Pamelor	none	{'e1': {'word': 'amitriptyline', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d716.s5.e1'}, 'e2': {'word': 'Pamelor', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d716.s5.e8'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	amitriptyline	imipramine	none	{'e1': {'word': 'amitriptyline', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d716.s5.e1'}, 'e2': {'word': 'imipramine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d716.s5.e9'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	amitriptyline	Tofranil	none	{'e1': {'word': 'amitriptyline', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d716.s5.e1'}, 'e2': {'word': 'Tofranil', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d716.s5.e10'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	amitriptyline	clomipramine	none	{'e1': {'word': 'amitriptyline', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d716.s5.e1'}, 'e2': {'word': 'clomipramine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d716.s5.e11'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	amitriptyline	Anafranil	none	{'e1': {'word': 'amitriptyline', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d716.s5.e1'}, 'e2': {'word': 'Anafranil', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d716.s5.e12'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	amitriptyline	protriptyline	none	{'e1': {'word': 'amitriptyline', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d716.s5.e1'}, 'e2': {'word': 'protriptyline', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d716.s5.e13'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	amitriptyline	Vivactil	none	{'e1': {'word': 'amitriptyline', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d716.s5.e1'}, 'e2': {'word': 'Vivactil', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d716.s5.e14'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	amitriptyline	desipramine	none	{'e1': {'word': 'amitriptyline', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d716.s5.e1'}, 'e2': {'word': 'desipramine', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d716.s5.e15'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	amitriptyline	Norpramin	none	{'e1': {'word': 'amitriptyline', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d716.s5.e1'}, 'e2': {'word': 'Norpramin', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d716.s5.e16'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Elavil	amoxapine	none	{'e1': {'word': 'Elavil', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d716.s5.e2'}, 'e2': {'word': 'amoxapine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d716.s5.e3'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Elavil	Asendin	none	{'e1': {'word': 'Elavil', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d716.s5.e2'}, 'e2': {'word': 'Asendin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d716.s5.e4'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Elavil	doxepin	none	{'e1': {'word': 'Elavil', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d716.s5.e2'}, 'e2': {'word': 'doxepin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d716.s5.e5'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Elavil	Sinequan	none	{'e1': {'word': 'Elavil', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d716.s5.e2'}, 'e2': {'word': 'Sinequan', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d716.s5.e6'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Elavil	nortriptyline	none	{'e1': {'word': 'Elavil', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d716.s5.e2'}, 'e2': {'word': 'nortriptyline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d716.s5.e7'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Elavil	Pamelor	none	{'e1': {'word': 'Elavil', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d716.s5.e2'}, 'e2': {'word': 'Pamelor', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d716.s5.e8'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Elavil	imipramine	none	{'e1': {'word': 'Elavil', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d716.s5.e2'}, 'e2': {'word': 'imipramine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d716.s5.e9'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Elavil	Tofranil	none	{'e1': {'word': 'Elavil', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d716.s5.e2'}, 'e2': {'word': 'Tofranil', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d716.s5.e10'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Elavil	clomipramine	none	{'e1': {'word': 'Elavil', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d716.s5.e2'}, 'e2': {'word': 'clomipramine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d716.s5.e11'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Elavil	Anafranil	none	{'e1': {'word': 'Elavil', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d716.s5.e2'}, 'e2': {'word': 'Anafranil', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d716.s5.e12'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Elavil	protriptyline	none	{'e1': {'word': 'Elavil', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d716.s5.e2'}, 'e2': {'word': 'protriptyline', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d716.s5.e13'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Elavil	Vivactil	none	{'e1': {'word': 'Elavil', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d716.s5.e2'}, 'e2': {'word': 'Vivactil', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d716.s5.e14'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Elavil	desipramine	none	{'e1': {'word': 'Elavil', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d716.s5.e2'}, 'e2': {'word': 'desipramine', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d716.s5.e15'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Elavil	Norpramin	none	{'e1': {'word': 'Elavil', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d716.s5.e2'}, 'e2': {'word': 'Norpramin', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d716.s5.e16'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	amoxapine	Asendin	none	{'e1': {'word': 'amoxapine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d716.s5.e3'}, 'e2': {'word': 'Asendin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d716.s5.e4'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	amoxapine	doxepin	none	{'e1': {'word': 'amoxapine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d716.s5.e3'}, 'e2': {'word': 'doxepin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d716.s5.e5'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	amoxapine	Sinequan	none	{'e1': {'word': 'amoxapine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d716.s5.e3'}, 'e2': {'word': 'Sinequan', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d716.s5.e6'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	amoxapine	nortriptyline	none	{'e1': {'word': 'amoxapine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d716.s5.e3'}, 'e2': {'word': 'nortriptyline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d716.s5.e7'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	amoxapine	Pamelor	none	{'e1': {'word': 'amoxapine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d716.s5.e3'}, 'e2': {'word': 'Pamelor', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d716.s5.e8'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	amoxapine	imipramine	none	{'e1': {'word': 'amoxapine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d716.s5.e3'}, 'e2': {'word': 'imipramine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d716.s5.e9'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	amoxapine	Tofranil	none	{'e1': {'word': 'amoxapine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d716.s5.e3'}, 'e2': {'word': 'Tofranil', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d716.s5.e10'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	amoxapine	clomipramine	none	{'e1': {'word': 'amoxapine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d716.s5.e3'}, 'e2': {'word': 'clomipramine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d716.s5.e11'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	amoxapine	Anafranil	none	{'e1': {'word': 'amoxapine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d716.s5.e3'}, 'e2': {'word': 'Anafranil', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d716.s5.e12'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	amoxapine	protriptyline	none	{'e1': {'word': 'amoxapine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d716.s5.e3'}, 'e2': {'word': 'protriptyline', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d716.s5.e13'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	amoxapine	Vivactil	none	{'e1': {'word': 'amoxapine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d716.s5.e3'}, 'e2': {'word': 'Vivactil', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d716.s5.e14'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	amoxapine	desipramine	none	{'e1': {'word': 'amoxapine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d716.s5.e3'}, 'e2': {'word': 'desipramine', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d716.s5.e15'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	amoxapine	Norpramin	none	{'e1': {'word': 'amoxapine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d716.s5.e3'}, 'e2': {'word': 'Norpramin', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d716.s5.e16'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Asendin	doxepin	none	{'e1': {'word': 'Asendin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d716.s5.e4'}, 'e2': {'word': 'doxepin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d716.s5.e5'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Asendin	Sinequan	none	{'e1': {'word': 'Asendin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d716.s5.e4'}, 'e2': {'word': 'Sinequan', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d716.s5.e6'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Asendin	nortriptyline	none	{'e1': {'word': 'Asendin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d716.s5.e4'}, 'e2': {'word': 'nortriptyline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d716.s5.e7'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Asendin	Pamelor	none	{'e1': {'word': 'Asendin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d716.s5.e4'}, 'e2': {'word': 'Pamelor', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d716.s5.e8'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Asendin	imipramine	none	{'e1': {'word': 'Asendin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d716.s5.e4'}, 'e2': {'word': 'imipramine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d716.s5.e9'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Asendin	Tofranil	none	{'e1': {'word': 'Asendin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d716.s5.e4'}, 'e2': {'word': 'Tofranil', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d716.s5.e10'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Asendin	clomipramine	none	{'e1': {'word': 'Asendin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d716.s5.e4'}, 'e2': {'word': 'clomipramine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d716.s5.e11'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Asendin	Anafranil	none	{'e1': {'word': 'Asendin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d716.s5.e4'}, 'e2': {'word': 'Anafranil', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d716.s5.e12'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Asendin	protriptyline	none	{'e1': {'word': 'Asendin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d716.s5.e4'}, 'e2': {'word': 'protriptyline', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d716.s5.e13'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Asendin	Vivactil	none	{'e1': {'word': 'Asendin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d716.s5.e4'}, 'e2': {'word': 'Vivactil', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d716.s5.e14'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Asendin	desipramine	none	{'e1': {'word': 'Asendin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d716.s5.e4'}, 'e2': {'word': 'desipramine', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d716.s5.e15'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Asendin	Norpramin	none	{'e1': {'word': 'Asendin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d716.s5.e4'}, 'e2': {'word': 'Norpramin', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d716.s5.e16'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	doxepin	Sinequan	none	{'e1': {'word': 'doxepin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d716.s5.e5'}, 'e2': {'word': 'Sinequan', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d716.s5.e6'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	doxepin	nortriptyline	none	{'e1': {'word': 'doxepin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d716.s5.e5'}, 'e2': {'word': 'nortriptyline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d716.s5.e7'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	doxepin	Pamelor	none	{'e1': {'word': 'doxepin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d716.s5.e5'}, 'e2': {'word': 'Pamelor', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d716.s5.e8'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	doxepin	imipramine	none	{'e1': {'word': 'doxepin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d716.s5.e5'}, 'e2': {'word': 'imipramine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d716.s5.e9'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	doxepin	Tofranil	none	{'e1': {'word': 'doxepin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d716.s5.e5'}, 'e2': {'word': 'Tofranil', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d716.s5.e10'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	doxepin	clomipramine	none	{'e1': {'word': 'doxepin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d716.s5.e5'}, 'e2': {'word': 'clomipramine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d716.s5.e11'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	doxepin	Anafranil	none	{'e1': {'word': 'doxepin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d716.s5.e5'}, 'e2': {'word': 'Anafranil', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d716.s5.e12'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	doxepin	protriptyline	none	{'e1': {'word': 'doxepin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d716.s5.e5'}, 'e2': {'word': 'protriptyline', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d716.s5.e13'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	doxepin	Vivactil	none	{'e1': {'word': 'doxepin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d716.s5.e5'}, 'e2': {'word': 'Vivactil', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d716.s5.e14'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	doxepin	desipramine	none	{'e1': {'word': 'doxepin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d716.s5.e5'}, 'e2': {'word': 'desipramine', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d716.s5.e15'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	doxepin	Norpramin	none	{'e1': {'word': 'doxepin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d716.s5.e5'}, 'e2': {'word': 'Norpramin', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d716.s5.e16'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Sinequan	nortriptyline	none	{'e1': {'word': 'Sinequan', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d716.s5.e6'}, 'e2': {'word': 'nortriptyline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d716.s5.e7'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Sinequan	Pamelor	none	{'e1': {'word': 'Sinequan', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d716.s5.e6'}, 'e2': {'word': 'Pamelor', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d716.s5.e8'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Sinequan	imipramine	none	{'e1': {'word': 'Sinequan', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d716.s5.e6'}, 'e2': {'word': 'imipramine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d716.s5.e9'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Sinequan	Tofranil	none	{'e1': {'word': 'Sinequan', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d716.s5.e6'}, 'e2': {'word': 'Tofranil', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d716.s5.e10'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Sinequan	clomipramine	none	{'e1': {'word': 'Sinequan', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d716.s5.e6'}, 'e2': {'word': 'clomipramine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d716.s5.e11'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Sinequan	Anafranil	none	{'e1': {'word': 'Sinequan', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d716.s5.e6'}, 'e2': {'word': 'Anafranil', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d716.s5.e12'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Sinequan	protriptyline	none	{'e1': {'word': 'Sinequan', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d716.s5.e6'}, 'e2': {'word': 'protriptyline', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d716.s5.e13'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Sinequan	Vivactil	none	{'e1': {'word': 'Sinequan', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d716.s5.e6'}, 'e2': {'word': 'Vivactil', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d716.s5.e14'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Sinequan	desipramine	none	{'e1': {'word': 'Sinequan', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d716.s5.e6'}, 'e2': {'word': 'desipramine', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d716.s5.e15'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Sinequan	Norpramin	none	{'e1': {'word': 'Sinequan', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d716.s5.e6'}, 'e2': {'word': 'Norpramin', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d716.s5.e16'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	nortriptyline	Pamelor	none	{'e1': {'word': 'nortriptyline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d716.s5.e7'}, 'e2': {'word': 'Pamelor', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d716.s5.e8'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	nortriptyline	imipramine	none	{'e1': {'word': 'nortriptyline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d716.s5.e7'}, 'e2': {'word': 'imipramine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d716.s5.e9'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	nortriptyline	Tofranil	none	{'e1': {'word': 'nortriptyline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d716.s5.e7'}, 'e2': {'word': 'Tofranil', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d716.s5.e10'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	nortriptyline	clomipramine	none	{'e1': {'word': 'nortriptyline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d716.s5.e7'}, 'e2': {'word': 'clomipramine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d716.s5.e11'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	nortriptyline	Anafranil	none	{'e1': {'word': 'nortriptyline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d716.s5.e7'}, 'e2': {'word': 'Anafranil', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d716.s5.e12'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	nortriptyline	protriptyline	none	{'e1': {'word': 'nortriptyline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d716.s5.e7'}, 'e2': {'word': 'protriptyline', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d716.s5.e13'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	nortriptyline	Vivactil	none	{'e1': {'word': 'nortriptyline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d716.s5.e7'}, 'e2': {'word': 'Vivactil', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d716.s5.e14'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	nortriptyline	desipramine	none	{'e1': {'word': 'nortriptyline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d716.s5.e7'}, 'e2': {'word': 'desipramine', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d716.s5.e15'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	nortriptyline	Norpramin	none	{'e1': {'word': 'nortriptyline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d716.s5.e7'}, 'e2': {'word': 'Norpramin', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d716.s5.e16'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Pamelor	imipramine	none	{'e1': {'word': 'Pamelor', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d716.s5.e8'}, 'e2': {'word': 'imipramine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d716.s5.e9'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Pamelor	Tofranil	none	{'e1': {'word': 'Pamelor', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d716.s5.e8'}, 'e2': {'word': 'Tofranil', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d716.s5.e10'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Pamelor	clomipramine	none	{'e1': {'word': 'Pamelor', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d716.s5.e8'}, 'e2': {'word': 'clomipramine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d716.s5.e11'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Pamelor	Anafranil	none	{'e1': {'word': 'Pamelor', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d716.s5.e8'}, 'e2': {'word': 'Anafranil', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d716.s5.e12'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Pamelor	protriptyline	none	{'e1': {'word': 'Pamelor', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d716.s5.e8'}, 'e2': {'word': 'protriptyline', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d716.s5.e13'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Pamelor	Vivactil	none	{'e1': {'word': 'Pamelor', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d716.s5.e8'}, 'e2': {'word': 'Vivactil', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d716.s5.e14'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Pamelor	desipramine	none	{'e1': {'word': 'Pamelor', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d716.s5.e8'}, 'e2': {'word': 'desipramine', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d716.s5.e15'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Pamelor	Norpramin	none	{'e1': {'word': 'Pamelor', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d716.s5.e8'}, 'e2': {'word': 'Norpramin', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d716.s5.e16'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	imipramine	Tofranil	none	{'e1': {'word': 'imipramine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d716.s5.e9'}, 'e2': {'word': 'Tofranil', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d716.s5.e10'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	imipramine	clomipramine	none	{'e1': {'word': 'imipramine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d716.s5.e9'}, 'e2': {'word': 'clomipramine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d716.s5.e11'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	imipramine	Anafranil	none	{'e1': {'word': 'imipramine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d716.s5.e9'}, 'e2': {'word': 'Anafranil', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d716.s5.e12'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	imipramine	protriptyline	none	{'e1': {'word': 'imipramine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d716.s5.e9'}, 'e2': {'word': 'protriptyline', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d716.s5.e13'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	imipramine	Vivactil	none	{'e1': {'word': 'imipramine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d716.s5.e9'}, 'e2': {'word': 'Vivactil', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d716.s5.e14'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	imipramine	desipramine	none	{'e1': {'word': 'imipramine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d716.s5.e9'}, 'e2': {'word': 'desipramine', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d716.s5.e15'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	imipramine	Norpramin	none	{'e1': {'word': 'imipramine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d716.s5.e9'}, 'e2': {'word': 'Norpramin', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d716.s5.e16'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Tofranil	clomipramine	none	{'e1': {'word': 'Tofranil', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d716.s5.e10'}, 'e2': {'word': 'clomipramine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d716.s5.e11'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Tofranil	Anafranil	none	{'e1': {'word': 'Tofranil', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d716.s5.e10'}, 'e2': {'word': 'Anafranil', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d716.s5.e12'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Tofranil	protriptyline	none	{'e1': {'word': 'Tofranil', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d716.s5.e10'}, 'e2': {'word': 'protriptyline', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d716.s5.e13'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Tofranil	Vivactil	none	{'e1': {'word': 'Tofranil', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d716.s5.e10'}, 'e2': {'word': 'Vivactil', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d716.s5.e14'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Tofranil	desipramine	none	{'e1': {'word': 'Tofranil', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d716.s5.e10'}, 'e2': {'word': 'desipramine', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d716.s5.e15'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Tofranil	Norpramin	none	{'e1': {'word': 'Tofranil', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d716.s5.e10'}, 'e2': {'word': 'Norpramin', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d716.s5.e16'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	clomipramine	Anafranil	none	{'e1': {'word': 'clomipramine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d716.s5.e11'}, 'e2': {'word': 'Anafranil', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d716.s5.e12'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	clomipramine	protriptyline	none	{'e1': {'word': 'clomipramine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d716.s5.e11'}, 'e2': {'word': 'protriptyline', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d716.s5.e13'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	clomipramine	Vivactil	none	{'e1': {'word': 'clomipramine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d716.s5.e11'}, 'e2': {'word': 'Vivactil', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d716.s5.e14'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	clomipramine	desipramine	none	{'e1': {'word': 'clomipramine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d716.s5.e11'}, 'e2': {'word': 'desipramine', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d716.s5.e15'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	clomipramine	Norpramin	none	{'e1': {'word': 'clomipramine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d716.s5.e11'}, 'e2': {'word': 'Norpramin', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d716.s5.e16'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Anafranil	protriptyline	none	{'e1': {'word': 'Anafranil', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d716.s5.e12'}, 'e2': {'word': 'protriptyline', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d716.s5.e13'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Anafranil	Vivactil	none	{'e1': {'word': 'Anafranil', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d716.s5.e12'}, 'e2': {'word': 'Vivactil', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d716.s5.e14'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Anafranil	desipramine	none	{'e1': {'word': 'Anafranil', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d716.s5.e12'}, 'e2': {'word': 'desipramine', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d716.s5.e15'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Anafranil	Norpramin	none	{'e1': {'word': 'Anafranil', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d716.s5.e12'}, 'e2': {'word': 'Norpramin', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d716.s5.e16'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	protriptyline	Vivactil	none	{'e1': {'word': 'protriptyline', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d716.s5.e13'}, 'e2': {'word': 'Vivactil', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d716.s5.e14'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	protriptyline	desipramine	none	{'e1': {'word': 'protriptyline', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d716.s5.e13'}, 'e2': {'word': 'desipramine', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d716.s5.e15'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	protriptyline	Norpramin	none	{'e1': {'word': 'protriptyline', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d716.s5.e13'}, 'e2': {'word': 'Norpramin', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d716.s5.e16'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Vivactil	desipramine	none	{'e1': {'word': 'Vivactil', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d716.s5.e14'}, 'e2': {'word': 'desipramine', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d716.s5.e15'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	Vivactil	Norpramin	none	{'e1': {'word': 'Vivactil', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d716.s5.e14'}, 'e2': {'word': 'Norpramin', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d716.s5.e16'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin). 	desipramine	Norpramin	none	{'e1': {'word': 'desipramine', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d716.s5.e15'}, 'e2': {'word': 'Norpramin', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d716.s5.e16'}, 'sentence_id': 'DDI-DrugBank.d716.s5'}	taking medication tell doctor taking tricyclic antidepressant amitriptyline Elavil amoxapine Asendin doxepin Sinequan nortriptyline Pamelor imipramine Tofranil clomipramine Anafranil protriptyline Vivactil desipramine Norpramin
Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine	Vindesine	Phenytoin	int	{'e1': {'word': 'Vindesine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d782.s0.e0'}, 'e2': {'word': 'Phenytoin', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d782.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d782.s0'}	Vindesine interact drugs following categories Blood dyscrasia cause unpredictable myelotoxicity Bone marrow depressants cause predictable dose related myelotoxicity Radiation therapy may cause marrow depression Neurotoxic medications cause neurologic toxicity Phenytoin increase seizure activity Live virus vaccines may potentiate replication vaccine virus may increase side effects vaccination decrease patient 's response vaccine Mitomycin C may cause shortness breath bronchospasm Killed virus vaccines may decrease patient 's response vaccine
Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine	Vindesine	Live virus vaccines	int	{'e1': {'word': 'Vindesine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d782.s0.e0'}, 'e2': {'word': 'Live virus vaccines', 'word_index': [(33, 35)], 'id': 'DDI-DrugBank.d782.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d782.s0'}	Vindesine interact drugs following categories Blood dyscrasia cause unpredictable myelotoxicity Bone marrow depressants cause predictable dose related myelotoxicity Radiation therapy may cause marrow depression Neurotoxic medications cause neurologic toxicity Phenytoin increase seizure activity Live virus vaccines may potentiate replication vaccine virus may increase side effects vaccination decrease patient 's response vaccine Mitomycin C may cause shortness breath bronchospasm Killed virus vaccines may decrease patient 's response vaccine
Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine	Vindesine	vaccine	none	{'e1': {'word': 'Vindesine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d782.s0.e0'}, 'e2': {'word': 'vaccine', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d782.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d782.s0'}	Vindesine interact drugs following categories Blood dyscrasia cause unpredictable myelotoxicity Bone marrow depressants cause predictable dose related myelotoxicity Radiation therapy may cause marrow depression Neurotoxic medications cause neurologic toxicity Phenytoin increase seizure activity Live virus vaccines may potentiate replication vaccine virus may increase side effects vaccination decrease patient 's response vaccine Mitomycin C may cause shortness breath bronchospasm Killed virus vaccines may decrease patient 's response vaccine
Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine	Vindesine	Mitomycin-C	int	{'e1': {'word': 'Vindesine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d782.s0.e0'}, 'e2': {'word': 'Mitomycin-C', 'word_index': [(51, 52)], 'id': 'DDI-DrugBank.d782.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d782.s0'}	Vindesine interact drugs following categories Blood dyscrasia cause unpredictable myelotoxicity Bone marrow depressants cause predictable dose related myelotoxicity Radiation therapy may cause marrow depression Neurotoxic medications cause neurologic toxicity Phenytoin increase seizure activity Live virus vaccines may potentiate replication vaccine virus may increase side effects vaccination decrease patient 's response vaccine Mitomycin C may cause shortness breath bronchospasm Killed virus vaccines may decrease patient 's response vaccine
Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine	Vindesine	Killed virus vaccines	int	{'e1': {'word': 'Vindesine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d782.s0.e0'}, 'e2': {'word': 'Killed virus vaccines', 'word_index': [(58, 60)], 'id': 'DDI-DrugBank.d782.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d782.s0'}	Vindesine interact drugs following categories Blood dyscrasia cause unpredictable myelotoxicity Bone marrow depressants cause predictable dose related myelotoxicity Radiation therapy may cause marrow depression Neurotoxic medications cause neurologic toxicity Phenytoin increase seizure activity Live virus vaccines may potentiate replication vaccine virus may increase side effects vaccination decrease patient 's response vaccine Mitomycin C may cause shortness breath bronchospasm Killed virus vaccines may decrease patient 's response vaccine
Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine	Vindesine	vaccine	none	{'e1': {'word': 'Vindesine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d782.s0.e0'}, 'e2': {'word': 'vaccine', 'word_index': [(66, 66)], 'id': 'DDI-DrugBank.d782.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d782.s0'}	Vindesine interact drugs following categories Blood dyscrasia cause unpredictable myelotoxicity Bone marrow depressants cause predictable dose related myelotoxicity Radiation therapy may cause marrow depression Neurotoxic medications cause neurologic toxicity Phenytoin increase seizure activity Live virus vaccines may potentiate replication vaccine virus may increase side effects vaccination decrease patient 's response vaccine Mitomycin C may cause shortness breath bronchospasm Killed virus vaccines may decrease patient 's response vaccine
Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine	Phenytoin	Live virus vaccines	none	{'e1': {'word': 'Phenytoin', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d782.s0.e1'}, 'e2': {'word': 'Live virus vaccines', 'word_index': [(33, 35)], 'id': 'DDI-DrugBank.d782.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d782.s0'}	Vindesine interact drugs following categories Blood dyscrasia cause unpredictable myelotoxicity Bone marrow depressants cause predictable dose related myelotoxicity Radiation therapy may cause marrow depression Neurotoxic medications cause neurologic toxicity Phenytoin increase seizure activity Live virus vaccines may potentiate replication vaccine virus may increase side effects vaccination decrease patient 's response vaccine Mitomycin C may cause shortness breath bronchospasm Killed virus vaccines may decrease patient 's response vaccine
Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine	Phenytoin	vaccine	none	{'e1': {'word': 'Phenytoin', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d782.s0.e1'}, 'e2': {'word': 'vaccine', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d782.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d782.s0'}	Vindesine interact drugs following categories Blood dyscrasia cause unpredictable myelotoxicity Bone marrow depressants cause predictable dose related myelotoxicity Radiation therapy may cause marrow depression Neurotoxic medications cause neurologic toxicity Phenytoin increase seizure activity Live virus vaccines may potentiate replication vaccine virus may increase side effects vaccination decrease patient 's response vaccine Mitomycin C may cause shortness breath bronchospasm Killed virus vaccines may decrease patient 's response vaccine
Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine	Phenytoin	Mitomycin-C	none	{'e1': {'word': 'Phenytoin', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d782.s0.e1'}, 'e2': {'word': 'Mitomycin-C', 'word_index': [(51, 52)], 'id': 'DDI-DrugBank.d782.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d782.s0'}	Vindesine interact drugs following categories Blood dyscrasia cause unpredictable myelotoxicity Bone marrow depressants cause predictable dose related myelotoxicity Radiation therapy may cause marrow depression Neurotoxic medications cause neurologic toxicity Phenytoin increase seizure activity Live virus vaccines may potentiate replication vaccine virus may increase side effects vaccination decrease patient 's response vaccine Mitomycin C may cause shortness breath bronchospasm Killed virus vaccines may decrease patient 's response vaccine
Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine	Phenytoin	Killed virus vaccines	none	{'e1': {'word': 'Phenytoin', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d782.s0.e1'}, 'e2': {'word': 'Killed virus vaccines', 'word_index': [(58, 60)], 'id': 'DDI-DrugBank.d782.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d782.s0'}	Vindesine interact drugs following categories Blood dyscrasia cause unpredictable myelotoxicity Bone marrow depressants cause predictable dose related myelotoxicity Radiation therapy may cause marrow depression Neurotoxic medications cause neurologic toxicity Phenytoin increase seizure activity Live virus vaccines may potentiate replication vaccine virus may increase side effects vaccination decrease patient 's response vaccine Mitomycin C may cause shortness breath bronchospasm Killed virus vaccines may decrease patient 's response vaccine
Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine	Phenytoin	vaccine	none	{'e1': {'word': 'Phenytoin', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d782.s0.e1'}, 'e2': {'word': 'vaccine', 'word_index': [(66, 66)], 'id': 'DDI-DrugBank.d782.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d782.s0'}	Vindesine interact drugs following categories Blood dyscrasia cause unpredictable myelotoxicity Bone marrow depressants cause predictable dose related myelotoxicity Radiation therapy may cause marrow depression Neurotoxic medications cause neurologic toxicity Phenytoin increase seizure activity Live virus vaccines may potentiate replication vaccine virus may increase side effects vaccination decrease patient 's response vaccine Mitomycin C may cause shortness breath bronchospasm Killed virus vaccines may decrease patient 's response vaccine
Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine	Live virus vaccines	vaccine	none	{'e1': {'word': 'Live virus vaccines', 'word_index': [(33, 35)], 'id': 'DDI-DrugBank.d782.s0.e2'}, 'e2': {'word': 'vaccine', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d782.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d782.s0'}	Vindesine interact drugs following categories Blood dyscrasia cause unpredictable myelotoxicity Bone marrow depressants cause predictable dose related myelotoxicity Radiation therapy may cause marrow depression Neurotoxic medications cause neurologic toxicity Phenytoin increase seizure activity Live virus vaccines may potentiate replication vaccine virus may increase side effects vaccination decrease patient 's response vaccine Mitomycin C may cause shortness breath bronchospasm Killed virus vaccines may decrease patient 's response vaccine
Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine	Live virus vaccines	Mitomycin-C	none	{'e1': {'word': 'Live virus vaccines', 'word_index': [(33, 35)], 'id': 'DDI-DrugBank.d782.s0.e2'}, 'e2': {'word': 'Mitomycin-C', 'word_index': [(51, 52)], 'id': 'DDI-DrugBank.d782.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d782.s0'}	Vindesine interact drugs following categories Blood dyscrasia cause unpredictable myelotoxicity Bone marrow depressants cause predictable dose related myelotoxicity Radiation therapy may cause marrow depression Neurotoxic medications cause neurologic toxicity Phenytoin increase seizure activity Live virus vaccines may potentiate replication vaccine virus may increase side effects vaccination decrease patient 's response vaccine Mitomycin C may cause shortness breath bronchospasm Killed virus vaccines may decrease patient 's response vaccine
Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine	Live virus vaccines	Killed virus vaccines	none	{'e1': {'word': 'Live virus vaccines', 'word_index': [(33, 35)], 'id': 'DDI-DrugBank.d782.s0.e2'}, 'e2': {'word': 'Killed virus vaccines', 'word_index': [(58, 60)], 'id': 'DDI-DrugBank.d782.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d782.s0'}	Vindesine interact drugs following categories Blood dyscrasia cause unpredictable myelotoxicity Bone marrow depressants cause predictable dose related myelotoxicity Radiation therapy may cause marrow depression Neurotoxic medications cause neurologic toxicity Phenytoin increase seizure activity Live virus vaccines may potentiate replication vaccine virus may increase side effects vaccination decrease patient 's response vaccine Mitomycin C may cause shortness breath bronchospasm Killed virus vaccines may decrease patient 's response vaccine
Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine	Live virus vaccines	vaccine	none	{'e1': {'word': 'Live virus vaccines', 'word_index': [(33, 35)], 'id': 'DDI-DrugBank.d782.s0.e2'}, 'e2': {'word': 'vaccine', 'word_index': [(66, 66)], 'id': 'DDI-DrugBank.d782.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d782.s0'}	Vindesine interact drugs following categories Blood dyscrasia cause unpredictable myelotoxicity Bone marrow depressants cause predictable dose related myelotoxicity Radiation therapy may cause marrow depression Neurotoxic medications cause neurologic toxicity Phenytoin increase seizure activity Live virus vaccines may potentiate replication vaccine virus may increase side effects vaccination decrease patient 's response vaccine Mitomycin C may cause shortness breath bronchospasm Killed virus vaccines may decrease patient 's response vaccine
Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine	vaccine	Mitomycin-C	none	{'e1': {'word': 'vaccine', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d782.s0.e3'}, 'e2': {'word': 'Mitomycin-C', 'word_index': [(51, 52)], 'id': 'DDI-DrugBank.d782.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d782.s0'}	Vindesine interact drugs following categories Blood dyscrasia cause unpredictable myelotoxicity Bone marrow depressants cause predictable dose related myelotoxicity Radiation therapy may cause marrow depression Neurotoxic medications cause neurologic toxicity Phenytoin increase seizure activity Live virus vaccines may potentiate replication vaccine virus may increase side effects vaccination decrease patient 's response vaccine Mitomycin C may cause shortness breath bronchospasm Killed virus vaccines may decrease patient 's response vaccine
Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine	vaccine	Killed virus vaccines	none	{'e1': {'word': 'vaccine', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d782.s0.e3'}, 'e2': {'word': 'Killed virus vaccines', 'word_index': [(58, 60)], 'id': 'DDI-DrugBank.d782.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d782.s0'}	Vindesine interact drugs following categories Blood dyscrasia cause unpredictable myelotoxicity Bone marrow depressants cause predictable dose related myelotoxicity Radiation therapy may cause marrow depression Neurotoxic medications cause neurologic toxicity Phenytoin increase seizure activity Live virus vaccines may potentiate replication vaccine virus may increase side effects vaccination decrease patient 's response vaccine Mitomycin C may cause shortness breath bronchospasm Killed virus vaccines may decrease patient 's response vaccine
Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine	vaccine	vaccine	none	{'e1': {'word': 'vaccine', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d782.s0.e3'}, 'e2': {'word': 'vaccine', 'word_index': [(66, 66)], 'id': 'DDI-DrugBank.d782.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d782.s0'}	Vindesine interact drugs following categories Blood dyscrasia cause unpredictable myelotoxicity Bone marrow depressants cause predictable dose related myelotoxicity Radiation therapy may cause marrow depression Neurotoxic medications cause neurologic toxicity Phenytoin increase seizure activity Live virus vaccines may potentiate replication vaccine virus may increase side effects vaccination decrease patient 's response vaccine Mitomycin C may cause shortness breath bronchospasm Killed virus vaccines may decrease patient 's response vaccine
Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine	Mitomycin-C	Killed virus vaccines	none	{'e1': {'word': 'Mitomycin-C', 'word_index': [(51, 52)], 'id': 'DDI-DrugBank.d782.s0.e4'}, 'e2': {'word': 'Killed virus vaccines', 'word_index': [(58, 60)], 'id': 'DDI-DrugBank.d782.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d782.s0'}	Vindesine interact drugs following categories Blood dyscrasia cause unpredictable myelotoxicity Bone marrow depressants cause predictable dose related myelotoxicity Radiation therapy may cause marrow depression Neurotoxic medications cause neurologic toxicity Phenytoin increase seizure activity Live virus vaccines may potentiate replication vaccine virus may increase side effects vaccination decrease patient 's response vaccine Mitomycin C may cause shortness breath bronchospasm Killed virus vaccines may decrease patient 's response vaccine
Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine	Mitomycin-C	vaccine	none	{'e1': {'word': 'Mitomycin-C', 'word_index': [(51, 52)], 'id': 'DDI-DrugBank.d782.s0.e4'}, 'e2': {'word': 'vaccine', 'word_index': [(66, 66)], 'id': 'DDI-DrugBank.d782.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d782.s0'}	Vindesine interact drugs following categories Blood dyscrasia cause unpredictable myelotoxicity Bone marrow depressants cause predictable dose related myelotoxicity Radiation therapy may cause marrow depression Neurotoxic medications cause neurologic toxicity Phenytoin increase seizure activity Live virus vaccines may potentiate replication vaccine virus may increase side effects vaccination decrease patient 's response vaccine Mitomycin C may cause shortness breath bronchospasm Killed virus vaccines may decrease patient 's response vaccine
Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine	Killed virus vaccines	vaccine	none	{'e1': {'word': 'Killed virus vaccines', 'word_index': [(58, 60)], 'id': 'DDI-DrugBank.d782.s0.e5'}, 'e2': {'word': 'vaccine', 'word_index': [(66, 66)], 'id': 'DDI-DrugBank.d782.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d782.s0'}	Vindesine interact drugs following categories Blood dyscrasia cause unpredictable myelotoxicity Bone marrow depressants cause predictable dose related myelotoxicity Radiation therapy may cause marrow depression Neurotoxic medications cause neurologic toxicity Phenytoin increase seizure activity Live virus vaccines may potentiate replication vaccine virus may increase side effects vaccination decrease patient 's response vaccine Mitomycin C may cause shortness breath bronchospasm Killed virus vaccines may decrease patient 's response vaccine
In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. 	TOBI	TOBI	none	{'e1': {'word': 'TOBI', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d624.s0.e0'}, 'e2': {'word': 'TOBI', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d624.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d624.s0'}	clinical studies TOBI patients taking TOBI concomitantly dornase alfa PULMOZYME Genentech beta agonists inhaled corticosteroids anti-pseudomonal antibiotics parenteral aminoglycosides demonstrated adverse experience profiles similar study population whole
In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. 	TOBI	dornase alfa	none	{'e1': {'word': 'TOBI', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d624.s0.e0'}, 'e2': {'word': 'dornase alfa', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d624.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d624.s0'}	clinical studies TOBI patients taking TOBI concomitantly dornase alfa PULMOZYME Genentech beta agonists inhaled corticosteroids anti-pseudomonal antibiotics parenteral aminoglycosides demonstrated adverse experience profiles similar study population whole
In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. 	TOBI	PULMOZYME	none	{'e1': {'word': 'TOBI', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d624.s0.e0'}, 'e2': {'word': 'PULMOZYME', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d624.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d624.s0'}	clinical studies TOBI patients taking TOBI concomitantly dornase alfa PULMOZYME Genentech beta agonists inhaled corticosteroids anti-pseudomonal antibiotics parenteral aminoglycosides demonstrated adverse experience profiles similar study population whole
In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. 	TOBI	(beta)-agonists	none	{'e1': {'word': 'TOBI', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d624.s0.e0'}, 'e2': {'word': '(beta)-agonists', 'word_index': [(11, 12)], 'id': 'DDI-DrugBank.d624.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d624.s0'}	clinical studies TOBI patients taking TOBI concomitantly dornase alfa PULMOZYME Genentech beta agonists inhaled corticosteroids anti-pseudomonal antibiotics parenteral aminoglycosides demonstrated adverse experience profiles similar study population whole
In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. 	TOBI	corticosteroids	none	{'e1': {'word': 'TOBI', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d624.s0.e0'}, 'e2': {'word': 'corticosteroids', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d624.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d624.s0'}	clinical studies TOBI patients taking TOBI concomitantly dornase alfa PULMOZYME Genentech beta agonists inhaled corticosteroids anti-pseudomonal antibiotics parenteral aminoglycosides demonstrated adverse experience profiles similar study population whole
In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. 	TOBI	anti-pseudomonal antibiotics	none	{'e1': {'word': 'TOBI', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d624.s0.e0'}, 'e2': {'word': 'anti-pseudomonal antibiotics', 'word_index': [(15, 16)], 'id': 'DDI-DrugBank.d624.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d624.s0'}	clinical studies TOBI patients taking TOBI concomitantly dornase alfa PULMOZYME Genentech beta agonists inhaled corticosteroids anti-pseudomonal antibiotics parenteral aminoglycosides demonstrated adverse experience profiles similar study population whole
In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. 	TOBI	aminoglycosides	none	{'e1': {'word': 'TOBI', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d624.s0.e0'}, 'e2': {'word': 'aminoglycosides', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d624.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d624.s0'}	clinical studies TOBI patients taking TOBI concomitantly dornase alfa PULMOZYME Genentech beta agonists inhaled corticosteroids anti-pseudomonal antibiotics parenteral aminoglycosides demonstrated adverse experience profiles similar study population whole
In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. 	TOBI	dornase alfa	effect	{'e1': {'word': 'TOBI', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d624.s0.e1'}, 'e2': {'word': 'dornase alfa', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d624.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d624.s0'}	clinical studies TOBI patients taking TOBI concomitantly dornase alfa PULMOZYME Genentech beta agonists inhaled corticosteroids anti-pseudomonal antibiotics parenteral aminoglycosides demonstrated adverse experience profiles similar study population whole
In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. 	TOBI	PULMOZYME	effect	{'e1': {'word': 'TOBI', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d624.s0.e1'}, 'e2': {'word': 'PULMOZYME', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d624.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d624.s0'}	clinical studies TOBI patients taking TOBI concomitantly dornase alfa PULMOZYME Genentech beta agonists inhaled corticosteroids anti-pseudomonal antibiotics parenteral aminoglycosides demonstrated adverse experience profiles similar study population whole
In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. 	TOBI	(beta)-agonists	effect	{'e1': {'word': 'TOBI', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d624.s0.e1'}, 'e2': {'word': '(beta)-agonists', 'word_index': [(11, 12)], 'id': 'DDI-DrugBank.d624.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d624.s0'}	clinical studies TOBI patients taking TOBI concomitantly dornase alfa PULMOZYME Genentech beta agonists inhaled corticosteroids anti-pseudomonal antibiotics parenteral aminoglycosides demonstrated adverse experience profiles similar study population whole
In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. 	TOBI	corticosteroids	effect	{'e1': {'word': 'TOBI', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d624.s0.e1'}, 'e2': {'word': 'corticosteroids', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d624.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d624.s0'}	clinical studies TOBI patients taking TOBI concomitantly dornase alfa PULMOZYME Genentech beta agonists inhaled corticosteroids anti-pseudomonal antibiotics parenteral aminoglycosides demonstrated adverse experience profiles similar study population whole
In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. 	TOBI	anti-pseudomonal antibiotics	effect	{'e1': {'word': 'TOBI', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d624.s0.e1'}, 'e2': {'word': 'anti-pseudomonal antibiotics', 'word_index': [(15, 16)], 'id': 'DDI-DrugBank.d624.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d624.s0'}	clinical studies TOBI patients taking TOBI concomitantly dornase alfa PULMOZYME Genentech beta agonists inhaled corticosteroids anti-pseudomonal antibiotics parenteral aminoglycosides demonstrated adverse experience profiles similar study population whole
In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. 	TOBI	aminoglycosides	effect	{'e1': {'word': 'TOBI', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d624.s0.e1'}, 'e2': {'word': 'aminoglycosides', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d624.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d624.s0'}	clinical studies TOBI patients taking TOBI concomitantly dornase alfa PULMOZYME Genentech beta agonists inhaled corticosteroids anti-pseudomonal antibiotics parenteral aminoglycosides demonstrated adverse experience profiles similar study population whole
In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. 	dornase alfa	PULMOZYME	none	{'e1': {'word': 'dornase alfa', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d624.s0.e2'}, 'e2': {'word': 'PULMOZYME', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d624.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d624.s0'}	clinical studies TOBI patients taking TOBI concomitantly dornase alfa PULMOZYME Genentech beta agonists inhaled corticosteroids anti-pseudomonal antibiotics parenteral aminoglycosides demonstrated adverse experience profiles similar study population whole
In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. 	dornase alfa	(beta)-agonists	none	{'e1': {'word': 'dornase alfa', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d624.s0.e2'}, 'e2': {'word': '(beta)-agonists', 'word_index': [(11, 12)], 'id': 'DDI-DrugBank.d624.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d624.s0'}	clinical studies TOBI patients taking TOBI concomitantly dornase alfa PULMOZYME Genentech beta agonists inhaled corticosteroids anti-pseudomonal antibiotics parenteral aminoglycosides demonstrated adverse experience profiles similar study population whole
In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. 	dornase alfa	corticosteroids	none	{'e1': {'word': 'dornase alfa', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d624.s0.e2'}, 'e2': {'word': 'corticosteroids', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d624.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d624.s0'}	clinical studies TOBI patients taking TOBI concomitantly dornase alfa PULMOZYME Genentech beta agonists inhaled corticosteroids anti-pseudomonal antibiotics parenteral aminoglycosides demonstrated adverse experience profiles similar study population whole
In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. 	dornase alfa	anti-pseudomonal antibiotics	none	{'e1': {'word': 'dornase alfa', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d624.s0.e2'}, 'e2': {'word': 'anti-pseudomonal antibiotics', 'word_index': [(15, 16)], 'id': 'DDI-DrugBank.d624.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d624.s0'}	clinical studies TOBI patients taking TOBI concomitantly dornase alfa PULMOZYME Genentech beta agonists inhaled corticosteroids anti-pseudomonal antibiotics parenteral aminoglycosides demonstrated adverse experience profiles similar study population whole
In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. 	dornase alfa	aminoglycosides	none	{'e1': {'word': 'dornase alfa', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d624.s0.e2'}, 'e2': {'word': 'aminoglycosides', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d624.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d624.s0'}	clinical studies TOBI patients taking TOBI concomitantly dornase alfa PULMOZYME Genentech beta agonists inhaled corticosteroids anti-pseudomonal antibiotics parenteral aminoglycosides demonstrated adverse experience profiles similar study population whole
In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. 	PULMOZYME	(beta)-agonists	none	{'e1': {'word': 'PULMOZYME', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d624.s0.e3'}, 'e2': {'word': '(beta)-agonists', 'word_index': [(11, 12)], 'id': 'DDI-DrugBank.d624.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d624.s0'}	clinical studies TOBI patients taking TOBI concomitantly dornase alfa PULMOZYME Genentech beta agonists inhaled corticosteroids anti-pseudomonal antibiotics parenteral aminoglycosides demonstrated adverse experience profiles similar study population whole
In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. 	PULMOZYME	corticosteroids	none	{'e1': {'word': 'PULMOZYME', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d624.s0.e3'}, 'e2': {'word': 'corticosteroids', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d624.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d624.s0'}	clinical studies TOBI patients taking TOBI concomitantly dornase alfa PULMOZYME Genentech beta agonists inhaled corticosteroids anti-pseudomonal antibiotics parenteral aminoglycosides demonstrated adverse experience profiles similar study population whole
In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. 	PULMOZYME	anti-pseudomonal antibiotics	none	{'e1': {'word': 'PULMOZYME', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d624.s0.e3'}, 'e2': {'word': 'anti-pseudomonal antibiotics', 'word_index': [(15, 16)], 'id': 'DDI-DrugBank.d624.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d624.s0'}	clinical studies TOBI patients taking TOBI concomitantly dornase alfa PULMOZYME Genentech beta agonists inhaled corticosteroids anti-pseudomonal antibiotics parenteral aminoglycosides demonstrated adverse experience profiles similar study population whole
In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. 	PULMOZYME	aminoglycosides	none	{'e1': {'word': 'PULMOZYME', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d624.s0.e3'}, 'e2': {'word': 'aminoglycosides', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d624.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d624.s0'}	clinical studies TOBI patients taking TOBI concomitantly dornase alfa PULMOZYME Genentech beta agonists inhaled corticosteroids anti-pseudomonal antibiotics parenteral aminoglycosides demonstrated adverse experience profiles similar study population whole
In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. 	(beta)-agonists	corticosteroids	none	{'e1': {'word': '(beta)-agonists', 'word_index': [(11, 12)], 'id': 'DDI-DrugBank.d624.s0.e4'}, 'e2': {'word': 'corticosteroids', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d624.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d624.s0'}	clinical studies TOBI patients taking TOBI concomitantly dornase alfa PULMOZYME Genentech beta agonists inhaled corticosteroids anti-pseudomonal antibiotics parenteral aminoglycosides demonstrated adverse experience profiles similar study population whole
In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. 	(beta)-agonists	anti-pseudomonal antibiotics	none	{'e1': {'word': '(beta)-agonists', 'word_index': [(11, 12)], 'id': 'DDI-DrugBank.d624.s0.e4'}, 'e2': {'word': 'anti-pseudomonal antibiotics', 'word_index': [(15, 16)], 'id': 'DDI-DrugBank.d624.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d624.s0'}	clinical studies TOBI patients taking TOBI concomitantly dornase alfa PULMOZYME Genentech beta agonists inhaled corticosteroids anti-pseudomonal antibiotics parenteral aminoglycosides demonstrated adverse experience profiles similar study population whole
In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. 	(beta)-agonists	aminoglycosides	none	{'e1': {'word': '(beta)-agonists', 'word_index': [(11, 12)], 'id': 'DDI-DrugBank.d624.s0.e4'}, 'e2': {'word': 'aminoglycosides', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d624.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d624.s0'}	clinical studies TOBI patients taking TOBI concomitantly dornase alfa PULMOZYME Genentech beta agonists inhaled corticosteroids anti-pseudomonal antibiotics parenteral aminoglycosides demonstrated adverse experience profiles similar study population whole
In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. 	corticosteroids	anti-pseudomonal antibiotics	none	{'e1': {'word': 'corticosteroids', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d624.s0.e5'}, 'e2': {'word': 'anti-pseudomonal antibiotics', 'word_index': [(15, 16)], 'id': 'DDI-DrugBank.d624.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d624.s0'}	clinical studies TOBI patients taking TOBI concomitantly dornase alfa PULMOZYME Genentech beta agonists inhaled corticosteroids anti-pseudomonal antibiotics parenteral aminoglycosides demonstrated adverse experience profiles similar study population whole
In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. 	corticosteroids	aminoglycosides	none	{'e1': {'word': 'corticosteroids', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d624.s0.e5'}, 'e2': {'word': 'aminoglycosides', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d624.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d624.s0'}	clinical studies TOBI patients taking TOBI concomitantly dornase alfa PULMOZYME Genentech beta agonists inhaled corticosteroids anti-pseudomonal antibiotics parenteral aminoglycosides demonstrated adverse experience profiles similar study population whole
In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. 	anti-pseudomonal antibiotics	aminoglycosides	none	{'e1': {'word': 'anti-pseudomonal antibiotics', 'word_index': [(15, 16)], 'id': 'DDI-DrugBank.d624.s0.e6'}, 'e2': {'word': 'aminoglycosides', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d624.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d624.s0'}	clinical studies TOBI patients taking TOBI concomitantly dornase alfa PULMOZYME Genentech beta agonists inhaled corticosteroids anti-pseudomonal antibiotics parenteral aminoglycosides demonstrated adverse experience profiles similar study population whole
Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. 	diuretics	aminoglycoside	effect	{'e1': {'word': 'diuretics', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d624.s2.e0'}, 'e2': {'word': 'aminoglycoside', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d624.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d624.s2'}	diuretics enhance aminoglycoside toxicity altering antibiotic concentrations serum tissue
Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. 	diuretics	antibiotic	none	{'e1': {'word': 'diuretics', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d624.s2.e0'}, 'e2': {'word': 'antibiotic', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d624.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d624.s2'}	diuretics enhance aminoglycoside toxicity altering antibiotic concentrations serum tissue
Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. 	aminoglycoside	antibiotic	none	{'e1': {'word': 'aminoglycoside', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d624.s2.e1'}, 'e2': {'word': 'antibiotic', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d624.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d624.s2'}	diuretics enhance aminoglycoside toxicity altering antibiotic concentrations serum tissue
TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.	TOBI	ethacrynic acid	advise	{'e1': {'word': 'TOBI', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d624.s3.e0'}, 'e2': {'word': 'ethacrynic acid', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d624.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d624.s3'}	TOBI administered concomitantly ethacrynic acid furosemide urea mannitol
TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.	TOBI	furosemide	advise	{'e1': {'word': 'TOBI', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d624.s3.e0'}, 'e2': {'word': 'furosemide', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d624.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d624.s3'}	TOBI administered concomitantly ethacrynic acid furosemide urea mannitol
TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.	TOBI	urea	advise	{'e1': {'word': 'TOBI', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d624.s3.e0'}, 'e2': {'word': 'urea', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d624.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d624.s3'}	TOBI administered concomitantly ethacrynic acid furosemide urea mannitol
TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.	TOBI	mannitol	advise	{'e1': {'word': 'TOBI', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d624.s3.e0'}, 'e2': {'word': 'mannitol', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d624.s3.e4'}, 'sentence_id': 'DDI-DrugBank.d624.s3'}	TOBI administered concomitantly ethacrynic acid furosemide urea mannitol
TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.	ethacrynic acid	furosemide	none	{'e1': {'word': 'ethacrynic acid', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d624.s3.e1'}, 'e2': {'word': 'furosemide', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d624.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d624.s3'}	TOBI administered concomitantly ethacrynic acid furosemide urea mannitol
TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.	ethacrynic acid	urea	none	{'e1': {'word': 'ethacrynic acid', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d624.s3.e1'}, 'e2': {'word': 'urea', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d624.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d624.s3'}	TOBI administered concomitantly ethacrynic acid furosemide urea mannitol
TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.	ethacrynic acid	mannitol	none	{'e1': {'word': 'ethacrynic acid', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d624.s3.e1'}, 'e2': {'word': 'mannitol', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d624.s3.e4'}, 'sentence_id': 'DDI-DrugBank.d624.s3'}	TOBI administered concomitantly ethacrynic acid furosemide urea mannitol
TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.	furosemide	urea	none	{'e1': {'word': 'furosemide', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d624.s3.e2'}, 'e2': {'word': 'urea', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d624.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d624.s3'}	TOBI administered concomitantly ethacrynic acid furosemide urea mannitol
TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.	furosemide	mannitol	none	{'e1': {'word': 'furosemide', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d624.s3.e2'}, 'e2': {'word': 'mannitol', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d624.s3.e4'}, 'sentence_id': 'DDI-DrugBank.d624.s3'}	TOBI administered concomitantly ethacrynic acid furosemide urea mannitol
TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.	urea	mannitol	none	{'e1': {'word': 'urea', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d624.s3.e3'}, 'e2': {'word': 'mannitol', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d624.s3.e4'}, 'sentence_id': 'DDI-DrugBank.d624.s3'}	TOBI administered concomitantly ethacrynic acid furosemide urea mannitol
No pharmacokinetic interaction between 85 mg/m2 ELOXATIN and infusional 5-FU has been observed in patients treated every 2 weeks. 	ELOXATIN	5-FU	none	{'e1': {'word': 'ELOXATIN', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d728.s1.e0'}, 'e2': {'word': '5-FU', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d728.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d728.s1'}	pharmacokinetic interaction NUMBER mg / m2 ELOXATIN infusional NUMBER FU observed patients treated every NUMBER weeks
Increases of 5-FU plasma concentrations by approximately 20% have been observed with doses of 130 mg/m2 ELOXATIN dosed every 3 weeks. 	5-FU	ELOXATIN	mechanism	{'e1': {'word': '5-FU', 'word_index': [(1, 2)], 'id': 'DDI-DrugBank.d728.s2.e0'}, 'e2': {'word': 'ELOXATIN', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d728.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d728.s2'}	Increases NUMBER FU plasma concentrations approximately NUMBER % observed doses NUMBER mg / m2 ELOXATIN dosed every NUMBER weeks
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	Central Nervous System Depressants	MEPERIDINE	none	{'e1': {'word': 'Central Nervous System Depressants', 'word_index': [(1, 4)], 'id': 'DDI-DrugBank.d703.s0.e0'}, 'e2': {'word': 'MEPERIDINE', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d703.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE HYPNOTICS INCLUDING BARBITURATES TRICYCLIC ANTIDEPRESSANTS CNS DEPRESSANTS INCLUDING ALCOHOL
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	Central Nervous System Depressants	NARCOTIC ANALGESICS	none	{'e1': {'word': 'Central Nervous System Depressants', 'word_index': [(1, 4)], 'id': 'DDI-DrugBank.d703.s0.e0'}, 'e2': {'word': 'NARCOTIC ANALGESICS', 'word_index': [(14, 15)], 'id': 'DDI-DrugBank.d703.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE HYPNOTICS INCLUDING BARBITURATES TRICYCLIC ANTIDEPRESSANTS CNS DEPRESSANTS INCLUDING ALCOHOL
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	Central Nervous System Depressants	ANESTHETICS	none	{'e1': {'word': 'Central Nervous System Depressants', 'word_index': [(1, 4)], 'id': 'DDI-DrugBank.d703.s0.e0'}, 'e2': {'word': 'ANESTHETICS', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d703.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE HYPNOTICS INCLUDING BARBITURATES TRICYCLIC ANTIDEPRESSANTS CNS DEPRESSANTS INCLUDING ALCOHOL
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	Central Nervous System Depressants	PHENOTHIAZINES	none	{'e1': {'word': 'Central Nervous System Depressants', 'word_index': [(1, 4)], 'id': 'DDI-DrugBank.d703.s0.e0'}, 'e2': {'word': 'PHENOTHIAZINES', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d703.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE HYPNOTICS INCLUDING BARBITURATES TRICYCLIC ANTIDEPRESSANTS CNS DEPRESSANTS INCLUDING ALCOHOL
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	Central Nervous System Depressants	TRANQUILIZERS	none	{'e1': {'word': 'Central Nervous System Depressants', 'word_index': [(1, 4)], 'id': 'DDI-DrugBank.d703.s0.e0'}, 'e2': {'word': 'TRANQUILIZERS', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d703.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE HYPNOTICS INCLUDING BARBITURATES TRICYCLIC ANTIDEPRESSANTS CNS DEPRESSANTS INCLUDING ALCOHOL
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	Central Nervous System Depressants	SEDATIVE-HYPNOTICS	none	{'e1': {'word': 'Central Nervous System Depressants', 'word_index': [(1, 4)], 'id': 'DDI-DrugBank.d703.s0.e0'}, 'e2': {'word': 'SEDATIVE-HYPNOTICS', 'word_index': [(20, 21)], 'id': 'DDI-DrugBank.d703.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE HYPNOTICS INCLUDING BARBITURATES TRICYCLIC ANTIDEPRESSANTS CNS DEPRESSANTS INCLUDING ALCOHOL
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	Central Nervous System Depressants	BARBITURATES	none	{'e1': {'word': 'Central Nervous System Depressants', 'word_index': [(1, 4)], 'id': 'DDI-DrugBank.d703.s0.e0'}, 'e2': {'word': 'BARBITURATES', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d703.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE- ( BARBITURATES ) ANTIDEPRESSANTS AND DEPRESSANTS ( ALCOHOL )
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	Central Nervous System Depressants	TRICYCLIC ANTIDEPRESSANTS	none	{'e1': {'word': 'Central Nervous System Depressants', 'word_index': [(1, 4)], 'id': 'DDI-DrugBank.d703.s0.e0'}, 'e2': {'word': 'TRICYCLIC ANTIDEPRESSANTS', 'word_index': [(24, 25)], 'id': 'DDI-DrugBank.d703.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE- ( BARBITURATES ) TRICYCLIC ANTIDEPRESSANTS AND DEPRESSANTS ( ALCOHOL )
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	Central Nervous System Depressants	CNS DEPRESSANTS	none	{'e1': {'word': 'Central Nervous System Depressants', 'word_index': [(1, 4)], 'id': 'DDI-DrugBank.d703.s0.e0'}, 'e2': {'word': 'CNS DEPRESSANTS', 'word_index': [(26, 27)], 'id': 'DDI-DrugBank.d703.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE HYPNOTICS INCLUDING BARBITURATES TRICYCLIC ANTIDEPRESSANTS CNS DEPRESSANTS INCLUDING ALCOHOL
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	Central Nervous System Depressants	ALCOHOL	none	{'e1': {'word': 'Central Nervous System Depressants', 'word_index': [(1, 4)], 'id': 'DDI-DrugBank.d703.s0.e0'}, 'e2': {'word': 'ALCOHOL', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d703.s0.e10'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE HYPNOTICS INCLUDING BARBITURATES TRICYCLIC ANTIDEPRESSANTS CNS DEPRESSANTS INCLUDING ALCOHOL
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	MEPERIDINE	NARCOTIC ANALGESICS	advise	{'e1': {'word': 'MEPERIDINE', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d703.s0.e1'}, 'e2': {'word': 'NARCOTIC ANALGESICS', 'word_index': [(14, 15)], 'id': 'DDI-DrugBank.d703.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE HYPNOTICS INCLUDING BARBITURATES TRICYCLIC ANTIDEPRESSANTS CNS DEPRESSANTS INCLUDING ALCOHOL
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	MEPERIDINE	ANESTHETICS	advise	{'e1': {'word': 'MEPERIDINE', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d703.s0.e1'}, 'e2': {'word': 'ANESTHETICS', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d703.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE HYPNOTICS INCLUDING BARBITURATES TRICYCLIC ANTIDEPRESSANTS CNS DEPRESSANTS INCLUDING ALCOHOL
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	MEPERIDINE	PHENOTHIAZINES	advise	{'e1': {'word': 'MEPERIDINE', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d703.s0.e1'}, 'e2': {'word': 'PHENOTHIAZINES', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d703.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE HYPNOTICS INCLUDING BARBITURATES TRICYCLIC ANTIDEPRESSANTS CNS DEPRESSANTS INCLUDING ALCOHOL
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	MEPERIDINE	TRANQUILIZERS	advise	{'e1': {'word': 'MEPERIDINE', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d703.s0.e1'}, 'e2': {'word': 'TRANQUILIZERS', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d703.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE HYPNOTICS INCLUDING BARBITURATES TRICYCLIC ANTIDEPRESSANTS CNS DEPRESSANTS INCLUDING ALCOHOL
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	MEPERIDINE	SEDATIVE-HYPNOTICS	advise	{'e1': {'word': 'MEPERIDINE', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d703.s0.e1'}, 'e2': {'word': 'SEDATIVE-HYPNOTICS', 'word_index': [(20, 21)], 'id': 'DDI-DrugBank.d703.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE HYPNOTICS INCLUDING BARBITURATES TRICYCLIC ANTIDEPRESSANTS CNS DEPRESSANTS INCLUDING ALCOHOL
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	MEPERIDINE	BARBITURATES	advise	{'e1': {'word': 'MEPERIDINE', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d703.s0.e1'}, 'e2': {'word': 'BARBITURATES', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d703.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE- ( BARBITURATES ) ANTIDEPRESSANTS AND DEPRESSANTS ( ALCOHOL )
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	MEPERIDINE	TRICYCLIC ANTIDEPRESSANTS	advise	{'e1': {'word': 'MEPERIDINE', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d703.s0.e1'}, 'e2': {'word': 'TRICYCLIC ANTIDEPRESSANTS', 'word_index': [(24, 25)], 'id': 'DDI-DrugBank.d703.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE- ( BARBITURATES ) TRICYCLIC ANTIDEPRESSANTS AND DEPRESSANTS ( ALCOHOL )
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	MEPERIDINE	CNS DEPRESSANTS	advise	{'e1': {'word': 'MEPERIDINE', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d703.s0.e1'}, 'e2': {'word': 'CNS DEPRESSANTS', 'word_index': [(26, 27)], 'id': 'DDI-DrugBank.d703.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE HYPNOTICS INCLUDING BARBITURATES TRICYCLIC ANTIDEPRESSANTS CNS DEPRESSANTS INCLUDING ALCOHOL
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	MEPERIDINE	ALCOHOL	advise	{'e1': {'word': 'MEPERIDINE', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d703.s0.e1'}, 'e2': {'word': 'ALCOHOL', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d703.s0.e10'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE HYPNOTICS INCLUDING BARBITURATES TRICYCLIC ANTIDEPRESSANTS CNS DEPRESSANTS INCLUDING ALCOHOL
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	NARCOTIC ANALGESICS	ANESTHETICS	none	{'e1': {'word': 'NARCOTIC ANALGESICS', 'word_index': [(14, 15)], 'id': 'DDI-DrugBank.d703.s0.e2'}, 'e2': {'word': 'ANESTHETICS', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d703.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE HYPNOTICS INCLUDING BARBITURATES TRICYCLIC ANTIDEPRESSANTS CNS DEPRESSANTS INCLUDING ALCOHOL
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	NARCOTIC ANALGESICS	PHENOTHIAZINES	none	{'e1': {'word': 'NARCOTIC ANALGESICS', 'word_index': [(14, 15)], 'id': 'DDI-DrugBank.d703.s0.e2'}, 'e2': {'word': 'PHENOTHIAZINES', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d703.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE HYPNOTICS INCLUDING BARBITURATES TRICYCLIC ANTIDEPRESSANTS CNS DEPRESSANTS INCLUDING ALCOHOL
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	NARCOTIC ANALGESICS	TRANQUILIZERS	none	{'e1': {'word': 'NARCOTIC ANALGESICS', 'word_index': [(14, 15)], 'id': 'DDI-DrugBank.d703.s0.e2'}, 'e2': {'word': 'TRANQUILIZERS', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d703.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE HYPNOTICS INCLUDING BARBITURATES TRICYCLIC ANTIDEPRESSANTS CNS DEPRESSANTS INCLUDING ALCOHOL
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	NARCOTIC ANALGESICS	SEDATIVE-HYPNOTICS	none	{'e1': {'word': 'NARCOTIC ANALGESICS', 'word_index': [(14, 15)], 'id': 'DDI-DrugBank.d703.s0.e2'}, 'e2': {'word': 'SEDATIVE-HYPNOTICS', 'word_index': [(20, 21)], 'id': 'DDI-DrugBank.d703.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE HYPNOTICS INCLUDING BARBITURATES TRICYCLIC ANTIDEPRESSANTS CNS DEPRESSANTS INCLUDING ALCOHOL
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	NARCOTIC ANALGESICS	BARBITURATES	none	{'e1': {'word': 'NARCOTIC ANALGESICS', 'word_index': [(14, 15)], 'id': 'DDI-DrugBank.d703.s0.e2'}, 'e2': {'word': 'BARBITURATES', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d703.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE HYPNOTICS INCLUDING BARBITURATES TRICYCLIC ANTIDEPRESSANTS CNS DEPRESSANTS INCLUDING ALCOHOL
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	NARCOTIC ANALGESICS	TRICYCLIC ANTIDEPRESSANTS	none	{'e1': {'word': 'NARCOTIC ANALGESICS', 'word_index': [(14, 15)], 'id': 'DDI-DrugBank.d703.s0.e2'}, 'e2': {'word': 'TRICYCLIC ANTIDEPRESSANTS', 'word_index': [(24, 25)], 'id': 'DDI-DrugBank.d703.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE HYPNOTICS INCLUDING BARBITURATES TRICYCLIC ANTIDEPRESSANTS CNS DEPRESSANTS INCLUDING ALCOHOL
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	NARCOTIC ANALGESICS	CNS DEPRESSANTS	none	{'e1': {'word': 'NARCOTIC ANALGESICS', 'word_index': [(14, 15)], 'id': 'DDI-DrugBank.d703.s0.e2'}, 'e2': {'word': 'CNS DEPRESSANTS', 'word_index': [(26, 27)], 'id': 'DDI-DrugBank.d703.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE HYPNOTICS INCLUDING BARBITURATES TRICYCLIC ANTIDEPRESSANTS CNS DEPRESSANTS INCLUDING ALCOHOL
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	NARCOTIC ANALGESICS	ALCOHOL	none	{'e1': {'word': 'NARCOTIC ANALGESICS', 'word_index': [(14, 15)], 'id': 'DDI-DrugBank.d703.s0.e2'}, 'e2': {'word': 'ALCOHOL', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d703.s0.e10'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE HYPNOTICS INCLUDING BARBITURATES TRICYCLIC ANTIDEPRESSANTS CNS DEPRESSANTS INCLUDING ALCOHOL
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	ANESTHETICS	PHENOTHIAZINES	none	{'e1': {'word': 'ANESTHETICS', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d703.s0.e3'}, 'e2': {'word': 'PHENOTHIAZINES', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d703.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE HYPNOTICS INCLUDING BARBITURATES TRICYCLIC ANTIDEPRESSANTS CNS DEPRESSANTS INCLUDING ALCOHOL
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	ANESTHETICS	TRANQUILIZERS	none	{'e1': {'word': 'ANESTHETICS', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d703.s0.e3'}, 'e2': {'word': 'TRANQUILIZERS', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d703.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE HYPNOTICS INCLUDING BARBITURATES TRICYCLIC ANTIDEPRESSANTS CNS DEPRESSANTS INCLUDING ALCOHOL
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	ANESTHETICS	SEDATIVE-HYPNOTICS	none	{'e1': {'word': 'ANESTHETICS', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d703.s0.e3'}, 'e2': {'word': 'SEDATIVE-HYPNOTICS', 'word_index': [(20, 21)], 'id': 'DDI-DrugBank.d703.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE HYPNOTICS INCLUDING BARBITURATES TRICYCLIC ANTIDEPRESSANTS CNS DEPRESSANTS INCLUDING ALCOHOL
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	ANESTHETICS	BARBITURATES	none	{'e1': {'word': 'ANESTHETICS', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d703.s0.e3'}, 'e2': {'word': 'BARBITURATES', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d703.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE HYPNOTICS INCLUDING BARBITURATES TRICYCLIC ANTIDEPRESSANTS CNS DEPRESSANTS INCLUDING ALCOHOL
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	ANESTHETICS	TRICYCLIC ANTIDEPRESSANTS	none	{'e1': {'word': 'ANESTHETICS', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d703.s0.e3'}, 'e2': {'word': 'TRICYCLIC ANTIDEPRESSANTS', 'word_index': [(24, 25)], 'id': 'DDI-DrugBank.d703.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE HYPNOTICS INCLUDING BARBITURATES TRICYCLIC ANTIDEPRESSANTS CNS DEPRESSANTS INCLUDING ALCOHOL
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	ANESTHETICS	CNS DEPRESSANTS	none	{'e1': {'word': 'ANESTHETICS', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d703.s0.e3'}, 'e2': {'word': 'CNS DEPRESSANTS', 'word_index': [(26, 27)], 'id': 'DDI-DrugBank.d703.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE HYPNOTICS INCLUDING BARBITURATES TRICYCLIC ANTIDEPRESSANTS CNS DEPRESSANTS INCLUDING ALCOHOL
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	ANESTHETICS	ALCOHOL	none	{'e1': {'word': 'ANESTHETICS', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d703.s0.e3'}, 'e2': {'word': 'ALCOHOL', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d703.s0.e10'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE HYPNOTICS INCLUDING BARBITURATES TRICYCLIC ANTIDEPRESSANTS CNS DEPRESSANTS INCLUDING ALCOHOL
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	PHENOTHIAZINES	TRANQUILIZERS	none	{'e1': {'word': 'PHENOTHIAZINES', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d703.s0.e4'}, 'e2': {'word': 'TRANQUILIZERS', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d703.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE HYPNOTICS INCLUDING BARBITURATES TRICYCLIC ANTIDEPRESSANTS CNS DEPRESSANTS INCLUDING ALCOHOL
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	PHENOTHIAZINES	SEDATIVE-HYPNOTICS	none	{'e1': {'word': 'PHENOTHIAZINES', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d703.s0.e4'}, 'e2': {'word': 'SEDATIVE-HYPNOTICS', 'word_index': [(20, 21)], 'id': 'DDI-DrugBank.d703.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE HYPNOTICS INCLUDING BARBITURATES TRICYCLIC ANTIDEPRESSANTS CNS DEPRESSANTS INCLUDING ALCOHOL
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	PHENOTHIAZINES	BARBITURATES	none	{'e1': {'word': 'PHENOTHIAZINES', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d703.s0.e4'}, 'e2': {'word': 'BARBITURATES', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d703.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE HYPNOTICS INCLUDING BARBITURATES TRICYCLIC ANTIDEPRESSANTS CNS DEPRESSANTS INCLUDING ALCOHOL
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	PHENOTHIAZINES	TRICYCLIC ANTIDEPRESSANTS	none	{'e1': {'word': 'PHENOTHIAZINES', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d703.s0.e4'}, 'e2': {'word': 'TRICYCLIC ANTIDEPRESSANTS', 'word_index': [(24, 25)], 'id': 'DDI-DrugBank.d703.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE HYPNOTICS INCLUDING BARBITURATES TRICYCLIC ANTIDEPRESSANTS CNS DEPRESSANTS INCLUDING ALCOHOL
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	PHENOTHIAZINES	CNS DEPRESSANTS	none	{'e1': {'word': 'PHENOTHIAZINES', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d703.s0.e4'}, 'e2': {'word': 'CNS DEPRESSANTS', 'word_index': [(26, 27)], 'id': 'DDI-DrugBank.d703.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE HYPNOTICS INCLUDING BARBITURATES TRICYCLIC ANTIDEPRESSANTS CNS DEPRESSANTS INCLUDING ALCOHOL
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	PHENOTHIAZINES	ALCOHOL	none	{'e1': {'word': 'PHENOTHIAZINES', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d703.s0.e4'}, 'e2': {'word': 'ALCOHOL', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d703.s0.e10'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE HYPNOTICS INCLUDING BARBITURATES TRICYCLIC ANTIDEPRESSANTS CNS DEPRESSANTS INCLUDING ALCOHOL
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	TRANQUILIZERS	SEDATIVE-HYPNOTICS	none	{'e1': {'word': 'TRANQUILIZERS', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d703.s0.e5'}, 'e2': {'word': 'SEDATIVE-HYPNOTICS', 'word_index': [(20, 21)], 'id': 'DDI-DrugBank.d703.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE HYPNOTICS INCLUDING BARBITURATES TRICYCLIC ANTIDEPRESSANTS CNS DEPRESSANTS INCLUDING ALCOHOL
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	TRANQUILIZERS	BARBITURATES	none	{'e1': {'word': 'TRANQUILIZERS', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d703.s0.e5'}, 'e2': {'word': 'BARBITURATES', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d703.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE HYPNOTICS INCLUDING BARBITURATES TRICYCLIC ANTIDEPRESSANTS CNS DEPRESSANTS INCLUDING ALCOHOL
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	TRANQUILIZERS	TRICYCLIC ANTIDEPRESSANTS	none	{'e1': {'word': 'TRANQUILIZERS', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d703.s0.e5'}, 'e2': {'word': 'TRICYCLIC ANTIDEPRESSANTS', 'word_index': [(24, 25)], 'id': 'DDI-DrugBank.d703.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE HYPNOTICS INCLUDING BARBITURATES TRICYCLIC ANTIDEPRESSANTS CNS DEPRESSANTS INCLUDING ALCOHOL
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	TRANQUILIZERS	CNS DEPRESSANTS	none	{'e1': {'word': 'TRANQUILIZERS', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d703.s0.e5'}, 'e2': {'word': 'CNS DEPRESSANTS', 'word_index': [(26, 27)], 'id': 'DDI-DrugBank.d703.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE HYPNOTICS INCLUDING BARBITURATES TRICYCLIC ANTIDEPRESSANTS CNS DEPRESSANTS INCLUDING ALCOHOL
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	TRANQUILIZERS	ALCOHOL	none	{'e1': {'word': 'TRANQUILIZERS', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d703.s0.e5'}, 'e2': {'word': 'ALCOHOL', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d703.s0.e10'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE HYPNOTICS INCLUDING BARBITURATES TRICYCLIC ANTIDEPRESSANTS CNS DEPRESSANTS INCLUDING ALCOHOL
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	SEDATIVE-HYPNOTICS	BARBITURATES	none	{'e1': {'word': 'SEDATIVE-HYPNOTICS', 'word_index': [(20, 21)], 'id': 'DDI-DrugBank.d703.s0.e6'}, 'e2': {'word': 'BARBITURATES', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d703.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE HYPNOTICS INCLUDING BARBITURATES TRICYCLIC ANTIDEPRESSANTS CNS DEPRESSANTS INCLUDING ALCOHOL
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	SEDATIVE-HYPNOTICS	TRICYCLIC ANTIDEPRESSANTS	none	{'e1': {'word': 'SEDATIVE-HYPNOTICS', 'word_index': [(20, 21)], 'id': 'DDI-DrugBank.d703.s0.e6'}, 'e2': {'word': 'TRICYCLIC ANTIDEPRESSANTS', 'word_index': [(24, 25)], 'id': 'DDI-DrugBank.d703.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE HYPNOTICS INCLUDING BARBITURATES TRICYCLIC ANTIDEPRESSANTS CNS DEPRESSANTS INCLUDING ALCOHOL
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	SEDATIVE-HYPNOTICS	CNS DEPRESSANTS	none	{'e1': {'word': 'SEDATIVE-HYPNOTICS', 'word_index': [(20, 21)], 'id': 'DDI-DrugBank.d703.s0.e6'}, 'e2': {'word': 'CNS DEPRESSANTS', 'word_index': [(26, 27)], 'id': 'DDI-DrugBank.d703.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE HYPNOTICS INCLUDING BARBITURATES TRICYCLIC ANTIDEPRESSANTS CNS DEPRESSANTS INCLUDING ALCOHOL
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	SEDATIVE-HYPNOTICS	ALCOHOL	none	{'e1': {'word': 'SEDATIVE-HYPNOTICS', 'word_index': [(20, 21)], 'id': 'DDI-DrugBank.d703.s0.e6'}, 'e2': {'word': 'ALCOHOL', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d703.s0.e10'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE HYPNOTICS INCLUDING BARBITURATES TRICYCLIC ANTIDEPRESSANTS CNS DEPRESSANTS INCLUDING ALCOHOL
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	BARBITURATES	TRICYCLIC ANTIDEPRESSANTS	none	{'e1': {'word': 'BARBITURATES', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d703.s0.e7'}, 'e2': {'word': 'TRICYCLIC ANTIDEPRESSANTS', 'word_index': [(24, 25)], 'id': 'DDI-DrugBank.d703.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE- ( BARBITURATES ) TRICYCLIC ANTIDEPRESSANTS AND DEPRESSANTS ( ALCOHOL )
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	BARBITURATES	CNS DEPRESSANTS	none	{'e1': {'word': 'BARBITURATES', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d703.s0.e7'}, 'e2': {'word': 'CNS DEPRESSANTS', 'word_index': [(26, 27)], 'id': 'DDI-DrugBank.d703.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE- ( BARBITURATES ) ANTIDEPRESSANTS AND CNS DEPRESSANTS ( ALCOHOL )
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	BARBITURATES	ALCOHOL	none	{'e1': {'word': 'BARBITURATES', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d703.s0.e7'}, 'e2': {'word': 'ALCOHOL', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d703.s0.e10'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE- ( BARBITURATES ) ANTIDEPRESSANTS AND DEPRESSANTS ( ALCOHOL )
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	TRICYCLIC ANTIDEPRESSANTS	CNS DEPRESSANTS	none	{'e1': {'word': 'TRICYCLIC ANTIDEPRESSANTS', 'word_index': [(24, 25)], 'id': 'DDI-DrugBank.d703.s0.e8'}, 'e2': {'word': 'CNS DEPRESSANTS', 'word_index': [(27, 28)], 'id': 'DDI-DrugBank.d703.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE- ( BARBITURATES ) TRICYCLIC ANTIDEPRESSANTS AND CNS DEPRESSANTS ( ALCOHOL )
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	TRICYCLIC ANTIDEPRESSANTS	ALCOHOL	none	{'e1': {'word': 'TRICYCLIC ANTIDEPRESSANTS', 'word_index': [(24, 25)], 'id': 'DDI-DrugBank.d703.s0.e8'}, 'e2': {'word': 'ALCOHOL', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d703.s0.e10'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE- ( BARBITURATES ) TRICYCLIC ANTIDEPRESSANTS AND DEPRESSANTS ( ALCOHOL )
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). 	CNS DEPRESSANTS	ALCOHOL	none	{'e1': {'word': 'CNS DEPRESSANTS', 'word_index': [(26, 27)], 'id': 'DDI-DrugBank.d703.s0.e9'}, 'e2': {'word': 'ALCOHOL', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d703.s0.e10'}, 'sentence_id': 'DDI-DrugBank.d703.s0'}	Interaction Central Nervous System Depressants MEPERIDINE USED GREAT CAUTION REDUCED DOSAGE PATIENTS CONCURRENTLY RECEIVING NARCOTIC ANALGESICS GENERAL ANESTHETICS PHENOTHIAZINES TRANQUILIZERS SEDATIVE HYPNOTICS INCLUDING BARBITURATES TRICYCLIC ANTIDEPRESSANTS CNS DEPRESSANTS INCLUDING ALCOHOL
Mitotane has been reported to accelerate the metabolism of warfarin by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for warfarin. 	Mitotane	warfarin	mechanism	{'e1': {'word': 'Mitotane', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d717.s0.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d717.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d717.s0'}	Mitotane reported accelerate metabolism warfarin mechanism hepatic microsomal enzyme induction leading increase dosage requirements warfarin
Mitotane has been reported to accelerate the metabolism of warfarin by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for warfarin. 	Mitotane	warfarin	none	{'e1': {'word': 'Mitotane', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d717.s0.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d717.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d717.s0'}	Mitotane reported accelerate metabolism warfarin mechanism hepatic microsomal enzyme induction leading increase dosage requirements warfarin
Mitotane has been reported to accelerate the metabolism of warfarin by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for warfarin. 	warfarin	warfarin	none	{'e1': {'word': 'warfarin', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d717.s0.e1'}, 'e2': {'word': 'warfarin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d717.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d717.s0'}	Mitotane reported accelerate metabolism warfarin mechanism hepatic microsomal enzyme induction leading increase dosage requirements warfarin
Therefore, physicians should closely monitor patients for a change in anticoagulant dosage requirements when administering Mitotane to patients on coumarin-type anticoagulants. 	anticoagulant	Mitotane	none	{'e1': {'word': 'anticoagulant', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d717.s1.e0'}, 'e2': {'word': 'Mitotane', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d717.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d717.s1'}	Therefore physicians closely monitor patients change anticoagulant dosage requirements administering Mitotane patients coumarin type anticoagulants
Therefore, physicians should closely monitor patients for a change in anticoagulant dosage requirements when administering Mitotane to patients on coumarin-type anticoagulants. 	anticoagulant	coumarin-type anticoagulants	none	{'e1': {'word': 'anticoagulant', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d717.s1.e0'}, 'e2': {'word': 'coumarin-type anticoagulants', 'word_index': [(12, 14)], 'id': 'DDI-DrugBank.d717.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d717.s1'}	Therefore physicians closely monitor patients change anticoagulant dosage requirements administering Mitotane patients coumarin type anticoagulants
Therefore, physicians should closely monitor patients for a change in anticoagulant dosage requirements when administering Mitotane to patients on coumarin-type anticoagulants. 	Mitotane	coumarin-type anticoagulants	advise	{'e1': {'word': 'Mitotane', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d717.s1.e1'}, 'e2': {'word': 'coumarin-type anticoagulants', 'word_index': [(12, 14)], 'id': 'DDI-DrugBank.d717.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d717.s1'}	Therefore physicians closely monitor patients change anticoagulant dosage requirements administering Mitotane patients coumarin type anticoagulants
Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. 	phenobarbital	phenytoin	none	{'e1': {'word': 'phenobarbital', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d653.s1.e0'}, 'e2': {'word': 'phenytoin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d653.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d653.s1'}	Drugs induce hepatic enzymes phenobarbital phenytoin rifampin may increase clearance corticosteroids may require increases corticosteroid dose achieve desired response
Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. 	phenobarbital	rifampin	none	{'e1': {'word': 'phenobarbital', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d653.s1.e0'}, 'e2': {'word': 'rifampin', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d653.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d653.s1'}	Drugs induce hepatic enzymes phenobarbital phenytoin rifampin may increase clearance corticosteroids may require increases corticosteroid dose achieve desired response
Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. 	phenobarbital	corticosteroids	mechanism	{'e1': {'word': 'phenobarbital', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d653.s1.e0'}, 'e2': {'word': 'corticosteroids', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d653.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d653.s1'}	Drugs induce hepatic enzymes phenobarbital phenytoin rifampin may increase clearance corticosteroids may require increases corticosteroid dose achieve desired response
Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. 	phenobarbital	corticosteroid	mechanism	{'e1': {'word': 'phenobarbital', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d653.s1.e0'}, 'e2': {'word': 'corticosteroid', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d653.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d653.s1'}	Drugs induce hepatic enzymes phenobarbital phenytoin rifampin may increase clearance corticosteroids may require increases corticosteroid dose achieve desired response
Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. 	phenytoin	rifampin	none	{'e1': {'word': 'phenytoin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d653.s1.e1'}, 'e2': {'word': 'rifampin', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d653.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d653.s1'}	Drugs induce hepatic enzymes phenobarbital phenytoin rifampin may increase clearance corticosteroids may require increases corticosteroid dose achieve desired response
Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. 	phenytoin	corticosteroids	mechanism	{'e1': {'word': 'phenytoin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d653.s1.e1'}, 'e2': {'word': 'corticosteroids', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d653.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d653.s1'}	Drugs induce hepatic enzymes phenobarbital phenytoin rifampin may increase clearance corticosteroids may require increases corticosteroid dose achieve desired response
Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. 	phenytoin	corticosteroid	mechanism	{'e1': {'word': 'phenytoin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d653.s1.e1'}, 'e2': {'word': 'corticosteroid', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d653.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d653.s1'}	Drugs induce hepatic enzymes phenobarbital phenytoin rifampin may increase clearance corticosteroids may require increases corticosteroid dose achieve desired response
Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. 	rifampin	corticosteroids	mechanism	{'e1': {'word': 'rifampin', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d653.s1.e2'}, 'e2': {'word': 'corticosteroids', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d653.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d653.s1'}	Drugs induce hepatic enzymes phenobarbital phenytoin rifampin may increase clearance corticosteroids may require increases corticosteroid dose achieve desired response
Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. 	rifampin	corticosteroid	mechanism	{'e1': {'word': 'rifampin', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d653.s1.e2'}, 'e2': {'word': 'corticosteroid', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d653.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d653.s1'}	Drugs induce hepatic enzymes phenobarbital phenytoin rifampin may increase clearance corticosteroids may require increases corticosteroid dose achieve desired response
Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. 	corticosteroids	corticosteroid	none	{'e1': {'word': 'corticosteroids', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d653.s1.e3'}, 'e2': {'word': 'corticosteroid', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d653.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d653.s1'}	Drugs induce hepatic enzymes phenobarbital phenytoin rifampin may increase clearance corticosteroids may require increases corticosteroid dose achieve desired response
Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance. 	troleandomycin	ketoconazole	none	{'e1': {'word': 'troleandomycin', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d653.s2.e0'}, 'e2': {'word': 'ketoconazole', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d653.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d653.s2'}	Drugs troleandomycin ketoconazole may inhibit metabolism corticosteroids thus decrease clearance
Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance. 	troleandomycin	corticosteroids	mechanism	{'e1': {'word': 'troleandomycin', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d653.s2.e0'}, 'e2': {'word': 'corticosteroids', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d653.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d653.s2'}	Drugs troleandomycin ketoconazole may inhibit metabolism corticosteroids thus decrease clearance
Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance. 	ketoconazole	corticosteroids	mechanism	{'e1': {'word': 'ketoconazole', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d653.s2.e1'}, 'e2': {'word': 'corticosteroids', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d653.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d653.s2'}	Drugs troleandomycin ketoconazole may inhibit metabolism corticosteroids thus decrease clearance
Corticosteroids may increase the clearance of chronic high dose aspirin. 	Corticosteroids	aspirin	mechanism	{'e1': {'word': 'Corticosteroids', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d653.s4.e0'}, 'e2': {'word': 'aspirin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d653.s4.e1'}, 'sentence_id': 'DDI-DrugBank.d653.s4'}	Corticosteroids may increase clearance chronic high dose aspirin
This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn. 	salicylate	salicylate	none	{'e1': {'word': 'salicylate', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d653.s5.e0'}, 'e2': {'word': 'salicylate', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d653.s5.e1'}, 'sentence_id': 'DDI-DrugBank.d653.s5'}	could lead decreased salicylate serum levels increase risk salicylate toxicity corticosteroid withdrawn
This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn. 	salicylate	corticosteroid	none	{'e1': {'word': 'salicylate', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d653.s5.e0'}, 'e2': {'word': 'corticosteroid', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d653.s5.e2'}, 'sentence_id': 'DDI-DrugBank.d653.s5'}	could lead decreased salicylate serum levels increase risk salicylate toxicity corticosteroid withdrawn
This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn. 	salicylate	corticosteroid	effect	{'e1': {'word': 'salicylate', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d653.s5.e1'}, 'e2': {'word': 'corticosteroid', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d653.s5.e2'}, 'sentence_id': 'DDI-DrugBank.d653.s5'}	could lead decreased salicylate serum levels increase risk salicylate toxicity corticosteroid withdrawn
Aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia. 	Aspirin	corticosteroids	advise	{'e1': {'word': 'Aspirin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d653.s6.e0'}, 'e2': {'word': 'corticosteroids', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d653.s6.e1'}, 'sentence_id': 'DDI-DrugBank.d653.s6'}	Aspirin used cautiously conjunction corticosteroids patients suffering hypoprothrombinemia
The effect of corticosteroids on oral anticoagulants is variable. 	corticosteroids	anticoagulants	effect	{'e1': {'word': 'corticosteroids', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d653.s7.e0'}, 'e2': {'word': 'anticoagulants', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d653.s7.e1'}, 'sentence_id': 'DDI-DrugBank.d653.s7'}	effect corticosteroids oral anticoagulants variable
There are reports of enhanced as well as diminished effects of anticoagulants when given concurrently with corticosteroids. 	anticoagulants	corticosteroids	effect	{'e1': {'word': 'anticoagulants', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d653.s8.e0'}, 'e2': {'word': 'corticosteroids', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d653.s8.e1'}, 'sentence_id': 'DDI-DrugBank.d653.s8'}	reports enhanced well diminished effects anticoagulants given concurrently corticosteroids
Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. 	Central Nervous System Depressants	morphine	none	{'e1': {'word': 'Central Nervous System Depressants', 'word_index': [(1, 4)], 'id': 'DDI-DrugBank.d637.s0.e0'}, 'e2': {'word': 'morphine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d637.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d637.s0'}	Use Central Nervous System Depressants depressant effects morphine potentiated presence CNS depressants alcohol sedatives antihistaminics psychotropic drugs
Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. 	Central Nervous System Depressants	CNS depressants	none	{'e1': {'word': 'Central Nervous System Depressants', 'word_index': [(1, 4)], 'id': 'DDI-DrugBank.d637.s0.e0'}, 'e2': {'word': 'CNS depressants', 'word_index': [(10, 11)], 'id': 'DDI-DrugBank.d637.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d637.s0'}	Use Central Nervous System Depressants depressant effects morphine potentiated presence CNS depressants alcohol sedatives antihistaminics psychotropic drugs
Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. 	Central Nervous System Depressants	alcohol	none	{'e1': {'word': 'Central Nervous System Depressants', 'word_index': [(1, 4)], 'id': 'DDI-DrugBank.d637.s0.e0'}, 'e2': {'word': 'alcohol', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d637.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d637.s0'}	Use Central Nervous System Depressants depressant effects morphine potentiated presence CNS depressants alcohol sedatives antihistaminics psychotropic drugs
Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. 	Central Nervous System Depressants	sedatives	none	{'e1': {'word': 'Central Nervous System Depressants', 'word_index': [(1, 4)], 'id': 'DDI-DrugBank.d637.s0.e0'}, 'e2': {'word': 'sedatives', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d637.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d637.s0'}	Use Central Nervous System Depressants depressant effects morphine potentiated presence CNS depressants alcohol sedatives antihistaminics psychotropic drugs
Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. 	Central Nervous System Depressants	antihistaminics	none	{'e1': {'word': 'Central Nervous System Depressants', 'word_index': [(1, 4)], 'id': 'DDI-DrugBank.d637.s0.e0'}, 'e2': {'word': 'antihistaminics', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d637.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d637.s0'}	Use Central Nervous System Depressants depressant effects morphine potentiated presence CNS depressants alcohol sedatives antihistaminics psychotropic drugs
Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. 	Central Nervous System Depressants	psychotropic drugs	none	{'e1': {'word': 'Central Nervous System Depressants', 'word_index': [(1, 4)], 'id': 'DDI-DrugBank.d637.s0.e0'}, 'e2': {'word': 'psychotropic drugs', 'word_index': [(15, 16)], 'id': 'DDI-DrugBank.d637.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d637.s0'}	Use Central Nervous System Depressants depressant effects morphine potentiated presence CNS depressants alcohol sedatives antihistaminics psychotropic drugs
Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. 	morphine	CNS depressants	effect	{'e1': {'word': 'morphine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d637.s0.e1'}, 'e2': {'word': 'CNS depressants', 'word_index': [(10, 11)], 'id': 'DDI-DrugBank.d637.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d637.s0'}	Use Central Nervous System Depressants depressant effects morphine potentiated presence CNS depressants alcohol sedatives antihistaminics psychotropic drugs
Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. 	morphine	alcohol	effect	{'e1': {'word': 'morphine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d637.s0.e1'}, 'e2': {'word': 'alcohol', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d637.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d637.s0'}	Use Central Nervous System Depressants depressant effects morphine potentiated presence CNS depressants alcohol sedatives antihistaminics psychotropic drugs
Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. 	morphine	sedatives	effect	{'e1': {'word': 'morphine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d637.s0.e1'}, 'e2': {'word': 'sedatives', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d637.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d637.s0'}	Use Central Nervous System Depressants depressant effects morphine potentiated presence CNS depressants alcohol sedatives antihistaminics psychotropic drugs
Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. 	morphine	antihistaminics	effect	{'e1': {'word': 'morphine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d637.s0.e1'}, 'e2': {'word': 'antihistaminics', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d637.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d637.s0'}	Use Central Nervous System Depressants depressant effects morphine potentiated presence CNS depressants alcohol sedatives antihistaminics psychotropic drugs
Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. 	morphine	psychotropic drugs	effect	{'e1': {'word': 'morphine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d637.s0.e1'}, 'e2': {'word': 'psychotropic drugs', 'word_index': [(15, 16)], 'id': 'DDI-DrugBank.d637.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d637.s0'}	Use Central Nervous System Depressants depressant effects morphine potentiated presence CNS depressants alcohol sedatives antihistaminics psychotropic drugs
Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. 	CNS depressants	alcohol	none	{'e1': {'word': 'CNS depressants', 'word_index': [(10, 11)], 'id': 'DDI-DrugBank.d637.s0.e2'}, 'e2': {'word': 'alcohol', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d637.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d637.s0'}	Use Central Nervous System Depressants depressant effects morphine potentiated presence CNS depressants alcohol sedatives antihistaminics psychotropic drugs
Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. 	CNS depressants	sedatives	none	{'e1': {'word': 'CNS depressants', 'word_index': [(10, 11)], 'id': 'DDI-DrugBank.d637.s0.e2'}, 'e2': {'word': 'sedatives', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d637.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d637.s0'}	Use Central Nervous System Depressants depressant effects morphine potentiated presence CNS depressants alcohol sedatives antihistaminics psychotropic drugs
Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. 	CNS depressants	antihistaminics	none	{'e1': {'word': 'CNS depressants', 'word_index': [(10, 11)], 'id': 'DDI-DrugBank.d637.s0.e2'}, 'e2': {'word': 'antihistaminics', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d637.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d637.s0'}	Use Central Nervous System Depressants depressant effects morphine potentiated presence CNS depressants alcohol sedatives antihistaminics psychotropic drugs
Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. 	CNS depressants	psychotropic drugs	none	{'e1': {'word': 'CNS depressants', 'word_index': [(10, 11)], 'id': 'DDI-DrugBank.d637.s0.e2'}, 'e2': {'word': 'psychotropic drugs', 'word_index': [(15, 16)], 'id': 'DDI-DrugBank.d637.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d637.s0'}	Use Central Nervous System Depressants depressant effects morphine potentiated presence CNS depressants alcohol sedatives antihistaminics psychotropic drugs
Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. 	alcohol	sedatives	none	{'e1': {'word': 'alcohol', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d637.s0.e3'}, 'e2': {'word': 'sedatives', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d637.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d637.s0'}	Use Central Nervous System Depressants depressant effects morphine potentiated presence CNS depressants alcohol sedatives antihistaminics psychotropic drugs
Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. 	alcohol	antihistaminics	none	{'e1': {'word': 'alcohol', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d637.s0.e3'}, 'e2': {'word': 'antihistaminics', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d637.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d637.s0'}	Use Central Nervous System Depressants depressant effects morphine potentiated presence CNS depressants alcohol sedatives antihistaminics psychotropic drugs
Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. 	alcohol	psychotropic drugs	none	{'e1': {'word': 'alcohol', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d637.s0.e3'}, 'e2': {'word': 'psychotropic drugs', 'word_index': [(15, 16)], 'id': 'DDI-DrugBank.d637.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d637.s0'}	Use Central Nervous System Depressants depressant effects morphine potentiated presence CNS depressants alcohol sedatives antihistaminics psychotropic drugs
Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. 	sedatives	antihistaminics	none	{'e1': {'word': 'sedatives', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d637.s0.e4'}, 'e2': {'word': 'antihistaminics', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d637.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d637.s0'}	Use Central Nervous System Depressants depressant effects morphine potentiated presence CNS depressants alcohol sedatives antihistaminics psychotropic drugs
Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. 	sedatives	psychotropic drugs	none	{'e1': {'word': 'sedatives', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d637.s0.e4'}, 'e2': {'word': 'psychotropic drugs', 'word_index': [(15, 16)], 'id': 'DDI-DrugBank.d637.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d637.s0'}	Use Central Nervous System Depressants depressant effects morphine potentiated presence CNS depressants alcohol sedatives antihistaminics psychotropic drugs
Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. 	antihistaminics	psychotropic drugs	none	{'e1': {'word': 'antihistaminics', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d637.s0.e5'}, 'e2': {'word': 'psychotropic drugs', 'word_index': [(15, 16)], 'id': 'DDI-DrugBank.d637.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d637.s0'}	Use Central Nervous System Depressants depressant effects morphine potentiated presence CNS depressants alcohol sedatives antihistaminics psychotropic drugs
Use of neuroleptics in conjunction with oral morphine may increase the risk of respiratory depression, hypotension and profound sedation or coma. 	neuroleptics	morphine	effect	{'e1': {'word': 'neuroleptics', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d637.s1.e0'}, 'e2': {'word': 'morphine', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d637.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d637.s1'}	Use neuroleptics conjunction oral morphine may increase risk respiratory depression hypotension profound sedation coma
Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. 	Mixed Agonist/Antagonist Opioid Analgesics	Agonist/antagonist analgesics	none	{'e1': {'word': 'Mixed Agonist/Antagonist Opioid Analgesics', 'word_index': [(1, 5)], 'id': 'DDI-DrugBank.d637.s2.e0'}, 'e2': {'word': 'Agonist/antagonist analgesics', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d637.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d637.s2'}	Interaction Mixed Agonist Antagonist Opioid Analgesics Agonist/antagonist ( i.e. pentazocine nalbuphine butorphanol or should patients have are course therapy a agonist analgesic .
Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. 	Mixed Agonist/Antagonist Opioid Analgesics	pentazocine	none	{'e1': {'word': 'Mixed Agonist/Antagonist Opioid Analgesics', 'word_index': [(1, 5)], 'id': 'DDI-DrugBank.d637.s2.e0'}, 'e2': {'word': 'pentazocine', 'word_index': [(9, 8)], 'id': 'DDI-DrugBank.d637.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d637.s2'}	Interaction Mixed Agonist Antagonist Opioid Analgesics Agonist/antagonist ( i.e. , nalbuphine butorphanol or should patients have are course therapy a agonist analgesic .
Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. 	Mixed Agonist/Antagonist Opioid Analgesics	nalbuphine	none	{'e1': {'word': 'Mixed Agonist/Antagonist Opioid Analgesics', 'word_index': [(1, 5)], 'id': 'DDI-DrugBank.d637.s2.e0'}, 'e2': {'word': 'nalbuphine', 'word_index': [(10, 9)], 'id': 'DDI-DrugBank.d637.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d637.s2'}	Interaction Mixed Agonist Antagonist Opioid Analgesics Agonist/antagonist ( i.e. pentazocine , butorphanol or should patients have are course therapy a agonist analgesic .
Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. 	Mixed Agonist/Antagonist Opioid Analgesics	butorphanol	none	{'e1': {'word': 'Mixed Agonist/Antagonist Opioid Analgesics', 'word_index': [(1, 5)], 'id': 'DDI-DrugBank.d637.s2.e0'}, 'e2': {'word': 'butorphanol', 'word_index': [(11, 10)], 'id': 'DDI-DrugBank.d637.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d637.s2'}	Interaction Mixed Agonist Antagonist Opioid Analgesics Agonist/antagonist ( i.e. pentazocine nalbuphine , or should patients have are course therapy a agonist analgesic .
Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. 	Mixed Agonist/Antagonist Opioid Analgesics	buprenorphine	none	{'e1': {'word': 'Mixed Agonist/Antagonist Opioid Analgesics', 'word_index': [(1, 5)], 'id': 'DDI-DrugBank.d637.s2.e0'}, 'e2': {'word': 'buprenorphine', 'word_index': [(13, 12)], 'id': 'DDI-DrugBank.d637.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d637.s2'}	Interaction Mixed Agonist Antagonist Opioid Analgesics Agonist/antagonist ( i.e. pentazocine nalbuphine butorphanol or ) should patients have are course therapy a agonist analgesic .
Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. 	Mixed Agonist/Antagonist Opioid Analgesics	opioid agonist analgesic	none	{'e1': {'word': 'Mixed Agonist/Antagonist Opioid Analgesics', 'word_index': [(1, 5)], 'id': 'DDI-DrugBank.d637.s2.e0'}, 'e2': {'word': 'opioid agonist analgesic', 'word_index': [(20, 22)], 'id': 'DDI-DrugBank.d637.s2.e6'}, 'sentence_id': 'DDI-DrugBank.d637.s2'}	Interaction Mixed Agonist Antagonist Opioid Analgesics Agonist/antagonist ( i.e. pentazocine nalbuphine butorphanol or should patients have are course therapy a opioid agonist analgesic .
Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. 	Agonist/antagonist analgesics	pentazocine	none	{'e1': {'word': 'Agonist/antagonist analgesics', 'word_index': [(6, 8)], 'id': 'DDI-DrugBank.d637.s2.e1'}, 'e2': {'word': 'pentazocine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d637.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d637.s2'}	Interaction Mixed Agonist Antagonist Opioid Analgesics Agonist antagonist analgesics i.e. pentazocine nalbuphine butorphanol buprenorphine administered patients received receiving course therapy proof opioid agonist analgesic
Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. 	Agonist/antagonist analgesics	nalbuphine	none	{'e1': {'word': 'Agonist/antagonist analgesics', 'word_index': [(6, 8)], 'id': 'DDI-DrugBank.d637.s2.e1'}, 'e2': {'word': 'nalbuphine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d637.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d637.s2'}	Interaction Mixed Agonist Antagonist Opioid Analgesics Agonist antagonist analgesics i.e. pentazocine nalbuphine butorphanol buprenorphine administered patients received receiving course therapy proof opioid agonist analgesic
Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. 	Agonist/antagonist analgesics	butorphanol	none	{'e1': {'word': 'Agonist/antagonist analgesics', 'word_index': [(6, 8)], 'id': 'DDI-DrugBank.d637.s2.e1'}, 'e2': {'word': 'butorphanol', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d637.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d637.s2'}	Interaction Mixed Agonist Antagonist Opioid Analgesics Agonist antagonist analgesics i.e. pentazocine nalbuphine butorphanol buprenorphine administered patients received receiving course therapy proof opioid agonist analgesic
Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. 	Agonist/antagonist analgesics	buprenorphine	none	{'e1': {'word': 'Agonist/antagonist analgesics', 'word_index': [(6, 8)], 'id': 'DDI-DrugBank.d637.s2.e1'}, 'e2': {'word': 'buprenorphine', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d637.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d637.s2'}	Interaction Mixed Agonist Antagonist Opioid Analgesics Agonist antagonist analgesics i.e. pentazocine nalbuphine butorphanol buprenorphine administered patients received receiving course therapy proof opioid agonist analgesic
Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. 	Agonist/antagonist analgesics	opioid agonist analgesic	advise	{'e1': {'word': 'Agonist/antagonist analgesics', 'word_index': [(6, 8)], 'id': 'DDI-DrugBank.d637.s2.e1'}, 'e2': {'word': 'opioid agonist analgesic', 'word_index': [(21, 23)], 'id': 'DDI-DrugBank.d637.s2.e6'}, 'sentence_id': 'DDI-DrugBank.d637.s2'}	Interaction Mixed Agonist Antagonist Opioid Analgesics Agonist antagonist analgesics i.e. pentazocine nalbuphine butorphanol buprenorphine administered patients received receiving course therapy proof opioid agonist analgesic
Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. 	pentazocine	nalbuphine	none	{'e1': {'word': 'pentazocine', 'word_index': [(9, 8)], 'id': 'DDI-DrugBank.d637.s2.e2'}, 'e2': {'word': 'nalbuphine', 'word_index': [(10, 9)], 'id': 'DDI-DrugBank.d637.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d637.s2'}	Interaction Mixed Agonist Antagonist Opioid Analgesics Agonist/antagonist ( i.e. , , butorphanol or should patients have are course therapy a agonist analgesic .
Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. 	pentazocine	butorphanol	none	{'e1': {'word': 'pentazocine', 'word_index': [(9, 8)], 'id': 'DDI-DrugBank.d637.s2.e2'}, 'e2': {'word': 'butorphanol', 'word_index': [(11, 10)], 'id': 'DDI-DrugBank.d637.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d637.s2'}	Interaction Mixed Agonist Antagonist Opioid Analgesics Agonist/antagonist ( i.e. , nalbuphine , or should patients have are course therapy a agonist analgesic .
Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. 	pentazocine	buprenorphine	none	{'e1': {'word': 'pentazocine', 'word_index': [(9, 8)], 'id': 'DDI-DrugBank.d637.s2.e2'}, 'e2': {'word': 'buprenorphine', 'word_index': [(13, 12)], 'id': 'DDI-DrugBank.d637.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d637.s2'}	Interaction Mixed Agonist Antagonist Opioid Analgesics Agonist/antagonist ( i.e. , nalbuphine butorphanol or ) should patients have are course therapy a agonist analgesic .
Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. 	pentazocine	opioid agonist analgesic	advise	{'e1': {'word': 'pentazocine', 'word_index': [(9, 8)], 'id': 'DDI-DrugBank.d637.s2.e2'}, 'e2': {'word': 'opioid agonist analgesic', 'word_index': [(20, 22)], 'id': 'DDI-DrugBank.d637.s2.e6'}, 'sentence_id': 'DDI-DrugBank.d637.s2'}	Interaction Mixed Agonist Antagonist Opioid Analgesics Agonist/antagonist ( i.e. , nalbuphine butorphanol or should patients have are course therapy a opioid agonist analgesic .
Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. 	nalbuphine	butorphanol	none	{'e1': {'word': 'nalbuphine', 'word_index': [(10, 9)], 'id': 'DDI-DrugBank.d637.s2.e3'}, 'e2': {'word': 'butorphanol', 'word_index': [(11, 10)], 'id': 'DDI-DrugBank.d637.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d637.s2'}	Interaction Mixed Agonist Antagonist Opioid Analgesics Agonist/antagonist ( i.e. pentazocine , , or should patients have are course therapy a agonist analgesic .
Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. 	nalbuphine	buprenorphine	none	{'e1': {'word': 'nalbuphine', 'word_index': [(10, 9)], 'id': 'DDI-DrugBank.d637.s2.e3'}, 'e2': {'word': 'buprenorphine', 'word_index': [(13, 12)], 'id': 'DDI-DrugBank.d637.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d637.s2'}	Interaction Mixed Agonist Antagonist Opioid Analgesics Agonist/antagonist ( i.e. pentazocine , butorphanol or ) should patients have are course therapy a agonist analgesic .
Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. 	nalbuphine	opioid agonist analgesic	advise	{'e1': {'word': 'nalbuphine', 'word_index': [(10, 9)], 'id': 'DDI-DrugBank.d637.s2.e3'}, 'e2': {'word': 'opioid agonist analgesic', 'word_index': [(20, 22)], 'id': 'DDI-DrugBank.d637.s2.e6'}, 'sentence_id': 'DDI-DrugBank.d637.s2'}	Interaction Mixed Agonist Antagonist Opioid Analgesics Agonist/antagonist ( i.e. pentazocine , butorphanol or should patients have are course therapy a opioid agonist analgesic .
Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. 	butorphanol	buprenorphine	none	{'e1': {'word': 'butorphanol', 'word_index': [(11, 10)], 'id': 'DDI-DrugBank.d637.s2.e4'}, 'e2': {'word': 'buprenorphine', 'word_index': [(13, 12)], 'id': 'DDI-DrugBank.d637.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d637.s2'}	Interaction Mixed Agonist Antagonist Opioid Analgesics Agonist/antagonist ( i.e. pentazocine nalbuphine , or ) should patients have are course therapy a agonist analgesic .
Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. 	butorphanol	opioid agonist analgesic	advise	{'e1': {'word': 'butorphanol', 'word_index': [(11, 10)], 'id': 'DDI-DrugBank.d637.s2.e4'}, 'e2': {'word': 'opioid agonist analgesic', 'word_index': [(20, 22)], 'id': 'DDI-DrugBank.d637.s2.e6'}, 'sentence_id': 'DDI-DrugBank.d637.s2'}	Interaction Mixed Agonist Antagonist Opioid Analgesics Agonist/antagonist ( i.e. pentazocine nalbuphine , or should patients have are course therapy a opioid agonist analgesic .
Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. 	buprenorphine	opioid agonist analgesic	advise	{'e1': {'word': 'buprenorphine', 'word_index': [(13, 12)], 'id': 'DDI-DrugBank.d637.s2.e5'}, 'e2': {'word': 'opioid agonist analgesic', 'word_index': [(21, 23)], 'id': 'DDI-DrugBank.d637.s2.e6'}, 'sentence_id': 'DDI-DrugBank.d637.s2'}	Interaction Mixed Agonist Antagonist Opioid Analgesics Agonist/antagonist ( i.e. pentazocine nalbuphine butorphanol or ) should patients have are course therapy a opioid agonist analgesic .
Concomitant use of alcohol with phentermine hydrochloride may result in an adverse drug interaction.	alcohol	phentermine hydrochloride	int	{'e1': {'word': 'alcohol', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d750.s0.e0'}, 'e2': {'word': 'phentermine hydrochloride', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d750.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d750.s0'}	Concomitant use alcohol phentermine hydrochloride may result adverse drug interaction
Co-administration of oral ketoconazole 200 mg twice daily increased retapamulin geometric mean AUC(0-24) and Cmax by 81% after topical application of retapamulin ointment, 1% on the abraded skin of healthy adult males. 	ketoconazole	retapamulin	none	{'e1': {'word': 'ketoconazole', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d654.s0.e0'}, 'e2': {'word': 'retapamulin', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d654.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d654.s0'}	Co-administration oral ketoconazole NUMBER mg twice daily increased retapamulin geometric mean AUC NUMBER - NUMBER Cmax NUMBER % topical application retapamulin ointment NUMBER % abraded skin healthy adult males
Co-administration of oral ketoconazole 200 mg twice daily increased retapamulin geometric mean AUC(0-24) and Cmax by 81% after topical application of retapamulin ointment, 1% on the abraded skin of healthy adult males. 	ketoconazole	retapamulin	mechanism	{'e1': {'word': 'ketoconazole', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d654.s0.e0'}, 'e2': {'word': 'retapamulin', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d654.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d654.s0'}	Co-administration oral ketoconazole NUMBER mg twice daily increased retapamulin geometric mean AUC NUMBER - NUMBER Cmax NUMBER % topical application retapamulin ointment NUMBER % abraded skin healthy adult males
Co-administration of oral ketoconazole 200 mg twice daily increased retapamulin geometric mean AUC(0-24) and Cmax by 81% after topical application of retapamulin ointment, 1% on the abraded skin of healthy adult males. 	retapamulin	retapamulin	none	{'e1': {'word': 'retapamulin', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d654.s0.e1'}, 'e2': {'word': 'retapamulin', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d654.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d654.s0'}	Co-administration oral ketoconazole NUMBER mg twice daily increased retapamulin geometric mean AUC NUMBER - NUMBER Cmax NUMBER % topical application retapamulin ointment NUMBER % abraded skin healthy adult males
Due to low systemic exposure to retapamulin following topical application in patients, dosage adjustments for retapamulin are unnecessary when co-administered with CYP3A4 inhibitors, such as ketoconazole. 	retapamulin	retapamulin	none	{'e1': {'word': 'retapamulin', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d654.s1.e0'}, 'e2': {'word': 'retapamulin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d654.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d654.s1'}	Due low systemic exposure retapamulin following topical application patients dosage adjustments retapamulin unnecessary co-administered CYP3A4 inhibitors ketoconazole
Due to low systemic exposure to retapamulin following topical application in patients, dosage adjustments for retapamulin are unnecessary when co-administered with CYP3A4 inhibitors, such as ketoconazole. 	retapamulin	ketoconazole	none	{'e1': {'word': 'retapamulin', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d654.s1.e0'}, 'e2': {'word': 'ketoconazole', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d654.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d654.s1'}	Due low systemic exposure retapamulin following topical application patients dosage adjustments retapamulin unnecessary co-administered CYP3A4 inhibitors ketoconazole
Due to low systemic exposure to retapamulin following topical application in patients, dosage adjustments for retapamulin are unnecessary when co-administered with CYP3A4 inhibitors, such as ketoconazole. 	retapamulin	ketoconazole	none	{'e1': {'word': 'retapamulin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d654.s1.e1'}, 'e2': {'word': 'ketoconazole', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d654.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d654.s1'}	Due low systemic exposure retapamulin following topical application patients dosage adjustments retapamulin unnecessary co-administered CYP3A4 inhibitors ketoconazole
Based on in vitro P450 inhibition studies and the low systemic exposure observed following topical application of ALTABAX, retapamulin is unlikely to affect the metabolism of other P450 substrates. 	ALTABAX	retapamulin	none	{'e1': {'word': 'ALTABAX', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d654.s2.e0'}, 'e2': {'word': 'retapamulin', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d654.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d654.s2'}	Based vitro P450 inhibition studies low systemic exposure observed following topical application ALTABAX retapamulin unlikely affect metabolism P450 substrates
In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.	heparin	vitamin K antagonists	none	{'e1': {'word': 'heparin', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d618.s1.e0'}, 'e2': {'word': 'vitamin K antagonists', 'word_index': [(4, 6)], 'id': 'DDI-DrugBank.d618.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d618.s1'}	addition bleeding associated heparin vitamin K antagonists drugs alter platelet function aspirin dipyridamole abciximab may increase risk bleeding administered prior Retavase therapy
In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.	heparin	aspirin	none	{'e1': {'word': 'heparin', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d618.s1.e0'}, 'e2': {'word': 'aspirin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d618.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d618.s1'}	addition bleeding associated heparin vitamin K antagonists drugs alter platelet function aspirin dipyridamole abciximab may increase risk bleeding administered prior Retavase therapy
In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.	heparin	dipyridamole	none	{'e1': {'word': 'heparin', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d618.s1.e0'}, 'e2': {'word': 'dipyridamole', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d618.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d618.s1'}	addition bleeding associated heparin vitamin K antagonists drugs alter platelet function aspirin dipyridamole abciximab may increase risk bleeding administered prior Retavase therapy
In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.	heparin	abciximab	none	{'e1': {'word': 'heparin', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d618.s1.e0'}, 'e2': {'word': 'abciximab', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d618.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d618.s1'}	addition bleeding associated heparin vitamin K antagonists drugs alter platelet function aspirin dipyridamole abciximab may increase risk bleeding administered prior Retavase therapy
In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.	heparin	Retavase	effect	{'e1': {'word': 'heparin', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d618.s1.e0'}, 'e2': {'word': 'Retavase', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d618.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d618.s1'}	addition bleeding associated heparin vitamin K antagonists drugs alter platelet function aspirin dipyridamole abciximab may increase risk bleeding administered prior Retavase therapy
In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.	vitamin K antagonists	aspirin	none	{'e1': {'word': 'vitamin K antagonists', 'word_index': [(4, 6)], 'id': 'DDI-DrugBank.d618.s1.e1'}, 'e2': {'word': 'aspirin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d618.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d618.s1'}	addition bleeding associated heparin vitamin K antagonists drugs alter platelet function aspirin dipyridamole abciximab may increase risk bleeding administered prior Retavase therapy
In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.	vitamin K antagonists	dipyridamole	none	{'e1': {'word': 'vitamin K antagonists', 'word_index': [(4, 6)], 'id': 'DDI-DrugBank.d618.s1.e1'}, 'e2': {'word': 'dipyridamole', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d618.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d618.s1'}	addition bleeding associated heparin vitamin K antagonists drugs alter platelet function aspirin dipyridamole abciximab may increase risk bleeding administered prior Retavase therapy
In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.	vitamin K antagonists	abciximab	none	{'e1': {'word': 'vitamin K antagonists', 'word_index': [(4, 6)], 'id': 'DDI-DrugBank.d618.s1.e1'}, 'e2': {'word': 'abciximab', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d618.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d618.s1'}	addition bleeding associated heparin vitamin K antagonists drugs alter platelet function aspirin dipyridamole abciximab may increase risk bleeding administered prior Retavase therapy
In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.	vitamin K antagonists	Retavase	effect	{'e1': {'word': 'vitamin K antagonists', 'word_index': [(4, 6)], 'id': 'DDI-DrugBank.d618.s1.e1'}, 'e2': {'word': 'Retavase', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d618.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d618.s1'}	addition bleeding associated heparin vitamin K antagonists drugs alter platelet function aspirin dipyridamole abciximab may increase risk bleeding administered prior Retavase therapy
In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.	aspirin	dipyridamole	none	{'e1': {'word': 'aspirin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d618.s1.e2'}, 'e2': {'word': 'dipyridamole', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d618.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d618.s1'}	addition bleeding associated heparin vitamin K antagonists drugs alter platelet function aspirin dipyridamole abciximab may increase risk bleeding administered prior Retavase therapy
In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.	aspirin	abciximab	none	{'e1': {'word': 'aspirin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d618.s1.e2'}, 'e2': {'word': 'abciximab', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d618.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d618.s1'}	addition bleeding associated heparin vitamin K antagonists drugs alter platelet function aspirin dipyridamole abciximab may increase risk bleeding administered prior Retavase therapy
In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.	aspirin	Retavase	effect	{'e1': {'word': 'aspirin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d618.s1.e2'}, 'e2': {'word': 'Retavase', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d618.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d618.s1'}	addition bleeding associated heparin vitamin K antagonists drugs alter platelet function aspirin dipyridamole abciximab may increase risk bleeding administered prior Retavase therapy
In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.	dipyridamole	abciximab	none	{'e1': {'word': 'dipyridamole', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d618.s1.e3'}, 'e2': {'word': 'abciximab', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d618.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d618.s1'}	addition bleeding associated heparin vitamin K antagonists drugs alter platelet function aspirin dipyridamole abciximab may increase risk bleeding administered prior Retavase therapy
In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.	dipyridamole	Retavase	effect	{'e1': {'word': 'dipyridamole', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d618.s1.e3'}, 'e2': {'word': 'Retavase', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d618.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d618.s1'}	addition bleeding associated heparin vitamin K antagonists drugs alter platelet function aspirin dipyridamole abciximab may increase risk bleeding administered prior Retavase therapy
In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.	abciximab	Retavase	effect	{'e1': {'word': 'abciximab', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d618.s1.e4'}, 'e2': {'word': 'Retavase', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d618.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d618.s1'}	addition bleeding associated heparin vitamin K antagonists drugs alter platelet function aspirin dipyridamole abciximab may increase risk bleeding administered prior Retavase therapy
Dosages of concomitantly administered opioids should be reduced by approximately half, because levomepromazine amplifies the therapeutic actions and side-effects of opioids. 	opioids	levomepromazine	effect	{'e1': {'word': 'opioids', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d756.s0.e0'}, 'e2': {'word': 'levomepromazine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d756.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d756.s0'}	Dosages concomitantly administered opioids reduced approximately half levomepromazine amplifies therapeutic actions side effects opioids
Dosages of concomitantly administered opioids should be reduced by approximately half, because levomepromazine amplifies the therapeutic actions and side-effects of opioids. 	opioids	opioids	none	{'e1': {'word': 'opioids', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d756.s0.e0'}, 'e2': {'word': 'opioids', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d756.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d756.s0'}	Dosages concomitantly administered opioids reduced approximately half levomepromazine amplifies therapeutic actions side effects opioids
Dosages of concomitantly administered opioids should be reduced by approximately half, because levomepromazine amplifies the therapeutic actions and side-effects of opioids. 	levomepromazine	opioids	effect	{'e1': {'word': 'levomepromazine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d756.s0.e1'}, 'e2': {'word': 'opioids', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d756.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d756.s0'}	Dosages concomitantly administered opioids reduced approximately half levomepromazine amplifies therapeutic actions side effects opioids
Combination with tramadol (Ultram) is associated with increased risk of seizures. 	tramadol	Ultram	none	{'e1': {'word': 'tramadol', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d756.s1.e0'}, 'e2': {'word': 'Ultram', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d756.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d756.s1'}	Combination tramadol Ultram associated increased risk seizures
Additive sedative effects and confusional states may emerge if levomepromazine is given with benzodiazepines or barbiturates. 	levomepromazine	benzodiazepines	effect	{'e1': {'word': 'levomepromazine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d756.s2.e0'}, 'e2': {'word': 'benzodiazepines', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d756.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d756.s2'}	Additive sedative effects confusional states may emerge levomepromazine given benzodiazepines barbiturates
Additive sedative effects and confusional states may emerge if levomepromazine is given with benzodiazepines or barbiturates. 	levomepromazine	barbiturates	effect	{'e1': {'word': 'levomepromazine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d756.s2.e0'}, 'e2': {'word': 'barbiturates', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d756.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d756.s2'}	Additive sedative effects confusional states may emerge levomepromazine given benzodiazepines barbiturates
Additive sedative effects and confusional states may emerge if levomepromazine is given with benzodiazepines or barbiturates. 	benzodiazepines	barbiturates	none	{'e1': {'word': 'benzodiazepines', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d756.s2.e1'}, 'e2': {'word': 'barbiturates', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d756.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d756.s2'}	Additive sedative effects confusional states may emerge levomepromazine given benzodiazepines barbiturates
Exert particular caution in combining levomepromazine with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. 	levomepromazine	anticholinergic drugs	advise	{'e1': {'word': 'levomepromazine', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d756.s4.e0'}, 'e2': {'word': 'anticholinergic drugs', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d756.s4.e1'}, 'sentence_id': 'DDI-DrugBank.d756.s4'}	Exert particular caution combining levomepromazine anticholinergic drugs tricyclic antidepressants antiparkinsonian agents Particularly elderly may develop delirium high fever severe obstipation even ileus glaucoma
Exert particular caution in combining levomepromazine with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. 	levomepromazine	tricyclic antidepressants	advise	{'e1': {'word': 'levomepromazine', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d756.s4.e0'}, 'e2': {'word': 'tricyclic antidepressants', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d756.s4.e2'}, 'sentence_id': 'DDI-DrugBank.d756.s4'}	Exert particular caution combining levomepromazine anticholinergic drugs tricyclic antidepressants antiparkinsonian agents Particularly elderly may develop delirium high fever severe obstipation even ileus glaucoma
Exert particular caution in combining levomepromazine with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. 	levomepromazine	antiparkinsonian-agents	advise	{'e1': {'word': 'levomepromazine', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d756.s4.e0'}, 'e2': {'word': 'antiparkinsonian-agents', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d756.s4.e3'}, 'sentence_id': 'DDI-DrugBank.d756.s4'}	Exert particular caution combining levomepromazine anticholinergic drugs tricyclic antidepressants antiparkinsonian agents Particularly elderly may develop delirium high fever severe obstipation even ileus glaucoma
Exert particular caution in combining levomepromazine with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. 	anticholinergic drugs	tricyclic antidepressants	none	{'e1': {'word': 'anticholinergic drugs', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d756.s4.e1'}, 'e2': {'word': 'tricyclic antidepressants', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d756.s4.e2'}, 'sentence_id': 'DDI-DrugBank.d756.s4'}	Exert particular caution combining levomepromazine anticholinergic drugs tricyclic antidepressants antiparkinsonian agents Particularly elderly may develop delirium high fever severe obstipation even ileus glaucoma
Exert particular caution in combining levomepromazine with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. 	anticholinergic drugs	antiparkinsonian-agents	none	{'e1': {'word': 'anticholinergic drugs', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d756.s4.e1'}, 'e2': {'word': 'antiparkinsonian-agents', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d756.s4.e3'}, 'sentence_id': 'DDI-DrugBank.d756.s4'}	Exert particular caution combining levomepromazine anticholinergic drugs tricyclic antidepressants antiparkinsonian agents Particularly elderly may develop delirium high fever severe obstipation even ileus glaucoma
Exert particular caution in combining levomepromazine with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. 	tricyclic antidepressants	antiparkinsonian-agents	none	{'e1': {'word': 'tricyclic antidepressants', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d756.s4.e2'}, 'e2': {'word': 'antiparkinsonian-agents', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d756.s4.e3'}, 'sentence_id': 'DDI-DrugBank.d756.s4'}	Exert particular caution combining levomepromazine anticholinergic drugs tricyclic antidepressants antiparkinsonian agents Particularly elderly may develop delirium high fever severe obstipation even ileus glaucoma
Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine. 	Caffeine	ephedrine	none	{'e1': {'word': 'Caffeine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d756.s7.e0'}, 'e2': {'word': 'ephedrine', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d756.s7.e1'}, 'sentence_id': 'DDI-DrugBank.d756.s7'}	Caffeine stimulantes ephedrine amphetamine type may counteract specific actions levomepromazine
Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine. 	Caffeine	amphetamine	none	{'e1': {'word': 'Caffeine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d756.s7.e0'}, 'e2': {'word': 'amphetamine', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d756.s7.e2'}, 'sentence_id': 'DDI-DrugBank.d756.s7'}	Caffeine stimulantes ephedrine amphetamine type may counteract specific actions levomepromazine
Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine. 	Caffeine	levomepromazine	effect	{'e1': {'word': 'Caffeine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d756.s7.e0'}, 'e2': {'word': 'levomepromazine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d756.s7.e3'}, 'sentence_id': 'DDI-DrugBank.d756.s7'}	Caffeine stimulantes ephedrine amphetamine type may counteract specific actions levomepromazine
Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine. 	ephedrine	amphetamine	none	{'e1': {'word': 'ephedrine', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d756.s7.e1'}, 'e2': {'word': 'amphetamine', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d756.s7.e2'}, 'sentence_id': 'DDI-DrugBank.d756.s7'}	Caffeine stimulantes ephedrine amphetamine type may counteract specific actions levomepromazine
Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine. 	ephedrine	levomepromazine	effect	{'e1': {'word': 'ephedrine', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d756.s7.e1'}, 'e2': {'word': 'levomepromazine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d756.s7.e3'}, 'sentence_id': 'DDI-DrugBank.d756.s7'}	Caffeine stimulantes ephedrine amphetamine type may counteract specific actions levomepromazine
Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine. 	amphetamine	levomepromazine	effect	{'e1': {'word': 'amphetamine', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d756.s7.e2'}, 'e2': {'word': 'levomepromazine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d756.s7.e3'}, 'sentence_id': 'DDI-DrugBank.d756.s7'}	Caffeine stimulantes ephedrine amphetamine type may counteract specific actions levomepromazine
Limited evidence suggests that ascorbic acid may influence the intensity and duration of action of bishydroxycoumarin.	ascorbic acid	bishydroxycoumarin	mechanism	{'e1': {'word': 'ascorbic acid', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d759.s0.e0'}, 'e2': {'word': 'bishydroxycoumarin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d759.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d759.s0'}	Limited evidence suggests ascorbic acid may influence intensity duration action bishydroxycoumarin
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	anticholinergic drugs	amantadine	effect	{'e1': {'word': 'anticholinergic drugs', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d585.s0.e0'}, 'e2': {'word': 'amantadine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d585.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	anticholinergic drugs	antiarrhythmic agents of class I	effect	{'e1': {'word': 'anticholinergic drugs', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d585.s0.e0'}, 'e2': {'word': 'antiarrhythmic agents of class I', 'word_index': [(11, 13)], 'id': 'DDI-DrugBank.d585.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	anticholinergic drugs	quinidine	effect	{'e1': {'word': 'anticholinergic drugs', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d585.s0.e0'}, 'e2': {'word': 'quinidine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d585.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	anticholinergic drugs	antihistamines	effect	{'e1': {'word': 'anticholinergic drugs', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d585.s0.e0'}, 'e2': {'word': 'antihistamines', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d585.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	anticholinergic drugs	antipsychotic agents	effect	{'e1': {'word': 'anticholinergic drugs', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d585.s0.e0'}, 'e2': {'word': 'antipsychotic agents', 'word_index': [(17, 18)], 'id': 'DDI-DrugBank.d585.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	anticholinergic drugs	phenothiazines	effect	{'e1': {'word': 'anticholinergic drugs', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d585.s0.e0'}, 'e2': {'word': 'phenothiazines', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d585.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	anticholinergic drugs	benzodiazepines	effect	{'e1': {'word': 'anticholinergic drugs', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d585.s0.e0'}, 'e2': {'word': 'benzodiazepines', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d585.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	anticholinergic drugs	MAO inhibitors	effect	{'e1': {'word': 'anticholinergic drugs', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d585.s0.e0'}, 'e2': {'word': 'MAO inhibitors', 'word_index': [(22, 23)], 'id': 'DDI-DrugBank.d585.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	anticholinergic drugs	narcotic analgesics	effect	{'e1': {'word': 'anticholinergic drugs', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d585.s0.e0'}, 'e2': {'word': 'narcotic analgesics', 'word_index': [(24, 25)], 'id': 'DDI-DrugBank.d585.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	anticholinergic drugs	meperidine	effect	{'e1': {'word': 'anticholinergic drugs', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d585.s0.e0'}, 'e2': {'word': 'meperidine', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d585.s0.e10'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	anticholinergic drugs	nitrates	effect	{'e1': {'word': 'anticholinergic drugs', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d585.s0.e0'}, 'e2': {'word': 'nitrates', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d585.s0.e11'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	anticholinergic drugs	nitrites	effect	{'e1': {'word': 'anticholinergic drugs', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d585.s0.e0'}, 'e2': {'word': 'nitrites', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d585.s0.e12'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	anticholinergic drugs	sympathomimetic agents	effect	{'e1': {'word': 'anticholinergic drugs', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d585.s0.e0'}, 'e2': {'word': 'sympathomimetic agents', 'word_index': [(30, 31)], 'id': 'DDI-DrugBank.d585.s0.e13'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	anticholinergic drugs	tricyclic antidepressants	effect	{'e1': {'word': 'anticholinergic drugs', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d585.s0.e0'}, 'e2': {'word': 'tricyclic antidepressants', 'word_index': [(32, 33)], 'id': 'DDI-DrugBank.d585.s0.e14'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	amantadine	antiarrhythmic agents of class I	none	{'e1': {'word': 'amantadine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d585.s0.e1'}, 'e2': {'word': 'antiarrhythmic agents of class I', 'word_index': [(11, 13)], 'id': 'DDI-DrugBank.d585.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	amantadine	quinidine	none	{'e1': {'word': 'amantadine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d585.s0.e1'}, 'e2': {'word': 'quinidine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d585.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	amantadine	antihistamines	none	{'e1': {'word': 'amantadine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d585.s0.e1'}, 'e2': {'word': 'antihistamines', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d585.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	amantadine	antipsychotic agents	none	{'e1': {'word': 'amantadine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d585.s0.e1'}, 'e2': {'word': 'antipsychotic agents', 'word_index': [(17, 18)], 'id': 'DDI-DrugBank.d585.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	amantadine	phenothiazines	none	{'e1': {'word': 'amantadine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d585.s0.e1'}, 'e2': {'word': 'phenothiazines', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d585.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	amantadine	benzodiazepines	none	{'e1': {'word': 'amantadine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d585.s0.e1'}, 'e2': {'word': 'benzodiazepines', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d585.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	amantadine	MAO inhibitors	none	{'e1': {'word': 'amantadine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d585.s0.e1'}, 'e2': {'word': 'MAO inhibitors', 'word_index': [(22, 23)], 'id': 'DDI-DrugBank.d585.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	amantadine	narcotic analgesics	none	{'e1': {'word': 'amantadine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d585.s0.e1'}, 'e2': {'word': 'narcotic analgesics', 'word_index': [(24, 25)], 'id': 'DDI-DrugBank.d585.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	amantadine	meperidine	none	{'e1': {'word': 'amantadine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d585.s0.e1'}, 'e2': {'word': 'meperidine', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d585.s0.e10'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	amantadine	nitrates	none	{'e1': {'word': 'amantadine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d585.s0.e1'}, 'e2': {'word': 'nitrates', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d585.s0.e11'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	amantadine	nitrites	none	{'e1': {'word': 'amantadine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d585.s0.e1'}, 'e2': {'word': 'nitrites', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d585.s0.e12'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	amantadine	sympathomimetic agents	none	{'e1': {'word': 'amantadine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d585.s0.e1'}, 'e2': {'word': 'sympathomimetic agents', 'word_index': [(30, 31)], 'id': 'DDI-DrugBank.d585.s0.e13'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	amantadine	tricyclic antidepressants	none	{'e1': {'word': 'amantadine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d585.s0.e1'}, 'e2': {'word': 'tricyclic antidepressants', 'word_index': [(32, 33)], 'id': 'DDI-DrugBank.d585.s0.e14'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	antiarrhythmic agents of class I	quinidine	none	{'e1': {'word': 'antiarrhythmic agents of class I', 'word_index': [(11, 13)], 'id': 'DDI-DrugBank.d585.s0.e2'}, 'e2': {'word': 'quinidine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d585.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	antiarrhythmic agents of class I	antihistamines	none	{'e1': {'word': 'antiarrhythmic agents of class I', 'word_index': [(11, 13)], 'id': 'DDI-DrugBank.d585.s0.e2'}, 'e2': {'word': 'antihistamines', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d585.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	antiarrhythmic agents of class I	antipsychotic agents	none	{'e1': {'word': 'antiarrhythmic agents of class I', 'word_index': [(11, 13)], 'id': 'DDI-DrugBank.d585.s0.e2'}, 'e2': {'word': 'antipsychotic agents', 'word_index': [(17, 18)], 'id': 'DDI-DrugBank.d585.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	antiarrhythmic agents of class I	phenothiazines	none	{'e1': {'word': 'antiarrhythmic agents of class I', 'word_index': [(11, 13)], 'id': 'DDI-DrugBank.d585.s0.e2'}, 'e2': {'word': 'phenothiazines', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d585.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	antiarrhythmic agents of class I	benzodiazepines	none	{'e1': {'word': 'antiarrhythmic agents of class I', 'word_index': [(11, 13)], 'id': 'DDI-DrugBank.d585.s0.e2'}, 'e2': {'word': 'benzodiazepines', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d585.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	antiarrhythmic agents of class I	MAO inhibitors	none	{'e1': {'word': 'antiarrhythmic agents of class I', 'word_index': [(11, 13)], 'id': 'DDI-DrugBank.d585.s0.e2'}, 'e2': {'word': 'MAO inhibitors', 'word_index': [(22, 23)], 'id': 'DDI-DrugBank.d585.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	antiarrhythmic agents of class I	narcotic analgesics	none	{'e1': {'word': 'antiarrhythmic agents of class I', 'word_index': [(11, 13)], 'id': 'DDI-DrugBank.d585.s0.e2'}, 'e2': {'word': 'narcotic analgesics', 'word_index': [(24, 25)], 'id': 'DDI-DrugBank.d585.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	antiarrhythmic agents of class I	meperidine	none	{'e1': {'word': 'antiarrhythmic agents of class I', 'word_index': [(11, 13)], 'id': 'DDI-DrugBank.d585.s0.e2'}, 'e2': {'word': 'meperidine', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d585.s0.e10'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	antiarrhythmic agents of class I	nitrates	none	{'e1': {'word': 'antiarrhythmic agents of class I', 'word_index': [(11, 13)], 'id': 'DDI-DrugBank.d585.s0.e2'}, 'e2': {'word': 'nitrates', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d585.s0.e11'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	antiarrhythmic agents of class I	nitrites	none	{'e1': {'word': 'antiarrhythmic agents of class I', 'word_index': [(11, 13)], 'id': 'DDI-DrugBank.d585.s0.e2'}, 'e2': {'word': 'nitrites', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d585.s0.e12'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	antiarrhythmic agents of class I	sympathomimetic agents	none	{'e1': {'word': 'antiarrhythmic agents of class I', 'word_index': [(11, 13)], 'id': 'DDI-DrugBank.d585.s0.e2'}, 'e2': {'word': 'sympathomimetic agents', 'word_index': [(30, 31)], 'id': 'DDI-DrugBank.d585.s0.e13'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	antiarrhythmic agents of class I	tricyclic antidepressants	none	{'e1': {'word': 'antiarrhythmic agents of class I', 'word_index': [(11, 13)], 'id': 'DDI-DrugBank.d585.s0.e2'}, 'e2': {'word': 'tricyclic antidepressants', 'word_index': [(32, 33)], 'id': 'DDI-DrugBank.d585.s0.e14'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	quinidine	antihistamines	none	{'e1': {'word': 'quinidine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d585.s0.e3'}, 'e2': {'word': 'antihistamines', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d585.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	quinidine	antipsychotic agents	none	{'e1': {'word': 'quinidine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d585.s0.e3'}, 'e2': {'word': 'antipsychotic agents', 'word_index': [(17, 18)], 'id': 'DDI-DrugBank.d585.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	quinidine	phenothiazines	none	{'e1': {'word': 'quinidine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d585.s0.e3'}, 'e2': {'word': 'phenothiazines', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d585.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	quinidine	benzodiazepines	none	{'e1': {'word': 'quinidine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d585.s0.e3'}, 'e2': {'word': 'benzodiazepines', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d585.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	quinidine	MAO inhibitors	none	{'e1': {'word': 'quinidine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d585.s0.e3'}, 'e2': {'word': 'MAO inhibitors', 'word_index': [(22, 23)], 'id': 'DDI-DrugBank.d585.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	quinidine	narcotic analgesics	none	{'e1': {'word': 'quinidine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d585.s0.e3'}, 'e2': {'word': 'narcotic analgesics', 'word_index': [(24, 25)], 'id': 'DDI-DrugBank.d585.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	quinidine	meperidine	none	{'e1': {'word': 'quinidine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d585.s0.e3'}, 'e2': {'word': 'meperidine', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d585.s0.e10'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	quinidine	nitrates	none	{'e1': {'word': 'quinidine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d585.s0.e3'}, 'e2': {'word': 'nitrates', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d585.s0.e11'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	quinidine	nitrites	none	{'e1': {'word': 'quinidine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d585.s0.e3'}, 'e2': {'word': 'nitrites', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d585.s0.e12'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	quinidine	sympathomimetic agents	none	{'e1': {'word': 'quinidine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d585.s0.e3'}, 'e2': {'word': 'sympathomimetic agents', 'word_index': [(30, 31)], 'id': 'DDI-DrugBank.d585.s0.e13'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	quinidine	tricyclic antidepressants	none	{'e1': {'word': 'quinidine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d585.s0.e3'}, 'e2': {'word': 'tricyclic antidepressants', 'word_index': [(32, 33)], 'id': 'DDI-DrugBank.d585.s0.e14'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	antihistamines	antipsychotic agents	none	{'e1': {'word': 'antihistamines', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d585.s0.e4'}, 'e2': {'word': 'antipsychotic agents', 'word_index': [(17, 18)], 'id': 'DDI-DrugBank.d585.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	antihistamines	phenothiazines	none	{'e1': {'word': 'antihistamines', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d585.s0.e4'}, 'e2': {'word': 'phenothiazines', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d585.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	antihistamines	benzodiazepines	none	{'e1': {'word': 'antihistamines', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d585.s0.e4'}, 'e2': {'word': 'benzodiazepines', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d585.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	antihistamines	MAO inhibitors	none	{'e1': {'word': 'antihistamines', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d585.s0.e4'}, 'e2': {'word': 'MAO inhibitors', 'word_index': [(22, 23)], 'id': 'DDI-DrugBank.d585.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	antihistamines	narcotic analgesics	none	{'e1': {'word': 'antihistamines', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d585.s0.e4'}, 'e2': {'word': 'narcotic analgesics', 'word_index': [(24, 25)], 'id': 'DDI-DrugBank.d585.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	antihistamines	meperidine	none	{'e1': {'word': 'antihistamines', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d585.s0.e4'}, 'e2': {'word': 'meperidine', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d585.s0.e10'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	antihistamines	nitrates	none	{'e1': {'word': 'antihistamines', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d585.s0.e4'}, 'e2': {'word': 'nitrates', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d585.s0.e11'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	antihistamines	nitrites	none	{'e1': {'word': 'antihistamines', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d585.s0.e4'}, 'e2': {'word': 'nitrites', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d585.s0.e12'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	antihistamines	sympathomimetic agents	none	{'e1': {'word': 'antihistamines', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d585.s0.e4'}, 'e2': {'word': 'sympathomimetic agents', 'word_index': [(30, 31)], 'id': 'DDI-DrugBank.d585.s0.e13'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	antihistamines	tricyclic antidepressants	none	{'e1': {'word': 'antihistamines', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d585.s0.e4'}, 'e2': {'word': 'tricyclic antidepressants', 'word_index': [(32, 33)], 'id': 'DDI-DrugBank.d585.s0.e14'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	antipsychotic agents	phenothiazines	none	{'e1': {'word': 'antipsychotic agents', 'word_index': [(17, 18)], 'id': 'DDI-DrugBank.d585.s0.e5'}, 'e2': {'word': 'phenothiazines', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d585.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	antipsychotic agents	benzodiazepines	none	{'e1': {'word': 'antipsychotic agents', 'word_index': [(17, 18)], 'id': 'DDI-DrugBank.d585.s0.e5'}, 'e2': {'word': 'benzodiazepines', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d585.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	antipsychotic agents	MAO inhibitors	none	{'e1': {'word': 'antipsychotic agents', 'word_index': [(17, 18)], 'id': 'DDI-DrugBank.d585.s0.e5'}, 'e2': {'word': 'MAO inhibitors', 'word_index': [(22, 23)], 'id': 'DDI-DrugBank.d585.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	antipsychotic agents	narcotic analgesics	none	{'e1': {'word': 'antipsychotic agents', 'word_index': [(17, 18)], 'id': 'DDI-DrugBank.d585.s0.e5'}, 'e2': {'word': 'narcotic analgesics', 'word_index': [(24, 25)], 'id': 'DDI-DrugBank.d585.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	antipsychotic agents	meperidine	none	{'e1': {'word': 'antipsychotic agents', 'word_index': [(17, 18)], 'id': 'DDI-DrugBank.d585.s0.e5'}, 'e2': {'word': 'meperidine', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d585.s0.e10'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	antipsychotic agents	nitrates	none	{'e1': {'word': 'antipsychotic agents', 'word_index': [(17, 18)], 'id': 'DDI-DrugBank.d585.s0.e5'}, 'e2': {'word': 'nitrates', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d585.s0.e11'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	antipsychotic agents	nitrites	none	{'e1': {'word': 'antipsychotic agents', 'word_index': [(17, 18)], 'id': 'DDI-DrugBank.d585.s0.e5'}, 'e2': {'word': 'nitrites', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d585.s0.e12'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	antipsychotic agents	sympathomimetic agents	none	{'e1': {'word': 'antipsychotic agents', 'word_index': [(17, 18)], 'id': 'DDI-DrugBank.d585.s0.e5'}, 'e2': {'word': 'sympathomimetic agents', 'word_index': [(30, 31)], 'id': 'DDI-DrugBank.d585.s0.e13'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	antipsychotic agents	tricyclic antidepressants	none	{'e1': {'word': 'antipsychotic agents', 'word_index': [(17, 18)], 'id': 'DDI-DrugBank.d585.s0.e5'}, 'e2': {'word': 'tricyclic antidepressants', 'word_index': [(32, 33)], 'id': 'DDI-DrugBank.d585.s0.e14'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	phenothiazines	benzodiazepines	none	{'e1': {'word': 'phenothiazines', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d585.s0.e6'}, 'e2': {'word': 'benzodiazepines', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d585.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	phenothiazines	MAO inhibitors	none	{'e1': {'word': 'phenothiazines', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d585.s0.e6'}, 'e2': {'word': 'MAO inhibitors', 'word_index': [(22, 23)], 'id': 'DDI-DrugBank.d585.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	phenothiazines	narcotic analgesics	none	{'e1': {'word': 'phenothiazines', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d585.s0.e6'}, 'e2': {'word': 'narcotic analgesics', 'word_index': [(24, 25)], 'id': 'DDI-DrugBank.d585.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	phenothiazines	meperidine	none	{'e1': {'word': 'phenothiazines', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d585.s0.e6'}, 'e2': {'word': 'meperidine', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d585.s0.e10'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	phenothiazines	nitrates	none	{'e1': {'word': 'phenothiazines', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d585.s0.e6'}, 'e2': {'word': 'nitrates', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d585.s0.e11'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	phenothiazines	nitrites	none	{'e1': {'word': 'phenothiazines', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d585.s0.e6'}, 'e2': {'word': 'nitrites', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d585.s0.e12'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	phenothiazines	sympathomimetic agents	none	{'e1': {'word': 'phenothiazines', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d585.s0.e6'}, 'e2': {'word': 'sympathomimetic agents', 'word_index': [(30, 31)], 'id': 'DDI-DrugBank.d585.s0.e13'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	phenothiazines	tricyclic antidepressants	none	{'e1': {'word': 'phenothiazines', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d585.s0.e6'}, 'e2': {'word': 'tricyclic antidepressants', 'word_index': [(32, 33)], 'id': 'DDI-DrugBank.d585.s0.e14'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	benzodiazepines	MAO inhibitors	none	{'e1': {'word': 'benzodiazepines', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d585.s0.e7'}, 'e2': {'word': 'MAO inhibitors', 'word_index': [(22, 23)], 'id': 'DDI-DrugBank.d585.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	benzodiazepines	narcotic analgesics	none	{'e1': {'word': 'benzodiazepines', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d585.s0.e7'}, 'e2': {'word': 'narcotic analgesics', 'word_index': [(24, 25)], 'id': 'DDI-DrugBank.d585.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	benzodiazepines	meperidine	none	{'e1': {'word': 'benzodiazepines', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d585.s0.e7'}, 'e2': {'word': 'meperidine', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d585.s0.e10'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	benzodiazepines	nitrates	none	{'e1': {'word': 'benzodiazepines', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d585.s0.e7'}, 'e2': {'word': 'nitrates', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d585.s0.e11'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	benzodiazepines	nitrites	none	{'e1': {'word': 'benzodiazepines', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d585.s0.e7'}, 'e2': {'word': 'nitrites', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d585.s0.e12'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	benzodiazepines	sympathomimetic agents	none	{'e1': {'word': 'benzodiazepines', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d585.s0.e7'}, 'e2': {'word': 'sympathomimetic agents', 'word_index': [(30, 31)], 'id': 'DDI-DrugBank.d585.s0.e13'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	benzodiazepines	tricyclic antidepressants	none	{'e1': {'word': 'benzodiazepines', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d585.s0.e7'}, 'e2': {'word': 'tricyclic antidepressants', 'word_index': [(32, 33)], 'id': 'DDI-DrugBank.d585.s0.e14'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	MAO inhibitors	narcotic analgesics	none	{'e1': {'word': 'MAO inhibitors', 'word_index': [(22, 23)], 'id': 'DDI-DrugBank.d585.s0.e8'}, 'e2': {'word': 'narcotic analgesics', 'word_index': [(24, 25)], 'id': 'DDI-DrugBank.d585.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	MAO inhibitors	meperidine	none	{'e1': {'word': 'MAO inhibitors', 'word_index': [(22, 23)], 'id': 'DDI-DrugBank.d585.s0.e8'}, 'e2': {'word': 'meperidine', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d585.s0.e10'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	MAO inhibitors	nitrates	none	{'e1': {'word': 'MAO inhibitors', 'word_index': [(22, 23)], 'id': 'DDI-DrugBank.d585.s0.e8'}, 'e2': {'word': 'nitrates', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d585.s0.e11'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	MAO inhibitors	nitrites	none	{'e1': {'word': 'MAO inhibitors', 'word_index': [(22, 23)], 'id': 'DDI-DrugBank.d585.s0.e8'}, 'e2': {'word': 'nitrites', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d585.s0.e12'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	MAO inhibitors	sympathomimetic agents	none	{'e1': {'word': 'MAO inhibitors', 'word_index': [(22, 23)], 'id': 'DDI-DrugBank.d585.s0.e8'}, 'e2': {'word': 'sympathomimetic agents', 'word_index': [(30, 31)], 'id': 'DDI-DrugBank.d585.s0.e13'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	MAO inhibitors	tricyclic antidepressants	none	{'e1': {'word': 'MAO inhibitors', 'word_index': [(22, 23)], 'id': 'DDI-DrugBank.d585.s0.e8'}, 'e2': {'word': 'tricyclic antidepressants', 'word_index': [(32, 33)], 'id': 'DDI-DrugBank.d585.s0.e14'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	narcotic analgesics	meperidine	none	{'e1': {'word': 'narcotic analgesics', 'word_index': [(24, 25)], 'id': 'DDI-DrugBank.d585.s0.e9'}, 'e2': {'word': 'meperidine', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d585.s0.e10'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	narcotic analgesics	nitrates	none	{'e1': {'word': 'narcotic analgesics', 'word_index': [(24, 25)], 'id': 'DDI-DrugBank.d585.s0.e9'}, 'e2': {'word': 'nitrates', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d585.s0.e11'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	narcotic analgesics	nitrites	none	{'e1': {'word': 'narcotic analgesics', 'word_index': [(24, 25)], 'id': 'DDI-DrugBank.d585.s0.e9'}, 'e2': {'word': 'nitrites', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d585.s0.e12'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	narcotic analgesics	sympathomimetic agents	none	{'e1': {'word': 'narcotic analgesics', 'word_index': [(24, 25)], 'id': 'DDI-DrugBank.d585.s0.e9'}, 'e2': {'word': 'sympathomimetic agents', 'word_index': [(30, 31)], 'id': 'DDI-DrugBank.d585.s0.e13'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	narcotic analgesics	tricyclic antidepressants	none	{'e1': {'word': 'narcotic analgesics', 'word_index': [(24, 25)], 'id': 'DDI-DrugBank.d585.s0.e9'}, 'e2': {'word': 'tricyclic antidepressants', 'word_index': [(32, 33)], 'id': 'DDI-DrugBank.d585.s0.e14'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	meperidine	nitrates	none	{'e1': {'word': 'meperidine', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d585.s0.e10'}, 'e2': {'word': 'nitrates', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d585.s0.e11'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	meperidine	nitrites	none	{'e1': {'word': 'meperidine', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d585.s0.e10'}, 'e2': {'word': 'nitrites', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d585.s0.e12'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	meperidine	sympathomimetic agents	none	{'e1': {'word': 'meperidine', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d585.s0.e10'}, 'e2': {'word': 'sympathomimetic agents', 'word_index': [(30, 31)], 'id': 'DDI-DrugBank.d585.s0.e13'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	meperidine	tricyclic antidepressants	none	{'e1': {'word': 'meperidine', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d585.s0.e10'}, 'e2': {'word': 'tricyclic antidepressants', 'word_index': [(32, 33)], 'id': 'DDI-DrugBank.d585.s0.e14'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	nitrates	nitrites	none	{'e1': {'word': 'nitrates', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d585.s0.e11'}, 'e2': {'word': 'nitrites', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d585.s0.e12'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	nitrates	sympathomimetic agents	none	{'e1': {'word': 'nitrates', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d585.s0.e11'}, 'e2': {'word': 'sympathomimetic agents', 'word_index': [(30, 31)], 'id': 'DDI-DrugBank.d585.s0.e13'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	nitrates	tricyclic antidepressants	none	{'e1': {'word': 'nitrates', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d585.s0.e11'}, 'e2': {'word': 'tricyclic antidepressants', 'word_index': [(32, 33)], 'id': 'DDI-DrugBank.d585.s0.e14'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	nitrites	sympathomimetic agents	none	{'e1': {'word': 'nitrites', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d585.s0.e12'}, 'e2': {'word': 'sympathomimetic agents', 'word_index': [(30, 31)], 'id': 'DDI-DrugBank.d585.s0.e13'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	nitrites	tricyclic antidepressants	none	{'e1': {'word': 'nitrites', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d585.s0.e12'}, 'e2': {'word': 'tricyclic antidepressants', 'word_index': [(32, 33)], 'id': 'DDI-DrugBank.d585.s0.e14'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. 	sympathomimetic agents	tricyclic antidepressants	none	{'e1': {'word': 'sympathomimetic agents', 'word_index': [(30, 31)], 'id': 'DDI-DrugBank.d585.s0.e13'}, 'e2': {'word': 'tricyclic antidepressants', 'word_index': [(32, 33)], 'id': 'DDI-DrugBank.d585.s0.e14'}, 'sentence_id': 'DDI-DrugBank.d585.s0'}	following agents may increase certain actions side effects anticholinergic drugs amantadine antiarrhythmic agents class e.g. quinidine antihistamines antipsychotic agents e.g. phenothiazines benzodiazepines MAO inhibitors narcotic analgesics e.g. meperidine nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity
Anticholinergics antagonize the effects of antiglaucoma agents. 	Anticholinergics	antiglaucoma agents	effect	{'e1': {'word': 'Anticholinergics', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d585.s1.e0'}, 'e2': {'word': 'antiglaucoma agents', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d585.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d585.s1'}	Anticholinergics antagonize effects antiglaucoma agents
Anticholinergic drugs in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as corticosteroids. 	Anticholinergic drugs	corticosteroids	effect	{'e1': {'word': 'Anticholinergic drugs', 'word_index': [(0, 1)], 'id': 'DDI-DrugBank.d585.s2.e0'}, 'e2': {'word': 'corticosteroids', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d585.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d585.s2'}	Anticholinergic drugs presence increased intraocular pressure may hazardous taken concurrently agents corticosteroids
Anticholinergic agents may affect gastrointestinal absorption of various drugs, such as slowly dissolving dosage forms of digoxin; 	Anticholinergic agents	digoxin	mechanism	{'e1': {'word': 'Anticholinergic agents', 'word_index': [(0, 1)], 'id': 'DDI-DrugBank.d585.s3.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d585.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d585.s3'}	Anticholinergic agents may affect gastrointestinal absorption various drugs slowly dissolving dosage forms digoxin
Anticholinergic drugs may antagonize the effects of drugs that alter gastrointestinal motility, such as metoclopramide. 	Anticholinergic drugs	metoclopramide	effect	{'e1': {'word': 'Anticholinergic drugs', 'word_index': [(0, 1)], 'id': 'DDI-DrugBank.d585.s5.e0'}, 'e2': {'word': 'metoclopramide', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d585.s5.e1'}, 'sentence_id': 'DDI-DrugBank.d585.s5'}	Anticholinergic drugs may antagonize effects drugs alter gastrointestinal motility metoclopramide
Because antacids may interfere with the absorption of anticholinergic agents, simultaneous use of these drugs should be avoided. 	antacids	anticholinergic agents	mechanism	{'e1': {'word': 'antacids', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d585.s6.e0'}, 'e2': {'word': 'anticholinergic agents', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d585.s6.e1'}, 'sentence_id': 'DDI-DrugBank.d585.s6'}	antacids may interfere absorption anticholinergic agents simultaneous use drugs avoided
Mequitazine can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and alcohol.	Mequitazine	CNS depressant	int	{'e1': {'word': 'Mequitazine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d699.s0.e0'}, 'e2': {'word': 'CNS depressant', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d699.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d699.s0'}	Mequitazine interact CNS depressant antichlolinergic TCA MAOIs alcohol
Mequitazine can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and alcohol.	Mequitazine	antichlolinergic	int	{'e1': {'word': 'Mequitazine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d699.s0.e0'}, 'e2': {'word': 'antichlolinergic', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d699.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d699.s0'}	Mequitazine interact CNS depressant antichlolinergic TCA MAOIs alcohol
Mequitazine can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and alcohol.	Mequitazine	TCA	int	{'e1': {'word': 'Mequitazine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d699.s0.e0'}, 'e2': {'word': 'TCA', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d699.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d699.s0'}	Mequitazine interact CNS depressant antichlolinergic TCA MAOIs alcohol
Mequitazine can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and alcohol.	Mequitazine	MAOIs	int	{'e1': {'word': 'Mequitazine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d699.s0.e0'}, 'e2': {'word': 'MAOIs', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d699.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d699.s0'}	Mequitazine interact CNS depressant antichlolinergic TCA MAOIs alcohol
Mequitazine can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and alcohol.	Mequitazine	alcohol	int	{'e1': {'word': 'Mequitazine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d699.s0.e0'}, 'e2': {'word': 'alcohol', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d699.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d699.s0'}	Mequitazine interact CNS depressant antichlolinergic TCA MAOIs alcohol
Mequitazine can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and alcohol.	CNS depressant	antichlolinergic	none	{'e1': {'word': 'CNS depressant', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d699.s0.e1'}, 'e2': {'word': 'antichlolinergic', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d699.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d699.s0'}	Mequitazine interact CNS depressant antichlolinergic TCA MAOIs alcohol
Mequitazine can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and alcohol.	CNS depressant	TCA	none	{'e1': {'word': 'CNS depressant', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d699.s0.e1'}, 'e2': {'word': 'TCA', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d699.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d699.s0'}	Mequitazine interact CNS depressant antichlolinergic TCA MAOIs alcohol
Mequitazine can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and alcohol.	CNS depressant	MAOIs	none	{'e1': {'word': 'CNS depressant', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d699.s0.e1'}, 'e2': {'word': 'MAOIs', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d699.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d699.s0'}	Mequitazine interact CNS depressant antichlolinergic TCA MAOIs alcohol
Mequitazine can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and alcohol.	CNS depressant	alcohol	none	{'e1': {'word': 'CNS depressant', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d699.s0.e1'}, 'e2': {'word': 'alcohol', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d699.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d699.s0'}	Mequitazine interact CNS depressant antichlolinergic TCA MAOIs alcohol
Mequitazine can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and alcohol.	antichlolinergic	TCA	none	{'e1': {'word': 'antichlolinergic', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d699.s0.e2'}, 'e2': {'word': 'TCA', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d699.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d699.s0'}	Mequitazine interact CNS depressant antichlolinergic TCA MAOIs alcohol
Mequitazine can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and alcohol.	antichlolinergic	MAOIs	none	{'e1': {'word': 'antichlolinergic', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d699.s0.e2'}, 'e2': {'word': 'MAOIs', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d699.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d699.s0'}	Mequitazine interact CNS depressant antichlolinergic TCA MAOIs alcohol
Mequitazine can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and alcohol.	antichlolinergic	alcohol	none	{'e1': {'word': 'antichlolinergic', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d699.s0.e2'}, 'e2': {'word': 'alcohol', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d699.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d699.s0'}	Mequitazine interact CNS depressant antichlolinergic TCA MAOIs alcohol
Mequitazine can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and alcohol.	TCA	MAOIs	none	{'e1': {'word': 'TCA', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d699.s0.e3'}, 'e2': {'word': 'MAOIs', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d699.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d699.s0'}	Mequitazine interact CNS depressant antichlolinergic TCA MAOIs alcohol
Mequitazine can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and alcohol.	TCA	alcohol	none	{'e1': {'word': 'TCA', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d699.s0.e3'}, 'e2': {'word': 'alcohol', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d699.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d699.s0'}	Mequitazine interact CNS depressant antichlolinergic TCA MAOIs alcohol
Mequitazine can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and alcohol.	MAOIs	alcohol	none	{'e1': {'word': 'MAOIs', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d699.s0.e4'}, 'e2': {'word': 'alcohol', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d699.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d699.s0'}	Mequitazine interact CNS depressant antichlolinergic TCA MAOIs alcohol
Trilostane may interact with aminoglutethimide or mitotane (causing too great a decrease in adrenal function).	Trilostane	aminoglutethimide	int	{'e1': {'word': 'Trilostane', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d774.s0.e0'}, 'e2': {'word': 'aminoglutethimide', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d774.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d774.s0'}	Trilostane may interact aminoglutethimide mitotane causing great decrease adrenal function
Trilostane may interact with aminoglutethimide or mitotane (causing too great a decrease in adrenal function).	Trilostane	mitotane	int	{'e1': {'word': 'Trilostane', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d774.s0.e0'}, 'e2': {'word': 'mitotane', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d774.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d774.s0'}	Trilostane may interact aminoglutethimide mitotane causing great decrease adrenal function
Trilostane may interact with aminoglutethimide or mitotane (causing too great a decrease in adrenal function).	aminoglutethimide	mitotane	none	{'e1': {'word': 'aminoglutethimide', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d774.s0.e1'}, 'e2': {'word': 'mitotane', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d774.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d774.s0'}	Trilostane may interact aminoglutethimide mitotane causing great decrease adrenal function
Reduced absorption of folic acid and digoxin have been reported when those agents were administered concomitantly with sulfasalazine. 	folic acid	digoxin	none	{'e1': {'word': 'folic acid', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d693.s0.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d693.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d693.s0'}	Reduced absorption folic acid digoxin reported agents administered concomitantly sulfasalazine
Reduced absorption of folic acid and digoxin have been reported when those agents were administered concomitantly with sulfasalazine. 	folic acid	sulfasalazine	mechanism	{'e1': {'word': 'folic acid', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d693.s0.e0'}, 'e2': {'word': 'sulfasalazine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d693.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d693.s0'}	Reduced absorption folic acid digoxin reported agents administered concomitantly sulfasalazine
Reduced absorption of folic acid and digoxin have been reported when those agents were administered concomitantly with sulfasalazine. 	digoxin	sulfasalazine	mechanism	{'e1': {'word': 'digoxin', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d693.s0.e1'}, 'e2': {'word': 'sulfasalazine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d693.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d693.s0'}	Reduced absorption folic acid digoxin reported agents administered concomitantly sulfasalazine
When daily doses of sulfasalazine 2 g and weekly doses of methotrexate 7.5 mg were coadministered to 15 rheumatoid arthritis patients in a drug-drug interaction study, the pharmacokinetic disposition of the drugs was not altered. 	sulfasalazine	methotrexate	none	{'e1': {'word': 'sulfasalazine', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d693.s1.e0'}, 'e2': {'word': 'methotrexate', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d693.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d693.s1'}	daily doses sulfasalazine NUMBER g weekly doses methotrexate NUMBER mg coadministered NUMBER rheumatoid arthritis patients drug drug interaction study pharmacokinetic disposition drugs altered
Daily doses of sulfasalazine 2 g (maximum 3 g) and weekly doses of methotrexate 7.5 mg (maximum 15 mg) were administered alone or in combination to 310 rheumatoid arthritis patients in two controlled 52-week clinical studies. 	sulfasalazine	methotrexate	none	{'e1': {'word': 'sulfasalazine', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d693.s2.e0'}, 'e2': {'word': 'methotrexate', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d693.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d693.s2'}	Daily doses sulfasalazine NUMBER g maximum NUMBER g weekly doses methotrexate NUMBER mg maximum NUMBER mg administered alone combination NUMBER rheumatoid arthritis patients NUMBER controlled NUMBER week clinical studies
Patients receiving antibiotics and sulfonamides generally should not be treated with ganglion blockers.  	antibiotics	sulfonamides	none	{'e1': {'word': 'antibiotics', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d579.s0.e0'}, 'e2': {'word': 'sulfonamides', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d579.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d579.s0'}	Patients receiving antibiotics sulfonamides generally treated ganglion blockers
Patients receiving antibiotics and sulfonamides generally should not be treated with ganglion blockers.  	antibiotics	ganglion blockers	advise	{'e1': {'word': 'antibiotics', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d579.s0.e0'}, 'e2': {'word': 'ganglion blockers', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d579.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d579.s0'}	Patients receiving antibiotics sulfonamides generally treated ganglion blockers
Patients receiving antibiotics and sulfonamides generally should not be treated with ganglion blockers.  	sulfonamides	ganglion blockers	advise	{'e1': {'word': 'sulfonamides', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d579.s0.e1'}, 'e2': {'word': 'ganglion blockers', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d579.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d579.s0'}	Patients receiving antibiotics sulfonamides generally treated ganglion blockers
The action of Mecamylamine may be potentiated by anesthesia, other antihypertensive drugs and alcohol.	Mecamylamine	antihypertensive drugs	effect	{'e1': {'word': 'Mecamylamine', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d579.s1.e0'}, 'e2': {'word': 'antihypertensive drugs', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d579.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d579.s1'}	action Mecamylamine may potentiated anesthesia antihypertensive drugs alcohol
The action of Mecamylamine may be potentiated by anesthesia, other antihypertensive drugs and alcohol.	Mecamylamine	alcohol	effect	{'e1': {'word': 'Mecamylamine', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d579.s1.e0'}, 'e2': {'word': 'alcohol', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d579.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d579.s1'}	action Mecamylamine may potentiated anesthesia antihypertensive drugs alcohol
The action of Mecamylamine may be potentiated by anesthesia, other antihypertensive drugs and alcohol.	antihypertensive drugs	alcohol	none	{'e1': {'word': 'antihypertensive drugs', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d579.s1.e1'}, 'e2': {'word': 'alcohol', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d579.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d579.s1'}	action Mecamylamine may potentiated anesthesia antihypertensive drugs alcohol
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	Methscopolamine	antidepressants	none	{'e1': {'word': 'Methscopolamine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d655.s0.e0'}, 'e2': {'word': 'antidepressants', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d655.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	Methscopolamine	tricyclic	int	{'e1': {'word': 'Methscopolamine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d655.s0.e0'}, 'e2': {'word': 'tricyclic', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d655.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	Methscopolamine	MAO inhibitors	int	{'e1': {'word': 'Methscopolamine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d655.s0.e0'}, 'e2': {'word': 'MAO inhibitors', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d655.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	Methscopolamine	phenelzine	int	{'e1': {'word': 'Methscopolamine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d655.s0.e0'}, 'e2': {'word': 'phenelzine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d655.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	Methscopolamine	linezolid	int	{'e1': {'word': 'Methscopolamine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d655.s0.e0'}, 'e2': {'word': 'linezolid', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d655.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	Methscopolamine	tranylcypromine	int	{'e1': {'word': 'Methscopolamine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d655.s0.e0'}, 'e2': {'word': 'tranylcypromine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d655.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	Methscopolamine	isocarboxazid	int	{'e1': {'word': 'Methscopolamine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d655.s0.e0'}, 'e2': {'word': 'isocarboxazid', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d655.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	Methscopolamine	selegiline	int	{'e1': {'word': 'Methscopolamine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d655.s0.e0'}, 'e2': {'word': 'selegiline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d655.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	Methscopolamine	furazolidone	int	{'e1': {'word': 'Methscopolamine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d655.s0.e0'}, 'e2': {'word': 'furazolidone', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d655.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	Methscopolamine	quinidine	int	{'e1': {'word': 'Methscopolamine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d655.s0.e0'}, 'e2': {'word': 'quinidine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d655.s0.e10'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	Methscopolamine	amantadine	int	{'e1': {'word': 'Methscopolamine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d655.s0.e0'}, 'e2': {'word': 'amantadine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d655.s0.e11'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	Methscopolamine	antihistamines	int	{'e1': {'word': 'Methscopolamine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d655.s0.e0'}, 'e2': {'word': 'antihistamines', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d655.s0.e12'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	Methscopolamine	diphenhydramine	int	{'e1': {'word': 'Methscopolamine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d655.s0.e0'}, 'e2': {'word': 'diphenhydramine', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d655.s0.e13'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	Methscopolamine	anticholinergics	int	{'e1': {'word': 'Methscopolamine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d655.s0.e0'}, 'e2': {'word': 'anticholinergics', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d655.s0.e14'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	Methscopolamine	potassium chloride	int	{'e1': {'word': 'Methscopolamine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d655.s0.e0'}, 'e2': {'word': 'potassium chloride', 'word_index': [(21, 22)], 'id': 'DDI-DrugBank.d655.s0.e15'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	Methscopolamine	antacids	int	{'e1': {'word': 'Methscopolamine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d655.s0.e0'}, 'e2': {'word': 'antacids', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d655.s0.e16'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	Methscopolamine	absorbent-type anti-diarrhea medicines	int	{'e1': {'word': 'Methscopolamine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d655.s0.e0'}, 'e2': {'word': 'absorbent-type anti-diarrhea medicines', 'word_index': [(25, 28)], 'id': 'DDI-DrugBank.d655.s0.e17'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	Methscopolamine	kaolin	int	{'e1': {'word': 'Methscopolamine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d655.s0.e0'}, 'e2': {'word': 'kaolin', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d655.s0.e18'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	Methscopolamine	pectin	int	{'e1': {'word': 'Methscopolamine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d655.s0.e0'}, 'e2': {'word': 'pectin', 'word_index': [(31, 31)], 'id': 'DDI-DrugBank.d655.s0.e19'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	Methscopolamine	phenothiazines	int	{'e1': {'word': 'Methscopolamine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d655.s0.e0'}, 'e2': {'word': 'phenothiazines', 'word_index': [(32, 32)], 'id': 'DDI-DrugBank.d655.s0.e20'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	Methscopolamine	chlorpromazine	int	{'e1': {'word': 'Methscopolamine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d655.s0.e0'}, 'e2': {'word': 'chlorpromazine', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d655.s0.e21'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	Methscopolamine	promethazine	int	{'e1': {'word': 'Methscopolamine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d655.s0.e0'}, 'e2': {'word': 'promethazine', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d655.s0.e22'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antidepressants	tricyclic	none	{'e1': {'word': 'antidepressants', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d655.s0.e1'}, 'e2': {'word': 'tricyclic', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d655.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antidepressants	MAO inhibitors	none	{'e1': {'word': 'antidepressants', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d655.s0.e1'}, 'e2': {'word': 'MAO inhibitors', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d655.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antidepressants	phenelzine	none	{'e1': {'word': 'antidepressants', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d655.s0.e1'}, 'e2': {'word': 'phenelzine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d655.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antidepressants	linezolid	none	{'e1': {'word': 'antidepressants', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d655.s0.e1'}, 'e2': {'word': 'linezolid', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d655.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antidepressants	tranylcypromine	none	{'e1': {'word': 'antidepressants', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d655.s0.e1'}, 'e2': {'word': 'tranylcypromine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d655.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antidepressants	isocarboxazid	none	{'e1': {'word': 'antidepressants', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d655.s0.e1'}, 'e2': {'word': 'isocarboxazid', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d655.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antidepressants	selegiline	none	{'e1': {'word': 'antidepressants', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d655.s0.e1'}, 'e2': {'word': 'selegiline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d655.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antidepressants	furazolidone	none	{'e1': {'word': 'antidepressants', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d655.s0.e1'}, 'e2': {'word': 'furazolidone', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d655.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antidepressants	quinidine	none	{'e1': {'word': 'antidepressants', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d655.s0.e1'}, 'e2': {'word': 'quinidine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d655.s0.e10'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antidepressants	amantadine	none	{'e1': {'word': 'antidepressants', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d655.s0.e1'}, 'e2': {'word': 'amantadine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d655.s0.e11'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antidepressants	antihistamines	none	{'e1': {'word': 'antidepressants', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d655.s0.e1'}, 'e2': {'word': 'antihistamines', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d655.s0.e12'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antidepressants	diphenhydramine	none	{'e1': {'word': 'antidepressants', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d655.s0.e1'}, 'e2': {'word': 'diphenhydramine', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d655.s0.e13'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antidepressants	anticholinergics	none	{'e1': {'word': 'antidepressants', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d655.s0.e1'}, 'e2': {'word': 'anticholinergics', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d655.s0.e14'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antidepressants	potassium chloride	none	{'e1': {'word': 'antidepressants', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d655.s0.e1'}, 'e2': {'word': 'potassium chloride', 'word_index': [(21, 22)], 'id': 'DDI-DrugBank.d655.s0.e15'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antidepressants	antacids	none	{'e1': {'word': 'antidepressants', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d655.s0.e1'}, 'e2': {'word': 'antacids', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d655.s0.e16'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antidepressants	absorbent-type anti-diarrhea medicines	none	{'e1': {'word': 'antidepressants', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d655.s0.e1'}, 'e2': {'word': 'absorbent-type anti-diarrhea medicines', 'word_index': [(25, 28)], 'id': 'DDI-DrugBank.d655.s0.e17'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antidepressants	kaolin	none	{'e1': {'word': 'antidepressants', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d655.s0.e1'}, 'e2': {'word': 'kaolin', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d655.s0.e18'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antidepressants	pectin	none	{'e1': {'word': 'antidepressants', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d655.s0.e1'}, 'e2': {'word': 'pectin', 'word_index': [(31, 31)], 'id': 'DDI-DrugBank.d655.s0.e19'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antidepressants	phenothiazines	none	{'e1': {'word': 'antidepressants', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d655.s0.e1'}, 'e2': {'word': 'phenothiazines', 'word_index': [(32, 32)], 'id': 'DDI-DrugBank.d655.s0.e20'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antidepressants	chlorpromazine	none	{'e1': {'word': 'antidepressants', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d655.s0.e1'}, 'e2': {'word': 'chlorpromazine', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d655.s0.e21'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antidepressants	promethazine	none	{'e1': {'word': 'antidepressants', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d655.s0.e1'}, 'e2': {'word': 'promethazine', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d655.s0.e22'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tricyclic	MAO inhibitors	none	{'e1': {'word': 'tricyclic', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d655.s0.e2'}, 'e2': {'word': 'MAO inhibitors', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d655.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tricyclic	phenelzine	none	{'e1': {'word': 'tricyclic', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d655.s0.e2'}, 'e2': {'word': 'phenelzine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d655.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tricyclic	linezolid	none	{'e1': {'word': 'tricyclic', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d655.s0.e2'}, 'e2': {'word': 'linezolid', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d655.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tricyclic	tranylcypromine	none	{'e1': {'word': 'tricyclic', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d655.s0.e2'}, 'e2': {'word': 'tranylcypromine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d655.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tricyclic	isocarboxazid	none	{'e1': {'word': 'tricyclic', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d655.s0.e2'}, 'e2': {'word': 'isocarboxazid', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d655.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tricyclic	selegiline	none	{'e1': {'word': 'tricyclic', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d655.s0.e2'}, 'e2': {'word': 'selegiline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d655.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tricyclic	furazolidone	none	{'e1': {'word': 'tricyclic', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d655.s0.e2'}, 'e2': {'word': 'furazolidone', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d655.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tricyclic	quinidine	none	{'e1': {'word': 'tricyclic', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d655.s0.e2'}, 'e2': {'word': 'quinidine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d655.s0.e10'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tricyclic	amantadine	none	{'e1': {'word': 'tricyclic', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d655.s0.e2'}, 'e2': {'word': 'amantadine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d655.s0.e11'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tricyclic	antihistamines	none	{'e1': {'word': 'tricyclic', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d655.s0.e2'}, 'e2': {'word': 'antihistamines', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d655.s0.e12'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tricyclic	diphenhydramine	none	{'e1': {'word': 'tricyclic', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d655.s0.e2'}, 'e2': {'word': 'diphenhydramine', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d655.s0.e13'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tricyclic	anticholinergics	none	{'e1': {'word': 'tricyclic', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d655.s0.e2'}, 'e2': {'word': 'anticholinergics', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d655.s0.e14'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tricyclic	potassium chloride	none	{'e1': {'word': 'tricyclic', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d655.s0.e2'}, 'e2': {'word': 'potassium chloride', 'word_index': [(21, 22)], 'id': 'DDI-DrugBank.d655.s0.e15'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tricyclic	antacids	none	{'e1': {'word': 'tricyclic', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d655.s0.e2'}, 'e2': {'word': 'antacids', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d655.s0.e16'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tricyclic	absorbent-type anti-diarrhea medicines	none	{'e1': {'word': 'tricyclic', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d655.s0.e2'}, 'e2': {'word': 'absorbent-type anti-diarrhea medicines', 'word_index': [(25, 28)], 'id': 'DDI-DrugBank.d655.s0.e17'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tricyclic	kaolin	none	{'e1': {'word': 'tricyclic', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d655.s0.e2'}, 'e2': {'word': 'kaolin', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d655.s0.e18'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tricyclic	pectin	none	{'e1': {'word': 'tricyclic', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d655.s0.e2'}, 'e2': {'word': 'pectin', 'word_index': [(31, 31)], 'id': 'DDI-DrugBank.d655.s0.e19'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tricyclic	phenothiazines	none	{'e1': {'word': 'tricyclic', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d655.s0.e2'}, 'e2': {'word': 'phenothiazines', 'word_index': [(32, 32)], 'id': 'DDI-DrugBank.d655.s0.e20'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tricyclic	chlorpromazine	none	{'e1': {'word': 'tricyclic', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d655.s0.e2'}, 'e2': {'word': 'chlorpromazine', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d655.s0.e21'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tricyclic	promethazine	none	{'e1': {'word': 'tricyclic', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d655.s0.e2'}, 'e2': {'word': 'promethazine', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d655.s0.e22'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	MAO inhibitors	phenelzine	none	{'e1': {'word': 'MAO inhibitors', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d655.s0.e3'}, 'e2': {'word': 'phenelzine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d655.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	MAO inhibitors	linezolid	none	{'e1': {'word': 'MAO inhibitors', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d655.s0.e3'}, 'e2': {'word': 'linezolid', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d655.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	MAO inhibitors	tranylcypromine	none	{'e1': {'word': 'MAO inhibitors', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d655.s0.e3'}, 'e2': {'word': 'tranylcypromine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d655.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	MAO inhibitors	isocarboxazid	none	{'e1': {'word': 'MAO inhibitors', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d655.s0.e3'}, 'e2': {'word': 'isocarboxazid', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d655.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	MAO inhibitors	selegiline	none	{'e1': {'word': 'MAO inhibitors', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d655.s0.e3'}, 'e2': {'word': 'selegiline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d655.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	MAO inhibitors	furazolidone	none	{'e1': {'word': 'MAO inhibitors', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d655.s0.e3'}, 'e2': {'word': 'furazolidone', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d655.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	MAO inhibitors	quinidine	none	{'e1': {'word': 'MAO inhibitors', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d655.s0.e3'}, 'e2': {'word': 'quinidine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d655.s0.e10'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	MAO inhibitors	amantadine	none	{'e1': {'word': 'MAO inhibitors', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d655.s0.e3'}, 'e2': {'word': 'amantadine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d655.s0.e11'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	MAO inhibitors	antihistamines	none	{'e1': {'word': 'MAO inhibitors', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d655.s0.e3'}, 'e2': {'word': 'antihistamines', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d655.s0.e12'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	MAO inhibitors	diphenhydramine	none	{'e1': {'word': 'MAO inhibitors', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d655.s0.e3'}, 'e2': {'word': 'diphenhydramine', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d655.s0.e13'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	MAO inhibitors	anticholinergics	none	{'e1': {'word': 'MAO inhibitors', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d655.s0.e3'}, 'e2': {'word': 'anticholinergics', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d655.s0.e14'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	MAO inhibitors	potassium chloride	none	{'e1': {'word': 'MAO inhibitors', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d655.s0.e3'}, 'e2': {'word': 'potassium chloride', 'word_index': [(21, 22)], 'id': 'DDI-DrugBank.d655.s0.e15'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	MAO inhibitors	antacids	none	{'e1': {'word': 'MAO inhibitors', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d655.s0.e3'}, 'e2': {'word': 'antacids', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d655.s0.e16'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	MAO inhibitors	absorbent-type anti-diarrhea medicines	none	{'e1': {'word': 'MAO inhibitors', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d655.s0.e3'}, 'e2': {'word': 'absorbent-type anti-diarrhea medicines', 'word_index': [(25, 28)], 'id': 'DDI-DrugBank.d655.s0.e17'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	MAO inhibitors	kaolin	none	{'e1': {'word': 'MAO inhibitors', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d655.s0.e3'}, 'e2': {'word': 'kaolin', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d655.s0.e18'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	MAO inhibitors	pectin	none	{'e1': {'word': 'MAO inhibitors', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d655.s0.e3'}, 'e2': {'word': 'pectin', 'word_index': [(31, 31)], 'id': 'DDI-DrugBank.d655.s0.e19'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	MAO inhibitors	phenothiazines	none	{'e1': {'word': 'MAO inhibitors', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d655.s0.e3'}, 'e2': {'word': 'phenothiazines', 'word_index': [(32, 32)], 'id': 'DDI-DrugBank.d655.s0.e20'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	MAO inhibitors	chlorpromazine	none	{'e1': {'word': 'MAO inhibitors', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d655.s0.e3'}, 'e2': {'word': 'chlorpromazine', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d655.s0.e21'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	MAO inhibitors	promethazine	none	{'e1': {'word': 'MAO inhibitors', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d655.s0.e3'}, 'e2': {'word': 'promethazine', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d655.s0.e22'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	phenelzine	linezolid	none	{'e1': {'word': 'phenelzine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d655.s0.e4'}, 'e2': {'word': 'linezolid', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d655.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	phenelzine	tranylcypromine	none	{'e1': {'word': 'phenelzine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d655.s0.e4'}, 'e2': {'word': 'tranylcypromine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d655.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	phenelzine	isocarboxazid	none	{'e1': {'word': 'phenelzine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d655.s0.e4'}, 'e2': {'word': 'isocarboxazid', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d655.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	phenelzine	selegiline	none	{'e1': {'word': 'phenelzine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d655.s0.e4'}, 'e2': {'word': 'selegiline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d655.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	phenelzine	furazolidone	none	{'e1': {'word': 'phenelzine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d655.s0.e4'}, 'e2': {'word': 'furazolidone', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d655.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	phenelzine	quinidine	none	{'e1': {'word': 'phenelzine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d655.s0.e4'}, 'e2': {'word': 'quinidine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d655.s0.e10'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	phenelzine	amantadine	none	{'e1': {'word': 'phenelzine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d655.s0.e4'}, 'e2': {'word': 'amantadine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d655.s0.e11'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	phenelzine	antihistamines	none	{'e1': {'word': 'phenelzine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d655.s0.e4'}, 'e2': {'word': 'antihistamines', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d655.s0.e12'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	phenelzine	diphenhydramine	none	{'e1': {'word': 'phenelzine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d655.s0.e4'}, 'e2': {'word': 'diphenhydramine', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d655.s0.e13'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	phenelzine	anticholinergics	none	{'e1': {'word': 'phenelzine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d655.s0.e4'}, 'e2': {'word': 'anticholinergics', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d655.s0.e14'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	phenelzine	potassium chloride	none	{'e1': {'word': 'phenelzine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d655.s0.e4'}, 'e2': {'word': 'potassium chloride', 'word_index': [(21, 22)], 'id': 'DDI-DrugBank.d655.s0.e15'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	phenelzine	antacids	none	{'e1': {'word': 'phenelzine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d655.s0.e4'}, 'e2': {'word': 'antacids', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d655.s0.e16'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	phenelzine	absorbent-type anti-diarrhea medicines	none	{'e1': {'word': 'phenelzine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d655.s0.e4'}, 'e2': {'word': 'absorbent-type anti-diarrhea medicines', 'word_index': [(25, 28)], 'id': 'DDI-DrugBank.d655.s0.e17'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	phenelzine	kaolin	none	{'e1': {'word': 'phenelzine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d655.s0.e4'}, 'e2': {'word': 'kaolin', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d655.s0.e18'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	phenelzine	pectin	none	{'e1': {'word': 'phenelzine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d655.s0.e4'}, 'e2': {'word': 'pectin', 'word_index': [(31, 31)], 'id': 'DDI-DrugBank.d655.s0.e19'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	phenelzine	phenothiazines	none	{'e1': {'word': 'phenelzine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d655.s0.e4'}, 'e2': {'word': 'phenothiazines', 'word_index': [(32, 32)], 'id': 'DDI-DrugBank.d655.s0.e20'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	phenelzine	chlorpromazine	none	{'e1': {'word': 'phenelzine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d655.s0.e4'}, 'e2': {'word': 'chlorpromazine', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d655.s0.e21'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	phenelzine	promethazine	none	{'e1': {'word': 'phenelzine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d655.s0.e4'}, 'e2': {'word': 'promethazine', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d655.s0.e22'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	linezolid	tranylcypromine	none	{'e1': {'word': 'linezolid', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d655.s0.e5'}, 'e2': {'word': 'tranylcypromine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d655.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	linezolid	isocarboxazid	none	{'e1': {'word': 'linezolid', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d655.s0.e5'}, 'e2': {'word': 'isocarboxazid', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d655.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	linezolid	selegiline	none	{'e1': {'word': 'linezolid', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d655.s0.e5'}, 'e2': {'word': 'selegiline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d655.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	linezolid	furazolidone	none	{'e1': {'word': 'linezolid', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d655.s0.e5'}, 'e2': {'word': 'furazolidone', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d655.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	linezolid	quinidine	none	{'e1': {'word': 'linezolid', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d655.s0.e5'}, 'e2': {'word': 'quinidine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d655.s0.e10'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	linezolid	amantadine	none	{'e1': {'word': 'linezolid', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d655.s0.e5'}, 'e2': {'word': 'amantadine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d655.s0.e11'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	linezolid	antihistamines	none	{'e1': {'word': 'linezolid', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d655.s0.e5'}, 'e2': {'word': 'antihistamines', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d655.s0.e12'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	linezolid	diphenhydramine	none	{'e1': {'word': 'linezolid', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d655.s0.e5'}, 'e2': {'word': 'diphenhydramine', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d655.s0.e13'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	linezolid	anticholinergics	none	{'e1': {'word': 'linezolid', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d655.s0.e5'}, 'e2': {'word': 'anticholinergics', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d655.s0.e14'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	linezolid	potassium chloride	none	{'e1': {'word': 'linezolid', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d655.s0.e5'}, 'e2': {'word': 'potassium chloride', 'word_index': [(21, 22)], 'id': 'DDI-DrugBank.d655.s0.e15'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	linezolid	antacids	none	{'e1': {'word': 'linezolid', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d655.s0.e5'}, 'e2': {'word': 'antacids', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d655.s0.e16'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	linezolid	absorbent-type anti-diarrhea medicines	none	{'e1': {'word': 'linezolid', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d655.s0.e5'}, 'e2': {'word': 'absorbent-type anti-diarrhea medicines', 'word_index': [(25, 28)], 'id': 'DDI-DrugBank.d655.s0.e17'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	linezolid	kaolin	none	{'e1': {'word': 'linezolid', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d655.s0.e5'}, 'e2': {'word': 'kaolin', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d655.s0.e18'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	linezolid	pectin	none	{'e1': {'word': 'linezolid', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d655.s0.e5'}, 'e2': {'word': 'pectin', 'word_index': [(31, 31)], 'id': 'DDI-DrugBank.d655.s0.e19'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	linezolid	phenothiazines	none	{'e1': {'word': 'linezolid', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d655.s0.e5'}, 'e2': {'word': 'phenothiazines', 'word_index': [(32, 32)], 'id': 'DDI-DrugBank.d655.s0.e20'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	linezolid	chlorpromazine	none	{'e1': {'word': 'linezolid', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d655.s0.e5'}, 'e2': {'word': 'chlorpromazine', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d655.s0.e21'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	linezolid	promethazine	none	{'e1': {'word': 'linezolid', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d655.s0.e5'}, 'e2': {'word': 'promethazine', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d655.s0.e22'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tranylcypromine	isocarboxazid	none	{'e1': {'word': 'tranylcypromine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d655.s0.e6'}, 'e2': {'word': 'isocarboxazid', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d655.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tranylcypromine	selegiline	none	{'e1': {'word': 'tranylcypromine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d655.s0.e6'}, 'e2': {'word': 'selegiline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d655.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tranylcypromine	furazolidone	none	{'e1': {'word': 'tranylcypromine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d655.s0.e6'}, 'e2': {'word': 'furazolidone', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d655.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tranylcypromine	quinidine	none	{'e1': {'word': 'tranylcypromine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d655.s0.e6'}, 'e2': {'word': 'quinidine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d655.s0.e10'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tranylcypromine	amantadine	none	{'e1': {'word': 'tranylcypromine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d655.s0.e6'}, 'e2': {'word': 'amantadine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d655.s0.e11'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tranylcypromine	antihistamines	none	{'e1': {'word': 'tranylcypromine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d655.s0.e6'}, 'e2': {'word': 'antihistamines', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d655.s0.e12'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tranylcypromine	diphenhydramine	none	{'e1': {'word': 'tranylcypromine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d655.s0.e6'}, 'e2': {'word': 'diphenhydramine', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d655.s0.e13'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tranylcypromine	anticholinergics	none	{'e1': {'word': 'tranylcypromine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d655.s0.e6'}, 'e2': {'word': 'anticholinergics', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d655.s0.e14'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tranylcypromine	potassium chloride	none	{'e1': {'word': 'tranylcypromine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d655.s0.e6'}, 'e2': {'word': 'potassium chloride', 'word_index': [(21, 22)], 'id': 'DDI-DrugBank.d655.s0.e15'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tranylcypromine	antacids	none	{'e1': {'word': 'tranylcypromine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d655.s0.e6'}, 'e2': {'word': 'antacids', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d655.s0.e16'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tranylcypromine	absorbent-type anti-diarrhea medicines	none	{'e1': {'word': 'tranylcypromine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d655.s0.e6'}, 'e2': {'word': 'absorbent-type anti-diarrhea medicines', 'word_index': [(25, 28)], 'id': 'DDI-DrugBank.d655.s0.e17'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tranylcypromine	kaolin	none	{'e1': {'word': 'tranylcypromine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d655.s0.e6'}, 'e2': {'word': 'kaolin', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d655.s0.e18'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tranylcypromine	pectin	none	{'e1': {'word': 'tranylcypromine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d655.s0.e6'}, 'e2': {'word': 'pectin', 'word_index': [(31, 31)], 'id': 'DDI-DrugBank.d655.s0.e19'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tranylcypromine	phenothiazines	none	{'e1': {'word': 'tranylcypromine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d655.s0.e6'}, 'e2': {'word': 'phenothiazines', 'word_index': [(32, 32)], 'id': 'DDI-DrugBank.d655.s0.e20'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tranylcypromine	chlorpromazine	none	{'e1': {'word': 'tranylcypromine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d655.s0.e6'}, 'e2': {'word': 'chlorpromazine', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d655.s0.e21'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tranylcypromine	promethazine	none	{'e1': {'word': 'tranylcypromine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d655.s0.e6'}, 'e2': {'word': 'promethazine', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d655.s0.e22'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	isocarboxazid	selegiline	none	{'e1': {'word': 'isocarboxazid', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d655.s0.e7'}, 'e2': {'word': 'selegiline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d655.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	isocarboxazid	furazolidone	none	{'e1': {'word': 'isocarboxazid', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d655.s0.e7'}, 'e2': {'word': 'furazolidone', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d655.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	isocarboxazid	quinidine	none	{'e1': {'word': 'isocarboxazid', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d655.s0.e7'}, 'e2': {'word': 'quinidine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d655.s0.e10'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	isocarboxazid	amantadine	none	{'e1': {'word': 'isocarboxazid', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d655.s0.e7'}, 'e2': {'word': 'amantadine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d655.s0.e11'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	isocarboxazid	antihistamines	none	{'e1': {'word': 'isocarboxazid', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d655.s0.e7'}, 'e2': {'word': 'antihistamines', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d655.s0.e12'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	isocarboxazid	diphenhydramine	none	{'e1': {'word': 'isocarboxazid', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d655.s0.e7'}, 'e2': {'word': 'diphenhydramine', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d655.s0.e13'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	isocarboxazid	anticholinergics	none	{'e1': {'word': 'isocarboxazid', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d655.s0.e7'}, 'e2': {'word': 'anticholinergics', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d655.s0.e14'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	isocarboxazid	potassium chloride	none	{'e1': {'word': 'isocarboxazid', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d655.s0.e7'}, 'e2': {'word': 'potassium chloride', 'word_index': [(21, 22)], 'id': 'DDI-DrugBank.d655.s0.e15'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	isocarboxazid	antacids	none	{'e1': {'word': 'isocarboxazid', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d655.s0.e7'}, 'e2': {'word': 'antacids', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d655.s0.e16'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	isocarboxazid	absorbent-type anti-diarrhea medicines	none	{'e1': {'word': 'isocarboxazid', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d655.s0.e7'}, 'e2': {'word': 'absorbent-type anti-diarrhea medicines', 'word_index': [(25, 28)], 'id': 'DDI-DrugBank.d655.s0.e17'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	isocarboxazid	kaolin	none	{'e1': {'word': 'isocarboxazid', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d655.s0.e7'}, 'e2': {'word': 'kaolin', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d655.s0.e18'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	isocarboxazid	pectin	none	{'e1': {'word': 'isocarboxazid', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d655.s0.e7'}, 'e2': {'word': 'pectin', 'word_index': [(31, 31)], 'id': 'DDI-DrugBank.d655.s0.e19'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	isocarboxazid	phenothiazines	none	{'e1': {'word': 'isocarboxazid', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d655.s0.e7'}, 'e2': {'word': 'phenothiazines', 'word_index': [(32, 32)], 'id': 'DDI-DrugBank.d655.s0.e20'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	isocarboxazid	chlorpromazine	none	{'e1': {'word': 'isocarboxazid', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d655.s0.e7'}, 'e2': {'word': 'chlorpromazine', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d655.s0.e21'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	isocarboxazid	promethazine	none	{'e1': {'word': 'isocarboxazid', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d655.s0.e7'}, 'e2': {'word': 'promethazine', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d655.s0.e22'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	selegiline	furazolidone	none	{'e1': {'word': 'selegiline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d655.s0.e8'}, 'e2': {'word': 'furazolidone', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d655.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	selegiline	quinidine	none	{'e1': {'word': 'selegiline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d655.s0.e8'}, 'e2': {'word': 'quinidine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d655.s0.e10'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	selegiline	amantadine	none	{'e1': {'word': 'selegiline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d655.s0.e8'}, 'e2': {'word': 'amantadine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d655.s0.e11'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	selegiline	antihistamines	none	{'e1': {'word': 'selegiline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d655.s0.e8'}, 'e2': {'word': 'antihistamines', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d655.s0.e12'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	selegiline	diphenhydramine	none	{'e1': {'word': 'selegiline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d655.s0.e8'}, 'e2': {'word': 'diphenhydramine', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d655.s0.e13'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	selegiline	anticholinergics	none	{'e1': {'word': 'selegiline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d655.s0.e8'}, 'e2': {'word': 'anticholinergics', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d655.s0.e14'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	selegiline	potassium chloride	none	{'e1': {'word': 'selegiline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d655.s0.e8'}, 'e2': {'word': 'potassium chloride', 'word_index': [(21, 22)], 'id': 'DDI-DrugBank.d655.s0.e15'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	selegiline	antacids	none	{'e1': {'word': 'selegiline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d655.s0.e8'}, 'e2': {'word': 'antacids', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d655.s0.e16'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	selegiline	absorbent-type anti-diarrhea medicines	none	{'e1': {'word': 'selegiline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d655.s0.e8'}, 'e2': {'word': 'absorbent-type anti-diarrhea medicines', 'word_index': [(25, 28)], 'id': 'DDI-DrugBank.d655.s0.e17'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	selegiline	kaolin	none	{'e1': {'word': 'selegiline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d655.s0.e8'}, 'e2': {'word': 'kaolin', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d655.s0.e18'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	selegiline	pectin	none	{'e1': {'word': 'selegiline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d655.s0.e8'}, 'e2': {'word': 'pectin', 'word_index': [(31, 31)], 'id': 'DDI-DrugBank.d655.s0.e19'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	selegiline	phenothiazines	none	{'e1': {'word': 'selegiline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d655.s0.e8'}, 'e2': {'word': 'phenothiazines', 'word_index': [(32, 32)], 'id': 'DDI-DrugBank.d655.s0.e20'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	selegiline	chlorpromazine	none	{'e1': {'word': 'selegiline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d655.s0.e8'}, 'e2': {'word': 'chlorpromazine', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d655.s0.e21'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	selegiline	promethazine	none	{'e1': {'word': 'selegiline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d655.s0.e8'}, 'e2': {'word': 'promethazine', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d655.s0.e22'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	furazolidone	quinidine	none	{'e1': {'word': 'furazolidone', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d655.s0.e9'}, 'e2': {'word': 'quinidine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d655.s0.e10'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	furazolidone	amantadine	none	{'e1': {'word': 'furazolidone', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d655.s0.e9'}, 'e2': {'word': 'amantadine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d655.s0.e11'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	furazolidone	antihistamines	none	{'e1': {'word': 'furazolidone', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d655.s0.e9'}, 'e2': {'word': 'antihistamines', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d655.s0.e12'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	furazolidone	diphenhydramine	none	{'e1': {'word': 'furazolidone', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d655.s0.e9'}, 'e2': {'word': 'diphenhydramine', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d655.s0.e13'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	furazolidone	anticholinergics	none	{'e1': {'word': 'furazolidone', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d655.s0.e9'}, 'e2': {'word': 'anticholinergics', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d655.s0.e14'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	furazolidone	potassium chloride	none	{'e1': {'word': 'furazolidone', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d655.s0.e9'}, 'e2': {'word': 'potassium chloride', 'word_index': [(21, 22)], 'id': 'DDI-DrugBank.d655.s0.e15'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	furazolidone	antacids	none	{'e1': {'word': 'furazolidone', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d655.s0.e9'}, 'e2': {'word': 'antacids', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d655.s0.e16'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	furazolidone	absorbent-type anti-diarrhea medicines	none	{'e1': {'word': 'furazolidone', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d655.s0.e9'}, 'e2': {'word': 'absorbent-type anti-diarrhea medicines', 'word_index': [(25, 28)], 'id': 'DDI-DrugBank.d655.s0.e17'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	furazolidone	kaolin	none	{'e1': {'word': 'furazolidone', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d655.s0.e9'}, 'e2': {'word': 'kaolin', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d655.s0.e18'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	furazolidone	pectin	none	{'e1': {'word': 'furazolidone', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d655.s0.e9'}, 'e2': {'word': 'pectin', 'word_index': [(31, 31)], 'id': 'DDI-DrugBank.d655.s0.e19'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	furazolidone	phenothiazines	none	{'e1': {'word': 'furazolidone', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d655.s0.e9'}, 'e2': {'word': 'phenothiazines', 'word_index': [(32, 32)], 'id': 'DDI-DrugBank.d655.s0.e20'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	furazolidone	chlorpromazine	none	{'e1': {'word': 'furazolidone', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d655.s0.e9'}, 'e2': {'word': 'chlorpromazine', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d655.s0.e21'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	furazolidone	promethazine	none	{'e1': {'word': 'furazolidone', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d655.s0.e9'}, 'e2': {'word': 'promethazine', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d655.s0.e22'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	quinidine	amantadine	none	{'e1': {'word': 'quinidine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d655.s0.e10'}, 'e2': {'word': 'amantadine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d655.s0.e11'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	quinidine	antihistamines	none	{'e1': {'word': 'quinidine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d655.s0.e10'}, 'e2': {'word': 'antihistamines', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d655.s0.e12'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	quinidine	diphenhydramine	none	{'e1': {'word': 'quinidine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d655.s0.e10'}, 'e2': {'word': 'diphenhydramine', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d655.s0.e13'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	quinidine	anticholinergics	none	{'e1': {'word': 'quinidine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d655.s0.e10'}, 'e2': {'word': 'anticholinergics', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d655.s0.e14'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	quinidine	potassium chloride	none	{'e1': {'word': 'quinidine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d655.s0.e10'}, 'e2': {'word': 'potassium chloride', 'word_index': [(21, 22)], 'id': 'DDI-DrugBank.d655.s0.e15'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	quinidine	antacids	none	{'e1': {'word': 'quinidine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d655.s0.e10'}, 'e2': {'word': 'antacids', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d655.s0.e16'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	quinidine	absorbent-type anti-diarrhea medicines	none	{'e1': {'word': 'quinidine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d655.s0.e10'}, 'e2': {'word': 'absorbent-type anti-diarrhea medicines', 'word_index': [(25, 28)], 'id': 'DDI-DrugBank.d655.s0.e17'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	quinidine	kaolin	none	{'e1': {'word': 'quinidine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d655.s0.e10'}, 'e2': {'word': 'kaolin', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d655.s0.e18'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	quinidine	pectin	none	{'e1': {'word': 'quinidine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d655.s0.e10'}, 'e2': {'word': 'pectin', 'word_index': [(31, 31)], 'id': 'DDI-DrugBank.d655.s0.e19'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	quinidine	phenothiazines	none	{'e1': {'word': 'quinidine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d655.s0.e10'}, 'e2': {'word': 'phenothiazines', 'word_index': [(32, 32)], 'id': 'DDI-DrugBank.d655.s0.e20'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	quinidine	chlorpromazine	none	{'e1': {'word': 'quinidine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d655.s0.e10'}, 'e2': {'word': 'chlorpromazine', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d655.s0.e21'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	quinidine	promethazine	none	{'e1': {'word': 'quinidine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d655.s0.e10'}, 'e2': {'word': 'promethazine', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d655.s0.e22'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	amantadine	antihistamines	none	{'e1': {'word': 'amantadine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d655.s0.e11'}, 'e2': {'word': 'antihistamines', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d655.s0.e12'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	amantadine	diphenhydramine	none	{'e1': {'word': 'amantadine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d655.s0.e11'}, 'e2': {'word': 'diphenhydramine', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d655.s0.e13'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	amantadine	anticholinergics	none	{'e1': {'word': 'amantadine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d655.s0.e11'}, 'e2': {'word': 'anticholinergics', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d655.s0.e14'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	amantadine	potassium chloride	none	{'e1': {'word': 'amantadine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d655.s0.e11'}, 'e2': {'word': 'potassium chloride', 'word_index': [(21, 22)], 'id': 'DDI-DrugBank.d655.s0.e15'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	amantadine	antacids	none	{'e1': {'word': 'amantadine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d655.s0.e11'}, 'e2': {'word': 'antacids', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d655.s0.e16'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	amantadine	absorbent-type anti-diarrhea medicines	none	{'e1': {'word': 'amantadine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d655.s0.e11'}, 'e2': {'word': 'absorbent-type anti-diarrhea medicines', 'word_index': [(25, 28)], 'id': 'DDI-DrugBank.d655.s0.e17'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	amantadine	kaolin	none	{'e1': {'word': 'amantadine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d655.s0.e11'}, 'e2': {'word': 'kaolin', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d655.s0.e18'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	amantadine	pectin	none	{'e1': {'word': 'amantadine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d655.s0.e11'}, 'e2': {'word': 'pectin', 'word_index': [(31, 31)], 'id': 'DDI-DrugBank.d655.s0.e19'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	amantadine	phenothiazines	none	{'e1': {'word': 'amantadine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d655.s0.e11'}, 'e2': {'word': 'phenothiazines', 'word_index': [(32, 32)], 'id': 'DDI-DrugBank.d655.s0.e20'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	amantadine	chlorpromazine	none	{'e1': {'word': 'amantadine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d655.s0.e11'}, 'e2': {'word': 'chlorpromazine', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d655.s0.e21'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	amantadine	promethazine	none	{'e1': {'word': 'amantadine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d655.s0.e11'}, 'e2': {'word': 'promethazine', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d655.s0.e22'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antihistamines	diphenhydramine	none	{'e1': {'word': 'antihistamines', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d655.s0.e12'}, 'e2': {'word': 'diphenhydramine', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d655.s0.e13'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antihistamines	anticholinergics	none	{'e1': {'word': 'antihistamines', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d655.s0.e12'}, 'e2': {'word': 'anticholinergics', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d655.s0.e14'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antihistamines	potassium chloride	none	{'e1': {'word': 'antihistamines', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d655.s0.e12'}, 'e2': {'word': 'potassium chloride', 'word_index': [(21, 22)], 'id': 'DDI-DrugBank.d655.s0.e15'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antihistamines	antacids	none	{'e1': {'word': 'antihistamines', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d655.s0.e12'}, 'e2': {'word': 'antacids', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d655.s0.e16'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antihistamines	absorbent-type anti-diarrhea medicines	none	{'e1': {'word': 'antihistamines', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d655.s0.e12'}, 'e2': {'word': 'absorbent-type anti-diarrhea medicines', 'word_index': [(25, 28)], 'id': 'DDI-DrugBank.d655.s0.e17'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antihistamines	kaolin	none	{'e1': {'word': 'antihistamines', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d655.s0.e12'}, 'e2': {'word': 'kaolin', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d655.s0.e18'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antihistamines	pectin	none	{'e1': {'word': 'antihistamines', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d655.s0.e12'}, 'e2': {'word': 'pectin', 'word_index': [(31, 31)], 'id': 'DDI-DrugBank.d655.s0.e19'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antihistamines	phenothiazines	none	{'e1': {'word': 'antihistamines', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d655.s0.e12'}, 'e2': {'word': 'phenothiazines', 'word_index': [(32, 32)], 'id': 'DDI-DrugBank.d655.s0.e20'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antihistamines	chlorpromazine	none	{'e1': {'word': 'antihistamines', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d655.s0.e12'}, 'e2': {'word': 'chlorpromazine', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d655.s0.e21'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antihistamines	promethazine	none	{'e1': {'word': 'antihistamines', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d655.s0.e12'}, 'e2': {'word': 'promethazine', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d655.s0.e22'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	diphenhydramine	anticholinergics	none	{'e1': {'word': 'diphenhydramine', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d655.s0.e13'}, 'e2': {'word': 'anticholinergics', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d655.s0.e14'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	diphenhydramine	potassium chloride	none	{'e1': {'word': 'diphenhydramine', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d655.s0.e13'}, 'e2': {'word': 'potassium chloride', 'word_index': [(21, 22)], 'id': 'DDI-DrugBank.d655.s0.e15'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	diphenhydramine	antacids	none	{'e1': {'word': 'diphenhydramine', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d655.s0.e13'}, 'e2': {'word': 'antacids', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d655.s0.e16'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	diphenhydramine	absorbent-type anti-diarrhea medicines	none	{'e1': {'word': 'diphenhydramine', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d655.s0.e13'}, 'e2': {'word': 'absorbent-type anti-diarrhea medicines', 'word_index': [(25, 28)], 'id': 'DDI-DrugBank.d655.s0.e17'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	diphenhydramine	kaolin	none	{'e1': {'word': 'diphenhydramine', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d655.s0.e13'}, 'e2': {'word': 'kaolin', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d655.s0.e18'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	diphenhydramine	pectin	none	{'e1': {'word': 'diphenhydramine', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d655.s0.e13'}, 'e2': {'word': 'pectin', 'word_index': [(31, 31)], 'id': 'DDI-DrugBank.d655.s0.e19'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	diphenhydramine	phenothiazines	none	{'e1': {'word': 'diphenhydramine', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d655.s0.e13'}, 'e2': {'word': 'phenothiazines', 'word_index': [(32, 32)], 'id': 'DDI-DrugBank.d655.s0.e20'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	diphenhydramine	chlorpromazine	none	{'e1': {'word': 'diphenhydramine', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d655.s0.e13'}, 'e2': {'word': 'chlorpromazine', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d655.s0.e21'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	diphenhydramine	promethazine	none	{'e1': {'word': 'diphenhydramine', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d655.s0.e13'}, 'e2': {'word': 'promethazine', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d655.s0.e22'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	anticholinergics	potassium chloride	none	{'e1': {'word': 'anticholinergics', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d655.s0.e14'}, 'e2': {'word': 'potassium chloride', 'word_index': [(21, 22)], 'id': 'DDI-DrugBank.d655.s0.e15'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	anticholinergics	antacids	none	{'e1': {'word': 'anticholinergics', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d655.s0.e14'}, 'e2': {'word': 'antacids', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d655.s0.e16'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	anticholinergics	absorbent-type anti-diarrhea medicines	none	{'e1': {'word': 'anticholinergics', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d655.s0.e14'}, 'e2': {'word': 'absorbent-type anti-diarrhea medicines', 'word_index': [(25, 28)], 'id': 'DDI-DrugBank.d655.s0.e17'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	anticholinergics	kaolin	none	{'e1': {'word': 'anticholinergics', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d655.s0.e14'}, 'e2': {'word': 'kaolin', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d655.s0.e18'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	anticholinergics	pectin	none	{'e1': {'word': 'anticholinergics', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d655.s0.e14'}, 'e2': {'word': 'pectin', 'word_index': [(31, 31)], 'id': 'DDI-DrugBank.d655.s0.e19'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	anticholinergics	phenothiazines	none	{'e1': {'word': 'anticholinergics', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d655.s0.e14'}, 'e2': {'word': 'phenothiazines', 'word_index': [(32, 32)], 'id': 'DDI-DrugBank.d655.s0.e20'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	anticholinergics	chlorpromazine	none	{'e1': {'word': 'anticholinergics', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d655.s0.e14'}, 'e2': {'word': 'chlorpromazine', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d655.s0.e21'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	anticholinergics	promethazine	none	{'e1': {'word': 'anticholinergics', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d655.s0.e14'}, 'e2': {'word': 'promethazine', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d655.s0.e22'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	potassium chloride	antacids	none	{'e1': {'word': 'potassium chloride', 'word_index': [(21, 22)], 'id': 'DDI-DrugBank.d655.s0.e15'}, 'e2': {'word': 'antacids', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d655.s0.e16'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	potassium chloride	absorbent-type anti-diarrhea medicines	none	{'e1': {'word': 'potassium chloride', 'word_index': [(21, 22)], 'id': 'DDI-DrugBank.d655.s0.e15'}, 'e2': {'word': 'absorbent-type anti-diarrhea medicines', 'word_index': [(25, 28)], 'id': 'DDI-DrugBank.d655.s0.e17'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	potassium chloride	kaolin	none	{'e1': {'word': 'potassium chloride', 'word_index': [(21, 22)], 'id': 'DDI-DrugBank.d655.s0.e15'}, 'e2': {'word': 'kaolin', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d655.s0.e18'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	potassium chloride	pectin	none	{'e1': {'word': 'potassium chloride', 'word_index': [(21, 22)], 'id': 'DDI-DrugBank.d655.s0.e15'}, 'e2': {'word': 'pectin', 'word_index': [(31, 31)], 'id': 'DDI-DrugBank.d655.s0.e19'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	potassium chloride	phenothiazines	none	{'e1': {'word': 'potassium chloride', 'word_index': [(21, 22)], 'id': 'DDI-DrugBank.d655.s0.e15'}, 'e2': {'word': 'phenothiazines', 'word_index': [(32, 32)], 'id': 'DDI-DrugBank.d655.s0.e20'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	potassium chloride	chlorpromazine	none	{'e1': {'word': 'potassium chloride', 'word_index': [(21, 22)], 'id': 'DDI-DrugBank.d655.s0.e15'}, 'e2': {'word': 'chlorpromazine', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d655.s0.e21'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	potassium chloride	promethazine	none	{'e1': {'word': 'potassium chloride', 'word_index': [(21, 22)], 'id': 'DDI-DrugBank.d655.s0.e15'}, 'e2': {'word': 'promethazine', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d655.s0.e22'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antacids	absorbent-type anti-diarrhea medicines	none	{'e1': {'word': 'antacids', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d655.s0.e16'}, 'e2': {'word': 'absorbent-type anti-diarrhea medicines', 'word_index': [(25, 28)], 'id': 'DDI-DrugBank.d655.s0.e17'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antacids	kaolin	none	{'e1': {'word': 'antacids', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d655.s0.e16'}, 'e2': {'word': 'kaolin', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d655.s0.e18'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antacids	pectin	none	{'e1': {'word': 'antacids', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d655.s0.e16'}, 'e2': {'word': 'pectin', 'word_index': [(31, 31)], 'id': 'DDI-DrugBank.d655.s0.e19'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antacids	phenothiazines	none	{'e1': {'word': 'antacids', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d655.s0.e16'}, 'e2': {'word': 'phenothiazines', 'word_index': [(32, 32)], 'id': 'DDI-DrugBank.d655.s0.e20'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antacids	chlorpromazine	none	{'e1': {'word': 'antacids', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d655.s0.e16'}, 'e2': {'word': 'chlorpromazine', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d655.s0.e21'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antacids	promethazine	none	{'e1': {'word': 'antacids', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d655.s0.e16'}, 'e2': {'word': 'promethazine', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d655.s0.e22'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	absorbent-type anti-diarrhea medicines	kaolin	none	{'e1': {'word': 'absorbent-type anti-diarrhea medicines', 'word_index': [(25, 28)], 'id': 'DDI-DrugBank.d655.s0.e17'}, 'e2': {'word': 'kaolin', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d655.s0.e18'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	absorbent-type anti-diarrhea medicines	pectin	none	{'e1': {'word': 'absorbent-type anti-diarrhea medicines', 'word_index': [(25, 28)], 'id': 'DDI-DrugBank.d655.s0.e17'}, 'e2': {'word': 'pectin', 'word_index': [(31, 31)], 'id': 'DDI-DrugBank.d655.s0.e19'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	absorbent-type anti-diarrhea medicines	phenothiazines	none	{'e1': {'word': 'absorbent-type anti-diarrhea medicines', 'word_index': [(25, 28)], 'id': 'DDI-DrugBank.d655.s0.e17'}, 'e2': {'word': 'phenothiazines', 'word_index': [(32, 32)], 'id': 'DDI-DrugBank.d655.s0.e20'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	absorbent-type anti-diarrhea medicines	chlorpromazine	none	{'e1': {'word': 'absorbent-type anti-diarrhea medicines', 'word_index': [(25, 28)], 'id': 'DDI-DrugBank.d655.s0.e17'}, 'e2': {'word': 'chlorpromazine', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d655.s0.e21'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	absorbent-type anti-diarrhea medicines	promethazine	none	{'e1': {'word': 'absorbent-type anti-diarrhea medicines', 'word_index': [(25, 28)], 'id': 'DDI-DrugBank.d655.s0.e17'}, 'e2': {'word': 'promethazine', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d655.s0.e22'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	kaolin	pectin	none	{'e1': {'word': 'kaolin', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d655.s0.e18'}, 'e2': {'word': 'pectin', 'word_index': [(31, 31)], 'id': 'DDI-DrugBank.d655.s0.e19'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	kaolin	phenothiazines	none	{'e1': {'word': 'kaolin', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d655.s0.e18'}, 'e2': {'word': 'phenothiazines', 'word_index': [(32, 32)], 'id': 'DDI-DrugBank.d655.s0.e20'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	kaolin	chlorpromazine	none	{'e1': {'word': 'kaolin', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d655.s0.e18'}, 'e2': {'word': 'chlorpromazine', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d655.s0.e21'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	kaolin	promethazine	none	{'e1': {'word': 'kaolin', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d655.s0.e18'}, 'e2': {'word': 'promethazine', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d655.s0.e22'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	pectin	phenothiazines	none	{'e1': {'word': 'pectin', 'word_index': [(31, 31)], 'id': 'DDI-DrugBank.d655.s0.e19'}, 'e2': {'word': 'phenothiazines', 'word_index': [(32, 32)], 'id': 'DDI-DrugBank.d655.s0.e20'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	pectin	chlorpromazine	none	{'e1': {'word': 'pectin', 'word_index': [(31, 31)], 'id': 'DDI-DrugBank.d655.s0.e19'}, 'e2': {'word': 'chlorpromazine', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d655.s0.e21'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	pectin	promethazine	none	{'e1': {'word': 'pectin', 'word_index': [(31, 31)], 'id': 'DDI-DrugBank.d655.s0.e19'}, 'e2': {'word': 'promethazine', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d655.s0.e22'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	phenothiazines	chlorpromazine	none	{'e1': {'word': 'phenothiazines', 'word_index': [(32, 32)], 'id': 'DDI-DrugBank.d655.s0.e20'}, 'e2': {'word': 'chlorpromazine', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d655.s0.e21'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	phenothiazines	promethazine	none	{'e1': {'word': 'phenothiazines', 'word_index': [(32, 32)], 'id': 'DDI-DrugBank.d655.s0.e20'}, 'e2': {'word': 'promethazine', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d655.s0.e22'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	chlorpromazine	promethazine	none	{'e1': {'word': 'chlorpromazine', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d655.s0.e21'}, 'e2': {'word': 'promethazine', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d655.s0.e22'}, 'sentence_id': 'DDI-DrugBank.d655.s0'}	Methscopolamine may interact antidepressants tricyclic type MAO inhibitors e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone quinidine amantadine antihistamines e.g. diphenhydramine anticholinergics potassium chloride supplements antacids absorbent type anti-diarrhea medicines e.g. kaolin pectin phenothiazines e.g. chlorpromazine promethazine
Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.	aspirin	methazolamide	advise	{'e1': {'word': 'aspirin', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d630.s1.e0'}, 'e2': {'word': 'methazolamide', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d630.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d630.s1'}	Caution advised patients receiving high dose aspirin methazolamide concomitantly anorexia tachypnea lethargy coma death reported concomitant use high dose aspirin carbonic anhydrase inhibitors
Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.	aspirin	aspirin	none	{'e1': {'word': 'aspirin', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d630.s1.e0'}, 'e2': {'word': 'aspirin', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d630.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d630.s1'}	Caution advised patients receiving high dose aspirin methazolamide concomitantly anorexia tachypnea lethargy coma death reported concomitant use high dose aspirin carbonic anhydrase inhibitors
Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.	aspirin	carbonic anhydrase inhibitors	none	{'e1': {'word': 'aspirin', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d630.s1.e0'}, 'e2': {'word': 'carbonic anhydrase inhibitors', 'word_index': [(20, 22)], 'id': 'DDI-DrugBank.d630.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d630.s1'}	Caution advised patients receiving high dose aspirin methazolamide concomitantly anorexia tachypnea lethargy coma death reported concomitant use high dose aspirin carbonic anhydrase inhibitors
Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.	methazolamide	aspirin	none	{'e1': {'word': 'methazolamide', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d630.s1.e1'}, 'e2': {'word': 'aspirin', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d630.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d630.s1'}	Caution advised patients receiving high dose aspirin methazolamide concomitantly anorexia tachypnea lethargy coma death reported concomitant use high dose aspirin carbonic anhydrase inhibitors
Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.	methazolamide	carbonic anhydrase inhibitors	none	{'e1': {'word': 'methazolamide', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d630.s1.e1'}, 'e2': {'word': 'carbonic anhydrase inhibitors', 'word_index': [(20, 22)], 'id': 'DDI-DrugBank.d630.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d630.s1'}	Caution advised patients receiving high dose aspirin methazolamide concomitantly anorexia tachypnea lethargy coma death reported concomitant use high dose aspirin carbonic anhydrase inhibitors
Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.	aspirin	carbonic anhydrase inhibitors	effect	{'e1': {'word': 'aspirin', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d630.s1.e2'}, 'e2': {'word': 'carbonic anhydrase inhibitors', 'word_index': [(20, 22)], 'id': 'DDI-DrugBank.d630.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d630.s1'}	Caution advised patients receiving high dose aspirin methazolamide concomitantly anorexia tachypnea lethargy coma death reported concomitant use high dose aspirin carbonic anhydrase inhibitors
Drug Interactions: The use of ZEMURON    (rocuronium bromide) Injection before succinylcholine, for the purpose of attenuating some of the side effects of succinylcholine, has not been studied. 	ZEMURON	rocuronium bromide	none	{'e1': {'word': 'ZEMURON', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d661.s0.e0'}, 'e2': {'word': 'rocuronium bromide', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d661.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d661.s0'}	Drug Interactions use ZEMURON rocuronium bromide Injection succinylcholine purpose attenuating side effects succinylcholine studied
Drug Interactions: The use of ZEMURON    (rocuronium bromide) Injection before succinylcholine, for the purpose of attenuating some of the side effects of succinylcholine, has not been studied. 	ZEMURON	succinylcholine	none	{'e1': {'word': 'ZEMURON', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d661.s0.e0'}, 'e2': {'word': 'succinylcholine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d661.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d661.s0'}	Drug Interactions use ZEMURON rocuronium bromide Injection succinylcholine purpose attenuating side effects succinylcholine studied
Drug Interactions: The use of ZEMURON    (rocuronium bromide) Injection before succinylcholine, for the purpose of attenuating some of the side effects of succinylcholine, has not been studied. 	ZEMURON	succinylcholine	none	{'e1': {'word': 'ZEMURON', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d661.s0.e0'}, 'e2': {'word': 'succinylcholine', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d661.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d661.s0'}	Drug Interactions use ZEMURON rocuronium bromide Injection succinylcholine purpose attenuating side effects succinylcholine studied
Drug Interactions: The use of ZEMURON    (rocuronium bromide) Injection before succinylcholine, for the purpose of attenuating some of the side effects of succinylcholine, has not been studied. 	rocuronium bromide	succinylcholine	none	{'e1': {'word': 'rocuronium bromide', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d661.s0.e1'}, 'e2': {'word': 'succinylcholine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d661.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d661.s0'}	Drug Interactions use ZEMURON rocuronium bromide Injection succinylcholine purpose attenuating side effects succinylcholine studied
Drug Interactions: The use of ZEMURON    (rocuronium bromide) Injection before succinylcholine, for the purpose of attenuating some of the side effects of succinylcholine, has not been studied. 	rocuronium bromide	succinylcholine	none	{'e1': {'word': 'rocuronium bromide', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d661.s0.e1'}, 'e2': {'word': 'succinylcholine', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d661.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d661.s0'}	Drug Interactions use ZEMURON rocuronium bromide Injection succinylcholine purpose attenuating side effects succinylcholine studied
Drug Interactions: The use of ZEMURON    (rocuronium bromide) Injection before succinylcholine, for the purpose of attenuating some of the side effects of succinylcholine, has not been studied. 	succinylcholine	succinylcholine	none	{'e1': {'word': 'succinylcholine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d661.s0.e2'}, 'e2': {'word': 'succinylcholine', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d661.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d661.s0'}	Drug Interactions use ZEMURON rocuronium bromide Injection succinylcholine purpose attenuating side effects succinylcholine studied
If ZEMURON    is administered following administration of succinylcholine, it should not be given until recovery from succinylcholine has been observed. 	ZEMURON	succinylcholine	advise	{'e1': {'word': 'ZEMURON', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d661.s1.e0'}, 'e2': {'word': 'succinylcholine', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d661.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d661.s1'}	ZEMURON administered following administration succinylcholine given recovery succinylcholine observed
If ZEMURON    is administered following administration of succinylcholine, it should not be given until recovery from succinylcholine has been observed. 	ZEMURON	succinylcholine	none	{'e1': {'word': 'ZEMURON', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d661.s1.e0'}, 'e2': {'word': 'succinylcholine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d661.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d661.s1'}	ZEMURON administered following administration succinylcholine given recovery succinylcholine observed
If ZEMURON    is administered following administration of succinylcholine, it should not be given until recovery from succinylcholine has been observed. 	succinylcholine	succinylcholine	none	{'e1': {'word': 'succinylcholine', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d661.s1.e1'}, 'e2': {'word': 'succinylcholine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d661.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d661.s1'}	ZEMURON administered following administration succinylcholine given recovery succinylcholine observed
The median duration of action of ZEMURON    0.6 mg/kg administered after a 1 mg/kg dose of succinylcholine when T 1 returned to 75% of control was 36 minutes (range 14-57, n=12) vs. 	ZEMURON	succinylcholine	none	{'e1': {'word': 'ZEMURON', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d661.s2.e0'}, 'e2': {'word': 'succinylcholine', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d661.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d661.s2'}	median duration action ZEMURON NUMBER mg / kg administered NUMBER mg / kg dose succinylcholine NUMBER returned NUMBER % control NUMBER minutes range NUMBER - NUMBER n = NUMBER vs
There are no controlled studies documenting the use of ZEMURON    before or after other nondepolarizing muscle relaxants. 	ZEMURON	nondepolarizing muscle relaxants	none	{'e1': {'word': 'ZEMURON', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d661.s4.e0'}, 'e2': {'word': 'nondepolarizing muscle relaxants', 'word_index': [(5, 7)], 'id': 'DDI-DrugBank.d661.s4.e1'}, 'sentence_id': 'DDI-DrugBank.d661.s4'}	controlled studies documenting use ZEMURON nondepolarizing muscle relaxants
Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine. 	abacavir	lamivudine	none	{'e1': {'word': 'abacavir', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d610.s0.e0'}, 'e2': {'word': 'lamivudine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d610.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d610.s0'}	Pharmacokinetic properties abacavir altered addition either lamivudine zidovudine combination lamivudine zidovudine
Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine. 	abacavir	zidovudine	none	{'e1': {'word': 'abacavir', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d610.s0.e0'}, 'e2': {'word': 'zidovudine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d610.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d610.s0'}	Pharmacokinetic properties abacavir altered addition either lamivudine zidovudine combination lamivudine zidovudine
Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine. 	abacavir	lamivudine	none	{'e1': {'word': 'abacavir', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d610.s0.e0'}, 'e2': {'word': 'lamivudine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d610.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d610.s0'}	Pharmacokinetic properties abacavir altered addition either lamivudine zidovudine combination lamivudine zidovudine
Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine. 	abacavir	zidovudine	none	{'e1': {'word': 'abacavir', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d610.s0.e0'}, 'e2': {'word': 'zidovudine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d610.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d610.s0'}	Pharmacokinetic properties abacavir altered addition either lamivudine zidovudine combination lamivudine zidovudine
Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine. 	lamivudine	zidovudine	none	{'e1': {'word': 'lamivudine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d610.s0.e1'}, 'e2': {'word': 'zidovudine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d610.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d610.s0'}	Pharmacokinetic properties abacavir altered addition either lamivudine zidovudine combination lamivudine zidovudine
Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine. 	lamivudine	lamivudine	none	{'e1': {'word': 'lamivudine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d610.s0.e1'}, 'e2': {'word': 'lamivudine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d610.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d610.s0'}	Pharmacokinetic properties abacavir altered addition either lamivudine zidovudine combination lamivudine zidovudine
Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine. 	lamivudine	zidovudine	none	{'e1': {'word': 'lamivudine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d610.s0.e1'}, 'e2': {'word': 'zidovudine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d610.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d610.s0'}	Pharmacokinetic properties abacavir altered addition either lamivudine zidovudine combination lamivudine zidovudine
Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine. 	zidovudine	lamivudine	none	{'e1': {'word': 'zidovudine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d610.s0.e2'}, 'e2': {'word': 'lamivudine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d610.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d610.s0'}	Pharmacokinetic properties abacavir altered addition either lamivudine zidovudine combination lamivudine zidovudine
Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine. 	zidovudine	zidovudine	none	{'e1': {'word': 'zidovudine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d610.s0.e2'}, 'e2': {'word': 'zidovudine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d610.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d610.s0'}	Pharmacokinetic properties abacavir altered addition either lamivudine zidovudine combination lamivudine zidovudine
Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine. 	lamivudine	zidovudine	none	{'e1': {'word': 'lamivudine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d610.s0.e3'}, 'e2': {'word': 'zidovudine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d610.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d610.s0'}	Pharmacokinetic properties abacavir altered addition either lamivudine zidovudine combination lamivudine zidovudine
No clinically significant changes to lamivudine or zidovudine pharmacokinetics were observed following concomitant administration of abacavir. 	lamivudine	zidovudine	none	{'e1': {'word': 'lamivudine', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d610.s1.e0'}, 'e2': {'word': 'zidovudine', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d610.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d610.s1'}	clinically significant changes lamivudine zidovudine pharmacokinetics observed following concomitant administration abacavir
No clinically significant changes to lamivudine or zidovudine pharmacokinetics were observed following concomitant administration of abacavir. 	lamivudine	abacavir	none	{'e1': {'word': 'lamivudine', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d610.s1.e0'}, 'e2': {'word': 'abacavir', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d610.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d610.s1'}	clinically significant changes lamivudine zidovudine pharmacokinetics observed following concomitant administration abacavir
No clinically significant changes to lamivudine or zidovudine pharmacokinetics were observed following concomitant administration of abacavir. 	zidovudine	abacavir	none	{'e1': {'word': 'zidovudine', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d610.s1.e1'}, 'e2': {'word': 'abacavir', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d610.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d610.s1'}	clinically significant changes lamivudine zidovudine pharmacokinetics observed following concomitant administration abacavir
Abacavir has no effect on the pharmacokinetic properties of ethanol. 	Abacavir	ethanol	none	{'e1': {'word': 'Abacavir', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d610.s2.e0'}, 'e2': {'word': 'ethanol', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d610.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d610.s2'}	Abacavir effect pharmacokinetic properties ethanol
Ethanol decreases the elimination of abacavir causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir. 	Ethanol	abacavir	mechanism	{'e1': {'word': 'Ethanol', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d610.s3.e0'}, 'e2': {'word': 'abacavir', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d610.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d610.s3'}	Ethanol decreases elimination abacavir causing increase overall exposure addition methadone clinically significant effect pharmacokinetic properties abacavir
Ethanol decreases the elimination of abacavir causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir. 	Ethanol	methadone	none	{'e1': {'word': 'Ethanol', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d610.s3.e0'}, 'e2': {'word': 'methadone', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d610.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d610.s3'}	Ethanol decreases elimination abacavir causing increase overall exposure addition methadone clinically significant effect pharmacokinetic properties abacavir
Ethanol decreases the elimination of abacavir causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir. 	Ethanol	abacavir	none	{'e1': {'word': 'Ethanol', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d610.s3.e0'}, 'e2': {'word': 'abacavir', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d610.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d610.s3'}	Ethanol decreases elimination abacavir causing increase overall exposure addition methadone clinically significant effect pharmacokinetic properties abacavir
Ethanol decreases the elimination of abacavir causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir. 	abacavir	methadone	none	{'e1': {'word': 'abacavir', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d610.s3.e1'}, 'e2': {'word': 'methadone', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d610.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d610.s3'}	Ethanol decreases elimination abacavir causing increase overall exposure addition methadone clinically significant effect pharmacokinetic properties abacavir
Ethanol decreases the elimination of abacavir causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir. 	abacavir	abacavir	none	{'e1': {'word': 'abacavir', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d610.s3.e1'}, 'e2': {'word': 'abacavir', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d610.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d610.s3'}	Ethanol decreases elimination abacavir causing increase overall exposure addition methadone clinically significant effect pharmacokinetic properties abacavir
Ethanol decreases the elimination of abacavir causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir. 	methadone	abacavir	none	{'e1': {'word': 'methadone', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d610.s3.e2'}, 'e2': {'word': 'abacavir', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d610.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d610.s3'}	Ethanol decreases elimination abacavir causing increase overall exposure addition methadone clinically significant effect pharmacokinetic properties abacavir
In a study of 11 HIV-infected patients receiving methadone-maintenance therapy (40 mg and 90 mg daily) with 600 mg of ZIAGEN twice daily (twice the currently recommended dose), oral methadone clearance increased 22% (90% CI 6% to 42%). 	methadone	ZIAGEN	mechanism	{'e1': {'word': 'methadone', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d610.s4.e0'}, 'e2': {'word': 'ZIAGEN', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d610.s4.e1'}, 'sentence_id': 'DDI-DrugBank.d610.s4'}	study NUMBER HIV infected patients receiving methadone maintenance therapy NUMBER mg NUMBER mg daily NUMBER mg ZIAGEN twice daily twice currently recommended dose oral methadone clearance increased NUMBER % NUMBER % CI NUMBER % NUMBER %
In a study of 11 HIV-infected patients receiving methadone-maintenance therapy (40 mg and 90 mg daily) with 600 mg of ZIAGEN twice daily (twice the currently recommended dose), oral methadone clearance increased 22% (90% CI 6% to 42%). 	methadone	methadone	none	{'e1': {'word': 'methadone', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d610.s4.e0'}, 'e2': {'word': 'methadone', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d610.s4.e2'}, 'sentence_id': 'DDI-DrugBank.d610.s4'}	study NUMBER HIV infected patients receiving methadone maintenance therapy NUMBER mg NUMBER mg daily NUMBER mg ZIAGEN twice daily twice currently recommended dose oral methadone clearance increased NUMBER % NUMBER % CI NUMBER % NUMBER %
In a study of 11 HIV-infected patients receiving methadone-maintenance therapy (40 mg and 90 mg daily) with 600 mg of ZIAGEN twice daily (twice the currently recommended dose), oral methadone clearance increased 22% (90% CI 6% to 42%). 	ZIAGEN	methadone	none	{'e1': {'word': 'ZIAGEN', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d610.s4.e1'}, 'e2': {'word': 'methadone', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d610.s4.e2'}, 'sentence_id': 'DDI-DrugBank.d610.s4'}	study NUMBER HIV infected patients receiving methadone maintenance therapy NUMBER mg NUMBER mg daily NUMBER mg ZIAGEN twice daily twice currently recommended dose oral methadone clearance increased NUMBER % NUMBER % CI NUMBER % NUMBER %
Potential for INVEGA    to Affect Other Drugs Paliperidone is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes. 	INVEGA	Paliperidone	none	{'e1': {'word': 'INVEGA', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d670.s0.e0'}, 'e2': {'word': 'Paliperidone', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d670.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d670.s0'}	Potential INVEGA Affect Drugs Paliperidone expected cause clinically important pharmacokinetic interactions drugs metabolized cytochrome P450 isozymes
Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other centrally acting drugs and alcohol. 	paliperidone	INVEGA	none	{'e1': {'word': 'paliperidone', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d670.s6.e0'}, 'e2': {'word': 'INVEGA', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d670.s6.e1'}, 'sentence_id': 'DDI-DrugBank.d670.s6'}	Given primary CNS effects paliperidone INVEGA used caution combination centrally acting drugs alcohol
Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other centrally acting drugs and alcohol. 	paliperidone	centrally acting drugs	advise	{'e1': {'word': 'paliperidone', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d670.s6.e0'}, 'e2': {'word': 'centrally acting drugs', 'word_index': [(9, 11)], 'id': 'DDI-DrugBank.d670.s6.e2'}, 'sentence_id': 'DDI-DrugBank.d670.s6'}	Given primary CNS effects paliperidone INVEGA used caution combination centrally acting drugs alcohol
Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other centrally acting drugs and alcohol. 	paliperidone	alcohol	advise	{'e1': {'word': 'paliperidone', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d670.s6.e0'}, 'e2': {'word': 'alcohol', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d670.s6.e3'}, 'sentence_id': 'DDI-DrugBank.d670.s6'}	Given primary CNS effects paliperidone INVEGA used caution combination centrally acting drugs alcohol
Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other centrally acting drugs and alcohol. 	INVEGA	centrally acting drugs	advise	{'e1': {'word': 'INVEGA', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d670.s6.e1'}, 'e2': {'word': 'centrally acting drugs', 'word_index': [(9, 11)], 'id': 'DDI-DrugBank.d670.s6.e2'}, 'sentence_id': 'DDI-DrugBank.d670.s6'}	Given primary CNS effects paliperidone INVEGA used caution combination centrally acting drugs alcohol
Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other centrally acting drugs and alcohol. 	INVEGA	alcohol	advise	{'e1': {'word': 'INVEGA', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d670.s6.e1'}, 'e2': {'word': 'alcohol', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d670.s6.e3'}, 'sentence_id': 'DDI-DrugBank.d670.s6'}	Given primary CNS effects paliperidone INVEGA used caution combination centrally acting drugs alcohol
Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other centrally acting drugs and alcohol. 	centrally acting drugs	alcohol	none	{'e1': {'word': 'centrally acting drugs', 'word_index': [(9, 11)], 'id': 'DDI-DrugBank.d670.s6.e2'}, 'e2': {'word': 'alcohol', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d670.s6.e3'}, 'sentence_id': 'DDI-DrugBank.d670.s6'}	Given primary CNS effects paliperidone INVEGA used caution combination centrally acting drugs alcohol
Paliperidone may antagonize the effect of levodopa and other dopamine agonists. 	Paliperidone	levodopa	effect	{'e1': {'word': 'Paliperidone', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d670.s7.e0'}, 'e2': {'word': 'levodopa', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d670.s7.e1'}, 'sentence_id': 'DDI-DrugBank.d670.s7'}	Paliperidone may antagonize effect levodopa dopamine agonists
Paliperidone may antagonize the effect of levodopa and other dopamine agonists. 	Paliperidone	dopamine agonists	effect	{'e1': {'word': 'Paliperidone', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d670.s7.e0'}, 'e2': {'word': 'dopamine agonists', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d670.s7.e2'}, 'sentence_id': 'DDI-DrugBank.d670.s7'}	Paliperidone may antagonize effect levodopa dopamine agonists
Paliperidone may antagonize the effect of levodopa and other dopamine agonists. 	levodopa	dopamine agonists	none	{'e1': {'word': 'levodopa', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d670.s7.e1'}, 'e2': {'word': 'dopamine agonists', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d670.s7.e2'}, 'sentence_id': 'DDI-DrugBank.d670.s7'}	Paliperidone may antagonize effect levodopa dopamine agonists
Potential for Other Drugs to Affect INVEGA    Paliperidone is not a substrate of CYP1A2, CYP2A6, CYP2C9, and CYP2C19, so that an interaction with inhibitors or inducers of these isozymes is unlikely. 	INVEGA	Paliperidone	none	{'e1': {'word': 'INVEGA', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d670.s9.e0'}, 'e2': {'word': 'Paliperidone', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d670.s9.e1'}, 'sentence_id': 'DDI-DrugBank.d670.s9'}	Potential Drugs Affect INVEGA Paliperidone substrate CYP1A2 CYP2A6 CYP2C9 CYP2C19 interaction inhibitors inducers isozymes unlikely
Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of zidovudine or rifabutin to warrant dosage adjustment when megestrol acetate is administered with these drugs. 	zidovudine	rifabutin	none	{'e1': {'word': 'zidovudine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d688.s0.e0'}, 'e2': {'word': 'rifabutin', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d688.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d688.s0'}	Pharmacokinetic studies show significant alterations pharmacokinetic parameters zidovudine rifabutin warrant dosage adjustment megestrol acetate administered drugs
Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of zidovudine or rifabutin to warrant dosage adjustment when megestrol acetate is administered with these drugs. 	zidovudine	megestrol acetate	none	{'e1': {'word': 'zidovudine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d688.s0.e0'}, 'e2': {'word': 'megestrol acetate', 'word_index': [(12, 13)], 'id': 'DDI-DrugBank.d688.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d688.s0'}	Pharmacokinetic studies show significant alterations pharmacokinetic parameters zidovudine rifabutin warrant dosage adjustment megestrol acetate administered drugs
Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of zidovudine or rifabutin to warrant dosage adjustment when megestrol acetate is administered with these drugs. 	rifabutin	megestrol acetate	none	{'e1': {'word': 'rifabutin', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d688.s0.e1'}, 'e2': {'word': 'megestrol acetate', 'word_index': [(12, 13)], 'id': 'DDI-DrugBank.d688.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d688.s0'}	Pharmacokinetic studies show significant alterations pharmacokinetic parameters zidovudine rifabutin warrant dosage adjustment megestrol acetate administered drugs
A pharmacokinetic study demonstrated that coadministration of megestrol acetate and indinavir results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of indinavir. 	megestrol acetate	indinavir	mechanism	{'e1': {'word': 'megestrol acetate', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d688.s1.e0'}, 'e2': {'word': 'indinavir', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d688.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d688.s1'}	pharmacokinetic study demonstrated coadministration megestrol acetate indinavir results significant decrease pharmacokinetic parameters ~ NUMBER % Cmax ~ NUMBER % AUC indinavir
A pharmacokinetic study demonstrated that coadministration of megestrol acetate and indinavir results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of indinavir. 	megestrol acetate	indinavir	none	{'e1': {'word': 'megestrol acetate', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d688.s1.e0'}, 'e2': {'word': 'indinavir', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d688.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d688.s1'}	pharmacokinetic study demonstrated coadministration megestrol acetate indinavir results significant decrease pharmacokinetic parameters ~ NUMBER % Cmax ~ NUMBER % AUC indinavir
A pharmacokinetic study demonstrated that coadministration of megestrol acetate and indinavir results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of indinavir. 	indinavir	indinavir	none	{'e1': {'word': 'indinavir', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d688.s1.e1'}, 'e2': {'word': 'indinavir', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d688.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d688.s1'}	pharmacokinetic study demonstrated coadministration megestrol acetate indinavir results significant decrease pharmacokinetic parameters ~ NUMBER % Cmax ~ NUMBER % AUC indinavir
Administration of a higher dose of indinavir should be considered when coadministering with megestrol acetate. 	indinavir	megestrol acetate	advise	{'e1': {'word': 'indinavir', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d688.s2.e0'}, 'e2': {'word': 'megestrol acetate', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d688.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d688.s2'}	Administration higher dose indinavir considered coadministering megestrol acetate
The effects of indinavir, zidovudine or rifabutin on the pharmacokinetics of megestrol acetate were not studied.	indinavir	zidovudine	none	{'e1': {'word': 'indinavir', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d688.s3.e0'}, 'e2': {'word': 'zidovudine', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d688.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d688.s3'}	effects indinavir zidovudine rifabutin pharmacokinetics megestrol acetate studied
The effects of indinavir, zidovudine or rifabutin on the pharmacokinetics of megestrol acetate were not studied.	indinavir	rifabutin	none	{'e1': {'word': 'indinavir', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d688.s3.e0'}, 'e2': {'word': 'rifabutin', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d688.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d688.s3'}	effects indinavir zidovudine rifabutin pharmacokinetics megestrol acetate studied
The effects of indinavir, zidovudine or rifabutin on the pharmacokinetics of megestrol acetate were not studied.	indinavir	megestrol acetate	none	{'e1': {'word': 'indinavir', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d688.s3.e0'}, 'e2': {'word': 'megestrol acetate', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d688.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d688.s3'}	effects indinavir zidovudine rifabutin pharmacokinetics megestrol acetate studied
The effects of indinavir, zidovudine or rifabutin on the pharmacokinetics of megestrol acetate were not studied.	zidovudine	rifabutin	none	{'e1': {'word': 'zidovudine', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d688.s3.e1'}, 'e2': {'word': 'rifabutin', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d688.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d688.s3'}	effects indinavir zidovudine rifabutin pharmacokinetics megestrol acetate studied
The effects of indinavir, zidovudine or rifabutin on the pharmacokinetics of megestrol acetate were not studied.	zidovudine	megestrol acetate	none	{'e1': {'word': 'zidovudine', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d688.s3.e1'}, 'e2': {'word': 'megestrol acetate', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d688.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d688.s3'}	effects indinavir zidovudine rifabutin pharmacokinetics megestrol acetate studied
The effects of indinavir, zidovudine or rifabutin on the pharmacokinetics of megestrol acetate were not studied.	rifabutin	megestrol acetate	none	{'e1': {'word': 'rifabutin', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d688.s3.e2'}, 'e2': {'word': 'megestrol acetate', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d688.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d688.s3'}	effects indinavir zidovudine rifabutin pharmacokinetics megestrol acetate studied
The in vitro binding of warfarin to human plasma proteins is unaffected by tolmetin, and tolmetin does not alter the prothrombin time of normal volunteers. 	warfarin	tolmetin	none	{'e1': {'word': 'warfarin', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d608.s0.e0'}, 'e2': {'word': 'tolmetin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d608.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d608.s0'}	vitro binding warfarin human plasma proteins unaffected tolmetin tolmetin alter prothrombin time normal volunteers
The in vitro binding of warfarin to human plasma proteins is unaffected by tolmetin, and tolmetin does not alter the prothrombin time of normal volunteers. 	warfarin	tolmetin	none	{'e1': {'word': 'warfarin', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d608.s0.e0'}, 'e2': {'word': 'tolmetin', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d608.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d608.s0'}	vitro binding warfarin human plasma proteins unaffected tolmetin tolmetin alter prothrombin time normal volunteers
The in vitro binding of warfarin to human plasma proteins is unaffected by tolmetin, and tolmetin does not alter the prothrombin time of normal volunteers. 	tolmetin	tolmetin	none	{'e1': {'word': 'tolmetin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d608.s0.e1'}, 'e2': {'word': 'tolmetin', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d608.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d608.s0'}	vitro binding warfarin human plasma proteins unaffected tolmetin tolmetin alter prothrombin time normal volunteers
However, increased prothrombin time and bleeding have been reported in patients on concomitant TOLECTIN and warfarin therapy. 	TOLECTIN	warfarin	effect	{'e1': {'word': 'TOLECTIN', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d608.s1.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d608.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d608.s1'}	However increased prothrombin time bleeding reported patients concomitant TOLECTIN warfarin therapy
Therefore, caution should be exercised when administering TOLECTIN to patients on anticoagulants. 	TOLECTIN	anticoagulants	advise	{'e1': {'word': 'TOLECTIN', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d608.s2.e0'}, 'e2': {'word': 'anticoagulants', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d608.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d608.s2'}	Therefore caution exercised administering TOLECTIN patients anticoagulants
In adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents. 	sulfonylureas	insulin	none	{'e1': {'word': 'sulfonylureas', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d608.s3.e0'}, 'e2': {'word': 'insulin', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d608.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d608.s3'}	adult diabetic patients treatment either sulfonylureas insulin change clinical effects either TOLECTIN hypoglycemic agents
In adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents. 	sulfonylureas	TOLECTIN	none	{'e1': {'word': 'sulfonylureas', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d608.s3.e0'}, 'e2': {'word': 'TOLECTIN', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d608.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d608.s3'}	adult diabetic patients treatment either sulfonylureas insulin change clinical effects either TOLECTIN hypoglycemic agents
In adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents. 	sulfonylureas	hypoglycemic agents	none	{'e1': {'word': 'sulfonylureas', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d608.s3.e0'}, 'e2': {'word': 'hypoglycemic agents', 'word_index': [(12, 13)], 'id': 'DDI-DrugBank.d608.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d608.s3'}	adult diabetic patients treatment either sulfonylureas insulin change clinical effects either TOLECTIN hypoglycemic agents
In adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents. 	insulin	TOLECTIN	none	{'e1': {'word': 'insulin', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d608.s3.e1'}, 'e2': {'word': 'TOLECTIN', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d608.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d608.s3'}	adult diabetic patients treatment either sulfonylureas insulin change clinical effects either TOLECTIN hypoglycemic agents
In adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents. 	insulin	hypoglycemic agents	none	{'e1': {'word': 'insulin', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d608.s3.e1'}, 'e2': {'word': 'hypoglycemic agents', 'word_index': [(12, 13)], 'id': 'DDI-DrugBank.d608.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d608.s3'}	adult diabetic patients treatment either sulfonylureas insulin change clinical effects either TOLECTIN hypoglycemic agents
In adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents. 	TOLECTIN	hypoglycemic agents	none	{'e1': {'word': 'TOLECTIN', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d608.s3.e2'}, 'e2': {'word': 'hypoglycemic agents', 'word_index': [(12, 13)], 'id': 'DDI-DrugBank.d608.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d608.s3'}	adult diabetic patients treatment either sulfonylureas insulin change clinical effects either TOLECTIN hypoglycemic agents
Caution should be used if TOLECTIN is administered concomitantly with methotrexate. 	TOLECTIN	methotrexate	advise	{'e1': {'word': 'TOLECTIN', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d608.s4.e0'}, 'e2': {'word': 'methotrexate', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d608.s4.e1'}, 'sentence_id': 'DDI-DrugBank.d608.s4'}	Caution used TOLECTIN administered concomitantly methotrexate
TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate. 	TOLECTIN	nonsteroidal anti-inflammatory drugs	none	{'e1': {'word': 'TOLECTIN', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d608.s5.e0'}, 'e2': {'word': 'nonsteroidal anti-inflammatory drugs', 'word_index': [(1, 3)], 'id': 'DDI-DrugBank.d608.s5.e1'}, 'sentence_id': 'DDI-DrugBank.d608.s5'}	TOLECTIN nonsteroidal anti-inflammatory drugs reported reduce tubular secretion methotrexate animal model possibly enhancing toxicity methotrexate
TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate. 	TOLECTIN	methotrexate	mechanism	{'e1': {'word': 'TOLECTIN', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d608.s5.e0'}, 'e2': {'word': 'methotrexate', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d608.s5.e2'}, 'sentence_id': 'DDI-DrugBank.d608.s5'}	TOLECTIN nonsteroidal anti-inflammatory drugs reported reduce tubular secretion methotrexate animal model possibly enhancing toxicity methotrexate
TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate. 	TOLECTIN	methotrexate	none	{'e1': {'word': 'TOLECTIN', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d608.s5.e0'}, 'e2': {'word': 'methotrexate', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d608.s5.e3'}, 'sentence_id': 'DDI-DrugBank.d608.s5'}	TOLECTIN nonsteroidal anti-inflammatory drugs reported reduce tubular secretion methotrexate animal model possibly enhancing toxicity methotrexate
TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate. 	nonsteroidal anti-inflammatory drugs	methotrexate	mechanism	{'e1': {'word': 'nonsteroidal anti-inflammatory drugs', 'word_index': [(1, 3)], 'id': 'DDI-DrugBank.d608.s5.e1'}, 'e2': {'word': 'methotrexate', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d608.s5.e2'}, 'sentence_id': 'DDI-DrugBank.d608.s5'}	TOLECTIN nonsteroidal anti-inflammatory drugs reported reduce tubular secretion methotrexate animal model possibly enhancing toxicity methotrexate
TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate. 	nonsteroidal anti-inflammatory drugs	methotrexate	none	{'e1': {'word': 'nonsteroidal anti-inflammatory drugs', 'word_index': [(1, 3)], 'id': 'DDI-DrugBank.d608.s5.e1'}, 'e2': {'word': 'methotrexate', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d608.s5.e3'}, 'sentence_id': 'DDI-DrugBank.d608.s5'}	TOLECTIN nonsteroidal anti-inflammatory drugs reported reduce tubular secretion methotrexate animal model possibly enhancing toxicity methotrexate
TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate. 	methotrexate	methotrexate	none	{'e1': {'word': 'methotrexate', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d608.s5.e2'}, 'e2': {'word': 'methotrexate', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d608.s5.e3'}, 'sentence_id': 'DDI-DrugBank.d608.s5'}	TOLECTIN nonsteroidal anti-inflammatory drugs reported reduce tubular secretion methotrexate animal model possibly enhancing toxicity methotrexate
When administered concurrently, testolactone may increase the effects of oral anticoagulants; 	testolactone	anticoagulants	effect	{'e1': {'word': 'testolactone', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d658.s0.e0'}, 'e2': {'word': 'anticoagulants', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d658.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d658.s0'}	administered concurrently testolactone may increase effects oral anticoagulants
Hypokalemia may develop during concomitant use of steroids or ACTH. 	steroids	ACTH	none	{'e1': {'word': 'steroids', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d736.s1.e0'}, 'e2': {'word': 'ACTH', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d736.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d736.s1'}	Hypokalemia may develop concomitant use steroids ACTH
Thiazides may decrease arterial responsiveness to norepinephrine. 	Thiazides	norepinephrine	effect	{'e1': {'word': 'Thiazides', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d736.s3.e0'}, 'e2': {'word': 'norepinephrine', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d736.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d736.s3'}	Thiazides may decrease arterial responsiveness norepinephrine
Thiazide drugs may increase the responsiveness of tubocurarine. 	Thiazide drugs	tubocurarine	effect	{'e1': {'word': 'Thiazide drugs', 'word_index': [(0, 1)], 'id': 'DDI-DrugBank.d736.s5.e0'}, 'e2': {'word': 'tubocurarine', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d736.s5.e1'}, 'sentence_id': 'DDI-DrugBank.d736.s5'}	Thiazide drugs may increase responsiveness tubocurarine
Lithium renal clearance is reduced by thiazides, increasing the risk of lithium toxicity. 	Lithium	thiazides	mechanism	{'e1': {'word': 'Lithium', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d736.s6.e0'}, 'e2': {'word': 'thiazides', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d736.s6.e1'}, 'sentence_id': 'DDI-DrugBank.d736.s6'}	Lithium renal clearance reduced thiazides increasing risk lithium toxicity
Lithium renal clearance is reduced by thiazides, increasing the risk of lithium toxicity. 	Lithium	lithium	none	{'e1': {'word': 'Lithium', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d736.s6.e0'}, 'e2': {'word': 'lithium', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d736.s6.e2'}, 'sentence_id': 'DDI-DrugBank.d736.s6'}	Lithium renal clearance reduced thiazides increasing risk lithium toxicity
Lithium renal clearance is reduced by thiazides, increasing the risk of lithium toxicity. 	thiazides	lithium	none	{'e1': {'word': 'thiazides', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d736.s6.e1'}, 'e2': {'word': 'lithium', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d736.s6.e2'}, 'sentence_id': 'DDI-DrugBank.d736.s6'}	Lithium renal clearance reduced thiazides increasing risk lithium toxicity
Thiazides may add to or potentiate the action of other antihypertensive drugs. 	Thiazides	antihypertensive drugs	effect	{'e1': {'word': 'Thiazides', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d736.s7.e0'}, 'e2': {'word': 'antihypertensive drugs', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d736.s7.e1'}, 'sentence_id': 'DDI-DrugBank.d736.s7'}	Thiazides may add potentiate action antihypertensive drugs
Potentiation occurs with ganglionic or peripheral adrenergic blocking drugs.	ganglionic adrenergic blocking drugs	peripheral adrenergic blocking drugs	none	{'e1': {'word': 'ganglionic adrenergic blocking drugs', 'word_index': [(2, 2), (7, 9)], 'id': 'DDI-DrugBank.d736.s8.e0'}, 'e2': {'word': 'peripheral adrenergic blocking drugs', 'word_index': [(3, 6)], 'id': 'DDI-DrugBank.d736.s8.e1'}, 'sentence_id': 'DDI-DrugBank.d736.s8'}	Potentiation occurs ganglionic peripheral adrenergic blocking drugs adrenergic blocking drugs
Due to its effects on gastric emptying, SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors). 	SYMLIN	anticholinergic agents	advise	{'e1': {'word': 'SYMLIN', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d632.s0.e0'}, 'e2': {'word': 'anticholinergic agents', 'word_index': [(14, 15)], 'id': 'DDI-DrugBank.d632.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d632.s0'}	Due effects gastric emptying SYMLIN therapy considered patients taking drugs alter gastrointestinal motility e.g. anticholinergic agents atropine agents slow intestinal absorption nutrients e.g. alpha glucosidase inhibitors
Due to its effects on gastric emptying, SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors). 	SYMLIN	atropine	advise	{'e1': {'word': 'SYMLIN', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d632.s0.e0'}, 'e2': {'word': 'atropine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d632.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d632.s0'}	Due effects gastric emptying SYMLIN therapy considered patients taking drugs alter gastrointestinal motility e.g. anticholinergic agents atropine agents slow intestinal absorption nutrients e.g. alpha glucosidase inhibitors
Due to its effects on gastric emptying, SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors). 	SYMLIN	alpha glucosidase inhibitors	advise	{'e1': {'word': 'SYMLIN', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d632.s0.e0'}, 'e2': {'word': 'alpha glucosidase inhibitors', 'word_index': [(23, 25)], 'id': 'DDI-DrugBank.d632.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d632.s0'}	Due effects gastric emptying SYMLIN therapy considered patients taking drugs alter gastrointestinal motility e.g. anticholinergic agents atropine agents slow intestinal absorption nutrients e.g. alpha glucosidase inhibitors
Due to its effects on gastric emptying, SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors). 	anticholinergic agents	atropine	none	{'e1': {'word': 'anticholinergic agents', 'word_index': [(14, 15)], 'id': 'DDI-DrugBank.d632.s0.e1'}, 'e2': {'word': 'atropine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d632.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d632.s0'}	Due effects gastric emptying SYMLIN therapy considered patients taking drugs alter gastrointestinal motility e.g. anticholinergic agents atropine agents slow intestinal absorption nutrients e.g. alpha glucosidase inhibitors
Due to its effects on gastric emptying, SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors). 	anticholinergic agents	alpha glucosidase inhibitors	none	{'e1': {'word': 'anticholinergic agents', 'word_index': [(14, 15)], 'id': 'DDI-DrugBank.d632.s0.e1'}, 'e2': {'word': 'alpha glucosidase inhibitors', 'word_index': [(23, 25)], 'id': 'DDI-DrugBank.d632.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d632.s0'}	Due effects gastric emptying SYMLIN therapy considered patients taking drugs alter gastrointestinal motility e.g. anticholinergic agents atropine agents slow intestinal absorption nutrients e.g. alpha glucosidase inhibitors
Due to its effects on gastric emptying, SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors). 	atropine	alpha glucosidase inhibitors	none	{'e1': {'word': 'atropine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d632.s0.e2'}, 'e2': {'word': 'alpha glucosidase inhibitors', 'word_index': [(23, 25)], 'id': 'DDI-DrugBank.d632.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d632.s0'}	Due effects gastric emptying SYMLIN therapy considered patients taking drugs alter gastrointestinal motility e.g. anticholinergic agents atropine agents slow intestinal absorption nutrients e.g. alpha glucosidase inhibitors
When the rapid onset of a concomitant orally administered agent is a critical determinant of effectiveness (such as analgesics), the agent should be administered at least 1 hour prior to or 2 hours after SYMLIN injection. 	analgesics	SYMLIN	advise	{'e1': {'word': 'analgesics', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d632.s3.e0'}, 'e2': {'word': 'SYMLIN', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d632.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d632.s3'}	rapid onset concomitant orally administered agent critical determinant effectiveness analgesics agent administered least NUMBER hour prior NUMBER hours SYMLIN injection
In clinical trials, the concomitant use of sulfonylureas or biguanides did not alter the adverse event profile of SYMLIN. 	sulfonylureas	biguanides	none	{'e1': {'word': 'sulfonylureas', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d632.s4.e0'}, 'e2': {'word': 'biguanides', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d632.s4.e1'}, 'sentence_id': 'DDI-DrugBank.d632.s4'}	clinical trials concomitant use sulfonylureas biguanides alter adverse event profile SYMLIN
In clinical trials, the concomitant use of sulfonylureas or biguanides did not alter the adverse event profile of SYMLIN. 	sulfonylureas	SYMLIN	none	{'e1': {'word': 'sulfonylureas', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d632.s4.e0'}, 'e2': {'word': 'SYMLIN', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d632.s4.e2'}, 'sentence_id': 'DDI-DrugBank.d632.s4'}	clinical trials concomitant use sulfonylureas biguanides alter adverse event profile SYMLIN
In clinical trials, the concomitant use of sulfonylureas or biguanides did not alter the adverse event profile of SYMLIN. 	biguanides	SYMLIN	none	{'e1': {'word': 'biguanides', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d632.s4.e1'}, 'e2': {'word': 'SYMLIN', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d632.s4.e2'}, 'sentence_id': 'DDI-DrugBank.d632.s4'}	clinical trials concomitant use sulfonylureas biguanides alter adverse event profile SYMLIN
No formal interaction studies have been performed to assess the effect of SYMLIN on the kinetics of oral antidiabetic agents. 	SYMLIN	antidiabetic agents	none	{'e1': {'word': 'SYMLIN', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d632.s5.e0'}, 'e2': {'word': 'antidiabetic agents', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d632.s5.e1'}, 'sentence_id': 'DDI-DrugBank.d632.s5'}	formal interaction studies performed assess effect SYMLIN kinetics oral antidiabetic agents
Mixing SYMLIN and Insulin The pharmacokinetic parameters of SYMLIN were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant human insulin immediately prior to injection. 	SYMLIN	Insulin	none	{'e1': {'word': 'SYMLIN', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d632.s6.e0'}, 'e2': {'word': 'Insulin', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d632.s6.e1'}, 'sentence_id': 'DDI-DrugBank.d632.s6'}	Mixing SYMLIN Insulin pharmacokinetic parameters SYMLIN altered mixed regular NPH NUMBER NUMBER premixed formulations recombinant human insulin immediately prior injection
Mixing SYMLIN and Insulin The pharmacokinetic parameters of SYMLIN were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant human insulin immediately prior to injection. 	SYMLIN	SYMLIN	none	{'e1': {'word': 'SYMLIN', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d632.s6.e0'}, 'e2': {'word': 'SYMLIN', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d632.s6.e2'}, 'sentence_id': 'DDI-DrugBank.d632.s6'}	Mixing SYMLIN Insulin pharmacokinetic parameters SYMLIN altered mixed regular NPH NUMBER NUMBER premixed formulations recombinant human insulin immediately prior injection
Mixing SYMLIN and Insulin The pharmacokinetic parameters of SYMLIN were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant human insulin immediately prior to injection. 	SYMLIN	human insulin	none	{'e1': {'word': 'SYMLIN', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d632.s6.e0'}, 'e2': {'word': 'human insulin', 'word_index': [(15, 16)], 'id': 'DDI-DrugBank.d632.s6.e3'}, 'sentence_id': 'DDI-DrugBank.d632.s6'}	Mixing SYMLIN Insulin pharmacokinetic parameters SYMLIN altered mixed regular NPH NUMBER NUMBER premixed formulations recombinant human insulin immediately prior injection
Mixing SYMLIN and Insulin The pharmacokinetic parameters of SYMLIN were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant human insulin immediately prior to injection. 	Insulin	SYMLIN	none	{'e1': {'word': 'Insulin', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d632.s6.e1'}, 'e2': {'word': 'SYMLIN', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d632.s6.e2'}, 'sentence_id': 'DDI-DrugBank.d632.s6'}	Mixing SYMLIN Insulin pharmacokinetic parameters SYMLIN altered mixed regular NPH NUMBER NUMBER premixed formulations recombinant human insulin immediately prior injection
Mixing SYMLIN and Insulin The pharmacokinetic parameters of SYMLIN were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant human insulin immediately prior to injection. 	Insulin	human insulin	none	{'e1': {'word': 'Insulin', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d632.s6.e1'}, 'e2': {'word': 'human insulin', 'word_index': [(15, 16)], 'id': 'DDI-DrugBank.d632.s6.e3'}, 'sentence_id': 'DDI-DrugBank.d632.s6'}	Mixing SYMLIN Insulin pharmacokinetic parameters SYMLIN altered mixed regular NPH NUMBER NUMBER premixed formulations recombinant human insulin immediately prior injection
Mixing SYMLIN and Insulin The pharmacokinetic parameters of SYMLIN were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant human insulin immediately prior to injection. 	SYMLIN	human insulin	mechanism	{'e1': {'word': 'SYMLIN', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d632.s6.e2'}, 'e2': {'word': 'human insulin', 'word_index': [(15, 16)], 'id': 'DDI-DrugBank.d632.s6.e3'}, 'sentence_id': 'DDI-DrugBank.d632.s6'}	Mixing SYMLIN Insulin pharmacokinetic parameters SYMLIN altered mixed regular NPH NUMBER NUMBER premixed formulations recombinant human insulin immediately prior injection
Thus, SYMLIN and insulin should not be mixed and must be administered separately.	SYMLIN	insulin	none	{'e1': {'word': 'SYMLIN', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d632.s7.e0'}, 'e2': {'word': 'insulin', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d632.s7.e1'}, 'sentence_id': 'DDI-DrugBank.d632.s7'}	Thus SYMLIN insulin mixed must administered separately
Since trimetrexate is metabolized by a P450 enzyme system, drugs that induce or inhibit this drug metabolizing enzyme system may elicit important drug-drug interactions that may alter trimetrexate plasma concentrations. 	trimetrexate	trimetrexate	none	{'e1': {'word': 'trimetrexate', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d766.s0.e0'}, 'e2': {'word': 'trimetrexate', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d766.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d766.s0'}	Since trimetrexate metabolized P450 enzyme system drugs induce inhibit drug metabolizing enzyme system may elicit important drug drug interactions may alter trimetrexate plasma concentrations
Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. 	trimetrexate	erythromycin	effect	{'e1': {'word': 'trimetrexate', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d766.s1.e0'}, 'e2': {'word': 'erythromycin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d766.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d766.s1'}	Agents might coadministered trimetrexate AIDS patients indications could elicit activity include erythromycin rifampin rifabutin ketoconazole fluconazole
Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. 	trimetrexate	rifampin	effect	{'e1': {'word': 'trimetrexate', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d766.s1.e0'}, 'e2': {'word': 'rifampin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d766.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d766.s1'}	Agents might coadministered trimetrexate AIDS patients indications could elicit activity include erythromycin rifampin rifabutin ketoconazole fluconazole
Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. 	trimetrexate	rifabutin	effect	{'e1': {'word': 'trimetrexate', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d766.s1.e0'}, 'e2': {'word': 'rifabutin', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d766.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d766.s1'}	Agents might coadministered trimetrexate AIDS patients indications could elicit activity include erythromycin rifampin rifabutin ketoconazole fluconazole
Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. 	trimetrexate	ketoconazole	effect	{'e1': {'word': 'trimetrexate', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d766.s1.e0'}, 'e2': {'word': 'ketoconazole', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d766.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d766.s1'}	Agents might coadministered trimetrexate AIDS patients indications could elicit activity include erythromycin rifampin rifabutin ketoconazole fluconazole
Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. 	trimetrexate	fluconazole	effect	{'e1': {'word': 'trimetrexate', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d766.s1.e0'}, 'e2': {'word': 'fluconazole', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d766.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d766.s1'}	Agents might coadministered trimetrexate AIDS patients indications could elicit activity include erythromycin rifampin rifabutin ketoconazole fluconazole
Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. 	erythromycin	rifampin	none	{'e1': {'word': 'erythromycin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d766.s1.e1'}, 'e2': {'word': 'rifampin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d766.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d766.s1'}	Agents might coadministered trimetrexate AIDS patients indications could elicit activity include erythromycin rifampin rifabutin ketoconazole fluconazole
Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. 	erythromycin	rifabutin	none	{'e1': {'word': 'erythromycin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d766.s1.e1'}, 'e2': {'word': 'rifabutin', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d766.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d766.s1'}	Agents might coadministered trimetrexate AIDS patients indications could elicit activity include erythromycin rifampin rifabutin ketoconazole fluconazole
Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. 	erythromycin	ketoconazole	none	{'e1': {'word': 'erythromycin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d766.s1.e1'}, 'e2': {'word': 'ketoconazole', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d766.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d766.s1'}	Agents might coadministered trimetrexate AIDS patients indications could elicit activity include erythromycin rifampin rifabutin ketoconazole fluconazole
Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. 	erythromycin	fluconazole	none	{'e1': {'word': 'erythromycin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d766.s1.e1'}, 'e2': {'word': 'fluconazole', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d766.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d766.s1'}	Agents might coadministered trimetrexate AIDS patients indications could elicit activity include erythromycin rifampin rifabutin ketoconazole fluconazole
Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. 	rifampin	rifabutin	none	{'e1': {'word': 'rifampin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d766.s1.e2'}, 'e2': {'word': 'rifabutin', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d766.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d766.s1'}	Agents might coadministered trimetrexate AIDS patients indications could elicit activity include erythromycin rifampin rifabutin ketoconazole fluconazole
Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. 	rifampin	ketoconazole	none	{'e1': {'word': 'rifampin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d766.s1.e2'}, 'e2': {'word': 'ketoconazole', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d766.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d766.s1'}	Agents might coadministered trimetrexate AIDS patients indications could elicit activity include erythromycin rifampin rifabutin ketoconazole fluconazole
Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. 	rifampin	fluconazole	none	{'e1': {'word': 'rifampin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d766.s1.e2'}, 'e2': {'word': 'fluconazole', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d766.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d766.s1'}	Agents might coadministered trimetrexate AIDS patients indications could elicit activity include erythromycin rifampin rifabutin ketoconazole fluconazole
Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. 	rifabutin	ketoconazole	none	{'e1': {'word': 'rifabutin', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d766.s1.e3'}, 'e2': {'word': 'ketoconazole', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d766.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d766.s1'}	Agents might coadministered trimetrexate AIDS patients indications could elicit activity include erythromycin rifampin rifabutin ketoconazole fluconazole
Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. 	rifabutin	fluconazole	none	{'e1': {'word': 'rifabutin', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d766.s1.e3'}, 'e2': {'word': 'fluconazole', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d766.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d766.s1'}	Agents might coadministered trimetrexate AIDS patients indications could elicit activity include erythromycin rifampin rifabutin ketoconazole fluconazole
Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole. 	ketoconazole	fluconazole	none	{'e1': {'word': 'ketoconazole', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d766.s1.e4'}, 'e2': {'word': 'fluconazole', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d766.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d766.s1'}	Agents might coadministered trimetrexate AIDS patients indications could elicit activity include erythromycin rifampin rifabutin ketoconazole fluconazole
In vitro perfusion of isolated rat liver has shown that cimetidine caused a significant reduction in trimetrexate metabolism and that acetaminophen altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites. 	cimetidine	trimetrexate	mechanism	{'e1': {'word': 'cimetidine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d766.s2.e0'}, 'e2': {'word': 'trimetrexate', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d766.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d766.s2'}	vitro perfusion isolated rat liver shown cimetidine caused significant reduction trimetrexate metabolism acetaminophen altered relative concentration trimetrexate metabolites possibly competing sulfate metabolites
In vitro perfusion of isolated rat liver has shown that cimetidine caused a significant reduction in trimetrexate metabolism and that acetaminophen altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites. 	cimetidine	acetaminophen	none	{'e1': {'word': 'cimetidine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d766.s2.e0'}, 'e2': {'word': 'acetaminophen', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d766.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d766.s2'}	vitro perfusion isolated rat liver shown cimetidine caused significant reduction trimetrexate metabolism acetaminophen altered relative concentration trimetrexate metabolites possibly competing sulfate metabolites
In vitro perfusion of isolated rat liver has shown that cimetidine caused a significant reduction in trimetrexate metabolism and that acetaminophen altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites. 	trimetrexate	acetaminophen	none	{'e1': {'word': 'trimetrexate', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d766.s2.e1'}, 'e2': {'word': 'acetaminophen', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d766.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d766.s2'}	vitro perfusion isolated rat liver shown cimetidine caused significant reduction trimetrexate metabolism acetaminophen altered relative concentration trimetrexate metabolites possibly competing sulfate metabolites
Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism. 	imidazole drugs	clotrimazole	none	{'e1': {'word': 'imidazole drugs', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d766.s3.e0'}, 'e2': {'word': 'clotrimazole', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d766.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d766.s3'}	Based vitro rat liver model nitrogen substituted imidazole drugs clotrimazole ketoconazole miconazole potent non-competitive inhibitors trimetrexate metabolism
Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism. 	imidazole drugs	ketoconazole	none	{'e1': {'word': 'imidazole drugs', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d766.s3.e0'}, 'e2': {'word': 'ketoconazole', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d766.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d766.s3'}	Based vitro rat liver model nitrogen substituted imidazole drugs clotrimazole ketoconazole miconazole potent non-competitive inhibitors trimetrexate metabolism
Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism. 	imidazole drugs	miconazole	none	{'e1': {'word': 'imidazole drugs', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d766.s3.e0'}, 'e2': {'word': 'miconazole', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d766.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d766.s3'}	Based vitro rat liver model nitrogen substituted imidazole drugs clotrimazole ketoconazole miconazole potent non-competitive inhibitors trimetrexate metabolism
Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism. 	imidazole drugs	trimetrexate	mechanism	{'e1': {'word': 'imidazole drugs', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d766.s3.e0'}, 'e2': {'word': 'trimetrexate', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d766.s3.e4'}, 'sentence_id': 'DDI-DrugBank.d766.s3'}	Based vitro rat liver model nitrogen substituted imidazole drugs clotrimazole ketoconazole miconazole potent non-competitive inhibitors trimetrexate metabolism
Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism. 	clotrimazole	ketoconazole	none	{'e1': {'word': 'clotrimazole', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d766.s3.e1'}, 'e2': {'word': 'ketoconazole', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d766.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d766.s3'}	Based vitro rat liver model nitrogen substituted imidazole drugs clotrimazole ketoconazole miconazole potent non-competitive inhibitors trimetrexate metabolism
Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism. 	clotrimazole	miconazole	none	{'e1': {'word': 'clotrimazole', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d766.s3.e1'}, 'e2': {'word': 'miconazole', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d766.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d766.s3'}	Based vitro rat liver model nitrogen substituted imidazole drugs clotrimazole ketoconazole miconazole potent non-competitive inhibitors trimetrexate metabolism
Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism. 	clotrimazole	trimetrexate	mechanism	{'e1': {'word': 'clotrimazole', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d766.s3.e1'}, 'e2': {'word': 'trimetrexate', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d766.s3.e4'}, 'sentence_id': 'DDI-DrugBank.d766.s3'}	Based vitro rat liver model nitrogen substituted imidazole drugs clotrimazole ketoconazole miconazole potent non-competitive inhibitors trimetrexate metabolism
Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism. 	ketoconazole	miconazole	none	{'e1': {'word': 'ketoconazole', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d766.s3.e2'}, 'e2': {'word': 'miconazole', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d766.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d766.s3'}	Based vitro rat liver model nitrogen substituted imidazole drugs clotrimazole ketoconazole miconazole potent non-competitive inhibitors trimetrexate metabolism
Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism. 	ketoconazole	trimetrexate	mechanism	{'e1': {'word': 'ketoconazole', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d766.s3.e2'}, 'e2': {'word': 'trimetrexate', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d766.s3.e4'}, 'sentence_id': 'DDI-DrugBank.d766.s3'}	Based vitro rat liver model nitrogen substituted imidazole drugs clotrimazole ketoconazole miconazole potent non-competitive inhibitors trimetrexate metabolism
Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism. 	miconazole	trimetrexate	mechanism	{'e1': {'word': 'miconazole', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d766.s3.e3'}, 'e2': {'word': 'trimetrexate', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d766.s3.e4'}, 'sentence_id': 'DDI-DrugBank.d766.s3'}	Based vitro rat liver model nitrogen substituted imidazole drugs clotrimazole ketoconazole miconazole potent non-competitive inhibitors trimetrexate metabolism
Acromegalic patients with diabetes mellitus being treated with insulin and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with SOMAVERT. 	insulin	hypoglycemic	none	{'e1': {'word': 'insulin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d744.s0.e0'}, 'e2': {'word': 'hypoglycemic', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d744.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d744.s0'}	Acromegalic patients diabetes mellitus treated insulin oral hypoglycemic agents may require dose reductions therapeutic agents initiation therapy SOMAVERT
Acromegalic patients with diabetes mellitus being treated with insulin and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with SOMAVERT. 	insulin	SOMAVERT	advise	{'e1': {'word': 'insulin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d744.s0.e0'}, 'e2': {'word': 'SOMAVERT', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d744.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d744.s0'}	Acromegalic patients diabetes mellitus treated insulin oral hypoglycemic agents may require dose reductions therapeutic agents initiation therapy SOMAVERT
Acromegalic patients with diabetes mellitus being treated with insulin and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with SOMAVERT. 	hypoglycemic	SOMAVERT	advise	{'e1': {'word': 'hypoglycemic', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d744.s0.e1'}, 'e2': {'word': 'SOMAVERT', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d744.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d744.s0'}	Acromegalic patients diabetes mellitus treated insulin oral hypoglycemic agents may require dose reductions therapeutic agents initiation therapy SOMAVERT
In clinical studies, patients on opioids often needed higher serum pegvisomant concentrations to achieve appropriate IGF-I suppression compared with patients not receiving opioids. 	opioids	pegvisomant	mechanism	{'e1': {'word': 'opioids', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d744.s1.e0'}, 'e2': {'word': 'pegvisomant', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d744.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d744.s1'}	clinical studies patients opioids often needed higher serum pegvisomant concentrations achieve appropriate IGF suppression compared patients receiving opioids
In clinical studies, patients on opioids often needed higher serum pegvisomant concentrations to achieve appropriate IGF-I suppression compared with patients not receiving opioids. 	opioids	opioids	none	{'e1': {'word': 'opioids', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d744.s1.e0'}, 'e2': {'word': 'opioids', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d744.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d744.s1'}	clinical studies patients opioids often needed higher serum pegvisomant concentrations achieve appropriate IGF suppression compared patients receiving opioids
In clinical studies, patients on opioids often needed higher serum pegvisomant concentrations to achieve appropriate IGF-I suppression compared with patients not receiving opioids. 	pegvisomant	opioids	none	{'e1': {'word': 'pegvisomant', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d744.s1.e1'}, 'e2': {'word': 'opioids', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d744.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d744.s1'}	clinical studies patients opioids often needed higher serum pegvisomant concentrations achieve appropriate IGF suppression compared patients receiving opioids
Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. 	Antacids	Myfortic	none	{'e1': {'word': 'Antacids', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d700.s0.e0'}, 'e2': {'word': 'Myfortic', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d700.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d700.s0'}	Antacids Absorption single dose Myfortic decreased administered NUMBER stable renal transplant patients also taking magnesium aluminum containing antacids NUMBER mL mean Cmax AUC NUMBER - values MPA NUMBER % NUMBER % lower respectively Myfortic administered alone fasting conditions
Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. 	Antacids	magnesium	none	{'e1': {'word': 'Antacids', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d700.s0.e0'}, 'e2': {'word': 'magnesium', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d700.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d700.s0'}	Antacids Absorption single dose Myfortic decreased administered NUMBER stable renal transplant patients also taking magnesium aluminum containing antacids NUMBER mL mean Cmax AUC NUMBER - values MPA NUMBER % NUMBER % lower respectively Myfortic administered alone fasting conditions
Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. 	Antacids	aluminum	none	{'e1': {'word': 'Antacids', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d700.s0.e0'}, 'e2': {'word': 'aluminum', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d700.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d700.s0'}	Antacids Absorption single dose Myfortic decreased administered NUMBER stable renal transplant patients also taking magnesium aluminum containing antacids NUMBER mL mean Cmax AUC NUMBER - values MPA NUMBER % NUMBER % lower respectively Myfortic administered alone fasting conditions
Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. 	Antacids	antacids	none	{'e1': {'word': 'Antacids', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d700.s0.e0'}, 'e2': {'word': 'antacids', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d700.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d700.s0'}	Antacids Absorption single dose Myfortic decreased administered NUMBER stable renal transplant patients also taking magnesium aluminum containing antacids NUMBER mL mean Cmax AUC NUMBER - values MPA NUMBER % NUMBER % lower respectively Myfortic administered alone fasting conditions
Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. 	Antacids	Myfortic	none	{'e1': {'word': 'Antacids', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d700.s0.e0'}, 'e2': {'word': 'Myfortic', 'word_index': [(33, 33)], 'id': 'DDI-DrugBank.d700.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d700.s0'}	Antacids Absorption single dose Myfortic decreased administered NUMBER stable renal transplant patients also taking magnesium aluminum containing antacids NUMBER mL mean Cmax AUC NUMBER - values MPA NUMBER % NUMBER % lower respectively Myfortic administered alone fasting conditions
Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. 	Myfortic	magnesium	mechanism	{'e1': {'word': 'Myfortic', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d700.s0.e1'}, 'e2': {'word': 'magnesium', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d700.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d700.s0'}	Antacids Absorption single dose Myfortic decreased administered NUMBER stable renal transplant patients also taking magnesium aluminum containing antacids NUMBER mL mean Cmax AUC NUMBER - values MPA NUMBER % NUMBER % lower respectively Myfortic administered alone fasting conditions
Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. 	Myfortic	aluminum	mechanism	{'e1': {'word': 'Myfortic', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d700.s0.e1'}, 'e2': {'word': 'aluminum', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d700.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d700.s0'}	Antacids Absorption single dose Myfortic decreased administered NUMBER stable renal transplant patients also taking magnesium aluminum containing antacids NUMBER mL mean Cmax AUC NUMBER - values MPA NUMBER % NUMBER % lower respectively Myfortic administered alone fasting conditions
Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. 	Myfortic	antacids	none	{'e1': {'word': 'Myfortic', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d700.s0.e1'}, 'e2': {'word': 'antacids', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d700.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d700.s0'}	Antacids Absorption single dose Myfortic decreased administered NUMBER stable renal transplant patients also taking magnesium aluminum containing antacids NUMBER mL mean Cmax AUC NUMBER - values MPA NUMBER % NUMBER % lower respectively Myfortic administered alone fasting conditions
Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. 	Myfortic	Myfortic	none	{'e1': {'word': 'Myfortic', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d700.s0.e1'}, 'e2': {'word': 'Myfortic', 'word_index': [(33, 33)], 'id': 'DDI-DrugBank.d700.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d700.s0'}	Antacids Absorption single dose Myfortic decreased administered NUMBER stable renal transplant patients also taking magnesium aluminum containing antacids NUMBER mL mean Cmax AUC NUMBER - values MPA NUMBER % NUMBER % lower respectively Myfortic administered alone fasting conditions
Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. 	magnesium	aluminum	none	{'e1': {'word': 'magnesium', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d700.s0.e2'}, 'e2': {'word': 'aluminum', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d700.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d700.s0'}	Antacids Absorption single dose Myfortic decreased administered NUMBER stable renal transplant patients also taking magnesium aluminum containing antacids NUMBER mL mean Cmax AUC NUMBER - values MPA NUMBER % NUMBER % lower respectively Myfortic administered alone fasting conditions
Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. 	magnesium	antacids	none	{'e1': {'word': 'magnesium', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d700.s0.e2'}, 'e2': {'word': 'antacids', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d700.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d700.s0'}	Antacids Absorption single dose Myfortic decreased administered NUMBER stable renal transplant patients also taking magnesium aluminum containing antacids NUMBER mL mean Cmax AUC NUMBER - values MPA NUMBER % NUMBER % lower respectively Myfortic administered alone fasting conditions
Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. 	magnesium	Myfortic	none	{'e1': {'word': 'magnesium', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d700.s0.e2'}, 'e2': {'word': 'Myfortic', 'word_index': [(33, 33)], 'id': 'DDI-DrugBank.d700.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d700.s0'}	Antacids Absorption single dose Myfortic decreased administered NUMBER stable renal transplant patients also taking magnesium aluminum containing antacids NUMBER mL mean Cmax AUC NUMBER - values MPA NUMBER % NUMBER % lower respectively Myfortic administered alone fasting conditions
Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. 	aluminum	antacids	none	{'e1': {'word': 'aluminum', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d700.s0.e3'}, 'e2': {'word': 'antacids', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d700.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d700.s0'}	Antacids Absorption single dose Myfortic decreased administered NUMBER stable renal transplant patients also taking magnesium aluminum containing antacids NUMBER mL mean Cmax AUC NUMBER - values MPA NUMBER % NUMBER % lower respectively Myfortic administered alone fasting conditions
Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. 	aluminum	Myfortic	none	{'e1': {'word': 'aluminum', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d700.s0.e3'}, 'e2': {'word': 'Myfortic', 'word_index': [(33, 33)], 'id': 'DDI-DrugBank.d700.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d700.s0'}	Antacids Absorption single dose Myfortic decreased administered NUMBER stable renal transplant patients also taking magnesium aluminum containing antacids NUMBER mL mean Cmax AUC NUMBER - values MPA NUMBER % NUMBER % lower respectively Myfortic administered alone fasting conditions
Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. 	antacids	Myfortic	none	{'e1': {'word': 'antacids', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d700.s0.e4'}, 'e2': {'word': 'Myfortic', 'word_index': [(33, 33)], 'id': 'DDI-DrugBank.d700.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d700.s0'}	Antacids Absorption single dose Myfortic decreased administered NUMBER stable renal transplant patients also taking magnesium aluminum containing antacids NUMBER mL mean Cmax AUC NUMBER - values MPA NUMBER % NUMBER % lower respectively Myfortic administered alone fasting conditions
It is recommended that Myfortic and antacids not be administered simultaneously. 	Myfortic	antacids	advise	{'e1': {'word': 'Myfortic', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d700.s1.e0'}, 'e2': {'word': 'antacids', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d700.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d700.s1'}	recommended Myfortic antacids administered simultaneously
Cyclosporine: When studied in stable renal transplant patients, cyclosporine, USP (MODIFIED) pharmacokinetics were unaffected by steady state dosing of Myfortic. 	Cyclosporine	cyclosporine	none	{'e1': {'word': 'Cyclosporine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d700.s2.e0'}, 'e2': {'word': 'cyclosporine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d700.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d700.s2'}	Cyclosporine studied stable renal transplant patients cyclosporine USP MODIFIED pharmacokinetics unaffected steady state dosing Myfortic
Cyclosporine: When studied in stable renal transplant patients, cyclosporine, USP (MODIFIED) pharmacokinetics were unaffected by steady state dosing of Myfortic. 	Cyclosporine	Myfortic	none	{'e1': {'word': 'Cyclosporine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d700.s2.e0'}, 'e2': {'word': 'Myfortic', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d700.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d700.s2'}	Cyclosporine studied stable renal transplant patients cyclosporine USP MODIFIED pharmacokinetics unaffected steady state dosing Myfortic
Cyclosporine: When studied in stable renal transplant patients, cyclosporine, USP (MODIFIED) pharmacokinetics were unaffected by steady state dosing of Myfortic. 	cyclosporine	Myfortic	none	{'e1': {'word': 'cyclosporine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d700.s2.e1'}, 'e2': {'word': 'Myfortic', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d700.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d700.s2'}	Cyclosporine studied stable renal transplant patients cyclosporine USP MODIFIED pharmacokinetics unaffected steady state dosing Myfortic
Acyclovir/Ganciclovir: may be taken with Myfortic; 	Acyclovir	Ganciclovir	none	{'e1': {'word': 'Acyclovir', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d700.s3.e0'}, 'e2': {'word': 'Ganciclovir', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d700.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d700.s3'}	Acyclovir Ganciclovir may taken Myfortic
Acyclovir/Ganciclovir: may be taken with Myfortic; 	Acyclovir	Myfortic	none	{'e1': {'word': 'Acyclovir', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d700.s3.e0'}, 'e2': {'word': 'Myfortic', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d700.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d700.s3'}	Acyclovir Ganciclovir may taken Myfortic
Acyclovir/Ganciclovir: may be taken with Myfortic; 	Ganciclovir	Myfortic	none	{'e1': {'word': 'Ganciclovir', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d700.s3.e1'}, 'e2': {'word': 'Myfortic', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d700.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d700.s3'}	Acyclovir Ganciclovir may taken Myfortic
Both acyclovir/ganciclovir and MPAG concentrations are increased in the presence of renal impairment, their coexistence may compete for tubular secretion and further increase in the concentrations of the two. 	acyclovir	ganciclovir	none	{'e1': {'word': 'acyclovir', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d700.s5.e0'}, 'e2': {'word': 'ganciclovir', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d700.s5.e1'}, 'sentence_id': 'DDI-DrugBank.d700.s5'}	acyclovir ganciclovir MPAG concentrations increased presence renal impairment coexistence may compete tubular secretion increase concentrations NUMBER
Both acyclovir/ganciclovir and MPAG concentrations are increased in the presence of renal impairment, their coexistence may compete for tubular secretion and further increase in the concentrations of the two. 	acyclovir	MPAG	none	{'e1': {'word': 'acyclovir', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d700.s5.e0'}, 'e2': {'word': 'MPAG', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d700.s5.e2'}, 'sentence_id': 'DDI-DrugBank.d700.s5'}	acyclovir ganciclovir MPAG concentrations increased presence renal impairment coexistence may compete tubular secretion increase concentrations NUMBER
Both acyclovir/ganciclovir and MPAG concentrations are increased in the presence of renal impairment, their coexistence may compete for tubular secretion and further increase in the concentrations of the two. 	ganciclovir	MPAG	none	{'e1': {'word': 'ganciclovir', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d700.s5.e1'}, 'e2': {'word': 'MPAG', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d700.s5.e2'}, 'sentence_id': 'DDI-DrugBank.d700.s5'}	acyclovir ganciclovir MPAG concentrations increased presence renal impairment coexistence may compete tubular secretion increase concentrations NUMBER
Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. 	Azathioprine	Mycophenolate Mofetil	none	{'e1': {'word': 'Azathioprine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d700.s6.e0'}, 'e2': {'word': 'Mycophenolate Mofetil', 'word_index': [(1, 2)], 'id': 'DDI-DrugBank.d700.s6.e1'}, 'sentence_id': 'DDI-DrugBank.d700.s6'}	Azathioprine Mycophenolate Mofetil Given azathioprine mycophenolate mofetil inhibit purine metabolism recommended Myfortic administered concomitantly azathioprine mycophenolate mofetil
Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. 	Azathioprine	azathioprine	none	{'e1': {'word': 'Azathioprine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d700.s6.e0'}, 'e2': {'word': 'azathioprine', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d700.s6.e2'}, 'sentence_id': 'DDI-DrugBank.d700.s6'}	Azathioprine Mycophenolate Mofetil Given azathioprine mycophenolate mofetil inhibit purine metabolism recommended Myfortic administered concomitantly azathioprine mycophenolate mofetil
Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. 	Azathioprine	mycophenolate mofetil	none	{'e1': {'word': 'Azathioprine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d700.s6.e0'}, 'e2': {'word': 'mycophenolate mofetil', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d700.s6.e3'}, 'sentence_id': 'DDI-DrugBank.d700.s6'}	Azathioprine Mycophenolate Mofetil Given azathioprine mycophenolate mofetil inhibit purine metabolism recommended Myfortic administered concomitantly azathioprine mycophenolate mofetil
Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. 	Azathioprine	Myfortic	none	{'e1': {'word': 'Azathioprine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d700.s6.e0'}, 'e2': {'word': 'Myfortic', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d700.s6.e4'}, 'sentence_id': 'DDI-DrugBank.d700.s6'}	Azathioprine Mycophenolate Mofetil Given azathioprine mycophenolate mofetil inhibit purine metabolism recommended Myfortic administered concomitantly azathioprine mycophenolate mofetil
Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. 	Azathioprine	azathioprine	none	{'e1': {'word': 'Azathioprine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d700.s6.e0'}, 'e2': {'word': 'azathioprine', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d700.s6.e5'}, 'sentence_id': 'DDI-DrugBank.d700.s6'}	Azathioprine Mycophenolate Mofetil Given azathioprine mycophenolate mofetil inhibit purine metabolism recommended Myfortic administered concomitantly azathioprine mycophenolate mofetil
Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. 	Azathioprine	mycophenolate mofetil	none	{'e1': {'word': 'Azathioprine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d700.s6.e0'}, 'e2': {'word': 'mycophenolate mofetil', 'word_index': [(15, 16)], 'id': 'DDI-DrugBank.d700.s6.e6'}, 'sentence_id': 'DDI-DrugBank.d700.s6'}	Azathioprine Mycophenolate Mofetil Given azathioprine mycophenolate mofetil inhibit purine metabolism recommended Myfortic administered concomitantly azathioprine mycophenolate mofetil
Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. 	Mycophenolate Mofetil	azathioprine	none	{'e1': {'word': 'Mycophenolate Mofetil', 'word_index': [(1, 2)], 'id': 'DDI-DrugBank.d700.s6.e1'}, 'e2': {'word': 'azathioprine', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d700.s6.e2'}, 'sentence_id': 'DDI-DrugBank.d700.s6'}	Azathioprine Mycophenolate Mofetil Given azathioprine mycophenolate mofetil inhibit purine metabolism recommended Myfortic administered concomitantly azathioprine mycophenolate mofetil
Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. 	Mycophenolate Mofetil	mycophenolate mofetil	none	{'e1': {'word': 'Mycophenolate Mofetil', 'word_index': [(1, 2)], 'id': 'DDI-DrugBank.d700.s6.e1'}, 'e2': {'word': 'mycophenolate mofetil', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d700.s6.e3'}, 'sentence_id': 'DDI-DrugBank.d700.s6'}	Azathioprine Mycophenolate Mofetil Given azathioprine mycophenolate mofetil inhibit purine metabolism recommended Myfortic administered concomitantly azathioprine mycophenolate mofetil
Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. 	Mycophenolate Mofetil	Myfortic	none	{'e1': {'word': 'Mycophenolate Mofetil', 'word_index': [(1, 2)], 'id': 'DDI-DrugBank.d700.s6.e1'}, 'e2': {'word': 'Myfortic', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d700.s6.e4'}, 'sentence_id': 'DDI-DrugBank.d700.s6'}	Azathioprine Mycophenolate Mofetil Given azathioprine mycophenolate mofetil inhibit purine metabolism recommended Myfortic administered concomitantly azathioprine mycophenolate mofetil
Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. 	Mycophenolate Mofetil	azathioprine	none	{'e1': {'word': 'Mycophenolate Mofetil', 'word_index': [(1, 2)], 'id': 'DDI-DrugBank.d700.s6.e1'}, 'e2': {'word': 'azathioprine', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d700.s6.e5'}, 'sentence_id': 'DDI-DrugBank.d700.s6'}	Azathioprine Mycophenolate Mofetil Given azathioprine mycophenolate mofetil inhibit purine metabolism recommended Myfortic administered concomitantly azathioprine mycophenolate mofetil
Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. 	Mycophenolate Mofetil	mycophenolate mofetil	none	{'e1': {'word': 'Mycophenolate Mofetil', 'word_index': [(1, 2)], 'id': 'DDI-DrugBank.d700.s6.e1'}, 'e2': {'word': 'mycophenolate mofetil', 'word_index': [(15, 16)], 'id': 'DDI-DrugBank.d700.s6.e6'}, 'sentence_id': 'DDI-DrugBank.d700.s6'}	Azathioprine Mycophenolate Mofetil Given azathioprine mycophenolate mofetil inhibit purine metabolism recommended Myfortic administered concomitantly azathioprine mycophenolate mofetil
Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. 	azathioprine	mycophenolate mofetil	none	{'e1': {'word': 'azathioprine', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d700.s6.e2'}, 'e2': {'word': 'mycophenolate mofetil', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d700.s6.e3'}, 'sentence_id': 'DDI-DrugBank.d700.s6'}	Azathioprine Mycophenolate Mofetil Given azathioprine mycophenolate mofetil inhibit purine metabolism recommended Myfortic administered concomitantly azathioprine mycophenolate mofetil
Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. 	azathioprine	Myfortic	none	{'e1': {'word': 'azathioprine', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d700.s6.e2'}, 'e2': {'word': 'Myfortic', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d700.s6.e4'}, 'sentence_id': 'DDI-DrugBank.d700.s6'}	Azathioprine Mycophenolate Mofetil Given azathioprine mycophenolate mofetil inhibit purine metabolism recommended Myfortic administered concomitantly azathioprine mycophenolate mofetil
Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. 	azathioprine	azathioprine	none	{'e1': {'word': 'azathioprine', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d700.s6.e2'}, 'e2': {'word': 'azathioprine', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d700.s6.e5'}, 'sentence_id': 'DDI-DrugBank.d700.s6'}	Azathioprine Mycophenolate Mofetil Given azathioprine mycophenolate mofetil inhibit purine metabolism recommended Myfortic administered concomitantly azathioprine mycophenolate mofetil
Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. 	azathioprine	mycophenolate mofetil	none	{'e1': {'word': 'azathioprine', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d700.s6.e2'}, 'e2': {'word': 'mycophenolate mofetil', 'word_index': [(15, 16)], 'id': 'DDI-DrugBank.d700.s6.e6'}, 'sentence_id': 'DDI-DrugBank.d700.s6'}	Azathioprine Mycophenolate Mofetil Given azathioprine mycophenolate mofetil inhibit purine metabolism recommended Myfortic administered concomitantly azathioprine mycophenolate mofetil
Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. 	mycophenolate mofetil	Myfortic	none	{'e1': {'word': 'mycophenolate mofetil', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d700.s6.e3'}, 'e2': {'word': 'Myfortic', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d700.s6.e4'}, 'sentence_id': 'DDI-DrugBank.d700.s6'}	Azathioprine Mycophenolate Mofetil Given azathioprine mycophenolate mofetil inhibit purine metabolism recommended Myfortic administered concomitantly azathioprine mycophenolate mofetil
Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. 	mycophenolate mofetil	azathioprine	none	{'e1': {'word': 'mycophenolate mofetil', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d700.s6.e3'}, 'e2': {'word': 'azathioprine', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d700.s6.e5'}, 'sentence_id': 'DDI-DrugBank.d700.s6'}	Azathioprine Mycophenolate Mofetil Given azathioprine mycophenolate mofetil inhibit purine metabolism recommended Myfortic administered concomitantly azathioprine mycophenolate mofetil
Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. 	mycophenolate mofetil	mycophenolate mofetil	none	{'e1': {'word': 'mycophenolate mofetil', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d700.s6.e3'}, 'e2': {'word': 'mycophenolate mofetil', 'word_index': [(15, 16)], 'id': 'DDI-DrugBank.d700.s6.e6'}, 'sentence_id': 'DDI-DrugBank.d700.s6'}	Azathioprine Mycophenolate Mofetil Given azathioprine mycophenolate mofetil inhibit purine metabolism recommended Myfortic administered concomitantly azathioprine mycophenolate mofetil
Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. 	Myfortic	azathioprine	advise	{'e1': {'word': 'Myfortic', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d700.s6.e4'}, 'e2': {'word': 'azathioprine', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d700.s6.e5'}, 'sentence_id': 'DDI-DrugBank.d700.s6'}	Azathioprine Mycophenolate Mofetil Given azathioprine mycophenolate mofetil inhibit purine metabolism recommended Myfortic administered concomitantly azathioprine mycophenolate mofetil
Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. 	Myfortic	mycophenolate mofetil	advise	{'e1': {'word': 'Myfortic', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d700.s6.e4'}, 'e2': {'word': 'mycophenolate mofetil', 'word_index': [(15, 16)], 'id': 'DDI-DrugBank.d700.s6.e6'}, 'sentence_id': 'DDI-DrugBank.d700.s6'}	Azathioprine Mycophenolate Mofetil Given azathioprine mycophenolate mofetil inhibit purine metabolism recommended Myfortic administered concomitantly azathioprine mycophenolate mofetil
Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. 	azathioprine	mycophenolate mofetil	none	{'e1': {'word': 'azathioprine', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d700.s6.e5'}, 'e2': {'word': 'mycophenolate mofetil', 'word_index': [(15, 16)], 'id': 'DDI-DrugBank.d700.s6.e6'}, 'sentence_id': 'DDI-DrugBank.d700.s6'}	Azathioprine Mycophenolate Mofetil Given azathioprine mycophenolate mofetil inhibit purine metabolism recommended Myfortic administered concomitantly azathioprine mycophenolate mofetil
Cholestyramine and Drugs that Bind Bile Acids: These drugs interrupt enterohepatic recirculation and reduce MPA exposure when coadministered with mycophenolate mofetil. 	Cholestyramine	MPA	none	{'e1': {'word': 'Cholestyramine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d700.s7.e0'}, 'e2': {'word': 'MPA', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d700.s7.e1'}, 'sentence_id': 'DDI-DrugBank.d700.s7'}	Cholestyramine Drugs Bind Bile Acids drugs interrupt enterohepatic recirculation reduce MPA exposure coadministered mycophenolate mofetil
Cholestyramine and Drugs that Bind Bile Acids: These drugs interrupt enterohepatic recirculation and reduce MPA exposure when coadministered with mycophenolate mofetil. 	Cholestyramine	mycophenolate mofetil	none	{'e1': {'word': 'Cholestyramine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d700.s7.e0'}, 'e2': {'word': 'mycophenolate mofetil', 'word_index': [(13, 14)], 'id': 'DDI-DrugBank.d700.s7.e2'}, 'sentence_id': 'DDI-DrugBank.d700.s7'}	Cholestyramine Drugs Bind Bile Acids drugs interrupt enterohepatic recirculation reduce MPA exposure coadministered mycophenolate mofetil
Cholestyramine and Drugs that Bind Bile Acids: These drugs interrupt enterohepatic recirculation and reduce MPA exposure when coadministered with mycophenolate mofetil. 	MPA	mycophenolate mofetil	none	{'e1': {'word': 'MPA', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d700.s7.e1'}, 'e2': {'word': 'mycophenolate mofetil', 'word_index': [(13, 14)], 'id': 'DDI-DrugBank.d700.s7.e2'}, 'sentence_id': 'DDI-DrugBank.d700.s7'}	Cholestyramine Drugs Bind Bile Acids drugs interrupt enterohepatic recirculation reduce MPA exposure coadministered mycophenolate mofetil
Therefore, do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of Myfortic. 	Myfortic	cholestyramine	advise	{'e1': {'word': 'Myfortic', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d700.s8.e0'}, 'e2': {'word': 'cholestyramine', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d700.s8.e1'}, 'sentence_id': 'DDI-DrugBank.d700.s8'}	Therefore administer Myfortic cholestyramine agents may interfere enterohepatic recirculation drugs may bind bile acids example bile acid sequestrates oral activated charcoal potential reduce efficacy Myfortic
Therefore, do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of Myfortic. 	Myfortic	activated charcoal	advise	{'e1': {'word': 'Myfortic', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d700.s8.e0'}, 'e2': {'word': 'activated charcoal', 'word_index': [(19, 20)], 'id': 'DDI-DrugBank.d700.s8.e2'}, 'sentence_id': 'DDI-DrugBank.d700.s8'}	Therefore administer Myfortic cholestyramine agents may interfere enterohepatic recirculation drugs may bind bile acids example bile acid sequestrates oral activated charcoal potential reduce efficacy Myfortic
Therefore, do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of Myfortic. 	Myfortic	Myfortic	none	{'e1': {'word': 'Myfortic', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d700.s8.e0'}, 'e2': {'word': 'Myfortic', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d700.s8.e3'}, 'sentence_id': 'DDI-DrugBank.d700.s8'}	Therefore administer Myfortic cholestyramine agents may interfere enterohepatic recirculation drugs may bind bile acids example bile acid sequestrates oral activated charcoal potential reduce efficacy Myfortic
Therefore, do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of Myfortic. 	cholestyramine	activated charcoal	none	{'e1': {'word': 'cholestyramine', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d700.s8.e1'}, 'e2': {'word': 'activated charcoal', 'word_index': [(19, 20)], 'id': 'DDI-DrugBank.d700.s8.e2'}, 'sentence_id': 'DDI-DrugBank.d700.s8'}	Therefore administer Myfortic cholestyramine agents may interfere enterohepatic recirculation drugs may bind bile acids example bile acid sequestrates oral activated charcoal potential reduce efficacy Myfortic
Therefore, do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of Myfortic. 	cholestyramine	Myfortic	none	{'e1': {'word': 'cholestyramine', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d700.s8.e1'}, 'e2': {'word': 'Myfortic', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d700.s8.e3'}, 'sentence_id': 'DDI-DrugBank.d700.s8'}	Therefore administer Myfortic cholestyramine agents may interfere enterohepatic recirculation drugs may bind bile acids example bile acid sequestrates oral activated charcoal potential reduce efficacy Myfortic
Therefore, do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of Myfortic. 	activated charcoal	Myfortic	none	{'e1': {'word': 'activated charcoal', 'word_index': [(19, 20)], 'id': 'DDI-DrugBank.d700.s8.e2'}, 'e2': {'word': 'Myfortic', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d700.s8.e3'}, 'sentence_id': 'DDI-DrugBank.d700.s8'}	Therefore administer Myfortic cholestyramine agents may interfere enterohepatic recirculation drugs may bind bile acids example bile acid sequestrates oral activated charcoal potential reduce efficacy Myfortic
Oral Contraceptives: Given the different metabolism of Myfortic and oral contraceptives, no drug interaction between these two classes of drug is expected. 	Contraceptives	Myfortic	none	{'e1': {'word': 'Contraceptives', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d700.s9.e0'}, 'e2': {'word': 'Myfortic', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d700.s9.e1'}, 'sentence_id': 'DDI-DrugBank.d700.s9'}	Oral Contraceptives Given different metabolism Myfortic oral contraceptives drug interaction NUMBER classes drug expected
Oral Contraceptives: Given the different metabolism of Myfortic and oral contraceptives, no drug interaction between these two classes of drug is expected. 	Contraceptives	contraceptives	none	{'e1': {'word': 'Contraceptives', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d700.s9.e0'}, 'e2': {'word': 'contraceptives', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d700.s9.e2'}, 'sentence_id': 'DDI-DrugBank.d700.s9'}	Oral Contraceptives Given different metabolism Myfortic oral contraceptives drug interaction NUMBER classes drug expected
Oral Contraceptives: Given the different metabolism of Myfortic and oral contraceptives, no drug interaction between these two classes of drug is expected. 	Myfortic	contraceptives	none	{'e1': {'word': 'Myfortic', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d700.s9.e1'}, 'e2': {'word': 'contraceptives', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d700.s9.e2'}, 'sentence_id': 'DDI-DrugBank.d700.s9'}	Oral Contraceptives Given different metabolism Myfortic oral contraceptives drug interaction NUMBER classes drug expected
However, in a drug-drug interaction study, mean levonorgesterol AUC was decreased by 15% when coadministered with mycophenolate mofetil. 	levonorgesterol	mycophenolate mofetil	mechanism	{'e1': {'word': 'levonorgesterol', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d700.s10.e0'}, 'e2': {'word': 'mycophenolate mofetil', 'word_index': [(12, 13)], 'id': 'DDI-DrugBank.d700.s10.e1'}, 'sentence_id': 'DDI-DrugBank.d700.s10'}	However drug drug interaction study mean levonorgesterol AUC decreased NUMBER % coadministered mycophenolate mofetil
Therefore, it is recommended that oral contraceptives are co- administered with Myfortic with caution and additional birth control methods be considered. 	contraceptives	Myfortic	advise	{'e1': {'word': 'contraceptives', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d700.s11.e0'}, 'e2': {'word': 'Myfortic', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d700.s11.e1'}, 'sentence_id': 'DDI-DrugBank.d700.s11'}	Therefore recommended oral contraceptives co- administered Myfortic caution additional birth control methods considered
Live Vaccines: During treatment with Myfortic, the use of live attenuated vaccines should be avoided and patients should be advised that vaccinations may be less effective. 	Live Vaccines	Myfortic	none	{'e1': {'word': 'Live Vaccines', 'word_index': [(0, 1)], 'id': 'DDI-DrugBank.d700.s12.e0'}, 'e2': {'word': 'Myfortic', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d700.s12.e1'}, 'sentence_id': 'DDI-DrugBank.d700.s12'}	Live Vaccines treatment Myfortic use live attenuated vaccines avoided patients advised vaccinations may less effective
Live Vaccines: During treatment with Myfortic, the use of live attenuated vaccines should be avoided and patients should be advised that vaccinations may be less effective. 	Live Vaccines	live attenuated vaccines	none	{'e1': {'word': 'Live Vaccines', 'word_index': [(0, 1)], 'id': 'DDI-DrugBank.d700.s12.e0'}, 'e2': {'word': 'live attenuated vaccines', 'word_index': [(5, 7)], 'id': 'DDI-DrugBank.d700.s12.e2'}, 'sentence_id': 'DDI-DrugBank.d700.s12'}	Live Vaccines treatment Myfortic use live attenuated vaccines avoided patients advised vaccinations may less effective
Live Vaccines: During treatment with Myfortic, the use of live attenuated vaccines should be avoided and patients should be advised that vaccinations may be less effective. 	Myfortic	live attenuated vaccines	advise	{'e1': {'word': 'Myfortic', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d700.s12.e1'}, 'e2': {'word': 'live attenuated vaccines', 'word_index': [(5, 7)], 'id': 'DDI-DrugBank.d700.s12.e2'}, 'sentence_id': 'DDI-DrugBank.d700.s12'}	Live Vaccines treatment Myfortic use live attenuated vaccines avoided patients advised vaccinations may less effective
Interference of MPAG hydrolysis may lead to less MPA available for absorption.	MPAG	MPA	none	{'e1': {'word': 'MPAG', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d700.s16.e0'}, 'e2': {'word': 'MPA', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d700.s16.e1'}, 'sentence_id': 'DDI-DrugBank.d700.s16'}	Interference MPAG hydrolysis may lead less MPA available absorption
CHEMET is not known to interact with other drugs including iron supplements; 	CHEMET	iron	none	{'e1': {'word': 'CHEMET', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d732.s0.e0'}, 'e2': {'word': 'iron', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d732.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d732.s0'}	CHEMET known interact drugs including iron supplements
Concomitant administration of CHEMET with other chelation therapy, such as CaNa 2 EDTA is not recommended. 	CHEMET	CaNa 2 EDTA	advise	{'e1': {'word': 'CHEMET', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d732.s2.e0'}, 'e2': {'word': 'CaNa 2 EDTA', 'word_index': [(5, 7)], 'id': 'DDI-DrugBank.d732.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d732.s2'}	Concomitant administration CHEMET chelation therapy CaNa NUMBER EDTA recommended
Caution should be exercised when administering ZADAXIN therapy in combination with other immunomodulating drugs. 	ZADAXIN	immunomodulating drugs	advise	{'e1': {'word': 'ZADAXIN', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d616.s1.e0'}, 'e2': {'word': 'immunomodulating drugs', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d616.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d616.s1'}	Caution exercised administering ZADAXIN therapy combination immunomodulating drugs
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	pantoprazole	theophylline	none	{'e1': {'word': 'pantoprazole', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d680.s1.e0'}, 'e2': {'word': 'theophylline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d680.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	pantoprazole	cisapride	none	{'e1': {'word': 'pantoprazole', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d680.s1.e0'}, 'e2': {'word': 'cisapride', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d680.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	pantoprazole	antipyrine	none	{'e1': {'word': 'pantoprazole', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d680.s1.e0'}, 'e2': {'word': 'antipyrine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d680.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	pantoprazole	caffeine	none	{'e1': {'word': 'pantoprazole', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d680.s1.e0'}, 'e2': {'word': 'caffeine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d680.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	pantoprazole	carbamazepine	none	{'e1': {'word': 'pantoprazole', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d680.s1.e0'}, 'e2': {'word': 'carbamazepine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d680.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	pantoprazole	diazepam	none	{'e1': {'word': 'pantoprazole', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d680.s1.e0'}, 'e2': {'word': 'diazepam', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d680.s1.e6'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	pantoprazole	desmethyldiazepam	none	{'e1': {'word': 'pantoprazole', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d680.s1.e0'}, 'e2': {'word': 'desmethyldiazepam', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d680.s1.e7'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	pantoprazole	diclofenac	none	{'e1': {'word': 'pantoprazole', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d680.s1.e0'}, 'e2': {'word': 'diclofenac', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d680.s1.e8'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	pantoprazole	naproxen	none	{'e1': {'word': 'pantoprazole', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d680.s1.e0'}, 'e2': {'word': 'naproxen', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d680.s1.e9'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	pantoprazole	piroxicam	none	{'e1': {'word': 'pantoprazole', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d680.s1.e0'}, 'e2': {'word': 'piroxicam', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d680.s1.e10'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	pantoprazole	digoxin	none	{'e1': {'word': 'pantoprazole', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d680.s1.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(25, 25)], 'id': 'DDI-DrugBank.d680.s1.e11'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	pantoprazole	ethanol	none	{'e1': {'word': 'pantoprazole', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d680.s1.e0'}, 'e2': {'word': 'ethanol', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d680.s1.e12'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	pantoprazole	glyburide	none	{'e1': {'word': 'pantoprazole', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d680.s1.e0'}, 'e2': {'word': 'glyburide', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d680.s1.e13'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	pantoprazole	contraceptive	none	{'e1': {'word': 'pantoprazole', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d680.s1.e0'}, 'e2': {'word': 'contraceptive', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d680.s1.e14'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	pantoprazole	levonorgestrel	none	{'e1': {'word': 'pantoprazole', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d680.s1.e0'}, 'e2': {'word': 'levonorgestrel', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d680.s1.e15'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	pantoprazole	ethinyl estradiol	none	{'e1': {'word': 'pantoprazole', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d680.s1.e0'}, 'e2': {'word': 'ethinyl estradiol', 'word_index': [(31, 32)], 'id': 'DDI-DrugBank.d680.s1.e16'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	pantoprazole	metoprolol	none	{'e1': {'word': 'pantoprazole', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d680.s1.e0'}, 'e2': {'word': 'metoprolol', 'word_index': [(33, 33)], 'id': 'DDI-DrugBank.d680.s1.e17'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	pantoprazole	nifedipine	none	{'e1': {'word': 'pantoprazole', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d680.s1.e0'}, 'e2': {'word': 'nifedipine', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d680.s1.e18'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	pantoprazole	phenytoin	none	{'e1': {'word': 'pantoprazole', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d680.s1.e0'}, 'e2': {'word': 'phenytoin', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d680.s1.e19'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	pantoprazole	warfarin	none	{'e1': {'word': 'pantoprazole', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d680.s1.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d680.s1.e20'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	pantoprazole	midazolam	none	{'e1': {'word': 'pantoprazole', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d680.s1.e0'}, 'e2': {'word': 'midazolam', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d680.s1.e21'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	pantoprazole	clarithromycin	none	{'e1': {'word': 'pantoprazole', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d680.s1.e0'}, 'e2': {'word': 'clarithromycin', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d680.s1.e22'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	pantoprazole	metronidazole	none	{'e1': {'word': 'pantoprazole', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d680.s1.e0'}, 'e2': {'word': 'metronidazole', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d680.s1.e23'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	pantoprazole	amoxicillin	none	{'e1': {'word': 'pantoprazole', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d680.s1.e0'}, 'e2': {'word': 'amoxicillin', 'word_index': [(40, 40)], 'id': 'DDI-DrugBank.d680.s1.e24'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	theophylline	cisapride	none	{'e1': {'word': 'theophylline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d680.s1.e1'}, 'e2': {'word': 'cisapride', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d680.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	theophylline	antipyrine	none	{'e1': {'word': 'theophylline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d680.s1.e1'}, 'e2': {'word': 'antipyrine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d680.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	theophylline	caffeine	none	{'e1': {'word': 'theophylline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d680.s1.e1'}, 'e2': {'word': 'caffeine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d680.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	theophylline	carbamazepine	none	{'e1': {'word': 'theophylline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d680.s1.e1'}, 'e2': {'word': 'carbamazepine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d680.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	theophylline	diazepam	none	{'e1': {'word': 'theophylline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d680.s1.e1'}, 'e2': {'word': 'diazepam', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d680.s1.e6'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	theophylline	desmethyldiazepam	none	{'e1': {'word': 'theophylline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d680.s1.e1'}, 'e2': {'word': 'desmethyldiazepam', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d680.s1.e7'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	theophylline	diclofenac	none	{'e1': {'word': 'theophylline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d680.s1.e1'}, 'e2': {'word': 'diclofenac', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d680.s1.e8'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	theophylline	naproxen	none	{'e1': {'word': 'theophylline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d680.s1.e1'}, 'e2': {'word': 'naproxen', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d680.s1.e9'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	theophylline	piroxicam	none	{'e1': {'word': 'theophylline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d680.s1.e1'}, 'e2': {'word': 'piroxicam', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d680.s1.e10'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	theophylline	digoxin	none	{'e1': {'word': 'theophylline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d680.s1.e1'}, 'e2': {'word': 'digoxin', 'word_index': [(25, 25)], 'id': 'DDI-DrugBank.d680.s1.e11'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	theophylline	ethanol	none	{'e1': {'word': 'theophylline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d680.s1.e1'}, 'e2': {'word': 'ethanol', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d680.s1.e12'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	theophylline	glyburide	none	{'e1': {'word': 'theophylline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d680.s1.e1'}, 'e2': {'word': 'glyburide', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d680.s1.e13'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	theophylline	contraceptive	none	{'e1': {'word': 'theophylline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d680.s1.e1'}, 'e2': {'word': 'contraceptive', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d680.s1.e14'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	theophylline	levonorgestrel	none	{'e1': {'word': 'theophylline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d680.s1.e1'}, 'e2': {'word': 'levonorgestrel', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d680.s1.e15'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	theophylline	ethinyl estradiol	none	{'e1': {'word': 'theophylline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d680.s1.e1'}, 'e2': {'word': 'ethinyl estradiol', 'word_index': [(31, 32)], 'id': 'DDI-DrugBank.d680.s1.e16'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	theophylline	metoprolol	none	{'e1': {'word': 'theophylline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d680.s1.e1'}, 'e2': {'word': 'metoprolol', 'word_index': [(33, 33)], 'id': 'DDI-DrugBank.d680.s1.e17'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	theophylline	nifedipine	none	{'e1': {'word': 'theophylline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d680.s1.e1'}, 'e2': {'word': 'nifedipine', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d680.s1.e18'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	theophylline	phenytoin	none	{'e1': {'word': 'theophylline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d680.s1.e1'}, 'e2': {'word': 'phenytoin', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d680.s1.e19'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	theophylline	warfarin	none	{'e1': {'word': 'theophylline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d680.s1.e1'}, 'e2': {'word': 'warfarin', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d680.s1.e20'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	theophylline	midazolam	none	{'e1': {'word': 'theophylline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d680.s1.e1'}, 'e2': {'word': 'midazolam', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d680.s1.e21'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	theophylline	clarithromycin	none	{'e1': {'word': 'theophylline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d680.s1.e1'}, 'e2': {'word': 'clarithromycin', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d680.s1.e22'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	theophylline	metronidazole	none	{'e1': {'word': 'theophylline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d680.s1.e1'}, 'e2': {'word': 'metronidazole', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d680.s1.e23'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	theophylline	amoxicillin	none	{'e1': {'word': 'theophylline', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d680.s1.e1'}, 'e2': {'word': 'amoxicillin', 'word_index': [(40, 40)], 'id': 'DDI-DrugBank.d680.s1.e24'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	cisapride	antipyrine	none	{'e1': {'word': 'cisapride', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d680.s1.e2'}, 'e2': {'word': 'antipyrine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d680.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	cisapride	caffeine	none	{'e1': {'word': 'cisapride', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d680.s1.e2'}, 'e2': {'word': 'caffeine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d680.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	cisapride	carbamazepine	none	{'e1': {'word': 'cisapride', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d680.s1.e2'}, 'e2': {'word': 'carbamazepine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d680.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	cisapride	diazepam	none	{'e1': {'word': 'cisapride', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d680.s1.e2'}, 'e2': {'word': 'diazepam', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d680.s1.e6'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	cisapride	desmethyldiazepam	none	{'e1': {'word': 'cisapride', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d680.s1.e2'}, 'e2': {'word': 'desmethyldiazepam', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d680.s1.e7'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	cisapride	diclofenac	none	{'e1': {'word': 'cisapride', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d680.s1.e2'}, 'e2': {'word': 'diclofenac', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d680.s1.e8'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	cisapride	naproxen	none	{'e1': {'word': 'cisapride', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d680.s1.e2'}, 'e2': {'word': 'naproxen', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d680.s1.e9'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	cisapride	piroxicam	none	{'e1': {'word': 'cisapride', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d680.s1.e2'}, 'e2': {'word': 'piroxicam', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d680.s1.e10'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	cisapride	digoxin	none	{'e1': {'word': 'cisapride', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d680.s1.e2'}, 'e2': {'word': 'digoxin', 'word_index': [(25, 25)], 'id': 'DDI-DrugBank.d680.s1.e11'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	cisapride	ethanol	none	{'e1': {'word': 'cisapride', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d680.s1.e2'}, 'e2': {'word': 'ethanol', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d680.s1.e12'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	cisapride	glyburide	none	{'e1': {'word': 'cisapride', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d680.s1.e2'}, 'e2': {'word': 'glyburide', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d680.s1.e13'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	cisapride	contraceptive	none	{'e1': {'word': 'cisapride', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d680.s1.e2'}, 'e2': {'word': 'contraceptive', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d680.s1.e14'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	cisapride	levonorgestrel	none	{'e1': {'word': 'cisapride', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d680.s1.e2'}, 'e2': {'word': 'levonorgestrel', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d680.s1.e15'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	cisapride	ethinyl estradiol	none	{'e1': {'word': 'cisapride', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d680.s1.e2'}, 'e2': {'word': 'ethinyl estradiol', 'word_index': [(31, 32)], 'id': 'DDI-DrugBank.d680.s1.e16'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	cisapride	metoprolol	none	{'e1': {'word': 'cisapride', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d680.s1.e2'}, 'e2': {'word': 'metoprolol', 'word_index': [(33, 33)], 'id': 'DDI-DrugBank.d680.s1.e17'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	cisapride	nifedipine	none	{'e1': {'word': 'cisapride', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d680.s1.e2'}, 'e2': {'word': 'nifedipine', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d680.s1.e18'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	cisapride	phenytoin	none	{'e1': {'word': 'cisapride', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d680.s1.e2'}, 'e2': {'word': 'phenytoin', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d680.s1.e19'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	cisapride	warfarin	none	{'e1': {'word': 'cisapride', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d680.s1.e2'}, 'e2': {'word': 'warfarin', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d680.s1.e20'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	cisapride	midazolam	none	{'e1': {'word': 'cisapride', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d680.s1.e2'}, 'e2': {'word': 'midazolam', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d680.s1.e21'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	cisapride	clarithromycin	none	{'e1': {'word': 'cisapride', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d680.s1.e2'}, 'e2': {'word': 'clarithromycin', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d680.s1.e22'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	cisapride	metronidazole	none	{'e1': {'word': 'cisapride', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d680.s1.e2'}, 'e2': {'word': 'metronidazole', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d680.s1.e23'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	cisapride	amoxicillin	none	{'e1': {'word': 'cisapride', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d680.s1.e2'}, 'e2': {'word': 'amoxicillin', 'word_index': [(40, 40)], 'id': 'DDI-DrugBank.d680.s1.e24'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	antipyrine	caffeine	none	{'e1': {'word': 'antipyrine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d680.s1.e3'}, 'e2': {'word': 'caffeine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d680.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	antipyrine	carbamazepine	none	{'e1': {'word': 'antipyrine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d680.s1.e3'}, 'e2': {'word': 'carbamazepine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d680.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	antipyrine	diazepam	none	{'e1': {'word': 'antipyrine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d680.s1.e3'}, 'e2': {'word': 'diazepam', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d680.s1.e6'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	antipyrine	desmethyldiazepam	none	{'e1': {'word': 'antipyrine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d680.s1.e3'}, 'e2': {'word': 'desmethyldiazepam', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d680.s1.e7'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	antipyrine	diclofenac	none	{'e1': {'word': 'antipyrine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d680.s1.e3'}, 'e2': {'word': 'diclofenac', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d680.s1.e8'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	antipyrine	naproxen	none	{'e1': {'word': 'antipyrine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d680.s1.e3'}, 'e2': {'word': 'naproxen', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d680.s1.e9'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	antipyrine	piroxicam	none	{'e1': {'word': 'antipyrine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d680.s1.e3'}, 'e2': {'word': 'piroxicam', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d680.s1.e10'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	antipyrine	digoxin	none	{'e1': {'word': 'antipyrine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d680.s1.e3'}, 'e2': {'word': 'digoxin', 'word_index': [(25, 25)], 'id': 'DDI-DrugBank.d680.s1.e11'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	antipyrine	ethanol	none	{'e1': {'word': 'antipyrine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d680.s1.e3'}, 'e2': {'word': 'ethanol', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d680.s1.e12'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	antipyrine	glyburide	none	{'e1': {'word': 'antipyrine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d680.s1.e3'}, 'e2': {'word': 'glyburide', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d680.s1.e13'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	antipyrine	contraceptive	none	{'e1': {'word': 'antipyrine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d680.s1.e3'}, 'e2': {'word': 'contraceptive', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d680.s1.e14'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	antipyrine	levonorgestrel	none	{'e1': {'word': 'antipyrine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d680.s1.e3'}, 'e2': {'word': 'levonorgestrel', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d680.s1.e15'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	antipyrine	ethinyl estradiol	none	{'e1': {'word': 'antipyrine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d680.s1.e3'}, 'e2': {'word': 'ethinyl estradiol', 'word_index': [(31, 32)], 'id': 'DDI-DrugBank.d680.s1.e16'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	antipyrine	metoprolol	none	{'e1': {'word': 'antipyrine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d680.s1.e3'}, 'e2': {'word': 'metoprolol', 'word_index': [(33, 33)], 'id': 'DDI-DrugBank.d680.s1.e17'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	antipyrine	nifedipine	none	{'e1': {'word': 'antipyrine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d680.s1.e3'}, 'e2': {'word': 'nifedipine', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d680.s1.e18'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	antipyrine	phenytoin	none	{'e1': {'word': 'antipyrine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d680.s1.e3'}, 'e2': {'word': 'phenytoin', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d680.s1.e19'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	antipyrine	warfarin	none	{'e1': {'word': 'antipyrine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d680.s1.e3'}, 'e2': {'word': 'warfarin', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d680.s1.e20'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	antipyrine	midazolam	none	{'e1': {'word': 'antipyrine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d680.s1.e3'}, 'e2': {'word': 'midazolam', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d680.s1.e21'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	antipyrine	clarithromycin	none	{'e1': {'word': 'antipyrine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d680.s1.e3'}, 'e2': {'word': 'clarithromycin', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d680.s1.e22'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	antipyrine	metronidazole	none	{'e1': {'word': 'antipyrine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d680.s1.e3'}, 'e2': {'word': 'metronidazole', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d680.s1.e23'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	antipyrine	amoxicillin	none	{'e1': {'word': 'antipyrine', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d680.s1.e3'}, 'e2': {'word': 'amoxicillin', 'word_index': [(40, 40)], 'id': 'DDI-DrugBank.d680.s1.e24'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	caffeine	carbamazepine	none	{'e1': {'word': 'caffeine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d680.s1.e4'}, 'e2': {'word': 'carbamazepine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d680.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	caffeine	diazepam	none	{'e1': {'word': 'caffeine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d680.s1.e4'}, 'e2': {'word': 'diazepam', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d680.s1.e6'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	caffeine	desmethyldiazepam	none	{'e1': {'word': 'caffeine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d680.s1.e4'}, 'e2': {'word': 'desmethyldiazepam', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d680.s1.e7'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	caffeine	diclofenac	none	{'e1': {'word': 'caffeine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d680.s1.e4'}, 'e2': {'word': 'diclofenac', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d680.s1.e8'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	caffeine	naproxen	none	{'e1': {'word': 'caffeine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d680.s1.e4'}, 'e2': {'word': 'naproxen', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d680.s1.e9'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	caffeine	piroxicam	none	{'e1': {'word': 'caffeine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d680.s1.e4'}, 'e2': {'word': 'piroxicam', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d680.s1.e10'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	caffeine	digoxin	none	{'e1': {'word': 'caffeine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d680.s1.e4'}, 'e2': {'word': 'digoxin', 'word_index': [(25, 25)], 'id': 'DDI-DrugBank.d680.s1.e11'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	caffeine	ethanol	none	{'e1': {'word': 'caffeine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d680.s1.e4'}, 'e2': {'word': 'ethanol', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d680.s1.e12'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	caffeine	glyburide	none	{'e1': {'word': 'caffeine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d680.s1.e4'}, 'e2': {'word': 'glyburide', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d680.s1.e13'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	caffeine	contraceptive	none	{'e1': {'word': 'caffeine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d680.s1.e4'}, 'e2': {'word': 'contraceptive', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d680.s1.e14'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	caffeine	levonorgestrel	none	{'e1': {'word': 'caffeine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d680.s1.e4'}, 'e2': {'word': 'levonorgestrel', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d680.s1.e15'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	caffeine	ethinyl estradiol	none	{'e1': {'word': 'caffeine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d680.s1.e4'}, 'e2': {'word': 'ethinyl estradiol', 'word_index': [(31, 32)], 'id': 'DDI-DrugBank.d680.s1.e16'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	caffeine	metoprolol	none	{'e1': {'word': 'caffeine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d680.s1.e4'}, 'e2': {'word': 'metoprolol', 'word_index': [(33, 33)], 'id': 'DDI-DrugBank.d680.s1.e17'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	caffeine	nifedipine	none	{'e1': {'word': 'caffeine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d680.s1.e4'}, 'e2': {'word': 'nifedipine', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d680.s1.e18'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	caffeine	phenytoin	none	{'e1': {'word': 'caffeine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d680.s1.e4'}, 'e2': {'word': 'phenytoin', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d680.s1.e19'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	caffeine	warfarin	none	{'e1': {'word': 'caffeine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d680.s1.e4'}, 'e2': {'word': 'warfarin', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d680.s1.e20'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	caffeine	midazolam	none	{'e1': {'word': 'caffeine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d680.s1.e4'}, 'e2': {'word': 'midazolam', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d680.s1.e21'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	caffeine	clarithromycin	none	{'e1': {'word': 'caffeine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d680.s1.e4'}, 'e2': {'word': 'clarithromycin', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d680.s1.e22'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	caffeine	metronidazole	none	{'e1': {'word': 'caffeine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d680.s1.e4'}, 'e2': {'word': 'metronidazole', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d680.s1.e23'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	caffeine	amoxicillin	none	{'e1': {'word': 'caffeine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d680.s1.e4'}, 'e2': {'word': 'amoxicillin', 'word_index': [(40, 40)], 'id': 'DDI-DrugBank.d680.s1.e24'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	carbamazepine	diazepam	none	{'e1': {'word': 'carbamazepine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d680.s1.e5'}, 'e2': {'word': 'diazepam', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d680.s1.e6'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	carbamazepine	desmethyldiazepam	none	{'e1': {'word': 'carbamazepine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d680.s1.e5'}, 'e2': {'word': 'desmethyldiazepam', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d680.s1.e7'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	carbamazepine	diclofenac	none	{'e1': {'word': 'carbamazepine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d680.s1.e5'}, 'e2': {'word': 'diclofenac', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d680.s1.e8'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	carbamazepine	naproxen	none	{'e1': {'word': 'carbamazepine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d680.s1.e5'}, 'e2': {'word': 'naproxen', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d680.s1.e9'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	carbamazepine	piroxicam	none	{'e1': {'word': 'carbamazepine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d680.s1.e5'}, 'e2': {'word': 'piroxicam', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d680.s1.e10'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	carbamazepine	digoxin	none	{'e1': {'word': 'carbamazepine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d680.s1.e5'}, 'e2': {'word': 'digoxin', 'word_index': [(25, 25)], 'id': 'DDI-DrugBank.d680.s1.e11'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	carbamazepine	ethanol	none	{'e1': {'word': 'carbamazepine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d680.s1.e5'}, 'e2': {'word': 'ethanol', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d680.s1.e12'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	carbamazepine	glyburide	none	{'e1': {'word': 'carbamazepine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d680.s1.e5'}, 'e2': {'word': 'glyburide', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d680.s1.e13'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	carbamazepine	contraceptive	none	{'e1': {'word': 'carbamazepine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d680.s1.e5'}, 'e2': {'word': 'contraceptive', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d680.s1.e14'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	carbamazepine	levonorgestrel	none	{'e1': {'word': 'carbamazepine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d680.s1.e5'}, 'e2': {'word': 'levonorgestrel', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d680.s1.e15'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	carbamazepine	ethinyl estradiol	none	{'e1': {'word': 'carbamazepine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d680.s1.e5'}, 'e2': {'word': 'ethinyl estradiol', 'word_index': [(31, 32)], 'id': 'DDI-DrugBank.d680.s1.e16'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	carbamazepine	metoprolol	none	{'e1': {'word': 'carbamazepine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d680.s1.e5'}, 'e2': {'word': 'metoprolol', 'word_index': [(33, 33)], 'id': 'DDI-DrugBank.d680.s1.e17'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	carbamazepine	nifedipine	none	{'e1': {'word': 'carbamazepine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d680.s1.e5'}, 'e2': {'word': 'nifedipine', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d680.s1.e18'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	carbamazepine	phenytoin	none	{'e1': {'word': 'carbamazepine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d680.s1.e5'}, 'e2': {'word': 'phenytoin', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d680.s1.e19'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	carbamazepine	warfarin	none	{'e1': {'word': 'carbamazepine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d680.s1.e5'}, 'e2': {'word': 'warfarin', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d680.s1.e20'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	carbamazepine	midazolam	none	{'e1': {'word': 'carbamazepine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d680.s1.e5'}, 'e2': {'word': 'midazolam', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d680.s1.e21'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	carbamazepine	clarithromycin	none	{'e1': {'word': 'carbamazepine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d680.s1.e5'}, 'e2': {'word': 'clarithromycin', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d680.s1.e22'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	carbamazepine	metronidazole	none	{'e1': {'word': 'carbamazepine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d680.s1.e5'}, 'e2': {'word': 'metronidazole', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d680.s1.e23'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	carbamazepine	amoxicillin	none	{'e1': {'word': 'carbamazepine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d680.s1.e5'}, 'e2': {'word': 'amoxicillin', 'word_index': [(40, 40)], 'id': 'DDI-DrugBank.d680.s1.e24'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	diazepam	desmethyldiazepam	none	{'e1': {'word': 'diazepam', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d680.s1.e6'}, 'e2': {'word': 'desmethyldiazepam', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d680.s1.e7'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	diazepam	diclofenac	none	{'e1': {'word': 'diazepam', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d680.s1.e6'}, 'e2': {'word': 'diclofenac', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d680.s1.e8'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	diazepam	naproxen	none	{'e1': {'word': 'diazepam', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d680.s1.e6'}, 'e2': {'word': 'naproxen', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d680.s1.e9'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	diazepam	piroxicam	none	{'e1': {'word': 'diazepam', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d680.s1.e6'}, 'e2': {'word': 'piroxicam', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d680.s1.e10'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	diazepam	digoxin	none	{'e1': {'word': 'diazepam', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d680.s1.e6'}, 'e2': {'word': 'digoxin', 'word_index': [(25, 25)], 'id': 'DDI-DrugBank.d680.s1.e11'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	diazepam	ethanol	none	{'e1': {'word': 'diazepam', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d680.s1.e6'}, 'e2': {'word': 'ethanol', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d680.s1.e12'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	diazepam	glyburide	none	{'e1': {'word': 'diazepam', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d680.s1.e6'}, 'e2': {'word': 'glyburide', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d680.s1.e13'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	diazepam	contraceptive	none	{'e1': {'word': 'diazepam', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d680.s1.e6'}, 'e2': {'word': 'contraceptive', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d680.s1.e14'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	diazepam	levonorgestrel	none	{'e1': {'word': 'diazepam', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d680.s1.e6'}, 'e2': {'word': 'levonorgestrel', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d680.s1.e15'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	diazepam	ethinyl estradiol	none	{'e1': {'word': 'diazepam', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d680.s1.e6'}, 'e2': {'word': 'ethinyl estradiol', 'word_index': [(31, 32)], 'id': 'DDI-DrugBank.d680.s1.e16'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	diazepam	metoprolol	none	{'e1': {'word': 'diazepam', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d680.s1.e6'}, 'e2': {'word': 'metoprolol', 'word_index': [(33, 33)], 'id': 'DDI-DrugBank.d680.s1.e17'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	diazepam	nifedipine	none	{'e1': {'word': 'diazepam', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d680.s1.e6'}, 'e2': {'word': 'nifedipine', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d680.s1.e18'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	diazepam	phenytoin	none	{'e1': {'word': 'diazepam', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d680.s1.e6'}, 'e2': {'word': 'phenytoin', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d680.s1.e19'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	diazepam	warfarin	none	{'e1': {'word': 'diazepam', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d680.s1.e6'}, 'e2': {'word': 'warfarin', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d680.s1.e20'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	diazepam	midazolam	none	{'e1': {'word': 'diazepam', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d680.s1.e6'}, 'e2': {'word': 'midazolam', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d680.s1.e21'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	diazepam	clarithromycin	none	{'e1': {'word': 'diazepam', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d680.s1.e6'}, 'e2': {'word': 'clarithromycin', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d680.s1.e22'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	diazepam	metronidazole	none	{'e1': {'word': 'diazepam', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d680.s1.e6'}, 'e2': {'word': 'metronidazole', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d680.s1.e23'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	diazepam	amoxicillin	none	{'e1': {'word': 'diazepam', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d680.s1.e6'}, 'e2': {'word': 'amoxicillin', 'word_index': [(40, 40)], 'id': 'DDI-DrugBank.d680.s1.e24'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	desmethyldiazepam	diclofenac	none	{'e1': {'word': 'desmethyldiazepam', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d680.s1.e7'}, 'e2': {'word': 'diclofenac', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d680.s1.e8'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	desmethyldiazepam	naproxen	none	{'e1': {'word': 'desmethyldiazepam', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d680.s1.e7'}, 'e2': {'word': 'naproxen', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d680.s1.e9'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	desmethyldiazepam	piroxicam	none	{'e1': {'word': 'desmethyldiazepam', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d680.s1.e7'}, 'e2': {'word': 'piroxicam', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d680.s1.e10'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	desmethyldiazepam	digoxin	none	{'e1': {'word': 'desmethyldiazepam', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d680.s1.e7'}, 'e2': {'word': 'digoxin', 'word_index': [(25, 25)], 'id': 'DDI-DrugBank.d680.s1.e11'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	desmethyldiazepam	ethanol	none	{'e1': {'word': 'desmethyldiazepam', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d680.s1.e7'}, 'e2': {'word': 'ethanol', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d680.s1.e12'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	desmethyldiazepam	glyburide	none	{'e1': {'word': 'desmethyldiazepam', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d680.s1.e7'}, 'e2': {'word': 'glyburide', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d680.s1.e13'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	desmethyldiazepam	contraceptive	none	{'e1': {'word': 'desmethyldiazepam', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d680.s1.e7'}, 'e2': {'word': 'contraceptive', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d680.s1.e14'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	desmethyldiazepam	levonorgestrel	none	{'e1': {'word': 'desmethyldiazepam', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d680.s1.e7'}, 'e2': {'word': 'levonorgestrel', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d680.s1.e15'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	desmethyldiazepam	ethinyl estradiol	none	{'e1': {'word': 'desmethyldiazepam', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d680.s1.e7'}, 'e2': {'word': 'ethinyl estradiol', 'word_index': [(31, 32)], 'id': 'DDI-DrugBank.d680.s1.e16'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	desmethyldiazepam	metoprolol	none	{'e1': {'word': 'desmethyldiazepam', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d680.s1.e7'}, 'e2': {'word': 'metoprolol', 'word_index': [(33, 33)], 'id': 'DDI-DrugBank.d680.s1.e17'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	desmethyldiazepam	nifedipine	none	{'e1': {'word': 'desmethyldiazepam', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d680.s1.e7'}, 'e2': {'word': 'nifedipine', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d680.s1.e18'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	desmethyldiazepam	phenytoin	none	{'e1': {'word': 'desmethyldiazepam', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d680.s1.e7'}, 'e2': {'word': 'phenytoin', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d680.s1.e19'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	desmethyldiazepam	warfarin	none	{'e1': {'word': 'desmethyldiazepam', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d680.s1.e7'}, 'e2': {'word': 'warfarin', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d680.s1.e20'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	desmethyldiazepam	midazolam	none	{'e1': {'word': 'desmethyldiazepam', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d680.s1.e7'}, 'e2': {'word': 'midazolam', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d680.s1.e21'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	desmethyldiazepam	clarithromycin	none	{'e1': {'word': 'desmethyldiazepam', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d680.s1.e7'}, 'e2': {'word': 'clarithromycin', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d680.s1.e22'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	desmethyldiazepam	metronidazole	none	{'e1': {'word': 'desmethyldiazepam', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d680.s1.e7'}, 'e2': {'word': 'metronidazole', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d680.s1.e23'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	desmethyldiazepam	amoxicillin	none	{'e1': {'word': 'desmethyldiazepam', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d680.s1.e7'}, 'e2': {'word': 'amoxicillin', 'word_index': [(40, 40)], 'id': 'DDI-DrugBank.d680.s1.e24'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	diclofenac	naproxen	none	{'e1': {'word': 'diclofenac', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d680.s1.e8'}, 'e2': {'word': 'naproxen', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d680.s1.e9'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	diclofenac	piroxicam	none	{'e1': {'word': 'diclofenac', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d680.s1.e8'}, 'e2': {'word': 'piroxicam', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d680.s1.e10'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	diclofenac	digoxin	none	{'e1': {'word': 'diclofenac', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d680.s1.e8'}, 'e2': {'word': 'digoxin', 'word_index': [(25, 25)], 'id': 'DDI-DrugBank.d680.s1.e11'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	diclofenac	ethanol	none	{'e1': {'word': 'diclofenac', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d680.s1.e8'}, 'e2': {'word': 'ethanol', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d680.s1.e12'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	diclofenac	glyburide	none	{'e1': {'word': 'diclofenac', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d680.s1.e8'}, 'e2': {'word': 'glyburide', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d680.s1.e13'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	diclofenac	contraceptive	none	{'e1': {'word': 'diclofenac', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d680.s1.e8'}, 'e2': {'word': 'contraceptive', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d680.s1.e14'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	diclofenac	levonorgestrel	none	{'e1': {'word': 'diclofenac', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d680.s1.e8'}, 'e2': {'word': 'levonorgestrel', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d680.s1.e15'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	diclofenac	ethinyl estradiol	none	{'e1': {'word': 'diclofenac', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d680.s1.e8'}, 'e2': {'word': 'ethinyl estradiol', 'word_index': [(31, 32)], 'id': 'DDI-DrugBank.d680.s1.e16'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	diclofenac	metoprolol	none	{'e1': {'word': 'diclofenac', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d680.s1.e8'}, 'e2': {'word': 'metoprolol', 'word_index': [(33, 33)], 'id': 'DDI-DrugBank.d680.s1.e17'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	diclofenac	nifedipine	none	{'e1': {'word': 'diclofenac', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d680.s1.e8'}, 'e2': {'word': 'nifedipine', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d680.s1.e18'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	diclofenac	phenytoin	none	{'e1': {'word': 'diclofenac', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d680.s1.e8'}, 'e2': {'word': 'phenytoin', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d680.s1.e19'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	diclofenac	warfarin	none	{'e1': {'word': 'diclofenac', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d680.s1.e8'}, 'e2': {'word': 'warfarin', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d680.s1.e20'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	diclofenac	midazolam	none	{'e1': {'word': 'diclofenac', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d680.s1.e8'}, 'e2': {'word': 'midazolam', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d680.s1.e21'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	diclofenac	clarithromycin	none	{'e1': {'word': 'diclofenac', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d680.s1.e8'}, 'e2': {'word': 'clarithromycin', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d680.s1.e22'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	diclofenac	metronidazole	none	{'e1': {'word': 'diclofenac', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d680.s1.e8'}, 'e2': {'word': 'metronidazole', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d680.s1.e23'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	diclofenac	amoxicillin	none	{'e1': {'word': 'diclofenac', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d680.s1.e8'}, 'e2': {'word': 'amoxicillin', 'word_index': [(40, 40)], 'id': 'DDI-DrugBank.d680.s1.e24'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	naproxen	piroxicam	none	{'e1': {'word': 'naproxen', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d680.s1.e9'}, 'e2': {'word': 'piroxicam', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d680.s1.e10'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	naproxen	digoxin	none	{'e1': {'word': 'naproxen', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d680.s1.e9'}, 'e2': {'word': 'digoxin', 'word_index': [(25, 25)], 'id': 'DDI-DrugBank.d680.s1.e11'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	naproxen	ethanol	none	{'e1': {'word': 'naproxen', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d680.s1.e9'}, 'e2': {'word': 'ethanol', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d680.s1.e12'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	naproxen	glyburide	none	{'e1': {'word': 'naproxen', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d680.s1.e9'}, 'e2': {'word': 'glyburide', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d680.s1.e13'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	naproxen	contraceptive	none	{'e1': {'word': 'naproxen', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d680.s1.e9'}, 'e2': {'word': 'contraceptive', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d680.s1.e14'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	naproxen	levonorgestrel	none	{'e1': {'word': 'naproxen', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d680.s1.e9'}, 'e2': {'word': 'levonorgestrel', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d680.s1.e15'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	naproxen	ethinyl estradiol	none	{'e1': {'word': 'naproxen', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d680.s1.e9'}, 'e2': {'word': 'ethinyl estradiol', 'word_index': [(31, 32)], 'id': 'DDI-DrugBank.d680.s1.e16'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	naproxen	metoprolol	none	{'e1': {'word': 'naproxen', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d680.s1.e9'}, 'e2': {'word': 'metoprolol', 'word_index': [(33, 33)], 'id': 'DDI-DrugBank.d680.s1.e17'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	naproxen	nifedipine	none	{'e1': {'word': 'naproxen', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d680.s1.e9'}, 'e2': {'word': 'nifedipine', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d680.s1.e18'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	naproxen	phenytoin	none	{'e1': {'word': 'naproxen', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d680.s1.e9'}, 'e2': {'word': 'phenytoin', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d680.s1.e19'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	naproxen	warfarin	none	{'e1': {'word': 'naproxen', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d680.s1.e9'}, 'e2': {'word': 'warfarin', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d680.s1.e20'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	naproxen	midazolam	none	{'e1': {'word': 'naproxen', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d680.s1.e9'}, 'e2': {'word': 'midazolam', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d680.s1.e21'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	naproxen	clarithromycin	none	{'e1': {'word': 'naproxen', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d680.s1.e9'}, 'e2': {'word': 'clarithromycin', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d680.s1.e22'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	naproxen	metronidazole	none	{'e1': {'word': 'naproxen', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d680.s1.e9'}, 'e2': {'word': 'metronidazole', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d680.s1.e23'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	naproxen	amoxicillin	none	{'e1': {'word': 'naproxen', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d680.s1.e9'}, 'e2': {'word': 'amoxicillin', 'word_index': [(40, 40)], 'id': 'DDI-DrugBank.d680.s1.e24'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	piroxicam	digoxin	none	{'e1': {'word': 'piroxicam', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d680.s1.e10'}, 'e2': {'word': 'digoxin', 'word_index': [(25, 25)], 'id': 'DDI-DrugBank.d680.s1.e11'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	piroxicam	ethanol	none	{'e1': {'word': 'piroxicam', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d680.s1.e10'}, 'e2': {'word': 'ethanol', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d680.s1.e12'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	piroxicam	glyburide	none	{'e1': {'word': 'piroxicam', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d680.s1.e10'}, 'e2': {'word': 'glyburide', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d680.s1.e13'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	piroxicam	contraceptive	none	{'e1': {'word': 'piroxicam', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d680.s1.e10'}, 'e2': {'word': 'contraceptive', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d680.s1.e14'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	piroxicam	levonorgestrel	none	{'e1': {'word': 'piroxicam', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d680.s1.e10'}, 'e2': {'word': 'levonorgestrel', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d680.s1.e15'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	piroxicam	ethinyl estradiol	none	{'e1': {'word': 'piroxicam', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d680.s1.e10'}, 'e2': {'word': 'ethinyl estradiol', 'word_index': [(31, 32)], 'id': 'DDI-DrugBank.d680.s1.e16'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	piroxicam	metoprolol	none	{'e1': {'word': 'piroxicam', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d680.s1.e10'}, 'e2': {'word': 'metoprolol', 'word_index': [(33, 33)], 'id': 'DDI-DrugBank.d680.s1.e17'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	piroxicam	nifedipine	none	{'e1': {'word': 'piroxicam', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d680.s1.e10'}, 'e2': {'word': 'nifedipine', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d680.s1.e18'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	piroxicam	phenytoin	none	{'e1': {'word': 'piroxicam', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d680.s1.e10'}, 'e2': {'word': 'phenytoin', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d680.s1.e19'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	piroxicam	warfarin	none	{'e1': {'word': 'piroxicam', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d680.s1.e10'}, 'e2': {'word': 'warfarin', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d680.s1.e20'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	piroxicam	midazolam	none	{'e1': {'word': 'piroxicam', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d680.s1.e10'}, 'e2': {'word': 'midazolam', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d680.s1.e21'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	piroxicam	clarithromycin	none	{'e1': {'word': 'piroxicam', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d680.s1.e10'}, 'e2': {'word': 'clarithromycin', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d680.s1.e22'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	piroxicam	metronidazole	none	{'e1': {'word': 'piroxicam', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d680.s1.e10'}, 'e2': {'word': 'metronidazole', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d680.s1.e23'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	piroxicam	amoxicillin	none	{'e1': {'word': 'piroxicam', 'word_index': [(24, 24)], 'id': 'DDI-DrugBank.d680.s1.e10'}, 'e2': {'word': 'amoxicillin', 'word_index': [(40, 40)], 'id': 'DDI-DrugBank.d680.s1.e24'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	digoxin	ethanol	none	{'e1': {'word': 'digoxin', 'word_index': [(25, 25)], 'id': 'DDI-DrugBank.d680.s1.e11'}, 'e2': {'word': 'ethanol', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d680.s1.e12'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	digoxin	glyburide	none	{'e1': {'word': 'digoxin', 'word_index': [(25, 25)], 'id': 'DDI-DrugBank.d680.s1.e11'}, 'e2': {'word': 'glyburide', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d680.s1.e13'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	digoxin	contraceptive	none	{'e1': {'word': 'digoxin', 'word_index': [(25, 25)], 'id': 'DDI-DrugBank.d680.s1.e11'}, 'e2': {'word': 'contraceptive', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d680.s1.e14'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	digoxin	levonorgestrel	none	{'e1': {'word': 'digoxin', 'word_index': [(25, 25)], 'id': 'DDI-DrugBank.d680.s1.e11'}, 'e2': {'word': 'levonorgestrel', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d680.s1.e15'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	digoxin	ethinyl estradiol	none	{'e1': {'word': 'digoxin', 'word_index': [(25, 25)], 'id': 'DDI-DrugBank.d680.s1.e11'}, 'e2': {'word': 'ethinyl estradiol', 'word_index': [(31, 32)], 'id': 'DDI-DrugBank.d680.s1.e16'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	digoxin	metoprolol	none	{'e1': {'word': 'digoxin', 'word_index': [(25, 25)], 'id': 'DDI-DrugBank.d680.s1.e11'}, 'e2': {'word': 'metoprolol', 'word_index': [(33, 33)], 'id': 'DDI-DrugBank.d680.s1.e17'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	digoxin	nifedipine	none	{'e1': {'word': 'digoxin', 'word_index': [(25, 25)], 'id': 'DDI-DrugBank.d680.s1.e11'}, 'e2': {'word': 'nifedipine', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d680.s1.e18'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	digoxin	phenytoin	none	{'e1': {'word': 'digoxin', 'word_index': [(25, 25)], 'id': 'DDI-DrugBank.d680.s1.e11'}, 'e2': {'word': 'phenytoin', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d680.s1.e19'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	digoxin	warfarin	none	{'e1': {'word': 'digoxin', 'word_index': [(25, 25)], 'id': 'DDI-DrugBank.d680.s1.e11'}, 'e2': {'word': 'warfarin', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d680.s1.e20'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	digoxin	midazolam	none	{'e1': {'word': 'digoxin', 'word_index': [(25, 25)], 'id': 'DDI-DrugBank.d680.s1.e11'}, 'e2': {'word': 'midazolam', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d680.s1.e21'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	digoxin	clarithromycin	none	{'e1': {'word': 'digoxin', 'word_index': [(25, 25)], 'id': 'DDI-DrugBank.d680.s1.e11'}, 'e2': {'word': 'clarithromycin', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d680.s1.e22'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	digoxin	metronidazole	none	{'e1': {'word': 'digoxin', 'word_index': [(25, 25)], 'id': 'DDI-DrugBank.d680.s1.e11'}, 'e2': {'word': 'metronidazole', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d680.s1.e23'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	digoxin	amoxicillin	none	{'e1': {'word': 'digoxin', 'word_index': [(25, 25)], 'id': 'DDI-DrugBank.d680.s1.e11'}, 'e2': {'word': 'amoxicillin', 'word_index': [(40, 40)], 'id': 'DDI-DrugBank.d680.s1.e24'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	ethanol	glyburide	none	{'e1': {'word': 'ethanol', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d680.s1.e12'}, 'e2': {'word': 'glyburide', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d680.s1.e13'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	ethanol	contraceptive	none	{'e1': {'word': 'ethanol', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d680.s1.e12'}, 'e2': {'word': 'contraceptive', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d680.s1.e14'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	ethanol	levonorgestrel	none	{'e1': {'word': 'ethanol', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d680.s1.e12'}, 'e2': {'word': 'levonorgestrel', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d680.s1.e15'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	ethanol	ethinyl estradiol	none	{'e1': {'word': 'ethanol', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d680.s1.e12'}, 'e2': {'word': 'ethinyl estradiol', 'word_index': [(31, 32)], 'id': 'DDI-DrugBank.d680.s1.e16'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	ethanol	metoprolol	none	{'e1': {'word': 'ethanol', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d680.s1.e12'}, 'e2': {'word': 'metoprolol', 'word_index': [(33, 33)], 'id': 'DDI-DrugBank.d680.s1.e17'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	ethanol	nifedipine	none	{'e1': {'word': 'ethanol', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d680.s1.e12'}, 'e2': {'word': 'nifedipine', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d680.s1.e18'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	ethanol	phenytoin	none	{'e1': {'word': 'ethanol', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d680.s1.e12'}, 'e2': {'word': 'phenytoin', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d680.s1.e19'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	ethanol	warfarin	none	{'e1': {'word': 'ethanol', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d680.s1.e12'}, 'e2': {'word': 'warfarin', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d680.s1.e20'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	ethanol	midazolam	none	{'e1': {'word': 'ethanol', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d680.s1.e12'}, 'e2': {'word': 'midazolam', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d680.s1.e21'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	ethanol	clarithromycin	none	{'e1': {'word': 'ethanol', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d680.s1.e12'}, 'e2': {'word': 'clarithromycin', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d680.s1.e22'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	ethanol	metronidazole	none	{'e1': {'word': 'ethanol', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d680.s1.e12'}, 'e2': {'word': 'metronidazole', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d680.s1.e23'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	ethanol	amoxicillin	none	{'e1': {'word': 'ethanol', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d680.s1.e12'}, 'e2': {'word': 'amoxicillin', 'word_index': [(40, 40)], 'id': 'DDI-DrugBank.d680.s1.e24'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	glyburide	contraceptive	none	{'e1': {'word': 'glyburide', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d680.s1.e13'}, 'e2': {'word': 'contraceptive', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d680.s1.e14'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	glyburide	levonorgestrel	none	{'e1': {'word': 'glyburide', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d680.s1.e13'}, 'e2': {'word': 'levonorgestrel', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d680.s1.e15'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	glyburide	ethinyl estradiol	none	{'e1': {'word': 'glyburide', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d680.s1.e13'}, 'e2': {'word': 'ethinyl estradiol', 'word_index': [(31, 32)], 'id': 'DDI-DrugBank.d680.s1.e16'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	glyburide	metoprolol	none	{'e1': {'word': 'glyburide', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d680.s1.e13'}, 'e2': {'word': 'metoprolol', 'word_index': [(33, 33)], 'id': 'DDI-DrugBank.d680.s1.e17'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	glyburide	nifedipine	none	{'e1': {'word': 'glyburide', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d680.s1.e13'}, 'e2': {'word': 'nifedipine', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d680.s1.e18'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	glyburide	phenytoin	none	{'e1': {'word': 'glyburide', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d680.s1.e13'}, 'e2': {'word': 'phenytoin', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d680.s1.e19'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	glyburide	warfarin	none	{'e1': {'word': 'glyburide', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d680.s1.e13'}, 'e2': {'word': 'warfarin', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d680.s1.e20'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	glyburide	midazolam	none	{'e1': {'word': 'glyburide', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d680.s1.e13'}, 'e2': {'word': 'midazolam', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d680.s1.e21'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	glyburide	clarithromycin	none	{'e1': {'word': 'glyburide', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d680.s1.e13'}, 'e2': {'word': 'clarithromycin', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d680.s1.e22'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	glyburide	metronidazole	none	{'e1': {'word': 'glyburide', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d680.s1.e13'}, 'e2': {'word': 'metronidazole', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d680.s1.e23'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	glyburide	amoxicillin	none	{'e1': {'word': 'glyburide', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d680.s1.e13'}, 'e2': {'word': 'amoxicillin', 'word_index': [(40, 40)], 'id': 'DDI-DrugBank.d680.s1.e24'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	contraceptive	levonorgestrel	none	{'e1': {'word': 'contraceptive', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d680.s1.e14'}, 'e2': {'word': 'levonorgestrel', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d680.s1.e15'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	contraceptive	ethinyl estradiol	none	{'e1': {'word': 'contraceptive', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d680.s1.e14'}, 'e2': {'word': 'ethinyl estradiol', 'word_index': [(31, 32)], 'id': 'DDI-DrugBank.d680.s1.e16'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	contraceptive	metoprolol	none	{'e1': {'word': 'contraceptive', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d680.s1.e14'}, 'e2': {'word': 'metoprolol', 'word_index': [(33, 33)], 'id': 'DDI-DrugBank.d680.s1.e17'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	contraceptive	nifedipine	none	{'e1': {'word': 'contraceptive', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d680.s1.e14'}, 'e2': {'word': 'nifedipine', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d680.s1.e18'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	contraceptive	phenytoin	none	{'e1': {'word': 'contraceptive', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d680.s1.e14'}, 'e2': {'word': 'phenytoin', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d680.s1.e19'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	contraceptive	warfarin	none	{'e1': {'word': 'contraceptive', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d680.s1.e14'}, 'e2': {'word': 'warfarin', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d680.s1.e20'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	contraceptive	midazolam	none	{'e1': {'word': 'contraceptive', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d680.s1.e14'}, 'e2': {'word': 'midazolam', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d680.s1.e21'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	contraceptive	clarithromycin	none	{'e1': {'word': 'contraceptive', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d680.s1.e14'}, 'e2': {'word': 'clarithromycin', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d680.s1.e22'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	contraceptive	metronidazole	none	{'e1': {'word': 'contraceptive', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d680.s1.e14'}, 'e2': {'word': 'metronidazole', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d680.s1.e23'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	contraceptive	amoxicillin	none	{'e1': {'word': 'contraceptive', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d680.s1.e14'}, 'e2': {'word': 'amoxicillin', 'word_index': [(40, 40)], 'id': 'DDI-DrugBank.d680.s1.e24'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	levonorgestrel	ethinyl estradiol	none	{'e1': {'word': 'levonorgestrel', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d680.s1.e15'}, 'e2': {'word': 'ethinyl estradiol', 'word_index': [(31, 32)], 'id': 'DDI-DrugBank.d680.s1.e16'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	levonorgestrel	metoprolol	none	{'e1': {'word': 'levonorgestrel', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d680.s1.e15'}, 'e2': {'word': 'metoprolol', 'word_index': [(33, 33)], 'id': 'DDI-DrugBank.d680.s1.e17'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	levonorgestrel	nifedipine	none	{'e1': {'word': 'levonorgestrel', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d680.s1.e15'}, 'e2': {'word': 'nifedipine', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d680.s1.e18'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	levonorgestrel	phenytoin	none	{'e1': {'word': 'levonorgestrel', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d680.s1.e15'}, 'e2': {'word': 'phenytoin', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d680.s1.e19'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	levonorgestrel	warfarin	none	{'e1': {'word': 'levonorgestrel', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d680.s1.e15'}, 'e2': {'word': 'warfarin', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d680.s1.e20'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	levonorgestrel	midazolam	none	{'e1': {'word': 'levonorgestrel', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d680.s1.e15'}, 'e2': {'word': 'midazolam', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d680.s1.e21'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	levonorgestrel	clarithromycin	none	{'e1': {'word': 'levonorgestrel', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d680.s1.e15'}, 'e2': {'word': 'clarithromycin', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d680.s1.e22'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	levonorgestrel	metronidazole	none	{'e1': {'word': 'levonorgestrel', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d680.s1.e15'}, 'e2': {'word': 'metronidazole', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d680.s1.e23'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	levonorgestrel	amoxicillin	none	{'e1': {'word': 'levonorgestrel', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d680.s1.e15'}, 'e2': {'word': 'amoxicillin', 'word_index': [(40, 40)], 'id': 'DDI-DrugBank.d680.s1.e24'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	ethinyl estradiol	metoprolol	none	{'e1': {'word': 'ethinyl estradiol', 'word_index': [(31, 32)], 'id': 'DDI-DrugBank.d680.s1.e16'}, 'e2': {'word': 'metoprolol', 'word_index': [(33, 33)], 'id': 'DDI-DrugBank.d680.s1.e17'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	ethinyl estradiol	nifedipine	none	{'e1': {'word': 'ethinyl estradiol', 'word_index': [(31, 32)], 'id': 'DDI-DrugBank.d680.s1.e16'}, 'e2': {'word': 'nifedipine', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d680.s1.e18'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	ethinyl estradiol	phenytoin	none	{'e1': {'word': 'ethinyl estradiol', 'word_index': [(31, 32)], 'id': 'DDI-DrugBank.d680.s1.e16'}, 'e2': {'word': 'phenytoin', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d680.s1.e19'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	ethinyl estradiol	warfarin	none	{'e1': {'word': 'ethinyl estradiol', 'word_index': [(31, 32)], 'id': 'DDI-DrugBank.d680.s1.e16'}, 'e2': {'word': 'warfarin', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d680.s1.e20'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	ethinyl estradiol	midazolam	none	{'e1': {'word': 'ethinyl estradiol', 'word_index': [(31, 32)], 'id': 'DDI-DrugBank.d680.s1.e16'}, 'e2': {'word': 'midazolam', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d680.s1.e21'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	ethinyl estradiol	clarithromycin	none	{'e1': {'word': 'ethinyl estradiol', 'word_index': [(31, 32)], 'id': 'DDI-DrugBank.d680.s1.e16'}, 'e2': {'word': 'clarithromycin', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d680.s1.e22'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	ethinyl estradiol	metronidazole	none	{'e1': {'word': 'ethinyl estradiol', 'word_index': [(31, 32)], 'id': 'DDI-DrugBank.d680.s1.e16'}, 'e2': {'word': 'metronidazole', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d680.s1.e23'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	ethinyl estradiol	amoxicillin	none	{'e1': {'word': 'ethinyl estradiol', 'word_index': [(31, 32)], 'id': 'DDI-DrugBank.d680.s1.e16'}, 'e2': {'word': 'amoxicillin', 'word_index': [(40, 40)], 'id': 'DDI-DrugBank.d680.s1.e24'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	metoprolol	nifedipine	none	{'e1': {'word': 'metoprolol', 'word_index': [(33, 33)], 'id': 'DDI-DrugBank.d680.s1.e17'}, 'e2': {'word': 'nifedipine', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d680.s1.e18'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	metoprolol	phenytoin	none	{'e1': {'word': 'metoprolol', 'word_index': [(33, 33)], 'id': 'DDI-DrugBank.d680.s1.e17'}, 'e2': {'word': 'phenytoin', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d680.s1.e19'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	metoprolol	warfarin	none	{'e1': {'word': 'metoprolol', 'word_index': [(33, 33)], 'id': 'DDI-DrugBank.d680.s1.e17'}, 'e2': {'word': 'warfarin', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d680.s1.e20'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	metoprolol	midazolam	none	{'e1': {'word': 'metoprolol', 'word_index': [(33, 33)], 'id': 'DDI-DrugBank.d680.s1.e17'}, 'e2': {'word': 'midazolam', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d680.s1.e21'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	metoprolol	clarithromycin	none	{'e1': {'word': 'metoprolol', 'word_index': [(33, 33)], 'id': 'DDI-DrugBank.d680.s1.e17'}, 'e2': {'word': 'clarithromycin', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d680.s1.e22'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	metoprolol	metronidazole	none	{'e1': {'word': 'metoprolol', 'word_index': [(33, 33)], 'id': 'DDI-DrugBank.d680.s1.e17'}, 'e2': {'word': 'metronidazole', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d680.s1.e23'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	metoprolol	amoxicillin	none	{'e1': {'word': 'metoprolol', 'word_index': [(33, 33)], 'id': 'DDI-DrugBank.d680.s1.e17'}, 'e2': {'word': 'amoxicillin', 'word_index': [(40, 40)], 'id': 'DDI-DrugBank.d680.s1.e24'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	nifedipine	phenytoin	none	{'e1': {'word': 'nifedipine', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d680.s1.e18'}, 'e2': {'word': 'phenytoin', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d680.s1.e19'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	nifedipine	warfarin	none	{'e1': {'word': 'nifedipine', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d680.s1.e18'}, 'e2': {'word': 'warfarin', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d680.s1.e20'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	nifedipine	midazolam	none	{'e1': {'word': 'nifedipine', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d680.s1.e18'}, 'e2': {'word': 'midazolam', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d680.s1.e21'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	nifedipine	clarithromycin	none	{'e1': {'word': 'nifedipine', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d680.s1.e18'}, 'e2': {'word': 'clarithromycin', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d680.s1.e22'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	nifedipine	metronidazole	none	{'e1': {'word': 'nifedipine', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d680.s1.e18'}, 'e2': {'word': 'metronidazole', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d680.s1.e23'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	nifedipine	amoxicillin	none	{'e1': {'word': 'nifedipine', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d680.s1.e18'}, 'e2': {'word': 'amoxicillin', 'word_index': [(40, 40)], 'id': 'DDI-DrugBank.d680.s1.e24'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	phenytoin	warfarin	none	{'e1': {'word': 'phenytoin', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d680.s1.e19'}, 'e2': {'word': 'warfarin', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d680.s1.e20'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	phenytoin	midazolam	none	{'e1': {'word': 'phenytoin', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d680.s1.e19'}, 'e2': {'word': 'midazolam', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d680.s1.e21'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	phenytoin	clarithromycin	none	{'e1': {'word': 'phenytoin', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d680.s1.e19'}, 'e2': {'word': 'clarithromycin', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d680.s1.e22'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	phenytoin	metronidazole	none	{'e1': {'word': 'phenytoin', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d680.s1.e19'}, 'e2': {'word': 'metronidazole', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d680.s1.e23'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	phenytoin	amoxicillin	none	{'e1': {'word': 'phenytoin', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d680.s1.e19'}, 'e2': {'word': 'amoxicillin', 'word_index': [(40, 40)], 'id': 'DDI-DrugBank.d680.s1.e24'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	warfarin	midazolam	none	{'e1': {'word': 'warfarin', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d680.s1.e20'}, 'e2': {'word': 'midazolam', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d680.s1.e21'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	warfarin	clarithromycin	none	{'e1': {'word': 'warfarin', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d680.s1.e20'}, 'e2': {'word': 'clarithromycin', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d680.s1.e22'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	warfarin	metronidazole	none	{'e1': {'word': 'warfarin', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d680.s1.e20'}, 'e2': {'word': 'metronidazole', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d680.s1.e23'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	warfarin	amoxicillin	none	{'e1': {'word': 'warfarin', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d680.s1.e20'}, 'e2': {'word': 'amoxicillin', 'word_index': [(40, 40)], 'id': 'DDI-DrugBank.d680.s1.e24'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	midazolam	clarithromycin	none	{'e1': {'word': 'midazolam', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d680.s1.e21'}, 'e2': {'word': 'clarithromycin', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d680.s1.e22'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	midazolam	metronidazole	none	{'e1': {'word': 'midazolam', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d680.s1.e21'}, 'e2': {'word': 'metronidazole', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d680.s1.e23'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	midazolam	amoxicillin	none	{'e1': {'word': 'midazolam', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d680.s1.e21'}, 'e2': {'word': 'amoxicillin', 'word_index': [(40, 40)], 'id': 'DDI-DrugBank.d680.s1.e24'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	clarithromycin	metronidazole	none	{'e1': {'word': 'clarithromycin', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d680.s1.e22'}, 'e2': {'word': 'metronidazole', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d680.s1.e23'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	clarithromycin	amoxicillin	none	{'e1': {'word': 'clarithromycin', 'word_index': [(38, 38)], 'id': 'DDI-DrugBank.d680.s1.e22'}, 'e2': {'word': 'amoxicillin', 'word_index': [(40, 40)], 'id': 'DDI-DrugBank.d680.s1.e24'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. 	metronidazole	amoxicillin	none	{'e1': {'word': 'metronidazole', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d680.s1.e23'}, 'e2': {'word': 'amoxicillin', 'word_index': [(40, 40)], 'id': 'DDI-DrugBank.d680.s1.e24'}, 'sentence_id': 'DDI-DrugBank.d680.s1'}	Based studies evaluating possible interactions pantoprazole drugs dosage adjustment needed concomitant use following theophylline cisapride antipyrine caffeine carbamazepine diazepam active metabolite desmethyldiazepam diclofenac naproxen piroxicam digoxin ethanol glyburide oral contraceptive levonorgestrel ethinyl estradiol metoprolol nifedipine phenytoin warfarin midazolam clarithromycin metronidazole amoxicillin
Therefore, when coadministered with pantoprazole, adjustment of the dosage of pantoprazole or of such drugs may not be necessary. 	pantoprazole	pantoprazole	none	{'e1': {'word': 'pantoprazole', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d680.s3.e0'}, 'e2': {'word': 'pantoprazole', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d680.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d680.s3'}	Therefore coadministered pantoprazole adjustment dosage pantoprazole drugs may necessary
There have been postmarketing reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including pantoprazole, and warfarin concomitantly. 	proton pump inhibitors	pantoprazole	none	{'e1': {'word': 'proton pump inhibitors', 'word_index': [(8, 10)], 'id': 'DDI-DrugBank.d680.s5.e0'}, 'e2': {'word': 'pantoprazole', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d680.s5.e1'}, 'sentence_id': 'DDI-DrugBank.d680.s5'}	postmarketing reports increased INR prothrombin time patients receiving proton pump inhibitors including pantoprazole warfarin concomitantly
There have been postmarketing reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including pantoprazole, and warfarin concomitantly. 	proton pump inhibitors	warfarin	effect	{'e1': {'word': 'proton pump inhibitors', 'word_index': [(8, 10)], 'id': 'DDI-DrugBank.d680.s5.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d680.s5.e2'}, 'sentence_id': 'DDI-DrugBank.d680.s5'}	postmarketing reports increased INR prothrombin time patients receiving proton pump inhibitors including pantoprazole warfarin concomitantly
There have been postmarketing reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including pantoprazole, and warfarin concomitantly. 	pantoprazole	warfarin	effect	{'e1': {'word': 'pantoprazole', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d680.s5.e1'}, 'e2': {'word': 'warfarin', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d680.s5.e2'}, 'sentence_id': 'DDI-DrugBank.d680.s5'}	postmarketing reports increased INR prothrombin time patients receiving proton pump inhibitors including pantoprazole warfarin concomitantly
Patients treated with proton pump inhibitors and warfarin concomitantly should be monitored for increases in INR and prothrombin time. 	proton pump inhibitors	warfarin	advise	{'e1': {'word': 'proton pump inhibitors', 'word_index': [(2, 4)], 'id': 'DDI-DrugBank.d680.s7.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d680.s7.e1'}, 'sentence_id': 'DDI-DrugBank.d680.s7'}	Patients treated proton pump inhibitors warfarin concomitantly monitored increases INR prothrombin time
Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts). 	pantoprazole	ketoconazole	mechanism	{'e1': {'word': 'pantoprazole', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d680.s8.e0'}, 'e2': {'word': 'ketoconazole', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d680.s8.e1'}, 'sentence_id': 'DDI-DrugBank.d680.s8'}	profound long lasting inhibition gastric acid secretion pantoprazole may interfere absorption drugs gastric pH important determinant bioavailability eg ketoconazole ampicillin esters iron salts
Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts). 	pantoprazole	ampicillin	mechanism	{'e1': {'word': 'pantoprazole', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d680.s8.e0'}, 'e2': {'word': 'ampicillin', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d680.s8.e2'}, 'sentence_id': 'DDI-DrugBank.d680.s8'}	profound long lasting inhibition gastric acid secretion pantoprazole may interfere absorption drugs gastric pH important determinant bioavailability eg ketoconazole ampicillin esters iron salts
Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts). 	pantoprazole	iron	mechanism	{'e1': {'word': 'pantoprazole', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d680.s8.e0'}, 'e2': {'word': 'iron', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d680.s8.e3'}, 'sentence_id': 'DDI-DrugBank.d680.s8'}	profound long lasting inhibition gastric acid secretion pantoprazole may interfere absorption drugs gastric pH important determinant bioavailability eg ketoconazole ampicillin esters iron salts
Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts). 	ketoconazole	ampicillin	none	{'e1': {'word': 'ketoconazole', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d680.s8.e1'}, 'e2': {'word': 'ampicillin', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d680.s8.e2'}, 'sentence_id': 'DDI-DrugBank.d680.s8'}	profound long lasting inhibition gastric acid secretion pantoprazole may interfere absorption drugs gastric pH important determinant bioavailability eg ketoconazole ampicillin esters iron salts
Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts). 	ketoconazole	iron	none	{'e1': {'word': 'ketoconazole', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d680.s8.e1'}, 'e2': {'word': 'iron', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d680.s8.e3'}, 'sentence_id': 'DDI-DrugBank.d680.s8'}	profound long lasting inhibition gastric acid secretion pantoprazole may interfere absorption drugs gastric pH important determinant bioavailability eg ketoconazole ampicillin esters iron salts
Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts). 	ampicillin	iron	none	{'e1': {'word': 'ampicillin', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d680.s8.e2'}, 'e2': {'word': 'iron', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d680.s8.e3'}, 'sentence_id': 'DDI-DrugBank.d680.s8'}	profound long lasting inhibition gastric acid secretion pantoprazole may interfere absorption drugs gastric pH important determinant bioavailability eg ketoconazole ampicillin esters iron salts
Laboratory Tests There have been reports of false-positive urine screening tests for tetrahydrocannabinol (THC) in patients receiving most proton pump inhibitors, including pantoprazole. 	tetrahydrocannabinol	THC	none	{'e1': {'word': 'tetrahydrocannabinol', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d680.s9.e0'}, 'e2': {'word': 'THC', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d680.s9.e1'}, 'sentence_id': 'DDI-DrugBank.d680.s9'}	Laboratory Tests reports false positive urine screening tests tetrahydrocannabinol THC patients receiving proton pump inhibitors including pantoprazole
Laboratory Tests There have been reports of false-positive urine screening tests for tetrahydrocannabinol (THC) in patients receiving most proton pump inhibitors, including pantoprazole. 	tetrahydrocannabinol	proton pump inhibitors	none	{'e1': {'word': 'tetrahydrocannabinol', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d680.s9.e0'}, 'e2': {'word': 'proton pump inhibitors', 'word_index': [(12, 14)], 'id': 'DDI-DrugBank.d680.s9.e2'}, 'sentence_id': 'DDI-DrugBank.d680.s9'}	Laboratory Tests reports false positive urine screening tests tetrahydrocannabinol THC patients receiving proton pump inhibitors including pantoprazole
Laboratory Tests There have been reports of false-positive urine screening tests for tetrahydrocannabinol (THC) in patients receiving most proton pump inhibitors, including pantoprazole. 	tetrahydrocannabinol	pantoprazole	none	{'e1': {'word': 'tetrahydrocannabinol', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d680.s9.e0'}, 'e2': {'word': 'pantoprazole', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d680.s9.e3'}, 'sentence_id': 'DDI-DrugBank.d680.s9'}	Laboratory Tests reports false positive urine screening tests tetrahydrocannabinol THC patients receiving proton pump inhibitors including pantoprazole
Laboratory Tests There have been reports of false-positive urine screening tests for tetrahydrocannabinol (THC) in patients receiving most proton pump inhibitors, including pantoprazole. 	THC	proton pump inhibitors	none	{'e1': {'word': 'THC', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d680.s9.e1'}, 'e2': {'word': 'proton pump inhibitors', 'word_index': [(12, 14)], 'id': 'DDI-DrugBank.d680.s9.e2'}, 'sentence_id': 'DDI-DrugBank.d680.s9'}	Laboratory Tests reports false positive urine screening tests tetrahydrocannabinol THC patients receiving proton pump inhibitors including pantoprazole
Laboratory Tests There have been reports of false-positive urine screening tests for tetrahydrocannabinol (THC) in patients receiving most proton pump inhibitors, including pantoprazole. 	THC	pantoprazole	none	{'e1': {'word': 'THC', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d680.s9.e1'}, 'e2': {'word': 'pantoprazole', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d680.s9.e3'}, 'sentence_id': 'DDI-DrugBank.d680.s9'}	Laboratory Tests reports false positive urine screening tests tetrahydrocannabinol THC patients receiving proton pump inhibitors including pantoprazole
Laboratory Tests There have been reports of false-positive urine screening tests for tetrahydrocannabinol (THC) in patients receiving most proton pump inhibitors, including pantoprazole. 	proton pump inhibitors	pantoprazole	none	{'e1': {'word': 'proton pump inhibitors', 'word_index': [(12, 14)], 'id': 'DDI-DrugBank.d680.s9.e2'}, 'e2': {'word': 'pantoprazole', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d680.s9.e3'}, 'sentence_id': 'DDI-DrugBank.d680.s9'}	Laboratory Tests reports false positive urine screening tests tetrahydrocannabinol THC patients receiving proton pump inhibitors including pantoprazole
Other beta adrenergic aerosol bronchodilators should not be used concomitantly with Alupent    (metaproterenol sulfate USP) because they may have additive effects. 	beta adrenergic aerosol bronchodilators	Alupent	advise	{'e1': {'word': 'beta adrenergic aerosol bronchodilators', 'word_index': [(0, 3)], 'id': 'DDI-DrugBank.d611.s0.e0'}, 'e2': {'word': 'Alupent', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d611.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d611.s0'}	beta adrenergic aerosol bronchodilators used concomitantly Alupent metaproterenol sulfate USP may additive effects
Other beta adrenergic aerosol bronchodilators should not be used concomitantly with Alupent    (metaproterenol sulfate USP) because they may have additive effects. 	beta adrenergic aerosol bronchodilators	metaproterenol sulfate	advise	{'e1': {'word': 'beta adrenergic aerosol bronchodilators', 'word_index': [(0, 3)], 'id': 'DDI-DrugBank.d611.s0.e0'}, 'e2': {'word': 'metaproterenol sulfate', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d611.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d611.s0'}	beta adrenergic aerosol bronchodilators used concomitantly Alupent metaproterenol sulfate USP may additive effects
Other beta adrenergic aerosol bronchodilators should not be used concomitantly with Alupent    (metaproterenol sulfate USP) because they may have additive effects. 	Alupent	metaproterenol sulfate	none	{'e1': {'word': 'Alupent', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d611.s0.e1'}, 'e2': {'word': 'metaproterenol sulfate', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d611.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d611.s0'}	beta adrenergic aerosol bronchodilators used concomitantly Alupent metaproterenol sulfate USP may additive effects
Beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, since the action of beta adrenergic agonists on the vascular system may be potentiated.	Beta adrenergic agonists	monoamine oxidase inhibitors	advise	{'e1': {'word': 'Beta adrenergic agonists', 'word_index': [(0, 2)], 'id': 'DDI-DrugBank.d611.s1.e0'}, 'e2': {'word': 'monoamine oxidase inhibitors', 'word_index': [(7, 9)], 'id': 'DDI-DrugBank.d611.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d611.s1'}	Beta adrenergic agonists administered caution patients treated monoamine oxidase inhibitors tricyclic antidepressants since action beta adrenergic agonists vascular system may potentiated
Beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, since the action of beta adrenergic agonists on the vascular system may be potentiated.	Beta adrenergic agonists	tricyclic antidepressants	advise	{'e1': {'word': 'Beta adrenergic agonists', 'word_index': [(0, 2)], 'id': 'DDI-DrugBank.d611.s1.e0'}, 'e2': {'word': 'tricyclic antidepressants', 'word_index': [(10, 11)], 'id': 'DDI-DrugBank.d611.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d611.s1'}	Beta adrenergic agonists administered caution patients treated monoamine oxidase inhibitors tricyclic antidepressants since action beta adrenergic agonists vascular system may potentiated
Beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, since the action of beta adrenergic agonists on the vascular system may be potentiated.	Beta adrenergic agonists	beta adrenergic agonists	none	{'e1': {'word': 'Beta adrenergic agonists', 'word_index': [(0, 2)], 'id': 'DDI-DrugBank.d611.s1.e0'}, 'e2': {'word': 'beta adrenergic agonists', 'word_index': [(14, 16)], 'id': 'DDI-DrugBank.d611.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d611.s1'}	Beta adrenergic agonists administered caution patients treated monoamine oxidase inhibitors tricyclic antidepressants since action beta adrenergic agonists vascular system may potentiated
Beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, since the action of beta adrenergic agonists on the vascular system may be potentiated.	monoamine oxidase inhibitors	tricyclic antidepressants	none	{'e1': {'word': 'monoamine oxidase inhibitors', 'word_index': [(7, 9)], 'id': 'DDI-DrugBank.d611.s1.e1'}, 'e2': {'word': 'tricyclic antidepressants', 'word_index': [(10, 11)], 'id': 'DDI-DrugBank.d611.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d611.s1'}	Beta adrenergic agonists administered caution patients treated monoamine oxidase inhibitors tricyclic antidepressants since action beta adrenergic agonists vascular system may potentiated
Beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, since the action of beta adrenergic agonists on the vascular system may be potentiated.	monoamine oxidase inhibitors	beta adrenergic agonists	none	{'e1': {'word': 'monoamine oxidase inhibitors', 'word_index': [(7, 9)], 'id': 'DDI-DrugBank.d611.s1.e1'}, 'e2': {'word': 'beta adrenergic agonists', 'word_index': [(14, 16)], 'id': 'DDI-DrugBank.d611.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d611.s1'}	Beta adrenergic agonists administered caution patients treated monoamine oxidase inhibitors tricyclic antidepressants since action beta adrenergic agonists vascular system may potentiated
Beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, since the action of beta adrenergic agonists on the vascular system may be potentiated.	tricyclic antidepressants	beta adrenergic agonists	none	{'e1': {'word': 'tricyclic antidepressants', 'word_index': [(10, 11)], 'id': 'DDI-DrugBank.d611.s1.e2'}, 'e2': {'word': 'beta adrenergic agonists', 'word_index': [(14, 16)], 'id': 'DDI-DrugBank.d611.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d611.s1'}	Beta adrenergic agonists administered caution patients treated monoamine oxidase inhibitors tricyclic antidepressants since action beta adrenergic agonists vascular system may potentiated
Cholestyramine: Concomitant cholestyramine administration decreased the mean AUC of total ezetimibe approximately 55%. 	Cholestyramine	cholestyramine	none	{'e1': {'word': 'Cholestyramine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d572.s0.e0'}, 'e2': {'word': 'cholestyramine', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d572.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d572.s0'}	Cholestyramine Concomitant cholestyramine administration decreased mean AUC total ezetimibe approximately NUMBER %
Cholestyramine: Concomitant cholestyramine administration decreased the mean AUC of total ezetimibe approximately 55%. 	Cholestyramine	ezetimibe	none	{'e1': {'word': 'Cholestyramine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d572.s0.e0'}, 'e2': {'word': 'ezetimibe', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d572.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d572.s0'}	Cholestyramine Concomitant cholestyramine administration decreased mean AUC total ezetimibe approximately NUMBER %
Cholestyramine: Concomitant cholestyramine administration decreased the mean AUC of total ezetimibe approximately 55%. 	cholestyramine	ezetimibe	mechanism	{'e1': {'word': 'cholestyramine', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d572.s0.e1'}, 'e2': {'word': 'ezetimibe', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d572.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d572.s0'}	Cholestyramine Concomitant cholestyramine administration decreased mean AUC total ezetimibe approximately NUMBER %
The incremental LDL-C reduction due to adding ezetimibe to cholestyramine may be reduced by this interaction. 	ezetimibe	cholestyramine	effect	{'e1': {'word': 'ezetimibe', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d572.s1.e0'}, 'e2': {'word': 'cholestyramine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d572.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d572.s1'}	incremental LDL C reduction due adding ezetimibe cholestyramine may reduced interaction
Fibrates: The safety and effectiveness of ezetimibe administered with fibrates have not been established. 	Fibrates	ezetimibe	none	{'e1': {'word': 'Fibrates', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d572.s2.e0'}, 'e2': {'word': 'ezetimibe', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d572.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d572.s2'}	Fibrates safety effectiveness ezetimibe administered fibrates established
Fibrates: The safety and effectiveness of ezetimibe administered with fibrates have not been established. 	Fibrates	fibrates	none	{'e1': {'word': 'Fibrates', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d572.s2.e0'}, 'e2': {'word': 'fibrates', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d572.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d572.s2'}	Fibrates safety effectiveness ezetimibe administered fibrates established
Fibrates: The safety and effectiveness of ezetimibe administered with fibrates have not been established. 	ezetimibe	fibrates	none	{'e1': {'word': 'ezetimibe', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d572.s2.e1'}, 'e2': {'word': 'fibrates', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d572.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d572.s2'}	Fibrates safety effectiveness ezetimibe administered fibrates established
Co-administration of ZETIA with fibrates is not recommended until use in patients is studied. 	ZETIA	fibrates	advise	{'e1': {'word': 'ZETIA', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d572.s5.e0'}, 'e2': {'word': 'fibrates', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d572.s5.e1'}, 'sentence_id': 'DDI-DrugBank.d572.s5'}	Co-administration ZETIA fibrates recommended use patients studied
Fenofibrate: In a pharmacokinetic study, concomitant fenofibrate administration increased total ezetimibe concentrations approximately 1.5-fold. 	Fenofibrate	fenofibrate	none	{'e1': {'word': 'Fenofibrate', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d572.s6.e0'}, 'e2': {'word': 'fenofibrate', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d572.s6.e1'}, 'sentence_id': 'DDI-DrugBank.d572.s6'}	Fenofibrate pharmacokinetic study concomitant fenofibrate administration increased total ezetimibe concentrations approximately 1.5-fold
Fenofibrate: In a pharmacokinetic study, concomitant fenofibrate administration increased total ezetimibe concentrations approximately 1.5-fold. 	Fenofibrate	ezetimibe	none	{'e1': {'word': 'Fenofibrate', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d572.s6.e0'}, 'e2': {'word': 'ezetimibe', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d572.s6.e2'}, 'sentence_id': 'DDI-DrugBank.d572.s6'}	Fenofibrate pharmacokinetic study concomitant fenofibrate administration increased total ezetimibe concentrations approximately 1.5-fold
Fenofibrate: In a pharmacokinetic study, concomitant fenofibrate administration increased total ezetimibe concentrations approximately 1.5-fold. 	fenofibrate	ezetimibe	mechanism	{'e1': {'word': 'fenofibrate', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d572.s6.e1'}, 'e2': {'word': 'ezetimibe', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d572.s6.e2'}, 'sentence_id': 'DDI-DrugBank.d572.s6'}	Fenofibrate pharmacokinetic study concomitant fenofibrate administration increased total ezetimibe concentrations approximately 1.5-fold
Gemfibrozil: In a pharmacokinetic study, concomitant gemfibrozil administration increased total ezetimibe concentrations approximately 1.7-fold. 	Gemfibrozil	gemfibrozil	none	{'e1': {'word': 'Gemfibrozil', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d572.s7.e0'}, 'e2': {'word': 'gemfibrozil', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d572.s7.e1'}, 'sentence_id': 'DDI-DrugBank.d572.s7'}	Gemfibrozil pharmacokinetic study concomitant gemfibrozil administration increased total ezetimibe concentrations approximately 1.7-fold
Gemfibrozil: In a pharmacokinetic study, concomitant gemfibrozil administration increased total ezetimibe concentrations approximately 1.7-fold. 	Gemfibrozil	ezetimibe	none	{'e1': {'word': 'Gemfibrozil', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d572.s7.e0'}, 'e2': {'word': 'ezetimibe', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d572.s7.e2'}, 'sentence_id': 'DDI-DrugBank.d572.s7'}	Gemfibrozil pharmacokinetic study concomitant gemfibrozil administration increased total ezetimibe concentrations approximately 1.7-fold
Gemfibrozil: In a pharmacokinetic study, concomitant gemfibrozil administration increased total ezetimibe concentrations approximately 1.7-fold. 	gemfibrozil	ezetimibe	none	{'e1': {'word': 'gemfibrozil', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d572.s7.e1'}, 'e2': {'word': 'ezetimibe', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d572.s7.e2'}, 'sentence_id': 'DDI-DrugBank.d572.s7'}	Gemfibrozil pharmacokinetic study concomitant gemfibrozil administration increased total ezetimibe concentrations approximately 1.7-fold
HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. 	HMG-CoA reductase inhibitors	ezetimibe	none	{'e1': {'word': 'HMG-CoA reductase inhibitors', 'word_index': [(0, 3)], 'id': 'DDI-DrugBank.d572.s8.e0'}, 'e2': {'word': 'ezetimibe', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d572.s8.e1'}, 'sentence_id': 'DDI-DrugBank.d572.s8'}	HMG CoA reductase inhibitors clinically significant pharmacokinetic interactions seen ezetimibe co-administered atorvastatin simvastatin pravastatin lovastatin fluvastatin
HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. 	HMG-CoA reductase inhibitors	atorvastatin	none	{'e1': {'word': 'HMG-CoA reductase inhibitors', 'word_index': [(0, 3)], 'id': 'DDI-DrugBank.d572.s8.e0'}, 'e2': {'word': 'atorvastatin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d572.s8.e2'}, 'sentence_id': 'DDI-DrugBank.d572.s8'}	HMG CoA reductase inhibitors clinically significant pharmacokinetic interactions seen ezetimibe co-administered atorvastatin simvastatin pravastatin lovastatin fluvastatin
HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. 	HMG-CoA reductase inhibitors	simvastatin	none	{'e1': {'word': 'HMG-CoA reductase inhibitors', 'word_index': [(0, 3)], 'id': 'DDI-DrugBank.d572.s8.e0'}, 'e2': {'word': 'simvastatin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d572.s8.e3'}, 'sentence_id': 'DDI-DrugBank.d572.s8'}	HMG CoA reductase inhibitors clinically significant pharmacokinetic interactions seen ezetimibe co-administered atorvastatin simvastatin pravastatin lovastatin fluvastatin
HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. 	HMG-CoA reductase inhibitors	pravastatin	none	{'e1': {'word': 'HMG-CoA reductase inhibitors', 'word_index': [(0, 3)], 'id': 'DDI-DrugBank.d572.s8.e0'}, 'e2': {'word': 'pravastatin', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d572.s8.e4'}, 'sentence_id': 'DDI-DrugBank.d572.s8'}	HMG CoA reductase inhibitors clinically significant pharmacokinetic interactions seen ezetimibe co-administered atorvastatin simvastatin pravastatin lovastatin fluvastatin
HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. 	HMG-CoA reductase inhibitors	lovastatin	none	{'e1': {'word': 'HMG-CoA reductase inhibitors', 'word_index': [(0, 3)], 'id': 'DDI-DrugBank.d572.s8.e0'}, 'e2': {'word': 'lovastatin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d572.s8.e5'}, 'sentence_id': 'DDI-DrugBank.d572.s8'}	HMG CoA reductase inhibitors clinically significant pharmacokinetic interactions seen ezetimibe co-administered atorvastatin simvastatin pravastatin lovastatin fluvastatin
HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. 	HMG-CoA reductase inhibitors	fluvastatin	none	{'e1': {'word': 'HMG-CoA reductase inhibitors', 'word_index': [(0, 3)], 'id': 'DDI-DrugBank.d572.s8.e0'}, 'e2': {'word': 'fluvastatin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d572.s8.e6'}, 'sentence_id': 'DDI-DrugBank.d572.s8'}	HMG CoA reductase inhibitors clinically significant pharmacokinetic interactions seen ezetimibe co-administered atorvastatin simvastatin pravastatin lovastatin fluvastatin
HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. 	ezetimibe	atorvastatin	none	{'e1': {'word': 'ezetimibe', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d572.s8.e1'}, 'e2': {'word': 'atorvastatin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d572.s8.e2'}, 'sentence_id': 'DDI-DrugBank.d572.s8'}	HMG CoA reductase inhibitors clinically significant pharmacokinetic interactions seen ezetimibe co-administered atorvastatin simvastatin pravastatin lovastatin fluvastatin
HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. 	ezetimibe	simvastatin	none	{'e1': {'word': 'ezetimibe', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d572.s8.e1'}, 'e2': {'word': 'simvastatin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d572.s8.e3'}, 'sentence_id': 'DDI-DrugBank.d572.s8'}	HMG CoA reductase inhibitors clinically significant pharmacokinetic interactions seen ezetimibe co-administered atorvastatin simvastatin pravastatin lovastatin fluvastatin
HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. 	ezetimibe	pravastatin	none	{'e1': {'word': 'ezetimibe', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d572.s8.e1'}, 'e2': {'word': 'pravastatin', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d572.s8.e4'}, 'sentence_id': 'DDI-DrugBank.d572.s8'}	HMG CoA reductase inhibitors clinically significant pharmacokinetic interactions seen ezetimibe co-administered atorvastatin simvastatin pravastatin lovastatin fluvastatin
HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. 	ezetimibe	lovastatin	none	{'e1': {'word': 'ezetimibe', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d572.s8.e1'}, 'e2': {'word': 'lovastatin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d572.s8.e5'}, 'sentence_id': 'DDI-DrugBank.d572.s8'}	HMG CoA reductase inhibitors clinically significant pharmacokinetic interactions seen ezetimibe co-administered atorvastatin simvastatin pravastatin lovastatin fluvastatin
HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. 	ezetimibe	fluvastatin	none	{'e1': {'word': 'ezetimibe', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d572.s8.e1'}, 'e2': {'word': 'fluvastatin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d572.s8.e6'}, 'sentence_id': 'DDI-DrugBank.d572.s8'}	HMG CoA reductase inhibitors clinically significant pharmacokinetic interactions seen ezetimibe co-administered atorvastatin simvastatin pravastatin lovastatin fluvastatin
HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. 	atorvastatin	simvastatin	none	{'e1': {'word': 'atorvastatin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d572.s8.e2'}, 'e2': {'word': 'simvastatin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d572.s8.e3'}, 'sentence_id': 'DDI-DrugBank.d572.s8'}	HMG CoA reductase inhibitors clinically significant pharmacokinetic interactions seen ezetimibe co-administered atorvastatin simvastatin pravastatin lovastatin fluvastatin
HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. 	atorvastatin	pravastatin	none	{'e1': {'word': 'atorvastatin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d572.s8.e2'}, 'e2': {'word': 'pravastatin', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d572.s8.e4'}, 'sentence_id': 'DDI-DrugBank.d572.s8'}	HMG CoA reductase inhibitors clinically significant pharmacokinetic interactions seen ezetimibe co-administered atorvastatin simvastatin pravastatin lovastatin fluvastatin
HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. 	atorvastatin	lovastatin	none	{'e1': {'word': 'atorvastatin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d572.s8.e2'}, 'e2': {'word': 'lovastatin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d572.s8.e5'}, 'sentence_id': 'DDI-DrugBank.d572.s8'}	HMG CoA reductase inhibitors clinically significant pharmacokinetic interactions seen ezetimibe co-administered atorvastatin simvastatin pravastatin lovastatin fluvastatin
HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. 	atorvastatin	fluvastatin	none	{'e1': {'word': 'atorvastatin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d572.s8.e2'}, 'e2': {'word': 'fluvastatin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d572.s8.e6'}, 'sentence_id': 'DDI-DrugBank.d572.s8'}	HMG CoA reductase inhibitors clinically significant pharmacokinetic interactions seen ezetimibe co-administered atorvastatin simvastatin pravastatin lovastatin fluvastatin
HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. 	simvastatin	pravastatin	none	{'e1': {'word': 'simvastatin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d572.s8.e3'}, 'e2': {'word': 'pravastatin', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d572.s8.e4'}, 'sentence_id': 'DDI-DrugBank.d572.s8'}	HMG CoA reductase inhibitors clinically significant pharmacokinetic interactions seen ezetimibe co-administered atorvastatin simvastatin pravastatin lovastatin fluvastatin
HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. 	simvastatin	lovastatin	none	{'e1': {'word': 'simvastatin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d572.s8.e3'}, 'e2': {'word': 'lovastatin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d572.s8.e5'}, 'sentence_id': 'DDI-DrugBank.d572.s8'}	HMG CoA reductase inhibitors clinically significant pharmacokinetic interactions seen ezetimibe co-administered atorvastatin simvastatin pravastatin lovastatin fluvastatin
HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. 	simvastatin	fluvastatin	none	{'e1': {'word': 'simvastatin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d572.s8.e3'}, 'e2': {'word': 'fluvastatin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d572.s8.e6'}, 'sentence_id': 'DDI-DrugBank.d572.s8'}	HMG CoA reductase inhibitors clinically significant pharmacokinetic interactions seen ezetimibe co-administered atorvastatin simvastatin pravastatin lovastatin fluvastatin
HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. 	pravastatin	lovastatin	none	{'e1': {'word': 'pravastatin', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d572.s8.e4'}, 'e2': {'word': 'lovastatin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d572.s8.e5'}, 'sentence_id': 'DDI-DrugBank.d572.s8'}	HMG CoA reductase inhibitors clinically significant pharmacokinetic interactions seen ezetimibe co-administered atorvastatin simvastatin pravastatin lovastatin fluvastatin
HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. 	pravastatin	fluvastatin	none	{'e1': {'word': 'pravastatin', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d572.s8.e4'}, 'e2': {'word': 'fluvastatin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d572.s8.e6'}, 'sentence_id': 'DDI-DrugBank.d572.s8'}	HMG CoA reductase inhibitors clinically significant pharmacokinetic interactions seen ezetimibe co-administered atorvastatin simvastatin pravastatin lovastatin fluvastatin
HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. 	lovastatin	fluvastatin	none	{'e1': {'word': 'lovastatin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d572.s8.e5'}, 'e2': {'word': 'fluvastatin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d572.s8.e6'}, 'sentence_id': 'DDI-DrugBank.d572.s8'}	HMG CoA reductase inhibitors clinically significant pharmacokinetic interactions seen ezetimibe co-administered atorvastatin simvastatin pravastatin lovastatin fluvastatin
Cyclosporine: The total ezetimibe level increased 12-fold in one renal transplant patient receiving multiple medications, including cyclosporine. 	Cyclosporine	ezetimibe	none	{'e1': {'word': 'Cyclosporine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d572.s9.e0'}, 'e2': {'word': 'ezetimibe', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d572.s9.e1'}, 'sentence_id': 'DDI-DrugBank.d572.s9'}	Cyclosporine total ezetimibe level increased 12-fold NUMBER renal transplant patient receiving multiple medications including cyclosporine
Cyclosporine: The total ezetimibe level increased 12-fold in one renal transplant patient receiving multiple medications, including cyclosporine. 	Cyclosporine	cyclosporine	none	{'e1': {'word': 'Cyclosporine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d572.s9.e0'}, 'e2': {'word': 'cyclosporine', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d572.s9.e2'}, 'sentence_id': 'DDI-DrugBank.d572.s9'}	Cyclosporine total ezetimibe level increased 12-fold NUMBER renal transplant patient receiving multiple medications including cyclosporine
Cyclosporine: The total ezetimibe level increased 12-fold in one renal transplant patient receiving multiple medications, including cyclosporine. 	ezetimibe	cyclosporine	mechanism	{'e1': {'word': 'ezetimibe', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d572.s9.e1'}, 'e2': {'word': 'cyclosporine', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d572.s9.e2'}, 'sentence_id': 'DDI-DrugBank.d572.s9'}	Cyclosporine total ezetimibe level increased NUMBER in NUMBER transplant patient receiving multiple medications , cyclosporine .
Patients who take both ezetimibe and cyclosporine should be carefully monitored. 	ezetimibe	cyclosporine	advise	{'e1': {'word': 'ezetimibe', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d572.s10.e0'}, 'e2': {'word': 'cyclosporine', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d572.s10.e1'}, 'sentence_id': 'DDI-DrugBank.d572.s10'}	Patients take ezetimibe cyclosporine carefully monitored
Carcinogenesis, Mutagenesis, Impairment of Fertility A 104-week dietary carcinogenicity study with ezetimibe was conducted in rats at doses up to 1500 mg/kg/day (males) and 500 mg/kg/day (females) (~20 times the human exposure at 10 mg daily based on AUC0-24hr for total ezetimibe). 	ezetimibe	ezetimibe	none	{'e1': {'word': 'ezetimibe', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d572.s11.e0'}, 'e2': {'word': 'ezetimibe', 'word_index': [(39, 39)], 'id': 'DDI-DrugBank.d572.s11.e1'}, 'sentence_id': 'DDI-DrugBank.d572.s11'}	Carcinogenesis Mutagenesis Impairment Fertility NUMBER week dietary carcinogenicity study ezetimibe conducted rats doses NUMBER mg / kg / day males NUMBER mg / kg / day females ~ NUMBER times human exposure NUMBER mg daily based AUC0 NUMBER for ezetimibe )
A 104-week dietary carcinogenicity study with ezetimibe was also conducted in mice at doses up to 500 mg/kg/day (>150 times the human exposure at 10 mg daily based on AUC0-24hr for total ezetimibe). 	ezetimibe	ezetimibe	none	{'e1': {'word': 'ezetimibe', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d572.s12.e0'}, 'e2': {'word': 'ezetimibe', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d572.s12.e1'}, 'sentence_id': 'DDI-DrugBank.d572.s12'}	NUMBER week dietary carcinogenicity study ezetimibe also conducted mice doses NUMBER mg / kg / day > NUMBER times human exposure NUMBER mg daily based AUC0 NUMBER for ezetimibe )
In oral (gavage) fertility studies of ezetimibe conducted in rats, there was no evidence of reproductive toxicity at doses up to 1000 mg/kg/day in male or female rats (~7 times the human exposure at 10 mg daily based on AUC0-24hr for total ezetimibe). 	ezetimibe	ezetimibe	none	{'e1': {'word': 'ezetimibe', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d572.s17.e0'}, 'e2': {'word': 'ezetimibe', 'word_index': [(32, 32)], 'id': 'DDI-DrugBank.d572.s17.e1'}, 'sentence_id': 'DDI-DrugBank.d572.s17'}	oral gavage fertility studies ezetimibe conducted rats evidence reproductive toxicity doses NUMBER mg / kg / day male female rats ~ NUMBER times human exposure NUMBER mg daily based AUC0 24hr total ezetimibe
In rabbits treated with ezetimibe, an increased incidence of extra thoracic ribs was observed at 1000 mg/kg/day (150 times the human exposure at 10 mg daily based on AUC0-24hr for total ezetimibe). 	ezetimibe	ezetimibe	none	{'e1': {'word': 'ezetimibe', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d572.s22.e0'}, 'e2': {'word': 'ezetimibe', 'word_index': [(26, 26)], 'id': 'DDI-DrugBank.d572.s22.e1'}, 'sentence_id': 'DDI-DrugBank.d572.s22'}	rabbits treated ezetimibe increased incidence extra thoracic ribs observed NUMBER mg / kg / day NUMBER times human exposure NUMBER mg daily based AUC0 24hr total ezetimibe
Multiple dose studies of ezetimibe given in combination with HMG-CoA reductase inhibitors (statins) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures. 	ezetimibe	HMG-CoA reductase inhibitors	none	{'e1': {'word': 'ezetimibe', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d572.s24.e0'}, 'e2': {'word': 'HMG-CoA reductase inhibitors', 'word_index': [(6, 9)], 'id': 'DDI-DrugBank.d572.s24.e1'}, 'sentence_id': 'DDI-DrugBank.d572.s24'}	Multiple dose studies ezetimibe given combination HMG CoA reductase inhibitors statins rats rabbits organogenesis result higher ezetimibe statin exposures
Multiple dose studies of ezetimibe given in combination with HMG-CoA reductase inhibitors (statins) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures. 	ezetimibe	statins	none	{'e1': {'word': 'ezetimibe', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d572.s24.e0'}, 'e2': {'word': 'statins', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d572.s24.e2'}, 'sentence_id': 'DDI-DrugBank.d572.s24'}	Multiple dose studies ezetimibe given combination HMG CoA reductase inhibitors statins rats rabbits organogenesis result higher ezetimibe statin exposures
Multiple dose studies of ezetimibe given in combination with HMG-CoA reductase inhibitors (statins) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures. 	ezetimibe	ezetimibe	none	{'e1': {'word': 'ezetimibe', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d572.s24.e0'}, 'e2': {'word': 'ezetimibe', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d572.s24.e3'}, 'sentence_id': 'DDI-DrugBank.d572.s24'}	Multiple dose studies ezetimibe given combination HMG CoA reductase inhibitors statins rats rabbits organogenesis result higher ezetimibe statin exposures
Multiple dose studies of ezetimibe given in combination with HMG-CoA reductase inhibitors (statins) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures. 	HMG-CoA reductase inhibitors	statins	none	{'e1': {'word': 'HMG-CoA reductase inhibitors', 'word_index': [(6, 9)], 'id': 'DDI-DrugBank.d572.s24.e1'}, 'e2': {'word': 'statins', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d572.s24.e2'}, 'sentence_id': 'DDI-DrugBank.d572.s24'}	Multiple dose studies ezetimibe given combination HMG CoA reductase inhibitors statins rats rabbits organogenesis result higher ezetimibe statin exposures
Multiple dose studies of ezetimibe given in combination with HMG-CoA reductase inhibitors (statins) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures. 	HMG-CoA reductase inhibitors	ezetimibe	none	{'e1': {'word': 'HMG-CoA reductase inhibitors', 'word_index': [(6, 9)], 'id': 'DDI-DrugBank.d572.s24.e1'}, 'e2': {'word': 'ezetimibe', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d572.s24.e3'}, 'sentence_id': 'DDI-DrugBank.d572.s24'}	Multiple dose studies ezetimibe given combination HMG CoA reductase inhibitors statins rats rabbits organogenesis result higher ezetimibe statin exposures
Multiple dose studies of ezetimibe given in combination with HMG-CoA reductase inhibitors (statins) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures. 	statins	ezetimibe	none	{'e1': {'word': 'statins', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d572.s24.e2'}, 'e2': {'word': 'ezetimibe', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d572.s24.e3'}, 'sentence_id': 'DDI-DrugBank.d572.s24'}	Multiple dose studies ezetimibe given combination HMG CoA reductase inhibitors statins rats rabbits organogenesis result higher ezetimibe statin exposures
When ZETIA is administered with an HMG-CoA reductase inhibitor in a woman of childbearing potential, refer to the pregnancy category and package labeling for the HMG-CoA reductase inhibitor. 	ZETIA	HMG-CoA reductase inhibitor	none	{'e1': {'word': 'ZETIA', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d572.s27.e0'}, 'e2': {'word': 'HMG-CoA reductase inhibitor', 'word_index': [(2, 5)], 'id': 'DDI-DrugBank.d572.s27.e1'}, 'sentence_id': 'DDI-DrugBank.d572.s27'}	ZETIA administered HMG CoA reductase inhibitor woman childbearing potential refer pregnancy category package labeling HMG CoA reductase inhibitor
When ZETIA is administered with an HMG-CoA reductase inhibitor in a woman of childbearing potential, refer to the pregnancy category and package labeling for the HMG-CoA reductase inhibitor. 	ZETIA	HMG-CoA reductase inhibitor	none	{'e1': {'word': 'ZETIA', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d572.s27.e0'}, 'e2': {'word': 'HMG-CoA reductase inhibitor', 'word_index': [(14, 17)], 'id': 'DDI-DrugBank.d572.s27.e2'}, 'sentence_id': 'DDI-DrugBank.d572.s27'}	ZETIA administered HMG CoA reductase inhibitor woman childbearing potential refer pregnancy category package labeling HMG CoA reductase inhibitor
When ZETIA is administered with an HMG-CoA reductase inhibitor in a woman of childbearing potential, refer to the pregnancy category and package labeling for the HMG-CoA reductase inhibitor. 	HMG-CoA reductase inhibitor	HMG-CoA reductase inhibitor	none	{'e1': {'word': 'HMG-CoA reductase inhibitor', 'word_index': [(2, 5)], 'id': 'DDI-DrugBank.d572.s27.e1'}, 'e2': {'word': 'HMG-CoA reductase inhibitor', 'word_index': [(14, 17)], 'id': 'DDI-DrugBank.d572.s27.e2'}, 'sentence_id': 'DDI-DrugBank.d572.s27'}	ZETIA administered HMG CoA reductase inhibitor woman childbearing potential refer pregnancy category package labeling HMG CoA reductase inhibitor
DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.  	ALKERAN	live organism vaccines	none	{'e1': {'word': 'ALKERAN', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d625.s0.e0'}, 'e2': {'word': 'live organism vaccines', 'word_index': [(9, 11)], 'id': 'DDI-DrugBank.d625.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d625.s0'}	DRUG INTERACTIONS known drug drug interactions oral ALKERAN Vaccinations live organism vaccines recommended immunocompromised individuals Nalidixic acid together high dose intravenous melphalan caused deaths children due haemorrhagic enterocolitis
DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.  	ALKERAN	Nalidixic acid	none	{'e1': {'word': 'ALKERAN', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d625.s0.e0'}, 'e2': {'word': 'Nalidixic acid', 'word_index': [(15, 16)], 'id': 'DDI-DrugBank.d625.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d625.s0'}	DRUG INTERACTIONS known drug drug interactions oral ALKERAN Vaccinations live organism vaccines recommended immunocompromised individuals Nalidixic acid together high dose intravenous melphalan caused deaths children due haemorrhagic enterocolitis
DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.  	ALKERAN	melphalan	none	{'e1': {'word': 'ALKERAN', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d625.s0.e0'}, 'e2': {'word': 'melphalan', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d625.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d625.s0'}	DRUG INTERACTIONS known drug drug interactions oral ALKERAN Vaccinations live organism vaccines recommended immunocompromised individuals Nalidixic acid together high dose intravenous melphalan caused deaths children due haemorrhagic enterocolitis
DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.  	live organism vaccines	Nalidixic acid	none	{'e1': {'word': 'live organism vaccines', 'word_index': [(9, 11)], 'id': 'DDI-DrugBank.d625.s0.e1'}, 'e2': {'word': 'Nalidixic acid', 'word_index': [(15, 16)], 'id': 'DDI-DrugBank.d625.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d625.s0'}	DRUG INTERACTIONS known drug drug interactions oral ALKERAN Vaccinations live organism vaccines recommended immunocompromised individuals Nalidixic acid together high dose intravenous melphalan caused deaths children due haemorrhagic enterocolitis
DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.  	live organism vaccines	melphalan	none	{'e1': {'word': 'live organism vaccines', 'word_index': [(9, 11)], 'id': 'DDI-DrugBank.d625.s0.e1'}, 'e2': {'word': 'melphalan', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d625.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d625.s0'}	DRUG INTERACTIONS known drug drug interactions oral ALKERAN Vaccinations live organism vaccines recommended immunocompromised individuals Nalidixic acid together high dose intravenous melphalan caused deaths children due haemorrhagic enterocolitis
DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.  	Nalidixic acid	melphalan	effect	{'e1': {'word': 'Nalidixic acid', 'word_index': [(15, 16)], 'id': 'DDI-DrugBank.d625.s0.e2'}, 'e2': {'word': 'melphalan', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d625.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d625.s0'}	DRUG INTERACTIONS known drug drug interactions oral ALKERAN Vaccinations live organism vaccines recommended immunocompromised individuals Nalidixic acid together high dose intravenous melphalan caused deaths children due haemorrhagic enterocolitis
Impaired renal function has been described in bone marrow transplant patients who were conditioned with high-dose intravenous melphalan and who subsequently received cyclosporin to prevent graft-versus-host disease	melphalan	cyclosporin	effect	{'e1': {'word': 'melphalan', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d625.s1.e0'}, 'e2': {'word': 'cyclosporin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d625.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d625.s1'}	Impaired renal function described bone marrow transplant patients conditioned high dose intravenous melphalan subsequently received cyclosporin prevent graft versus host disease
Pilocarpine should be administered with caution to patients taking beta adrenergic antagonists because of the possibility of conduction disturbances. 	Pilocarpine	beta adrenergic antagonists	advise	{'e1': {'word': 'Pilocarpine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d627.s0.e0'}, 'e2': {'word': 'beta adrenergic antagonists', 'word_index': [(5, 7)], 'id': 'DDI-DrugBank.d627.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d627.s0'}	Pilocarpine administered caution patients taking beta adrenergic antagonists possibility conduction disturbances
These effects should be considered when anticholinergic properties may be contributing to the therapeutic effect of concomitant medication (e.g., atropine, inhaled ipratropium). 	atropine	ipratropium	none	{'e1': {'word': 'atropine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d627.s3.e0'}, 'e2': {'word': 'ipratropium', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d627.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d627.s3'}	effects considered anticholinergic properties may contributing therapeutic effect concomitant medication e.g. atropine inhaled ipratropium
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	acetylsalicylic acid	calcium	none	{'e1': {'word': 'acetylsalicylic acid', 'word_index': [(18, 19)], 'id': 'DDI-DrugBank.d627.s4.e0'}, 'e2': {'word': 'calcium', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d627.s4.e1'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	acetylsalicylic acid	conjugated estrogens	none	{'e1': {'word': 'acetylsalicylic acid', 'word_index': [(18, 19)], 'id': 'DDI-DrugBank.d627.s4.e0'}, 'e2': {'word': 'conjugated estrogens', 'word_index': [(23, 24)], 'id': 'DDI-DrugBank.d627.s4.e2'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	acetylsalicylic acid	hydroxychloroquine sulfate	none	{'e1': {'word': 'acetylsalicylic acid', 'word_index': [(18, 19)], 'id': 'DDI-DrugBank.d627.s4.e0'}, 'e2': {'word': 'hydroxychloroquine sulfate', 'word_index': [(25, 26)], 'id': 'DDI-DrugBank.d627.s4.e3'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	acetylsalicylic acid	ibuprofen	none	{'e1': {'word': 'acetylsalicylic acid', 'word_index': [(18, 19)], 'id': 'DDI-DrugBank.d627.s4.e0'}, 'e2': {'word': 'ibuprofen', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d627.s4.e4'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	acetylsalicylic acid	levothyroxine sodium	none	{'e1': {'word': 'acetylsalicylic acid', 'word_index': [(18, 19)], 'id': 'DDI-DrugBank.d627.s4.e0'}, 'e2': {'word': 'levothyroxine sodium', 'word_index': [(28, 29)], 'id': 'DDI-DrugBank.d627.s4.e5'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	acetylsalicylic acid	medroxyprogesterone acetate	none	{'e1': {'word': 'acetylsalicylic acid', 'word_index': [(18, 19)], 'id': 'DDI-DrugBank.d627.s4.e0'}, 'e2': {'word': 'medroxyprogesterone acetate', 'word_index': [(30, 31)], 'id': 'DDI-DrugBank.d627.s4.e6'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	acetylsalicylic acid	methotrexate	none	{'e1': {'word': 'acetylsalicylic acid', 'word_index': [(18, 19)], 'id': 'DDI-DrugBank.d627.s4.e0'}, 'e2': {'word': 'methotrexate', 'word_index': [(32, 32)], 'id': 'DDI-DrugBank.d627.s4.e7'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	acetylsalicylic acid	multivitamins	none	{'e1': {'word': 'acetylsalicylic acid', 'word_index': [(18, 19)], 'id': 'DDI-DrugBank.d627.s4.e0'}, 'e2': {'word': 'multivitamins', 'word_index': [(33, 33)], 'id': 'DDI-DrugBank.d627.s4.e8'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	acetylsalicylic acid	naproxen	none	{'e1': {'word': 'acetylsalicylic acid', 'word_index': [(18, 19)], 'id': 'DDI-DrugBank.d627.s4.e0'}, 'e2': {'word': 'naproxen', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d627.s4.e9'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	acetylsalicylic acid	omeprazole	none	{'e1': {'word': 'acetylsalicylic acid', 'word_index': [(18, 19)], 'id': 'DDI-DrugBank.d627.s4.e0'}, 'e2': {'word': 'omeprazole', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d627.s4.e10'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	acetylsalicylic acid	paracetamol	none	{'e1': {'word': 'acetylsalicylic acid', 'word_index': [(18, 19)], 'id': 'DDI-DrugBank.d627.s4.e0'}, 'e2': {'word': 'paracetamol', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d627.s4.e11'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	acetylsalicylic acid	prednisone	none	{'e1': {'word': 'acetylsalicylic acid', 'word_index': [(18, 19)], 'id': 'DDI-DrugBank.d627.s4.e0'}, 'e2': {'word': 'prednisone', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d627.s4.e12'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	calcium	conjugated estrogens	none	{'e1': {'word': 'calcium', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d627.s4.e1'}, 'e2': {'word': 'conjugated estrogens', 'word_index': [(23, 24)], 'id': 'DDI-DrugBank.d627.s4.e2'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	calcium	hydroxychloroquine sulfate	none	{'e1': {'word': 'calcium', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d627.s4.e1'}, 'e2': {'word': 'hydroxychloroquine sulfate', 'word_index': [(25, 26)], 'id': 'DDI-DrugBank.d627.s4.e3'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	calcium	ibuprofen	none	{'e1': {'word': 'calcium', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d627.s4.e1'}, 'e2': {'word': 'ibuprofen', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d627.s4.e4'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	calcium	levothyroxine sodium	none	{'e1': {'word': 'calcium', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d627.s4.e1'}, 'e2': {'word': 'levothyroxine sodium', 'word_index': [(28, 29)], 'id': 'DDI-DrugBank.d627.s4.e5'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	calcium	medroxyprogesterone acetate	none	{'e1': {'word': 'calcium', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d627.s4.e1'}, 'e2': {'word': 'medroxyprogesterone acetate', 'word_index': [(30, 31)], 'id': 'DDI-DrugBank.d627.s4.e6'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	calcium	methotrexate	none	{'e1': {'word': 'calcium', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d627.s4.e1'}, 'e2': {'word': 'methotrexate', 'word_index': [(32, 32)], 'id': 'DDI-DrugBank.d627.s4.e7'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	calcium	multivitamins	none	{'e1': {'word': 'calcium', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d627.s4.e1'}, 'e2': {'word': 'multivitamins', 'word_index': [(33, 33)], 'id': 'DDI-DrugBank.d627.s4.e8'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	calcium	naproxen	none	{'e1': {'word': 'calcium', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d627.s4.e1'}, 'e2': {'word': 'naproxen', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d627.s4.e9'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	calcium	omeprazole	none	{'e1': {'word': 'calcium', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d627.s4.e1'}, 'e2': {'word': 'omeprazole', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d627.s4.e10'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	calcium	paracetamol	none	{'e1': {'word': 'calcium', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d627.s4.e1'}, 'e2': {'word': 'paracetamol', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d627.s4.e11'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	calcium	prednisone	none	{'e1': {'word': 'calcium', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d627.s4.e1'}, 'e2': {'word': 'prednisone', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d627.s4.e12'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	conjugated estrogens	hydroxychloroquine sulfate	none	{'e1': {'word': 'conjugated estrogens', 'word_index': [(23, 24)], 'id': 'DDI-DrugBank.d627.s4.e2'}, 'e2': {'word': 'hydroxychloroquine sulfate', 'word_index': [(25, 26)], 'id': 'DDI-DrugBank.d627.s4.e3'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	conjugated estrogens	ibuprofen	none	{'e1': {'word': 'conjugated estrogens', 'word_index': [(23, 24)], 'id': 'DDI-DrugBank.d627.s4.e2'}, 'e2': {'word': 'ibuprofen', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d627.s4.e4'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	conjugated estrogens	levothyroxine sodium	none	{'e1': {'word': 'conjugated estrogens', 'word_index': [(23, 24)], 'id': 'DDI-DrugBank.d627.s4.e2'}, 'e2': {'word': 'levothyroxine sodium', 'word_index': [(28, 29)], 'id': 'DDI-DrugBank.d627.s4.e5'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	conjugated estrogens	medroxyprogesterone acetate	none	{'e1': {'word': 'conjugated estrogens', 'word_index': [(23, 24)], 'id': 'DDI-DrugBank.d627.s4.e2'}, 'e2': {'word': 'medroxyprogesterone acetate', 'word_index': [(30, 31)], 'id': 'DDI-DrugBank.d627.s4.e6'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	conjugated estrogens	methotrexate	none	{'e1': {'word': 'conjugated estrogens', 'word_index': [(23, 24)], 'id': 'DDI-DrugBank.d627.s4.e2'}, 'e2': {'word': 'methotrexate', 'word_index': [(32, 32)], 'id': 'DDI-DrugBank.d627.s4.e7'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	conjugated estrogens	multivitamins	none	{'e1': {'word': 'conjugated estrogens', 'word_index': [(23, 24)], 'id': 'DDI-DrugBank.d627.s4.e2'}, 'e2': {'word': 'multivitamins', 'word_index': [(33, 33)], 'id': 'DDI-DrugBank.d627.s4.e8'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	conjugated estrogens	naproxen	none	{'e1': {'word': 'conjugated estrogens', 'word_index': [(23, 24)], 'id': 'DDI-DrugBank.d627.s4.e2'}, 'e2': {'word': 'naproxen', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d627.s4.e9'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	conjugated estrogens	omeprazole	none	{'e1': {'word': 'conjugated estrogens', 'word_index': [(23, 24)], 'id': 'DDI-DrugBank.d627.s4.e2'}, 'e2': {'word': 'omeprazole', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d627.s4.e10'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	conjugated estrogens	paracetamol	none	{'e1': {'word': 'conjugated estrogens', 'word_index': [(23, 24)], 'id': 'DDI-DrugBank.d627.s4.e2'}, 'e2': {'word': 'paracetamol', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d627.s4.e11'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	conjugated estrogens	prednisone	none	{'e1': {'word': 'conjugated estrogens', 'word_index': [(23, 24)], 'id': 'DDI-DrugBank.d627.s4.e2'}, 'e2': {'word': 'prednisone', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d627.s4.e12'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	hydroxychloroquine sulfate	ibuprofen	none	{'e1': {'word': 'hydroxychloroquine sulfate', 'word_index': [(25, 26)], 'id': 'DDI-DrugBank.d627.s4.e3'}, 'e2': {'word': 'ibuprofen', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d627.s4.e4'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	hydroxychloroquine sulfate	levothyroxine sodium	none	{'e1': {'word': 'hydroxychloroquine sulfate', 'word_index': [(25, 26)], 'id': 'DDI-DrugBank.d627.s4.e3'}, 'e2': {'word': 'levothyroxine sodium', 'word_index': [(28, 29)], 'id': 'DDI-DrugBank.d627.s4.e5'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	hydroxychloroquine sulfate	medroxyprogesterone acetate	none	{'e1': {'word': 'hydroxychloroquine sulfate', 'word_index': [(25, 26)], 'id': 'DDI-DrugBank.d627.s4.e3'}, 'e2': {'word': 'medroxyprogesterone acetate', 'word_index': [(30, 31)], 'id': 'DDI-DrugBank.d627.s4.e6'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	hydroxychloroquine sulfate	methotrexate	none	{'e1': {'word': 'hydroxychloroquine sulfate', 'word_index': [(25, 26)], 'id': 'DDI-DrugBank.d627.s4.e3'}, 'e2': {'word': 'methotrexate', 'word_index': [(32, 32)], 'id': 'DDI-DrugBank.d627.s4.e7'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	hydroxychloroquine sulfate	multivitamins	none	{'e1': {'word': 'hydroxychloroquine sulfate', 'word_index': [(25, 26)], 'id': 'DDI-DrugBank.d627.s4.e3'}, 'e2': {'word': 'multivitamins', 'word_index': [(33, 33)], 'id': 'DDI-DrugBank.d627.s4.e8'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	hydroxychloroquine sulfate	naproxen	none	{'e1': {'word': 'hydroxychloroquine sulfate', 'word_index': [(25, 26)], 'id': 'DDI-DrugBank.d627.s4.e3'}, 'e2': {'word': 'naproxen', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d627.s4.e9'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	hydroxychloroquine sulfate	omeprazole	none	{'e1': {'word': 'hydroxychloroquine sulfate', 'word_index': [(25, 26)], 'id': 'DDI-DrugBank.d627.s4.e3'}, 'e2': {'word': 'omeprazole', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d627.s4.e10'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	hydroxychloroquine sulfate	paracetamol	none	{'e1': {'word': 'hydroxychloroquine sulfate', 'word_index': [(25, 26)], 'id': 'DDI-DrugBank.d627.s4.e3'}, 'e2': {'word': 'paracetamol', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d627.s4.e11'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	hydroxychloroquine sulfate	prednisone	none	{'e1': {'word': 'hydroxychloroquine sulfate', 'word_index': [(25, 26)], 'id': 'DDI-DrugBank.d627.s4.e3'}, 'e2': {'word': 'prednisone', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d627.s4.e12'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	ibuprofen	levothyroxine sodium	none	{'e1': {'word': 'ibuprofen', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d627.s4.e4'}, 'e2': {'word': 'levothyroxine sodium', 'word_index': [(28, 29)], 'id': 'DDI-DrugBank.d627.s4.e5'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	ibuprofen	medroxyprogesterone acetate	none	{'e1': {'word': 'ibuprofen', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d627.s4.e4'}, 'e2': {'word': 'medroxyprogesterone acetate', 'word_index': [(30, 31)], 'id': 'DDI-DrugBank.d627.s4.e6'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	ibuprofen	methotrexate	none	{'e1': {'word': 'ibuprofen', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d627.s4.e4'}, 'e2': {'word': 'methotrexate', 'word_index': [(32, 32)], 'id': 'DDI-DrugBank.d627.s4.e7'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	ibuprofen	multivitamins	none	{'e1': {'word': 'ibuprofen', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d627.s4.e4'}, 'e2': {'word': 'multivitamins', 'word_index': [(33, 33)], 'id': 'DDI-DrugBank.d627.s4.e8'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	ibuprofen	naproxen	none	{'e1': {'word': 'ibuprofen', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d627.s4.e4'}, 'e2': {'word': 'naproxen', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d627.s4.e9'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	ibuprofen	omeprazole	none	{'e1': {'word': 'ibuprofen', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d627.s4.e4'}, 'e2': {'word': 'omeprazole', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d627.s4.e10'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	ibuprofen	paracetamol	none	{'e1': {'word': 'ibuprofen', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d627.s4.e4'}, 'e2': {'word': 'paracetamol', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d627.s4.e11'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	ibuprofen	prednisone	none	{'e1': {'word': 'ibuprofen', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d627.s4.e4'}, 'e2': {'word': 'prednisone', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d627.s4.e12'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	levothyroxine sodium	medroxyprogesterone acetate	none	{'e1': {'word': 'levothyroxine sodium', 'word_index': [(28, 29)], 'id': 'DDI-DrugBank.d627.s4.e5'}, 'e2': {'word': 'medroxyprogesterone acetate', 'word_index': [(30, 31)], 'id': 'DDI-DrugBank.d627.s4.e6'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	levothyroxine sodium	methotrexate	none	{'e1': {'word': 'levothyroxine sodium', 'word_index': [(28, 29)], 'id': 'DDI-DrugBank.d627.s4.e5'}, 'e2': {'word': 'methotrexate', 'word_index': [(32, 32)], 'id': 'DDI-DrugBank.d627.s4.e7'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	levothyroxine sodium	multivitamins	none	{'e1': {'word': 'levothyroxine sodium', 'word_index': [(28, 29)], 'id': 'DDI-DrugBank.d627.s4.e5'}, 'e2': {'word': 'multivitamins', 'word_index': [(33, 33)], 'id': 'DDI-DrugBank.d627.s4.e8'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	levothyroxine sodium	naproxen	none	{'e1': {'word': 'levothyroxine sodium', 'word_index': [(28, 29)], 'id': 'DDI-DrugBank.d627.s4.e5'}, 'e2': {'word': 'naproxen', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d627.s4.e9'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	levothyroxine sodium	omeprazole	none	{'e1': {'word': 'levothyroxine sodium', 'word_index': [(28, 29)], 'id': 'DDI-DrugBank.d627.s4.e5'}, 'e2': {'word': 'omeprazole', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d627.s4.e10'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	levothyroxine sodium	paracetamol	none	{'e1': {'word': 'levothyroxine sodium', 'word_index': [(28, 29)], 'id': 'DDI-DrugBank.d627.s4.e5'}, 'e2': {'word': 'paracetamol', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d627.s4.e11'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	levothyroxine sodium	prednisone	none	{'e1': {'word': 'levothyroxine sodium', 'word_index': [(28, 29)], 'id': 'DDI-DrugBank.d627.s4.e5'}, 'e2': {'word': 'prednisone', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d627.s4.e12'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	medroxyprogesterone acetate	methotrexate	none	{'e1': {'word': 'medroxyprogesterone acetate', 'word_index': [(30, 31)], 'id': 'DDI-DrugBank.d627.s4.e6'}, 'e2': {'word': 'methotrexate', 'word_index': [(32, 32)], 'id': 'DDI-DrugBank.d627.s4.e7'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	medroxyprogesterone acetate	multivitamins	none	{'e1': {'word': 'medroxyprogesterone acetate', 'word_index': [(30, 31)], 'id': 'DDI-DrugBank.d627.s4.e6'}, 'e2': {'word': 'multivitamins', 'word_index': [(33, 33)], 'id': 'DDI-DrugBank.d627.s4.e8'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	medroxyprogesterone acetate	naproxen	none	{'e1': {'word': 'medroxyprogesterone acetate', 'word_index': [(30, 31)], 'id': 'DDI-DrugBank.d627.s4.e6'}, 'e2': {'word': 'naproxen', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d627.s4.e9'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	medroxyprogesterone acetate	omeprazole	none	{'e1': {'word': 'medroxyprogesterone acetate', 'word_index': [(30, 31)], 'id': 'DDI-DrugBank.d627.s4.e6'}, 'e2': {'word': 'omeprazole', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d627.s4.e10'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	medroxyprogesterone acetate	paracetamol	none	{'e1': {'word': 'medroxyprogesterone acetate', 'word_index': [(30, 31)], 'id': 'DDI-DrugBank.d627.s4.e6'}, 'e2': {'word': 'paracetamol', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d627.s4.e11'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	medroxyprogesterone acetate	prednisone	none	{'e1': {'word': 'medroxyprogesterone acetate', 'word_index': [(30, 31)], 'id': 'DDI-DrugBank.d627.s4.e6'}, 'e2': {'word': 'prednisone', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d627.s4.e12'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	methotrexate	multivitamins	none	{'e1': {'word': 'methotrexate', 'word_index': [(32, 32)], 'id': 'DDI-DrugBank.d627.s4.e7'}, 'e2': {'word': 'multivitamins', 'word_index': [(33, 33)], 'id': 'DDI-DrugBank.d627.s4.e8'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	methotrexate	naproxen	none	{'e1': {'word': 'methotrexate', 'word_index': [(32, 32)], 'id': 'DDI-DrugBank.d627.s4.e7'}, 'e2': {'word': 'naproxen', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d627.s4.e9'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	methotrexate	omeprazole	none	{'e1': {'word': 'methotrexate', 'word_index': [(32, 32)], 'id': 'DDI-DrugBank.d627.s4.e7'}, 'e2': {'word': 'omeprazole', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d627.s4.e10'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	methotrexate	paracetamol	none	{'e1': {'word': 'methotrexate', 'word_index': [(32, 32)], 'id': 'DDI-DrugBank.d627.s4.e7'}, 'e2': {'word': 'paracetamol', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d627.s4.e11'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	methotrexate	prednisone	none	{'e1': {'word': 'methotrexate', 'word_index': [(32, 32)], 'id': 'DDI-DrugBank.d627.s4.e7'}, 'e2': {'word': 'prednisone', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d627.s4.e12'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	multivitamins	naproxen	none	{'e1': {'word': 'multivitamins', 'word_index': [(33, 33)], 'id': 'DDI-DrugBank.d627.s4.e8'}, 'e2': {'word': 'naproxen', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d627.s4.e9'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	multivitamins	omeprazole	none	{'e1': {'word': 'multivitamins', 'word_index': [(33, 33)], 'id': 'DDI-DrugBank.d627.s4.e8'}, 'e2': {'word': 'omeprazole', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d627.s4.e10'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	multivitamins	paracetamol	none	{'e1': {'word': 'multivitamins', 'word_index': [(33, 33)], 'id': 'DDI-DrugBank.d627.s4.e8'}, 'e2': {'word': 'paracetamol', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d627.s4.e11'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	multivitamins	prednisone	none	{'e1': {'word': 'multivitamins', 'word_index': [(33, 33)], 'id': 'DDI-DrugBank.d627.s4.e8'}, 'e2': {'word': 'prednisone', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d627.s4.e12'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	naproxen	omeprazole	none	{'e1': {'word': 'naproxen', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d627.s4.e9'}, 'e2': {'word': 'omeprazole', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d627.s4.e10'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	naproxen	paracetamol	none	{'e1': {'word': 'naproxen', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d627.s4.e9'}, 'e2': {'word': 'paracetamol', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d627.s4.e11'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	naproxen	prednisone	none	{'e1': {'word': 'naproxen', 'word_index': [(34, 34)], 'id': 'DDI-DrugBank.d627.s4.e9'}, 'e2': {'word': 'prednisone', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d627.s4.e12'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	omeprazole	paracetamol	none	{'e1': {'word': 'omeprazole', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d627.s4.e10'}, 'e2': {'word': 'paracetamol', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d627.s4.e11'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	omeprazole	prednisone	none	{'e1': {'word': 'omeprazole', 'word_index': [(35, 35)], 'id': 'DDI-DrugBank.d627.s4.e10'}, 'e2': {'word': 'prednisone', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d627.s4.e12'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	paracetamol	prednisone	none	{'e1': {'word': 'paracetamol', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d627.s4.e11'}, 'e2': {'word': 'prednisone', 'word_index': [(37, 37)], 'id': 'DDI-DrugBank.d627.s4.e12'}, 'sentence_id': 'DDI-DrugBank.d627.s4'}	formal drug interaction studies performed following concomitant drugs used least NUMBER % patients either Sj grens efficacy studies acetylsalicylic acid artificial tears calcium conjugated estrogens hydroxychloroquine sulfate ibuprofen levothyroxine sodium medroxyprogesterone acetate methotrexate multivitamins naproxen omeprazole paracetamol prednisone
Some anticonvulsants may interact with Mephenytoin. 	anticonvulsants	Mephenytoin	int	{'e1': {'word': 'anticonvulsants', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d636.s0.e0'}, 'e2': {'word': 'Mephenytoin', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d636.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d636.s0'}	anticonvulsants may interact Mephenytoin
Those anticonvulsants include divalproex sodium, valproic acid, and phenobarbital. 	anticonvulsants	divalproex sodium	none	{'e1': {'word': 'anticonvulsants', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d636.s2.e0'}, 'e2': {'word': 'divalproex sodium', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d636.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d636.s2'}	anticonvulsants include divalproex sodium valproic acid phenobarbital
Those anticonvulsants include divalproex sodium, valproic acid, and phenobarbital. 	anticonvulsants	valproic acid	none	{'e1': {'word': 'anticonvulsants', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d636.s2.e0'}, 'e2': {'word': 'valproic acid', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d636.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d636.s2'}	anticonvulsants include divalproex sodium valproic acid phenobarbital
Those anticonvulsants include divalproex sodium, valproic acid, and phenobarbital. 	anticonvulsants	phenobarbital	none	{'e1': {'word': 'anticonvulsants', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d636.s2.e0'}, 'e2': {'word': 'phenobarbital', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d636.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d636.s2'}	anticonvulsants include divalproex sodium valproic acid phenobarbital
Those anticonvulsants include divalproex sodium, valproic acid, and phenobarbital. 	divalproex sodium	valproic acid	none	{'e1': {'word': 'divalproex sodium', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d636.s2.e1'}, 'e2': {'word': 'valproic acid', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d636.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d636.s2'}	anticonvulsants include divalproex sodium valproic acid phenobarbital
Those anticonvulsants include divalproex sodium, valproic acid, and phenobarbital. 	divalproex sodium	phenobarbital	none	{'e1': {'word': 'divalproex sodium', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d636.s2.e1'}, 'e2': {'word': 'phenobarbital', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d636.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d636.s2'}	anticonvulsants include divalproex sodium valproic acid phenobarbital
Those anticonvulsants include divalproex sodium, valproic acid, and phenobarbital. 	valproic acid	phenobarbital	none	{'e1': {'word': 'valproic acid', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d636.s2.e2'}, 'e2': {'word': 'phenobarbital', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d636.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d636.s2'}	anticonvulsants include divalproex sodium valproic acid phenobarbital
Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.	Mephenytoin	steroid medications	effect	{'e1': {'word': 'Mephenytoin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d636.s3.e0'}, 'e2': {'word': 'steroid medications', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d636.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d636.s3'}	Mephenytoin may also affect effects drugs include steroid medications warfarin certain heart medicines birth control pills anti-infective medicines furosemide theophylline Please note Mephenytoin may interact drugs listed
Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.	Mephenytoin	warfarin	effect	{'e1': {'word': 'Mephenytoin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d636.s3.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d636.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d636.s3'}	Mephenytoin may also affect effects drugs include steroid medications warfarin certain heart medicines birth control pills anti-infective medicines furosemide theophylline Please note Mephenytoin may interact drugs listed
Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.	Mephenytoin	anti-infective medicines	effect	{'e1': {'word': 'Mephenytoin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d636.s3.e0'}, 'e2': {'word': 'anti-infective medicines', 'word_index': [(16, 17)], 'id': 'DDI-DrugBank.d636.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d636.s3'}	Mephenytoin may also affect effects drugs include steroid medications warfarin certain heart medicines birth control pills anti-infective medicines furosemide theophylline Please note Mephenytoin may interact drugs listed
Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.	Mephenytoin	furosemide	effect	{'e1': {'word': 'Mephenytoin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d636.s3.e0'}, 'e2': {'word': 'furosemide', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d636.s3.e4'}, 'sentence_id': 'DDI-DrugBank.d636.s3'}	Mephenytoin may also affect effects drugs include steroid medications warfarin certain heart medicines birth control pills anti-infective medicines furosemide theophylline Please note Mephenytoin may interact drugs listed
Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.	Mephenytoin	theophylline	effect	{'e1': {'word': 'Mephenytoin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d636.s3.e0'}, 'e2': {'word': 'theophylline', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d636.s3.e5'}, 'sentence_id': 'DDI-DrugBank.d636.s3'}	Mephenytoin may also affect effects drugs include steroid medications warfarin certain heart medicines birth control pills anti-infective medicines furosemide theophylline Please note Mephenytoin may interact drugs listed
Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.	Mephenytoin	Mephenytoin	none	{'e1': {'word': 'Mephenytoin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d636.s3.e0'}, 'e2': {'word': 'Mephenytoin', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d636.s3.e6'}, 'sentence_id': 'DDI-DrugBank.d636.s3'}	Mephenytoin may also affect effects drugs include steroid medications warfarin certain heart medicines birth control pills anti-infective medicines furosemide theophylline Please note Mephenytoin may interact drugs listed
Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.	steroid medications	warfarin	none	{'e1': {'word': 'steroid medications', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d636.s3.e1'}, 'e2': {'word': 'warfarin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d636.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d636.s3'}	Mephenytoin may also affect effects drugs include steroid medications warfarin certain heart medicines birth control pills anti-infective medicines furosemide theophylline Please note Mephenytoin may interact drugs listed
Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.	steroid medications	anti-infective medicines	none	{'e1': {'word': 'steroid medications', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d636.s3.e1'}, 'e2': {'word': 'anti-infective medicines', 'word_index': [(16, 17)], 'id': 'DDI-DrugBank.d636.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d636.s3'}	Mephenytoin may also affect effects drugs include steroid medications warfarin certain heart medicines birth control pills anti-infective medicines furosemide theophylline Please note Mephenytoin may interact drugs listed
Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.	steroid medications	furosemide	none	{'e1': {'word': 'steroid medications', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d636.s3.e1'}, 'e2': {'word': 'furosemide', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d636.s3.e4'}, 'sentence_id': 'DDI-DrugBank.d636.s3'}	Mephenytoin may also affect effects drugs include steroid medications warfarin certain heart medicines birth control pills anti-infective medicines furosemide theophylline Please note Mephenytoin may interact drugs listed
Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.	steroid medications	theophylline	none	{'e1': {'word': 'steroid medications', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d636.s3.e1'}, 'e2': {'word': 'theophylline', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d636.s3.e5'}, 'sentence_id': 'DDI-DrugBank.d636.s3'}	Mephenytoin may also affect effects drugs include steroid medications warfarin certain heart medicines birth control pills anti-infective medicines furosemide theophylline Please note Mephenytoin may interact drugs listed
Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.	steroid medications	Mephenytoin	none	{'e1': {'word': 'steroid medications', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d636.s3.e1'}, 'e2': {'word': 'Mephenytoin', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d636.s3.e6'}, 'sentence_id': 'DDI-DrugBank.d636.s3'}	Mephenytoin may also affect effects drugs include steroid medications warfarin certain heart medicines birth control pills anti-infective medicines furosemide theophylline Please note Mephenytoin may interact drugs listed
Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.	warfarin	anti-infective medicines	none	{'e1': {'word': 'warfarin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d636.s3.e2'}, 'e2': {'word': 'anti-infective medicines', 'word_index': [(16, 17)], 'id': 'DDI-DrugBank.d636.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d636.s3'}	Mephenytoin may also affect effects drugs include steroid medications warfarin certain heart medicines birth control pills anti-infective medicines furosemide theophylline Please note Mephenytoin may interact drugs listed
Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.	warfarin	furosemide	none	{'e1': {'word': 'warfarin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d636.s3.e2'}, 'e2': {'word': 'furosemide', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d636.s3.e4'}, 'sentence_id': 'DDI-DrugBank.d636.s3'}	Mephenytoin may also affect effects drugs include steroid medications warfarin certain heart medicines birth control pills anti-infective medicines furosemide theophylline Please note Mephenytoin may interact drugs listed
Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.	warfarin	theophylline	none	{'e1': {'word': 'warfarin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d636.s3.e2'}, 'e2': {'word': 'theophylline', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d636.s3.e5'}, 'sentence_id': 'DDI-DrugBank.d636.s3'}	Mephenytoin may also affect effects drugs include steroid medications warfarin certain heart medicines birth control pills anti-infective medicines furosemide theophylline Please note Mephenytoin may interact drugs listed
Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.	warfarin	Mephenytoin	none	{'e1': {'word': 'warfarin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d636.s3.e2'}, 'e2': {'word': 'Mephenytoin', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d636.s3.e6'}, 'sentence_id': 'DDI-DrugBank.d636.s3'}	Mephenytoin may also affect effects drugs include steroid medications warfarin certain heart medicines birth control pills anti-infective medicines furosemide theophylline Please note Mephenytoin may interact drugs listed
Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.	anti-infective medicines	furosemide	none	{'e1': {'word': 'anti-infective medicines', 'word_index': [(16, 17)], 'id': 'DDI-DrugBank.d636.s3.e3'}, 'e2': {'word': 'furosemide', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d636.s3.e4'}, 'sentence_id': 'DDI-DrugBank.d636.s3'}	Mephenytoin may also affect effects drugs include steroid medications warfarin certain heart medicines birth control pills anti-infective medicines furosemide theophylline Please note Mephenytoin may interact drugs listed
Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.	anti-infective medicines	theophylline	none	{'e1': {'word': 'anti-infective medicines', 'word_index': [(16, 17)], 'id': 'DDI-DrugBank.d636.s3.e3'}, 'e2': {'word': 'theophylline', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d636.s3.e5'}, 'sentence_id': 'DDI-DrugBank.d636.s3'}	Mephenytoin may also affect effects drugs include steroid medications warfarin certain heart medicines birth control pills anti-infective medicines furosemide theophylline Please note Mephenytoin may interact drugs listed
Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.	anti-infective medicines	Mephenytoin	none	{'e1': {'word': 'anti-infective medicines', 'word_index': [(16, 17)], 'id': 'DDI-DrugBank.d636.s3.e3'}, 'e2': {'word': 'Mephenytoin', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d636.s3.e6'}, 'sentence_id': 'DDI-DrugBank.d636.s3'}	Mephenytoin may also affect effects drugs include steroid medications warfarin certain heart medicines birth control pills anti-infective medicines furosemide theophylline Please note Mephenytoin may interact drugs listed
Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.	furosemide	theophylline	none	{'e1': {'word': 'furosemide', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d636.s3.e4'}, 'e2': {'word': 'theophylline', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d636.s3.e5'}, 'sentence_id': 'DDI-DrugBank.d636.s3'}	Mephenytoin may also affect effects drugs include steroid medications warfarin certain heart medicines birth control pills anti-infective medicines furosemide theophylline Please note Mephenytoin may interact drugs listed
Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.	furosemide	Mephenytoin	none	{'e1': {'word': 'furosemide', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d636.s3.e4'}, 'e2': {'word': 'Mephenytoin', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d636.s3.e6'}, 'sentence_id': 'DDI-DrugBank.d636.s3'}	Mephenytoin may also affect effects drugs include steroid medications warfarin certain heart medicines birth control pills anti-infective medicines furosemide theophylline Please note Mephenytoin may interact drugs listed
Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.	theophylline	Mephenytoin	none	{'e1': {'word': 'theophylline', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d636.s3.e5'}, 'e2': {'word': 'Mephenytoin', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d636.s3.e6'}, 'sentence_id': 'DDI-DrugBank.d636.s3'}	Mephenytoin may also affect effects drugs include steroid medications warfarin certain heart medicines birth control pills anti-infective medicines furosemide theophylline Please note Mephenytoin may interact drugs listed
The CNS depressant effects of oxycodone hydrochloride may be additive with that of other CNS depressants..	oxycodone hydrochloride	CNS depressants	effect	{'e1': {'word': 'oxycodone hydrochloride', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d758.s0.e0'}, 'e2': {'word': 'CNS depressants', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d758.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d758.s0'}	CNS depressant effects oxycodone hydrochloride may additive CNS depressants
Caution should be observed in administering DEMSER to patients receiving phenothiazines or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis. 	DEMSER	phenothiazines	advise	{'e1': {'word': 'DEMSER', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d715.s0.e0'}, 'e2': {'word': 'phenothiazines', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d715.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d715.s0'}	Caution observed administering DEMSER patients receiving phenothiazines haloperidol extrapyramidal effects drugs expected potentiated inhibition catecholamine synthesis
Caution should be observed in administering DEMSER to patients receiving phenothiazines or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis. 	DEMSER	haloperidol	advise	{'e1': {'word': 'DEMSER', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d715.s0.e0'}, 'e2': {'word': 'haloperidol', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d715.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d715.s0'}	Caution observed administering DEMSER patients receiving phenothiazines haloperidol extrapyramidal effects drugs expected potentiated inhibition catecholamine synthesis
Caution should be observed in administering DEMSER to patients receiving phenothiazines or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis. 	phenothiazines	haloperidol	none	{'e1': {'word': 'phenothiazines', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d715.s0.e1'}, 'e2': {'word': 'haloperidol', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d715.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d715.s0'}	Caution observed administering DEMSER patients receiving phenothiazines haloperidol extrapyramidal effects drugs expected potentiated inhibition catecholamine synthesis
Concurrent use of DEMSER with alcohol or other CNS depressants can increase their sedative effects.	DEMSER	alcohol	effect	{'e1': {'word': 'DEMSER', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d715.s1.e0'}, 'e2': {'word': 'alcohol', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d715.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d715.s1'}	Concurrent use DEMSER alcohol CNS depressants increase sedative effects
Concurrent use of DEMSER with alcohol or other CNS depressants can increase their sedative effects.	DEMSER	CNS depressants	effect	{'e1': {'word': 'DEMSER', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d715.s1.e0'}, 'e2': {'word': 'CNS depressants', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d715.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d715.s1'}	Concurrent use DEMSER alcohol CNS depressants increase sedative effects
Concurrent use of DEMSER with alcohol or other CNS depressants can increase their sedative effects.	alcohol	CNS depressants	none	{'e1': {'word': 'alcohol', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d715.s1.e1'}, 'e2': {'word': 'CNS depressants', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d715.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d715.s1'}	Concurrent use DEMSER alcohol CNS depressants increase sedative effects
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	hypoglycemics	Coumarin-type anticoagulants	none	{'e1': {'word': 'hypoglycemics', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d776.s2.e0'}, 'e2': {'word': 'Coumarin-type anticoagulants', 'word_index': [(5, 7)], 'id': 'DDI-DrugBank.d776.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	hypoglycemics	Phenytoin	none	{'e1': {'word': 'hypoglycemics', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d776.s2.e0'}, 'e2': {'word': 'Phenytoin', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d776.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	hypoglycemics	Cyclosporine	none	{'e1': {'word': 'hypoglycemics', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d776.s2.e0'}, 'e2': {'word': 'Cyclosporine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d776.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	hypoglycemics	Rifampin	none	{'e1': {'word': 'hypoglycemics', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d776.s2.e0'}, 'e2': {'word': 'Rifampin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d776.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	hypoglycemics	Theophylline	none	{'e1': {'word': 'hypoglycemics', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d776.s2.e0'}, 'e2': {'word': 'Theophylline', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d776.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	hypoglycemics	Terfenadine	none	{'e1': {'word': 'hypoglycemics', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d776.s2.e0'}, 'e2': {'word': 'Terfenadine', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d776.s2.e6'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	hypoglycemics	Cisapride	none	{'e1': {'word': 'hypoglycemics', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d776.s2.e0'}, 'e2': {'word': 'Cisapride', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d776.s2.e7'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	hypoglycemics	Astemizole	none	{'e1': {'word': 'hypoglycemics', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d776.s2.e0'}, 'e2': {'word': 'Astemizole', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d776.s2.e8'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	hypoglycemics	Rifabutin	none	{'e1': {'word': 'hypoglycemics', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d776.s2.e0'}, 'e2': {'word': 'Rifabutin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d776.s2.e9'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	hypoglycemics	Tacrolimus	none	{'e1': {'word': 'hypoglycemics', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d776.s2.e0'}, 'e2': {'word': 'Tacrolimus', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d776.s2.e10'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	hypoglycemics	Short-acting benzodiazepines	none	{'e1': {'word': 'hypoglycemics', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d776.s2.e0'}, 'e2': {'word': 'Short-acting benzodiazepines', 'word_index': [(17, 19)], 'id': 'DDI-DrugBank.d776.s2.e11'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	hypoglycemics	hypoglycemics	none	{'e1': {'word': 'hypoglycemics', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d776.s2.e0'}, 'e2': {'word': 'hypoglycemics', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d776.s2.e12'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	hypoglycemics	DIFLUCAN	none	{'e1': {'word': 'hypoglycemics', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d776.s2.e0'}, 'e2': {'word': 'DIFLUCAN', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d776.s2.e13'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	hypoglycemics	hypoglycemic agents	none	{'e1': {'word': 'hypoglycemics', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d776.s2.e0'}, 'e2': {'word': 'hypoglycemic agents', 'word_index': [(30, 31)], 'id': 'DDI-DrugBank.d776.s2.e14'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Coumarin-type anticoagulants	Phenytoin	none	{'e1': {'word': 'Coumarin-type anticoagulants', 'word_index': [(5, 7)], 'id': 'DDI-DrugBank.d776.s2.e1'}, 'e2': {'word': 'Phenytoin', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d776.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Coumarin-type anticoagulants	Cyclosporine	none	{'e1': {'word': 'Coumarin-type anticoagulants', 'word_index': [(5, 7)], 'id': 'DDI-DrugBank.d776.s2.e1'}, 'e2': {'word': 'Cyclosporine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d776.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Coumarin-type anticoagulants	Rifampin	none	{'e1': {'word': 'Coumarin-type anticoagulants', 'word_index': [(5, 7)], 'id': 'DDI-DrugBank.d776.s2.e1'}, 'e2': {'word': 'Rifampin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d776.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Coumarin-type anticoagulants	Theophylline	none	{'e1': {'word': 'Coumarin-type anticoagulants', 'word_index': [(5, 7)], 'id': 'DDI-DrugBank.d776.s2.e1'}, 'e2': {'word': 'Theophylline', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d776.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Coumarin-type anticoagulants	Terfenadine	none	{'e1': {'word': 'Coumarin-type anticoagulants', 'word_index': [(5, 7)], 'id': 'DDI-DrugBank.d776.s2.e1'}, 'e2': {'word': 'Terfenadine', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d776.s2.e6'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Coumarin-type anticoagulants	Cisapride	none	{'e1': {'word': 'Coumarin-type anticoagulants', 'word_index': [(5, 7)], 'id': 'DDI-DrugBank.d776.s2.e1'}, 'e2': {'word': 'Cisapride', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d776.s2.e7'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Coumarin-type anticoagulants	Astemizole	none	{'e1': {'word': 'Coumarin-type anticoagulants', 'word_index': [(5, 7)], 'id': 'DDI-DrugBank.d776.s2.e1'}, 'e2': {'word': 'Astemizole', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d776.s2.e8'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Coumarin-type anticoagulants	Rifabutin	none	{'e1': {'word': 'Coumarin-type anticoagulants', 'word_index': [(5, 7)], 'id': 'DDI-DrugBank.d776.s2.e1'}, 'e2': {'word': 'Rifabutin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d776.s2.e9'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Coumarin-type anticoagulants	Tacrolimus	none	{'e1': {'word': 'Coumarin-type anticoagulants', 'word_index': [(5, 7)], 'id': 'DDI-DrugBank.d776.s2.e1'}, 'e2': {'word': 'Tacrolimus', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d776.s2.e10'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Coumarin-type anticoagulants	Short-acting benzodiazepines	none	{'e1': {'word': 'Coumarin-type anticoagulants', 'word_index': [(5, 7)], 'id': 'DDI-DrugBank.d776.s2.e1'}, 'e2': {'word': 'Short-acting benzodiazepines', 'word_index': [(17, 19)], 'id': 'DDI-DrugBank.d776.s2.e11'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Coumarin-type anticoagulants	hypoglycemics	none	{'e1': {'word': 'Coumarin-type anticoagulants', 'word_index': [(5, 7)], 'id': 'DDI-DrugBank.d776.s2.e1'}, 'e2': {'word': 'hypoglycemics', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d776.s2.e12'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Coumarin-type anticoagulants	DIFLUCAN	none	{'e1': {'word': 'Coumarin-type anticoagulants', 'word_index': [(5, 7)], 'id': 'DDI-DrugBank.d776.s2.e1'}, 'e2': {'word': 'DIFLUCAN', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d776.s2.e13'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Coumarin-type anticoagulants	hypoglycemic agents	none	{'e1': {'word': 'Coumarin-type anticoagulants', 'word_index': [(5, 7)], 'id': 'DDI-DrugBank.d776.s2.e1'}, 'e2': {'word': 'hypoglycemic agents', 'word_index': [(30, 31)], 'id': 'DDI-DrugBank.d776.s2.e14'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Phenytoin	Cyclosporine	none	{'e1': {'word': 'Phenytoin', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d776.s2.e2'}, 'e2': {'word': 'Cyclosporine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d776.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Phenytoin	Rifampin	none	{'e1': {'word': 'Phenytoin', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d776.s2.e2'}, 'e2': {'word': 'Rifampin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d776.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Phenytoin	Theophylline	none	{'e1': {'word': 'Phenytoin', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d776.s2.e2'}, 'e2': {'word': 'Theophylline', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d776.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Phenytoin	Terfenadine	none	{'e1': {'word': 'Phenytoin', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d776.s2.e2'}, 'e2': {'word': 'Terfenadine', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d776.s2.e6'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Phenytoin	Cisapride	none	{'e1': {'word': 'Phenytoin', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d776.s2.e2'}, 'e2': {'word': 'Cisapride', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d776.s2.e7'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Phenytoin	Astemizole	none	{'e1': {'word': 'Phenytoin', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d776.s2.e2'}, 'e2': {'word': 'Astemizole', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d776.s2.e8'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Phenytoin	Rifabutin	none	{'e1': {'word': 'Phenytoin', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d776.s2.e2'}, 'e2': {'word': 'Rifabutin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d776.s2.e9'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Phenytoin	Tacrolimus	none	{'e1': {'word': 'Phenytoin', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d776.s2.e2'}, 'e2': {'word': 'Tacrolimus', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d776.s2.e10'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Phenytoin	Short-acting benzodiazepines	none	{'e1': {'word': 'Phenytoin', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d776.s2.e2'}, 'e2': {'word': 'Short-acting benzodiazepines', 'word_index': [(17, 19)], 'id': 'DDI-DrugBank.d776.s2.e11'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Phenytoin	hypoglycemics	none	{'e1': {'word': 'Phenytoin', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d776.s2.e2'}, 'e2': {'word': 'hypoglycemics', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d776.s2.e12'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Phenytoin	DIFLUCAN	none	{'e1': {'word': 'Phenytoin', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d776.s2.e2'}, 'e2': {'word': 'DIFLUCAN', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d776.s2.e13'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Phenytoin	hypoglycemic agents	none	{'e1': {'word': 'Phenytoin', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d776.s2.e2'}, 'e2': {'word': 'hypoglycemic agents', 'word_index': [(30, 31)], 'id': 'DDI-DrugBank.d776.s2.e14'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Cyclosporine	Rifampin	none	{'e1': {'word': 'Cyclosporine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d776.s2.e3'}, 'e2': {'word': 'Rifampin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d776.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Cyclosporine	Theophylline	none	{'e1': {'word': 'Cyclosporine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d776.s2.e3'}, 'e2': {'word': 'Theophylline', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d776.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Cyclosporine	Terfenadine	none	{'e1': {'word': 'Cyclosporine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d776.s2.e3'}, 'e2': {'word': 'Terfenadine', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d776.s2.e6'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Cyclosporine	Cisapride	none	{'e1': {'word': 'Cyclosporine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d776.s2.e3'}, 'e2': {'word': 'Cisapride', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d776.s2.e7'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Cyclosporine	Astemizole	none	{'e1': {'word': 'Cyclosporine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d776.s2.e3'}, 'e2': {'word': 'Astemizole', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d776.s2.e8'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Cyclosporine	Rifabutin	none	{'e1': {'word': 'Cyclosporine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d776.s2.e3'}, 'e2': {'word': 'Rifabutin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d776.s2.e9'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Cyclosporine	Tacrolimus	none	{'e1': {'word': 'Cyclosporine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d776.s2.e3'}, 'e2': {'word': 'Tacrolimus', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d776.s2.e10'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Cyclosporine	Short-acting benzodiazepines	none	{'e1': {'word': 'Cyclosporine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d776.s2.e3'}, 'e2': {'word': 'Short-acting benzodiazepines', 'word_index': [(17, 19)], 'id': 'DDI-DrugBank.d776.s2.e11'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Cyclosporine	hypoglycemics	none	{'e1': {'word': 'Cyclosporine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d776.s2.e3'}, 'e2': {'word': 'hypoglycemics', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d776.s2.e12'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Cyclosporine	DIFLUCAN	none	{'e1': {'word': 'Cyclosporine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d776.s2.e3'}, 'e2': {'word': 'DIFLUCAN', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d776.s2.e13'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Cyclosporine	hypoglycemic agents	none	{'e1': {'word': 'Cyclosporine', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d776.s2.e3'}, 'e2': {'word': 'hypoglycemic agents', 'word_index': [(30, 31)], 'id': 'DDI-DrugBank.d776.s2.e14'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Rifampin	Theophylline	none	{'e1': {'word': 'Rifampin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d776.s2.e4'}, 'e2': {'word': 'Theophylline', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d776.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Rifampin	Terfenadine	none	{'e1': {'word': 'Rifampin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d776.s2.e4'}, 'e2': {'word': 'Terfenadine', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d776.s2.e6'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Rifampin	Cisapride	none	{'e1': {'word': 'Rifampin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d776.s2.e4'}, 'e2': {'word': 'Cisapride', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d776.s2.e7'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Rifampin	Astemizole	none	{'e1': {'word': 'Rifampin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d776.s2.e4'}, 'e2': {'word': 'Astemizole', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d776.s2.e8'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Rifampin	Rifabutin	none	{'e1': {'word': 'Rifampin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d776.s2.e4'}, 'e2': {'word': 'Rifabutin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d776.s2.e9'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Rifampin	Tacrolimus	none	{'e1': {'word': 'Rifampin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d776.s2.e4'}, 'e2': {'word': 'Tacrolimus', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d776.s2.e10'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Rifampin	Short-acting benzodiazepines	none	{'e1': {'word': 'Rifampin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d776.s2.e4'}, 'e2': {'word': 'Short-acting benzodiazepines', 'word_index': [(17, 19)], 'id': 'DDI-DrugBank.d776.s2.e11'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Rifampin	hypoglycemics	none	{'e1': {'word': 'Rifampin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d776.s2.e4'}, 'e2': {'word': 'hypoglycemics', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d776.s2.e12'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Rifampin	DIFLUCAN	none	{'e1': {'word': 'Rifampin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d776.s2.e4'}, 'e2': {'word': 'DIFLUCAN', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d776.s2.e13'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Rifampin	hypoglycemic agents	none	{'e1': {'word': 'Rifampin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d776.s2.e4'}, 'e2': {'word': 'hypoglycemic agents', 'word_index': [(30, 31)], 'id': 'DDI-DrugBank.d776.s2.e14'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Theophylline	Terfenadine	none	{'e1': {'word': 'Theophylline', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d776.s2.e5'}, 'e2': {'word': 'Terfenadine', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d776.s2.e6'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Theophylline	Cisapride	none	{'e1': {'word': 'Theophylline', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d776.s2.e5'}, 'e2': {'word': 'Cisapride', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d776.s2.e7'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Theophylline	Astemizole	none	{'e1': {'word': 'Theophylline', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d776.s2.e5'}, 'e2': {'word': 'Astemizole', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d776.s2.e8'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Theophylline	Rifabutin	none	{'e1': {'word': 'Theophylline', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d776.s2.e5'}, 'e2': {'word': 'Rifabutin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d776.s2.e9'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Theophylline	Tacrolimus	none	{'e1': {'word': 'Theophylline', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d776.s2.e5'}, 'e2': {'word': 'Tacrolimus', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d776.s2.e10'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Theophylline	Short-acting benzodiazepines	none	{'e1': {'word': 'Theophylline', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d776.s2.e5'}, 'e2': {'word': 'Short-acting benzodiazepines', 'word_index': [(17, 19)], 'id': 'DDI-DrugBank.d776.s2.e11'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Theophylline	hypoglycemics	none	{'e1': {'word': 'Theophylline', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d776.s2.e5'}, 'e2': {'word': 'hypoglycemics', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d776.s2.e12'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Theophylline	DIFLUCAN	none	{'e1': {'word': 'Theophylline', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d776.s2.e5'}, 'e2': {'word': 'DIFLUCAN', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d776.s2.e13'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Theophylline	hypoglycemic agents	none	{'e1': {'word': 'Theophylline', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d776.s2.e5'}, 'e2': {'word': 'hypoglycemic agents', 'word_index': [(30, 31)], 'id': 'DDI-DrugBank.d776.s2.e14'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Terfenadine	Cisapride	none	{'e1': {'word': 'Terfenadine', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d776.s2.e6'}, 'e2': {'word': 'Cisapride', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d776.s2.e7'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Terfenadine	Astemizole	none	{'e1': {'word': 'Terfenadine', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d776.s2.e6'}, 'e2': {'word': 'Astemizole', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d776.s2.e8'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Terfenadine	Rifabutin	none	{'e1': {'word': 'Terfenadine', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d776.s2.e6'}, 'e2': {'word': 'Rifabutin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d776.s2.e9'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Terfenadine	Tacrolimus	none	{'e1': {'word': 'Terfenadine', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d776.s2.e6'}, 'e2': {'word': 'Tacrolimus', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d776.s2.e10'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Terfenadine	Short-acting benzodiazepines	none	{'e1': {'word': 'Terfenadine', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d776.s2.e6'}, 'e2': {'word': 'Short-acting benzodiazepines', 'word_index': [(17, 19)], 'id': 'DDI-DrugBank.d776.s2.e11'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Terfenadine	hypoglycemics	none	{'e1': {'word': 'Terfenadine', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d776.s2.e6'}, 'e2': {'word': 'hypoglycemics', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d776.s2.e12'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Terfenadine	DIFLUCAN	none	{'e1': {'word': 'Terfenadine', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d776.s2.e6'}, 'e2': {'word': 'DIFLUCAN', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d776.s2.e13'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Terfenadine	hypoglycemic agents	none	{'e1': {'word': 'Terfenadine', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d776.s2.e6'}, 'e2': {'word': 'hypoglycemic agents', 'word_index': [(30, 31)], 'id': 'DDI-DrugBank.d776.s2.e14'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Cisapride	Astemizole	none	{'e1': {'word': 'Cisapride', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d776.s2.e7'}, 'e2': {'word': 'Astemizole', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d776.s2.e8'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Cisapride	Rifabutin	none	{'e1': {'word': 'Cisapride', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d776.s2.e7'}, 'e2': {'word': 'Rifabutin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d776.s2.e9'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Cisapride	Tacrolimus	none	{'e1': {'word': 'Cisapride', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d776.s2.e7'}, 'e2': {'word': 'Tacrolimus', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d776.s2.e10'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Cisapride	Short-acting benzodiazepines	none	{'e1': {'word': 'Cisapride', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d776.s2.e7'}, 'e2': {'word': 'Short-acting benzodiazepines', 'word_index': [(17, 19)], 'id': 'DDI-DrugBank.d776.s2.e11'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Cisapride	hypoglycemics	none	{'e1': {'word': 'Cisapride', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d776.s2.e7'}, 'e2': {'word': 'hypoglycemics', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d776.s2.e12'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Cisapride	DIFLUCAN	none	{'e1': {'word': 'Cisapride', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d776.s2.e7'}, 'e2': {'word': 'DIFLUCAN', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d776.s2.e13'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Cisapride	hypoglycemic agents	none	{'e1': {'word': 'Cisapride', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d776.s2.e7'}, 'e2': {'word': 'hypoglycemic agents', 'word_index': [(30, 31)], 'id': 'DDI-DrugBank.d776.s2.e14'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Astemizole	Rifabutin	none	{'e1': {'word': 'Astemizole', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d776.s2.e8'}, 'e2': {'word': 'Rifabutin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d776.s2.e9'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Astemizole	Tacrolimus	none	{'e1': {'word': 'Astemizole', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d776.s2.e8'}, 'e2': {'word': 'Tacrolimus', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d776.s2.e10'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Astemizole	Short-acting benzodiazepines	none	{'e1': {'word': 'Astemizole', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d776.s2.e8'}, 'e2': {'word': 'Short-acting benzodiazepines', 'word_index': [(17, 19)], 'id': 'DDI-DrugBank.d776.s2.e11'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Astemizole	hypoglycemics	none	{'e1': {'word': 'Astemizole', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d776.s2.e8'}, 'e2': {'word': 'hypoglycemics', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d776.s2.e12'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Astemizole	DIFLUCAN	none	{'e1': {'word': 'Astemizole', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d776.s2.e8'}, 'e2': {'word': 'DIFLUCAN', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d776.s2.e13'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Astemizole	hypoglycemic agents	none	{'e1': {'word': 'Astemizole', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d776.s2.e8'}, 'e2': {'word': 'hypoglycemic agents', 'word_index': [(30, 31)], 'id': 'DDI-DrugBank.d776.s2.e14'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Rifabutin	Tacrolimus	none	{'e1': {'word': 'Rifabutin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d776.s2.e9'}, 'e2': {'word': 'Tacrolimus', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d776.s2.e10'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Rifabutin	Short-acting benzodiazepines	none	{'e1': {'word': 'Rifabutin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d776.s2.e9'}, 'e2': {'word': 'Short-acting benzodiazepines', 'word_index': [(17, 19)], 'id': 'DDI-DrugBank.d776.s2.e11'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Rifabutin	hypoglycemics	none	{'e1': {'word': 'Rifabutin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d776.s2.e9'}, 'e2': {'word': 'hypoglycemics', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d776.s2.e12'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Rifabutin	DIFLUCAN	none	{'e1': {'word': 'Rifabutin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d776.s2.e9'}, 'e2': {'word': 'DIFLUCAN', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d776.s2.e13'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Rifabutin	hypoglycemic agents	none	{'e1': {'word': 'Rifabutin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d776.s2.e9'}, 'e2': {'word': 'hypoglycemic agents', 'word_index': [(30, 31)], 'id': 'DDI-DrugBank.d776.s2.e14'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Tacrolimus	Short-acting benzodiazepines	none	{'e1': {'word': 'Tacrolimus', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d776.s2.e10'}, 'e2': {'word': 'Short-acting benzodiazepines', 'word_index': [(17, 19)], 'id': 'DDI-DrugBank.d776.s2.e11'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Tacrolimus	hypoglycemics	none	{'e1': {'word': 'Tacrolimus', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d776.s2.e10'}, 'e2': {'word': 'hypoglycemics', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d776.s2.e12'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Tacrolimus	DIFLUCAN	none	{'e1': {'word': 'Tacrolimus', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d776.s2.e10'}, 'e2': {'word': 'DIFLUCAN', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d776.s2.e13'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Tacrolimus	hypoglycemic agents	none	{'e1': {'word': 'Tacrolimus', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d776.s2.e10'}, 'e2': {'word': 'hypoglycemic agents', 'word_index': [(30, 31)], 'id': 'DDI-DrugBank.d776.s2.e14'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Short-acting benzodiazepines	hypoglycemics	none	{'e1': {'word': 'Short-acting benzodiazepines', 'word_index': [(17, 19)], 'id': 'DDI-DrugBank.d776.s2.e11'}, 'e2': {'word': 'hypoglycemics', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d776.s2.e12'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Short-acting benzodiazepines	DIFLUCAN	none	{'e1': {'word': 'Short-acting benzodiazepines', 'word_index': [(17, 19)], 'id': 'DDI-DrugBank.d776.s2.e11'}, 'e2': {'word': 'DIFLUCAN', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d776.s2.e13'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	Short-acting benzodiazepines	hypoglycemic agents	none	{'e1': {'word': 'Short-acting benzodiazepines', 'word_index': [(17, 19)], 'id': 'DDI-DrugBank.d776.s2.e11'}, 'e2': {'word': 'hypoglycemic agents', 'word_index': [(30, 31)], 'id': 'DDI-DrugBank.d776.s2.e14'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	hypoglycemics	DIFLUCAN	none	{'e1': {'word': 'hypoglycemics', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d776.s2.e12'}, 'e2': {'word': 'DIFLUCAN', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d776.s2.e13'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	hypoglycemics	hypoglycemic agents	none	{'e1': {'word': 'hypoglycemics', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d776.s2.e12'}, 'e2': {'word': 'hypoglycemic agents', 'word_index': [(30, 31)], 'id': 'DDI-DrugBank.d776.s2.e14'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; 	DIFLUCAN	hypoglycemic agents	effect	{'e1': {'word': 'DIFLUCAN', 'word_index': [(28, 28)], 'id': 'DDI-DrugBank.d776.s2.e13'}, 'e2': {'word': 'hypoglycemic agents', 'word_index': [(30, 31)], 'id': 'DDI-DrugBank.d776.s2.e14'}, 'sentence_id': 'DDI-DrugBank.d776.s2'}	described greater detail Oral hypoglycemics Coumarin type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Tacrolimus Short acting benzodiazepines Oral hypoglycemics Clinically significant hypoglycemia may precipitated use DIFLUCAN oral hypoglycemic agents
one fatality has been reported from hypoglycemia in association with combined DIFLUCAN and glyburide use. 	DIFLUCAN	glyburide	effect	{'e1': {'word': 'DIFLUCAN', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d776.s3.e0'}, 'e2': {'word': 'glyburide', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d776.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d776.s3'}	NUMBER fatality reported hypoglycemia association combined DIFLUCAN glyburide use
DIFLUCAN reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these agents. 	DIFLUCAN	tolbutamide	mechanism	{'e1': {'word': 'DIFLUCAN', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d776.s4.e0'}, 'e2': {'word': 'tolbutamide', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d776.s4.e1'}, 'sentence_id': 'DDI-DrugBank.d776.s4'}	DIFLUCAN reduces metabolism tolbutamide glyburide glipizide increases plasma concentration agents
DIFLUCAN reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these agents. 	DIFLUCAN	glyburide	mechanism	{'e1': {'word': 'DIFLUCAN', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d776.s4.e0'}, 'e2': {'word': 'glyburide', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d776.s4.e2'}, 'sentence_id': 'DDI-DrugBank.d776.s4'}	DIFLUCAN reduces metabolism tolbutamide glyburide glipizide increases plasma concentration agents
DIFLUCAN reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these agents. 	DIFLUCAN	glipizide	mechanism	{'e1': {'word': 'DIFLUCAN', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d776.s4.e0'}, 'e2': {'word': 'glipizide', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d776.s4.e3'}, 'sentence_id': 'DDI-DrugBank.d776.s4'}	DIFLUCAN reduces metabolism tolbutamide glyburide glipizide increases plasma concentration agents
DIFLUCAN reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these agents. 	tolbutamide	glyburide	none	{'e1': {'word': 'tolbutamide', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d776.s4.e1'}, 'e2': {'word': 'glyburide', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d776.s4.e2'}, 'sentence_id': 'DDI-DrugBank.d776.s4'}	DIFLUCAN reduces metabolism tolbutamide glyburide glipizide increases plasma concentration agents
DIFLUCAN reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these agents. 	tolbutamide	glipizide	none	{'e1': {'word': 'tolbutamide', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d776.s4.e1'}, 'e2': {'word': 'glipizide', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d776.s4.e3'}, 'sentence_id': 'DDI-DrugBank.d776.s4'}	DIFLUCAN reduces metabolism tolbutamide glyburide glipizide increases plasma concentration agents
DIFLUCAN reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these agents. 	glyburide	glipizide	none	{'e1': {'word': 'glyburide', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d776.s4.e2'}, 'e2': {'word': 'glipizide', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d776.s4.e3'}, 'sentence_id': 'DDI-DrugBank.d776.s4'}	DIFLUCAN reduces metabolism tolbutamide glyburide glipizide increases plasma concentration agents
When DIFLUCAN is used concomitantly with these or other sulfonylurea oral hypoglycemic agents, blood glucose concentrations should be carefully monitored and the dose of the sulfonylurea should be adjusted as necessary. 	DIFLUCAN	sulfonylurea oral hypoglycemic agents	advise	{'e1': {'word': 'DIFLUCAN', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d776.s5.e0'}, 'e2': {'word': 'sulfonylurea oral hypoglycemic agents', 'word_index': [(3, 6)], 'id': 'DDI-DrugBank.d776.s5.e1'}, 'sentence_id': 'DDI-DrugBank.d776.s5'}	DIFLUCAN used concomitantly sulfonylurea oral hypoglycemic agents blood glucose concentrations carefully monitored dose sulfonylurea adjusted necessary
When DIFLUCAN is used concomitantly with these or other sulfonylurea oral hypoglycemic agents, blood glucose concentrations should be carefully monitored and the dose of the sulfonylurea should be adjusted as necessary. 	DIFLUCAN	sulfonylurea	none	{'e1': {'word': 'DIFLUCAN', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d776.s5.e0'}, 'e2': {'word': 'sulfonylurea', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d776.s5.e2'}, 'sentence_id': 'DDI-DrugBank.d776.s5'}	DIFLUCAN used concomitantly sulfonylurea oral hypoglycemic agents blood glucose concentrations carefully monitored dose sulfonylurea adjusted necessary
When DIFLUCAN is used concomitantly with these or other sulfonylurea oral hypoglycemic agents, blood glucose concentrations should be carefully monitored and the dose of the sulfonylurea should be adjusted as necessary. 	sulfonylurea oral hypoglycemic agents	sulfonylurea	none	{'e1': {'word': 'sulfonylurea oral hypoglycemic agents', 'word_index': [(3, 6)], 'id': 'DDI-DrugBank.d776.s5.e1'}, 'e2': {'word': 'sulfonylurea', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d776.s5.e2'}, 'sentence_id': 'DDI-DrugBank.d776.s5'}	DIFLUCAN used concomitantly sulfonylurea oral hypoglycemic agents blood glucose concentrations carefully monitored dose sulfonylurea adjusted necessary
Coumarin-type anticoagulants: Prothrombin time may be increased in patients receiving concomitant DIFLUCAN and coumarin-type anticoagulants. 	Coumarin-type anticoagulants	DIFLUCAN	none	{'e1': {'word': 'Coumarin-type anticoagulants', 'word_index': [(0, 2)], 'id': 'DDI-DrugBank.d776.s6.e0'}, 'e2': {'word': 'DIFLUCAN', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d776.s6.e1'}, 'sentence_id': 'DDI-DrugBank.d776.s6'}	Coumarin type anticoagulants Prothrombin time may increased patients receiving concomitant DIFLUCAN coumarin type anticoagulants
Coumarin-type anticoagulants: Prothrombin time may be increased in patients receiving concomitant DIFLUCAN and coumarin-type anticoagulants. 	Coumarin-type anticoagulants	coumarin-type anticoagulants	none	{'e1': {'word': 'Coumarin-type anticoagulants', 'word_index': [(0, 2)], 'id': 'DDI-DrugBank.d776.s6.e0'}, 'e2': {'word': 'coumarin-type anticoagulants', 'word_index': [(11, 13)], 'id': 'DDI-DrugBank.d776.s6.e2'}, 'sentence_id': 'DDI-DrugBank.d776.s6'}	Coumarin type anticoagulants Prothrombin time may increased patients receiving concomitant DIFLUCAN coumarin type anticoagulants
Coumarin-type anticoagulants: Prothrombin time may be increased in patients receiving concomitant DIFLUCAN and coumarin-type anticoagulants. 	DIFLUCAN	coumarin-type anticoagulants	effect	{'e1': {'word': 'DIFLUCAN', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d776.s6.e1'}, 'e2': {'word': 'coumarin-type anticoagulants', 'word_index': [(11, 13)], 'id': 'DDI-DrugBank.d776.s6.e2'}, 'sentence_id': 'DDI-DrugBank.d776.s6'}	Coumarin type anticoagulants Prothrombin time may increased patients receiving concomitant DIFLUCAN coumarin type anticoagulants
In post-marketing experience, as with other azole antifungals, bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving fluconazole concurrently with warfarin. 	azole antifungals	fluconazole	none	{'e1': {'word': 'azole antifungals', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d776.s7.e0'}, 'e2': {'word': 'fluconazole', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d776.s7.e1'}, 'sentence_id': 'DDI-DrugBank.d776.s7'}	post-marketing experience azole antifungals bleeding events bruising epistaxis gastrointestinal bleeding hematuria melena reported association increases prothrombin time patients receiving fluconazole concurrently warfarin
In post-marketing experience, as with other azole antifungals, bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving fluconazole concurrently with warfarin. 	azole antifungals	warfarin	none	{'e1': {'word': 'azole antifungals', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d776.s7.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d776.s7.e2'}, 'sentence_id': 'DDI-DrugBank.d776.s7'}	post-marketing experience azole antifungals bleeding events bruising epistaxis gastrointestinal bleeding hematuria melena reported association increases prothrombin time patients receiving fluconazole concurrently warfarin
In post-marketing experience, as with other azole antifungals, bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving fluconazole concurrently with warfarin. 	fluconazole	warfarin	effect	{'e1': {'word': 'fluconazole', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d776.s7.e1'}, 'e2': {'word': 'warfarin', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d776.s7.e2'}, 'sentence_id': 'DDI-DrugBank.d776.s7'}	post-marketing experience azole antifungals bleeding events bruising epistaxis gastrointestinal bleeding hematuria melena reported association increases prothrombin time patients receiving fluconazole concurrently warfarin
Careful monitoring of prothrombin time in patients receiving DIFLUCAN and coumarin-type anticoagulants is recommended. 	DIFLUCAN	coumarin-type anticoagulants	advise	{'e1': {'word': 'DIFLUCAN', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d776.s8.e0'}, 'e2': {'word': 'coumarin-type anticoagulants', 'word_index': [(7, 9)], 'id': 'DDI-DrugBank.d776.s8.e1'}, 'sentence_id': 'DDI-DrugBank.d776.s8'}	Careful monitoring prothrombin time patients receiving DIFLUCAN coumarin type anticoagulants recommended
Phenytoin: DIFLUCAN increases the plasma concentrations of phenytoin. 	Phenytoin	DIFLUCAN	none	{'e1': {'word': 'Phenytoin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d776.s10.e0'}, 'e2': {'word': 'DIFLUCAN', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d776.s10.e1'}, 'sentence_id': 'DDI-DrugBank.d776.s10'}	Phenytoin DIFLUCAN increases plasma concentrations phenytoin
Phenytoin: DIFLUCAN increases the plasma concentrations of phenytoin. 	Phenytoin	phenytoin	none	{'e1': {'word': 'Phenytoin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d776.s10.e0'}, 'e2': {'word': 'phenytoin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d776.s10.e2'}, 'sentence_id': 'DDI-DrugBank.d776.s10'}	Phenytoin DIFLUCAN increases plasma concentrations phenytoin
Phenytoin: DIFLUCAN increases the plasma concentrations of phenytoin. 	DIFLUCAN	phenytoin	mechanism	{'e1': {'word': 'DIFLUCAN', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d776.s10.e1'}, 'e2': {'word': 'phenytoin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d776.s10.e2'}, 'sentence_id': 'DDI-DrugBank.d776.s10'}	Phenytoin DIFLUCAN increases plasma concentrations phenytoin
Careful monitoring of phenytoin concentrations in patients receiving DIFLUCAN and phenytoin is recommended. 	phenytoin	DIFLUCAN	none	{'e1': {'word': 'phenytoin', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d776.s11.e0'}, 'e2': {'word': 'DIFLUCAN', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d776.s11.e1'}, 'sentence_id': 'DDI-DrugBank.d776.s11'}	Careful monitoring phenytoin concentrations patients receiving DIFLUCAN phenytoin recommended
Careful monitoring of phenytoin concentrations in patients receiving DIFLUCAN and phenytoin is recommended. 	phenytoin	phenytoin	none	{'e1': {'word': 'phenytoin', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d776.s11.e0'}, 'e2': {'word': 'phenytoin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d776.s11.e2'}, 'sentence_id': 'DDI-DrugBank.d776.s11'}	Careful monitoring phenytoin concentrations patients receiving DIFLUCAN phenytoin recommended
Careful monitoring of phenytoin concentrations in patients receiving DIFLUCAN and phenytoin is recommended. 	DIFLUCAN	phenytoin	advise	{'e1': {'word': 'DIFLUCAN', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d776.s11.e1'}, 'e2': {'word': 'phenytoin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d776.s11.e2'}, 'sentence_id': 'DDI-DrugBank.d776.s11'}	Careful monitoring phenytoin concentrations patients receiving DIFLUCAN phenytoin recommended
Cyclosporine: DIFLUCAN may significantly increase cyclosporine levels in renal transplant patients with or without renal impairment. 	Cyclosporine	DIFLUCAN	none	{'e1': {'word': 'Cyclosporine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d776.s13.e0'}, 'e2': {'word': 'DIFLUCAN', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d776.s13.e1'}, 'sentence_id': 'DDI-DrugBank.d776.s13'}	Cyclosporine DIFLUCAN may significantly increase cyclosporine levels renal transplant patients without renal impairment
Cyclosporine: DIFLUCAN may significantly increase cyclosporine levels in renal transplant patients with or without renal impairment. 	Cyclosporine	cyclosporine	none	{'e1': {'word': 'Cyclosporine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d776.s13.e0'}, 'e2': {'word': 'cyclosporine', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d776.s13.e2'}, 'sentence_id': 'DDI-DrugBank.d776.s13'}	Cyclosporine DIFLUCAN may significantly increase cyclosporine levels renal transplant patients without renal impairment
Cyclosporine: DIFLUCAN may significantly increase cyclosporine levels in renal transplant patients with or without renal impairment. 	DIFLUCAN	cyclosporine	mechanism	{'e1': {'word': 'DIFLUCAN', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d776.s13.e1'}, 'e2': {'word': 'cyclosporine', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d776.s13.e2'}, 'sentence_id': 'DDI-DrugBank.d776.s13'}	Cyclosporine DIFLUCAN may significantly increase cyclosporine levels renal transplant patients without renal impairment
Careful monitoring of cyclosporine concentrations and serum creatinine is recommended in patients receiving DIFLUCAN and cyclosporine. 	cyclosporine	DIFLUCAN	none	{'e1': {'word': 'cyclosporine', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d776.s14.e0'}, 'e2': {'word': 'DIFLUCAN', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d776.s14.e1'}, 'sentence_id': 'DDI-DrugBank.d776.s14'}	Careful monitoring cyclosporine concentrations serum creatinine recommended patients receiving DIFLUCAN cyclosporine
Careful monitoring of cyclosporine concentrations and serum creatinine is recommended in patients receiving DIFLUCAN and cyclosporine. 	cyclosporine	cyclosporine	none	{'e1': {'word': 'cyclosporine', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d776.s14.e0'}, 'e2': {'word': 'cyclosporine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d776.s14.e2'}, 'sentence_id': 'DDI-DrugBank.d776.s14'}	Careful monitoring cyclosporine concentrations serum creatinine recommended patients receiving DIFLUCAN cyclosporine
Careful monitoring of cyclosporine concentrations and serum creatinine is recommended in patients receiving DIFLUCAN and cyclosporine. 	DIFLUCAN	cyclosporine	advise	{'e1': {'word': 'DIFLUCAN', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d776.s14.e1'}, 'e2': {'word': 'cyclosporine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d776.s14.e2'}, 'sentence_id': 'DDI-DrugBank.d776.s14'}	Careful monitoring cyclosporine concentrations serum creatinine recommended patients receiving DIFLUCAN cyclosporine
Rifampin: Rifampin enhances the metabolism of concurrently administered DIFLUCAN. 	Rifampin	Rifampin	none	{'e1': {'word': 'Rifampin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d776.s16.e0'}, 'e2': {'word': 'Rifampin', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d776.s16.e1'}, 'sentence_id': 'DDI-DrugBank.d776.s16'}	Rifampin Rifampin enhances metabolism concurrently administered DIFLUCAN
Rifampin: Rifampin enhances the metabolism of concurrently administered DIFLUCAN. 	Rifampin	DIFLUCAN	none	{'e1': {'word': 'Rifampin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d776.s16.e0'}, 'e2': {'word': 'DIFLUCAN', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d776.s16.e2'}, 'sentence_id': 'DDI-DrugBank.d776.s16'}	Rifampin Rifampin enhances metabolism concurrently administered DIFLUCAN
Rifampin: Rifampin enhances the metabolism of concurrently administered DIFLUCAN. 	Rifampin	DIFLUCAN	mechanism	{'e1': {'word': 'Rifampin', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d776.s16.e1'}, 'e2': {'word': 'DIFLUCAN', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d776.s16.e2'}, 'sentence_id': 'DDI-DrugBank.d776.s16'}	Rifampin Rifampin enhances metabolism concurrently administered DIFLUCAN
Depending on clinical circumstances, consideration should be given to increasing the dose of DIFLUCAN when it is administered with rifampin. 	DIFLUCAN	rifampin	advise	{'e1': {'word': 'DIFLUCAN', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d776.s17.e0'}, 'e2': {'word': 'rifampin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d776.s17.e1'}, 'sentence_id': 'DDI-DrugBank.d776.s17'}	Depending clinical circumstances consideration given increasing dose DIFLUCAN administered rifampin
Theophylline: DIFLUCAN increases the serum concentrations of theophylline. 	Theophylline	DIFLUCAN	none	{'e1': {'word': 'Theophylline', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d776.s18.e0'}, 'e2': {'word': 'DIFLUCAN', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d776.s18.e1'}, 'sentence_id': 'DDI-DrugBank.d776.s18'}	Theophylline DIFLUCAN increases serum concentrations theophylline
Theophylline: DIFLUCAN increases the serum concentrations of theophylline. 	Theophylline	theophylline	none	{'e1': {'word': 'Theophylline', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d776.s18.e0'}, 'e2': {'word': 'theophylline', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d776.s18.e2'}, 'sentence_id': 'DDI-DrugBank.d776.s18'}	Theophylline DIFLUCAN increases serum concentrations theophylline
Theophylline: DIFLUCAN increases the serum concentrations of theophylline. 	DIFLUCAN	theophylline	mechanism	{'e1': {'word': 'DIFLUCAN', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d776.s18.e1'}, 'e2': {'word': 'theophylline', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d776.s18.e2'}, 'sentence_id': 'DDI-DrugBank.d776.s18'}	Theophylline DIFLUCAN increases serum concentrations theophylline
Careful monitoring of serum theophylline concentrations in patients receiving DIFLUCAN and theophylline is recommended. 	theophylline	DIFLUCAN	none	{'e1': {'word': 'theophylline', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d776.s19.e0'}, 'e2': {'word': 'DIFLUCAN', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d776.s19.e1'}, 'sentence_id': 'DDI-DrugBank.d776.s19'}	Careful monitoring serum theophylline concentrations patients receiving DIFLUCAN theophylline recommended
Careful monitoring of serum theophylline concentrations in patients receiving DIFLUCAN and theophylline is recommended. 	theophylline	theophylline	none	{'e1': {'word': 'theophylline', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d776.s19.e0'}, 'e2': {'word': 'theophylline', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d776.s19.e2'}, 'sentence_id': 'DDI-DrugBank.d776.s19'}	Careful monitoring serum theophylline concentrations patients receiving DIFLUCAN theophylline recommended
Careful monitoring of serum theophylline concentrations in patients receiving DIFLUCAN and theophylline is recommended. 	DIFLUCAN	theophylline	advise	{'e1': {'word': 'DIFLUCAN', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d776.s19.e1'}, 'e2': {'word': 'theophylline', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d776.s19.e2'}, 'sentence_id': 'DDI-DrugBank.d776.s19'}	Careful monitoring serum theophylline concentrations patients receiving DIFLUCAN theophylline recommended
Terfenadine: Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving azole antifungals in conjunction with terfenadine, interaction studies have been performed. 	Terfenadine	azole antifungals	none	{'e1': {'word': 'Terfenadine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d776.s20.e0'}, 'e2': {'word': 'azole antifungals', 'word_index': [(11, 12)], 'id': 'DDI-DrugBank.d776.s20.e1'}, 'sentence_id': 'DDI-DrugBank.d776.s20'}	Terfenadine occurrence serious cardiac dysrhythmias secondary prolongation QTc interval patients receiving azole antifungals conjunction terfenadine interaction studies performed
Terfenadine: Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving azole antifungals in conjunction with terfenadine, interaction studies have been performed. 	Terfenadine	terfenadine	none	{'e1': {'word': 'Terfenadine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d776.s20.e0'}, 'e2': {'word': 'terfenadine', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d776.s20.e2'}, 'sentence_id': 'DDI-DrugBank.d776.s20'}	Terfenadine occurrence serious cardiac dysrhythmias secondary prolongation QTc interval patients receiving azole antifungals conjunction terfenadine interaction studies performed
Terfenadine: Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving azole antifungals in conjunction with terfenadine, interaction studies have been performed. 	azole antifungals	terfenadine	effect	{'e1': {'word': 'azole antifungals', 'word_index': [(11, 12)], 'id': 'DDI-DrugBank.d776.s20.e1'}, 'e2': {'word': 'terfenadine', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d776.s20.e2'}, 'sentence_id': 'DDI-DrugBank.d776.s20'}	Terfenadine occurrence serious cardiac dysrhythmias secondary prolongation QTc interval patients receiving azole antifungals conjunction terfenadine interaction studies performed
Another study at a 400-mg and 800-mg daily dose of fluconazole demonstrated that DIFLUCAN taken in doses of 400 mg per day or greater significantly increases plasma levels of terfenadine when taken concomitantly. 	fluconazole	DIFLUCAN	none	{'e1': {'word': 'fluconazole', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d776.s22.e0'}, 'e2': {'word': 'DIFLUCAN', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d776.s22.e1'}, 'sentence_id': 'DDI-DrugBank.d776.s22'}	Another study NUMBER mg NUMBER mg daily dose fluconazole demonstrated DIFLUCAN taken doses NUMBER mg per day greater significantly increases plasma levels terfenadine taken concomitantly
Another study at a 400-mg and 800-mg daily dose of fluconazole demonstrated that DIFLUCAN taken in doses of 400 mg per day or greater significantly increases plasma levels of terfenadine when taken concomitantly. 	fluconazole	terfenadine	none	{'e1': {'word': 'fluconazole', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d776.s22.e0'}, 'e2': {'word': 'terfenadine', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d776.s22.e2'}, 'sentence_id': 'DDI-DrugBank.d776.s22'}	Another study NUMBER mg NUMBER mg daily dose fluconazole demonstrated DIFLUCAN taken doses NUMBER mg per day greater significantly increases plasma levels terfenadine taken concomitantly
Another study at a 400-mg and 800-mg daily dose of fluconazole demonstrated that DIFLUCAN taken in doses of 400 mg per day or greater significantly increases plasma levels of terfenadine when taken concomitantly. 	DIFLUCAN	terfenadine	mechanism	{'e1': {'word': 'DIFLUCAN', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d776.s22.e1'}, 'e2': {'word': 'terfenadine', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d776.s22.e2'}, 'sentence_id': 'DDI-DrugBank.d776.s22'}	Another study NUMBER mg NUMBER mg daily dose fluconazole demonstrated DIFLUCAN taken doses NUMBER mg per day greater significantly increases plasma levels terfenadine taken concomitantly
The combined use of fluconazole at doses of 400 mg or greater with terfenadine is contraindicated. 	fluconazole	terfenadine	advise	{'e1': {'word': 'fluconazole', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d776.s23.e0'}, 'e2': {'word': 'terfenadine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d776.s23.e1'}, 'sentence_id': 'DDI-DrugBank.d776.s23'}	combined use fluconazole doses NUMBER mg greater terfenadine contraindicated
The coadministration of fluconazole at doses lower than 400 mg/day with terfenadine should be carefully monitored. 	fluconazole	terfenadine	advise	{'e1': {'word': 'fluconazole', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d776.s24.e0'}, 'e2': {'word': 'terfenadine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d776.s24.e1'}, 'sentence_id': 'DDI-DrugBank.d776.s24'}	coadministration fluconazole doses lower NUMBER mg / day terfenadine carefully monitored
Cisapride: There have been reports of cardiac events, including torsade de pointes in patients to whom fluconazole and cisapride were coadministered. 	Cisapride	fluconazole	none	{'e1': {'word': 'Cisapride', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d776.s25.e0'}, 'e2': {'word': 'fluconazole', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d776.s25.e1'}, 'sentence_id': 'DDI-DrugBank.d776.s25'}	Cisapride reports cardiac events including torsade de pointes patients fluconazole cisapride coadministered
Cisapride: There have been reports of cardiac events, including torsade de pointes in patients to whom fluconazole and cisapride were coadministered. 	Cisapride	cisapride	none	{'e1': {'word': 'Cisapride', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d776.s25.e0'}, 'e2': {'word': 'cisapride', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d776.s25.e2'}, 'sentence_id': 'DDI-DrugBank.d776.s25'}	Cisapride reports cardiac events including torsade de pointes patients fluconazole cisapride coadministered
Cisapride: There have been reports of cardiac events, including torsade de pointes in patients to whom fluconazole and cisapride were coadministered. 	fluconazole	cisapride	effect	{'e1': {'word': 'fluconazole', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d776.s25.e1'}, 'e2': {'word': 'cisapride', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d776.s25.e2'}, 'sentence_id': 'DDI-DrugBank.d776.s25'}	Cisapride reports cardiac events including torsade de pointes patients fluconazole cisapride coadministered
A controlled study found that concomitant fluconazole 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval.	fluconazole	cisapride	mechanism	{'e1': {'word': 'fluconazole', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d776.s26.e0'}, 'e2': {'word': 'cisapride', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d776.s26.e1'}, 'sentence_id': 'DDI-DrugBank.d776.s26'}	controlled study found concomitant fluconazole NUMBER mg daily cisapride NUMBER mg NUMBER times day yielded significant increase cisapride plasma levels prolongation QTc interval
A controlled study found that concomitant fluconazole 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval.	fluconazole	cisapride	none	{'e1': {'word': 'fluconazole', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d776.s26.e0'}, 'e2': {'word': 'cisapride', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d776.s26.e2'}, 'sentence_id': 'DDI-DrugBank.d776.s26'}	controlled study found concomitant fluconazole NUMBER mg daily cisapride NUMBER mg NUMBER times day yielded significant increase cisapride plasma levels prolongation QTc interval
A controlled study found that concomitant fluconazole 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval.	cisapride	cisapride	none	{'e1': {'word': 'cisapride', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d776.s26.e1'}, 'e2': {'word': 'cisapride', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d776.s26.e2'}, 'sentence_id': 'DDI-DrugBank.d776.s26'}	controlled study found concomitant fluconazole NUMBER mg daily cisapride NUMBER mg NUMBER times day yielded significant increase cisapride plasma levels prolongation QTc interval
The combined use of fluconazole with cisapride is contraindicated. 	fluconazole	cisapride	advise	{'e1': {'word': 'fluconazole', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d776.s27.e0'}, 'e2': {'word': 'cisapride', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d776.s27.e1'}, 'sentence_id': 'DDI-DrugBank.d776.s27'}	combined use fluconazole cisapride contraindicated
Astemizole: The use of fluconazole in patients concurrently taking astemizole or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs. 	Astemizole	fluconazole	none	{'e1': {'word': 'Astemizole', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d776.s28.e0'}, 'e2': {'word': 'fluconazole', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d776.s28.e1'}, 'sentence_id': 'DDI-DrugBank.d776.s28'}	Astemizole use fluconazole patients concurrently taking astemizole drugs metabolized cytochrome P450 system may associated elevations serum levels drugs
Astemizole: The use of fluconazole in patients concurrently taking astemizole or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs. 	Astemizole	astemizole	none	{'e1': {'word': 'Astemizole', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d776.s28.e0'}, 'e2': {'word': 'astemizole', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d776.s28.e2'}, 'sentence_id': 'DDI-DrugBank.d776.s28'}	Astemizole use fluconazole patients concurrently taking astemizole drugs metabolized cytochrome P450 system may associated elevations serum levels drugs
Astemizole: The use of fluconazole in patients concurrently taking astemizole or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs. 	fluconazole	astemizole	mechanism	{'e1': {'word': 'fluconazole', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d776.s28.e1'}, 'e2': {'word': 'astemizole', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d776.s28.e2'}, 'sentence_id': 'DDI-DrugBank.d776.s28'}	Astemizole use fluconazole patients concurrently taking astemizole drugs metabolized cytochrome P450 system may associated elevations serum levels drugs
Rifabutin: There have been reports of uveitis in patients to whom fluconazole and rifabutin were coadministered. 	Rifabutin	fluconazole	none	{'e1': {'word': 'Rifabutin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d776.s31.e0'}, 'e2': {'word': 'fluconazole', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d776.s31.e1'}, 'sentence_id': 'DDI-DrugBank.d776.s31'}	Rifabutin reports uveitis patients fluconazole rifabutin coadministered
Rifabutin: There have been reports of uveitis in patients to whom fluconazole and rifabutin were coadministered. 	Rifabutin	rifabutin	none	{'e1': {'word': 'Rifabutin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d776.s31.e0'}, 'e2': {'word': 'rifabutin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d776.s31.e2'}, 'sentence_id': 'DDI-DrugBank.d776.s31'}	Rifabutin reports uveitis patients fluconazole rifabutin coadministered
Rifabutin: There have been reports of uveitis in patients to whom fluconazole and rifabutin were coadministered. 	fluconazole	rifabutin	effect	{'e1': {'word': 'fluconazole', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d776.s31.e1'}, 'e2': {'word': 'rifabutin', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d776.s31.e2'}, 'sentence_id': 'DDI-DrugBank.d776.s31'}	Rifabutin reports uveitis patients fluconazole rifabutin coadministered
Patients receiving rifabutin and fluconazole concomitantly should be carefully monitored. 	rifabutin	fluconazole	advise	{'e1': {'word': 'rifabutin', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d776.s32.e0'}, 'e2': {'word': 'fluconazole', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d776.s32.e1'}, 'sentence_id': 'DDI-DrugBank.d776.s32'}	Patients receiving rifabutin fluconazole concomitantly carefully monitored
Tacrolimus: There have been reports of nephrotoxicity in patients to whom fluconazole and tacrolimus were coadministered. 	Tacrolimus	fluconazole	none	{'e1': {'word': 'Tacrolimus', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d776.s33.e0'}, 'e2': {'word': 'fluconazole', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d776.s33.e1'}, 'sentence_id': 'DDI-DrugBank.d776.s33'}	Tacrolimus reports nephrotoxicity patients fluconazole tacrolimus coadministered
Tacrolimus: There have been reports of nephrotoxicity in patients to whom fluconazole and tacrolimus were coadministered. 	Tacrolimus	tacrolimus	none	{'e1': {'word': 'Tacrolimus', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d776.s33.e0'}, 'e2': {'word': 'tacrolimus', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d776.s33.e2'}, 'sentence_id': 'DDI-DrugBank.d776.s33'}	Tacrolimus reports nephrotoxicity patients fluconazole tacrolimus coadministered
Tacrolimus: There have been reports of nephrotoxicity in patients to whom fluconazole and tacrolimus were coadministered. 	fluconazole	tacrolimus	effect	{'e1': {'word': 'fluconazole', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d776.s33.e1'}, 'e2': {'word': 'tacrolimus', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d776.s33.e2'}, 'sentence_id': 'DDI-DrugBank.d776.s33'}	Tacrolimus reports nephrotoxicity patients fluconazole tacrolimus coadministered
Patients receiving tacrolimus and fluconazole concomitantly should be carefully monitored. 	tacrolimus	fluconazole	advise	{'e1': {'word': 'tacrolimus', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d776.s34.e0'}, 'e2': {'word': 'fluconazole', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d776.s34.e1'}, 'sentence_id': 'DDI-DrugBank.d776.s34'}	Patients receiving tacrolimus fluconazole concomitantly carefully monitored
Short-acting Benzodiazepines: Following oral administration of midazolam, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects. 	Short-acting Benzodiazepines	midazolam	none	{'e1': {'word': 'Short-acting Benzodiazepines', 'word_index': [(0, 2)], 'id': 'DDI-DrugBank.d776.s35.e0'}, 'e2': {'word': 'midazolam', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d776.s35.e1'}, 'sentence_id': 'DDI-DrugBank.d776.s35'}	Short acting Benzodiazepines Following oral administration midazolam fluconazole resulted substantial increases midazolam concentrations psychomotor effects
Short-acting Benzodiazepines: Following oral administration of midazolam, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects. 	Short-acting Benzodiazepines	fluconazole	none	{'e1': {'word': 'Short-acting Benzodiazepines', 'word_index': [(0, 2)], 'id': 'DDI-DrugBank.d776.s35.e0'}, 'e2': {'word': 'fluconazole', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d776.s35.e2'}, 'sentence_id': 'DDI-DrugBank.d776.s35'}	Short acting Benzodiazepines Following oral administration midazolam fluconazole resulted substantial increases midazolam concentrations psychomotor effects
Short-acting Benzodiazepines: Following oral administration of midazolam, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects. 	Short-acting Benzodiazepines	midazolam	none	{'e1': {'word': 'Short-acting Benzodiazepines', 'word_index': [(0, 2)], 'id': 'DDI-DrugBank.d776.s35.e0'}, 'e2': {'word': 'midazolam', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d776.s35.e3'}, 'sentence_id': 'DDI-DrugBank.d776.s35'}	Short acting Benzodiazepines Following oral administration midazolam fluconazole resulted substantial increases midazolam concentrations psychomotor effects
Short-acting Benzodiazepines: Following oral administration of midazolam, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects. 	midazolam	fluconazole	mechanism	{'e1': {'word': 'midazolam', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d776.s35.e1'}, 'e2': {'word': 'fluconazole', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d776.s35.e2'}, 'sentence_id': 'DDI-DrugBank.d776.s35'}	Short acting Benzodiazepines Following oral administration midazolam fluconazole resulted substantial increases midazolam concentrations psychomotor effects
Short-acting Benzodiazepines: Following oral administration of midazolam, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects. 	midazolam	midazolam	none	{'e1': {'word': 'midazolam', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d776.s35.e1'}, 'e2': {'word': 'midazolam', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d776.s35.e3'}, 'sentence_id': 'DDI-DrugBank.d776.s35'}	Short acting Benzodiazepines Following oral administration midazolam fluconazole resulted substantial increases midazolam concentrations psychomotor effects
Short-acting Benzodiazepines: Following oral administration of midazolam, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects. 	fluconazole	midazolam	none	{'e1': {'word': 'fluconazole', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d776.s35.e2'}, 'e2': {'word': 'midazolam', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d776.s35.e3'}, 'sentence_id': 'DDI-DrugBank.d776.s35'}	Short acting Benzodiazepines Following oral administration midazolam fluconazole resulted substantial increases midazolam concentrations psychomotor effects
This effect on midazolam appears to be more pronounced following oral administration of fluconazole than with fluconazole administered intravenously. 	midazolam	fluconazole	effect	{'e1': {'word': 'midazolam', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d776.s36.e0'}, 'e2': {'word': 'fluconazole', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d776.s36.e1'}, 'sentence_id': 'DDI-DrugBank.d776.s36'}	effect midazolam appears pronounced following oral administration fluconazole fluconazole administered intravenously
This effect on midazolam appears to be more pronounced following oral administration of fluconazole than with fluconazole administered intravenously. 	midazolam	fluconazole	none	{'e1': {'word': 'midazolam', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d776.s36.e0'}, 'e2': {'word': 'fluconazole', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d776.s36.e2'}, 'sentence_id': 'DDI-DrugBank.d776.s36'}	effect midazolam appears pronounced following oral administration fluconazole fluconazole administered intravenously
This effect on midazolam appears to be more pronounced following oral administration of fluconazole than with fluconazole administered intravenously. 	fluconazole	fluconazole	none	{'e1': {'word': 'fluconazole', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d776.s36.e1'}, 'e2': {'word': 'fluconazole', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d776.s36.e2'}, 'sentence_id': 'DDI-DrugBank.d776.s36'}	effect midazolam appears pronounced following oral administration fluconazole fluconazole administered intravenously
If short-acting benzodiazepines, which are metabolized by the cytochrome P450 system, are concomitantly administered with fluconazole, consideration should be given to decreasing the benzodiazepine dosage, and the patients should be appropriately monitored. 	short-acting benzodiazepines	fluconazole	advise	{'e1': {'word': 'short-acting benzodiazepines', 'word_index': [(0, 2)], 'id': 'DDI-DrugBank.d776.s37.e0'}, 'e2': {'word': 'fluconazole', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d776.s37.e1'}, 'sentence_id': 'DDI-DrugBank.d776.s37'}	short acting benzodiazepines metabolized cytochrome P450 system concomitantly administered fluconazole consideration given decreasing benzodiazepine dosage patients appropriately monitored
If short-acting benzodiazepines, which are metabolized by the cytochrome P450 system, are concomitantly administered with fluconazole, consideration should be given to decreasing the benzodiazepine dosage, and the patients should be appropriately monitored. 	short-acting benzodiazepines	benzodiazepine	none	{'e1': {'word': 'short-acting benzodiazepines', 'word_index': [(0, 2)], 'id': 'DDI-DrugBank.d776.s37.e0'}, 'e2': {'word': 'benzodiazepine', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d776.s37.e2'}, 'sentence_id': 'DDI-DrugBank.d776.s37'}	short acting benzodiazepines metabolized cytochrome P450 system concomitantly administered fluconazole consideration given decreasing benzodiazepine dosage patients appropriately monitored
If short-acting benzodiazepines, which are metabolized by the cytochrome P450 system, are concomitantly administered with fluconazole, consideration should be given to decreasing the benzodiazepine dosage, and the patients should be appropriately monitored. 	fluconazole	benzodiazepine	none	{'e1': {'word': 'fluconazole', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d776.s37.e1'}, 'e2': {'word': 'benzodiazepine', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d776.s37.e2'}, 'sentence_id': 'DDI-DrugBank.d776.s37'}	short acting benzodiazepines metabolized cytochrome P450 system concomitantly administered fluconazole consideration given decreasing benzodiazepine dosage patients appropriately monitored
Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; 	Fluconazole	ethinyl estradiol	mechanism	{'e1': {'word': 'Fluconazole', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d776.s38.e0'}, 'e2': {'word': 'ethinyl estradiol', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d776.s38.e1'}, 'sentence_id': 'DDI-DrugBank.d776.s38'}	Fluconazole tablets coadministered ethinyl estradiol levonorgestrel containing oral contraceptives produced overall mean increase ethinyl estradiol levonorgestrel levels
Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; 	Fluconazole	levonorgestrel	mechanism	{'e1': {'word': 'Fluconazole', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d776.s38.e0'}, 'e2': {'word': 'levonorgestrel', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d776.s38.e2'}, 'sentence_id': 'DDI-DrugBank.d776.s38'}	Fluconazole tablets coadministered ethinyl estradiol levonorgestrel containing oral contraceptives produced overall mean increase ethinyl estradiol levonorgestrel levels
Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; 	Fluconazole	contraceptives	none	{'e1': {'word': 'Fluconazole', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d776.s38.e0'}, 'e2': {'word': 'contraceptives', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d776.s38.e3'}, 'sentence_id': 'DDI-DrugBank.d776.s38'}	Fluconazole tablets coadministered ethinyl estradiol levonorgestrel containing oral contraceptives produced overall mean increase ethinyl estradiol levonorgestrel levels
Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; 	Fluconazole	ethinyl estradiol	none	{'e1': {'word': 'Fluconazole', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d776.s38.e0'}, 'e2': {'word': 'ethinyl estradiol', 'word_index': [(13, 14)], 'id': 'DDI-DrugBank.d776.s38.e4'}, 'sentence_id': 'DDI-DrugBank.d776.s38'}	Fluconazole tablets coadministered ethinyl estradiol levonorgestrel containing oral contraceptives produced overall mean increase ethinyl estradiol levonorgestrel levels
Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; 	Fluconazole	levonorgestrel	none	{'e1': {'word': 'Fluconazole', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d776.s38.e0'}, 'e2': {'word': 'levonorgestrel', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d776.s38.e5'}, 'sentence_id': 'DDI-DrugBank.d776.s38'}	Fluconazole tablets coadministered ethinyl estradiol levonorgestrel containing oral contraceptives produced overall mean increase ethinyl estradiol levonorgestrel levels
Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; 	ethinyl estradiol	levonorgestrel	none	{'e1': {'word': 'ethinyl estradiol', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d776.s38.e1'}, 'e2': {'word': 'levonorgestrel', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d776.s38.e2'}, 'sentence_id': 'DDI-DrugBank.d776.s38'}	Fluconazole tablets coadministered ethinyl estradiol levonorgestrel containing oral contraceptives produced overall mean increase ethinyl estradiol levonorgestrel levels
Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; 	ethinyl estradiol	contraceptives	none	{'e1': {'word': 'ethinyl estradiol', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d776.s38.e1'}, 'e2': {'word': 'contraceptives', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d776.s38.e3'}, 'sentence_id': 'DDI-DrugBank.d776.s38'}	Fluconazole tablets coadministered ethinyl estradiol levonorgestrel containing oral contraceptives produced overall mean increase ethinyl estradiol levonorgestrel levels
Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; 	ethinyl estradiol	ethinyl estradiol	none	{'e1': {'word': 'ethinyl estradiol', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d776.s38.e1'}, 'e2': {'word': 'ethinyl estradiol', 'word_index': [(13, 14)], 'id': 'DDI-DrugBank.d776.s38.e4'}, 'sentence_id': 'DDI-DrugBank.d776.s38'}	Fluconazole tablets coadministered ethinyl estradiol levonorgestrel containing oral contraceptives produced overall mean increase ethinyl estradiol levonorgestrel levels
Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; 	ethinyl estradiol	levonorgestrel	none	{'e1': {'word': 'ethinyl estradiol', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d776.s38.e1'}, 'e2': {'word': 'levonorgestrel', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d776.s38.e5'}, 'sentence_id': 'DDI-DrugBank.d776.s38'}	Fluconazole tablets coadministered ethinyl estradiol levonorgestrel containing oral contraceptives produced overall mean increase ethinyl estradiol levonorgestrel levels
Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; 	levonorgestrel	contraceptives	none	{'e1': {'word': 'levonorgestrel', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d776.s38.e2'}, 'e2': {'word': 'contraceptives', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d776.s38.e3'}, 'sentence_id': 'DDI-DrugBank.d776.s38'}	Fluconazole tablets coadministered ethinyl estradiol levonorgestrel containing oral contraceptives produced overall mean increase ethinyl estradiol levonorgestrel levels
Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; 	levonorgestrel	ethinyl estradiol	none	{'e1': {'word': 'levonorgestrel', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d776.s38.e2'}, 'e2': {'word': 'ethinyl estradiol', 'word_index': [(13, 14)], 'id': 'DDI-DrugBank.d776.s38.e4'}, 'sentence_id': 'DDI-DrugBank.d776.s38'}	Fluconazole tablets coadministered ethinyl estradiol levonorgestrel containing oral contraceptives produced overall mean increase ethinyl estradiol levonorgestrel levels
Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; 	levonorgestrel	levonorgestrel	none	{'e1': {'word': 'levonorgestrel', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d776.s38.e2'}, 'e2': {'word': 'levonorgestrel', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d776.s38.e5'}, 'sentence_id': 'DDI-DrugBank.d776.s38'}	Fluconazole tablets coadministered ethinyl estradiol levonorgestrel containing oral contraceptives produced overall mean increase ethinyl estradiol levonorgestrel levels
Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; 	contraceptives	ethinyl estradiol	none	{'e1': {'word': 'contraceptives', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d776.s38.e3'}, 'e2': {'word': 'ethinyl estradiol', 'word_index': [(13, 14)], 'id': 'DDI-DrugBank.d776.s38.e4'}, 'sentence_id': 'DDI-DrugBank.d776.s38'}	Fluconazole tablets coadministered ethinyl estradiol levonorgestrel containing oral contraceptives produced overall mean increase ethinyl estradiol levonorgestrel levels
Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; 	contraceptives	levonorgestrel	none	{'e1': {'word': 'contraceptives', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d776.s38.e3'}, 'e2': {'word': 'levonorgestrel', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d776.s38.e5'}, 'sentence_id': 'DDI-DrugBank.d776.s38'}	Fluconazole tablets coadministered ethinyl estradiol levonorgestrel containing oral contraceptives produced overall mean increase ethinyl estradiol levonorgestrel levels
Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; 	ethinyl estradiol	levonorgestrel	none	{'e1': {'word': 'ethinyl estradiol', 'word_index': [(13, 14)], 'id': 'DDI-DrugBank.d776.s38.e4'}, 'e2': {'word': 'levonorgestrel', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d776.s38.e5'}, 'sentence_id': 'DDI-DrugBank.d776.s38'}	Fluconazole tablets coadministered ethinyl estradiol levonorgestrel containing oral contraceptives produced overall mean increase ethinyl estradiol levonorgestrel levels
however, in some patients there were decreases up to 47% and 33% of ethinyl estradiol and levonorgestrel levels. 	ethinyl estradiol	levonorgestrel	none	{'e1': {'word': 'ethinyl estradiol', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d776.s39.e0'}, 'e2': {'word': 'levonorgestrel', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d776.s39.e1'}, 'sentence_id': 'DDI-DrugBank.d776.s39'}	however patients decreases NUMBER % NUMBER % ethinyl estradiol levonorgestrel levels
The data presently available indicate that the decreases in some individual ethinyl estradiol and levonorgestrel AUC values with fluconazole treatment are likely the result of random variation. 	ethinyl estradiol	levonorgestrel	none	{'e1': {'word': 'ethinyl estradiol', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d776.s40.e0'}, 'e2': {'word': 'levonorgestrel', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d776.s40.e1'}, 'sentence_id': 'DDI-DrugBank.d776.s40'}	data presently available indicate decreases individual ethinyl estradiol levonorgestrel AUC values fluconazole treatment likely result random variation
The data presently available indicate that the decreases in some individual ethinyl estradiol and levonorgestrel AUC values with fluconazole treatment are likely the result of random variation. 	ethinyl estradiol	fluconazole	none	{'e1': {'word': 'ethinyl estradiol', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d776.s40.e0'}, 'e2': {'word': 'fluconazole', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d776.s40.e2'}, 'sentence_id': 'DDI-DrugBank.d776.s40'}	data presently available indicate decreases individual ethinyl estradiol levonorgestrel AUC values fluconazole treatment likely result random variation
The data presently available indicate that the decreases in some individual ethinyl estradiol and levonorgestrel AUC values with fluconazole treatment are likely the result of random variation. 	levonorgestrel	fluconazole	none	{'e1': {'word': 'levonorgestrel', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d776.s40.e1'}, 'e2': {'word': 'fluconazole', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d776.s40.e2'}, 'sentence_id': 'DDI-DrugBank.d776.s40'}	data presently available indicate decreases individual ethinyl estradiol levonorgestrel AUC values fluconazole treatment likely result random variation
While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. 	fluconazole	ethinyl estradiol	mechanism	{'e1': {'word': 'fluconazole', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d776.s41.e0'}, 'e2': {'word': 'ethinyl estradiol', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d776.s41.e1'}, 'sentence_id': 'DDI-DrugBank.d776.s41'}	evidence fluconazole inhibit metabolism ethinyl estradiol levonorgestrel evidence fluconazole net inducer ethinyl estradiol levonorgestrel metabolism
While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. 	fluconazole	levonorgestrel	mechanism	{'e1': {'word': 'fluconazole', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d776.s41.e0'}, 'e2': {'word': 'levonorgestrel', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d776.s41.e2'}, 'sentence_id': 'DDI-DrugBank.d776.s41'}	evidence fluconazole inhibit metabolism ethinyl estradiol levonorgestrel evidence fluconazole net inducer ethinyl estradiol levonorgestrel metabolism
While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. 	fluconazole	fluconazole	none	{'e1': {'word': 'fluconazole', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d776.s41.e0'}, 'e2': {'word': 'fluconazole', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d776.s41.e3'}, 'sentence_id': 'DDI-DrugBank.d776.s41'}	evidence fluconazole inhibit metabolism ethinyl estradiol levonorgestrel evidence fluconazole net inducer ethinyl estradiol levonorgestrel metabolism
While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. 	fluconazole	ethinyl estradiol	none	{'e1': {'word': 'fluconazole', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d776.s41.e0'}, 'e2': {'word': 'ethinyl estradiol', 'word_index': [(11, 12)], 'id': 'DDI-DrugBank.d776.s41.e4'}, 'sentence_id': 'DDI-DrugBank.d776.s41'}	evidence fluconazole inhibit metabolism ethinyl estradiol levonorgestrel evidence fluconazole net inducer ethinyl estradiol levonorgestrel metabolism
While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. 	fluconazole	levonorgestrel	none	{'e1': {'word': 'fluconazole', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d776.s41.e0'}, 'e2': {'word': 'levonorgestrel', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d776.s41.e5'}, 'sentence_id': 'DDI-DrugBank.d776.s41'}	evidence fluconazole inhibit metabolism ethinyl estradiol levonorgestrel evidence fluconazole net inducer ethinyl estradiol levonorgestrel metabolism
While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. 	ethinyl estradiol	levonorgestrel	none	{'e1': {'word': 'ethinyl estradiol', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d776.s41.e1'}, 'e2': {'word': 'levonorgestrel', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d776.s41.e2'}, 'sentence_id': 'DDI-DrugBank.d776.s41'}	evidence fluconazole inhibit metabolism ethinyl estradiol levonorgestrel evidence fluconazole net inducer ethinyl estradiol levonorgestrel metabolism
While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. 	ethinyl estradiol	fluconazole	none	{'e1': {'word': 'ethinyl estradiol', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d776.s41.e1'}, 'e2': {'word': 'fluconazole', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d776.s41.e3'}, 'sentence_id': 'DDI-DrugBank.d776.s41'}	evidence fluconazole inhibit metabolism ethinyl estradiol levonorgestrel evidence fluconazole net inducer ethinyl estradiol levonorgestrel metabolism
While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. 	ethinyl estradiol	ethinyl estradiol	none	{'e1': {'word': 'ethinyl estradiol', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d776.s41.e1'}, 'e2': {'word': 'ethinyl estradiol', 'word_index': [(11, 12)], 'id': 'DDI-DrugBank.d776.s41.e4'}, 'sentence_id': 'DDI-DrugBank.d776.s41'}	evidence fluconazole inhibit metabolism ethinyl estradiol levonorgestrel evidence fluconazole net inducer ethinyl estradiol levonorgestrel metabolism
While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. 	ethinyl estradiol	levonorgestrel	none	{'e1': {'word': 'ethinyl estradiol', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d776.s41.e1'}, 'e2': {'word': 'levonorgestrel', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d776.s41.e5'}, 'sentence_id': 'DDI-DrugBank.d776.s41'}	evidence fluconazole inhibit metabolism ethinyl estradiol levonorgestrel evidence fluconazole net inducer ethinyl estradiol levonorgestrel metabolism
While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. 	levonorgestrel	fluconazole	none	{'e1': {'word': 'levonorgestrel', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d776.s41.e2'}, 'e2': {'word': 'fluconazole', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d776.s41.e3'}, 'sentence_id': 'DDI-DrugBank.d776.s41'}	evidence fluconazole inhibit metabolism ethinyl estradiol levonorgestrel evidence fluconazole net inducer ethinyl estradiol levonorgestrel metabolism
While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. 	levonorgestrel	ethinyl estradiol	none	{'e1': {'word': 'levonorgestrel', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d776.s41.e2'}, 'e2': {'word': 'ethinyl estradiol', 'word_index': [(11, 12)], 'id': 'DDI-DrugBank.d776.s41.e4'}, 'sentence_id': 'DDI-DrugBank.d776.s41'}	evidence fluconazole inhibit metabolism ethinyl estradiol levonorgestrel evidence fluconazole net inducer ethinyl estradiol levonorgestrel metabolism
While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. 	levonorgestrel	levonorgestrel	none	{'e1': {'word': 'levonorgestrel', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d776.s41.e2'}, 'e2': {'word': 'levonorgestrel', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d776.s41.e5'}, 'sentence_id': 'DDI-DrugBank.d776.s41'}	evidence fluconazole inhibit metabolism ethinyl estradiol levonorgestrel evidence fluconazole net inducer ethinyl estradiol levonorgestrel metabolism
While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. 	fluconazole	ethinyl estradiol	none	{'e1': {'word': 'fluconazole', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d776.s41.e3'}, 'e2': {'word': 'ethinyl estradiol', 'word_index': [(11, 12)], 'id': 'DDI-DrugBank.d776.s41.e4'}, 'sentence_id': 'DDI-DrugBank.d776.s41'}	evidence fluconazole inhibit metabolism ethinyl estradiol levonorgestrel evidence fluconazole net inducer ethinyl estradiol levonorgestrel metabolism
While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. 	fluconazole	levonorgestrel	none	{'e1': {'word': 'fluconazole', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d776.s41.e3'}, 'e2': {'word': 'levonorgestrel', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d776.s41.e5'}, 'sentence_id': 'DDI-DrugBank.d776.s41'}	evidence fluconazole inhibit metabolism ethinyl estradiol levonorgestrel evidence fluconazole net inducer ethinyl estradiol levonorgestrel metabolism
While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. 	ethinyl estradiol	levonorgestrel	none	{'e1': {'word': 'ethinyl estradiol', 'word_index': [(11, 12)], 'id': 'DDI-DrugBank.d776.s41.e4'}, 'e2': {'word': 'levonorgestrel', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d776.s41.e5'}, 'sentence_id': 'DDI-DrugBank.d776.s41'}	evidence fluconazole inhibit metabolism ethinyl estradiol levonorgestrel evidence fluconazole net inducer ethinyl estradiol levonorgestrel metabolism
Ritalin may decrease the hypotensive effect of guanethidine. 	Ritalin	guanethidine	effect	{'e1': {'word': 'Ritalin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d638.s0.e0'}, 'e2': {'word': 'guanethidine', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d638.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d638.s0'}	Ritalin may decrease hypotensive effect guanethidine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	Ritalin	coumarin anticoagulants	mechanism	{'e1': {'word': 'Ritalin', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d638.s2.e0'}, 'e2': {'word': 'coumarin anticoagulants', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d638.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	Ritalin	anticonvulsants	mechanism	{'e1': {'word': 'Ritalin', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d638.s2.e0'}, 'e2': {'word': 'anticonvulsants', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d638.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	Ritalin	phenobarbital	mechanism	{'e1': {'word': 'Ritalin', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d638.s2.e0'}, 'e2': {'word': 'phenobarbital', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d638.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	Ritalin	diphenylhydantoin	mechanism	{'e1': {'word': 'Ritalin', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d638.s2.e0'}, 'e2': {'word': 'diphenylhydantoin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d638.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	Ritalin	primidone	mechanism	{'e1': {'word': 'Ritalin', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d638.s2.e0'}, 'e2': {'word': 'primidone', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d638.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	Ritalin	phenylbutazone	mechanism	{'e1': {'word': 'Ritalin', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d638.s2.e0'}, 'e2': {'word': 'phenylbutazone', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d638.s2.e6'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	Ritalin	tricyclic drugs	mechanism	{'e1': {'word': 'Ritalin', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d638.s2.e0'}, 'e2': {'word': 'tricyclic drugs', 'word_index': [(15, 16)], 'id': 'DDI-DrugBank.d638.s2.e7'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	Ritalin	imipramine	mechanism	{'e1': {'word': 'Ritalin', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d638.s2.e0'}, 'e2': {'word': 'imipramine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d638.s2.e8'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	Ritalin	clomipramine	mechanism	{'e1': {'word': 'Ritalin', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d638.s2.e0'}, 'e2': {'word': 'clomipramine', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d638.s2.e9'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	Ritalin	desipramine	mechanism	{'e1': {'word': 'Ritalin', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d638.s2.e0'}, 'e2': {'word': 'desipramine', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d638.s2.e10'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	coumarin anticoagulants	anticonvulsants	none	{'e1': {'word': 'coumarin anticoagulants', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d638.s2.e1'}, 'e2': {'word': 'anticonvulsants', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d638.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	coumarin anticoagulants	phenobarbital	none	{'e1': {'word': 'coumarin anticoagulants', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d638.s2.e1'}, 'e2': {'word': 'phenobarbital', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d638.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	coumarin anticoagulants	diphenylhydantoin	none	{'e1': {'word': 'coumarin anticoagulants', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d638.s2.e1'}, 'e2': {'word': 'diphenylhydantoin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d638.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	coumarin anticoagulants	primidone	none	{'e1': {'word': 'coumarin anticoagulants', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d638.s2.e1'}, 'e2': {'word': 'primidone', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d638.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	coumarin anticoagulants	phenylbutazone	none	{'e1': {'word': 'coumarin anticoagulants', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d638.s2.e1'}, 'e2': {'word': 'phenylbutazone', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d638.s2.e6'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	coumarin anticoagulants	tricyclic drugs	none	{'e1': {'word': 'coumarin anticoagulants', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d638.s2.e1'}, 'e2': {'word': 'tricyclic drugs', 'word_index': [(15, 16)], 'id': 'DDI-DrugBank.d638.s2.e7'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	coumarin anticoagulants	imipramine	none	{'e1': {'word': 'coumarin anticoagulants', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d638.s2.e1'}, 'e2': {'word': 'imipramine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d638.s2.e8'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	coumarin anticoagulants	clomipramine	none	{'e1': {'word': 'coumarin anticoagulants', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d638.s2.e1'}, 'e2': {'word': 'clomipramine', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d638.s2.e9'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	coumarin anticoagulants	desipramine	none	{'e1': {'word': 'coumarin anticoagulants', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d638.s2.e1'}, 'e2': {'word': 'desipramine', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d638.s2.e10'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	anticonvulsants	phenobarbital	none	{'e1': {'word': 'anticonvulsants', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d638.s2.e2'}, 'e2': {'word': 'phenobarbital', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d638.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	anticonvulsants	diphenylhydantoin	none	{'e1': {'word': 'anticonvulsants', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d638.s2.e2'}, 'e2': {'word': 'diphenylhydantoin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d638.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	anticonvulsants	primidone	none	{'e1': {'word': 'anticonvulsants', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d638.s2.e2'}, 'e2': {'word': 'primidone', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d638.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	anticonvulsants	phenylbutazone	none	{'e1': {'word': 'anticonvulsants', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d638.s2.e2'}, 'e2': {'word': 'phenylbutazone', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d638.s2.e6'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	anticonvulsants	tricyclic drugs	none	{'e1': {'word': 'anticonvulsants', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d638.s2.e2'}, 'e2': {'word': 'tricyclic drugs', 'word_index': [(15, 16)], 'id': 'DDI-DrugBank.d638.s2.e7'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	anticonvulsants	imipramine	none	{'e1': {'word': 'anticonvulsants', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d638.s2.e2'}, 'e2': {'word': 'imipramine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d638.s2.e8'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	anticonvulsants	clomipramine	none	{'e1': {'word': 'anticonvulsants', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d638.s2.e2'}, 'e2': {'word': 'clomipramine', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d638.s2.e9'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	anticonvulsants	desipramine	none	{'e1': {'word': 'anticonvulsants', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d638.s2.e2'}, 'e2': {'word': 'desipramine', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d638.s2.e10'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	phenobarbital	diphenylhydantoin	none	{'e1': {'word': 'phenobarbital', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d638.s2.e3'}, 'e2': {'word': 'diphenylhydantoin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d638.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	phenobarbital	primidone	none	{'e1': {'word': 'phenobarbital', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d638.s2.e3'}, 'e2': {'word': 'primidone', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d638.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	phenobarbital	phenylbutazone	none	{'e1': {'word': 'phenobarbital', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d638.s2.e3'}, 'e2': {'word': 'phenylbutazone', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d638.s2.e6'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	phenobarbital	tricyclic drugs	none	{'e1': {'word': 'phenobarbital', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d638.s2.e3'}, 'e2': {'word': 'tricyclic drugs', 'word_index': [(15, 16)], 'id': 'DDI-DrugBank.d638.s2.e7'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	phenobarbital	imipramine	none	{'e1': {'word': 'phenobarbital', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d638.s2.e3'}, 'e2': {'word': 'imipramine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d638.s2.e8'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	phenobarbital	clomipramine	none	{'e1': {'word': 'phenobarbital', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d638.s2.e3'}, 'e2': {'word': 'clomipramine', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d638.s2.e9'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	phenobarbital	desipramine	none	{'e1': {'word': 'phenobarbital', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d638.s2.e3'}, 'e2': {'word': 'desipramine', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d638.s2.e10'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	diphenylhydantoin	primidone	none	{'e1': {'word': 'diphenylhydantoin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d638.s2.e4'}, 'e2': {'word': 'primidone', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d638.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	diphenylhydantoin	phenylbutazone	none	{'e1': {'word': 'diphenylhydantoin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d638.s2.e4'}, 'e2': {'word': 'phenylbutazone', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d638.s2.e6'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	diphenylhydantoin	tricyclic drugs	none	{'e1': {'word': 'diphenylhydantoin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d638.s2.e4'}, 'e2': {'word': 'tricyclic drugs', 'word_index': [(15, 16)], 'id': 'DDI-DrugBank.d638.s2.e7'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	diphenylhydantoin	imipramine	none	{'e1': {'word': 'diphenylhydantoin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d638.s2.e4'}, 'e2': {'word': 'imipramine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d638.s2.e8'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	diphenylhydantoin	clomipramine	none	{'e1': {'word': 'diphenylhydantoin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d638.s2.e4'}, 'e2': {'word': 'clomipramine', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d638.s2.e9'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	diphenylhydantoin	desipramine	none	{'e1': {'word': 'diphenylhydantoin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d638.s2.e4'}, 'e2': {'word': 'desipramine', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d638.s2.e10'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	primidone	phenylbutazone	none	{'e1': {'word': 'primidone', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d638.s2.e5'}, 'e2': {'word': 'phenylbutazone', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d638.s2.e6'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	primidone	tricyclic drugs	none	{'e1': {'word': 'primidone', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d638.s2.e5'}, 'e2': {'word': 'tricyclic drugs', 'word_index': [(15, 16)], 'id': 'DDI-DrugBank.d638.s2.e7'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	primidone	imipramine	none	{'e1': {'word': 'primidone', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d638.s2.e5'}, 'e2': {'word': 'imipramine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d638.s2.e8'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	primidone	clomipramine	none	{'e1': {'word': 'primidone', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d638.s2.e5'}, 'e2': {'word': 'clomipramine', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d638.s2.e9'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	primidone	desipramine	none	{'e1': {'word': 'primidone', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d638.s2.e5'}, 'e2': {'word': 'desipramine', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d638.s2.e10'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	phenylbutazone	tricyclic drugs	none	{'e1': {'word': 'phenylbutazone', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d638.s2.e6'}, 'e2': {'word': 'tricyclic drugs', 'word_index': [(15, 16)], 'id': 'DDI-DrugBank.d638.s2.e7'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	phenylbutazone	imipramine	none	{'e1': {'word': 'phenylbutazone', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d638.s2.e6'}, 'e2': {'word': 'imipramine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d638.s2.e8'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	phenylbutazone	clomipramine	none	{'e1': {'word': 'phenylbutazone', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d638.s2.e6'}, 'e2': {'word': 'clomipramine', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d638.s2.e9'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	phenylbutazone	desipramine	none	{'e1': {'word': 'phenylbutazone', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d638.s2.e6'}, 'e2': {'word': 'desipramine', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d638.s2.e10'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	tricyclic drugs	imipramine	none	{'e1': {'word': 'tricyclic drugs', 'word_index': [(15, 16)], 'id': 'DDI-DrugBank.d638.s2.e7'}, 'e2': {'word': 'imipramine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d638.s2.e8'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	tricyclic drugs	clomipramine	none	{'e1': {'word': 'tricyclic drugs', 'word_index': [(15, 16)], 'id': 'DDI-DrugBank.d638.s2.e7'}, 'e2': {'word': 'clomipramine', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d638.s2.e9'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	tricyclic drugs	desipramine	none	{'e1': {'word': 'tricyclic drugs', 'word_index': [(15, 16)], 'id': 'DDI-DrugBank.d638.s2.e7'}, 'e2': {'word': 'desipramine', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d638.s2.e10'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	imipramine	clomipramine	none	{'e1': {'word': 'imipramine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d638.s2.e8'}, 'e2': {'word': 'clomipramine', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d638.s2.e9'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	imipramine	desipramine	none	{'e1': {'word': 'imipramine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d638.s2.e8'}, 'e2': {'word': 'desipramine', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d638.s2.e10'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). 	clomipramine	desipramine	none	{'e1': {'word': 'clomipramine', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d638.s2.e9'}, 'e2': {'word': 'desipramine', 'word_index': [(19, 19)], 'id': 'DDI-DrugBank.d638.s2.e10'}, 'sentence_id': 'DDI-DrugBank.d638.s2'}	Human pharmacologic studies shown Ritalin may inhibit metabolism coumarin anticoagulants anticonvulsants phenobarbital diphenylhydantoin primidone phenylbutazone tricyclic drugs imipramine clomipramine desipramine
The safety of using methylphenidate in combination with clonidine or other centrally acting alpha-2 agonists has not been systemically evaluated.    	methylphenidate	clonidine	none	{'e1': {'word': 'methylphenidate', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d638.s5.e0'}, 'e2': {'word': 'clonidine', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d638.s5.e1'}, 'sentence_id': 'DDI-DrugBank.d638.s5'}	safety using methylphenidate combination clonidine centrally acting alpha NUMBER agonists systemically evaluated
The safety of using methylphenidate in combination with clonidine or other centrally acting alpha-2 agonists has not been systemically evaluated.    	methylphenidate	alpha-2 agonists	none	{'e1': {'word': 'methylphenidate', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d638.s5.e0'}, 'e2': {'word': 'alpha-2 agonists', 'word_index': [(7, 9)], 'id': 'DDI-DrugBank.d638.s5.e2'}, 'sentence_id': 'DDI-DrugBank.d638.s5'}	safety using methylphenidate combination clonidine centrally acting alpha NUMBER agonists systemically evaluated
The safety of using methylphenidate in combination with clonidine or other centrally acting alpha-2 agonists has not been systemically evaluated.    	clonidine	alpha-2 agonists	none	{'e1': {'word': 'clonidine', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d638.s5.e1'}, 'e2': {'word': 'alpha-2 agonists', 'word_index': [(7, 9)], 'id': 'DDI-DrugBank.d638.s5.e2'}, 'sentence_id': 'DDI-DrugBank.d638.s5'}	safety using methylphenidate combination clonidine centrally acting alpha NUMBER agonists systemically evaluated
Drug Interactions: Women on oral contraceptives have shown a significant increase in plasma vitamin A levels.	contraceptives	vitamin A	mechanism	{'e1': {'word': 'contraceptives', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d651.s0.e0'}, 'e2': {'word': 'vitamin A', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d651.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d651.s0'}	Drug Interactions Women oral contraceptives shown significant increase plasma vitamin levels
Zidovudine competitively inhibits the intracellular phosphorylation of stavudine. 	Zidovudine	stavudine	effect	{'e1': {'word': 'Zidovudine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d727.s0.e0'}, 'e2': {'word': 'stavudine', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d727.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d727.s0'}	Zidovudine competitively inhibits intracellular phosphorylation stavudine
Therefore, use of zidovudine in combination with ZERIT should be avoided. 	zidovudine	ZERIT	advise	{'e1': {'word': 'zidovudine', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d727.s1.e0'}, 'e2': {'word': 'ZERIT', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d727.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d727.s1'}	Therefore use zidovudine combination ZERIT avoided
In vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by doxorubicin and ribavirin. 	stavudine	doxorubicin	effect	{'e1': {'word': 'stavudine', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d727.s2.e0'}, 'e2': {'word': 'doxorubicin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d727.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d727.s2'}	vitro data indicate phosphorylation stavudine also inhibited relevant concentrations doxorubicin ribavirin
In vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by doxorubicin and ribavirin. 	stavudine	ribavirin	effect	{'e1': {'word': 'stavudine', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d727.s2.e0'}, 'e2': {'word': 'ribavirin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d727.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d727.s2'}	vitro data indicate phosphorylation stavudine also inhibited relevant concentrations doxorubicin ribavirin
In vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by doxorubicin and ribavirin. 	doxorubicin	ribavirin	none	{'e1': {'word': 'doxorubicin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d727.s2.e1'}, 'e2': {'word': 'ribavirin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d727.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d727.s2'}	vitro data indicate phosphorylation stavudine also inhibited relevant concentrations doxorubicin ribavirin
The interaction of Streptase, Streptokinase, with other drugs has not been well studied. 	Streptase	Streptokinase	none	{'e1': {'word': 'Streptase', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d777.s0.e0'}, 'e2': {'word': 'Streptokinase', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d777.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d777.s0'}	interaction Streptase Streptokinase drugs well studied
Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. 	Anticoagulants	Antiplatelet Agents	none	{'e1': {'word': 'Anticoagulants', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d777.s1.e0'}, 'e2': {'word': 'Antiplatelet Agents', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d777.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d777.s1'}	Use Anticoagulants Antiplatelet Agents Streptase Streptokinase alone combination antiplatelet agents anticoagulants may cause bleeding complications
Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. 	Anticoagulants	Streptase	none	{'e1': {'word': 'Anticoagulants', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d777.s1.e0'}, 'e2': {'word': 'Streptase', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d777.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d777.s1'}	Use Anticoagulants Antiplatelet Agents Streptase Streptokinase alone combination antiplatelet agents anticoagulants may cause bleeding complications
Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. 	Anticoagulants	Streptokinase	none	{'e1': {'word': 'Anticoagulants', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d777.s1.e0'}, 'e2': {'word': 'Streptokinase', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d777.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d777.s1'}	Use Anticoagulants Antiplatelet Agents Streptase Streptokinase alone combination antiplatelet agents anticoagulants may cause bleeding complications
Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. 	Anticoagulants	antiplatelet agents	none	{'e1': {'word': 'Anticoagulants', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d777.s1.e0'}, 'e2': {'word': 'antiplatelet agents', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d777.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d777.s1'}	Use Anticoagulants Antiplatelet Agents Streptase Streptokinase alone combination antiplatelet agents anticoagulants may cause bleeding complications
Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. 	Anticoagulants	anticoagulants	none	{'e1': {'word': 'Anticoagulants', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d777.s1.e0'}, 'e2': {'word': 'anticoagulants', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d777.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d777.s1'}	Use Anticoagulants Antiplatelet Agents Streptase Streptokinase alone combination antiplatelet agents anticoagulants may cause bleeding complications
Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. 	Antiplatelet Agents	Streptase	none	{'e1': {'word': 'Antiplatelet Agents', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d777.s1.e1'}, 'e2': {'word': 'Streptase', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d777.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d777.s1'}	Use Anticoagulants Antiplatelet Agents Streptase Streptokinase alone combination antiplatelet agents anticoagulants may cause bleeding complications
Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. 	Antiplatelet Agents	Streptokinase	none	{'e1': {'word': 'Antiplatelet Agents', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d777.s1.e1'}, 'e2': {'word': 'Streptokinase', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d777.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d777.s1'}	Use Anticoagulants Antiplatelet Agents Streptase Streptokinase alone combination antiplatelet agents anticoagulants may cause bleeding complications
Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. 	Antiplatelet Agents	antiplatelet agents	none	{'e1': {'word': 'Antiplatelet Agents', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d777.s1.e1'}, 'e2': {'word': 'antiplatelet agents', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d777.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d777.s1'}	Use Anticoagulants Antiplatelet Agents Streptase Streptokinase alone combination antiplatelet agents anticoagulants may cause bleeding complications
Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. 	Antiplatelet Agents	anticoagulants	none	{'e1': {'word': 'Antiplatelet Agents', 'word_index': [(2, 3)], 'id': 'DDI-DrugBank.d777.s1.e1'}, 'e2': {'word': 'anticoagulants', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d777.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d777.s1'}	Use Anticoagulants Antiplatelet Agents Streptase Streptokinase alone combination antiplatelet agents anticoagulants may cause bleeding complications
Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. 	Streptase	Streptokinase	none	{'e1': {'word': 'Streptase', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d777.s1.e2'}, 'e2': {'word': 'Streptokinase', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d777.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d777.s1'}	Use Anticoagulants Antiplatelet Agents Streptase Streptokinase alone combination antiplatelet agents anticoagulants may cause bleeding complications
Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. 	Streptase	antiplatelet agents	effect	{'e1': {'word': 'Streptase', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d777.s1.e2'}, 'e2': {'word': 'antiplatelet agents', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d777.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d777.s1'}	Use Anticoagulants Antiplatelet Agents Streptase Streptokinase alone combination antiplatelet agents anticoagulants may cause bleeding complications
Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. 	Streptase	anticoagulants	effect	{'e1': {'word': 'Streptase', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d777.s1.e2'}, 'e2': {'word': 'anticoagulants', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d777.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d777.s1'}	Use Anticoagulants Antiplatelet Agents Streptase Streptokinase alone combination antiplatelet agents anticoagulants may cause bleeding complications
Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. 	Streptokinase	antiplatelet agents	effect	{'e1': {'word': 'Streptokinase', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d777.s1.e3'}, 'e2': {'word': 'antiplatelet agents', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d777.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d777.s1'}	Use Anticoagulants Antiplatelet Agents Streptase Streptokinase alone combination antiplatelet agents anticoagulants may cause bleeding complications
Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. 	Streptokinase	anticoagulants	effect	{'e1': {'word': 'Streptokinase', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d777.s1.e3'}, 'e2': {'word': 'anticoagulants', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d777.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d777.s1'}	Use Anticoagulants Antiplatelet Agents Streptase Streptokinase alone combination antiplatelet agents anticoagulants may cause bleeding complications
Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. 	antiplatelet agents	anticoagulants	none	{'e1': {'word': 'antiplatelet agents', 'word_index': [(8, 9)], 'id': 'DDI-DrugBank.d777.s1.e4'}, 'e2': {'word': 'anticoagulants', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d777.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d777.s1'}	Use Anticoagulants Antiplatelet Agents Streptase Streptokinase alone combination antiplatelet agents anticoagulants may cause bleeding complications
In the treatment of acute MI, aspirin, when not otherwise contraindicated, should be administered with Streptokinase ( see below ). 	aspirin	Streptokinase	none	{'e1': {'word': 'aspirin', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d777.s3.e0'}, 'e2': {'word': 'Streptokinase', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d777.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d777.s3'}	treatment acute MI aspirin otherwise contraindicated administered Streptokinase see
Anticoagulation and Antiplatelets After Treatment for Myocardial Infarction -- In the treatment of acute myocardial infarction, the use of aspirin has been shown to reduce the incidence of reinfarction and stroke. 	Antiplatelets	aspirin	none	{'e1': {'word': 'Antiplatelets', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d777.s4.e0'}, 'e2': {'word': 'aspirin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d777.s4.e1'}, 'sentence_id': 'DDI-DrugBank.d777.s4'}	Anticoagulation Antiplatelets Treatment Myocardial Infarction treatment acute myocardial infarction use aspirin shown reduce incidence reinfarction stroke
The addition of aspirin to Streptokinase causes a minimal increase in the risk of minor bleeding (3.9% vs. 3.1%), but does not appear to increase the incidence of major bleeding (see	aspirin	Streptokinase	effect	{'e1': {'word': 'aspirin', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d777.s5.e0'}, 'e2': {'word': 'Streptokinase', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d777.s5.e1'}, 'sentence_id': 'DDI-DrugBank.d777.s5'}	addition aspirin Streptokinase causes minimal increase risk minor bleeding NUMBER % vs. NUMBER % appear increase incidence major bleeding see
SKELAXIN may enhance the effects of alcohol, barbiturates and other CNS depressants.	SKELAXIN	alcohol	effect	{'e1': {'word': 'SKELAXIN', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d605.s0.e0'}, 'e2': {'word': 'alcohol', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d605.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d605.s0'}	SKELAXIN may enhance effects alcohol barbiturates CNS depressants
SKELAXIN may enhance the effects of alcohol, barbiturates and other CNS depressants.	SKELAXIN	barbiturates	effect	{'e1': {'word': 'SKELAXIN', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d605.s0.e0'}, 'e2': {'word': 'barbiturates', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d605.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d605.s0'}	SKELAXIN may enhance effects alcohol barbiturates CNS depressants
SKELAXIN may enhance the effects of alcohol, barbiturates and other CNS depressants.	SKELAXIN	CNS depressants	effect	{'e1': {'word': 'SKELAXIN', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d605.s0.e0'}, 'e2': {'word': 'CNS depressants', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d605.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d605.s0'}	SKELAXIN may enhance effects alcohol barbiturates CNS depressants
SKELAXIN may enhance the effects of alcohol, barbiturates and other CNS depressants.	alcohol	barbiturates	none	{'e1': {'word': 'alcohol', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d605.s0.e1'}, 'e2': {'word': 'barbiturates', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d605.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d605.s0'}	SKELAXIN may enhance effects alcohol barbiturates CNS depressants
SKELAXIN may enhance the effects of alcohol, barbiturates and other CNS depressants.	alcohol	CNS depressants	none	{'e1': {'word': 'alcohol', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d605.s0.e1'}, 'e2': {'word': 'CNS depressants', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d605.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d605.s0'}	SKELAXIN may enhance effects alcohol barbiturates CNS depressants
SKELAXIN may enhance the effects of alcohol, barbiturates and other CNS depressants.	barbiturates	CNS depressants	none	{'e1': {'word': 'barbiturates', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d605.s0.e2'}, 'e2': {'word': 'CNS depressants', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d605.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d605.s0'}	SKELAXIN may enhance effects alcohol barbiturates CNS depressants
Sulfoxone may increase the effects of barbiturates, tolbutamide, and uricosurics. 	Sulfoxone	barbiturates	effect	{'e1': {'word': 'Sulfoxone', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d682.s0.e0'}, 'e2': {'word': 'barbiturates', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d682.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d682.s0'}	Sulfoxone may increase effects barbiturates tolbutamide uricosurics
Sulfoxone may increase the effects of barbiturates, tolbutamide, and uricosurics. 	Sulfoxone	tolbutamide	effect	{'e1': {'word': 'Sulfoxone', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d682.s0.e0'}, 'e2': {'word': 'tolbutamide', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d682.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d682.s0'}	Sulfoxone may increase effects barbiturates tolbutamide uricosurics
Sulfoxone may increase the effects of barbiturates, tolbutamide, and uricosurics. 	Sulfoxone	uricosurics	effect	{'e1': {'word': 'Sulfoxone', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d682.s0.e0'}, 'e2': {'word': 'uricosurics', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d682.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d682.s0'}	Sulfoxone may increase effects barbiturates tolbutamide uricosurics
Sulfoxone may increase the effects of barbiturates, tolbutamide, and uricosurics. 	barbiturates	tolbutamide	none	{'e1': {'word': 'barbiturates', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d682.s0.e1'}, 'e2': {'word': 'tolbutamide', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d682.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d682.s0'}	Sulfoxone may increase effects barbiturates tolbutamide uricosurics
Sulfoxone may increase the effects of barbiturates, tolbutamide, and uricosurics. 	barbiturates	uricosurics	none	{'e1': {'word': 'barbiturates', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d682.s0.e1'}, 'e2': {'word': 'uricosurics', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d682.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d682.s0'}	Sulfoxone may increase effects barbiturates tolbutamide uricosurics
Sulfoxone may increase the effects of barbiturates, tolbutamide, and uricosurics. 	tolbutamide	uricosurics	none	{'e1': {'word': 'tolbutamide', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d682.s0.e2'}, 'e2': {'word': 'uricosurics', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d682.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d682.s0'}	Sulfoxone may increase effects barbiturates tolbutamide uricosurics
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	thiazides	cyclosporine	none	{'e1': {'word': 'thiazides', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d682.s1.e0'}, 'e2': {'word': 'cyclosporine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d682.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d682.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	thiazides	sulfonylurea agents	none	{'e1': {'word': 'thiazides', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d682.s1.e0'}, 'e2': {'word': 'sulfonylurea agents', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d682.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d682.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	thiazides	warfarin	none	{'e1': {'word': 'thiazides', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d682.s1.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d682.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d682.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	thiazides	methotrexate	none	{'e1': {'word': 'thiazides', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d682.s1.e0'}, 'e2': {'word': 'methotrexate', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d682.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d682.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	thiazides	methotrexate	none	{'e1': {'word': 'thiazides', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d682.s1.e0'}, 'e2': {'word': 'methotrexate', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d682.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d682.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	thiazides	phenytoin	none	{'e1': {'word': 'thiazides', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d682.s1.e0'}, 'e2': {'word': 'phenytoin', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d682.s1.e6'}, 'sentence_id': 'DDI-DrugBank.d682.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	thiazides	phenytoin	none	{'e1': {'word': 'thiazides', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d682.s1.e0'}, 'e2': {'word': 'phenytoin', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d682.s1.e7'}, 'sentence_id': 'DDI-DrugBank.d682.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	cyclosporine	sulfonylurea agents	none	{'e1': {'word': 'cyclosporine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d682.s1.e1'}, 'e2': {'word': 'sulfonylurea agents', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d682.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d682.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	cyclosporine	warfarin	none	{'e1': {'word': 'cyclosporine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d682.s1.e1'}, 'e2': {'word': 'warfarin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d682.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d682.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	cyclosporine	methotrexate	none	{'e1': {'word': 'cyclosporine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d682.s1.e1'}, 'e2': {'word': 'methotrexate', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d682.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d682.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	cyclosporine	methotrexate	none	{'e1': {'word': 'cyclosporine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d682.s1.e1'}, 'e2': {'word': 'methotrexate', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d682.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d682.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	cyclosporine	phenytoin	none	{'e1': {'word': 'cyclosporine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d682.s1.e1'}, 'e2': {'word': 'phenytoin', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d682.s1.e6'}, 'sentence_id': 'DDI-DrugBank.d682.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	cyclosporine	phenytoin	none	{'e1': {'word': 'cyclosporine', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d682.s1.e1'}, 'e2': {'word': 'phenytoin', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d682.s1.e7'}, 'sentence_id': 'DDI-DrugBank.d682.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	sulfonylurea agents	warfarin	none	{'e1': {'word': 'sulfonylurea agents', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d682.s1.e2'}, 'e2': {'word': 'warfarin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d682.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d682.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	sulfonylurea agents	methotrexate	none	{'e1': {'word': 'sulfonylurea agents', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d682.s1.e2'}, 'e2': {'word': 'methotrexate', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d682.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d682.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	sulfonylurea agents	methotrexate	none	{'e1': {'word': 'sulfonylurea agents', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d682.s1.e2'}, 'e2': {'word': 'methotrexate', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d682.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d682.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	sulfonylurea agents	phenytoin	none	{'e1': {'word': 'sulfonylurea agents', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d682.s1.e2'}, 'e2': {'word': 'phenytoin', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d682.s1.e6'}, 'sentence_id': 'DDI-DrugBank.d682.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	sulfonylurea agents	phenytoin	none	{'e1': {'word': 'sulfonylurea agents', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d682.s1.e2'}, 'e2': {'word': 'phenytoin', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d682.s1.e7'}, 'sentence_id': 'DDI-DrugBank.d682.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	warfarin	methotrexate	none	{'e1': {'word': 'warfarin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d682.s1.e3'}, 'e2': {'word': 'methotrexate', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d682.s1.e4'}, 'sentence_id': 'DDI-DrugBank.d682.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	warfarin	methotrexate	none	{'e1': {'word': 'warfarin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d682.s1.e3'}, 'e2': {'word': 'methotrexate', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d682.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d682.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	warfarin	phenytoin	none	{'e1': {'word': 'warfarin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d682.s1.e3'}, 'e2': {'word': 'phenytoin', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d682.s1.e6'}, 'sentence_id': 'DDI-DrugBank.d682.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	warfarin	phenytoin	none	{'e1': {'word': 'warfarin', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d682.s1.e3'}, 'e2': {'word': 'phenytoin', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d682.s1.e7'}, 'sentence_id': 'DDI-DrugBank.d682.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	methotrexate	methotrexate	none	{'e1': {'word': 'methotrexate', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d682.s1.e4'}, 'e2': {'word': 'methotrexate', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d682.s1.e5'}, 'sentence_id': 'DDI-DrugBank.d682.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	methotrexate	phenytoin	none	{'e1': {'word': 'methotrexate', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d682.s1.e4'}, 'e2': {'word': 'phenytoin', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d682.s1.e6'}, 'sentence_id': 'DDI-DrugBank.d682.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	methotrexate	phenytoin	none	{'e1': {'word': 'methotrexate', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d682.s1.e4'}, 'e2': {'word': 'phenytoin', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d682.s1.e7'}, 'sentence_id': 'DDI-DrugBank.d682.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	methotrexate	phenytoin	none	{'e1': {'word': 'methotrexate', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d682.s1.e5'}, 'e2': {'word': 'phenytoin', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d682.s1.e6'}, 'sentence_id': 'DDI-DrugBank.d682.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	methotrexate	phenytoin	none	{'e1': {'word': 'methotrexate', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d682.s1.e5'}, 'e2': {'word': 'phenytoin', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d682.s1.e7'}, 'sentence_id': 'DDI-DrugBank.d682.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	phenytoin	phenytoin	none	{'e1': {'word': 'phenytoin', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d682.s1.e6'}, 'e2': {'word': 'phenytoin', 'word_index': [(27, 27)], 'id': 'DDI-DrugBank.d682.s1.e7'}, 'sentence_id': 'DDI-DrugBank.d682.s1'}	may also interact thiazides increased thrombocytopenia cyclosporine increased nephrotoxicity sulfonylurea agents increased hypoglycemic response warfarin increased anticoagulant effect methotrexate decreased renal excretion methotrexate phenytoin decreased hepatic clearance phenytoin
Since MEXITIL is a substrate for the metabolic pathways involving CYP2D6 and CYP1A2 enzymes, inhibition or induction of either of these enzymes would be expected to alter mexiletine plasma concentrations. 	MEXITIL	mexiletine	none	{'e1': {'word': 'MEXITIL', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d633.s0.e0'}, 'e2': {'word': 'mexiletine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d633.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d633.s0'}	Since MEXITIL substrate metabolic pathways involving CYP2D6 CYP1A2 enzymes inhibition induction either enzymes would expected alter mexiletine plasma concentrations
In a formal, single-dose interaction study (n = 6 males) the clearance of mexiletine was decreased by 38% following the coadministration of fluvoxamine, an inhibitor of CYP1A2. 	mexiletine	fluvoxamine	mechanism	{'e1': {'word': 'mexiletine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d633.s1.e0'}, 'e2': {'word': 'fluvoxamine', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d633.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d633.s1'}	formal single dose interaction study n = NUMBER males clearance mexiletine decreased NUMBER % following coadministration fluvoxamine inhibitor CYP1A2
In another formal study (n = 8 extensive and n = 7 poor metabolizers of CYP2D6), coadministration of propafenone did not alter the kinetics of mexiletine in the poor CYP2D6 metabolizer group. 	propafenone	mexiletine	none	{'e1': {'word': 'propafenone', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d633.s2.e0'}, 'e2': {'word': 'mexiletine', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d633.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d633.s2'}	another formal study n = NUMBER extensive n = NUMBER poor metabolizers CYP2D6 coadministration propafenone alter kinetics mexiletine poor CYP2D6 metabolizer group
In this crossover steady state study, the pharmacokinetics of propafenone were unaffected in either phenotype by the coadministration of mexiletine. 	propafenone	mexiletine	none	{'e1': {'word': 'propafenone', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d633.s4.e0'}, 'e2': {'word': 'mexiletine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d633.s4.e1'}, 'sentence_id': 'DDI-DrugBank.d633.s4'}	crossover steady state study pharmacokinetics propafenone unaffected either phenotype coadministration mexiletine
Addition of mexiletine to propafenone did not lead to further electrocardiographic parameters changes of QRS, QTc, RR, and PR intervals than propafenone alone. 	mexiletine	propafenone	none	{'e1': {'word': 'mexiletine', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d633.s5.e0'}, 'e2': {'word': 'propafenone', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d633.s5.e1'}, 'sentence_id': 'DDI-DrugBank.d633.s5'}	Addition mexiletine propafenone lead electrocardiographic parameters changes QRS QTc RR PR intervals propafenone alone
Addition of mexiletine to propafenone did not lead to further electrocardiographic parameters changes of QRS, QTc, RR, and PR intervals than propafenone alone. 	mexiletine	propafenone	none	{'e1': {'word': 'mexiletine', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d633.s5.e0'}, 'e2': {'word': 'propafenone', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d633.s5.e2'}, 'sentence_id': 'DDI-DrugBank.d633.s5'}	Addition mexiletine propafenone lead electrocardiographic parameters changes QRS QTc RR PR intervals propafenone alone
Addition of mexiletine to propafenone did not lead to further electrocardiographic parameters changes of QRS, QTc, RR, and PR intervals than propafenone alone. 	propafenone	propafenone	none	{'e1': {'word': 'propafenone', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d633.s5.e1'}, 'e2': {'word': 'propafenone', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d633.s5.e2'}, 'sentence_id': 'DDI-DrugBank.d633.s5'}	Addition mexiletine propafenone lead electrocardiographic parameters changes QRS QTc RR PR intervals propafenone alone
When concomitant administration of either of these two drugs with mexiletine is initiated, the dose of mexiletine should be slowly titrated to desired effect. 	mexiletine	mexiletine	none	{'e1': {'word': 'mexiletine', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d633.s6.e0'}, 'e2': {'word': 'mexiletine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d633.s6.e1'}, 'sentence_id': 'DDI-DrugBank.d633.s6'}	concomitant administration either NUMBER drugs mexiletine initiated dose mexiletine slowly titrated desired effect
In a large compassionate use program Mexitil    has been used concurrently with commonly employed antianginal, antihypertensive, and anticoagulant drugs without observed interactions. 	Mexitil	antihypertensive	none	{'e1': {'word': 'Mexitil', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d633.s7.e0'}, 'e2': {'word': 'antihypertensive', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d633.s7.e1'}, 'sentence_id': 'DDI-DrugBank.d633.s7'}	large compassionate use program Mexitil used concurrently commonly employed antianginal antihypertensive anticoagulant drugs without observed interactions
In a large compassionate use program Mexitil    has been used concurrently with commonly employed antianginal, antihypertensive, and anticoagulant drugs without observed interactions. 	Mexitil	anticoagulant drugs	none	{'e1': {'word': 'Mexitil', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d633.s7.e0'}, 'e2': {'word': 'anticoagulant drugs', 'word_index': [(11, 12)], 'id': 'DDI-DrugBank.d633.s7.e2'}, 'sentence_id': 'DDI-DrugBank.d633.s7'}	large compassionate use program Mexitil used concurrently commonly employed antianginal antihypertensive anticoagulant drugs without observed interactions
In a large compassionate use program Mexitil    has been used concurrently with commonly employed antianginal, antihypertensive, and anticoagulant drugs without observed interactions. 	antihypertensive	anticoagulant drugs	none	{'e1': {'word': 'antihypertensive', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d633.s7.e1'}, 'e2': {'word': 'anticoagulant drugs', 'word_index': [(11, 12)], 'id': 'DDI-DrugBank.d633.s7.e2'}, 'sentence_id': 'DDI-DrugBank.d633.s7'}	large compassionate use program Mexitil used concurrently commonly employed antianginal antihypertensive anticoagulant drugs without observed interactions
A variety of antiarrhythmics such as quinidine or propranolol were also added, sometimes with improved control of ventricular ectopy. 	antiarrhythmics	quinidine	none	{'e1': {'word': 'antiarrhythmics', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d633.s8.e0'}, 'e2': {'word': 'quinidine', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d633.s8.e1'}, 'sentence_id': 'DDI-DrugBank.d633.s8'}	variety antiarrhythmics quinidine propranolol also added sometimes improved control ventricular ectopy
A variety of antiarrhythmics such as quinidine or propranolol were also added, sometimes with improved control of ventricular ectopy. 	antiarrhythmics	propranolol	none	{'e1': {'word': 'antiarrhythmics', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d633.s8.e0'}, 'e2': {'word': 'propranolol', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d633.s8.e2'}, 'sentence_id': 'DDI-DrugBank.d633.s8'}	variety antiarrhythmics quinidine propranolol also added sometimes improved control ventricular ectopy
A variety of antiarrhythmics such as quinidine or propranolol were also added, sometimes with improved control of ventricular ectopy. 	quinidine	propranolol	none	{'e1': {'word': 'quinidine', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d633.s8.e1'}, 'e2': {'word': 'propranolol', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d633.s8.e2'}, 'sentence_id': 'DDI-DrugBank.d633.s8'}	variety antiarrhythmics quinidine propranolol also added sometimes improved control ventricular ectopy
When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. 	phenytoin	rifampin	none	{'e1': {'word': 'phenytoin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d633.s9.e0'}, 'e2': {'word': 'rifampin', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d633.s9.e1'}, 'sentence_id': 'DDI-DrugBank.d633.s9'}	phenytoin hepatic enzyme inducers rifampin phenobarbital taken concurrently Mexitil lowered Mexitil plasma levels reported
When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. 	phenytoin	phenobarbital	none	{'e1': {'word': 'phenytoin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d633.s9.e0'}, 'e2': {'word': 'phenobarbital', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d633.s9.e2'}, 'sentence_id': 'DDI-DrugBank.d633.s9'}	phenytoin hepatic enzyme inducers rifampin phenobarbital taken concurrently Mexitil lowered Mexitil plasma levels reported
When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. 	phenytoin	Mexitil	mechanism	{'e1': {'word': 'phenytoin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d633.s9.e0'}, 'e2': {'word': 'Mexitil', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d633.s9.e3'}, 'sentence_id': 'DDI-DrugBank.d633.s9'}	phenytoin hepatic enzyme inducers rifampin phenobarbital taken concurrently Mexitil lowered Mexitil plasma levels reported
When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. 	phenytoin	Mexitil	none	{'e1': {'word': 'phenytoin', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d633.s9.e0'}, 'e2': {'word': 'Mexitil', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d633.s9.e4'}, 'sentence_id': 'DDI-DrugBank.d633.s9'}	phenytoin hepatic enzyme inducers rifampin phenobarbital taken concurrently Mexitil lowered Mexitil plasma levels reported
When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. 	rifampin	phenobarbital	none	{'e1': {'word': 'rifampin', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d633.s9.e1'}, 'e2': {'word': 'phenobarbital', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d633.s9.e2'}, 'sentence_id': 'DDI-DrugBank.d633.s9'}	phenytoin hepatic enzyme inducers rifampin phenobarbital taken concurrently Mexitil lowered Mexitil plasma levels reported
When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. 	rifampin	Mexitil	mechanism	{'e1': {'word': 'rifampin', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d633.s9.e1'}, 'e2': {'word': 'Mexitil', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d633.s9.e3'}, 'sentence_id': 'DDI-DrugBank.d633.s9'}	phenytoin hepatic enzyme inducers rifampin phenobarbital taken concurrently Mexitil lowered Mexitil plasma levels reported
When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. 	rifampin	Mexitil	none	{'e1': {'word': 'rifampin', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d633.s9.e1'}, 'e2': {'word': 'Mexitil', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d633.s9.e4'}, 'sentence_id': 'DDI-DrugBank.d633.s9'}	phenytoin hepatic enzyme inducers rifampin phenobarbital taken concurrently Mexitil lowered Mexitil plasma levels reported
When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. 	phenobarbital	Mexitil	mechanism	{'e1': {'word': 'phenobarbital', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d633.s9.e2'}, 'e2': {'word': 'Mexitil', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d633.s9.e3'}, 'sentence_id': 'DDI-DrugBank.d633.s9'}	phenytoin hepatic enzyme inducers rifampin phenobarbital taken concurrently Mexitil lowered Mexitil plasma levels reported
When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. 	phenobarbital	Mexitil	none	{'e1': {'word': 'phenobarbital', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d633.s9.e2'}, 'e2': {'word': 'Mexitil', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d633.s9.e4'}, 'sentence_id': 'DDI-DrugBank.d633.s9'}	phenytoin hepatic enzyme inducers rifampin phenobarbital taken concurrently Mexitil lowered Mexitil plasma levels reported
When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. 	Mexitil	Mexitil	none	{'e1': {'word': 'Mexitil', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d633.s9.e3'}, 'e2': {'word': 'Mexitil', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d633.s9.e4'}, 'sentence_id': 'DDI-DrugBank.d633.s9'}	phenytoin hepatic enzyme inducers rifampin phenobarbital taken concurrently Mexitil lowered Mexitil plasma levels reported
In a formal study, benzodiazepines were shown not to affect Mexitil    plasma concentrations. 	benzodiazepines	Mexitil	none	{'e1': {'word': 'benzodiazepines', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d633.s11.e0'}, 'e2': {'word': 'Mexitil', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d633.s11.e1'}, 'sentence_id': 'DDI-DrugBank.d633.s11'}	formal study benzodiazepines shown affect Mexitil plasma concentrations
ECG intervals (PR, QRS, and QT) were not affected by concurrent Mexitil    and digoxin, diuretics, or propranolol. 	Mexitil	digoxin	none	{'e1': {'word': 'Mexitil', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d633.s12.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d633.s12.e1'}, 'sentence_id': 'DDI-DrugBank.d633.s12'}	ECG intervals PR QRS QT affected concurrent Mexitil digoxin diuretics propranolol
ECG intervals (PR, QRS, and QT) were not affected by concurrent Mexitil    and digoxin, diuretics, or propranolol. 	Mexitil	diuretics	none	{'e1': {'word': 'Mexitil', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d633.s12.e0'}, 'e2': {'word': 'diuretics', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d633.s12.e2'}, 'sentence_id': 'DDI-DrugBank.d633.s12'}	ECG intervals PR QRS QT affected concurrent Mexitil digoxin diuretics propranolol
ECG intervals (PR, QRS, and QT) were not affected by concurrent Mexitil    and digoxin, diuretics, or propranolol. 	Mexitil	propranolol	none	{'e1': {'word': 'Mexitil', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d633.s12.e0'}, 'e2': {'word': 'propranolol', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d633.s12.e3'}, 'sentence_id': 'DDI-DrugBank.d633.s12'}	ECG intervals PR QRS QT affected concurrent Mexitil digoxin diuretics propranolol
ECG intervals (PR, QRS, and QT) were not affected by concurrent Mexitil    and digoxin, diuretics, or propranolol. 	digoxin	diuretics	none	{'e1': {'word': 'digoxin', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d633.s12.e1'}, 'e2': {'word': 'diuretics', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d633.s12.e2'}, 'sentence_id': 'DDI-DrugBank.d633.s12'}	ECG intervals PR QRS QT affected concurrent Mexitil digoxin diuretics propranolol
ECG intervals (PR, QRS, and QT) were not affected by concurrent Mexitil    and digoxin, diuretics, or propranolol. 	digoxin	propranolol	none	{'e1': {'word': 'digoxin', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d633.s12.e1'}, 'e2': {'word': 'propranolol', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d633.s12.e3'}, 'sentence_id': 'DDI-DrugBank.d633.s12'}	ECG intervals PR QRS QT affected concurrent Mexitil digoxin diuretics propranolol
ECG intervals (PR, QRS, and QT) were not affected by concurrent Mexitil    and digoxin, diuretics, or propranolol. 	diuretics	propranolol	none	{'e1': {'word': 'diuretics', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d633.s12.e2'}, 'e2': {'word': 'propranolol', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d633.s12.e3'}, 'sentence_id': 'DDI-DrugBank.d633.s12'}	ECG intervals PR QRS QT affected concurrent Mexitil digoxin diuretics propranolol
Concurrent administration of cimetidine and Mexitil    has been reported to increase, decrease, or leave unchanged Mexitil    plasma levels; 	cimetidine	Mexitil	mechanism	{'e1': {'word': 'cimetidine', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d633.s13.e0'}, 'e2': {'word': 'Mexitil', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d633.s13.e1'}, 'sentence_id': 'DDI-DrugBank.d633.s13'}	Concurrent administration cimetidine Mexitil reported increase decrease leave unchanged Mexitil plasma levels
Concurrent administration of cimetidine and Mexitil    has been reported to increase, decrease, or leave unchanged Mexitil    plasma levels; 	cimetidine	Mexitil	none	{'e1': {'word': 'cimetidine', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d633.s13.e0'}, 'e2': {'word': 'Mexitil', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d633.s13.e2'}, 'sentence_id': 'DDI-DrugBank.d633.s13'}	Concurrent administration cimetidine Mexitil reported increase decrease leave unchanged Mexitil plasma levels
Concurrent administration of cimetidine and Mexitil    has been reported to increase, decrease, or leave unchanged Mexitil    plasma levels; 	Mexitil	Mexitil	none	{'e1': {'word': 'Mexitil', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d633.s13.e1'}, 'e2': {'word': 'Mexitil', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d633.s13.e2'}, 'sentence_id': 'DDI-DrugBank.d633.s13'}	Concurrent administration cimetidine Mexitil reported increase decrease leave unchanged Mexitil plasma levels
Mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels. 	Mexitil	digoxin	none	{'e1': {'word': 'Mexitil', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d633.s15.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d633.s15.e1'}, 'sentence_id': 'DDI-DrugBank.d633.s15'}	Mexitil alter serum digoxin levels magnesium aluminum hydroxide used treat gastrointestinal symptoms due Mexitil reported lower serum digoxin levels
Mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels. 	Mexitil	magnesium-aluminum hydroxide	none	{'e1': {'word': 'Mexitil', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d633.s15.e0'}, 'e2': {'word': 'magnesium-aluminum hydroxide', 'word_index': [(5, 7)], 'id': 'DDI-DrugBank.d633.s15.e2'}, 'sentence_id': 'DDI-DrugBank.d633.s15'}	Mexitil alter serum digoxin levels magnesium aluminum hydroxide used treat gastrointestinal symptoms due Mexitil reported lower serum digoxin levels
Mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels. 	Mexitil	Mexitil	none	{'e1': {'word': 'Mexitil', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d633.s15.e0'}, 'e2': {'word': 'Mexitil', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d633.s15.e3'}, 'sentence_id': 'DDI-DrugBank.d633.s15'}	Mexitil alter serum digoxin levels magnesium aluminum hydroxide used treat gastrointestinal symptoms due Mexitil reported lower serum digoxin levels
Mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels. 	Mexitil	digoxin	none	{'e1': {'word': 'Mexitil', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d633.s15.e0'}, 'e2': {'word': 'digoxin', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d633.s15.e4'}, 'sentence_id': 'DDI-DrugBank.d633.s15'}	Mexitil alter serum digoxin levels magnesium aluminum hydroxide used treat gastrointestinal symptoms due Mexitil reported lower serum digoxin levels
Mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels. 	digoxin	magnesium-aluminum hydroxide	none	{'e1': {'word': 'digoxin', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d633.s15.e1'}, 'e2': {'word': 'magnesium-aluminum hydroxide', 'word_index': [(5, 7)], 'id': 'DDI-DrugBank.d633.s15.e2'}, 'sentence_id': 'DDI-DrugBank.d633.s15'}	Mexitil alter serum digoxin levels magnesium aluminum hydroxide used treat gastrointestinal symptoms due Mexitil reported lower serum digoxin levels
Mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels. 	digoxin	Mexitil	none	{'e1': {'word': 'digoxin', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d633.s15.e1'}, 'e2': {'word': 'Mexitil', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d633.s15.e3'}, 'sentence_id': 'DDI-DrugBank.d633.s15'}	Mexitil alter serum digoxin levels magnesium aluminum hydroxide used treat gastrointestinal symptoms due Mexitil reported lower serum digoxin levels
Mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels. 	digoxin	digoxin	none	{'e1': {'word': 'digoxin', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d633.s15.e1'}, 'e2': {'word': 'digoxin', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d633.s15.e4'}, 'sentence_id': 'DDI-DrugBank.d633.s15'}	Mexitil alter serum digoxin levels magnesium aluminum hydroxide used treat gastrointestinal symptoms due Mexitil reported lower serum digoxin levels
Mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels. 	magnesium-aluminum hydroxide	Mexitil	none	{'e1': {'word': 'magnesium-aluminum hydroxide', 'word_index': [(5, 7)], 'id': 'DDI-DrugBank.d633.s15.e2'}, 'e2': {'word': 'Mexitil', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d633.s15.e3'}, 'sentence_id': 'DDI-DrugBank.d633.s15'}	Mexitil alter serum digoxin levels magnesium aluminum hydroxide used treat gastrointestinal symptoms due Mexitil reported lower serum digoxin levels
Mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels. 	magnesium-aluminum hydroxide	digoxin	mechanism	{'e1': {'word': 'magnesium-aluminum hydroxide', 'word_index': [(5, 7)], 'id': 'DDI-DrugBank.d633.s15.e2'}, 'e2': {'word': 'digoxin', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d633.s15.e4'}, 'sentence_id': 'DDI-DrugBank.d633.s15'}	Mexitil alter serum digoxin levels magnesium aluminum hydroxide used treat gastrointestinal symptoms due Mexitil reported lower serum digoxin levels
Mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels. 	Mexitil	digoxin	none	{'e1': {'word': 'Mexitil', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d633.s15.e3'}, 'e2': {'word': 'digoxin', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d633.s15.e4'}, 'sentence_id': 'DDI-DrugBank.d633.s15'}	Mexitil alter serum digoxin levels magnesium aluminum hydroxide used treat gastrointestinal symptoms due Mexitil reported lower serum digoxin levels
Concurrent use of Mexitil    and theophylline may lead to increased plasma theophylline levels. 	Mexitil	theophylline	mechanism	{'e1': {'word': 'Mexitil', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d633.s16.e0'}, 'e2': {'word': 'theophylline', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d633.s16.e1'}, 'sentence_id': 'DDI-DrugBank.d633.s16'}	Concurrent use Mexitil theophylline may lead increased plasma theophylline levels
Concurrent use of Mexitil    and theophylline may lead to increased plasma theophylline levels. 	Mexitil	theophylline	none	{'e1': {'word': 'Mexitil', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d633.s16.e0'}, 'e2': {'word': 'theophylline', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d633.s16.e2'}, 'sentence_id': 'DDI-DrugBank.d633.s16'}	Concurrent use Mexitil theophylline may lead increased plasma theophylline levels
Concurrent use of Mexitil    and theophylline may lead to increased plasma theophylline levels. 	theophylline	theophylline	none	{'e1': {'word': 'theophylline', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d633.s16.e1'}, 'e2': {'word': 'theophylline', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d633.s16.e2'}, 'sentence_id': 'DDI-DrugBank.d633.s16'}	Concurrent use Mexitil theophylline may lead increased plasma theophylline levels
This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. 	Mexitil	Theophylline	none	{'e1': {'word': 'Mexitil', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d633.s18.e0'}, 'e2': {'word': 'Theophylline', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d633.s18.e1'}, 'sentence_id': 'DDI-DrugBank.d633.s18'}	increase observed first test point second day starting Mexitil Theophylline plasma levels returned pre Mexitil values within NUMBER hours discontinuing Mexitil Mexitil theophylline used concurrently theophylline blood levels monitored particularly Mexitil dose changed
This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. 	Mexitil	Mexitil	none	{'e1': {'word': 'Mexitil', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d633.s18.e0'}, 'e2': {'word': 'Mexitil', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d633.s18.e2'}, 'sentence_id': 'DDI-DrugBank.d633.s18'}	increase observed first test point second day starting Mexitil Theophylline plasma levels returned pre Mexitil values within NUMBER hours discontinuing Mexitil Mexitil theophylline used concurrently theophylline blood levels monitored particularly Mexitil dose changed
This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. 	Mexitil	Mexitil	none	{'e1': {'word': 'Mexitil', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d633.s18.e0'}, 'e2': {'word': 'Mexitil', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d633.s18.e3'}, 'sentence_id': 'DDI-DrugBank.d633.s18'}	increase observed first test point second day starting Mexitil Theophylline plasma levels returned pre Mexitil values within NUMBER hours discontinuing Mexitil Mexitil theophylline used concurrently theophylline blood levels monitored particularly Mexitil dose changed
This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. 	Mexitil	Mexitil	none	{'e1': {'word': 'Mexitil', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d633.s18.e0'}, 'e2': {'word': 'Mexitil', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d633.s18.e4'}, 'sentence_id': 'DDI-DrugBank.d633.s18'}	increase observed first test point second day starting Mexitil Theophylline plasma levels returned pre Mexitil values within NUMBER hours discontinuing Mexitil Mexitil theophylline used concurrently theophylline blood levels monitored particularly Mexitil dose changed
This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. 	Mexitil	theophylline	none	{'e1': {'word': 'Mexitil', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d633.s18.e0'}, 'e2': {'word': 'theophylline', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d633.s18.e5'}, 'sentence_id': 'DDI-DrugBank.d633.s18'}	increase observed first test point second day starting Mexitil Theophylline plasma levels returned pre Mexitil values within NUMBER hours discontinuing Mexitil Mexitil theophylline used concurrently theophylline blood levels monitored particularly Mexitil dose changed
This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. 	Mexitil	theophylline	none	{'e1': {'word': 'Mexitil', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d633.s18.e0'}, 'e2': {'word': 'theophylline', 'word_index': [(25, 25)], 'id': 'DDI-DrugBank.d633.s18.e6'}, 'sentence_id': 'DDI-DrugBank.d633.s18'}	increase observed first test point second day starting Mexitil Theophylline plasma levels returned pre Mexitil values within NUMBER hours discontinuing Mexitil Mexitil theophylline used concurrently theophylline blood levels monitored particularly Mexitil dose changed
This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. 	Mexitil	Mexitil	none	{'e1': {'word': 'Mexitil', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d633.s18.e0'}, 'e2': {'word': 'Mexitil', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d633.s18.e7'}, 'sentence_id': 'DDI-DrugBank.d633.s18'}	increase observed first test point second day starting Mexitil Theophylline plasma levels returned pre Mexitil values within NUMBER hours discontinuing Mexitil Mexitil theophylline used concurrently theophylline blood levels monitored particularly Mexitil dose changed
This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. 	Theophylline	Mexitil	none	{'e1': {'word': 'Theophylline', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d633.s18.e1'}, 'e2': {'word': 'Mexitil', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d633.s18.e2'}, 'sentence_id': 'DDI-DrugBank.d633.s18'}	increase observed first test point second day starting Mexitil Theophylline plasma levels returned pre- Mexitil values within NUMBER hours discontinuing Mexitil Mexitil theophylline used concurrently theophylline blood levels monitored particularly Mexitil dose changed
This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. 	Theophylline	Mexitil	mechanism	{'e1': {'word': 'Theophylline', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d633.s18.e1'}, 'e2': {'word': 'Mexitil', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d633.s18.e3'}, 'sentence_id': 'DDI-DrugBank.d633.s18'}	increase observed first test point second day starting Mexitil Theophylline plasma levels returned pre Mexitil values within NUMBER hours discontinuing Mexitil Mexitil theophylline used concurrently theophylline blood levels monitored particularly Mexitil dose changed
This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. 	Theophylline	Mexitil	none	{'e1': {'word': 'Theophylline', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d633.s18.e1'}, 'e2': {'word': 'Mexitil', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d633.s18.e4'}, 'sentence_id': 'DDI-DrugBank.d633.s18'}	increase observed first test point second day starting Mexitil Theophylline plasma levels returned pre Mexitil values within NUMBER hours discontinuing Mexitil Mexitil theophylline used concurrently theophylline blood levels monitored particularly Mexitil dose changed
This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. 	Theophylline	theophylline	none	{'e1': {'word': 'Theophylline', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d633.s18.e1'}, 'e2': {'word': 'theophylline', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d633.s18.e5'}, 'sentence_id': 'DDI-DrugBank.d633.s18'}	increase observed first test point second day starting Mexitil Theophylline plasma levels returned pre Mexitil values within NUMBER hours discontinuing Mexitil Mexitil theophylline used concurrently theophylline blood levels monitored particularly Mexitil dose changed
This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. 	Theophylline	theophylline	none	{'e1': {'word': 'Theophylline', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d633.s18.e1'}, 'e2': {'word': 'theophylline', 'word_index': [(25, 25)], 'id': 'DDI-DrugBank.d633.s18.e6'}, 'sentence_id': 'DDI-DrugBank.d633.s18'}	increase observed first test point second day starting Mexitil Theophylline plasma levels returned pre Mexitil values within NUMBER hours discontinuing Mexitil Mexitil theophylline used concurrently theophylline blood levels monitored particularly Mexitil dose changed
This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. 	Theophylline	Mexitil	none	{'e1': {'word': 'Theophylline', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d633.s18.e1'}, 'e2': {'word': 'Mexitil', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d633.s18.e7'}, 'sentence_id': 'DDI-DrugBank.d633.s18'}	increase observed first test point second day starting Mexitil Theophylline plasma levels returned pre Mexitil values within NUMBER hours discontinuing Mexitil Mexitil theophylline used concurrently theophylline blood levels monitored particularly Mexitil dose changed
This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. 	Mexitil	Mexitil	none	{'e1': {'word': 'Mexitil', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d633.s18.e2'}, 'e2': {'word': 'Mexitil', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d633.s18.e3'}, 'sentence_id': 'DDI-DrugBank.d633.s18'}	increase observed first test point second day starting Mexitil Theophylline plasma levels returned pre Mexitil values within NUMBER hours discontinuing Mexitil Mexitil theophylline used concurrently theophylline blood levels monitored particularly Mexitil dose changed
This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. 	Mexitil	Mexitil	none	{'e1': {'word': 'Mexitil', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d633.s18.e2'}, 'e2': {'word': 'Mexitil', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d633.s18.e4'}, 'sentence_id': 'DDI-DrugBank.d633.s18'}	increase observed first test point second day starting Mexitil Theophylline plasma levels returned pre Mexitil values within NUMBER hours discontinuing Mexitil Mexitil theophylline used concurrently theophylline blood levels monitored particularly Mexitil dose changed
This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. 	Mexitil	theophylline	none	{'e1': {'word': 'Mexitil', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d633.s18.e2'}, 'e2': {'word': 'theophylline', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d633.s18.e5'}, 'sentence_id': 'DDI-DrugBank.d633.s18'}	increase observed first test point second day starting Mexitil Theophylline plasma levels returned pre Mexitil values within NUMBER hours discontinuing Mexitil Mexitil theophylline used concurrently theophylline blood levels monitored particularly Mexitil dose changed
This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. 	Mexitil	theophylline	none	{'e1': {'word': 'Mexitil', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d633.s18.e2'}, 'e2': {'word': 'theophylline', 'word_index': [(25, 25)], 'id': 'DDI-DrugBank.d633.s18.e6'}, 'sentence_id': 'DDI-DrugBank.d633.s18'}	increase observed first test point second day starting Mexitil Theophylline plasma levels returned pre Mexitil values within NUMBER hours discontinuing Mexitil Mexitil theophylline used concurrently theophylline blood levels monitored particularly Mexitil dose changed
This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. 	Mexitil	Mexitil	none	{'e1': {'word': 'Mexitil', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d633.s18.e2'}, 'e2': {'word': 'Mexitil', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d633.s18.e7'}, 'sentence_id': 'DDI-DrugBank.d633.s18'}	increase observed first test point second day starting Mexitil Theophylline plasma levels returned pre Mexitil values within NUMBER hours discontinuing Mexitil Mexitil theophylline used concurrently theophylline blood levels monitored particularly Mexitil dose changed
This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. 	Mexitil	Mexitil	none	{'e1': {'word': 'Mexitil', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d633.s18.e3'}, 'e2': {'word': 'Mexitil', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d633.s18.e4'}, 'sentence_id': 'DDI-DrugBank.d633.s18'}	increase observed first test point second day starting Mexitil Theophylline plasma levels returned pre Mexitil values within NUMBER hours discontinuing Mexitil Mexitil theophylline used concurrently theophylline blood levels monitored particularly Mexitil dose changed
This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. 	Mexitil	theophylline	none	{'e1': {'word': 'Mexitil', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d633.s18.e3'}, 'e2': {'word': 'theophylline', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d633.s18.e5'}, 'sentence_id': 'DDI-DrugBank.d633.s18'}	increase observed first test point second day starting Mexitil Theophylline plasma levels returned pre Mexitil values within NUMBER hours discontinuing Mexitil Mexitil theophylline used concurrently theophylline blood levels monitored particularly Mexitil dose changed
This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. 	Mexitil	theophylline	none	{'e1': {'word': 'Mexitil', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d633.s18.e3'}, 'e2': {'word': 'theophylline', 'word_index': [(25, 25)], 'id': 'DDI-DrugBank.d633.s18.e6'}, 'sentence_id': 'DDI-DrugBank.d633.s18'}	increase observed first test point second day starting Mexitil Theophylline plasma levels returned pre Mexitil values within NUMBER hours discontinuing Mexitil Mexitil theophylline used concurrently theophylline blood levels monitored particularly Mexitil dose changed
This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. 	Mexitil	Mexitil	none	{'e1': {'word': 'Mexitil', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d633.s18.e3'}, 'e2': {'word': 'Mexitil', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d633.s18.e7'}, 'sentence_id': 'DDI-DrugBank.d633.s18'}	increase observed first test point second day starting Mexitil Theophylline plasma levels returned pre Mexitil values within NUMBER hours discontinuing Mexitil Mexitil theophylline used concurrently theophylline blood levels monitored particularly Mexitil dose changed
This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. 	Mexitil	theophylline	advise	{'e1': {'word': 'Mexitil', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d633.s18.e4'}, 'e2': {'word': 'theophylline', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d633.s18.e5'}, 'sentence_id': 'DDI-DrugBank.d633.s18'}	increase observed first test point second day starting Mexitil Theophylline plasma levels returned pre Mexitil values within NUMBER hours discontinuing Mexitil Mexitil theophylline used concurrently theophylline blood levels monitored particularly Mexitil dose changed
This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. 	Mexitil	theophylline	none	{'e1': {'word': 'Mexitil', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d633.s18.e4'}, 'e2': {'word': 'theophylline', 'word_index': [(25, 25)], 'id': 'DDI-DrugBank.d633.s18.e6'}, 'sentence_id': 'DDI-DrugBank.d633.s18'}	increase observed first test point second day starting Mexitil Theophylline plasma levels returned pre Mexitil values within NUMBER hours discontinuing Mexitil Mexitil theophylline used concurrently theophylline blood levels monitored particularly Mexitil dose changed
This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. 	Mexitil	Mexitil	none	{'e1': {'word': 'Mexitil', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d633.s18.e4'}, 'e2': {'word': 'Mexitil', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d633.s18.e7'}, 'sentence_id': 'DDI-DrugBank.d633.s18'}	increase observed first test point second day starting Mexitil Theophylline plasma levels returned pre Mexitil values within NUMBER hours discontinuing Mexitil Mexitil theophylline used concurrently theophylline blood levels monitored particularly Mexitil dose changed
This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. 	theophylline	theophylline	none	{'e1': {'word': 'theophylline', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d633.s18.e5'}, 'e2': {'word': 'theophylline', 'word_index': [(25, 25)], 'id': 'DDI-DrugBank.d633.s18.e6'}, 'sentence_id': 'DDI-DrugBank.d633.s18'}	increase observed first test point second day starting Mexitil Theophylline plasma levels returned pre Mexitil values within NUMBER hours discontinuing Mexitil Mexitil theophylline used concurrently theophylline blood levels monitored particularly Mexitil dose changed
This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. 	theophylline	Mexitil	none	{'e1': {'word': 'theophylline', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d633.s18.e5'}, 'e2': {'word': 'Mexitil', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d633.s18.e7'}, 'sentence_id': 'DDI-DrugBank.d633.s18'}	increase observed first test point second day starting Mexitil Theophylline plasma levels returned pre Mexitil values within NUMBER hours discontinuing Mexitil Mexitil theophylline used concurrently theophylline blood levels monitored particularly Mexitil dose changed
This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. 	theophylline	Mexitil	none	{'e1': {'word': 'theophylline', 'word_index': [(25, 25)], 'id': 'DDI-DrugBank.d633.s18.e6'}, 'e2': {'word': 'Mexitil', 'word_index': [(30, 30)], 'id': 'DDI-DrugBank.d633.s18.e7'}, 'sentence_id': 'DDI-DrugBank.d633.s18'}	increase observed first test point second day starting Mexitil Theophylline plasma levels returned pre Mexitil values within NUMBER hours discontinuing Mexitil Mexitil theophylline used concurrently theophylline blood levels monitored particularly Mexitil dose changed
Additionally, in one controlled study in five normal subjects and seven patients, the clearance of caffeine was decreased 50% following the administration of Mexitil   .	caffeine	Mexitil	mechanism	{'e1': {'word': 'caffeine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d633.s20.e0'}, 'e2': {'word': 'Mexitil', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d633.s20.e1'}, 'sentence_id': 'DDI-DrugBank.d633.s20'}	Additionally NUMBER controlled study NUMBER normal subjects NUMBER patients clearance caffeine decreased NUMBER % following administration Mexitil
The CNS-depressant effect of propoxyphene is additive with that of other CNS depressants, including alcohol. 	propoxyphene	CNS depressants	effect	{'e1': {'word': 'propoxyphene', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d690.s0.e0'}, 'e2': {'word': 'CNS depressants', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d690.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d690.s0'}	CNS depressant effect propoxyphene additive CNS depressants including alcohol
The CNS-depressant effect of propoxyphene is additive with that of other CNS depressants, including alcohol. 	propoxyphene	alcohol	effect	{'e1': {'word': 'propoxyphene', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d690.s0.e0'}, 'e2': {'word': 'alcohol', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d690.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d690.s0'}	CNS depressant effect propoxyphene additive CNS depressants including alcohol
The CNS-depressant effect of propoxyphene is additive with that of other CNS depressants, including alcohol. 	CNS depressants	alcohol	none	{'e1': {'word': 'CNS depressants', 'word_index': [(5, 6)], 'id': 'DDI-DrugBank.d690.s0.e1'}, 'e2': {'word': 'alcohol', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d690.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d690.s0'}	CNS depressant effect propoxyphene additive CNS depressants including alcohol
Such occurrences have been reported when propoxyphene was administered to patients on antidepressants, anticonvulsants, or warfarin-like drugs. 	propoxyphene	antidepressants	none	{'e1': {'word': 'propoxyphene', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d690.s3.e0'}, 'e2': {'word': 'antidepressants', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d690.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d690.s3'}	occurrences reported propoxyphene administered patients antidepressants anticonvulsants warfarin like drugs
Such occurrences have been reported when propoxyphene was administered to patients on antidepressants, anticonvulsants, or warfarin-like drugs. 	propoxyphene	anticonvulsants	none	{'e1': {'word': 'propoxyphene', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d690.s3.e0'}, 'e2': {'word': 'anticonvulsants', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d690.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d690.s3'}	occurrences reported propoxyphene administered patients antidepressants anticonvulsants warfarin like drugs
Such occurrences have been reported when propoxyphene was administered to patients on antidepressants, anticonvulsants, or warfarin-like drugs. 	propoxyphene	warfarin	none	{'e1': {'word': 'propoxyphene', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d690.s3.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d690.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d690.s3'}	occurrences reported propoxyphene administered patients antidepressants anticonvulsants warfarin like drugs
Such occurrences have been reported when propoxyphene was administered to patients on antidepressants, anticonvulsants, or warfarin-like drugs. 	antidepressants	anticonvulsants	none	{'e1': {'word': 'antidepressants', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d690.s3.e1'}, 'e2': {'word': 'anticonvulsants', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d690.s3.e2'}, 'sentence_id': 'DDI-DrugBank.d690.s3'}	occurrences reported propoxyphene administered patients antidepressants anticonvulsants warfarin like drugs
Such occurrences have been reported when propoxyphene was administered to patients on antidepressants, anticonvulsants, or warfarin-like drugs. 	antidepressants	warfarin	none	{'e1': {'word': 'antidepressants', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d690.s3.e1'}, 'e2': {'word': 'warfarin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d690.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d690.s3'}	occurrences reported propoxyphene administered patients antidepressants anticonvulsants warfarin like drugs
Such occurrences have been reported when propoxyphene was administered to patients on antidepressants, anticonvulsants, or warfarin-like drugs. 	anticonvulsants	warfarin	none	{'e1': {'word': 'anticonvulsants', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d690.s3.e2'}, 'e2': {'word': 'warfarin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d690.s3.e3'}, 'sentence_id': 'DDI-DrugBank.d690.s3'}	occurrences reported propoxyphene administered patients antidepressants anticonvulsants warfarin like drugs
A study published in 2002 found that vigabatrin causes a statistically significant increase in plasma clearance of carbamazepine. 	vigabatrin	carbamazepine	mechanism	{'e1': {'word': 'vigabatrin', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d613.s0.e0'}, 'e2': {'word': 'carbamazepine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d613.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d613.s0'}	study published NUMBER found vigabatrin causes statistically significant increase plasma clearance carbamazepine
In 1984, Drs Rimmer and Richens at the University of Wales reported that administering vigabatrin with phenytoin lowered the serum phenytoin concentration in patients with treatment-resistant epilepsy. 	vigabatrin	phenytoin	mechanism	{'e1': {'word': 'vigabatrin', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d613.s1.e0'}, 'e2': {'word': 'phenytoin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d613.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d613.s1'}	NUMBER Drs Rimmer Richens University Wales reported administering vigabatrin phenytoin lowered serum phenytoin concentration patients treatment resistant epilepsy
In 1984, Drs Rimmer and Richens at the University of Wales reported that administering vigabatrin with phenytoin lowered the serum phenytoin concentration in patients with treatment-resistant epilepsy. 	vigabatrin	phenytoin	none	{'e1': {'word': 'vigabatrin', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d613.s1.e0'}, 'e2': {'word': 'phenytoin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d613.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d613.s1'}	NUMBER Drs Rimmer Richens University Wales reported administering vigabatrin phenytoin lowered serum phenytoin concentration patients treatment resistant epilepsy
In 1984, Drs Rimmer and Richens at the University of Wales reported that administering vigabatrin with phenytoin lowered the serum phenytoin concentration in patients with treatment-resistant epilepsy. 	phenytoin	phenytoin	none	{'e1': {'word': 'phenytoin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d613.s1.e1'}, 'e2': {'word': 'phenytoin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d613.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d613.s1'}	NUMBER Drs Rimmer Richens University Wales reported administering vigabatrin phenytoin lowered serum phenytoin concentration patients treatment resistant epilepsy
Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents. 	reserpine	beta-blocking agents	effect	{'e1': {'word': 'reserpine', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d666.s0.e0'}, 'e2': {'word': 'beta-blocking agents', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d666.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d666.s0'}	Catecholamine depleting drugs e.g. reserpine may additive effect given beta-blocking agents
Pindolol has been used with a variety of antihypertensive agents, including hydrochlorothiazide, hydralazine, and guanethidine without unexpected adverse interactions. 	Pindolol	antihypertensive agents	none	{'e1': {'word': 'Pindolol', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d666.s2.e0'}, 'e2': {'word': 'antihypertensive agents', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d666.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d666.s2'}	Pindolol used variety antihypertensive agents including hydrochlorothiazide hydralazine guanethidine without unexpected adverse interactions
Pindolol has been used with a variety of antihypertensive agents, including hydrochlorothiazide, hydralazine, and guanethidine without unexpected adverse interactions. 	Pindolol	hydrochlorothiazide	none	{'e1': {'word': 'Pindolol', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d666.s2.e0'}, 'e2': {'word': 'hydrochlorothiazide', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d666.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d666.s2'}	Pindolol used variety antihypertensive agents including hydrochlorothiazide hydralazine guanethidine without unexpected adverse interactions
Pindolol has been used with a variety of antihypertensive agents, including hydrochlorothiazide, hydralazine, and guanethidine without unexpected adverse interactions. 	Pindolol	hydralazine	none	{'e1': {'word': 'Pindolol', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d666.s2.e0'}, 'e2': {'word': 'hydralazine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d666.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d666.s2'}	Pindolol used variety antihypertensive agents including hydrochlorothiazide hydralazine guanethidine without unexpected adverse interactions
Pindolol has been used with a variety of antihypertensive agents, including hydrochlorothiazide, hydralazine, and guanethidine without unexpected adverse interactions. 	Pindolol	guanethidine	none	{'e1': {'word': 'Pindolol', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d666.s2.e0'}, 'e2': {'word': 'guanethidine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d666.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d666.s2'}	Pindolol used variety antihypertensive agents including hydrochlorothiazide hydralazine guanethidine without unexpected adverse interactions
Pindolol has been used with a variety of antihypertensive agents, including hydrochlorothiazide, hydralazine, and guanethidine without unexpected adverse interactions. 	antihypertensive agents	hydrochlorothiazide	none	{'e1': {'word': 'antihypertensive agents', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d666.s2.e1'}, 'e2': {'word': 'hydrochlorothiazide', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d666.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d666.s2'}	Pindolol used variety antihypertensive agents including hydrochlorothiazide hydralazine guanethidine without unexpected adverse interactions
Pindolol has been used with a variety of antihypertensive agents, including hydrochlorothiazide, hydralazine, and guanethidine without unexpected adverse interactions. 	antihypertensive agents	hydralazine	none	{'e1': {'word': 'antihypertensive agents', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d666.s2.e1'}, 'e2': {'word': 'hydralazine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d666.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d666.s2'}	Pindolol used variety antihypertensive agents including hydrochlorothiazide hydralazine guanethidine without unexpected adverse interactions
Pindolol has been used with a variety of antihypertensive agents, including hydrochlorothiazide, hydralazine, and guanethidine without unexpected adverse interactions. 	antihypertensive agents	guanethidine	none	{'e1': {'word': 'antihypertensive agents', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d666.s2.e1'}, 'e2': {'word': 'guanethidine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d666.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d666.s2'}	Pindolol used variety antihypertensive agents including hydrochlorothiazide hydralazine guanethidine without unexpected adverse interactions
Pindolol has been used with a variety of antihypertensive agents, including hydrochlorothiazide, hydralazine, and guanethidine without unexpected adverse interactions. 	hydrochlorothiazide	hydralazine	none	{'e1': {'word': 'hydrochlorothiazide', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d666.s2.e2'}, 'e2': {'word': 'hydralazine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d666.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d666.s2'}	Pindolol used variety antihypertensive agents including hydrochlorothiazide hydralazine guanethidine without unexpected adverse interactions
Pindolol has been used with a variety of antihypertensive agents, including hydrochlorothiazide, hydralazine, and guanethidine without unexpected adverse interactions. 	hydrochlorothiazide	guanethidine	none	{'e1': {'word': 'hydrochlorothiazide', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d666.s2.e2'}, 'e2': {'word': 'guanethidine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d666.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d666.s2'}	Pindolol used variety antihypertensive agents including hydrochlorothiazide hydralazine guanethidine without unexpected adverse interactions
Pindolol has been used with a variety of antihypertensive agents, including hydrochlorothiazide, hydralazine, and guanethidine without unexpected adverse interactions. 	hydralazine	guanethidine	none	{'e1': {'word': 'hydralazine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d666.s2.e3'}, 'e2': {'word': 'guanethidine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d666.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d666.s2'}	Pindolol used variety antihypertensive agents including hydrochlorothiazide hydralazine guanethidine without unexpected adverse interactions
Pindolol has been shown to increase serum thioridazine levels when both drugs are co-administered. 	Pindolol	thioridazine	mechanism	{'e1': {'word': 'Pindolol', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d666.s3.e0'}, 'e2': {'word': 'thioridazine', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d666.s3.e1'}, 'sentence_id': 'DDI-DrugBank.d666.s3'}	Pindolol shown increase serum thioridazine levels drugs co-administered
Do not exceed a 5 mg daily dose of VESIcare when administered with therapeutic doses of ketoconazole or other potent CYP3A4 inhibitors. 	VESIcare	ketoconazole	advise	{'e1': {'word': 'VESIcare', 'word_index': [(5, 5)], 'id': 'DDI-DrugBank.d738.s0.e0'}, 'e2': {'word': 'ketoconazole', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d738.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d738.s0'}	exceed NUMBER mg daily dose VESIcare administered therapeutic doses ketoconazole potent CYP3A4 inhibitors
Patients with Congenital or Acquired QT Prolongation In a study of the effect of solifenacin on the QT interval in 76 healthy women, the QT prolonging effect appeared less with solifenacin 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of solifenacin 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose. 	solifenacin	solifenacin	none	{'e1': {'word': 'solifenacin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d738.s1.e0'}, 'e2': {'word': 'solifenacin', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d738.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d738.s1'}	Patients Congenital Acquired QT Prolongation study effect solifenacin QT interval NUMBER healthy women QT prolonging effect appeared less solifenacin NUMBER mg NUMBER mg NUMBER times maximum recommended dose effect solifenacin NUMBER mg appear large positive control moxifloxacin therapeutic dose
Patients with Congenital or Acquired QT Prolongation In a study of the effect of solifenacin on the QT interval in 76 healthy women, the QT prolonging effect appeared less with solifenacin 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of solifenacin 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose. 	solifenacin	solifenacin	none	{'e1': {'word': 'solifenacin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d738.s1.e0'}, 'e2': {'word': 'solifenacin', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d738.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d738.s1'}	Patients Congenital Acquired QT Prolongation study effect solifenacin QT interval NUMBER healthy women QT prolonging effect appeared less solifenacin NUMBER mg NUMBER mg NUMBER times maximum recommended dose effect solifenacin NUMBER mg appear large positive control moxifloxacin therapeutic dose
Patients with Congenital or Acquired QT Prolongation In a study of the effect of solifenacin on the QT interval in 76 healthy women, the QT prolonging effect appeared less with solifenacin 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of solifenacin 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose. 	solifenacin	moxifloxacin	none	{'e1': {'word': 'solifenacin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d738.s1.e0'}, 'e2': {'word': 'moxifloxacin', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d738.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d738.s1'}	Patients Congenital Acquired QT Prolongation study effect solifenacin QT interval NUMBER healthy women QT prolonging effect appeared less solifenacin NUMBER mg NUMBER mg NUMBER times maximum recommended dose effect solifenacin NUMBER mg appear large positive control moxifloxacin therapeutic dose
Patients with Congenital or Acquired QT Prolongation In a study of the effect of solifenacin on the QT interval in 76 healthy women, the QT prolonging effect appeared less with solifenacin 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of solifenacin 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose. 	solifenacin	solifenacin	none	{'e1': {'word': 'solifenacin', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d738.s1.e1'}, 'e2': {'word': 'solifenacin', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d738.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d738.s1'}	Patients Congenital Acquired QT Prolongation study effect solifenacin QT interval NUMBER healthy women QT prolonging effect appeared less solifenacin NUMBER mg NUMBER mg NUMBER times maximum recommended dose effect solifenacin NUMBER mg appear large positive control moxifloxacin therapeutic dose
Patients with Congenital or Acquired QT Prolongation In a study of the effect of solifenacin on the QT interval in 76 healthy women, the QT prolonging effect appeared less with solifenacin 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of solifenacin 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose. 	solifenacin	moxifloxacin	none	{'e1': {'word': 'solifenacin', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d738.s1.e1'}, 'e2': {'word': 'moxifloxacin', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d738.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d738.s1'}	Patients Congenital Acquired QT Prolongation study effect solifenacin QT interval NUMBER healthy women QT prolonging effect appeared less solifenacin NUMBER mg NUMBER mg NUMBER times maximum recommended dose effect solifenacin NUMBER mg appear large positive control moxifloxacin therapeutic dose
Patients with Congenital or Acquired QT Prolongation In a study of the effect of solifenacin on the QT interval in 76 healthy women, the QT prolonging effect appeared less with solifenacin 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of solifenacin 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose. 	solifenacin	moxifloxacin	none	{'e1': {'word': 'solifenacin', 'word_index': [(29, 29)], 'id': 'DDI-DrugBank.d738.s1.e2'}, 'e2': {'word': 'moxifloxacin', 'word_index': [(36, 36)], 'id': 'DDI-DrugBank.d738.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d738.s1'}	Patients Congenital Acquired QT Prolongation study effect solifenacin QT interval NUMBER healthy women QT prolonging effect appeared less solifenacin NUMBER mg NUMBER mg NUMBER times maximum recommended dose effect solifenacin NUMBER mg appear large positive control moxifloxacin therapeutic dose
In a pharmacokinetic study of 18 chronic hepatitis C patients concomitantly receiving methadone, treatment with PEG-Intron once weekly for 4 weeks was associated with a mean increase of 16% in methadone AUC; 	methadone	PEG-Intron	mechanism	{'e1': {'word': 'methadone', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d741.s0.e0'}, 'e2': {'word': 'PEG-Intron', 'word_index': [(11, 12)], 'id': 'DDI-DrugBank.d741.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d741.s0'}	pharmacokinetic study NUMBER chronic hepatitis C patients concomitantly receiving methadone treatment PEG Intron weekly NUMBER weeks associated mean increase NUMBER % methadone AUC
In a pharmacokinetic study of 18 chronic hepatitis C patients concomitantly receiving methadone, treatment with PEG-Intron once weekly for 4 weeks was associated with a mean increase of 16% in methadone AUC; 	methadone	methadone	none	{'e1': {'word': 'methadone', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d741.s0.e0'}, 'e2': {'word': 'methadone', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d741.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d741.s0'}	pharmacokinetic study NUMBER chronic hepatitis C patients concomitantly receiving methadone treatment PEG Intron weekly NUMBER weeks associated mean increase NUMBER % methadone AUC
In a pharmacokinetic study of 18 chronic hepatitis C patients concomitantly receiving methadone, treatment with PEG-Intron once weekly for 4 weeks was associated with a mean increase of 16% in methadone AUC; 	PEG-Intron	methadone	none	{'e1': {'word': 'PEG-Intron', 'word_index': [(11, 12)], 'id': 'DDI-DrugBank.d741.s0.e1'}, 'e2': {'word': 'methadone', 'word_index': [(21, 21)], 'id': 'DDI-DrugBank.d741.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d741.s0'}	pharmacokinetic study NUMBER chronic hepatitis C patients concomitantly receiving methadone treatment PEG Intron weekly NUMBER weeks associated mean increase NUMBER % methadone AUC
Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).	Celontin	methsuximide	none	{'e1': {'word': 'Celontin', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d587.s0.e0'}, 'e2': {'word': 'methsuximide', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d587.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d587.s0'}	Since Celontin methsuximide may interact concurrently administered antiepileptic drugs periodic serum level determinations drugs may necessary eg methsuximide may increase plasma concentrations phenytoin phenobarbital
Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).	Celontin	antiepileptic drugs	advise	{'e1': {'word': 'Celontin', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d587.s0.e0'}, 'e2': {'word': 'antiepileptic drugs', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d587.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d587.s0'}	Since Celontin methsuximide may interact concurrently administered antiepileptic drugs periodic serum level determinations drugs may necessary eg methsuximide may increase plasma concentrations phenytoin phenobarbital
Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).	Celontin	methsuximide	none	{'e1': {'word': 'Celontin', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d587.s0.e0'}, 'e2': {'word': 'methsuximide', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d587.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d587.s0'}	Since Celontin methsuximide may interact concurrently administered antiepileptic drugs periodic serum level determinations drugs may necessary eg methsuximide may increase plasma concentrations phenytoin phenobarbital
Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).	Celontin	phenytoin	none	{'e1': {'word': 'Celontin', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d587.s0.e0'}, 'e2': {'word': 'phenytoin', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d587.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d587.s0'}	Since Celontin methsuximide may interact concurrently administered antiepileptic drugs periodic serum level determinations drugs may necessary eg methsuximide may increase plasma concentrations phenytoin phenobarbital
Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).	Celontin	phenobarbital	none	{'e1': {'word': 'Celontin', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d587.s0.e0'}, 'e2': {'word': 'phenobarbital', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d587.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d587.s0'}	Since Celontin methsuximide may interact concurrently administered antiepileptic drugs periodic serum level determinations drugs may necessary eg methsuximide may increase plasma concentrations phenytoin phenobarbital
Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).	methsuximide	antiepileptic drugs	advise	{'e1': {'word': 'methsuximide', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d587.s0.e1'}, 'e2': {'word': 'antiepileptic drugs', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d587.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d587.s0'}	Since Celontin methsuximide may interact concurrently administered antiepileptic drugs periodic serum level determinations drugs may necessary eg methsuximide may increase plasma concentrations phenytoin phenobarbital
Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).	methsuximide	methsuximide	none	{'e1': {'word': 'methsuximide', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d587.s0.e1'}, 'e2': {'word': 'methsuximide', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d587.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d587.s0'}	Since Celontin methsuximide may interact concurrently administered antiepileptic drugs periodic serum level determinations drugs may necessary eg methsuximide may increase plasma concentrations phenytoin phenobarbital
Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).	methsuximide	phenytoin	none	{'e1': {'word': 'methsuximide', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d587.s0.e1'}, 'e2': {'word': 'phenytoin', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d587.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d587.s0'}	Since Celontin methsuximide may interact concurrently administered antiepileptic drugs periodic serum level determinations drugs may necessary eg methsuximide may increase plasma concentrations phenytoin phenobarbital
Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).	methsuximide	phenobarbital	none	{'e1': {'word': 'methsuximide', 'word_index': [(2, 2)], 'id': 'DDI-DrugBank.d587.s0.e1'}, 'e2': {'word': 'phenobarbital', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d587.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d587.s0'}	Since Celontin methsuximide may interact concurrently administered antiepileptic drugs periodic serum level determinations drugs may necessary eg methsuximide may increase plasma concentrations phenytoin phenobarbital
Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).	antiepileptic drugs	methsuximide	none	{'e1': {'word': 'antiepileptic drugs', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d587.s0.e2'}, 'e2': {'word': 'methsuximide', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d587.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d587.s0'}	Since Celontin methsuximide may interact concurrently administered antiepileptic drugs periodic serum level determinations drugs may necessary eg methsuximide may increase plasma concentrations phenytoin phenobarbital
Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).	antiepileptic drugs	phenytoin	none	{'e1': {'word': 'antiepileptic drugs', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d587.s0.e2'}, 'e2': {'word': 'phenytoin', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d587.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d587.s0'}	Since Celontin methsuximide may interact concurrently administered antiepileptic drugs periodic serum level determinations drugs may necessary eg methsuximide may increase plasma concentrations phenytoin phenobarbital
Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).	antiepileptic drugs	phenobarbital	none	{'e1': {'word': 'antiepileptic drugs', 'word_index': [(7, 8)], 'id': 'DDI-DrugBank.d587.s0.e2'}, 'e2': {'word': 'phenobarbital', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d587.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d587.s0'}	Since Celontin methsuximide may interact concurrently administered antiepileptic drugs periodic serum level determinations drugs may necessary eg methsuximide may increase plasma concentrations phenytoin phenobarbital
Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).	methsuximide	phenytoin	mechanism	{'e1': {'word': 'methsuximide', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d587.s0.e3'}, 'e2': {'word': 'phenytoin', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d587.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d587.s0'}	Since Celontin methsuximide may interact concurrently administered antiepileptic drugs periodic serum level determinations drugs may necessary eg methsuximide may increase plasma concentrations phenytoin phenobarbital
Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).	methsuximide	phenobarbital	mechanism	{'e1': {'word': 'methsuximide', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d587.s0.e3'}, 'e2': {'word': 'phenobarbital', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d587.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d587.s0'}	Since Celontin methsuximide may interact concurrently administered antiepileptic drugs periodic serum level determinations drugs may necessary eg methsuximide may increase plasma concentrations phenytoin phenobarbital
Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).	phenytoin	phenobarbital	none	{'e1': {'word': 'phenytoin', 'word_index': [(22, 22)], 'id': 'DDI-DrugBank.d587.s0.e4'}, 'e2': {'word': 'phenobarbital', 'word_index': [(23, 23)], 'id': 'DDI-DrugBank.d587.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d587.s0'}	Since Celontin methsuximide may interact concurrently administered antiepileptic drugs periodic serum level determinations drugs may necessary eg methsuximide may increase plasma concentrations phenytoin phenobarbital
Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. 	Triprolidine	central nervous system depressants	effect	{'e1': {'word': 'Triprolidine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d615.s0.e0'}, 'e2': {'word': 'central nervous system depressants', 'word_index': [(5, 8)], 'id': 'DDI-DrugBank.d615.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d615.s0'}	Triprolidine may enhance sedative effects central nervous system depressants including alcohol barbiturates hypnotics narcotic analgesics sedatives tranquillisers
Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. 	Triprolidine	alcohol	effect	{'e1': {'word': 'Triprolidine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d615.s0.e0'}, 'e2': {'word': 'alcohol', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d615.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d615.s0'}	Triprolidine may enhance sedative effects central nervous system depressants including alcohol barbiturates hypnotics narcotic analgesics sedatives tranquillisers
Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. 	Triprolidine	barbiturates	effect	{'e1': {'word': 'Triprolidine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d615.s0.e0'}, 'e2': {'word': 'barbiturates', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d615.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d615.s0'}	Triprolidine may enhance sedative effects central nervous system depressants including alcohol barbiturates hypnotics narcotic analgesics sedatives tranquillisers
Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. 	Triprolidine	hypnotics	effect	{'e1': {'word': 'Triprolidine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d615.s0.e0'}, 'e2': {'word': 'hypnotics', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d615.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d615.s0'}	Triprolidine may enhance sedative effects central nervous system depressants including alcohol barbiturates hypnotics narcotic analgesics sedatives tranquillisers
Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. 	Triprolidine	narcotic analgesics	effect	{'e1': {'word': 'Triprolidine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d615.s0.e0'}, 'e2': {'word': 'narcotic analgesics', 'word_index': [(13, 14)], 'id': 'DDI-DrugBank.d615.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d615.s0'}	Triprolidine may enhance sedative effects central nervous system depressants including alcohol barbiturates hypnotics narcotic analgesics sedatives tranquillisers
Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. 	Triprolidine	sedatives	effect	{'e1': {'word': 'Triprolidine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d615.s0.e0'}, 'e2': {'word': 'sedatives', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d615.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d615.s0'}	Triprolidine may enhance sedative effects central nervous system depressants including alcohol barbiturates hypnotics narcotic analgesics sedatives tranquillisers
Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. 	Triprolidine	tranquillisers	effect	{'e1': {'word': 'Triprolidine', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d615.s0.e0'}, 'e2': {'word': 'tranquillisers', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d615.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d615.s0'}	Triprolidine may enhance sedative effects central nervous system depressants including alcohol barbiturates hypnotics narcotic analgesics sedatives tranquillisers
Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. 	central nervous system depressants	alcohol	none	{'e1': {'word': 'central nervous system depressants', 'word_index': [(5, 8)], 'id': 'DDI-DrugBank.d615.s0.e1'}, 'e2': {'word': 'alcohol', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d615.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d615.s0'}	Triprolidine may enhance sedative effects central nervous system depressants including alcohol barbiturates hypnotics narcotic analgesics sedatives tranquillisers
Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. 	central nervous system depressants	barbiturates	none	{'e1': {'word': 'central nervous system depressants', 'word_index': [(5, 8)], 'id': 'DDI-DrugBank.d615.s0.e1'}, 'e2': {'word': 'barbiturates', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d615.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d615.s0'}	Triprolidine may enhance sedative effects central nervous system depressants including alcohol barbiturates hypnotics narcotic analgesics sedatives tranquillisers
Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. 	central nervous system depressants	hypnotics	none	{'e1': {'word': 'central nervous system depressants', 'word_index': [(5, 8)], 'id': 'DDI-DrugBank.d615.s0.e1'}, 'e2': {'word': 'hypnotics', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d615.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d615.s0'}	Triprolidine may enhance sedative effects central nervous system depressants including alcohol barbiturates hypnotics narcotic analgesics sedatives tranquillisers
Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. 	central nervous system depressants	narcotic analgesics	none	{'e1': {'word': 'central nervous system depressants', 'word_index': [(5, 8)], 'id': 'DDI-DrugBank.d615.s0.e1'}, 'e2': {'word': 'narcotic analgesics', 'word_index': [(13, 14)], 'id': 'DDI-DrugBank.d615.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d615.s0'}	Triprolidine may enhance sedative effects central nervous system depressants including alcohol barbiturates hypnotics narcotic analgesics sedatives tranquillisers
Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. 	central nervous system depressants	sedatives	none	{'e1': {'word': 'central nervous system depressants', 'word_index': [(5, 8)], 'id': 'DDI-DrugBank.d615.s0.e1'}, 'e2': {'word': 'sedatives', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d615.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d615.s0'}	Triprolidine may enhance sedative effects central nervous system depressants including alcohol barbiturates hypnotics narcotic analgesics sedatives tranquillisers
Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. 	central nervous system depressants	tranquillisers	none	{'e1': {'word': 'central nervous system depressants', 'word_index': [(5, 8)], 'id': 'DDI-DrugBank.d615.s0.e1'}, 'e2': {'word': 'tranquillisers', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d615.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d615.s0'}	Triprolidine may enhance sedative effects central nervous system depressants including alcohol barbiturates hypnotics narcotic analgesics sedatives tranquillisers
Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. 	alcohol	barbiturates	none	{'e1': {'word': 'alcohol', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d615.s0.e2'}, 'e2': {'word': 'barbiturates', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d615.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d615.s0'}	Triprolidine may enhance sedative effects central nervous system depressants including alcohol barbiturates hypnotics narcotic analgesics sedatives tranquillisers
Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. 	alcohol	hypnotics	none	{'e1': {'word': 'alcohol', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d615.s0.e2'}, 'e2': {'word': 'hypnotics', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d615.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d615.s0'}	Triprolidine may enhance sedative effects central nervous system depressants including alcohol barbiturates hypnotics narcotic analgesics sedatives tranquillisers
Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. 	alcohol	narcotic analgesics	none	{'e1': {'word': 'alcohol', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d615.s0.e2'}, 'e2': {'word': 'narcotic analgesics', 'word_index': [(13, 14)], 'id': 'DDI-DrugBank.d615.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d615.s0'}	Triprolidine may enhance sedative effects central nervous system depressants including alcohol barbiturates hypnotics narcotic analgesics sedatives tranquillisers
Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. 	alcohol	sedatives	none	{'e1': {'word': 'alcohol', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d615.s0.e2'}, 'e2': {'word': 'sedatives', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d615.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d615.s0'}	Triprolidine may enhance sedative effects central nervous system depressants including alcohol barbiturates hypnotics narcotic analgesics sedatives tranquillisers
Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. 	alcohol	tranquillisers	none	{'e1': {'word': 'alcohol', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d615.s0.e2'}, 'e2': {'word': 'tranquillisers', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d615.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d615.s0'}	Triprolidine may enhance sedative effects central nervous system depressants including alcohol barbiturates hypnotics narcotic analgesics sedatives tranquillisers
Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. 	barbiturates	hypnotics	none	{'e1': {'word': 'barbiturates', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d615.s0.e3'}, 'e2': {'word': 'hypnotics', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d615.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d615.s0'}	Triprolidine may enhance sedative effects central nervous system depressants including alcohol barbiturates hypnotics narcotic analgesics sedatives tranquillisers
Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. 	barbiturates	narcotic analgesics	none	{'e1': {'word': 'barbiturates', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d615.s0.e3'}, 'e2': {'word': 'narcotic analgesics', 'word_index': [(13, 14)], 'id': 'DDI-DrugBank.d615.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d615.s0'}	Triprolidine may enhance sedative effects central nervous system depressants including alcohol barbiturates hypnotics narcotic analgesics sedatives tranquillisers
Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. 	barbiturates	sedatives	none	{'e1': {'word': 'barbiturates', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d615.s0.e3'}, 'e2': {'word': 'sedatives', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d615.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d615.s0'}	Triprolidine may enhance sedative effects central nervous system depressants including alcohol barbiturates hypnotics narcotic analgesics sedatives tranquillisers
Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. 	barbiturates	tranquillisers	none	{'e1': {'word': 'barbiturates', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d615.s0.e3'}, 'e2': {'word': 'tranquillisers', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d615.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d615.s0'}	Triprolidine may enhance sedative effects central nervous system depressants including alcohol barbiturates hypnotics narcotic analgesics sedatives tranquillisers
Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. 	hypnotics	narcotic analgesics	none	{'e1': {'word': 'hypnotics', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d615.s0.e4'}, 'e2': {'word': 'narcotic analgesics', 'word_index': [(13, 14)], 'id': 'DDI-DrugBank.d615.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d615.s0'}	Triprolidine may enhance sedative effects central nervous system depressants including alcohol barbiturates hypnotics narcotic analgesics sedatives tranquillisers
Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. 	hypnotics	sedatives	none	{'e1': {'word': 'hypnotics', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d615.s0.e4'}, 'e2': {'word': 'sedatives', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d615.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d615.s0'}	Triprolidine may enhance sedative effects central nervous system depressants including alcohol barbiturates hypnotics narcotic analgesics sedatives tranquillisers
Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. 	hypnotics	tranquillisers	none	{'e1': {'word': 'hypnotics', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d615.s0.e4'}, 'e2': {'word': 'tranquillisers', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d615.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d615.s0'}	Triprolidine may enhance sedative effects central nervous system depressants including alcohol barbiturates hypnotics narcotic analgesics sedatives tranquillisers
Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. 	narcotic analgesics	sedatives	none	{'e1': {'word': 'narcotic analgesics', 'word_index': [(13, 14)], 'id': 'DDI-DrugBank.d615.s0.e5'}, 'e2': {'word': 'sedatives', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d615.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d615.s0'}	Triprolidine may enhance sedative effects central nervous system depressants including alcohol barbiturates hypnotics narcotic analgesics sedatives tranquillisers
Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. 	narcotic analgesics	tranquillisers	none	{'e1': {'word': 'narcotic analgesics', 'word_index': [(13, 14)], 'id': 'DDI-DrugBank.d615.s0.e5'}, 'e2': {'word': 'tranquillisers', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d615.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d615.s0'}	Triprolidine may enhance sedative effects central nervous system depressants including alcohol barbiturates hypnotics narcotic analgesics sedatives tranquillisers
Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. 	sedatives	tranquillisers	none	{'e1': {'word': 'sedatives', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d615.s0.e6'}, 'e2': {'word': 'tranquillisers', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d615.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d615.s0'}	Triprolidine may enhance sedative effects central nervous system depressants including alcohol barbiturates hypnotics narcotic analgesics sedatives tranquillisers
The effects of anticholinergic drugs, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine. 	anticholinergic drugs	atropine	none	{'e1': {'word': 'anticholinergic drugs', 'word_index': [(1, 2)], 'id': 'DDI-DrugBank.d615.s1.e0'}, 'e2': {'word': 'atropine', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d615.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d615.s1'}	effects anticholinergic drugs atropine tricyclic antidepressants may enhanced concomitant administration triprolidine
The effects of anticholinergic drugs, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine. 	anticholinergic drugs	tricyclic antidepressants	none	{'e1': {'word': 'anticholinergic drugs', 'word_index': [(1, 2)], 'id': 'DDI-DrugBank.d615.s1.e0'}, 'e2': {'word': 'tricyclic antidepressants', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d615.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d615.s1'}	effects anticholinergic drugs atropine tricyclic antidepressants may enhanced concomitant administration triprolidine
The effects of anticholinergic drugs, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine. 	anticholinergic drugs	triprolidine	effect	{'e1': {'word': 'anticholinergic drugs', 'word_index': [(1, 2)], 'id': 'DDI-DrugBank.d615.s1.e0'}, 'e2': {'word': 'triprolidine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d615.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d615.s1'}	effects anticholinergic drugs atropine tricyclic antidepressants may enhanced concomitant administration triprolidine
The effects of anticholinergic drugs, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine. 	atropine	tricyclic antidepressants	none	{'e1': {'word': 'atropine', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d615.s1.e1'}, 'e2': {'word': 'tricyclic antidepressants', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d615.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d615.s1'}	effects anticholinergic drugs atropine tricyclic antidepressants may enhanced concomitant administration triprolidine
The effects of anticholinergic drugs, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine. 	atropine	triprolidine	effect	{'e1': {'word': 'atropine', 'word_index': [(3, 3)], 'id': 'DDI-DrugBank.d615.s1.e1'}, 'e2': {'word': 'triprolidine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d615.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d615.s1'}	effects anticholinergic drugs atropine tricyclic antidepressants may enhanced concomitant administration triprolidine
The effects of anticholinergic drugs, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine. 	tricyclic antidepressants	triprolidine	effect	{'e1': {'word': 'tricyclic antidepressants', 'word_index': [(4, 5)], 'id': 'DDI-DrugBank.d615.s1.e2'}, 'e2': {'word': 'triprolidine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d615.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d615.s1'}	effects anticholinergic drugs atropine tricyclic antidepressants may enhanced concomitant administration triprolidine
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	SUTENT	ketoconazole	mechanism	{'e1': {'word': 'SUTENT', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d639.s0.e0'}, 'e2': {'word': 'ketoconazole', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d639.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	SUTENT	itraconazole	mechanism	{'e1': {'word': 'SUTENT', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d639.s0.e0'}, 'e2': {'word': 'itraconazole', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d639.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	SUTENT	clarithromycin	mechanism	{'e1': {'word': 'SUTENT', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d639.s0.e0'}, 'e2': {'word': 'clarithromycin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d639.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	SUTENT	atazanavir	mechanism	{'e1': {'word': 'SUTENT', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d639.s0.e0'}, 'e2': {'word': 'atazanavir', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d639.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	SUTENT	indinavir	mechanism	{'e1': {'word': 'SUTENT', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d639.s0.e0'}, 'e2': {'word': 'indinavir', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d639.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	SUTENT	nefazodone	mechanism	{'e1': {'word': 'SUTENT', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d639.s0.e0'}, 'e2': {'word': 'nefazodone', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d639.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	SUTENT	nelfinavir	mechanism	{'e1': {'word': 'SUTENT', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d639.s0.e0'}, 'e2': {'word': 'nelfinavir', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d639.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	SUTENT	ritonavir	mechanism	{'e1': {'word': 'SUTENT', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d639.s0.e0'}, 'e2': {'word': 'ritonavir', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d639.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	SUTENT	saquinavir	mechanism	{'e1': {'word': 'SUTENT', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d639.s0.e0'}, 'e2': {'word': 'saquinavir', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d639.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	SUTENT	telithromycin	mechanism	{'e1': {'word': 'SUTENT', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d639.s0.e0'}, 'e2': {'word': 'telithromycin', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d639.s0.e10'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	SUTENT	voriconizole	mechanism	{'e1': {'word': 'SUTENT', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d639.s0.e0'}, 'e2': {'word': 'voriconizole', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d639.s0.e11'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	SUTENT	sunitinib	none	{'e1': {'word': 'SUTENT', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d639.s0.e0'}, 'e2': {'word': 'sunitinib', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d639.s0.e12'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	ketoconazole	itraconazole	none	{'e1': {'word': 'ketoconazole', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d639.s0.e1'}, 'e2': {'word': 'itraconazole', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d639.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	ketoconazole	clarithromycin	none	{'e1': {'word': 'ketoconazole', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d639.s0.e1'}, 'e2': {'word': 'clarithromycin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d639.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	ketoconazole	atazanavir	none	{'e1': {'word': 'ketoconazole', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d639.s0.e1'}, 'e2': {'word': 'atazanavir', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d639.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	ketoconazole	indinavir	none	{'e1': {'word': 'ketoconazole', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d639.s0.e1'}, 'e2': {'word': 'indinavir', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d639.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	ketoconazole	nefazodone	none	{'e1': {'word': 'ketoconazole', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d639.s0.e1'}, 'e2': {'word': 'nefazodone', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d639.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	ketoconazole	nelfinavir	none	{'e1': {'word': 'ketoconazole', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d639.s0.e1'}, 'e2': {'word': 'nelfinavir', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d639.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	ketoconazole	ritonavir	none	{'e1': {'word': 'ketoconazole', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d639.s0.e1'}, 'e2': {'word': 'ritonavir', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d639.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	ketoconazole	saquinavir	none	{'e1': {'word': 'ketoconazole', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d639.s0.e1'}, 'e2': {'word': 'saquinavir', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d639.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	ketoconazole	telithromycin	none	{'e1': {'word': 'ketoconazole', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d639.s0.e1'}, 'e2': {'word': 'telithromycin', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d639.s0.e10'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	ketoconazole	voriconizole	none	{'e1': {'word': 'ketoconazole', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d639.s0.e1'}, 'e2': {'word': 'voriconizole', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d639.s0.e11'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	ketoconazole	sunitinib	none	{'e1': {'word': 'ketoconazole', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d639.s0.e1'}, 'e2': {'word': 'sunitinib', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d639.s0.e12'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	itraconazole	clarithromycin	none	{'e1': {'word': 'itraconazole', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d639.s0.e2'}, 'e2': {'word': 'clarithromycin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d639.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	itraconazole	atazanavir	none	{'e1': {'word': 'itraconazole', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d639.s0.e2'}, 'e2': {'word': 'atazanavir', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d639.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	itraconazole	indinavir	none	{'e1': {'word': 'itraconazole', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d639.s0.e2'}, 'e2': {'word': 'indinavir', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d639.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	itraconazole	nefazodone	none	{'e1': {'word': 'itraconazole', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d639.s0.e2'}, 'e2': {'word': 'nefazodone', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d639.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	itraconazole	nelfinavir	none	{'e1': {'word': 'itraconazole', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d639.s0.e2'}, 'e2': {'word': 'nelfinavir', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d639.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	itraconazole	ritonavir	none	{'e1': {'word': 'itraconazole', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d639.s0.e2'}, 'e2': {'word': 'ritonavir', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d639.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	itraconazole	saquinavir	none	{'e1': {'word': 'itraconazole', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d639.s0.e2'}, 'e2': {'word': 'saquinavir', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d639.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	itraconazole	telithromycin	none	{'e1': {'word': 'itraconazole', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d639.s0.e2'}, 'e2': {'word': 'telithromycin', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d639.s0.e10'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	itraconazole	voriconizole	none	{'e1': {'word': 'itraconazole', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d639.s0.e2'}, 'e2': {'word': 'voriconizole', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d639.s0.e11'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	itraconazole	sunitinib	none	{'e1': {'word': 'itraconazole', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d639.s0.e2'}, 'e2': {'word': 'sunitinib', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d639.s0.e12'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	clarithromycin	atazanavir	none	{'e1': {'word': 'clarithromycin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d639.s0.e3'}, 'e2': {'word': 'atazanavir', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d639.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	clarithromycin	indinavir	none	{'e1': {'word': 'clarithromycin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d639.s0.e3'}, 'e2': {'word': 'indinavir', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d639.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	clarithromycin	nefazodone	none	{'e1': {'word': 'clarithromycin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d639.s0.e3'}, 'e2': {'word': 'nefazodone', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d639.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	clarithromycin	nelfinavir	none	{'e1': {'word': 'clarithromycin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d639.s0.e3'}, 'e2': {'word': 'nelfinavir', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d639.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	clarithromycin	ritonavir	none	{'e1': {'word': 'clarithromycin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d639.s0.e3'}, 'e2': {'word': 'ritonavir', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d639.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	clarithromycin	saquinavir	none	{'e1': {'word': 'clarithromycin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d639.s0.e3'}, 'e2': {'word': 'saquinavir', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d639.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	clarithromycin	telithromycin	none	{'e1': {'word': 'clarithromycin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d639.s0.e3'}, 'e2': {'word': 'telithromycin', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d639.s0.e10'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	clarithromycin	voriconizole	none	{'e1': {'word': 'clarithromycin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d639.s0.e3'}, 'e2': {'word': 'voriconizole', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d639.s0.e11'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	clarithromycin	sunitinib	none	{'e1': {'word': 'clarithromycin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d639.s0.e3'}, 'e2': {'word': 'sunitinib', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d639.s0.e12'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	atazanavir	indinavir	none	{'e1': {'word': 'atazanavir', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d639.s0.e4'}, 'e2': {'word': 'indinavir', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d639.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	atazanavir	nefazodone	none	{'e1': {'word': 'atazanavir', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d639.s0.e4'}, 'e2': {'word': 'nefazodone', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d639.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	atazanavir	nelfinavir	none	{'e1': {'word': 'atazanavir', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d639.s0.e4'}, 'e2': {'word': 'nelfinavir', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d639.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	atazanavir	ritonavir	none	{'e1': {'word': 'atazanavir', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d639.s0.e4'}, 'e2': {'word': 'ritonavir', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d639.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	atazanavir	saquinavir	none	{'e1': {'word': 'atazanavir', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d639.s0.e4'}, 'e2': {'word': 'saquinavir', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d639.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	atazanavir	telithromycin	none	{'e1': {'word': 'atazanavir', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d639.s0.e4'}, 'e2': {'word': 'telithromycin', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d639.s0.e10'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	atazanavir	voriconizole	none	{'e1': {'word': 'atazanavir', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d639.s0.e4'}, 'e2': {'word': 'voriconizole', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d639.s0.e11'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	atazanavir	sunitinib	none	{'e1': {'word': 'atazanavir', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d639.s0.e4'}, 'e2': {'word': 'sunitinib', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d639.s0.e12'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	indinavir	nefazodone	none	{'e1': {'word': 'indinavir', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d639.s0.e5'}, 'e2': {'word': 'nefazodone', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d639.s0.e6'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	indinavir	nelfinavir	none	{'e1': {'word': 'indinavir', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d639.s0.e5'}, 'e2': {'word': 'nelfinavir', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d639.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	indinavir	ritonavir	none	{'e1': {'word': 'indinavir', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d639.s0.e5'}, 'e2': {'word': 'ritonavir', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d639.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	indinavir	saquinavir	none	{'e1': {'word': 'indinavir', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d639.s0.e5'}, 'e2': {'word': 'saquinavir', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d639.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	indinavir	telithromycin	none	{'e1': {'word': 'indinavir', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d639.s0.e5'}, 'e2': {'word': 'telithromycin', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d639.s0.e10'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	indinavir	voriconizole	none	{'e1': {'word': 'indinavir', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d639.s0.e5'}, 'e2': {'word': 'voriconizole', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d639.s0.e11'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	indinavir	sunitinib	none	{'e1': {'word': 'indinavir', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d639.s0.e5'}, 'e2': {'word': 'sunitinib', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d639.s0.e12'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	nefazodone	nelfinavir	none	{'e1': {'word': 'nefazodone', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d639.s0.e6'}, 'e2': {'word': 'nelfinavir', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d639.s0.e7'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	nefazodone	ritonavir	none	{'e1': {'word': 'nefazodone', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d639.s0.e6'}, 'e2': {'word': 'ritonavir', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d639.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	nefazodone	saquinavir	none	{'e1': {'word': 'nefazodone', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d639.s0.e6'}, 'e2': {'word': 'saquinavir', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d639.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	nefazodone	telithromycin	none	{'e1': {'word': 'nefazodone', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d639.s0.e6'}, 'e2': {'word': 'telithromycin', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d639.s0.e10'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	nefazodone	voriconizole	none	{'e1': {'word': 'nefazodone', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d639.s0.e6'}, 'e2': {'word': 'voriconizole', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d639.s0.e11'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	nefazodone	sunitinib	none	{'e1': {'word': 'nefazodone', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d639.s0.e6'}, 'e2': {'word': 'sunitinib', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d639.s0.e12'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	nelfinavir	ritonavir	none	{'e1': {'word': 'nelfinavir', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d639.s0.e7'}, 'e2': {'word': 'ritonavir', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d639.s0.e8'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	nelfinavir	saquinavir	none	{'e1': {'word': 'nelfinavir', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d639.s0.e7'}, 'e2': {'word': 'saquinavir', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d639.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	nelfinavir	telithromycin	none	{'e1': {'word': 'nelfinavir', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d639.s0.e7'}, 'e2': {'word': 'telithromycin', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d639.s0.e10'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	nelfinavir	voriconizole	none	{'e1': {'word': 'nelfinavir', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d639.s0.e7'}, 'e2': {'word': 'voriconizole', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d639.s0.e11'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	nelfinavir	sunitinib	none	{'e1': {'word': 'nelfinavir', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d639.s0.e7'}, 'e2': {'word': 'sunitinib', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d639.s0.e12'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	ritonavir	saquinavir	none	{'e1': {'word': 'ritonavir', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d639.s0.e8'}, 'e2': {'word': 'saquinavir', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d639.s0.e9'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	ritonavir	telithromycin	none	{'e1': {'word': 'ritonavir', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d639.s0.e8'}, 'e2': {'word': 'telithromycin', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d639.s0.e10'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	ritonavir	voriconizole	none	{'e1': {'word': 'ritonavir', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d639.s0.e8'}, 'e2': {'word': 'voriconizole', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d639.s0.e11'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	ritonavir	sunitinib	none	{'e1': {'word': 'ritonavir', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d639.s0.e8'}, 'e2': {'word': 'sunitinib', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d639.s0.e12'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	saquinavir	telithromycin	none	{'e1': {'word': 'saquinavir', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d639.s0.e9'}, 'e2': {'word': 'telithromycin', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d639.s0.e10'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	saquinavir	voriconizole	none	{'e1': {'word': 'saquinavir', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d639.s0.e9'}, 'e2': {'word': 'voriconizole', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d639.s0.e11'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	saquinavir	sunitinib	none	{'e1': {'word': 'saquinavir', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d639.s0.e9'}, 'e2': {'word': 'sunitinib', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d639.s0.e12'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	telithromycin	voriconizole	none	{'e1': {'word': 'telithromycin', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d639.s0.e10'}, 'e2': {'word': 'voriconizole', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d639.s0.e11'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	telithromycin	sunitinib	none	{'e1': {'word': 'telithromycin', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d639.s0.e10'}, 'e2': {'word': 'sunitinib', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d639.s0.e12'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations. 	voriconizole	sunitinib	none	{'e1': {'word': 'voriconizole', 'word_index': [(17, 17)], 'id': 'DDI-DrugBank.d639.s0.e11'}, 'e2': {'word': 'sunitinib', 'word_index': [(20, 20)], 'id': 'DDI-DrugBank.d639.s0.e12'}, 'sentence_id': 'DDI-DrugBank.d639.s0'}	Co-administration SUTENT strong inhibitors CYP3A4 family e.g. ketoconazole itraconazole clarithromycin atazanavir indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin voriconizole may increases sunitinib concentrations
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. 	SUTENT	dexamethasone	mechanism	{'e1': {'word': 'SUTENT', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d639.s2.e0'}, 'e2': {'word': 'dexamethasone', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d639.s2.e1'}, 'sentence_id': 'DDI-DrugBank.d639.s2'}	Co-administration SUTENT inducers CYP3A4 family e.g. dexamethasone phenytoin carbamazepine rifampin rifabutin rifapentin phenobarbital St. Johns Wort may decrease sunitinib concentrations
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. 	SUTENT	phenytoin	mechanism	{'e1': {'word': 'SUTENT', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d639.s2.e0'}, 'e2': {'word': 'phenytoin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d639.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d639.s2'}	Co-administration SUTENT inducers CYP3A4 family e.g. dexamethasone phenytoin carbamazepine rifampin rifabutin rifapentin phenobarbital St. Johns Wort may decrease sunitinib concentrations
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. 	SUTENT	carbamazepine	mechanism	{'e1': {'word': 'SUTENT', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d639.s2.e0'}, 'e2': {'word': 'carbamazepine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d639.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d639.s2'}	Co-administration SUTENT inducers CYP3A4 family e.g. dexamethasone phenytoin carbamazepine rifampin rifabutin rifapentin phenobarbital St. Johns Wort may decrease sunitinib concentrations
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. 	SUTENT	rifampin	mechanism	{'e1': {'word': 'SUTENT', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d639.s2.e0'}, 'e2': {'word': 'rifampin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d639.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d639.s2'}	Co-administration SUTENT inducers CYP3A4 family e.g. dexamethasone phenytoin carbamazepine rifampin rifabutin rifapentin phenobarbital St. Johns Wort may decrease sunitinib concentrations
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. 	SUTENT	rifabutin	mechanism	{'e1': {'word': 'SUTENT', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d639.s2.e0'}, 'e2': {'word': 'rifabutin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d639.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d639.s2'}	Co-administration SUTENT inducers CYP3A4 family e.g. dexamethasone phenytoin carbamazepine rifampin rifabutin rifapentin phenobarbital St. Johns Wort may decrease sunitinib concentrations
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. 	SUTENT	rifapentin	mechanism	{'e1': {'word': 'SUTENT', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d639.s2.e0'}, 'e2': {'word': 'rifapentin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d639.s2.e6'}, 'sentence_id': 'DDI-DrugBank.d639.s2'}	Co-administration SUTENT inducers CYP3A4 family e.g. dexamethasone phenytoin carbamazepine rifampin rifabutin rifapentin phenobarbital St. Johns Wort may decrease sunitinib concentrations
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. 	SUTENT	phenobarbital	mechanism	{'e1': {'word': 'SUTENT', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d639.s2.e0'}, 'e2': {'word': 'phenobarbital', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d639.s2.e7'}, 'sentence_id': 'DDI-DrugBank.d639.s2'}	Co-administration SUTENT inducers CYP3A4 family e.g. dexamethasone phenytoin carbamazepine rifampin rifabutin rifapentin phenobarbital St. Johns Wort may decrease sunitinib concentrations
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. 	SUTENT	sunitinib	none	{'e1': {'word': 'SUTENT', 'word_index': [(1, 1)], 'id': 'DDI-DrugBank.d639.s2.e0'}, 'e2': {'word': 'sunitinib', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d639.s2.e8'}, 'sentence_id': 'DDI-DrugBank.d639.s2'}	Co-administration SUTENT inducers CYP3A4 family e.g. dexamethasone phenytoin carbamazepine rifampin rifabutin rifapentin phenobarbital St. Johns Wort may decrease sunitinib concentrations
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. 	dexamethasone	phenytoin	none	{'e1': {'word': 'dexamethasone', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d639.s2.e1'}, 'e2': {'word': 'phenytoin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d639.s2.e2'}, 'sentence_id': 'DDI-DrugBank.d639.s2'}	Co-administration SUTENT inducers CYP3A4 family e.g. dexamethasone phenytoin carbamazepine rifampin rifabutin rifapentin phenobarbital St. Johns Wort may decrease sunitinib concentrations
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. 	dexamethasone	carbamazepine	none	{'e1': {'word': 'dexamethasone', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d639.s2.e1'}, 'e2': {'word': 'carbamazepine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d639.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d639.s2'}	Co-administration SUTENT inducers CYP3A4 family e.g. dexamethasone phenytoin carbamazepine rifampin rifabutin rifapentin phenobarbital St. Johns Wort may decrease sunitinib concentrations
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. 	dexamethasone	rifampin	none	{'e1': {'word': 'dexamethasone', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d639.s2.e1'}, 'e2': {'word': 'rifampin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d639.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d639.s2'}	Co-administration SUTENT inducers CYP3A4 family e.g. dexamethasone phenytoin carbamazepine rifampin rifabutin rifapentin phenobarbital St. Johns Wort may decrease sunitinib concentrations
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. 	dexamethasone	rifabutin	none	{'e1': {'word': 'dexamethasone', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d639.s2.e1'}, 'e2': {'word': 'rifabutin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d639.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d639.s2'}	Co-administration SUTENT inducers CYP3A4 family e.g. dexamethasone phenytoin carbamazepine rifampin rifabutin rifapentin phenobarbital St. Johns Wort may decrease sunitinib concentrations
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. 	dexamethasone	rifapentin	none	{'e1': {'word': 'dexamethasone', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d639.s2.e1'}, 'e2': {'word': 'rifapentin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d639.s2.e6'}, 'sentence_id': 'DDI-DrugBank.d639.s2'}	Co-administration SUTENT inducers CYP3A4 family e.g. dexamethasone phenytoin carbamazepine rifampin rifabutin rifapentin phenobarbital St. Johns Wort may decrease sunitinib concentrations
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. 	dexamethasone	phenobarbital	none	{'e1': {'word': 'dexamethasone', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d639.s2.e1'}, 'e2': {'word': 'phenobarbital', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d639.s2.e7'}, 'sentence_id': 'DDI-DrugBank.d639.s2'}	Co-administration SUTENT inducers CYP3A4 family e.g. dexamethasone phenytoin carbamazepine rifampin rifabutin rifapentin phenobarbital St. Johns Wort may decrease sunitinib concentrations
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. 	dexamethasone	sunitinib	none	{'e1': {'word': 'dexamethasone', 'word_index': [(6, 6)], 'id': 'DDI-DrugBank.d639.s2.e1'}, 'e2': {'word': 'sunitinib', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d639.s2.e8'}, 'sentence_id': 'DDI-DrugBank.d639.s2'}	Co-administration SUTENT inducers CYP3A4 family e.g. dexamethasone phenytoin carbamazepine rifampin rifabutin rifapentin phenobarbital St. Johns Wort may decrease sunitinib concentrations
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. 	phenytoin	carbamazepine	none	{'e1': {'word': 'phenytoin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d639.s2.e2'}, 'e2': {'word': 'carbamazepine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d639.s2.e3'}, 'sentence_id': 'DDI-DrugBank.d639.s2'}	Co-administration SUTENT inducers CYP3A4 family e.g. dexamethasone phenytoin carbamazepine rifampin rifabutin rifapentin phenobarbital St. Johns Wort may decrease sunitinib concentrations
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. 	phenytoin	rifampin	none	{'e1': {'word': 'phenytoin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d639.s2.e2'}, 'e2': {'word': 'rifampin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d639.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d639.s2'}	Co-administration SUTENT inducers CYP3A4 family e.g. dexamethasone phenytoin carbamazepine rifampin rifabutin rifapentin phenobarbital St. Johns Wort may decrease sunitinib concentrations
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. 	phenytoin	rifabutin	none	{'e1': {'word': 'phenytoin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d639.s2.e2'}, 'e2': {'word': 'rifabutin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d639.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d639.s2'}	Co-administration SUTENT inducers CYP3A4 family e.g. dexamethasone phenytoin carbamazepine rifampin rifabutin rifapentin phenobarbital St. Johns Wort may decrease sunitinib concentrations
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. 	phenytoin	rifapentin	none	{'e1': {'word': 'phenytoin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d639.s2.e2'}, 'e2': {'word': 'rifapentin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d639.s2.e6'}, 'sentence_id': 'DDI-DrugBank.d639.s2'}	Co-administration SUTENT inducers CYP3A4 family e.g. dexamethasone phenytoin carbamazepine rifampin rifabutin rifapentin phenobarbital St. Johns Wort may decrease sunitinib concentrations
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. 	phenytoin	phenobarbital	none	{'e1': {'word': 'phenytoin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d639.s2.e2'}, 'e2': {'word': 'phenobarbital', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d639.s2.e7'}, 'sentence_id': 'DDI-DrugBank.d639.s2'}	Co-administration SUTENT inducers CYP3A4 family e.g. dexamethasone phenytoin carbamazepine rifampin rifabutin rifapentin phenobarbital St. Johns Wort may decrease sunitinib concentrations
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. 	phenytoin	sunitinib	none	{'e1': {'word': 'phenytoin', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d639.s2.e2'}, 'e2': {'word': 'sunitinib', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d639.s2.e8'}, 'sentence_id': 'DDI-DrugBank.d639.s2'}	Co-administration SUTENT inducers CYP3A4 family e.g. dexamethasone phenytoin carbamazepine rifampin rifabutin rifapentin phenobarbital St. Johns Wort may decrease sunitinib concentrations
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. 	carbamazepine	rifampin	none	{'e1': {'word': 'carbamazepine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d639.s2.e3'}, 'e2': {'word': 'rifampin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d639.s2.e4'}, 'sentence_id': 'DDI-DrugBank.d639.s2'}	Co-administration SUTENT inducers CYP3A4 family e.g. dexamethasone phenytoin carbamazepine rifampin rifabutin rifapentin phenobarbital St. Johns Wort may decrease sunitinib concentrations
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. 	carbamazepine	rifabutin	none	{'e1': {'word': 'carbamazepine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d639.s2.e3'}, 'e2': {'word': 'rifabutin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d639.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d639.s2'}	Co-administration SUTENT inducers CYP3A4 family e.g. dexamethasone phenytoin carbamazepine rifampin rifabutin rifapentin phenobarbital St. Johns Wort may decrease sunitinib concentrations
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. 	carbamazepine	rifapentin	none	{'e1': {'word': 'carbamazepine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d639.s2.e3'}, 'e2': {'word': 'rifapentin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d639.s2.e6'}, 'sentence_id': 'DDI-DrugBank.d639.s2'}	Co-administration SUTENT inducers CYP3A4 family e.g. dexamethasone phenytoin carbamazepine rifampin rifabutin rifapentin phenobarbital St. Johns Wort may decrease sunitinib concentrations
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. 	carbamazepine	phenobarbital	none	{'e1': {'word': 'carbamazepine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d639.s2.e3'}, 'e2': {'word': 'phenobarbital', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d639.s2.e7'}, 'sentence_id': 'DDI-DrugBank.d639.s2'}	Co-administration SUTENT inducers CYP3A4 family e.g. dexamethasone phenytoin carbamazepine rifampin rifabutin rifapentin phenobarbital St. Johns Wort may decrease sunitinib concentrations
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. 	carbamazepine	sunitinib	none	{'e1': {'word': 'carbamazepine', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d639.s2.e3'}, 'e2': {'word': 'sunitinib', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d639.s2.e8'}, 'sentence_id': 'DDI-DrugBank.d639.s2'}	Co-administration SUTENT inducers CYP3A4 family e.g. dexamethasone phenytoin carbamazepine rifampin rifabutin rifapentin phenobarbital St. Johns Wort may decrease sunitinib concentrations
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. 	rifampin	rifabutin	none	{'e1': {'word': 'rifampin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d639.s2.e4'}, 'e2': {'word': 'rifabutin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d639.s2.e5'}, 'sentence_id': 'DDI-DrugBank.d639.s2'}	Co-administration SUTENT inducers CYP3A4 family e.g. dexamethasone phenytoin carbamazepine rifampin rifabutin rifapentin phenobarbital St. Johns Wort may decrease sunitinib concentrations
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. 	rifampin	rifapentin	none	{'e1': {'word': 'rifampin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d639.s2.e4'}, 'e2': {'word': 'rifapentin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d639.s2.e6'}, 'sentence_id': 'DDI-DrugBank.d639.s2'}	Co-administration SUTENT inducers CYP3A4 family e.g. dexamethasone phenytoin carbamazepine rifampin rifabutin rifapentin phenobarbital St. Johns Wort may decrease sunitinib concentrations
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. 	rifampin	phenobarbital	none	{'e1': {'word': 'rifampin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d639.s2.e4'}, 'e2': {'word': 'phenobarbital', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d639.s2.e7'}, 'sentence_id': 'DDI-DrugBank.d639.s2'}	Co-administration SUTENT inducers CYP3A4 family e.g. dexamethasone phenytoin carbamazepine rifampin rifabutin rifapentin phenobarbital St. Johns Wort may decrease sunitinib concentrations
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. 	rifampin	sunitinib	none	{'e1': {'word': 'rifampin', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d639.s2.e4'}, 'e2': {'word': 'sunitinib', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d639.s2.e8'}, 'sentence_id': 'DDI-DrugBank.d639.s2'}	Co-administration SUTENT inducers CYP3A4 family e.g. dexamethasone phenytoin carbamazepine rifampin rifabutin rifapentin phenobarbital St. Johns Wort may decrease sunitinib concentrations
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. 	rifabutin	rifapentin	none	{'e1': {'word': 'rifabutin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d639.s2.e5'}, 'e2': {'word': 'rifapentin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d639.s2.e6'}, 'sentence_id': 'DDI-DrugBank.d639.s2'}	Co-administration SUTENT inducers CYP3A4 family e.g. dexamethasone phenytoin carbamazepine rifampin rifabutin rifapentin phenobarbital St. Johns Wort may decrease sunitinib concentrations
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. 	rifabutin	phenobarbital	none	{'e1': {'word': 'rifabutin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d639.s2.e5'}, 'e2': {'word': 'phenobarbital', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d639.s2.e7'}, 'sentence_id': 'DDI-DrugBank.d639.s2'}	Co-administration SUTENT inducers CYP3A4 family e.g. dexamethasone phenytoin carbamazepine rifampin rifabutin rifapentin phenobarbital St. Johns Wort may decrease sunitinib concentrations
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. 	rifabutin	sunitinib	none	{'e1': {'word': 'rifabutin', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d639.s2.e5'}, 'e2': {'word': 'sunitinib', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d639.s2.e8'}, 'sentence_id': 'DDI-DrugBank.d639.s2'}	Co-administration SUTENT inducers CYP3A4 family e.g. dexamethasone phenytoin carbamazepine rifampin rifabutin rifapentin phenobarbital St. Johns Wort may decrease sunitinib concentrations
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. 	rifapentin	phenobarbital	none	{'e1': {'word': 'rifapentin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d639.s2.e6'}, 'e2': {'word': 'phenobarbital', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d639.s2.e7'}, 'sentence_id': 'DDI-DrugBank.d639.s2'}	Co-administration SUTENT inducers CYP3A4 family e.g. dexamethasone phenytoin carbamazepine rifampin rifabutin rifapentin phenobarbital St. Johns Wort may decrease sunitinib concentrations
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. 	rifapentin	sunitinib	none	{'e1': {'word': 'rifapentin', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d639.s2.e6'}, 'e2': {'word': 'sunitinib', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d639.s2.e8'}, 'sentence_id': 'DDI-DrugBank.d639.s2'}	Co-administration SUTENT inducers CYP3A4 family e.g. dexamethasone phenytoin carbamazepine rifampin rifabutin rifapentin phenobarbital St. Johns Wort may decrease sunitinib concentrations
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations. 	phenobarbital	sunitinib	none	{'e1': {'word': 'phenobarbital', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d639.s2.e7'}, 'e2': {'word': 'sunitinib', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d639.s2.e8'}, 'sentence_id': 'DDI-DrugBank.d639.s2'}	Co-administration SUTENT inducers CYP3A4 family e.g. dexamethasone phenytoin carbamazepine rifampin rifabutin rifapentin phenobarbital St. Johns Wort may decrease sunitinib concentrations
ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS. 	ASPIRIN	SALICYLATE DRUGS	none	{'e1': {'word': 'ASPIRIN', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d576.s1.e0'}, 'e2': {'word': 'SALICYLATE DRUGS', 'word_index': [(1, 2)], 'id': 'DDI-DrugBank.d576.s1.e1'}, 'sentence_id': 'DDI-DrugBank.d576.s1'}	ASPIRIN SALICYLATE DRUGS ADDITIVE DISALCID MAY INCREASE PLASMA CONCENTRATIONS SALICYLIC ACID TOXIC LEVELS
ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS. 	ASPIRIN	DISALCID	effect	{'e1': {'word': 'ASPIRIN', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d576.s1.e0'}, 'e2': {'word': 'DISALCID', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d576.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d576.s1'}	ASPIRIN SALICYLATE DRUGS ADDITIVE DISALCID MAY INCREASE PLASMA CONCENTRATIONS SALICYLIC ACID TOXIC LEVELS
ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS. 	ASPIRIN	SALICYLIC ACID	none	{'e1': {'word': 'ASPIRIN', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d576.s1.e0'}, 'e2': {'word': 'SALICYLIC ACID', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d576.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d576.s1'}	ASPIRIN SALICYLATE DRUGS ADDITIVE DISALCID MAY INCREASE PLASMA CONCENTRATIONS SALICYLIC ACID TOXIC LEVELS
ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS. 	SALICYLATE DRUGS	DISALCID	effect	{'e1': {'word': 'SALICYLATE DRUGS', 'word_index': [(1, 2)], 'id': 'DDI-DrugBank.d576.s1.e1'}, 'e2': {'word': 'DISALCID', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d576.s1.e2'}, 'sentence_id': 'DDI-DrugBank.d576.s1'}	ASPIRIN SALICYLATE DRUGS ADDITIVE DISALCID MAY INCREASE PLASMA CONCENTRATIONS SALICYLIC ACID TOXIC LEVELS
ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS. 	SALICYLATE DRUGS	SALICYLIC ACID	none	{'e1': {'word': 'SALICYLATE DRUGS', 'word_index': [(1, 2)], 'id': 'DDI-DrugBank.d576.s1.e1'}, 'e2': {'word': 'SALICYLIC ACID', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d576.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d576.s1'}	ASPIRIN SALICYLATE DRUGS ADDITIVE DISALCID MAY INCREASE PLASMA CONCENTRATIONS SALICYLIC ACID TOXIC LEVELS
ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS. 	DISALCID	SALICYLIC ACID	none	{'e1': {'word': 'DISALCID', 'word_index': [(4, 4)], 'id': 'DDI-DrugBank.d576.s1.e2'}, 'e2': {'word': 'SALICYLIC ACID', 'word_index': [(9, 10)], 'id': 'DDI-DrugBank.d576.s1.e3'}, 'sentence_id': 'DDI-DrugBank.d576.s1'}	ASPIRIN SALICYLATE DRUGS ADDITIVE DISALCID MAY INCREASE PLASMA CONCENTRATIONS SALICYLIC ACID TOXIC LEVELS
Salicylates given concomitantly with anticoagulant drugs may predispose to systemic bleeding. 	Salicylates	anticoagulant drugs	effect	{'e1': {'word': 'Salicylates', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d576.s4.e0'}, 'e2': {'word': 'anticoagulant drugs', 'word_index': [(3, 4)], 'id': 'DDI-DrugBank.d576.s4.e1'}, 'sentence_id': 'DDI-DrugBank.d576.s4'}	Salicylates given concomitantly anticoagulant drugs may predispose systemic bleeding
Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. 	Salicylates	antidiabetic drugs	effect	{'e1': {'word': 'Salicylates', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d576.s5.e0'}, 'e2': {'word': 'antidiabetic drugs', 'word_index': [(6, 7)], 'id': 'DDI-DrugBank.d576.s5.e1'}, 'sentence_id': 'DDI-DrugBank.d576.s5'}	Salicylates may enhance hypoglycemic effect oral antidiabetic drugs sulfonylurea class
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	Salicylate	penicillin	mechanism	{'e1': {'word': 'Salicylate', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d576.s6.e0'}, 'e2': {'word': 'penicillin', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d576.s6.e1'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	Salicylate	thiopental	mechanism	{'e1': {'word': 'Salicylate', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d576.s6.e0'}, 'e2': {'word': 'thiopental', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d576.s6.e2'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	Salicylate	thyroxine	mechanism	{'e1': {'word': 'Salicylate', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d576.s6.e0'}, 'e2': {'word': 'thyroxine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d576.s6.e3'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	Salicylate	triiodothyronine	mechanism	{'e1': {'word': 'Salicylate', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d576.s6.e0'}, 'e2': {'word': 'triiodothyronine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d576.s6.e4'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	Salicylate	phenytoin	mechanism	{'e1': {'word': 'Salicylate', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d576.s6.e0'}, 'e2': {'word': 'phenytoin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d576.s6.e5'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	Salicylate	sulfinpyrazone	mechanism	{'e1': {'word': 'Salicylate', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d576.s6.e0'}, 'e2': {'word': 'sulfinpyrazone', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d576.s6.e6'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	Salicylate	naproxen	mechanism	{'e1': {'word': 'Salicylate', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d576.s6.e0'}, 'e2': {'word': 'naproxen', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d576.s6.e7'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	Salicylate	warfarin	mechanism	{'e1': {'word': 'Salicylate', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d576.s6.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d576.s6.e8'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	Salicylate	methotrexate	mechanism	{'e1': {'word': 'Salicylate', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d576.s6.e0'}, 'e2': {'word': 'methotrexate', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d576.s6.e9'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	Salicylate	corticosteroids	mechanism	{'e1': {'word': 'Salicylate', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d576.s6.e0'}, 'e2': {'word': 'corticosteroids', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d576.s6.e10'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	penicillin	thiopental	none	{'e1': {'word': 'penicillin', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d576.s6.e1'}, 'e2': {'word': 'thiopental', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d576.s6.e2'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	penicillin	thyroxine	none	{'e1': {'word': 'penicillin', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d576.s6.e1'}, 'e2': {'word': 'thyroxine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d576.s6.e3'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	penicillin	triiodothyronine	none	{'e1': {'word': 'penicillin', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d576.s6.e1'}, 'e2': {'word': 'triiodothyronine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d576.s6.e4'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	penicillin	phenytoin	none	{'e1': {'word': 'penicillin', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d576.s6.e1'}, 'e2': {'word': 'phenytoin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d576.s6.e5'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	penicillin	sulfinpyrazone	none	{'e1': {'word': 'penicillin', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d576.s6.e1'}, 'e2': {'word': 'sulfinpyrazone', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d576.s6.e6'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	penicillin	naproxen	none	{'e1': {'word': 'penicillin', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d576.s6.e1'}, 'e2': {'word': 'naproxen', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d576.s6.e7'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	penicillin	warfarin	none	{'e1': {'word': 'penicillin', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d576.s6.e1'}, 'e2': {'word': 'warfarin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d576.s6.e8'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	penicillin	methotrexate	none	{'e1': {'word': 'penicillin', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d576.s6.e1'}, 'e2': {'word': 'methotrexate', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d576.s6.e9'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	penicillin	corticosteroids	none	{'e1': {'word': 'penicillin', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d576.s6.e1'}, 'e2': {'word': 'corticosteroids', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d576.s6.e10'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	thiopental	thyroxine	none	{'e1': {'word': 'thiopental', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d576.s6.e2'}, 'e2': {'word': 'thyroxine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d576.s6.e3'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	thiopental	triiodothyronine	none	{'e1': {'word': 'thiopental', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d576.s6.e2'}, 'e2': {'word': 'triiodothyronine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d576.s6.e4'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	thiopental	phenytoin	none	{'e1': {'word': 'thiopental', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d576.s6.e2'}, 'e2': {'word': 'phenytoin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d576.s6.e5'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	thiopental	sulfinpyrazone	none	{'e1': {'word': 'thiopental', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d576.s6.e2'}, 'e2': {'word': 'sulfinpyrazone', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d576.s6.e6'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	thiopental	naproxen	none	{'e1': {'word': 'thiopental', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d576.s6.e2'}, 'e2': {'word': 'naproxen', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d576.s6.e7'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	thiopental	warfarin	none	{'e1': {'word': 'thiopental', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d576.s6.e2'}, 'e2': {'word': 'warfarin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d576.s6.e8'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	thiopental	methotrexate	none	{'e1': {'word': 'thiopental', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d576.s6.e2'}, 'e2': {'word': 'methotrexate', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d576.s6.e9'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	thiopental	corticosteroids	none	{'e1': {'word': 'thiopental', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d576.s6.e2'}, 'e2': {'word': 'corticosteroids', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d576.s6.e10'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	thyroxine	triiodothyronine	none	{'e1': {'word': 'thyroxine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d576.s6.e3'}, 'e2': {'word': 'triiodothyronine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d576.s6.e4'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	thyroxine	phenytoin	none	{'e1': {'word': 'thyroxine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d576.s6.e3'}, 'e2': {'word': 'phenytoin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d576.s6.e5'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	thyroxine	sulfinpyrazone	none	{'e1': {'word': 'thyroxine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d576.s6.e3'}, 'e2': {'word': 'sulfinpyrazone', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d576.s6.e6'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	thyroxine	naproxen	none	{'e1': {'word': 'thyroxine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d576.s6.e3'}, 'e2': {'word': 'naproxen', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d576.s6.e7'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	thyroxine	warfarin	none	{'e1': {'word': 'thyroxine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d576.s6.e3'}, 'e2': {'word': 'warfarin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d576.s6.e8'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	thyroxine	methotrexate	none	{'e1': {'word': 'thyroxine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d576.s6.e3'}, 'e2': {'word': 'methotrexate', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d576.s6.e9'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	thyroxine	corticosteroids	none	{'e1': {'word': 'thyroxine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d576.s6.e3'}, 'e2': {'word': 'corticosteroids', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d576.s6.e10'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	triiodothyronine	phenytoin	none	{'e1': {'word': 'triiodothyronine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d576.s6.e4'}, 'e2': {'word': 'phenytoin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d576.s6.e5'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	triiodothyronine	sulfinpyrazone	none	{'e1': {'word': 'triiodothyronine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d576.s6.e4'}, 'e2': {'word': 'sulfinpyrazone', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d576.s6.e6'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	triiodothyronine	naproxen	none	{'e1': {'word': 'triiodothyronine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d576.s6.e4'}, 'e2': {'word': 'naproxen', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d576.s6.e7'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	triiodothyronine	warfarin	none	{'e1': {'word': 'triiodothyronine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d576.s6.e4'}, 'e2': {'word': 'warfarin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d576.s6.e8'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	triiodothyronine	methotrexate	none	{'e1': {'word': 'triiodothyronine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d576.s6.e4'}, 'e2': {'word': 'methotrexate', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d576.s6.e9'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	triiodothyronine	corticosteroids	none	{'e1': {'word': 'triiodothyronine', 'word_index': [(11, 11)], 'id': 'DDI-DrugBank.d576.s6.e4'}, 'e2': {'word': 'corticosteroids', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d576.s6.e10'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	phenytoin	sulfinpyrazone	none	{'e1': {'word': 'phenytoin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d576.s6.e5'}, 'e2': {'word': 'sulfinpyrazone', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d576.s6.e6'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	phenytoin	naproxen	none	{'e1': {'word': 'phenytoin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d576.s6.e5'}, 'e2': {'word': 'naproxen', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d576.s6.e7'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	phenytoin	warfarin	none	{'e1': {'word': 'phenytoin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d576.s6.e5'}, 'e2': {'word': 'warfarin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d576.s6.e8'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	phenytoin	methotrexate	none	{'e1': {'word': 'phenytoin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d576.s6.e5'}, 'e2': {'word': 'methotrexate', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d576.s6.e9'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	phenytoin	corticosteroids	none	{'e1': {'word': 'phenytoin', 'word_index': [(12, 12)], 'id': 'DDI-DrugBank.d576.s6.e5'}, 'e2': {'word': 'corticosteroids', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d576.s6.e10'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	sulfinpyrazone	naproxen	none	{'e1': {'word': 'sulfinpyrazone', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d576.s6.e6'}, 'e2': {'word': 'naproxen', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d576.s6.e7'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	sulfinpyrazone	warfarin	none	{'e1': {'word': 'sulfinpyrazone', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d576.s6.e6'}, 'e2': {'word': 'warfarin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d576.s6.e8'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	sulfinpyrazone	methotrexate	none	{'e1': {'word': 'sulfinpyrazone', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d576.s6.e6'}, 'e2': {'word': 'methotrexate', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d576.s6.e9'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	sulfinpyrazone	corticosteroids	none	{'e1': {'word': 'sulfinpyrazone', 'word_index': [(13, 13)], 'id': 'DDI-DrugBank.d576.s6.e6'}, 'e2': {'word': 'corticosteroids', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d576.s6.e10'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	naproxen	warfarin	none	{'e1': {'word': 'naproxen', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d576.s6.e7'}, 'e2': {'word': 'warfarin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d576.s6.e8'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	naproxen	methotrexate	none	{'e1': {'word': 'naproxen', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d576.s6.e7'}, 'e2': {'word': 'methotrexate', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d576.s6.e9'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	naproxen	corticosteroids	none	{'e1': {'word': 'naproxen', 'word_index': [(14, 14)], 'id': 'DDI-DrugBank.d576.s6.e7'}, 'e2': {'word': 'corticosteroids', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d576.s6.e10'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	warfarin	methotrexate	none	{'e1': {'word': 'warfarin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d576.s6.e8'}, 'e2': {'word': 'methotrexate', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d576.s6.e9'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	warfarin	corticosteroids	none	{'e1': {'word': 'warfarin', 'word_index': [(15, 15)], 'id': 'DDI-DrugBank.d576.s6.e8'}, 'e2': {'word': 'corticosteroids', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d576.s6.e10'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. 	methotrexate	corticosteroids	none	{'e1': {'word': 'methotrexate', 'word_index': [(16, 16)], 'id': 'DDI-DrugBank.d576.s6.e9'}, 'e2': {'word': 'corticosteroids', 'word_index': [(18, 18)], 'id': 'DDI-DrugBank.d576.s6.e10'}, 'sentence_id': 'DDI-DrugBank.d576.s6'}	Salicylate competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids
Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. 	Posicor	terfenadine	mechanism	{'e1': {'word': 'Posicor', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d783.s0.e0'}, 'e2': {'word': 'terfenadine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d783.s0.e1'}, 'sentence_id': 'DDI-DrugBank.d783.s0'}	Posicor inhibits liver 's ability metabolize drugs terfenadine astemizole cisapride cyclosporine tricyclic antidepressants
Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. 	Posicor	astemizole	mechanism	{'e1': {'word': 'Posicor', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d783.s0.e0'}, 'e2': {'word': 'astemizole', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d783.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d783.s0'}	Posicor inhibits liver 's ability metabolize drugs terfenadine astemizole cisapride cyclosporine tricyclic antidepressants
Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. 	Posicor	cisapride	mechanism	{'e1': {'word': 'Posicor', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d783.s0.e0'}, 'e2': {'word': 'cisapride', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d783.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d783.s0'}	Posicor inhibits liver 's ability metabolize drugs terfenadine astemizole cisapride cyclosporine tricyclic antidepressants
Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. 	Posicor	cyclosporine	mechanism	{'e1': {'word': 'Posicor', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d783.s0.e0'}, 'e2': {'word': 'cyclosporine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d783.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d783.s0'}	Posicor inhibits liver 's ability metabolize drugs terfenadine astemizole cisapride cyclosporine tricyclic antidepressants
Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. 	Posicor	tricyclic antidepressants	mechanism	{'e1': {'word': 'Posicor', 'word_index': [(0, 0)], 'id': 'DDI-DrugBank.d783.s0.e0'}, 'e2': {'word': 'tricyclic antidepressants', 'word_index': [(11, 12)], 'id': 'DDI-DrugBank.d783.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d783.s0'}	Posicor inhibits liver 's ability metabolize drugs terfenadine astemizole cisapride cyclosporine tricyclic antidepressants
Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. 	terfenadine	astemizole	none	{'e1': {'word': 'terfenadine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d783.s0.e1'}, 'e2': {'word': 'astemizole', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d783.s0.e2'}, 'sentence_id': 'DDI-DrugBank.d783.s0'}	Posicor inhibits liver 's ability metabolize drugs terfenadine astemizole cisapride cyclosporine tricyclic antidepressants
Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. 	terfenadine	cisapride	none	{'e1': {'word': 'terfenadine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d783.s0.e1'}, 'e2': {'word': 'cisapride', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d783.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d783.s0'}	Posicor inhibits liver 's ability metabolize drugs terfenadine astemizole cisapride cyclosporine tricyclic antidepressants
Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. 	terfenadine	cyclosporine	none	{'e1': {'word': 'terfenadine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d783.s0.e1'}, 'e2': {'word': 'cyclosporine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d783.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d783.s0'}	Posicor inhibits liver 's ability metabolize drugs terfenadine astemizole cisapride cyclosporine tricyclic antidepressants
Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. 	terfenadine	tricyclic antidepressants	none	{'e1': {'word': 'terfenadine', 'word_index': [(7, 7)], 'id': 'DDI-DrugBank.d783.s0.e1'}, 'e2': {'word': 'tricyclic antidepressants', 'word_index': [(11, 12)], 'id': 'DDI-DrugBank.d783.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d783.s0'}	Posicor inhibits liver 's ability metabolize drugs terfenadine astemizole cisapride cyclosporine tricyclic antidepressants
Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. 	astemizole	cisapride	none	{'e1': {'word': 'astemizole', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d783.s0.e2'}, 'e2': {'word': 'cisapride', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d783.s0.e3'}, 'sentence_id': 'DDI-DrugBank.d783.s0'}	Posicor inhibits liver 's ability metabolize drugs terfenadine astemizole cisapride cyclosporine tricyclic antidepressants
Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. 	astemizole	cyclosporine	none	{'e1': {'word': 'astemizole', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d783.s0.e2'}, 'e2': {'word': 'cyclosporine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d783.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d783.s0'}	Posicor inhibits liver 's ability metabolize drugs terfenadine astemizole cisapride cyclosporine tricyclic antidepressants
Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. 	astemizole	tricyclic antidepressants	none	{'e1': {'word': 'astemizole', 'word_index': [(8, 8)], 'id': 'DDI-DrugBank.d783.s0.e2'}, 'e2': {'word': 'tricyclic antidepressants', 'word_index': [(11, 12)], 'id': 'DDI-DrugBank.d783.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d783.s0'}	Posicor inhibits liver 's ability metabolize drugs terfenadine astemizole cisapride cyclosporine tricyclic antidepressants
Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. 	cisapride	cyclosporine	none	{'e1': {'word': 'cisapride', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d783.s0.e3'}, 'e2': {'word': 'cyclosporine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d783.s0.e4'}, 'sentence_id': 'DDI-DrugBank.d783.s0'}	Posicor inhibits liver 's ability metabolize drugs terfenadine astemizole cisapride cyclosporine tricyclic antidepressants
Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. 	cisapride	tricyclic antidepressants	none	{'e1': {'word': 'cisapride', 'word_index': [(9, 9)], 'id': 'DDI-DrugBank.d783.s0.e3'}, 'e2': {'word': 'tricyclic antidepressants', 'word_index': [(11, 12)], 'id': 'DDI-DrugBank.d783.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d783.s0'}	Posicor inhibits liver 's ability metabolize drugs terfenadine astemizole cisapride cyclosporine tricyclic antidepressants
Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. 	cyclosporine	tricyclic antidepressants	none	{'e1': {'word': 'cyclosporine', 'word_index': [(10, 10)], 'id': 'DDI-DrugBank.d783.s0.e4'}, 'e2': {'word': 'tricyclic antidepressants', 'word_index': [(11, 12)], 'id': 'DDI-DrugBank.d783.s0.e5'}, 'sentence_id': 'DDI-DrugBank.d783.s0'}	Posicor inhibits liver 's ability metabolize drugs terfenadine astemizole cisapride cyclosporine tricyclic antidepressants
